{"generated":"2026-09-21T07:07:28.077Z","today":"2026-09-21","total":12360,"findings":[{"check":"soc-cites-dead","severity":"high","id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","detail":"standard-of-care row \"Brain\" cites Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/","detail":"standard-of-care row \"Progression on avapritinib\" cites VOYAGER (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"approvals-vs-regional","severity":"medium","id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/","detail":"EU first approval year 2009 in approvals but 2025 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","detail":"EU first approval year 2011 in approvals but 2010 in regional-approvals.ts"},{"check":"asof-before-regulatory-event","severity":"medium","id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","detail":"asOf 2026-09-06 predates the approval dated 2026-09-09 (US): FDA grants accelerated approval to sevabertinib for locally advanced or metastat"},{"check":"duplicate-name","severity":"medium","id":"nct06223841","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06223841/","detail":"same normalised name as nct06581419 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct06581419","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06581419/","detail":"same normalised name as nct06223841 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct06212752","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With","route":"/trials/nct06212752/","detail":"same normalised name as nct05722015 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct05722015","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With","route":"/trials/nct05722015/","detail":"same normalised name as nct06212752 (trial)"},{"check":"duplicate-name","severity":"medium","id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","detail":"same normalised name as aml-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"aml-signalling","kind":"pathway","name":"Acute myeloid leukaemia (KEGG map)","route":"/pathways/aml-signalling/","detail":"same normalised name as aml (cancer)"},{"check":"duplicate-name","severity":"medium","id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/","detail":"same normalised name as nct07480213 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/","detail":"same normalised name as nct07744256 (trial)"},{"check":"duplicate-name","severity":"medium","id":"alsf","kind":"institution","name":"Alex's Lemonade Stand Foundation","route":"/institutions/alsf/","detail":"same normalised name as alexs-lemonade-stand (collection)"},{"check":"duplicate-name","severity":"medium","id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","detail":"same normalised name as alsf (institution)"},{"check":"duplicate-name","severity":"medium","id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/","detail":"same normalised name as paper-young-angiosarcoma-review-lancet-oncol-2010 (paper)"},{"check":"duplicate-name","severity":"medium","id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","detail":"same normalised name as angiosarcoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","detail":"same normalised name as autologous-stem-cell-transplant (technology)"},{"check":"duplicate-name","severity":"medium","id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","detail":"same normalised name as autologous-transplant (term)"},{"check":"duplicate-name","severity":"medium","id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","detail":"same normalised name as basal-cell-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"basal-cell-carcinoma-signalling","kind":"pathway","name":"Basal cell carcinoma (KEGG map)","route":"/pathways/basal-cell-carcinoma-signalling/","detail":"same normalised name as basal-cell-carcinoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","detail":"same normalised name as bcr-abl1-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","detail":"same normalised name as bcr-abl (target)"},{"check":"duplicate-name","severity":"medium","id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","detail":"same normalised name as bevacizumab-glioma (drug)"},{"check":"duplicate-name","severity":"medium","id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","detail":"same normalised name as bevacizumab (drug)"},{"check":"duplicate-name","severity":"medium","id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/","detail":"same normalised name as cholangiocarcinoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","detail":"same normalised name as biliary-tract-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","detail":"same normalised name as brachytherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"brachytherapy-term","kind":"term","name":"Brachytherapy (internal radiotherapy)","route":"/terms/brachytherapy-term/","detail":"same normalised name as brachytherapy (technology)"},{"check":"duplicate-name","severity":"medium","id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","detail":"same normalised name as secondary-brain-tumours (cancer)"},{"check":"duplicate-name","severity":"medium","id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","detail":"same normalised name as brain-metastases (term)"},{"check":"duplicate-name","severity":"medium","id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","detail":"same normalised name as breast-cancer-signalling (pathway), breast-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","detail":"same normalised name as breast-cancer-signalling (pathway), breast-cancer-jbcs (journal)"},{"check":"duplicate-name","severity":"medium","id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","detail":"same normalised name as breast-cancer-jbcs (journal), breast-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","detail":"same normalised name as bcrf (institution)"},{"check":"duplicate-name","severity":"medium","id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","detail":"same normalised name as src-bcrf (collection)"},{"check":"duplicate-name","severity":"medium","id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","detail":"same normalised name as cachexia (term)"},{"check":"duplicate-name","severity":"medium","id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","detail":"same normalised name as cachexia-biology (pathway)"},{"check":"duplicate-name","severity":"medium","id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","detail":"same normalised name as cell-term (term)"},{"check":"duplicate-name","severity":"medium","id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","detail":"same normalised name as cell (journal)"},{"check":"duplicate-name","severity":"medium","id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","detail":"same normalised name as chemotherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","detail":"same normalised name as chemotherapy (section)"},{"check":"duplicate-name","severity":"medium","id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","detail":"same normalised name as cml-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"cml-signalling","kind":"pathway","name":"Chronic myeloid leukaemia (KEGG map)","route":"/pathways/cml-signalling/","detail":"same normalised name as cml (cancer)"},{"check":"duplicate-name","severity":"medium","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"same normalised name as colorectal-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/","detail":"same normalised name as colorectal (cancer)"},{"check":"duplicate-name","severity":"medium","id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/","detail":"same normalised name as drug-efflux-pumps (pathway)"},{"check":"duplicate-name","severity":"medium","id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/","detail":"same normalised name as efflux-pump (term)"},{"check":"duplicate-name","severity":"medium","id":"dcis","kind":"term","name":"Ductal carcinoma in situ (DCIS)","route":"/terms/dcis/","detail":"same normalised name as ductal-carcinoma-in-situ (cancer)"},{"check":"duplicate-name","severity":"medium","id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","detail":"same normalised name as dcis (term)"},{"check":"duplicate-name","severity":"medium","id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","detail":"same normalised name as eclipse-shield (trial)"},{"check":"duplicate-name","severity":"medium","id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","detail":"same normalised name as eclipse-psma (trial)"},{"check":"duplicate-name","severity":"medium","id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","detail":"same normalised name as endometrial-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"endometrial-cancer-signalling","kind":"pathway","name":"Endometrial cancer (KEGG map)","route":"/pathways/endometrial-cancer-signalling/","detail":"same normalised name as endometrial (cancer)"},{"check":"duplicate-name","severity":"medium","id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","detail":"same normalised name as gastric-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","detail":"same normalised name as gastric-cancer (journal)"},{"check":"duplicate-name","severity":"medium","id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","detail":"same normalised name as hepatocellular-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"hepatocellular-carcinoma-signalling","kind":"pathway","name":"Hepatocellular carcinoma (KEGG map)","route":"/pathways/hepatocellular-carcinoma-signalling/","detail":"same normalised name as hcc (cancer)"},{"check":"duplicate-name","severity":"medium","id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","detail":"same normalised name as immunotherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","detail":"same normalised name as immunotherapy (section)"},{"check":"duplicate-name","severity":"medium","id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","detail":"same normalised name as incan-mexico (institution)"},{"check":"duplicate-name","severity":"medium","id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","detail":"same normalised name as inc-colombia (institution)"},{"check":"duplicate-name","severity":"medium","id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","detail":"same normalised name as inca-uruguay (institution), inc-chile (institution)"},{"check":"duplicate-name","severity":"medium","id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","detail":"same normalised name as inc-argentina (institution), inca-uruguay (institution)"},{"check":"duplicate-name","severity":"medium","id":"inca-uruguay","kind":"institution","name":"Instituto Nacional del Cáncer (Uruguay)","route":"/institutions/inca-uruguay/","detail":"same normalised name as inc-argentina (institution), inc-chile (institution)"},{"check":"duplicate-name","severity":"medium","id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","detail":"same normalised name as bcg-and-intravesical-therapy (technology)"},{"check":"duplicate-name","severity":"medium","id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","detail":"same normalised name as intravesical-therapy (term)"},{"check":"duplicate-name","severity":"medium","id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/","detail":"same normalised name as inxmed-shanghai (company)"},{"check":"duplicate-name","severity":"medium","id":"inxmed-shanghai","kind":"company","name":"InxMed (Shanghai)","route":"/companies/inxmed-shanghai/","detail":"same normalised name as inxmed (company)"},{"check":"duplicate-name","severity":"medium","id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","detail":"same normalised name as leukaemia-type (term)"},{"check":"duplicate-name","severity":"medium","id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","detail":"same normalised name as leukaemia (cancer)"},{"check":"duplicate-name","severity":"medium","id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","detail":"same normalised name as lgsoc (term)"},{"check":"duplicate-name","severity":"medium","id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","detail":"same normalised name as low-grade-serous-ovarian-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","detail":"same normalised name as lung-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","detail":"same normalised name as lung-cancer-journal (journal)"},{"check":"duplicate-name","severity":"medium","id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","detail":"same normalised name as macmillan-cancer-support (institution)"},{"check":"duplicate-name","severity":"medium","id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","detail":"same normalised name as src-macmillan (collection)"},{"check":"duplicate-name","severity":"medium","id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","detail":"same normalised name as melanoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"melanoma-signalling","kind":"pathway","name":"Melanoma (KEGG map)","route":"/pathways/melanoma-signalling/","detail":"same normalised name as melanoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"mra","kind":"institution","name":"Melanoma Research Alliance","route":"/institutions/mra/","detail":"same normalised name as melanoma-research-alliance (collection)"},{"check":"duplicate-name","severity":"medium","id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","detail":"same normalised name as mra (institution)"},{"check":"duplicate-name","severity":"medium","id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","detail":"same normalised name as microsoft-research (company)"},{"check":"duplicate-name","severity":"medium","id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","detail":"same normalised name as microsoft (company)"},{"check":"duplicate-name","severity":"medium","id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","detail":"same normalised name as nogapendekin-alfa-inbakicept (drug)"},{"check":"duplicate-name","severity":"medium","id":"nogapendekin-alfa-inbakicept","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa-inbakicept/","detail":"same normalised name as nogapendekin-alfa (drug)"},{"check":"duplicate-name","severity":"medium","id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/","detail":"same normalised name as nsclc (cancer)"},{"check":"duplicate-name","severity":"medium","id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","detail":"same normalised name as nsclc-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","detail":"same normalised name as oncogene-journal (journal)"},{"check":"duplicate-name","severity":"medium","id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","detail":"same normalised name as oncogene (term)"},{"check":"duplicate-name","severity":"medium","id":"oncology-karger","kind":"journal","name":"Oncology","route":"/journals/oncology-karger/","detail":"same normalised name as oncology-williston-park (journal)"},{"check":"duplicate-name","severity":"medium","id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/","detail":"same normalised name as oncology-karger (journal)"},{"check":"duplicate-name","severity":"medium","id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","detail":"same normalised name as prostate-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","detail":"same normalised name as prostate (cancer)"},{"check":"duplicate-name","severity":"medium","id":"pcf","kind":"institution","name":"Prostate Cancer Foundation","route":"/institutions/pcf/","detail":"same normalised name as prostate-cancer-foundation (collection)"},{"check":"duplicate-name","severity":"medium","id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","detail":"same normalised name as pcf (institution)"},{"check":"duplicate-name","severity":"medium","id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","detail":"same normalised name as renal-cell-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/","detail":"same normalised name as rcc (cancer)"},{"check":"duplicate-name","severity":"medium","id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/","detail":"same normalised name as sclc (cancer)"},{"check":"duplicate-name","severity":"medium","id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","detail":"same normalised name as sclc-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/","detail":"same normalised name as st-baldricks-foundation (institution)"},{"check":"duplicate-name","severity":"medium","id":"st-baldricks-foundation","kind":"institution","name":"St. Baldrick's Foundation","route":"/institutions/st-baldricks-foundation/","detail":"same normalised name as st-baldricks (collection)"},{"check":"duplicate-name","severity":"medium","id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/","detail":"same normalised name as stereotactic-radiosurgery (term)"},{"check":"duplicate-name","severity":"medium","id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/","detail":"same normalised name as radiosurgery-srs (technology)"},{"check":"duplicate-name","severity":"medium","id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/","detail":"same normalised name as nct05409066 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct05409066","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct05409066/","detail":"same normalised name as nct06191744 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/","detail":"same normalised name as nct06125522 (trial), nct05573555 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct05573555","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","route":"/trials/nct05573555/","detail":"same normalised name as nct06125522 (trial), nct05548127 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct06125522","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","route":"/trials/nct06125522/","detail":"same normalised name as nct05548127 (trial), nct05573555 (trial)"},{"check":"duplicate-name","severity":"medium","id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","detail":"same normalised name as src-targeted-oncology (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","detail":"same normalised name as targeted-oncology (journal)"},{"check":"duplicate-name","severity":"medium","id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","detail":"same normalised name as targeted-therapy (section)"},{"check":"duplicate-name","severity":"medium","id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","detail":"same normalised name as targeted-therapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","detail":"same normalised name as thyroid-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"thyroid-cancer-signalling","kind":"pathway","name":"Thyroid cancer (KEGG map)","route":"/pathways/thyroid-cancer-signalling/","detail":"same normalised name as thyroid (cancer)"},{"check":"duplicate-name","severity":"medium","id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","detail":"same normalised name as valius-sciences (company)"},{"check":"duplicate-name","severity":"medium","id":"valius-sciences","kind":"company","name":"Valius Sciences","route":"/companies/valius-sciences/","detail":"same normalised name as valius (company)"},{"check":"duplicate-name","severity":"medium","id":"ventana-pd-l1-sp142","kind":"drug","name":"VENTANA PD-L1 (SP142) Assay","route":"/drugs/ventana-pd-l1-sp142/","detail":"same normalised name as ventana-pd-l1-sp263 (drug)"},{"check":"duplicate-name","severity":"medium","id":"ventana-pd-l1-sp263","kind":"drug","name":"VENTANA PD-L1 (SP263) Assay","route":"/drugs/ventana-pd-l1-sp263/","detail":"same normalised name as ventana-pd-l1-sp142 (drug)"},{"check":"future-year-in-text","severity":"medium","id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","detail":"mentions 2040"},{"check":"future-year-in-text","severity":"medium","id":"idea-cost-real-time-pa-fhir","kind":"idea","name":"Answer prior authorisation requests in seconds from the medical record","route":"/ideas/idea-cost-real-time-pa-fhir/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"idea-reg-biosimilar-no-efficacy-trial","kind":"idea","name":"Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials","route":"/ideas/idea-reg-biosimilar-no-efficacy-trial/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","route":"/institutions/ellison-institute/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/","detail":"mentions 2029"},{"check":"future-year-in-text","severity":"medium","id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"julio-oliveira","kind":"person","name":"Júlio Oliveira","route":"/people/julio-oliveira/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"larry-ellison","kind":"person","name":"Larry Ellison","route":"/people/larry-ellison/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","detail":"mentions 2056"},{"check":"future-year-in-text","severity":"medium","id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"oncotherm","kind":"company","name":"Oncotherm","route":"/companies/oncotherm/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","route":"/people/oscar-arrieta-rodriguez/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/","detail":"mentions 2090"},{"check":"future-year-in-text","severity":"medium","id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","route":"/people/stanislaw-klek/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","detail":"mentions 2056"},{"check":"future-year-in-text","severity":"medium","id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","detail":"mentions 2033"},{"check":"future-year-in-text","severity":"medium","id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","route":"/people/vadims-beluns/","detail":"mentions 2031"},{"check":"future-year-in-text","severity":"medium","id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/","detail":"mentions 2028"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","detail":"\"CARGO Therapeutics\" and \"CARTx Therapeutics\" (cartx-therapeutics) differ by at most two characters; if they are one thing, keep cargo-therapeutics, move \"CARTx Therapeutics\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","detail":"\"CheckMate 9DW\" and \"CheckMate 9ER\" (checkmate-9er) differ by at most two characters; if they are one thing, keep checkmate-9dw, move \"CheckMate 9ER\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/","detail":"\"Corbus Pharmaceuticals\" and \"Corvus Pharmaceuticals\" (corvus-pharmaceuticals) differ by at most two characters; if they are one thing, keep corbus-pharmaceuticals, move \"Corvus Pharmaceuticals\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016","kind":"paper","name":"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016/","detail":"\"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer\" and \"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer\" (paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017) differ by at most two characters; if they are one thing, keep paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016, move \"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"dysphagia","kind":"term","name":"Dysphagia (difficulty swallowing)","route":"/terms/dysphagia/","detail":"\"Dysphagia (difficulty swallowing)\" and \"Dysplasia (pre-cancerous change)\" (dysplasia) differ by at most two characters; if they are one thing, keep dysphagia, move \"Dysplasia (pre-cancerous change)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","detail":"\"Feng Zhang\" and \"Feng Wang\" (wang-feng-sysucc) differ by at most two characters; if they are one thing, keep feng-zhang, move \"Feng Wang\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/","detail":"\"Instituto Nacional de Câncer (INCA)\" and \"Instituto Nacional del Cáncer (Uruguay)\" (inca-uruguay) differ by at most two characters; if they are one thing, keep inca-brazil, move \"Instituto Nacional del Cáncer (Uruguay)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","detail":"\"Instituto Nacional del Cáncer (Argentina)\" and \"Instituto Nacional de Câncer (INCA)\" (inca-brazil) differ by at most two characters; if they are one thing, keep inc-argentina, move \"Instituto Nacional de Câncer (INCA)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","detail":"\"Instituto Nacional del Cáncer (Chile)\" and \"Instituto Nacional de Câncer (INCA)\" (inca-brazil) differ by at most two characters; if they are one thing, keep inc-chile, move \"Instituto Nacional de Câncer (INCA)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"majic-et","kind":"trial","name":"MAJIC-ET","route":"/trials/majic-et/","detail":"\"MAJIC-ET\" and \"MAJIC-PV\" (majic-pv) differ by at most two characters; if they are one thing, keep majic-et, move \"MAJIC-PV\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/","detail":"\"NAVIGATE\" and \"NAVIGATOR\" (navigator) differ by at most two characters; if they are one thing, keep navigate, move \"NAVIGATOR\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","detail":"\"Neoplasia\" and \"Neoplasma\" (neoplasma) differ by at most two characters; if they are one thing, keep neoplasia, move \"Neoplasma\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","detail":"\"Newly diagnosed multiple myeloma, transplant-eligible\" and \"Newly diagnosed multiple myeloma, transplant-ineligible\" (myeloma-transplant-ineligible) differ by at most two characters; if they are one thing, keep myeloma-transplant-eligible, move \"Newly diagnosed multiple myeloma, transplant-ineligible\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"nicolas-penel","kind":"person","name":"Nicolas Penel","route":"/people/nicolas-penel/","detail":"\"Nicolas Penel\" and \"Nicolas Revel\" (nicolas-revel) differ by at most two characters; if they are one thing, keep nicolas-penel, move \"Nicolas Revel\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","detail":"\"Tae Won Kim\" and \"Tae-You Kim\" (kim-tae-you) differ by at most two characters; if they are one thing, keep kim-tae-won, move \"Tae-You Kim\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct05955391/","detail":"\"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)\" and \"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)\" (nsclc-3) differ by at most two characters; if they are one thing, keep nct05955391, move \"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)\" into its aka and repoint links"},{"check":"outcome-no-source","severity":"medium","id":"alliance-n0574","kind":"trial","name":"Alliance N0574 (NCCTG N0574)","route":"/trials/alliance-n0574/","detail":"1 of 1 structured outcome carry numbers without a source: Cognitive deterioration at 3 months"},{"check":"outcome-no-source","severity":"medium","id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","detail":"1 of 3 structured outcomes carry numbers without a source: Confirmed objective response rate (BICR)"},{"check":"outcome-no-source","severity":"medium","id":"bonner-cetuximab-rt","kind":"trial","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","detail":"1 of 1 structured outcome carry numbers without a source: Locoregional control (primary) and overall survival"},{"check":"outcome-no-source","severity":"medium","id":"calgb-9343","kind":"trial","name":"CALGB 9343","route":"/trials/calgb-9343/","detail":"1 of 1 structured outcome carry numbers without a source: Locoregional recurrence at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"cao-aro-aio-94","kind":"trial","name":"CAO/ARO/AIO-94 (German Rectal Cancer Study)","route":"/trials/cao-aro-aio-94/","detail":"1 of 1 structured outcome carry numbers without a source: Local recurrence at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"captain-1st","kind":"trial","name":"CAPTAIN-1st","route":"/trials/captain-1st/","detail":"1 of 1 structured outcome carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","detail":"1 of 1 structured outcome carry numbers without a source: Biochemical or clinical failure-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"cyto-pv","kind":"trial","name":"CYTO-PV","route":"/trials/cyto-pv/","detail":"1 of 1 structured outcome carry numbers without a source: Cardiovascular death or major thrombosis"},{"check":"outcome-no-source","severity":"medium","id":"dahanca-5","kind":"trial","name":"DAHANCA 5","route":"/trials/dahanca-5/","detail":"1 of 1 structured outcome carry numbers without a source: Locoregional control at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"dbcg-82bc","kind":"trial","name":"DBCG 82b and 82c","route":"/trials/dbcg-82bc/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 10 years (82b)"},{"check":"outcome-no-source","severity":"medium","id":"ecog-e3311","kind":"trial","name":"ECOG-ACRIN E3311","route":"/trials/ecog-e3311/","detail":"1 of 1 structured outcome carry numbers without a source: Progression-free survival at 2 years"},{"check":"outcome-no-source","severity":"medium","id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"slotman-pci-es-sclc","kind":"trial","name":"EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer","route":"/trials/slotman-pci-es-sclc/","detail":"1 of 1 structured outcome carry numbers without a source: Symptomatic brain metastases within 1 year"},{"check":"outcome-no-source","severity":"medium","id":"eortc-22922","kind":"trial","name":"EORTC 22922/10925","route":"/trials/eortc-22922/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall survival; Pathologic complete response"},{"check":"outcome-no-source","severity":"medium","id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (ESR1-mutant)"},{"check":"outcome-no-source","severity":"medium","id":"fast-forward","kind":"trial","name":"FAST-Forward","route":"/trials/fast-forward/","detail":"1 of 1 structured outcome carry numbers without a source: Ipsilateral breast tumour relapse at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","detail":"1 of 1 structured outcome carry numbers without a source: Failure-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"import-low","kind":"trial","name":"IMPORT LOW","route":"/trials/import-low/","detail":"1 of 1 structured outcome carry numbers without a source: Local relapse at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"int-0116","kind":"trial","name":"INT-0116 (Macdonald trial)","route":"/trials/int-0116/","detail":"1 of 1 structured outcome carry numbers without a source: Median overall survival"},{"check":"outcome-no-source","severity":"medium","id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall response rate; Overall survival (median)"},{"check":"outcome-no-source","severity":"medium","id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival (final)"},{"check":"outcome-no-source","severity":"medium","id":"low-pv","kind":"trial","name":"Low-PV","route":"/trials/low-pv/","detail":"1 of 1 structured outcome carry numbers without a source: Response at 12 months"},{"check":"outcome-no-source","severity":"medium","id":"lumina","kind":"trial","name":"LUMINA","route":"/trials/lumina/","detail":"1 of 1 structured outcome carry numbers without a source: Local recurrence at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"majic-pv","kind":"trial","name":"MAJIC-PV","route":"/trials/majic-pv/","detail":"1 of 1 structured outcome carry numbers without a source: Complete response within 1 year"},{"check":"outcome-no-source","severity":"medium","id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"ma-20","kind":"trial","name":"NCIC MA.20","route":"/trials/ma-20/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-free survival at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"nivopostop","kind":"trial","name":"NIVOPOSTOP (GORTEC 2018-01)","route":"/trials/nivopostop/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-free survival at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"nsabp-b39","kind":"trial","name":"NSABP B-39/RTOG 0413","route":"/trials/nsabp-b39/","detail":"1 of 1 structured outcome carry numbers without a source: Ipsilateral breast tumour recurrence at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","detail":"1 of 1 structured outcome carry numbers without a source: Freedom from biochemical or clinical failure at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","detail":"1 of 1 structured outcome carry numbers without a source: Biochemical failure-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"prime-ii","kind":"trial","name":"PRIME II","route":"/trials/prime-ii/","detail":"1 of 1 structured outcome carry numbers without a source: Ipsilateral breast tumour recurrence at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-free survival at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-related treatment failure at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"response","kind":"trial","name":"RESPONSE","route":"/trials/response/","detail":"1 of 1 structured outcome carry numbers without a source: Haematocrit control plus 35% spleen reduction at week 32"},{"check":"outcome-no-source","severity":"medium","id":"response-2","kind":"trial","name":"RESPONSE-2","route":"/trials/response-2/","detail":"1 of 1 structured outcome carry numbers without a source: Haematocrit control at week 28"},{"check":"outcome-no-source","severity":"medium","id":"rtog-0617","kind":"trial","name":"RTOG 0617","route":"/trials/rtog-0617/","detail":"1 of 1 structured outcome carry numbers without a source: Median overall survival"},{"check":"outcome-no-source","severity":"medium","id":"rtog-1016","kind":"trial","name":"RTOG 1016","route":"/trials/rtog-1016/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"rtog-91-11","kind":"trial","name":"RTOG 91-11","route":"/trials/rtog-91-11/","detail":"1 of 1 structured outcome carry numbers without a source: Laryngectomy-free survival driver: larynx preservation at 2 years"},{"check":"outcome-no-source","severity":"medium","id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","detail":"1 of 1 structured outcome carry numbers without a source: Median overall survival, 1p/19q co-deleted"},{"check":"outcome-no-source","severity":"medium","id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 12 years"},{"check":"outcome-no-source","severity":"medium","id":"start-b","kind":"trial","name":"START-B (UK Standardisation of Breast Radiotherapy)","route":"/trials/start-b/","detail":"1 of 1 structured outcome carry numbers without a source: Local-regional relapse at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","detail":"2 of 2 structured outcomes carry numbers without a source: Complete response rate (CIS); Duration of CR ≥12 months"},{"check":"outcome-no-source","severity":"medium","id":"verify","kind":"trial","name":"VERIFY","route":"/trials/verify/","detail":"1 of 1 structured outcome carry numbers without a source: Clinical response weeks 20 to 32"},{"check":"pipeline-cites-dead","severity":"medium","id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","detail":"pipeline lists Fianlimab + cemiplimab phase 3 (first-line melanoma) (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","detail":"pipeline lists IMbrave050 (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/","detail":"pipeline lists XPORT-EC-042 / ENGOT-EN20 / GOG-3083 (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","detail":"pipeline lists Tazemetostat (status withdrawn)"},{"check":"pipeline-cites-dead","severity":"medium","id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","detail":"pipeline lists Anetumab ravtansine (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","detail":"pipeline lists Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","detail":"pipeline lists De-ESCALaTE HPV (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","detail":"pipeline lists AMPLIFY-7P (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","detail":"pipeline lists RELATIVITY-098 (status negative)"},{"check":"status-vs-approvals","severity":"medium","id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","detail":"US/EU approvals recorded (US 1999) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","detail":"US/EU approvals recorded (US 1990) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","detail":"US/EU approvals recorded (US 2012) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","detail":"US/EU approvals recorded (US 2004) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","detail":"US/EU approvals recorded (US 1997) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","detail":"US/EU approvals recorded (US 1985) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","detail":"US/EU approvals recorded (US 2008) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/","detail":"US/EU approvals recorded (US 2018) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","detail":"US/EU approvals recorded (US 1981) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","detail":"US/EU approvals recorded (US 1954) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","detail":"US/EU approvals recorded (US 1970) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","detail":"US/EU approvals recorded (US 2018) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","detail":"US/EU approvals recorded (US 1999) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","detail":"US/EU approvals recorded (US 2004) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","detail":"US/EU approvals recorded (US 1985) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/","detail":"US/EU approvals recorded (EU 2019) but status is \"phase-3\""},{"check":"status-vs-approvals","severity":"medium","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"US/EU approvals recorded (US 2011) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","detail":"US/EU approvals recorded (US 1995) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","detail":"US/EU approvals recorded (US 2014) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/","detail":"US/EU approvals recorded (US 2018) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","detail":"US/EU approvals recorded (US 2008) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","detail":"US/EU approvals recorded (US 1991) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","detail":"US/EU approvals recorded (US 1982) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","detail":"US/EU approvals recorded (US 1992) but status is \"established\""},{"check":"text-vs-structured","severity":"medium","id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","detail":"text says randomised 368 but enrolled is 366"},{"check":"unsourced-numbers","severity":"medium","id":"aml-myelodysplasia-related","kind":"term","name":"AML with myelodysplasia-related gene mutations (AML-MR)","route":"/terms/aml-myelodysplasia-related/","detail":"1 number in the text (9.6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"b-all-cytogenetic-risk","kind":"term","name":"B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)","route":"/terms/b-all-cytogenetic-risk/","detail":"5 numbers in the text (0.01 percent, 95 percent, 2 percent, 15 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"abl1-kinase-domain-mutations","kind":"term","name":"BCR::ABL1 kinase domain mutations (T315I and others)","route":"/terms/abl1-kinase-domain-mutations/","detail":"2 numbers in the text (3 percent, 20 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"brca-reversion-mutations","kind":"term","name":"BRCA reversion mutations","route":"/terms/brca-reversion-mutations/","detail":"1 number in the text (40 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"btki-bcl2i-resistance-mutations","kind":"term","name":"BTK C481S, PLCG2 and BCL2 G101V resistance mutations","route":"/terms/btki-bcl2i-resistance-mutations/","detail":"1 number in the text (80 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/","detail":"2 numbers in the text (23 percent, 98 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"dipss-mipss70","kind":"term","name":"DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)","route":"/terms/dipss-mipss70/","detail":"1 number in the text (1 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/","detail":"2 numbers in the text (60 percent, 20 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"gist-risk-stratification","kind":"term","name":"GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)","route":"/terms/gist-risk-stratification/","detail":"3 numbers in the text (2 percent, 90 percent, 82 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"gracell-biotechnologies","kind":"company","name":"Gracell Biotechnologies","route":"/companies/gracell-biotechnologies/","detail":"1 number in the text (1.2 billion) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"gsk2256098","kind":"drug","name":"GSK2256098","route":"/drugs/gsk2256098/","detail":"2 numbers in the text (83 percent, 33 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","detail":"1 number in the text (30 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"histological-response-induction","kind":"term","name":"Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma)","route":"/terms/histological-response-induction/","detail":"7 numbers in the text (90 percent, 50 percent, 75 percent, 57 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","detail":"1 number in the text (80 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","detail":"5 numbers in the text (3 percent, 20 percent, 4 percent, 30 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","detail":"1 number in the text (10 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mipi","kind":"term","name":"MIPI (Mantle Cell Lymphoma International Prognostic Index)","route":"/terms/mipi/","detail":"4 numbers in the text (30 percent, 51 months, 29 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mlh1-promoter-methylation","kind":"term","name":"MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)","route":"/terms/mlh1-promoter-methylation/","detail":"2 numbers in the text (70 percent, 90 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mpn-driver-mutations","kind":"term","name":"MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden","route":"/terms/mpn-driver-mutations/","detail":"4 numbers in the text (95 percent, 3 percent, 60 percent, 50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"patidegib","kind":"drug","name":"Patidegib","route":"/drugs/patidegib/","detail":"1 number in the text (2 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ph-like-all","kind":"term","name":"Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia","route":"/terms/ph-like-all/","detail":"3 numbers in the text (15 percent, 30 percent, 20 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","detail":"1 number in the text (50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"2 numbers in the text (7 percent, 40 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/","detail":"1 number in the text (40 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","detail":"1 number in the text (15 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sokal-elts-scores","kind":"term","name":"Sokal and ELTS risk scores (chronic myeloid leukaemia)","route":"/terms/sokal-elts-scores/","detail":"4 numbers in the text (12 percent, 10 percent, 1 percent, 0.1 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/","detail":"4 numbers in the text (95 percent, 100 percent, 70 percent, 80 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/","detail":"1 number in the text (85 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"3 numbers in the text (90 percent, 70 percent, 5 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"wilms-risk-markers","kind":"term","name":"Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)","route":"/terms/wilms-risk-markers/","detail":"1 number in the text (30 percent) but no link, Wikipedia page or registry id"},{"check":"approvals-vs-regional","severity":"low","id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","detail":"regional-approvals.ts records EU approved 2008 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","detail":"regional-approvals.ts records EU approved 2005 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","detail":"regional-approvals.ts records EU approved 1986 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","detail":"regional-approvals.ts records EU approved 1979 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/","detail":"regional-approvals.ts records EU approved 2001 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","detail":"regional-approvals.ts records EU approved 1995 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","detail":"regional-approvals.ts records EU approved 1971 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","detail":"regional-approvals.ts records EU approved 2005 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","detail":"regional-approvals.ts records EU approved 2009 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","detail":"regional-approvals.ts records EU approved 1999 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","detail":"regional-approvals.ts records EU approved 1987 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","detail":"regional-approvals.ts records EU approved 1980 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","detail":"regional-approvals.ts records EU approved 2001 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","detail":"regional-approvals.ts records EU approved 2008 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","detail":"regional-approvals.ts records EU approved 2007 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","detail":"regional-approvals.ts records EU conditional 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","detail":"regional-approvals.ts records EU approved 1993 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","detail":"regional-approvals.ts records EU approved 2007 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","detail":"regional-approvals.ts records EU approved 2010 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","detail":"regional-approvals.ts records EU approved 1970 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","detail":"regional-approvals.ts records EU approved 1990 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","detail":"regional-approvals.ts records EU approved 1998 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rolapitant","kind":"drug","name":"Rolapitant","route":"/drugs/rolapitant/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","detail":"regional-approvals.ts records EU approved 1988 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","detail":"regional-approvals.ts records EU approved 1973 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","detail":"regional-approvals.ts records EU approved 2000 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","detail":"regional-approvals.ts records EU conditional 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approved-only-live-trials","severity":"low","id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","detail":"status \"approved\" but every linked trial is still running (Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","detail":"status \"approved\" but every linked trial is still running (SPEARHEAD-3 Pediatric Study: recruiting, Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/","detail":"status \"approved\" but every linked trial is still running (NCI-MATCH (EAY131): active, Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","detail":"status \"approved\" but every linked trial is still running (IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers: recruiting, Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca: recruiting, A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/","detail":"status \"approved\" but every linked trial is still running (Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tregzi","kind":"drug","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","detail":"status \"approved\" but every linked trial is still running (Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/","detail":"status \"approved\" but every linked trial is still running (A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","detail":"status \"approved\" but every linked trial is still running (Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma: recruiting, A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","detail":"status \"approved\" but every linked trial is still running (A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC: active, AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): recruiting, A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC: active, Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.: recruiting, Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: active, Study of Oral MRT-2359 With Apalutamide in Prostate Cancer: recruiting, A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer: active, An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC): active, A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy: active, An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS: active, A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer: active, A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","detail":"status \"approved\" but every linked trial is still running (Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","detail":"status \"approved\" but every linked trial is still running (Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP: recruiting, Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.: recruiting, A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: active, Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia: recruiting, Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia: active, A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): active, Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/","detail":"status \"approved\" but every linked trial is still running (To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/","detail":"status \"approved\" but every linked trial is still running (TAPUR (Targeted Agent and Profiling Utilization Registry): recruiting, A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","detail":"status \"approved\" but every linked trial is still running (A Study of Daratumumab: active, A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: active, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: recruiting, Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: active, A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: recruiting, A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W: active, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: active, A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe: recruiting, A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory: active, A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: recruiting, Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM): active, A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: recruiting, A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","detail":"status \"approved\" but every linked trial is still running (A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/","detail":"status \"approved\" but every linked trial is still running (A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of : recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/","detail":"status \"approved\" but every linked trial is still running (L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re: recruiting, Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML: recruiting, A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML: active, Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2: active, A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia: recruiting, Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL): recruiting, A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation: active, Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","detail":"status \"approved\" but every linked trial is still running (Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML: recruiting, A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML: active, A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","detail":"status \"approved\" but every linked trial is still running (A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia: active, Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2: active, Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML: recruiting, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","detail":"status \"approved\" but every linked trial is still running (A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","detail":"status \"approved\" but every linked trial is still running (A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o: recruiting, Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.: recruiting, Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer: recruiting, To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer: recruiting, A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2: active, DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy: recruiting, DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer: recruiting, To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2: recruiting, A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors: active, A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.: recruiting, Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2: active, A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors: recruiting, A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer: active, Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer: recruiting, A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","detail":"status \"approved\" but every linked trial is still running (ACTION: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/","detail":"status \"approved\" but every linked trial is still running (A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","detail":"status \"approved\" but every linked trial is still running (A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","detail":"status \"approved\" but every linked trial is still running (A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re: recruiting, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: recruiting, Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: active, A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez: active, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","detail":"status \"approved\" but every linked trial is still running (Beat AML Master Trial: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","detail":"status \"approved\" but every linked trial is still running (eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients: active, Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","detail":"status \"approved\" but every linked trial is still running (Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer: recruiting, Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors: recruiting, Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC: recruiting, ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors: recruiting, Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC: active, KN035 for dMMR/MSI-H Advanced Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/","detail":"status \"approved\" but every linked trial is still running (A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/","detail":"status \"approved\" but every linked trial is still running (A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With: active, Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients: recruiting, A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl: active, A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/","detail":"status \"approved\" but every linked trial is still running (A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma: active, A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo: active, Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma: active, Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC): recruiting, A Phase 1/2 Trial of ADI-270 in ccRCC: active, DALY II USA/ MB-CART2019.1 for DLBCL: recruiting, Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L: active, Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma: recruiting, Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer: recruiting, Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma: recruiting, Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer: active, A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel: recruiting, EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC: recruiting, IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers: recruiting, Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma: recruiting, A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL): active, Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: active, Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT): active, Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma: recruiting, Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients: recruiting, Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC: recruiting, Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma: recruiting, Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer: recruiting, Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma: recruiting, Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2): active, Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors: recruiting, Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma: recruiting, Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors: recruiting, A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008): active, A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML: active, Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma: recruiting, A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma: recruiting, Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS: recruiting, Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL: recruiting, A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation: active, Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood: active, Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","detail":"status \"approved\" but every linked trial is still running (PSMA PET Combined With MRI for the Detection of PCa: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","detail":"status \"approved\" but every linked trial is still running (D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar: recruiting, Study to Evaluate D-1553 in Subjects With Solid Tumors: active, Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","detail":"status \"approved\" but every linked trial is still running (Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer: recruiting, Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): active, Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/","detail":"status \"approved\" but every linked trial is still running (JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation: active, Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation: recruiting, A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib: recruiting, A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1: recruiting, A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China: active, A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.: recruiting, JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/","detail":"status \"approved\" but every linked trial is still running (A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N: recruiting, Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors: recruiting, Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/","detail":"status \"approved\" but every linked trial is still running (A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19): recruiting, Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","detail":"status \"approved\" but every linked trial is still running (Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females: recruiting, A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","detail":"status \"approved\" but every linked trial is still running (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly: active, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants : active, A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma: recruiting, A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe: recruiting, A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","detail":"status \"approved\" but every linked trial is still running (Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"idarubicin","kind":"drug","name":"Idarubicin","route":"/drugs/idarubicin/","detail":"status \"approved\" but every linked trial is still running (A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"idelalisib","kind":"drug","name":"Idelalisib","route":"/drugs/idelalisib/","detail":"status \"approved\" but every linked trial is still running (A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors: recruiting, A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/","detail":"status \"approved\" but every linked trial is still running (A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric): recruiting, Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia: recruiting, Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/","detail":"status \"approved\" but every linked trial is still running (Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/","detail":"status \"approved\" but every linked trial is still running (ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC: active, ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"megestrol","kind":"drug","name":"Megestrol acetate","route":"/drugs/megestrol/","detail":"status \"approved\" but every linked trial is still running (A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): recruiting, Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/","detail":"status \"approved\" but every linked trial is still running (A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC: recruiting, IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"mitoxantrone","kind":"drug","name":"Mitoxantrone","route":"/drugs/mitoxantrone/","detail":"status \"approved\" but every linked trial is still running (A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML: active, Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL: active, A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","detail":"status \"approved\" but every linked trial is still running (Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","detail":"status \"approved\" but every linked trial is still running (Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer: recruiting, A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/","detail":"status \"approved\" but every linked trial is still running (Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"nilotinib","kind":"drug","name":"Nilotinib","route":"/drugs/nilotinib/","detail":"status \"approved\" but every linked trial is still running (A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: active, A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","detail":"status \"approved\" but every linked trial is still running (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo: active, A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant: recruiting, A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell : active, A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa: recruiting, A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy : recruiting, A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","detail":"status \"approved\" but every linked trial is still running (Study of Olutasidenib and Temozolomide in HGG: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/","detail":"status \"approved\" but every linked trial is still running (Study of Olverembatinib (HQP1351) in Patients With CML-CP: recruiting, A Study of Olverembatinib in SDH-deficient GIST.: recruiting, A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1): recruiting, Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/","detail":"status \"approved\" but every linked trial is still running (Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","detail":"status \"approved\" but every linked trial is still running (A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL: recruiting, Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma: recruiting, A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/","detail":"status \"approved\" but every linked trial is still running (Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/","detail":"status \"approved\" but every linked trial is still running (Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/","detail":"status \"approved\" but every linked trial is still running (CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","detail":"status \"approved\" but every linked trial is still running (Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.: recruiting, A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: active, Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C: recruiting, Clinical Studies for the Treatment of Advanced Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","detail":"status \"approved\" but every linked trial is still running (Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN: active, A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML): recruiting, IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/","detail":"status \"approved\" but every linked trial is still running (A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re: recruiting, A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03): recruiting, All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo: active, A Study of Daratumumab: active, A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: active, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: recruiting, A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) : active, A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re: recruiting, A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma: active, Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: active, A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments: recruiting, A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: recruiting, A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez: active, A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi: active, Selinexor and Backbone Treatments of Multiple Myeloma Patients: recruiting, Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: recruiting, A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma : recruiting, A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma: recruiting, A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: recruiting, Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma: recruiting, AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma: recruiting, A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme: recruiting, A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: recruiting, Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi: active, A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/","detail":"status \"approved\" but every linked trial is still running (To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/","detail":"status \"approved\" but every linked trial is still running (A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer: active, A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin: recruiting, MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II): recruiting, Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: recruiting, OH2 Injection in Combination With HX008 for Melanoma.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/","detail":"status \"approved\" but every linked trial is still running (Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","detail":"status \"approved\" but every linked trial is still running (A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","detail":"status \"approved\" but every linked trial is still running (A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations: recruiting, A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements: recruiting, A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","detail":"status \"approved\" but every linked trial is still running (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: active, Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","route":"/drugs/rezvilutamide/","detail":"status \"approved\" but every linked trial is still running (A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer: recruiting, A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: recruiting, A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","detail":"status \"approved\" but every linked trial is still running (A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan: active, Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A: active, A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: active, A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc: recruiting, A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021): recruiting, A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl: recruiting, A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015): active, Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P: recruiting, A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With: active, Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287: recruiting, A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P: active, A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm: recruiting, A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan: recruiting, Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005): active, A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients: active, Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With: active, Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01): active, SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.: recruiting, A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-: active, Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto: recruiting, A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A): recruiting, A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04): active, Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012): recruiting, Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06): recruiting, KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J): recruiting, A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010): recruiting, A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031): recruiting, A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032): recruiting, A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F): recruiting, A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B): recruiting, A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027): recruiting, Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma: recruiting, Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06): recruiting, Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06): recruiting, Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01): recruiting, A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","detail":"status \"approved\" but every linked trial is still running (Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","detail":"status \"approved\" but every linked trial is still running (CELESTIAL-TNCLL: active, A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac: recruiting, A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.: recruiting, Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma: active, A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: recruiting, A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL): recruiting, A Study of BGB-11417 in Participants With Myeloid Malignancies: recruiting, A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: recruiting, Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: active, A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies: recruiting, A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia: active, A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","detail":"status \"approved\" but every linked trial is still running (A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins: recruiting, A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28): active, Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6): active, Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1): active, Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8): recruiting, A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21): recruiting, DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","detail":"status \"approved\" but every linked trial is still running (A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu: recruiting, A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","detail":"status \"approved\" but every linked trial is still running (A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/","detail":"status \"approved\" but every linked trial is still running (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV): recruiting, A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients: recruiting, Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/","detail":"status \"approved\" but every linked trial is still running (Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"therascreen-cdx","kind":"drug","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","route":"/drugs/therascreen-cdx/","detail":"status \"approved\" but every linked trial is still running (EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/","detail":"status \"approved\" but every linked trial is still running (A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps: recruiting, A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi: active, Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent: recruiting, A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma: recruiting, A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi: active, A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti: active, A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies: active, A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat: active, A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma: active, A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li: active, A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma: recruiting, An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: active, A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","detail":"status \"approved\" but every linked trial is still running (Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","detail":"status \"approved\" but every linked trial is still running (A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients: recruiting, A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: recruiting, Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL): recruiting, Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/","detail":"status \"approved\" but every linked trial is still running (Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma: recruiting, Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/","detail":"status \"approved\" but every linked trial is still running (A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).: active, A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2): recruiting, Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI: recruiting, APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors: recruiting, Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.: recruiting, A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"vinflunine","kind":"drug","name":"Vinflunine","route":"/drugs/vinflunine/","detail":"status \"approved\" but every linked trial is still running (A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","detail":"status \"approved\" but every linked trial is still running (A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","detail":"status \"approved\" but every linked trial is still running (A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/","detail":"status \"approved\" but every linked trial is still running (A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic: recruiting, Study of Novel Treatment Combinations in Patients With Lung Cancer: active, Study With Various Immunotherapy Treatments in Participants With Lung Cancer: active, Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer: active, Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst: active, A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o: recruiting, Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors: recruiting, Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer: recruiting, Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread: active, A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"future-year-in-text","severity":"low","id":"nct04910685","kind":"trial","name":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","route":"/trials/nct04910685/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","route":"/trials/nct05907954/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03731260","kind":"trial","name":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo ","route":"/trials/nct03731260/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07314723","kind":"trial","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","route":"/trials/nct07314723/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06592326","kind":"trial","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06592326/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07563738","kind":"trial","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","route":"/trials/nct07563738/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","route":"/trials/nct07332000/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06508983","kind":"trial","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","route":"/trials/nct06508983/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07454720","kind":"trial","name":"A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07454720/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06922383","kind":"trial","name":"A Clinical Study of Arfolitixorin in Patients With mCRC","route":"/trials/nct06922383/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07489495","kind":"trial","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","route":"/trials/nct07489495/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227402","kind":"trial","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","route":"/trials/nct07227402/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07190248","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","route":"/trials/nct07190248/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07209111","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","route":"/trials/nct07209111/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06997497","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","route":"/trials/nct06997497/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227597","kind":"trial","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","route":"/trials/nct07227597/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446153","kind":"trial","name":"A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","route":"/trials/nct07446153/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06925737","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","route":"/trials/nct06925737/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06863272","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","route":"/trials/nct06863272/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06833073","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","route":"/trials/nct06833073/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06961006","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","route":"/trials/nct06961006/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06305767","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","route":"/trials/nct06305767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06208410","kind":"trial","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","route":"/trials/nct06208410/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05579132","kind":"trial","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","route":"/trials/nct05579132/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07519772","kind":"trial","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","route":"/trials/nct07519772/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07286149","kind":"trial","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","route":"/trials/nct07286149/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06428409","kind":"trial","name":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","route":"/trials/nct06428409/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07222488","kind":"trial","name":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","route":"/trials/nct07222488/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07043725","kind":"trial","name":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct07043725/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07060807","kind":"trial","name":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","route":"/trials/nct07060807/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06843447","kind":"trial","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","route":"/trials/nct06843447/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07216703","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","route":"/trials/nct07216703/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06637423","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","route":"/trials/nct06637423/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","route":"/trials/nct06966700/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06643754","kind":"trial","name":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct06643754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407283","kind":"trial","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","route":"/trials/nct07407283/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07676162","kind":"trial","name":"A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal","route":"/trials/nct07676162/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06778031","kind":"trial","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct06778031/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","route":"/trials/nct07597629/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06340568","kind":"trial","name":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","route":"/trials/nct06340568/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07003074","kind":"trial","name":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07003074/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06459973","kind":"trial","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","route":"/trials/nct06459973/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06890884","kind":"trial","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","route":"/trials/nct06890884/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06962267","kind":"trial","name":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","route":"/trials/nct06962267/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07222969","kind":"trial","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","route":"/trials/nct07222969/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06827236","kind":"trial","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","route":"/trials/nct06827236/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06892548","kind":"trial","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","route":"/trials/nct06892548/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05755113","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","route":"/trials/nct05755113/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07079631","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3","route":"/trials/nct07079631/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070232","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","route":"/trials/nct07070232/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","route":"/trials/nct04183166/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","route":"/trials/nct05890742/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04534205","kind":"trial","name":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","route":"/trials/nct04534205/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07513376","kind":"trial","name":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ","route":"/trials/nct07513376/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554339","kind":"trial","name":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","route":"/trials/nct07554339/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07032077","kind":"trial","name":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","route":"/trials/nct07032077/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405151","kind":"trial","name":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","route":"/trials/nct07405151/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07111546","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","route":"/trials/nct07111546/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07634471","kind":"trial","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","route":"/trials/nct07634471/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","route":"/trials/nct07570173/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07318558","kind":"trial","name":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","route":"/trials/nct07318558/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07419295","kind":"trial","name":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","route":"/trials/nct07419295/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07111832","kind":"trial","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","route":"/trials/nct07111832/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06561607","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct06561607/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","route":"/trials/nct07367529/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07255404","kind":"trial","name":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N","route":"/trials/nct07255404/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07297212","kind":"trial","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","route":"/trials/nct07297212/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07049055","kind":"trial","name":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","route":"/trials/nct07049055/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06581419","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06581419/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06292208","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","route":"/trials/nct06292208/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07582432","kind":"trial","name":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","route":"/trials/nct07582432/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07111520","kind":"trial","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","route":"/trials/nct07111520/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07186842","kind":"trial","name":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","route":"/trials/nct07186842/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04529772","kind":"trial","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","route":"/trials/nct04529772/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03075696","kind":"trial","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","route":"/trials/nct03075696/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07692204","kind":"trial","name":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct07692204/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07231068","kind":"trial","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","route":"/trials/nct07231068/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07255664","kind":"trial","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","route":"/trials/nct07255664/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06413680","kind":"trial","name":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav","route":"/trials/nct06413680/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07354711","kind":"trial","name":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","route":"/trials/nct07354711/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07439094","kind":"trial","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","route":"/trials/nct07439094/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06921837","kind":"trial","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","route":"/trials/nct06921837/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07220616","kind":"trial","name":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","route":"/trials/nct07220616/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05908643","kind":"trial","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","route":"/trials/nct05908643/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct05584670/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07147348","kind":"trial","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","route":"/trials/nct07147348/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06363994","kind":"trial","name":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","route":"/trials/nct06363994/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07459751","kind":"trial","name":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07459751/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868277","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06868277/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06627647","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","route":"/trials/nct06627647/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06692738","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","route":"/trials/nct06692738/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03591510","kind":"trial","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","route":"/trials/nct03591510/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05984277","kind":"trial","name":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung","route":"/trials/nct05984277/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05120349","kind":"trial","name":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","route":"/trials/nct05120349/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07105215","kind":"trial","name":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","route":"/trials/nct07105215/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229638","kind":"trial","name":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","route":"/trials/nct07229638/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05999994","kind":"trial","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","route":"/trials/nct05999994/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06630234","kind":"trial","name":"A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","route":"/trials/nct06630234/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07681596","kind":"trial","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07681596/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04256317","kind":"trial","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","route":"/trials/nct04256317/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"g-hope-002","kind":"trial","name":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","route":"/trials/g-hope-002/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07579234/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04669171","kind":"trial","name":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","route":"/trials/nct04669171/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07636785","kind":"trial","name":"A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","route":"/trials/nct07636785/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07157033","kind":"trial","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","route":"/trials/nct07157033/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05593094","kind":"trial","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","route":"/trials/nct05593094/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06163430","kind":"trial","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","route":"/trials/nct06163430/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","route":"/trials/nct06956690/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06427941","kind":"trial","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","route":"/trials/nct06427941/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","route":"/trials/nct06384807/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05886920","kind":"trial","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","route":"/trials/nct05886920/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04988555","kind":"trial","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","route":"/trials/nct04988555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07328217","kind":"trial","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","route":"/trials/nct07328217/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07629726","kind":"trial","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","route":"/trials/nct07629726/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06480240","kind":"trial","name":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","route":"/trials/nct06480240/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","route":"/trials/nct07491497/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07020221","kind":"trial","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","route":"/trials/nct07020221/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06265727","kind":"trial","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","route":"/trials/nct06265727/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06725758","kind":"trial","name":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","route":"/trials/nct06725758/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05150691","kind":"trial","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05150691/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05914116","kind":"trial","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05914116/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07160725","kind":"trial","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","route":"/trials/nct07160725/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06785636","kind":"trial","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","route":"/trials/nct06785636/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07766018","kind":"trial","name":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer","route":"/trials/nct07766018/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06668103","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","route":"/trials/nct06668103/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07164170","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","route":"/trials/nct07164170/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07623616","kind":"trial","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","route":"/trials/nct07623616/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07102381","kind":"trial","name":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","route":"/trials/nct07102381/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","route":"/trials/nct05548296/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","route":"/trials/nct07562581/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07743112","kind":"trial","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","route":"/trials/nct07743112/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07659795","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","route":"/trials/nct07659795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct07659782/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07644559","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","route":"/trials/nct07644559/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005154","kind":"trial","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","route":"/trials/nct07005154/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06985147","kind":"trial","name":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","route":"/trials/nct06985147/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06745323","kind":"trial","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","route":"/trials/nct06745323/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06710288","kind":"trial","name":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P","route":"/trials/nct06710288/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04485949","kind":"trial","name":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","route":"/trials/nct04485949/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06007690","kind":"trial","name":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","route":"/trials/nct06007690/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06774131","kind":"trial","name":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","route":"/trials/nct06774131/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","route":"/trials/nct03459534/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06601335","kind":"trial","name":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","route":"/trials/nct06601335/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07174908","kind":"trial","name":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07174908/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07182682","kind":"trial","name":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins","route":"/trials/nct07182682/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06496178","kind":"trial","name":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P","route":"/trials/nct06496178/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05862272","kind":"trial","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","route":"/trials/nct05862272/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","route":"/trials/nct06971523/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07136142","kind":"trial","name":"A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07136142/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229612","kind":"trial","name":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07229612/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","route":"/trials/nct07253116/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04685226","kind":"trial","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","route":"/trials/nct04685226/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07069062","kind":"trial","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","route":"/trials/nct07069062/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06922357","kind":"trial","name":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06922357/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07417189","kind":"trial","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","route":"/trials/nct07417189/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06245330","kind":"trial","name":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","route":"/trials/nct06245330/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07123454","kind":"trial","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","route":"/trials/nct07123454/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06741644","kind":"trial","name":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","route":"/trials/nct06741644/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05415072","kind":"trial","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","route":"/trials/nct05415072/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07083323","kind":"trial","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","route":"/trials/nct07083323/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06712680","kind":"trial","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","route":"/trials/nct06712680/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05615974","kind":"trial","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct05615974/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06682780","kind":"trial","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","route":"/trials/nct06682780/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07075328","kind":"trial","name":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","route":"/trials/nct07075328/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953323","kind":"trial","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","route":"/trials/nct06953323/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06084884","kind":"trial","name":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","route":"/trials/nct06084884/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05315167","kind":"trial","name":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","route":"/trials/nct05315167/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","route":"/trials/nct07362940/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","route":"/trials/nct07811037/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06797986","kind":"trial","name":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","route":"/trials/nct06797986/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07392736","kind":"trial","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","route":"/trials/nct07392736/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07243340","kind":"trial","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","route":"/trials/nct07243340/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","route":"/trials/nct07777211/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07228247","kind":"trial","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","route":"/trials/nct07228247/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","route":"/trials/nct07744763/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05133882","kind":"trial","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","route":"/trials/nct05133882/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06474455","kind":"trial","name":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct06474455/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07466160","kind":"trial","name":"A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors","route":"/trials/nct07466160/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05910827","kind":"trial","name":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","route":"/trials/nct05910827/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07002177","kind":"trial","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","route":"/trials/nct07002177/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07283367","kind":"trial","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","route":"/trials/nct07283367/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07547553","kind":"trial","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","route":"/trials/nct07547553/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07361003","kind":"trial","name":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07361003/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07052253","kind":"trial","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","route":"/trials/nct07052253/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07241767","kind":"trial","name":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","route":"/trials/nct07241767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07331155","kind":"trial","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","route":"/trials/nct07331155/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07308106","kind":"trial","name":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","route":"/trials/nct07308106/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07253142","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","route":"/trials/nct07253142/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06907615","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06907615/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07390383","kind":"trial","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","route":"/trials/nct07390383/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07489716","kind":"trial","name":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","route":"/trials/nct07489716/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405801","kind":"trial","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","route":"/trials/nct07405801/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07591090","kind":"trial","name":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","route":"/trials/nct07591090/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07669779","kind":"trial","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07669779/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07474727","kind":"trial","name":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","route":"/trials/nct07474727/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06832202","kind":"trial","name":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","route":"/trials/nct06832202/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07071714","kind":"trial","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","route":"/trials/nct07071714/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07230405","kind":"trial","name":"A Phase II Study of SKB571 in Patients With Lung Cancer","route":"/trials/nct07230405/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06241846","kind":"trial","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","route":"/trials/nct06241846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07444437","kind":"trial","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","route":"/trials/nct07444437/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07310784","kind":"trial","name":"A Phase II Trial of LM103 in Advanced Melanoma","route":"/trials/nct07310784/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07462143","kind":"trial","name":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07462143/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07761429","kind":"trial","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","route":"/trials/nct07761429/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06844357","kind":"trial","name":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","route":"/trials/nct06844357/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06361888","kind":"trial","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","route":"/trials/nct06361888/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07521852","kind":"trial","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","route":"/trials/nct07521852/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07168200","kind":"trial","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","route":"/trials/nct07168200/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07023315","kind":"trial","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","route":"/trials/nct07023315/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06532006","kind":"trial","name":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","route":"/trials/nct06532006/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07011056","kind":"trial","name":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","route":"/trials/nct07011056/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05262010","kind":"trial","name":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","route":"/trials/nct05262010/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07103668","kind":"trial","name":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","route":"/trials/nct07103668/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564324","kind":"trial","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","route":"/trials/nct06564324/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06383767","kind":"trial","name":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06383767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06732323","kind":"trial","name":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06732323/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07409428","kind":"trial","name":"A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct07409428/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953999","kind":"trial","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","route":"/trials/nct06953999/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","route":"/trials/nct07533123/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07441460","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","route":"/trials/nct07441460/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764875","kind":"trial","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","route":"/trials/nct06764875/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229625","kind":"trial","name":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07229625/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"taishan-301","kind":"trial","name":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)","route":"/trials/taishan-301/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06612151","kind":"trial","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","route":"/trials/nct06612151/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06465914","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","route":"/trials/nct06465914/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06908304","kind":"trial","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","route":"/trials/nct06908304/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07349069","kind":"trial","name":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","route":"/trials/nct07349069/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","route":"/trials/nct05888493/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07365995","kind":"trial","name":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07365995/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06126640","kind":"trial","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","route":"/trials/nct06126640/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07647328","kind":"trial","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","route":"/trials/nct07647328/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764186","kind":"trial","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","route":"/trials/nct06764186/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","route":"/trials/nct06247605/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764940","kind":"trial","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","route":"/trials/nct06764940/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06389292","kind":"trial","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","route":"/trials/nct06389292/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06996782/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06140524","kind":"trial","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","route":"/trials/nct06140524/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05955508","kind":"trial","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","route":"/trials/nct05955508/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","route":"/trials/nct06717126/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07207070","kind":"trial","name":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct07207070/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06992258","kind":"trial","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","route":"/trials/nct06992258/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06581406","kind":"trial","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","route":"/trials/nct06581406/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07172919","kind":"trial","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","route":"/trials/nct07172919/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05862285","kind":"trial","name":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","route":"/trials/nct05862285/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07569042","kind":"trial","name":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct07569042/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05643742","kind":"trial","name":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct05643742/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","route":"/trials/nct06150885/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07365319","kind":"trial","name":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer","route":"/trials/nct07365319/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05329766","kind":"trial","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","route":"/trials/nct05329766/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03930953","kind":"trial","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","route":"/trials/nct03930953/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct00781612","kind":"trial","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","route":"/trials/nct00781612/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07415031","kind":"trial","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","route":"/trials/nct07415031/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06614192","kind":"trial","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06228326","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","route":"/trials/nct06228326/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05970497","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05970497/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06413706","kind":"trial","name":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","route":"/trials/nct06413706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07391657","kind":"trial","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","route":"/trials/nct07391657/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07502300","kind":"trial","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","route":"/trials/nct07502300/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07640789","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s","route":"/trials/nct07640789/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06857175","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","route":"/trials/nct06857175/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07648914","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)","route":"/trials/nct07648914/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06994195","kind":"trial","name":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK","route":"/trials/nct06994195/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07582315","kind":"trial","name":"A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)","route":"/trials/nct07582315/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07518147","kind":"trial","name":"A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment","route":"/trials/nct07518147/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07678957","kind":"trial","name":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct07678957/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04576156","kind":"trial","name":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","route":"/trials/nct04576156/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258511","kind":"trial","name":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07258511/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07518186/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mountaintap-30","kind":"trial","name":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","route":"/trials/mountaintap-30/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07138209","kind":"trial","name":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07138209/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07217301","kind":"trial","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct07217301/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05455320","kind":"trial","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","route":"/trials/nct05455320/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005128","kind":"trial","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","route":"/trials/nct07005128/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06435429","kind":"trial","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o","route":"/trials/nct06435429/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07541079","kind":"trial","name":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","route":"/trials/nct07541079/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06096779","kind":"trial","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","route":"/trials/nct06096779/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07807163","kind":"trial","name":"A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC","route":"/trials/nct07807163/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06244771","kind":"trial","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","route":"/trials/nct06244771/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06970639","kind":"trial","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","route":"/trials/nct06970639/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07124117","kind":"trial","name":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","route":"/trials/nct07124117/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05920356","kind":"trial","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","route":"/trials/nct05920356/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04873362","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","route":"/trials/nct04873362/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04931342","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","route":"/trials/nct04931342/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05535244","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi","route":"/trials/nct05535244/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06793215","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","route":"/trials/nct06793215/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06790693","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","route":"/trials/nct06790693/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04524871","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","route":"/trials/nct04524871/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05170204","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","route":"/trials/nct05170204/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04802759","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","route":"/trials/nct04802759/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03424005","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","route":"/trials/nct03424005/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06588478","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct06588478/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07602777","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","route":"/trials/nct07602777/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","route":"/trials/nct07589634/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","route":"/trials/nct05583617/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05789082","kind":"trial","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","route":"/trials/nct05789082/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05207670","kind":"trial","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","route":"/trials/nct05207670/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04774718","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","route":"/trials/nct04774718/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04246086","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","route":"/trials/nct04246086/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07567846","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","route":"/trials/nct07567846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","route":"/trials/nct06314373/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02960022","kind":"trial","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","route":"/trials/nct02960022/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07541430","kind":"trial","name":"A Study in Adults With Desmoid Tumors","route":"/trials/nct07541430/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07280377","kind":"trial","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","route":"/trials/nct07280377/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04471727","kind":"trial","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","route":"/trials/nct04471727/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03768063","kind":"trial","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","route":"/trials/nct03768063/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06378593","kind":"trial","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","route":"/trials/nct06378593/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05526755","kind":"trial","name":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","route":"/trials/nct05526755/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05141721","kind":"trial","name":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05141721/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05592626","kind":"trial","name":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","route":"/trials/nct05592626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07299825/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07244705","kind":"trial","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","route":"/trials/nct07244705/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05951959","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","route":"/trials/nct05951959/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05057494","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05057494/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06875310","kind":"trial","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","route":"/trials/nct06875310/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06307431","kind":"trial","name":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","route":"/trials/nct06307431/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05142423","kind":"trial","name":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","route":"/trials/nct05142423/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07010263","kind":"trial","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","route":"/trials/nct07010263/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06938321","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06938321/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07114315","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07114315/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07623356/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct07465757/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06369285","kind":"trial","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct06369285/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06095505/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06385080","kind":"trial","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","route":"/trials/nct06385080/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05488314","kind":"trial","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05488314/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06750094","kind":"trial","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","route":"/trials/nct06750094/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06662786","kind":"trial","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","route":"/trials/nct06662786/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227025","kind":"trial","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07227025/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07276399","kind":"trial","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","route":"/trials/nct07276399/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06667076","kind":"trial","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667076/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05498428","kind":"trial","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct05498428/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05379595","kind":"trial","name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct05379595/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","route":"/trials/nct06777316/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04657068","kind":"trial","name":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","route":"/trials/nct04657068/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05067140","kind":"trial","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","route":"/trials/nct05067140/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06699212","kind":"trial","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","route":"/trials/nct06699212/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07673887","kind":"trial","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","route":"/trials/nct07673887/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07730021","kind":"trial","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","route":"/trials/nct07730021/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07488676","kind":"trial","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","route":"/trials/nct07488676/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06072781","kind":"trial","name":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","route":"/trials/nct06072781/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","route":"/trials/nct06130553/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07544056","kind":"trial","name":"A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07544056/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06679101","kind":"trial","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","route":"/trials/nct06679101/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04771130","kind":"trial","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","route":"/trials/nct04771130/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06970743","kind":"trial","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","route":"/trials/nct06970743/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06706076","kind":"trial","name":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","route":"/trials/nct06706076/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","route":"/trials/nct04219254/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03526835","kind":"trial","name":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","route":"/trials/nct03526835/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07054567","kind":"trial","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","route":"/trials/nct07054567/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05880706","kind":"trial","name":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ","route":"/trials/nct05880706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07642024","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU","route":"/trials/nct07642024/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06838273","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas","route":"/trials/nct06838273/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554456","kind":"trial","name":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","route":"/trials/nct07554456/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06787664","kind":"trial","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","route":"/trials/nct06787664/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06475300","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ","route":"/trials/nct06475300/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06437522","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06437522/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06978114","kind":"trial","name":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06978114/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06962787","kind":"trial","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","route":"/trials/nct06962787/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07518173","kind":"trial","name":"A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M","route":"/trials/nct07518173/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07264816","kind":"trial","name":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS","route":"/trials/nct07264816/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06957886","kind":"trial","name":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","route":"/trials/nct06957886/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07606599","kind":"trial","name":"A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure","route":"/trials/nct07606599/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06830889","kind":"trial","name":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","route":"/trials/nct06830889/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07178795","kind":"trial","name":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","route":"/trials/nct07178795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06891833","kind":"trial","name":"A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea","route":"/trials/nct06891833/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07255872","kind":"trial","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","route":"/trials/nct07255872/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07654400","kind":"trial","name":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07654400/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06852222","kind":"trial","name":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","route":"/trials/nct06852222/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04895709","kind":"trial","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct04895709/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06697197","kind":"trial","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct06697197/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07492680","kind":"trial","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","route":"/trials/nct07492680/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05608044","kind":"trial","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","route":"/trials/nct05608044/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02972840","kind":"trial","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","route":"/trials/nct02972840/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06345729","kind":"trial","name":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","route":"/trials/nct06345729/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05774951","kind":"trial","name":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","route":"/trials/nct05774951/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06915246","kind":"trial","name":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","route":"/trials/nct06915246/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06465329","kind":"trial","name":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce","route":"/trials/nct06465329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06550895","kind":"trial","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","route":"/trials/nct06550895/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05263960","kind":"trial","name":"A Study of CM350 in Patients With Advanced Solid Tumors","route":"/trials/nct05263960/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05759728","kind":"trial","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","route":"/trials/nct05759728/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05908734","kind":"trial","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05908734/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03314181","kind":"trial","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","route":"/trials/nct03314181/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06246643","kind":"trial","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","route":"/trials/nct06246643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070219","kind":"trial","name":"A Study of CTD402 in T-ALL/LBL Patients","route":"/trials/nct07070219/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"companion-002","kind":"trial","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","route":"/trials/companion-002/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05732103","kind":"trial","name":"A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","route":"/trials/nct05732103/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05410145","kind":"trial","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","route":"/trials/nct05410145/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05438043","kind":"trial","name":"A Study of Daratumumab","route":"/trials/nct05438043/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07205822","kind":"trial","name":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","route":"/trials/nct07205822/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05785741","kind":"trial","name":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05785741/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07263594","kind":"trial","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","route":"/trials/nct07263594/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06873555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05765812","kind":"trial","name":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","route":"/trials/nct05765812/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06577025","kind":"trial","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","route":"/trials/nct06577025/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07315750","kind":"trial","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct07315750/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06966453","kind":"trial","name":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","route":"/trials/nct06966453/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06157892","kind":"trial","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","route":"/trials/nct06157892/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06751329","kind":"trial","name":"A Study of DM002 in Patients With Advanced Solid Tumors","route":"/trials/nct06751329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06515990","kind":"trial","name":"A Study of DM005 in Patients With Advanced Solid Tumors","route":"/trials/nct06515990/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07108270","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","route":"/trials/nct07108270/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06640049","kind":"trial","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","route":"/trials/nct06640049/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06256588","kind":"trial","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06256588/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06522737","kind":"trial","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","route":"/trials/nct06522737/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154264","kind":"trial","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","route":"/trials/nct07154264/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tai-shan6","kind":"trial","name":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","route":"/trials/tai-shan6/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04008797","kind":"trial","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","route":"/trials/nct04008797/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04078295","kind":"trial","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","route":"/trials/nct04078295/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05845814","kind":"trial","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","route":"/trials/nct05845814/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06483334","kind":"trial","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","route":"/trials/nct06483334/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06492616","kind":"trial","name":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","route":"/trials/nct06492616/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","route":"/trials/nct07271667/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","route":"/trials/nct05377996/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","route":"/trials/nct05443126/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03980054","kind":"trial","name":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","route":"/trials/nct03980054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06782555","kind":"trial","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","route":"/trials/nct06782555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07312188/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06842498","kind":"trial","name":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06842498/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06064877","kind":"trial","name":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06064877/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06119581","kind":"trial","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","route":"/trials/nct06119581/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06980480","kind":"trial","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","route":"/trials/nct06980480/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07259590","kind":"trial","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct07259590/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500676","kind":"trial","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","route":"/trials/nct06500676/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07172802","kind":"trial","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07172802/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05520567","kind":"trial","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","route":"/trials/nct05520567/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07452198","kind":"trial","name":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07452198/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07099898","kind":"trial","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","route":"/trials/nct07099898/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07124936","kind":"trial","name":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","route":"/trials/nct07124936/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07805551","kind":"trial","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07805551/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06172478","kind":"trial","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06172478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","route":"/trials/nct07678684/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07140393","kind":"trial","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","route":"/trials/nct07140393/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06520488","kind":"trial","name":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","route":"/trials/nct06520488/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07389733","kind":"trial","name":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","route":"/trials/nct07389733/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06147570","kind":"trial","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","route":"/trials/nct06147570/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07468851","kind":"trial","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","route":"/trials/nct07468851/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06081920","kind":"trial","name":"A Study of IBI363 in Subjects With Advanced Melanoma","route":"/trials/nct06081920/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07218926","kind":"trial","name":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","route":"/trials/nct07218926/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07630974","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","route":"/trials/nct07630974/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06644781","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","route":"/trials/nct06644781/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","route":"/trials/nct06365840/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287098","kind":"trial","name":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","route":"/trials/nct07287098/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05514054","kind":"trial","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","route":"/trials/nct05514054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07023627","kind":"trial","name":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07023627/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05957367","kind":"trial","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","route":"/trials/nct05957367/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06077760","kind":"trial","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","route":"/trials/nct06077760/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221474","kind":"trial","name":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","route":"/trials/nct07221474/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07122414","kind":"trial","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","route":"/trials/nct07122414/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07424287","kind":"trial","name":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","route":"/trials/nct07424287/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780085","kind":"trial","name":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","route":"/trials/nct06780085/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06827613","kind":"trial","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","route":"/trials/nct06827613/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07815665","kind":"trial","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","route":"/trials/nct07815665/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05276726","kind":"trial","name":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","route":"/trials/nct05276726/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868849","kind":"trial","name":"A Study of JMT203 in Patients With Cancer Cachexia","route":"/trials/nct06868849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04133636","kind":"trial","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","route":"/trials/nct04133636/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05421663","kind":"trial","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05421663/","detail":"mentions 2041 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06667908","kind":"trial","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667908/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564272","kind":"trial","name":"A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","route":"/trials/nct06564272/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07609823","kind":"trial","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct07609823/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07042802","kind":"trial","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","route":"/trials/nct07042802/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06481592","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","route":"/trials/nct06481592/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288203","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","route":"/trials/nct07288203/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07359820","kind":"trial","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","route":"/trials/nct07359820/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868199","kind":"trial","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","route":"/trials/nct06868199/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07669415","kind":"trial","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","route":"/trials/nct07669415/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07112222","kind":"trial","name":"A Study of LM-350 in Subjects With Advanced Solid Tumours","route":"/trials/nct07112222/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","route":"/trials/nct06730347/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07459634","kind":"trial","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","route":"/trials/nct07459634/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06378177","kind":"trial","name":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","route":"/trials/nct06378177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06952803","kind":"trial","name":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","route":"/trials/nct06952803/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07326488","kind":"trial","name":"A Study of MHB009C in Patients With Advanced Solid Tumors","route":"/trials/nct07326488/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229599","kind":"trial","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","route":"/trials/nct07229599/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07130383","kind":"trial","name":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","route":"/trials/nct07130383/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06345482","kind":"trial","name":"A Study of MHB039A for Advanced Solid Tumor","route":"/trials/nct06345482/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192107","kind":"trial","name":"A Study of MHB042C in Patients With Advanced Solid Tumors","route":"/trials/nct07192107/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06985355","kind":"trial","name":"A Study of MHB046C Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06985355/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192120","kind":"trial","name":"A Study of MHB048C in Patients With Advanced Solid Tumors","route":"/trials/nct07192120/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07126665","kind":"trial","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07126665/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06954246","kind":"trial","name":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06954246/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06979596","kind":"trial","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","route":"/trials/nct06979596/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06796907","kind":"trial","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","route":"/trials/nct06796907/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07701486","kind":"trial","name":"A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer","route":"/trials/nct07701486/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07208149","kind":"trial","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07208149/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06976190","kind":"trial","name":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin","route":"/trials/nct06976190/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05688605","kind":"trial","name":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","route":"/trials/nct05688605/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07093970","kind":"trial","name":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct07093970/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07116616","kind":"trial","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07116616/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05658562","kind":"trial","name":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","route":"/trials/nct05658562/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943521","kind":"trial","name":"A Study of MT-4561 in Patients With Various Advanced Solid Tumors","route":"/trials/nct06943521/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03862430","kind":"trial","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","route":"/trials/nct03862430/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07026279","kind":"trial","name":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07026279/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855771","kind":"trial","name":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","route":"/trials/nct06855771/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03162536","kind":"trial","name":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","route":"/trials/nct03162536/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05947851","kind":"trial","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","route":"/trials/nct05947851/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05624554","kind":"trial","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","route":"/trials/nct05624554/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07586202","kind":"trial","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","route":"/trials/nct07586202/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06686576","kind":"trial","name":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct06686576/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","route":"/trials/nct05751928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07170644","kind":"trial","name":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","route":"/trials/nct07170644/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03873402","kind":"trial","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","route":"/trials/nct03873402/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07069712","kind":"trial","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","route":"/trials/nct07069712/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07098338","kind":"trial","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07098338/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06792695","kind":"trial","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","route":"/trials/nct06792695/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07450859","kind":"trial","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07450859/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","route":"/trials/nct07221500/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06365853","kind":"trial","name":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit","route":"/trials/nct06365853/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07734116","kind":"trial","name":"A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.","route":"/trials/nct07734116/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06136650","kind":"trial","name":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","route":"/trials/nct06136650/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06362369","kind":"trial","name":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","route":"/trials/nct06362369/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07266428","kind":"trial","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","route":"/trials/nct07266428/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06987500","kind":"trial","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","route":"/trials/nct06987500/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07225946","kind":"trial","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07225946/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06941272","kind":"trial","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","route":"/trials/nct06941272/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05334823","kind":"trial","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","route":"/trials/nct05334823/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","route":"/trials/nct05652686/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06041802","kind":"trial","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","route":"/trials/nct06041802/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02332668","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","route":"/trials/nct02332668/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06623422","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","route":"/trials/nct06623422/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07302347","kind":"trial","name":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","route":"/trials/nct07302347/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06731907","kind":"trial","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","route":"/trials/nct06731907/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05254743","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05254743/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05879055","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","route":"/trials/nct05879055/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"proceade-crc-03","kind":"trial","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","route":"/trials/proceade-crc-03/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06914128","kind":"trial","name":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","route":"/trials/nct06914128/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","route":"/trials/nct05487391/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05690945","kind":"trial","name":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","route":"/trials/nct05690945/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06911827","kind":"trial","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","route":"/trials/nct06911827/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06660654","kind":"trial","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","route":"/trials/nct06660654/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06155396","kind":"trial","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","route":"/trials/nct06155396/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","route":"/trials/nct06678659/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04077099","kind":"trial","name":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","route":"/trials/nct04077099/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03093116","kind":"trial","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","route":"/trials/nct03093116/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221253","kind":"trial","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","route":"/trials/nct07221253/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07609862","kind":"trial","name":"A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","route":"/trials/nct07609862/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07189065","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","route":"/trials/nct07189065/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07377578","kind":"trial","name":"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct07377578/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07648030","kind":"trial","name":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","route":"/trials/nct07648030/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06926920","kind":"trial","name":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","route":"/trials/nct06926920/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06312176","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","route":"/trials/nct06312176/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06841354","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","route":"/trials/nct06841354/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07060989","kind":"trial","name":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","route":"/trials/nct07060989/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04414475","kind":"trial","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","route":"/trials/nct04414475/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07726992","kind":"trial","name":"A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC","route":"/trials/nct07726992/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06754930","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","route":"/trials/nct06754930/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764628","kind":"trial","name":"A Study of SHR-4375 in Subjects With Solid Tumors","route":"/trials/nct06764628/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07298772","kind":"trial","name":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07298772/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229586","kind":"trial","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","route":"/trials/nct07229586/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06828354","kind":"trial","name":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","route":"/trials/nct06828354/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07450976","kind":"trial","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","route":"/trials/nct07450976/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07418749","kind":"trial","name":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","route":"/trials/nct07418749/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07230106","kind":"trial","name":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","route":"/trials/nct07230106/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"simrise","kind":"trial","name":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","route":"/trials/simrise/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07241936","kind":"trial","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","route":"/trials/nct07241936/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06670196","kind":"trial","name":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan","route":"/trials/nct06670196/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07071337","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","route":"/trials/nct07071337/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07448922","kind":"trial","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct07448922/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07019675","kind":"trial","name":"A Study of SKB518 in Patients With Lung Cancer","route":"/trials/nct07019675/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04521231","kind":"trial","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","route":"/trials/nct04521231/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07134088","kind":"trial","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","route":"/trials/nct07134088/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06508658","kind":"trial","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","route":"/trials/nct06508658/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06549595","kind":"trial","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","route":"/trials/nct06549595/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06533644","kind":"trial","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06533644/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06271837","kind":"trial","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","route":"/trials/nct06271837/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06971614","kind":"trial","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","route":"/trials/nct06971614/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06846671","kind":"trial","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","route":"/trials/nct06846671/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04712643","kind":"trial","name":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","route":"/trials/nct04712643/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06456463","kind":"trial","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","route":"/trials/nct06456463/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07205718","kind":"trial","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","route":"/trials/nct07205718/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07436728","kind":"trial","name":"A Study of TAK-505 in Adults With Solid Tumors","route":"/trials/nct07436728/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hr-nmibc","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","route":"/trials/hr-nmibc/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06211764","kind":"trial","name":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","route":"/trials/nct06211764/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05552222","kind":"trial","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","route":"/trials/nct05552222/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pik3ca-2","kind":"trial","name":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","route":"/trials/pik3ca-2/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05968326","kind":"trial","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","route":"/trials/nct05968326/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07742215","kind":"trial","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","route":"/trials/nct07742215/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07015242","kind":"trial","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","route":"/trials/nct07015242/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07439653","kind":"trial","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","route":"/trials/nct07439653/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06431490","kind":"trial","name":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","route":"/trials/nct06431490/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07679360","kind":"trial","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","route":"/trials/nct07679360/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05423262","kind":"trial","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","route":"/trials/nct05423262/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05440708","kind":"trial","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05440708/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06497985","kind":"trial","name":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","route":"/trials/nct06497985/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04104776","kind":"trial","name":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","route":"/trials/nct04104776/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06644768","kind":"trial","name":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","route":"/trials/nct06644768/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06930794","kind":"trial","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","route":"/trials/nct06930794/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07689201","kind":"trial","name":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","route":"/trials/nct07689201/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02966756","kind":"trial","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct02966756/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07218380","kind":"trial","name":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","route":"/trials/nct07218380/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943833","kind":"trial","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","route":"/trials/nct06943833/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07699328","kind":"trial","name":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07699328/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07093814","kind":"trial","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","route":"/trials/nct07093814/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589257","kind":"trial","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","route":"/trials/nct07589257/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213674","kind":"trial","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","route":"/trials/nct07213674/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407933","kind":"trial","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07407933/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07739758/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258979","kind":"trial","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","route":"/trials/nct07258979/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05434234","kind":"trial","name":"A Study of YL201 in Patients With Advanced Solid Tumors","route":"/trials/nct05434234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07197827","kind":"trial","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","route":"/trials/nct07197827/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05100862","kind":"trial","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom","route":"/trials/nct05100862/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05118789","kind":"trial","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","route":"/trials/nct05118789/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05458297","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-","route":"/trials/nct05458297/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05406401","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","route":"/trials/nct05406401/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05967689","kind":"trial","name":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","route":"/trials/nct05967689/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06885281","kind":"trial","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","route":"/trials/nct06885281/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","route":"/trials/dllevate/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03505320","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","route":"/trials/nct03505320/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06901531","kind":"trial","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","route":"/trials/nct06901531/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07525206","kind":"trial","name":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07525206/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07095452","kind":"trial","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","route":"/trials/nct07095452/","detail":"mentions 2042 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07023289","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o","route":"/trials/nct07023289/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07196644","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan","route":"/trials/nct07196644/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155187","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07155187/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059845","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","route":"/trials/nct07059845/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953960","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","route":"/trials/nct06953960/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07581002","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct07581002/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06568939","kind":"trial","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","route":"/trials/nct06568939/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005102","kind":"trial","name":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07005102/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06890338","kind":"trial","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","route":"/trials/nct06890338/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06090539","kind":"trial","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","route":"/trials/nct06090539/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06892522","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","route":"/trials/nct06892522/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07024784","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","route":"/trials/nct07024784/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06312137","kind":"trial","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","route":"/trials/nct06312137/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06305247","kind":"trial","name":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06305247/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05428969","kind":"trial","name":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","route":"/trials/nct05428969/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06109272","kind":"trial","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05503797","kind":"trial","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","route":"/trials/nct05503797/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06631989","kind":"trial","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06631989/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868485","kind":"trial","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06868485/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04224493","kind":"trial","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","route":"/trials/nct04224493/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06669247","kind":"trial","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","route":"/trials/nct06669247/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04817007","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","route":"/trials/nct04817007/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07325136","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","route":"/trials/nct07325136/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06969430","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct06969430/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07680764","kind":"trial","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","route":"/trials/nct07680764/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","route":"/trials/nct06898450/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06035497","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","route":"/trials/nct06035497/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213817","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct07213817/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213830","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","route":"/trials/nct07213830/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07128199","kind":"trial","name":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","route":"/trials/nct07128199/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06311721","kind":"trial","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","route":"/trials/nct06311721/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05794906","kind":"trial","name":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer","route":"/trials/nct05794906/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06939595","kind":"trial","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","route":"/trials/nct06939595/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06091865","kind":"trial","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","route":"/trials/nct06091865/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","route":"/trials/nct05827016/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07393282","kind":"trial","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","route":"/trials/nct07393282/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07079228","kind":"trial","name":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","route":"/trials/nct07079228/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06952504","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan","route":"/trials/nct06952504/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06459180","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With","route":"/trials/nct06459180/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07566052","kind":"trial","name":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","route":"/trials/nct07566052/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07063745","kind":"trial","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","route":"/trials/nct07063745/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764485","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct06764485/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"quintessential-2","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","route":"/trials/quintessential-2/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06646276","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)","route":"/trials/nct06646276/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06911502","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","route":"/trials/nct06911502/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06561386","kind":"trial","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N","route":"/trials/nct06561386/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06984588","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","route":"/trials/nct06984588/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05963074","kind":"trial","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct05963074/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06598007","kind":"trial","name":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","route":"/trials/nct06598007/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06988488","kind":"trial","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","route":"/trials/nct06988488/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06692166","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06692166/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06054555","kind":"trial","name":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","route":"/trials/nct06054555/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07029737","kind":"trial","name":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","route":"/trials/nct07029737/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07365241","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","route":"/trials/nct07365241/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05283720","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","route":"/trials/nct05283720/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05451810","kind":"trial","name":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr","route":"/trials/nct05451810/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07749586","kind":"trial","name":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","route":"/trials/nct07749586/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06590246","kind":"trial","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","route":"/trials/nct06590246/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07522073/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","route":"/trials/nct07460375/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07564401","kind":"trial","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","route":"/trials/nct07564401/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07149857","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","route":"/trials/nct07149857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06065748","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","route":"/trials/nct06065748/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554521","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","route":"/trials/nct07554521/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05645107","kind":"trial","name":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","route":"/trials/nct05645107/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07668752","kind":"trial","name":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","route":"/trials/nct07668752/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06084936","kind":"trial","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct06084936/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05533775","kind":"trial","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","route":"/trials/nct05533775/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07294508","kind":"trial","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07294508/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06387069","kind":"trial","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","route":"/trials/nct06387069/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05319730","kind":"trial","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","route":"/trials/nct05319730/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04064060","kind":"trial","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","route":"/trials/nct04064060/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05519085","kind":"trial","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","route":"/trials/nct05519085/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05751512","kind":"trial","name":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","route":"/trials/nct05751512/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500884","kind":"trial","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","route":"/trials/nct06500884/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07361497","kind":"trial","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","route":"/trials/nct07361497/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06356311","kind":"trial","name":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","route":"/trials/nct06356311/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06351631","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","route":"/trials/nct06351631/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","route":"/trials/nct07206498/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05318573","kind":"trial","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","route":"/trials/nct05318573/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06542250","kind":"trial","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","route":"/trials/nct06542250/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04554914","kind":"trial","name":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","route":"/trials/nct04554914/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06919965","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06919965/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06319820","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","route":"/trials/nct06319820/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06820463","kind":"trial","name":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,","route":"/trials/nct06820463/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07100106","kind":"trial","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","route":"/trials/nct07100106/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07409272","kind":"trial","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","route":"/trials/nct07409272/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227311","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","route":"/trials/nct07227311/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","route":"/trials/nct07541170/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05296798","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","route":"/trials/nct05296798/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07490262","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment","route":"/trials/nct07490262/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","route":"/trials/nct07082686/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06330064","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","route":"/trials/nct06330064/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04245839","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct04245839/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03178552","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct03178552/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06824467","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","route":"/trials/nct06824467/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284849","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","route":"/trials/nct07284849/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06010329","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","route":"/trials/nct06010329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06010342","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","route":"/trials/nct06010342/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07284758/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07361510","kind":"trial","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","route":"/trials/nct07361510/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","route":"/trials/nct07811193/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155174","kind":"trial","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","route":"/trials/nct07155174/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06428019","kind":"trial","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct06428019/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06682793","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","route":"/trials/nct06682793/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06166836","kind":"trial","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","route":"/trials/nct06166836/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","route":"/trials/nct06780137/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06818643","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","route":"/trials/nct06818643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06663137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","route":"/trials/nct06663137/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221357","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","route":"/trials/nct07221357/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221149","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","route":"/trials/nct07221149/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07570823","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct07570823/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562022","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct07562022/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07297329","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","route":"/trials/nct07297329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06973187","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct06973187/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06948448","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","route":"/trials/nct06948448/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04570423","kind":"trial","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","route":"/trials/nct04570423/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06116136","kind":"trial","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","route":"/trials/nct06116136/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07291076","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","route":"/trials/nct07291076/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07362459","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer","route":"/trials/nct07362459/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04077723","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","route":"/trials/nct04077723/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06609005","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06609005/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07498725","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","route":"/trials/nct07498725/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07223047","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","route":"/trials/nct07223047/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04300556","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","route":"/trials/nct04300556/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07293351","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","route":"/trials/nct07293351/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06618287","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","route":"/trials/nct06618287/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","route":"/trials/nct06656390/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","route":"/trials/nct07612891/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07610798","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","route":"/trials/nct07610798/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06746116","kind":"trial","name":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment","route":"/trials/nct06746116/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","route":"/trials/nct05941507/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06946797","kind":"trial","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","route":"/trials/nct06946797/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06717347","kind":"trial","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","route":"/trials/nct06717347/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07354022","kind":"trial","name":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy","route":"/trials/nct07354022/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06349980","kind":"trial","name":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","route":"/trials/nct06349980/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04590326","kind":"trial","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","route":"/trials/nct04590326/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07475806","kind":"trial","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","route":"/trials/nct07475806/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06747585","kind":"trial","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","route":"/trials/nct06747585/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07169734","kind":"trial","name":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","route":"/trials/nct07169734/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","route":"/trials/nct07538804/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"invincible-3","kind":"trial","name":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","route":"/trials/invincible-3/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07286331","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","route":"/trials/nct07286331/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07286266","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","route":"/trials/nct07286266/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943872","kind":"trial","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","route":"/trials/nct06943872/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07188558","kind":"trial","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","route":"/trials/nct07188558/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06634589","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct06634589/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05801029","kind":"trial","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth","route":"/trials/nct05801029/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","route":"/trials/nct07055594/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07115043","kind":"trial","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","route":"/trials/nct07115043/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07277231","kind":"trial","name":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct07277231/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05361174","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","route":"/trials/nct05361174/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06742996","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac","route":"/trials/nct06742996/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04002297","kind":"trial","name":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl","route":"/trials/nct04002297/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05714839","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","route":"/trials/nct05714839/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06940739","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","route":"/trials/nct06940739/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213609","kind":"trial","name":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct07213609/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06697184","kind":"trial","name":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","route":"/trials/nct06697184/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154290","kind":"trial","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07154290/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07585266","kind":"trial","name":"A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)","route":"/trials/nct07585266/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05623020","kind":"trial","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","route":"/trials/nct05623020/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","route":"/trials/himalayas-1/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06989437","kind":"trial","name":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","route":"/trials/nct06989437/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05262400","kind":"trial","name":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","route":"/trials/nct05262400/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07062965","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","route":"/trials/nct07062965/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nsclc-4","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-4/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192614","kind":"trial","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","route":"/trials/nct07192614/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07450599","kind":"trial","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","route":"/trials/nct07450599/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05785767","kind":"trial","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","route":"/trials/nct05785767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06452277","kind":"trial","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","route":"/trials/nct06452277/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06760819","kind":"trial","name":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","route":"/trials/nct06760819/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05748171","kind":"trial","name":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","route":"/trials/nct05748171/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06769698","kind":"trial","name":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous ","route":"/trials/nct06769698/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07265674","kind":"trial","name":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","route":"/trials/nct07265674/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287150","kind":"trial","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07287150/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07054190","kind":"trial","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","route":"/trials/nct07054190/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06619509","kind":"trial","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","route":"/trials/nct06619509/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06885034","kind":"trial","name":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)","route":"/trials/nct06885034/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06246916","kind":"trial","name":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","route":"/trials/nct06246916/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05562830","kind":"trial","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","route":"/trials/nct05562830/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","route":"/trials/nct07213804/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07673029","kind":"trial","name":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07673029/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03634540","kind":"trial","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","route":"/trials/nct03634540/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06679985","kind":"trial","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","route":"/trials/nct06679985/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232849","kind":"trial","name":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07232849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07003321","kind":"trial","name":"A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07003321/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06555068","kind":"trial","name":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients","route":"/trials/nct06555068/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07281976","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","route":"/trials/nct07281976/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06624644","kind":"trial","name":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","route":"/trials/nct06624644/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07028281","kind":"trial","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07028281/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07268040","kind":"trial","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07268040/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07196774","kind":"trial","name":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","route":"/trials/nct07196774/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07393542","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07393542/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059221","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","route":"/trials/nct07059221/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06639347","kind":"trial","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","route":"/trials/nct06639347/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06417554","kind":"trial","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","route":"/trials/nct06417554/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06895928","kind":"trial","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","route":"/trials/nct06895928/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07497386","kind":"trial","name":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","route":"/trials/nct07497386/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06545955","kind":"trial","name":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","route":"/trials/nct06545955/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06149286","kind":"trial","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","route":"/trials/nct06149286/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05125016","kind":"trial","name":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","route":"/trials/nct05125016/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06230224","kind":"trial","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","route":"/trials/nct06230224/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07336446","kind":"trial","name":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","route":"/trials/nct07336446/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05557591","kind":"trial","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","route":"/trials/nct05557591/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05800015","kind":"trial","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","route":"/trials/nct05800015/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05730036","kind":"trial","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","route":"/trials/nct05730036/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06097364","kind":"trial","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","route":"/trials/nct06097364/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","route":"/trials/nct06091254/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07455851","kind":"trial","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07455851/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05828511","kind":"trial","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","route":"/trials/nct05828511/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","route":"/trials/nct07285694/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"abbv-706","kind":"drug","name":"ABBV-706","route":"/drugs/abbv-706/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05422911","kind":"trial","name":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","route":"/trials/nct05422911/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07158918","kind":"trial","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","route":"/trials/nct07158918/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","route":"/trials/nct07327034/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"absk061","kind":"drug","name":"ABSK061","route":"/drugs/absk061/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"abt-301","kind":"drug","name":"ABT-301","route":"/drugs/abt-301/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"acasunlimab","kind":"drug","name":"Acasunlimab","route":"/drugs/acasunlimab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05355298","kind":"trial","name":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","route":"/trials/nct05355298/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03686124","kind":"trial","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct03686124/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06911333/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07523555","kind":"trial","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","route":"/trials/nct07523555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04587830","kind":"trial","name":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","route":"/trials/nct04587830/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"adi-peg20","kind":"drug","name":"ADI-PEG20","route":"/drugs/adi-peg20/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06041776","kind":"trial","name":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","route":"/trials/nct06041776/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05270044","kind":"trial","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","route":"/trials/nct05270044/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07225621","kind":"trial","name":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","route":"/trials/nct07225621/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"aurora","kind":"trial","name":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","route":"/trials/aurora/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06600022","kind":"trial","name":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","route":"/trials/nct06600022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06951503","kind":"trial","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","route":"/trials/nct06951503/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"allo-647","kind":"drug","name":"ALLO-647","route":"/drugs/allo-647/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04616209/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05948943","kind":"trial","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","route":"/trials/nct05948943/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05876754","kind":"trial","name":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","route":"/trials/nct05876754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07293754","kind":"trial","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","route":"/trials/nct07293754/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02531516","kind":"trial","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","route":"/trials/nct02531516/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03897881","kind":"trial","name":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN","route":"/trials/nct03897881/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","route":"/trials/nct07033026/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06401356","kind":"trial","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","route":"/trials/nct06401356/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05112965","kind":"trial","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","route":"/trials/nct05112965/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03844048","kind":"trial","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","route":"/trials/nct03844048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07604766","kind":"trial","name":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can","route":"/trials/nct07604766/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07206056","kind":"trial","name":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","route":"/trials/nct07206056/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05907057","kind":"trial","name":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","route":"/trials/nct05907057/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06991556","kind":"trial","name":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc","route":"/trials/nct06991556/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02955940","kind":"trial","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","route":"/trials/nct02955940/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07720284","kind":"trial","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","route":"/trials/nct07720284/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","route":"/trials/nct07359066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589569","kind":"trial","name":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","route":"/trials/nct07589569/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07371663","kind":"trial","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07371663/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07444541","kind":"trial","name":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct07444541/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","route":"/trials/nct05701306/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"arlocabtagene-autoleucel","kind":"drug","name":"Arlocabtagene Autoleucel","route":"/drugs/arlocabtagene-autoleucel/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109531","kind":"trial","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","route":"/trials/nct07109531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"asp2138","kind":"drug","name":"ASP2138","route":"/drugs/asp2138/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"at101","kind":"drug","name":"AT101","route":"/drugs/at101/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","route":"/trials/nct07374419/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07562152/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"atigotatug","kind":"drug","name":"Atigotatug","route":"/drugs/atigotatug/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04614103","kind":"trial","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct04614103/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06241781/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","route":"/trials/nct05850234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06106945","kind":"trial","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","route":"/trials/nct06106945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd0486","kind":"drug","name":"AZD0486","route":"/drugs/azd0486/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07215585","kind":"trial","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","route":"/trials/nct07215585/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06137118","kind":"trial","name":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","route":"/trials/nct06137118/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06137144","kind":"trial","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","route":"/trials/nct06137144/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd4045","kind":"drug","name":"AZD4045","route":"/drugs/azd4045/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd4360","kind":"drug","name":"AZD4360","route":"/drugs/azd4360/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd4512","kind":"drug","name":"AZD4512","route":"/drugs/azd4512/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd5335","kind":"drug","name":"AZD5335","route":"/drugs/azd5335/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07218809","kind":"trial","name":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","route":"/trials/nct07218809/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd5492","kind":"drug","name":"AZD5492","route":"/drugs/azd5492/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd5863","kind":"drug","name":"AZD5863","route":"/drugs/azd5863/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd6621","kind":"drug","name":"AZD6621","route":"/drugs/azd6621/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd9750","kind":"drug","name":"AZD9750","route":"/drugs/azd9750/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd9793","kind":"drug","name":"AZD9793","route":"/drugs/azd9793/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07469774","kind":"trial","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07469774/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bcb-276","kind":"drug","name":"BCB-276","route":"/drugs/bcb-276/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07486817","kind":"trial","name":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","route":"/trials/nct07486817/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06324357","kind":"trial","name":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit","route":"/trials/nct06324357/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07195695","kind":"trial","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","route":"/trials/nct07195695/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06581432","kind":"trial","name":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","route":"/trials/nct06581432/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bebt-209","kind":"drug","name":"BEBT-209","route":"/drugs/bebt-209/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07195591","kind":"trial","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","route":"/trials/nct07195591/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07449754","kind":"trial","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","route":"/trials/nct07449754/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04924075","kind":"trial","name":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","route":"/trials/nct04924075/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bgb-43395","kind":"drug","name":"BGB-43395","route":"/drugs/bgb-43395/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07492641","kind":"trial","name":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","route":"/trials/nct07492641/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07523529","kind":"trial","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","route":"/trials/nct07523529/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07625644","kind":"trial","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","route":"/trials/nct07625644/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bleximenib","kind":"drug","name":"Bleximenib","route":"/drugs/bleximenib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05317858","kind":"trial","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","route":"/trials/nct05317858/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bms-986365","kind":"drug","name":"BMS-986365","route":"/drugs/bms-986365/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bnt113","kind":"drug","name":"BNT113","route":"/drugs/bnt113/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bomedemstat","kind":"drug","name":"Bomedemstat","route":"/drugs/bomedemstat/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-bray-globocan-2022-cacancer-2024","kind":"paper","name":"Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries","route":"/key-papers/paper-bray-globocan-2022-cacancer-2024/","detail":"mentions 2050 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"budigalimab","kind":"drug","name":"Budigalimab","route":"/drugs/budigalimab/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cadance-304","kind":"trial","name":"CaDAnCe-304","route":"/trials/cadance-304/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04862663","kind":"trial","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","route":"/trials/nct04862663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07087054","kind":"trial","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","route":"/trials/nct07087054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cart84","kind":"drug","name":"CART84","route":"/drugs/cart84/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","route":"/trials/nct06690775/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07322094","kind":"trial","name":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov","route":"/trials/nct07322094/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06538857","kind":"trial","name":"CEB-01 in Locally Resectable Pancreatic Cancer","route":"/trials/nct06538857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06986811","kind":"trial","name":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","route":"/trials/nct06986811/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"century-therapeutics","kind":"company","name":"Century Therapeutics","route":"/companies/century-therapeutics/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07555938","kind":"trial","name":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","route":"/trials/nct07555938/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cgt4859","kind":"drug","name":"CGT4859","route":"/drugs/cgt4859/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05833724","kind":"trial","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","route":"/trials/nct05833724/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07512583","kind":"trial","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","route":"/trials/nct07512583/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06821503","kind":"trial","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","route":"/trials/nct06821503/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07522151","kind":"trial","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","route":"/trials/nct07522151/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06680752","kind":"trial","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","route":"/trials/nct06680752/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04668690","kind":"trial","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","route":"/trials/nct04668690/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07036250","kind":"trial","name":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","route":"/trials/nct07036250/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","route":"/trials/nct07545603/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07385703/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06879145","kind":"trial","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","route":"/trials/nct06879145/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03067051","kind":"trial","name":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","route":"/trials/nct03067051/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07122063","kind":"trial","name":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","route":"/trials/nct07122063/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","route":"/trials/nct07367516/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02781883","kind":"trial","name":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","route":"/trials/nct02781883/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06781567","kind":"trial","name":"Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma","route":"/trials/nct06781567/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06745908","kind":"trial","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","route":"/trials/nct06745908/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07008976","kind":"trial","name":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","route":"/trials/nct07008976/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07299747/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","route":"/trials/nct06975410/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","route":"/trials/nct05523947/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07548177","kind":"trial","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","route":"/trials/nct07548177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06699836","kind":"trial","name":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen","route":"/trials/nct06699836/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05874414","kind":"trial","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","route":"/trials/nct05874414/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07398339","kind":"trial","name":"Cosiporfin Sodium for Injection Photodynamic Therapy","route":"/trials/nct07398339/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"crb-701","kind":"drug","name":"CRB-701","route":"/drugs/crb-701/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"crc01","kind":"drug","name":"CRC01","route":"/drugs/crc01/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ctx112","kind":"drug","name":"CTX112","route":"/drugs/ctx112/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07664150","kind":"trial","name":"CW-301 FIH Study of CAN016","route":"/trials/nct07664150/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"d07001","kind":"drug","name":"D07001","route":"/drugs/d07001/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06622057","kind":"trial","name":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06622057/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","route":"/trials/nct07288879/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07472517","kind":"trial","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","route":"/trials/nct07472517/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07544654","kind":"trial","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","route":"/trials/nct07544654/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05882058","kind":"trial","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct05882058/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","route":"/trials/nct05555732/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05566795","kind":"trial","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","route":"/trials/nct05566795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06953089/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06989112","kind":"trial","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","route":"/trials/nct06989112/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05911295","kind":"trial","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","route":"/trials/nct05911295/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"dji136","kind":"drug","name":"DJI136","route":"/drugs/dji136/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04567420","kind":"trial","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","route":"/trials/nct04567420/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288112","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","route":"/trials/nct07288112/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06805305","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","route":"/trials/nct06805305/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06239194","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","route":"/trials/nct06239194/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07249905","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","route":"/trials/nct07249905/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04140500","kind":"trial","name":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","route":"/trials/nct04140500/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05431270","kind":"trial","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","route":"/trials/nct05431270/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02174549","kind":"trial","name":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","route":"/trials/nct02174549/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05751798/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07467863/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07486089","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","route":"/trials/nct07486089/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","route":"/trials/nct07510802/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07462650/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","route":"/trials/nct07589543/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07627711","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07627711/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07641023","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07641023/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551349","kind":"trial","name":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07551349/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551362","kind":"trial","name":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","route":"/trials/nct07551362/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07627698","kind":"trial","name":"Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma","route":"/trials/nct07627698/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","route":"/trials/nct07502287/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07500220","kind":"trial","name":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","route":"/trials/nct07500220/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07641036","kind":"trial","name":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","route":"/trials/nct07641036/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","route":"/trials/nct07510815/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","route":"/trials/nct07480954/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","route":"/trials/nct07617753/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07589517/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480928","kind":"trial","name":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07480928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06992609","kind":"trial","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","route":"/trials/nct06992609/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03833154","kind":"trial","name":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","route":"/trials/nct03833154/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070440","kind":"trial","name":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","route":"/trials/nct07070440/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059650","kind":"trial","name":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","route":"/trials/nct07059650/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06539182","kind":"trial","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","route":"/trials/nct06539182/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","route":"/drugs/e-edv-d682/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","route":"/trials/nct06926075/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07455734","kind":"trial","name":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","route":"/trials/nct07455734/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eb-car30-nk","kind":"drug","name":"EB-CAR30-NK","route":"/drugs/eb-car30-nk/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eb-mf-car-nk-01","kind":"drug","name":"EB-MF-CAR-NK-01","route":"/drugs/eb-mf-car-nk-01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eb-nk-301","kind":"drug","name":"EB-NK-301","route":"/drugs/eb-nk-301/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06556563","kind":"trial","name":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","route":"/trials/nct06556563/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07473128","kind":"trial","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","route":"/trials/nct07473128/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06463665","kind":"trial","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","route":"/trials/nct06463665/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06959082","kind":"trial","name":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","route":"/trials/nct06959082/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","route":"/trials/nct05304481/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct07480356/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07379047","kind":"trial","name":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","route":"/trials/nct07379047/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04728893","kind":"trial","name":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","route":"/trials/nct04728893/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","route":"/trials/nct06082102/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04241185","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","route":"/trials/nct04241185/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07498478","kind":"trial","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","route":"/trials/nct07498478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06995677/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03567889","kind":"trial","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","route":"/trials/nct03567889/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07617805","kind":"trial","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","route":"/trials/nct07617805/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07262619","kind":"trial","name":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic","route":"/trials/nct07262619/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","route":"/trials/nct06525298/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"elenestinib","kind":"drug","name":"Elenestinib","route":"/drugs/elenestinib/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"emactuzumab","kind":"drug","name":"Emactuzumab","route":"/drugs/emactuzumab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07566156","kind":"trial","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","route":"/trials/nct07566156/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"englumafusp-alfa","kind":"drug","name":"Englumafusp alfa","route":"/drugs/englumafusp-alfa/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06120140","kind":"trial","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","route":"/trials/nct06120140/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"env-501","kind":"drug","name":"ENV-501","route":"/drugs/env-501/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04891198","kind":"trial","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","route":"/trials/nct04891198/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ep0062","kind":"drug","name":"EP0062","route":"/drugs/ep0062/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04634357","kind":"trial","name":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","route":"/trials/nct04634357/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eu-hta-regulation","kind":"term","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","route":"/terms/eu-hta-regulation/","detail":"mentions 2028, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06806033","kind":"trial","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","route":"/trials/nct06806033/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","route":"/trials/nct04390737/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07095868","kind":"trial","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","route":"/trials/nct07095868/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05037279","kind":"trial","name":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","route":"/trials/nct05037279/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07617493","kind":"trial","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","route":"/trials/nct07617493/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05696626","kind":"trial","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","route":"/trials/nct05696626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07669519","kind":"trial","name":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","route":"/trials/nct07669519/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06824064","kind":"trial","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","route":"/trials/nct06824064/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07056777","kind":"trial","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","route":"/trials/nct07056777/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","route":"/trials/nct07136181/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407803","kind":"trial","name":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","route":"/trials/nct07407803/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06824168","kind":"trial","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","route":"/trials/nct06824168/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405164","kind":"trial","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","route":"/trials/nct07405164/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06465433","kind":"trial","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","route":"/trials/nct06465433/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ficlatuzumab","kind":"drug","name":"Ficlatuzumab","route":"/drugs/ficlatuzumab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06669117","kind":"trial","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","route":"/trials/nct06669117/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06956001","kind":"trial","name":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","route":"/trials/nct06956001/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05120596","kind":"trial","name":"First in Human Study of T3P-Y058-739 (T3P)","route":"/trials/nct05120596/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","route":"/trials/nct06795022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","route":"/trials/nct06877650/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07216560","kind":"trial","name":"First-in-human Study of 7MW4911 in GI Cancer","route":"/trials/nct07216560/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07265622","kind":"trial","name":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","route":"/trials/nct07265622/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06797999","kind":"trial","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","route":"/trials/nct06797999/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","route":"/trials/nct05438329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06554795","kind":"trial","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","route":"/trials/nct06554795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04243499","kind":"trial","name":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","route":"/trials/nct04243499/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05768139","kind":"trial","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","route":"/trials/nct05768139/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04725474","kind":"trial","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","route":"/trials/nct04725474/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07529717","kind":"trial","name":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","route":"/trials/nct07529717/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","route":"/trials/nct07136779/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07700160","kind":"trial","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","route":"/trials/nct07700160/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07332455","kind":"trial","name":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","route":"/trials/nct07332455/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06636682","kind":"trial","name":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","route":"/trials/nct06636682/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05919264","kind":"trial","name":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05919264/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446322","kind":"trial","name":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","route":"/trials/nct07446322/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","detail":"mentions 2068 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07710885/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06506955","kind":"trial","name":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","route":"/trials/nct06506955/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06190899","kind":"trial","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06190899/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06533579","kind":"trial","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","route":"/trials/nct06533579/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07432295","kind":"trial","name":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","route":"/trials/nct07432295/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07209813/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05804370","kind":"trial","name":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","route":"/trials/nct05804370/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04121455","kind":"trial","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","route":"/trials/nct04121455/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"golseek-1","kind":"trial","name":"GOLSEEK-1","route":"/trials/golseek-1/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04864054","kind":"trial","name":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","route":"/trials/nct04864054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06566547","kind":"trial","name":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06566547/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"grt-c901","kind":"drug","name":"GRT-C901","route":"/drugs/grt-c901/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"grt-r902","kind":"drug","name":"GRT-R902","route":"/drugs/grt-r902/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06948981","kind":"trial","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","route":"/trials/nct06948981/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hdm2017","kind":"drug","name":"HDM2017","route":"/drugs/hdm2017/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05586074","kind":"trial","name":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","route":"/trials/nct05586074/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","route":"/people/hitoshi-ishikawa/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hlx22","kind":"drug","name":"HLX22","route":"/drugs/hlx22/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmpl-306","kind":"drug","name":"HMPL-306","route":"/drugs/hmpl-306/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmpl-453","kind":"drug","name":"HMPL-453","route":"/drugs/hmpl-453/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04353375","kind":"trial","name":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct04353375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmpl-760","kind":"drug","name":"HMPL-760","route":"/drugs/hmpl-760/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07396584","kind":"trial","name":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","route":"/trials/nct07396584/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232875","kind":"trial","name":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07232875/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07296341","kind":"trial","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07296341/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hrs-8080","kind":"drug","name":"HRS-8080","route":"/drugs/hrs-8080/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07790510","kind":"trial","name":"HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07790510/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06708663","kind":"trial","name":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","route":"/trials/nct06708663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"iah0968","kind":"drug","name":"IAH0968","route":"/drugs/iah0968/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ibi310","kind":"drug","name":"IBI310","route":"/drugs/ibi310/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07483554","kind":"trial","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","route":"/trials/nct07483554/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07377643","kind":"trial","name":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","route":"/trials/nct07377643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07722494","kind":"trial","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","route":"/trials/nct07722494/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"icp-248","kind":"drug","name":"ICP-248","route":"/drugs/icp-248/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"apex-03","kind":"trial","name":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","route":"/trials/apex-03/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05987332","kind":"trial","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","route":"/trials/nct05987332/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idrx-42","kind":"drug","name":"IDRX-42","route":"/drugs/idrx-42/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ifupinostat","kind":"drug","name":"Ifupinostat","route":"/drugs/ifupinostat/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07452224/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","route":"/trials/nct07680439/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05958121","kind":"trial","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct05958121/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04086264","kind":"trial","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","route":"/trials/nct04086264/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","detail":"mentions 2056 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07441174","kind":"trial","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07441174/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06295731","kind":"trial","name":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","route":"/trials/nct06295731/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"inca33890","kind":"drug","name":"INCA33890","route":"/drugs/inca33890/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"incb161734","kind":"drug","name":"INCB161734","route":"/drugs/incb161734/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02843945","kind":"trial","name":"Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","route":"/trials/nct02843945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"insight-gist","kind":"trial","name":"INSIGHT","route":"/trials/insight-gist/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"int230-6","kind":"drug","name":"INT230-6","route":"/drugs/int230-6/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03257033","kind":"trial","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","route":"/trials/nct03257033/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","route":"/trials/nct07339176/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07429266","kind":"trial","name":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","route":"/trials/nct07429266/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04851717","kind":"trial","name":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","route":"/trials/nct04851717/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06787612","kind":"trial","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","route":"/trials/nct06787612/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ipatasertib","kind":"drug","name":"Ipatasertib","route":"/drugs/ipatasertib/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07508761","kind":"trial","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","route":"/trials/nct07508761/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05742607","kind":"trial","name":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","route":"/trials/nct05742607/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07238283","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct07238283/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07356973","kind":"trial","name":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","route":"/trials/nct07356973/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04270409","kind":"trial","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","route":"/trials/nct04270409/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ivdr","kind":"term","name":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","route":"/terms/ivdr/","detail":"mentions 2029, 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06928389/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06127407","kind":"trial","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","route":"/trials/nct06127407/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06549946","kind":"trial","name":"Ixovex-1 Single Agent and Combination Therapy","route":"/trials/nct06549946/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06416410","kind":"trial","name":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","route":"/trials/nct06416410/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06973564","kind":"trial","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","route":"/trials/nct06973564/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06386146","kind":"trial","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","route":"/trials/nct06386146/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jdq443","kind":"drug","name":"JDQ443","route":"/drugs/jdq443/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-90014496","kind":"drug","name":"JNJ-90014496","route":"/drugs/jnj-90014496/","detail":"mentions 2041 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-90301900","kind":"drug","name":"JNJ-90301900","route":"/drugs/jnj-90301900/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04892173","kind":"trial","name":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","route":"/trials/nct04892173/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","route":"/journals/journal-of-cancer-survivorship/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"js105","kind":"drug","name":"JS105","route":"/drugs/js105/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"js111","kind":"drug","name":"JS111","route":"/drugs/js111/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06940401","kind":"trial","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","route":"/trials/nct06940401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07481058","kind":"trial","name":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","route":"/trials/nct07481058/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04165070","kind":"trial","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","route":"/trials/nct04165070/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07252739","kind":"trial","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","route":"/trials/nct07252739/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232602","kind":"trial","name":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","route":"/trials/nct07232602/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05294172","kind":"trial","name":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05294172/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07406633","kind":"trial","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","route":"/trials/nct07406633/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06788756","kind":"trial","name":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re","route":"/trials/nct06788756/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227350","kind":"trial","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct07227350/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227870","kind":"trial","name":"L19IL2/TNF in Patients With Basal Cell Carcinoma","route":"/trials/nct07227870/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04752722","kind":"trial","name":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","route":"/trials/nct04752722/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lirafugratinib","kind":"drug","name":"Lirafugratinib","route":"/drugs/lirafugratinib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"livmoniplimab","kind":"drug","name":"Livmoniplimab","route":"/drugs/livmoniplimab/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07362186/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lns8801","kind":"drug","name":"LNS8801","route":"/drugs/lns8801/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06652633","kind":"trial","name":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","route":"/trials/nct06652633/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03435796","kind":"trial","name":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","route":"/trials/nct03435796/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07162181","kind":"trial","name":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","route":"/trials/nct07162181/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06216301","kind":"trial","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","route":"/trials/nct06216301/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06496048","kind":"trial","name":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","route":"/trials/nct06496048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05319314","kind":"trial","name":"LYL273 for Patients With Relapsed or Refractory mCRC","route":"/trials/nct05319314/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"m108","kind":"drug","name":"M108","route":"/drugs/m108/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06177041","kind":"trial","name":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","route":"/trials/nct06177041/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-cost-biosimilar-default-substitution","kind":"idea","name":"Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab","route":"/ideas/idea-cost-biosimilar-default-substitution/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","detail":"mentions 2051 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mavrostobart","kind":"drug","name":"Mavrostobart","route":"/drugs/mavrostobart/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06097728","kind":"trial","name":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","route":"/trials/nct06097728/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06134232","kind":"trial","name":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","route":"/trials/nct06134232/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05445778","kind":"trial","name":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C","route":"/trials/nct05445778/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07431827","kind":"trial","name":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","route":"/trials/nct07431827/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05429632","kind":"trial","name":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","route":"/trials/nct05429632/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06493552","kind":"trial","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","route":"/trials/nct06493552/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07479485","kind":"trial","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","route":"/trials/nct07479485/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07639450","kind":"trial","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","route":"/trials/nct07639450/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06061809","kind":"trial","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","route":"/trials/nct06061809/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07150663","kind":"trial","name":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07150663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"navlimetostat","kind":"drug","name":"Navlimetostat","route":"/drugs/navlimetostat/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nb003","kind":"drug","name":"NB003","route":"/drugs/nb003/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06012695","kind":"trial","name":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","route":"/trials/nct06012695/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","route":"/trials/nct06765109/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07306624","kind":"trial","name":"Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer","route":"/trials/nct07306624/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05061550","kind":"trial","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","route":"/trials/nct05061550/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07015190","kind":"trial","name":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","route":"/trials/nct07015190/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07412613","kind":"trial","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","route":"/trials/nct07412613/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05702229","kind":"trial","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct05702229/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07324304","kind":"trial","name":"NWRD06 DNA Plasmid for HCC After Curative Resection.","route":"/trials/nct07324304/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07382531","kind":"trial","name":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","route":"/trials/nct07382531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05671510","kind":"trial","name":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","route":"/trials/nct05671510/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","route":"/trials/nct05271318/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04975997","kind":"trial","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","route":"/trials/nct04975997/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06514534","kind":"trial","name":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","route":"/trials/nct06514534/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05735080","kind":"trial","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","route":"/trials/nct05735080/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05491525","kind":"trial","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","route":"/trials/nct05491525/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","route":"/trials/nct05438420/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06998407","kind":"trial","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","route":"/trials/nct06998407/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07295821","kind":"trial","name":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","route":"/trials/nct07295821/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06468033","kind":"trial","name":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","route":"/trials/nct06468033/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07033598","kind":"trial","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","route":"/trials/nct07033598/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07085767","kind":"trial","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct07085767/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03899155","kind":"trial","name":"Pan Tumor Rollover Study","route":"/trials/nct03899155/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07761533","kind":"trial","name":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS","route":"/trials/nct07761533/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06788912","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","route":"/trials/nct06788912/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05903833","kind":"trial","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","route":"/trials/nct05903833/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04976634","kind":"trial","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","route":"/trials/nct04976634/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06960577","kind":"trial","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","route":"/trials/nct06960577/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06631092","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","route":"/trials/nct06631092/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","route":"/trials/nct07002203/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pf-07248144","kind":"drug","name":"PF-07248144","route":"/drugs/pf-07248144/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pf-08046054","kind":"drug","name":"PF-08046054","route":"/drugs/pf-08046054/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","route":"/trials/nct04910022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05671822","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","route":"/trials/nct05671822/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04379596","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","route":"/trials/nct04379596/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07612280","kind":"trial","name":"Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis","route":"/trials/nct07612280/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","route":"/trials/nct07145255/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07529808","kind":"trial","name":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","route":"/trials/nct07529808/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","route":"/trials/nct07589530/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06993844","kind":"trial","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","route":"/trials/nct06993844/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06249048","kind":"trial","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct06249048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07751042","kind":"trial","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct07751042/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06795412","kind":"trial","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct06795412/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07605962","kind":"trial","name":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","route":"/trials/nct07605962/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05573126","kind":"trial","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","route":"/trials/nct05573126/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","route":"/trials/nct05288205/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07148128","kind":"trial","name":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","route":"/trials/nct07148128/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07415863","kind":"trial","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","route":"/trials/nct07415863/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06162572","kind":"trial","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06162572/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","route":"/trials/nct07168226/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05363280","kind":"trial","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","route":"/trials/nct05363280/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07024706","kind":"trial","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","route":"/trials/nct07024706/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06589440","kind":"trial","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","route":"/trials/nct06589440/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06567743","kind":"trial","name":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","route":"/trials/nct06567743/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04613596","kind":"trial","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","route":"/trials/nct04613596/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07106762","kind":"trial","name":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","route":"/trials/nct07106762/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06757634","kind":"trial","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","route":"/trials/nct06757634/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06982521","kind":"trial","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","route":"/trials/nct06982521/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06467357","kind":"trial","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","route":"/trials/nct06467357/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","route":"/trials/nct07154706/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05232916","kind":"trial","name":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","route":"/trials/nct05232916/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07778316","kind":"trial","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","route":"/trials/nct07778316/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06118788/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct06735144/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06144671","kind":"trial","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","route":"/trials/nct06144671/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07073534","kind":"trial","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","route":"/trials/nct07073534/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06212076","kind":"trial","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","route":"/trials/nct06212076/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03960840","kind":"trial","name":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","route":"/trials/nct03960840/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07050641","kind":"trial","name":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","route":"/trials/nct07050641/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06730009","kind":"trial","name":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","route":"/trials/nct06730009/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07235176","kind":"trial","name":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","route":"/trials/nct07235176/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07239596","kind":"trial","name":"Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","route":"/trials/nct07239596/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","route":"/trials/nct05720130/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07175220","kind":"trial","name":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","route":"/trials/nct07175220/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05739981","kind":"trial","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05739981/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","route":"/trials/nct07314294/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07387081","kind":"trial","name":"Phase II Study of LM-24C5","route":"/trials/nct07387081/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07724756","kind":"trial","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","route":"/trials/nct07724756/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","route":"/trials/nct07018050/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07329322","kind":"trial","name":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto","route":"/trials/nct07329322/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232290","kind":"trial","name":"Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","route":"/trials/nct07232290/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07310173","kind":"trial","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","route":"/trials/nct07310173/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07291037","kind":"trial","name":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti","route":"/trials/nct07291037/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06123754","kind":"trial","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","route":"/trials/nct06123754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07228832","kind":"trial","name":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07228832/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06921785","kind":"trial","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","route":"/trials/nct06921785/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07170995","kind":"trial","name":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva","route":"/trials/nct07170995/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07262567","kind":"trial","name":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","route":"/trials/nct07262567/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03016819","kind":"trial","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","route":"/trials/nct03016819/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06350097","kind":"trial","name":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L","route":"/trials/nct06350097/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05687266","kind":"trial","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","route":"/trials/nct05687266/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632912","kind":"trial","name":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","route":"/trials/nct06632912/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","route":"/trials/nct05827081/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06807359","kind":"trial","name":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","route":"/trials/nct06807359/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07416994","kind":"trial","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07416994/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06947928","kind":"trial","name":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car","route":"/trials/nct06947928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","route":"/trials/nct04624204/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07133750","kind":"trial","name":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07133750/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06616532","kind":"trial","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","route":"/trials/nct06616532/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06419621","kind":"trial","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","route":"/trials/nct06419621/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06752811","kind":"trial","name":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct06752811/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04365374","kind":"trial","name":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","route":"/trials/nct04365374/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","route":"/drugs/precemtabart-tocentecan/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07510828","kind":"trial","name":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","route":"/trials/nct07510828/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06460298","kind":"trial","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06460298/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07605728","kind":"trial","name":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","route":"/trials/nct07605728/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06244992","kind":"trial","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06244992/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07586124","kind":"trial","name":"Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma","route":"/trials/nct07586124/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06665100","kind":"trial","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","route":"/trials/nct06665100/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"purinostat","kind":"drug","name":"Purinostat","route":"/drugs/purinostat/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07044336","kind":"trial","name":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","route":"/trials/nct07044336/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07463573","kind":"trial","name":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct07463573/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"qls31905","kind":"drug","name":"QLS31905","route":"/drugs/qls31905/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","route":"/trials/nct05703971/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04486833","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","route":"/trials/nct04486833/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"quemliclustat","kind":"drug","name":"Quemliclustat","route":"/drugs/quemliclustat/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03228667","kind":"trial","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","route":"/trials/nct03228667/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"radcomp","kind":"trial","name":"RADCOMP","route":"/trials/radcomp/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/","detail":"mentions 2040 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014","kind":"paper","name":"Rahib 2014: projecting US cancer incidence and deaths to 2030","route":"/key-papers/paper-rahib-projecting-cancer-deaths-2030-cancerres-2014/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06867705","kind":"trial","name":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","route":"/trials/nct06867705/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rc148","kind":"drug","name":"RC148","route":"/drugs/rc148/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sqnsclc","kind":"trial","name":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","route":"/trials/sqnsclc/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07006077","kind":"trial","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","route":"/trials/nct07006077/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07594106","kind":"trial","name":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate ","route":"/trials/nct07594106/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07259317","kind":"trial","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07259317/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06679634","kind":"trial","name":"Retinoblastoma Phase II Expanded Access Clinical Trial","route":"/trials/nct06679634/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05973773","kind":"trial","name":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","route":"/trials/nct05973773/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02934568","kind":"trial","name":"Ribociclib (LEE011) Rollover Study for Continued Access","route":"/trials/nct02934568/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06109779","kind":"trial","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","route":"/trials/nct06109779/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ro7771950","kind":"drug","name":"RO7771950","route":"/drugs/ro7771950/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07413939","kind":"trial","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","route":"/trials/nct07413939/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07342478","kind":"trial","name":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","route":"/trials/nct07342478/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","route":"/trials/nct04421963/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05629234","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","route":"/trials/nct05629234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05201066","kind":"trial","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","route":"/trials/nct05201066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","route":"/drugs/rondecabtagene-autoleucel/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07173751","kind":"trial","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","route":"/trials/nct07173751/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","route":"/trials/nct05966194/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05101070","kind":"trial","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","route":"/trials/nct05101070/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06170788","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","route":"/trials/nct06170788/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06132958","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","route":"/trials/nct06132958/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","route":"/trials/nct06393374/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","route":"/trials/nct06074588/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06305754","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","route":"/trials/nct06305754/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07324629","kind":"trial","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","route":"/trials/nct07324629/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","route":"/trials/nct06937177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07387926","kind":"trial","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","route":"/trials/nct07387926/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06712355","kind":"trial","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","route":"/trials/nct06712355/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06697301","kind":"trial","name":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma","route":"/trials/nct06697301/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05704244","kind":"trial","name":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","route":"/trials/nct05704244/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06947291","kind":"trial","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","route":"/trials/nct06947291/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","route":"/trials/nct07471789/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06771622","kind":"trial","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","route":"/trials/nct06771622/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","route":"/trials/nct06506643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","route":"/trials/nct06047379/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06060613","kind":"trial","name":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","route":"/trials/nct06060613/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03934372","kind":"trial","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","route":"/trials/nct03934372/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03793478","kind":"trial","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","route":"/trials/nct03793478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06191263","kind":"trial","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","route":"/trials/nct06191263/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07102901","kind":"trial","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","route":"/trials/nct07102901/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06016920","kind":"trial","name":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma","route":"/trials/nct06016920/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04623541","kind":"trial","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","route":"/trials/nct04623541/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct05951179/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04938817","kind":"trial","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","route":"/trials/nct04938817/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06334432","kind":"trial","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","route":"/trials/nct06334432/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","route":"/trials/nct06508931/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04663347","kind":"trial","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","route":"/trials/nct04663347/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07575191","kind":"trial","name":"Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","route":"/trials/nct07575191/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06750185","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","route":"/trials/nct06750185/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06449222","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","route":"/trials/nct06449222/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06841055","kind":"trial","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","route":"/trials/nct06841055/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","route":"/trials/nct05732831/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06712316","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","route":"/trials/nct06712316/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","route":"/trials/nct06087653/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","route":"/trials/nct06635785/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06449209","kind":"trial","name":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","route":"/trials/nct06449209/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05338931","kind":"trial","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","route":"/trials/nct05338931/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04589234","kind":"trial","name":"Saltikva for Metastatic Pancreatic Cancer","route":"/trials/nct04589234/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07558733","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","route":"/trials/nct07558733/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06463028","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial ","route":"/trials/nct06463028/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06380751","kind":"trial","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","route":"/trials/nct06380751/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06120491","kind":"trial","name":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","route":"/trials/nct06120491/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05374603","kind":"trial","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","route":"/trials/nct05374603/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04079166","kind":"trial","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","route":"/trials/nct04079166/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctb14","kind":"drug","name":"SCTB14","route":"/drugs/sctb14/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctb35","kind":"drug","name":"SCTB35","route":"/drugs/sctb35/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctb41","kind":"drug","name":"SCTB41","route":"/drugs/sctb41/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07662395","kind":"trial","name":"SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662395/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctc21c","kind":"drug","name":"SCTC21C","route":"/drugs/sctc21c/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02343042","kind":"trial","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","route":"/trials/nct02343042/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07181499","kind":"trial","name":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","route":"/trials/nct07181499/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"setidegrasib","kind":"drug","name":"Setidegrasib","route":"/drugs/setidegrasib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06080776","kind":"trial","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","route":"/trials/nct06080776/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"shr-1501","kind":"drug","name":"SHR-1501","route":"/drugs/shr-1501/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06123494","kind":"trial","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","route":"/trials/nct06123494/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"shr-a1912","kind":"drug","name":"SHR-A1912","route":"/drugs/shr-a1912/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05303519","kind":"trial","name":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","route":"/trials/nct05303519/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sim0270","kind":"drug","name":"SIM0270","route":"/drugs/sim0270/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07648264","kind":"trial","name":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","route":"/trials/nct07648264/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07165886","kind":"trial","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","route":"/trials/nct07165886/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07459998","kind":"trial","name":"SKB103 for Injection in Advanced Solid Tumors","route":"/trials/nct07459998/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07380386","kind":"trial","name":"SKB105 for Injection in Advanced Solid Tumors","route":"/trials/nct07380386/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","route":"/trials/nct07586943/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05642780","kind":"trial","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","route":"/trials/nct05642780/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","route":"/trials/nct07697586/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07700667","kind":"trial","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","route":"/trials/nct07700667/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","route":"/trials/nct07296809/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07545265","kind":"trial","name":"SKB565 for Injection in Advanced Solid Tumors","route":"/trials/nct07545265/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07341737","kind":"trial","name":"SL-28 for Advanced Solid Tumours","route":"/trials/nct07341737/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06526819","kind":"trial","name":"SMP-3124LP in Adults With Advanced Solid Tumors","route":"/trials/nct06526819/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07391813","kind":"trial","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","route":"/trials/nct07391813/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06736704","kind":"trial","name":"SNV4818 in Participants With Advanced Solid Tumors","route":"/trials/nct06736704/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07431281","kind":"trial","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","route":"/trials/nct07431281/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05902169","kind":"trial","name":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","route":"/trials/nct05902169/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06561048","kind":"trial","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","route":"/trials/nct06561048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"spevatamig","kind":"drug","name":"Spevatamig","route":"/drugs/spevatamig/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05482893","kind":"trial","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","route":"/trials/nct05482893/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06975293","kind":"trial","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","route":"/trials/nct06975293/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07007312","kind":"trial","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","route":"/trials/nct07007312/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06158841","kind":"trial","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","route":"/trials/nct06158841/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04524000","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04524000/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04544189","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04544189/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06225596","kind":"trial","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","route":"/trials/nct06225596/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct06792253/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07189455","kind":"trial","name":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","route":"/trials/nct07189455/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06117774","kind":"trial","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","route":"/trials/nct06117774/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05607420","kind":"trial","name":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05607420/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06921928","kind":"trial","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","route":"/trials/nct06921928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05226871","kind":"trial","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","route":"/trials/nct05226871/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07300943","kind":"trial","name":"Study in Advanced Solid Tumor Patients","route":"/trials/nct07300943/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03600441/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05952024","kind":"trial","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","route":"/trials/nct05952024/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","route":"/trials/nct06380660/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05317819","kind":"trial","name":"Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05317819/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","route":"/trials/nct07804186/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284433","kind":"trial","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct07284433/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04208178","kind":"trial","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","route":"/trials/nct04208178/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287917","kind":"trial","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","route":"/trials/nct07287917/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07346144","kind":"trial","name":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","route":"/trials/nct07346144/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06710132","kind":"trial","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","route":"/trials/nct06710132/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05898399","kind":"trial","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","route":"/trials/nct05898399/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05267626","kind":"trial","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","route":"/trials/nct05267626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05371093","kind":"trial","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct05371093/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","route":"/trials/nct07181161/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155226","kind":"trial","name":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","route":"/trials/nct07155226/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109219","kind":"trial","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","route":"/trials/nct07109219/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446855","kind":"trial","name":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","route":"/trials/nct07446855/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","route":"/trials/nct04644068/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05367440","kind":"trial","name":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","route":"/trials/nct05367440/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06005493","kind":"trial","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06005493/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06514027","kind":"trial","name":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","route":"/trials/nct06514027/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06428396","kind":"trial","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","route":"/trials/nct06428396/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04662255","kind":"trial","name":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","route":"/trials/nct04662255/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07011719/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07019779","kind":"trial","name":"Study of CM518D1 in Patients With Advanced Solid Tumors","route":"/trials/nct07019779/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07030257","kind":"trial","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07030257/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07283835","kind":"trial","name":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","route":"/trials/nct07283835/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","route":"/trials/nct06881784/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05215340","kind":"trial","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","route":"/trials/nct05215340/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07129993","kind":"trial","name":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07129993/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05651022","kind":"trial","name":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","route":"/trials/nct05651022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07527858","kind":"trial","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","route":"/trials/nct07527858/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05320198","kind":"trial","name":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","route":"/trials/nct05320198/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04550260","kind":"trial","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","route":"/trials/nct04550260/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06726148","kind":"trial","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","route":"/trials/nct06726148/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04836507","kind":"trial","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","route":"/trials/nct04836507/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04417621","kind":"trial","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","route":"/trials/nct04417621/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03876769","kind":"trial","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","route":"/trials/nct03876769/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06726265","kind":"trial","name":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ","route":"/trials/nct06726265/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05316155","kind":"trial","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","route":"/trials/nct05316155/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06567015","kind":"trial","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","route":"/trials/nct06567015/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06584032","kind":"trial","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","route":"/trials/nct06584032/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070518","kind":"trial","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","route":"/trials/nct07070518/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288359","kind":"trial","name":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","route":"/trials/nct07288359/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06800313","kind":"trial","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","route":"/trials/nct06800313/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06834672","kind":"trial","name":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","route":"/trials/nct06834672/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05745623","kind":"trial","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","route":"/trials/nct05745623/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03947385","kind":"trial","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","route":"/trials/nct03947385/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","route":"/trials/nct04198766/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06585410","kind":"trial","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","route":"/trials/nct06585410/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06414460","kind":"trial","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","route":"/trials/nct06414460/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06566079","kind":"trial","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","route":"/trials/nct06566079/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07100080","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy","route":"/trials/nct07100080/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07640295","kind":"trial","name":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","route":"/trials/nct07640295/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04699188","kind":"trial","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct04699188/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06667960","kind":"trial","name":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct06667960/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06253663","kind":"trial","name":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L","route":"/trials/nct06253663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04501120","kind":"trial","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","route":"/trials/nct04501120/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06088290","kind":"trial","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","route":"/trials/nct06088290/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05734066","kind":"trial","name":"Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma","route":"/trials/nct05734066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06128837","kind":"trial","name":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","route":"/trials/nct06128837/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04956640","kind":"trial","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","route":"/trials/nct04956640/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","route":"/trials/nct07448116/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","route":"/trials/nct04930432/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05533697","kind":"trial","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","route":"/trials/nct05533697/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06727565","kind":"trial","name":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst","route":"/trials/nct06727565/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05633667","kind":"trial","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","route":"/trials/nct05633667/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07520006","kind":"trial","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","route":"/trials/nct07520006/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07516093","kind":"trial","name":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","route":"/trials/nct07516093/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06890598","kind":"trial","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","route":"/trials/nct06890598/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06161974","kind":"trial","name":"Study of Olutasidenib and Temozolomide in HGG","route":"/trials/nct06161974/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07282587","kind":"trial","name":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","route":"/trials/nct07282587/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06136624","kind":"trial","name":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","route":"/trials/nct06136624/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","route":"/trials/nct07079475/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","route":"/trials/nct07745361/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05287945","kind":"trial","name":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","route":"/trials/nct05287945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04094311","kind":"trial","name":"Study of Out of Specification for Tisagenlecleucel","route":"/trials/nct04094311/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06596694","kind":"trial","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","route":"/trials/nct06596694/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06797635","kind":"trial","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","route":"/trials/nct06797635/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06686394","kind":"trial","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","route":"/trials/nct06686394/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02861573","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","route":"/trials/nct02861573/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02628067","kind":"trial","name":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","route":"/trials/nct02628067/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05609968","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","route":"/trials/nct05609968/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05239741","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","route":"/trials/nct05239741/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05173987","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","route":"/trials/nct05173987/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03725059","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","route":"/trials/nct03725059/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07777822","kind":"trial","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","route":"/trials/nct07777822/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04380636","kind":"trial","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","route":"/trials/nct04380636/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05855200","kind":"trial","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct05855200/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07775287","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","route":"/trials/nct07775287/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07702032","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta","route":"/trials/nct07702032/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06760637","kind":"trial","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","route":"/trials/nct06760637/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07499362","kind":"trial","name":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","route":"/trials/nct07499362/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07644039","kind":"trial","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","route":"/trials/nct07644039/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06608927","kind":"trial","name":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06608927/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06445062","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","route":"/trials/nct06445062/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03564340","kind":"trial","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","route":"/trials/nct03564340/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07125872","kind":"trial","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","route":"/trials/nct07125872/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06118086","kind":"trial","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","route":"/trials/nct06118086/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04683250","kind":"trial","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","route":"/trials/nct04683250/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07211958","kind":"trial","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","route":"/trials/nct07211958/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03767348","kind":"trial","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","route":"/trials/nct03767348/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05733598","kind":"trial","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","route":"/trials/nct05733598/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05101096","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","route":"/trials/nct05101096/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct05186974/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03547973","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","route":"/trials/nct03547973/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06801834","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06801834/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06486441","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im","route":"/trials/nct06486441/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05840211","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","route":"/trials/nct05840211/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07473167","kind":"trial","name":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","route":"/trials/nct07473167/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07326566","kind":"trial","name":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","route":"/trials/nct07326566/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","route":"/trials/nct07765446/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06252649","kind":"trial","name":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal","route":"/trials/nct06252649/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","route":"/trials/nct05098132/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/","detail":"mentions 2037 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05409066","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct05409066/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03155191","kind":"trial","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct03155191/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06731478","kind":"trial","name":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct06731478/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06284590","kind":"trial","name":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients","route":"/trials/nct06284590/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03967977","kind":"trial","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","route":"/trials/nct03967977/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07100730","kind":"trial","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","route":"/trials/nct07100730/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07022483","kind":"trial","name":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","route":"/trials/nct07022483/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06819007","kind":"trial","name":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-","route":"/trials/nct06819007/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06899126","kind":"trial","name":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","route":"/trials/nct06899126/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02899052","kind":"trial","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","route":"/trials/nct02899052/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03069469","kind":"trial","name":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor","route":"/trials/nct03069469/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06535607","kind":"trial","name":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","route":"/trials/nct06535607/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07823049","kind":"trial","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","route":"/trials/nct07823049/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06082167","kind":"trial","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06082167/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06840483","kind":"trial","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","route":"/trials/nct06840483/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06903377/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06883526","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","route":"/trials/nct06883526/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06927687","kind":"trial","name":"Study of ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06927687/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06938880","kind":"trial","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06938880/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258121","kind":"trial","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","route":"/trials/nct07258121/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07805954","kind":"trial","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","route":"/trials/nct07805954/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03040973","kind":"trial","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","route":"/trials/nct03040973/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07387471","kind":"trial","name":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu","route":"/trials/nct07387471/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05985655","kind":"trial","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","route":"/trials/nct05985655/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct04879043/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05546866","kind":"trial","name":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","route":"/trials/nct05546866/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05038735","kind":"trial","name":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","route":"/trials/nct05038735/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07166094","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","route":"/trials/nct07166094/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288177","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","route":"/trials/nct07288177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07225270","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","route":"/trials/nct07225270/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07564141","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","route":"/trials/nct07564141/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05257993","kind":"trial","name":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv","route":"/trials/nct05257993/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221734","kind":"trial","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","route":"/trials/nct07221734/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04464226","kind":"trial","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","route":"/trials/nct04464226/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04925479","kind":"trial","name":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","route":"/trials/nct04925479/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07354074","kind":"trial","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","route":"/trials/nct07354074/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632951","kind":"trial","name":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","route":"/trials/nct06632951/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06772623","kind":"trial","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","route":"/trials/nct06772623/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nsclc-2","kind":"trial","name":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-2/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04068597","kind":"trial","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","route":"/trials/nct04068597/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05379946","kind":"trial","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","route":"/trials/nct05379946/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07185997","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W","route":"/trials/nct07185997/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07214779","kind":"trial","name":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07214779/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05168566","kind":"trial","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05168566/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","route":"/trials/nct07341100/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07427394","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","route":"/trials/nct07427394/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04581512","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of EP0042","route":"/trials/nct04581512/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06922591","kind":"trial","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","route":"/trials/nct06922591/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","route":"/trials/nct04665206/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05727904","kind":"trial","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","route":"/trials/nct05727904/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04349436","kind":"trial","name":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","route":"/trials/nct04349436/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05317416","kind":"trial","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","route":"/trials/nct05317416/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06904235","kind":"trial","name":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","route":"/trials/nct06904235/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05676931","kind":"trial","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","route":"/trials/nct05676931/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","route":"/trials/nct06353386/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06395103","kind":"trial","name":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","route":"/trials/nct06395103/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780098","kind":"trial","name":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","route":"/trials/nct06780098/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07049926","kind":"trial","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","route":"/trials/nct07049926/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06469944","kind":"trial","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","route":"/trials/nct06469944/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06445972","kind":"trial","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","route":"/trials/nct06445972/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780111","kind":"trial","name":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","route":"/trials/nct06780111/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-sung-globocan-2020-cacancer-2021","kind":"paper","name":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer","route":"/key-papers/paper-sung-globocan-2020-cacancer-2021/","detail":"mentions 2040 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06526793","kind":"trial","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","route":"/trials/nct06526793/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07509151","kind":"trial","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","route":"/trials/nct07509151/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-gi-03","kind":"trial","name":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","route":"/trials/symbiotic-gi-03/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227012","kind":"trial","name":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a","route":"/trials/nct07227012/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-gi-16","kind":"trial","name":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","route":"/trials/symbiotic-gi-16/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07421700","kind":"trial","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","route":"/trials/nct07421700/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227415","kind":"trial","name":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With ","route":"/trials/nct07227415/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-lung-01","kind":"trial","name":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/symbiotic-lung-01/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-lung-04","kind":"trial","name":"Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","route":"/trials/symbiotic-lung-04/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07489066","kind":"trial","name":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","route":"/trials/nct07489066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07476287","kind":"trial","name":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed","route":"/trials/nct07476287/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227298","kind":"trial","name":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","route":"/trials/nct07227298/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sys6023","kind":"drug","name":"SYS6023","route":"/drugs/sys6023/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"t3011","kind":"drug","name":"T3011","route":"/drugs/t3011/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","route":"/trials/nct05862324/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tak-928","kind":"drug","name":"TAK-928","route":"/drugs/tak-928/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tar-210","kind":"drug","name":"TAR-210","route":"/drugs/tar-210/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","route":"/trials/nct07598955/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04701476","kind":"trial","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","route":"/trials/nct04701476/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tbi-1501","kind":"drug","name":"TBI-1501","route":"/drugs/tbi-1501/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tc011","kind":"drug","name":"TC011","route":"/drugs/tc011/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05549297","kind":"trial","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","route":"/trials/nct05549297/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tersolisib","kind":"drug","name":"Tersolisib","route":"/drugs/tersolisib/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06861088","kind":"trial","name":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","route":"/trials/nct06861088/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07565285","kind":"trial","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","route":"/trials/nct07565285/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07114861","kind":"trial","name":"The KN510713 Study in Combination With mFOLFIRINOX","route":"/trials/nct07114861/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04329728","kind":"trial","name":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","route":"/trials/nct04329728/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05771584","kind":"trial","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","route":"/trials/nct05771584/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05208944","kind":"trial","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","route":"/trials/nct05208944/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06758401","kind":"trial","name":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu","route":"/trials/nct06758401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07028853","kind":"trial","name":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En","route":"/trials/nct07028853/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06072131","kind":"trial","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","route":"/trials/nct06072131/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06504732","kind":"trial","name":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","route":"/trials/nct06504732/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06478719","kind":"trial","name":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","route":"/trials/nct06478719/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07795034","kind":"trial","name":"To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies","route":"/trials/nct07795034/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05541822","kind":"trial","name":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","route":"/trials/nct05541822/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07454187/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06378242","kind":"trial","name":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","route":"/trials/nct06378242/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07368998","kind":"trial","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","route":"/trials/nct07368998/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tq-b3234","kind":"drug","name":"TQ-B3234","route":"/drugs/tq-b3234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07047365","kind":"trial","name":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","route":"/trials/nct07047365/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05950945","kind":"trial","name":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","route":"/trials/nct05950945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05294731","kind":"trial","name":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","route":"/trials/nct05294731/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tri-611","kind":"drug","name":"TRI-611","route":"/drugs/tri-611/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07246863","kind":"trial","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07246863/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07098988/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06510374","kind":"trial","name":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06510374/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109414","kind":"trial","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","route":"/trials/nct07109414/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07216443","kind":"trial","name":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct07216443/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04542824","kind":"trial","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","route":"/trials/nct04542824/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","route":"/trials/nct06618235/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06472245","kind":"trial","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","route":"/trials/nct06472245/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06635824","kind":"trial","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","route":"/trials/nct06635824/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07805252","kind":"trial","name":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","route":"/trials/nct07805252/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04969315","kind":"trial","name":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma","route":"/trials/nct04969315/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05458674","kind":"trial","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","route":"/trials/nct05458674/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07190300","kind":"trial","name":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in ","route":"/trials/nct07190300/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04589845","kind":"trial","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","route":"/trials/nct04589845/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ugn-104","kind":"drug","name":"UGN-104","route":"/drugs/ugn-104/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"uliledlimab","kind":"drug","name":"Uliledlimab","route":"/drugs/uliledlimab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"velzatinib","kind":"drug","name":"Velzatinib","route":"/drugs/velzatinib/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"vepugratinib","kind":"drug","name":"Vepugratinib","route":"/drugs/vepugratinib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07219459","kind":"trial","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","route":"/trials/nct07219459/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03556228","kind":"trial","name":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","route":"/trials/nct03556228/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06448754","kind":"trial","name":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","route":"/trials/nct06448754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"vrn110755","kind":"drug","name":"VRN110755","route":"/drugs/vrn110755/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"vs-7375","kind":"drug","name":"VS-7375","route":"/drugs/vs-7375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","route":"/trials/nct04644289/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05709249","kind":"trial","name":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","route":"/trials/nct05709249/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05684965","kind":"trial","name":"XTX301 in Patients With Advanced Solid Tumors","route":"/trials/nct05684965/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","route":"/trials/nct07461454/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943755","kind":"trial","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","route":"/trials/nct06943755/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06933329","kind":"trial","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06933329/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct07038096/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05502237","kind":"trial","name":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct05502237/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zovegalisib","kind":"drug","name":"Zovegalisib","route":"/drugs/zovegalisib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"name-collision-across-kinds","severity":"low","id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","detail":"\"cytarabine anthracycline\" is also Cytarabine + anthracycline ('7+3') (cytarabine-7-3, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","detail":"\"cpx 351\" is also CPX-351 (liposomal daunorubicin-cytarabine) (cpx-351, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","detail":"\"titan\" is also TITAN (whole-slide multimodal model) (titan, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/","detail":"\"anvisa\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/","detail":"\"allogeneic stem cell transplantation\" is also Allogeneic stem cell transplantation (allogeneic-hsct, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/","detail":"\"allogeneic stem cell transplantation\" is also Allogeneic stem cell transplant (allo-SCT) (allogeneic-transplant, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct02531516","kind":"trial","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","route":"/trials/nct02531516/","detail":"\"atlas\" is also Atlas (Aignostics, Mayo Clinic, Charité) (atlas-aignostics, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","detail":"\"erythropoiesis stimulating agent\" is also Epoetin alfa (epoetin-alfa, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","detail":"\"angiosarcoma\" is also Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma) (vascular-tumours, cancer), Angiosarcoma (angiosarcoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"atlas-aignostics","kind":"technology","name":"Atlas (Aignostics, Mayo Clinic, Charité)","route":"/technologies/atlas-aignostics/","detail":"\"atlas\" is also An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS (nct02531516, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","detail":"\"autologous stem cell transplant\" is also Autologous stem cell transplant (high-dose therapy) (autologous-stem-cell-transplant, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","detail":"\"autologous stem cell transplant\" is also Autologous stem cell transplant (ASCT) (autologous-transplant, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","detail":"\"bcr abl1\" is also BCR::ABL1 (Philadelphia chromosome) (bcr-abl1-signalling, pathway), Philadelphia chromosome (Ph+, BCR::ABL1) (philadelphia-chromosome, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","detail":"\"bcr abl1\" is also BCR::ABL1 (Philadelphia chromosome) (bcr-abl, target), Philadelphia chromosome (Ph+, BCR::ABL1) (philadelphia-chromosome, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","detail":"\"psa recurrence\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","detail":"\"breast cancer\" is also Breast cancer (KEGG map) (breast-cancer-signalling, pathway), Breast cancer (all types) (breast-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","detail":"\"breast cancer\" is also Breast cancer (KEGG map) (breast-cancer-signalling, pathway), Breast cancer (breast-cancer-jbcs, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","detail":"\"breast cancer\" is also Breast cancer (breast-cancer-jbcs, journal), Breast cancer (all types) (breast-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","detail":"\"cancer of unknown primary\" is also Primary tumour (primary-tumour, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","detail":"\"capox\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","detail":"\"cell\" is also Cell (cell-term, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","detail":"\"cell\" is also Cell (cell, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/","detail":"\"cereblon e3 ligase modulators\" is also Immunomodulatory drugs (IMiDs) and CELMoDs (imid, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","route":"/companies/chan-zuckerberg-initiative/","detail":"\"chan zuckerberg initiative\" is also Priscilla Chan (priscilla-chan, person); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","detail":"\"cpx 351\" is also 7+3 induction chemotherapy (seven-plus-three, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","detail":"\"cytarabine anthracycline\" is also 7+3 induction chemotherapy (seven-plus-three, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/","detail":"\"uicc\" is also Union for International Cancer Control (uicc, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","detail":"\"erythropoiesis stimulating agent\" is also Anaemia (anaemia, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","detail":"\"chmp\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"flot-term","kind":"term","name":"FLOT regimen (perioperative chemotherapy for gastric cancer)","route":"/terms/flot-term/","detail":"\"flot4\" is also FLOT4-AIO (flot4, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/","detail":"\"flot4\" is also FLOT regimen (perioperative chemotherapy for gastric cancer) (flot-term, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","detail":"\"folfiri\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","detail":"\"folfox\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"nalirifox\" is also NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) (nalirifox, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"folfox\" is also FOLFOX (5-FU, leucovorin, oxaliplatin) (folfox, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"folfiri\" is also FOLFIRI (5-FU, leucovorin, irinotecan) (folfiri, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"capox\" is also CAPOX (capecitabine, oxaliplatin) (capox, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","detail":"\"gastric cancer\" is also Gastric cancer (KEGG map) (gastric-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","detail":"\"gastric cancer\" is also Gastric cancer (gastric-cancer, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","detail":"\"gemcitabine nab paclitaxel\" is also Taxanes (paclitaxel, docetaxel, nab-paclitaxel) (taxane, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","detail":"\"g ba\" is also Health technology assessment (HTA), reimbursement and QALYs (hta, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","detail":"\"health canada\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","detail":"\"g ba\" is also Gemeinsamer Bundesausschuss / IQWiG (g-ba-iqwig, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","detail":"\"pbac\" is also Pharmaceutical Benefits Advisory Committee (pbac, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","detail":"\"hormonal therapy\" is also Hormone therapy (hormone-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/","detail":"\"progesterone receptor\" is also Progesterone receptor (PGR) (pgr, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","detail":"\"hormonal therapy\" is also Hormonal Therapy (hormonal, section); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/","detail":"\"hpv positive head and neck cancer\" is also Oropharyngeal cancer (tonsil and base of tongue) (oropharyngeal-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","detail":"\"icans\" is also Institut Strauss (institut-strauss, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"immuno-oncology","kind":"term","name":"Immuno-oncology (IO) and checkpoint blockade","route":"/terms/immuno-oncology/","detail":"\"pd 1\" is also PD-1 (pd1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","detail":"\"cereblon e3 ligase modulators\" is also Cereblon E3 ligase modulators (CELMoDs) (celmods, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","detail":"\"imid\" is also Institute of Mother and Child, Warsaw (institute-of-mother-and-child, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/","detail":"\"in vivo\" is also In vivo (in-vivo, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"in-vivo","kind":"journal","name":"In vivo","route":"/journals/in-vivo/","detail":"\"in vivo\" is also In vitro and in vivo (in-vitro-in-vivo, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/","detail":"\"icans\" is also ICANS (neurotoxicity) (icans, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","detail":"\"imid\" is also Immunomodulatory drugs (IMiDs) and CELMoDs (imid, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","detail":"\"intravesical bcg\" is also Intravesical therapy (BCG and bladder instillations) (intravesical-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","detail":"\"intravesical bcg\" is also Intravesical BCG (bcg-intravesical, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","detail":"\"intravesical therapy\" is also Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy) (bcg-and-intravesical-therapy, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","detail":"\"intravesical therapy\" is also Intravesical therapy (BCG and bladder instillations) (intravesical-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","detail":"\"lacc\" is also Locally advanced cervical cancer (locally-advanced-cervical-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","detail":"\"leukemia\" is also Leukemia (leukemia, journal), Leukaemia (tissue type) (leukaemia-type, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","detail":"\"leukaemia\" is also Leukaemia (tissue type) (leukaemia-type, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","detail":"\"leukemia\" is also Leukemia (leukemia, journal), Leukaemia (all types) (leukaemia, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","detail":"\"leukaemia\" is also Leukaemia (all types) (leukaemia, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","detail":"\"leukemia\" is also Leukaemia (tissue type) (leukaemia-type, term), Leukaemia (all types) (leukaemia, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/","detail":"\"lacc\" is also LACC (Laparoscopic Approach to Cervical Cancer) (lacc, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","detail":"\"low grade serous ovarian cancer\" is also Low-grade serous ovarian cancer (LGSOC) (lgsoc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","detail":"\"low grade serous ovarian cancer\" is also Low-grade serous ovarian cancer (low-grade-serous-ovarian-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","detail":"\"lung cancer\" is also Lung cancer (all types) (lung-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","detail":"\"lung cancer\" is also Lung cancer (lung-cancer-journal, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/","detail":"\"lymphoma\" is also Non-Hodgkin lymphoma (all types) (non-hodgkin-lymphoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"mcrpc\" is also Metastatic castration-resistant prostate cancer (prostate-mcrpc, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"mhspc\" is also Metastatic hormone-sensitive prostate cancer (prostate-mhspc, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"psa recurrence\" is also Biochemical recurrence of prostate cancer (prostate-bcr, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","detail":"\"mhra\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","detail":"\"mcrpc\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","detail":"\"mhspc\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/","detail":"\"mibc\" is also Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC) (nmibc-vs-mibc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","detail":"\"nalirifox\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","detail":"\"nmpa\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","detail":"\"lymphoma\" is also Lymphoma (tissue type) (lymphoma-type, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","detail":"\"nmibc\" is also Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC) (nmibc-vs-mibc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","detail":"\"mibc\" is also Muscle-invasive and advanced bladder cancer (muscle-invasive-bladder-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","detail":"\"nmibc\" is also Non-muscle-invasive bladder cancer (non-muscle-invasive-bladder-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","detail":"\"oncogene\" is also Oncogene (oncogene-journal, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","detail":"\"oncogene\" is also Oncogene (oncogene, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oral-serds","kind":"technology","name":"Oral SERDs","route":"/technologies/oral-serds/","detail":"\"oral serds\" is also Selective oestrogen receptor degrader (SERD) (serd, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","detail":"\"hpv positive head and neck cancer\" is also HPV-positive (p16) head and neck cancer (hpv-p16, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","detail":"\"pd 1\" is also Immune checkpoint (immune-checkpoint, term), Immuno-oncology (IO) and checkpoint blockade (immuno-oncology, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/","detail":"\"pbac\" is also Health technology assessment (HTA), reimbursement and QALYs (hta, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","detail":"\"pmda\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"philadelphia-chromosome","kind":"term","name":"Philadelphia chromosome (Ph+, BCR::ABL1)","route":"/terms/philadelphia-chromosome/","detail":"\"bcr abl1\" is also BCR::ABL1 (Philadelphia chromosome) (bcr-abl, target), BCR::ABL1 (Philadelphia chromosome) (bcr-abl1-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/","detail":"\"platinum etoposide\" is also Platinum-sensitive / platinum-resistant (platinum-sensitivity, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/","detail":"\"platinum etoposide\" is also Platinum + etoposide (EP / CE) (platinum-etoposide, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","detail":"\"cancer of unknown primary\" is also Cancer of unknown primary (CUP) (cancer-of-unknown-primary, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/","detail":"\"chan zuckerberg initiative\" is also Chan Zuckerberg Initiative (Biohub) (chan-zuckerberg-initiative, company); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","detail":"\"prodige 23\" is also Total neoadjuvant therapy (TNT, rectal cancer) (total-neoadjuvant-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","detail":"\"progesterone receptor\" is also Hormone receptor status (ER / PR) (hormone-receptor-status, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","detail":"\"standardised uptake value\" is also Standardised uptake value (SUV) (suv, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","detail":"\"radiation oncology\" is also Radiotherapy (radiotherapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","detail":"\"radiation therapy\" is also Radiotherapy (radiotherapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","detail":"\"radioembolisation\" is also TARE / SIRT (radioembolisation with yttrium-90) (tare, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/","detail":"\"radiosensitisers\" is also Radiotherapy (radiotherapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","detail":"\"radiation therapy\" is also Radiation Therapy (radiation, section); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","detail":"\"radiation oncology\" is also Radiation oncology (radiation-oncology, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","detail":"\"radiosensitisers\" is also Radiosensitisers (radiosensitisers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","detail":"\"rapido\" is also Total neoadjuvant therapy (TNT, rectal cancer) (total-neoadjuvant-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"chmp\" is also European Medicines Agency (ema, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"mhra\" is also Medicines and Healthcare products Regulatory Agency (mhra, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"pmda\" is also Pharmaceuticals and Medical Devices Agency (pmda, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"nmpa\" is also National Medical Products Administration / Center for Drug Evaluation (nmpa-cde, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"health canada\" is also Health Canada (health-canada, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"swissmedic\" is also Swissmedic (swissmedic, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"anvisa\" is also Agência Nacional de Vigilância Sanitária (anvisa, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/","detail":"\"retroperitoneal sarcoma\" is also Retroperitoneum (retroperitoneum, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"retroperitoneum","kind":"term","name":"Retroperitoneum","route":"/terms/retroperitoneum/","detail":"\"retroperitoneal sarcoma\" is also Retroperitoneal sarcoma (retroperitoneal-sarcoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","route":"/terms/serd/","detail":"\"oral serds\" is also Oral SERDs (oral-serds, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","detail":"\"standardised uptake value\" is also Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC) (quantitative-imaging-biomarkers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"swissmedic","kind":"institution","name":"Swissmedic","route":"/institutions/swissmedic/","detail":"\"swissmedic\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/","detail":"\"t cell exhaustion\" is also T-cell exhaustion (t-cell-exhaustion, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"t-cell-exhaustion","kind":"pathway","name":"T-cell exhaustion","route":"/pathways/t-cell-exhaustion/","detail":"\"t cell exhaustion\" is also T cell (t-cell, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","detail":"\"radioembolisation\" is also Radioembolisation (TARE / SIRT, yttrium-90) (radioembolisation-tare, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","detail":"\"targeted oncology\" is also Targeted Oncology (src-targeted-oncology, collection); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","detail":"\"targeted oncology\" is also Targeted oncology (targeted-oncology, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"taxane","kind":"term","name":"Taxanes (paclitaxel, docetaxel, nab-paclitaxel)","route":"/terms/taxane/","detail":"\"gemcitabine nab paclitaxel\" is also Gemcitabine + nab-paclitaxel (gemcitabine-nab-paclitaxel, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"titan","kind":"technology","name":"TITAN (whole-slide multimodal model)","route":"/technologies/titan/","detail":"\"titan\" is also A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (nct02489318, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","detail":"\"rapido\" is also RAPIDO (rapido, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","detail":"\"prodige 23\" is also PRODIGE 23 (prodige-23, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","detail":"\"uicc\" is also Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC) (staging-systems, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","detail":"\"angiosarcoma\" is also Angiosarcoma (review) (paper-young-angiosarcoma-review-lancet-oncol-2010, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"near-duplicate-name","severity":"low","id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","detail":"name overlaps with Doxorubicin (doxorubicin)"},{"check":"near-duplicate-name","severity":"low","id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","detail":"name overlaps with 5-Aminolevulinic acid (oral, for glioma surgery) (aminolevulinic-acid-gleolan)"},{"check":"near-duplicate-name","severity":"low","id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/","detail":"name overlaps with Pegfilgrastim (pegfilgrastim)"},{"check":"near-duplicate-name","severity":"low","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"name overlaps with Ropeginterferon alfa-2b (ropeginterferon-alfa-2b)"},{"check":"near-duplicate-name","severity":"low","id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct06735144/","detail":"name overlaps with A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors (nct07136142)"},{"check":"near-duplicate-name","severity":"low","id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/","detail":"name overlaps with A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) (nct06943833)"},{"check":"near-duplicate-name","severity":"low","id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/","detail":"name overlaps with Tumour markers (CEA, LDH, chromogranin, thyroglobulin) (tumour-markers)"},{"check":"orphan","severity":"low","id":"nct07222969","kind":"trial","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","route":"/trials/nct07222969/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05908643","kind":"trial","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","route":"/trials/nct05908643/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06277219","kind":"trial","name":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","route":"/trials/nct06277219/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07185880","kind":"trial","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","route":"/trials/nct07185880/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","route":"/trials/nct06971523/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","route":"/trials/nct07253116/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","route":"/trials/nct07811037/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06810804","kind":"trial","name":"A Phase IIa Study to Evaluate NBQ72S","route":"/trials/nct06810804/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","route":"/trials/nct06150885/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","route":"/trials/nct06314373/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07192588","kind":"trial","name":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","route":"/trials/nct07192588/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","route":"/trials/nct07678684/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05710848","kind":"trial","name":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","route":"/trials/nct05710848/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","route":"/trials/nct06656390/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","route":"/trials/nct07055594/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06911333/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04616209/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","route":"/trials/nct07033026/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","route":"/trials/nct07359066/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"arden-bio","kind":"company","name":"Arden Bio","route":"/companies/arden-bio/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","route":"/trials/nct07374419/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05261750","kind":"trial","name":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","route":"/trials/nct05261750/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","route":"/institutions/center-for-metabolic-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06126510","kind":"trial","name":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","route":"/trials/nct06126510/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07664150","kind":"trial","name":"CW-301 FIH Study of CAN016","route":"/trials/nct07664150/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"dcvc","kind":"company","name":"DCVC","route":"/companies/dcvc/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","route":"/companies/ecor1-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07276789","kind":"trial","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","route":"/trials/nct07276789/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","route":"/trials/nct05304481/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05374915","kind":"trial","name":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","route":"/trials/nct05374915/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","route":"/companies/eqt-life-sciences/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06262139","kind":"trial","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","route":"/trials/nct06262139/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06612281","kind":"trial","name":"Evaluation of Gixam's Performance in a FIT Negative Population","route":"/trials/nct06612281/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06824064","kind":"trial","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","route":"/trials/nct06824064/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","route":"/trials/nct07136181/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06154291","kind":"trial","name":"FIH XON7 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06154291/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ignitus-bio","kind":"company","name":"Ignitus Bio","route":"/companies/ignitus-bio/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06687681","kind":"trial","name":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","route":"/trials/nct06687681/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct03096093","kind":"trial","name":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","route":"/trials/nct03096093/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","route":"/companies/mckesson-ventures/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04651634","kind":"trial","name":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","route":"/trials/nct04651634/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04974008","kind":"trial","name":"Osteosarcoma Maintenance Therapy With OST31-164","route":"/trials/nct04974008/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05801237","kind":"trial","name":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","route":"/trials/nct05801237/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"perita-bio","kind":"company","name":"Perita Bio","route":"/companies/perita-bio/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","route":"/trials/nct07002203/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04643418","kind":"trial","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06938867","kind":"trial","name":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","route":"/trials/nct06938867/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","route":"/trials/nct07168226/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06118788/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","route":"/trials/nct05720130/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","route":"/trials/nct07314294/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04165590","kind":"trial","name":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","route":"/trials/nct04165590/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06665100","kind":"trial","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","route":"/trials/nct06665100/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"rarivive","kind":"company","name":"Rarivive","route":"/companies/rarivive/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07006077","kind":"trial","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","route":"/trials/nct07006077/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","route":"/trials/nct06937177/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05558007","kind":"trial","name":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","route":"/trials/nct05558007/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","route":"/trials/nct06506643/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04959903","kind":"trial","name":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","route":"/trials/nct04959903/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06737081","kind":"trial","name":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","route":"/trials/nct06737081/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"sante-ventures","kind":"company","name":"Sante Ventures","route":"/companies/sante-ventures/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06616389","kind":"trial","name":"Study of ODX (OsteoDex) in Multiple Myeloma","route":"/trials/nct06616389/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","route":"/trials/nct07765446/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06260774","kind":"trial","name":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","route":"/trials/nct06260774/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06580301","kind":"trial","name":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","route":"/trials/nct06580301/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05499013","kind":"trial","name":"Study to Assess SLN124 in Patients With Polycythemia Vera","route":"/trials/nct05499013/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06234098","kind":"trial","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","route":"/trials/nct06234098/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07114861","kind":"trial","name":"The KN510713 Study in Combination With mFOLFIRINOX","route":"/trials/nct07114861/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"regional-approval-only","severity":"low","id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/","detail":"approved only outside US/EU (JP 2002); status \"established\" describes the global stage"},{"check":"text-says-approved","severity":"low","id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"aminoglutethimide","kind":"drug","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","detail":"text mentions approval but status is \"historic\""},{"check":"text-says-approved","severity":"low","id":"amsacrine","kind":"drug","name":"Amsacrine","route":"/drugs/amsacrine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"cam2029","kind":"drug","name":"CAM2029 (octreotide subcutaneous depot)","route":"/drugs/cam2029/","detail":"text mentions approval but status is \"phase-3\""},{"check":"text-says-approved","severity":"low","id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"metyrapone","kind":"drug","name":"Metyrapone","route":"/drugs/metyrapone/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"pipobroman","kind":"drug","name":"Pipobroman","route":"/drugs/pipobroman/","detail":"text mentions approval but status is \"historic\""},{"check":"text-says-approved","severity":"low","id":"plicamycin","kind":"drug","name":"Plicamycin","route":"/drugs/plicamycin/","detail":"text mentions approval but status is \"historic\""},{"check":"text-says-approved","severity":"low","id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"uracil-mustard","kind":"drug","name":"Uracil mustard","route":"/drugs/uracil-mustard/","detail":"text mentions approval but status is \"historic\""},{"check":"text-vs-structured","severity":"low","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"text mentions approval in 2000 but the earliest recorded approval is 2011; add the missing approvals[] row or correct the year"},{"check":"unsourced","severity":"low","id":"1p19q-codeletion","kind":"term","name":"1p/19q codeletion","route":"/terms/1p19q-codeletion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"aml-myelodysplasia-related","kind":"term","name":"AML with myelodysplasia-related gene mutations (AML-MR)","route":"/terms/aml-myelodysplasia-related/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"angela-lamarca","kind":"person","name":"Angela Lamarca","route":"/people/angela-lamarca/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"b-all-cytogenetic-risk","kind":"term","name":"B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)","route":"/terms/b-all-cytogenetic-risk/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"abl1-kinase-domain-mutations","kind":"term","name":"BCR::ABL1 kinase domain mutations (T315I and others)","route":"/terms/abl1-kinase-domain-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"brca-reversion-mutations","kind":"term","name":"BRCA reversion mutations","route":"/terms/brca-reversion-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"brigimadlin","kind":"drug","name":"Brigimadlin","route":"/drugs/brigimadlin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"btki-bcl2i-resistance-mutations","kind":"term","name":"BTK C481S, PLCG2 and BCL2 G101V resistance mutations","route":"/terms/btki-bcl2i-resistance-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"carotuximab","kind":"drug","name":"Carotuximab","route":"/drugs/carotuximab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"china-hgr-rules","kind":"term","name":"China Human Genetic Resources rules (2019, 2023)","route":"/terms/china-hgr-rules/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-pv-clone-directed-therapy","kind":"idea","name":"Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission","route":"/ideas/idea-pv-clone-directed-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"daromun","kind":"drug","name":"Daromun","route":"/drugs/daromun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-dearnaley","kind":"person","name":"David Dearnaley","route":"/people/david-dearnaley/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"depth-of-invasion","kind":"term","name":"Depth of invasion (DOI)","route":"/terms/depth-of-invasion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dipss-mipss70","kind":"term","name":"DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)","route":"/terms/dipss-mipss70/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"disease-volume-chaarted","kind":"term","name":"Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk","route":"/terms/disease-volume-chaarted/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-efflux-agnostic","kind":"idea","name":"Efflux-agnostic therapy for mesenchymal TNBC","route":"/ideas/idea-efflux-agnostic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ependymoma-molecular-groups","kind":"term","name":"Ependymoma molecular groups (PF-A, PF-B, ZFTA, YAP1, MYCN)","route":"/terms/ependymoma-molecular-groups/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"extranodal-extension","kind":"term","name":"Extranodal extension (ENE)","route":"/terms/extranodal-extension/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","route":"/people/francesco-lo-coco/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gerald-prager","kind":"person","name":"Gerald W. Prager","route":"/people/gerald-prager/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","route":"/people/gerhardt-attard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gi-6301","kind":"drug","name":"GI-6301","route":"/drugs/gi-6301/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gist-risk-stratification","kind":"term","name":"GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)","route":"/terms/gist-risk-stratification/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"graded-prognostic-assessment","kind":"term","name":"Graded Prognostic Assessment (GPA) for brain metastases","route":"/terms/graded-prognostic-assessment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gsk2256098","kind":"drug","name":"GSK2256098","route":"/drugs/gsk2256098/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","route":"/people/hansjochen-wilke/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hb-200","kind":"drug","name":"HB-200","route":"/drugs/hb-200/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-pv-hepcidin-first","kind":"idea","name":"Hepcidin-based control as first-line treatment in low-risk polycythaemia vera","route":"/ideas/idea-pv-hepcidin-first/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"histological-response-induction","kind":"term","name":"Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma)","route":"/terms/histological-response-induction/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ihc-autostainers-histology-automation","kind":"technology","name":"Histology automation and IHC autostainers","route":"/technologies/ihc-autostainers-histology-automation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","route":"/people/hyung-ho-kim/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"inca033989","kind":"drug","name":"INCA033989","route":"/drugs/inca033989/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"interferon-gamma-signature","kind":"term","name":"Interferon-gamma gene signature (T-cell-inflamed signature)","route":"/terms/interferon-gamma-signature/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ipset-thrombosis","kind":"term","name":"IPSET-thrombosis score (essential thrombocythaemia)","route":"/terms/ipset-thrombosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","route":"/people/jeffrey-gershenwald/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jens-hoeppner","kind":"person","name":"Jens Höppner","route":"/people/jens-hoeppner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"joel-guigay","kind":"person","name":"Joël Guigay","route":"/people/joel-guigay/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","route":"/people/kimberly-dunsmore/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"manish-shah","kind":"person","name":"Manish A. Shah","route":"/people/manish-shah/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"maria-de-santis","kind":"person","name":"Maria De Santis","route":"/people/maria-de-santis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mipi","kind":"term","name":"MIPI (Mantle Cell Lymphoma International Prognostic Index)","route":"/terms/mipi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mlh1-promoter-methylation","kind":"term","name":"MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)","route":"/terms/mlh1-promoter-methylation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mpn-driver-mutations","kind":"term","name":"MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden","route":"/terms/mpn-driver-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"neovax","kind":"drug","name":"NeoVax","route":"/drugs/neovax/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nsmp","kind":"term","name":"No specific molecular profile (NSMP) endometrial cancer","route":"/terms/nsmp/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"obrixtamig","kind":"drug","name":"Obrixtamig","route":"/drugs/obrixtamig/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pharmacy-automation","kind":"technology","name":"Oncology pharmacy automation and compounding robots","route":"/technologies/pharmacy-automation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paltusotine","kind":"drug","name":"Paltusotine","route":"/drugs/paltusotine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patidegib","kind":"drug","name":"Patidegib","route":"/drugs/patidegib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-organoid-guided-adc","kind":"idea","name":"Patient-derived organoids to pick ADC payloads","route":"/ideas/idea-organoid-guided-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patricia-pautier","kind":"person","name":"Patricia Pautier","route":"/people/patricia-pautier/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ph-like-all","kind":"term","name":"Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia","route":"/terms/ph-like-all/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pretext-chic","kind":"term","name":"PRETEXT and CHIC risk groups (hepatoblastoma)","route":"/terms/pretext-chic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","route":"/people/rashmi-murthy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"registry-based-trial","kind":"term","name":"Registry-based randomised trial","route":"/terms/registry-based-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-doebele","kind":"person","name":"Robert C. Doebele","route":"/people/robert-doebele/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","route":"/people/rupert-bartsch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tarlatamab-vs-idxd-sequence","kind":"pairing","name":"Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC","route":"/pairings/tarlatamab-vs-idxd-sequence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sokal-elts-scores","kind":"term","name":"Sokal and ELTS risk scores (chronic myeloid leukaemia)","route":"/terms/sokal-elts-scores/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"wilms-risk-markers","kind":"term","name":"Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)","route":"/terms/wilms-risk-markers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"zanidatamab-zovodotin","kind":"drug","name":"Zanidatamab zovodotin","route":"/drugs/zanidatamab-zovodotin/","detail":"no external link or Wikipedia reference"}],"staleness":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","asOf":"2026-09-04","days":17},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","asOf":"2026-09-04","days":17},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","asOf":"2026-09-04","days":17},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","asOf":"2026-09-04","days":17},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","asOf":"2026-09-04","days":17},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","asOf":"2026-09-04","days":17},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/","asOf":"2026-09-04","days":17},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","asOf":"2026-09-04","days":17},{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/","asOf":"2026-09-04","days":17},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","asOf":"2026-09-04","days":17},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","asOf":"2026-09-04","days":17},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","asOf":"2026-09-04","days":17},{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/","asOf":"2026-09-04","days":17},{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/","asOf":"2026-09-04","days":17},{"id":"extragonadal-germ-cell-tumour","kind":"cancer","name":"Extragonadal germ cell tumour","route":"/cancers/extragonadal-germ-cell-tumour/","asOf":"2026-09-04","days":17},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/","asOf":"2026-09-04","days":17},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/","asOf":"2026-09-04","days":17},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/","asOf":"2026-09-04","days":17},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/","asOf":"2026-09-04","days":17},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/","asOf":"2026-09-04","days":17},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","asOf":"2026-09-04","days":17},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","asOf":"2026-09-04","days":17},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","asOf":"2026-09-04","days":17},{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/","asOf":"2026-09-04","days":17},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","asOf":"2026-09-04","days":17},{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/","asOf":"2026-09-04","days":17},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/","asOf":"2026-09-04","days":17},{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","asOf":"2026-09-04","days":17},{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/","asOf":"2026-09-04","days":17},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/","asOf":"2026-09-04","days":17},{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/","asOf":"2026-09-04","days":17},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/","asOf":"2026-09-04","days":17},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/","asOf":"2026-09-04","days":17},{"id":"nutrition-lifestyle","kind":"section","name":"Diet, Exercise & Lifestyle","route":"/fronts/nutrition-lifestyle/","asOf":"2026-09-04","days":17},{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/","asOf":"2026-09-04","days":17},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","asOf":"2026-09-04","days":17},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/","asOf":"2026-09-04","days":17},{"id":"ultrasound","kind":"technology","name":"Ultrasound","route":"/technologies/ultrasound/","asOf":"2026-09-04","days":17},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/","asOf":"2026-09-04","days":17},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","asOf":"2026-09-04","days":17},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","asOf":"2026-09-04","days":17},{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","asOf":"2026-09-04","days":17},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","asOf":"2026-09-04","days":17},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","asOf":"2026-09-04","days":17},{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","asOf":"2026-09-04","days":17},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","asOf":"2026-09-04","days":17},{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/","asOf":"2026-09-04","days":17},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/","asOf":"2026-09-04","days":17},{"id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/","asOf":"2026-09-04","days":17},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","asOf":"2026-09-04","days":17},{"id":"whole-body-mri","kind":"technology","name":"Whole-body MRI","route":"/technologies/whole-body-mri/","asOf":"2026-09-04","days":17},{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/","asOf":"2026-09-04","days":17},{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/","asOf":"2026-09-04","days":17},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/","asOf":"2026-09-04","days":17},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/","asOf":"2026-09-04","days":17},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/","asOf":"2026-09-04","days":17},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/","asOf":"2026-09-04","days":17},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/","asOf":"2026-09-04","days":17},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","asOf":"2026-09-04","days":17},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/","asOf":"2026-09-04","days":17},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/","asOf":"2026-09-04","days":17},{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/","asOf":"2026-09-04","days":17},{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/","asOf":"2026-09-04","days":17},{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/","asOf":"2026-09-04","days":17},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","asOf":"2026-09-04","days":17},{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/","asOf":"2026-09-04","days":17},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/","asOf":"2026-09-04","days":17},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/","asOf":"2026-09-04","days":17},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/","asOf":"2026-09-04","days":17},{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/","asOf":"2026-09-04","days":17},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","asOf":"2026-09-04","days":17},{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/","asOf":"2026-09-04","days":17},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/","asOf":"2026-09-04","days":17},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/","asOf":"2026-09-04","days":17},{"id":"hifu-histotripsy","kind":"technology","name":"Focused ultrasound & histotripsy","route":"/technologies/hifu-histotripsy/","asOf":"2026-09-04","days":17},{"id":"irreversible-electroporation","kind":"technology","name":"Irreversible electroporation (NanoKnife)","route":"/technologies/irreversible-electroporation/","asOf":"2026-09-04","days":17},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/","asOf":"2026-09-04","days":17},{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","asOf":"2026-09-04","days":17},{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/","asOf":"2026-09-04","days":17},{"id":"flash-rt","kind":"technology","name":"FLASH radiotherapy","route":"/technologies/flash-rt/","asOf":"2026-09-04","days":17},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","asOf":"2026-09-04","days":17},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","asOf":"2026-09-04","days":17},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","asOf":"2026-09-04","days":17},{"id":"bnct","kind":"technology","name":"Boron neutron capture therapy","route":"/technologies/bnct/","asOf":"2026-09-04","days":17},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/","asOf":"2026-09-04","days":17},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/","asOf":"2026-09-04","days":17},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/","asOf":"2026-09-04","days":17},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/","asOf":"2026-09-04","days":17},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/","asOf":"2026-09-04","days":17},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/","asOf":"2026-09-04","days":17},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/","asOf":"2026-09-04","days":17},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/","asOf":"2026-09-04","days":17},{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/","asOf":"2026-09-04","days":17},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/","asOf":"2026-09-04","days":17},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/","asOf":"2026-09-04","days":17},{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/","asOf":"2026-09-04","days":17},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/","asOf":"2026-09-04","days":17},{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/","asOf":"2026-09-04","days":17},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/","asOf":"2026-09-04","days":17},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","asOf":"2026-09-04","days":17},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/","asOf":"2026-09-04","days":17},{"id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/","asOf":"2026-09-04","days":17},{"id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","asOf":"2026-09-04","days":17},{"id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","asOf":"2026-09-04","days":17},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","asOf":"2026-09-04","days":17},{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/","asOf":"2026-09-04","days":17},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","asOf":"2026-09-04","days":17},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/","asOf":"2026-09-04","days":17},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/","asOf":"2026-09-04","days":17},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/","asOf":"2026-09-04","days":17},{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/","asOf":"2026-09-04","days":17},{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/","asOf":"2026-09-04","days":17},{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","asOf":"2026-09-04","days":17},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/","asOf":"2026-09-04","days":17},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/","asOf":"2026-09-04","days":17},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/","asOf":"2026-09-04","days":17},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/","asOf":"2026-09-04","days":17},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/","asOf":"2026-09-04","days":17},{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/","asOf":"2026-09-04","days":17},{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/","asOf":"2026-09-04","days":17},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/","asOf":"2026-09-04","days":17},{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/","asOf":"2026-09-04","days":17},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/","asOf":"2026-09-04","days":17},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","asOf":"2026-09-04","days":17},{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/","asOf":"2026-09-04","days":17},{"id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/","asOf":"2026-09-04","days":17},{"id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/","asOf":"2026-09-04","days":17},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/","asOf":"2026-09-04","days":17},{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/","asOf":"2026-09-04","days":17},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/","asOf":"2026-09-04","days":17},{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/","asOf":"2026-09-04","days":17},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/","asOf":"2026-09-04","days":17},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/","asOf":"2026-09-04","days":17},{"id":"ttfields","kind":"technology","name":"Tumour treating fields (TTFields)","route":"/technologies/ttfields/","asOf":"2026-09-04","days":17},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/","asOf":"2026-09-04","days":17},{"id":"hyperthermia","kind":"technology","name":"Hyperthermia","route":"/technologies/hyperthermia/","asOf":"2026-09-04","days":17},{"id":"spatial-transcriptomics","kind":"technology","name":"Spatial transcriptomics","route":"/technologies/spatial-transcriptomics/","asOf":"2026-09-04","days":17},{"id":"imaging-mass-cytometry","kind":"technology","name":"Imaging mass cytometry","route":"/technologies/imaging-mass-cytometry/","asOf":"2026-09-04","days":17},{"id":"multiplex-immunofluorescence","kind":"technology","name":"Multiplex immunofluorescence","route":"/technologies/multiplex-immunofluorescence/","asOf":"2026-09-04","days":17},{"id":"ai-pathology-scoring","kind":"technology","name":"AI scoring of biomarkers and grade on pathology slides","route":"/technologies/ai-pathology-scoring/","asOf":"2026-09-04","days":17},{"id":"radiomics","kind":"technology","name":"Radiomics","route":"/technologies/radiomics/","asOf":"2026-09-04","days":17},{"id":"ctc-capture","kind":"technology","name":"Circulating tumour cell capture","route":"/technologies/ctc-capture/","asOf":"2026-09-04","days":17},{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/","asOf":"2026-09-04","days":17},{"id":"gene-expression-prognostic-assays","kind":"technology","name":"Gene-expression prognostic assays","route":"/technologies/gene-expression-prognostic-assays/","asOf":"2026-09-04","days":17},{"id":"oncology-pharmacogenomics","kind":"technology","name":"Pharmacogenomic testing before chemotherapy","route":"/technologies/oncology-pharmacogenomics/","asOf":"2026-09-04","days":17},{"id":"ai-mammography-screening","kind":"technology","name":"AI-assisted mammography screening","route":"/technologies/ai-mammography-screening/","asOf":"2026-09-04","days":17},{"id":"ai-endoscopy-detection","kind":"technology","name":"AI polyp detection in colonoscopy","route":"/technologies/ai-endoscopy-detection/","asOf":"2026-09-04","days":17},{"id":"cns-tumour-methylation-classifier","kind":"technology","name":"Methylation classifier for brain tumours","route":"/technologies/cns-tumour-methylation-classifier/","asOf":"2026-09-04","days":17},{"id":"clonal-evolution-tracking","kind":"technology","name":"Tumour clonal evolution tracking","route":"/technologies/clonal-evolution-tracking/","asOf":"2026-09-04","days":17},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/","asOf":"2026-09-04","days":17},{"id":"lag3-blockade","kind":"technology","name":"LAG-3 blockade","route":"/technologies/lag3-blockade/","asOf":"2026-09-04","days":17},{"id":"tim3-blockade","kind":"technology","name":"TIM-3 blockade","route":"/technologies/tim3-blockade/","asOf":"2026-09-04","days":17},{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/","asOf":"2026-09-04","days":17},{"id":"cd40-agonists","kind":"technology","name":"CD40 agonist antibodies","route":"/technologies/cd40-agonists/","asOf":"2026-09-04","days":17},{"id":"immunocytokines","kind":"technology","name":"Immunocytokines (antibody-cytokine fusions)","route":"/technologies/immunocytokines/","asOf":"2026-09-04","days":17},{"id":"nk-cell-engagers","kind":"technology","name":"NK cell engagers","route":"/technologies/nk-cell-engagers/","asOf":"2026-09-04","days":17},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/","asOf":"2026-09-04","days":17},{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/","asOf":"2026-09-04","days":17},{"id":"bacterial-vector-vaccines","kind":"technology","name":"Bacterial vector cancer vaccines","route":"/technologies/bacterial-vector-vaccines/","asOf":"2026-09-04","days":17},{"id":"gamma-delta-t-cell-therapy","kind":"technology","name":"Gamma-delta T cell therapy","route":"/technologies/gamma-delta-t-cell-therapy/","asOf":"2026-09-04","days":17},{"id":"nk-cell-therapy","kind":"technology","name":"NK cell therapy and CAR-NK","route":"/technologies/nk-cell-therapy/","asOf":"2026-09-04","days":17},{"id":"virus-specific-t-cells","kind":"technology","name":"Virus-specific T cells","route":"/technologies/virus-specific-t-cells/","asOf":"2026-09-04","days":17},{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/","asOf":"2026-09-04","days":17},{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/","asOf":"2026-09-04","days":17},{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","route":"/technologies/radioligand-dosimetry/","asOf":"2026-09-04","days":17},{"id":"menin-inhibitors","kind":"technology","name":"Menin inhibitors","route":"/technologies/menin-inhibitors/","asOf":"2026-09-04","days":17},{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/","asOf":"2026-09-04","days":17},{"id":"idh-inhibitors","kind":"technology","name":"IDH inhibitors","route":"/technologies/idh-inhibitors/","asOf":"2026-09-04","days":17},{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/","asOf":"2026-09-04","days":17},{"id":"mdm2-inhibitors","kind":"technology","name":"MDM2 inhibitors","route":"/technologies/mdm2-inhibitors/","asOf":"2026-09-04","days":17},{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/","asOf":"2026-09-04","days":17},{"id":"oral-serds","kind":"technology","name":"Oral SERDs","route":"/technologies/oral-serds/","asOf":"2026-09-04","days":17},{"id":"hedgehog-inhibitors","kind":"technology","name":"Hedgehog pathway inhibitors","route":"/technologies/hedgehog-inhibitors/","asOf":"2026-09-04","days":17},{"id":"gamma-secretase-inhibitors","kind":"technology","name":"Gamma-secretase inhibitors","route":"/technologies/gamma-secretase-inhibitors/","asOf":"2026-09-04","days":17},{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/","asOf":"2026-09-04","days":17},{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/","asOf":"2026-09-04","days":17},{"id":"atr-chk1-inhibitors","kind":"technology","name":"ATR and CHK1 inhibitors","route":"/technologies/atr-chk1-inhibitors/","asOf":"2026-09-04","days":17},{"id":"kat6-inhibitors","kind":"technology","name":"KAT6 inhibitors","route":"/technologies/kat6-inhibitors/","asOf":"2026-09-04","days":17},{"id":"genetically-engineered-mouse-models","kind":"technology","name":"Genetically engineered mouse models","route":"/technologies/genetically-engineered-mouse-models/","asOf":"2026-09-04","days":17},{"id":"humanised-mouse-models","kind":"technology","name":"Humanised mouse models","route":"/technologies/humanised-mouse-models/","asOf":"2026-09-04","days":17},{"id":"cancer-cell-line-encyclopedias","kind":"technology","name":"Cancer cell line encyclopedias and dependency maps","route":"/technologies/cancer-cell-line-encyclopedias/","asOf":"2026-09-04","days":17},{"id":"tumour-on-chip","kind":"technology","name":"Tumour-on-a-chip","route":"/technologies/tumour-on-chip/","asOf":"2026-09-04","days":17},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","asOf":"2026-09-04","days":17},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","asOf":"2026-09-04","days":17},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","asOf":"2026-09-04","days":17},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","asOf":"2026-09-04","days":17},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","asOf":"2026-09-04","days":17},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","asOf":"2026-09-04","days":17},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/","asOf":"2026-09-04","days":17},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","asOf":"2026-09-04","days":17},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","asOf":"2026-09-04","days":17},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","asOf":"2026-09-04","days":17},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","asOf":"2026-09-04","days":17},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","asOf":"2026-09-04","days":17},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/","asOf":"2026-09-04","days":17},{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/","asOf":"2026-09-04","days":17},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","asOf":"2026-09-04","days":17},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","asOf":"2026-09-04","days":17},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","asOf":"2026-09-04","days":17},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/","asOf":"2026-09-04","days":17},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","asOf":"2026-09-04","days":17},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","asOf":"2026-09-04","days":17},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","asOf":"2026-09-04","days":17},{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/","asOf":"2026-09-04","days":17},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/","asOf":"2026-09-04","days":17},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/","asOf":"2026-09-04","days":17},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/","asOf":"2026-09-04","days":17},{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/","asOf":"2026-09-04","days":17},{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/","asOf":"2026-09-04","days":17},{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/","asOf":"2026-09-04","days":17},{"id":"gp100","kind":"target","name":"gp100 (PMEL)","route":"/targets/gp100/","asOf":"2026-09-04","days":17},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","asOf":"2026-09-04","days":17},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","asOf":"2026-09-04","days":17},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/","asOf":"2026-09-04","days":17},{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/","asOf":"2026-09-04","days":17},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/","asOf":"2026-09-04","days":17},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","asOf":"2026-09-04","days":17},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","asOf":"2026-09-04","days":17},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","asOf":"2026-09-04","days":17},{"id":"met","kind":"target","name":"MET","route":"/targets/met/","asOf":"2026-09-04","days":17},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","asOf":"2026-09-04","days":17},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","asOf":"2026-09-04","days":17},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","asOf":"2026-09-04","days":17},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/","asOf":"2026-09-04","days":17},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/","asOf":"2026-09-04","days":17},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","asOf":"2026-09-04","days":17},{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","asOf":"2026-09-04","days":17},{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/","asOf":"2026-09-04","days":17},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","asOf":"2026-09-04","days":17},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/","asOf":"2026-09-04","days":17},{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/","asOf":"2026-09-04","days":17},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","asOf":"2026-09-04","days":17},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/","asOf":"2026-09-04","days":17},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","asOf":"2026-09-04","days":17},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","asOf":"2026-09-04","days":17},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","asOf":"2026-09-04","days":17},{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/","asOf":"2026-09-04","days":17},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","asOf":"2026-09-04","days":17},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","asOf":"2026-09-04","days":17},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","asOf":"2026-09-04","days":17},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","asOf":"2026-09-04","days":17},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/","asOf":"2026-09-04","days":17},{"id":"cyp17a1","kind":"target","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","route":"/targets/cyp17a1/","asOf":"2026-09-04","days":17},{"id":"aromatase","kind":"target","name":"Aromatase (CYP19A1)","route":"/targets/aromatase/","asOf":"2026-09-04","days":17},{"id":"proteasome","kind":"target","name":"Proteasome (PSMB5)","route":"/targets/proteasome/","asOf":"2026-09-04","days":17},{"id":"cereblon","kind":"target","name":"Cereblon (CRBN)","route":"/targets/cereblon/","asOf":"2026-09-04","days":17},{"id":"top1","kind":"target","name":"Topoisomerase I (TOP1)","route":"/targets/top1/","asOf":"2026-09-04","days":17},{"id":"top2a","kind":"target","name":"Topoisomerase II alpha (TOP2A)","route":"/targets/top2a/","asOf":"2026-09-04","days":17},{"id":"tyms","kind":"target","name":"Thymidylate synthase (TYMS)","route":"/targets/tyms/","asOf":"2026-09-04","days":17},{"id":"dhfr","kind":"target","name":"Dihydrofolate reductase (DHFR)","route":"/targets/dhfr/","asOf":"2026-09-04","days":17},{"id":"gnrhr","kind":"target","name":"GnRH receptor (GNRHR)","route":"/targets/gnrhr/","asOf":"2026-09-04","days":17},{"id":"xpo1","kind":"target","name":"Exportin-1 (XPO1)","route":"/targets/xpo1/","asOf":"2026-09-04","days":17},{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/","asOf":"2026-09-04","days":17},{"id":"tubulin","kind":"target","name":"Tubulin (microtubules)","route":"/targets/tubulin/","asOf":"2026-09-04","days":17},{"id":"dnmt1","kind":"target","name":"DNMT1 (DNA methyltransferase 1)","route":"/targets/dnmt1/","asOf":"2026-09-04","days":17},{"id":"rrm1","kind":"target","name":"Ribonucleotide reductase (RRM1)","route":"/targets/rrm1/","asOf":"2026-09-04","days":17},{"id":"pik3cd","kind":"target","name":"PI3K delta (PIK3CD)","route":"/targets/pik3cd/","asOf":"2026-09-04","days":17},{"id":"rara","kind":"target","name":"Retinoic acid receptor alpha (RARA)","route":"/targets/rara/","asOf":"2026-09-04","days":17},{"id":"fgfr3-receptor","kind":"target","name":"FGFR3","route":"/targets/fgfr3-receptor/","asOf":"2026-09-04","days":17},{"id":"pdgfrb","kind":"target","name":"PDGFRB","route":"/targets/pdgfrb/","asOf":"2026-09-04","days":17},{"id":"src","kind":"target","name":"SRC family kinases","route":"/targets/src/","asOf":"2026-09-04","days":17},{"id":"ifnar1","kind":"target","name":"Interferon alpha receptor (IFNAR1)","route":"/targets/ifnar1/","asOf":"2026-09-04","days":17},{"id":"csf3r","kind":"target","name":"G-CSF receptor (CSF3R)","route":"/targets/csf3r/","asOf":"2026-09-04","days":17},{"id":"htr3a","kind":"target","name":"5-HT3 receptor (HTR3A)","route":"/targets/htr3a/","asOf":"2026-09-04","days":17},{"id":"tacr1","kind":"target","name":"NK1 receptor (TACR1)","route":"/targets/tacr1/","asOf":"2026-09-04","days":17},{"id":"epor","kind":"target","name":"Erythropoietin receptor (EPOR)","route":"/targets/epor/","asOf":"2026-09-04","days":17},{"id":"axl","kind":"target","name":"AXL","route":"/targets/axl/","asOf":"2026-09-04","days":17},{"id":"glucocorticoid-receptor","kind":"target","name":"Glucocorticoid receptor (NR3C1)","route":"/targets/glucocorticoid-receptor/","asOf":"2026-09-04","days":17},{"id":"gamma-secretase","kind":"target","name":"Gamma-secretase (PSEN1)","route":"/targets/gamma-secretase/","asOf":"2026-09-04","days":17},{"id":"fgfr1","kind":"target","name":"FGFR1","route":"/targets/fgfr1/","asOf":"2026-09-04","days":17},{"id":"erbb4","kind":"target","name":"HER4 (ERBB4)","route":"/targets/erbb4/","asOf":"2026-09-04","days":17},{"id":"ada","kind":"target","name":"Adenosine deaminase (ADA)","route":"/targets/ada/","asOf":"2026-09-04","days":17},{"id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","asOf":"2026-09-04","days":17},{"id":"eef2","kind":"target","name":"Elongation factor 2 (EEF2)","route":"/targets/eef2/","asOf":"2026-09-04","days":17},{"id":"fkbp12","kind":"target","name":"FKBP12 (FKBP1A)","route":"/targets/fkbp12/","asOf":"2026-09-04","days":17},{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/","asOf":"2026-09-04","days":17},{"id":"gart","kind":"target","name":"GART (trifunctional purine synthesis enzyme)","route":"/targets/gart/","asOf":"2026-09-04","days":17},{"id":"tlr7","kind":"target","name":"Toll-like receptor 7 (TLR7)","route":"/targets/tlr7/","asOf":"2026-09-04","days":17},{"id":"pap","kind":"target","name":"Prostatic acid phosphatase (ACP3, PAP)","route":"/targets/pap/","asOf":"2026-09-04","days":17},{"id":"ron","kind":"target","name":"RON receptor (MST1R)","route":"/targets/ron/","asOf":"2026-09-04","days":17},{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","route":"/targets/ddr2/","asOf":"2026-09-04","days":17},{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/","asOf":"2026-09-04","days":17},{"id":"raf1","kind":"target","name":"CRAF (RAF1)","route":"/targets/raf1/","asOf":"2026-09-04","days":17},{"id":"pkc","kind":"target","name":"Protein kinase C family (PKC)","route":"/targets/pkc/","asOf":"2026-09-04","days":17},{"id":"cox2","kind":"target","name":"COX-2 (PTGS2)","route":"/targets/cox2/","asOf":"2026-09-04","days":17},{"id":"tshr","kind":"target","name":"TSH receptor (TSHR)","route":"/targets/tshr/","asOf":"2026-09-04","days":17},{"id":"igf1r","kind":"target","name":"IGF-1 receptor (IGF1R)","route":"/targets/igf1r/","asOf":"2026-09-04","days":17},{"id":"tie2","kind":"target","name":"TIE2 receptor (TEK)","route":"/targets/tie2/","asOf":"2026-09-04","days":17},{"id":"il11ra","kind":"target","name":"IL-11 receptor alpha","route":"/targets/il11ra/","asOf":"2026-09-04","days":17},{"id":"csf2ra","kind":"target","name":"GM-CSF receptor (CSF2RA)","route":"/targets/csf2ra/","asOf":"2026-09-04","days":17},{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/","asOf":"2026-09-04","days":17},{"id":"hck","kind":"target","name":"HCK kinase","route":"/targets/hck/","asOf":"2026-09-04","days":17},{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/","asOf":"2026-09-04","days":17},{"id":"frk","kind":"target","name":"FRK kinase","route":"/targets/frk/","asOf":"2026-09-04","days":17},{"id":"xdh","kind":"target","name":"Xanthine oxidase (XDH)","route":"/targets/xdh/","asOf":"2026-09-04","days":17},{"id":"txnrd1","kind":"target","name":"Thioredoxin reductase 1","route":"/targets/txnrd1/","asOf":"2026-09-04","days":17},{"id":"gsr","kind":"target","name":"Glutathione reductase","route":"/targets/gsr/","asOf":"2026-09-04","days":17},{"id":"pola1","kind":"target","name":"DNA polymerase alpha (POLA1)","route":"/targets/pola1/","asOf":"2026-09-04","days":17},{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/","asOf":"2026-09-04","days":17},{"id":"srd5a2","kind":"target","name":"5-alpha-reductase type 2 (SRD5A2)","route":"/targets/srd5a2/","asOf":"2026-09-04","days":17},{"id":"drd2","kind":"target","name":"Dopamine D2 receptor","route":"/targets/drd2/","asOf":"2026-09-04","days":17},{"id":"oprm1","kind":"target","name":"Mu-opioid receptor","route":"/targets/oprm1/","asOf":"2026-09-04","days":17},{"id":"cnr1","kind":"target","name":"Cannabinoid receptor 1","route":"/targets/cnr1/","asOf":"2026-09-04","days":17},{"id":"tph1","kind":"target","name":"Tryptophan hydroxylase 1","route":"/targets/tph1/","asOf":"2026-09-04","days":17},{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/","asOf":"2026-09-04","days":17},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","asOf":"2026-09-04","days":17},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","asOf":"2026-09-04","days":17},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","asOf":"2026-09-04","days":17},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","asOf":"2026-09-04","days":17},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","asOf":"2026-09-04","days":17},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","asOf":"2026-09-04","days":17},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","asOf":"2026-09-04","days":17},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","asOf":"2026-09-04","days":17},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","asOf":"2026-09-04","days":17},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","asOf":"2026-09-04","days":17},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","asOf":"2026-09-04","days":17},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","asOf":"2026-09-04","days":17},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","asOf":"2026-09-04","days":17},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/","asOf":"2026-09-04","days":17},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","asOf":"2026-09-04","days":17},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","asOf":"2026-09-04","days":17},{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","asOf":"2026-09-04","days":17},{"id":"tilatamig-samrotecan","kind":"drug","name":"Tilatamig samrotecan","route":"/drugs/tilatamig-samrotecan/","asOf":"2026-09-04","days":17},{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","asOf":"2026-09-04","days":17},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","asOf":"2026-09-04","days":17},{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/","asOf":"2026-09-04","days":17},{"id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","asOf":"2026-09-04","days":17},{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/","asOf":"2026-09-04","days":17},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","asOf":"2026-09-04","days":17},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","asOf":"2026-09-04","days":17},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","asOf":"2026-09-04","days":17},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","asOf":"2026-09-04","days":17},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","asOf":"2026-09-04","days":17},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","asOf":"2026-09-04","days":17},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","asOf":"2026-09-04","days":17},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","asOf":"2026-09-04","days":17},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","asOf":"2026-09-04","days":17},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","asOf":"2026-09-04","days":17},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","asOf":"2026-09-04","days":17},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","asOf":"2026-09-04","days":17},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","asOf":"2026-09-04","days":17},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","asOf":"2026-09-04","days":17},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","asOf":"2026-09-04","days":17},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","asOf":"2026-09-04","days":17},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","asOf":"2026-09-04","days":17},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","asOf":"2026-09-04","days":17},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","asOf":"2026-09-04","days":17},{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","asOf":"2026-09-04","days":17},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","asOf":"2026-09-04","days":17},{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","asOf":"2026-09-04","days":17},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","asOf":"2026-09-04","days":17},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","asOf":"2026-09-04","days":17},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","asOf":"2026-09-04","days":17},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","asOf":"2026-09-04","days":17},{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","asOf":"2026-09-04","days":17},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","asOf":"2026-09-04","days":17},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","asOf":"2026-09-04","days":17},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","asOf":"2026-09-04","days":17},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","asOf":"2026-09-04","days":17},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","asOf":"2026-09-04","days":17},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","asOf":"2026-09-04","days":17},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","asOf":"2026-09-04","days":17},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","asOf":"2026-09-04","days":17},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","asOf":"2026-09-04","days":17},{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","asOf":"2026-09-04","days":17},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","asOf":"2026-09-04","days":17},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","asOf":"2026-09-04","days":17},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","asOf":"2026-09-04","days":17},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","asOf":"2026-09-04","days":17},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","asOf":"2026-09-04","days":17},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","asOf":"2026-09-04","days":17},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","asOf":"2026-09-04","days":17},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","asOf":"2026-09-04","days":17},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","asOf":"2026-09-04","days":17},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","asOf":"2026-09-04","days":17},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","asOf":"2026-09-04","days":17},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","asOf":"2026-09-04","days":17},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","asOf":"2026-09-04","days":17},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","asOf":"2026-09-04","days":17},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","asOf":"2026-09-04","days":17},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","asOf":"2026-09-04","days":17},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","asOf":"2026-09-04","days":17},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","asOf":"2026-09-04","days":17},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","asOf":"2026-09-04","days":17},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","asOf":"2026-09-04","days":17},{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","asOf":"2026-09-04","days":17},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","asOf":"2026-09-04","days":17},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","asOf":"2026-09-04","days":17},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","asOf":"2026-09-04","days":17},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","asOf":"2026-09-04","days":17},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","asOf":"2026-09-04","days":17},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","asOf":"2026-09-04","days":17},{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","asOf":"2026-09-04","days":17},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","asOf":"2026-09-04","days":17},{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/","asOf":"2026-09-04","days":17},{"id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/","asOf":"2026-09-04","days":17},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","asOf":"2026-09-04","days":17},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","asOf":"2026-09-04","days":17},{"id":"omidubicel","kind":"drug","name":"Omidubicel","route":"/drugs/omidubicel/","asOf":"2026-09-04","days":17},{"id":"remestemcel-l","kind":"drug","name":"Remestemcel-L","route":"/drugs/remestemcel-l/","asOf":"2026-09-04","days":17},{"id":"hepzato","kind":"drug","name":"Melphalan hepatic delivery system","route":"/drugs/hepzato/","asOf":"2026-09-04","days":17},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","asOf":"2026-09-04","days":17},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","asOf":"2026-09-04","days":17},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/","asOf":"2026-09-04","days":17},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/","asOf":"2026-09-04","days":17},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","asOf":"2026-09-04","days":17},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/","asOf":"2026-09-04","days":17},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","asOf":"2026-09-04","days":17},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","asOf":"2026-09-04","days":17},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","asOf":"2026-09-04","days":17},{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/","asOf":"2026-09-04","days":17},{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/","asOf":"2026-09-04","days":17},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","asOf":"2026-09-04","days":17},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/","asOf":"2026-09-04","days":17},{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","asOf":"2026-09-04","days":17},{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/","asOf":"2026-09-04","days":17},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/","asOf":"2026-09-04","days":17},{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/","asOf":"2026-09-04","days":17},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/","asOf":"2026-09-04","days":17},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/","asOf":"2026-09-04","days":17},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","asOf":"2026-09-04","days":17},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/","asOf":"2026-09-04","days":17},{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","asOf":"2026-09-04","days":17},{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/","asOf":"2026-09-04","days":17},{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/","asOf":"2026-09-04","days":17},{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","route":"/companies/adc-therapeutics/","asOf":"2026-09-04","days":17},{"id":"zymeworks","kind":"company","name":"Zymeworks","route":"/companies/zymeworks/","asOf":"2026-09-04","days":17},{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/","asOf":"2026-09-04","days":17},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/","asOf":"2026-09-04","days":17},{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/","asOf":"2026-09-04","days":17},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/","asOf":"2026-09-04","days":17},{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/","asOf":"2026-09-04","days":17},{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","asOf":"2026-09-04","days":17},{"id":"merus","kind":"company","name":"Merus","route":"/companies/merus/","asOf":"2026-09-04","days":17},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/","asOf":"2026-09-04","days":17},{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/","asOf":"2026-09-04","days":17},{"id":"arvinas","kind":"company","name":"Arvinas","route":"/companies/arvinas/","asOf":"2026-09-04","days":17},{"id":"nuvalent","kind":"company","name":"Nuvalent","route":"/companies/nuvalent/","asOf":"2026-09-04","days":17},{"id":"celcuity","kind":"company","name":"Celcuity","route":"/companies/celcuity/","asOf":"2026-09-04","days":17},{"id":"menarini","kind":"company","name":"Menarini / Stemline","route":"/companies/menarini/","asOf":"2026-09-04","days":17},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","asOf":"2026-09-04","days":17},{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","route":"/companies/syndax/","asOf":"2026-09-04","days":17},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/","asOf":"2026-09-04","days":17},{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/","asOf":"2026-09-04","days":17},{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/","asOf":"2026-09-04","days":17},{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/","asOf":"2026-09-04","days":17},{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/","asOf":"2026-09-04","days":17},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/","asOf":"2026-09-04","days":17},{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/","asOf":"2026-09-04","days":17},{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","asOf":"2026-09-04","days":17},{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","asOf":"2026-09-04","days":17},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","asOf":"2026-09-04","days":17},{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","asOf":"2026-09-04","days":17},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","asOf":"2026-09-04","days":17},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","asOf":"2026-09-04","days":17},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","asOf":"2026-09-04","days":17},{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","asOf":"2026-09-04","days":17},{"id":"foundation-medicine","kind":"company","name":"Foundation Medicine (Roche)","route":"/companies/foundation-medicine/","asOf":"2026-09-04","days":17},{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/","asOf":"2026-09-04","days":17},{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/","asOf":"2026-09-04","days":17},{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/","asOf":"2026-09-04","days":17},{"id":"exact-sciences","kind":"company","name":"Exact Sciences (Abbott)","route":"/companies/exact-sciences/","asOf":"2026-09-04","days":17},{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/","asOf":"2026-09-04","days":17},{"id":"caris","kind":"company","name":"Caris Life Sciences","route":"/companies/caris/","asOf":"2026-09-04","days":17},{"id":"bostongene","kind":"company","name":"BostonGene","route":"/companies/bostongene/","asOf":"2026-09-04","days":17},{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/","asOf":"2026-09-04","days":17},{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/","asOf":"2026-09-04","days":17},{"id":"artera","kind":"company","name":"Artera","route":"/companies/artera/","asOf":"2026-09-04","days":17},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/","asOf":"2026-09-04","days":17},{"id":"pathai","kind":"company","name":"PathAI","route":"/companies/pathai/","asOf":"2026-09-04","days":17},{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/","asOf":"2026-09-04","days":17},{"id":"novocure","kind":"company","name":"Novocure","route":"/companies/novocure/","asOf":"2026-09-04","days":17},{"id":"intuitive-surgical","kind":"company","name":"Intuitive Surgical","route":"/companies/intuitive-surgical/","asOf":"2026-09-04","days":17},{"id":"histosonics","kind":"company","name":"HistoSonics","route":"/companies/histosonics/","asOf":"2026-09-04","days":17},{"id":"insightec","kind":"company","name":"Insightec","route":"/companies/insightec/","asOf":"2026-09-04","days":17},{"id":"varian","kind":"company","name":"Varian (Siemens Healthineers)","route":"/companies/varian/","asOf":"2026-09-04","days":17},{"id":"elekta","kind":"company","name":"Elekta","route":"/companies/elekta/","asOf":"2026-09-04","days":17},{"id":"reflexion","kind":"company","name":"RefleXion Medical","route":"/companies/reflexion/","asOf":"2026-09-04","days":17},{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","asOf":"2026-09-04","days":17},{"id":"mevion","kind":"company","name":"Mevion Medical Systems","route":"/companies/mevion/","asOf":"2026-09-04","days":17},{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","asOf":"2026-09-04","days":17},{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","asOf":"2026-09-04","days":17},{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","asOf":"2026-09-04","days":17},{"id":"cancer-commons","kind":"company","name":"Cancer Commons","route":"/companies/cancer-commons/","asOf":"2026-09-04","days":17},{"id":"celldex","kind":"company","name":"Celldex Therapeutics","route":"/companies/celldex/","asOf":"2026-09-04","days":17},{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","asOf":"2026-09-04","days":17},{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","route":"/companies/keymed/","asOf":"2026-09-04","days":17},{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/","asOf":"2026-09-04","days":17},{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/","asOf":"2026-09-04","days":17},{"id":"serova","kind":"company","name":"Serova","route":"/companies/serova/","asOf":"2026-09-04","days":17},{"id":"bulsara-bioworks","kind":"company","name":"Bulsara Bioworks","route":"/companies/bulsara-bioworks/","asOf":"2026-09-04","days":17},{"id":"circle-pharma","kind":"company","name":"Circle Pharma","route":"/companies/circle-pharma/","asOf":"2026-09-04","days":17},{"id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","asOf":"2026-09-04","days":17},{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","route":"/companies/elucidate-bio/","asOf":"2026-09-04","days":17},{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","route":"/companies/sengine/","asOf":"2026-09-04","days":17},{"id":"champions-oncology","kind":"company","name":"Champions Oncology","route":"/companies/champions-oncology/","asOf":"2026-09-04","days":17},{"id":"navexio","kind":"company","name":"Navexio","route":"/companies/navexio/","asOf":"2026-09-04","days":17},{"id":"patient-data-vault","kind":"company","name":"Patient Data Vault (data-vault.health)","route":"/companies/patient-data-vault/","asOf":"2026-09-04","days":17},{"id":"more-health","kind":"company","name":"MORE Health","route":"/companies/more-health/","asOf":"2026-09-04","days":17},{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/","asOf":"2026-09-04","days":17},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/","asOf":"2026-09-04","days":17},{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/","asOf":"2026-09-04","days":17},{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/","asOf":"2026-09-04","days":17},{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","asOf":"2026-09-04","days":17},{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/","asOf":"2026-09-04","days":17},{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/","asOf":"2026-09-04","days":17},{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/","asOf":"2026-09-04","days":17},{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","asOf":"2026-09-04","days":17},{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","asOf":"2026-09-04","days":17},{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","asOf":"2026-09-04","days":17},{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","asOf":"2026-09-04","days":17},{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/","asOf":"2026-09-04","days":17},{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","asOf":"2026-09-04","days":17},{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/","asOf":"2026-09-04","days":17},{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/","asOf":"2026-09-04","days":17},{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","route":"/companies/synaffix/","asOf":"2026-09-04","days":17},{"id":"kymera","kind":"company","name":"Kymera Therapeutics","route":"/companies/kymera/","asOf":"2026-09-04","days":17},{"id":"nurix","kind":"company","name":"Nurix Therapeutics","route":"/companies/nurix/","asOf":"2026-09-04","days":17},{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/","asOf":"2026-09-04","days":17},{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/","asOf":"2026-09-04","days":17},{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/","asOf":"2026-09-04","days":17},{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","asOf":"2026-09-04","days":17},{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","route":"/companies/quanta-therapeutics/","asOf":"2026-09-04","days":17},{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/","asOf":"2026-09-04","days":17},{"id":"sana-biotechnology","kind":"company","name":"Sana Biotechnology","route":"/companies/sana-biotechnology/","asOf":"2026-09-04","days":17},{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/","asOf":"2026-09-04","days":17},{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/","asOf":"2026-09-04","days":17},{"id":"nkarta","kind":"company","name":"Nkarta","route":"/companies/nkarta/","asOf":"2026-09-04","days":17},{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","route":"/companies/fate-therapeutics/","asOf":"2026-09-04","days":17},{"id":"freenome","kind":"company","name":"Freenome","route":"/companies/freenome/","asOf":"2026-09-04","days":17},{"id":"delfi-diagnostics","kind":"company","name":"DELFI Diagnostics","route":"/companies/delfi-diagnostics/","asOf":"2026-09-04","days":17},{"id":"harbinger-health","kind":"company","name":"Harbinger Health","route":"/companies/harbinger-health/","asOf":"2026-09-04","days":17},{"id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","asOf":"2026-09-04","days":17},{"id":"foresight-diagnostics","kind":"company","name":"Foresight Diagnostics","route":"/companies/foresight-diagnostics/","asOf":"2026-09-04","days":17},{"id":"lunit","kind":"company","name":"Lunit","route":"/companies/lunit/","asOf":"2026-09-04","days":17},{"id":"aidoc","kind":"company","name":"Aidoc","route":"/companies/aidoc/","asOf":"2026-09-04","days":17},{"id":"xilis","kind":"company","name":"Xilis","route":"/companies/xilis/","asOf":"2026-09-04","days":17},{"id":"curesponse","kind":"company","name":"Curesponse","route":"/companies/curesponse/","asOf":"2026-09-04","days":17},{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","asOf":"2026-09-04","days":17},{"id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","asOf":"2026-09-04","days":17},{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","asOf":"2026-09-04","days":17},{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","asOf":"2026-09-04","days":17},{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/","asOf":"2026-09-04","days":17},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","asOf":"2026-09-04","days":17},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","asOf":"2026-09-04","days":17},{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/","asOf":"2026-09-04","days":17},{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/","asOf":"2026-09-04","days":17},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","asOf":"2026-09-04","days":17},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/","asOf":"2026-09-04","days":17},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","asOf":"2026-09-04","days":17},{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/","asOf":"2026-09-04","days":17},{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/","asOf":"2026-09-04","days":17},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","asOf":"2026-09-04","days":17},{"id":"ieo-milan","kind":"institution","name":"IEO (European Institute of Oncology)","route":"/institutions/ieo-milan/","asOf":"2026-09-04","days":17},{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","asOf":"2026-09-04","days":17},{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/","asOf":"2026-09-04","days":17},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","asOf":"2026-09-04","days":17},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","asOf":"2026-09-04","days":17},{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/","asOf":"2026-09-04","days":17},{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/","asOf":"2026-09-04","days":17},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","asOf":"2026-09-04","days":17},{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","route":"/institutions/sirio-libanes/","asOf":"2026-09-04","days":17},{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/","asOf":"2026-09-04","days":17},{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/","asOf":"2026-09-04","days":17},{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/","asOf":"2026-09-04","days":17},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/","asOf":"2026-09-04","days":17},{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/","asOf":"2026-09-04","days":17},{"id":"jfcr","kind":"institution","name":"Cancer Institute Hospital of JFCR","route":"/institutions/jfcr/","asOf":"2026-09-04","days":17},{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","route":"/institutions/int-milan/","asOf":"2026-09-04","days":17},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/","asOf":"2026-09-04","days":17},{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","route":"/institutions/gemelli/","asOf":"2026-09-04","days":17},{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/","asOf":"2026-09-04","days":17},{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","asOf":"2026-09-04","days":17},{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/","asOf":"2026-09-04","days":17},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","asOf":"2026-09-04","days":17},{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","route":"/institutions/mount-sinai/","asOf":"2026-09-04","days":17},{"id":"la-paz","kind":"institution","name":"Hospital Universitario La Paz","route":"/institutions/la-paz/","asOf":"2026-09-04","days":17},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","asOf":"2026-09-04","days":17},{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","route":"/institutions/gregorio-maranon/","asOf":"2026-09-04","days":17},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","asOf":"2026-09-04","days":17},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/","asOf":"2026-09-04","days":17},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","asOf":"2026-09-04","days":17},{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/","asOf":"2026-09-04","days":17},{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/","asOf":"2026-09-04","days":17},{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","route":"/institutions/michigan-rogel/","asOf":"2026-09-04","days":17},{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","route":"/institutions/wustl-siteman/","asOf":"2026-09-04","days":17},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","asOf":"2026-09-04","days":17},{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/","asOf":"2026-09-04","days":17},{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/","asOf":"2026-09-04","days":17},{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","route":"/institutions/cold-spring-harbor/","asOf":"2026-09-04","days":17},{"id":"francis-crick","kind":"institution","name":"The Francis Crick Institute","route":"/institutions/francis-crick/","asOf":"2026-09-04","days":17},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/","asOf":"2026-09-04","days":17},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","asOf":"2026-09-04","days":17},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/","asOf":"2026-09-04","days":17},{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","route":"/institutions/dkfz/","asOf":"2026-09-04","days":17},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/","asOf":"2026-09-04","days":17},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","asOf":"2026-09-04","days":17},{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","route":"/institutions/west-china/","asOf":"2026-09-04","days":17},{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/","asOf":"2026-09-04","days":17},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/","asOf":"2026-09-04","days":17},{"id":"curie-nki-eortc","kind":"institution","name":"EORTC","route":"/institutions/curie-nki-eortc/","asOf":"2026-09-04","days":17},{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","route":"/institutions/asco/","asOf":"2026-09-04","days":17},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/","asOf":"2026-09-04","days":17},{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/","asOf":"2026-09-04","days":17},{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/","asOf":"2026-09-04","days":17},{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/","asOf":"2026-09-04","days":17},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/","asOf":"2026-09-04","days":17},{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/","asOf":"2026-09-04","days":17},{"id":"ddr","kind":"pathway","name":"DNA damage response & homologous recombination","route":"/pathways/ddr/","asOf":"2026-09-04","days":17},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/","asOf":"2026-09-04","days":17},{"id":"cgas-sting","kind":"pathway","name":"cGAS-STING innate sensing","route":"/pathways/cgas-sting/","asOf":"2026-09-04","days":17},{"id":"er-signaling","kind":"pathway","name":"Oestrogen receptor signalling","route":"/pathways/er-signaling/","asOf":"2026-09-04","days":17},{"id":"ar-signaling","kind":"pathway","name":"Androgen receptor signalling","route":"/pathways/ar-signaling/","asOf":"2026-09-04","days":17},{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/","asOf":"2026-09-04","days":17},{"id":"vegf-angiogenesis","kind":"pathway","name":"VEGF angiogenesis","route":"/pathways/vegf-angiogenesis/","asOf":"2026-09-04","days":17},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","asOf":"2026-09-04","days":17},{"id":"wnt","kind":"pathway","name":"Wnt / β-catenin","route":"/pathways/wnt/","asOf":"2026-09-04","days":17},{"id":"emt","kind":"pathway","name":"Epithelial-mesenchymal transition & drug efflux","route":"/pathways/emt/","asOf":"2026-09-04","days":17},{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/","asOf":"2026-09-04","days":17},{"id":"idh-2hg","kind":"pathway","name":"Mutant IDH / 2-hydroxyglutarate","route":"/pathways/idh-2hg/","asOf":"2026-09-04","days":17},{"id":"fgfr-signalling","kind":"pathway","name":"FGF / FGFR signalling","route":"/pathways/fgfr-signalling/","asOf":"2026-09-04","days":17},{"id":"menin-kmt2a","kind":"pathway","name":"Menin / KMT2A (HOXA9-MEIS1 axis)","route":"/pathways/menin-kmt2a/","asOf":"2026-09-04","days":17},{"id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","asOf":"2026-09-04","days":17},{"id":"cd47-sirpa","kind":"pathway","name":"CD47 / SIRPα (the 'don't eat me' signal)","route":"/pathways/cd47-sirpa/","asOf":"2026-09-04","days":17},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","asOf":"2026-09-04","days":17},{"id":"linker","kind":"term","name":"Linker (ADC)","route":"/terms/linker/","asOf":"2026-09-04","days":17},{"id":"dar","kind":"term","name":"Drug-to-antibody ratio (DAR)","route":"/terms/dar/","asOf":"2026-09-04","days":17},{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/","asOf":"2026-09-04","days":17},{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/","asOf":"2026-09-04","days":17},{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/","asOf":"2026-09-04","days":17},{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/","asOf":"2026-09-04","days":17},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/","asOf":"2026-09-04","days":17},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/","asOf":"2026-09-04","days":17},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/","asOf":"2026-09-04","days":17},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/","asOf":"2026-09-04","days":17},{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","asOf":"2026-09-04","days":17},{"id":"hazard-ratio","kind":"term","name":"Hazard ratio (HR)","route":"/terms/hazard-ratio/","asOf":"2026-09-04","days":17},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","asOf":"2026-09-04","days":17},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","asOf":"2026-09-04","days":17},{"id":"ppv","kind":"term","name":"Positive predictive value (PPV)","route":"/terms/ppv/","asOf":"2026-09-04","days":17},{"id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/","asOf":"2026-09-04","days":17},{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","asOf":"2026-09-04","days":17},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/","asOf":"2026-09-04","days":17},{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","asOf":"2026-09-04","days":17},{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/","asOf":"2026-09-04","days":17},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/","asOf":"2026-09-04","days":17},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/","asOf":"2026-09-04","days":17},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/","asOf":"2026-09-04","days":17},{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/","asOf":"2026-09-04","days":17},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/","asOf":"2026-09-04","days":17},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/","asOf":"2026-09-04","days":17},{"id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/","asOf":"2026-09-04","days":17},{"id":"vus","kind":"term","name":"Variant of uncertain significance (VUS)","route":"/terms/vus/","asOf":"2026-09-04","days":17},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/","asOf":"2026-09-04","days":17},{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/","asOf":"2026-09-04","days":17},{"id":"mutational-signature","kind":"term","name":"Mutational signature","route":"/terms/mutational-signature/","asOf":"2026-09-04","days":17},{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/","asOf":"2026-09-04","days":17},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/","asOf":"2026-09-04","days":17},{"id":"oncogene-addiction","kind":"term","name":"Oncogene addiction","route":"/terms/oncogene-addiction/","asOf":"2026-09-04","days":17},{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/","asOf":"2026-09-04","days":17},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/","asOf":"2026-09-04","days":17},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","asOf":"2026-09-04","days":17},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","asOf":"2026-09-04","days":17},{"id":"abscopal-effect","kind":"term","name":"Abscopal effect","route":"/terms/abscopal-effect/","asOf":"2026-09-04","days":17},{"id":"immunogenic-cell-death","kind":"term","name":"Immunogenic cell death","route":"/terms/immunogenic-cell-death/","asOf":"2026-09-04","days":17},{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/","asOf":"2026-09-04","days":17},{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/","asOf":"2026-09-04","days":17},{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","asOf":"2026-09-04","days":17},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/","asOf":"2026-09-04","days":17},{"id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/","asOf":"2026-09-04","days":17},{"id":"standard-of-care","kind":"term","name":"Standard of care","route":"/terms/standard-of-care/","asOf":"2026-09-04","days":17},{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/","asOf":"2026-09-04","days":17},{"id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/","asOf":"2026-09-04","days":17},{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/","asOf":"2026-09-04","days":17},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/","asOf":"2026-09-04","days":17},{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/","asOf":"2026-09-04","days":17},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/","asOf":"2026-09-04","days":17},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","asOf":"2026-09-04","days":17},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","asOf":"2026-09-04","days":17},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","asOf":"2026-09-04","days":17},{"id":"germline-vs-somatic","kind":"term","name":"Germline vs somatic mutations","route":"/terms/germline-vs-somatic/","asOf":"2026-09-04","days":17},{"id":"tnm-staging","kind":"term","name":"TNM staging","route":"/terms/tnm-staging/","asOf":"2026-09-04","days":17},{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/","asOf":"2026-09-04","days":17},{"id":"adc-sequencing","kind":"term","name":"ADC sequencing","route":"/terms/adc-sequencing/","asOf":"2026-09-04","days":17},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","asOf":"2026-09-04","days":17},{"id":"luminosity","kind":"trial","name":"LUMINOSITY","route":"/trials/luminosity/","asOf":"2026-09-04","days":17},{"id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/","asOf":"2026-09-04","days":17},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","asOf":"2026-09-04","days":17},{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","asOf":"2026-09-04","days":17},{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","asOf":"2026-09-04","days":17},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","asOf":"2026-09-04","days":17},{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","asOf":"2026-09-04","days":17},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","asOf":"2026-09-04","days":17},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","asOf":"2026-09-04","days":17},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","asOf":"2026-09-04","days":17},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","asOf":"2026-09-04","days":17},{"id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","asOf":"2026-09-04","days":17},{"id":"izabright-breast01","kind":"trial","name":"IZABRIGHT-Breast01","route":"/trials/izabright-breast01/","asOf":"2026-09-04","days":17},{"id":"optimice-pcr","kind":"trial","name":"OptimICE-pCR (A012103)","route":"/trials/optimice-pcr/","asOf":"2026-09-04","days":17},{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","route":"/trials/scarlet-s2212/","asOf":"2026-09-04","days":17},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","asOf":"2026-09-04","days":17},{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/","asOf":"2026-09-04","days":17},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","asOf":"2026-09-04","days":17},{"id":"destiny-breast06","kind":"trial","name":"DESTINY-Breast06","route":"/trials/destiny-breast06/","asOf":"2026-09-04","days":17},{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","asOf":"2026-09-04","days":17},{"id":"destiny-breast11","kind":"trial","name":"DESTINY-Breast11","route":"/trials/destiny-breast11/","asOf":"2026-09-04","days":17},{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/","asOf":"2026-09-04","days":17},{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","asOf":"2026-09-04","days":17},{"id":"veritac-2","kind":"trial","name":"VERITAC-2","route":"/trials/veritac-2/","asOf":"2026-09-04","days":17},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","asOf":"2026-09-04","days":17},{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/","asOf":"2026-09-04","days":17},{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/","asOf":"2026-09-04","days":17},{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","asOf":"2026-09-04","days":17},{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/","asOf":"2026-09-04","days":17},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","asOf":"2026-09-04","days":17},{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","asOf":"2026-09-04","days":17},{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/","asOf":"2026-09-04","days":17},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/","asOf":"2026-09-04","days":17},{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/","asOf":"2026-09-04","days":17},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","asOf":"2026-09-04","days":17},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","asOf":"2026-09-04","days":17},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","asOf":"2026-09-04","days":17},{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/","asOf":"2026-09-04","days":17},{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/","asOf":"2026-09-04","days":17},{"id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","route":"/pairings/adc-plus-io/","asOf":"2026-09-04","days":17},{"id":"cdk46-plus-endocrine","kind":"pairing","name":"CDK4/6 inhibitor + endocrine therapy","route":"/pairings/cdk46-plus-endocrine/","asOf":"2026-09-04","days":17},{"id":"braf-plus-mek","kind":"pairing","name":"BRAF inhibitor + MEK inhibitor","route":"/pairings/braf-plus-mek/","asOf":"2026-09-04","days":17},{"id":"kras-plus-egfr-crc","kind":"pairing","name":"KRAS G12C inhibitor + anti-EGFR antibody (colorectal)","route":"/pairings/kras-plus-egfr-crc/","asOf":"2026-09-04","days":17},{"id":"io-plus-vegf","kind":"pairing","name":"PD-1 blockade + VEGF inhibition","route":"/pairings/io-plus-vegf/","asOf":"2026-09-04","days":17},{"id":"parp-plus-arpi","kind":"pairing","name":"PARP inhibitor + AR pathway inhibitor (prostate)","route":"/pairings/parp-plus-arpi/","asOf":"2026-09-04","days":17},{"id":"vaccine-plus-pd1","kind":"pairing","name":"Personalised neoantigen vaccine + PD-1 blockade","route":"/pairings/vaccine-plus-pd1/","asOf":"2026-09-04","days":17},{"id":"radiation-plus-io","kind":"pairing","name":"Radiotherapy + immunotherapy","route":"/pairings/radiation-plus-io/","asOf":"2026-09-04","days":17},{"id":"oncolytic-plus-pd1","kind":"pairing","name":"Oncolytic virus + PD-1 blockade","route":"/pairings/oncolytic-plus-pd1/","asOf":"2026-09-04","days":17},{"id":"platinum-plus-hrd","kind":"pairing","name":"Platinum chemotherapy in HRD tumours","route":"/pairings/platinum-plus-hrd/","asOf":"2026-09-04","days":17},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","asOf":"2026-09-04","days":17},{"id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/","asOf":"2026-09-04","days":17},{"id":"ctdna-mrd-to-adjuvant","kind":"pairing","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/","asOf":"2026-09-04","days":17},{"id":"her2-low-to-tdxd","kind":"pairing","name":"HER2-low scoring → T-DXd","route":"/pairings/her2-low-to-tdxd/","asOf":"2026-09-04","days":17},{"id":"germline-to-parp","kind":"pairing","name":"Germline BRCA test → adjuvant PARP inhibitor","route":"/pairings/germline-to-parp/","asOf":"2026-09-04","days":17},{"id":"ai-pathology-to-adt","kind":"pairing","name":"AI pathology → androgen deprivation duration","route":"/pairings/ai-pathology-to-adt/","asOf":"2026-09-04","days":17},{"id":"tki-then-adc-lung","kind":"pairing","name":"EGFR TKI → ADC on progression","route":"/pairings/tki-then-adc-lung/","asOf":"2026-09-04","days":17},{"id":"io-then-til","kind":"pairing","name":"PD-1 failure → TIL therapy","route":"/pairings/io-then-til/","asOf":"2026-09-04","days":17},{"id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","asOf":"2026-09-04","days":17},{"id":"adc-after-adc-caution","kind":"pairing","name":"Caution: TOP1 ADC immediately after TOP1 ADC","route":"/pairings/adc-after-adc-caution/","asOf":"2026-09-04","days":17},{"id":"tigit-plus-pd1-caution","kind":"pairing","name":"Caution: TIGIT + PD-(L)1 blockade","route":"/pairings/tigit-plus-pd1-caution/","asOf":"2026-09-04","days":17},{"id":"ild-overlap-caution","kind":"pairing","name":"Caution: DXd ADC + agents with pneumonitis risk","route":"/pairings/ild-overlap-caution/","asOf":"2026-09-04","days":17},{"id":"proton-vs-imrt","kind":"pairing","name":"Caution: proton therapy vs IMRT","route":"/pairings/proton-vs-imrt/","asOf":"2026-09-04","days":17},{"id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/","asOf":"2026-09-04","days":17},{"id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/","asOf":"2026-09-04","days":17},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/","asOf":"2026-09-04","days":17},{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/","asOf":"2026-09-04","days":17},{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/","asOf":"2026-09-04","days":17},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","asOf":"2026-09-04","days":17},{"id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/","asOf":"2026-09-04","days":17},{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/","asOf":"2026-09-04","days":17},{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/","asOf":"2026-09-04","days":17},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","asOf":"2026-09-04","days":17},{"id":"idea-payload-switching","kind":"idea","name":"Payload-class switching as the rule for ADC sequencing","route":"/ideas/idea-payload-switching/","asOf":"2026-09-04","days":17},{"id":"idea-post-neoadjuvant-adc","kind":"idea","name":"ADC for residual disease after KEYNOTE-522","route":"/ideas/idea-post-neoadjuvant-adc/","asOf":"2026-09-04","days":17},{"id":"idea-ctdna-escalation-tnbc","kind":"idea","name":"ctDNA-triggered escalation in early TNBC","route":"/ideas/idea-ctdna-escalation-tnbc/","asOf":"2026-09-04","days":17},{"id":"idea-efflux-agnostic","kind":"idea","name":"Efflux-agnostic therapy for mesenchymal TNBC","route":"/ideas/idea-efflux-agnostic/","asOf":"2026-09-04","days":17},{"id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","asOf":"2026-09-04","days":17},{"id":"idea-in-vivo-car-solid","kind":"idea","name":"In vivo CAR-T against solid-tumour antigens","route":"/ideas/idea-in-vivo-car-solid/","asOf":"2026-09-04","days":17},{"id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/","asOf":"2026-09-04","days":17},{"id":"idea-til-guided-deescalation","kind":"idea","name":"TIL-based omission of chemotherapy in stage I TNBC","route":"/ideas/idea-til-guided-deescalation/","asOf":"2026-09-04","days":17},{"id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/","asOf":"2026-09-04","days":17},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","asOf":"2026-09-04","days":17},{"id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","route":"/ideas/idea-shared-kras-vaccine-adjuvant/","asOf":"2026-09-04","days":17},{"id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/","asOf":"2026-09-04","days":17},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/","asOf":"2026-09-04","days":17},{"id":"idea-organoid-guided-adc","kind":"idea","name":"Patient-derived organoids to pick ADC payloads","route":"/ideas/idea-organoid-guided-adc/","asOf":"2026-09-04","days":17},{"id":"idea-dual-payload-first","kind":"idea","name":"Dual-payload ADCs in first line to prevent resistance","route":"/ideas/idea-dual-payload-first/","asOf":"2026-09-04","days":17},{"id":"idea-cd8-pet-io","kind":"idea","name":"CD8 PET to stop or switch immunotherapy early","route":"/ideas/idea-cd8-pet-io/","asOf":"2026-09-04","days":17},{"id":"idea-exercise-as-adjuvant","kind":"idea","name":"Structured exercise prescribed like a drug in all curative-intent cancer care","route":"/ideas/idea-exercise-as-adjuvant/","asOf":"2026-09-04","days":17},{"id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/","asOf":"2026-09-04","days":17},{"id":"idea-interception-vaccines","kind":"idea","name":"Cancer interception vaccines for high-risk carriers","route":"/ideas/idea-interception-vaccines/","asOf":"2026-09-04","days":17},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","asOf":"2026-09-04","days":17},{"id":"oncokb","kind":"collection","name":"OncoKB","route":"/collections/oncokb/","asOf":"2026-09-04","days":17},{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/","asOf":"2026-09-04","days":17},{"id":"cbioportal","kind":"collection","name":"cBioPortal for Cancer Genomics","route":"/collections/cbioportal/","asOf":"2026-09-04","days":17},{"id":"tcga-gdc","kind":"collection","name":"TCGA / NCI Genomic Data Commons","route":"/collections/tcga-gdc/","asOf":"2026-09-04","days":17},{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","route":"/collections/depmap/","asOf":"2026-09-04","days":17},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/","asOf":"2026-09-04","days":17},{"id":"cosmic","kind":"collection","name":"COSMIC (Catalogue of Somatic Mutations in Cancer)","route":"/collections/cosmic/","asOf":"2026-09-04","days":17},{"id":"clinvar","kind":"collection","name":"ClinVar","route":"/collections/clinvar/","asOf":"2026-09-04","days":17},{"id":"drugbank-chembl","kind":"collection","name":"DrugBank & ChEMBL","route":"/collections/drugbank-chembl/","asOf":"2026-09-04","days":17},{"id":"ttd","kind":"collection","name":"Therapeutic Target Database (TTD)","route":"/collections/ttd/","asOf":"2026-09-04","days":17},{"id":"adcdb","kind":"collection","name":"ADCdb / ADC Review","route":"/collections/adcdb/","asOf":"2026-09-04","days":17},{"id":"nccn","kind":"collection","name":"NCCN Guidelines","route":"/collections/nccn/","asOf":"2026-09-04","days":17},{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/","asOf":"2026-09-04","days":17},{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/","asOf":"2026-09-04","days":17},{"id":"seer","kind":"collection","name":"SEER (Surveillance, Epidemiology, and End Results)","route":"/collections/seer/","asOf":"2026-09-04","days":17},{"id":"globocan","kind":"collection","name":"GLOBOCAN / Global Cancer Observatory","route":"/collections/globocan/","asOf":"2026-09-04","days":17},{"id":"cancer-gov-pdq","kind":"collection","name":"NCI PDQ Cancer Information Summaries","route":"/collections/cancer-gov-pdq/","asOf":"2026-09-04","days":17},{"id":"awesome-cancer-variant-resources","kind":"collection","name":"awesome-cancer-variant-resources","route":"/collections/awesome-cancer-variant-resources/","asOf":"2026-09-04","days":17},{"id":"genie","kind":"collection","name":"AACR Project GENIE","route":"/collections/genie/","asOf":"2026-09-04","days":17},{"id":"hpa","kind":"collection","name":"Human Protein Atlas","route":"/collections/hpa/","asOf":"2026-09-04","days":17},{"id":"cptac","kind":"collection","name":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","route":"/collections/cptac/","asOf":"2026-09-04","days":17},{"id":"cellxgene-hca","kind":"collection","name":"CZ CELLxGENE / Human Cell Atlas","route":"/collections/cellxgene-hca/","asOf":"2026-09-04","days":17},{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","route":"/collections/cancer-models/","asOf":"2026-09-04","days":17},{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/","asOf":"2026-09-04","days":17},{"id":"eudract-ctis","kind":"collection","name":"EU Clinical Trials Register / CTIS","route":"/collections/eudract-ctis/","asOf":"2026-09-04","days":17},{"id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals: Oncology","route":"/collections/newsweek-hospitals/","asOf":"2026-09-04","days":17},{"id":"nature-index","kind":"collection","name":"Nature Index: Healthcare and Cancer institutions","route":"/collections/nature-index/","asOf":"2026-09-04","days":17},{"id":"scimago-oncology","kind":"collection","name":"SCImago Institutions Rankings: Oncology","route":"/collections/scimago-oncology/","asOf":"2026-09-04","days":17},{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","route":"/collections/nci-cancer-centers/","asOf":"2026-09-04","days":17},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","asOf":"2026-09-06","days":15},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","asOf":"2026-09-06","days":15},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","asOf":"2026-09-06","days":15},{"id":"nlst-nelson","kind":"trial","name":"NLST & NELSON (low-dose CT screening)","route":"/trials/nlst-nelson/","asOf":"2026-09-06","days":15},{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/","asOf":"2026-09-06","days":15},{"id":"alina","kind":"trial","name":"ALINA","route":"/trials/alina/","asOf":"2026-09-06","days":15},{"id":"pacific","kind":"trial","name":"PACIFIC","route":"/trials/pacific/","asOf":"2026-09-06","days":15},{"id":"laura","kind":"trial","name":"LAURA","route":"/trials/laura/","asOf":"2026-09-06","days":15},{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","asOf":"2026-09-06","days":15},{"id":"keynote-671","kind":"trial","name":"KEYNOTE-671","route":"/trials/keynote-671/","asOf":"2026-09-06","days":15},{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","asOf":"2026-09-06","days":15},{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/","asOf":"2026-09-06","days":15},{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/","asOf":"2026-09-06","days":15},{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/","asOf":"2026-09-06","days":15},{"id":"tropion-lung05","kind":"trial","name":"TROPION-Lung05","route":"/trials/tropion-lung05/","asOf":"2026-09-06","days":15},{"id":"krystal-12","kind":"trial","name":"KRYSTAL-12","route":"/trials/krystal-12/","asOf":"2026-09-06","days":15},{"id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/","asOf":"2026-09-06","days":15},{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/","asOf":"2026-09-06","days":15},{"id":"libretto-431","kind":"trial","name":"LIBRETTO-431","route":"/trials/libretto-431/","asOf":"2026-09-06","days":15},{"id":"telimet-nsclc-01","kind":"trial","name":"TeliMET NSCLC-01","route":"/trials/telimet-nsclc-01/","asOf":"2026-09-06","days":15},{"id":"alkove-1","kind":"trial","name":"ALKOVE-1","route":"/trials/alkove-1/","asOf":"2026-09-06","days":15},{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/","asOf":"2026-09-06","days":15},{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","asOf":"2026-09-06","days":15},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/","asOf":"2026-09-06","days":15},{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","asOf":"2026-09-06","days":15},{"id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","asOf":"2026-09-06","days":15},{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","asOf":"2026-09-06","days":15},{"id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","asOf":"2026-09-06","days":15},{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","asOf":"2026-09-06","days":15},{"id":"divarasib","kind":"drug","name":"Divarasib","route":"/drugs/divarasib/","asOf":"2026-09-06","days":15},{"id":"olomorasib","kind":"drug","name":"Olomorasib","route":"/drugs/olomorasib/","asOf":"2026-09-06","days":15},{"id":"neladalkib","kind":"drug","name":"Neladalkib","route":"/drugs/neladalkib/","asOf":"2026-09-06","days":15},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","asOf":"2026-09-06","days":15},{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/","asOf":"2026-09-06","days":15},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","asOf":"2026-09-06","days":15},{"id":"robotic-bronchoscopy","kind":"technology","name":"Robotic and navigational bronchoscopy","route":"/technologies/robotic-bronchoscopy/","asOf":"2026-09-06","days":15},{"id":"tps","kind":"term","name":"Tumour proportion score (TPS)","route":"/terms/tps/","asOf":"2026-09-06","days":15},{"id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/","asOf":"2026-09-06","days":15},{"id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","asOf":"2026-09-06","days":15},{"id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","asOf":"2026-09-06","days":15},{"id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","asOf":"2026-09-06","days":15},{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/","asOf":"2026-09-06","days":15},{"id":"oligoprogression","kind":"term","name":"Oligoprogression","route":"/terms/oligoprogression/","asOf":"2026-09-06","days":15},{"id":"amivantamab-plus-lazertinib","kind":"pairing","name":"Amivantamab + lazertinib (first-line EGFR NSCLC)","route":"/pairings/amivantamab-plus-lazertinib/","asOf":"2026-09-06","days":15},{"id":"pd1-plus-chemo-pdl1-low","kind":"pairing","name":"PD-1 blockade + chemotherapy in PD-L1-low NSCLC","route":"/pairings/pd1-plus-chemo-pdl1-low/","asOf":"2026-09-06","days":15},{"id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/","asOf":"2026-09-06","days":15},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","asOf":"2026-09-06","days":15},{"id":"sumitomo-pharma","kind":"company","name":"Sumitomo Pharma (Myovant)","route":"/companies/sumitomo-pharma/","asOf":"2026-09-06","days":15},{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/","asOf":"2026-09-06","days":15},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","asOf":"2026-09-06","days":15},{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","asOf":"2026-09-06","days":15},{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","asOf":"2026-09-06","days":15},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","asOf":"2026-09-06","days":15},{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","asOf":"2026-09-06","days":15},{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/","asOf":"2026-09-06","days":15},{"id":"mp-mri","kind":"technology","name":"Multiparametric prostate MRI (PI-RADS)","route":"/technologies/mp-mri/","asOf":"2026-09-06","days":15},{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/","asOf":"2026-09-06","days":15},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","asOf":"2026-09-06","days":15},{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/","asOf":"2026-09-06","days":15},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","asOf":"2026-09-06","days":15},{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","asOf":"2026-09-06","days":15},{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/","asOf":"2026-09-06","days":15},{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","asOf":"2026-09-06","days":15},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","asOf":"2026-09-06","days":15},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","asOf":"2026-09-06","days":15},{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","asOf":"2026-09-06","days":15},{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","asOf":"2026-09-06","days":15},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","asOf":"2026-09-06","days":15},{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","asOf":"2026-09-06","days":15},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","asOf":"2026-09-06","days":15},{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","asOf":"2026-09-06","days":15},{"id":"xaluritamig","kind":"drug","name":"Xaluritamig","route":"/drugs/xaluritamig/","asOf":"2026-09-06","days":15},{"id":"pasritamig","kind":"drug","name":"Pasritamig","route":"/drugs/pasritamig/","asOf":"2026-09-06","days":15},{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","asOf":"2026-09-06","days":15},{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","asOf":"2026-09-06","days":15},{"id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","asOf":"2026-09-06","days":15},{"id":"masofaniten","kind":"drug","name":"Masofaniten","route":"/drugs/masofaniten/","asOf":"2026-09-06","days":15},{"id":"decipher-prostate","kind":"drug","name":"Decipher Prostate","route":"/drugs/decipher-prostate/","asOf":"2026-09-06","days":15},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","asOf":"2026-09-06","days":15},{"id":"precision-mri","kind":"trial","name":"PRECISION","route":"/trials/precision-mri/","asOf":"2026-09-06","days":15},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","asOf":"2026-09-06","days":15},{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","asOf":"2026-09-06","days":15},{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","asOf":"2026-09-06","days":15},{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","asOf":"2026-09-06","days":15},{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/","asOf":"2026-09-06","days":15},{"id":"peace-1","kind":"trial","name":"PEACE-1","route":"/trials/peace-1/","asOf":"2026-09-06","days":15},{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","asOf":"2026-09-06","days":15},{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/","asOf":"2026-09-06","days":15},{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","asOf":"2026-09-06","days":15},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","asOf":"2026-09-06","days":15},{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","asOf":"2026-09-06","days":15},{"id":"capitello-281","kind":"trial","name":"CAPItello-281","route":"/trials/capitello-281/","asOf":"2026-09-06","days":15},{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","asOf":"2026-09-06","days":15},{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","asOf":"2026-09-06","days":15},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","asOf":"2026-09-06","days":15},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","asOf":"2026-09-06","days":15},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","asOf":"2026-09-06","days":15},{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","asOf":"2026-09-06","days":15},{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/","asOf":"2026-09-06","days":15},{"id":"xalute","kind":"trial","name":"XALute","route":"/trials/xalute/","asOf":"2026-09-06","days":15},{"id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","asOf":"2026-09-06","days":15},{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/","asOf":"2026-09-06","days":15},{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","asOf":"2026-09-06","days":15},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","asOf":"2026-09-06","days":15},{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","asOf":"2026-09-06","days":15},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","asOf":"2026-09-06","days":15},{"id":"zoldonrasib","kind":"drug","name":"Zoldonrasib","route":"/drugs/zoldonrasib/","asOf":"2026-09-06","days":15},{"id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/","asOf":"2026-09-06","days":15},{"id":"mrtx1133","kind":"drug","name":"MRTX1133","route":"/drugs/mrtx1133/","asOf":"2026-09-06","days":15},{"id":"eli-002-7p","kind":"drug","name":"ELI-002 7P","route":"/drugs/eli-002-7p/","asOf":"2026-09-06","days":15},{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","asOf":"2026-09-06","days":15},{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/","asOf":"2026-09-06","days":15},{"id":"prodige-24","kind":"trial","name":"PRODIGE 24 / CCTG PA6","route":"/trials/prodige-24/","asOf":"2026-09-06","days":15},{"id":"preopanc","kind":"trial","name":"PREOPANC-1 / PREOPANC-2","route":"/trials/preopanc/","asOf":"2026-09-06","days":15},{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","asOf":"2026-09-06","days":15},{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/","asOf":"2026-09-06","days":15},{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/","asOf":"2026-09-06","days":15},{"id":"pancreatic-surveillance","kind":"technology","name":"High-risk pancreatic surveillance (CAPS / PRECEDE)","route":"/technologies/pancreatic-surveillance/","asOf":"2026-09-06","days":15},{"id":"pdac-organoid-pharmacotyping","kind":"technology","name":"PDAC organoid pharmacotyping","route":"/technologies/pdac-organoid-pharmacotyping/","asOf":"2026-09-06","days":15},{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","asOf":"2026-09-06","days":15},{"id":"desmoplasia","kind":"term","name":"Desmoplasia (tumour stroma)","route":"/terms/desmoplasia/","asOf":"2026-09-06","days":15},{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","asOf":"2026-09-06","days":15},{"id":"elicio-therapeutics","kind":"company","name":"Elicio Therapeutics","route":"/companies/elicio-therapeutics/","asOf":"2026-09-06","days":15},{"id":"idea-ras-inhibitor-neoadjuvant-pdac","kind":"idea","name":"RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable","route":"/ideas/idea-ras-inhibitor-neoadjuvant-pdac/","asOf":"2026-09-06","days":15},{"id":"idea-mced-new-onset-diabetes","kind":"idea","name":"Blood-based pancreatic cancer detection in new-onset diabetes","route":"/ideas/idea-mced-new-onset-diabetes/","asOf":"2026-09-06","days":15},{"id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","asOf":"2026-09-06","days":15},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","asOf":"2026-09-06","days":15},{"id":"lomustine","kind":"drug","name":"Lomustine (CCNU)","route":"/drugs/lomustine/","asOf":"2026-09-06","days":15},{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","asOf":"2026-09-06","days":15},{"id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","asOf":"2026-09-06","days":15},{"id":"tovorafenib","kind":"drug","name":"Tovorafenib","route":"/drugs/tovorafenib/","asOf":"2026-09-06","days":15},{"id":"dcvax-l","kind":"drug","name":"DCVax-L","route":"/drugs/dcvax-l/","asOf":"2026-09-06","days":15},{"id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/","asOf":"2026-09-06","days":15},{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/","asOf":"2026-09-06","days":15},{"id":"ef-14","kind":"trial","name":"EF-14","route":"/trials/ef-14/","asOf":"2026-09-06","days":15},{"id":"indigo","kind":"trial","name":"INDIGO","route":"/trials/indigo/","asOf":"2026-09-06","days":15},{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/","asOf":"2026-09-06","days":15},{"id":"litt","kind":"technology","name":"Laser interstitial thermal therapy (LITT)","route":"/technologies/litt/","asOf":"2026-09-06","days":15},{"id":"bbb-focused-ultrasound","kind":"technology","name":"Focused-ultrasound blood-brain barrier opening","route":"/technologies/bbb-focused-ultrasound/","asOf":"2026-09-06","days":15},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/","asOf":"2026-09-06","days":15},{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/","asOf":"2026-09-06","days":15},{"id":"h3k27m","kind":"term","name":"H3 K27M (diffuse midline glioma)","route":"/terms/h3k27m/","asOf":"2026-09-06","days":15},{"id":"egfrviii","kind":"term","name":"EGFRvIII","route":"/terms/egfrviii/","asOf":"2026-09-06","days":15},{"id":"blood-brain-barrier","kind":"term","name":"Blood-brain barrier (BBB)","route":"/terms/blood-brain-barrier/","asOf":"2026-09-06","days":15},{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/","asOf":"2026-09-06","days":15},{"id":"northwest-biotherapeutics","kind":"company","name":"Northwest Biotherapeutics","route":"/companies/northwest-biotherapeutics/","asOf":"2026-09-06","days":15},{"id":"idea-neoadjuvant-io-glioblastoma","kind":"idea","name":"Neoadjuvant immunotherapy with surgical window for glioblastoma","route":"/ideas/idea-neoadjuvant-io-glioblastoma/","asOf":"2026-09-06","days":15},{"id":"idea-fus-plus-adc-glioma","kind":"idea","name":"Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma","route":"/ideas/idea-fus-plus-adc-glioma/","asOf":"2026-09-06","days":15},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/","asOf":"2026-09-06","days":15},{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/","asOf":"2026-09-06","days":15},{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/","asOf":"2026-09-06","days":15},{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/","asOf":"2026-09-06","days":15},{"id":"bempegaldesleukin","kind":"drug","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/","asOf":"2026-09-06","days":15},{"id":"adu-s100","kind":"drug","name":"ADU-S100 (MIW815)","route":"/drugs/adu-s100/","asOf":"2026-09-06","days":15},{"id":"eprenetapopt","kind":"drug","name":"Eprenetapopt","route":"/drugs/eprenetapopt/","asOf":"2026-09-06","days":15},{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/","asOf":"2026-09-06","days":15},{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","asOf":"2026-09-06","days":15},{"id":"epacadostat","kind":"drug","name":"Epacadostat","route":"/drugs/epacadostat/","asOf":"2026-09-06","days":15},{"id":"trastuzumab-duocarmazine","kind":"drug","name":"Trastuzumab duocarmazine","route":"/drugs/trastuzumab-duocarmazine/","asOf":"2026-09-06","days":15},{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","asOf":"2026-09-06","days":15},{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","asOf":"2026-09-06","days":15},{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","asOf":"2026-09-06","days":15},{"id":"swog","kind":"institution","name":"SWOG Cancer Research Network","route":"/institutions/swog/","asOf":"2026-09-06","days":15},{"id":"nrg-oncology","kind":"institution","name":"NRG Oncology","route":"/institutions/nrg-oncology/","asOf":"2026-09-06","days":15},{"id":"alliance-oncology","kind":"institution","name":"Alliance for Clinical Trials in Oncology","route":"/institutions/alliance-oncology/","asOf":"2026-09-06","days":15},{"id":"ecog-acrin","kind":"institution","name":"ECOG-ACRIN Cancer Research Group","route":"/institutions/ecog-acrin/","asOf":"2026-09-06","days":15},{"id":"childrens-oncology-group","kind":"institution","name":"Children's Oncology Group (COG)","route":"/institutions/childrens-oncology-group/","asOf":"2026-09-06","days":15},{"id":"cctg","kind":"institution","name":"Canadian Cancer Trials Group (CCTG)","route":"/institutions/cctg/","asOf":"2026-09-06","days":15},{"id":"big","kind":"institution","name":"Breast International Group (BIG)","route":"/institutions/big/","asOf":"2026-09-06","days":15},{"id":"gbg","kind":"institution","name":"German Breast Group (GBG)","route":"/institutions/gbg/","asOf":"2026-09-06","days":15},{"id":"jcog","kind":"institution","name":"Japan Clinical Oncology Group (JCOG)","route":"/institutions/jcog/","asOf":"2026-09-06","days":15},{"id":"unicancer","kind":"institution","name":"UNICANCER","route":"/institutions/unicancer/","asOf":"2026-09-06","days":15},{"id":"nccn-org","kind":"institution","name":"National Comprehensive Cancer Network (NCCN)","route":"/institutions/nccn-org/","asOf":"2026-09-06","days":15},{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/","asOf":"2026-09-06","days":15},{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/","asOf":"2026-09-06","days":15},{"id":"adc-payload-neutralizer","kind":"technology","name":"ADC payload neutralisers","route":"/technologies/adc-payload-neutralizer/","asOf":"2026-09-06","days":15},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","asOf":"2026-09-07","days":14},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","asOf":"2026-09-07","days":14},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","asOf":"2026-09-07","days":14},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","asOf":"2026-09-07","days":14},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","asOf":"2026-09-07","days":14},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","asOf":"2026-09-07","days":14},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","asOf":"2026-09-07","days":14},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","asOf":"2026-09-07","days":14},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","asOf":"2026-09-07","days":14},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","asOf":"2026-09-07","days":14},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","asOf":"2026-09-07","days":14},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","asOf":"2026-09-07","days":14},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","asOf":"2026-09-07","days":14},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/","asOf":"2026-09-07","days":14},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","asOf":"2026-09-07","days":14},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","asOf":"2026-09-07","days":14},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","asOf":"2026-09-07","days":14},{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/","asOf":"2026-09-07","days":14},{"id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","asOf":"2026-09-07","days":14},{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","asOf":"2026-09-07","days":14},{"id":"solar-1","kind":"trial","name":"SOLAR-1","route":"/trials/solar-1/","asOf":"2026-09-07","days":14},{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","asOf":"2026-09-07","days":14},{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","asOf":"2026-09-07","days":14},{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","asOf":"2026-09-07","days":14},{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","asOf":"2026-09-07","days":14},{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","asOf":"2026-09-07","days":14},{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","asOf":"2026-09-07","days":14},{"id":"persevera","kind":"trial","name":"persevERA","route":"/trials/persevera/","asOf":"2026-09-07","days":14},{"id":"lidera","kind":"trial","name":"lidERA","route":"/trials/lidera/","asOf":"2026-09-07","days":14},{"id":"postmonarch","kind":"trial","name":"postMONARCH","route":"/trials/postmonarch/","asOf":"2026-09-07","days":14},{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/","asOf":"2026-09-07","days":14},{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","asOf":"2026-09-07","days":14},{"id":"soft-text","kind":"trial","name":"SOFT & TEXT","route":"/trials/soft-text/","asOf":"2026-09-07","days":14},{"id":"pallas-penelope-b","kind":"trial","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","asOf":"2026-09-07","days":14},{"id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/","asOf":"2026-09-07","days":14},{"id":"fourlight-1","kind":"trial","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","asOf":"2026-09-07","days":14},{"id":"cambria","kind":"trial","name":"CAMBRIA-1 & CAMBRIA-2","route":"/trials/cambria/","asOf":"2026-09-07","days":14},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","asOf":"2026-09-07","days":14},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","asOf":"2026-09-07","days":14},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","asOf":"2026-09-07","days":14},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","asOf":"2026-09-07","days":14},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","asOf":"2026-09-07","days":14},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","asOf":"2026-09-07","days":14},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","asOf":"2026-09-07","days":14},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","asOf":"2026-09-07","days":14},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","asOf":"2026-09-07","days":14},{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/","asOf":"2026-09-07","days":14},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","asOf":"2026-09-07","days":14},{"id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","route":"/drugs/mammaprint/","asOf":"2026-09-07","days":14},{"id":"esr1-mutation","kind":"term","name":"ESR1 mutation","route":"/terms/esr1-mutation/","asOf":"2026-09-07","days":14},{"id":"oral-serd","kind":"term","name":"Oral SERD","route":"/terms/oral-serd/","asOf":"2026-09-07","days":14},{"id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/","asOf":"2026-09-07","days":14},{"id":"ovarian-function-suppression","kind":"term","name":"Ovarian function suppression (OFS)","route":"/terms/ovarian-function-suppression/","asOf":"2026-09-07","days":14},{"id":"late-recurrence","kind":"term","name":"Late recurrence","route":"/terms/late-recurrence/","asOf":"2026-09-07","days":14},{"id":"oral-serd-plus-cdk46-after-esr1","kind":"pairing","name":"Oral SERD + CDK4/6 inhibitor after ESR1 emergence","route":"/pairings/oral-serd-plus-cdk46-after-esr1/","asOf":"2026-09-07","days":14},{"id":"pi3k-pathway-plus-endocrine","kind":"pairing","name":"PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)","route":"/pairings/pi3k-pathway-plus-endocrine/","asOf":"2026-09-07","days":14},{"id":"genomic-assay-to-chemo-omission","kind":"pairing","name":"Gene-expression assay → chemotherapy omission","route":"/pairings/genomic-assay-to-chemo-omission/","asOf":"2026-09-07","days":14},{"id":"idea-ctdna-switch-generalised","kind":"idea","name":"Molecular-progression switching beyond ESR1","route":"/ideas/idea-ctdna-switch-generalised/","asOf":"2026-09-07","days":14},{"id":"idea-cdk4-selective-first-line","kind":"idea","name":"CDK4-selective inhibitors as the new first-line backbone","route":"/ideas/idea-cdk4-selective-first-line/","asOf":"2026-09-07","days":14},{"id":"idea-late-recurrence-interception","kind":"idea","name":"Intercepting late recurrence with ctDNA surveillance and oral SERDs","route":"/ideas/idea-late-recurrence-interception/","asOf":"2026-09-07","days":14},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","asOf":"2026-09-07","days":14},{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/","asOf":"2026-09-07","days":14},{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/","asOf":"2026-09-07","days":14},{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","asOf":"2026-09-07","days":14},{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/","asOf":"2026-09-07","days":14},{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/","asOf":"2026-09-07","days":14},{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/","asOf":"2026-09-07","days":14},{"id":"destiny-breast05","kind":"trial","name":"DESTINY-Breast05","route":"/trials/destiny-breast05/","asOf":"2026-09-07","days":14},{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/","asOf":"2026-09-07","days":14},{"id":"her2climb-02","kind":"trial","name":"HER2CLIMB-02","route":"/trials/her2climb-02/","asOf":"2026-09-07","days":14},{"id":"her2climb-05","kind":"trial","name":"HER2CLIMB-05","route":"/trials/her2climb-05/","asOf":"2026-09-07","days":14},{"id":"destiny-breast12","kind":"trial","name":"DESTINY-Breast12","route":"/trials/destiny-breast12/","asOf":"2026-09-07","days":14},{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","asOf":"2026-09-07","days":14},{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/","asOf":"2026-09-07","days":14},{"id":"apt-trial","kind":"trial","name":"APT (adjuvant paclitaxel-trastuzumab)","route":"/trials/apt-trial/","asOf":"2026-09-07","days":14},{"id":"horizon-breast01","kind":"trial","name":"HORIZON-Breast01","route":"/trials/horizon-breast01/","asOf":"2026-09-07","days":14},{"id":"ace-breast-02","kind":"trial","name":"ACE-Breast-02","route":"/trials/ace-breast-02/","asOf":"2026-09-07","days":14},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","asOf":"2026-09-07","days":14},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","asOf":"2026-09-07","days":14},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","asOf":"2026-09-07","days":14},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","asOf":"2026-09-07","days":14},{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/","asOf":"2026-09-07","days":14},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","asOf":"2026-09-07","days":14},{"id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/","asOf":"2026-09-07","days":14},{"id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/","asOf":"2026-09-07","days":14},{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/","asOf":"2026-09-07","days":14},{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","asOf":"2026-09-07","days":14},{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","asOf":"2026-09-07","days":14},{"id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/","asOf":"2026-09-07","days":14},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/","asOf":"2026-09-07","days":14},{"id":"tucatinib-triplet-brain-mets","kind":"pairing","name":"Tucatinib + trastuzumab + capecitabine for brain metastases","route":"/pairings/tucatinib-triplet-brain-mets/","asOf":"2026-09-07","days":14},{"id":"pet-adapted-her2-deescalation","kind":"pairing","name":"Early FDG-PET response → chemotherapy omission (HER2+)","route":"/pairings/pet-adapted-her2-deescalation/","asOf":"2026-09-07","days":14},{"id":"idea-tdxd-first-then-nothing","kind":"idea","name":"Can T-DXd alone cure early HER2-positive disease?","route":"/ideas/idea-tdxd-first-then-nothing/","asOf":"2026-09-07","days":14},{"id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/","asOf":"2026-09-07","days":14},{"id":"idea-her2-adc-sequencing-payload","kind":"idea","name":"Sequencing HER2 ADCs by payload after T-DXd","route":"/ideas/idea-her2-adc-sequencing-payload/","asOf":"2026-09-07","days":14},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","asOf":"2026-09-07","days":14},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","asOf":"2026-09-07","days":14},{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","route":"/companies/elevar-therapeutics/","asOf":"2026-09-07","days":14},{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","asOf":"2026-09-07","days":14},{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","asOf":"2026-09-07","days":14},{"id":"tace","kind":"technology","name":"Transarterial chemoembolisation (TACE)","route":"/technologies/tace/","asOf":"2026-09-07","days":14},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","asOf":"2026-09-07","days":14},{"id":"liver-transplant-oncology","kind":"technology","name":"Liver transplantation for cancer (Milan criteria and beyond)","route":"/technologies/liver-transplant-oncology/","asOf":"2026-09-07","days":14},{"id":"hcc-surveillance","kind":"technology","name":"HCC surveillance in cirrhosis (ultrasound + AFP)","route":"/technologies/hcc-surveillance/","asOf":"2026-09-07","days":14},{"id":"afp","kind":"term","name":"Alpha-fetoprotein (AFP)","route":"/terms/afp/","asOf":"2026-09-07","days":14},{"id":"child-pugh-albi","kind":"term","name":"Child-Pugh and ALBI liver-function scores","route":"/terms/child-pugh-albi/","asOf":"2026-09-07","days":14},{"id":"bclc-staging","kind":"term","name":"BCLC staging","route":"/terms/bclc-staging/","asOf":"2026-09-07","days":14},{"id":"hbv-hcv","kind":"term","name":"Hepatitis B and C as cancer causes","route":"/terms/hbv-hcv/","asOf":"2026-09-07","days":14},{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","asOf":"2026-09-07","days":14},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","asOf":"2026-09-07","days":14},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","asOf":"2026-09-07","days":14},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","asOf":"2026-09-07","days":14},{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","asOf":"2026-09-07","days":14},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","asOf":"2026-09-07","days":14},{"id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","asOf":"2026-09-07","days":14},{"id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/","asOf":"2026-09-07","days":14},{"id":"resorce","kind":"trial","name":"RESORCE","route":"/trials/resorce/","asOf":"2026-09-07","days":14},{"id":"celestial","kind":"trial","name":"CELESTIAL","route":"/trials/celestial/","asOf":"2026-09-07","days":14},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","asOf":"2026-09-07","days":14},{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","asOf":"2026-09-07","days":14},{"id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","asOf":"2026-09-07","days":14},{"id":"leap-002","kind":"trial","name":"LEAP-002","route":"/trials/leap-002/","asOf":"2026-09-07","days":14},{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","asOf":"2026-09-07","days":14},{"id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/","asOf":"2026-09-07","days":14},{"id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","asOf":"2026-09-07","days":14},{"id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","asOf":"2026-09-07","days":14},{"id":"emerald-3","kind":"trial","name":"EMERALD-3","route":"/trials/emerald-3/","asOf":"2026-09-07","days":14},{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","asOf":"2026-09-07","days":14},{"id":"tace-plus-systemic","kind":"pairing","name":"TACE + immunotherapy/anti-VEGF","route":"/pairings/tace-plus-systemic/","asOf":"2026-09-07","days":14},{"id":"io-varices-caution","kind":"pairing","name":"Caution: bevacizumab-based regimens with untreated varices","route":"/pairings/io-varices-caution/","asOf":"2026-09-07","days":14},{"id":"idea-hcc-io-before-transplant","kind":"idea","name":"Immunotherapy downstaging to transplant with a safe washout","route":"/ideas/idea-hcc-io-before-transplant/","asOf":"2026-09-07","days":14},{"id":"idea-hcc-blood-surveillance","kind":"idea","name":"Blood-based HCC surveillance to replace six-monthly ultrasound","route":"/ideas/idea-hcc-blood-surveillance/","asOf":"2026-09-07","days":14},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","asOf":"2026-09-07","days":14},{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","asOf":"2026-09-07","days":14},{"id":"transthera","kind":"company","name":"TransThera Sciences","route":"/companies/transthera/","asOf":"2026-09-07","days":14},{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","asOf":"2026-09-07","days":14},{"id":"biliary-anatomy-subtypes","kind":"term","name":"Intrahepatic, perihilar, distal and gallbladder cancer","route":"/terms/biliary-anatomy-subtypes/","asOf":"2026-09-07","days":14},{"id":"fgfr2-fusion","kind":"term","name":"FGFR2 fusions and rearrangements","route":"/terms/fgfr2-fusion/","asOf":"2026-09-07","days":14},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/","asOf":"2026-09-07","days":14},{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","asOf":"2026-09-07","days":14},{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/","asOf":"2026-09-07","days":14},{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","asOf":"2026-09-07","days":14},{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/","asOf":"2026-09-07","days":14},{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","asOf":"2026-09-07","days":14},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","asOf":"2026-09-07","days":14},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","asOf":"2026-09-07","days":14},{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","asOf":"2026-09-07","days":14},{"id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/","asOf":"2026-09-07","days":14},{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","asOf":"2026-09-07","days":14},{"id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","asOf":"2026-09-07","days":14},{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/","asOf":"2026-09-07","days":14},{"id":"first-308","kind":"trial","name":"FIRST-308","route":"/trials/first-308/","asOf":"2026-09-07","days":14},{"id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/","asOf":"2026-09-07","days":14},{"id":"gemcis-plus-io-btc","kind":"pairing","name":"Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer","route":"/pairings/gemcis-plus-io-btc/","asOf":"2026-09-07","days":14},{"id":"idea-btc-ctdna-fgfr-resistance","kind":"idea","name":"ctDNA-guided switching among FGFR inhibitors","route":"/ideas/idea-btc-ctdna-fgfr-resistance/","asOf":"2026-09-07","days":14},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","asOf":"2026-09-07","days":14},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","asOf":"2026-09-07","days":14},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","asOf":"2026-09-07","days":14},{"id":"chromogranin-a","kind":"term","name":"Chromogranin A","route":"/terms/chromogranin-a/","asOf":"2026-09-07","days":14},{"id":"carcinoid-syndrome","kind":"term","name":"Carcinoid syndrome and carcinoid heart disease","route":"/terms/carcinoid-syndrome/","asOf":"2026-09-07","days":14},{"id":"men1-hereditary-net","kind":"term","name":"MEN1 and hereditary neuroendocrine syndromes","route":"/terms/men1-hereditary-net/","asOf":"2026-09-07","days":14},{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","asOf":"2026-09-07","days":14},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","asOf":"2026-09-07","days":14},{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","asOf":"2026-09-07","days":14},{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","asOf":"2026-09-07","days":14},{"id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","route":"/drugs/capecitabine-temozolomide/","asOf":"2026-09-07","days":14},{"id":"promid","kind":"trial","name":"PROMID","route":"/trials/promid/","asOf":"2026-09-07","days":14},{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","asOf":"2026-09-07","days":14},{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","asOf":"2026-09-07","days":14},{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","asOf":"2026-09-07","days":14},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","asOf":"2026-09-07","days":14},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","asOf":"2026-09-07","days":14},{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","asOf":"2026-09-07","days":14},{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/","asOf":"2026-09-07","days":14},{"id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/","asOf":"2026-09-07","days":14},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","asOf":"2026-09-07","days":14},{"id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/","asOf":"2026-09-07","days":14},{"id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/","asOf":"2026-09-07","days":14},{"id":"keynote-006","kind":"trial","name":"KEYNOTE-006","route":"/trials/keynote-006/","asOf":"2026-09-07","days":14},{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","asOf":"2026-09-07","days":14},{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/","asOf":"2026-09-07","days":14},{"id":"swog-s1801","kind":"trial","name":"SWOG S1801","route":"/trials/swog-s1801/","asOf":"2026-09-07","days":14},{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","asOf":"2026-09-07","days":14},{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/","asOf":"2026-09-07","days":14},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","asOf":"2026-09-07","days":14},{"id":"dreamseq","kind":"trial","name":"DREAMseq (ECOG-ACRIN EA6134)","route":"/trials/dreamseq/","asOf":"2026-09-07","days":14},{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/","asOf":"2026-09-07","days":14},{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/","asOf":"2026-09-07","days":14},{"id":"mslt-ii","kind":"trial","name":"MSLT-II","route":"/trials/mslt-ii/","asOf":"2026-09-07","days":14},{"id":"prism-mel-301","kind":"trial","name":"PRISM-MEL-301","route":"/trials/prism-mel-301/","asOf":"2026-09-07","days":14},{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","asOf":"2026-09-07","days":14},{"id":"relativity-098","kind":"trial","name":"RELATIVITY-098","route":"/trials/relativity-098/","asOf":"2026-09-07","days":14},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","asOf":"2026-09-07","days":14},{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","asOf":"2026-09-07","days":14},{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","asOf":"2026-09-07","days":14},{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/","asOf":"2026-09-07","days":14},{"id":"fianlimab","kind":"drug","name":"Fianlimab","route":"/drugs/fianlimab/","asOf":"2026-09-07","days":14},{"id":"dermoscopy-ai","kind":"technology","name":"Dermoscopy, total-body photography & AI skin analysis","route":"/technologies/dermoscopy-ai/","asOf":"2026-09-07","days":14},{"id":"breslow-thickness","kind":"term","name":"Breslow thickness","route":"/terms/breslow-thickness/","asOf":"2026-09-07","days":14},{"id":"ulceration-melanoma","kind":"term","name":"Ulceration (melanoma)","route":"/terms/ulceration-melanoma/","asOf":"2026-09-07","days":14},{"id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","route":"/terms/major-pathological-response/","asOf":"2026-09-07","days":14},{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/","asOf":"2026-09-07","days":14},{"id":"io-first-then-braf-mek","kind":"pairing","name":"Immunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)","route":"/pairings/io-first-then-braf-mek/","asOf":"2026-09-07","days":14},{"id":"neoadjuvant-io-response-adapted","kind":"pairing","name":"Neoadjuvant immunotherapy → response-adapted adjuvant","route":"/pairings/neoadjuvant-io-response-adapted/","asOf":"2026-09-07","days":14},{"id":"lag3-adjuvant-caution","kind":"pairing","name":"Caution: LAG-3 blockade outside active disease","route":"/pairings/lag3-adjuvant-caution/","asOf":"2026-09-07","days":14},{"id":"idea-ctdna-guided-adjuvant-melanoma","kind":"idea","name":"ctDNA-guided adjuvant therapy in stage II-III melanoma","route":"/ideas/idea-ctdna-guided-adjuvant-melanoma/","asOf":"2026-09-07","days":14},{"id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/","asOf":"2026-09-07","days":14},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/","asOf":"2026-09-07","days":14},{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/","asOf":"2026-09-07","days":14},{"id":"keynote-689","kind":"trial","name":"KEYNOTE-689","route":"/trials/keynote-689/","asOf":"2026-09-07","days":14},{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/","asOf":"2026-09-07","days":14},{"id":"checkmate-141","kind":"trial","name":"CheckMate 141","route":"/trials/checkmate-141/","asOf":"2026-09-07","days":14},{"id":"rtog-0129","kind":"trial","name":"RTOG 0129 (HPV analysis)","route":"/trials/rtog-0129/","asOf":"2026-09-07","days":14},{"id":"nrg-hn002-hn005","kind":"trial","name":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation)","route":"/trials/nrg-hn002-hn005/","asOf":"2026-09-07","days":14},{"id":"javelin-hn-100","kind":"trial","name":"JAVELIN Head and Neck 100","route":"/trials/javelin-hn-100/","asOf":"2026-09-07","days":14},{"id":"trilynx","kind":"trial","name":"TrilynX","route":"/trials/trilynx/","asOf":"2026-09-07","days":14},{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/","asOf":"2026-09-07","days":14},{"id":"liger-hn1","kind":"trial","name":"LiGeR-HN1","route":"/trials/liger-hn1/","asOf":"2026-09-07","days":14},{"id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","asOf":"2026-09-07","days":14},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","asOf":"2026-09-07","days":14},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/","asOf":"2026-09-07","days":14},{"id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","asOf":"2026-09-07","days":14},{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/","asOf":"2026-09-07","days":14},{"id":"tors","kind":"technology","name":"Transoral robotic surgery (TORS)","route":"/technologies/tors/","asOf":"2026-09-07","days":14},{"id":"cthpv-dna","kind":"technology","name":"Circulating tumour HPV DNA (ctHPV-DNA)","route":"/technologies/cthpv-dna/","asOf":"2026-09-07","days":14},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/","asOf":"2026-09-07","days":14},{"id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","asOf":"2026-09-07","days":14},{"id":"io-before-surgery-hnscc","kind":"pairing","name":"Immunotherapy before surgery rather than with chemoradiation (HNSCC)","route":"/pairings/io-before-surgery-hnscc/","asOf":"2026-09-07","days":14},{"id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/","asOf":"2026-09-07","days":14},{"id":"hpv-deescalation-caution","kind":"pairing","name":"Caution: de-escalating radiation on HPV status alone","route":"/pairings/hpv-deescalation-caution/","asOf":"2026-09-07","days":14},{"id":"idea-cthpv-adapted-deescalation","kind":"idea","name":"ctHPV-DNA-adapted de-escalation of chemoradiation","route":"/ideas/idea-cthpv-adapted-deescalation/","asOf":"2026-09-07","days":14},{"id":"idea-photoimmunotherapy-plus-pd1","kind":"idea","name":"Photoimmunotherapy as an in situ vaccine with PD-1 blockade","route":"/ideas/idea-photoimmunotherapy-plus-pd1/","asOf":"2026-09-07","days":14},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","asOf":"2026-09-07","days":14},{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","asOf":"2026-09-07","days":14},{"id":"libretto-531","kind":"trial","name":"LIBRETTO-531","route":"/trials/libretto-531/","asOf":"2026-09-07","days":14},{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","asOf":"2026-09-07","days":14},{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","asOf":"2026-09-07","days":14},{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","asOf":"2026-09-07","days":14},{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","asOf":"2026-09-07","days":14},{"id":"roar-atc","kind":"trial","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/","asOf":"2026-09-07","days":14},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","asOf":"2026-09-07","days":14},{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","asOf":"2026-09-07","days":14},{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","asOf":"2026-09-07","days":14},{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","asOf":"2026-09-07","days":14},{"id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/","asOf":"2026-09-07","days":14},{"id":"active-surveillance-thyroid","kind":"technology","name":"Active surveillance of papillary microcarcinoma","route":"/technologies/active-surveillance-thyroid/","asOf":"2026-09-07","days":14},{"id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","asOf":"2026-09-07","days":14},{"id":"low-risk-dtc","kind":"term","name":"Low-risk differentiated thyroid cancer (ATA risk)","route":"/terms/low-risk-dtc/","asOf":"2026-09-07","days":14},{"id":"bethesda-category","kind":"term","name":"Bethesda category (thyroid cytology)","route":"/terms/bethesda-category/","asOf":"2026-09-07","days":14},{"id":"tsh-suppression","kind":"term","name":"TSH suppression","route":"/terms/tsh-suppression/","asOf":"2026-09-07","days":14},{"id":"tert-promoter","kind":"term","name":"TERT promoter mutation","route":"/terms/tert-promoter/","asOf":"2026-09-07","days":14},{"id":"braf-mek-neoadjuvant-atc","kind":"pairing","name":"BRAF/MEK inhibition → surgery in anaplastic thyroid cancer","route":"/pairings/braf-mek-neoadjuvant-atc/","asOf":"2026-09-07","days":14},{"id":"redifferentiation-rai","kind":"pairing","name":"MAPK inhibitor redifferentiation → radioiodine","route":"/pairings/redifferentiation-rai/","asOf":"2026-09-07","days":14},{"id":"idea-thyroid-overdiagnosis-reversal","kind":"idea","name":"Ultrasound restraint and surveillance to reverse thyroid cancer overdiagnosis","route":"/ideas/idea-thyroid-overdiagnosis-reversal/","asOf":"2026-09-07","days":14},{"id":"idea-atc-triplet-io","kind":"idea","name":"BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer","route":"/ideas/idea-atc-triplet-io/","asOf":"2026-09-07","days":14},{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/","asOf":"2026-09-07","days":14},{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","asOf":"2026-09-07","days":14},{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/","asOf":"2026-09-07","days":14},{"id":"atomic","kind":"trial","name":"ATOMIC (Alliance A021502)","route":"/trials/atomic/","asOf":"2026-09-07","days":14},{"id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","asOf":"2026-09-07","days":14},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","asOf":"2026-09-07","days":14},{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/","asOf":"2026-09-07","days":14},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","asOf":"2026-09-07","days":14},{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER & MOUNTAINEER-03","route":"/trials/mountaineer/","asOf":"2026-09-07","days":14},{"id":"destiny-crc02","kind":"trial","name":"DESTINY-CRC02","route":"/trials/destiny-crc02/","asOf":"2026-09-07","days":14},{"id":"sunlight","kind":"trial","name":"SUNLIGHT","route":"/trials/sunlight/","asOf":"2026-09-07","days":14},{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/","asOf":"2026-09-07","days":14},{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/","asOf":"2026-09-07","days":14},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","asOf":"2026-09-07","days":14},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","asOf":"2026-09-07","days":14},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","asOf":"2026-09-07","days":14},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","asOf":"2026-09-07","days":14},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","asOf":"2026-09-07","days":14},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","asOf":"2026-09-07","days":14},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","asOf":"2026-09-07","days":14},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","asOf":"2026-09-07","days":14},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","asOf":"2026-09-07","days":14},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","asOf":"2026-09-07","days":14},{"id":"cms-subtypes","kind":"term","name":"Consensus molecular subtypes (CMS1-4)","route":"/terms/cms-subtypes/","asOf":"2026-09-07","days":14},{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","asOf":"2026-09-07","days":14},{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","asOf":"2026-09-07","days":14},{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","asOf":"2026-09-07","days":14},{"id":"anti-egfr-left-sided","kind":"pairing","name":"Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC","route":"/pairings/anti-egfr-left-sided/","asOf":"2026-09-07","days":14},{"id":"neoadjuvant-io-dmmr","kind":"pairing","name":"Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer","route":"/pairings/neoadjuvant-io-dmmr/","asOf":"2026-09-07","days":14},{"id":"idea-ctdna-guided-adjuvant-crc","kind":"idea","name":"ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer","route":"/ideas/idea-ctdna-guided-adjuvant-crc/","asOf":"2026-09-07","days":14},{"id":"idea-immunotherapy-mss-crc","kind":"idea","name":"Making microsatellite-stable colorectal cancer immunotherapy-responsive","route":"/ideas/idea-immunotherapy-mss-crc/","asOf":"2026-09-07","days":14},{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/","asOf":"2026-09-07","days":14},{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","asOf":"2026-09-07","days":14},{"id":"keynote-859","kind":"trial","name":"KEYNOTE-859","route":"/trials/keynote-859/","asOf":"2026-09-07","days":14},{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/","asOf":"2026-09-07","days":14},{"id":"matterhorn","kind":"trial","name":"MATTERHORN","route":"/trials/matterhorn/","asOf":"2026-09-07","days":14},{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/","asOf":"2026-09-07","days":14},{"id":"herizon-gea-01","kind":"trial","name":"HERIZON-GEA-01","route":"/trials/herizon-gea-01/","asOf":"2026-09-07","days":14},{"id":"destiny-gastric04","kind":"trial","name":"DESTINY-Gastric04","route":"/trials/destiny-gastric04/","asOf":"2026-09-07","days":14},{"id":"rainbow","kind":"trial","name":"RAINBOW","route":"/trials/rainbow/","asOf":"2026-09-07","days":14},{"id":"clarity-gastric01","kind":"trial","name":"CLARITY-Gastric 01","route":"/trials/clarity-gastric01/","asOf":"2026-09-07","days":14},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/","asOf":"2026-09-07","days":14},{"id":"bemarituzumab","kind":"drug","name":"Bemarituzumab","route":"/drugs/bemarituzumab/","asOf":"2026-09-07","days":14},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/","asOf":"2026-09-07","days":14},{"id":"siewert-classification","kind":"term","name":"Siewert classification (GEJ tumours)","route":"/terms/siewert-classification/","asOf":"2026-09-07","days":14},{"id":"lauren-classification","kind":"term","name":"Lauren classification (intestinal vs diffuse)","route":"/terms/lauren-classification/","asOf":"2026-09-07","days":14},{"id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/","asOf":"2026-09-07","days":14},{"id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/","asOf":"2026-09-07","days":14},{"id":"cldn18-antibody-then-adc","kind":"pairing","name":"CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression","route":"/pairings/cldn18-antibody-then-adc/","asOf":"2026-09-07","days":14},{"id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/","asOf":"2026-09-07","days":14},{"id":"idea-peritoneal-directed-gastric","kind":"idea","name":"Peritoneal-directed therapy for gastric cancer","route":"/ideas/idea-peritoneal-directed-gastric/","asOf":"2026-09-07","days":14},{"id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","asOf":"2026-09-07","days":14},{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","asOf":"2026-09-07","days":14},{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/","asOf":"2026-09-07","days":14},{"id":"keynote-590","kind":"trial","name":"KEYNOTE-590","route":"/trials/keynote-590/","asOf":"2026-09-07","days":14},{"id":"checkmate-648","kind":"trial","name":"CheckMate 648","route":"/trials/checkmate-648/","asOf":"2026-09-07","days":14},{"id":"rationale-306","kind":"trial","name":"RATIONALE-306","route":"/trials/rationale-306/","asOf":"2026-09-07","days":14},{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","route":"/trials/escort-1st/","asOf":"2026-09-07","days":14},{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/","asOf":"2026-09-07","days":14},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","asOf":"2026-09-07","days":14},{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/","asOf":"2026-09-07","days":14},{"id":"endoscopic-resection","kind":"technology","name":"Endoscopic resection (EMR / ESD)","route":"/technologies/endoscopic-resection/","asOf":"2026-09-07","days":14},{"id":"barretts-esophagus","kind":"term","name":"Barrett's oesophagus","route":"/terms/barretts-esophagus/","asOf":"2026-09-07","days":14},{"id":"escc-vs-eac","kind":"term","name":"Squamous cell carcinoma vs adenocarcinoma of the oesophagus","route":"/terms/escc-vs-eac/","asOf":"2026-09-07","days":14},{"id":"cross-then-nivolumab","kind":"pairing","name":"CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease","route":"/pairings/cross-then-nivolumab/","asOf":"2026-09-07","days":14},{"id":"idea-organ-preservation-esophageal","kind":"idea","name":"Organ preservation as the default after complete response in oesophageal cancer","route":"/ideas/idea-organ-preservation-esophageal/","asOf":"2026-09-07","days":14},{"id":"idea-non-endoscopic-barretts-screening","kind":"idea","name":"Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma","route":"/ideas/idea-non-endoscopic-barretts-screening/","asOf":"2026-09-07","days":14},{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","asOf":"2026-09-07","days":14},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","asOf":"2026-09-07","days":14},{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","asOf":"2026-09-07","days":14},{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","asOf":"2026-09-07","days":14},{"id":"atlantis","kind":"trial","name":"ATLANTIS","route":"/trials/atlantis/","asOf":"2026-09-07","days":14},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","asOf":"2026-09-07","days":14},{"id":"ideate-lung02","kind":"trial","name":"IDeate-Lung02","route":"/trials/ideate-lung02/","asOf":"2026-09-07","days":14},{"id":"astrum-005","kind":"trial","name":"ASTRUM-005","route":"/trials/astrum-005/","asOf":"2026-09-07","days":14},{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/","asOf":"2026-09-07","days":14},{"id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/","asOf":"2026-09-07","days":14},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/","asOf":"2026-09-07","days":14},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","asOf":"2026-09-07","days":14},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","asOf":"2026-09-07","days":14},{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/","asOf":"2026-09-07","days":14},{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/","asOf":"2026-09-07","days":14},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/","asOf":"2026-09-07","days":14},{"id":"chemo-io-then-maintenance-sclc","kind":"pairing","name":"Chemo-immunotherapy induction → maintenance intensification (SCLC)","route":"/pairings/chemo-io-then-maintenance-sclc/","asOf":"2026-09-07","days":14},{"id":"tarlatamab-vs-idxd-sequence","kind":"pairing","name":"Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC","route":"/pairings/tarlatamab-vs-idxd-sequence/","asOf":"2026-09-07","days":14},{"id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/","asOf":"2026-09-07","days":14},{"id":"idea-mri-surveillance-replaces-pci","kind":"idea","name":"MRI surveillance replaces prophylactic cranial irradiation in SCLC","route":"/ideas/idea-mri-surveillance-replaces-pci/","asOf":"2026-09-07","days":14},{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/","asOf":"2026-09-07","days":14},{"id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","asOf":"2026-09-07","days":14},{"id":"maps","kind":"trial","name":"MAPS","route":"/trials/maps/","asOf":"2026-09-07","days":14},{"id":"mars-2","kind":"trial","name":"MARS 2","route":"/trials/mars-2/","asOf":"2026-09-07","days":14},{"id":"lume-meso","kind":"trial","name":"LUME-Meso","route":"/trials/lume-meso/","asOf":"2026-09-07","days":14},{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","asOf":"2026-09-07","days":14},{"id":"dream3r","kind":"trial","name":"DREAM3R","route":"/trials/dream3r/","asOf":"2026-09-07","days":14},{"id":"stellar","kind":"trial","name":"STELLAR","route":"/trials/stellar/","asOf":"2026-09-07","days":14},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","asOf":"2026-09-07","days":14},{"id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","asOf":"2026-09-07","days":14},{"id":"pleurectomy-decortication","kind":"technology","name":"Extended pleurectomy/decortication & radical mesothelioma surgery","route":"/technologies/pleurectomy-decortication/","asOf":"2026-09-07","days":14},{"id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/","asOf":"2026-09-07","days":14},{"id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/","asOf":"2026-09-07","days":14},{"id":"idea-adc-for-mesothelioma","kind":"idea","name":"Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work","route":"/ideas/idea-adc-for-mesothelioma/","asOf":"2026-09-07","days":14},{"id":"idea-mtap-prmt5-mesothelioma","kind":"idea","name":"PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma","route":"/ideas/idea-mtap-prmt5-mesothelioma/","asOf":"2026-09-07","days":14},{"id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/","asOf":"2026-09-07","days":14},{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","asOf":"2026-09-07","days":14},{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","asOf":"2026-09-07","days":14},{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","asOf":"2026-09-07","days":14},{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","asOf":"2026-09-07","days":14},{"id":"potomac","kind":"trial","name":"POTOMAC","route":"/trials/potomac/","asOf":"2026-09-07","days":14},{"id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","asOf":"2026-09-07","days":14},{"id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/","asOf":"2026-09-07","days":14},{"id":"quilt-3-032","kind":"trial","name":"QUILT 3.032","route":"/trials/quilt-3-032/","asOf":"2026-09-07","days":14},{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/","asOf":"2026-09-07","days":14},{"id":"javelin-bladder-100","kind":"trial","name":"JAVELIN Bladder 100","route":"/trials/javelin-bladder-100/","asOf":"2026-09-07","days":14},{"id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","asOf":"2026-09-07","days":14},{"id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/","asOf":"2026-09-07","days":14},{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","asOf":"2026-09-07","days":14},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","asOf":"2026-09-07","days":14},{"id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","asOf":"2026-09-07","days":14},{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","asOf":"2026-09-07","days":14},{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","asOf":"2026-09-07","days":14},{"id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/","asOf":"2026-09-07","days":14},{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","asOf":"2026-09-07","days":14},{"id":"cystoscopy-turbt","kind":"technology","name":"Cystoscopy, blue-light imaging & TURBT","route":"/technologies/cystoscopy-turbt/","asOf":"2026-09-07","days":14},{"id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","asOf":"2026-09-07","days":14},{"id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","route":"/terms/bcg-unresponsive/","asOf":"2026-09-07","days":14},{"id":"fgfr3","kind":"term","name":"FGFR3 alterations (bladder cancer)","route":"/terms/fgfr3/","asOf":"2026-09-07","days":14},{"id":"cg-oncology","kind":"company","name":"CG Oncology","route":"/companies/cg-oncology/","asOf":"2026-09-07","days":14},{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/","asOf":"2026-09-07","days":14},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","asOf":"2026-09-07","days":14},{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","route":"/companies/bicycle-therapeutics/","asOf":"2026-09-07","days":14},{"id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","route":"/pairings/ev-pembro-continuum/","asOf":"2026-09-07","days":14},{"id":"durvalumab-plus-bcg","kind":"pairing","name":"Durvalumab + BCG in BCG-naive high-risk NMIBC","route":"/pairings/durvalumab-plus-bcg/","asOf":"2026-09-07","days":14},{"id":"idea-bladder-preservation-mibc","kind":"idea","name":"Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response","route":"/ideas/idea-bladder-preservation-mibc/","asOf":"2026-09-07","days":14},{"id":"idea-urine-ctdna-surveillance","kind":"idea","name":"Urine tumour DNA to replace surveillance cystoscopy in NMIBC","route":"/ideas/idea-urine-ctdna-surveillance/","asOf":"2026-09-07","days":14},{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/","asOf":"2026-09-07","days":14},{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/","asOf":"2026-09-07","days":14},{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","asOf":"2026-09-07","days":14},{"id":"clear","kind":"trial","name":"CLEAR (KEYNOTE-581)","route":"/trials/clear/","asOf":"2026-09-07","days":14},{"id":"keynote-564","kind":"trial","name":"KEYNOTE-564","route":"/trials/keynote-564/","asOf":"2026-09-07","days":14},{"id":"litespark-022","kind":"trial","name":"LITESPARK-022","route":"/trials/litespark-022/","asOf":"2026-09-07","days":14},{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/","asOf":"2026-09-07","days":14},{"id":"litespark-012","kind":"trial","name":"LITESPARK-012","route":"/trials/litespark-012/","asOf":"2026-09-07","days":14},{"id":"cosmic-313","kind":"trial","name":"COSMIC-313","route":"/trials/cosmic-313/","asOf":"2026-09-07","days":14},{"id":"contact-03","kind":"trial","name":"CONTACT-03","route":"/trials/contact-03/","asOf":"2026-09-07","days":14},{"id":"tinivo-2","kind":"trial","name":"TiNivo-2","route":"/trials/tinivo-2/","asOf":"2026-09-07","days":14},{"id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","asOf":"2026-09-07","days":14},{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","asOf":"2026-09-07","days":14},{"id":"partial-nephrectomy-active-surveillance","kind":"technology","name":"Partial nephrectomy, ablation & active surveillance of small renal masses","route":"/technologies/partial-nephrectomy-active-surveillance/","asOf":"2026-09-07","days":14},{"id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","asOf":"2026-09-07","days":14},{"id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","route":"/terms/imdc-risk/","asOf":"2026-09-07","days":14},{"id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","route":"/terms/sarcomatoid-rcc/","asOf":"2026-09-07","days":14},{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","route":"/companies/aveo/","asOf":"2026-09-07","days":14},{"id":"io-rechallenge-caution-rcc","kind":"pairing","name":"Caution: PD-1 rechallenge after progression on immunotherapy (RCC)","route":"/pairings/io-rechallenge-caution-rcc/","asOf":"2026-09-07","days":14},{"id":"risk-directed-first-line-rcc","kind":"pairing","name":"IMDC risk → first-line regimen choice (RCC)","route":"/pairings/risk-directed-first-line-rcc/","asOf":"2026-09-07","days":14},{"id":"idea-adjuvant-selection-rcc","kind":"idea","name":"Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)","route":"/ideas/idea-adjuvant-selection-rcc/","asOf":"2026-09-07","days":14},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/","asOf":"2026-09-07","days":14},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","asOf":"2026-09-07","days":14},{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/","asOf":"2026-09-07","days":14},{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/","asOf":"2026-09-07","days":14},{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/","asOf":"2026-09-07","days":14},{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/","asOf":"2026-09-07","days":14},{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/","asOf":"2026-09-07","days":14},{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/","asOf":"2026-09-07","days":14},{"id":"desktop-iii","kind":"trial","name":"DESKTOP III / ENGOT-ov20","route":"/trials/desktop-iii/","asOf":"2026-09-07","days":14},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/","asOf":"2026-09-07","days":14},{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/","asOf":"2026-09-07","days":14},{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","asOf":"2026-09-07","days":14},{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/","asOf":"2026-09-07","days":14},{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/","asOf":"2026-09-07","days":14},{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","asOf":"2026-09-07","days":14},{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/","asOf":"2026-09-07","days":14},{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","asOf":"2026-09-07","days":14},{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","asOf":"2026-09-07","days":14},{"id":"trabectedin","kind":"drug","name":"Trabectedin","route":"/drugs/trabectedin/","asOf":"2026-09-07","days":14},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","asOf":"2026-09-07","days":14},{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/","asOf":"2026-09-07","days":14},{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/","asOf":"2026-09-07","days":14},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","asOf":"2026-09-07","days":14},{"id":"ca-125","kind":"term","name":"CA-125","route":"/terms/ca-125/","asOf":"2026-09-07","days":14},{"id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","asOf":"2026-09-07","days":14},{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/","asOf":"2026-09-07","days":14},{"id":"risk-reducing-salpingectomy","kind":"technology","name":"Risk-reducing and opportunistic salpingectomy","route":"/technologies/risk-reducing-salpingectomy/","asOf":"2026-09-07","days":14},{"id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/","asOf":"2026-09-07","days":14},{"id":"hipec-at-interval-surgery","kind":"pairing","name":"HIPEC at interval cytoreductive surgery","route":"/pairings/hipec-at-interval-surgery/","asOf":"2026-09-07","days":14},{"id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/","asOf":"2026-09-07","days":14},{"id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/","asOf":"2026-09-07","days":14},{"id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/","asOf":"2026-09-07","days":14},{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","asOf":"2026-09-07","days":14},{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","asOf":"2026-09-07","days":14},{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","asOf":"2026-09-07","days":14},{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/","asOf":"2026-09-07","days":14},{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/","asOf":"2026-09-07","days":14},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","asOf":"2026-09-07","days":14},{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","route":"/trials/xport-ec-042/","asOf":"2026-09-07","days":14},{"id":"fires-sentor","kind":"trial","name":"FIRES & SENTOR (sentinel node mapping)","route":"/trials/fires-sentor/","asOf":"2026-09-07","days":14},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","asOf":"2026-09-07","days":14},{"id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","asOf":"2026-09-07","days":14},{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","route":"/terms/endometrial-molecular-classes/","asOf":"2026-09-07","days":14},{"id":"fertility-sparing-endometrial","kind":"technology","name":"Fertility-sparing hormonal treatment of early endometrial cancer","route":"/technologies/fertility-sparing-endometrial/","asOf":"2026-09-07","days":14},{"id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/","asOf":"2026-09-07","days":14},{"id":"lenvatinib-plus-pembrolizumab","kind":"pairing","name":"Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)","route":"/pairings/lenvatinib-plus-pembrolizumab/","asOf":"2026-09-07","days":14},{"id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/","asOf":"2026-09-07","days":14},{"id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/","asOf":"2026-09-07","days":14},{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","asOf":"2026-09-07","days":14},{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/","asOf":"2026-09-07","days":14},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/","asOf":"2026-09-07","days":14},{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/","asOf":"2026-09-07","days":14},{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/","asOf":"2026-09-07","days":14},{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/","asOf":"2026-09-07","days":14},{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/","asOf":"2026-09-07","days":14},{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/","asOf":"2026-09-07","days":14},{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","asOf":"2026-09-07","days":14},{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/","asOf":"2026-09-07","days":14},{"id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/","asOf":"2026-09-07","days":14},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","asOf":"2026-09-07","days":14},{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/","asOf":"2026-09-07","days":14},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","asOf":"2026-09-07","days":14},{"id":"cin-hsil","kind":"term","name":"Cervical precancer (CIN, HSIL/LSIL)","route":"/terms/cin-hsil/","asOf":"2026-09-07","days":14},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/","asOf":"2026-09-07","days":14},{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/","asOf":"2026-09-07","days":14},{"id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/","asOf":"2026-09-07","days":14},{"id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/","asOf":"2026-09-07","days":14},{"id":"io-plus-crt-cervical","kind":"pairing","name":"PD-1 blockade + chemoradiation (locally advanced cervical cancer)","route":"/pairings/io-plus-crt-cervical/","asOf":"2026-09-07","days":14},{"id":"caution-mis-radical-hysterectomy","kind":"pairing","name":"Caution: minimally invasive radical hysterectomy for early cervical cancer","route":"/pairings/caution-mis-radical-hysterectomy/","asOf":"2026-09-07","days":14},{"id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/","asOf":"2026-09-07","days":14},{"id":"idea-hpv-ctdna-cervical","kind":"idea","name":"HPV circulating tumour DNA to guide cervical cancer therapy","route":"/ideas/idea-hpv-ctdna-cervical/","asOf":"2026-09-07","days":14},{"id":"kura-oncology","kind":"company","name":"Kura Oncology","route":"/companies/kura-oncology/","asOf":"2026-09-07","days":14},{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/","asOf":"2026-09-07","days":14},{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","route":"/companies/rigel-pharmaceuticals/","asOf":"2026-09-07","days":14},{"id":"kmt2a","kind":"target","name":"KMT2A (MLL) rearrangement","route":"/targets/kmt2a/","asOf":"2026-09-07","days":14},{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/","asOf":"2026-09-07","days":14},{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/","asOf":"2026-09-07","days":14},{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/","asOf":"2026-09-07","days":14},{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","asOf":"2026-09-07","days":14},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/","asOf":"2026-09-07","days":14},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/","asOf":"2026-09-07","days":14},{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/","asOf":"2026-09-07","days":14},{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/","asOf":"2026-09-07","days":14},{"id":"bh3-profiling","kind":"technology","name":"BH3 profiling (functional apoptosis testing)","route":"/technologies/bh3-profiling/","asOf":"2026-09-07","days":14},{"id":"eln-risk","kind":"term","name":"ELN 2022 risk classification","route":"/terms/eln-risk/","asOf":"2026-09-07","days":14},{"id":"flt3-itd-allelic-ratio","kind":"term","name":"FLT3-ITD allelic ratio","route":"/terms/flt3-itd-allelic-ratio/","asOf":"2026-09-07","days":14},{"id":"ighv-status","kind":"term","name":"IGHV mutational status","route":"/terms/ighv-status/","asOf":"2026-09-07","days":14},{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","asOf":"2026-09-07","days":14},{"id":"richter-transformation","kind":"term","name":"Richter transformation","route":"/terms/richter-transformation/","asOf":"2026-09-07","days":14},{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/","asOf":"2026-09-07","days":14},{"id":"tumor-lysis-syndrome","kind":"term","name":"Tumour lysis syndrome (TLS)","route":"/terms/tumor-lysis-syndrome/","asOf":"2026-09-07","days":14},{"id":"differentiation-syndrome","kind":"term","name":"Differentiation syndrome","route":"/terms/differentiation-syndrome/","asOf":"2026-09-07","days":14},{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","asOf":"2026-09-07","days":14},{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","asOf":"2026-09-07","days":14},{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","asOf":"2026-09-07","days":14},{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","asOf":"2026-09-07","days":14},{"id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","asOf":"2026-09-07","days":14},{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","asOf":"2026-09-07","days":14},{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","asOf":"2026-09-07","days":14},{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","asOf":"2026-09-07","days":14},{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","asOf":"2026-09-07","days":14},{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","asOf":"2026-09-07","days":14},{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","asOf":"2026-09-07","days":14},{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","asOf":"2026-09-07","days":14},{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","asOf":"2026-09-07","days":14},{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","asOf":"2026-09-07","days":14},{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/","asOf":"2026-09-07","days":14},{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","asOf":"2026-09-07","days":14},{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","asOf":"2026-09-07","days":14},{"id":"alfa-0701","kind":"trial","name":"ALFA-0701","route":"/trials/alfa-0701/","asOf":"2026-09-07","days":14},{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/","asOf":"2026-09-07","days":14},{"id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","asOf":"2026-09-07","days":14},{"id":"cpx-351-301","kind":"trial","name":"CPX-351 Study 301","route":"/trials/cpx-351-301/","asOf":"2026-09-07","days":14},{"id":"ascertain-v","kind":"trial","name":"ASCERTAIN-V","route":"/trials/ascertain-v/","asOf":"2026-09-07","days":14},{"id":"myelomatch","kind":"trial","name":"myeloMATCH","route":"/trials/myelomatch/","asOf":"2026-09-07","days":14},{"id":"venetoclax-plus-hma","kind":"pairing","name":"Venetoclax + hypomethylating agent","route":"/pairings/venetoclax-plus-hma/","asOf":"2026-09-07","days":14},{"id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","route":"/pairings/flt3i-plus-7-3/","asOf":"2026-09-07","days":14},{"id":"menin-plus-venetoclax-hma","kind":"pairing","name":"Menin inhibitor + venetoclax + azacitidine","route":"/pairings/menin-plus-venetoclax-hma/","asOf":"2026-09-07","days":14},{"id":"idea-mrd-guided-transplant-aml","kind":"idea","name":"MRD-guided transplant decisions in intermediate-risk AML","route":"/ideas/idea-mrd-guided-transplant-aml/","asOf":"2026-09-07","days":14},{"id":"idea-shortened-venetoclax","kind":"idea","name":"Shorter venetoclax courses in unfit AML","route":"/ideas/idea-shortened-venetoclax/","asOf":"2026-09-07","days":14},{"id":"autolus","kind":"company","name":"Autolus Therapeutics","route":"/companies/autolus/","asOf":"2026-09-07","days":14},{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","route":"/companies/adaptive-biotechnologies/","asOf":"2026-09-07","days":14},{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","asOf":"2026-09-07","days":14},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","asOf":"2026-09-07","days":14},{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","asOf":"2026-09-07","days":14},{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","asOf":"2026-09-07","days":14},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","asOf":"2026-09-07","days":14},{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","asOf":"2026-09-07","days":14},{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","asOf":"2026-09-07","days":14},{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/","asOf":"2026-09-07","days":14},{"id":"tower","kind":"trial","name":"TOWER","route":"/trials/tower/","asOf":"2026-09-07","days":14},{"id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/","asOf":"2026-09-07","days":14},{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","asOf":"2026-09-07","days":14},{"id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","asOf":"2026-09-07","days":14},{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/","asOf":"2026-09-07","days":14},{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","asOf":"2026-09-07","days":14},{"id":"interfant-06","kind":"trial","name":"Interfant-06","route":"/trials/interfant-06/","asOf":"2026-09-07","days":14},{"id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/","asOf":"2026-09-07","days":14},{"id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/","asOf":"2026-09-07","days":14},{"id":"inotuzumab-then-transplant-caution","kind":"pairing","name":"Caution: inotuzumab before transplant (veno-occlusive disease)","route":"/pairings/inotuzumab-then-transplant-caution/","asOf":"2026-09-07","days":14},{"id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/","asOf":"2026-09-07","days":14},{"id":"idea-menin-infant-all","kind":"idea","name":"Menin inhibitors for infant KMT2A-rearranged ALL","route":"/ideas/idea-menin-infant-all/","asOf":"2026-09-07","days":14},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","asOf":"2026-09-07","days":14},{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","asOf":"2026-09-07","days":14},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","asOf":"2026-09-07","days":14},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","asOf":"2026-09-07","days":14},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","asOf":"2026-09-07","days":14},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","asOf":"2026-09-07","days":14},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","asOf":"2026-09-07","days":14},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","asOf":"2026-09-07","days":14},{"id":"bgb-16673","kind":"drug","name":"BGB-16673","route":"/drugs/bgb-16673/","asOf":"2026-09-07","days":14},{"id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","asOf":"2026-09-07","days":14},{"id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/","asOf":"2026-09-07","days":14},{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","asOf":"2026-09-07","days":14},{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/","asOf":"2026-09-07","days":14},{"id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/","asOf":"2026-09-07","days":14},{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","asOf":"2026-09-07","days":14},{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","asOf":"2026-09-07","days":14},{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/","asOf":"2026-09-07","days":14},{"id":"glow","kind":"trial","name":"GLOW","route":"/trials/glow/","asOf":"2026-09-07","days":14},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","asOf":"2026-09-07","days":14},{"id":"bruin-cll-321","kind":"trial","name":"BRUIN CLL-321","route":"/trials/bruin-cll-321/","asOf":"2026-09-07","days":14},{"id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","asOf":"2026-09-07","days":14},{"id":"celestial-tncll","kind":"trial","name":"CELESTIAL-TNCLL","route":"/trials/celestial-tncll/","asOf":"2026-09-07","days":14},{"id":"cadance-304","kind":"trial","name":"CaDAnCe-304","route":"/trials/cadance-304/","asOf":"2026-09-07","days":14},{"id":"bellwave-011","kind":"trial","name":"BELLWAVE-011","route":"/trials/bellwave-011/","asOf":"2026-09-07","days":14},{"id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/","asOf":"2026-09-07","days":14},{"id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","route":"/pairings/venetoclax-plus-obinutuzumab/","asOf":"2026-09-07","days":14},{"id":"cit-in-del17p-caution","kind":"pairing","name":"Caution: chemoimmunotherapy in del(17p)/TP53 CLL","route":"/pairings/cit-in-del17p-caution/","asOf":"2026-09-07","days":14},{"id":"btki-ibrutinib-cardiac-caution","kind":"pairing","name":"Caution: ibrutinib in patients with cardiac risk","route":"/pairings/btki-ibrutinib-cardiac-caution/","asOf":"2026-09-07","days":14},{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/","asOf":"2026-09-07","days":14},{"id":"idea-btk-degrader-frontline","kind":"idea","name":"BTK degraders to pre-empt resistance in frontline CLL","route":"/ideas/idea-btk-degrader-frontline/","asOf":"2026-09-07","days":14},{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/","asOf":"2026-09-07","days":14},{"id":"ipi-score","kind":"term","name":"International Prognostic Index (IPI)","route":"/terms/ipi-score/","asOf":"2026-09-07","days":14},{"id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/","asOf":"2026-09-07","days":14},{"id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/","asOf":"2026-09-07","days":14},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/","asOf":"2026-09-07","days":14},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","asOf":"2026-09-07","days":14},{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","asOf":"2026-09-07","days":14},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/","asOf":"2026-09-07","days":14},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","asOf":"2026-09-07","days":14},{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","asOf":"2026-09-07","days":14},{"id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","asOf":"2026-09-07","days":14},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","asOf":"2026-09-07","days":14},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/","asOf":"2026-09-07","days":14},{"id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/","asOf":"2026-09-07","days":14},{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/","asOf":"2026-09-07","days":14},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","asOf":"2026-09-07","days":14},{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","asOf":"2026-09-07","days":14},{"id":"epcore-dlbcl-2","kind":"trial","name":"EPCORE DLBCL-2","route":"/trials/epcore-dlbcl-2/","asOf":"2026-09-07","days":14},{"id":"frontmind","kind":"trial","name":"frontMIND","route":"/trials/frontmind/","asOf":"2026-09-07","days":14},{"id":"l-mind","kind":"trial","name":"L-MIND","route":"/trials/l-mind/","asOf":"2026-09-07","days":14},{"id":"lotis-2","kind":"trial","name":"LOTIS-2","route":"/trials/lotis-2/","asOf":"2026-09-07","days":14},{"id":"waveline-003","kind":"trial","name":"waveLINE-003","route":"/trials/waveline-003/","asOf":"2026-09-07","days":14},{"id":"sunmo","kind":"trial","name":"SUNMO","route":"/trials/sunmo/","asOf":"2026-09-07","days":14},{"id":"golseek-1","kind":"trial","name":"GOLSEEK-1","route":"/trials/golseek-1/","asOf":"2026-09-07","days":14},{"id":"belinda","kind":"trial","name":"BELINDA","route":"/trials/belinda/","asOf":"2026-09-07","days":14},{"id":"bispecific-plus-adc-lymphoma","kind":"pairing","name":"CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)","route":"/pairings/bispecific-plus-adc-lymphoma/","asOf":"2026-09-07","days":14},{"id":"car-t-before-transplant-lbcl","kind":"pairing","name":"Early relapse: CAR-T before transplant","route":"/pairings/car-t-before-transplant-lbcl/","asOf":"2026-09-07","days":14},{"id":"idea-ctdna-guided-dlbcl-frontline","kind":"idea","name":"ctDNA-guided escalation and de-escalation in frontline DLBCL","route":"/ideas/idea-ctdna-guided-dlbcl-frontline/","asOf":"2026-09-07","days":14},{"id":"idea-bispecific-vs-car-t-second-line","kind":"idea","name":"Head-to-head bispecific vs CAR-T in second-line LBCL","route":"/ideas/idea-bispecific-vs-car-t-second-line/","asOf":"2026-09-07","days":14},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","asOf":"2026-09-07","days":14},{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/","asOf":"2026-09-07","days":14},{"id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/","asOf":"2026-09-07","days":14},{"id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/","asOf":"2026-09-07","days":14},{"id":"smoldering-myeloma","kind":"term","name":"Smouldering myeloma / MGUS","route":"/terms/smoldering-myeloma/","asOf":"2026-09-07","days":14},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","asOf":"2026-09-07","days":14},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","asOf":"2026-09-07","days":14},{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","asOf":"2026-09-07","days":14},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","asOf":"2026-09-07","days":14},{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","asOf":"2026-09-07","days":14},{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","asOf":"2026-09-07","days":14},{"id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/","asOf":"2026-09-07","days":14},{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","asOf":"2026-09-07","days":14},{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","asOf":"2026-09-07","days":14},{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","asOf":"2026-09-07","days":14},{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","asOf":"2026-09-07","days":14},{"id":"mezigdomide","kind":"drug","name":"Mezigdomide","route":"/drugs/mezigdomide/","asOf":"2026-09-07","days":14},{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","asOf":"2026-09-07","days":14},{"id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/","asOf":"2026-09-07","days":14},{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/","asOf":"2026-09-07","days":14},{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","asOf":"2026-09-07","days":14},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/","asOf":"2026-09-07","days":14},{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/","asOf":"2026-09-07","days":14},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","asOf":"2026-09-07","days":14},{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/","asOf":"2026-09-07","days":14},{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","asOf":"2026-09-07","days":14},{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","asOf":"2026-09-07","days":14},{"id":"linker-mm1","kind":"trial","name":"LINKER-MM1","route":"/trials/linker-mm1/","asOf":"2026-09-07","days":14},{"id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/","asOf":"2026-09-07","days":14},{"id":"dreamm-8","kind":"trial","name":"DREAMM-8","route":"/trials/dreamm-8/","asOf":"2026-09-07","days":14},{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","asOf":"2026-09-07","days":14},{"id":"cartitude-5","kind":"trial","name":"CARTITUDE-5","route":"/trials/cartitude-5/","asOf":"2026-09-07","days":14},{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/","asOf":"2026-09-07","days":14},{"id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/","asOf":"2026-09-07","days":14},{"id":"bcma-then-gprc5d","kind":"pairing","name":"BCMA-directed therapy → GPRC5D-directed therapy","route":"/pairings/bcma-then-gprc5d/","asOf":"2026-09-07","days":14},{"id":"bispecific-infection-prophylaxis","kind":"pairing","name":"Caution: T-cell redirectors and infections","route":"/pairings/bispecific-infection-prophylaxis/","asOf":"2026-09-07","days":14},{"id":"idea-mrd-guided-stop-myeloma","kind":"idea","name":"MRD-guided treatment-free intervals in myeloma","route":"/ideas/idea-mrd-guided-stop-myeloma/","asOf":"2026-09-07","days":14},{"id":"idea-car-t-replaces-transplant","kind":"idea","name":"One CAR-T infusion instead of autologous transplant","route":"/ideas/idea-car-t-replaces-transplant/","asOf":"2026-09-07","days":14},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/","asOf":"2026-09-07","days":14},{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","asOf":"2026-09-07","days":14},{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/","asOf":"2026-09-07","days":14},{"id":"reed-sternberg-cell","kind":"term","name":"Reed-Sternberg cell","route":"/terms/reed-sternberg-cell/","asOf":"2026-09-07","days":14},{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/","asOf":"2026-09-07","days":14},{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","asOf":"2026-09-07","days":14},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","asOf":"2026-09-07","days":14},{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","asOf":"2026-09-07","days":14},{"id":"keynote-204","kind":"trial","name":"KEYNOTE-204","route":"/trials/keynote-204/","asOf":"2026-09-07","days":14},{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","asOf":"2026-09-07","days":14},{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/","asOf":"2026-09-07","days":14},{"id":"aethera","kind":"trial","name":"AETHERA","route":"/trials/aethera/","asOf":"2026-09-07","days":14},{"id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/","asOf":"2026-09-07","days":14},{"id":"bleomycin-omission-caution","kind":"pairing","name":"Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF","route":"/pairings/bleomycin-omission-caution/","asOf":"2026-09-07","days":14},{"id":"idea-chemo-free-hodgkin","kind":"idea","name":"Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage","route":"/ideas/idea-chemo-free-hodgkin/","asOf":"2026-09-07","days":14},{"id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/","asOf":"2026-09-07","days":14},{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/","asOf":"2026-09-07","days":14},{"id":"springworks","kind":"company","name":"SpringWorks Therapeutics (Merck KGaA)","route":"/companies/springworks/","asOf":"2026-09-07","days":14},{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/","asOf":"2026-09-07","days":14},{"id":"limb-salvage-surgery","kind":"technology","name":"Limb-salvage surgery and endoprosthetic reconstruction","route":"/technologies/limb-salvage-surgery/","asOf":"2026-09-07","days":14},{"id":"fnclcc-grade","kind":"term","name":"FNCLCC grade (soft-tissue sarcoma)","route":"/terms/fnclcc-grade/","asOf":"2026-09-07","days":14},{"id":"sarcoma-histotype-tailoring","kind":"term","name":"Histotype-tailored therapy","route":"/terms/sarcoma-histotype-tailoring/","asOf":"2026-09-07","days":14},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","asOf":"2026-09-07","days":14},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","asOf":"2026-09-07","days":14},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","asOf":"2026-09-07","days":14},{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","asOf":"2026-09-07","days":14},{"id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/","asOf":"2026-09-07","days":14},{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/","asOf":"2026-09-07","days":14},{"id":"vimseltinib","kind":"drug","name":"Vimseltinib","route":"/drugs/vimseltinib/","asOf":"2026-09-07","days":14},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","asOf":"2026-09-07","days":14},{"id":"isg-sts-1001","kind":"trial","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","asOf":"2026-09-07","days":14},{"id":"announce","kind":"trial","name":"ANNOUNCE","route":"/trials/announce/","asOf":"2026-09-07","days":14},{"id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/","asOf":"2026-09-07","days":14},{"id":"insight-gist","kind":"trial","name":"INSIGHT","route":"/trials/insight-gist/","asOf":"2026-09-07","days":14},{"id":"voyager","kind":"trial","name":"VOYAGER","route":"/trials/voyager/","asOf":"2026-09-07","days":14},{"id":"defi","kind":"trial","name":"DeFi","route":"/trials/defi/","asOf":"2026-09-07","days":14},{"id":"motion","kind":"trial","name":"MOTION","route":"/trials/motion/","asOf":"2026-09-07","days":14},{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","asOf":"2026-09-07","days":14},{"id":"euro-ewing-2012","kind":"trial","name":"Euro Ewing 2012","route":"/trials/euro-ewing-2012/","asOf":"2026-09-07","days":14},{"id":"int-0091","kind":"trial","name":"INT-0091 (Ewing sarcoma)","route":"/trials/int-0091/","asOf":"2026-09-07","days":14},{"id":"ssgxviii","kind":"trial","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","route":"/trials/ssgxviii/","asOf":"2026-09-07","days":14},{"id":"ctdna-genotype-gist-tki","kind":"pairing","name":"ctDNA KIT genotyping → TKI selection in GIST","route":"/pairings/ctdna-genotype-gist-tki/","asOf":"2026-09-07","days":14},{"id":"doxorubicin-cardio-caution","kind":"pairing","name":"Caution: cumulative anthracycline dose and the heart","route":"/pairings/doxorubicin-cardio-caution/","asOf":"2026-09-07","days":14},{"id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","route":"/ideas/idea-tcr-t-beyond-hla-a2/","asOf":"2026-09-07","days":14},{"id":"idea-desmoid-intermittent-dosing","kind":"idea","name":"Intermittent or stop-and-restart nirogacestat in desmoid tumours","route":"/ideas/idea-desmoid-intermittent-dosing/","asOf":"2026-09-07","days":14},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","asOf":"2026-09-07","days":14},{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/","asOf":"2026-09-07","days":14},{"id":"tandem-transplant","kind":"technology","name":"Tandem autologous transplant","route":"/technologies/tandem-transplant/","asOf":"2026-09-07","days":14},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","asOf":"2026-09-07","days":14},{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","route":"/terms/inrg-staging/","asOf":"2026-09-07","days":14},{"id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/","asOf":"2026-09-07","days":14},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/","asOf":"2026-09-07","days":14},{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/","asOf":"2026-09-07","days":14},{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","asOf":"2026-09-07","days":14},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","asOf":"2026-09-07","days":14},{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","asOf":"2026-09-07","days":14},{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/","asOf":"2026-09-07","days":14},{"id":"hr-nbl1","kind":"trial","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/","asOf":"2026-09-07","days":14},{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","asOf":"2026-09-07","days":14},{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","asOf":"2026-09-07","days":14},{"id":"naxitamab-201","kind":"trial","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/","asOf":"2026-09-07","days":14},{"id":"nmtrc003","kind":"trial","name":"NMTRC003/003B (DFMO maintenance)","route":"/trials/nmtrc003/","asOf":"2026-09-07","days":14},{"id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","route":"/pairings/anti-gd2-plus-chemo-relapse/","asOf":"2026-09-07","days":14},{"id":"il2-anti-gd2-caution","kind":"pairing","name":"Caution: IL-2 added to anti-GD2 therapy","route":"/pairings/il2-anti-gd2-caution/","asOf":"2026-09-07","days":14},{"id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/","asOf":"2026-09-07","days":14},{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/","asOf":"2026-09-07","days":14},{"id":"in-vivo-gene-editing-cancer","kind":"technology","name":"In vivo base and prime editing for cancer","route":"/technologies/in-vivo-gene-editing-cancer/","asOf":"2026-09-08","days":13},{"id":"epigenetic-editing","kind":"technology","name":"Epigenetic editing (durable gene silencing)","route":"/technologies/epigenetic-editing/","asOf":"2026-09-08","days":13},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/","asOf":"2026-09-08","days":13},{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/","asOf":"2026-09-08","days":13},{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/","asOf":"2026-09-08","days":13},{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/","asOf":"2026-09-08","days":13},{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/","asOf":"2026-09-08","days":13},{"id":"tumour-microbiome-targeting","kind":"technology","name":"Targeting the tumour's own microbes","route":"/technologies/tumour-microbiome-targeting/","asOf":"2026-09-08","days":13},{"id":"dna-origami-nanorobots","kind":"technology","name":"DNA origami nanorobots","route":"/technologies/dna-origami-nanorobots/","asOf":"2026-09-08","days":13},{"id":"magnetic-nanoparticle-hyperthermia","kind":"technology","name":"Magnetic nanoparticle hyperthermia","route":"/technologies/magnetic-nanoparticle-hyperthermia/","asOf":"2026-09-08","days":13},{"id":"photothermal-nanoparticles","kind":"technology","name":"Photothermal (plasmonic) nanoparticle ablation","route":"/technologies/photothermal-nanoparticles/","asOf":"2026-09-08","days":13},{"id":"sonodynamic-therapy","kind":"technology","name":"Sonodynamic therapy","route":"/technologies/sonodynamic-therapy/","asOf":"2026-09-08","days":13},{"id":"radiodynamic-therapy","kind":"technology","name":"Radiodynamic therapy and radiosensitising nanoparticles","route":"/technologies/radiodynamic-therapy/","asOf":"2026-09-08","days":13},{"id":"vhee-radiotherapy","kind":"technology","name":"Very-high-energy electron therapy","route":"/technologies/vhee-radiotherapy/","asOf":"2026-09-08","days":13},{"id":"proton-arc-therapy","kind":"technology","name":"Proton arc therapy","route":"/technologies/proton-arc-therapy/","asOf":"2026-09-08","days":13},{"id":"lattice-radiotherapy","kind":"technology","name":"Lattice and GRID radiotherapy","route":"/technologies/lattice-radiotherapy/","asOf":"2026-09-08","days":13},{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","asOf":"2026-09-08","days":13},{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","asOf":"2026-09-08","days":13},{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","asOf":"2026-09-08","days":13},{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/","asOf":"2026-09-08","days":13},{"id":"cachexia-therapy","kind":"technology","name":"Cachexia-directed therapy (GDF-15 blockade)","route":"/technologies/cachexia-therapy/","asOf":"2026-09-08","days":13},{"id":"chronotherapy","kind":"technology","name":"Chronotherapy: timing treatment to the body clock","route":"/technologies/chronotherapy/","asOf":"2026-09-08","days":13},{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/","asOf":"2026-09-08","days":13},{"id":"senescence-targeting","kind":"technology","name":"Senolytics and senescence-directed therapy","route":"/technologies/senescence-targeting/","asOf":"2026-09-08","days":13},{"id":"il12-electroporation","kind":"technology","name":"Intratumoural gene electrotransfer (IL-12 plasmid)","route":"/technologies/il12-electroporation/","asOf":"2026-09-08","days":13},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/","asOf":"2026-09-08","days":13},{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/","asOf":"2026-09-08","days":13},{"id":"antibody-oligonucleotide-conjugates","kind":"technology","name":"Antibody-oligonucleotide conjugates","route":"/technologies/antibody-oligonucleotide-conjugates/","asOf":"2026-09-08","days":13},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/","asOf":"2026-09-08","days":13},{"id":"in-situ-vaccination","kind":"technology","name":"In situ vaccination","route":"/technologies/in-situ-vaccination/","asOf":"2026-09-08","days":13},{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/","asOf":"2026-09-08","days":13},{"id":"trained-innate-immunity","kind":"technology","name":"Trained innate immunity","route":"/technologies/trained-innate-immunity/","asOf":"2026-09-08","days":13},{"id":"histotripsy-immune-priming","kind":"technology","name":"Histotripsy as an immune primer","route":"/technologies/histotripsy-immune-priming/","asOf":"2026-09-08","days":13},{"id":"mechanobiology-therapy","kind":"technology","name":"Targeting tumour mechanics and pressure","route":"/technologies/mechanobiology-therapy/","asOf":"2026-09-08","days":13},{"id":"hypoxia-activated-therapy","kind":"technology","name":"Hypoxia-activated prodrugs","route":"/technologies/hypoxia-activated-therapy/","asOf":"2026-09-08","days":13},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/","asOf":"2026-09-08","days":13},{"id":"n-of-1-platforms","kind":"technology","name":"N-of-1 and rapid platform trials","route":"/technologies/n-of-1-platforms/","asOf":"2026-09-08","days":13},{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/","asOf":"2026-09-08","days":13},{"id":"breath-vocs","kind":"technology","name":"Breath and volatile-organic-compound detection","route":"/technologies/breath-vocs/","asOf":"2026-09-08","days":13},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/","asOf":"2026-09-08","days":13},{"id":"total-body-pet-screening","kind":"technology","name":"Total-body PET for screening and ultra-low-dose imaging","route":"/technologies/total-body-pet-screening/","asOf":"2026-09-08","days":13},{"id":"quantum-dot-imaging","kind":"technology","name":"Quantum-dot and molecular ultrasound imaging agents","route":"/technologies/quantum-dot-imaging/","asOf":"2026-09-08","days":13},{"id":"organoid-guided-therapy-scale","kind":"technology","name":"Organoid-guided therapy at scale","route":"/technologies/organoid-guided-therapy-scale/","asOf":"2026-09-08","days":13},{"id":"spatial-omics-guided-therapy","kind":"technology","name":"Spatial-omics-guided treatment selection","route":"/technologies/spatial-omics-guided-therapy/","asOf":"2026-09-08","days":13},{"id":"exosome-therapeutics","kind":"technology","name":"Engineered exosomes as drug carriers","route":"/technologies/exosome-therapeutics/","asOf":"2026-09-08","days":13},{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","asOf":"2026-09-08","days":13},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","asOf":"2026-09-08","days":13},{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","route":"/people/jean-charles-soria/","asOf":"2026-09-08","days":13},{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","route":"/people/benjamin-besse/","asOf":"2026-09-08","days":13},{"id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","route":"/people/aurelien-marabelle/","asOf":"2026-09-08","days":13},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","asOf":"2026-09-08","days":13},{"id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","route":"/people/laurence-zitvogel/","asOf":"2026-09-08","days":13},{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","asOf":"2026-09-08","days":13},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","asOf":"2026-09-08","days":13},{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","asOf":"2026-09-08","days":13},{"id":"nicholas-james","kind":"person","name":"Nicholas James","route":"/people/nicholas-james/","asOf":"2026-09-08","days":13},{"id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/","asOf":"2026-09-08","days":13},{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","asOf":"2026-09-08","days":13},{"id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","route":"/people/uwe-oelfke/","asOf":"2026-09-08","days":13},{"id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","asOf":"2026-09-08","days":13},{"id":"paul-workman","kind":"person","name":"Paul Workman","route":"/people/paul-workman/","asOf":"2026-09-08","days":13},{"id":"chris-lord","kind":"person","name":"Christopher Lord","route":"/people/chris-lord/","asOf":"2026-09-08","days":13},{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/","asOf":"2026-09-08","days":13},{"id":"mel-greaves","kind":"person","name":"Mel Greaves","route":"/people/mel-greaves/","asOf":"2026-09-08","days":13},{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","asOf":"2026-09-08","days":13},{"id":"paul-nurse","kind":"person","name":"Paul Nurse","route":"/people/paul-nurse/","asOf":"2026-09-08","days":13},{"id":"caetano-reis-e-sousa","kind":"person","name":"Caetano Reis e Sousa","route":"/people/caetano-reis-e-sousa/","asOf":"2026-09-08","days":13},{"id":"erik-sahai","kind":"person","name":"Erik Sahai","route":"/people/erik-sahai/","asOf":"2026-09-08","days":13},{"id":"michelle-mitchell","kind":"person","name":"Michelle Mitchell","route":"/people/michelle-mitchell/","asOf":"2026-09-08","days":13},{"id":"iain-foulkes","kind":"person","name":"Iain Foulkes","route":"/people/iain-foulkes/","asOf":"2026-09-08","days":13},{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/","asOf":"2026-09-08","days":13},{"id":"caroline-dive","kind":"person","name":"Caroline Dive","route":"/people/caroline-dive/","asOf":"2026-09-08","days":13},{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/","asOf":"2026-09-08","days":13},{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","route":"/people/andrew-wardley/","asOf":"2026-09-08","days":13},{"id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","route":"/people/ananya-choudhury/","asOf":"2026-09-08","days":13},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","asOf":"2026-09-08","days":13},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","asOf":"2026-09-08","days":13},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","asOf":"2026-09-08","days":13},{"id":"stefan-froehling","kind":"person","name":"Stefan Fröhling","route":"/people/stefan-froehling/","asOf":"2026-09-08","days":13},{"id":"juergen-debus","kind":"person","name":"Jürgen Debus","route":"/people/juergen-debus/","asOf":"2026-09-08","days":13},{"id":"andreas-von-deimling","kind":"person","name":"Andreas von Deimling","route":"/people/andreas-von-deimling/","asOf":"2026-09-08","days":13},{"id":"michael-baumann","kind":"person","name":"Michael Baumann","route":"/people/michael-baumann/","asOf":"2026-09-08","days":13},{"id":"stefan-pfister","kind":"person","name":"Stefan Pfister","route":"/people/stefan-pfister/","asOf":"2026-09-08","days":13},{"id":"hermann-brenner","kind":"person","name":"Hermann Brenner","route":"/people/hermann-brenner/","asOf":"2026-09-08","days":13},{"id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","route":"/people/andreas-trumpp/","asOf":"2026-09-08","days":13},{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","route":"/people/steven-le-gouill/","asOf":"2026-09-08","days":13},{"id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","route":"/people/francois-clement-bidard/","asOf":"2026-09-08","days":13},{"id":"sergio-roman-roman","kind":"person","name":"Sergio Roman-Roman","route":"/people/sergio-roman-roman/","asOf":"2026-09-08","days":13},{"id":"olivier-delattre","kind":"person","name":"Olivier Delattre","route":"/people/olivier-delattre/","asOf":"2026-09-08","days":13},{"id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","route":"/people/eliane-piaggio/","asOf":"2026-09-08","days":13},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","asOf":"2026-09-08","days":13},{"id":"paolo-veronesi","kind":"person","name":"Paolo Veronesi","route":"/people/paolo-veronesi/","asOf":"2026-09-08","days":13},{"id":"roberto-orecchia","kind":"person","name":"Roberto Orecchia","route":"/people/roberto-orecchia/","asOf":"2026-09-08","days":13},{"id":"pier-giuseppe-pelicci","kind":"person","name":"Pier Giuseppe Pelicci","route":"/people/pier-giuseppe-pelicci/","asOf":"2026-09-08","days":13},{"id":"alessandro-gronchi","kind":"person","name":"Alessandro Gronchi","route":"/people/alessandro-gronchi/","asOf":"2026-09-08","days":13},{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/","asOf":"2026-09-08","days":13},{"id":"marco-guzzo","kind":"person","name":"Marco Guzzo","route":"/people/marco-guzzo/","asOf":"2026-09-08","days":13},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","asOf":"2026-09-08","days":13},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","asOf":"2026-09-08","days":13},{"id":"elena-garralda","kind":"person","name":"Elena Garralda","route":"/people/elena-garralda/","asOf":"2026-09-08","days":13},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","asOf":"2026-09-08","days":13},{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","asOf":"2026-09-08","days":13},{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/","asOf":"2026-09-08","days":13},{"id":"ulrich-keilholz","kind":"person","name":"Ulrich Keilholz","route":"/people/ulrich-keilholz/","asOf":"2026-09-08","days":13},{"id":"lars-bullinger","kind":"person","name":"Lars Bullinger","route":"/people/lars-bullinger/","asOf":"2026-09-08","days":13},{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","route":"/people/angelika-eggert/","asOf":"2026-09-08","days":13},{"id":"christof-von-kalle","kind":"person","name":"Christof von Kalle","route":"/people/christof-von-kalle/","asOf":"2026-09-08","days":13},{"id":"markus-graefen","kind":"person","name":"Markus Graefen","route":"/people/markus-graefen/","asOf":"2026-09-08","days":13},{"id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","route":"/people/carsten-bokemeyer/","asOf":"2026-09-08","days":13},{"id":"klaus-pantel","kind":"person","name":"Klaus Pantel","route":"/people/klaus-pantel/","asOf":"2026-09-08","days":13},{"id":"volker-heinemann","kind":"person","name":"Volker Heinemann","route":"/people/volker-heinemann/","asOf":"2026-09-08","days":13},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","asOf":"2026-09-08","days":13},{"id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","route":"/people/michael-von-bergwelt/","asOf":"2026-09-08","days":13},{"id":"claus-belka","kind":"person","name":"Claus Belka","route":"/people/claus-belka/","asOf":"2026-09-08","days":13},{"id":"michael-hallek","kind":"person","name":"Michael Hallek","route":"/people/michael-hallek/","asOf":"2026-09-08","days":13},{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/","asOf":"2026-09-08","days":13},{"id":"reinhard-buettner","kind":"person","name":"Reinhard Büttner","route":"/people/reinhard-buettner/","asOf":"2026-09-08","days":13},{"id":"roman-thomas","kind":"person","name":"Roman Thomas","route":"/people/roman-thomas/","asOf":"2026-09-08","days":13},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","asOf":"2026-09-08","days":13},{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/","asOf":"2026-09-08","days":13},{"id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","route":"/people/giampaolo-tortora/","asOf":"2026-09-08","days":13},{"id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","route":"/people/vincenzo-valentini/","asOf":"2026-09-08","days":13},{"id":"jonas-bergh","kind":"person","name":"Jonas Bergh","route":"/people/jonas-bergh/","asOf":"2026-09-08","days":13},{"id":"per-hall","kind":"person","name":"Per Hall","route":"/people/per-hall/","asOf":"2026-09-08","days":13},{"id":"rolf-kiessling","kind":"person","name":"Rolf Kiessling","route":"/people/rolf-kiessling/","asOf":"2026-09-08","days":13},{"id":"hans-gustaf-ljunggren","kind":"person","name":"Hans-Gustaf Ljunggren","route":"/people/hans-gustaf-ljunggren/","asOf":"2026-09-08","days":13},{"id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/","asOf":"2026-09-08","days":13},{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/","asOf":"2026-09-08","days":13},{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","asOf":"2026-09-08","days":13},{"id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/","asOf":"2026-09-08","days":13},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","asOf":"2026-09-08","days":13},{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/","asOf":"2026-09-08","days":13},{"id":"sabine-linn","kind":"person","name":"Sabine Linn","route":"/people/sabine-linn/","asOf":"2026-09-08","days":13},{"id":"jaime-feliu","kind":"person","name":"Jaime Feliu","route":"/people/jaime-feliu/","asOf":"2026-09-08","days":13},{"id":"enrique-espinosa","kind":"person","name":"Enrique Espinosa","route":"/people/enrique-espinosa/","asOf":"2026-09-08","days":13},{"id":"beatriz-castelo","kind":"person","name":"Beatriz Castelo","route":"/people/beatriz-castelo/","asOf":"2026-09-08","days":13},{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","asOf":"2026-09-08","days":13},{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","route":"/people/sara-lopez-tarruella/","asOf":"2026-09-08","days":13},{"id":"pilar-garrido","kind":"person","name":"Pilar Garrido","route":"/people/pilar-garrido/","asOf":"2026-09-08","days":13},{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","route":"/people/denis-lacombe/","asOf":"2026-09-08","days":13},{"id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","route":"/people/alexander-eggermont/","asOf":"2026-09-08","days":13},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","asOf":"2026-09-08","days":13},{"id":"michael-weller","kind":"person","name":"Michael Weller","route":"/people/michael-weller/","asOf":"2026-09-08","days":13},{"id":"roger-stupp","kind":"person","name":"Roger Stupp","route":"/people/roger-stupp/","asOf":"2026-09-08","days":13},{"id":"nathan-cherny","kind":"person","name":"Nathan Cherny","route":"/people/nathan-cherny/","asOf":"2026-09-08","days":13},{"id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","route":"/people/andres-cervantes/","asOf":"2026-09-08","days":13},{"id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/","asOf":"2026-09-08","days":13},{"id":"david-cameron","kind":"person","name":"David Cameron","route":"/people/david-cameron/","asOf":"2026-09-08","days":13},{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/","asOf":"2026-09-08","days":13},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","asOf":"2026-09-08","days":13},{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","route":"/people/gunter-von-minckwitz/","asOf":"2026-09-08","days":13},{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","route":"/people/carsten-denkert/","asOf":"2026-09-08","days":13},{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","asOf":"2026-09-08","days":13},{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","route":"/people/thomas-bachelot/","asOf":"2026-09-08","days":13},{"id":"christophe-le-tourneau","kind":"person","name":"Christophe Le Tourneau","route":"/people/christophe-le-tourneau/","asOf":"2026-09-08","days":13},{"id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","route":"/people/anthony-goncalves/","asOf":"2026-09-08","days":13},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","asOf":"2026-09-08","days":13},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","asOf":"2026-09-08","days":13},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","asOf":"2026-09-08","days":13},{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","asOf":"2026-09-08","days":13},{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","asOf":"2026-09-08","days":13},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","asOf":"2026-09-08","days":13},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","asOf":"2026-09-08","days":13},{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","asOf":"2026-09-08","days":13},{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","asOf":"2026-09-08","days":13},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","asOf":"2026-09-08","days":13},{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","asOf":"2026-09-08","days":13},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","asOf":"2026-09-08","days":13},{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","asOf":"2026-09-08","days":13},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","asOf":"2026-09-08","days":13},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","asOf":"2026-09-08","days":13},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","asOf":"2026-09-08","days":13},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","asOf":"2026-09-08","days":13},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","asOf":"2026-09-08","days":13},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","asOf":"2026-09-08","days":13},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","asOf":"2026-09-08","days":13},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","asOf":"2026-09-08","days":13},{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","asOf":"2026-09-08","days":13},{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","asOf":"2026-09-08","days":13},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","asOf":"2026-09-08","days":13},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","asOf":"2026-09-08","days":13},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","asOf":"2026-09-08","days":13},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","asOf":"2026-09-08","days":13},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","asOf":"2026-09-08","days":13},{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","asOf":"2026-09-08","days":13},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","asOf":"2026-09-08","days":13},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","asOf":"2026-09-08","days":13},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","asOf":"2026-09-08","days":13},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","asOf":"2026-09-08","days":13},{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","asOf":"2026-09-08","days":13},{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","asOf":"2026-09-08","days":13},{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","asOf":"2026-09-08","days":13},{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","asOf":"2026-09-08","days":13},{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","asOf":"2026-09-08","days":13},{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","asOf":"2026-09-08","days":13},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","asOf":"2026-09-08","days":13},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","asOf":"2026-09-08","days":13},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","asOf":"2026-09-08","days":13},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","asOf":"2026-09-08","days":13},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","asOf":"2026-09-08","days":13},{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","asOf":"2026-09-08","days":13},{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","asOf":"2026-09-08","days":13},{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","asOf":"2026-09-08","days":13},{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","asOf":"2026-09-08","days":13},{"id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","asOf":"2026-09-08","days":13},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","asOf":"2026-09-08","days":13},{"id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","asOf":"2026-09-08","days":13},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","asOf":"2026-09-08","days":13},{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","asOf":"2026-09-08","days":13},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","asOf":"2026-09-08","days":13},{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","asOf":"2026-09-08","days":13},{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","asOf":"2026-09-08","days":13},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","asOf":"2026-09-08","days":13},{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","asOf":"2026-09-08","days":13},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","asOf":"2026-09-08","days":13},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","asOf":"2026-09-08","days":13},{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","asOf":"2026-09-08","days":13},{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","asOf":"2026-09-08","days":13},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","asOf":"2026-09-08","days":13},{"id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","asOf":"2026-09-08","days":13},{"id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","asOf":"2026-09-08","days":13},{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","asOf":"2026-09-08","days":13},{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","asOf":"2026-09-08","days":13},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","asOf":"2026-09-08","days":13},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","asOf":"2026-09-08","days":13},{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","asOf":"2026-09-08","days":13},{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","asOf":"2026-09-08","days":13},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","asOf":"2026-09-08","days":13},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","asOf":"2026-09-08","days":13},{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","asOf":"2026-09-08","days":13},{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","asOf":"2026-09-08","days":13},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","asOf":"2026-09-08","days":13},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","asOf":"2026-09-08","days":13},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","asOf":"2026-09-08","days":13},{"id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","asOf":"2026-09-08","days":13},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","asOf":"2026-09-08","days":13},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","asOf":"2026-09-08","days":13},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","asOf":"2026-09-08","days":13},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","asOf":"2026-09-08","days":13},{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","asOf":"2026-09-08","days":13},{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","asOf":"2026-09-08","days":13},{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","asOf":"2026-09-08","days":13},{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","asOf":"2026-09-08","days":13},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","asOf":"2026-09-08","days":13},{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","asOf":"2026-09-08","days":13},{"id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","asOf":"2026-09-08","days":13},{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","asOf":"2026-09-08","days":13},{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","asOf":"2026-09-08","days":13},{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","asOf":"2026-09-08","days":13},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","asOf":"2026-09-08","days":13},{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","asOf":"2026-09-08","days":13},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","asOf":"2026-09-08","days":13},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","asOf":"2026-09-08","days":13},{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/","asOf":"2026-09-08","days":13},{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","asOf":"2026-09-08","days":13},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","asOf":"2026-09-08","days":13},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","asOf":"2026-09-08","days":13},{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/","asOf":"2026-09-08","days":13},{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","asOf":"2026-09-08","days":13},{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","asOf":"2026-09-08","days":13},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","asOf":"2026-09-08","days":13},{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","asOf":"2026-09-08","days":13},{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","asOf":"2026-09-08","days":13},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","asOf":"2026-09-08","days":13},{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","asOf":"2026-09-08","days":13},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","asOf":"2026-09-08","days":13},{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","asOf":"2026-09-08","days":13},{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","asOf":"2026-09-08","days":13},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","asOf":"2026-09-08","days":13},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","asOf":"2026-09-08","days":13},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","asOf":"2026-09-08","days":13},{"id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","route":"/people/william-kaelin/","asOf":"2026-09-08","days":13},{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","asOf":"2026-09-08","days":13},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","asOf":"2026-09-08","days":13},{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","asOf":"2026-09-08","days":13},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","asOf":"2026-09-08","days":13},{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","asOf":"2026-09-08","days":13},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","asOf":"2026-09-08","days":13},{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","asOf":"2026-09-08","days":13},{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","asOf":"2026-09-08","days":13},{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","asOf":"2026-09-08","days":13},{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","asOf":"2026-09-08","days":13},{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","asOf":"2026-09-08","days":13},{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","asOf":"2026-09-08","days":13},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","asOf":"2026-09-08","days":13},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","asOf":"2026-09-08","days":13},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","asOf":"2026-09-08","days":13},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","asOf":"2026-09-08","days":13},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","asOf":"2026-09-08","days":13},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","asOf":"2026-09-08","days":13},{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","asOf":"2026-09-08","days":13},{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","asOf":"2026-09-08","days":13},{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","asOf":"2026-09-08","days":13},{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","asOf":"2026-09-08","days":13},{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","asOf":"2026-09-08","days":13},{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","asOf":"2026-09-08","days":13},{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","asOf":"2026-09-08","days":13},{"id":"drew-weissman","kind":"person","name":"Drew Weissman","route":"/people/drew-weissman/","asOf":"2026-09-08","days":13},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","asOf":"2026-09-08","days":13},{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","route":"/people/angela-demichele/","asOf":"2026-09-08","days":13},{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","asOf":"2026-09-08","days":13},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","asOf":"2026-09-08","days":13},{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","asOf":"2026-09-08","days":13},{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","asOf":"2026-09-08","days":13},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","asOf":"2026-09-08","days":13},{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","asOf":"2026-09-08","days":13},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","asOf":"2026-09-08","days":13},{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","asOf":"2026-09-08","days":13},{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","asOf":"2026-09-08","days":13},{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","asOf":"2026-09-08","days":13},{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","asOf":"2026-09-08","days":13},{"id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","route":"/people/ramon-parsons/","asOf":"2026-09-08","days":13},{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","asOf":"2026-09-08","days":13},{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","asOf":"2026-09-08","days":13},{"id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/","asOf":"2026-09-08","days":13},{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","asOf":"2026-09-08","days":13},{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","asOf":"2026-09-08","days":13},{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","asOf":"2026-09-08","days":13},{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","asOf":"2026-09-08","days":13},{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","asOf":"2026-09-08","days":13},{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","asOf":"2026-09-08","days":13},{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","asOf":"2026-09-08","days":13},{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","asOf":"2026-09-08","days":13},{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","asOf":"2026-09-08","days":13},{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","asOf":"2026-09-08","days":13},{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","asOf":"2026-09-08","days":13},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","asOf":"2026-09-08","days":13},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","asOf":"2026-09-08","days":13},{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","route":"/people/andrew-aguirre/","asOf":"2026-09-08","days":13},{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","asOf":"2026-09-08","days":13},{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","asOf":"2026-09-08","days":13},{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","asOf":"2026-09-08","days":13},{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","asOf":"2026-09-08","days":13},{"id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","route":"/people/christopher-vakoc/","asOf":"2026-09-08","days":13},{"id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","route":"/people/adrian-krainer/","asOf":"2026-09-08","days":13},{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","asOf":"2026-09-08","days":13},{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","asOf":"2026-09-08","days":13},{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","asOf":"2026-09-08","days":13},{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","asOf":"2026-09-08","days":13},{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","asOf":"2026-09-08","days":13},{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","asOf":"2026-09-08","days":13},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","asOf":"2026-09-08","days":13},{"id":"john-dipersio","kind":"person","name":"John F. DiPersio","route":"/people/john-dipersio/","asOf":"2026-09-08","days":13},{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","asOf":"2026-09-08","days":13},{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","asOf":"2026-09-08","days":13},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","asOf":"2026-09-08","days":13},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","asOf":"2026-09-08","days":13},{"id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","route":"/people/shaomeng-wang/","asOf":"2026-09-08","days":13},{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","asOf":"2026-09-08","days":13},{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","asOf":"2026-09-08","days":13},{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","asOf":"2026-09-08","days":13},{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","asOf":"2026-09-08","days":13},{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","asOf":"2026-09-08","days":13},{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","asOf":"2026-09-08","days":13},{"id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","asOf":"2026-09-08","days":13},{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","asOf":"2026-09-08","days":13},{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","asOf":"2026-09-08","days":13},{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","route":"/people/shilpa-gupta/","asOf":"2026-09-08","days":13},{"id":"nathan-pennell","kind":"person","name":"Nathan A. Pennell","route":"/people/nathan-pennell/","asOf":"2026-09-08","days":13},{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","asOf":"2026-09-08","days":13},{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","asOf":"2026-09-08","days":13},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","asOf":"2026-09-08","days":13},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","asOf":"2026-09-08","days":13},{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","asOf":"2026-09-08","days":13},{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","asOf":"2026-09-08","days":13},{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","asOf":"2026-09-08","days":13},{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","asOf":"2026-09-08","days":13},{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","asOf":"2026-09-08","days":13},{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","asOf":"2026-09-08","days":13},{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","asOf":"2026-09-08","days":13},{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","asOf":"2026-09-08","days":13},{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","asOf":"2026-09-08","days":13},{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","asOf":"2026-09-08","days":13},{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","asOf":"2026-09-08","days":13},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","asOf":"2026-09-08","days":13},{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","asOf":"2026-09-08","days":13},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","asOf":"2026-09-08","days":13},{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","asOf":"2026-09-08","days":13},{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","asOf":"2026-09-08","days":13},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","asOf":"2026-09-08","days":13},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","asOf":"2026-09-08","days":13},{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","asOf":"2026-09-08","days":13},{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","asOf":"2026-09-08","days":13},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","asOf":"2026-09-08","days":13},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","asOf":"2026-09-08","days":13},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","asOf":"2026-09-08","days":13},{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","asOf":"2026-09-08","days":13},{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","asOf":"2026-09-08","days":13},{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","asOf":"2026-09-08","days":13},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","asOf":"2026-09-08","days":13},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","asOf":"2026-09-08","days":13},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","asOf":"2026-09-08","days":13},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","asOf":"2026-09-08","days":13},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","asOf":"2026-09-08","days":13},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","asOf":"2026-09-08","days":13},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","asOf":"2026-09-08","days":13},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","asOf":"2026-09-08","days":13},{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","asOf":"2026-09-08","days":13},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","asOf":"2026-09-08","days":13},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","asOf":"2026-09-08","days":13},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","asOf":"2026-09-08","days":13},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","asOf":"2026-09-08","days":13},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","asOf":"2026-09-08","days":13},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","asOf":"2026-09-08","days":13},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","asOf":"2026-09-08","days":13},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","asOf":"2026-09-08","days":13},{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","asOf":"2026-09-08","days":13},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","asOf":"2026-09-08","days":13},{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","asOf":"2026-09-08","days":13},{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","asOf":"2026-09-08","days":13},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","asOf":"2026-09-08","days":13},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","asOf":"2026-09-08","days":13},{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","asOf":"2026-09-08","days":13},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","asOf":"2026-09-08","days":13},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","asOf":"2026-09-08","days":13},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","asOf":"2026-09-08","days":13},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","asOf":"2026-09-08","days":13},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","asOf":"2026-09-08","days":13},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","asOf":"2026-09-08","days":13},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","asOf":"2026-09-08","days":13},{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","asOf":"2026-09-08","days":13},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","asOf":"2026-09-08","days":13},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","asOf":"2026-09-08","days":13},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","asOf":"2026-09-08","days":13},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","asOf":"2026-09-08","days":13},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","asOf":"2026-09-08","days":13},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","asOf":"2026-09-08","days":13},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","asOf":"2026-09-08","days":13},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","asOf":"2026-09-08","days":13},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","asOf":"2026-09-08","days":13},{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","asOf":"2026-09-08","days":13},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","asOf":"2026-09-08","days":13},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","asOf":"2026-09-08","days":13},{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","asOf":"2026-09-08","days":13},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","asOf":"2026-09-08","days":13},{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","asOf":"2026-09-08","days":13},{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","asOf":"2026-09-08","days":13},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","asOf":"2026-09-08","days":13},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","asOf":"2026-09-08","days":13},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","asOf":"2026-09-08","days":13},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","asOf":"2026-09-08","days":13},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","asOf":"2026-09-08","days":13},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","asOf":"2026-09-08","days":13},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","asOf":"2026-09-08","days":13},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","asOf":"2026-09-08","days":13},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","asOf":"2026-09-08","days":13},{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","asOf":"2026-09-08","days":13},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","asOf":"2026-09-08","days":13},{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","asOf":"2026-09-08","days":13},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","asOf":"2026-09-08","days":13},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","asOf":"2026-09-08","days":13},{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","asOf":"2026-09-08","days":13},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","asOf":"2026-09-08","days":13},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","asOf":"2026-09-08","days":13},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","asOf":"2026-09-08","days":13},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","asOf":"2026-09-08","days":13},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","asOf":"2026-09-08","days":13},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","asOf":"2026-09-08","days":13},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","asOf":"2026-09-08","days":13},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","asOf":"2026-09-08","days":13},{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","asOf":"2026-09-08","days":13},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","asOf":"2026-09-08","days":13},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","asOf":"2026-09-08","days":13},{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","asOf":"2026-09-08","days":13},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","asOf":"2026-09-08","days":13},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","asOf":"2026-09-08","days":13},{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","asOf":"2026-09-08","days":13},{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","asOf":"2026-09-08","days":13},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","asOf":"2026-09-08","days":13},{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","asOf":"2026-09-08","days":13},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","asOf":"2026-09-08","days":13},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","asOf":"2026-09-08","days":13},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","asOf":"2026-09-08","days":13},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","asOf":"2026-09-08","days":13},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","asOf":"2026-09-08","days":13},{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","asOf":"2026-09-08","days":13},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","asOf":"2026-09-08","days":13},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","asOf":"2026-09-08","days":13},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","asOf":"2026-09-08","days":13},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","asOf":"2026-09-08","days":13},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","asOf":"2026-09-08","days":13},{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","asOf":"2026-09-08","days":13},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","asOf":"2026-09-08","days":13},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","asOf":"2026-09-08","days":13},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","asOf":"2026-09-08","days":13},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","asOf":"2026-09-08","days":13},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","asOf":"2026-09-08","days":13},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","asOf":"2026-09-08","days":13},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","asOf":"2026-09-08","days":13},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","asOf":"2026-09-08","days":13},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","asOf":"2026-09-08","days":13},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","asOf":"2026-09-08","days":13},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","asOf":"2026-09-08","days":13},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","asOf":"2026-09-08","days":13},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","asOf":"2026-09-08","days":13},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","asOf":"2026-09-08","days":13},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","asOf":"2026-09-08","days":13},{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","asOf":"2026-09-08","days":13},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","asOf":"2026-09-08","days":13},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","asOf":"2026-09-08","days":13},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","asOf":"2026-09-08","days":13},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","asOf":"2026-09-08","days":13},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","asOf":"2026-09-08","days":13},{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","asOf":"2026-09-08","days":13},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","asOf":"2026-09-08","days":13},{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-multiregion-blocks-default","kind":"idea","name":"Bank three spatially separate tumour blocks from every resection","route":"/ideas/idea-bio1-multiregion-blocks-default/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-rapid-autopsy-network","kind":"idea","name":"A national rapid research autopsy network for end-stage cancer","route":"/ideas/idea-bio1-rapid-autopsy-network/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-ctdna-clone-report","kind":"idea","name":"A clone report from blood at every treatment cycle","route":"/ideas/idea-bio1-ctdna-clone-report/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-truncal-branch-labelling","kind":"idea","name":"Label every targetable mutation as truncal or branch on the report","route":"/ideas/idea-bio1-truncal-branch-labelling/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-outlier-lesion-biopsy","kind":"idea","name":"Biopsy the one lesion that is growing while the others shrink","route":"/ideas/idea-bio1-outlier-lesion-biopsy/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-barcoded-avatars-clonal-fitness","kind":"idea","name":"Barcode patient-derived tumours to watch which clones win under each drug","route":"/ideas/idea-bio1-barcoded-avatars-clonal-fitness/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-evolvability-index","kind":"idea","name":"A standard evolvability score for every tumour","route":"/ideas/idea-bio1-evolvability-index/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-adaptive-therapy-platform","kind":"idea","name":"A multi-cancer platform trial of adaptive (dose-holiday) therapy","route":"/ideas/idea-bio1-adaptive-therapy-platform/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-ctdna-adaptive-tki","kind":"idea","name":"ctDNA-guided dose holidays for lung cancer targeted therapy","route":"/ideas/idea-bio1-ctdna-adaptive-tki/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-first-strike-second-strike","kind":"idea","name":"Switch drugs at maximum response, not at relapse","route":"/ideas/idea-bio1-first-strike-second-strike/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-collateral-sensitivity-atlas","kind":"idea","name":"An open atlas of collateral sensitivity for every approved targeted drug","route":"/ideas/idea-bio1-collateral-sensitivity-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-evolutionary-double-bind","kind":"idea","name":"Design drug pairs where resisting one makes you vulnerable to the other","route":"/ideas/idea-bio1-evolutionary-double-bind/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-spatial-clone-immune-map","kind":"idea","name":"Map which tumour clones sit next to which immune cells before choosing therapy","route":"/ideas/idea-bio1-spatial-clone-immune-map/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-methylation-clone-tracking","kind":"idea","name":"Track clones in blood with methylation patterns instead of mutations","route":"/ideas/idea-bio1-methylation-clone-tracking/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-clonal-clearance-endpoint","kind":"idea","name":"Make clonal clearance, not tumour shrinkage, a trial endpoint","route":"/ideas/idea-bio1-clonal-clearance-endpoint/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-evolution-forecasting","kind":"idea","name":"Forecast the next resistance mutation like the weather","route":"/ideas/idea-bio1-evolution-forecasting/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-baseline-ultradeep-resistant-clones","kind":"idea","name":"Look for the resistant sub-population before the first dose","route":"/ideas/idea-bio1-baseline-ultradeep-resistant-clones/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-cfrna-plasticity-tracking","kind":"idea","name":"Detect tumours changing cell type from RNA in the blood","route":"/ideas/idea-bio1-cfrna-plasticity-tracking/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-evolutionary-tumour-boards","kind":"idea","name":"Evolutionary tumour boards with a modeller in the room","route":"/ideas/idea-bio1-evolutionary-tumour-boards/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-apobec-inhibitor-adjunct","kind":"idea","name":"Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy","route":"/ideas/idea-bio1-apobec-inhibitor-adjunct/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-cin-vulnerability-kif18a","kind":"idea","name":"Turn chromosomal chaos into a weakness with KIF18A inhibitors","route":"/ideas/idea-bio1-cin-vulnerability-kif18a/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-federated-evolution-atlas","kind":"idea","name":"Pool every multi-sample tumour genome into one open evolution atlas","route":"/ideas/idea-bio1-federated-evolution-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-clone-to-lesion-mapping","kind":"idea","name":"Match each blood-detected clone to the lesion it comes from on the scan","route":"/ideas/idea-bio1-clone-to-lesion-mapping/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-rebiopsy-before-switch","kind":"idea","name":"Re-test the metastasis, not the old primary, before every change of treatment","route":"/ideas/idea-bio1-rebiopsy-before-switch/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-clonal-neoantigen-vaccines","kind":"idea","name":"Vaccines aimed only at mutations shared by every tumour cell","route":"/ideas/idea-bio1-clonal-neoantigen-vaccines/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-myc-max-molecular-glue","kind":"idea","name":"Molecular glues that break the MYC-MAX partnership","route":"/ideas/idea-bio1-myc-max-molecular-glue/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-omomyc-mrna","kind":"idea","name":"mRNA-delivered MYC decoy proteins instead of MYC inhibitors","route":"/ideas/idea-bio1-omomyc-mrna/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-p53-mutant-reactivator-expansion","kind":"idea","name":"Extend p53 reactivation beyond the Y220C mutation","route":"/ideas/idea-bio1-p53-mutant-reactivator-expansion/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-mutant-p53-degrader","kind":"idea","name":"Degrade the damaged p53 protein rather than trying to repair it","route":"/ideas/idea-bio1-mutant-p53-degrader/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-pan-ras-covalent-g12d","kind":"idea","name":"Covalent chemistry for the RAS mutations that still have no drug","route":"/ideas/idea-bio1-pan-ras-covalent-g12d/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-covalent-ligandability-atlas","kind":"idea","name":"An open map of which cancer proteins any drug can stick to","route":"/ideas/idea-bio1-covalent-ligandability-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-fusion-tf-degraders","kind":"idea","name":"Degraders for the fusion proteins that drive childhood sarcomas","route":"/ideas/idea-bio1-fusion-tf-degraders/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-condensate-disruptors","kind":"idea","name":"Break up the liquid droplets where oncogenic transcription happens","route":"/ideas/idea-bio1-condensate-disruptors/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-tumour-restricted-e3-atlas","kind":"idea","name":"Find E3 ligases that only tumours have, and build degraders around them","route":"/ideas/idea-bio1-tumour-restricted-e3-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-antibody-degrader-conjugates","kind":"idea","name":"Use antibodies to deliver protein-destroying drugs into the right cells","route":"/ideas/idea-bio1-antibody-degrader-conjugates/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-lytac-surface-degraders","kind":"idea","name":"Drag cancer's surface and secreted proteins to the cell's recycling bin","route":"/ideas/idea-bio1-lytac-surface-degraders/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-rna-targeting-small-molecules","kind":"idea","name":"Small molecules that cut the RNA message of an undruggable oncogene","route":"/ideas/idea-bio1-rna-targeting-small-molecules/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-epigenetic-silencing-in-vivo","kind":"idea","name":"Switch off an undruggable oncogene permanently with epigenetic editing","route":"/ideas/idea-bio1-epigenetic-silencing-in-vivo/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-paralog-synthetic-lethality","kind":"idea","name":"Attack the backup copy when a tumour has lost the original gene","route":"/ideas/idea-bio1-paralog-synthetic-lethality/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-pp2a-activators","kind":"idea","name":"Turn a brake back on: drugs that reactivate the PP2A phosphatase","route":"/ideas/idea-bio1-pp2a-activators/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-wrn-msi-programme","kind":"idea","name":"WRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers","route":"/ideas/idea-bio1-wrn-msi-programme/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-macrocycle-ppi-campaign","kind":"idea","name":"Macrocyclic peptides to cover protein surfaces that pills cannot","route":"/ideas/idea-bio1-macrocycle-ppi-campaign/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-arv7-degrader","kind":"idea","name":"Destroy the truncated androgen receptor that hormone drugs cannot touch","route":"/ideas/idea-bio1-arv7-degrader/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-ai-binders-disordered-regions","kind":"idea","name":"AI-designed proteins that grip the floppy parts of cancer drivers","route":"/ideas/idea-bio1-ai-binders-disordered-regions/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-mrna-intrabodies","kind":"idea","name":"Instruct tumour cells to make antibodies against their own oncoprotein","route":"/ideas/idea-bio1-mrna-intrabodies/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-translation-dependency-myc","kind":"idea","name":"Starve MYC-driven tumours by blocking protein production machinery","route":"/ideas/idea-bio1-translation-dependency-myc/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-undruggable-open-consortium","kind":"idea","name":"A precompetitive consortium for the twenty hardest cancer targets","route":"/ideas/idea-bio1-undruggable-open-consortium/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-undruggable-market-commitment","kind":"idea","name":"A guaranteed purchase prize for the first drug against a named hard target","route":"/ideas/idea-bio1-undruggable-market-commitment/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-immune-matched-humanised-mice","kind":"idea","name":"Humanised mice with an immune system matched to the tumour donor","route":"/ideas/idea-bio1-immune-matched-humanised-mice/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-co-clinical-avatar-trials","kind":"idea","name":"Run the mouse or organoid trial at the same time as the human trial","route":"/ideas/idea-bio1-co-clinical-avatar-trials/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-organoid-immune-coculture","kind":"idea","name":"Grow tumour organoids together with the patient's own immune cells","route":"/ideas/idea-bio1-organoid-immune-coculture/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-tumour-on-chip-penetration","kind":"idea","name":"Tumour-on-a-chip with blood flow to test whether big drugs actually get in","route":"/ideas/idea-bio1-tumour-on-chip-penetration/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-in-silico-trials-dose","kind":"idea","name":"In silico trials to choose the dose before the first patient","route":"/ideas/idea-bio1-in-silico-trials-dose/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-preclinical-preregistration","kind":"idea","name":"Pre-register animal efficacy studies like clinical trials","route":"/ideas/idea-bio1-preclinical-preregistration/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-multicentre-mouse-trials","kind":"idea","name":"Multi-centre randomised animal trials before committing to a human trial","route":"/ideas/idea-bio1-multicentre-mouse-trials/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-model-predictivity-benchmark","kind":"idea","name":"Score every model system on how well it predicted real trial results","route":"/ideas/idea-bio1-model-predictivity-benchmark/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-negative-preclinical-repository","kind":"idea","name":"A home for the animal and organoid experiments that failed","route":"/ideas/idea-bio1-negative-preclinical-repository/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-tumour-slice-cultures","kind":"idea","name":"Test drugs on freshly cut slices of the patient's own tumour","route":"/ideas/idea-bio1-tumour-slice-cultures/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-metastatic-niche-models","kind":"idea","name":"Build laboratory models of the organs cancer spreads to","route":"/ideas/idea-bio1-metastatic-niche-models/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-aged-comorbid-models","kind":"idea","name":"Test cancer drugs in old and unhealthy animals, not just young fit ones","route":"/ideas/idea-bio1-aged-comorbid-models/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-comparative-oncology-dogs","kind":"idea","name":"Pet dogs with spontaneous cancer as a bridge before human trials","route":"/ideas/idea-bio1-comparative-oncology-dogs/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-zebrafish-avatars","kind":"idea","name":"Zebrafish avatars for a drug answer within a week","route":"/ideas/idea-bio1-zebrafish-avatars/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-multi-organ-chip-tox","kind":"idea","name":"Linked human organ chips to predict side effects before people are dosed","route":"/ideas/idea-bio1-multi-organ-chip-tox/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-rare-cancer-organoid-bank","kind":"idea","name":"An open organoid bank for cancers too rare to have models","route":"/ideas/idea-bio1-rare-cancer-organoid-bank/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-organoid-assay-clinical-validation","kind":"idea","name":"Hold organoid drug tests to the same standard as a diagnostic test","route":"/ideas/idea-bio1-organoid-assay-clinical-validation/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-organoid-cell-therapy-potency","kind":"idea","name":"Use patient organoids to check a cell therapy will work before infusing it","route":"/ideas/idea-bio1-organoid-cell-therapy-potency/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-somatic-crispr-gemms","kind":"idea","name":"Make bespoke mouse cancer models in weeks with in vivo gene editing","route":"/ideas/idea-bio1-somatic-crispr-gemms/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-ctc-derived-explants","kind":"idea","name":"Grow models from tumour cells in the blood when a biopsy is impossible","route":"/ideas/idea-bio1-ctc-derived-explants/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-model-authentication-mandate","kind":"idea","name":"Prove the cell line is what you say it is, or the paper does not run","route":"/ideas/idea-bio1-model-authentication-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-reverse-translation-resistance-models","kind":"idea","name":"Every resistance mechanism found in a patient must be rebuilt in the laboratory","route":"/ideas/idea-bio1-reverse-translation-resistance-models/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-ex-vivo-perfused-tumour","kind":"idea","name":"Keep a freshly removed tumour alive on a pump and test drugs in it","route":"/ideas/idea-bio1-ex-vivo-perfused-tumour/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-model-patient-matching","kind":"idea","name":"Pick the laboratory model that matches the patient, not the one to hand","route":"/ideas/idea-bio1-model-patient-matching/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-virtual-cell-perturbation","kind":"idea","name":"A virtual cancer cell that predicts what a drug will do before you test it","route":"/ideas/idea-bio1-virtual-cell-perturbation/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-mandatory-progression-biopsy","kind":"idea","name":"Fund a biopsy at progression, every time, as standard care","route":"/ideas/idea-bio1-mandatory-progression-biopsy/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-open-resistance-atlas","kind":"idea","name":"One open atlas of how tumours escape every drug","route":"/ideas/idea-bio1-open-resistance-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-upfront-bypass-combination","kind":"idea","name":"Add the second drug on day one when the escape route is predictable","route":"/ideas/idea-bio1-upfront-bypass-combination/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-pre-randomised-sequencing-trials","kind":"idea","name":"Randomise the next line of treatment before the first one fails","route":"/ideas/idea-bio1-pre-randomised-sequencing-trials/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-dual-antigen-adc-escape","kind":"idea","name":"Two-target antibody drugs to close the antigen escape route","route":"/ideas/idea-bio1-dual-antigen-adc-escape/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-adaptive-car-antigen-switch","kind":"idea","name":"Plan the second CAR-T target before the first one is lost","route":"/ideas/idea-bio1-adaptive-car-antigen-switch/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-drug-holiday-resensitisation","kind":"idea","name":"Pause a failed drug so the tumour becomes sensitive to it again","route":"/ideas/idea-bio1-drug-holiday-resensitisation/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-persister-ferroptosis","kind":"idea","name":"Kill the sleeping survivor cells with iron-dependent cell death","route":"/ideas/idea-bio1-persister-ferroptosis/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-epigenetic-persister-blockade","kind":"idea","name":"Block the chemical switch that lets cells hide from treatment","route":"/ideas/idea-bio1-epigenetic-persister-blockade/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-mutagenesis-blockade-rev1","kind":"idea","name":"Turn off the error-prone repair that manufactures resistance mutations","route":"/ideas/idea-bio1-mutagenesis-blockade-rev1/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-stress-response-blockade","kind":"idea","name":"Cut off the emergency programme cancer cells use to survive treatment","route":"/ideas/idea-bio1-stress-response-blockade/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-senolytics-after-therapy","kind":"idea","name":"Clear the zombie cells left behind by chemotherapy and radiotherapy","route":"/ideas/idea-bio1-senolytics-after-therapy/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-persister-metabolic-vulnerability","kind":"idea","name":"Starve the survivors: target the energy pathway drug-tolerant cells switch to","route":"/ideas/idea-bio1-persister-metabolic-vulnerability/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-molecular-progression-add-on","kind":"idea","name":"Add a drug when the blood test turns, without stopping the one that works","route":"/ideas/idea-bio1-molecular-progression-add-on/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-alternating-schedules","kind":"idea","name":"Rotate between drugs on a fixed schedule instead of waiting for failure","route":"/ideas/idea-bio1-alternating-schedules/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-resistance-mutation-vaccine","kind":"idea","name":"Vaccinate against the resistance mutation before it takes over","route":"/ideas/idea-bio1-resistance-mutation-vaccine/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-mechanism-matched-access","kind":"idea","name":"A fast route to the matched drug when it is licensed for another cancer","route":"/ideas/idea-bio1-mechanism-matched-access/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-resistance-platform-trial","kind":"idea","name":"A standing platform trial that assigns treatment by how the tumour escaped","route":"/ideas/idea-bio1-resistance-platform-trial/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-slfn11-payload-guidance","kind":"idea","name":"Use SLFN11 status to decide which antibody-drug payload to give next","route":"/ideas/idea-bio1-slfn11-payload-guidance/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-stromal-resistance-blockade","kind":"idea","name":"Block the survival signals the tumour's neighbours provide","route":"/ideas/idea-bio1-stromal-resistance-blockade/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-real-world-resistance-surveillance","kind":"idea","name":"Treat resistance like an infectious disease and run national surveillance","route":"/ideas/idea-bio1-real-world-resistance-surveillance/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-approval-linked-progression-sampling","kind":"idea","name":"Make post-progression sampling a condition of accelerated approval","route":"/ideas/idea-bio1-approval-linked-progression-sampling/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-drug-exposure-sanctuary-mapping","kind":"idea","name":"Find the parts of a tumour the drug never reaches","route":"/ideas/idea-bio1-drug-exposure-sanctuary-mapping/","asOf":"2026-09-08","days":13},{"id":"idea-bio1-immunopeptidome-timing","kind":"idea","name":"Time immunotherapy to the moment targeted drugs make tumours visible","route":"/ideas/idea-bio1-immunopeptidome-timing/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-antimetastatic-endpoint","kind":"idea","name":"A regulatory endpoint for drugs that block spread, not tumours","route":"/ideas/idea-bio2-antimetastatic-endpoint/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-ctc-clearance-go-nogo","kind":"idea","name":"Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs","route":"/ideas/idea-bio2-ctc-clearance-go-nogo/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-net-blockade-perioperative","kind":"idea","name":"Break the neutrophil DNA nets that catch tumour cells after surgery","route":"/ideas/idea-bio2-net-blockade-perioperative/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-perioperative-betablocker-nsaid","kind":"idea","name":"Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress","route":"/ideas/idea-bio2-perioperative-betablocker-nsaid/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-premetastatic-niche-assay","kind":"idea","name":"A blood test for the pre-metastatic niche","route":"/ideas/idea-bio2-premetastatic-niche-assay/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-inhaled-lung-niche-immunotherapy","kind":"idea","name":"Inhaled immune therapy to make the lung hostile to arriving tumour cells","route":"/ideas/idea-bio2-inhaled-lung-niche-immunotherapy/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-liver-niche-kupffer-reprogramming","kind":"idea","name":"Reprogramme the liver's own immune cells to refuse metastases","route":"/ideas/idea-bio2-liver-niche-kupffer-reprogramming/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-cxcr4-mobilise-then-kill","kind":"idea","name":"Flush dormant cells out of bone marrow, then kill them","route":"/ideas/idea-bio2-cxcr4-mobilise-then-kill/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-platelet-cloak-aspirin-mrd","kind":"idea","name":"Strip the platelet coat off travelling tumour cells in ctDNA-positive patients","route":"/ideas/idea-bio2-platelet-cloak-aspirin-mrd/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-rapid-autopsy-commons","kind":"idea","name":"A global rapid tissue donation network for metastatic disease","route":"/ideas/idea-bio2-rapid-autopsy-commons/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-metastasis-screen-standard","kind":"idea","name":"Make in vivo metastasis screens a required step in drug discovery","route":"/ideas/idea-bio2-metastasis-screen-standard/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-organotropism-atlas","kind":"idea","name":"An organotropism atlas that predicts where a cancer will spread","route":"/ideas/idea-bio2-organotropism-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-metastasis-funding-floor","kind":"idea","name":"Ring-fence a fifth of national cancer research money for metastasis","route":"/ideas/idea-bio2-metastasis-funding-floor/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-matrix-stiffness-prevention","kind":"idea","name":"Soften the tissue that new metastases need in order to grow","route":"/ideas/idea-bio2-matrix-stiffness-prevention/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-brain-met-prevention-trials","kind":"idea","name":"Prevention trials aimed only at brain metastasis","route":"/ideas/idea-bio2-brain-met-prevention-trials/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-oligometastatic-signature","kind":"idea","name":"A test to tell true oligometastatic disease from hidden widespread spread","route":"/ideas/idea-bio2-oligometastatic-signature/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-dormancy-selective-screen","kind":"idea","name":"A drug screen that only rewards killing sleeping cancer cells","route":"/ideas/idea-bio2-dormancy-selective-screen/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-autophagy-block-mrd","kind":"idea","name":"Block the recycling that keeps dormant cells alive","route":"/ideas/idea-bio2-autophagy-block-mrd/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-pro-dormancy-therapy","kind":"idea","name":"Keep dormant cells asleep instead of trying to kill them","route":"/ideas/idea-bio2-pro-dormancy-therapy/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-il1-awakening-blockade","kind":"idea","name":"Blunt the inflammation that wakes sleeping cancer cells","route":"/ideas/idea-bio2-il1-awakening-blockade/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-national-mrd-platform","kind":"idea","name":"A national platform trial that every ctDNA-positive patient can join","route":"/ideas/idea-bio2-national-mrd-platform/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-mrd-reference-standards","kind":"idea","name":"Reference materials and open proficiency testing for residual disease tests","route":"/ideas/idea-bio2-mrd-reference-standards/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-mrd-triggered-neoantigen-vaccine","kind":"idea","name":"Personalised vaccines given only when the blood test turns positive","route":"/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-nk-cells-for-mrd","kind":"idea","name":"Off-the-shelf natural killer cells to sweep up residual disease","route":"/ideas/idea-bio2-nk-cells-for-mrd/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-marrow-niche-on-chip","kind":"idea","name":"A bone marrow niche on a chip to study human dormancy","route":"/ideas/idea-bio2-marrow-niche-on-chip/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-localise-the-mrd","kind":"idea","name":"When the blood test is positive, hunt for the lesion with sensitive imaging","route":"/ideas/idea-bio2-localise-the-mrd/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-circadian-mrd-sampling","kind":"idea","name":"Take the blood test, and give the drug, at the right time of day","route":"/ideas/idea-bio2-circadian-mrd-sampling/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-mrd-guided-endocrine-duration","kind":"idea","name":"Use residual disease tests to decide who needs ten years of hormone therapy","route":"/ideas/idea-bio2-mrd-guided-endocrine-duration/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-mrd-coverage-with-evidence","kind":"idea","name":"Pay for residual disease tests only inside a trial or registry","route":"/ideas/idea-bio2-mrd-coverage-with-evidence/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-mrd-clinic-service","kind":"idea","name":"A dedicated clinic for people whose blood test says the cancer is back","route":"/ideas/idea-bio2-mrd-clinic-service/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-survivor-plasma-biobank","kind":"idea","name":"Bank yearly blood from cancer survivors so future tests can be validated","route":"/ideas/idea-bio2-survivor-plasma-biobank/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-trem2-myeloid-reprogramming","kind":"idea","name":"Reprogramme suppressive macrophages instead of trying to delete them","route":"/ideas/idea-bio2-trem2-myeloid-reprogramming/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-in-situ-vaccination-solid","kind":"idea","name":"Turn one tumour into a vaccine to treat all the others","route":"/ideas/idea-bio2-in-situ-vaccination-solid/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-oncolytic-regulated-il12","kind":"idea","name":"Oncolytic viruses that make interleukin-12 only inside the tumour","route":"/ideas/idea-bio2-oncolytic-regulated-il12/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-engineered-bacteria-payloads","kind":"idea","name":"Engineered bacteria that live in tumours and manufacture drugs there","route":"/ideas/idea-bio2-engineered-bacteria-payloads/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-tumour-anchored-tgfbeta-trap","kind":"idea","name":"Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere","route":"/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-lactate-acid-axis","kind":"idea","name":"De-acidify the tumour so T cells can work in it","route":"/ideas/idea-bio2-lactate-acid-axis/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-radiotherapy-sting-fractionation","kind":"idea","name":"Pick the radiation dose that switches the immune alarm on, not off","route":"/ideas/idea-bio2-radiotherapy-sting-fractionation/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-let-rbe-ab-selects-protons","kind":"idea","name":"Use LET, RBE and alpha/beta to decide when protons beat IMRT","route":"/ideas/idea-bio2-let-rbe-ab-selects-protons/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-tertiary-lymphoid-induction","kind":"idea","name":"Grow immune command posts inside tumours","route":"/ideas/idea-bio2-tertiary-lymphoid-induction/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-cxcr2-neutrophil-blockade","kind":"idea","name":"Clear the suppressive neutrophils out of pancreatic tumours first","route":"/ideas/idea-bio2-cxcr2-neutrophil-blockade/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-caf-subtype-assignment","kind":"idea","name":"Match therapy to the type of scar-forming cell in the tumour","route":"/ideas/idea-bio2-caf-subtype-assignment/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-implantable-microdevice-screen","kind":"idea","name":"Implant a tiny device that tests twenty drugs inside the patient's own tumour","route":"/ideas/idea-bio2-implantable-microdevice-screen/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-vascular-normalisation-window","kind":"idea","name":"Use imaging to find the window when tumour blood vessels are working properly","route":"/ideas/idea-bio2-vascular-normalisation-window/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-complement-c5ar-blockade","kind":"idea","name":"Block the complement signal that recruits tumour-protecting cells","route":"/ideas/idea-bio2-complement-c5ar-blockade/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-intracavitary-immunotherapy","kind":"idea","name":"Treat the body cavity, not the bloodstream, for surface spread","route":"/ideas/idea-bio2-intracavitary-immunotherapy/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-hypoxia-guided-adenosine","kind":"idea","name":"Use a hypoxia scan to pick patients for adenosine-pathway drugs","route":"/ideas/idea-bio2-hypoxia-guided-adenosine/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-histotripsy-immune-priming","kind":"idea","name":"Mechanically pulverise one tumour with ultrasound to wake the immune system","route":"/ideas/idea-bio2-histotripsy-immune-priming/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-trained-immunity-priming","kind":"idea","name":"Train the bone marrow to make better anti-tumour immune cells","route":"/ideas/idea-bio2-trained-immunity-priming/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-sonobiopsy","kind":"idea","name":"Ultrasound-assisted blood test instead of a brain biopsy","route":"/ideas/idea-bio2-sonobiopsy/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-intraventricular-car-t","kind":"idea","name":"Deliver CAR-T cells straight into the fluid around the brain","route":"/ideas/idea-bio2-intraventricular-car-t/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-robotic-convection-delivery","kind":"idea","name":"Robot-placed catheters and live imaging for drug infusion into brain tumours","route":"/ideas/idea-bio2-robotic-convection-delivery/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","route":"/ideas/idea-bio2-transferrin-shuttle-adc/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-implanted-ultrasound-repeat-dosing","kind":"idea","name":"A skull ultrasound implant that opens the barrier at every cycle","route":"/ideas/idea-bio2-implanted-ultrasound-repeat-dosing/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-cns-cohort-mandate","kind":"idea","name":"Stop excluding brain metastases from cancer trials","route":"/ideas/idea-bio2-cns-cohort-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-csf-ctdna-monitoring","kind":"idea","name":"Read the spinal fluid to track brain tumours without opening the skull","route":"/ideas/idea-bio2-csf-ctdna-monitoring/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-brain-exposure-disclosure","kind":"idea","name":"Require every oncology candidate to publish how much reaches the brain","route":"/ideas/idea-bio2-brain-exposure-disclosure/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-intranasal-delivery","kind":"idea","name":"Deliver drugs and cells to the brain through the nose","route":"/ideas/idea-bio2-intranasal-delivery/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-blood-csf-barrier-model","kind":"idea","name":"Build a human model of the barrier that guards the brain fluid","route":"/ideas/idea-bio2-blood-csf-barrier-model/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-fus-for-cell-entry","kind":"idea","name":"Open the barrier so engineered immune cells can enter the brain","route":"/ideas/idea-bio2-fus-for-cell-entry/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-gdf15-plus-exercise","kind":"idea","name":"Combine the new anti-wasting antibody with exercise and protein","route":"/ideas/idea-bio2-gdf15-plus-exercise/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-gdf15-stratified-enrolment","kind":"idea","name":"Select cachexia trial patients by the hormone driving their wasting","route":"/ideas/idea-bio2-gdf15-stratified-enrolment/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-cachexia-function-endpoint","kind":"idea","name":"Qualify a physical function endpoint so anti-wasting drugs can be approved","route":"/ideas/idea-bio2-cachexia-function-endpoint/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-prehabilitation-standard","kind":"idea","name":"Four weeks of training and nutrition before major cancer surgery, as standard","route":"/ideas/idea-bio2-prehabilitation-standard/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-exercise-reimbursement","kind":"idea","name":"Pay for supervised exercise the way we pay for drugs","route":"/ideas/idea-bio2-exercise-reimbursement/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-anamorelin-access","kind":"idea","name":"Get the one approved appetite drug licensed beyond a single country","route":"/ideas/idea-bio2-anamorelin-access/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-ai-sarcopenia-from-ct","kind":"idea","name":"Read muscle loss automatically from scans patients already have","route":"/ideas/idea-bio2-ai-sarcopenia-from-ct/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-lean-mass-dosing","kind":"idea","name":"Dose chemotherapy by muscle mass, not body surface area","route":"/ideas/idea-bio2-lean-mass-dosing/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-low-dose-olanzapine-appetite","kind":"idea","name":"A cheap old tablet to restore appetite","route":"/ideas/idea-bio2-low-dose-olanzapine-appetite/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-cachexia-pathway-code","kind":"idea","name":"Treat wasting like sepsis: a trigger, a bundle, an audit","route":"/ideas/idea-bio2-cachexia-pathway-code/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-protein-plus-training-during-io","kind":"idea","name":"Test protein and resistance training during immunotherapy","route":"/ideas/idea-bio2-protein-plus-training-during-io/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-remote-weight-step-monitoring","kind":"idea","name":"Catch wasting early with a smart scale and a step counter","route":"/ideas/idea-bio2-remote-weight-step-monitoring/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-rare-cancer-umbrella-platform","kind":"idea","name":"One standing umbrella trial for all rare cancers in a country","route":"/ideas/idea-bio2-rare-cancer-umbrella-platform/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-n-of-1-framework","kind":"idea","name":"A standing rulebook for one-patient treatments","route":"/ideas/idea-bio2-n-of-1-framework/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-paediatric-first-development","kind":"idea","name":"Develop drugs in children first when the target is a children's target","route":"/ideas/idea-bio2-paediatric-first-development/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-rare-cancer-telepathology-network","kind":"idea","name":"A same-week expert second opinion for every rare cancer diagnosis","route":"/ideas/idea-bio2-rare-cancer-telepathology-network/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-functional-precision-rare","kind":"idea","name":"Test drugs on the patient's own cancer cells when there is no trial to join","route":"/ideas/idea-bio2-functional-precision-rare/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-rare-cancer-prize-fund","kind":"idea","name":"Pay a prize for rare cancer drugs instead of hoping for a market","route":"/ideas/idea-bio2-rare-cancer-prize-fund/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the registry that already follows every patient","route":"/ideas/idea-bio2-registry-embedded-randomisation/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-patient-partnered-rare-commons","kind":"idea","name":"Let patients themselves donate their records and samples for ultra-rare cancers","route":"/ideas/idea-bio2-patient-partnered-rare-commons/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-mechanism-defined-baskets","kind":"idea","name":"Group trials by broken mechanism, not by organ or single mutation","route":"/ideas/idea-bio2-mechanism-defined-baskets/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-shared-compound-access-pool","kind":"idea","name":"A shared compound library that rare cancer researchers can actually use","route":"/ideas/idea-bio2-shared-compound-access-pool/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-bayesian-borrowing-acceptance","kind":"idea","name":"Agree in advance how to borrow evidence between similar rare cancers","route":"/ideas/idea-bio2-bayesian-borrowing-acceptance/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-rare-tumour-model-bank","kind":"idea","name":"An open model bank for the rare tumours nobody has models for","route":"/ideas/idea-bio2-rare-tumour-model-bank/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-tcr-repertoire-early-readout","kind":"idea","name":"Watch the immune system's response in the blood three weeks in","route":"/ideas/idea-bio2-tcr-repertoire-early-readout/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-fmt-plus-checkpoint-phase3","kind":"idea","name":"Take faecal transplant plus immunotherapy to a definitive trial","route":"/ideas/idea-bio2-fmt-plus-checkpoint-phase3/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-antibiotic-stewardship-io","kind":"idea","name":"Protect the gut flora of patients about to start immunotherapy","route":"/ideas/idea-bio2-antibiotic-stewardship-io/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-spatial-signature-cdx","kind":"idea","name":"Turn the map of immune cells inside a tumour into a standardised test","route":"/ideas/idea-bio2-spatial-signature-cdx/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-ctdna-six-week-io-switch","kind":"idea","name":"Use a blood test at six weeks to decide whether to keep going","route":"/ideas/idea-bio2-ctdna-six-week-io-switch/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-io-biomarker-data-commons","kind":"idea","name":"Pool every immunotherapy trial's biomarker data into one commons","route":"/ideas/idea-bio2-io-biomarker-data-commons/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-epigenetic-priming-cold-tumours","kind":"idea","name":"Unmask hidden antigens with a short epigenetic course before immunotherapy","route":"/ideas/idea-bio2-epigenetic-priming-cold-tumours/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-neoadjuvant-biomarker-engine","kind":"idea","name":"Use pre-surgery immunotherapy windows as the field's biomarker engine","route":"/ideas/idea-bio2-neoadjuvant-biomarker-engine/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-steroid-sparing-irae","kind":"idea","name":"Treat immunotherapy side-effects without wiping out the response","route":"/ideas/idea-bio2-steroid-sparing-irae/","asOf":"2026-09-08","days":13},{"id":"idea-bio2-fibre-diet-io-trial","kind":"idea","name":"Test a high-fibre diet as an immunotherapy adjunct","route":"/ideas/idea-bio2-fibre-diet-io-trial/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mced-stage-endpoint-surrogate","kind":"idea","name":"Let MCED trials read out on late-stage incidence, with mortality follow-up mandated","route":"/ideas/idea-prev-mced-stage-endpoint-surrogate/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mced-registry-randomised","kind":"idea","name":"Registry-based randomised MCED trial: a million people, no study visits","route":"/ideas/idea-prev-mced-registry-randomised/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mced-change-control-plan","kind":"idea","name":"Pre-agreed update rules so an MCED test is not obsolete when its trial reads out","route":"/ideas/idea-prev-mced-change-control-plan/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mced-positive-resolution-pathway","kind":"idea","name":"A 28-day national pathway for people with a positive multi-cancer blood test","route":"/ideas/idea-prev-mced-positive-resolution-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-prev-interval-cancer-audit-blood-tests","kind":"idea","name":"Mandatory interval-cancer audit for every blood-based screening test","route":"/ideas/idea-prev-interval-cancer-audit-blood-tests/","asOf":"2026-09-08","days":13},{"id":"idea-prev-ai-mammogram-risk-intervals","kind":"idea","name":"Set each woman's mammogram interval from her last mammogram, using AI risk","route":"/ideas/idea-prev-ai-mammogram-risk-intervals/","asOf":"2026-09-08","days":13},{"id":"idea-prev-lung-screening-risk-model-eligibility","kind":"idea","name":"Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers","route":"/ideas/idea-prev-lung-screening-risk-model-eligibility/","asOf":"2026-09-08","days":13},{"id":"idea-prev-ldct-ai-negative-triage","kind":"idea","name":"AI clears the normal lung screening scans so radiologists read only the suspicious ones","route":"/ideas/idea-prev-ldct-ai-negative-triage/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mammography-ai-stepped-wedge","kind":"idea","name":"Roll out AI-supported mammography nationally as a stepped-wedge trial","route":"/ideas/idea-prev-mammography-ai-stepped-wedge/","asOf":"2026-09-08","days":13},{"id":"idea-prev-opportunistic-ct-ai-registry","kind":"idea","name":"Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway","route":"/ideas/idea-prev-opportunistic-ct-ai-registry/","asOf":"2026-09-08","days":13},{"id":"idea-prev-pancreas-ai-prediagnostic-ct","kind":"idea","name":"AI that spots pancreatic cancer on scans taken a year before diagnosis","route":"/ideas/idea-prev-pancreas-ai-prediagnostic-ct/","asOf":"2026-09-08","days":13},{"id":"idea-prev-new-onset-diabetes-pancreas-pathway","kind":"idea","name":"New diabetes after 50 plus weight loss triggers a pancreatic cancer check","route":"/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-prev-breath-voc-symptomatic-ruleout","kind":"idea","name":"A breath test to rule out cancer in people with vague symptoms","route":"/ideas/idea-prev-breath-voc-symptomatic-ruleout/","asOf":"2026-09-08","days":13},{"id":"idea-prev-urine-dna-haematuria-triage","kind":"idea","name":"A urine DNA test to decide who with blood in the urine needs a camera test","route":"/ideas/idea-prev-urine-dna-haematuria-triage/","asOf":"2026-09-08","days":13},{"id":"idea-prev-weight-loss-auto-alert","kind":"idea","name":"Smart scales and health records flag unexplained weight loss for a cancer check","route":"/ideas/idea-prev-weight-loss-auto-alert/","asOf":"2026-09-08","days":13},{"id":"idea-prev-cgm-glycaemic-drift-pancreas","kind":"idea","name":"Glucose monitor data as an early pancreatic cancer signal","route":"/ideas/idea-prev-cgm-glycaemic-drift-pancreas/","asOf":"2026-09-08","days":13},{"id":"idea-prev-ehr-symptom-signature-prompts","kind":"idea","name":"Cancer risk scores running automatically in GP records to prompt urgent referral","route":"/ideas/idea-prev-ehr-symptom-signature-prompts/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mced-non-specific-symptom-triage","kind":"idea","name":"Multi-cancer blood test as the first step for patients with non-specific symptoms","route":"/ideas/idea-prev-mced-non-specific-symptom-triage/","asOf":"2026-09-08","days":13},{"id":"idea-prev-blood-count-trend-flags","kind":"idea","name":"Use the trend in routine blood counts, not a single threshold, to spot cancer","route":"/ideas/idea-prev-blood-count-trend-flags/","asOf":"2026-09-08","days":13},{"id":"idea-prev-fit-risk-adapted-thresholds","kind":"idea","name":"Personalised stool-test cut-offs by age, sex and prior results","route":"/ideas/idea-prev-fit-risk-adapted-thresholds/","asOf":"2026-09-08","days":13},{"id":"idea-prev-blood-crc-test-for-non-responders","kind":"idea","name":"Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy","route":"/ideas/idea-prev-blood-crc-test-for-non-responders/","asOf":"2026-09-08","days":13},{"id":"idea-prev-capsule-sponge-pharmacy","kind":"idea","name":"A swallowable sponge test for reflux patients, offered in pharmacies","route":"/ideas/idea-prev-capsule-sponge-pharmacy/","asOf":"2026-09-08","days":13},{"id":"idea-prev-gastric-serology-migrant-screening","kind":"idea","name":"Stomach cancer serology screening for high-risk migrant communities in low-incidence countries","route":"/ideas/idea-prev-gastric-serology-migrant-screening/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hcc-blood-surveillance-cirrhosis","kind":"idea","name":"Replace six-monthly ultrasound with a blood test for liver cancer in cirrhosis","route":"/ideas/idea-prev-hcc-blood-surveillance-cirrhosis/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mri-first-prostate-screening-prs","kind":"idea","name":"MRI-first prostate screening with genetic pre-selection","route":"/ideas/idea-prev-mri-first-prostate-screening-prs/","asOf":"2026-09-08","days":13},{"id":"idea-prev-oral-cancer-community-smartphone-ai","kind":"idea","name":"Community health workers with smartphone AI screen for mouth cancer in South Asia","route":"/ideas/idea-prev-oral-cancer-community-smartphone-ai/","asOf":"2026-09-08","days":13},{"id":"idea-prev-lmic-five-cancer-methylation-test","kind":"idea","name":"A ten-dollar blood test for the five cancers that kill most people in poorer countries","route":"/ideas/idea-prev-lmic-five-cancer-methylation-test/","asOf":"2026-09-08","days":13},{"id":"idea-prev-fragmentomics-first-tier","kind":"idea","name":"Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests","route":"/ideas/idea-prev-fragmentomics-first-tier/","asOf":"2026-09-08","days":13},{"id":"idea-prev-live-stage-dashboard","kind":"idea","name":"A live national dashboard of stage at diagnosis as the scorecard for early detection","route":"/ideas/idea-prev-live-stage-dashboard/","asOf":"2026-09-08","days":13},{"id":"idea-prev-open-stage-shift-microsimulation","kind":"idea","name":"Open-source models that translate stage shift into lives saved, for every cancer","route":"/ideas/idea-prev-open-stage-shift-microsimulation/","asOf":"2026-09-08","days":13},{"id":"idea-prev-emergency-department-cancer-test","kind":"idea","name":"A cancer blood test for older people arriving at A&E with unexplained symptoms","route":"/ideas/idea-prev-emergency-department-cancer-test/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mobile-lung-screening-deprived-areas","kind":"idea","name":"Take lung screening scanners to supermarket car parks in the poorest areas","route":"/ideas/idea-prev-mobile-lung-screening-deprived-areas/","asOf":"2026-09-08","days":13},{"id":"idea-prev-ebv-dna-npc-screening-scaleup","kind":"idea","name":"Blood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia","route":"/ideas/idea-prev-ebv-dna-npc-screening-scaleup/","asOf":"2026-09-08","days":13},{"id":"idea-prev-dental-oral-exam-standard","kind":"idea","name":"Make a two-minute mouth cancer check part of every dental visit","route":"/ideas/idea-prev-dental-oral-exam-standard/","asOf":"2026-09-08","days":13},{"id":"idea-prev-bundled-cancer-check-at-60","kind":"idea","name":"A single 'cancer check at 60' appointment bundling all screening tests","route":"/ideas/idea-prev-bundled-cancer-check-at-60/","asOf":"2026-09-08","days":13},{"id":"idea-prev-thyroid-no-screening-no-small-biopsy","kind":"idea","name":"Stop biopsying small thyroid nodules and never screen the thyroid","route":"/ideas/idea-prev-thyroid-no-screening-no-small-biopsy/","asOf":"2026-09-08","days":13},{"id":"idea-prev-ptmc-active-surveillance-default","kind":"idea","name":"Active surveillance as the default for tiny papillary thyroid cancers","route":"/ideas/idea-prev-ptmc-active-surveillance-default/","asOf":"2026-09-08","days":13},{"id":"idea-prev-low-risk-dcis-surveillance-pathway","kind":"idea","name":"After the COMET trial: surveillance pathways and a new name for low-risk DCIS","route":"/ideas/idea-prev-low-risk-dcis-surveillance-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-prev-indolent-lesion-nomenclature-body","kind":"idea","name":"An international body to rename indolent lesions so 'cancer' means something","route":"/ideas/idea-prev-indolent-lesion-nomenclature-body/","asOf":"2026-09-08","days":13},{"id":"idea-prev-gleason6-terminology-rct","kind":"idea","name":"Test whether calling Gleason 6 'not cancer' changes what men choose","route":"/ideas/idea-prev-gleason6-terminology-rct/","asOf":"2026-09-08","days":13},{"id":"idea-prev-prostate-as-triggered-biopsy","kind":"idea","name":"Prostate active surveillance without scheduled biopsies: MRI and blood tests decide","route":"/ideas/idea-prev-prostate-as-triggered-biopsy/","asOf":"2026-09-08","days":13},{"id":"idea-prev-small-renal-mass-surveillance","kind":"idea","name":"Watch small kidney tumours rather than remove them, with a national registry","route":"/ideas/idea-prev-small-renal-mass-surveillance/","asOf":"2026-09-08","days":13},{"id":"idea-prev-lung-nodule-ai-discharge","kind":"idea","name":"AI malignancy scores to end repeat scans and biopsies for benign lung nodules","route":"/ideas/idea-prev-lung-nodule-ai-discharge/","asOf":"2026-09-08","days":13},{"id":"idea-prev-blood-precursor-watch-registry","kind":"idea","name":"A watch-and-wait registry for blood precursor conditions found by chance","route":"/ideas/idea-prev-blood-precursor-watch-registry/","asOf":"2026-09-08","days":13},{"id":"idea-prev-annual-overdiagnosis-reporting","kind":"idea","name":"Every screening programme must publish its overdiagnosis rate each year","route":"/ideas/idea-prev-annual-overdiagnosis-reporting/","asOf":"2026-09-08","days":13},{"id":"idea-prev-screening-stop-by-life-expectancy","kind":"idea","name":"Stop screening by life expectancy, not birthday, with a tool in the record","route":"/ideas/idea-prev-screening-stop-by-life-expectancy/","asOf":"2026-09-08","days":13},{"id":"idea-prev-mced-pretest-decision-aid","kind":"idea","name":"A mandatory decision aid before any multi-cancer blood test","route":"/ideas/idea-prev-mced-pretest-decision-aid/","asOf":"2026-09-08","days":13},{"id":"idea-prev-barrett-surveillance-deescalation","kind":"idea","name":"Stop routine endoscopies for non-dysplastic Barrett's oesophagus","route":"/ideas/idea-prev-barrett-surveillance-deescalation/","asOf":"2026-09-08","days":13},{"id":"idea-prev-melanoma-ai-thick-melanoma-metric","kind":"idea","name":"Judge skin cancer AI by the thick melanomas it prevents, not the thin ones it finds","route":"/ideas/idea-prev-melanoma-ai-thick-melanoma-metric/","asOf":"2026-09-08","days":13},{"id":"idea-prev-incidentaloma-natural-history-cohort","kind":"idea","name":"A ten-year cohort of incidental findings to calibrate follow-up guidelines","route":"/ideas/idea-prev-incidentaloma-natural-history-cohort/","asOf":"2026-09-08","days":13},{"id":"idea-prev-ipmn-surveillance-stop-rule","kind":"idea","name":"Stop watching stable low-risk pancreatic cysts after five years","route":"/ideas/idea-prev-ipmn-surveillance-stop-rule/","asOf":"2026-09-08","days":13},{"id":"idea-prev-pathology-ai-borderline-anchor","kind":"idea","name":"AI second reads to stop borderline lesions being upgraded to cancer","route":"/ideas/idea-prev-pathology-ai-borderline-anchor/","asOf":"2026-09-08","days":13},{"id":"idea-prev-frail-elderly-primary-endocrine-breast","kind":"idea","name":"Hormone tablets instead of surgery for small breast cancers in the frail over-80s","route":"/ideas/idea-prev-frail-elderly-primary-endocrine-breast/","asOf":"2026-09-08","days":13},{"id":"idea-prev-omit-radiotherapy-low-risk-breast-default","kind":"idea","name":"Make skipping radiotherapy the default for very low-risk breast cancer","route":"/ideas/idea-prev-omit-radiotherapy-low-risk-breast-default/","asOf":"2026-09-08","days":13},{"id":"idea-prev-modern-autopsy-reservoir-studies","kind":"idea","name":"Modern autopsy studies to measure how much silent cancer people carry","route":"/ideas/idea-prev-modern-autopsy-reservoir-studies/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpv-single-dose-switch-catchup","kind":"idea","name":"Switch every country to single-dose HPV vaccination and add catch-up to age 26","route":"/ideas/idea-prev-hpv-single-dose-switch-catchup/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpv-vaccinate-at-screening","kind":"idea","name":"Offer HPV vaccination to women when they come for cervical screening or treatment","route":"/ideas/idea-prev-hpv-vaccinate-at-screening/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpv-self-sampling-mailed-default","kind":"idea","name":"Post every woman an HPV self-test kit instead of asking her to book a smear","route":"/ideas/idea-prev-hpv-self-sampling-mailed-default/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpv-same-day-screen-and-treat","kind":"idea","name":"Same-day HPV test and heat treatment of precancer by nurses in low-income settings","route":"/ideas/idea-prev-hpv-same-day-screen-and-treat/","asOf":"2026-09-08","days":13},{"id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hbv-treat-all-hcc","kind":"idea","name":"Treat everyone with chronic hepatitis B to prevent liver cancer","route":"/ideas/idea-prev-hbv-treat-all-hcc/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hcv-test-treat-surveillance-linkage","kind":"idea","name":"Cure hepatitis C in prisons and drug services, and enrol the cured in liver cancer surveillance","route":"/ideas/idea-prev-hcv-test-treat-surveillance-linkage/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpylori-family-test-and-treat","kind":"idea","name":"Family-based H. pylori test-and-treat to prevent stomach cancer","route":"/ideas/idea-prev-hpylori-family-test-and-treat/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpylori-stool-resistance-guided","kind":"idea","name":"Antibiotic-resistance testing from a stool sample before treating H. pylori","route":"/ideas/idea-prev-hpylori-stool-resistance-guided/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpylori-childhood-vaccine","kind":"idea","name":"A vaccine against H. pylori for children in high-risk regions","route":"/ideas/idea-prev-hpylori-childhood-vaccine/","asOf":"2026-09-08","days":13},{"id":"idea-prev-smokefree-generation-evaluation","kind":"idea","name":"Smoke-free generation laws with a built-in evaluation across countries","route":"/ideas/idea-prev-smokefree-generation-evaluation/","asOf":"2026-09-08","days":13},{"id":"idea-prev-very-low-nicotine-mandate","kind":"idea","name":"Make cigarettes non-addictive by capping their nicotine","route":"/ideas/idea-prev-very-low-nicotine-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-prev-opt-out-cessation-in-lung-screening","kind":"idea","name":"Every lung screening visit includes stop-smoking medicine, opt-out","route":"/ideas/idea-prev-opt-out-cessation-in-lung-screening/","asOf":"2026-09-08","days":13},{"id":"idea-prev-cytisine-essential-medicine","kind":"idea","name":"Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list","route":"/ideas/idea-prev-cytisine-essential-medicine/","asOf":"2026-09-08","days":13},{"id":"idea-prev-alcohol-cancer-warning-labels","kind":"idea","name":"Cancer warnings on alcohol labels, evaluated as a natural experiment","route":"/ideas/idea-prev-alcohol-cancer-warning-labels/","asOf":"2026-09-08","days":13},{"id":"idea-prev-minimum-unit-pricing-cancer-endpoints","kind":"idea","name":"Minimum alcohol pricing evaluated with cancer endpoints","route":"/ideas/idea-prev-minimum-unit-pricing-cancer-endpoints/","asOf":"2026-09-08","days":13},{"id":"idea-prev-glp1-cancer-prevention-rct","kind":"idea","name":"A trial of GLP-1 weight-loss drugs with cancer as the primary outcome","route":"/ideas/idea-prev-glp1-cancer-prevention-rct/","asOf":"2026-09-08","days":13},{"id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/","asOf":"2026-09-08","days":13},{"id":"idea-prev-chemoprevention-master-protocol","kind":"idea","name":"One master trial for cancer prevention drugs across many precancers","route":"/ideas/idea-prev-chemoprevention-master-protocol/","asOf":"2026-09-08","days":13},{"id":"idea-prev-low-dose-tamoxifen-uptake","kind":"idea","name":"Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses","route":"/ideas/idea-prev-low-dose-tamoxifen-uptake/","asOf":"2026-09-08","days":13},{"id":"idea-prev-opportunistic-salpingectomy-default","kind":"idea","name":"Remove the fallopian tubes during any pelvic surgery once childbearing is finished","route":"/ideas/idea-prev-opportunistic-salpingectomy-default/","asOf":"2026-09-08","days":13},{"id":"idea-prev-commercial-sunbed-ban","kind":"idea","name":"Ban commercial sunbeds","route":"/ideas/idea-prev-commercial-sunbed-ban/","asOf":"2026-09-08","days":13},{"id":"idea-prev-radon-testing-at-property-sale","kind":"idea","name":"Mandatory radon testing when homes are sold, with subsidised mitigation","route":"/ideas/idea-prev-radon-testing-at-property-sale/","asOf":"2026-09-08","days":13},{"id":"idea-prev-clean-air-never-smoker-endpoints","kind":"idea","name":"Evaluate clean-air policies using lung cancer in never-smokers","route":"/ideas/idea-prev-clean-air-never-smoker-endpoints/","asOf":"2026-09-08","days":13},{"id":"idea-prev-screening-default-appointments","kind":"idea","name":"Send screening invitations with a pre-booked time, not a request to call","route":"/ideas/idea-prev-screening-default-appointments/","asOf":"2026-09-08","days":13},{"id":"idea-prev-pharmacy-prevention-hub","kind":"idea","name":"Community pharmacies as one-stop cancer prevention hubs","route":"/ideas/idea-prev-pharmacy-prevention-hub/","asOf":"2026-09-08","days":13},{"id":"idea-prev-pay-for-prevention-outcomes","kind":"idea","name":"Pay insurers and health systems for cancers prevented and caught early","route":"/ideas/idea-prev-pay-for-prevention-outcomes/","asOf":"2026-09-08","days":13},{"id":"idea-prev-precursor-endpoints-for-approval","kind":"idea","name":"Regulators accept shrinking of precancer as the endpoint for prevention drug approval","route":"/ideas/idea-prev-precursor-endpoints-for-approval/","asOf":"2026-09-08","days":13},{"id":"idea-prev-hpv-male-catchup-oropharynx","kind":"idea","name":"Catch-up HPV vaccination for men to prevent throat cancer","route":"/ideas/idea-prev-hpv-male-catchup-oropharynx/","asOf":"2026-09-08","days":13},{"id":"idea-prev-ebv-vaccine","kind":"idea","name":"An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas","route":"/ideas/idea-prev-ebv-vaccine/","asOf":"2026-09-08","days":13},{"id":"idea-prev-cascade-direct-contact-relatives","kind":"idea","name":"Let clinics contact relatives directly when a cancer gene is found","route":"/ideas/idea-prev-cascade-direct-contact-relatives/","asOf":"2026-09-08","days":13},{"id":"idea-prev-population-germline-screening-at-30","kind":"idea","name":"Offer everyone at 30 a test for the cancer genes that matter","route":"/ideas/idea-prev-population-germline-screening-at-30/","asOf":"2026-09-08","days":13},{"id":"idea-prev-deferred-disclosure-newborn-genomes","kind":"idea","name":"Store adult-onset cancer gene results from newborn genomes and disclose at 18","route":"/ideas/idea-prev-deferred-disclosure-newborn-genomes/","asOf":"2026-09-08","days":13},{"id":"idea-prev-prs-screening-start-age","kind":"idea","name":"Use a polygenic risk score to set when screening starts","route":"/ideas/idea-prev-prs-screening-start-age/","asOf":"2026-09-08","days":13},{"id":"idea-prev-prs-ancestry-portability-standard","kind":"idea","name":"Build polygenic scores that work in every ancestry before deploying any","route":"/ideas/idea-prev-prs-ancestry-portability-standard/","asOf":"2026-09-08","days":13},{"id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/","asOf":"2026-09-08","days":13},{"id":"idea-prev-brca1-denosumab-prevention","kind":"idea","name":"A bone drug to prevent breast cancer in BRCA1 carriers","route":"/ideas/idea-prev-brca1-denosumab-prevention/","asOf":"2026-09-08","days":13},{"id":"idea-prev-lynch-aspirin-implementation","kind":"idea","name":"Get every Lynch syndrome carrier onto the right dose of aspirin","route":"/ideas/idea-prev-lynch-aspirin-implementation/","asOf":"2026-09-08","days":13},{"id":"idea-prev-reflex-germline-testing","kind":"idea","name":"Automatic germline testing for every cancer type where it changes care","route":"/ideas/idea-prev-reflex-germline-testing/","asOf":"2026-09-08","days":13},{"id":"idea-prev-traceback-deceased-probands","kind":"idea","name":"Go back to families of women who died of ovarian cancer and offer BRCA testing","route":"/ideas/idea-prev-traceback-deceased-probands/","asOf":"2026-09-08","days":13},{"id":"idea-prev-vus-saturation-editing-consortium","kind":"idea","name":"Test every possible mutation in every cancer gene so no result is 'uncertain'","route":"/ideas/idea-prev-vus-saturation-editing-consortium/","asOf":"2026-09-08","days":13},{"id":"idea-prev-li-fraumeni-mri-plus-cfdna","kind":"idea","name":"Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome","route":"/ideas/idea-prev-li-fraumeni-mri-plus-cfdna/","asOf":"2026-09-08","days":13},{"id":"idea-prev-genetic-counselling-chatbot","kind":"idea","name":"A chatbot for pre-test genetic counselling so counsellors see only who needs them","route":"/ideas/idea-prev-genetic-counselling-chatbot/","asOf":"2026-09-08","days":13},{"id":"idea-prev-family-history-auto-match","kind":"idea","name":"Family history collected by app and matched to testing criteria automatically","route":"/ideas/idea-prev-family-history-auto-match/","asOf":"2026-09-08","days":13},{"id":"idea-prev-genetic-non-discrimination-insurance","kind":"idea","name":"Ban life and disability insurers from using genetic results","route":"/ideas/idea-prev-genetic-non-discrimination-insurance/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-justify-every-exclusion","kind":"idea","name":"Default-inclusive eligibility: sponsors must justify every exclusion criterion","route":"/ideas/idea-tr1-justify-every-exclusion/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-brain-mets-default-included","kind":"idea","name":"Brain metastases included by default in every solid-tumour trial","route":"/ideas/idea-tr1-brain-mets-default-included/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-pk-informed-organ-thresholds","kind":"idea","name":"Replace fixed kidney and liver cut-offs with drug-specific, pharmacology-based thresholds","route":"/ideas/idea-tr1-pk-informed-organ-thresholds/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-prior-cancer-hiv-hepatitis-inclusion","kind":"idea","name":"Stop excluding people with a prior cancer, controlled HIV, or treated hepatitis","route":"/ideas/idea-tr1-prior-cancer-hiv-hepatitis-inclusion/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-just-in-time-site-network","kind":"idea","name":"Just-in-time site activation: open a site in two weeks when a patient appears","route":"/ideas/idea-tr1-just-in-time-site-network/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-national-master-trial-agreement","kind":"idea","name":"One national master contract and budget template for all cancer trials","route":"/ideas/idea-tr1-national-master-trial-agreement/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-mutual-recognition-ethics-review","kind":"idea","name":"Mutual recognition of ethics review across countries","route":"/ideas/idea-tr1-mutual-recognition-ethics-review/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-home-infusion-trial-drugs","kind":"idea","name":"Home infusion and local blood draws for trial drugs after the first cycles","route":"/ideas/idea-tr1-home-infusion-trial-drugs/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-remote-consent-tele-screening","kind":"idea","name":"Remote consent and tele-screening so the first trial visit is a video call","route":"/ideas/idea-tr1-remote-consent-tele-screening/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-community-site-quota","kind":"idea","name":"At least a third of pivotal-trial sites in community and rural settings","route":"/ideas/idea-tr1-community-site-quota/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-travel-lodging-in-every-budget","kind":"idea","name":"Travel, lodging and meals reimbursed as a standard line in every trial budget","route":"/ideas/idea-tr1-travel-lodging-in-every-budget/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-pay-participants-for-time","kind":"idea","name":"Pay trial participants for their time, not only their expenses","route":"/ideas/idea-tr1-pay-participants-for-time/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-lay-trial-navigators","kind":"idea","name":"Lay trial navigators funded per centre, evaluated in a randomised trial","route":"/ideas/idea-tr1-lay-trial-navigators/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-opt-out-research-contact-register","kind":"idea","name":"Every patient is asked once at diagnosis whether researchers may contact them","route":"/ideas/idea-tr1-opt-out-research-contact-register/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the cancer registry: registry-based trials for everyday questions","route":"/ideas/idea-tr1-registry-embedded-randomisation/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-rare-cancer-trial-in-a-box","kind":"idea","name":"Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer","route":"/ideas/idea-tr1-rare-cancer-trial-in-a-box/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-pre-consented-cohort-randomisation","kind":"idea","name":"Pre-consented cohorts that can be randomised to future trials (TwiCs)","route":"/ideas/idea-tr1-pre-consented-cohort-randomisation/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-public-screen-fail-reasons","kind":"idea","name":"Publish why patients were screened out of each trial","route":"/ideas/idea-tr1-public-screen-fail-reasons/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-eligibility-impact-statement","kind":"idea","name":"Simulate eligibility against real-world data before every protocol is locked","route":"/ideas/idea-tr1-eligibility-impact-statement/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-live-trial-slot-api","kind":"idea","name":"A live 'seats available' feed for trial slots, like airline inventory","route":"/ideas/idea-tr1-live-trial-slot-api/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-pathology-triggered-referral","kind":"idea","name":"The pathology lab triggers a trial referral the day a rare cancer is diagnosed","route":"/ideas/idea-tr1-pathology-triggered-referral/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-evening-weekend-trial-clinics","kind":"idea","name":"Evening and weekend trial clinics for working-age patients","route":"/ideas/idea-tr1-evening-weekend-trial-clinics/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-universal-routine-cost-coverage","kind":"idea","name":"Every payer covers routine care costs for trial participants, in every country","route":"/ideas/idea-tr1-universal-routine-cost-coverage/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-protected-physician-time-for-enrolment","kind":"idea","name":"Pay oncologists for the time it takes to enrol a patient","route":"/ideas/idea-tr1-protected-physician-time-for-enrolment/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-open-trials-inside-guidelines","kind":"idea","name":"Guidelines list the open trials at every decision point, updated monthly","route":"/ideas/idea-tr1-open-trials-inside-guidelines/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-mobile-research-units","kind":"idea","name":"Mobile research units bring trial visits to rural towns","route":"/ideas/idea-tr1-mobile-research-units/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-drop-non-essential-biopsies","kind":"idea","name":"Drop mandatory fresh biopsies where blood or archival tissue would do","route":"/ideas/idea-tr1-drop-non-essential-biopsies/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-external-control-rulebook","kind":"idea","name":"A public rulebook for when an external or synthetic control arm is acceptable","route":"/ideas/idea-tr1-external-control-rulebook/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-bayesian-borrowing-smaller-controls","kind":"idea","name":"Borrow from past control arms to shrink the control group in phase 3","route":"/ideas/idea-tr1-bayesian-borrowing-smaller-controls/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-seamless-2-3-with-prespecified-go","kind":"idea","name":"Seamless phase 2/3 with pre-registered go rules as the default for new agents","route":"/ideas/idea-tr1-seamless-2-3-with-prespecified-go/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-standing-platform-per-cancer","kind":"idea","name":"A standing platform trial for every major cancer, funded as infrastructure","route":"/ideas/idea-tr1-standing-platform-per-cancer/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-surrogate-validation-programme","kind":"idea","name":"An independent programme that validates surrogate endpoints, setting by setting","route":"/ideas/idea-tr1-surrogate-validation-programme/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-crossover-adjusted-survival-standard","kind":"idea","name":"Pre-specified crossover-adjusted survival in every trial that allows crossover","route":"/ideas/idea-tr1-crossover-adjusted-survival-standard/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-ttf-and-qol-coprimary","kind":"idea","name":"Time to treatment failure and quality of life as co-primary endpoints in non-curative trials","route":"/ideas/idea-tr1-ttf-and-qol-coprimary/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-win-ratio-net-benefit-endpoint","kind":"idea","name":"Win-ratio endpoints that weigh survival, toxicity and quality of life together","route":"/ideas/idea-tr1-win-ratio-net-benefit-endpoint/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-public-de-escalation-trial-fund","kind":"idea","name":"A public fund for trials that test less treatment","route":"/ideas/idea-tr1-public-de-escalation-trial-fund/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-immunotherapy-stop-trials","kind":"idea","name":"Randomised trials of stopping immunotherapy after one year versus continuing","route":"/ideas/idea-tr1-immunotherapy-stop-trials/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-ctdna-guided-stop-in-metastatic-disease","kind":"idea","name":"Use tumour DNA in blood to decide when to pause treatment in metastatic cancer","route":"/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-mams-for-sequencing-questions","kind":"idea","name":"Multi-arm, multi-stage trials to answer which order to give approved drugs","route":"/ideas/idea-tr1-mams-for-sequencing-questions/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-post-approval-pragmatic-trial-in-excluded","kind":"idea","name":"After approval, a pragmatic trial in the patients the pivotal trial excluded","route":"/ideas/idea-tr1-post-approval-pragmatic-trial-in-excluded/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-shared-control-arms-across-sponsors","kind":"idea","name":"Competing sponsors share one control arm in the same indication","route":"/ideas/idea-tr1-shared-control-arms-across-sponsors/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-tolerability-estimands","kind":"idea","name":"Define tolerability endpoints as rigorously as efficacy endpoints","route":"/ideas/idea-tr1-tolerability-estimands/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-power-for-meaningful-benefit","kind":"idea","name":"Power trials to detect a benefit patients would value, not the smallest detectable one","route":"/ideas/idea-tr1-power-for-meaningful-benefit/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-registry-linked-os-followup","kind":"idea","name":"Cheap long-term survival follow-up by linking trial participants to registries","route":"/ideas/idea-tr1-registry-linked-os-followup/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-shrinkage-subgroup-analysis","kind":"idea","name":"Bayesian shrinkage for subgroup claims to stop false 'works in this group' stories","route":"/ideas/idea-tr1-shrinkage-subgroup-analysis/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-ai-central-imaging-reads","kind":"idea","name":"AI-assisted central imaging reads to cut endpoint cost and variability","route":"/ideas/idea-tr1-ai-central-imaging-reads/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-public-trial-cost-benchmarks","kind":"idea","name":"Publish per-patient trial cost benchmarks and target halving them","route":"/ideas/idea-tr1-public-trial-cost-benchmarks/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-esource-ehr-to-edc","kind":"idea","name":"Direct record-to-database data capture: no manual transcription, no full source verification","route":"/ideas/idea-tr1-esource-ehr-to-edc/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-aggregated-n-of-1-supportive-care","kind":"idea","name":"Aggregated single-patient crossover trials for symptom and supportive treatments","route":"/ideas/idea-tr1-aggregated-n-of-1-supportive-care/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-aggressive-futility-boundaries","kind":"idea","name":"Stop failing trials earlier with pre-registered aggressive futility rules","route":"/ideas/idea-tr1-aggressive-futility-boundaries/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-window-of-opportunity-default","kind":"idea","name":"A short pre-surgery drug window as the default early test of new agents","route":"/ideas/idea-tr1-window-of-opportunity-default/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-randomised-phase-2-before-phase-3","kind":"idea","name":"Require a randomised phase 2 before any phase 3","route":"/ideas/idea-tr1-randomised-phase-2-before-phase-3/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-smart-designs-for-adaptive-strategies","kind":"idea","name":"SMART designs to test treatment strategies, not just single drugs","route":"/ideas/idea-tr1-smart-designs-for-adaptive-strategies/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-target-trial-emulation-to-prioritise-rcts","kind":"idea","name":"Emulate the trial in real-world data first to decide which trials to run","route":"/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-tumour-agnostic-approval-standard","kind":"idea","name":"A standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling","route":"/ideas/idea-tr1-tumour-agnostic-approval-standard/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-open-protocol-and-sap-library","kind":"idea","name":"Open-source protocol and statistical analysis plan templates with runnable code","route":"/ideas/idea-tr1-open-protocol-and-sap-library/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-validate-real-world-progression-endpoints","kind":"idea","name":"Validate real-world progression endpoints so pragmatic trials can use them","route":"/ideas/idea-tr1-validate-real-world-progression-endpoints/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-diversity-plans-with-consequences","kind":"idea","name":"Diversity action plans with consequences: unmet targets trigger post-approval requirements","route":"/ideas/idea-tr1-diversity-plans-with-consequences/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-incidence-weighted-enrolment-targets","kind":"idea","name":"Set trial enrolment targets from who actually gets the disease, and publish progress live","route":"/ideas/idea-tr1-incidence-weighted-enrolment-targets/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-ancestry-aware-pharmacology-programme","kind":"idea","name":"Ancestry-aware pharmacology: drug-level sub-studies across populations before approval","route":"/ideas/idea-tr1-ancestry-aware-pharmacology-programme/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-duffy-null-neutrophil-threshold","kind":"idea","name":"Fix the neutrophil count rule that excludes many people of African ancestry","route":"/ideas/idea-tr1-duffy-null-neutrophil-threshold/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-mandatory-older-adult-cohort","kind":"idea","name":"A mandatory over-70s cohort with geriatric assessment in every pivotal trial","route":"/ideas/idea-tr1-mandatory-older-adult-cohort/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-parallel-comorbidity-cohorts","kind":"idea","name":"Parallel real-world cohorts for sicker patients alongside every pivotal trial","route":"/ideas/idea-tr1-parallel-comorbidity-cohorts/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-lmic-sites-in-pivotal-trials","kind":"idea","name":"Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded","route":"/ideas/idea-tr1-lmic-sites-in-pivotal-trials/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-community-health-worker-recruitment","kind":"idea","name":"Community health workers and trusted local organisations paid to recruit for trials","route":"/ideas/idea-tr1-community-health-worker-recruitment/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-language-access-in-trials","kind":"idea","name":"Drop the 'must speak English' rule: translated consent and questionnaires as standard","route":"/ideas/idea-tr1-language-access-in-trials/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-site-equity-index","kind":"idea","name":"A public equity index for trial sites and sponsors, tied to funding","route":"/ideas/idea-tr1-site-equity-index/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-include-pregnancy-capable-people-sensibly","kind":"idea","name":"Stop over-excluding people who could become pregnant; study pregnancy exposure","route":"/ideas/idea-tr1-include-pregnancy-capable-people-sensibly/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-age-floor-twelve-for-adult-trials","kind":"idea","name":"Let adolescents from age 12 into adult trials when the cancer biology is the same","route":"/ideas/idea-tr1-age-floor-twelve-for-adult-trials/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-sex-stratified-pk-and-dosing","kind":"idea","name":"Analyse and dose by sex: women get more toxicity from many cancer drugs at the same dose","route":"/ideas/idea-tr1-sex-stratified-pk-and-dosing/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-disability-and-mental-illness-inclusion","kind":"idea","name":"Remove blanket exclusions for mental illness and dementia; support consent instead","route":"/ideas/idea-tr1-disability-and-mental-illness-inclusion/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-representativeness-in-the-label","kind":"idea","name":"Print the participation-to-prevalence ratio in every drug label and assessment report","route":"/ideas/idea-tr1-representativeness-in-the-label/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-diverse-investigator-pipeline","kind":"idea","name":"Fund investigators from under-represented communities and community sites to lead trials","route":"/ideas/idea-tr1-diverse-investigator-pipeline/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-paid-community-advisory-boards","kind":"idea","name":"Paid community advisory boards with power to change protocol burden","route":"/ideas/idea-tr1-paid-community-advisory-boards/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-post-marketing-safety-by-ancestry-and-sex","kind":"idea","name":"Post-marketing safety monitoring stratified by ancestry and sex, with label updates","route":"/ideas/idea-tr1-post-marketing-safety-by-ancestry-and-sex/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-ecog-2-dedicated-cohorts","kind":"idea","name":"Dedicated cohorts for patients with performance status 2 in first-line trials","route":"/ideas/idea-tr1-ecog-2-dedicated-cohorts/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-trial-desert-map","kind":"idea","name":"A public map of trial deserts to steer where new sites open","route":"/ideas/idea-tr1-trial-desert-map/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-randomised-dose-comparison-before-pivotal","kind":"idea","name":"Randomise at least two doses in phase 2 before any pivotal trial","route":"/ideas/idea-tr1-randomised-dose-comparison-before-pivotal/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-exposure-response-before-dose-selection","kind":"idea","name":"Exposure-response modelling with a pre-set target exposure before any dose is chosen","route":"/ideas/idea-tr1-exposure-response-before-dose-selection/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-public-dose-reduction-trials-of-approved-drugs","kind":"idea","name":"Publicly funded dose-reduction trials of expensive approved drugs","route":"/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-weight-based-vs-flat-dosing-trials","kind":"idea","name":"Test flat versus weight-based dosing of antibodies, and use dose banding to cut waste","route":"/ideas/idea-tr1-weight-based-vs-flat-dosing-trials/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-extended-interval-checkpoint-dosing","kind":"idea","name":"Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable","route":"/ideas/idea-tr1-extended-interval-checkpoint-dosing/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-therapeutic-drug-monitoring-for-oral-tkis","kind":"idea","name":"Measure blood levels of oral targeted drugs and adjust doses to a target range","route":"/ideas/idea-tr1-therapeutic-drug-monitoring-for-oral-tkis/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-intermittent-dosing-to-delay-resistance","kind":"idea","name":"Test intermittent dosing of targeted drugs to delay resistance, with honest priors","route":"/ideas/idea-tr1-intermittent-dosing-to-delay-resistance/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-adaptive-therapy-randomised-phase-2","kind":"idea","name":"Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials","route":"/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-start-low-titrate-up-oral-agents","kind":"idea","name":"Start low and step up: individualised titration of oral cancer drugs, randomised","route":"/ideas/idea-tr1-start-low-titrate-up-oral-agents/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-pre-emptive-pharmacogenomic-testing","kind":"idea","name":"Test DPYD, UGT1A1 and TPMT/NUDT15 before the first dose, everywhere","route":"/ideas/idea-tr1-pre-emptive-pharmacogenomic-testing/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-geriatric-dose-finding-cohorts","kind":"idea","name":"Dose-finding in older and frail patients, not extrapolation from fit ones","route":"/ideas/idea-tr1-geriatric-dose-finding-cohorts/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-model-based-dose-finding-with-late-toxicity","kind":"idea","name":"Retire the 3+3: model-based dose finding that counts late and chronic side effects","route":"/ideas/idea-tr1-model-based-dose-finding-with-late-toxicity/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-adc-dose-and-schedule-optimisation","kind":"idea","name":"Dose and schedule optimisation trials specific to antibody-drug conjugates","route":"/ideas/idea-tr1-adc-dose-and-schedule-optimisation/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-dose-evidence-statement-in-label","kind":"idea","name":"A 'dose evidence' panel in every label: how many doses were tested, and how","route":"/ideas/idea-tr1-dose-evidence-statement-in-label/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-patient-reported-toxicity-dose-algorithms","kind":"idea","name":"Dose adjustments driven by patients' own symptom reports, tested against clinician judgement","route":"/ideas/idea-tr1-patient-reported-toxicity-dose-algorithms/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-food-effect-dose-reduction","kind":"idea","name":"Use food effects to cut the dose and cost of oral drugs that absorb better with meals","route":"/ideas/idea-tr1-food-effect-dose-reduction/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-factorial-dose-finding-for-combinations","kind":"idea","name":"Factorial dose finding for drug combinations instead of full dose of everything","route":"/ideas/idea-tr1-factorial-dose-finding-for-combinations/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-organ-impairment-pk-before-approval","kind":"idea","name":"Kidney and liver impairment dosing studies completed before approval, not years after","route":"/ideas/idea-tr1-organ-impairment-pk-before-approval/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-low-dose-immunotherapy-for-lmic","kind":"idea","name":"Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live","route":"/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/","asOf":"2026-09-08","days":13},{"id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-perpetual-platforms","kind":"idea","name":"A perpetual platform trial in every major cancer, funded as infrastructure","route":"/ideas/idea-tr2-perpetual-platforms/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-shared-control-network","kind":"idea","name":"Shared concurrent control arms across sponsors' trials in the same setting","route":"/ideas/idea-tr2-shared-control-network/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-combination-template-agreement","kind":"idea","name":"A standard cross-company combination agreement that takes weeks, not years, to sign","route":"/ideas/idea-tr2-combination-template-agreement/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-public-combination-formulary","kind":"idea","name":"A publicly held library of investigational drugs available for academic combination trials","route":"/ideas/idea-tr2-public-combination-formulary/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-smart-sequencing-adc","kind":"idea","name":"Sequential multiple-assignment randomised trials to find the best order of ADCs","route":"/ideas/idea-tr2-smart-sequencing-adc/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-organoid-coclinical-arms","kind":"idea","name":"Grow each trial patient's tumour as organoids to decide which platform arm opens next","route":"/ideas/idea-tr2-organoid-coclinical-arms/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-organoid-matrix-atlas","kind":"idea","name":"A public atlas of drug-pair responses across a thousand patient-derived organoids","route":"/ideas/idea-tr2-organoid-matrix-atlas/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-combo-dose-matrix","kind":"idea","name":"Find the lowest effective doses of both drugs in a combination, not the highest tolerated","route":"/ideas/idea-tr2-combo-dose-matrix/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-neoadjuvant-combo-platform","kind":"idea","name":"Pre-surgery platform trials that test combinations on pathological response in months","route":"/ideas/idea-tr2-neoadjuvant-combo-platform/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-pragmatic-sequence-randomisation","kind":"idea","name":"Registry-embedded randomisation of treatment order in routine care","route":"/ideas/idea-tr2-pragmatic-sequence-randomisation/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-alternating-vs-concurrent","kind":"idea","name":"Test alternating drug schedules against giving both drugs at once","route":"/ideas/idea-tr2-alternating-vs-concurrent/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-factorial-adjuvant-generics","kind":"idea","name":"Factorial trials that test several cheap generics at once in the adjuvant setting","route":"/ideas/idea-tr2-factorial-adjuvant-generics/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-ctdna-futility-gates","kind":"idea","name":"Kill combination arms early using circulating tumour DNA, before waiting for scans","route":"/ideas/idea-tr2-ctdna-futility-gates/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-platform-single-ethics","kind":"idea","name":"One ethics approval and one consent form for a platform trial across countries","route":"/ideas/idea-tr2-platform-single-ethics/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-resistance-mechanism-baskets","kind":"idea","name":"Combination baskets defined by resistance mechanism rather than by cancer type","route":"/ideas/idea-tr2-resistance-mechanism-baskets/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-combination-utility","kind":"idea","name":"A non-profit phase 1b combination unit that any drug owner can use","route":"/ideas/idea-tr2-combination-utility/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-combination-patent-pool","kind":"idea","name":"A patent pool for combination method-of-use claims","route":"/ideas/idea-tr2-combination-patent-pool/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-sequence-registry","kind":"idea","name":"A registry of every treatment sequence patients actually receive, with outcomes","route":"/ideas/idea-tr2-sequence-registry/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-bandit-allocation","kind":"idea","name":"Let the trial learn: response-adaptive allocation across many combination arms","route":"/ideas/idea-tr2-bandit-allocation/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-qsp-combo-dosing","kind":"idea","name":"Mechanistic computer models to pick combination doses before dosing patients","route":"/ideas/idea-tr2-qsp-combo-dosing/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-combo-readiness-dossier","kind":"idea","name":"Every approved cancer drug ships with a public combination-readiness data pack","route":"/ideas/idea-tr2-combo-readiness-dossier/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-rt-drug-platform","kind":"idea","name":"A standing platform for testing new drugs with radiotherapy","route":"/ideas/idea-tr2-rt-drug-platform/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-paediatric-combo-prea","kind":"idea","name":"Make paediatric combination studies part of every relevant adult cancer drug approval","route":"/ideas/idea-tr2-paediatric-combo-prea/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-payer-combo-cwe","kind":"idea","name":"Payers cover off-label combinations only inside registry-randomised trials","route":"/ideas/idea-tr2-payer-combo-cwe/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-combination-forecast-tournament","kind":"idea","name":"An open forecasting tournament on which combination trials will succeed","route":"/ideas/idea-tr2-combination-forecast-tournament/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-antagonism-surveillance","kind":"idea","name":"Watch routine care for drug combinations that quietly make cancer treatment worse","route":"/ideas/idea-tr2-antagonism-surveillance/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-contribution-of-components-mandate","kind":"idea","name":"No accelerated approval for a combination without proof each part contributes","route":"/ideas/idea-tr2-contribution-of-components-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-window-of-opportunity-triplets","kind":"idea","name":"Two-week pre-operative windows to compare combination biology head to head","route":"/ideas/idea-tr2-window-of-opportunity-triplets/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-preclinical-negative-registry","kind":"idea","name":"A registry for preclinical experiments that did not work","route":"/ideas/idea-tr2-preclinical-negative-registry/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-negative-results-journal","kind":"idea","name":"A funder-backed, indexed journal of negative and inconclusive cancer results","route":"/ideas/idea-tr2-negative-results-journal/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-fdaaa-enforcement","kind":"idea","name":"Actually fine sponsors who do not post trial results","route":"/ideas/idea-tr2-fdaaa-enforcement/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-irb-results-gate","kind":"idea","name":"No new trial approval until the sponsor has reported its old ones","route":"/ideas/idea-tr2-irb-results-gate/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-termination-reports","kind":"idea","name":"Public post-mortem reports when a cancer drug programme is stopped","route":"/ideas/idea-tr2-termination-reports/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-shelved-asset-commons","kind":"idea","name":"A commons of shelved cancer drugs with their full data, open to new hypotheses","route":"/ideas/idea-tr2-shelved-asset-commons/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-outcome-switching-monitor","kind":"idea","name":"Automatically detect when a trial changes its outcomes after the fact","route":"/ideas/idea-tr2-outcome-switching-monitor/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-material-failure-disclosure","kind":"idea","name":"Listed companies must disclose top-line data, not just 'did not meet endpoint'","route":"/ideas/idea-tr2-material-failure-disclosure/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-failed-trial-biobank","kind":"idea","name":"Rescue the biological samples from failed trials for biomarker research","route":"/ideas/idea-tr2-failed-trial-biobank/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-failed-trial-ipd-default","kind":"idea","name":"Patient-level data from failed trials becomes open by default after two years","route":"/ideas/idea-tr2-failed-trial-ipd-default/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-writeup-grants","kind":"idea","name":"Small grants that pay scientists to write up abandoned projects","route":"/ideas/idea-tr2-writeup-grants/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-null-result-reporting","kind":"idea","name":"Grant progress reports must list what did not work","route":"/ideas/idea-tr2-null-result-reporting/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-negative-plenaries","kind":"idea","name":"Give negative trials plenary slots at the big cancer conferences","route":"/ideas/idea-tr2-negative-plenaries/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-failure-taxonomy","kind":"idea","name":"A machine-readable taxonomy of why cancer drugs fail","route":"/ideas/idea-tr2-failure-taxonomy/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-model-report-cards","kind":"idea","name":"Score every preclinical model by how often it predicted the clinical result","route":"/ideas/idea-tr2-model-report-cards/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-off-label-outcome-registry","kind":"idea","name":"Record what happens when doctors use cancer drugs off-label","route":"/ideas/idea-tr2-off-label-outcome-registry/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-retraction-propagation","kind":"idea","name":"Alert guidelines and trials when a paper they rely on is retracted","route":"/ideas/idea-tr2-retraction-propagation/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-reversal-registry","kind":"idea","name":"A public registry of cancer treatments that were later shown not to work","route":"/ideas/idea-tr2-reversal-registry/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-sponsor-transparency-score","kind":"idea","name":"A public transparency score for every trial sponsor, used by sites and patients","route":"/ideas/idea-tr2-sponsor-transparency-score/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-target-failure-index","kind":"idea","name":"A target de-risking index that counts failures as well as successes","route":"/ideas/idea-tr2-target-failure-index/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-her2-low-reference-materials","kind":"idea","name":"Calibrated reference slides so every lab scores HER2-low the same way","route":"/ideas/idea-tr2-her2-low-reference-materials/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-pdl1-digital-calibration","kind":"idea","name":"One digital PD-L1 scale that maps across all the competing assays","route":"/ideas/idea-tr2-pdl1-digital-calibration/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-marker-stratified-default","kind":"idea","name":"Test the drug in biomarker-negative patients too, so the biomarker can be validated","route":"/ideas/idea-tr2-marker-stratified-default/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-cdx-mutual-recognition","kind":"idea","name":"Regulators recognise each other's companion diagnostic approvals","route":"/ideas/idea-tr2-cdx-mutual-recognition/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-open-cdx-validation-sets","kind":"idea","name":"Public gold-standard datasets for validating every cancer biomarker test","route":"/ideas/idea-tr2-open-cdx-validation-sets/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-ctdna-mrd-qualification","kind":"idea","name":"Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials","route":"/ideas/idea-tr2-ctdna-mrd-qualification/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-psma-volume-qualification","kind":"idea","name":"Qualify PSMA PET tumour volume as a validated imaging biomarker","route":"/ideas/idea-tr2-psma-volume-qualification/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-bicr-discordance-public","kind":"idea","name":"Publish the disagreement between trial doctors and independent reviewers for every trial","route":"/ideas/idea-tr2-bicr-discordance-public/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-biomarker-evidence-grading","kind":"idea","name":"Label every biomarker claim with an evidence phase, like drugs","route":"/ideas/idea-tr2-biomarker-evidence-grading/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-eqa-public-results","kind":"idea","name":"Publish each laboratory's biomarker proficiency results","route":"/ideas/idea-tr2-eqa-public-results/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-ctdna-reference-plasma","kind":"idea","name":"Certified reference samples to benchmark every tumour-DNA blood test","route":"/ideas/idea-tr2-ctdna-reference-plasma/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-tmb-calibration-standard","kind":"idea","name":"A single calibrated tumour mutational burden across all sequencing panels","route":"/ideas/idea-tr2-tmb-calibration-standard/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-hrd-functional-standard","kind":"idea","name":"A functional test for homologous recombination deficiency validated across laboratories","route":"/ideas/idea-tr2-hrd-functional-standard/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-preanalytics-in-report","kind":"idea","name":"Record how long tissue waited before fixation in every pathology report","route":"/ideas/idea-tr2-preanalytics-in-report/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-cutpoint-lock","kind":"idea","name":"Lock the biomarker cut-off before phase 3, and publish it","route":"/ideas/idea-tr2-cutpoint-lock/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-prospective-retrospective-path","kind":"idea","name":"A formal regulatory route for validating a biomarker on archived trial samples","route":"/ideas/idea-tr2-prospective-retrospective-path/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-spatial-biomarker-standards","kind":"idea","name":"Standards for spatial and multiplex tissue biomarkers before they reach the clinic","route":"/ideas/idea-tr2-spatial-biomarker-standards/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-liquid-biopsy-challenge","kind":"idea","name":"An annual blinded shoot-out for liquid biopsy tests","route":"/ideas/idea-tr2-liquid-biopsy-challenge/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-radiomics-ibsi-mandate","kind":"idea","name":"No clinical claims for imaging-derived biomarkers without phantom and standards compliance","route":"/ideas/idea-tr2-radiomics-ibsi-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-biomarker-study-registry","kind":"idea","name":"Pre-register biomarker validation studies the way trials are registered","route":"/ideas/idea-tr2-biomarker-study-registry/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-biomarker-cwe","kind":"idea","name":"Pay for new biomarker tests only while evidence of clinical utility is being collected","route":"/ideas/idea-tr2-biomarker-cwe/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-ai-cdx-change-control","kind":"idea","name":"Version control and locked reference sets for AI algorithms used as companion diagnostics","route":"/ideas/idea-tr2-ai-cdx-change-control/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-label-assay-concordance","kind":"idea","name":"Drug labels must state which biomarker assays were validated and how they compare","route":"/ideas/idea-tr2-label-assay-concordance/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-biomarker-negative-arms","kind":"idea","name":"Randomised trials to test whether biomarker-negative patients really do not benefit","route":"/ideas/idea-tr2-biomarker-negative-arms/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-positivity-rate-surveillance","kind":"idea","name":"Monitor biomarker positivity rates across labs in real time to catch assay drift","route":"/ideas/idea-tr2-positivity-rate-surveillance/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-cell-line-authentication-mandate","kind":"idea","name":"Prove your cell lines are what you say they are, or the paper is not published","route":"/ideas/idea-tr2-cell-line-authentication-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-cell-line-passport","kind":"idea","name":"A digital passport for every cell culture: identity, contamination status, passage number","route":"/ideas/idea-tr2-cell-line-passport/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-preclinical-registered-reports","kind":"idea","name":"Registered reports for cancer biology: the plan is peer-reviewed before the result","route":"/ideas/idea-tr2-preclinical-registered-reports/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-replication-set-aside","kind":"idea","name":"Funders set aside a fixed share of budget for independent replication","route":"/ideas/idea-tr2-replication-set-aside/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-replication-before-ind","kind":"idea","name":"Independent replication of the key experiment before first-in-human academic trials","route":"/ideas/idea-tr2-replication-before-ind/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-automated-stats-check","kind":"idea","name":"Run automated statistics and image checks on every cancer manuscript before review","route":"/ideas/idea-tr2-automated-stats-check/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-raw-image-deposit","kind":"idea","name":"Deposit the raw blots, gels and microscopy images behind every figure","route":"/ideas/idea-tr2-raw-image-deposit/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-arrive-audit","kind":"idea","name":"Audit animal studies for randomisation and blinding, published by institution","route":"/ideas/idea-tr2-arrive-audit/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-multilab-preclinical","kind":"idea","name":"Multi-laboratory preclinical trials as the standard for go/no-go decisions","route":"/ideas/idea-tr2-multilab-preclinical/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-replication-bounties","kind":"idea","name":"Bounties for documented failed replications of high-impact findings","route":"/ideas/idea-tr2-replication-bounties/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-antibody-validation-mandate","kind":"idea","name":"Only use antibodies proven to hit their target with knockout controls","route":"/ideas/idea-tr2-antibody-validation-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-reference-compound-panels","kind":"idea","name":"Every drug screen includes standard reference compounds whose performance is published","route":"/ideas/idea-tr2-reference-compound-panels/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-timestamped-eln","kind":"idea","name":"Time-stamped electronic lab notebooks submitted with the paper","route":"/ideas/idea-tr2-timestamped-eln/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-animal-power-mandate","kind":"idea","name":"Pre-specified sample sizes for animal studies; no more 'representative' experiments","route":"/ideas/idea-tr2-animal-power-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-tenure-replication-credit","kind":"idea","name":"Count replications and open data in hiring and promotion","route":"/ideas/idea-tr2-tenure-replication-credit/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-random-audit","kind":"idea","name":"Random audits of published, funded research, like tax audits","route":"/ideas/idea-tr2-random-audit/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-replication-status-badge","kind":"idea","name":"A replication status badge on every cancer paper, visible in PubMed","route":"/ideas/idea-tr2-replication-status-badge/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-data-link-enforcement","kind":"idea","name":"Journals check that data links actually work, and flag papers whose data vanish","route":"/ideas/idea-tr2-data-link-enforcement/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-paid-statistical-review","kind":"idea","name":"Paid independent statistical review for preclinical papers that inform trials","route":"/ideas/idea-tr2-paid-statistical-review/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-reference-model-panels","kind":"idea","name":"Shared reference organoid and PDX panels that every lab can test against","route":"/ideas/idea-tr2-reference-model-panels/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-ai-external-validation-registry","kind":"idea","name":"A registry of external validation datasets for cancer AI models, with mandatory reporting","route":"/ideas/idea-tr2-ai-external-validation-registry/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-two-lab-rule","kind":"idea","name":"Top journals require an independent lab to reproduce key findings before publication","route":"/ideas/idea-tr2-two-lab-rule/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-preclinical-living-reviews","kind":"idea","name":"Living systematic reviews of animal and organoid evidence before every new trial","route":"/ideas/idea-tr2-preclinical-living-reviews/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-reagent-lot-ledger","kind":"idea","name":"Barcode every reagent lot so batch effects can be traced across experiments and labs","route":"/ideas/idea-tr2-reagent-lot-ledger/","asOf":"2026-09-08","days":13},{"id":"idea-tr2-phd-replication-year","kind":"idea","name":"Every cancer biology PhD begins with a funded replication of a published finding","route":"/ideas/idea-tr2-phd-replication-year/","asOf":"2026-09-08","days":13},{"id":"idea-reg-orbis-work-sharing","kind":"idea","name":"Turn Project Orbis into a work-sharing review with one shared assessment report","route":"/ideas/idea-reg-orbis-work-sharing/","asOf":"2026-09-08","days":13},{"id":"idea-reg-reliance-90-day-lmic","kind":"idea","name":"90-day reliance approval for cancer drugs cleared by two stringent regulators","route":"/ideas/idea-reg-reliance-90-day-lmic/","asOf":"2026-09-08","days":13},{"id":"idea-reg-single-global-dossier","kind":"idea","name":"One structured global dossier: submit the cancer drug file once, to a shared cloud","route":"/ideas/idea-reg-single-global-dossier/","asOf":"2026-09-08","days":13},{"id":"idea-reg-joint-scientific-advice-default","kind":"idea","name":"Joint FDA-EMA-MHRA-PMDA scientific advice by default before pivotal cancer trials","route":"/ideas/idea-reg-joint-scientific-advice-default/","asOf":"2026-09-08","days":13},{"id":"idea-reg-realtime-streaming-submission","kind":"idea","name":"Stream trial data to regulators as it accrues; review starts at last patient visit","route":"/ideas/idea-reg-realtime-streaming-submission/","asOf":"2026-09-08","days":13},{"id":"idea-reg-conditional-approval-sunset","kind":"idea","name":"Conditional approvals that lapse automatically if the confirmatory trial is late","route":"/ideas/idea-reg-conditional-approval-sunset/","asOf":"2026-09-08","days":13},{"id":"idea-reg-confirmatory-trial-escrow","kind":"idea","name":"Sponsors deposit the confirmatory trial budget in escrow at accelerated approval","route":"/ideas/idea-reg-confirmatory-trial-escrow/","asOf":"2026-09-08","days":13},{"id":"idea-reg-public-assessment-reports-all","kind":"idea","name":"Every regulator publishes its full assessment report so others can rely on it","route":"/ideas/idea-reg-public-assessment-reports-all/","asOf":"2026-09-08","days":13},{"id":"idea-reg-mutual-recognition-inspections-atmp","kind":"idea","name":"Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants","route":"/ideas/idea-reg-mutual-recognition-inspections-atmp/","asOf":"2026-09-08","days":13},{"id":"idea-reg-global-trial-application-portal","kind":"idea","name":"One clinical trial application accepted by regulators in every major region","route":"/ideas/idea-reg-global-trial-application-portal/","asOf":"2026-09-08","days":13},{"id":"idea-reg-diagnostic-reliance-pathway","kind":"idea","name":"A reliance pathway for companion diagnostics so the test arrives with the drug","route":"/ideas/idea-reg-diagnostic-reliance-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-reg-single-paediatric-plan","kind":"idea","name":"One global paediatric cancer development plan instead of separate FDA and EMA plans","route":"/ideas/idea-reg-single-paediatric-plan/","asOf":"2026-09-08","days":13},{"id":"idea-reg-tumour-agnostic-reliance","kind":"idea","name":"Adopt tumour-agnostic cancer drug labels across regions by reliance, not re-review","route":"/ideas/idea-reg-tumour-agnostic-reliance/","asOf":"2026-09-08","days":13},{"id":"idea-reg-label-divergence-index","kind":"idea","name":"A public index of how the same cancer drug's label differs between countries","route":"/ideas/idea-reg-label-divergence-index/","asOf":"2026-09-08","days":13},{"id":"idea-reg-approval-access-lag-tracker","kind":"idea","name":"Live tracker of the lag from first approval to real availability in every country","route":"/ideas/idea-reg-approval-access-lag-tracker/","asOf":"2026-09-08","days":13},{"id":"idea-reg-joint-regulator-hta-plan","kind":"idea","name":"One evidence plan agreed by regulator and payer before the pivotal trial","route":"/ideas/idea-reg-joint-regulator-hta-plan/","asOf":"2026-09-08","days":13},{"id":"idea-reg-mrct-no-bridging","kind":"idea","name":"One multiregional trial, no bridging studies: enforce ICH E17 in Japan and China","route":"/ideas/idea-reg-mrct-no-bridging/","asOf":"2026-09-08","days":13},{"id":"idea-reg-african-medicines-agency-oncology","kind":"idea","name":"Fund an oncology joint assessment unit inside the African Medicines Agency","route":"/ideas/idea-reg-african-medicines-agency-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-reg-open-source-dossier-tools","kind":"idea","name":"Open-source dossier-building software for academic sponsors and generic makers","route":"/ideas/idea-reg-open-source-dossier-tools/","asOf":"2026-09-08","days":13},{"id":"idea-reg-shared-ai-review-assistant","kind":"idea","name":"A shared AI review assistant that maps one dossier to every regulator's questions","route":"/ideas/idea-reg-shared-ai-review-assistant/","asOf":"2026-09-08","days":13},{"id":"idea-reg-shared-postmarketing-registry-condition","kind":"idea","name":"One international registry, not one per country, for conditional approvals","route":"/ideas/idea-reg-shared-postmarketing-registry-condition/","asOf":"2026-09-08","days":13},{"id":"idea-reg-manufacturing-change-passport","kind":"idea","name":"Manufacturing-change passport: one approved CMC change accepted everywhere in 30 days","route":"/ideas/idea-reg-manufacturing-change-passport/","asOf":"2026-09-08","days":13},{"id":"idea-reg-orphan-designation-reciprocity","kind":"idea","name":"Automatic reciprocity of orphan and rare-paediatric designations between regulators","route":"/ideas/idea-reg-orphan-designation-reciprocity/","asOf":"2026-09-08","days":13},{"id":"idea-reg-publish-all-rejections","kind":"idea","name":"Publish every complete response letter and negative opinion across all regulators","route":"/ideas/idea-reg-publish-all-rejections/","asOf":"2026-09-08","days":13},{"id":"idea-reg-global-dose-optimisation-guideline","kind":"idea","name":"Make pre-approval dose optimisation an ICH standard so it is done once worldwide","route":"/ideas/idea-reg-global-dose-optimisation-guideline/","asOf":"2026-09-08","days":13},{"id":"idea-reg-point-of-care-cart-network","kind":"idea","name":"Hospital-made CAR-T under one shared regulatory master file","route":"/ideas/idea-reg-point-of-care-cart-network/","asOf":"2026-09-08","days":13},{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/","asOf":"2026-09-08","days":13},{"id":"idea-reg-two-day-cart-rapid-release","kind":"idea","name":"Two-day CAR-T manufacture paired with rapid release tests that regulators accept","route":"/ideas/idea-reg-two-day-cart-rapid-release/","asOf":"2026-09-08","days":13},{"id":"idea-reg-ipsc-master-bank-qualified-once","kind":"idea","name":"Qualify one iPSC master cell bank once for many off-the-shelf cell products","route":"/ideas/idea-reg-ipsc-master-bank-qualified-once/","asOf":"2026-09-08","days":13},{"id":"idea-reg-closed-manufacturing-interop-standard","kind":"idea","name":"An open interoperability standard for closed automated cell-processing machines","route":"/ideas/idea-reg-closed-manufacturing-interop-standard/","asOf":"2026-09-08","days":13},{"id":"idea-reg-cart-potency-reference-standards","kind":"idea","name":"Public reference standards and potency assays for CAR-T so every lab measures alike","route":"/ideas/idea-reg-cart-potency-reference-standards/","asOf":"2026-09-08","days":13},{"id":"idea-reg-vein-to-vein-public-benchmark","kind":"idea","name":"Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product","route":"/ideas/idea-reg-vein-to-vein-public-benchmark/","asOf":"2026-09-08","days":13},{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/","asOf":"2026-09-08","days":13},{"id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/","asOf":"2026-09-08","days":13},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/","asOf":"2026-09-08","days":13},{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/","asOf":"2026-09-08","days":13},{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/","asOf":"2026-09-08","days":13},{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/","asOf":"2026-09-08","days":13},{"id":"idea-reg-adc-platform-designation","kind":"idea","name":"Platform designation for ADC linker-payloads so manufacturing data carry across","route":"/ideas/idea-reg-adc-platform-designation/","asOf":"2026-09-08","days":13},{"id":"idea-reg-hpapi-continuous-flow","kind":"idea","name":"Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze","route":"/ideas/idea-reg-hpapi-continuous-flow/","asOf":"2026-09-08","days":13},{"id":"idea-reg-open-source-lentiviral-vectors","kind":"idea","name":"Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T","route":"/ideas/idea-reg-open-source-lentiviral-vectors/","asOf":"2026-09-08","days":13},{"id":"idea-reg-non-viral-cart-manufacturing","kind":"idea","name":"Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route","route":"/ideas/idea-reg-non-viral-cart-manufacturing/","asOf":"2026-09-08","days":13},{"id":"idea-reg-manufacturing-slot-exchange","kind":"idea","name":"A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient","route":"/ideas/idea-reg-manufacturing-slot-exchange/","asOf":"2026-09-08","days":13},{"id":"idea-reg-hospital-exemption-harmonised","kind":"idea","name":"Harmonise Europe's hospital exemption for academic cell therapies, with one registry","route":"/ideas/idea-reg-hospital-exemption-harmonised/","asOf":"2026-09-08","days":13},{"id":"idea-reg-lmic-public-cart-manufacturing","kind":"idea","name":"Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000","route":"/ideas/idea-reg-lmic-public-cart-manufacturing/","asOf":"2026-09-08","days":13},{"id":"idea-reg-ai-process-control-cell-manufacturing","kind":"idea","name":"Digital batch records and AI process control to halve cell therapy batch failures","route":"/ideas/idea-reg-ai-process-control-cell-manufacturing/","asOf":"2026-09-08","days":13},{"id":"idea-reg-early-apheresis-banking","kind":"idea","name":"Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy","route":"/ideas/idea-reg-early-apheresis-banking/","asOf":"2026-09-08","days":13},{"id":"idea-reg-public-cell-therapy-foundries","kind":"idea","name":"Public cell-therapy foundries at cancer centres for academics and start-ups","route":"/ideas/idea-reg-public-cell-therapy-foundries/","asOf":"2026-09-08","days":13},{"id":"idea-reg-comparability-by-design-digital-twin","kind":"idea","name":"Comparability by design: a digital twin and sentinel panel for cell process changes","route":"/ideas/idea-reg-comparability-by-design-digital-twin/","asOf":"2026-09-08","days":13},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/","asOf":"2026-09-08","days":13},{"id":"idea-reg-cart-outcomes-refund","kind":"idea","name":"Full refund for CAR-T if the patient has not responded at three months","route":"/ideas/idea-reg-cart-outcomes-refund/","asOf":"2026-09-08","days":13},{"id":"idea-reg-io-subscription-national","kind":"idea","name":"Subscription pricing for checkpoint inhibitors: fixed national fee, unlimited use","route":"/ideas/idea-reg-io-subscription-national/","asOf":"2026-09-08","days":13},{"id":"idea-reg-indication-specific-pricing","kind":"idea","name":"Pay a different price for the same cancer drug depending on the indication","route":"/ideas/idea-reg-indication-specific-pricing/","asOf":"2026-09-08","days":13},{"id":"idea-reg-pooled-procurement-adult-essentials","kind":"idea","name":"Pooled international procurement of essential adult cancer medicines","route":"/ideas/idea-reg-pooled-procurement-adult-essentials/","asOf":"2026-09-08","days":13},{"id":"idea-reg-biosimilar-no-efficacy-trial","kind":"idea","name":"Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials","route":"/ideas/idea-reg-biosimilar-no-efficacy-trial/","asOf":"2026-09-08","days":13},{"id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","asOf":"2026-09-08","days":13},{"id":"idea-reg-patent-pool-oncology-eml","kind":"idea","name":"Medicines Patent Pool licences for every patented cancer drug on the WHO list","route":"/ideas/idea-reg-patent-pool-oncology-eml/","asOf":"2026-09-08","days":13},{"id":"idea-reg-price-anchored-to-mcbs","kind":"idea","name":"Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales","route":"/ideas/idea-reg-price-anchored-to-mcbs/","asOf":"2026-09-08","days":13},{"id":"idea-reg-weight-based-io-dosing-label","kind":"idea","name":"Restore weight-based dosing and vial sharing for immunotherapy in the label","route":"/ideas/idea-reg-weight-based-io-dosing-label/","asOf":"2026-09-08","days":13},{"id":"idea-reg-public-deescalation-trials-for-cost","kind":"idea","name":"Publicly funded trials of lower and less frequent doses of expensive cancer drugs","route":"/ideas/idea-reg-public-deescalation-trials-for-cost/","asOf":"2026-09-08","days":13},{"id":"idea-reg-financial-toxicity-vital-sign","kind":"idea","name":"Screen every cancer patient for financial toxicity as a vital sign, with navigation","route":"/ideas/idea-reg-financial-toxicity-vital-sign/","asOf":"2026-09-08","days":13},{"id":"idea-reg-net-price-transparency-registry","kind":"idea","name":"An international registry of real (net) cancer drug prices paid by public payers","route":"/ideas/idea-reg-net-price-transparency-registry/","asOf":"2026-09-08","days":13},{"id":"idea-reg-rd-cost-disclosure-condition","kind":"idea","name":"Disclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage","route":"/ideas/idea-reg-rd-cost-disclosure-condition/","asOf":"2026-09-08","days":13},{"id":"idea-reg-provisional-price-until-os","kind":"idea","name":"Provisional prices for surrogate-endpoint approvals, reset when survival data arrive","route":"/ideas/idea-reg-provisional-price-until-os/","asOf":"2026-09-08","days":13},{"id":"idea-reg-patent-buyout-prize","kind":"idea","name":"Buy out the patent on a curative cancer drug and sell it at generic prices","route":"/ideas/idea-reg-patent-buyout-prize/","asOf":"2026-09-08","days":13},{"id":"idea-reg-secondary-patent-thicket-limits","kind":"idea","name":"Limit secondary patents and pay-for-delay so cancer generics arrive on time","route":"/ideas/idea-reg-secondary-patent-thicket-limits/","asOf":"2026-09-08","days":13},{"id":"idea-reg-nonprofit-generic-chemo-manufacturer","kind":"idea","name":"A non-profit manufacturer for generic cancer drugs in chronic shortage","route":"/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/","asOf":"2026-09-08","days":13},{"id":"idea-reg-academic-cart-at-cost-coverage","kind":"idea","name":"Public payers cover academic CAR-T at cost as a benchmark for commercial prices","route":"/ideas/idea-reg-academic-cart-at-cost-coverage/","asOf":"2026-09-08","days":13},{"id":"idea-reg-combination-price-attribution","kind":"idea","name":"A combination pricing rule so two-drug regimens are not priced as two monopolies","route":"/ideas/idea-reg-combination-price-attribution/","asOf":"2026-09-08","days":13},{"id":"idea-reg-middle-income-negotiation-bloc","kind":"idea","name":"A joint price negotiation bloc for middle-income countries, modelled on Beneluxa","route":"/ideas/idea-reg-middle-income-negotiation-bloc/","asOf":"2026-09-08","days":13},{"id":"idea-reg-tiered-pricing-for-exclusivity","kind":"idea","name":"Grant extra exclusivity only in exchange for binding low prices in poorer countries","route":"/ideas/idea-reg-tiered-pricing-for-exclusivity/","asOf":"2026-09-08","days":13},{"id":"idea-reg-biosimilar-first-default-switching","kind":"idea","name":"Biosimilar-first defaults and payment parity in every cancer day unit","route":"/ideas/idea-reg-biosimilar-first-default-switching/","asOf":"2026-09-08","days":13},{"id":"idea-reg-annuity-payment-durable-therapies","kind":"idea","name":"Pay for one-time curative therapies as an annuity that stops at relapse","route":"/ideas/idea-reg-annuity-payment-durable-therapies/","asOf":"2026-09-08","days":13},{"id":"idea-reg-social-impact-bond-switching","kind":"idea","name":"Social impact bonds that fund biosimilar switching, repaid from payer savings","route":"/ideas/idea-reg-social-impact-bond-switching/","asOf":"2026-09-08","days":13},{"id":"idea-reg-market-expansion-repricing","kind":"idea","name":"Automatic price cuts when a cancer drug's approved indications and volumes expand","route":"/ideas/idea-reg-market-expansion-repricing/","asOf":"2026-09-08","days":13},{"id":"idea-reg-global-repurposing-fund","kind":"idea","name":"A public fund that pays for phase 3 trials of cheap, off-patent drugs against cancer","route":"/ideas/idea-reg-global-repurposing-fund/","asOf":"2026-09-08","days":13},{"id":"idea-reg-third-party-label-update","kind":"idea","name":"Let non-profits and academics add a cancer indication to an off-patent drug's label","route":"/ideas/idea-reg-third-party-label-update/","asOf":"2026-09-08","days":13},{"id":"idea-reg-repurposing-prize","kind":"idea","name":"A $50 million prize for the first off-patent drug proven to extend cancer survival","route":"/ideas/idea-reg-repurposing-prize/","asOf":"2026-09-08","days":13},{"id":"idea-reg-repurposing-social-impact-bond","kind":"idea","name":"A social impact bond: investors fund a repurposing trial, payers repay from savings","route":"/ideas/idea-reg-repurposing-social-impact-bond/","asOf":"2026-09-08","days":13},{"id":"idea-reg-aspirin-pik3ca-implementation","kind":"idea","name":"Get biomarker-directed aspirin after colorectal surgery into labels and guidelines","route":"/ideas/idea-reg-aspirin-pik3ca-implementation/","asOf":"2026-09-08","days":13},{"id":"idea-reg-recovery-style-platform-repurposing","kind":"idea","name":"A RECOVERY-style permanent platform trial of cheap drugs added to cancer care","route":"/ideas/idea-reg-recovery-style-platform-repurposing/","asOf":"2026-09-08","days":13},{"id":"idea-reg-perioperative-propranolol-etodolac","kind":"idea","name":"Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery","route":"/ideas/idea-reg-perioperative-propranolol-etodolac/","asOf":"2026-09-08","days":13},{"id":"idea-reg-statin-hcc-prevention-trial","kind":"idea","name":"A pragmatic trial of statins to prevent liver cancer in people with cirrhosis","route":"/ideas/idea-reg-statin-hcc-prevention-trial/","asOf":"2026-09-08","days":13},{"id":"idea-reg-evidence-gate-before-repurposing-phase3","kind":"idea","name":"Require genetic and target-trial evidence before funding any repurposing phase 3","route":"/ideas/idea-reg-evidence-gate-before-repurposing-phase3/","asOf":"2026-09-08","days":13},{"id":"idea-reg-target-trial-emulation-pipeline","kind":"idea","name":"An automated pipeline emulating trials of every common drug against every cancer","route":"/ideas/idea-reg-target-trial-emulation-pipeline/","asOf":"2026-09-08","days":13},{"id":"idea-reg-new-indication-exclusivity-off-patent","kind":"idea","name":"Three years of indication-specific exclusivity for proving a new cancer use of an old drug","route":"/ideas/idea-reg-new-indication-exclusivity-off-patent/","asOf":"2026-09-08","days":13},{"id":"idea-reg-delinked-market-entry-reward","kind":"idea","name":"A delinked market-entry reward paid by payers when a repurposed generic wins approval","route":"/ideas/idea-reg-delinked-market-entry-reward/","asOf":"2026-09-08","days":13},{"id":"idea-reg-generic-targeted-therapy-drup","kind":"idea","name":"A DRUP-style protocol for off-label generic targeted drugs in rare tumours","route":"/ideas/idea-reg-generic-targeted-therapy-drup/","asOf":"2026-09-08","days":13},{"id":"idea-reg-antihistamine-plus-io-trial","kind":"idea","name":"Randomise a cheap antihistamine alongside immunotherapy","route":"/ideas/idea-reg-antihistamine-plus-io-trial/","asOf":"2026-09-08","days":13},{"id":"idea-reg-vitamin-d-digestive-cancer-biomarker-trial","kind":"idea","name":"A biomarker-directed trial of vitamin D after surgery for digestive tract cancers","route":"/ideas/idea-reg-vitamin-d-digestive-cancer-biomarker-trial/","asOf":"2026-09-08","days":13},{"id":"idea-reg-losartan-pancreatic-stroma","kind":"idea","name":"Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3","route":"/ideas/idea-reg-losartan-pancreatic-stroma/","asOf":"2026-09-08","days":13},{"id":"idea-reg-regulator-ready-repurposing-dossiers","kind":"idea","name":"Fund regulator-ready evidence dossiers for the 20 best-supported off-patent drugs","route":"/ideas/idea-reg-regulator-ready-repurposing-dossiers/","asOf":"2026-09-08","days":13},{"id":"idea-reg-guideline-fast-track-repurposed","kind":"idea","name":"A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer","route":"/ideas/idea-reg-guideline-fast-track-repurposed/","asOf":"2026-09-08","days":13},{"id":"idea-reg-payer-coverage-off-label-generic-commitment","kind":"idea","name":"Payers pre-commit to cover off-label generics when a definitive trial is positive","route":"/ideas/idea-reg-payer-coverage-off-label-generic-commitment/","asOf":"2026-09-08","days":13},{"id":"idea-reg-nonprofit-marketing-authorisation-holder","kind":"idea","name":"A non-profit company to hold marketing authorisations for repurposed cancer drugs","route":"/ideas/idea-reg-nonprofit-marketing-authorisation-holder/","asOf":"2026-09-08","days":13},{"id":"idea-reg-metronomic-lmic-phase3-to-label","kind":"idea","name":"Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines","route":"/ideas/idea-reg-metronomic-lmic-phase3-to-label/","asOf":"2026-09-08","days":13},{"id":"idea-reg-generic-chemo-strategic-reserve","kind":"idea","name":"A strategic reserve of essential generic cancer drugs to end recurring shortages","route":"/ideas/idea-reg-generic-chemo-strategic-reserve/","asOf":"2026-09-08","days":13},{"id":"idea-reg-factorial-addon-arms-cooperative-trials","kind":"idea","name":"Add a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial","route":"/ideas/idea-reg-factorial-addon-arms-cooperative-trials/","asOf":"2026-09-08","days":13},{"id":"idea-reg-olanzapine-cachexia-global-confirmation","kind":"idea","name":"Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide","route":"/ideas/idea-reg-olanzapine-cachexia-global-confirmation/","asOf":"2026-09-08","days":13},{"id":"idea-reg-preregistered-ai-repurposing-scoring","kind":"idea","name":"Pre-registered, publicly scored AI ranking of repurposing candidates for cancer","route":"/ideas/idea-reg-preregistered-ai-repurposing-scoring/","asOf":"2026-09-08","days":13},{"id":"idea-acc-open-hardware-linac","kind":"idea","name":"An open-hardware radiotherapy machine built for unreliable power and dust","route":"/ideas/idea-acc-open-hardware-linac/","asOf":"2026-09-08","days":13},{"id":"idea-acc-linac-uptime-contracts","kind":"idea","name":"Pay for radiotherapy machine uptime, not for the machine","route":"/ideas/idea-acc-linac-uptime-contracts/","asOf":"2026-09-08","days":13},{"id":"idea-acc-hypofractionation-default-lmic","kind":"idea","name":"Make one-week radiotherapy the default in overloaded systems","route":"/ideas/idea-acc-hypofractionation-default-lmic/","asOf":"2026-09-08","days":13},{"id":"idea-acc-remote-planning-hubs","kind":"idea","name":"Round-the-clock remote treatment-planning hubs for clinics without physicists","route":"/ideas/idea-acc-remote-planning-hubs/","asOf":"2026-09-08","days":13},{"id":"idea-acc-modern-cobalt-bridge","kind":"idea","name":"Modernised cobalt-60 machines as a deliberate bridge where linacs cannot be kept running","route":"/ideas/idea-acc-modern-cobalt-bridge/","asOf":"2026-09-08","days":13},{"id":"idea-acc-pooled-procurement-radiotherapy","kind":"idea","name":"A Gavi-style pooled purchaser for radiotherapy equipment and service","route":"/ideas/idea-acc-pooled-procurement-radiotherapy/","asOf":"2026-09-08","days":13},{"id":"idea-acc-telepathology-district-network","kind":"idea","name":"Slide scanners in district hospitals wired to pathologists anywhere","route":"/ideas/idea-acc-telepathology-district-network/","asOf":"2026-09-08","days":13},{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/","asOf":"2026-09-08","days":13},{"id":"idea-acc-nurse-led-chemotherapy-units","kind":"idea","name":"Nurse-led chemotherapy day units with a doctor on a screen","route":"/ideas/idea-acc-nurse-led-chemotherapy-units/","asOf":"2026-09-08","days":13},{"id":"idea-acc-eml-listing-price-commitments","kind":"idea","name":"Tie WHO essential-medicines listing to a published tiered price and supply pledge","route":"/ideas/idea-acc-eml-listing-price-commitments/","asOf":"2026-09-08","days":13},{"id":"idea-acc-biosimilar-prequalification-pool","kind":"idea","name":"WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator","route":"/ideas/idea-acc-biosimilar-prequalification-pool/","asOf":"2026-09-08","days":13},{"id":"idea-acc-chemo-stockout-early-warning","kind":"idea","name":"A live stock-out map for essential chemotherapy drugs","route":"/ideas/idea-acc-chemo-stockout-early-warning/","asOf":"2026-09-08","days":13},{"id":"idea-acc-childhood-medicines-platform-scale","kind":"idea","name":"Guaranteed-quality childhood cancer medicines free of charge in 50 countries","route":"/ideas/idea-acc-childhood-medicines-platform-scale/","asOf":"2026-09-08","days":13},{"id":"idea-acc-hub-spoke-national-networks","kind":"idea","name":"National hub-and-spoke cancer networks with defined referral tiers","route":"/ideas/idea-acc-hub-spoke-national-networks/","asOf":"2026-09-08","days":13},{"id":"idea-acc-mobile-see-and-treat-units","kind":"idea","name":"Mobile diagnostic units that biopsy, scan and treat on the same visit","route":"/ideas/idea-acc-mobile-see-and-treat-units/","asOf":"2026-09-08","days":13},{"id":"idea-acc-hpv-self-sample-same-day-ablation","kind":"idea","name":"HPV self-testing with same-day treatment as the national cervical programme","route":"/ideas/idea-acc-hpv-self-sample-same-day-ablation/","asOf":"2026-09-08","days":13},{"id":"idea-acc-gbci-country-dashboards","kind":"idea","name":"Public country dashboards for the three WHO breast cancer targets","route":"/ideas/idea-acc-gbci-country-dashboards/","asOf":"2026-09-08","days":13},{"id":"idea-acc-infusion-sparing-regimens","kind":"idea","name":"Choose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint","route":"/ideas/idea-acc-infusion-sparing-regimens/","asOf":"2026-09-08","days":13},{"id":"idea-acc-metronomic-lmic-platform-trial","kind":"idea","name":"A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers","route":"/ideas/idea-acc-metronomic-lmic-platform-trial/","asOf":"2026-09-08","days":13},{"id":"idea-acc-global-cancer-financing-window","kind":"idea","name":"A dedicated global financing window for cancer, modelled on the Global Fund","route":"/ideas/idea-acc-global-cancer-financing-window/","asOf":"2026-09-08","days":13},{"id":"idea-acc-frugal-hdr-brachytherapy","kind":"idea","name":"Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre","route":"/ideas/idea-acc-frugal-hdr-brachytherapy/","asOf":"2026-09-08","days":13},{"id":"idea-acc-registries-as-aid-condition","kind":"idea","name":"Make a population cancer registry a condition of every cancer aid programme","route":"/ideas/idea-acc-registries-as-aid-condition/","asOf":"2026-09-08","days":13},{"id":"idea-acc-abandonment-stipends","kind":"idea","name":"Cash for transport and food to stop families abandoning curative treatment","route":"/ideas/idea-acc-abandonment-stipends/","asOf":"2026-09-08","days":13},{"id":"idea-acc-diaspora-tele-tumour-boards","kind":"idea","name":"Credentialed diaspora oncologists staffing remote tumour boards for home-country hospitals","route":"/ideas/idea-acc-diaspora-tele-tumour-boards/","asOf":"2026-09-08","days":13},{"id":"idea-acc-solar-microgrids-for-cancer-units","kind":"idea","name":"Solar microgrids so radiotherapy, pathology and drug fridges never lose power","route":"/ideas/idea-acc-solar-microgrids-for-cancer-units/","asOf":"2026-09-08","days":13},{"id":"idea-acc-clinical-officer-oncology-track","kind":"idea","name":"An 18-month oncology track for clinical officers and physician associates","route":"/ideas/idea-acc-clinical-officer-oncology-track/","asOf":"2026-09-08","days":13},{"id":"idea-acc-oncology-pharmacist-prescribing","kind":"idea","name":"Oncology pharmacists as protocol prescribers for supportive care and dose adjustments","route":"/ideas/idea-acc-oncology-pharmacist-prescribing/","asOf":"2026-09-08","days":13},{"id":"idea-acc-remote-medical-physics-qa","kind":"idea","name":"One medical physicist covering many radiotherapy machines through remote quality assurance","route":"/ideas/idea-acc-remote-medical-physics-qa/","asOf":"2026-09-08","days":13},{"id":"idea-acc-echo-tele-mentoring-oncology","kind":"idea","name":"Project ECHO tele-mentoring for district clinicians managing cancer","route":"/ideas/idea-acc-echo-tele-mentoring-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-acc-retention-packages-oncology","kind":"idea","name":"Retention packages so trained oncology staff stay: bonds, top-ups, working equipment","route":"/ideas/idea-acc-retention-packages-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-acc-regional-oncology-training-hubs","kind":"idea","name":"Regional training hubs that produce oncologists, physicists and radiographers in-region","route":"/ideas/idea-acc-regional-oncology-training-hubs/","asOf":"2026-09-08","days":13},{"id":"idea-acc-ambient-ai-documentation-oncology","kind":"idea","name":"Ambient AI note-taking to give oncologists back a day a week","route":"/ideas/idea-acc-ambient-ai-documentation-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-acc-advanced-practice-radiation-therapists","kind":"idea","name":"Advanced-practice radiation therapists doing contouring and on-treatment reviews","route":"/ideas/idea-acc-advanced-practice-radiation-therapists/","asOf":"2026-09-08","days":13},{"id":"idea-acc-nurse-led-follow-up-clinics","kind":"idea","name":"Nurse-led follow-up clinics for survivors, freeing oncologists for active treatment","route":"/ideas/idea-acc-nurse-led-follow-up-clinics/","asOf":"2026-09-08","days":13},{"id":"idea-acc-pathologist-assistants-and-ai-triage","kind":"idea","name":"Pathologist assistants plus AI triage to multiply pathologist capacity","route":"/ideas/idea-acc-pathologist-assistants-and-ai-triage/","asOf":"2026-09-08","days":13},{"id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","asOf":"2026-09-08","days":13},{"id":"idea-acc-fast-track-relicensing-oncologists","kind":"idea","name":"Fast-track relicensing for refugee, migrant and returning oncology professionals","route":"/ideas/idea-acc-fast-track-relicensing-oncologists/","asOf":"2026-09-08","days":13},{"id":"idea-acc-mainstream-tele-genetic-counselling","kind":"idea","name":"Oncology teams order germline tests; tele-genetic counsellors handle the results","route":"/ideas/idea-acc-mainstream-tele-genetic-counselling/","asOf":"2026-09-08","days":13},{"id":"idea-acc-community-health-workers-oncology","kind":"idea","name":"Community health workers trained in cancer triage, navigation and home palliative care","route":"/ideas/idea-acc-community-health-workers-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-acc-district-surgeon-oncology-mentorship","kind":"idea","name":"Structured mentorship so district general surgeons perform common cancer operations safely","route":"/ideas/idea-acc-district-surgeon-oncology-mentorship/","asOf":"2026-09-08","days":13},{"id":"idea-acc-one-stop-breast-diagnostic-clinic","kind":"idea","name":"One-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit","route":"/ideas/idea-acc-one-stop-breast-diagnostic-clinic/","asOf":"2026-09-08","days":13},{"id":"idea-acc-28-day-diagnosis-standard","kind":"idea","name":"A legislated, publicly reported 28-day standard from urgent referral to diagnosis","route":"/ideas/idea-acc-28-day-diagnosis-standard/","asOf":"2026-09-08","days":13},{"id":"idea-acc-funded-navigator-per-diagnosis","kind":"idea","name":"A paid patient navigator for every new cancer diagnosis, reimbursed as a service","route":"/ideas/idea-acc-funded-navigator-per-diagnosis/","asOf":"2026-09-08","days":13},{"id":"idea-acc-reflex-genomic-profiling-at-diagnosis","kind":"idea","name":"Pathologists order genomic profiling automatically at diagnosis of advanced cancer","route":"/ideas/idea-acc-reflex-genomic-profiling-at-diagnosis/","asOf":"2026-09-08","days":13},{"id":"idea-acc-guideline-concordance-dashboards","kind":"idea","name":"Live guideline-concordance dashboards for every tumour board, generated from the record","route":"/ideas/idea-acc-guideline-concordance-dashboards/","asOf":"2026-09-08","days":13},{"id":"idea-acc-national-virtual-mdt-rare-complex","kind":"idea","name":"Mandatory national virtual tumour boards for rare and complex cancers","route":"/ideas/idea-acc-national-virtual-mdt-rare-complex/","asOf":"2026-09-08","days":13},{"id":"idea-acc-portable-treatment-summary","kind":"idea","name":"A machine-readable treatment summary handed to every patient and readable by any hospital","route":"/ideas/idea-acc-portable-treatment-summary/","asOf":"2026-09-08","days":13},{"id":"idea-acc-primary-care-shared-care-agreements","kind":"idea","name":"Formal shared-care agreements between oncology and family doctors, with same-day e-consult","route":"/ideas/idea-acc-primary-care-shared-care-agreements/","asOf":"2026-09-08","days":13},{"id":"idea-acc-electronic-pro-monitoring-standard","kind":"idea","name":"Weekly electronic symptom reporting as a standard of care during systemic therapy","route":"/ideas/idea-acc-electronic-pro-monitoring-standard/","asOf":"2026-09-08","days":13},{"id":"idea-acc-tumour-board-implementation-audit","kind":"idea","name":"Audit whether tumour board recommendations were actually carried out","route":"/ideas/idea-acc-tumour-board-implementation-audit/","asOf":"2026-09-08","days":13},{"id":"idea-acc-acute-oncology-assessment-units","kind":"idea","name":"Acute oncology assessment units so sick cancer patients bypass the emergency department","route":"/ideas/idea-acc-acute-oncology-assessment-units/","asOf":"2026-09-08","days":13},{"id":"idea-acc-diagnostic-interval-public-registry","kind":"idea","name":"Record and publish the symptom-to-diagnosis interval for every cancer, by hospital","route":"/ideas/idea-acc-diagnostic-interval-public-registry/","asOf":"2026-09-08","days":13},{"id":"idea-acc-reflex-biomarker-panels-by-tumour","kind":"idea","name":"Standing reflex biomarker panels per tumour type, run without an oncologist's order","route":"/ideas/idea-acc-reflex-biomarker-panels-by-tumour/","asOf":"2026-09-08","days":13},{"id":"idea-acc-rapid-diagnostic-centres-vague-symptoms","kind":"idea","name":"Rapid diagnostic centres for people with vague but worrying symptoms","route":"/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/","asOf":"2026-09-08","days":13},{"id":"idea-acc-embedded-decision-aids","kind":"idea","name":"Decision aids built into the record for every preference-sensitive cancer choice","route":"/ideas/idea-acc-embedded-decision-aids/","asOf":"2026-09-08","days":13},{"id":"idea-acc-financial-toxicity-screening-at-diagnosis","kind":"idea","name":"Screen every patient for financial hardship at diagnosis and connect them to help","route":"/ideas/idea-acc-financial-toxicity-screening-at-diagnosis/","asOf":"2026-09-08","days":13},{"id":"idea-acc-universal-asynchronous-second-opinion","kind":"idea","name":"An asynchronous expert second opinion for every new advanced-cancer diagnosis","route":"/ideas/idea-acc-universal-asynchronous-second-opinion/","asOf":"2026-09-08","days":13},{"id":"idea-acc-episode-payment-tied-to-concordance","kind":"idea","name":"Bundled episode payments for cancer care with bonuses for guideline concordance","route":"/ideas/idea-acc-episode-payment-tied-to-concordance/","asOf":"2026-09-08","days":13},{"id":"idea-acc-transition-handoff-medication-reconciliation","kind":"idea","name":"A standard handoff with medication reconciliation at every cancer care transition","route":"/ideas/idea-acc-transition-handoff-medication-reconciliation/","asOf":"2026-09-08","days":13},{"id":"idea-acc-pathway-capacity-simulation","kind":"idea","name":"Simulate each hospital's cancer pathway as a queue to find and remove the waits","route":"/ideas/idea-acc-pathway-capacity-simulation/","asOf":"2026-09-08","days":13},{"id":"idea-acc-auto-generated-survivorship-plans","kind":"idea","name":"Survivorship care plans generated automatically from the treatment record","route":"/ideas/idea-acc-auto-generated-survivorship-plans/","asOf":"2026-09-08","days":13},{"id":"idea-acc-risk-stratified-cardio-oncology-pathway","kind":"idea","name":"A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy","route":"/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-acc-default-fertility-preservation-referral","kind":"idea","name":"Default fertility preservation referral for every patient under 40 before treatment","route":"/ideas/idea-acc-default-fertility-preservation-referral/","asOf":"2026-09-08","days":13},{"id":"idea-acc-national-late-effects-registry","kind":"idea","name":"A national late-effects registry linking treatment exposures to outcomes decades later","route":"/ideas/idea-acc-national-late-effects-registry/","asOf":"2026-09-08","days":13},{"id":"idea-acc-risk-stratified-follow-up","kind":"idea","name":"Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry","route":"/ideas/idea-acc-risk-stratified-follow-up/","asOf":"2026-09-08","days":13},{"id":"idea-acc-tailored-second-cancer-screening","kind":"idea","name":"Tailored screening for second cancers in survivors with known high-risk exposures","route":"/ideas/idea-acc-tailored-second-cancer-screening/","asOf":"2026-09-08","days":13},{"id":"idea-acc-return-to-work-rehabilitation","kind":"idea","name":"Vocational rehabilitation integrated into cancer care so survivors can return to work","route":"/ideas/idea-acc-return-to-work-rehabilitation/","asOf":"2026-09-08","days":13},{"id":"idea-acc-cognitive-rehabilitation-after-chemotherapy","kind":"idea","name":"Trials of structured cognitive rehabilitation for cancer-related cognitive impairment","route":"/ideas/idea-acc-cognitive-rehabilitation-after-chemotherapy/","asOf":"2026-09-08","days":13},{"id":"idea-acc-cardiometabolic-clinic-hormone-therapy","kind":"idea","name":"Cardiometabolic screening and treatment for survivors on long-term hormone therapy","route":"/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/","asOf":"2026-09-08","days":13},{"id":"idea-acc-aya-survivorship-passport","kind":"idea","name":"A survivorship passport app for adolescent and young adult survivors","route":"/ideas/idea-acc-aya-survivorship-passport/","asOf":"2026-09-08","days":13},{"id":"idea-acc-survivor-biobank-late-effect-prediction","kind":"idea","name":"A survivor biobank to find who will develop late effects before they do","route":"/ideas/idea-acc-survivor-biobank-late-effect-prediction/","asOf":"2026-09-08","days":13},{"id":"idea-acc-lymphoedema-prospective-surveillance","kind":"idea","name":"Prospective arm-volume surveillance to catch and reverse lymphoedema early","route":"/ideas/idea-acc-lymphoedema-prospective-surveillance/","asOf":"2026-09-08","days":13},{"id":"idea-acc-automatic-early-palliative-triggers","kind":"idea","name":"Automatic palliative care referral triggered by diagnosis, not by decline","route":"/ideas/idea-acc-automatic-early-palliative-triggers/","asOf":"2026-09-08","days":13},{"id":"idea-acc-balanced-opioid-policy-reform","kind":"idea","name":"National opioid quota reform so morphine reaches cancer patients","route":"/ideas/idea-acc-balanced-opioid-policy-reform/","asOf":"2026-09-08","days":13},{"id":"idea-acc-local-oral-morphine-production","kind":"idea","name":"Locally prepared oral morphine solution, licensed for nurse prescribing","route":"/ideas/idea-acc-local-oral-morphine-production/","asOf":"2026-09-08","days":13},{"id":"idea-acc-neighbourhood-palliative-networks","kind":"idea","name":"Volunteer-led neighbourhood palliative networks, the Kerala model, adapted elsewhere","route":"/ideas/idea-acc-neighbourhood-palliative-networks/","asOf":"2026-09-08","days":13},{"id":"idea-acc-tele-palliative-care-default","kind":"idea","name":"Video palliative care as an equivalent default option for patients far from a team","route":"/ideas/idea-acc-tele-palliative-care-default/","asOf":"2026-09-08","days":13},{"id":"idea-acc-earmarked-palliative-budget-share","kind":"idea","name":"Earmark a fixed share of every national cancer budget for palliative care","route":"/ideas/idea-acc-earmarked-palliative-budget-share/","asOf":"2026-09-08","days":13},{"id":"idea-acc-pain-control-public-audit","kind":"idea","name":"Measure and publish pain control rates in every cancer centre","route":"/ideas/idea-acc-pain-control-public-audit/","asOf":"2026-09-08","days":13},{"id":"idea-acc-serious-illness-conversation-prompts","kind":"idea","name":"Train every oncology team in serious-illness conversations and prompt them in the record","route":"/ideas/idea-acc-serious-illness-conversation-prompts/","asOf":"2026-09-08","days":13},{"id":"idea-acc-single-fraction-palliative-radiotherapy-default","kind":"idea","name":"Single-fraction radiotherapy as the default for painful bone metastases","route":"/ideas/idea-acc-single-fraction-palliative-radiotherapy-default/","asOf":"2026-09-08","days":13},{"id":"idea-acc-essential-palliative-package-in-uhc","kind":"idea","name":"Put the essential palliative care package into every universal health coverage benefit list","route":"/ideas/idea-acc-essential-palliative-package-in-uhc/","asOf":"2026-09-08","days":13},{"id":"idea-acc-paediatric-palliative-in-every-childhood-unit","kind":"idea","name":"A paediatric palliative care team in every childhood cancer unit","route":"/ideas/idea-acc-paediatric-palliative-in-every-childhood-unit/","asOf":"2026-09-08","days":13},{"id":"idea-acc-home-based-end-of-life-kits","kind":"idea","name":"Home end-of-life care kits and trained family carers where no hospice exists","route":"/ideas/idea-acc-home-based-end-of-life-kits/","asOf":"2026-09-08","days":13},{"id":"idea-acc-methadone-and-alternatives-where-morphine-fails","kind":"idea","name":"Trials of low-cost opioid alternatives where morphine supply is unreliable","route":"/ideas/idea-acc-methadone-and-alternatives-where-morphine-fails/","asOf":"2026-09-08","days":13},{"id":"idea-acc-geriatric-assessment-by-default","kind":"idea","name":"Geriatric assessment by default for every patient over 70 starting cancer treatment","route":"/ideas/idea-acc-geriatric-assessment-by-default/","asOf":"2026-09-08","days":13},{"id":"idea-acc-broad-eligibility-as-regulatory-default","kind":"idea","name":"Make sponsors justify every trial exclusion of older and multimorbid patients","route":"/ideas/idea-acc-broad-eligibility-as-regulatory-default/","asOf":"2026-09-08","days":13},{"id":"idea-acc-pragmatic-trials-over-75-function-endpoints","kind":"idea","name":"Pragmatic trials in patients over 75 with function, not just survival, as the primary endpoint","route":"/ideas/idea-acc-pragmatic-trials-over-75-function-endpoints/","asOf":"2026-09-08","days":13},{"id":"idea-acc-structured-deprescribing-at-diagnosis","kind":"idea","name":"Structured deprescribing review at cancer diagnosis and again at transition to palliative care","route":"/ideas/idea-acc-structured-deprescribing-at-diagnosis/","asOf":"2026-09-08","days":13},{"id":"idea-acc-home-chemotherapy-older-patients","kind":"idea","name":"Home administration of selected chemotherapy and immunotherapy for older and frail patients","route":"/ideas/idea-acc-home-chemotherapy-older-patients/","asOf":"2026-09-08","days":13},{"id":"idea-acc-hospital-at-home-oncology","kind":"idea","name":"Hospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home","route":"/ideas/idea-acc-hospital-at-home-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-acc-upfront-reduced-dose-trials-frail","kind":"idea","name":"Upfront reduced-dose regimens tested head-to-head in frail older patients","route":"/ideas/idea-acc-upfront-reduced-dose-trials-frail/","asOf":"2026-09-08","days":13},{"id":"idea-acc-electronic-frailty-index-oncology","kind":"idea","name":"An automatic electronic frailty index inside the oncology record","route":"/ideas/idea-acc-electronic-frailty-index-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-acc-geriatric-co-management-surgery","kind":"idea","name":"Geriatrician co-management for older patients having cancer surgery","route":"/ideas/idea-acc-geriatric-co-management-surgery/","asOf":"2026-09-08","days":13},{"id":"idea-acc-post-approval-evidence-over-75","kind":"idea","name":"Require post-approval evidence in patients over 75 and update labels accordingly","route":"/ideas/idea-acc-post-approval-evidence-over-75/","asOf":"2026-09-08","days":13},{"id":"idea-acc-caregiver-training-as-covered-service","kind":"idea","name":"Caregiver training and respite as a covered service in cancer care for older patients","route":"/ideas/idea-acc-caregiver-training-as-covered-service/","asOf":"2026-09-08","days":13},{"id":"idea-acc-pharmacist-interaction-review-oral-anticancer","kind":"idea","name":"Pharmacist interaction check before every oral cancer-drug prescription","route":"/ideas/idea-acc-pharmacist-interaction-review-oral-anticancer/","asOf":"2026-09-08","days":13},{"id":"idea-acc-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days spent in healthcare, as a standard outcome for older patients","route":"/ideas/idea-acc-time-toxicity-reporting/","asOf":"2026-09-08","days":13},{"id":"idea-acc-prehabilitation-older-surgery","kind":"idea","name":"Multimodal prehabilitation for older patients before major cancer surgery","route":"/ideas/idea-acc-prehabilitation-older-surgery/","asOf":"2026-09-08","days":13},{"id":"idea-acc-dementia-and-cancer-pathway","kind":"idea","name":"A defined pathway for patients with both dementia and cancer","route":"/ideas/idea-acc-dementia-and-cancer-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-data-mcode-payment-condition","kind":"idea","name":"No mCODE, no payment: tie oncology reimbursement to a minimal structured record","route":"/ideas/idea-data-mcode-payment-condition/","asOf":"2026-09-08","days":13},{"id":"idea-data-oncology-api-certification","kind":"idea","name":"Certify every oncology software product for a standard bulk data export","route":"/ideas/idea-data-oncology-api-certification/","asOf":"2026-09-08","days":13},{"id":"idea-data-national-cancer-data-space","kind":"idea","name":"A national cancer data space with one legal front door","route":"/ideas/idea-data-national-cancer-data-space/","asOf":"2026-09-08","days":13},{"id":"idea-data-federated-analytics-network","kind":"idea","name":"Send the code to the data: a federated analytics network of cancer centres","route":"/ideas/idea-data-federated-analytics-network/","asOf":"2026-09-08","days":13},{"id":"idea-data-federated-learning-imaging","kind":"idea","name":"Federated training of pathology and radiology models across hospitals","route":"/ideas/idea-data-federated-learning-imaging/","asOf":"2026-09-08","days":13},{"id":"idea-data-donor-card","kind":"idea","name":"A cancer data donor card: patient-controlled donation of records for research","route":"/ideas/idea-data-donor-card/","asOf":"2026-09-08","days":13},{"id":"idea-data-dynamic-consent-app","kind":"idea","name":"Dynamic consent with usage receipts","route":"/ideas/idea-data-dynamic-consent-app/","asOf":"2026-09-08","days":13},{"id":"idea-data-consent-in-the-pathway","kind":"idea","name":"Broad research consent as a routine step of the cancer pathway","route":"/ideas/idea-data-consent-in-the-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-data-accredited-tre-network","kind":"idea","name":"Accredited trusted research environments with curated cancer tables","route":"/ideas/idea-data-accredited-tre-network/","asOf":"2026-09-08","days":13},{"id":"idea-data-synthetic-companion-datasets","kind":"idea","name":"A synthetic twin of every restricted cancer dataset for code development","route":"/ideas/idea-data-synthetic-companion-datasets/","asOf":"2026-09-08","days":13},{"id":"idea-data-open-deidentification-pipeline","kind":"idea","name":"One certified open-source de-identification pipeline for scans and slides","route":"/ideas/idea-data-open-deidentification-pipeline/","asOf":"2026-09-08","days":13},{"id":"idea-data-national-slide-archive","kind":"idea","name":"Digitise the nation's pathology slides and link them to outcomes","route":"/ideas/idea-data-national-slide-archive/","asOf":"2026-09-08","days":13},{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/","asOf":"2026-09-08","days":13},{"id":"idea-data-automatic-outcome-linkage","kind":"idea","name":"Automatic weekly linkage of cancer registries to deaths, prescriptions and imaging","route":"/ideas/idea-data-automatic-outcome-linkage/","asOf":"2026-09-08","days":13},{"id":"idea-data-pro-as-structured-standard","kind":"idea","name":"Patient-reported symptoms captured as standard structured data in every clinic","route":"/ideas/idea-data-pro-as-structured-standard/","asOf":"2026-09-08","days":13},{"id":"idea-data-open-line-of-therapy-algorithms","kind":"idea","name":"Open, benchmarked algorithms for lines of therapy and progression from routine data","route":"/ideas/idea-data-open-line-of-therapy-algorithms/","asOf":"2026-09-08","days":13},{"id":"idea-data-point-of-care-randomisation","kind":"idea","name":"Point-of-care randomisation built into the oncology record","route":"/ideas/idea-data-point-of-care-randomisation/","asOf":"2026-09-08","days":13},{"id":"idea-data-procurement-open-api-clauses","kind":"idea","name":"Public procurement clauses banning data export fees and lock-in","route":"/ideas/idea-data-procurement-open-api-clauses/","asOf":"2026-09-08","days":13},{"id":"idea-data-privacy-preserving-linkage-tokens","kind":"idea","name":"Privacy-preserving linkage tokens for every cancer data holder","route":"/ideas/idea-data-privacy-preserving-linkage-tokens/","asOf":"2026-09-08","days":13},{"id":"idea-data-registry-in-a-box","kind":"idea","name":"Open-source cancer registry-in-a-box for low-resource settings","route":"/ideas/idea-data-registry-in-a-box/","asOf":"2026-09-08","days":13},{"id":"idea-data-trial-to-registry-bridge","kind":"idea","name":"Map trial case report forms to the registry standard so trial and routine data join","route":"/ideas/idea-data-trial-to-registry-bridge/","asOf":"2026-09-08","days":13},{"id":"idea-data-atlas-to-outcome-linkage","kind":"idea","name":"Link single-cell and spatial tumour atlases to clinical outcomes","route":"/ideas/idea-data-atlas-to-outcome-linkage/","asOf":"2026-09-08","days":13},{"id":"idea-data-radiotherapy-dose-repository","kind":"idea","name":"A national repository of radiotherapy dose plans linked to outcomes","route":"/ideas/idea-data-radiotherapy-dose-repository/","asOf":"2026-09-08","days":13},{"id":"idea-data-surgical-video-commons","kind":"idea","name":"A consented commons of surgical video linked to pathology and outcomes","route":"/ideas/idea-data-surgical-video-commons/","asOf":"2026-09-08","days":13},{"id":"idea-data-ipd-deposit-enforcement","kind":"idea","name":"Enforce individual participant data sharing as a condition of publication and funding","route":"/ideas/idea-data-ipd-deposit-enforcement/","asOf":"2026-09-08","days":13},{"id":"idea-data-common-biobank-consent-mta","kind":"idea","name":"A common consent and material transfer template for tumour biobanks","route":"/ideas/idea-data-common-biobank-consent-mta/","asOf":"2026-09-08","days":13},{"id":"idea-data-patient-held-cancer-record","kind":"idea","name":"A patient-held cancer record that travels across providers and borders","route":"/ideas/idea-data-patient-held-cancer-record/","asOf":"2026-09-08","days":13},{"id":"idea-data-cross-border-rare-cancer-pool","kind":"idea","name":"One legal framework for pooling rare cancer data across borders","route":"/ideas/idea-data-cross-border-rare-cancer-pool/","asOf":"2026-09-08","days":13},{"id":"idea-data-quality-scorecards","kind":"idea","name":"Public data-quality scorecards for every cancer centre","route":"/ideas/idea-data-quality-scorecards/","asOf":"2026-09-08","days":13},{"id":"idea-data-structured-radiology-response","kind":"idea","name":"Structured, coded radiology reports for cancer response instead of free text","route":"/ideas/idea-data-structured-radiology-response/","asOf":"2026-09-08","days":13},{"id":"idea-data-target-trial-emulation-standard","kind":"idea","name":"A pre-registered standard for emulating trials with real-world data","route":"/ideas/idea-data-target-trial-emulation-standard/","asOf":"2026-09-08","days":13},{"id":"idea-data-rwe-rct-calibration-library","kind":"idea","name":"An open library pairing completed cancer trials with real-world emulations","route":"/ideas/idea-data-rwe-rct-calibration-library/","asOf":"2026-09-08","days":13},{"id":"idea-data-accelerated-approval-registry-condition","kind":"idea","name":"Every patient on an accelerated-approval drug enrolled in a registry until confirmation","route":"/ideas/idea-data-accelerated-approval-registry-condition/","asOf":"2026-09-08","days":13},{"id":"idea-data-rwpfs-validation-programme","kind":"idea","name":"Validate real-world progression against central imaging review","route":"/ideas/idea-data-rwpfs-validation-programme/","asOf":"2026-09-08","days":13},{"id":"idea-data-registry-based-rcts","kind":"idea","name":"Registry-based randomised trials for oncology comparative effectiveness","route":"/ideas/idea-data-registry-based-rcts/","asOf":"2026-09-08","days":13},{"id":"idea-data-coverage-with-evidence-development","kind":"idea","name":"Payers fund cancer drugs conditionally on a registry with a pre-specified analysis","route":"/ideas/idea-data-coverage-with-evidence-development/","asOf":"2026-09-08","days":13},{"id":"idea-data-off-label-outcomes-registry","kind":"idea","name":"A structured registry for every off-label cancer drug use","route":"/ideas/idea-data-off-label-outcomes-registry/","asOf":"2026-09-08","days":13},{"id":"idea-data-real-world-dose-intensity","kind":"idea","name":"Real-world dose intensity and toxicity monitoring to revise labelled doses","route":"/ideas/idea-data-real-world-dose-intensity/","asOf":"2026-09-08","days":13},{"id":"idea-data-excluded-populations-rwe-mandate","kind":"idea","name":"Mandatory real-world reporting for patients excluded from pivotal trials","route":"/ideas/idea-data-excluded-populations-rwe-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-data-linked-pharmacovigilance-interactions","kind":"idea","name":"Linked prescribing and outcome data to find drug interactions with cancer therapy","route":"/ideas/idea-data-linked-pharmacovigilance-interactions/","asOf":"2026-09-08","days":13},{"id":"idea-data-access-programme-outcomes","kind":"idea","name":"One outcome record for every donated or discounted cancer drug pack","route":"/ideas/idea-data-access-programme-outcomes/","asOf":"2026-09-08","days":13},{"id":"idea-data-registry-genomics-linkage-programme","kind":"idea","name":"Link every national cancer registry to tumour genomics","route":"/ideas/idea-data-registry-genomics-linkage-programme/","asOf":"2026-09-08","days":13},{"id":"idea-data-observational-study-registration","kind":"idea","name":"Pre-registration and results reporting for real-world cancer studies","route":"/ideas/idea-data-observational-study-registration/","asOf":"2026-09-08","days":13},{"id":"idea-data-gcp-for-real-world-data","kind":"idea","name":"Good practice standards and inspection for real-world data sources","route":"/ideas/idea-data-gcp-for-real-world-data/","asOf":"2026-09-08","days":13},{"id":"idea-data-registry-follow-up-of-trial-participants","kind":"idea","name":"Follow every trial participant for 30 years through registry linkage","route":"/ideas/idea-data-registry-follow-up-of-trial-participants/","asOf":"2026-09-08","days":13},{"id":"idea-data-wearable-endpoints-validation","kind":"idea","name":"Wearable activity data as a validated real-world endpoint","route":"/ideas/idea-data-wearable-endpoints-validation/","asOf":"2026-09-08","days":13},{"id":"idea-data-external-control-arm-standard","kind":"idea","name":"Standards for external control arms built from federated real-world data","route":"/ideas/idea-data-external-control-arm-standard/","asOf":"2026-09-08","days":13},{"id":"idea-data-paediatric-rwe-consortium","kind":"idea","name":"An international consortium pooling the outcome of every treated child with cancer","route":"/ideas/idea-data-paediatric-rwe-consortium/","asOf":"2026-09-08","days":13},{"id":"idea-data-sequencing-analysis-per-approval","kind":"idea","name":"A real-world sequencing analysis within a year of every new approval","route":"/ideas/idea-data-sequencing-analysis-per-approval/","asOf":"2026-09-08","days":13},{"id":"idea-data-outcome-based-price-reassessment","kind":"idea","name":"Reassess cancer drug prices at three years using real-world outcomes","route":"/ideas/idea-data-outcome-based-price-reassessment/","asOf":"2026-09-08","days":13},{"id":"idea-data-computable-living-guidelines","kind":"idea","name":"Living guidelines published as versioned, computable rules","route":"/ideas/idea-data-computable-living-guidelines/","asOf":"2026-09-08","days":13},{"id":"idea-data-open-evidence-knowledge-graph","kind":"idea","name":"An open knowledge graph linking trials, results, biomarkers, drugs and recommendations","route":"/ideas/idea-data-open-evidence-knowledge-graph/","asOf":"2026-09-08","days":13},{"id":"idea-data-funded-living-systematic-reviews","kind":"idea","name":"Funded living systematic reviews for every major cancer indication","route":"/ideas/idea-data-funded-living-systematic-reviews/","asOf":"2026-09-08","days":13},{"id":"idea-data-plain-language-summary-mandate","kind":"idea","name":"A plain-language summary of every cancer trial result within a year","route":"/ideas/idea-data-plain-language-summary-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-data-structured-trial-results-deposit","kind":"idea","name":"Deposit trial results as structured data, not just PDFs","route":"/ideas/idea-data-structured-trial-results-deposit/","asOf":"2026-09-08","days":13},{"id":"idea-data-provenance-first-decision-support","kind":"idea","name":"Decision support that cites the exact trial and guideline line it relies on","route":"/ideas/idea-data-provenance-first-decision-support/","asOf":"2026-09-08","days":13},{"id":"idea-data-tumour-board-evidence-assistant","kind":"idea","name":"A tumour board assistant that cites its evidence and tracks outcomes","route":"/ideas/idea-data-tumour-board-evidence-assistant/","asOf":"2026-09-08","days":13},{"id":"idea-data-guideline-concordance-dashboards","kind":"idea","name":"Real-time guideline-concordance feedback for every cancer centre","route":"/ideas/idea-data-guideline-concordance-dashboards/","asOf":"2026-09-08","days":13},{"id":"idea-data-thirty-day-practice-change-learning","kind":"idea","name":"Micro-learning pushed to community oncologists within 30 days of a practice change","route":"/ideas/idea-data-thirty-day-practice-change-learning/","asOf":"2026-09-08","days":13},{"id":"idea-data-patient-explainers-per-recommendation","kind":"idea","name":"A plain-language explainer for every guideline recommendation, in every major language","route":"/ideas/idea-data-patient-explainers-per-recommendation/","asOf":"2026-09-08","days":13},{"id":"idea-data-evidence-to-adoption-tracker","kind":"idea","name":"A public tracker of how long each country takes to adopt new evidence","route":"/ideas/idea-data-evidence-to-adoption-tracker/","asOf":"2026-09-08","days":13},{"id":"idea-data-retraction-propagation","kind":"idea","name":"Automatic flagging of retracted or corrected evidence in guidelines and decision support","route":"/ideas/idea-data-retraction-propagation/","asOf":"2026-09-08","days":13},{"id":"idea-data-open-licensed-guidelines","kind":"idea","name":"Open licences for publicly funded cancer guidelines","route":"/ideas/idea-data-open-licensed-guidelines/","asOf":"2026-09-08","days":13},{"id":"idea-data-unanswered-questions-registry","kind":"idea","name":"A public registry of unanswered clinical questions linked to funding calls","route":"/ideas/idea-data-unanswered-questions-registry/","asOf":"2026-09-08","days":13},{"id":"idea-data-living-llm-oncology-benchmark","kind":"idea","name":"A monthly-updated benchmark for AI answers to oncology questions with citation accuracy","route":"/ideas/idea-data-living-llm-oncology-benchmark/","asOf":"2026-09-08","days":13},{"id":"idea-data-rapid-guideline-translation","kind":"idea","name":"Expert-verified translation of guideline updates into 20 languages within 30 days","route":"/ideas/idea-data-rapid-guideline-translation/","asOf":"2026-09-08","days":13},{"id":"idea-data-offline-cds-lmic-generalists","kind":"idea","name":"Offline decision support for generalists treating common cancers in low-resource settings","route":"/ideas/idea-data-offline-cds-lmic-generalists/","asOf":"2026-09-08","days":13},{"id":"idea-data-toxicity-cds-for-nurses","kind":"idea","name":"Toxicity-management decision support for nurses and pharmacists","route":"/ideas/idea-data-toxicity-cds-for-nurses/","asOf":"2026-09-08","days":13},{"id":"idea-data-72-hour-second-opinion-network","kind":"idea","name":"A digital second-opinion network answering community oncologists within 72 hours","route":"/ideas/idea-data-72-hour-second-opinion-network/","asOf":"2026-09-08","days":13},{"id":"idea-data-standard-of-care-change-alerts","kind":"idea","name":"Subscribable alerts when the standard of care changes for a patient's situation","route":"/ideas/idea-data-standard-of-care-change-alerts/","asOf":"2026-09-08","days":13},{"id":"idea-data-full-data-with-abstract","kind":"idea","name":"End the abstract-to-paper gap: require full results with any conference presentation","route":"/ideas/idea-data-full-data-with-abstract/","asOf":"2026-09-08","days":13},{"id":"idea-data-implementation-trials-programme","kind":"idea","name":"Randomised trials of how to spread proven cancer treatments, not just what works","route":"/ideas/idea-data-implementation-trials-programme/","asOf":"2026-09-08","days":13},{"id":"idea-data-wikipedia-oncology-editors","kind":"idea","name":"Fund expert editors for the cancer pages of Wikipedia and Wikidata","route":"/ideas/idea-data-wikipedia-oncology-editors/","asOf":"2026-09-08","days":13},{"id":"idea-data-order-set-defaults-30-days","kind":"idea","name":"Update hospital order sets within 30 days of a guideline change","route":"/ideas/idea-data-order-set-defaults-30-days/","asOf":"2026-09-08","days":13},{"id":"idea-data-standard-of-care-api","kind":"idea","name":"A public API serving the current standard of care for any cancer, stage and biomarker","route":"/ideas/idea-data-standard-of-care-api/","asOf":"2026-09-08","days":13},{"id":"idea-data-prospective-ai-trials-fund","kind":"idea","name":"A dedicated fund for randomised trials of cancer AI with patient outcomes","route":"/ideas/idea-data-prospective-ai-trials-fund/","asOf":"2026-09-08","days":13},{"id":"idea-data-clinical-ai-model-registry","kind":"idea","name":"A public registry of every AI model used in cancer care","route":"/ideas/idea-data-clinical-ai-model-registry/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-post-market-performance-reporting","kind":"idea","name":"Mandatory post-market performance reporting for cancer AI","route":"/ideas/idea-data-ai-post-market-performance-reporting/","asOf":"2026-09-08","days":13},{"id":"idea-data-drift-monitoring-standard","kind":"idea","name":"A standard for monitoring AI performance drift with pause thresholds","route":"/ideas/idea-data-drift-monitoring-standard/","asOf":"2026-09-08","days":13},{"id":"idea-data-sequestered-prospective-benchmarks","kind":"idea","name":"Sequestered, prospectively collected benchmark datasets that no one can train on","route":"/ideas/idea-data-sequestered-prospective-benchmarks/","asOf":"2026-09-08","days":13},{"id":"idea-data-neutral-ai-evaluator","kind":"idea","name":"A neutral public evaluator for cancer AI, on the model of NIST","route":"/ideas/idea-data-neutral-ai-evaluator/","asOf":"2026-09-08","days":13},{"id":"idea-data-regulatory-sandbox-adaptive-ai","kind":"idea","name":"A regulatory sandbox for continuously learning cancer AI","route":"/ideas/idea-data-regulatory-sandbox-adaptive-ai/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-liability-safe-harbour","kind":"idea","name":"A liability framework for clinical AI: safe harbour for clinicians, liability for makers","route":"/ideas/idea-data-ai-liability-safe-harbour/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-reimbursement-tied-to-outcomes","kind":"idea","name":"Pay for cancer AI only when it has outcome evidence, then pay properly","route":"/ideas/idea-data-ai-reimbursement-tied-to-outcomes/","asOf":"2026-09-08","days":13},{"id":"idea-data-silent-trial-before-deployment","kind":"idea","name":"A mandatory silent (shadow) trial before any cancer AI goes live","route":"/ideas/idea-data-silent-trial-before-deployment/","asOf":"2026-09-08","days":13},{"id":"idea-data-subgroup-performance-reporting-mandate","kind":"idea","name":"Mandatory subgroup performance reporting for cancer AI","route":"/ideas/idea-data-subgroup-performance-reporting-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-data-open-cell-foundation-model","kind":"idea","name":"An open foundation model of the cancer cell trained on perturbation data","route":"/ideas/idea-data-open-cell-foundation-model/","asOf":"2026-09-08","days":13},{"id":"idea-data-precompetitive-cancer-foundation-model","kind":"idea","name":"A pre-competitive consortium to train a shared multimodal cancer foundation model","route":"/ideas/idea-data-precompetitive-cancer-foundation-model/","asOf":"2026-09-08","days":13},{"id":"idea-data-open-weights-for-public-funded-ai","kind":"idea","name":"Publicly funded cancer AI must release open weights and model cards","route":"/ideas/idea-data-open-weights-for-public-funded-ai/","asOf":"2026-09-08","days":13},{"id":"idea-data-digital-twin-predict-then-observe","kind":"idea","name":"Digital twins for treatment selection, validated by predicting before observing","route":"/ideas/idea-data-digital-twin-predict-then-observe/","asOf":"2026-09-08","days":13},{"id":"idea-data-in-silico-trials-calibrated","kind":"idea","name":"In silico trials to prioritise combinations, scored against later real trials","route":"/ideas/idea-data-in-silico-trials-calibrated/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-pathology-evaluation-standard","kind":"idea","name":"A standard evaluation pathway for AI-assisted pathology, from reader study to deployment","route":"/ideas/idea-data-ai-pathology-evaluation-standard/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-screening-endpoints","kind":"idea","name":"Require stage-shift or interval-cancer endpoints for AI in cancer screening","route":"/ideas/idea-data-ai-screening-endpoints/","asOf":"2026-09-08","days":13},{"id":"idea-data-multisite-validation-precondition","kind":"idea","name":"External validation at five or more sites in two countries before clearance","route":"/ideas/idea-data-multisite-validation-precondition/","asOf":"2026-09-08","days":13},{"id":"idea-data-patient-facing-model-cards","kind":"idea","name":"Patients told which AI is used in their care, in plain language","route":"/ideas/idea-data-patient-facing-model-cards/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-red-team-programme","kind":"idea","name":"Red-team programmes that attack cancer AI before patients do","route":"/ideas/idea-data-ai-red-team-programme/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-audit-trail-in-ehr","kind":"idea","name":"Every AI output logged in the record with input hash, version and clinician response","route":"/ideas/idea-data-ai-audit-trail-in-ehr/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-decommissioning-rules","kind":"idea","name":"Rules for retiring cancer AI when performance drops or the standard of care moves","route":"/ideas/idea-data-ai-decommissioning-rules/","asOf":"2026-09-08","days":13},{"id":"idea-data-llm-documentation-rct-oncology","kind":"idea","name":"A randomised trial of AI scribes in oncology clinics measuring errors and time","route":"/ideas/idea-data-llm-documentation-rct-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-data-ai-vs-tumour-board-rct","kind":"idea","name":"A randomised trial of AI-generated treatment recommendations versus tumour boards","route":"/ideas/idea-data-ai-vs-tumour-board-rct/","asOf":"2026-09-08","days":13},{"id":"idea-fund-burden-weighted-portfolio","kind":"idea","name":"Burden-weighted portfolio targets for every major cancer funder","route":"/ideas/idea-fund-burden-weighted-portfolio/","asOf":"2026-09-08","days":13},{"id":"idea-fund-metastasis-moonshot","kind":"idea","name":"A ring-fenced metastasis programme with metastasis-specific endpoints","route":"/ideas/idea-fund-metastasis-moonshot/","asOf":"2026-09-08","days":13},{"id":"idea-fund-prevention-moonshot","kind":"idea","name":"A delivery-science moonshot for prevention we already own","route":"/ideas/idea-fund-prevention-moonshot/","asOf":"2026-09-08","days":13},{"id":"idea-fund-dollars-per-death-dashboard","kind":"idea","name":"A public dashboard of research money per death for every cancer","route":"/ideas/idea-fund-dollars-per-death-dashboard/","asOf":"2026-09-08","days":13},{"id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/","asOf":"2026-09-08","days":13},{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/","asOf":"2026-09-08","days":13},{"id":"idea-fund-neglected-cancer-lottery","kind":"idea","name":"Partial lottery funding for good proposals in under-funded cancers","route":"/ideas/idea-fund-neglected-cancer-lottery/","asOf":"2026-09-08","days":13},{"id":"idea-fund-ten-year-hard-problem-awards","kind":"idea","name":"Ten-year awards for scientists who commit to one hard problem","route":"/ideas/idea-fund-ten-year-hard-problem-awards/","asOf":"2026-09-08","days":13},{"id":"idea-fund-survivorship-endowment-levy","kind":"idea","name":"A survivorship research endowment funded by a levy on curative therapy prices","route":"/ideas/idea-fund-survivorship-endowment-levy/","asOf":"2026-09-08","days":13},{"id":"idea-fund-non-drug-trial-quota","kind":"idea","name":"A statutory minimum share of public trial money for surgery and radiotherapy","route":"/ideas/idea-fund-non-drug-trial-quota/","asOf":"2026-09-08","days":13},{"id":"idea-fund-replication-set-aside","kind":"idea","name":"Set aside 3% of grant budgets to replicate findings before translation","route":"/ideas/idea-fund-replication-set-aside/","asOf":"2026-09-08","days":13},{"id":"idea-fund-white-space-map","kind":"idea","name":"An annual map of high-burden questions that nobody is funding","route":"/ideas/idea-fund-white-space-map/","asOf":"2026-09-08","days":13},{"id":"idea-fund-programme-officer-incentives","kind":"idea","name":"Judge funding programme officers on burden alignment and trials completed","route":"/ideas/idea-fund-programme-officer-incentives/","asOf":"2026-09-08","days":13},{"id":"idea-fund-patient-burden-review-criterion","kind":"idea","name":"A formal patient-burden score in grant peer review","route":"/ideas/idea-fund-patient-burden-review-criterion/","asOf":"2026-09-08","days":13},{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/","asOf":"2026-09-08","days":13},{"id":"idea-fund-cachexia-programme","kind":"idea","name":"A dedicated programme for cachexia and treatment toxicity research","route":"/ideas/idea-fund-cachexia-programme/","asOf":"2026-09-08","days":13},{"id":"idea-fund-cross-funder-portfolio-registry","kind":"idea","name":"Mandatory machine-readable portfolio reporting for all large cancer funders","route":"/ideas/idea-fund-cross-funder-portfolio-registry/","asOf":"2026-09-08","days":13},{"id":"idea-fund-older-patients-trial-fund","kind":"idea","name":"A trials fund reserved for older and multimorbid patients","route":"/ideas/idea-fund-older-patients-trial-fund/","asOf":"2026-09-08","days":13},{"id":"idea-fund-fast-grants-oncology","kind":"idea","name":"Forty-eight-hour small grants for bold experiments in neglected cancers","route":"/ideas/idea-fund-fast-grants-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-fund-brain-metastases-programme","kind":"idea","name":"Treat brain metastases as a disease with its own trials programme","route":"/ideas/idea-fund-brain-metastases-programme/","asOf":"2026-09-08","days":13},{"id":"idea-fund-cure-prize","kind":"idea","name":"A billion-dollar prize for the first durable cure of a lethal metastatic cancer","route":"/ideas/idea-fund-cure-prize/","asOf":"2026-09-08","days":13},{"id":"idea-fund-first-in-class-prize","kind":"idea","name":"Milestone prizes for first-in-class mechanisms reaching human proof of concept","route":"/ideas/idea-fund-first-in-class-prize/","asOf":"2026-09-08","days":13},{"id":"idea-fund-amc-paediatric-rare","kind":"idea","name":"Advance market commitments for paediatric and rare cancer drugs","route":"/ideas/idea-fund-amc-paediatric-rare/","asOf":"2026-09-08","days":13},{"id":"idea-fund-conditional-transferable-voucher","kind":"idea","name":"Transferable priority vouchers for first-in-class drugs, with price conditions","route":"/ideas/idea-fund-conditional-transferable-voucher/","asOf":"2026-09-08","days":13},{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/","asOf":"2026-09-08","days":13},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/","asOf":"2026-09-08","days":13},{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/","asOf":"2026-09-08","days":13},{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/","asOf":"2026-09-08","days":13},{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","route":"/ideas/idea-fund-public-option-generic-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/","asOf":"2026-09-08","days":13},{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","route":"/ideas/idea-fund-mcbs-linked-pricing/","asOf":"2026-09-08","days":13},{"id":"idea-fund-head-to-head-mandate","kind":"idea","name":"Require head-to-head trials against the best in class for later entrants","route":"/ideas/idea-fund-head-to-head-mandate/","asOf":"2026-09-08","days":13},{"id":"idea-fund-health-impact-fund-oncology","kind":"idea","name":"A Health Impact Fund pilot that pays for measured health gain instead of price","route":"/ideas/idea-fund-health-impact-fund-oncology/","asOf":"2026-09-08","days":13},{"id":"idea-fund-sovereign-first-in-class-coinvestment","kind":"idea","name":"Public co-investment in first-in-class phase 1 with a royalty return","route":"/ideas/idea-fund-sovereign-first-in-class-coinvestment/","asOf":"2026-09-08","days":13},{"id":"idea-fund-academic-promotion-reform","kind":"idea","name":"Promote academics for trials completed, data shared and findings replicated","route":"/ideas/idea-fund-academic-promotion-reform/","asOf":"2026-09-08","days":13},{"id":"idea-fund-trial-completion-bonus","kind":"idea","name":"Pay investigators for finishing and publishing trials, not for enrolling patients","route":"/ideas/idea-fund-trial-completion-bonus/","asOf":"2026-09-08","days":13},{"id":"idea-fund-payer-funded-pragmatic-trials","kind":"idea","name":"Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments","route":"/ideas/idea-fund-payer-funded-pragmatic-trials/","asOf":"2026-09-08","days":13},{"id":"idea-fund-duration-trial-exclusivity","kind":"idea","name":"Extra exclusivity for sponsors who run treatment-duration and de-escalation trials","route":"/ideas/idea-fund-duration-trial-exclusivity/","asOf":"2026-09-08","days":13},{"id":"idea-fund-paediatric-deferral-escrow","kind":"idea","name":"Escrow a share of adult revenue until the paediatric study is done","route":"/ideas/idea-fund-paediatric-deferral-escrow/","asOf":"2026-09-08","days":13},{"id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/","asOf":"2026-09-08","days":13},{"id":"idea-fund-open-source-repurposing-leads","kind":"idea","name":"Patent-free open-source development of repurposed and off-patent cancer drugs","route":"/ideas/idea-fund-open-source-repurposing-leads/","asOf":"2026-09-08","days":13},{"id":"idea-fund-repurposing-indication-exclusivity","kind":"idea","name":"A repurposing label pathway with short exclusivity that non-profits can hold","route":"/ideas/idea-fund-repurposing-indication-exclusivity/","asOf":"2026-09-08","days":13},{"id":"idea-fund-social-impact-bonds-prevention","kind":"idea","name":"Social impact bonds for cancer prevention, repaid from avoided treatment costs","route":"/ideas/idea-fund-social-impact-bonds-prevention/","asOf":"2026-09-08","days":13},{"id":"idea-fund-global-access-licensing-royalties","kind":"idea","name":"University licences with royalties indexed to benefit and global access","route":"/ideas/idea-fund-global-access-licensing-royalties/","asOf":"2026-09-08","days":13},{"id":"idea-fund-phase-two-failure-reinsurance","kind":"idea","name":"Government reinsurance for phase 2 failures of first-in-class cancer drugs","route":"/ideas/idea-fund-phase-two-failure-reinsurance/","asOf":"2026-09-08","days":13},{"id":"idea-fund-translational-institutes-gmp","kind":"idea","name":"Regional translational institutes with academic GMP suites and IND teams","route":"/ideas/idea-fund-translational-institutes-gmp/","asOf":"2026-09-08","days":13},{"id":"idea-fund-ind-enabling-fund","kind":"idea","name":"A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks","route":"/ideas/idea-fund-ind-enabling-fund/","asOf":"2026-09-08","days":13},{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/","asOf":"2026-09-08","days":13},{"id":"idea-fund-phase-zero-fund","kind":"idea","name":"A phase 0 fund to test academic compounds in humans with microdoses and imaging","route":"/ideas/idea-fund-phase-zero-fund/","asOf":"2026-09-08","days":13},{"id":"idea-fund-public-nonprofit-cro","kind":"idea","name":"A national non-profit contract research organisation for academic oncology trials","route":"/ideas/idea-fund-public-nonprofit-cro/","asOf":"2026-09-08","days":13},{"id":"idea-fund-translational-fellowships","kind":"idea","name":"Two-year translational fellowships that pay scientists to develop their own discovery","route":"/ideas/idea-fund-translational-fellowships/","asOf":"2026-09-08","days":13},{"id":"idea-fund-target-validation-consortium","kind":"idea","name":"A pre-competitive consortium to validate or kill academic targets before licensing","route":"/ideas/idea-fund-target-validation-consortium/","asOf":"2026-09-08","days":13},{"id":"idea-fund-academic-adc-bispecific-platform","kind":"idea","name":"An open engineering platform for academic ADCs and bispecifics","route":"/ideas/idea-fund-academic-adc-bispecific-platform/","asOf":"2026-09-08","days":13},{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/","asOf":"2026-09-08","days":13},{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/","asOf":"2026-09-08","days":13},{"id":"idea-fund-stalled-asset-registry","kind":"idea","name":"A public registry of stalled academic assets and shelved company compounds","route":"/ideas/idea-fund-stalled-asset-registry/","asOf":"2026-09-08","days":13},{"id":"idea-fund-national-drug-development-office","kind":"idea","name":"Scale up public drug development that takes academic assets to phase 1","route":"/ideas/idea-fund-national-drug-development-office/","asOf":"2026-09-08","days":13},{"id":"idea-fund-device-and-technique-translation-fund","kind":"idea","name":"A translation fund for academic surgical devices and radiotherapy technology","route":"/ideas/idea-fund-device-and-technique-translation-fund/","asOf":"2026-09-08","days":13},{"id":"idea-fund-biomarker-validation-fund","kind":"idea","name":"A fund for prospective validation of academic biomarkers and companion diagnostics","route":"/ideas/idea-fund-biomarker-validation-fund/","asOf":"2026-09-08","days":13},{"id":"idea-fund-organoid-translation-gate","kind":"idea","name":"A funded organoid and PDX panel as the go/no-go gate before IND-enabling money","route":"/ideas/idea-fund-organoid-translation-gate/","asOf":"2026-09-08","days":13},{"id":"idea-fund-shared-personalised-therapy-gmp","kind":"idea","name":"Shared modular GMP facilities for academic personalised vaccines and cell products","route":"/ideas/idea-fund-shared-personalised-therapy-gmp/","asOf":"2026-09-08","days":13},{"id":"idea-fund-protected-time-physician-scientists","kind":"idea","name":"Hospital-funded protected time for clinician-scientists, repaid by trial revenue","route":"/ideas/idea-fund-protected-time-physician-scientists/","asOf":"2026-09-08","days":13},{"id":"idea-fund-royalty-pool-academic-assets","kind":"idea","name":"A diversified royalty pool that finances academic phase 1 trials across fifty assets","route":"/ideas/idea-fund-royalty-pool-academic-assets/","asOf":"2026-09-08","days":13},{"id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/","asOf":"2026-09-08","days":13},{"id":"idea-fund-academic-sponsor-indemnity-pool","kind":"idea","name":"A public indemnity pool so universities can sponsor first-in-human cancer trials","route":"/ideas/idea-fund-academic-sponsor-indemnity-pool/","asOf":"2026-09-08","days":13},{"id":"idea-fund-combination-patent-pool","kind":"idea","name":"An oncology patent pool for combination trials across companies","route":"/ideas/idea-fund-combination-patent-pool/","asOf":"2026-09-08","days":13},{"id":"idea-fund-compulsory-combination-access","kind":"idea","name":"A legal right to obtain marketed cancer drugs at cost for combination trials","route":"/ideas/idea-fund-compulsory-combination-access/","asOf":"2026-09-08","days":13},{"id":"idea-fund-standard-combination-agreement","kind":"idea","name":"A regulator-endorsed standard contract for inter-company combination trials","route":"/ideas/idea-fund-standard-combination-agreement/","asOf":"2026-09-08","days":13},{"id":"idea-fund-precompetitive-undruggable-consortium","kind":"idea","name":"An open-science consortium on the undruggable drivers, open until a candidate","route":"/ideas/idea-fund-precompetitive-undruggable-consortium/","asOf":"2026-09-08","days":13},{"id":"idea-fund-trial-data-trust","kind":"idea","name":"A single oncology trial data trust with mandatory deposit within eighteen months","route":"/ideas/idea-fund-trial-data-trust/","asOf":"2026-09-08","days":13},{"id":"idea-fund-control-arm-commons","kind":"idea","name":"A shared library of pooled control arms to shrink and speed future trials","route":"/ideas/idea-fund-control-arm-commons/","asOf":"2026-09-08","days":13},{"id":"idea-fund-universal-mta-fast-lane","kind":"idea","name":"A universal material transfer agreement with a thirty-day default","route":"/ideas/idea-fund-universal-mta-fast-lane/","asOf":"2026-09-08","days":13},{"id":"idea-fund-antitrust-safe-harbour","kind":"idea","name":"An antitrust safe harbour for cross-company combination trials and data pooling","route":"/ideas/idea-fund-antitrust-safe-harbour/","asOf":"2026-09-08","days":13},{"id":"idea-fund-open-results-bonus","kind":"idea","name":"Funder bonuses for releasing results and data within six months, negatives included","route":"/ideas/idea-fund-open-results-bonus/","asOf":"2026-09-08","days":13},{"id":"idea-fund-shelved-asset-escrow","kind":"idea","name":"Automatic offer of shelved cancer assets to non-profits after two years","route":"/ideas/idea-fund-shelved-asset-escrow/","asOf":"2026-09-08","days":13},{"id":"idea-fund-federated-learning-consortium","kind":"idea","name":"A federated learning consortium of cancer centres that jointly own the models","route":"/ideas/idea-fund-federated-learning-consortium/","asOf":"2026-09-08","days":13},{"id":"idea-fund-trial-biospecimen-commons","kind":"idea","name":"A commons for leftover trial biospecimens with standard access for approved research","route":"/ideas/idea-fund-trial-biospecimen-commons/","asOf":"2026-09-08","days":13},{"id":"idea-fund-neutral-platform-sponsor","kind":"idea","name":"A permanent neutral non-profit sponsor for multi-company platform trials","route":"/ideas/idea-fund-neutral-platform-sponsor/","asOf":"2026-09-08","days":13},{"id":"idea-fund-portable-patient-consent","kind":"idea","name":"Patient-held portable consent for reusing samples and data across studies","route":"/ideas/idea-fund-portable-patient-consent/","asOf":"2026-09-08","days":13},{"id":"idea-fund-scoop-protection-policy","kind":"idea","name":"Scoop protection and co-publication norms to reduce academic secrecy","route":"/ideas/idea-fund-scoop-protection-policy/","asOf":"2026-09-08","days":13},{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/","asOf":"2026-09-08","days":13},{"id":"idea-fund-radiotherapy-trials-infrastructure","kind":"idea","name":"Core-funded radiotherapy trials infrastructure with central quality assurance","route":"/ideas/idea-fund-radiotherapy-trials-infrastructure/","asOf":"2026-09-08","days":13},{"id":"idea-fund-device-technique-registry","kind":"idea","name":"Mandatory staged registries for new surgical techniques before wide adoption","route":"/ideas/idea-fund-device-technique-registry/","asOf":"2026-09-08","days":13},{"id":"idea-fund-surgical-ai-robotics-evaluation","kind":"idea","name":"An independent evaluation unit for surgical robots and AI, paid on evidence","route":"/ideas/idea-fund-surgical-ai-robotics-evaluation/","asOf":"2026-09-08","days":13},{"id":"idea-fund-flash-evidence-programme","kind":"idea","name":"A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards","route":"/ideas/idea-fund-flash-evidence-programme/","asOf":"2026-09-08","days":13},{"id":"idea-fund-proton-coverage-with-evidence","kind":"idea","name":"Pooled coverage-with-evidence for proton therapy across all centres","route":"/ideas/idea-fund-proton-coverage-with-evidence/","asOf":"2026-09-08","days":13},{"id":"idea-fund-surgeon-scientist-pathway","kind":"idea","name":"Funded research pathways for surgeon-scientists and radiation oncologist-scientists","route":"/ideas/idea-fund-surgeon-scientist-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-fund-course-based-radiotherapy-payment","kind":"idea","name":"Pay per course of radiotherapy, not per session, so short courses are not penalised","route":"/ideas/idea-fund-course-based-radiotherapy-payment/","asOf":"2026-09-08","days":13},{"id":"idea-fund-surgical-video-registry","kind":"idea","name":"A video-based surgical quality registry linking assessed skill to cancer outcomes","route":"/ideas/idea-fund-surgical-video-registry/","asOf":"2026-09-08","days":13},{"id":"idea-fund-organ-preservation-programme","kind":"idea","name":"A funded programme of organ-preservation trials to avoid radical surgery","route":"/ideas/idea-fund-organ-preservation-programme/","asOf":"2026-09-08","days":13},{"id":"idea-fund-omission-deescalation-trials","kind":"idea","name":"Payer-funded trials that omit surgery or radiotherapy in low-risk patients","route":"/ideas/idea-fund-omission-deescalation-trials/","asOf":"2026-09-08","days":13},{"id":"idea-fund-lmic-radiotherapy-finance","kind":"idea","name":"Blended finance and a low-cost linac to close the global radiotherapy gap","route":"/ideas/idea-fund-lmic-radiotherapy-finance/","asOf":"2026-09-08","days":13},{"id":"idea-fund-intraoperative-imaging-trials","kind":"idea","name":"A pragmatic trial network for intraoperative margin tools, paid on margin reduction","route":"/ideas/idea-fund-intraoperative-imaging-trials/","asOf":"2026-09-08","days":13},{"id":"idea-fund-rt-io-platform","kind":"idea","name":"A neutral platform trial for radiotherapy plus immunotherapy combinations","route":"/ideas/idea-fund-rt-io-platform/","asOf":"2026-09-08","days":13},{"id":"idea-fund-adaptive-radiotherapy-evidence","kind":"idea","name":"Coverage-with-evidence registries for MR-guided and adaptive radiotherapy","route":"/ideas/idea-fund-adaptive-radiotherapy-evidence/","asOf":"2026-09-08","days":13},{"id":"idea-fund-surgical-outcomes-public-reporting","kind":"idea","name":"Public risk-adjusted outcome reporting for cancer surgery to drive centralisation","route":"/ideas/idea-fund-surgical-outcomes-public-reporting/","asOf":"2026-09-08","days":13},{"id":"idea-fund-rt-planning-ai-capacity","kind":"idea","name":"Validate and reimburse AI contouring and planning to expand radiotherapy capacity","route":"/ideas/idea-fund-rt-planning-ai-capacity/","asOf":"2026-09-08","days":13},{"id":"idea-fund-ablation-versus-surgery-trials","kind":"idea","name":"Device-agnostic public trials of ablation technologies against surgery","route":"/ideas/idea-fund-ablation-versus-surgery-trials/","asOf":"2026-09-08","days":13},{"id":"idea-fund-radiotherapy-innovation-pathway","kind":"idea","name":"A regulatory pathway for new radiotherapy techniques modelled on drug development","route":"/ideas/idea-fund-radiotherapy-innovation-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-fund-technique-innovation-prize","kind":"idea","name":"Prizes for unpatentable surgical and radiotherapy techniques proven in trials","route":"/ideas/idea-fund-technique-innovation-prize/","asOf":"2026-09-08","days":13},{"id":"idea-moon-navigation-as-a-right","kind":"idea","name":"Patient navigation as a legal entitlement from the day of diagnosis","route":"/ideas/idea-moon-navigation-as-a-right/","asOf":"2026-09-08","days":13},{"id":"idea-moon-plain-language-consent","kind":"idea","name":"Two-page plain-language consent with teach-back for every cancer trial and treatment","route":"/ideas/idea-moon-plain-language-consent/","asOf":"2026-09-08","days":13},{"id":"idea-moon-results-in-plain-words","kind":"idea","name":"Every pathology and genomic report ships with a signed plain-language version","route":"/ideas/idea-moon-results-in-plain-words/","asOf":"2026-09-08","days":13},{"id":"idea-moon-pro-monitoring-standard","kind":"idea","name":"Weekly symptom check-ins with automatic alerts as standard of care on treatment","route":"/ideas/idea-moon-pro-monitoring-standard/","asOf":"2026-09-08","days":13},{"id":"idea-moon-certified-decision-aids","kind":"idea","name":"Certified decision aids required for every preference-sensitive cancer decision","route":"/ideas/idea-moon-certified-decision-aids/","asOf":"2026-09-08","days":13},{"id":"idea-moon-patient-designed-trials","kind":"idea","name":"Patient panels approve trial burden and endpoints as a condition of funding","route":"/ideas/idea-moon-patient-designed-trials/","asOf":"2026-09-08","days":13},{"id":"idea-moon-financial-toxicity-screening","kind":"idea","name":"Screen every patient for financial toxicity at diagnosis and refer like any other symptom","route":"/ideas/idea-moon-financial-toxicity-screening/","asOf":"2026-09-08","days":13},{"id":"idea-moon-goals-conversation-trigger","kind":"idea","name":"Algorithm-triggered goals-of-care conversations before crisis","route":"/ideas/idea-moon-goals-conversation-trigger/","asOf":"2026-09-08","days":13},{"id":"idea-moon-patient-held-cancer-record","kind":"idea","name":"A patient-owned, portable complete cancer record in a standard format","route":"/ideas/idea-moon-patient-held-cancer-record/","asOf":"2026-09-08","days":13},{"id":"idea-moon-funded-second-opinion","kind":"idea","name":"A funded expert second opinion for every new high-stakes or rare cancer diagnosis","route":"/ideas/idea-moon-funded-second-opinion/","asOf":"2026-09-08","days":13},{"id":"idea-moon-recorded-consultations","kind":"idea","name":"Recorded, AI-summarised consultations given to patients by default","route":"/ideas/idea-moon-recorded-consultations/","asOf":"2026-09-08","days":13},{"id":"idea-moon-question-prompt-lists","kind":"idea","name":"Question prompt lists sent to patients before every major consultation","route":"/ideas/idea-moon-question-prompt-lists/","asOf":"2026-09-08","days":13},{"id":"idea-moon-patient-experience-label","kind":"idea","name":"A mandatory patient-experience section in every cancer drug label and approval","route":"/ideas/idea-moon-patient-experience-label/","asOf":"2026-09-08","days":13},{"id":"idea-moon-results-back-to-participants","kind":"idea","name":"Plain-language trial results returned to every participant within a year","route":"/ideas/idea-moon-results-back-to-participants/","asOf":"2026-09-08","days":13},{"id":"idea-moon-peer-navigator-workforce","kind":"idea","name":"Paid survivor peer-navigators as a recognised health workforce role","route":"/ideas/idea-moon-peer-navigator-workforce/","asOf":"2026-09-08","days":13},{"id":"idea-moon-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days a treatment consumes, in every trial and decision aid","route":"/ideas/idea-moon-time-toxicity-reporting/","asOf":"2026-09-08","days":13},{"id":"idea-moon-preference-studies-before-phase3","kind":"idea","name":"Quantitative patient preference studies set the benefit-risk bar before phase 3","route":"/ideas/idea-moon-preference-studies-before-phase3/","asOf":"2026-09-08","days":13},{"id":"idea-moon-caregiver-in-the-plan","kind":"idea","name":"Formal caregiver assessment and training written into every treatment plan","route":"/ideas/idea-moon-caregiver-in-the-plan/","asOf":"2026-09-08","days":13},{"id":"idea-moon-literacy-first-design-standard","kind":"idea","name":"A health-literacy certification standard for oncology portals, letters and apps","route":"/ideas/idea-moon-literacy-first-design-standard/","asOf":"2026-09-08","days":13},{"id":"idea-moon-trial-eligibility-at-every-decision","kind":"idea","name":"Patients are told which trials they qualify for at every treatment decision, in writing","route":"/ideas/idea-moon-trial-eligibility-at-every-decision/","asOf":"2026-09-08","days":13},{"id":"idea-moon-toxicity-first-endpoints","kind":"idea","name":"Tolerability as a co-primary endpoint with its own label claim","route":"/ideas/idea-moon-toxicity-first-endpoints/","asOf":"2026-09-08","days":13},{"id":"idea-moon-pro-ctcae-in-every-pivotal-trial","kind":"idea","name":"Patient-reported side-effects (PRO-CTCAE) collected and published in every registrational trial","route":"/ideas/idea-moon-pro-ctcae-in-every-pivotal-trial/","asOf":"2026-09-08","days":13},{"id":"idea-moon-supportive-care-arpa","kind":"idea","name":"An ARPA-style programme to develop supportive-care drugs nobody else will","route":"/ideas/idea-moon-supportive-care-arpa/","asOf":"2026-09-08","days":13},{"id":"idea-moon-neuropathy-prevention-programme","kind":"idea","name":"A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression","route":"/ideas/idea-moon-neuropathy-prevention-programme/","asOf":"2026-09-08","days":13},{"id":"idea-moon-cardioprotection-by-default","kind":"idea","name":"Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy","route":"/ideas/idea-moon-cardioprotection-by-default/","asOf":"2026-09-08","days":13},{"id":"idea-moon-olanzapine-antiemetic-everywhere","kind":"idea","name":"Low-dose olanzapine and generic antiemetic bundles in every guideline and formulary","route":"/ideas/idea-moon-olanzapine-antiemetic-everywhere/","asOf":"2026-09-08","days":13},{"id":"idea-moon-post-approval-dose-deescalation","kind":"idea","name":"Randomised lower-dose trials for approved drugs with quality of life as the primary endpoint","route":"/ideas/idea-moon-post-approval-dose-deescalation/","asOf":"2026-09-08","days":13},{"id":"idea-moon-quality-adjusted-pricing","kind":"idea","name":"Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer","route":"/ideas/idea-moon-quality-adjusted-pricing/","asOf":"2026-09-08","days":13},{"id":"idea-moon-adult-late-effects-registry","kind":"idea","name":"A lifelong late-effects registry linked to every treatment for adult survivors","route":"/ideas/idea-moon-adult-late-effects-registry/","asOf":"2026-09-08","days":13},{"id":"idea-moon-cognitive-toxicity-programme","kind":"idea","name":"Measure and treat chemo brain with objective digital cognitive testing","route":"/ideas/idea-moon-cognitive-toxicity-programme/","asOf":"2026-09-08","days":13},{"id":"idea-moon-irae-prediction-and-prevention","kind":"idea","name":"Predict immune side-effects before they happen and pre-empt them","route":"/ideas/idea-moon-irae-prediction-and-prevention/","asOf":"2026-09-08","days":13},{"id":"idea-moon-fertility-preservation-default","kind":"idea","name":"Fertility preservation offered and funded by default before gonadotoxic treatment","route":"/ideas/idea-moon-fertility-preservation-default/","asOf":"2026-09-08","days":13},{"id":"idea-moon-hearing-protection-cisplatin","kind":"idea","name":"Protect hearing from cisplatin in adults as we now do in children","route":"/ideas/idea-moon-hearing-protection-cisplatin/","asOf":"2026-09-08","days":13},{"id":"idea-moon-hair-preservation-for-all","kind":"idea","name":"Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen","route":"/ideas/idea-moon-hair-preservation-for-all/","asOf":"2026-09-08","days":13},{"id":"idea-moon-oncology-hospital-at-home","kind":"idea","name":"Oncology hospital-at-home with remote monitoring for toxicity","route":"/ideas/idea-moon-oncology-hospital-at-home/","asOf":"2026-09-08","days":13},{"id":"idea-moon-supportive-care-platform-trial","kind":"idea","name":"A permanent platform trial for supportive-care interventions inside cooperative groups","route":"/ideas/idea-moon-supportive-care-platform-trial/","asOf":"2026-09-08","days":13},{"id":"idea-moon-open-pro-data-commons","kind":"idea","name":"An open commons of patient-reported outcome data from cancer trials","route":"/ideas/idea-moon-open-pro-data-commons/","asOf":"2026-09-08","days":13},{"id":"idea-moon-mucositis-taste-programme","kind":"idea","name":"Photobiomodulation and a taste and swallowing programme for mouth and throat toxicity","route":"/ideas/idea-moon-mucositis-taste-programme/","asOf":"2026-09-08","days":13},{"id":"idea-moon-sexual-health-as-toxicity-domain","kind":"idea","name":"Sexual health assessed and treated as a standard toxicity domain","route":"/ideas/idea-moon-sexual-health-as-toxicity-domain/","asOf":"2026-09-08","days":13},{"id":"idea-moon-quality-adjusted-survival-standard","kind":"idea","name":"Quality-adjusted survival reported in every trial publication and label","route":"/ideas/idea-moon-quality-adjusted-survival-standard/","asOf":"2026-09-08","days":13},{"id":"idea-moon-misinformation-rapid-response","kind":"idea","name":"A cancer misinformation rapid-response unit that rebuts within 48 hours","route":"/ideas/idea-moon-misinformation-rapid-response/","asOf":"2026-09-08","days":13},{"id":"idea-moon-verified-information-layer","kind":"idea","name":"A verified information layer that labels and links cancer content across platforms","route":"/ideas/idea-moon-verified-information-layer/","asOf":"2026-09-08","days":13},{"id":"idea-moon-clinician-creator-programme","kind":"idea","name":"Train and fund oncology clinicians as public content creators","route":"/ideas/idea-moon-clinician-creator-programme/","asOf":"2026-09-08","days":13},{"id":"idea-moon-prebunking-at-diagnosis","kind":"idea","name":"Inoculate newly diagnosed patients against common cancer scams","route":"/ideas/idea-moon-prebunking-at-diagnosis/","asOf":"2026-09-08","days":13},{"id":"idea-moon-unproven-clinic-registry","kind":"idea","name":"A public registry of unproven cancer clinics and reported outcomes","route":"/ideas/idea-moon-unproven-clinic-registry/","asOf":"2026-09-08","days":13},{"id":"idea-moon-supplement-interaction-database","kind":"idea","name":"An open supplement-drug interaction checker built into oncology prescribing","route":"/ideas/idea-moon-supplement-interaction-database/","asOf":"2026-09-08","days":13},{"id":"idea-moon-ban-unproven-therapy-ads","kind":"idea","name":"Ban and enforce against paid advertising of unproven cancer treatments","route":"/ideas/idea-moon-ban-unproven-therapy-ads/","asOf":"2026-09-08","days":13},{"id":"idea-moon-integrative-oncology-bridge","kind":"idea","name":"Evidence-based integrative oncology in every cancer centre to meet demand safely","route":"/ideas/idea-moon-integrative-oncology-bridge/","asOf":"2026-09-08","days":13},{"id":"idea-moon-ai-cancer-answer-audit","kind":"idea","name":"A public benchmark and audit of chatbot answers to cancer questions","route":"/ideas/idea-moon-ai-cancer-answer-audit/","asOf":"2026-09-08","days":13},{"id":"idea-moon-wikipedia-oncology-fellowships","kind":"idea","name":"Fund oncologists to maintain cancer articles on Wikipedia in many languages","route":"/ideas/idea-moon-wikipedia-oncology-fellowships/","asOf":"2026-09-08","days":13},{"id":"idea-moon-hpv-vaccine-confidence","kind":"idea","name":"Community-tailored HPV vaccine confidence campaigns with school-based delivery","route":"/ideas/idea-moon-hpv-vaccine-confidence/","asOf":"2026-09-08","days":13},{"id":"idea-moon-hype-index","kind":"idea","name":"An independent hype index grading cancer press releases and news stories","route":"/ideas/idea-moon-hype-index/","asOf":"2026-09-08","days":13},{"id":"idea-moon-patient-community-moderators","kind":"idea","name":"Trained moderators with evidence tools in online patient communities","route":"/ideas/idea-moon-patient-community-moderators/","asOf":"2026-09-08","days":13},{"id":"idea-moon-living-plain-evidence-summaries","kind":"idea","name":"Living plain-language evidence summaries for every common cancer question in 20 languages","route":"/ideas/idea-moon-living-plain-evidence-summaries/","asOf":"2026-09-08","days":13},{"id":"idea-moon-treatment-refusal-pathway","kind":"idea","name":"A structured pathway for patients declining proven treatment","route":"/ideas/idea-moon-treatment-refusal-pathway/","asOf":"2026-09-08","days":13},{"id":"idea-moon-population-interception","kind":"idea","name":"A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early","route":"/ideas/idea-moon-population-interception/","asOf":"2026-09-08","days":13},{"id":"idea-moon-universal-sequencing-learning-system","kind":"idea","name":"Universal tumour and germline sequencing at diagnosis feeding a shared learning system","route":"/ideas/idea-moon-universal-sequencing-learning-system/","asOf":"2026-09-08","days":13},{"id":"idea-moon-lynch-vaccine-phase3","kind":"idea","name":"A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval","route":"/ideas/idea-moon-lynch-vaccine-phase3/","asOf":"2026-09-08","days":13},{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/","asOf":"2026-09-08","days":13},{"id":"idea-moon-closed-loop-adaptive-therapy","kind":"idea","name":"Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models","route":"/ideas/idea-moon-closed-loop-adaptive-therapy/","asOf":"2026-09-08","days":13},{"id":"idea-moon-global-open-trials-os","kind":"idea","name":"A global open trials operating system any hospital can plug into","route":"/ideas/idea-moon-global-open-trials-os/","asOf":"2026-09-08","days":13},{"id":"idea-moon-open-cancer-cell-state-model","kind":"idea","name":"An open model of every cancer cell state, built from perturbation atlases","route":"/ideas/idea-moon-open-cancer-cell-state-model/","asOf":"2026-09-08","days":13},{"id":"idea-moon-cure-prizes","kind":"idea","name":"Cure-focused prizes: pay for verified long-term cures, not for drugs","route":"/ideas/idea-moon-cure-prizes/","asOf":"2026-09-08","days":13},{"id":"idea-moon-engineered-immune-surveillance","kind":"idea","name":"Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer","route":"/ideas/idea-moon-engineered-immune-surveillance/","asOf":"2026-09-08","days":13},{"id":"idea-moon-synthetic-lethality-map-every-driver","kind":"idea","name":"A synthetic lethality map for every cancer driver in every tissue context","route":"/ideas/idea-moon-synthetic-lethality-map-every-driver/","asOf":"2026-09-08","days":13},{"id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/","asOf":"2026-09-08","days":13},{"id":"idea-moon-eliminate-infection-cancers","kind":"idea","name":"Eliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV","route":"/ideas/idea-moon-eliminate-infection-cancers/","asOf":"2026-09-08","days":13},{"id":"idea-moon-mrd-weather-service","kind":"idea","name":"A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled","route":"/ideas/idea-moon-mrd-weather-service/","asOf":"2026-09-08","days":13},{"id":"idea-moon-dormancy-eradication-programme","kind":"idea","name":"Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells","route":"/ideas/idea-moon-dormancy-eradication-programme/","asOf":"2026-09-08","days":13},{"id":"idea-moon-validated-digital-twins","kind":"idea","name":"Whole-patient digital twins validated in prospective randomised trials","route":"/ideas/idea-moon-validated-digital-twins/","asOf":"2026-09-08","days":13},{"id":"idea-moon-negative-results-ledger","kind":"idea","name":"A global ledger of negative results and failed compounds with mandatory deposition","route":"/ideas/idea-moon-negative-results-ledger/","asOf":"2026-09-08","days":13},{"id":"idea-moon-generics-for-cancer-fund","kind":"idea","name":"A public fund and label pathway to trial generic drugs against cancer","route":"/ideas/idea-moon-generics-for-cancer-fund/","asOf":"2026-09-08","days":13},{"id":"idea-moon-pooled-procurement-licensing-pool","kind":"idea","name":"Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries","route":"/ideas/idea-moon-pooled-procurement-licensing-pool/","asOf":"2026-09-08","days":13},{"id":"idea-moon-brain-delivery-platform","kind":"idea","name":"A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics","route":"/ideas/idea-moon-brain-delivery-platform/","asOf":"2026-09-08","days":13},{"id":"idea-moon-rare-cancer-global-network","kind":"idea","name":"One global rare cancer network with n-of-1 and Bayesian trial frameworks","route":"/ideas/idea-moon-rare-cancer-global-network/","asOf":"2026-09-08","days":13},{"id":"idea-moon-cold-to-hot-programme","kind":"idea","name":"Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours","route":"/ideas/idea-moon-cold-to-hot-programme/","asOf":"2026-09-08","days":13},{"id":"idea-moon-cachexia-as-treatable-disease","kind":"idea","name":"Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles","route":"/ideas/idea-moon-cachexia-as-treatable-disease/","asOf":"2026-09-08","days":13},{"id":"idea-moon-individualised-dosing-all-oral-drugs","kind":"idea","name":"Model-informed individual dosing with drug-level monitoring for every oral cancer drug","route":"/ideas/idea-moon-individualised-dosing-all-oral-drugs/","asOf":"2026-09-08","days":13},{"id":"idea-moon-automated-combination-discovery","kind":"idea","name":"Automated combination discovery: patient-sample screens feeding Bayesian platform trials","route":"/ideas/idea-moon-automated-combination-discovery/","asOf":"2026-09-08","days":13},{"id":"idea-moon-indolence-classifiers-with-screening","kind":"idea","name":"Molecular indolence classifiers bundled with every screening programme","route":"/ideas/idea-moon-indolence-classifiers-with-screening/","asOf":"2026-09-08","days":13},{"id":"idea-moon-biomarker-validation-utility","kind":"idea","name":"A public biomarker validation utility with pre-diagnostic biobanks and blinded testing","route":"/ideas/idea-moon-biomarker-validation-utility/","asOf":"2026-09-08","days":13},{"id":"idea-moon-open-degrader-consortium","kind":"idea","name":"An open degrader consortium against every undruggable driver transcription factor","route":"/ideas/idea-moon-open-degrader-consortium/","asOf":"2026-09-08","days":13},{"id":"idea-moon-metastasis-prevention-indication","kind":"idea","name":"Metastasis prevention as a formal indication with its own trials and regulatory pathway","route":"/ideas/idea-moon-metastasis-prevention-indication/","asOf":"2026-09-08","days":13},{"id":"idea-moon-survivor-lifelong-care-model","kind":"idea","name":"Risk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care","route":"/ideas/idea-moon-survivor-lifelong-care-model/","asOf":"2026-09-08","days":13},{"id":"idea-moon-palliative-care-from-diagnosis-everywhere","kind":"idea","name":"Palliative care from diagnosis for every advanced cancer, including opioid access, worldwide","route":"/ideas/idea-moon-palliative-care-from-diagnosis-everywhere/","asOf":"2026-09-08","days":13},{"id":"idea-moon-geriatric-assessment-default","kind":"idea","name":"Geriatric assessment by default for every older patient, and trials that admit them","route":"/ideas/idea-moon-geriatric-assessment-default/","asOf":"2026-09-08","days":13},{"id":"idea-moon-self-driving-cancer-labs","kind":"idea","name":"Self-driving laboratories that run the cancer biology hypothesis loop autonomously","route":"/ideas/idea-moon-self-driving-cancer-labs/","asOf":"2026-09-08","days":13},{"id":"idea-moon-task-shifting-ai-oncology-capacity","kind":"idea","name":"Double oncology capacity in low-resource settings with task-shifting and AI decision support","route":"/ideas/idea-moon-task-shifting-ai-oncology-capacity/","asOf":"2026-09-08","days":13},{"id":"idea-moon-federated-rwe-network","kind":"idea","name":"A global federated real-world evidence network at regulatory grade","route":"/ideas/idea-moon-federated-rwe-network/","asOf":"2026-09-08","days":13},{"id":"idea-moon-pay-for-cure-contracts","kind":"idea","name":"Pay-for-cure contracts: instalment payments for curative therapies contingent on durable remission","route":"/ideas/idea-moon-pay-for-cure-contracts/","asOf":"2026-09-08","days":13},{"id":"idea-moon-open-source-oncology-drug-discovery","kind":"idea","name":"Open-source drug discovery to clinical proof of concept for neglected cancers","route":"/ideas/idea-moon-open-source-oncology-drug-discovery/","asOf":"2026-09-08","days":13},{"id":"idea-moon-public-phase1-factory","kind":"idea","name":"A public-benefit phase 1 factory that takes academic discoveries into first-in-human trials","route":"/ideas/idea-moon-public-phase1-factory/","asOf":"2026-09-08","days":13},{"id":"idea-moon-neoantigen-vaccines-at-scale","kind":"idea","name":"Personalised cancer vaccines at commodity cost through fully automated manufacturing","route":"/ideas/idea-moon-neoantigen-vaccines-at-scale/","asOf":"2026-09-08","days":13},{"id":"idea-moon-image-guided-surgery-everywhere","kind":"idea","name":"Real-time margin assessment and image-guided surgery as the global standard","route":"/ideas/idea-moon-image-guided-surgery-everywhere/","asOf":"2026-09-08","days":13},{"id":"idea-moon-compact-flash-proton","kind":"idea","name":"Compact FLASH and proton systems at the price of a conventional linac","route":"/ideas/idea-moon-compact-flash-proton/","asOf":"2026-09-08","days":13},{"id":"idea-moon-population-germline-screening","kind":"idea","name":"Population germline screening for hereditary cancer genes with cascade testing","route":"/ideas/idea-moon-population-germline-screening/","asOf":"2026-09-08","days":13},{"id":"idea-moon-living-machine-readable-guidelines","kind":"idea","name":"Living, machine-readable guidelines pushed to the point of care in every country","route":"/ideas/idea-moon-living-machine-readable-guidelines/","asOf":"2026-09-08","days":13},{"id":"idea-moon-continuous-ai-validation-registry","kind":"idea","name":"Continuous prospective validation for every oncology AI tool after deployment","route":"/ideas/idea-moon-continuous-ai-validation-registry/","asOf":"2026-09-08","days":13},{"id":"idea-moon-reciprocal-tumour-agnostic-approvals","kind":"idea","name":"Reciprocal recognition of tumour-agnostic and rare-indication approvals across regulators","route":"/ideas/idea-moon-reciprocal-tumour-agnostic-approvals/","asOf":"2026-09-08","days":13},{"id":"idea-moon-independent-replication-institute","kind":"idea","name":"An independent replication institute that re-tests key preclinical cancer findings before trials","route":"/ideas/idea-moon-independent-replication-institute/","asOf":"2026-09-08","days":13},{"id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","route":"/collections/src-npj-precision-oncology/","asOf":"2026-09-08","days":13},{"id":"src-ema-chmp","kind":"collection","name":"EMA news and CHMP meeting highlights","route":"/collections/src-ema-chmp/","asOf":"2026-09-08","days":13},{"id":"src-nice-ta","kind":"collection","name":"NICE technology appraisals","route":"/collections/src-nice-ta/","asOf":"2026-09-08","days":13},{"id":"src-asco-post","kind":"collection","name":"The ASCO Post","route":"/collections/src-asco-post/","asOf":"2026-09-08","days":13},{"id":"src-onclive","kind":"collection","name":"OncLive","route":"/collections/src-onclive/","asOf":"2026-09-08","days":13},{"id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","asOf":"2026-09-08","days":13},{"id":"src-cancer-network","kind":"collection","name":"CancerNetwork (ONCOLOGY)","route":"/collections/src-cancer-network/","asOf":"2026-09-08","days":13},{"id":"src-cancer-letter","kind":"collection","name":"The Cancer Letter","route":"/collections/src-cancer-letter/","asOf":"2026-09-08","days":13},{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/","asOf":"2026-09-08","days":13},{"id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","route":"/collections/src-fierce-biotech/","asOf":"2026-09-08","days":13},{"id":"src-stat-news","kind":"collection","name":"STAT News","route":"/collections/src-stat-news/","asOf":"2026-09-08","days":13},{"id":"src-biocentury","kind":"collection","name":"BioCentury","route":"/collections/src-biocentury/","asOf":"2026-09-08","days":13},{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","asOf":"2026-09-08","days":13},{"id":"src-adc-review","kind":"collection","name":"ADC Review","route":"/collections/src-adc-review/","asOf":"2026-09-08","days":13},{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","asOf":"2026-09-08","days":13},{"id":"src-oncodaily","kind":"collection","name":"OncoDaily","route":"/collections/src-oncodaily/","asOf":"2026-09-08","days":13},{"id":"src-healio-hemonc","kind":"collection","name":"Healio Hematology/Oncology","route":"/collections/src-healio-hemonc/","asOf":"2026-09-08","days":13},{"id":"src-medscape-oncology","kind":"collection","name":"Medscape Oncology","route":"/collections/src-medscape-oncology/","asOf":"2026-09-08","days":13},{"id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","route":"/collections/src-biopharma-dive/","asOf":"2026-09-08","days":13},{"id":"src-asco-meeting-library","kind":"collection","name":"ASCO Meeting Library","route":"/collections/src-asco-meeting-library/","asOf":"2026-09-08","days":13},{"id":"src-esmo-congress","kind":"collection","name":"ESMO Congress","route":"/collections/src-esmo-congress/","asOf":"2026-09-08","days":13},{"id":"src-aacr-annual","kind":"collection","name":"AACR Annual Meeting","route":"/collections/src-aacr-annual/","asOf":"2026-09-08","days":13},{"id":"src-ash-annual","kind":"collection","name":"ASH Annual Meeting","route":"/collections/src-ash-annual/","asOf":"2026-09-08","days":13},{"id":"src-sabcs","kind":"collection","name":"San Antonio Breast Cancer Symposium","route":"/collections/src-sabcs/","asOf":"2026-09-08","days":13},{"id":"src-astro","kind":"collection","name":"ASTRO Annual Meeting","route":"/collections/src-astro/","asOf":"2026-09-08","days":13},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","asOf":"2026-09-08","days":13},{"id":"src-asco-daily-news","kind":"collection","name":"ASCO Daily News","route":"/collections/src-asco-daily-news/","asOf":"2026-09-08","days":13},{"id":"src-nature-briefing-cancer","kind":"collection","name":"Nature Briefing: Cancer","route":"/collections/src-nature-briefing-cancer/","asOf":"2026-09-08","days":13},{"id":"src-cruk-about-cancer","kind":"collection","name":"Cancer Research UK: About Cancer","route":"/collections/src-cruk-about-cancer/","asOf":"2026-09-08","days":13},{"id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","asOf":"2026-09-08","days":13},{"id":"src-lbbc","kind":"collection","name":"Living Beyond Breast Cancer","route":"/collections/src-lbbc/","asOf":"2026-09-08","days":13},{"id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","asOf":"2026-09-08","days":13},{"id":"src-tnbc-foundation","kind":"collection","name":"Triple Negative Breast Cancer Foundation","route":"/collections/src-tnbc-foundation/","asOf":"2026-09-08","days":13},{"id":"src-semantic-scholar","kind":"collection","name":"Semantic Scholar","route":"/collections/src-semantic-scholar/","asOf":"2026-09-08","days":13},{"id":"src-dimensions","kind":"collection","name":"Dimensions","route":"/collections/src-dimensions/","asOf":"2026-09-08","days":13},{"id":"metastatic-cascade","kind":"pathway","name":"The metastatic cascade","route":"/pathways/metastatic-cascade/","asOf":"2026-09-08","days":13},{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/","asOf":"2026-09-08","days":13},{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/","asOf":"2026-09-08","days":13},{"id":"cancer-metabolism","kind":"pathway","name":"Cancer metabolism","route":"/pathways/cancer-metabolism/","asOf":"2026-09-08","days":13},{"id":"replication-stress","kind":"pathway","name":"DNA replication stress","route":"/pathways/replication-stress/","asOf":"2026-09-08","days":13},{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/","asOf":"2026-09-08","days":13},{"id":"telomere-maintenance","kind":"pathway","name":"Telomere maintenance & replicative immortality","route":"/pathways/telomere-maintenance/","asOf":"2026-09-08","days":13},{"id":"autophagy","kind":"pathway","name":"Autophagy","route":"/pathways/autophagy/","asOf":"2026-09-08","days":13},{"id":"ferroptosis-cell-death","kind":"pathway","name":"Ferroptosis & regulated cell death","route":"/pathways/ferroptosis-cell-death/","asOf":"2026-09-08","days":13},{"id":"senescence","kind":"pathway","name":"Cellular senescence","route":"/pathways/senescence/","asOf":"2026-09-08","days":13},{"id":"cancer-stem-cells-plasticity","kind":"pathway","name":"Cancer stem cells & phenotypic plasticity","route":"/pathways/cancer-stem-cells-plasticity/","asOf":"2026-09-08","days":13},{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/","asOf":"2026-09-08","days":13},{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/","asOf":"2026-09-08","days":13},{"id":"hedgehog","kind":"pathway","name":"Hedgehog signalling","route":"/pathways/hedgehog/","asOf":"2026-09-08","days":13},{"id":"notch","kind":"pathway","name":"Notch signalling","route":"/pathways/notch/","asOf":"2026-09-08","days":13},{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/","asOf":"2026-09-08","days":13},{"id":"tgf-beta","kind":"pathway","name":"TGF-β signalling","route":"/pathways/tgf-beta/","asOf":"2026-09-08","days":13},{"id":"hippo-yap","kind":"pathway","name":"Hippo-YAP/TAZ","route":"/pathways/hippo-yap/","asOf":"2026-09-08","days":13},{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/","asOf":"2026-09-08","days":13},{"id":"keap1-nrf2","kind":"pathway","name":"KEAP1-NRF2 antioxidant pathway","route":"/pathways/keap1-nrf2/","asOf":"2026-09-08","days":13},{"id":"swi-snf-chromatin","kind":"pathway","name":"SWI/SNF chromatin remodelling","route":"/pathways/swi-snf-chromatin/","asOf":"2026-09-08","days":13},{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/","asOf":"2026-09-08","days":13},{"id":"rna-splicing","kind":"pathway","name":"RNA splicing","route":"/pathways/rna-splicing/","asOf":"2026-09-08","days":13},{"id":"mrna-translation-eif4f","kind":"pathway","name":"mRNA translation (eIF4F / mTOR)","route":"/pathways/mrna-translation-eif4f/","asOf":"2026-09-08","days":13},{"id":"circadian-control","kind":"pathway","name":"Circadian control","route":"/pathways/circadian-control/","asOf":"2026-09-08","days":13},{"id":"microbiome-tumour","kind":"pathway","name":"Microbiome-tumour interactions","route":"/pathways/microbiome-tumour/","asOf":"2026-09-08","days":13},{"id":"cancer-neuroscience","kind":"pathway","name":"Cancer neuroscience (nerve-tumour signalling)","route":"/pathways/cancer-neuroscience/","asOf":"2026-09-08","days":13},{"id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","asOf":"2026-09-08","days":13},{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/","asOf":"2026-09-08","days":13},{"id":"field-cancerisation","kind":"pathway","name":"Field cancerisation","route":"/pathways/field-cancerisation/","asOf":"2026-09-08","days":13},{"id":"tumor-dormancy","kind":"pathway","name":"Tumour dormancy","route":"/pathways/tumor-dormancy/","asOf":"2026-09-08","days":13},{"id":"hallmarks-of-cancer","kind":"term","name":"Hallmarks of Cancer","route":"/terms/hallmarks-of-cancer/","asOf":"2026-09-08","days":13},{"id":"sustaining-proliferative-signaling","kind":"term","name":"Hallmark: sustaining proliferative signalling","route":"/terms/sustaining-proliferative-signaling/","asOf":"2026-09-08","days":13},{"id":"evading-growth-suppressors","kind":"term","name":"Hallmark: evading growth suppressors","route":"/terms/evading-growth-suppressors/","asOf":"2026-09-08","days":13},{"id":"resisting-cell-death","kind":"term","name":"Hallmark: resisting cell death","route":"/terms/resisting-cell-death/","asOf":"2026-09-08","days":13},{"id":"enabling-replicative-immortality","kind":"term","name":"Hallmark: enabling replicative immortality","route":"/terms/enabling-replicative-immortality/","asOf":"2026-09-08","days":13},{"id":"inducing-angiogenesis","kind":"term","name":"Hallmark: inducing or accessing vasculature","route":"/terms/inducing-angiogenesis/","asOf":"2026-09-08","days":13},{"id":"activating-invasion-metastasis","kind":"term","name":"Hallmark: activating invasion and metastasis","route":"/terms/activating-invasion-metastasis/","asOf":"2026-09-08","days":13},{"id":"deregulating-cellular-energetics","kind":"term","name":"Hallmark: reprogramming cellular metabolism","route":"/terms/deregulating-cellular-energetics/","asOf":"2026-09-08","days":13},{"id":"avoiding-immune-destruction","kind":"term","name":"Hallmark: avoiding immune destruction","route":"/terms/avoiding-immune-destruction/","asOf":"2026-09-08","days":13},{"id":"genome-instability-mutation","kind":"term","name":"Enabling characteristic: genome instability and mutation","route":"/terms/genome-instability-mutation/","asOf":"2026-09-08","days":13},{"id":"tumor-promoting-inflammation","kind":"term","name":"Enabling characteristic: tumour-promoting inflammation","route":"/terms/tumor-promoting-inflammation/","asOf":"2026-09-08","days":13},{"id":"unlocking-phenotypic-plasticity","kind":"term","name":"Hallmark (2022): unlocking phenotypic plasticity","route":"/terms/unlocking-phenotypic-plasticity/","asOf":"2026-09-08","days":13},{"id":"nonmutational-epigenetic-reprogramming","kind":"term","name":"Hallmark (2022): non-mutational epigenetic reprogramming","route":"/terms/nonmutational-epigenetic-reprogramming/","asOf":"2026-09-08","days":13},{"id":"polymorphic-microbiomes","kind":"term","name":"Hallmark (2022): polymorphic microbiomes","route":"/terms/polymorphic-microbiomes/","asOf":"2026-09-08","days":13},{"id":"senescent-cells","kind":"term","name":"Hallmark (2022): senescent cells","route":"/terms/senescent-cells/","asOf":"2026-09-08","days":13},{"id":"disseminated-tumor-cells","kind":"term","name":"Disseminated tumour cells (DTCs)","route":"/terms/disseminated-tumor-cells/","asOf":"2026-09-08","days":13},{"id":"warburg-effect","kind":"term","name":"Warburg effect","route":"/terms/warburg-effect/","asOf":"2026-09-08","days":13},{"id":"immune-exclusion","kind":"term","name":"Immune exclusion","route":"/terms/immune-exclusion/","asOf":"2026-09-08","days":13},{"id":"cancer-associated-fibroblasts","kind":"term","name":"Cancer-associated fibroblasts (CAFs)","route":"/terms/cancer-associated-fibroblasts/","asOf":"2026-09-08","days":13},{"id":"tumor-associated-macrophages","kind":"term","name":"Tumour-associated macrophages (TAMs)","route":"/terms/tumor-associated-macrophages/","asOf":"2026-09-08","days":13},{"id":"myeloid-derived-suppressor-cells","kind":"term","name":"Myeloid-derived suppressor cells (MDSCs)","route":"/terms/myeloid-derived-suppressor-cells/","asOf":"2026-09-08","days":13},{"id":"whole-genome-doubling","kind":"term","name":"Whole-genome doubling (WGD)","route":"/terms/whole-genome-doubling/","asOf":"2026-09-08","days":13},{"id":"idea-dtc-colonisation-determinants","kind":"idea","name":"What decides which disseminated cells ever colonise?","route":"/ideas/idea-dtc-colonisation-determinants/","asOf":"2026-09-08","days":13},{"id":"idea-immune-exclusion-drivers","kind":"idea","name":"What actually holds T cells at the tumour border?","route":"/ideas/idea-immune-exclusion-drivers/","asOf":"2026-09-08","days":13},{"id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/","asOf":"2026-09-08","days":13},{"id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/","asOf":"2026-09-08","days":13},{"id":"idea-neoantigen-immunogenicity-rules","kind":"idea","name":"What makes a neoantigen actually immunogenic?","route":"/ideas/idea-neoantigen-immunogenicity-rules/","asOf":"2026-09-08","days":13},{"id":"idea-dormancy-maintenance-therapy","kind":"idea","name":"Keep them asleep: dormancy maintenance as adjuvant therapy","route":"/ideas/idea-dormancy-maintenance-therapy/","asOf":"2026-09-08","days":13},{"id":"idea-metabolic-vulnerability-mapping","kind":"idea","name":"Map metabolic dependencies in the patient, not the dish","route":"/ideas/idea-metabolic-vulnerability-mapping/","asOf":"2026-09-08","days":13},{"id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","route":"/ideas/idea-senolytics-after-chemo/","asOf":"2026-09-08","days":13},{"id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/","asOf":"2026-09-08","days":13},{"id":"idea-nerve-tumour-blockade","kind":"idea","name":"Cut the nerve supply to tumours with old drugs","route":"/ideas/idea-nerve-tumour-blockade/","asOf":"2026-09-08","days":13},{"id":"idea-cachexia-gdf15-prevention","kind":"idea","name":"Treat cachexia before it starts","route":"/ideas/idea-cachexia-gdf15-prevention/","asOf":"2026-09-08","days":13},{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","asOf":"2026-09-08","days":13},{"id":"idea-field-interception","kind":"idea","name":"Intercept cancer at the field stage","route":"/ideas/idea-field-interception/","asOf":"2026-09-08","days":13},{"id":"idea-ferroptosis-persisters","kind":"idea","name":"Kill drug-tolerant persisters through ferroptosis","route":"/ideas/idea-ferroptosis-persisters/","asOf":"2026-09-08","days":13},{"id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/","asOf":"2026-09-08","days":13},{"id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","route":"/ideas/idea-chronotherapy-immunotherapy/","asOf":"2026-09-08","days":13},{"id":"idea-ecdna-targeting","kind":"idea","name":"Attack extrachromosomal DNA, the engine of oncogene amplification","route":"/ideas/idea-ecdna-targeting/","asOf":"2026-09-08","days":13},{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/","asOf":"2026-09-08","days":13},{"id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/","asOf":"2026-09-08","days":13},{"id":"closed-automated-cell-manufacturing","kind":"technology","name":"Closed automated cell-therapy manufacturing","route":"/technologies/closed-automated-cell-manufacturing/","asOf":"2026-09-08","days":13},{"id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","route":"/technologies/point-of-care-cell-manufacturing/","asOf":"2026-09-08","days":13},{"id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/","asOf":"2026-09-08","days":13},{"id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/","asOf":"2026-09-08","days":13},{"id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","route":"/technologies/adc-cdmo-manufacturing/","asOf":"2026-09-08","days":13},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/","asOf":"2026-09-08","days":13},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/","asOf":"2026-09-08","days":13},{"id":"long-read-sequencing","kind":"technology","name":"Long-read sequencing (PacBio, Oxford Nanopore)","route":"/technologies/long-read-sequencing/","asOf":"2026-09-08","days":13},{"id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/","asOf":"2026-09-08","days":13},{"id":"spatial-biology-instruments","kind":"technology","name":"Spatial biology instruments","route":"/technologies/spatial-biology-instruments/","asOf":"2026-09-08","days":13},{"id":"whole-slide-scanners","kind":"technology","name":"Whole-slide scanners and image management","route":"/technologies/whole-slide-scanners/","asOf":"2026-09-08","days":13},{"id":"treatment-planning-systems","kind":"technology","name":"Radiotherapy treatment planning and QA software","route":"/technologies/treatment-planning-systems/","asOf":"2026-09-08","days":13},{"id":"auto-contouring-ai","kind":"technology","name":"AI auto-contouring and adaptive planning","route":"/technologies/auto-contouring-ai/","asOf":"2026-09-08","days":13},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/","asOf":"2026-09-08","days":13},{"id":"clinical-trial-software","kind":"technology","name":"Clinical trial software (EDC, eCOA, CTMS, RTSM)","route":"/technologies/clinical-trial-software/","asOf":"2026-09-08","days":13},{"id":"decentralised-clinical-trials","kind":"technology","name":"Decentralised and hybrid clinical trials","route":"/technologies/decentralised-clinical-trials/","asOf":"2026-09-08","days":13},{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/","asOf":"2026-09-08","days":13},{"id":"contract-research-organisations","kind":"technology","name":"Contract research organisations (CROs)","route":"/technologies/contract-research-organisations/","asOf":"2026-09-08","days":13},{"id":"imaging-core-labs","kind":"technology","name":"Imaging core labs and central review","route":"/technologies/imaging-core-labs/","asOf":"2026-09-08","days":13},{"id":"biobanking","kind":"technology","name":"Biobanking and tissue procurement","route":"/technologies/biobanking/","asOf":"2026-09-08","days":13},{"id":"reference-laboratories","kind":"technology","name":"Reference laboratories and companion-diagnostic testing","route":"/technologies/reference-laboratories/","asOf":"2026-09-08","days":13},{"id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/","asOf":"2026-09-08","days":13},{"id":"nuclear-medicine-hardware","kind":"technology","name":"Nuclear medicine and total-body PET hardware","route":"/technologies/nuclear-medicine-hardware/","asOf":"2026-09-08","days":13},{"id":"remote-patient-monitoring","kind":"technology","name":"Electronic patient-reported outcomes and remote monitoring","route":"/technologies/remote-patient-monitoring/","asOf":"2026-09-08","days":13},{"id":"pharmacy-automation","kind":"technology","name":"Oncology pharmacy automation and compounding robots","route":"/technologies/pharmacy-automation/","asOf":"2026-09-08","days":13},{"id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/","asOf":"2026-09-08","days":13},{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/","asOf":"2026-09-08","days":13},{"id":"generic-drug-shortage-response","kind":"technology","name":"Generic oncology drug supply and shortage mitigation","route":"/technologies/generic-drug-shortage-response/","asOf":"2026-09-08","days":13},{"id":"hospital-information-systems-oncology","kind":"technology","name":"Oncology EHR modules and treatment pathways","route":"/technologies/hospital-information-systems-oncology/","asOf":"2026-09-08","days":13},{"id":"high-potency-payload-synthesis","kind":"technology","name":"Payload-linker synthesis (high-potency API)","route":"/technologies/high-potency-payload-synthesis/","asOf":"2026-09-08","days":13},{"id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/","asOf":"2026-09-08","days":13},{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/","asOf":"2026-09-08","days":13},{"id":"cell-therapy-orchestration-software","kind":"technology","name":"Cell-therapy orchestration and chain-of-identity software","route":"/technologies/cell-therapy-orchestration-software/","asOf":"2026-09-08","days":13},{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/","asOf":"2026-09-08","days":13},{"id":"allogeneic-cell-banking","kind":"technology","name":"Allogeneic donor and iPSC master cell banks","route":"/technologies/allogeneic-cell-banking/","asOf":"2026-09-08","days":13},{"id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/","asOf":"2026-09-08","days":13},{"id":"medical-cyclotrons-synthesis-modules","kind":"technology","name":"Medical cyclotrons, hot cells, and synthesis modules","route":"/technologies/medical-cyclotrons-synthesis-modules/","asOf":"2026-09-08","days":13},{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","asOf":"2026-09-08","days":13},{"id":"ngs-bioinformatics-software","kind":"technology","name":"Clinical NGS bioinformatics and variant interpretation","route":"/technologies/ngs-bioinformatics-software/","asOf":"2026-09-08","days":13},{"id":"genomics-cloud-platforms","kind":"technology","name":"Genomics cloud and secure research environments","route":"/technologies/genomics-cloud-platforms/","asOf":"2026-09-08","days":13},{"id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/","asOf":"2026-09-08","days":13},{"id":"cancer-registries-surveillance","kind":"technology","name":"Cancer registries and population surveillance","route":"/technologies/cancer-registries-surveillance/","asOf":"2026-09-08","days":13},{"id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/","asOf":"2026-09-08","days":13},{"id":"structural-biology-infrastructure","kind":"technology","name":"Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)","route":"/technologies/structural-biology-infrastructure/","asOf":"2026-09-08","days":13},{"id":"high-throughput-screening-libraries","kind":"technology","name":"High-throughput screening and DNA-encoded libraries","route":"/technologies/high-throughput-screening-libraries/","asOf":"2026-09-08","days":13},{"id":"preanalytics-sample-stabilisation","kind":"technology","name":"Pre-analytics: blood-collection tubes and tissue fixation","route":"/technologies/preanalytics-sample-stabilisation/","asOf":"2026-09-08","days":13},{"id":"ihc-autostainers-histology-automation","kind":"technology","name":"Histology automation and IHC autostainers","route":"/technologies/ihc-autostainers-histology-automation/","asOf":"2026-09-08","days":13},{"id":"infusion-devices-vascular-access","kind":"technology","name":"Infusion pumps, ports, and ambulatory chemotherapy devices","route":"/technologies/infusion-devices-vascular-access/","asOf":"2026-09-08","days":13},{"id":"federated-learning-medical-ai","kind":"technology","name":"Federated learning and privacy-preserving AI","route":"/technologies/federated-learning-medical-ai/","asOf":"2026-09-08","days":13},{"id":"telemedicine-teleoncology","kind":"technology","name":"Telemedicine, teleoncology, and telepathology","route":"/technologies/telemedicine-teleoncology/","asOf":"2026-09-08","days":13},{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/","asOf":"2026-09-08","days":13},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/","asOf":"2026-09-08","days":13},{"id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/","asOf":"2026-09-08","days":13},{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","route":"/companies/cytiva/","asOf":"2026-09-08","days":13},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","asOf":"2026-09-08","days":13},{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","route":"/companies/oxford-biomedica/","asOf":"2026-09-08","days":13},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/","asOf":"2026-09-08","days":13},{"id":"charles-river","kind":"company","name":"Charles River Laboratories","route":"/companies/charles-river/","asOf":"2026-09-08","days":13},{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/","asOf":"2026-09-08","days":13},{"id":"touchlight","kind":"company","name":"Touchlight","route":"/companies/touchlight/","asOf":"2026-09-08","days":13},{"id":"wuxi-xdc","kind":"company","name":"WuXi XDC","route":"/companies/wuxi-xdc/","asOf":"2026-09-08","days":13},{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","route":"/companies/samsung-biologics/","asOf":"2026-09-08","days":13},{"id":"piramal-pharma-solutions","kind":"company","name":"Piramal Pharma Solutions","route":"/companies/piramal-pharma-solutions/","asOf":"2026-09-08","days":13},{"id":"abzena","kind":"company","name":"Abzena","route":"/companies/abzena/","asOf":"2026-09-08","days":13},{"id":"catalent","kind":"company","name":"Catalent (Novo Holdings)","route":"/companies/catalent/","asOf":"2026-09-08","days":13},{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","asOf":"2026-09-08","days":13},{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","asOf":"2026-09-08","days":13},{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","asOf":"2026-09-08","days":13},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","asOf":"2026-09-08","days":13},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","asOf":"2026-09-08","days":13},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","asOf":"2026-09-08","days":13},{"id":"pacbio","kind":"company","name":"PacBio","route":"/companies/pacbio/","asOf":"2026-09-08","days":13},{"id":"oxford-nanopore","kind":"company","name":"Oxford Nanopore Technologies","route":"/companies/oxford-nanopore/","asOf":"2026-09-08","days":13},{"id":"ultima-genomics","kind":"company","name":"Ultima Genomics","route":"/companies/ultima-genomics/","asOf":"2026-09-08","days":13},{"id":"element-biosciences","kind":"company","name":"Element Biosciences","route":"/companies/element-biosciences/","asOf":"2026-09-08","days":13},{"id":"mgi-tech","kind":"company","name":"MGI Tech","route":"/companies/mgi-tech/","asOf":"2026-09-08","days":13},{"id":"bruker","kind":"company","name":"Bruker (Bruker Spatial Biology)","route":"/companies/bruker/","asOf":"2026-09-08","days":13},{"id":"vizgen","kind":"company","name":"Vizgen","route":"/companies/vizgen/","asOf":"2026-09-08","days":13},{"id":"akoya-biosciences","kind":"company","name":"Akoya Biosciences","route":"/companies/akoya-biosciences/","asOf":"2026-09-08","days":13},{"id":"leica-biosystems","kind":"company","name":"Leica Biosystems (Danaher)","route":"/companies/leica-biosystems/","asOf":"2026-09-08","days":13},{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","asOf":"2026-09-08","days":13},{"id":"3dhistech","kind":"company","name":"3DHISTECH","route":"/companies/3dhistech/","asOf":"2026-09-08","days":13},{"id":"philips","kind":"company","name":"Philips","route":"/companies/philips/","asOf":"2026-09-08","days":13},{"id":"sectra","kind":"company","name":"Sectra","route":"/companies/sectra/","asOf":"2026-09-08","days":13},{"id":"proscia","kind":"company","name":"Proscia","route":"/companies/proscia/","asOf":"2026-09-08","days":13},{"id":"indica-labs","kind":"company","name":"Indica Labs","route":"/companies/indica-labs/","asOf":"2026-09-08","days":13},{"id":"raysearch","kind":"company","name":"RaySearch Laboratories","route":"/companies/raysearch/","asOf":"2026-09-08","days":13},{"id":"sun-nuclear","kind":"company","name":"Sun Nuclear (Mirion)","route":"/companies/sun-nuclear/","asOf":"2026-09-08","days":13},{"id":"brainlab","kind":"company","name":"Brainlab","route":"/companies/brainlab/","asOf":"2026-09-08","days":13},{"id":"limbus-ai","kind":"company","name":"Limbus AI","route":"/companies/limbus-ai/","asOf":"2026-09-08","days":13},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","asOf":"2026-09-08","days":13},{"id":"therapanacea","kind":"company","name":"TheraPanacea","route":"/companies/therapanacea/","asOf":"2026-09-08","days":13},{"id":"mvision-ai","kind":"company","name":"MVision AI","route":"/companies/mvision-ai/","asOf":"2026-09-08","days":13},{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/","asOf":"2026-09-08","days":13},{"id":"concertai","kind":"company","name":"ConcertAI","route":"/companies/concertai/","asOf":"2026-09-08","days":13},{"id":"cota-healthcare","kind":"company","name":"COTA","route":"/companies/cota-healthcare/","asOf":"2026-09-08","days":13},{"id":"trinetx","kind":"company","name":"TriNetX","route":"/companies/trinetx/","asOf":"2026-09-08","days":13},{"id":"komodo-health","kind":"company","name":"Komodo Health","route":"/companies/komodo-health/","asOf":"2026-09-08","days":13},{"id":"datavant","kind":"company","name":"Datavant","route":"/companies/datavant/","asOf":"2026-09-08","days":13},{"id":"medidata","kind":"company","name":"Medidata (Dassault Systèmes)","route":"/companies/medidata/","asOf":"2026-09-08","days":13},{"id":"veeva-systems","kind":"company","name":"Veeva Systems","route":"/companies/veeva-systems/","asOf":"2026-09-08","days":13},{"id":"oracle-health-sciences","kind":"company","name":"Oracle Health (Cerner) & Oracle Life Sciences","route":"/companies/oracle-health-sciences/","asOf":"2026-09-08","days":13},{"id":"epic-systems","kind":"company","name":"Epic Systems","route":"/companies/epic-systems/","asOf":"2026-09-08","days":13},{"id":"medable","kind":"company","name":"Medable","route":"/companies/medable/","asOf":"2026-09-08","days":13},{"id":"science-37","kind":"company","name":"Science 37 (eMed)","route":"/companies/science-37/","asOf":"2026-09-08","days":13},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/","asOf":"2026-09-08","days":13},{"id":"oneoncology","kind":"company","name":"OneOncology","route":"/companies/oneoncology/","asOf":"2026-09-08","days":13},{"id":"florida-cancer-specialists","kind":"company","name":"Florida Cancer Specialists & Research Institute","route":"/companies/florida-cancer-specialists/","asOf":"2026-09-08","days":13},{"id":"sarah-cannon-research-institute","kind":"company","name":"Sarah Cannon Research Institute","route":"/companies/sarah-cannon-research-institute/","asOf":"2026-09-08","days":13},{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/","asOf":"2026-09-08","days":13},{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/","asOf":"2026-09-08","days":13},{"id":"parexel","kind":"company","name":"Parexel","route":"/companies/parexel/","asOf":"2026-09-08","days":13},{"id":"fortrea","kind":"company","name":"Fortrea","route":"/companies/fortrea/","asOf":"2026-09-08","days":13},{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/","asOf":"2026-09-08","days":13},{"id":"calyx","kind":"company","name":"Calyx","route":"/companies/calyx/","asOf":"2026-09-08","days":13},{"id":"clario","kind":"company","name":"Clario","route":"/companies/clario/","asOf":"2026-09-08","days":13},{"id":"discovery-life-sciences","kind":"company","name":"Discovery Life Sciences","route":"/companies/discovery-life-sciences/","asOf":"2026-09-08","days":13},{"id":"indivumed","kind":"company","name":"Indivumed","route":"/companies/indivumed/","asOf":"2026-09-08","days":13},{"id":"hub-organoids","kind":"company","name":"HUB Organoids","route":"/companies/hub-organoids/","asOf":"2026-09-08","days":13},{"id":"labcorp","kind":"company","name":"Labcorp","route":"/companies/labcorp/","asOf":"2026-09-08","days":13},{"id":"quest-diagnostics","kind":"company","name":"Quest Diagnostics","route":"/companies/quest-diagnostics/","asOf":"2026-09-08","days":13},{"id":"neogenomics","kind":"company","name":"NeoGenomics","route":"/companies/neogenomics/","asOf":"2026-09-08","days":13},{"id":"agilent","kind":"company","name":"Agilent Technologies (Dako)","route":"/companies/agilent/","asOf":"2026-09-08","days":13},{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","asOf":"2026-09-08","days":13},{"id":"kaiku-health","kind":"company","name":"Kaiku Health (Elekta)","route":"/companies/kaiku-health/","asOf":"2026-09-08","days":13},{"id":"omnicell","kind":"company","name":"Omnicell","route":"/companies/omnicell/","asOf":"2026-09-08","days":13},{"id":"becton-dickinson","kind":"company","name":"BD (Becton, Dickinson and Company)","route":"/companies/becton-dickinson/","asOf":"2026-09-08","days":13},{"id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","asOf":"2026-09-08","days":13},{"id":"google-health","kind":"company","name":"Google (Health, DeepMind, Verily)","route":"/companies/google-health/","asOf":"2026-09-08","days":13},{"id":"civica-rx","kind":"company","name":"Civica Rx","route":"/companies/civica-rx/","asOf":"2026-09-08","days":13},{"id":"terumo-bct","kind":"company","name":"Terumo Blood and Cell Technologies","route":"/companies/terumo-bct/","asOf":"2026-09-08","days":13},{"id":"fresenius-kabi","kind":"company","name":"Fresenius Kabi","route":"/companies/fresenius-kabi/","asOf":"2026-09-08","days":13},{"id":"cryoport","kind":"company","name":"Cryoport","route":"/companies/cryoport/","asOf":"2026-09-08","days":13},{"id":"biolife-solutions","kind":"company","name":"BioLife Solutions","route":"/companies/biolife-solutions/","asOf":"2026-09-08","days":13},{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/","asOf":"2026-09-08","days":13},{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","route":"/companies/boehringer-ingelheim-biox/","asOf":"2026-09-08","days":13},{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","asOf":"2026-09-08","days":13},{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","asOf":"2026-09-08","days":13},{"id":"sophia-genetics","kind":"company","name":"SOPHiA GENETICS","route":"/companies/sophia-genetics/","asOf":"2026-09-08","days":13},{"id":"qiagen","kind":"company","name":"QIAGEN","route":"/companies/qiagen/","asOf":"2026-09-08","days":13},{"id":"velsera","kind":"company","name":"Velsera (Seven Bridges and Pierian)","route":"/companies/velsera/","asOf":"2026-09-08","days":13},{"id":"dnanexus","kind":"company","name":"DNAnexus","route":"/companies/dnanexus/","asOf":"2026-09-08","days":13},{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","route":"/companies/standard-biotools/","asOf":"2026-09-08","days":13},{"id":"streck","kind":"company","name":"Streck","route":"/companies/streck/","asOf":"2026-09-08","days":13},{"id":"sakura-finetek","kind":"company","name":"Sakura Finetek","route":"/companies/sakura-finetek/","asOf":"2026-09-08","days":13},{"id":"baxter","kind":"company","name":"Baxter International","route":"/companies/baxter/","asOf":"2026-09-08","days":13},{"id":"b-braun","kind":"company","name":"B. Braun","route":"/companies/b-braun/","asOf":"2026-09-08","days":13},{"id":"project-optimus","kind":"term","name":"Project Optimus","route":"/terms/project-optimus/","asOf":"2026-09-08","days":13},{"id":"project-orbis","kind":"term","name":"Project Orbis","route":"/terms/project-orbis/","asOf":"2026-09-08","days":13},{"id":"real-time-oncology-review","kind":"term","name":"Real-Time Oncology Review (RTOR) and Assessment Aid","route":"/terms/real-time-oncology-review/","asOf":"2026-09-08","days":13},{"id":"project-frontrunner","kind":"term","name":"Project FrontRunner","route":"/terms/project-frontrunner/","asOf":"2026-09-08","days":13},{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/","asOf":"2026-09-08","days":13},{"id":"nccn-compendium","kind":"term","name":"NCCN Compendium and drug compendia","route":"/terms/nccn-compendium/","asOf":"2026-09-08","days":13},{"id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/","asOf":"2026-09-08","days":13},{"id":"omop-ohdsi","kind":"term","name":"OMOP common data model and OHDSI","route":"/terms/omop-ohdsi/","asOf":"2026-09-08","days":13},{"id":"mcode","kind":"term","name":"mCODE (minimal Common Oncology Data Elements)","route":"/terms/mcode/","asOf":"2026-09-08","days":13},{"id":"bicr","kind":"term","name":"Blinded independent central review (BICR)","route":"/terms/bicr/","asOf":"2026-09-08","days":13},{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/","asOf":"2026-09-08","days":13},{"id":"biosecure-act","kind":"term","name":"BIOSECURE Act","route":"/terms/biosecure-act/","asOf":"2026-09-08","days":13},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","asOf":"2026-09-08","days":13},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","asOf":"2026-09-08","days":13},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","asOf":"2026-09-08","days":13},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","asOf":"2026-09-08","days":13},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","asOf":"2026-09-08","days":13},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","asOf":"2026-09-08","days":13},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","asOf":"2026-09-08","days":13},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","asOf":"2026-09-08","days":13},{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","asOf":"2026-09-08","days":13},{"id":"bpdcn","kind":"cancer","name":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN)","route":"/cancers/bpdcn/","asOf":"2026-09-08","days":13},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","asOf":"2026-09-08","days":13},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","asOf":"2026-09-08","days":13},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","asOf":"2026-09-08","days":13},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","asOf":"2026-09-08","days":13},{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","asOf":"2026-09-08","days":13},{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","asOf":"2026-09-08","days":13},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","asOf":"2026-09-08","days":13},{"id":"appendiceal","kind":"cancer","name":"Appendiceal cancer and pseudomyxoma peritonei","route":"/cancers/appendiceal/","asOf":"2026-09-08","days":13},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","asOf":"2026-09-08","days":13},{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/","asOf":"2026-09-08","days":13},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","asOf":"2026-09-08","days":13},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","asOf":"2026-09-08","days":13},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/","asOf":"2026-09-08","days":13},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","asOf":"2026-09-08","days":13},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","asOf":"2026-09-08","days":13},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","asOf":"2026-09-08","days":13},{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","asOf":"2026-09-08","days":13},{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","asOf":"2026-09-08","days":13},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","asOf":"2026-09-08","days":13},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","asOf":"2026-09-08","days":13},{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","asOf":"2026-09-08","days":13},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","asOf":"2026-09-08","days":13},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","asOf":"2026-09-08","days":13},{"id":"nilotinib","kind":"drug","name":"Nilotinib","route":"/drugs/nilotinib/","asOf":"2026-09-08","days":13},{"id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/","asOf":"2026-09-08","days":13},{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/","asOf":"2026-09-08","days":13},{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/","asOf":"2026-09-08","days":13},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","asOf":"2026-09-08","days":13},{"id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/","asOf":"2026-09-08","days":13},{"id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/","asOf":"2026-09-08","days":13},{"id":"momelotinib","kind":"drug","name":"Momelotinib","route":"/drugs/momelotinib/","asOf":"2026-09-08","days":13},{"id":"hydroxyurea","kind":"drug","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/","asOf":"2026-09-08","days":13},{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/","asOf":"2026-09-08","days":13},{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/","asOf":"2026-09-08","days":13},{"id":"glasdegib","kind":"drug","name":"Glasdegib","route":"/drugs/glasdegib/","asOf":"2026-09-08","days":13},{"id":"arsenic-trioxide","kind":"drug","name":"Arsenic trioxide","route":"/drugs/arsenic-trioxide/","asOf":"2026-09-08","days":13},{"id":"tretinoin-atra","kind":"drug","name":"Tretinoin (all-trans retinoic acid, ATRA)","route":"/drugs/tretinoin-atra/","asOf":"2026-09-08","days":13},{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/","asOf":"2026-09-08","days":13},{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","asOf":"2026-09-08","days":13},{"id":"brexucabtagene-autoleucel","kind":"drug","name":"Brexucabtagene autoleucel","route":"/drugs/brexucabtagene-autoleucel/","asOf":"2026-09-08","days":13},{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/","asOf":"2026-09-08","days":13},{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/","asOf":"2026-09-08","days":13},{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/","asOf":"2026-09-08","days":13},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/","asOf":"2026-09-08","days":13},{"id":"cladribine","kind":"drug","name":"Cladribine","route":"/drugs/cladribine/","asOf":"2026-09-08","days":13},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/","asOf":"2026-09-08","days":13},{"id":"nogapendekin-alfa-inbakicept","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa-inbakicept/","asOf":"2026-09-08","days":13},{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/","asOf":"2026-09-08","days":13},{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/","asOf":"2026-09-08","days":13},{"id":"pentostatin","kind":"drug","name":"Pentostatin","route":"/drugs/pentostatin/","asOf":"2026-09-08","days":13},{"id":"moxetumomab-pasudotox","kind":"drug","name":"Moxetumomab pasudotox","route":"/drugs/moxetumomab-pasudotox/","asOf":"2026-09-08","days":13},{"id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","asOf":"2026-09-08","days":13},{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","asOf":"2026-09-08","days":13},{"id":"idelalisib","kind":"drug","name":"Idelalisib","route":"/drugs/idelalisib/","asOf":"2026-09-08","days":13},{"id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/","asOf":"2026-09-08","days":13},{"id":"copanlisib","kind":"drug","name":"Copanlisib","route":"/drugs/copanlisib/","asOf":"2026-09-08","days":13},{"id":"umbralisib","kind":"drug","name":"Umbralisib","route":"/drugs/umbralisib/","asOf":"2026-09-08","days":13},{"id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/","asOf":"2026-09-08","days":13},{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","asOf":"2026-09-08","days":13},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/","asOf":"2026-09-08","days":13},{"id":"thalidomide","kind":"drug","name":"Thalidomide","route":"/drugs/thalidomide/","asOf":"2026-09-08","days":13},{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/","asOf":"2026-09-08","days":13},{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/","asOf":"2026-09-08","days":13},{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/","asOf":"2026-09-08","days":13},{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/","asOf":"2026-09-08","days":13},{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","asOf":"2026-09-08","days":13},{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/","asOf":"2026-09-08","days":13},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","asOf":"2026-09-08","days":13},{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/","asOf":"2026-09-08","days":13},{"id":"sonidegib","kind":"drug","name":"Sonidegib","route":"/drugs/sonidegib/","asOf":"2026-09-08","days":13},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","asOf":"2026-09-08","days":13},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/","asOf":"2026-09-08","days":13},{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/","asOf":"2026-09-08","days":13},{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","asOf":"2026-09-08","days":13},{"id":"mobocertinib","kind":"drug","name":"Mobocertinib","route":"/drugs/mobocertinib/","asOf":"2026-09-08","days":13},{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","asOf":"2026-09-08","days":13},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/","asOf":"2026-09-08","days":13},{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/","asOf":"2026-09-08","days":13},{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","asOf":"2026-09-08","days":13},{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","asOf":"2026-09-08","days":13},{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/","asOf":"2026-09-08","days":13},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","asOf":"2026-09-08","days":13},{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","asOf":"2026-09-08","days":13},{"id":"temsirolimus","kind":"drug","name":"Temsirolimus","route":"/drugs/temsirolimus/","asOf":"2026-09-08","days":13},{"id":"pexidartinib","kind":"drug","name":"Pexidartinib","route":"/drugs/pexidartinib/","asOf":"2026-09-08","days":13},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","asOf":"2026-09-08","days":13},{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","asOf":"2026-09-08","days":13},{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/","asOf":"2026-09-08","days":13},{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/","asOf":"2026-09-08","days":13},{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/","asOf":"2026-09-08","days":13},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/","asOf":"2026-09-08","days":13},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/","asOf":"2026-09-08","days":13},{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/","asOf":"2026-09-08","days":13},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/","asOf":"2026-09-08","days":13},{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/","asOf":"2026-09-08","days":13},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","asOf":"2026-09-08","days":13},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/","asOf":"2026-09-08","days":13},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/","asOf":"2026-09-08","days":13},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/","asOf":"2026-09-08","days":13},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/","asOf":"2026-09-08","days":13},{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/","asOf":"2026-09-08","days":13},{"id":"dactinomycin","kind":"drug","name":"Dactinomycin (actinomycin D)","route":"/drugs/dactinomycin/","asOf":"2026-09-08","days":13},{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/","asOf":"2026-09-08","days":13},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/","asOf":"2026-09-08","days":13},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/","asOf":"2026-09-08","days":13},{"id":"mitotane","kind":"drug","name":"Mitotane","route":"/drugs/mitotane/","asOf":"2026-09-08","days":13},{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/","asOf":"2026-09-08","days":13},{"id":"sodium-thiosulfate","kind":"drug","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","asOf":"2026-09-08","days":13},{"id":"pafolacianine","kind":"drug","name":"Pafolacianine","route":"/drugs/pafolacianine/","asOf":"2026-09-08","days":13},{"id":"pegulicianine","kind":"drug","name":"Pegulicianine","route":"/drugs/pegulicianine/","asOf":"2026-09-08","days":13},{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","asOf":"2026-09-08","days":13},{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","asOf":"2026-09-08","days":13},{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","asOf":"2026-09-08","days":13},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","asOf":"2026-09-08","days":13},{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","asOf":"2026-09-08","days":13},{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","asOf":"2026-09-08","days":13},{"id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","asOf":"2026-09-08","days":13},{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/","asOf":"2026-09-08","days":13},{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","asOf":"2026-09-08","days":13},{"id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/","asOf":"2026-09-08","days":13},{"id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","asOf":"2026-09-08","days":13},{"id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/","asOf":"2026-09-08","days":13},{"id":"vindesine","kind":"drug","name":"Vindesine","route":"/drugs/vindesine/","asOf":"2026-09-08","days":13},{"id":"pixantrone","kind":"drug","name":"Pixantrone","route":"/drugs/pixantrone/","asOf":"2026-09-08","days":13},{"id":"abarelix","kind":"drug","name":"Abarelix","route":"/drugs/abarelix/","asOf":"2026-09-08","days":13},{"id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","asOf":"2026-09-08","days":13},{"id":"aminoglutethimide","kind":"drug","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","asOf":"2026-09-08","days":13},{"id":"diethylstilbestrol","kind":"drug","name":"Diethylstilbestrol","route":"/drugs/diethylstilbestrol/","asOf":"2026-09-08","days":13},{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","asOf":"2026-09-08","days":13},{"id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","asOf":"2026-09-08","days":13},{"id":"fluoxymesterone","kind":"drug","name":"Fluoxymesterone","route":"/drugs/fluoxymesterone/","asOf":"2026-09-08","days":13},{"id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","asOf":"2026-09-08","days":13},{"id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","asOf":"2026-09-08","days":13},{"id":"lenograstim","kind":"drug","name":"Lenograstim","route":"/drugs/lenograstim/","asOf":"2026-09-08","days":13},{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","asOf":"2026-09-08","days":13},{"id":"histrelin","kind":"drug","name":"Histrelin","route":"/drugs/histrelin/","asOf":"2026-09-08","days":13},{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/","asOf":"2026-09-08","days":13},{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/","asOf":"2026-09-08","days":13},{"id":"olaratumab","kind":"drug","name":"Olaratumab","route":"/drugs/olaratumab/","asOf":"2026-09-08","days":13},{"id":"hexaminolevulinate","kind":"drug","name":"Hexaminolevulinate","route":"/drugs/hexaminolevulinate/","asOf":"2026-09-08","days":13},{"id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","asOf":"2026-09-08","days":13},{"id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","asOf":"2026-09-08","days":13},{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","asOf":"2026-09-08","days":13},{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","asOf":"2026-09-08","days":13},{"id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","asOf":"2026-09-08","days":13},{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/","asOf":"2026-09-08","days":13},{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","asOf":"2026-09-08","days":13},{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","asOf":"2026-09-08","days":13},{"id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","asOf":"2026-09-08","days":13},{"id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","asOf":"2026-09-08","days":13},{"id":"plicamycin","kind":"drug","name":"Plicamycin","route":"/drugs/plicamycin/","asOf":"2026-09-08","days":13},{"id":"formestane","kind":"drug","name":"Formestane","route":"/drugs/formestane/","asOf":"2026-09-08","days":13},{"id":"amsacrine","kind":"drug","name":"Amsacrine","route":"/drugs/amsacrine/","asOf":"2026-09-08","days":13},{"id":"uracil-mustard","kind":"drug","name":"Uracil mustard","route":"/drugs/uracil-mustard/","asOf":"2026-09-08","days":13},{"id":"mitobronitol","kind":"drug","name":"Mitobronitol","route":"/drugs/mitobronitol/","asOf":"2026-09-08","days":13},{"id":"pipobroman","kind":"drug","name":"Pipobroman","route":"/drugs/pipobroman/","asOf":"2026-09-08","days":13},{"id":"oprelvekin","kind":"drug","name":"Oprelvekin","route":"/drugs/oprelvekin/","asOf":"2026-09-08","days":13},{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","asOf":"2026-09-08","days":13},{"id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","asOf":"2026-09-08","days":13},{"id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","asOf":"2026-09-08","days":13},{"id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","asOf":"2026-09-08","days":13},{"id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","asOf":"2026-09-08","days":13},{"id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","asOf":"2026-09-08","days":13},{"id":"nedaplatin","kind":"drug","name":"Nedaplatin","route":"/drugs/nedaplatin/","asOf":"2026-09-08","days":13},{"id":"doxifluridine","kind":"drug","name":"Doxifluridine","route":"/drugs/doxifluridine/","asOf":"2026-09-08","days":13},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/","asOf":"2026-09-08","days":13},{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/","asOf":"2026-09-08","days":13},{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","asOf":"2026-09-08","days":13},{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/","asOf":"2026-09-08","days":13},{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/","asOf":"2026-09-08","days":13},{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/","asOf":"2026-09-08","days":13},{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/","asOf":"2026-09-08","days":13},{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","asOf":"2026-09-08","days":13},{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/","asOf":"2026-09-08","days":13},{"id":"tim3","kind":"target","name":"TIM-3","route":"/targets/tim3/","asOf":"2026-09-08","days":13},{"id":"smoothened","kind":"target","name":"Smoothened (hedgehog pathway)","route":"/targets/smoothened/","asOf":"2026-09-08","days":13},{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/","asOf":"2026-09-08","days":13},{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/","asOf":"2026-09-08","days":13},{"id":"ewsr1-fli1","kind":"target","name":"EWSR1-FLI1 fusion","route":"/targets/ewsr1-fli1/","asOf":"2026-09-08","days":13},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","asOf":"2026-09-08","days":13},{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/","asOf":"2026-09-08","days":13},{"id":"cd73-adenosine","kind":"target","name":"CD73 / adenosine axis","route":"/targets/cd73-adenosine/","asOf":"2026-09-08","days":13},{"id":"vista","kind":"target","name":"VISTA","route":"/targets/vista/","asOf":"2026-09-08","days":13},{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/","asOf":"2026-09-08","days":13},{"id":"liv1","kind":"target","name":"LIV-1 (SLC39A6)","route":"/targets/liv1/","asOf":"2026-09-08","days":13},{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/","asOf":"2026-09-08","days":13},{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/","asOf":"2026-09-08","days":13},{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/","asOf":"2026-09-08","days":13},{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/","asOf":"2026-09-08","days":13},{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/","asOf":"2026-09-08","days":13},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","asOf":"2026-09-08","days":13},{"id":"hospice-end-of-life","kind":"technology","name":"Hospice and end-of-life care","route":"/technologies/hospice-end-of-life/","asOf":"2026-09-08","days":13},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","asOf":"2026-09-08","days":13},{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/","asOf":"2026-09-08","days":13},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","asOf":"2026-09-08","days":13},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","asOf":"2026-09-08","days":13},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","asOf":"2026-09-08","days":13},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","asOf":"2026-09-08","days":13},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","asOf":"2026-09-08","days":13},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","asOf":"2026-09-08","days":13},{"id":"oncology-nursing","kind":"technology","name":"Oncology nursing and nurse-led care","route":"/technologies/oncology-nursing/","asOf":"2026-09-08","days":13},{"id":"integrative-oncology","kind":"technology","name":"Evidence-based integrative oncology","route":"/technologies/integrative-oncology/","asOf":"2026-09-08","days":13},{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/","asOf":"2026-09-08","days":13},{"id":"bone-modifying-agents","kind":"technology","name":"Bone-modifying agents (bisphosphonates, denosumab)","route":"/technologies/bone-modifying-agents/","asOf":"2026-09-08","days":13},{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/","asOf":"2026-09-08","days":13},{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/","asOf":"2026-09-08","days":13},{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","asOf":"2026-09-08","days":13},{"id":"epro-symptom-monitoring","kind":"technology","name":"Electronic patient-reported outcome (ePRO) symptom monitoring","route":"/technologies/epro-symptom-monitoring/","asOf":"2026-09-08","days":13},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","asOf":"2026-09-08","days":13},{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/","asOf":"2026-09-08","days":13},{"id":"electrochemotherapy","kind":"technology","name":"Electrochemotherapy","route":"/technologies/electrochemotherapy/","asOf":"2026-09-08","days":13},{"id":"isolated-limb-perfusion","kind":"technology","name":"Isolated limb perfusion and infusion","route":"/technologies/isolated-limb-perfusion/","asOf":"2026-09-08","days":13},{"id":"percutaneous-hepatic-perfusion","kind":"technology","name":"Percutaneous hepatic perfusion (chemosaturation)","route":"/technologies/percutaneous-hepatic-perfusion/","asOf":"2026-09-08","days":13},{"id":"intraoperative-radiotherapy","kind":"technology","name":"Intraoperative radiotherapy (IORT)","route":"/technologies/intraoperative-radiotherapy/","asOf":"2026-09-08","days":13},{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","asOf":"2026-09-08","days":13},{"id":"rare-cancers","kind":"term","name":"Rare cancers","route":"/terms/rare-cancers/","asOf":"2026-09-08","days":13},{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/","asOf":"2026-09-08","days":13},{"id":"aya-oncology","kind":"term","name":"Adolescent and young adult (AYA) oncology","route":"/terms/aya-oncology/","asOf":"2026-09-08","days":13},{"id":"cancer-in-pregnancy","kind":"term","name":"Cancer during pregnancy","route":"/terms/cancer-in-pregnancy/","asOf":"2026-09-08","days":13},{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/","asOf":"2026-09-08","days":13},{"id":"li-fraumeni","kind":"term","name":"Li-Fraumeni syndrome (germline TP53)","route":"/terms/li-fraumeni/","asOf":"2026-09-08","days":13},{"id":"vhl-disease","kind":"term","name":"Von Hippel-Lindau disease","route":"/terms/vhl-disease/","asOf":"2026-09-08","days":13},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","asOf":"2026-09-08","days":13},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","asOf":"2026-09-08","days":13},{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","asOf":"2026-09-08","days":13},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/","asOf":"2026-09-08","days":13},{"id":"plasma-ebv-dna","kind":"term","name":"Plasma EBV DNA","route":"/terms/plasma-ebv-dna/","asOf":"2026-09-08","days":13},{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/","asOf":"2026-09-08","days":13},{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","route":"/collections/asco-guidelines/","asOf":"2026-09-08","days":13},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","asOf":"2026-09-08","days":13},{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","asOf":"2026-09-08","days":13},{"id":"american-cancer-society","kind":"collection","name":"American Cancer Society (ACS)","route":"/collections/american-cancer-society/","asOf":"2026-09-08","days":13},{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","route":"/collections/leukemia-lymphoma-society/","asOf":"2026-09-08","days":13},{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","asOf":"2026-09-08","days":13},{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","route":"/collections/mmrf/","asOf":"2026-09-08","days":13},{"id":"lymphoma-research-foundation","kind":"collection","name":"Lymphoma Research Foundation (LRF)","route":"/collections/lymphoma-research-foundation/","asOf":"2026-09-08","days":13},{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","route":"/collections/national-brain-tumor-society/","asOf":"2026-09-08","days":13},{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","asOf":"2026-09-08","days":13},{"id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/","asOf":"2026-09-08","days":13},{"id":"colorectal-cancer-alliance","kind":"collection","name":"Colorectal Cancer Alliance","route":"/collections/colorectal-cancer-alliance/","asOf":"2026-09-08","days":13},{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/","asOf":"2026-09-08","days":13},{"id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","asOf":"2026-09-08","days":13},{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","route":"/collections/ovarian-cancer-research-alliance/","asOf":"2026-09-08","days":13},{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","route":"/collections/susan-g-komen/","asOf":"2026-09-08","days":13},{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/","asOf":"2026-09-08","days":13},{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/","asOf":"2026-09-08","days":13},{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/","asOf":"2026-09-08","days":13},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/","asOf":"2026-09-08","days":13},{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/","asOf":"2026-09-08","days":13},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/","asOf":"2026-09-08","days":13},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-crown-nejm-2020","kind":"paper","name":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","route":"/key-papers/paper-crown-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/","asOf":"2026-09-08","days":13},{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/","asOf":"2026-09-08","days":13},{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/","asOf":"2026-09-08","days":13},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/","asOf":"2026-09-08","days":13},{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/","asOf":"2026-09-08","days":13},{"id":"paper-napoli-3-lancet-2023","kind":"paper","name":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","route":"/key-papers/paper-napoli-3-lancet-2023/","asOf":"2026-09-08","days":13},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/","asOf":"2026-09-08","days":13},{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/","asOf":"2026-09-08","days":13},{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/","asOf":"2026-09-08","days":13},{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/","asOf":"2026-09-08","days":13},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-cercek-dmmr-rectal-nejm-2022","kind":"paper","name":"Dostarlimab alone cures mismatch-repair-deficient rectal cancer without surgery or radiotherapy","route":"/key-papers/paper-cercek-dmmr-rectal-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","asOf":"2026-09-08","days":13},{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/","asOf":"2026-09-08","days":13},{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-niagara-nejm-2024","kind":"paper","name":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-niagara-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-clear-nejm-2021","kind":"paper","name":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","route":"/key-papers/paper-clear-nejm-2021/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/","asOf":"2026-09-08","days":13},{"id":"paper-sunrise-1-jco-2025","kind":"paper","name":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-sunrise-1-jco-2025/","asOf":"2026-09-08","days":13},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/","asOf":"2026-09-08","days":13},{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-a18-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-keynote-a18-lancet-2024/","asOf":"2026-09-08","days":13},{"id":"paper-ruby-nejm-2023","kind":"paper","name":"RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer","route":"/key-papers/paper-ruby-nejm-2023/","asOf":"2026-09-08","days":13},{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/","asOf":"2026-09-08","days":13},{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-relativity-047-nejm-2022","kind":"paper","name":"RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma","route":"/key-papers/paper-relativity-047-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/","asOf":"2026-09-08","days":13},{"id":"paper-indigo-nejm-2023","kind":"paper","name":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","route":"/key-papers/paper-indigo-nejm-2023/","asOf":"2026-09-08","days":13},{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/","asOf":"2026-09-08","days":13},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","asOf":"2026-09-08","days":13},{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/","asOf":"2026-09-08","days":13},{"id":"paper-slamon-trastuzumab-nejm-2001","kind":"paper","name":"Slamon 2001: adding trastuzumab to chemotherapy for HER2-positive metastatic breast cancer","route":"/key-papers/paper-slamon-trastuzumab-nejm-2001/","asOf":"2026-09-08","days":13},{"id":"paper-hurwitz-bevacizumab-crc-nejm-2004","kind":"paper","name":"Hurwitz 2004: bevacizumab with chemotherapy for metastatic colorectal cancer, the first anti-angiogenic drug to extend life","route":"/key-papers/paper-hurwitz-bevacizumab-crc-nejm-2004/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-024-nejm-2016","kind":"paper","name":"KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer","route":"/key-papers/paper-keynote-024-nejm-2016/","asOf":"2026-09-08","days":13},{"id":"paper-checkmate-057-nejm-2015","kind":"paper","name":"CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer","route":"/key-papers/paper-checkmate-057-nejm-2015/","asOf":"2026-09-08","days":13},{"id":"paper-checkmate-017-nejm-2015","kind":"paper","name":"CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy","route":"/key-papers/paper-checkmate-017-nejm-2015/","asOf":"2026-09-08","days":13},{"id":"paper-conroy-folfirinox-pancreatic-nejm-2011","kind":"paper","name":"Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)","route":"/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/","asOf":"2026-09-08","days":13},{"id":"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013","kind":"paper","name":"MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer","route":"/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-001-pembrolizumab-nsclc-nejm-2015","kind":"paper","name":"KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off","route":"/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-010-lancet-2016","kind":"paper","name":"KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer","route":"/key-papers/paper-keynote-010-lancet-2016/","asOf":"2026-09-08","days":13},{"id":"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","kind":"paper","name":"KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma","route":"/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/","asOf":"2026-09-08","days":13},{"id":"paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004","kind":"paper","name":"Sauer 2004: chemoradiotherapy before rather than after surgery for rectal cancer (CAO/ARO/AIO-94)","route":"/key-papers/paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004/","asOf":"2026-09-08","days":13},{"id":"paper-burris-gemcitabine-pancreatic-jco-1997","kind":"paper","name":"Burris 1997: gemcitabine becomes the first standard treatment for advanced pancreatic cancer","route":"/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/","asOf":"2026-09-08","days":13},{"id":"paper-toga-trastuzumab-gastric-lancet-2010","kind":"paper","name":"ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer","route":"/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/","asOf":"2026-09-08","days":13},{"id":"paper-druker-imatinib-phase1-nejm-2001","kind":"paper","name":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia","route":"/key-papers/paper-druker-imatinib-phase1-nejm-2001/","asOf":"2026-09-08","days":13},{"id":"paper-iris-imatinib-nejm-2003","kind":"paper","name":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","route":"/key-papers/paper-iris-imatinib-nejm-2003/","asOf":"2026-09-08","days":13},{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/","asOf":"2026-09-08","days":13},{"id":"paper-elevate-tn-acalabrutinib-lancet-2020","kind":"paper","name":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","route":"/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/","asOf":"2026-09-08","days":13},{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/","asOf":"2026-09-08","days":13},{"id":"paper-murano-venetoclax-rituximab-nejm-2018","kind":"paper","name":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","route":"/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/","asOf":"2026-09-08","days":13},{"id":"paper-maia-daratumumab-rd-nejm-2019","kind":"paper","name":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","route":"/key-papers/paper-maia-daratumumab-rd-nejm-2019/","asOf":"2026-09-08","days":13},{"id":"paper-perseus-dara-vrd-transplant-nejm-2024","kind":"paper","name":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","route":"/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/","asOf":"2026-09-08","days":13},{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/","asOf":"2026-09-08","days":13},{"id":"paper-cartitude-4-cilta-cel-nejm-2023","kind":"paper","name":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","route":"/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/","asOf":"2026-09-08","days":13},{"id":"paper-karmma-3-ide-cel-nejm-2023","kind":"paper","name":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","route":"/key-papers/paper-karmma-3-ide-cel-nejm-2023/","asOf":"2026-09-08","days":13},{"id":"paper-majestec-1-teclistamab-nejm-2022","kind":"paper","name":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","route":"/key-papers/paper-majestec-1-teclistamab-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/","asOf":"2026-09-08","days":13},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-transform-liso-cel-lancet-2022","kind":"paper","name":"TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma","route":"/key-papers/paper-transform-liso-cel-lancet-2022/","asOf":"2026-09-08","days":13},{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/","asOf":"2026-09-08","days":13},{"id":"paper-swog-s1826-nivolumab-avd-nejm-2024","kind":"paper","name":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","route":"/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","asOf":"2026-09-08","days":13},{"id":"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020","kind":"paper","name":"ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors","route":"/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-viale-a-venetoclax-azacitidine-nejm-2020","kind":"paper","name":"VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy","route":"/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-admiral-gilteritinib-flt3-nejm-2019","kind":"paper","name":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","route":"/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/","asOf":"2026-09-08","days":13},{"id":"paper-quantum-first-quizartinib-lancet-2023","kind":"paper","name":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","route":"/key-papers/paper-quantum-first-quizartinib-lancet-2023/","asOf":"2026-09-08","days":13},{"id":"paper-agile-ivosidenib-azacitidine-nejm-2022","kind":"paper","name":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","route":"/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/","asOf":"2026-09-08","days":13},{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/","asOf":"2026-09-08","days":13},{"id":"paper-ino-vate-inotuzumab-all-nejm-2016","kind":"paper","name":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL","route":"/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/","asOf":"2026-09-08","days":13},{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/","asOf":"2026-09-08","days":13},{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/","asOf":"2026-09-08","days":13},{"id":"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","kind":"paper","name":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","route":"/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/","asOf":"2026-09-08","days":13},{"id":"paper-momentum-momelotinib-lancet-2023","kind":"paper","name":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","route":"/key-papers/paper-momentum-momelotinib-lancet-2023/","asOf":"2026-09-08","days":13},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/","asOf":"2026-09-08","days":13},{"id":"paper-eliana-tisagenlecleucel-nejm-2018","kind":"paper","name":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","route":"/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/","asOf":"2026-09-08","days":13},{"id":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","kind":"paper","name":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/","asOf":"2026-09-08","days":13},{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/","asOf":"2026-09-08","days":13},{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/","asOf":"2026-09-08","days":13},{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/","asOf":"2026-09-08","days":13},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-spearhead-1-afami-cel-sarcoma-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-afami-cel-sarcoma-lancet-2024/","asOf":"2026-09-08","days":13},{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/","asOf":"2026-09-08","days":13},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/","asOf":"2026-09-08","days":13},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/","asOf":"2026-09-08","days":13},{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/","asOf":"2026-09-08","days":13},{"id":"paper-niche-2-neoadjuvant-colon-nejm-2024","kind":"paper","name":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients","route":"/key-papers/paper-niche-2-neoadjuvant-colon-nejm-2024/","asOf":"2026-09-08","days":13},{"id":"paper-cercek-dostarlimab-rectal-nejm-2022","kind":"paper","name":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","route":"/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/","asOf":"2026-09-08","days":13},{"id":"paper-checkmate-067-ten-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","route":"/key-papers/paper-checkmate-067-ten-year-nejm-2025/","asOf":"2026-09-08","days":13},{"id":"paper-asco-irae-guideline-jco-2021","kind":"paper","name":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","route":"/key-papers/paper-asco-irae-guideline-jco-2021/","asOf":"2026-09-08","days":13},{"id":"paper-pardoll-immune-checkpoint-blockade-nrc-2012","kind":"paper","name":"Pardoll 2012: the blockade of immune checkpoints in cancer immunotherapy","route":"/key-papers/paper-pardoll-immune-checkpoint-blockade-nrc-2012/","asOf":"2026-09-08","days":13},{"id":"paper-rizvi-mutational-landscape-pd1-science-2015","kind":"paper","name":"Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer","route":"/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/","asOf":"2026-09-08","days":13},{"id":"paper-galon-immune-contexture-colorectal-science-2006","kind":"paper","name":"Galon 2006: the type, density and location of immune cells in colorectal tumours predict outcome","route":"/key-papers/paper-galon-immune-contexture-colorectal-science-2006/","asOf":"2026-09-08","days":13},{"id":"paper-schreiber-cancer-immunoediting-science-2011","kind":"paper","name":"Schreiber, Old and Smyth 2011: cancer immunoediting","route":"/key-papers/paper-schreiber-cancer-immunoediting-science-2011/","asOf":"2026-09-08","days":13},{"id":"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","kind":"paper","name":"Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge","route":"/key-papers/paper-tumeh-pd1-adaptive-immune-resistance-nature-2014/","asOf":"2026-09-08","days":13},{"id":"paper-thorsson-immune-landscape-of-cancer-immunity-2018","kind":"paper","name":"Thorsson 2018: the immune landscape of cancer across 10,000 tumours","route":"/key-papers/paper-thorsson-immune-landscape-of-cancer-immunity-2018/","asOf":"2026-09-08","days":13},{"id":"paper-darnell-jak-stat-science-1994","kind":"paper","name":"Darnell, Kerr and Stark 1994: JAK-STAT pathways and transcriptional activation by interferons","route":"/key-papers/paper-darnell-jak-stat-science-1994/","asOf":"2026-09-08","days":13},{"id":"paper-binnewies-tumor-immune-microenvironment-natmed-2018","kind":"paper","name":"Binnewies 2018: understanding the tumour immune microenvironment for effective therapy","route":"/key-papers/paper-binnewies-tumor-immune-microenvironment-natmed-2018/","asOf":"2026-09-08","days":13},{"id":"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017","kind":"paper","name":"Li 2017: TIMER, a web server for estimating immune cells in tumour genomic data","route":"/key-papers/paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017/","asOf":"2026-09-08","days":13},{"id":"paper-cella-fact-g-jco-1993","kind":"paper","name":"Cella 1993: the Functional Assessment of Cancer Therapy (FACT-G) quality of life scale","route":"/key-papers/paper-cella-fact-g-jco-1993/","asOf":"2026-09-08","days":13},{"id":"paper-chen-mellman-cancer-immunity-cycle-immunity-2013","kind":"paper","name":"Chen and Mellman 2013: the cancer-immunity cycle","route":"/key-papers/paper-chen-mellman-cancer-immunity-cycle-immunity-2013/","asOf":"2026-09-08","days":13},{"id":"paper-ribas-wolchok-checkpoint-blockade-science-2018","kind":"paper","name":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","route":"/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/","asOf":"2026-09-08","days":13},{"id":"paper-li-timer2-nar-2020","kind":"paper","name":"Li 2020: TIMER2.0 for analysis of tumour-infiltrating immune cells","route":"/key-papers/paper-li-timer2-nar-2020/","asOf":"2026-09-08","days":13},{"id":"paper-nlst-nejm-2011","kind":"paper","name":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers","route":"/key-papers/paper-nlst-nejm-2011/","asOf":"2026-09-08","days":13},{"id":"paper-nelson-nejm-2020","kind":"paper","name":"NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms","route":"/key-papers/paper-nelson-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-nordicc-nejm-2022","kind":"paper","name":"NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected","route":"/key-papers/paper-nordicc-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-minnesota-fobt-nejm-1993","kind":"paper","name":"Minnesota trial: a yearly stool blood test cuts bowel cancer deaths by a third","route":"/key-papers/paper-minnesota-fobt-nejm-1993/","asOf":"2026-09-08","days":13},{"id":"paper-hpv-vaccine-sweden-nejm-2020","kind":"paper","name":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17","route":"/key-papers/paper-hpv-vaccine-sweden-nejm-2020/","asOf":"2026-09-08","days":13},{"id":"paper-hpv-vaccine-england-lancet-2021","kind":"paper","name":"England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13","route":"/key-papers/paper-hpv-vaccine-england-lancet-2021/","asOf":"2026-09-08","days":13},{"id":"paper-hpv-self-sampling-bmj-2018","kind":"paper","name":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening","route":"/key-papers/paper-hpv-self-sampling-bmj-2018/","asOf":"2026-09-08","days":13},{"id":"paper-masai-lancet-oncol-2023","kind":"paper","name":"MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload","route":"/key-papers/paper-masai-lancet-oncol-2023/","asOf":"2026-09-08","days":13},{"id":"paper-pathfinder-lancet-2023","kind":"paper","name":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","route":"/key-papers/paper-pathfinder-lancet-2023/","asOf":"2026-09-08","days":13},{"id":"paper-nhs-galleri-design-cancers-2022","kind":"paper","name":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","route":"/key-papers/paper-nhs-galleri-design-cancers-2022/","asOf":"2026-09-08","days":13},{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","asOf":"2026-09-08","days":13},{"id":"paper-imvigor011-nejm-2025","kind":"paper","name":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","route":"/key-papers/paper-imvigor011-nejm-2025/","asOf":"2026-09-08","days":13},{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/","asOf":"2026-09-08","days":13},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/","asOf":"2026-09-08","days":13},{"id":"paper-challenge-exercise-nejm-2025","kind":"paper","name":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","route":"/key-papers/paper-challenge-exercise-nejm-2025/","asOf":"2026-09-08","days":13},{"id":"paper-predimed-breast-jama-im-2015","kind":"paper","name":"PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers","route":"/key-papers/paper-predimed-breast-jama-im-2015/","asOf":"2026-09-08","days":13},{"id":"paper-body-fatness-iarc-nejm-2016","kind":"paper","name":"IARC verdict: excess body fat causes 13 cancers","route":"/key-papers/paper-body-fatness-iarc-nejm-2016/","asOf":"2026-09-08","days":13},{"id":"paper-capp2-aspirin-lynch-lancet-2020","kind":"paper","name":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years","route":"/key-papers/paper-capp2-aspirin-lynch-lancet-2020/","asOf":"2026-09-08","days":13},{"id":"paper-ibis-i-tamoxifen-lancet-oncol-2015","kind":"paper","name":"IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years","route":"/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/","asOf":"2026-09-08","days":13},{"id":"paper-brca-risk-reducing-surgery-jama-2010","kind":"paper","name":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","route":"/key-papers/paper-brca-risk-reducing-surgery-jama-2010/","asOf":"2026-09-08","days":13},{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/","asOf":"2026-09-08","days":13},{"id":"paper-doll-hill-smoking-lung-cancer-bmj-1950","kind":"paper","name":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer","route":"/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/","asOf":"2026-09-08","days":13},{"id":"paper-doll-peto-50-year-doctors-bmj-2004","kind":"paper","name":"Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back","route":"/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/","asOf":"2026-09-08","days":13},{"id":"paper-alcohol-cancer-burden-lancet-oncol-2021","kind":"paper","name":"Alcohol caused an estimated 741,000 cancers worldwide in 2020","route":"/key-papers/paper-alcohol-cancer-burden-lancet-oncol-2021/","asOf":"2026-09-08","days":13},{"id":"paper-basch-epro-survival-jama-2017","kind":"paper","name":"Basch: asking patients to report symptoms online during chemotherapy improved survival","route":"/key-papers/paper-basch-epro-survival-jama-2017/","asOf":"2026-09-08","days":13},{"id":"paper-temel-early-palliative-care-nejm-2010","kind":"paper","name":"Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer","route":"/key-papers/paper-temel-early-palliative-care-nejm-2010/","asOf":"2026-09-08","days":13},{"id":"paper-gap70-geriatric-assessment-lancet-2021","kind":"paper","name":"GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth","route":"/key-papers/paper-gap70-geriatric-assessment-lancet-2021/","asOf":"2026-09-08","days":13},{"id":"paper-drug-dosing-conundrum-nejm-2021","kind":"paper","name":"FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high","route":"/key-papers/paper-drug-dosing-conundrum-nejm-2021/","asOf":"2026-09-08","days":13},{"id":"paper-hallmarks-of-cancer-cell-2000","kind":"paper","name":"The Hallmarks of Cancer: six capabilities every tumour must acquire","route":"/key-papers/paper-hallmarks-of-cancer-cell-2000/","asOf":"2026-09-08","days":13},{"id":"paper-hallmarks-new-dimensions-cancer-discov-2022","kind":"paper","name":"Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells","route":"/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/","asOf":"2026-09-08","days":13},{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/","asOf":"2026-09-08","days":13},{"id":"paper-vogelstein-cancer-genome-landscapes-science-2013","kind":"paper","name":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","route":"/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/","asOf":"2026-09-08","days":13},{"id":"paper-gerlinger-intratumour-heterogeneity-nejm-2012","kind":"paper","name":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour","route":"/key-papers/paper-gerlinger-intratumour-heterogeneity-nejm-2012/","asOf":"2026-09-08","days":13},{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/","asOf":"2026-09-08","days":13},{"id":"paper-tracerx-evolution-nature-2023","kind":"paper","name":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse","route":"/key-papers/paper-tracerx-evolution-nature-2023/","asOf":"2026-09-08","days":13},{"id":"paper-martincorena-somatic-mutations-normal-skin-science-2015","kind":"paper","name":"Martincorena: normal sun-exposed skin is a patchwork of cancer-mutation clones","route":"/key-papers/paper-martincorena-somatic-mutations-normal-skin-science-2015/","asOf":"2026-09-08","days":13},{"id":"paper-jaiswal-chip-nejm-2014","kind":"paper","name":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","route":"/key-papers/paper-jaiswal-chip-nejm-2014/","asOf":"2026-09-08","days":13},{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/","asOf":"2026-09-08","days":13},{"id":"paper-alphafold2-jumper-nature-2021","kind":"paper","name":"AlphaFold 2: predicting protein structures to near-experimental accuracy","route":"/key-papers/paper-alphafold2-jumper-nature-2021/","asOf":"2026-09-08","days":13},{"id":"paper-ostrem-kras-g12c-nature-2013","kind":"paper","name":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","route":"/key-papers/paper-ostrem-kras-g12c-nature-2013/","asOf":"2026-09-08","days":13},{"id":"paper-protac-concept-sakamoto-pnas-2001","kind":"paper","name":"The first PROTAC: a chimeric molecule that tags a protein for destruction","route":"/key-papers/paper-protac-concept-sakamoto-pnas-2001/","asOf":"2026-09-08","days":13},{"id":"paper-leach-allison-ctla4-blockade-science-1996","kind":"paper","name":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","route":"/key-papers/paper-leach-allison-ctla4-blockade-science-1996/","asOf":"2026-09-08","days":13},{"id":"paper-iwai-pdl1-tumour-escape-pnas-2002","kind":"paper","name":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","route":"/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/","asOf":"2026-09-08","days":13},{"id":"paper-reproducibility-project-cancer-biology-elife-2021","kind":"paper","name":"Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication","route":"/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/","asOf":"2026-09-08","days":13},{"id":"paper-prasad-surrogate-endpoints-jama-im-2015","kind":"paper","name":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","route":"/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/","asOf":"2026-09-08","days":13},{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/","asOf":"2026-09-08","days":13},{"id":"paper-bray-globocan-2022-cacancer-2024","kind":"paper","name":"Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries","route":"/key-papers/paper-bray-globocan-2022-cacancer-2024/","asOf":"2026-09-08","days":13},{"id":"paper-slamon-her2-amplification-science-1987","kind":"paper","name":"Slamon 1987: HER2 gene amplification marks an aggressive form of breast cancer","route":"/key-papers/paper-slamon-her2-amplification-science-1987/","asOf":"2026-09-08","days":13},{"id":"paper-coussens-werb-inflammation-cancer-nature-2002","kind":"paper","name":"Coussens and Werb 2002: inflammation and cancer","route":"/key-papers/paper-coussens-werb-inflammation-cancer-nature-2002/","asOf":"2026-09-08","days":13},{"id":"paper-reya-cancer-stem-cells-nature-2001","kind":"paper","name":"Reya 2001: stem cells, cancer and cancer stem cells","route":"/key-papers/paper-reya-cancer-stem-cells-nature-2001/","asOf":"2026-09-08","days":13},{"id":"paper-esteva-skin-cancer-deep-learning-nature-2017","kind":"paper","name":"Esteva 2017: a deep neural network classifies skin cancer at dermatologist level","route":"/key-papers/paper-esteva-skin-cancer-deep-learning-nature-2017/","asOf":"2026-09-08","days":13},{"id":"paper-therasse-recist-jnci-2000","kind":"paper","name":"Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds","route":"/key-papers/paper-therasse-recist-jnci-2000/","asOf":"2026-09-08","days":13},{"id":"paper-aaronson-eortc-qlq-c30-jnci-1993","kind":"paper","name":"Aaronson 1993: the EORTC QLQ-C30 quality of life questionnaire","route":"/key-papers/paper-aaronson-eortc-qlq-c30-jnci-1993/","asOf":"2026-09-08","days":13},{"id":"paper-sung-globocan-2020-cacancer-2021","kind":"paper","name":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer","route":"/key-papers/paper-sung-globocan-2020-cacancer-2021/","asOf":"2026-09-08","days":13},{"id":"paper-bray-globocan-2018-cacancer-2018","kind":"paper","name":"Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers","route":"/key-papers/paper-bray-globocan-2018-cacancer-2018/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2024-cacancer-2024","kind":"paper","name":"Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report","route":"/key-papers/paper-siegel-cancer-statistics-2024-cacancer-2024/","asOf":"2026-09-08","days":13},{"id":"paper-chen-cancer-statistics-china-2015-cacancer-2016","kind":"paper","name":"Chen 2016: Cancer statistics in China, 2015","route":"/key-papers/paper-chen-cancer-statistics-china-2015-cacancer-2016/","asOf":"2026-09-08","days":13},{"id":"paper-calle-obesity-cancer-mortality-nejm-2003","kind":"paper","name":"Calle 2003: overweight, obesity and death from cancer in 900,000 US adults","route":"/key-papers/paper-calle-obesity-cancer-mortality-nejm-2003/","asOf":"2026-09-08","days":13},{"id":"paper-hollstein-p53-mutations-science-1991","kind":"paper","name":"Hollstein 1991: p53 mutations in human cancers","route":"/key-papers/paper-hollstein-p53-mutations-science-1991/","asOf":"2026-09-08","days":13},{"id":"paper-al-hajj-breast-cancer-stem-cells-pnas-2003","kind":"paper","name":"Al-Hajj 2003: prospective identification of tumorigenic breast cancer cells","route":"/key-papers/paper-al-hajj-breast-cancer-stem-cells-pnas-2003/","asOf":"2026-09-08","days":13},{"id":"paper-bao-glioma-stem-cells-radioresistance-nature-2006","kind":"paper","name":"Bao 2006: glioma stem cells resist radiotherapy by activating the DNA damage response","route":"/key-papers/paper-bao-glioma-stem-cells-radioresistance-nature-2006/","asOf":"2026-09-08","days":13},{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/","asOf":"2026-09-08","days":13},{"id":"paper-allemani-concord-3-lancet-2018","kind":"paper","name":"Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014","route":"/key-papers/paper-allemani-concord-3-lancet-2018/","asOf":"2026-09-08","days":13},{"id":"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017","kind":"paper","name":"Fitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015","route":"/key-papers/paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017/","asOf":"2026-09-08","days":13},{"id":"paper-torre-global-cancer-statistics-2012-cacancer-2015","kind":"paper","name":"Torre 2015: Global cancer statistics, 2012","route":"/key-papers/paper-torre-global-cancer-statistics-2012-cacancer-2015/","asOf":"2026-09-08","days":13},{"id":"paper-kalluri-weinberg-emt-basics-jci-2009","kind":"paper","name":"Kalluri and Weinberg 2009: the basics of epithelial-mesenchymal transition","route":"/key-papers/paper-kalluri-weinberg-emt-basics-jci-2009/","asOf":"2026-09-08","days":13},{"id":"paper-mani-emt-stem-cell-properties-cell-2008","kind":"paper","name":"Mani 2008: the epithelial-mesenchymal transition generates cells with properties of stem cells","route":"/key-papers/paper-mani-emt-stem-cell-properties-cell-2008/","asOf":"2026-09-08","days":13},{"id":"paper-thiery-emt-tumour-progression-nrc-2002","kind":"paper","name":"Thiery 2002: epithelial-mesenchymal transitions in tumour progression","route":"/key-papers/paper-thiery-emt-tumour-progression-nrc-2002/","asOf":"2026-09-08","days":13},{"id":"paper-quail-joyce-microenvironment-metastasis-natmed-2013","kind":"paper","name":"Quail and Joyce 2013: microenvironmental regulation of tumour progression and metastasis","route":"/key-papers/paper-quail-joyce-microenvironment-metastasis-natmed-2013/","asOf":"2026-09-08","days":13},{"id":"paper-grivennikov-immunity-inflammation-cancer-cell-2010","kind":"paper","name":"Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer","route":"/key-papers/paper-grivennikov-immunity-inflammation-cancer-cell-2010/","asOf":"2026-09-08","days":13},{"id":"paper-balkwill-mantovani-inflammation-virchow-lancet-2001","kind":"paper","name":"Balkwill and Mantovani 2001: inflammation and cancer, back to Virchow?","route":"/key-papers/paper-balkwill-mantovani-inflammation-virchow-lancet-2001/","asOf":"2026-09-08","days":13},{"id":"paper-levine-p53-gatekeeper-cell-1997","kind":"paper","name":"Levine 1997: p53, the cellular gatekeeper for growth and division","route":"/key-papers/paper-levine-p53-gatekeeper-cell-1997/","asOf":"2026-09-08","days":13},{"id":"paper-el-deiry-waf1-p21-cell-1993","kind":"paper","name":"El-Deiry 1993: WAF1, the gene through which p53 stops cell division","route":"/key-papers/paper-el-deiry-waf1-p21-cell-1993/","asOf":"2026-09-08","days":13},{"id":"paper-lamouille-emt-molecular-mechanisms-nrmcb-2014","kind":"paper","name":"Lamouille 2014: molecular mechanisms of epithelial-mesenchymal transition","route":"/key-papers/paper-lamouille-emt-molecular-mechanisms-nrmcb-2014/","asOf":"2026-09-08","days":13},{"id":"paper-lemmon-schlessinger-rtk-signalling-cell-2010","kind":"paper","name":"Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases","route":"/key-papers/paper-lemmon-schlessinger-rtk-signalling-cell-2010/","asOf":"2026-09-08","days":13},{"id":"paper-vogelstein-surfing-p53-network-nature-2000","kind":"paper","name":"Vogelstein, Lane and Levine 2000: surfing the p53 network","route":"/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/","asOf":"2026-09-08","days":13},{"id":"paper-sherr-roberts-cdk-inhibitors-genesdev-1999","kind":"paper","name":"Sherr and Roberts 1999: CDK inhibitors as regulators of the G1 phase","route":"/key-papers/paper-sherr-roberts-cdk-inhibitors-genesdev-1999/","asOf":"2026-09-08","days":13},{"id":"paper-jemal-global-cancer-statistics-2011-cacancer","kind":"paper","name":"Jemal 2011: Global cancer statistics (GLOBOCAN 2008)","route":"/key-papers/paper-jemal-global-cancer-statistics-2011-cacancer/","asOf":"2026-09-08","days":13},{"id":"paper-parkin-global-cancer-statistics-2002-cacancer-2005","kind":"paper","name":"Parkin 2005: Global cancer statistics, 2002","route":"/key-papers/paper-parkin-global-cancer-statistics-2002-cacancer-2005/","asOf":"2026-09-08","days":13},{"id":"paper-ferlay-globocan-2012-methods-ijc-2015","kind":"paper","name":"Ferlay 2015: sources, methods and major patterns in GLOBOCAN 2012","route":"/key-papers/paper-ferlay-globocan-2012-methods-ijc-2015/","asOf":"2026-09-08","days":13},{"id":"paper-ferlay-globocan-2018-methods-ijc-2019","kind":"paper","name":"Ferlay 2019: GLOBOCAN 2018 sources and methods","route":"/key-papers/paper-ferlay-globocan-2018-methods-ijc-2019/","asOf":"2026-09-08","days":13},{"id":"paper-ferlay-cancer-statistics-2020-overview-ijc-2021","kind":"paper","name":"Ferlay 2021: cancer statistics for the year 2020, an overview","route":"/key-papers/paper-ferlay-cancer-statistics-2020-overview-ijc-2021/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2019-cacancer-2019","kind":"paper","name":"Siegel 2019: Cancer statistics, 2019","route":"/key-papers/paper-siegel-cancer-statistics-2019-cacancer-2019/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2022-cacancer-2022","kind":"paper","name":"Siegel 2022: Cancer statistics, 2022","route":"/key-papers/paper-siegel-cancer-statistics-2022-cacancer-2022/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2023-cacancer-2023","kind":"paper","name":"Siegel 2023: Cancer statistics, 2023","route":"/key-papers/paper-siegel-cancer-statistics-2023-cacancer-2023/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2012-cacancer-2012","kind":"paper","name":"Siegel 2012: Cancer statistics, 2012","route":"/key-papers/paper-siegel-cancer-statistics-2012-cacancer-2012/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2015-cacancer-2015","kind":"paper","name":"Siegel 2015: Cancer statistics, 2015","route":"/key-papers/paper-siegel-cancer-statistics-2015-cacancer-2015/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2016-cacancer-2016","kind":"paper","name":"Siegel 2016: Cancer statistics, 2016","route":"/key-papers/paper-siegel-cancer-statistics-2016-cacancer-2016/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2017-cacancer-2017","kind":"paper","name":"Siegel 2017: Cancer statistics, 2017","route":"/key-papers/paper-siegel-cancer-statistics-2017-cacancer-2017/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2018-cacancer-2018","kind":"paper","name":"Siegel 2018: Cancer statistics, 2018","route":"/key-papers/paper-siegel-cancer-statistics-2018-cacancer-2018/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2021-cacancer-2021","kind":"paper","name":"Siegel 2021: Cancer statistics, 2021","route":"/key-papers/paper-siegel-cancer-statistics-2021-cacancer-2021/","asOf":"2026-09-08","days":13},{"id":"paper-veber-oral-bioavailability-jmedchem-2002","kind":"paper","name":"Veber 2002: molecular properties that influence the oral bioavailability of drug candidates","route":"/key-papers/paper-veber-oral-bioavailability-jmedchem-2002/","asOf":"2026-09-08","days":13},{"id":"paper-singh-brain-tumour-initiating-cells-nature-2004","kind":"paper","name":"Singh 2004: identification of human brain tumour initiating cells","route":"/key-papers/paper-singh-brain-tumour-initiating-cells-nature-2004/","asOf":"2026-09-08","days":13},{"id":"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014","kind":"paper","name":"Rahib 2014: projecting US cancer incidence and deaths to 2030","route":"/key-papers/paper-rahib-projecting-cancer-deaths-2030-cancerres-2014/","asOf":"2026-09-08","days":13},{"id":"paper-sato-lgr5-organoids-nature-2009","kind":"paper","name":"Sato 2009: single Lgr5 stem cells build crypt-villus organoids","route":"/key-papers/paper-sato-lgr5-organoids-nature-2009/","asOf":"2026-09-08","days":13},{"id":"paper-yarden-sliwkowski-erbb-network-nrmcb-2001","kind":"paper","name":"Yarden and Sliwkowski 2001: untangling the ErbB signalling network","route":"/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/","asOf":"2026-09-08","days":13},{"id":"paper-jemal-cancer-statistics-2007-cacancer-2007","kind":"paper","name":"Jemal 2007: Cancer statistics, 2007","route":"/key-papers/paper-jemal-cancer-statistics-2007-cacancer-2007/","asOf":"2026-09-08","days":13},{"id":"paper-jemal-cancer-statistics-2008-cacancer-2008","kind":"paper","name":"Jemal 2008: Cancer statistics, 2008","route":"/key-papers/paper-jemal-cancer-statistics-2008-cacancer-2008/","asOf":"2026-09-08","days":13},{"id":"paper-jemal-cancer-statistics-2009-cacancer-2009","kind":"paper","name":"Jemal 2009: Cancer statistics, 2009","route":"/key-papers/paper-jemal-cancer-statistics-2009-cacancer-2009/","asOf":"2026-09-08","days":13},{"id":"paper-jemal-cancer-statistics-2010-cacancer-2010","kind":"paper","name":"Jemal 2010: Cancer statistics, 2010","route":"/key-papers/paper-jemal-cancer-statistics-2010-cacancer-2010/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2013-cacancer-2013","kind":"paper","name":"Siegel 2013: Cancer statistics, 2013","route":"/key-papers/paper-siegel-cancer-statistics-2013-cacancer-2013/","asOf":"2026-09-08","days":13},{"id":"paper-siegel-cancer-statistics-2014-cacancer-2014","kind":"paper","name":"Siegel 2014: Cancer statistics, 2014","route":"/key-papers/paper-siegel-cancer-statistics-2014-cacancer-2014/","asOf":"2026-09-08","days":13},{"id":"structured-exercise-survivorship","kind":"technology","name":"Structured exercise programmes after curative treatment","route":"/technologies/structured-exercise-survivorship/","asOf":"2026-09-08","days":13},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","asOf":"2026-09-08","days":13},{"id":"resistance-training-cachexia","kind":"technology","name":"Resistance training and protein for cachexia and sarcopenia","route":"/technologies/resistance-training-cachexia/","asOf":"2026-09-08","days":13},{"id":"eras-perioperative-nutrition","kind":"technology","name":"Enhanced recovery (ERAS) and perioperative nutrition","route":"/technologies/eras-perioperative-nutrition/","asOf":"2026-09-08","days":13},{"id":"nutrition-screening-mnt","kind":"technology","name":"Oncology nutrition assessment and medical nutrition therapy","route":"/technologies/nutrition-screening-mnt/","asOf":"2026-09-08","days":13},{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/","asOf":"2026-09-08","days":13},{"id":"immunonutrition-perioperative","kind":"technology","name":"Immunonutrition before cancer surgery","route":"/technologies/immunonutrition-perioperative/","asOf":"2026-09-08","days":13},{"id":"fasting-mimicking-diet","kind":"technology","name":"Fasting and fasting-mimicking diets around chemotherapy","route":"/technologies/fasting-mimicking-diet/","asOf":"2026-09-08","days":13},{"id":"ketogenic-diet-glioblastoma","kind":"technology","name":"Ketogenic diets in glioblastoma","route":"/technologies/ketogenic-diet-glioblastoma/","asOf":"2026-09-08","days":13},{"id":"time-restricted-eating","kind":"technology","name":"Time-restricted eating in cancer prevention and survivorship","route":"/technologies/time-restricted-eating/","asOf":"2026-09-08","days":13},{"id":"mediterranean-plant-forward-diet","kind":"technology","name":"Mediterranean and plant-forward dietary patterns","route":"/technologies/mediterranean-plant-forward-diet/","asOf":"2026-09-08","days":13},{"id":"dietary-fibre-microbiome-io","kind":"technology","name":"Dietary fibre and the gut microbiome for immunotherapy response","route":"/technologies/dietary-fibre-microbiome-io/","asOf":"2026-09-08","days":13},{"id":"fmt-checkpoint-nonresponders","kind":"technology","name":"Faecal microbiota transplantation for PD-1 non-responders","route":"/technologies/fmt-checkpoint-nonresponders/","asOf":"2026-09-08","days":13},{"id":"probiotics-antibiotic-stewardship-io","kind":"technology","name":"Probiotics, antibiotics and stewardship around immunotherapy","route":"/technologies/probiotics-antibiotic-stewardship-io/","asOf":"2026-09-08","days":13},{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","asOf":"2026-09-08","days":13},{"id":"bariatric-surgery-cancer-incidence","kind":"technology","name":"Bariatric surgery and cancer incidence","route":"/technologies/bariatric-surgery-cancer-incidence/","asOf":"2026-09-08","days":13},{"id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","asOf":"2026-09-08","days":13},{"id":"vitamin-d-omega3-supplementation","kind":"technology","name":"Vitamin D and omega-3 supplementation","route":"/technologies/vitamin-d-omega3-supplementation/","asOf":"2026-09-08","days":13},{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","asOf":"2026-09-08","days":13},{"id":"coffee-intake-cancer","kind":"technology","name":"Coffee and tea intake","route":"/technologies/coffee-intake-cancer/","asOf":"2026-09-08","days":13},{"id":"red-processed-meat-reduction","kind":"technology","name":"Red and processed meat reduction","route":"/technologies/red-processed-meat-reduction/","asOf":"2026-09-08","days":13},{"id":"ultra-processed-food-ssb","kind":"technology","name":"Ultra-processed food and sugar-sweetened drinks","route":"/technologies/ultra-processed-food-ssb/","asOf":"2026-09-08","days":13},{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/","asOf":"2026-09-08","days":13},{"id":"sleep-circadian-interventions","kind":"technology","name":"Sleep and circadian interventions in cancer","route":"/technologies/sleep-circadian-interventions/","asOf":"2026-09-08","days":13},{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/","asOf":"2026-09-08","days":13},{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/","asOf":"2026-09-08","days":13},{"id":"soy-breast-cancer","kind":"technology","name":"Soy foods and breast cancer","route":"/technologies/soy-breast-cancer/","asOf":"2026-09-08","days":13},{"id":"dietary-supplements-treatment-interactions","kind":"technology","name":"Dietary supplements during cancer treatment: interactions and harms","route":"/technologies/dietary-supplements-treatment-interactions/","asOf":"2026-09-08","days":13},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","asOf":"2026-09-08","days":13},{"id":"sarcopenia","kind":"term","name":"Sarcopenia","route":"/terms/sarcopenia/","asOf":"2026-09-08","days":13},{"id":"immunonutrition","kind":"term","name":"Immunonutrition","route":"/terms/immunonutrition/","asOf":"2026-09-08","days":13},{"id":"glycaemic-index","kind":"term","name":"Glycaemic index and glycaemic load","route":"/terms/glycaemic-index/","asOf":"2026-09-08","days":13},{"id":"warburg-effect-diet-claims","kind":"term","name":"Warburg-effect diet claims ('sugar feeds cancer')","route":"/terms/warburg-effect-diet-claims/","asOf":"2026-09-08","days":13},{"id":"unproven-diet-claims","kind":"term","name":"Unproven diet claims (alkaline, juice, 'anti-cancer' diets)","route":"/terms/unproven-diet-claims/","asOf":"2026-09-08","days":13},{"id":"ultra-processed-food","kind":"term","name":"Ultra-processed food (NOVA group 4)","route":"/terms/ultra-processed-food/","asOf":"2026-09-08","days":13},{"id":"metabolic-syndrome","kind":"term","name":"Metabolic syndrome and insulin resistance","route":"/terms/metabolic-syndrome/","asOf":"2026-09-08","days":13},{"id":"prehabilitation-term","kind":"term","name":"Prehabilitation (the pre-treatment window)","route":"/terms/prehabilitation-term/","asOf":"2026-09-08","days":13},{"id":"met-hours","kind":"term","name":"MET-hours per week","route":"/terms/met-hours/","asOf":"2026-09-08","days":13},{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/","asOf":"2026-09-08","days":13},{"id":"gut-microbiome-diversity","kind":"term","name":"Gut microbiome diversity and composition","route":"/terms/gut-microbiome-diversity/","asOf":"2026-09-08","days":13},{"id":"dietary-pattern-scores","kind":"term","name":"Dietary pattern scores (Mediterranean, HEI, AHEI, DASH, WCRF/AICR)","route":"/terms/dietary-pattern-scores/","asOf":"2026-09-08","days":13},{"id":"nutrition-impact-symptoms","kind":"term","name":"Nutrition impact symptoms","route":"/terms/nutrition-impact-symptoms/","asOf":"2026-09-08","days":13},{"id":"malnutrition-screening","kind":"term","name":"Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA)","route":"/terms/malnutrition-screening/","asOf":"2026-09-08","days":13},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/","asOf":"2026-09-08","days":13},{"id":"energy-balance","kind":"term","name":"Energy balance","route":"/terms/energy-balance/","asOf":"2026-09-08","days":13},{"id":"alcohol-attributable-cancer","kind":"term","name":"Alcohol-attributable cancer","route":"/terms/alcohol-attributable-cancer/","asOf":"2026-09-08","days":13},{"id":"challenge","kind":"trial","name":"CHALLENGE (CCTG CO.21)","route":"/trials/challenge/","asOf":"2026-09-08","days":13},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","asOf":"2026-09-08","days":13},{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","asOf":"2026-09-08","days":13},{"id":"aspree","kind":"trial","name":"ASPREE (ASPirin in Reducing Events in the Elderly)","route":"/trials/aspree/","asOf":"2026-09-08","days":13},{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/","asOf":"2026-09-08","days":13},{"id":"add-aspirin","kind":"trial","name":"Add-Aspirin","route":"/trials/add-aspirin/","asOf":"2026-09-08","days":13},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","asOf":"2026-09-08","days":13},{"id":"ponsegromab-phase-2","kind":"trial","name":"Ponsegromab phase 2 in cancer cachexia","route":"/trials/ponsegromab-phase-2/","asOf":"2026-09-08","days":13},{"id":"olanzapine-appetite-tmh","kind":"trial","name":"Low-dose olanzapine for cancer anorexia (Tata Memorial)","route":"/trials/olanzapine-appetite-tmh/","asOf":"2026-09-08","days":13},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","asOf":"2026-09-08","days":13},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/","asOf":"2026-09-08","days":13},{"id":"ergo2","kind":"trial","name":"ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma","route":"/trials/ergo2/","asOf":"2026-09-08","days":13},{"id":"prehab-trial","kind":"trial","name":"PREHAB: multimodal prehabilitation before colorectal cancer surgery","route":"/trials/prehab-trial/","asOf":"2026-09-08","days":13},{"id":"whel","kind":"trial","name":"WHEL (Women's Healthy Eating and Living)","route":"/trials/whel/","asOf":"2026-09-08","days":13},{"id":"idea-nl-exercise-dose-finding","kind":"idea","name":"A dose-finding trial for exercise after cancer","route":"/ideas/idea-nl-exercise-dose-finding/","asOf":"2026-09-08","days":13},{"id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/","asOf":"2026-09-08","days":13},{"id":"idea-nl-ketogenic-gbm-definitive-trial","kind":"idea","name":"One definitive ketogenic diet trial in glioblastoma, then stop","route":"/ideas/idea-nl-ketogenic-gbm-definitive-trial/","asOf":"2026-09-08","days":13},{"id":"idea-nl-diet-covariates-io-trials","kind":"idea","name":"Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial","route":"/ideas/idea-nl-diet-covariates-io-trials/","asOf":"2026-09-08","days":13},{"id":"idea-nl-alcohol-minimum-pricing-cancer-endpoints","kind":"idea","name":"Evaluate alcohol minimum unit pricing against cancer incidence","route":"/ideas/idea-nl-alcohol-minimum-pricing-cancer-endpoints/","asOf":"2026-09-08","days":13},{"id":"idea-nl-upf-controlled-feeding-trial","kind":"idea","name":"Controlled feeding trials to separate ultra-processing from calories","route":"/ideas/idea-nl-upf-controlled-feeding-trial/","asOf":"2026-09-08","days":13},{"id":"idea-nl-antioxidant-supplement-harm-confirmation","kind":"idea","name":"Confirm or refute the harm of antioxidant supplements during chemotherapy","route":"/ideas/idea-nl-antioxidant-supplement-harm-confirmation/","asOf":"2026-09-08","days":13},{"id":"idea-nl-bariatric-cancer-registry-linkage","kind":"idea","name":"Link bariatric and GLP-1 registries to cancer registries in every country that has both","route":"/ideas/idea-nl-bariatric-cancer-registry-linkage/","asOf":"2026-09-08","days":13},{"id":"idea-nl-sleep-circadian-survivorship-rct","kind":"idea","name":"Treat insomnia in survivors and measure whether the cancer notices","route":"/ideas/idea-nl-sleep-circadian-survivorship-rct/","asOf":"2026-09-08","days":13},{"id":"idea-nl-dietitian-in-every-mdt","kind":"idea","name":"A dietitian in every gastrointestinal and head and neck tumour board","route":"/ideas/idea-nl-dietitian-in-every-mdt/","asOf":"2026-09-08","days":13},{"id":"idea-nl-ask-about-diet-prebunking","kind":"idea","name":"Ask about diet at diagnosis, and prebunk the myths before the internet does","route":"/ideas/idea-nl-ask-about-diet-prebunking/","asOf":"2026-09-08","days":13},{"id":"arc-institute","kind":"institution","name":"Arc Institute","route":"/institutions/arc-institute/","asOf":"2026-09-08","days":13},{"id":"institute-for-protein-design","kind":"institution","name":"Institute for Protein Design (University of Washington)","route":"/institutions/institute-for-protein-design/","asOf":"2026-09-08","days":13},{"id":"providence-health","kind":"institution","name":"Providence Health & Services","route":"/institutions/providence-health/","asOf":"2026-09-08","days":13},{"id":"yale-school-of-medicine","kind":"institution","name":"Yale School of Medicine / Yale Cancer Center","route":"/institutions/yale-school-of-medicine/","asOf":"2026-09-08","days":13},{"id":"google-deepmind","kind":"company","name":"Google DeepMind (and Google Research)","route":"/companies/google-deepmind/","asOf":"2026-09-08","days":13},{"id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","asOf":"2026-09-08","days":13},{"id":"nvidia","kind":"company","name":"NVIDIA","route":"/companies/nvidia/","asOf":"2026-09-08","days":13},{"id":"evolutionaryscale","kind":"company","name":"EvolutionaryScale","route":"/companies/evolutionaryscale/","asOf":"2026-09-08","days":13},{"id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","route":"/companies/vevo-therapeutics/","asOf":"2026-09-08","days":13},{"id":"bioptimus","kind":"company","name":"Bioptimus","route":"/companies/bioptimus/","asOf":"2026-09-08","days":13},{"id":"aignostics","kind":"company","name":"Aignostics","route":"/companies/aignostics/","asOf":"2026-09-08","days":13},{"id":"kaiko-ai","kind":"company","name":"kaiko.ai","route":"/companies/kaiko-ai/","asOf":"2026-09-08","days":13},{"id":"histai","kind":"company","name":"HistAI","route":"/companies/histai/","asOf":"2026-09-08","days":13},{"id":"chai-discovery","kind":"company","name":"Chai Discovery","route":"/companies/chai-discovery/","asOf":"2026-09-08","days":13},{"id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","route":"/companies/xaira-therapeutics/","asOf":"2026-09-08","days":13},{"id":"lila-sciences","kind":"company","name":"Lila Sciences","route":"/companies/lila-sciences/","asOf":"2026-09-08","days":13},{"id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/","asOf":"2026-09-08","days":13},{"id":"profluent-bio","kind":"company","name":"Profluent","route":"/companies/profluent-bio/","asOf":"2026-09-08","days":13},{"id":"latent-labs","kind":"company","name":"Latent Labs","route":"/companies/latent-labs/","asOf":"2026-09-08","days":13},{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","route":"/companies/genesis-molecular-ai/","asOf":"2026-09-08","days":13},{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","route":"/companies/iambic-therapeutics/","asOf":"2026-09-08","days":13},{"id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","route":"/companies/chan-zuckerberg-initiative/","asOf":"2026-09-08","days":13},{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","asOf":"2026-09-08","days":13},{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","asOf":"2026-09-08","days":13},{"id":"uk-biobank","kind":"collection","name":"UK Biobank","route":"/collections/uk-biobank/","asOf":"2026-09-08","days":13},{"id":"all-of-us","kind":"collection","name":"All of Us Research Program","route":"/collections/all-of-us/","asOf":"2026-09-08","days":13},{"id":"flatiron-foundation-cgdb","kind":"collection","name":"Flatiron Health and Foundation Medicine Clinico-Genomic Database","route":"/collections/flatiron-foundation-cgdb/","asOf":"2026-09-08","days":13},{"id":"cdas-nlst-plco","kind":"collection","name":"NCI CDAS: NLST and PLCO screening trial data","route":"/collections/cdas-nlst-plco/","asOf":"2026-09-08","days":13},{"id":"pathology-benchmarks","kind":"collection","name":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","route":"/collections/pathology-benchmarks/","asOf":"2026-09-08","days":13},{"id":"tahoe-100m","kind":"collection","name":"Tahoe-100M","route":"/collections/tahoe-100m/","asOf":"2026-09-08","days":13},{"id":"arc-virtual-cell-atlas","kind":"collection","name":"Arc Virtual Cell Atlas","route":"/collections/arc-virtual-cell-atlas/","asOf":"2026-09-08","days":13},{"id":"virchow","kind":"technology","name":"Virchow / Virchow2 (Paige, MSK)","route":"/technologies/virchow/","asOf":"2026-09-08","days":13},{"id":"uni-conch","kind":"technology","name":"UNI and CONCH (Harvard, Mahmood Lab)","route":"/technologies/uni-conch/","asOf":"2026-09-08","days":13},{"id":"titan","kind":"technology","name":"TITAN (whole-slide multimodal model)","route":"/technologies/titan/","asOf":"2026-09-08","days":13},{"id":"prov-gigapath","kind":"technology","name":"Prov-GigaPath (Microsoft, Providence)","route":"/technologies/prov-gigapath/","asOf":"2026-09-08","days":13},{"id":"chief","kind":"technology","name":"CHIEF (Harvard, Yu Lab)","route":"/technologies/chief/","asOf":"2026-09-08","days":13},{"id":"musk","kind":"technology","name":"MUSK (Stanford, vision-language pathology)","route":"/technologies/musk/","asOf":"2026-09-08","days":13},{"id":"h-optimus","kind":"technology","name":"H-optimus (Bioptimus)","route":"/technologies/h-optimus/","asOf":"2026-09-08","days":13},{"id":"pluto","kind":"technology","name":"PLUTO (PathAI)","route":"/technologies/pluto/","asOf":"2026-09-08","days":13},{"id":"hibou","kind":"technology","name":"Hibou (HistAI)","route":"/technologies/hibou/","asOf":"2026-09-08","days":13},{"id":"kaiko-midnight","kind":"technology","name":"Midnight (kaiko.ai)","route":"/technologies/kaiko-midnight/","asOf":"2026-09-08","days":13},{"id":"atlas-aignostics","kind":"technology","name":"Atlas (Aignostics, Mayo Clinic, Charité)","route":"/technologies/atlas-aignostics/","asOf":"2026-09-08","days":13},{"id":"phikon","kind":"technology","name":"Phikon / Phikon-v2 (Owkin)","route":"/technologies/phikon/","asOf":"2026-09-08","days":13},{"id":"merlin-ct","kind":"technology","name":"Merlin (Stanford abdominal CT vision-language model)","route":"/technologies/merlin-ct/","asOf":"2026-09-08","days":13},{"id":"radfm","kind":"technology","name":"RadFM (generalist radiology foundation model)","route":"/technologies/radfm/","asOf":"2026-09-08","days":13},{"id":"ct-fm","kind":"technology","name":"CT-FM (whole-body CT foundation model)","route":"/technologies/ct-fm/","asOf":"2026-09-08","days":13},{"id":"medsam","kind":"technology","name":"MedSAM / SAM-Med3D (segment anything for medicine)","route":"/technologies/medsam/","asOf":"2026-09-08","days":13},{"id":"sybil","kind":"technology","name":"Sybil (MIT/MGH lung cancer risk from CT)","route":"/technologies/sybil/","asOf":"2026-09-08","days":13},{"id":"mirai","kind":"technology","name":"Mirai (MIT breast cancer risk from mammograms)","route":"/technologies/mirai/","asOf":"2026-09-08","days":13},{"id":"med-gemini","kind":"technology","name":"Med-Gemini and MedLM (Google)","route":"/technologies/med-gemini/","asOf":"2026-09-08","days":13},{"id":"aidoc-care","kind":"technology","name":"Aidoc CARE (clinical radiology foundation model)","route":"/technologies/aidoc-care/","asOf":"2026-09-08","days":13},{"id":"geneformer","kind":"technology","name":"Geneformer","route":"/technologies/geneformer/","asOf":"2026-09-08","days":13},{"id":"scgpt","kind":"technology","name":"scGPT","route":"/technologies/scgpt/","asOf":"2026-09-08","days":13},{"id":"universal-cell-embedding","kind":"technology","name":"Universal Cell Embedding (UCE)","route":"/technologies/universal-cell-embedding/","asOf":"2026-09-08","days":13},{"id":"scfoundation","kind":"technology","name":"scFoundation (BioMap)","route":"/technologies/scfoundation/","asOf":"2026-09-08","days":13},{"id":"nicheformer","kind":"technology","name":"Nicheformer (spatial single-cell)","route":"/technologies/nicheformer/","asOf":"2026-09-08","days":13},{"id":"cellfm","kind":"technology","name":"CellFM","route":"/technologies/cellfm/","asOf":"2026-09-08","days":13},{"id":"genept","kind":"technology","name":"GenePT","route":"/technologies/genept/","asOf":"2026-09-08","days":13},{"id":"c2s-scale","kind":"technology","name":"Cell2Sentence / C2S-Scale (Yale, Google)","route":"/technologies/c2s-scale/","asOf":"2026-09-08","days":13},{"id":"state-arc","kind":"technology","name":"State (Arc Institute perturbation model)","route":"/technologies/state-arc/","asOf":"2026-09-08","days":13},{"id":"transcriptformer","kind":"technology","name":"TranscriptFormer and rBio (CZI virtual cell models)","route":"/technologies/transcriptformer/","asOf":"2026-09-08","days":13},{"id":"gears","kind":"technology","name":"GEARS and perturbation prediction benchmarks","route":"/technologies/gears/","asOf":"2026-09-08","days":13},{"id":"alphafold3","kind":"technology","name":"AlphaFold 3","route":"/technologies/alphafold3/","asOf":"2026-09-08","days":13},{"id":"boltz","kind":"technology","name":"Boltz-1 / Boltz-2 (MIT, open)","route":"/technologies/boltz/","asOf":"2026-09-08","days":13},{"id":"chai-1","kind":"technology","name":"Chai-1 / Chai-2","route":"/technologies/chai-1/","asOf":"2026-09-08","days":13},{"id":"esm3","kind":"technology","name":"ESM3 (EvolutionaryScale)","route":"/technologies/esm3/","asOf":"2026-09-08","days":13},{"id":"evo2","kind":"technology","name":"Evo 2 (Arc Institute, NVIDIA)","route":"/technologies/evo2/","asOf":"2026-09-08","days":13},{"id":"rfdiffusion","kind":"technology","name":"RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)","route":"/technologies/rfdiffusion/","asOf":"2026-09-08","days":13},{"id":"bioemu","kind":"technology","name":"BioEmu (Microsoft)","route":"/technologies/bioemu/","asOf":"2026-09-08","days":13},{"id":"nucleotide-transformer","kind":"technology","name":"Nucleotide Transformer (InstaDeep)","route":"/technologies/nucleotide-transformer/","asOf":"2026-09-08","days":13},{"id":"enformer-borzoi","kind":"technology","name":"Enformer and Borzoi (DeepMind, Calico)","route":"/technologies/enformer-borzoi/","asOf":"2026-09-08","days":13},{"id":"alphamissense","kind":"technology","name":"AlphaMissense","route":"/technologies/alphamissense/","asOf":"2026-09-08","days":13},{"id":"alphagenome","kind":"technology","name":"AlphaGenome","route":"/technologies/alphagenome/","asOf":"2026-09-08","days":13},{"id":"foresight-ehr","kind":"technology","name":"Foresight (generative EHR model)","route":"/technologies/foresight-ehr/","asOf":"2026-09-08","days":13},{"id":"tempus-multimodal","kind":"technology","name":"Tempus multimodal models","route":"/technologies/tempus-multimodal/","asOf":"2026-09-08","days":13},{"id":"bionemo","kind":"technology","name":"NVIDIA BioNeMo","route":"/technologies/bionemo/","asOf":"2026-09-08","days":13},{"id":"phenom-2","kind":"technology","name":"Phenom-2 and Recursion OS","route":"/technologies/phenom-2/","asOf":"2026-09-08","days":13},{"id":"chemistry42","kind":"technology","name":"Chemistry42 and Pharma.AI (Insilico)","route":"/technologies/chemistry42/","asOf":"2026-09-08","days":13},{"id":"virtual-cell","kind":"roadmap","name":"Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell","route":"/roadmaps/virtual-cell/","asOf":"2026-09-08","days":13},{"id":"ai-oncology-clinic","kind":"roadmap","name":"AI in the oncology clinic: from narrow cleared tools to multimodal decision support","route":"/roadmaps/ai-oncology-clinic/","asOf":"2026-09-08","days":13},{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","asOf":"2026-09-09","days":12},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","asOf":"2026-09-09","days":12},{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","asOf":"2026-09-09","days":12},{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","asOf":"2026-09-09","days":12},{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","asOf":"2026-09-09","days":12},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","asOf":"2026-09-09","days":12},{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","asOf":"2026-09-09","days":12},{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","asOf":"2026-09-09","days":12},{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","asOf":"2026-09-09","days":12},{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","asOf":"2026-09-09","days":12},{"id":"steve-jobs","kind":"person","name":"Steve Jobs","route":"/people/steve-jobs/","asOf":"2026-09-09","days":12},{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","asOf":"2026-09-09","days":12},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","asOf":"2026-09-09","days":12},{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","asOf":"2026-09-09","days":12},{"id":"ashya-king","kind":"person","name":"Ashya King","route":"/people/ashya-king/","asOf":"2026-09-09","days":12},{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","asOf":"2026-09-09","days":12},{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","asOf":"2026-09-09","days":12},{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","asOf":"2026-09-09","days":12},{"id":"rose-kushner","kind":"person","name":"Rose Kushner","route":"/people/rose-kushner/","asOf":"2026-09-09","days":12},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","asOf":"2026-09-09","days":12},{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","asOf":"2026-09-09","days":12},{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","asOf":"2026-09-09","days":12},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","asOf":"2026-09-09","days":12},{"id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","asOf":"2026-09-09","days":12},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","asOf":"2026-09-09","days":12},{"id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","asOf":"2026-09-09","days":12},{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","asOf":"2026-09-09","days":12},{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","asOf":"2026-09-09","days":12},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","asOf":"2026-09-09","days":12},{"id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","asOf":"2026-09-09","days":12},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","asOf":"2026-09-09","days":12},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","asOf":"2026-09-09","days":12},{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","asOf":"2026-09-09","days":12},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","asOf":"2026-09-09","days":12},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","asOf":"2026-09-09","days":12},{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","asOf":"2026-09-09","days":12},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","asOf":"2026-09-09","days":12},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","asOf":"2026-09-09","days":12},{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","asOf":"2026-09-09","days":12},{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","asOf":"2026-09-09","days":12},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","asOf":"2026-09-09","days":12},{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","asOf":"2026-09-09","days":12},{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","asOf":"2026-09-09","days":12},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","asOf":"2026-09-09","days":12},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","asOf":"2026-09-09","days":12},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","asOf":"2026-09-09","days":12},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","asOf":"2026-09-09","days":12},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","asOf":"2026-09-09","days":12},{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","asOf":"2026-09-09","days":12},{"id":"sid-sijbrandij","kind":"person","name":"Sid Sijbrandij","route":"/people/sid-sijbrandij/","asOf":"2026-09-09","days":12},{"id":"sn-38","kind":"term","name":"SN-38","route":"/terms/sn-38/","asOf":"2026-09-09","days":12},{"id":"dxd","kind":"term","name":"DXd","route":"/terms/dxd/","asOf":"2026-09-09","days":12},{"id":"exatecan","kind":"term","name":"Exatecan (and derivatives)","route":"/terms/exatecan/","asOf":"2026-09-09","days":12},{"id":"t030","kind":"term","name":"T030 (belotecan derivative)","route":"/terms/t030/","asOf":"2026-09-09","days":12},{"id":"mmae","kind":"term","name":"MMAE","route":"/terms/mmae/","asOf":"2026-09-09","days":12},{"id":"mmaf","kind":"term","name":"MMAF","route":"/terms/mmaf/","asOf":"2026-09-09","days":12},{"id":"dm1","kind":"term","name":"DM1","route":"/terms/dm1/","asOf":"2026-09-09","days":12},{"id":"dm4","kind":"term","name":"DM4","route":"/terms/dm4/","asOf":"2026-09-09","days":12},{"id":"pbd-sg3199","kind":"term","name":"PBD dimer (SG3199 / tesirine)","route":"/terms/pbd-sg3199/","asOf":"2026-09-09","days":12},{"id":"calicheamicin","kind":"term","name":"Calicheamicin","route":"/terms/calicheamicin/","asOf":"2026-09-09","days":12},{"id":"duocarmycin","kind":"term","name":"Duocarmycin (seco-DUBA)","route":"/terms/duocarmycin/","asOf":"2026-09-09","days":12},{"id":"topoisomerase-i-payloads","kind":"term","name":"Topoisomerase-I inhibitor payloads","route":"/terms/topoisomerase-i-payloads/","asOf":"2026-09-09","days":12},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/","asOf":"2026-09-09","days":12},{"id":"pbd-dimer-payloads","kind":"term","name":"DNA crosslinker payloads (PBD dimers)","route":"/terms/pbd-dimer-payloads/","asOf":"2026-09-09","days":12},{"id":"dna-cleaver-payloads","kind":"term","name":"DNA cleaver payloads (enediynes)","route":"/terms/dna-cleaver-payloads/","asOf":"2026-09-09","days":12},{"id":"dna-alkylator-payloads","kind":"term","name":"DNA alkylator payloads","route":"/terms/dna-alkylator-payloads/","asOf":"2026-09-09","days":12},{"id":"cl2a","kind":"term","name":"CL2A","route":"/terms/cl2a/","asOf":"2026-09-09","days":12},{"id":"ggfg","kind":"term","name":"Tetrapeptide GGFG (maleimide-GGFG-aminomethyl)","route":"/terms/ggfg/","asOf":"2026-09-09","days":12},{"id":"mc-vc-pabc","kind":"term","name":"mc-Val-Cit-PABC","route":"/terms/mc-vc-pabc/","asOf":"2026-09-09","days":12},{"id":"smcc","kind":"term","name":"SMCC (thioether, non-cleavable)","route":"/terms/smcc/","asOf":"2026-09-09","days":12},{"id":"sulfo-spdb","kind":"term","name":"Sulfo-SPDB (disulfide)","route":"/terms/sulfo-spdb/","asOf":"2026-09-09","days":12},{"id":"hydrazone","kind":"term","name":"Acid-labile hydrazone (AcBut)","route":"/terms/hydrazone/","asOf":"2026-09-09","days":12},{"id":"val-ala","kind":"term","name":"Val-Ala dipeptide","route":"/terms/val-ala/","asOf":"2026-09-09","days":12},{"id":"mc-non-cleavable","kind":"term","name":"Maleimidocaproyl (mc), non-cleavable","route":"/terms/mc-non-cleavable/","asOf":"2026-09-09","days":12},{"id":"hydrophilic-next-gen","kind":"term","name":"Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)","route":"/terms/hydrophilic-next-gen/","asOf":"2026-09-09","days":12},{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","asOf":"2026-09-09","days":12},{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","asOf":"2026-09-09","days":12},{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","asOf":"2026-09-09","days":12},{"id":"jama-internal-medicine","kind":"journal","name":"JAMA Internal Medicine","route":"/journals/jama-internal-medicine/","asOf":"2026-09-09","days":12},{"id":"bmj","kind":"journal","name":"BMJ","route":"/journals/bmj/","asOf":"2026-09-09","days":12},{"id":"annals-internal-medicine","kind":"journal","name":"Annals of Internal Medicine","route":"/journals/annals-internal-medicine/","asOf":"2026-09-09","days":12},{"id":"plos-medicine","kind":"journal","name":"PLOS Medicine","route":"/journals/plos-medicine/","asOf":"2026-09-09","days":12},{"id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","route":"/journals/lancet-global-health/","asOf":"2026-09-09","days":12},{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","asOf":"2026-09-09","days":12},{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","asOf":"2026-09-09","days":12},{"id":"jco-precision-oncology","kind":"journal","name":"JCO Precision Oncology","route":"/journals/jco-precision-oncology/","asOf":"2026-09-09","days":12},{"id":"jco-oncology-practice","kind":"journal","name":"JCO Oncology Practice","route":"/journals/jco-oncology-practice/","asOf":"2026-09-09","days":12},{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","asOf":"2026-09-09","days":12},{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/","asOf":"2026-09-09","days":12},{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/","asOf":"2026-09-09","days":12},{"id":"jnci","kind":"journal","name":"JNCI: Journal of the National Cancer Institute","route":"/journals/jnci/","asOf":"2026-09-09","days":12},{"id":"cancer-wiley","kind":"journal","name":"Cancer","route":"/journals/cancer-wiley/","asOf":"2026-09-09","days":12},{"id":"ca-cancer-journal","kind":"journal","name":"CA: A Cancer Journal for Clinicians","route":"/journals/ca-cancer-journal/","asOf":"2026-09-09","days":12},{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/","asOf":"2026-09-09","days":12},{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","route":"/journals/european-journal-of-cancer/","asOf":"2026-09-09","days":12},{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/","asOf":"2026-09-09","days":12},{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/","asOf":"2026-09-09","days":12},{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/","asOf":"2026-09-09","days":12},{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","asOf":"2026-09-09","days":12},{"id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","route":"/journals/european-urology-oncology/","asOf":"2026-09-09","days":12},{"id":"neuro-oncology","kind":"journal","name":"Neuro-Oncology","route":"/journals/neuro-oncology/","asOf":"2026-09-09","days":12},{"id":"radiotherapy-and-oncology","kind":"journal","name":"Radiotherapy and Oncology","route":"/journals/radiotherapy-and-oncology/","asOf":"2026-09-09","days":12},{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/","asOf":"2026-09-09","days":12},{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","asOf":"2026-09-09","days":12},{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","asOf":"2026-09-09","days":12},{"id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","route":"/journals/pediatric-blood-and-cancer/","asOf":"2026-09-09","days":12},{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/","asOf":"2026-09-09","days":12},{"id":"blood-advances","kind":"journal","name":"Blood Advances","route":"/journals/blood-advances/","asOf":"2026-09-09","days":12},{"id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","asOf":"2026-09-09","days":12},{"id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","route":"/journals/lancet-haematology/","asOf":"2026-09-09","days":12},{"id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/","asOf":"2026-09-09","days":12},{"id":"nature","kind":"journal","name":"Nature","route":"/journals/nature/","asOf":"2026-09-09","days":12},{"id":"science","kind":"journal","name":"Science","route":"/journals/science/","asOf":"2026-09-09","days":12},{"id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","asOf":"2026-09-09","days":12},{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/","asOf":"2026-09-09","days":12},{"id":"cell-stem-cell","kind":"journal","name":"Cell Stem Cell","route":"/journals/cell-stem-cell/","asOf":"2026-09-09","days":12},{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","asOf":"2026-09-09","days":12},{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/","asOf":"2026-09-09","days":12},{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/","asOf":"2026-09-09","days":12},{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/","asOf":"2026-09-09","days":12},{"id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","route":"/journals/nature-reviews-drug-discovery/","asOf":"2026-09-09","days":12},{"id":"nature-genetics","kind":"journal","name":"Nature Genetics","route":"/journals/nature-genetics/","asOf":"2026-09-09","days":12},{"id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","route":"/journals/nature-biotechnology/","asOf":"2026-09-09","days":12},{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/","asOf":"2026-09-09","days":12},{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","asOf":"2026-09-09","days":12},{"id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","route":"/journals/cancer-discovery/","asOf":"2026-09-09","days":12},{"id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/","asOf":"2026-09-09","days":12},{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","asOf":"2026-09-09","days":12},{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/","asOf":"2026-09-09","days":12},{"id":"molecular-cancer-therapeutics","kind":"journal","name":"Molecular Cancer Therapeutics","route":"/journals/molecular-cancer-therapeutics/","asOf":"2026-09-09","days":12},{"id":"cancer-epidemiology-biomarkers-prevention","kind":"journal","name":"Cancer Epidemiology, Biomarkers & Prevention","route":"/journals/cancer-epidemiology-biomarkers-prevention/","asOf":"2026-09-09","days":12},{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","route":"/journals/jitc/","asOf":"2026-09-09","days":12},{"id":"jci","kind":"journal","name":"Journal of Clinical Investigation","route":"/journals/jci/","asOf":"2026-09-09","days":12},{"id":"genes-and-development","kind":"journal","name":"Genes & Development","route":"/journals/genes-and-development/","asOf":"2026-09-09","days":12},{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/","asOf":"2026-09-09","days":12},{"id":"elife","kind":"journal","name":"eLife","route":"/journals/elife/","asOf":"2026-09-09","days":12},{"id":"cancers-mdpi","kind":"journal","name":"Cancers","route":"/journals/cancers-mdpi/","asOf":"2026-09-09","days":12},{"id":"clinical-pharmacology-and-therapeutics","kind":"journal","name":"Clinical Pharmacology & Therapeutics","route":"/journals/clinical-pharmacology-and-therapeutics/","asOf":"2026-09-09","days":12},{"id":"lancet-digital-health","kind":"journal","name":"The Lancet Digital Health","route":"/journals/lancet-digital-health/","asOf":"2026-09-09","days":12},{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/","asOf":"2026-09-09","days":12},{"id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/","asOf":"2026-09-09","days":12},{"id":"biorxiv","kind":"journal","name":"bioRxiv","route":"/journals/biorxiv/","asOf":"2026-09-09","days":12},{"id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","asOf":"2026-09-09","days":12},{"id":"cell-membrane","kind":"term","name":"Cell membrane","route":"/terms/cell-membrane/","asOf":"2026-09-09","days":12},{"id":"nucleus","kind":"term","name":"Nucleus","route":"/terms/nucleus/","asOf":"2026-09-09","days":12},{"id":"dna-term","kind":"term","name":"DNA","route":"/terms/dna-term/","asOf":"2026-09-09","days":12},{"id":"rna","kind":"term","name":"RNA","route":"/terms/rna/","asOf":"2026-09-09","days":12},{"id":"gene","kind":"term","name":"Gene","route":"/terms/gene/","asOf":"2026-09-09","days":12},{"id":"chromosome","kind":"term","name":"Chromosome","route":"/terms/chromosome/","asOf":"2026-09-09","days":12},{"id":"protein","kind":"term","name":"Protein","route":"/terms/protein/","asOf":"2026-09-09","days":12},{"id":"enzyme","kind":"term","name":"Enzyme","route":"/terms/enzyme/","asOf":"2026-09-09","days":12},{"id":"gene-expression","kind":"term","name":"Gene expression","route":"/terms/gene-expression/","asOf":"2026-09-09","days":12},{"id":"mutation","kind":"term","name":"Mutation","route":"/terms/mutation/","asOf":"2026-09-09","days":12},{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/","asOf":"2026-09-09","days":12},{"id":"amplification","kind":"term","name":"Amplification","route":"/terms/amplification/","asOf":"2026-09-09","days":12},{"id":"overexpression","kind":"term","name":"Overexpression","route":"/terms/overexpression/","asOf":"2026-09-09","days":12},{"id":"deletion","kind":"term","name":"Deletion","route":"/terms/deletion/","asOf":"2026-09-09","days":12},{"id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","asOf":"2026-09-09","days":12},{"id":"tumour-suppressor-gene","kind":"term","name":"Tumour suppressor gene","route":"/terms/tumour-suppressor-gene/","asOf":"2026-09-09","days":12},{"id":"receptor","kind":"term","name":"Receptor","route":"/terms/receptor/","asOf":"2026-09-09","days":12},{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","asOf":"2026-09-09","days":12},{"id":"growth-factor","kind":"term","name":"Growth factor","route":"/terms/growth-factor/","asOf":"2026-09-09","days":12},{"id":"growth-signal","kind":"term","name":"Growth signal","route":"/terms/growth-signal/","asOf":"2026-09-09","days":12},{"id":"signalling-pathway","kind":"term","name":"Signalling pathway","route":"/terms/signalling-pathway/","asOf":"2026-09-09","days":12},{"id":"downstream","kind":"term","name":"Downstream and upstream","route":"/terms/downstream/","asOf":"2026-09-09","days":12},{"id":"kinase","kind":"term","name":"Kinase","route":"/terms/kinase/","asOf":"2026-09-09","days":12},{"id":"phosphorylation","kind":"term","name":"Phosphorylation","route":"/terms/phosphorylation/","asOf":"2026-09-09","days":12},{"id":"inhibitor","kind":"term","name":"Inhibitor","route":"/terms/inhibitor/","asOf":"2026-09-09","days":12},{"id":"agonist-antagonist","kind":"term","name":"Agonist and antagonist","route":"/terms/agonist-antagonist/","asOf":"2026-09-09","days":12},{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/","asOf":"2026-09-09","days":12},{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","asOf":"2026-09-09","days":12},{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/","asOf":"2026-09-09","days":12},{"id":"monoclonal","kind":"term","name":"Monoclonal","route":"/terms/monoclonal/","asOf":"2026-09-09","days":12},{"id":"cell-cycle","kind":"term","name":"Cell cycle","route":"/terms/cell-cycle/","asOf":"2026-09-09","days":12},{"id":"cell-division","kind":"term","name":"Cell division","route":"/terms/cell-division/","asOf":"2026-09-09","days":12},{"id":"proliferation","kind":"term","name":"Proliferation","route":"/terms/proliferation/","asOf":"2026-09-09","days":12},{"id":"differentiation","kind":"term","name":"Differentiation","route":"/terms/differentiation/","asOf":"2026-09-09","days":12},{"id":"stem-cell","kind":"term","name":"Stem cell","route":"/terms/stem-cell/","asOf":"2026-09-09","days":12},{"id":"apoptosis","kind":"term","name":"Apoptosis","route":"/terms/apoptosis/","asOf":"2026-09-09","days":12},{"id":"necrosis","kind":"term","name":"Necrosis","route":"/terms/necrosis/","asOf":"2026-09-09","days":12},{"id":"angiogenesis","kind":"term","name":"Angiogenesis","route":"/terms/angiogenesis/","asOf":"2026-09-09","days":12},{"id":"benign-vs-malignant","kind":"term","name":"Benign versus malignant","route":"/terms/benign-vs-malignant/","asOf":"2026-09-09","days":12},{"id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","asOf":"2026-09-09","days":12},{"id":"metastasis","kind":"term","name":"Metastasis","route":"/terms/metastasis/","asOf":"2026-09-09","days":12},{"id":"lesion","kind":"term","name":"Lesion","route":"/terms/lesion/","asOf":"2026-09-09","days":12},{"id":"carcinoma","kind":"term","name":"Carcinoma","route":"/terms/carcinoma/","asOf":"2026-09-09","days":12},{"id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","asOf":"2026-09-09","days":12},{"id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/","asOf":"2026-09-09","days":12},{"id":"sarcoma-type","kind":"term","name":"Sarcoma (tissue type)","route":"/terms/sarcoma-type/","asOf":"2026-09-09","days":12},{"id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/","asOf":"2026-09-09","days":12},{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","asOf":"2026-09-09","days":12},{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","asOf":"2026-09-09","days":12},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/","asOf":"2026-09-09","days":12},{"id":"cancer-stage","kind":"term","name":"Stage","route":"/terms/cancer-stage/","asOf":"2026-09-09","days":12},{"id":"in-situ","kind":"term","name":"In situ","route":"/terms/in-situ/","asOf":"2026-09-09","days":12},{"id":"invasive-cancer","kind":"term","name":"Invasive","route":"/terms/invasive-cancer/","asOf":"2026-09-09","days":12},{"id":"lymph-node","kind":"term","name":"Lymph node","route":"/terms/lymph-node/","asOf":"2026-09-09","days":12},{"id":"biopsy","kind":"term","name":"Biopsy","route":"/terms/biopsy/","asOf":"2026-09-09","days":12},{"id":"histology","kind":"term","name":"Histology","route":"/terms/histology/","asOf":"2026-09-09","days":12},{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/","asOf":"2026-09-09","days":12},{"id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/","asOf":"2026-09-09","days":12},{"id":"genomic-profiling","kind":"term","name":"Genomic profiling","route":"/terms/genomic-profiling/","asOf":"2026-09-09","days":12},{"id":"immune-system","kind":"term","name":"Immune system","route":"/terms/immune-system/","asOf":"2026-09-09","days":12},{"id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/","asOf":"2026-09-09","days":12},{"id":"b-cell","kind":"term","name":"B cell","route":"/terms/b-cell/","asOf":"2026-09-09","days":12},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/","asOf":"2026-09-09","days":12},{"id":"macrophage","kind":"term","name":"Macrophage","route":"/terms/macrophage/","asOf":"2026-09-09","days":12},{"id":"cytokine","kind":"term","name":"Cytokine","route":"/terms/cytokine/","asOf":"2026-09-09","days":12},{"id":"inflammation","kind":"term","name":"Inflammation","route":"/terms/inflammation/","asOf":"2026-09-09","days":12},{"id":"immune-checkpoint","kind":"term","name":"Immune checkpoint","route":"/terms/immune-checkpoint/","asOf":"2026-09-09","days":12},{"id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","asOf":"2026-09-09","days":12},{"id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","asOf":"2026-09-09","days":12},{"id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","asOf":"2026-09-09","days":12},{"id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","asOf":"2026-09-09","days":12},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","asOf":"2026-09-09","days":12},{"id":"systemic-vs-local-therapy","kind":"term","name":"Systemic versus local therapy","route":"/terms/systemic-vs-local-therapy/","asOf":"2026-09-09","days":12},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/","asOf":"2026-09-09","days":12},{"id":"palliative-treatment","kind":"term","name":"Palliative","route":"/terms/palliative-treatment/","asOf":"2026-09-09","days":12},{"id":"remission","kind":"term","name":"Remission","route":"/terms/remission/","asOf":"2026-09-09","days":12},{"id":"complete-response","kind":"term","name":"Complete response","route":"/terms/complete-response/","asOf":"2026-09-09","days":12},{"id":"partial-response","kind":"term","name":"Partial response","route":"/terms/partial-response/","asOf":"2026-09-09","days":12},{"id":"stable-disease","kind":"term","name":"Stable disease","route":"/terms/stable-disease/","asOf":"2026-09-09","days":12},{"id":"progression","kind":"term","name":"Progression","route":"/terms/progression/","asOf":"2026-09-09","days":12},{"id":"relapse-recurrence","kind":"term","name":"Recurrence and relapse","route":"/terms/relapse-recurrence/","asOf":"2026-09-09","days":12},{"id":"refractory","kind":"term","name":"Refractory","route":"/terms/refractory/","asOf":"2026-09-09","days":12},{"id":"duration-of-response","kind":"term","name":"Duration of response","route":"/terms/duration-of-response/","asOf":"2026-09-09","days":12},{"id":"prognosis","kind":"term","name":"Prognosis","route":"/terms/prognosis/","asOf":"2026-09-09","days":12},{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/","asOf":"2026-09-09","days":12},{"id":"trial-phases","kind":"term","name":"Phase 1, 2 and 3 trials","route":"/terms/trial-phases/","asOf":"2026-09-09","days":12},{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/","asOf":"2026-09-09","days":12},{"id":"placebo","kind":"term","name":"Placebo","route":"/terms/placebo/","asOf":"2026-09-09","days":12},{"id":"blinding","kind":"term","name":"Blinded trial","route":"/terms/blinding/","asOf":"2026-09-09","days":12},{"id":"endpoint","kind":"term","name":"Endpoint","route":"/terms/endpoint/","asOf":"2026-09-09","days":12},{"id":"surrogate-endpoint","kind":"term","name":"Surrogate endpoint","route":"/terms/surrogate-endpoint/","asOf":"2026-09-09","days":12},{"id":"hazard-ratio-basics","kind":"term","name":"Reading a hazard ratio","route":"/terms/hazard-ratio-basics/","asOf":"2026-09-09","days":12},{"id":"median-survival","kind":"term","name":"Median survival","route":"/terms/median-survival/","asOf":"2026-09-09","days":12},{"id":"confidence-interval","kind":"term","name":"Confidence interval","route":"/terms/confidence-interval/","asOf":"2026-09-09","days":12},{"id":"p-value","kind":"term","name":"P-value","route":"/terms/p-value/","asOf":"2026-09-09","days":12},{"id":"dose","kind":"term","name":"Dose","route":"/terms/dose/","asOf":"2026-09-09","days":12},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","asOf":"2026-09-09","days":12},{"id":"toxicity-grade","kind":"term","name":"Toxicity grade","route":"/terms/toxicity-grade/","asOf":"2026-09-09","days":12},{"id":"side-effect-vs-adverse-event","kind":"term","name":"Side effect versus adverse event","route":"/terms/side-effect-vs-adverse-event/","asOf":"2026-09-09","days":12},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/","asOf":"2026-09-09","days":12},{"id":"prodrug","kind":"term","name":"Prodrug","route":"/terms/prodrug/","asOf":"2026-09-09","days":12},{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/","asOf":"2026-09-09","days":12},{"id":"orphan-drug","kind":"term","name":"Orphan drug","route":"/terms/orphan-drug/","asOf":"2026-09-09","days":12},{"id":"incidence-vs-prevalence","kind":"term","name":"Incidence versus prevalence","route":"/terms/incidence-vs-prevalence/","asOf":"2026-09-09","days":12},{"id":"mortality","kind":"term","name":"Mortality","route":"/terms/mortality/","asOf":"2026-09-09","days":12},{"id":"risk-factor","kind":"term","name":"Risk factor","route":"/terms/risk-factor/","asOf":"2026-09-09","days":12},{"id":"screening","kind":"term","name":"Screening","route":"/terms/screening/","asOf":"2026-09-09","days":12},{"id":"early-detection-term","kind":"term","name":"Early detection","route":"/terms/early-detection-term/","asOf":"2026-09-09","days":12},{"id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/","asOf":"2026-09-09","days":12},{"id":"preclinical","kind":"term","name":"Preclinical","route":"/terms/preclinical/","asOf":"2026-09-09","days":12},{"id":"model-organism","kind":"term","name":"Model organism","route":"/terms/model-organism/","asOf":"2026-09-09","days":12},{"id":"cell-line","kind":"term","name":"Cell line","route":"/terms/cell-line/","asOf":"2026-09-09","days":12},{"id":"organoid","kind":"term","name":"Organoid","route":"/terms/organoid/","asOf":"2026-09-09","days":12},{"id":"oesophagectomy","kind":"term","name":"Oesophagectomy","route":"/terms/oesophagectomy/","asOf":"2026-09-09","days":12},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","asOf":"2026-09-09","days":12},{"id":"lobectomy","kind":"term","name":"Lobectomy","route":"/terms/lobectomy/","asOf":"2026-09-09","days":12},{"id":"segmentectomy","kind":"term","name":"Segmentectomy (sublobar resection)","route":"/terms/segmentectomy/","asOf":"2026-09-09","days":12},{"id":"pneumonectomy","kind":"term","name":"Pneumonectomy","route":"/terms/pneumonectomy/","asOf":"2026-09-09","days":12},{"id":"cystectomy","kind":"term","name":"Radical cystectomy","route":"/terms/cystectomy/","asOf":"2026-09-09","days":12},{"id":"nephrectomy","kind":"term","name":"Nephrectomy","route":"/terms/nephrectomy/","asOf":"2026-09-09","days":12},{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","asOf":"2026-09-09","days":12},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","asOf":"2026-09-09","days":12},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","asOf":"2026-09-09","days":12},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","asOf":"2026-09-09","days":12},{"id":"gastrectomy","kind":"term","name":"Gastrectomy","route":"/terms/gastrectomy/","asOf":"2026-09-09","days":12},{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","asOf":"2026-09-09","days":12},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","asOf":"2026-09-09","days":12},{"id":"abdominoperineal-resection","kind":"term","name":"Abdominoperineal resection","route":"/terms/abdominoperineal-resection/","asOf":"2026-09-09","days":12},{"id":"hepatectomy","kind":"term","name":"Hepatectomy (liver resection)","route":"/terms/hepatectomy/","asOf":"2026-09-09","days":12},{"id":"prostatectomy","kind":"term","name":"Radical prostatectomy","route":"/terms/prostatectomy/","asOf":"2026-09-09","days":12},{"id":"orchiectomy","kind":"term","name":"Orchiectomy","route":"/terms/orchiectomy/","asOf":"2026-09-09","days":12},{"id":"hysterectomy","kind":"term","name":"Hysterectomy","route":"/terms/hysterectomy/","asOf":"2026-09-09","days":12},{"id":"salpingo-oophorectomy","kind":"term","name":"Salpingo-oophorectomy","route":"/terms/salpingo-oophorectomy/","asOf":"2026-09-09","days":12},{"id":"debulking","kind":"term","name":"Debulking (cytoreductive surgery)","route":"/terms/debulking/","asOf":"2026-09-09","days":12},{"id":"thyroidectomy","kind":"term","name":"Thyroidectomy","route":"/terms/thyroidectomy/","asOf":"2026-09-09","days":12},{"id":"adrenalectomy","kind":"term","name":"Adrenalectomy","route":"/terms/adrenalectomy/","asOf":"2026-09-09","days":12},{"id":"turbt","kind":"term","name":"Transurethral resection of bladder tumour (TURBT)","route":"/terms/turbt/","asOf":"2026-09-09","days":12},{"id":"limb-salvage-term","kind":"term","name":"Limb-salvage surgery","route":"/terms/limb-salvage-term/","asOf":"2026-09-09","days":12},{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","asOf":"2026-09-09","days":12},{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","asOf":"2026-09-09","days":12},{"id":"endoscopic-resection-term","kind":"term","name":"EMR and ESD (endoscopic mucosal resection, endoscopic submucosal dissection)","route":"/terms/endoscopic-resection-term/","asOf":"2026-09-09","days":12},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","asOf":"2026-09-09","days":12},{"id":"endoscopy","kind":"term","name":"Endoscopy (EGD, EUS, ERCP)","route":"/terms/endoscopy/","asOf":"2026-09-09","days":12},{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","asOf":"2026-09-09","days":12},{"id":"staging-laparoscopy","kind":"term","name":"Laparoscopy (keyhole surgery)","route":"/terms/staging-laparoscopy/","asOf":"2026-09-09","days":12},{"id":"minimally-invasive-surgery","kind":"term","name":"Minimally invasive surgery (laparoscopic, robotic, VATS)","route":"/terms/minimally-invasive-surgery/","asOf":"2026-09-09","days":12},{"id":"radiofrequency-ablation","kind":"term","name":"Radiofrequency ablation (RFA)","route":"/terms/radiofrequency-ablation/","asOf":"2026-09-09","days":12},{"id":"microwave-ablation","kind":"term","name":"Microwave ablation (MWA)","route":"/terms/microwave-ablation/","asOf":"2026-09-09","days":12},{"id":"cryoablation","kind":"term","name":"Cryoablation","route":"/terms/cryoablation/","asOf":"2026-09-09","days":12},{"id":"tace-term","kind":"term","name":"TACE (transarterial chemoembolisation)","route":"/terms/tace-term/","asOf":"2026-09-09","days":12},{"id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","asOf":"2026-09-09","days":12},{"id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/","asOf":"2026-09-09","days":12},{"id":"wbrt","kind":"term","name":"Whole-brain radiotherapy (WBRT)","route":"/terms/wbrt/","asOf":"2026-09-09","days":12},{"id":"pci-term","kind":"term","name":"Prophylactic cranial irradiation (PCI)","route":"/terms/pci-term/","asOf":"2026-09-09","days":12},{"id":"biliary-stent","kind":"term","name":"Stenting (biliary, oesophageal, airway)","route":"/terms/biliary-stent/","asOf":"2026-09-09","days":12},{"id":"pleurodesis","kind":"term","name":"Pleurodesis and indwelling pleural catheter","route":"/terms/pleurodesis/","asOf":"2026-09-09","days":12},{"id":"apheresis","kind":"term","name":"Apheresis (leukapheresis)","route":"/terms/apheresis/","asOf":"2026-09-09","days":12},{"id":"intrathecal-therapy","kind":"term","name":"Intrathecal therapy (lumbar puncture, Ommaya reservoir)","route":"/terms/intrathecal-therapy/","asOf":"2026-09-09","days":12},{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/","asOf":"2026-09-09","days":12},{"id":"feeding-tube","kind":"term","name":"Feeding tube (gastrostomy, PEG, jejunostomy)","route":"/terms/feeding-tube/","asOf":"2026-09-09","days":12},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","asOf":"2026-09-09","days":12},{"id":"core-needle-biopsy","kind":"term","name":"Core needle biopsy and fine-needle aspiration (FNA)","route":"/terms/core-needle-biopsy/","asOf":"2026-09-09","days":12},{"id":"hipec-procedure","kind":"term","name":"HIPEC (hyperthermic intraperitoneal chemotherapy)","route":"/terms/hipec-procedure/","asOf":"2026-09-09","days":12},{"id":"brachytherapy-term","kind":"term","name":"Brachytherapy (internal radiotherapy)","route":"/terms/brachytherapy-term/","asOf":"2026-09-09","days":12},{"id":"sbrt-term","kind":"term","name":"Stereotactic body radiotherapy (SBRT / SABR)","route":"/terms/sbrt-term/","asOf":"2026-09-09","days":12},{"id":"imrt-term","kind":"term","name":"IMRT / IGRT / VMAT (modern external beam radiotherapy)","route":"/terms/imrt-term/","asOf":"2026-09-09","days":12},{"id":"mediastinum","kind":"term","name":"Mediastinum","route":"/terms/mediastinum/","asOf":"2026-09-09","days":12},{"id":"peritoneum","kind":"term","name":"Peritoneum and peritoneal metastases","route":"/terms/peritoneum/","asOf":"2026-09-09","days":12},{"id":"pleura","kind":"term","name":"Pleura","route":"/terms/pleura/","asOf":"2026-09-09","days":12},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/","asOf":"2026-09-09","days":12},{"id":"retroperitoneum","kind":"term","name":"Retroperitoneum","route":"/terms/retroperitoneum/","asOf":"2026-09-09","days":12},{"id":"lymph-node-status","kind":"term","name":"Lymph node status (node-positive / node-negative)","route":"/terms/lymph-node-status/","asOf":"2026-09-09","days":12},{"id":"gej","kind":"term","name":"Gastro-oesophageal junction (GEJ)","route":"/terms/gej/","asOf":"2026-09-09","days":12},{"id":"head-neck-subsites","kind":"term","name":"Head and neck subsites (oral cavity, oropharynx, larynx)","route":"/terms/head-neck-subsites/","asOf":"2026-09-09","days":12},{"id":"leptomeningeal-disease","kind":"term","name":"Leptomeningeal disease","route":"/terms/leptomeningeal-disease/","asOf":"2026-09-09","days":12},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","asOf":"2026-09-09","days":12},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","asOf":"2026-09-09","days":12},{"id":"portal-vein-tumour-thrombus","kind":"term","name":"Portal vein tumour thrombus (macrovascular invasion)","route":"/terms/portal-vein-tumour-thrombus/","asOf":"2026-09-09","days":12},{"id":"lymphovascular-invasion","kind":"term","name":"Lymphovascular invasion (LVI)","route":"/terms/lymphovascular-invasion/","asOf":"2026-09-09","days":12},{"id":"perineural-invasion","kind":"term","name":"Perineural invasion (PNI)","route":"/terms/perineural-invasion/","asOf":"2026-09-09","days":12},{"id":"resection-margins","kind":"term","name":"Resection margins (R0 / R1 / R2)","route":"/terms/resection-margins/","asOf":"2026-09-09","days":12},{"id":"tumour-differentiation","kind":"term","name":"Tumour differentiation (well / moderately / poorly differentiated)","route":"/terms/tumour-differentiation/","asOf":"2026-09-09","days":12},{"id":"dysplasia","kind":"term","name":"Dysplasia (pre-cancerous change)","route":"/terms/dysplasia/","asOf":"2026-09-09","days":12},{"id":"carcinoma-in-situ","kind":"term","name":"Carcinoma in situ (CIS)","route":"/terms/carcinoma-in-situ/","asOf":"2026-09-09","days":12},{"id":"dcis","kind":"term","name":"Ductal carcinoma in situ (DCIS)","route":"/terms/dcis/","asOf":"2026-09-09","days":12},{"id":"pd-l1-testing","kind":"term","name":"PD-L1 expression testing (22C3, SP142, SP263)","route":"/terms/pd-l1-testing/","asOf":"2026-09-09","days":12},{"id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/","asOf":"2026-09-09","days":12},{"id":"her2-positive","kind":"term","name":"HER2-positive (IHC 3+ or ISH-amplified)","route":"/terms/her2-positive/","asOf":"2026-09-09","days":12},{"id":"fish","kind":"term","name":"FISH / ISH (in situ hybridisation)","route":"/terms/fish/","asOf":"2026-09-09","days":12},{"id":"tumour-markers","kind":"term","name":"Tumour markers (CEA, LDH, chromogranin, thyroglobulin)","route":"/terms/tumour-markers/","asOf":"2026-09-09","days":12},{"id":"child-pugh","kind":"term","name":"Child-Pugh score","route":"/terms/child-pugh/","asOf":"2026-09-09","days":12},{"id":"cirrhosis","kind":"term","name":"Cirrhosis","route":"/terms/cirrhosis/","asOf":"2026-09-09","days":12},{"id":"hpv-status","kind":"term","name":"HPV status (HPV-positive / HPV-negative)","route":"/terms/hpv-status/","asOf":"2026-09-09","days":12},{"id":"ebv-term","kind":"term","name":"Epstein-Barr virus (EBV) in cancer","route":"/terms/ebv-term/","asOf":"2026-09-09","days":12},{"id":"mss-pmmr","kind":"term","name":"Microsatellite-stable (MSS) / mismatch-repair proficient (pMMR)","route":"/terms/mss-pmmr/","asOf":"2026-09-09","days":12},{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/","asOf":"2026-09-09","days":12},{"id":"wild-type","kind":"term","name":"Wild-type (WT)","route":"/terms/wild-type/","asOf":"2026-09-09","days":12},{"id":"gene-amplification","kind":"term","name":"Gene amplification and copy-number change","route":"/terms/gene-amplification/","asOf":"2026-09-09","days":12},{"id":"egfr-mutation-subtypes","kind":"term","name":"EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)","route":"/terms/egfr-mutation-subtypes/","asOf":"2026-09-09","days":12},{"id":"kras-mutation-subtypes","kind":"term","name":"KRAS mutation subtypes (G12C, G12D, G12V)","route":"/terms/kras-mutation-subtypes/","asOf":"2026-09-09","days":12},{"id":"braf-v600-mutation","kind":"term","name":"BRAF V600E mutation","route":"/terms/braf-v600-mutation/","asOf":"2026-09-09","days":12},{"id":"gatekeeper-mutation","kind":"term","name":"On-target resistance mutations (gatekeeper, solvent-front, compound)","route":"/terms/gatekeeper-mutation/","asOf":"2026-09-09","days":12},{"id":"stk11-keap1","kind":"term","name":"STK11 / KEAP1 co-mutations","route":"/terms/stk11-keap1/","asOf":"2026-09-09","days":12},{"id":"tp53-mutated","kind":"term","name":"TP53-mutated (p53-abnormal)","route":"/terms/tp53-mutated/","asOf":"2026-09-09","days":12},{"id":"cytogenetics","kind":"term","name":"Cytogenetics and karyotype","route":"/terms/cytogenetics/","asOf":"2026-09-09","days":12},{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/","asOf":"2026-09-09","days":12},{"id":"blasts","kind":"term","name":"Blasts (leukaemic blast cells)","route":"/terms/blasts/","asOf":"2026-09-09","days":12},{"id":"cfdna","kind":"term","name":"Cell-free DNA (cfDNA)","route":"/terms/cfdna/","asOf":"2026-09-09","days":12},{"id":"umrd","kind":"term","name":"Undetectable MRD (uMRD / MRD-negative)","route":"/terms/umrd/","asOf":"2026-09-09","days":12},{"id":"deauville","kind":"term","name":"Deauville score and PET-adapted therapy","route":"/terms/deauville/","asOf":"2026-09-09","days":12},{"id":"molecular-response","kind":"term","name":"Molecular response (MMR, MR4, treatment-free remission)","route":"/terms/molecular-response/","asOf":"2026-09-09","days":12},{"id":"philadelphia-chromosome","kind":"term","name":"Philadelphia chromosome (Ph+, BCR::ABL1)","route":"/terms/philadelphia-chromosome/","asOf":"2026-09-09","days":12},{"id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/","asOf":"2026-09-09","days":12},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/","asOf":"2026-09-09","days":12},{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/","asOf":"2026-09-09","days":12},{"id":"induction-therapy","kind":"term","name":"Induction therapy","route":"/terms/induction-therapy/","asOf":"2026-09-09","days":12},{"id":"consolidation-therapy","kind":"term","name":"Consolidation therapy","route":"/terms/consolidation-therapy/","asOf":"2026-09-09","days":12},{"id":"salvage-therapy","kind":"term","name":"Salvage therapy","route":"/terms/salvage-therapy/","asOf":"2026-09-09","days":12},{"id":"relapsed-refractory","kind":"term","name":"Relapsed / refractory (R/R)","route":"/terms/relapsed-refractory/","asOf":"2026-09-09","days":12},{"id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/","asOf":"2026-09-09","days":12},{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","asOf":"2026-09-09","days":12},{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/","asOf":"2026-09-09","days":12},{"id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","asOf":"2026-09-09","days":12},{"id":"aromatase-inhibitor","kind":"term","name":"Aromatase inhibitor","route":"/terms/aromatase-inhibitor/","asOf":"2026-09-09","days":12},{"id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","route":"/terms/serd/","asOf":"2026-09-09","days":12},{"id":"hypofractionation","kind":"term","name":"Hypofractionation (fewer, larger radiotherapy doses)","route":"/terms/hypofractionation/","asOf":"2026-09-09","days":12},{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/","asOf":"2026-09-09","days":12},{"id":"re-irradiation","kind":"term","name":"Re-irradiation","route":"/terms/re-irradiation/","asOf":"2026-09-09","days":12},{"id":"dose-dense-chemotherapy","kind":"term","name":"Dose-dense and metronomic chemotherapy","route":"/terms/dose-dense-chemotherapy/","asOf":"2026-09-09","days":12},{"id":"doublet-triplet","kind":"term","name":"Doublet, triplet and quadruplet regimens","route":"/terms/doublet-triplet/","asOf":"2026-09-09","days":12},{"id":"chemotherapy-regimen","kind":"term","name":"Regimen and cycles","route":"/terms/chemotherapy-regimen/","asOf":"2026-09-09","days":12},{"id":"anthracycline","kind":"term","name":"Anthracyclines (doxorubicin, epirubicin)","route":"/terms/anthracycline/","asOf":"2026-09-09","days":12},{"id":"taxane","kind":"term","name":"Taxanes (paclitaxel, docetaxel, nab-paclitaxel)","route":"/terms/taxane/","asOf":"2026-09-09","days":12},{"id":"alkylating-agent","kind":"term","name":"Alkylating agents and antimetabolites","route":"/terms/alkylating-agent/","asOf":"2026-09-09","days":12},{"id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","asOf":"2026-09-09","days":12},{"id":"flot-term","kind":"term","name":"FLOT regimen (perioperative chemotherapy for gastric cancer)","route":"/terms/flot-term/","asOf":"2026-09-09","days":12},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/","asOf":"2026-09-09","days":12},{"id":"abvd-beacopp","kind":"term","name":"ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)","route":"/terms/abvd-beacopp/","asOf":"2026-09-09","days":12},{"id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","asOf":"2026-09-09","days":12},{"id":"vrd","kind":"term","name":"VRd and Dara-VRd (myeloma induction regimens)","route":"/terms/vrd/","asOf":"2026-09-09","days":12},{"id":"proteasome-inhibitor","kind":"term","name":"Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)","route":"/terms/proteasome-inhibitor/","asOf":"2026-09-09","days":12},{"id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","asOf":"2026-09-09","days":12},{"id":"hma","kind":"term","name":"Hypomethylating agents (azacitidine, decitabine)","route":"/terms/hma/","asOf":"2026-09-09","days":12},{"id":"tki-term","kind":"term","name":"Tyrosine kinase inhibitor (TKI)","route":"/terms/tki-term/","asOf":"2026-09-09","days":12},{"id":"immuno-oncology","kind":"term","name":"Immuno-oncology (IO) and checkpoint blockade","route":"/terms/immuno-oncology/","asOf":"2026-09-09","days":12},{"id":"backbone-add-on","kind":"term","name":"Backbone, add-on and monotherapy","route":"/terms/backbone-add-on/","asOf":"2026-09-09","days":12},{"id":"cross-resistance","kind":"term","name":"Cross-resistance","route":"/terms/cross-resistance/","asOf":"2026-09-09","days":12},{"id":"rechallenge","kind":"term","name":"Rechallenge and retreatment","route":"/terms/rechallenge/","asOf":"2026-09-09","days":12},{"id":"fixed-duration","kind":"term","name":"Fixed-duration vs continuous therapy","route":"/terms/fixed-duration/","asOf":"2026-09-09","days":12},{"id":"step-up-dosing","kind":"term","name":"Step-up dosing (T-cell engagers)","route":"/terms/step-up-dosing/","asOf":"2026-09-09","days":12},{"id":"de-escalation","kind":"term","name":"De-escalation, escalation and response-adapted therapy","route":"/terms/de-escalation/","asOf":"2026-09-09","days":12},{"id":"organ-preservation","kind":"term","name":"Organ preservation (watch-and-wait, bladder-sparing, larynx preservation)","route":"/terms/organ-preservation/","asOf":"2026-09-09","days":12},{"id":"active-surveillance-term","kind":"term","name":"Active surveillance and observation","route":"/terms/active-surveillance-term/","asOf":"2026-09-09","days":12},{"id":"curative-intent","kind":"term","name":"Curative intent vs palliative intent","route":"/terms/curative-intent/","asOf":"2026-09-09","days":12},{"id":"locally-advanced","kind":"term","name":"Locally advanced and locoregional disease","route":"/terms/locally-advanced/","asOf":"2026-09-09","days":12},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","asOf":"2026-09-09","days":12},{"id":"limited-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (small-cell lung cancer)","route":"/terms/limited-extensive-stage/","asOf":"2026-09-09","days":12},{"id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","asOf":"2026-09-09","days":12},{"id":"intraperitoneal-chemotherapy","kind":"term","name":"Intraperitoneal (IP) chemotherapy","route":"/terms/intraperitoneal-chemotherapy/","asOf":"2026-09-09","days":12},{"id":"liver-directed-therapy","kind":"term","name":"Liver-directed therapy (TACE, TARE, HAI, ablation)","route":"/terms/liver-directed-therapy/","asOf":"2026-09-09","days":12},{"id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","asOf":"2026-09-09","days":12},{"id":"downstaging","kind":"term","name":"Downstaging and conversion therapy","route":"/terms/downstaging/","asOf":"2026-09-09","days":12},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","asOf":"2026-09-09","days":12},{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/","asOf":"2026-09-09","days":12},{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","route":"/terms/conditioning-regimen/","asOf":"2026-09-09","days":12},{"id":"gvhd","kind":"term","name":"Graft-versus-host disease (GVHD) and graft-versus-leukaemia","route":"/terms/gvhd/","asOf":"2026-09-09","days":12},{"id":"lymphodepletion","kind":"term","name":"Lymphodepletion before CAR-T","route":"/terms/lymphodepletion/","asOf":"2026-09-09","days":12},{"id":"bridging-therapy","kind":"term","name":"Bridging therapy","route":"/terms/bridging-therapy/","asOf":"2026-09-09","days":12},{"id":"vein-to-vein-time","kind":"term","name":"Vein-to-vein time and manufacturing slots","route":"/terms/vein-to-vein-time/","asOf":"2026-09-09","days":12},{"id":"antigen-escape","kind":"term","name":"Antigen escape (antigen loss, lineage switch)","route":"/terms/antigen-escape/","asOf":"2026-09-09","days":12},{"id":"t-cell-exhaustion-term","kind":"term","name":"T-cell exhaustion and CAR-T persistence","route":"/terms/t-cell-exhaustion-term/","asOf":"2026-09-09","days":12},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/","asOf":"2026-09-09","days":12},{"id":"radioiodine-term","kind":"term","name":"Radioiodine therapy (I-131)","route":"/terms/radioiodine-term/","asOf":"2026-09-09","days":12},{"id":"cns-penetration","kind":"term","name":"CNS penetration (brain-penetrant drugs)","route":"/terms/cns-penetration/","asOf":"2026-09-09","days":12},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","asOf":"2026-09-09","days":12},{"id":"therapeutic-index","kind":"term","name":"Therapeutic index (therapeutic window)","route":"/terms/therapeutic-index/","asOf":"2026-09-09","days":12},{"id":"centralisation","kind":"term","name":"Centralisation and high-volume centres","route":"/terms/centralisation/","asOf":"2026-09-09","days":12},{"id":"surgical-morbidity","kind":"term","name":"Surgical morbidity and postoperative complications","route":"/terms/surgical-morbidity/","asOf":"2026-09-09","days":12},{"id":"confirmatory-trial","kind":"term","name":"Confirmatory trial","route":"/terms/confirmatory-trial/","asOf":"2026-09-09","days":12},{"id":"complete-response-letter","kind":"term","name":"Complete response letter (CRL)","route":"/terms/complete-response-letter/","asOf":"2026-09-09","days":12},{"id":"label-indication","kind":"term","name":"Label, indication and label expansion","route":"/terms/label-indication/","asOf":"2026-09-09","days":12},{"id":"bla-nda","kind":"term","name":"BLA / NDA / MAA (marketing applications) and PDUFA dates","route":"/terms/bla-nda/","asOf":"2026-09-09","days":12},{"id":"orphan-designation","kind":"term","name":"Orphan drug designation","route":"/terms/orphan-designation/","asOf":"2026-09-09","days":12},{"id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/","asOf":"2026-09-09","days":12},{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/","asOf":"2026-09-09","days":12},{"id":"full-approval","kind":"term","name":"Full (traditional, regular) approval","route":"/terms/full-approval/","asOf":"2026-09-09","days":12},{"id":"approval-withdrawal","kind":"term","name":"Indication withdrawal","route":"/terms/approval-withdrawal/","asOf":"2026-09-09","days":12},{"id":"odac","kind":"term","name":"ODAC (Oncologic Drugs Advisory Committee)","route":"/terms/odac/","asOf":"2026-09-09","days":12},{"id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","asOf":"2026-09-09","days":12},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","asOf":"2026-09-09","days":12},{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/","asOf":"2026-09-09","days":12},{"id":"non-inferiority","kind":"term","name":"Non-inferiority trial","route":"/terms/non-inferiority/","asOf":"2026-09-09","days":12},{"id":"futility","kind":"term","name":"Futility analysis (stopped for futility)","route":"/terms/futility/","asOf":"2026-09-09","days":12},{"id":"interim-analysis","kind":"term","name":"Interim analysis, readout and data cut-off","route":"/terms/interim-analysis/","asOf":"2026-09-09","days":12},{"id":"primary-endpoint","kind":"term","name":"Primary, secondary and co-primary endpoints","route":"/terms/primary-endpoint/","asOf":"2026-09-09","days":12},{"id":"intention-to-treat","kind":"term","name":"Intention-to-treat (ITT) and per-protocol analysis","route":"/terms/intention-to-treat/","asOf":"2026-09-09","days":12},{"id":"prespecified-vs-post-hoc","kind":"term","name":"Pre-specified vs post-hoc analysis","route":"/terms/prespecified-vs-post-hoc/","asOf":"2026-09-09","days":12},{"id":"subgroup-analysis","kind":"term","name":"Subgroup analysis (forest plots)","route":"/terms/subgroup-analysis/","asOf":"2026-09-09","days":12},{"id":"statistical-significance","kind":"term","name":"Statistical significance (P values, alpha, multiplicity)","route":"/terms/statistical-significance/","asOf":"2026-09-09","days":12},{"id":"double-blind","kind":"term","name":"Blinding (double-blind, open-label, placebo-controlled)","route":"/terms/double-blind/","asOf":"2026-09-09","days":12},{"id":"single-arm","kind":"term","name":"Single-arm trial","route":"/terms/single-arm/","asOf":"2026-09-09","days":12},{"id":"external-control-arm","kind":"term","name":"External and synthetic control arms","route":"/terms/external-control-arm/","asOf":"2026-09-09","days":12},{"id":"control-arm","kind":"term","name":"Control arm and comparator (investigator's choice)","route":"/terms/control-arm/","asOf":"2026-09-09","days":12},{"id":"dose-limiting-toxicity","kind":"term","name":"Dose-limiting toxicity (DLT)","route":"/terms/dose-limiting-toxicity/","asOf":"2026-09-09","days":12},{"id":"mtd","kind":"term","name":"Maximum tolerated dose (MTD)","route":"/terms/mtd/","asOf":"2026-09-09","days":12},{"id":"rp2d","kind":"term","name":"Recommended phase 2 dose (RP2D)","route":"/terms/rp2d/","asOf":"2026-09-09","days":12},{"id":"dose-escalation-design","kind":"term","name":"Dose-escalation designs (3+3, BOIN, dose-expansion)","route":"/terms/dose-escalation-design/","asOf":"2026-09-09","days":12},{"id":"first-in-human","kind":"term","name":"First-in-human (FIH) trial","route":"/terms/first-in-human/","asOf":"2026-09-09","days":12},{"id":"window-of-opportunity-trial","kind":"term","name":"Window-of-opportunity trial","route":"/terms/window-of-opportunity-trial/","asOf":"2026-09-09","days":12},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/","asOf":"2026-09-09","days":12},{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/","asOf":"2026-09-09","days":12},{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/","asOf":"2026-09-09","days":12},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/","asOf":"2026-09-09","days":12},{"id":"progressive-disease","kind":"term","name":"Progressive disease and radiographic progression","route":"/terms/progressive-disease/","asOf":"2026-09-09","days":12},{"id":"duration-of-response-term","kind":"term","name":"Duration of response (DoR) and disease control rate (DCR)","route":"/terms/duration-of-response-term/","asOf":"2026-09-09","days":12},{"id":"ttp","kind":"term","name":"Time to progression (TTP) and time to next treatment (TTNT)","route":"/terms/ttp/","asOf":"2026-09-09","days":12},{"id":"landmark-survival","kind":"term","name":"Landmark and milestone survival (5-year survival, median follow-up)","route":"/terms/landmark-survival/","asOf":"2026-09-09","days":12},{"id":"data-maturity","kind":"term","name":"Data maturity (immature vs mature survival data)","route":"/terms/data-maturity/","asOf":"2026-09-09","days":12},{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/","asOf":"2026-09-09","days":12},{"id":"ctcae-grading","kind":"term","name":"CTCAE toxicity grading (grade 3-4 adverse events)","route":"/terms/ctcae-grading/","asOf":"2026-09-09","days":12},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/","asOf":"2026-09-09","days":12},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","asOf":"2026-09-09","days":12},{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/","asOf":"2026-09-09","days":12},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","asOf":"2026-09-09","days":12},{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/","asOf":"2026-09-09","days":12},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","asOf":"2026-09-09","days":12},{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","asOf":"2026-09-09","days":12},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","asOf":"2026-09-09","days":12},{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/","asOf":"2026-09-09","days":12},{"id":"hepatotoxicity","kind":"term","name":"Hepatotoxicity (liver enzyme elevation)","route":"/terms/hepatotoxicity/","asOf":"2026-09-09","days":12},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/","asOf":"2026-09-09","days":12},{"id":"immune-endocrinopathy","kind":"term","name":"Immune-related endocrinopathies (thyroiditis, hypophysitis)","route":"/terms/immune-endocrinopathy/","asOf":"2026-09-09","days":12},{"id":"myocarditis","kind":"term","name":"Immune-related myocarditis","route":"/terms/myocarditis/","asOf":"2026-09-09","days":12},{"id":"ocular-toxicity","kind":"term","name":"Ocular toxicity (keratopathy, blurred vision)","route":"/terms/ocular-toxicity/","asOf":"2026-09-09","days":12},{"id":"qt-prolongation","kind":"term","name":"QT prolongation","route":"/terms/qt-prolongation/","asOf":"2026-09-09","days":12},{"id":"hyperglycaemia","kind":"term","name":"Hyperglycaemia (PI3K/AKT inhibitor class effect)","route":"/terms/hyperglycaemia/","asOf":"2026-09-09","days":12},{"id":"rash-skin-toxicity","kind":"term","name":"Rash and skin toxicity (acneiform rash, paronychia)","route":"/terms/rash-skin-toxicity/","asOf":"2026-09-09","days":12},{"id":"extravasation-infusion-reaction","kind":"term","name":"Infusion reactions, hypersensitivity and extravasation","route":"/terms/extravasation-infusion-reaction/","asOf":"2026-09-09","days":12},{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/","asOf":"2026-09-09","days":12},{"id":"antiangiogenic-toxicities","kind":"term","name":"Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation)","route":"/terms/antiangiogenic-toxicities/","asOf":"2026-09-09","days":12},{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/","asOf":"2026-09-09","days":12},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/","asOf":"2026-09-09","days":12},{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/","asOf":"2026-09-09","days":12},{"id":"dose-modification","kind":"term","name":"Dose reduction, interruption and discontinuation","route":"/terms/dose-modification/","asOf":"2026-09-09","days":12},{"id":"obstructive-jaundice","kind":"term","name":"Obstructive jaundice and biliary obstruction","route":"/terms/obstructive-jaundice/","asOf":"2026-09-09","days":12},{"id":"dysphagia","kind":"term","name":"Dysphagia (difficulty swallowing)","route":"/terms/dysphagia/","asOf":"2026-09-09","days":12},{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","route":"/institutions/oneal-uab/","asOf":"2026-09-09","days":12},{"id":"arizona-cancer-center","kind":"institution","name":"University of Arizona Cancer Center","route":"/institutions/arizona-cancer-center/","asOf":"2026-09-09","days":12},{"id":"uci-chao","kind":"institution","name":"Chao Family Comprehensive Cancer Center, UC Irvine","route":"/institutions/uci-chao/","asOf":"2026-09-09","days":12},{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/","asOf":"2026-09-09","days":12},{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/","asOf":"2026-09-09","days":12},{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/","asOf":"2026-09-09","days":12},{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","route":"/institutions/colorado-cancer-center/","asOf":"2026-09-09","days":12},{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/","asOf":"2026-09-09","days":12},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/","asOf":"2026-09-09","days":12},{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","route":"/institutions/northwestern-lurie/","asOf":"2026-09-09","days":12},{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/","asOf":"2026-09-09","days":12},{"id":"iu-simon","kind":"institution","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","route":"/institutions/iu-simon/","asOf":"2026-09-09","days":12},{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","route":"/institutions/iowa-holden/","asOf":"2026-09-09","days":12},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/","asOf":"2026-09-09","days":12},{"id":"kentucky-markey","kind":"institution","name":"Markey Cancer Center, University of Kentucky","route":"/institutions/kentucky-markey/","asOf":"2026-09-09","days":12},{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","asOf":"2026-09-09","days":12},{"id":"karmanos","kind":"institution","name":"Barbara Ann Karmanos Cancer Institute","route":"/institutions/karmanos/","asOf":"2026-09-09","days":12},{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","route":"/institutions/minnesota-masonic/","asOf":"2026-09-09","days":12},{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","route":"/institutions/dartmouth-cancer-center/","asOf":"2026-09-09","days":12},{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/","asOf":"2026-09-09","days":12},{"id":"unm-cancer-center","kind":"institution","name":"University of New Mexico Comprehensive Cancer Center","route":"/institutions/unm-cancer-center/","asOf":"2026-09-09","days":12},{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","route":"/institutions/montefiore-einstein/","asOf":"2026-09-09","days":12},{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/","asOf":"2026-09-09","days":12},{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/","asOf":"2026-09-09","days":12},{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/","asOf":"2026-09-09","days":12},{"id":"wake-forest-cancer","kind":"institution","name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","route":"/institutions/wake-forest-cancer/","asOf":"2026-09-09","days":12},{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","route":"/institutions/case-ccc/","asOf":"2026-09-09","days":12},{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/","asOf":"2026-09-09","days":12},{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/","asOf":"2026-09-09","days":12},{"id":"fox-chase","kind":"institution","name":"Fox Chase Cancer Center","route":"/institutions/fox-chase/","asOf":"2026-09-09","days":12},{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/","asOf":"2026-09-09","days":12},{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","route":"/institutions/upmc-hillman/","asOf":"2026-09-09","days":12},{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","asOf":"2026-09-09","days":12},{"id":"baylor-duncan","kind":"institution","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","route":"/institutions/baylor-duncan/","asOf":"2026-09-09","days":12},{"id":"utsw-simmons","kind":"institution","name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern","route":"/institutions/utsw-simmons/","asOf":"2026-09-09","days":12},{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/","asOf":"2026-09-09","days":12},{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","route":"/institutions/vcu-massey/","asOf":"2026-09-09","days":12},{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","route":"/institutions/uva-cancer-center/","asOf":"2026-09-09","days":12},{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/","asOf":"2026-09-09","days":12},{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","asOf":"2026-09-09","days":12},{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/","asOf":"2026-09-09","days":12},{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/","asOf":"2026-09-09","days":12},{"id":"hawaii-cancer-center","kind":"institution","name":"University of Hawai'i Cancer Center","route":"/institutions/hawaii-cancer-center/","asOf":"2026-09-09","days":12},{"id":"nebraska-buffett","kind":"institution","name":"Fred & Pamela Buffett Cancer Center","route":"/institutions/nebraska-buffett/","asOf":"2026-09-09","days":12},{"id":"wilmot","kind":"institution","name":"Wilmot Cancer Institute, University of Rochester","route":"/institutions/wilmot/","asOf":"2026-09-09","days":12},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/","asOf":"2026-09-09","days":12},{"id":"musc-hollings","kind":"institution","name":"MUSC Hollings Cancer Center","route":"/institutions/musc-hollings/","asOf":"2026-09-09","days":12},{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","route":"/institutions/mays-cancer-center/","asOf":"2026-09-09","days":12},{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","route":"/institutions/salk-institute/","asOf":"2026-09-09","days":12},{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/","asOf":"2026-09-09","days":12},{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","route":"/institutions/cancer-center-at-illinois/","asOf":"2026-09-09","days":12},{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/","asOf":"2026-09-09","days":12},{"id":"jackson-laboratory","kind":"institution","name":"The Jackson Laboratory Cancer Center","route":"/institutions/jackson-laboratory/","asOf":"2026-09-09","days":12},{"id":"mit-koch","kind":"institution","name":"David H. Koch Institute for Integrative Cancer Research at MIT","route":"/institutions/mit-koch/","asOf":"2026-09-09","days":12},{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/","asOf":"2026-09-09","days":12},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/","asOf":"2026-09-09","days":12},{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/","asOf":"2026-09-09","days":12},{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/","asOf":"2026-09-09","days":12},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/","asOf":"2026-09-09","days":12},{"id":"city-of-hope-orange-county","kind":"institution","name":"City of Hope Orange County","route":"/institutions/city-of-hope-orange-county/","asOf":"2026-09-09","days":12},{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","route":"/institutions/cedars-sinai-cancer/","asOf":"2026-09-09","days":12},{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"intermountain-cancer","kind":"institution","name":"Intermountain Health Cancer Center","route":"/institutions/intermountain-cancer/","asOf":"2026-09-09","days":12},{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","route":"/institutions/kaiser-permanente-research/","asOf":"2026-09-09","days":12},{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/","asOf":"2026-09-09","days":12},{"id":"texas-childrens","kind":"institution","name":"Texas Children's Cancer and Hematology Center","route":"/institutions/texas-childrens/","asOf":"2026-09-09","days":12},{"id":"nationwide-childrens","kind":"institution","name":"Nationwide Children's Hospital","route":"/institutions/nationwide-childrens/","asOf":"2026-09-09","days":12},{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/","asOf":"2026-09-09","days":12},{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/","asOf":"2026-09-09","days":12},{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/","asOf":"2026-09-09","days":12},{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/","asOf":"2026-09-09","days":12},{"id":"ottawa-hospital","kind":"institution","name":"The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","route":"/institutions/ottawa-hospital/","asOf":"2026-09-09","days":12},{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","route":"/institutions/sunnybrook-odette/","asOf":"2026-09-09","days":12},{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","route":"/institutions/juravinski/","asOf":"2026-09-09","days":12},{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","asOf":"2026-09-09","days":12},{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/","asOf":"2026-09-09","days":12},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/","asOf":"2026-09-09","days":12},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/","asOf":"2026-09-09","days":12},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/","asOf":"2026-09-09","days":12},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/","asOf":"2026-09-09","days":12},{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","route":"/institutions/zhongshan-hospital-fudan/","asOf":"2026-09-09","days":12},{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/","asOf":"2026-09-09","days":12},{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","route":"/institutions/sysu-first-affiliated-hospital/","asOf":"2026-09-09","days":12},{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/","asOf":"2026-09-09","days":12},{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/","asOf":"2026-09-09","days":12},{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/","asOf":"2026-09-09","days":12},{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","asOf":"2026-09-09","days":12},{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","route":"/institutions/henan-cancer-hospital/","asOf":"2026-09-09","days":12},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","asOf":"2026-09-09","days":12},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/","asOf":"2026-09-09","days":12},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/","asOf":"2026-09-09","days":12},{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","route":"/institutions/union-hospital-wuhan/","asOf":"2026-09-09","days":12},{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","route":"/institutions/queen-mary-hospital-hku/","asOf":"2026-09-09","days":12},{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/","asOf":"2026-09-09","days":12},{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","asOf":"2026-09-09","days":12},{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","route":"/institutions/chang-gung-memorial-hospital/","asOf":"2026-09-09","days":12},{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","asOf":"2026-09-09","days":12},{"id":"koo-foundation-sun-yat-sen-cancer-center","kind":"institution","name":"Koo Foundation Sun Yat-Sen Cancer Center","route":"/institutions/koo-foundation-sun-yat-sen-cancer-center/","asOf":"2026-09-09","days":12},{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/","asOf":"2026-09-09","days":12},{"id":"osaka-international-cancer-institute","kind":"institution","name":"Osaka International Cancer Institute","route":"/institutions/osaka-international-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"aichi-cancer-center","kind":"institution","name":"Aichi Cancer Center","route":"/institutions/aichi-cancer-center/","asOf":"2026-09-09","days":12},{"id":"shizuoka-cancer-center","kind":"institution","name":"Shizuoka Cancer Center","route":"/institutions/shizuoka-cancer-center/","asOf":"2026-09-09","days":12},{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","route":"/institutions/kyushu-university-hospital/","asOf":"2026-09-09","days":12},{"id":"hokkaido-university-hospital","kind":"institution","name":"Hokkaido University Hospital","route":"/institutions/hokkaido-university-hospital/","asOf":"2026-09-09","days":12},{"id":"tohoku-university-hospital","kind":"institution","name":"Tohoku University Hospital","route":"/institutions/tohoku-university-hospital/","asOf":"2026-09-09","days":12},{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","route":"/institutions/keio-university-hospital/","asOf":"2026-09-09","days":12},{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","route":"/institutions/gunma-heavy-ion-medical-center/","asOf":"2026-09-09","days":12},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/","asOf":"2026-09-09","days":12},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","asOf":"2026-09-09","days":12},{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","route":"/institutions/ncc-korea/","asOf":"2026-09-09","days":12},{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","route":"/institutions/seoul-st-marys-hospital/","asOf":"2026-09-09","days":12},{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","asOf":"2026-09-09","days":12},{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/","asOf":"2026-09-09","days":12},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","asOf":"2026-09-09","days":12},{"id":"rgci","kind":"institution","name":"Rajiv Gandhi Cancer Institute and Research Centre","route":"/institutions/rgci/","asOf":"2026-09-09","days":12},{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","route":"/institutions/kidwai-memorial-institute-of-oncology/","asOf":"2026-09-09","days":12},{"id":"cancer-institute-adyar","kind":"institution","name":"Cancer Institute (WIA), Adyar","route":"/institutions/cancer-institute-adyar/","asOf":"2026-09-09","days":12},{"id":"tata-medical-center-kolkata","kind":"institution","name":"Tata Medical Center, Kolkata","route":"/institutions/tata-medical-center-kolkata/","asOf":"2026-09-09","days":12},{"id":"hcg","kind":"institution","name":"HealthCare Global Enterprises","route":"/institutions/hcg/","asOf":"2026-09-09","days":12},{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","route":"/institutions/apollo-hospitals/","asOf":"2026-09-09","days":12},{"id":"cmc-vellore","kind":"institution","name":"Christian Medical College, Vellore","route":"/institutions/cmc-vellore/","asOf":"2026-09-09","days":12},{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","route":"/institutions/pgimer-chandigarh/","asOf":"2026-09-09","days":12},{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/","asOf":"2026-09-09","days":12},{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/","asOf":"2026-09-09","days":12},{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/","asOf":"2026-09-09","days":12},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/","asOf":"2026-09-09","days":12},{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","route":"/institutions/qimr-berghofer/","asOf":"2026-09-09","days":12},{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/","asOf":"2026-09-09","days":12},{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/","asOf":"2026-09-09","days":12},{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","route":"/institutions/auckland-city-hospital/","asOf":"2026-09-09","days":12},{"id":"siriraj-hospital","kind":"institution","name":"Siriraj Hospital, Mahidol University","route":"/institutions/siriraj-hospital/","asOf":"2026-09-09","days":12},{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","route":"/institutions/chulabhorn-hospital/","asOf":"2026-09-09","days":12},{"id":"ramathibodi-hospital","kind":"institution","name":"Ramathibodi Hospital, Mahidol University","route":"/institutions/ramathibodi-hospital/","asOf":"2026-09-09","days":12},{"id":"dharmais-cancer-hospital","kind":"institution","name":"Dharmais National Cancer Center","route":"/institutions/dharmais-cancer-hospital/","asOf":"2026-09-09","days":12},{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","route":"/institutions/ummc-kuala-lumpur/","asOf":"2026-09-09","days":12},{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/","asOf":"2026-09-09","days":12},{"id":"k-hospital-hanoi","kind":"institution","name":"Vietnam National Cancer Hospital (K Hospital)","route":"/institutions/k-hospital-hanoi/","asOf":"2026-09-09","days":12},{"id":"hcmc-oncology-hospital","kind":"institution","name":"Ho Chi Minh City Oncology Hospital","route":"/institutions/hcmc-oncology-hospital/","asOf":"2026-09-09","days":12},{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","route":"/institutions/khcc/","asOf":"2026-09-09","days":12},{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","asOf":"2026-09-09","days":12},{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","route":"/institutions/tawam-hospital/","asOf":"2026-09-09","days":12},{"id":"cleveland-clinic-abu-dhabi","kind":"institution","name":"Cleveland Clinic Abu Dhabi","route":"/institutions/cleveland-clinic-abu-dhabi/","asOf":"2026-09-09","days":12},{"id":"hamad-medical-corporation","kind":"institution","name":"Hamad Medical Corporation / National Center for Cancer Care and Research","route":"/institutions/hamad-medical-corporation/","asOf":"2026-09-09","days":12},{"id":"tehran-cancer-institute","kind":"institution","name":"Cancer Institute of Iran, Imam Khomeini Hospital Complex","route":"/institutions/tehran-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/","asOf":"2026-09-09","days":12},{"id":"ac-camargo","kind":"institution","name":"A.C. Camargo Cancer Center","route":"/institutions/ac-camargo/","asOf":"2026-09-09","days":12},{"id":"hospital-de-amor-barretos","kind":"institution","name":"Hospital de Amor (Barretos Cancer Hospital)","route":"/institutions/hospital-de-amor-barretos/","asOf":"2026-09-09","days":12},{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/","asOf":"2026-09-09","days":12},{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","asOf":"2026-09-09","days":12},{"id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","asOf":"2026-09-09","days":12},{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","route":"/institutions/inen-peru/","asOf":"2026-09-09","days":12},{"id":"instituto-alexander-fleming","kind":"institution","name":"Instituto Alexander Fleming","route":"/institutions/instituto-alexander-fleming/","asOf":"2026-09-09","days":12},{"id":"falp-chile","kind":"institution","name":"Fundación Arturo López Pérez","route":"/institutions/falp-chile/","asOf":"2026-09-09","days":12},{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","route":"/institutions/groote-schuur-uct/","asOf":"2026-09-09","days":12},{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","route":"/institutions/wits-charlotte-maxeke/","asOf":"2026-09-09","days":12},{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/","asOf":"2026-09-09","days":12},{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","route":"/institutions/ocean-road-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/","asOf":"2026-09-09","days":12},{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","route":"/institutions/luth-lagos/","asOf":"2026-09-09","days":12},{"id":"nci-cairo","kind":"institution","name":"National Cancer Institute, Cairo University","route":"/institutions/nci-cairo/","asOf":"2026-09-09","days":12},{"id":"cche-57357","kind":"institution","name":"Children's Cancer Hospital Egypt 57357","route":"/institutions/cche-57357/","asOf":"2026-09-09","days":12},{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","route":"/institutions/institut-national-oncologie-rabat/","asOf":"2026-09-09","days":12},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/","asOf":"2026-09-09","days":12},{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/","asOf":"2026-09-09","days":12},{"id":"blida-anti-cancer-center","kind":"institution","name":"Anti-Cancer Center of Blida","route":"/institutions/blida-anti-cancer-center/","asOf":"2026-09-09","days":12},{"id":"jinshazhou-hospital","kind":"institution","name":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine","route":"/institutions/jinshazhou-hospital/","asOf":"2026-09-09","days":12},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/","asOf":"2026-09-09","days":12},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","asOf":"2026-09-09","days":12},{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","asOf":"2026-09-09","days":12},{"id":"cecurio","kind":"institution","name":"CeCurio (MVZ Tübingen oncology)","route":"/institutions/cecurio/","asOf":"2026-09-09","days":12},{"id":"immunocine","kind":"institution","name":"Immunocine","route":"/institutions/immunocine/","asOf":"2026-09-09","days":12},{"id":"houston-methodist-rna-therapeutics","kind":"institution","name":"Houston Methodist Center for RNA Therapeutics","route":"/institutions/houston-methodist-rna-therapeutics/","asOf":"2026-09-09","days":12},{"id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","route":"/institutions/center-for-metabolic-oncology/","asOf":"2026-09-09","days":12},{"id":"asthra-health","kind":"institution","name":"Asthra Health","route":"/institutions/asthra-health/","asOf":"2026-09-09","days":12},{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","route":"/institutions/sarcoma-oncology-center/","asOf":"2026-09-09","days":12},{"id":"docrates","kind":"institution","name":"Docrates Cancer Center","route":"/institutions/docrates/","asOf":"2026-09-09","days":12},{"id":"abcsg","kind":"institution","name":"Austrian Breast & Colorectal Cancer Study Group","route":"/institutions/abcsg/","asOf":"2026-09-09","days":12},{"id":"wjog","kind":"institution","name":"West Japan Oncology Group","route":"/institutions/wjog/","asOf":"2026-09-09","days":12},{"id":"kcsg","kind":"institution","name":"Korean Cancer Study Group","route":"/institutions/kcsg/","asOf":"2026-09-09","days":12},{"id":"trog","kind":"institution","name":"TROG Cancer Research","route":"/institutions/trog/","asOf":"2026-09-09","days":12},{"id":"anzup","kind":"institution","name":"ANZUP Cancer Trials Group","route":"/institutions/anzup/","asOf":"2026-09-09","days":12},{"id":"agitg","kind":"institution","name":"Australasian Gastro-Intestinal Trials Group","route":"/institutions/agitg/","asOf":"2026-09-09","days":12},{"id":"breast-cancer-trials","kind":"institution","name":"Breast Cancer Trials","route":"/institutions/breast-cancer-trials/","asOf":"2026-09-09","days":12},{"id":"geicam","kind":"institution","name":"GEICAM Spanish Breast Cancer Group","route":"/institutions/geicam/","asOf":"2026-09-09","days":12},{"id":"solti","kind":"institution","name":"SOLTI Cancer Research Group","route":"/institutions/solti/","asOf":"2026-09-09","days":12},{"id":"hovon","kind":"institution","name":"HOVON","route":"/institutions/hovon/","asOf":"2026-09-09","days":12},{"id":"gimema","kind":"institution","name":"GIMEMA","route":"/institutions/gimema/","asOf":"2026-09-09","days":12},{"id":"ielsg","kind":"institution","name":"International Extranodal Lymphoma Study Group","route":"/institutions/ielsg/","asOf":"2026-09-09","days":12},{"id":"lysa","kind":"institution","name":"LYSA (The Lymphoma Study Association)","route":"/institutions/lysa/","asOf":"2026-09-09","days":12},{"id":"german-lymphoma-alliance","kind":"institution","name":"German Lymphoma Alliance","route":"/institutions/german-lymphoma-alliance/","asOf":"2026-09-09","days":12},{"id":"ghsg","kind":"institution","name":"German Hodgkin Study Group","route":"/institutions/ghsg/","asOf":"2026-09-09","days":12},{"id":"nordic-lymphoma-group","kind":"institution","name":"Nordic Lymphoma Group","route":"/institutions/nordic-lymphoma-group/","asOf":"2026-09-09","days":12},{"id":"cclg","kind":"institution","name":"Children's Cancer and Leukaemia Group","route":"/institutions/cclg/","asOf":"2026-09-09","days":12},{"id":"siop-europe","kind":"institution","name":"SIOP Europe (European Society for Paediatric Oncology)","route":"/institutions/siop-europe/","asOf":"2026-09-09","days":12},{"id":"etop-ibcsg","kind":"institution","name":"ETOP IBCSG Partners Foundation","route":"/institutions/etop-ibcsg/","asOf":"2026-09-09","days":12},{"id":"ifct","kind":"institution","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/institutions/ifct/","asOf":"2026-09-09","days":12},{"id":"arcagy-gineco","kind":"institution","name":"ARCAGY-GINECO","route":"/institutions/arcagy-gineco/","asOf":"2026-09-09","days":12},{"id":"gog-foundation","kind":"institution","name":"GOG Foundation","route":"/institutions/gog-foundation/","asOf":"2026-09-09","days":12},{"id":"nsabp-foundation","kind":"institution","name":"NSABP Foundation","route":"/institutions/nsabp-foundation/","asOf":"2026-09-09","days":12},{"id":"fondation-arc","kind":"institution","name":"Fondation ARC pour la recherche sur le cancer","route":"/institutions/fondation-arc/","asOf":"2026-09-09","days":12},{"id":"ligue-contre-le-cancer","kind":"institution","name":"Ligue nationale contre le cancer","route":"/institutions/ligue-contre-le-cancer/","asOf":"2026-09-09","days":12},{"id":"deutsche-krebshilfe","kind":"institution","name":"Deutsche Krebshilfe","route":"/institutions/deutsche-krebshilfe/","asOf":"2026-09-09","days":12},{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/","asOf":"2026-09-09","days":12},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/","asOf":"2026-09-09","days":12},{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/","asOf":"2026-09-09","days":12},{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","route":"/institutions/canadian-cancer-society/","asOf":"2026-09-09","days":12},{"id":"irish-cancer-society","kind":"institution","name":"Irish Cancer Society","route":"/institutions/irish-cancer-society/","asOf":"2026-09-09","days":12},{"id":"worldwide-cancer-research","kind":"institution","name":"Worldwide Cancer Research","route":"/institutions/worldwide-cancer-research/","asOf":"2026-09-09","days":12},{"id":"wellcome","kind":"institution","name":"Wellcome","route":"/institutions/wellcome/","asOf":"2026-09-09","days":12},{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/","asOf":"2026-09-09","days":12},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/","asOf":"2026-09-09","days":12},{"id":"v-foundation","kind":"institution","name":"The V Foundation for Cancer Research","route":"/institutions/v-foundation/","asOf":"2026-09-09","days":12},{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","route":"/institutions/stand-up-to-cancer/","asOf":"2026-09-09","days":12},{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","asOf":"2026-09-09","days":12},{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/","asOf":"2026-09-09","days":12},{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/","asOf":"2026-09-09","days":12},{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","route":"/institutions/mark-foundation/","asOf":"2026-09-09","days":12},{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","route":"/institutions/emerson-collective/","asOf":"2026-09-09","days":12},{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","route":"/institutions/cz-biohub/","asOf":"2026-09-09","days":12},{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/","asOf":"2026-09-09","days":12},{"id":"cancer-grand-challenges","kind":"institution","name":"Cancer Grand Challenges","route":"/institutions/cancer-grand-challenges/","asOf":"2026-09-09","days":12},{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","route":"/institutions/arpa-h/","asOf":"2026-09-09","days":12},{"id":"movember","kind":"institution","name":"Movember","route":"/institutions/movember/","asOf":"2026-09-09","days":12},{"id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","asOf":"2026-09-09","days":12},{"id":"marie-curie-uk","kind":"institution","name":"Marie Curie","route":"/institutions/marie-curie-uk/","asOf":"2026-09-09","days":12},{"id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","asOf":"2026-09-09","days":12},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/","asOf":"2026-09-09","days":12},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","asOf":"2026-09-09","days":12},{"id":"fda-oce","kind":"institution","name":"FDA Oncology Center of Excellence","route":"/institutions/fda-oce/","asOf":"2026-09-09","days":12},{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","asOf":"2026-09-09","days":12},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","asOf":"2026-09-09","days":12},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/","asOf":"2026-09-09","days":12},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","asOf":"2026-09-09","days":12},{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","asOf":"2026-09-09","days":12},{"id":"tga","kind":"institution","name":"Therapeutic Goods Administration","route":"/institutions/tga/","asOf":"2026-09-09","days":12},{"id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","asOf":"2026-09-09","days":12},{"id":"swissmedic","kind":"institution","name":"Swissmedic","route":"/institutions/swissmedic/","asOf":"2026-09-09","days":12},{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","route":"/institutions/has-france/","asOf":"2026-09-09","days":12},{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","asOf":"2026-09-09","days":12},{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","route":"/institutions/smc/","asOf":"2026-09-09","days":12},{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/","asOf":"2026-09-09","days":12},{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/","asOf":"2026-09-09","days":12},{"id":"cofepris","kind":"institution","name":"Comisión Federal para la Protección contra Riesgos Sanitarios","route":"/institutions/cofepris/","asOf":"2026-09-09","days":12},{"id":"cdsco","kind":"institution","name":"Central Drugs Standard Control Organization","route":"/institutions/cdsco/","asOf":"2026-09-09","days":12},{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/","asOf":"2026-09-09","days":12},{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","route":"/institutions/astro/","asOf":"2026-09-09","days":12},{"id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","asOf":"2026-09-09","days":12},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","asOf":"2026-09-09","days":12},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","asOf":"2026-09-09","days":12},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/","asOf":"2026-09-09","days":12},{"id":"sso","kind":"institution","name":"Society of Surgical Oncology","route":"/institutions/sso/","asOf":"2026-09-09","days":12},{"id":"esso","kind":"institution","name":"European Society of Surgical Oncology","route":"/institutions/esso/","asOf":"2026-09-09","days":12},{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/","asOf":"2026-09-09","days":12},{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/","asOf":"2026-09-09","days":12},{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","route":"/institutions/ispor/","asOf":"2026-09-09","days":12},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/","asOf":"2026-09-09","days":12},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/","asOf":"2026-09-09","days":12},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/","asOf":"2026-09-09","days":12},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/","asOf":"2026-09-09","days":12},{"id":"isoqol","kind":"institution","name":"International Society for Quality of Life Research","route":"/institutions/isoqol/","asOf":"2026-09-09","days":12},{"id":"mascc","kind":"institution","name":"Multinational Association of Supportive Care in Cancer","route":"/institutions/mascc/","asOf":"2026-09-09","days":12},{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","route":"/institutions/espen/","asOf":"2026-09-09","days":12},{"id":"cdisc","kind":"institution","name":"Clinical Data Interchange Standards Consortium","route":"/institutions/cdisc/","asOf":"2026-09-09","days":12},{"id":"hl7","kind":"institution","name":"HL7 International","route":"/institutions/hl7/","asOf":"2026-09-09","days":12},{"id":"vivli","kind":"institution","name":"Vivli","route":"/institutions/vivli/","asOf":"2026-09-09","days":12},{"id":"yoda-project","kind":"institution","name":"Yale University Open Data Access (YODA) Project","route":"/institutions/yoda-project/","asOf":"2026-09-09","days":12},{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","route":"/institutions/institut-bergonie/","asOf":"2026-09-09","days":12},{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/","asOf":"2026-09-09","days":12},{"id":"institut-paoli-calmettes","kind":"institution","name":"Institut Paoli-Calmettes","route":"/institutions/institut-paoli-calmettes/","asOf":"2026-09-09","days":12},{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","route":"/institutions/iuct-oncopole/","asOf":"2026-09-09","days":12},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/","asOf":"2026-09-09","days":12},{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","route":"/institutions/centre-antoine-lacassagne/","asOf":"2026-09-09","days":12},{"id":"inca","kind":"institution","name":"Institut National du Cancer","route":"/institutions/inca/","asOf":"2026-09-09","days":12},{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/","asOf":"2026-09-09","days":12},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","asOf":"2026-09-09","days":12},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","asOf":"2026-09-09","days":12},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","asOf":"2026-09-09","days":12},{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/","asOf":"2026-09-09","days":12},{"id":"ccc-freiburg","kind":"institution","name":"Comprehensive Cancer Center Freiburg (CCCF)","route":"/institutions/ccc-freiburg/","asOf":"2026-09-09","days":12},{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/","asOf":"2026-09-09","days":12},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","asOf":"2026-09-09","days":12},{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/","asOf":"2026-09-09","days":12},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","asOf":"2026-09-09","days":12},{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/","asOf":"2026-09-09","days":12},{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","asOf":"2026-09-09","days":12},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/","asOf":"2026-09-09","days":12},{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","route":"/institutions/leeds-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/","asOf":"2026-09-09","days":12},{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","route":"/institutions/edinburgh-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"velindre-cardiff","kind":"institution","name":"Velindre Cancer Centre","route":"/institutions/velindre-cardiff/","asOf":"2026-09-09","days":12},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/","asOf":"2026-09-09","days":12},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/","asOf":"2026-09-09","days":12},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/","asOf":"2026-09-09","days":12},{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/","asOf":"2026-09-09","days":12},{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","route":"/institutions/great-ormond-street/","asOf":"2026-09-09","days":12},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","asOf":"2026-09-09","days":12},{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","asOf":"2026-09-09","days":12},{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","route":"/institutions/birmingham-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","asOf":"2026-09-09","days":12},{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/","asOf":"2026-09-09","days":12},{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/","asOf":"2026-09-09","days":12},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/","asOf":"2026-09-09","days":12},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/","asOf":"2026-09-09","days":12},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","asOf":"2026-09-09","days":12},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/","asOf":"2026-09-09","days":12},{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/","asOf":"2026-09-09","days":12},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/","asOf":"2026-09-09","days":12},{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","asOf":"2026-09-09","days":12},{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/","asOf":"2026-09-09","days":12},{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/","asOf":"2026-09-09","days":12},{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","route":"/institutions/incliva-valencia/","asOf":"2026-09-09","days":12},{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/","asOf":"2026-09-09","days":12},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/","asOf":"2026-09-09","days":12},{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/","asOf":"2026-09-09","days":12},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/","asOf":"2026-09-09","days":12},{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/","asOf":"2026-09-09","days":12},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","asOf":"2026-09-09","days":12},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","asOf":"2026-09-09","days":12},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","asOf":"2026-09-09","days":12},{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/","asOf":"2026-09-09","days":12},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/","asOf":"2026-09-09","days":12},{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","route":"/institutions/aarhus-university-hospital/","asOf":"2026-09-09","days":12},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","asOf":"2026-09-09","days":12},{"id":"helsinki-hus","kind":"institution","name":"HUS Comprehensive Cancer Center, Helsinki University Hospital","route":"/institutions/helsinki-hus/","asOf":"2026-09-09","days":12},{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","asOf":"2026-09-09","days":12},{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/","asOf":"2026-09-09","days":12},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","asOf":"2026-09-09","days":12},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","asOf":"2026-09-09","days":12},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/","asOf":"2026-09-09","days":12},{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","route":"/institutions/hug-geneva/","asOf":"2026-09-09","days":12},{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","asOf":"2026-09-09","days":12},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","asOf":"2026-09-09","days":12},{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/","asOf":"2026-09-09","days":12},{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","route":"/institutions/ipo-porto/","asOf":"2026-09-09","days":12},{"id":"ipo-lisboa","kind":"institution","name":"Instituto Português de Oncologia de Lisboa Francisco Gentil","route":"/institutions/ipo-lisboa/","asOf":"2026-09-09","days":12},{"id":"champalimaud","kind":"institution","name":"Champalimaud Foundation, Champalimaud Clinical Centre","route":"/institutions/champalimaud/","asOf":"2026-09-09","days":12},{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/","asOf":"2026-09-09","days":12},{"id":"mou-brno","kind":"institution","name":"Masaryk Memorial Cancer Institute","route":"/institutions/mou-brno/","asOf":"2026-09-09","days":12},{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","route":"/institutions/noi-budapest/","asOf":"2026-09-09","days":12},{"id":"onkoloski-institut-ljubljana","kind":"institution","name":"Institute of Oncology Ljubljana","route":"/institutions/onkoloski-institut-ljubljana/","asOf":"2026-09-09","days":12},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/","asOf":"2026-09-09","days":12},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/","asOf":"2026-09-09","days":12},{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","route":"/institutions/tel-aviv-sourasky/","asOf":"2026-09-09","days":12},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/","asOf":"2026-09-09","days":12},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/","asOf":"2026-09-09","days":12},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/","asOf":"2026-09-09","days":12},{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","route":"/institutions/istanbul-oncology-institute/","asOf":"2026-09-09","days":12},{"id":"ecco","kind":"institution","name":"European Cancer Organisation","route":"/institutions/ecco/","asOf":"2026-09-09","days":12},{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","route":"/institutions/eacr/","asOf":"2026-09-09","days":12},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/","asOf":"2026-09-09","days":12},{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","route":"/institutions/odense-university-hospital/","asOf":"2026-09-09","days":12},{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","route":"/institutions/aalborg-university-hospital/","asOf":"2026-09-09","days":12},{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","route":"/institutions/oulu-university-hospital/","asOf":"2026-09-09","days":12},{"id":"landspitali","kind":"institution","name":"Landspítali, the National University Hospital of Iceland","route":"/institutions/landspitali/","asOf":"2026-09-09","days":12},{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","route":"/institutions/motol-university-hospital/","asOf":"2026-09-09","days":12},{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","route":"/institutions/mater-misericordiae/","asOf":"2026-09-09","days":12},{"id":"institut-godinot","kind":"institution","name":"Institut Godinot","route":"/institutions/institut-godinot/","asOf":"2026-09-09","days":12},{"id":"centre-georges-francois-leclerc","kind":"institution","name":"Centre Georges-François Leclerc","route":"/institutions/centre-georges-francois-leclerc/","asOf":"2026-09-09","days":12},{"id":"institut-de-cancerologie-de-lorraine","kind":"institution","name":"Institut de Cancérologie de Lorraine","route":"/institutions/institut-de-cancerologie-de-lorraine/","asOf":"2026-09-09","days":12},{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","route":"/institutions/north-estonia-medical-centre/","asOf":"2026-09-09","days":12},{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","route":"/institutions/east-tallinn-central-hospital/","asOf":"2026-09-09","days":12},{"id":"fondazione-poliambulanza","kind":"institution","name":"Fondazione Poliambulanza","route":"/institutions/fondazione-poliambulanza/","asOf":"2026-09-09","days":12},{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","route":"/institutions/policlinico-san-matteo/","asOf":"2026-09-09","days":12},{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","route":"/institutions/haukeland-university-hospital/","asOf":"2026-09-09","days":12},{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","route":"/institutions/akershus-university-hospital/","asOf":"2026-09-09","days":12},{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","route":"/institutions/pauls-stradins-clinical-university-hospital/","asOf":"2026-09-09","days":12},{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","route":"/institutions/santaros-klinikos/","asOf":"2026-09-09","days":12},{"id":"klaipeda-university-hospital","kind":"institution","name":"Klaipėda University Hospital","route":"/institutions/klaipeda-university-hospital/","asOf":"2026-09-09","days":12},{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","route":"/institutions/orebro-university-hospital/","asOf":"2026-09-09","days":12},{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/","asOf":"2026-09-09","days":12},{"id":"hospital-sant-joan-de-reus","kind":"institution","name":"Hospital Universitari Sant Joan de Reus","route":"/institutions/hospital-sant-joan-de-reus/","asOf":"2026-09-09","days":12},{"id":"uck-gdansk","kind":"institution","name":"University Clinical Centre, Gdańsk","route":"/institutions/uck-gdansk/","asOf":"2026-09-09","days":12},{"id":"polish-mothers-memorial-hospital","kind":"institution","name":"Polish Mother's Memorial Hospital Research Institute","route":"/institutions/polish-mothers-memorial-hospital/","asOf":"2026-09-09","days":12},{"id":"oncology-institute-of-vojvodina","kind":"institution","name":"Oncology Institute of Vojvodina","route":"/institutions/oncology-institute-of-vojvodina/","asOf":"2026-09-09","days":12},{"id":"mater-private","kind":"institution","name":"Mater Private Network","route":"/institutions/mater-private/","asOf":"2026-09-09","days":12},{"id":"iknl","kind":"institution","name":"Netherlands Comprehensive Cancer Organisation (IKNL)","route":"/institutions/iknl/","asOf":"2026-09-09","days":12},{"id":"bank-of-cyprus-oncology-centre","kind":"institution","name":"Bank of Cyprus Oncology Centre","route":"/institutions/bank-of-cyprus-oncology-centre/","asOf":"2026-09-09","days":12},{"id":"zealand-university-hospital","kind":"institution","name":"Zealand University Hospital","route":"/institutions/zealand-university-hospital/","asOf":"2026-09-09","days":12},{"id":"uz-brussel-cancer-centre","kind":"institution","name":"Brussels Cancer Centre (UZ Brussel)","route":"/institutions/uz-brussel-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"sestre-milosrdnice-tumors","kind":"institution","name":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre","route":"/institutions/sestre-milosrdnice-tumors/","asOf":"2026-09-09","days":12},{"id":"german-oncology-center-limassol","kind":"institution","name":"German Oncology Center","route":"/institutions/german-oncology-center-limassol/","asOf":"2026-09-09","days":12},{"id":"metaxa-cancer-hospital","kind":"institution","name":"Metaxa Cancer Hospital, Piraeus","route":"/institutions/metaxa-cancer-hospital/","asOf":"2026-09-09","days":12},{"id":"university-hospital-waterford","kind":"institution","name":"University Hospital Waterford","route":"/institutions/university-hospital-waterford/","asOf":"2026-09-09","days":12},{"id":"mediterranean-institute-of-oncology","kind":"institution","name":"Mediterranean Institute of Oncology (IOM)","route":"/institutions/mediterranean-institute-of-oncology/","asOf":"2026-09-09","days":12},{"id":"kauno-klinikos","kind":"institution","name":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos","route":"/institutions/kauno-klinikos/","asOf":"2026-09-09","days":12},{"id":"oncological-institute-moldova","kind":"institution","name":"Oncological Institute of Moldova","route":"/institutions/oncological-institute-moldova/","asOf":"2026-09-09","days":12},{"id":"university-clinic-radiotherapy-oncology-skopje","kind":"institution","name":"University Clinic for Radiotherapy and Oncology, Skopje","route":"/institutions/university-clinic-radiotherapy-oncology-skopje/","asOf":"2026-09-09","days":12},{"id":"oncosalud-auna","kind":"institution","name":"Oncosalud (AUNA)","route":"/institutions/oncosalud-auna/","asOf":"2026-09-09","days":12},{"id":"iasi-regional-oncology-institute","kind":"institution","name":"Iași Regional Oncology Institute","route":"/institutions/iasi-regional-oncology-institute/","asOf":"2026-09-09","days":12},{"id":"clara-campal-oncology-centre","kind":"institution","name":"Centro Integral Oncológico Clara Campal (HM CIOCC)","route":"/institutions/clara-campal-oncology-centre/","asOf":"2026-09-09","days":12},{"id":"virgen-de-la-victoria-malaga","kind":"institution","name":"Hospital Universitario Virgen de la Victoria","route":"/institutions/virgen-de-la-victoria-malaga/","asOf":"2026-09-09","days":12},{"id":"doctor-peset-valencia","kind":"institution","name":"Hospital Universitario Doctor Peset","route":"/institutions/doctor-peset-valencia/","asOf":"2026-09-09","days":12},{"id":"umea-university-hospital","kind":"institution","name":"Umeå University Hospital (Norrland University Hospital)","route":"/institutions/umea-university-hospital/","asOf":"2026-09-09","days":12},{"id":"aga-khan-hospital-dar-es-salaam","kind":"institution","name":"The Aga Khan Hospital, Dar es Salaam","route":"/institutions/aga-khan-hospital-dar-es-salaam/","asOf":"2026-09-09","days":12},{"id":"dokuz-eylul-institute-of-oncology","kind":"institution","name":"Dokuz Eylül University Institute of Oncology","route":"/institutions/dokuz-eylul-institute-of-oncology/","asOf":"2026-09-09","days":12},{"id":"kavetsky-institute-kyiv","kind":"institution","name":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology","route":"/institutions/kavetsky-institute-kyiv/","asOf":"2026-09-09","days":12},{"id":"northern-cancer-alliance","kind":"institution","name":"Northern Cancer Alliance","route":"/institutions/northern-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"lancashire-south-cumbria-cancer-alliance","kind":"institution","name":"Lancashire and South Cumbria Cancer Alliance","route":"/institutions/lancashire-south-cumbria-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"west-yorkshire-harrogate-cancer-alliance","kind":"institution","name":"West Yorkshire and Harrogate Cancer Alliance","route":"/institutions/west-yorkshire-harrogate-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"humber-north-yorkshire-cancer-alliance","kind":"institution","name":"Humber & North Yorkshire Cancer Alliance","route":"/institutions/humber-north-yorkshire-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"cheshire-merseyside-cancer-alliance","kind":"institution","name":"Cheshire and Merseyside Cancer Alliance","route":"/institutions/cheshire-merseyside-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"greater-manchester-cancer-alliance","kind":"institution","name":"Greater Manchester Cancer Alliance","route":"/institutions/greater-manchester-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"south-yorkshire-bassetlaw-cancer-alliance","kind":"institution","name":"South Yorkshire and Bassetlaw Cancer Alliance","route":"/institutions/south-yorkshire-bassetlaw-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"west-midlands-cancer-alliance","kind":"institution","name":"West Midlands Cancer Alliance","route":"/institutions/west-midlands-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"east-midlands-cancer-alliance","kind":"institution","name":"East Midlands Cancer Alliance","route":"/institutions/east-midlands-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"east-of-england-cancer-alliance","kind":"institution","name":"East of England Cancer Alliance","route":"/institutions/east-of-england-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"north-central-london-cancer-alliance","kind":"institution","name":"North Central London Cancer Alliance","route":"/institutions/north-central-london-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"north-east-london-cancer-alliance","kind":"institution","name":"North East London Cancer Alliance","route":"/institutions/north-east-london-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"south-east-london-cancer-alliance","kind":"institution","name":"South East London Cancer Alliance","route":"/institutions/south-east-london-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"kent-medway-cancer-alliance","kind":"institution","name":"Kent and Medway Cancer Alliance","route":"/institutions/kent-medway-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"surrey-sussex-cancer-alliance","kind":"institution","name":"Surrey and Sussex Cancer Alliance","route":"/institutions/surrey-sussex-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"wessex-cancer-alliance","kind":"institution","name":"Wessex Cancer Alliance","route":"/institutions/wessex-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"thames-valley-cancer-alliance","kind":"institution","name":"Thames Valley Cancer Alliance","route":"/institutions/thames-valley-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"swag-cancer-alliance","kind":"institution","name":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance","route":"/institutions/swag-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"peninsula-cancer-alliance","kind":"institution","name":"Peninsula Cancer Alliance","route":"/institutions/peninsula-cancer-alliance/","asOf":"2026-09-09","days":12},{"id":"mother-teresa-hospital-tirana","kind":"institution","name":"University Hospital Center \"Mother Teresa\", Tirana","route":"/institutions/mother-teresa-hospital-tirana/","asOf":"2026-09-09","days":12},{"id":"institut-sainte-catherine","kind":"institution","name":"Institut Sainte Catherine","route":"/institutions/institut-sainte-catherine/","asOf":"2026-09-09","days":12},{"id":"hellenic-cancer-federation","kind":"institution","name":"Hellenic Cancer Federation (ELLOK)","route":"/institutions/hellenic-cancer-federation/","asOf":"2026-09-09","days":12},{"id":"koranyi-institute-budapest","kind":"institution","name":"National Korányi Institute for Pulmonology","route":"/institutions/koranyi-institute-budapest/","asOf":"2026-09-09","days":12},{"id":"favo","kind":"institution","name":"FAVO, Italian Federation of Voluntary Associations in Oncology","route":"/institutions/favo/","asOf":"2026-09-09","days":12},{"id":"nio-gliwice","kind":"institution","name":"National Institute of Oncology, Gliwice Branch","route":"/institutions/nio-gliwice/","asOf":"2026-09-09","days":12},{"id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","asOf":"2026-09-09","days":12},{"id":"biomedical-research-center-sas","kind":"institution","name":"Biomedical Research Center of the Slovak Academy of Sciences","route":"/institutions/biomedical-research-center-sas/","asOf":"2026-09-09","days":12},{"id":"aecc","kind":"institution","name":"Spanish Association Against Cancer (AECC)","route":"/institutions/aecc/","asOf":"2026-09-09","days":12},{"id":"tatarstan-cancer-center","kind":"institution","name":"Tatarstan Cancer Center, Kazan","route":"/institutions/tatarstan-cancer-center/","asOf":"2026-09-09","days":12},{"id":"mid-western-cancer-centre","kind":"institution","name":"Mid-Western Cancer Centre, University Hospital Limerick","route":"/institutions/mid-western-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"nmrrc-moscow","kind":"institution","name":"National Medical Research Radiological Centre (NMRRC)","route":"/institutions/nmrrc-moscow/","asOf":"2026-09-09","days":12},{"id":"aidport","kind":"institution","name":"AidPort Clinical Trial Hospital","route":"/institutions/aidport/","asOf":"2026-09-09","days":12},{"id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/","asOf":"2026-09-09","days":12},{"id":"capio-st-goran","kind":"institution","name":"Capio S:t Göran's Hospital","route":"/institutions/capio-st-goran/","asOf":"2026-09-09","days":12},{"id":"heart-and-brain-pleven","kind":"institution","name":"Heart and Brain Hospital, Pleven","route":"/institutions/heart-and-brain-pleven/","asOf":"2026-09-09","days":12},{"id":"bjcn","kind":"institution","name":"Bulgarian Joint Cancer Network (BJCN)","route":"/institutions/bjcn/","asOf":"2026-09-09","days":12},{"id":"iba-masaryk","kind":"institution","name":"Institute of Biostatistics and Analyses, Masaryk University","route":"/institutions/iba-masaryk/","asOf":"2026-09-09","days":12},{"id":"fondazione-the-bridge","kind":"institution","name":"Fondazione The Bridge","route":"/institutions/fondazione-the-bridge/","asOf":"2026-09-09","days":12},{"id":"cancer-free-future-association","kind":"institution","name":"Cancer Free Future Association (CFFA)","route":"/institutions/cancer-free-future-association/","asOf":"2026-09-09","days":12},{"id":"sgccn","kind":"institution","name":"Stockholm Gotland Comprehensive Cancer Network (SGCCN)","route":"/institutions/sgccn/","asOf":"2026-09-09","days":12},{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","route":"/institutions/ramon-y-cajal/","asOf":"2026-09-09","days":12},{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","route":"/institutions/clinico-san-carlos/","asOf":"2026-09-09","days":12},{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","route":"/institutions/la-princesa/","asOf":"2026-09-09","days":12},{"id":"puerta-de-hierro","kind":"institution","name":"Hospital Universitario Puerta de Hierro Majadahonda","route":"/institutions/puerta-de-hierro/","asOf":"2026-09-09","days":12},{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","route":"/institutions/herlev-hospital/","asOf":"2026-09-09","days":12},{"id":"greater-poland-cancer-centre","kind":"institution","name":"Greater Poland Cancer Centre","route":"/institutions/greater-poland-cancer-centre/","asOf":"2026-09-09","days":12},{"id":"henri-mondor","kind":"institution","name":"AP-HP Henri-Mondor University Hospitals Cancer Institute","route":"/institutions/henri-mondor/","asOf":"2026-09-09","days":12},{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","route":"/institutions/blokhin-cancer-center/","asOf":"2026-09-09","days":12},{"id":"aphp-paris-saclay-cancer-institute","kind":"institution","name":"AP-HP Paris-Saclay University Hospitals Cancer Institute","route":"/institutions/aphp-paris-saclay-cancer-institute/","asOf":"2026-09-09","days":12},{"id":"inc-luxembourg","kind":"institution","name":"Institut National du Cancer, Luxembourg","route":"/institutions/inc-luxembourg/","asOf":"2026-09-09","days":12},{"id":"nci-ukraine","kind":"institution","name":"National Cancer Institute of Ukraine","route":"/institutions/nci-ukraine/","asOf":"2026-09-09","days":12},{"id":"fican","kind":"institution","name":"Finnish Cancer Center (FICAN)","route":"/institutions/fican/","asOf":"2026-09-09","days":12},{"id":"basement-membrane-tissue-barriers","kind":"pathway","name":"Basement membrane & tissue barriers","route":"/pathways/basement-membrane-tissue-barriers/","asOf":"2026-09-09","days":12},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/","asOf":"2026-09-09","days":12},{"id":"extrinsic-apoptosis-death-receptors","kind":"pathway","name":"Extrinsic apoptosis (death receptors)","route":"/pathways/extrinsic-apoptosis-death-receptors/","asOf":"2026-09-09","days":12},{"id":"p53-mdm2-axis","kind":"pathway","name":"The p53 network (guardian of the genome)","route":"/pathways/p53-mdm2-axis/","asOf":"2026-09-09","days":12},{"id":"mutagenesis-signatures","kind":"pathway","name":"Mutagenesis & mutational signatures","route":"/pathways/mutagenesis-signatures/","asOf":"2026-09-09","days":12},{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/","asOf":"2026-09-09","days":12},{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/","asOf":"2026-09-09","days":12},{"id":"cell-cycle-engine-cdks","kind":"pathway","name":"The cell-cycle engine (cyclins & CDKs)","route":"/pathways/cell-cycle-engine-cdks/","asOf":"2026-09-09","days":12},{"id":"dna-replication-licensing","kind":"pathway","name":"DNA replication & origin licensing","route":"/pathways/dna-replication-licensing/","asOf":"2026-09-09","days":12},{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/","asOf":"2026-09-09","days":12},{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/","asOf":"2026-09-09","days":12},{"id":"transcription-addiction","kind":"pathway","name":"Transcriptional machinery & addiction","route":"/pathways/transcription-addiction/","asOf":"2026-09-09","days":12},{"id":"ubiquitin-proteasome-system","kind":"pathway","name":"Ubiquitin-proteasome system & protein homeostasis","route":"/pathways/ubiquitin-proteasome-system/","asOf":"2026-09-09","days":12},{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/","asOf":"2026-09-09","days":12},{"id":"mismatch-repair-msi","kind":"pathway","name":"Mismatch repair & microsatellite instability","route":"/pathways/mismatch-repair-msi/","asOf":"2026-09-09","days":12},{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/","asOf":"2026-09-09","days":12},{"id":"synthetic-lethality-map","kind":"pathway","name":"Synthetic lethality: paired dependencies","route":"/pathways/synthetic-lethality-map/","asOf":"2026-09-09","days":12},{"id":"glutamine-metabolism","kind":"pathway","name":"Glutamine addiction","route":"/pathways/glutamine-metabolism/","asOf":"2026-09-09","days":12},{"id":"lipid-metabolism-cancer","kind":"pathway","name":"Lipid synthesis, uptake & cholesterol","route":"/pathways/lipid-metabolism-cancer/","asOf":"2026-09-09","days":12},{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/","asOf":"2026-09-09","days":12},{"id":"nutrient-competition-tme","kind":"pathway","name":"Nutrient competition & metabolic immunosuppression","route":"/pathways/nutrient-competition-tme/","asOf":"2026-09-09","days":12},{"id":"t-cell-exhaustion","kind":"pathway","name":"T-cell exhaustion","route":"/pathways/t-cell-exhaustion/","asOf":"2026-09-09","days":12},{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/","asOf":"2026-09-09","days":12},{"id":"myeloid-suppression-axis","kind":"pathway","name":"Myeloid suppression: TAMs, MDSCs & don't-eat-me signals","route":"/pathways/myeloid-suppression-axis/","asOf":"2026-09-09","days":12},{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/","asOf":"2026-09-09","days":12},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/","asOf":"2026-09-09","days":12},{"id":"invasion-ecm-degradation","kind":"pathway","name":"Invasion: proteases, adhesion & the invasive front","route":"/pathways/invasion-ecm-degradation/","asOf":"2026-09-09","days":12},{"id":"intravasation-ctc-survival","kind":"pathway","name":"Intravasation & circulating tumour cells","route":"/pathways/intravasation-ctc-survival/","asOf":"2026-09-09","days":12},{"id":"pre-metastatic-niche","kind":"pathway","name":"The pre-metastatic niche","route":"/pathways/pre-metastatic-niche/","asOf":"2026-09-09","days":12},{"id":"organ-tropism-seed-soil","kind":"pathway","name":"Organ tropism: seed and soil","route":"/pathways/organ-tropism-seed-soil/","asOf":"2026-09-09","days":12},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/","asOf":"2026-09-09","days":12},{"id":"caf-activation-desmoplasia","kind":"pathway","name":"Fibroblast activation, desmoplasia & matrix stiffness","route":"/pathways/caf-activation-desmoplasia/","asOf":"2026-09-09","days":12},{"id":"resistance-routes-map","kind":"pathway","name":"Resistance routes: how a blocked pathway comes back","route":"/pathways/resistance-routes-map/","asOf":"2026-09-09","days":12},{"id":"drug-tolerant-persisters","kind":"pathway","name":"Drug-tolerant persister cells","route":"/pathways/drug-tolerant-persisters/","asOf":"2026-09-09","days":12},{"id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/","asOf":"2026-09-09","days":12},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","asOf":"2026-09-09","days":12},{"id":"daniel-ludwig","kind":"person","name":"Daniel K. Ludwig","route":"/people/daniel-ludwig/","asOf":"2026-09-10","days":11},{"id":"sean-parker","kind":"person","name":"Sean Parker","route":"/people/sean-parker/","asOf":"2026-09-10","days":11},{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","route":"/people/michael-bloomberg/","asOf":"2026-09-10","days":11},{"id":"sidney-kimmel","kind":"person","name":"Sidney Kimmel","route":"/people/sidney-kimmel/","asOf":"2026-09-10","days":11},{"id":"david-koch","kind":"person","name":"David H. Koch","route":"/people/david-koch/","asOf":"2026-09-10","days":11},{"id":"eli-broad","kind":"person","name":"Eli Broad","route":"/people/eli-broad/","asOf":"2026-09-10","days":11},{"id":"jon-huntsman","kind":"person","name":"Jon M. Huntsman Sr.","route":"/people/jon-huntsman/","asOf":"2026-09-10","days":11},{"id":"phil-knight","kind":"person","name":"Phil Knight","route":"/people/phil-knight/","asOf":"2026-09-10","days":11},{"id":"gert-boyle","kind":"person","name":"Gert Boyle","route":"/people/gert-boyle/","asOf":"2026-09-10","days":11},{"id":"larry-ellison","kind":"person","name":"Larry Ellison","route":"/people/larry-ellison/","asOf":"2026-09-10","days":11},{"id":"herbert-irving","kind":"person","name":"Herbert Irving","route":"/people/herbert-irving/","asOf":"2026-09-10","days":11},{"id":"mortimer-zuckerman","kind":"person","name":"Mortimer Zuckerman","route":"/people/mortimer-zuckerman/","asOf":"2026-09-10","days":11},{"id":"helen-diller","kind":"person","name":"Helen Diller","route":"/people/helen-diller/","asOf":"2026-09-10","days":11},{"id":"leonard-abramson","kind":"person","name":"Leonard Abramson","route":"/people/leonard-abramson/","asOf":"2026-09-10","days":11},{"id":"richard-rogel","kind":"person","name":"Richard Rogel","route":"/people/richard-rogel/","asOf":"2026-09-10","days":11},{"id":"sanford-weill","kind":"person","name":"Sanford I. Weill","route":"/people/sanford-weill/","asOf":"2026-09-10","days":11},{"id":"john-jacob-astor-iii","kind":"person","name":"John Jacob Astor III","route":"/people/john-jacob-astor-iii/","asOf":"2026-09-10","days":11},{"id":"john-d-rockefeller-jr","kind":"person","name":"John D. Rockefeller Jr.","route":"/people/john-d-rockefeller-jr/","asOf":"2026-09-10","days":11},{"id":"alfred-sloan","kind":"person","name":"Alfred P. Sloan Jr.","route":"/people/alfred-sloan/","asOf":"2026-09-10","days":11},{"id":"charles-kettering","kind":"person","name":"Charles F. Kettering","route":"/people/charles-kettering/","asOf":"2026-09-10","days":11},{"id":"monroe-anderson","kind":"person","name":"Monroe Dunaway Anderson","route":"/people/monroe-anderson/","asOf":"2026-09-10","days":11},{"id":"robert-woodruff","kind":"person","name":"Robert W. Woodruff","route":"/people/robert-woodruff/","asOf":"2026-09-10","days":11},{"id":"lucille-markey","kind":"person","name":"Lucille P. Markey","route":"/people/lucille-markey/","asOf":"2026-09-10","days":11},{"id":"martha-ingram","kind":"person","name":"Martha Rivers Ingram","route":"/people/martha-ingram/","asOf":"2026-09-10","days":11},{"id":"ann-lurie","kind":"person","name":"Ann Lurie","route":"/people/ann-lurie/","asOf":"2026-09-10","days":11},{"id":"goh-cheng-liang","kind":"person","name":"Goh Cheng Liang","route":"/people/goh-cheng-liang/","asOf":"2026-09-10","days":11},{"id":"michael-milken","kind":"person","name":"Michael Milken","route":"/people/michael-milken/","asOf":"2026-09-10","days":11},{"id":"leon-black","kind":"person","name":"Leon Black","route":"/people/leon-black/","asOf":"2026-09-10","days":11},{"id":"debra-black","kind":"person","name":"Debra Black","route":"/people/debra-black/","asOf":"2026-09-10","days":11},{"id":"albert-lasker","kind":"person","name":"Albert Lasker","route":"/people/albert-lasker/","asOf":"2026-09-10","days":11},{"id":"walter-winchell","kind":"person","name":"Walter Winchell","route":"/people/walter-winchell/","asOf":"2026-09-10","days":11},{"id":"sherry-lansing","kind":"person","name":"Sherry Lansing","route":"/people/sherry-lansing/","asOf":"2026-09-10","days":11},{"id":"marc-lustgarten","kind":"person","name":"Marc Lustgarten","route":"/people/marc-lustgarten/","asOf":"2026-09-10","days":11},{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/","asOf":"2026-09-10","days":11},{"id":"bill-gates","kind":"person","name":"Bill Gates","route":"/people/bill-gates/","asOf":"2026-09-10","days":11},{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","route":"/people/li-ka-shing/","asOf":"2026-09-10","days":11},{"id":"dorabji-tata","kind":"person","name":"Sir Dorabji Tata","route":"/people/dorabji-tata/","asOf":"2026-09-10","days":11},{"id":"ratan-tata","kind":"person","name":"Ratan Tata","route":"/people/ratan-tata/","asOf":"2026-09-10","days":11},{"id":"ted-williams","kind":"person","name":"Ted Williams","route":"/people/ted-williams/","asOf":"2026-09-10","days":11},{"id":"billy-starr","kind":"person","name":"Billy Starr","route":"/people/billy-starr/","asOf":"2026-09-10","days":11},{"id":"chris-hoy","kind":"person","name":"Sir Chris Hoy","route":"/people/chris-hoy/","asOf":"2026-09-10","days":11},{"id":"iwona-lugowska","kind":"person","name":"Iwona Ługowska","route":"/people/iwona-lugowska/","asOf":"2026-09-10","days":11},{"id":"claudio-lombardo","kind":"person","name":"Claudio Lombardo","route":"/people/claudio-lombardo/","asOf":"2026-09-10","days":11},{"id":"matthew-hurles","kind":"person","name":"Matthew Hurles","route":"/people/matthew-hurles/","asOf":"2026-09-10","days":11},{"id":"michael-stratton","kind":"person","name":"Michael Stratton","route":"/people/michael-stratton/","asOf":"2026-09-10","days":11},{"id":"david-probert","kind":"person","name":"David Probert","route":"/people/david-probert/","asOf":"2026-09-10","days":11},{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","route":"/people/sandra-demaria/","asOf":"2026-09-10","days":11},{"id":"ziyu-li","kind":"person","name":"Ziyu Li","route":"/people/ziyu-li/","asOf":"2026-09-10","days":11},{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/","asOf":"2026-09-10","days":11},{"id":"barbara-jereczek-fossa","kind":"person","name":"Barbara Jereczek-Fossa","route":"/people/barbara-jereczek-fossa/","asOf":"2026-09-10","days":11},{"id":"matthias-guckenberger","kind":"person","name":"Matthias Guckenberger","route":"/people/matthias-guckenberger/","asOf":"2026-09-10","days":11},{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","asOf":"2026-09-10","days":11},{"id":"martin-schuler","kind":"person","name":"Martin Schuler","route":"/people/martin-schuler/","asOf":"2026-09-10","days":11},{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","asOf":"2026-09-10","days":11},{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","route":"/people/matthew-powell/","asOf":"2026-09-10","days":11},{"id":"karen-lu","kind":"person","name":"Karen H. Lu","route":"/people/karen-lu/","asOf":"2026-09-10","days":11},{"id":"josep-maria-campistol","kind":"person","name":"Josep Maria Campistol","route":"/people/josep-maria-campistol/","asOf":"2026-09-10","days":11},{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/","asOf":"2026-09-10","days":11},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/","asOf":"2026-09-10","days":11},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/","asOf":"2026-09-10","days":11},{"id":"ian-davis","kind":"person","name":"Ian Davis","route":"/people/ian-davis/","asOf":"2026-09-10","days":11},{"id":"samantha-oakes","kind":"person","name":"Samantha Oakes","route":"/people/samantha-oakes/","asOf":"2026-09-10","days":11},{"id":"monika-janicke","kind":"person","name":"Monika Jänicke","route":"/people/monika-janicke/","asOf":"2026-09-10","days":11},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","route":"/people/virginia-pappas/","asOf":"2026-09-10","days":11},{"id":"yitshak-kreiss","kind":"person","name":"Yitshak Kreiss","route":"/people/yitshak-kreiss/","asOf":"2026-09-10","days":11},{"id":"daniel-aebersold","kind":"person","name":"Daniel M. Aebersold","route":"/people/daniel-aebersold/","asOf":"2026-09-10","days":11},{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","asOf":"2026-09-10","days":11},{"id":"karen-kelly","kind":"person","name":"Karen Kelly","route":"/people/karen-kelly/","asOf":"2026-09-10","days":11},{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","route":"/people/nicolaas-schaap/","asOf":"2026-09-10","days":11},{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","route":"/people/marc-raaijmakers/","asOf":"2026-09-10","days":11},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","asOf":"2026-09-10","days":11},{"id":"tedros-adhanom-ghebreyesus","kind":"person","name":"Tedros Adhanom Ghebreyesus","route":"/people/tedros-adhanom-ghebreyesus/","asOf":"2026-09-10","days":11},{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","route":"/people/yoram-weiss/","asOf":"2026-09-10","days":11},{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","route":"/people/konstanze-doehner/","asOf":"2026-09-10","days":11},{"id":"brian-huntly","kind":"person","name":"Brian Huntly","route":"/people/brian-huntly/","asOf":"2026-09-10","days":11},{"id":"anna-sapino","kind":"person","name":"Anna Sapino","route":"/people/anna-sapino/","asOf":"2026-09-10","days":11},{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","asOf":"2026-09-10","days":11},{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/","asOf":"2026-09-10","days":11},{"id":"alon-chen","kind":"person","name":"Alon Chen","route":"/people/alon-chen/","asOf":"2026-09-10","days":11},{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","route":"/people/wouter-de-laat/","asOf":"2026-09-10","days":11},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/","asOf":"2026-09-10","days":11},{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","route":"/people/chong-jen-yu/","asOf":"2026-09-10","days":11},{"id":"lawrence-tallon","kind":"person","name":"Lawrence Tallon","route":"/people/lawrence-tallon/","asOf":"2026-09-10","days":11},{"id":"linda-tantawi","kind":"person","name":"Linda Tantawi","route":"/people/linda-tantawi/","asOf":"2026-09-10","days":11},{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","asOf":"2026-09-10","days":11},{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","route":"/people/ane-gerda-eriksson/","asOf":"2026-09-10","days":11},{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/","asOf":"2026-09-10","days":11},{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/","asOf":"2026-09-10","days":11},{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","asOf":"2026-09-10","days":11},{"id":"madeline-bell","kind":"person","name":"Madeline Bell","route":"/people/madeline-bell/","asOf":"2026-09-10","days":11},{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","asOf":"2026-09-10","days":11},{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","route":"/people/sunil-lakhani/","asOf":"2026-09-10","days":11},{"id":"donna-mckay","kind":"person","name":"Donna McKay","route":"/people/donna-mckay/","asOf":"2026-09-10","days":11},{"id":"dorraya-el-ashry","kind":"person","name":"Dorraya El-Ashry","route":"/people/dorraya-el-ashry/","asOf":"2026-09-10","days":11},{"id":"kirsten-schmieder","kind":"person","name":"Kirsten Schmieder","route":"/people/kirsten-schmieder/","asOf":"2026-09-10","days":11},{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","route":"/people/sascha-dietrich/","asOf":"2026-09-10","days":11},{"id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","asOf":"2026-09-10","days":11},{"id":"tari-king","kind":"person","name":"Tari A. King","route":"/people/tari-king/","asOf":"2026-09-10","days":11},{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","route":"/people/rasmus-mogelvang/","asOf":"2026-09-10","days":11},{"id":"kjetil-tasken","kind":"person","name":"Kjetil Taskén","route":"/people/kjetil-tasken/","asOf":"2026-09-10","days":11},{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/","asOf":"2026-09-10","days":11},{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/","asOf":"2026-09-10","days":11},{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/","asOf":"2026-09-10","days":11},{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","route":"/people/rebecca-dent/","asOf":"2026-09-10","days":11},{"id":"alexandre-chan","kind":"person","name":"Alexandre Chan","route":"/people/alexandre-chan/","asOf":"2026-09-10","days":11},{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","asOf":"2026-09-10","days":11},{"id":"simona-sancini","kind":"person","name":"Simona Sancini","route":"/people/simona-sancini/","asOf":"2026-09-10","days":11},{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","asOf":"2026-09-10","days":11},{"id":"nu-zhang","kind":"person","name":"Nu Zhang","route":"/people/nu-zhang/","asOf":"2026-09-10","days":11},{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","asOf":"2026-09-10","days":11},{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","asOf":"2026-09-10","days":11},{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","asOf":"2026-09-10","days":11},{"id":"geoff-parnell","kind":"person","name":"Geoff Parnell","route":"/people/geoff-parnell/","asOf":"2026-09-10","days":11},{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","route":"/people/christos-karapetis/","asOf":"2026-09-10","days":11},{"id":"rakesh-padiyath","kind":"person","name":"Rakesh Padiyath","route":"/people/rakesh-padiyath/","asOf":"2026-09-10","days":11},{"id":"astrid-beiglbock","kind":"person","name":"Astrid Beiglböck","route":"/people/astrid-beiglbock/","asOf":"2026-09-10","days":11},{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","asOf":"2026-09-10","days":11},{"id":"martin-siess","kind":"person","name":"Martin Siess","route":"/people/martin-siess/","asOf":"2026-09-10","days":11},{"id":"julian-adams","kind":"person","name":"Julian Adams","route":"/people/julian-adams/","asOf":"2026-09-10","days":11},{"id":"chiara-gibertoni","kind":"person","name":"Chiara Gibertoni","route":"/people/chiara-gibertoni/","asOf":"2026-09-10","days":11},{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","asOf":"2026-09-10","days":11},{"id":"beata-jagielska","kind":"person","name":"Beata Jagielska","route":"/people/beata-jagielska/","asOf":"2026-09-10","days":11},{"id":"michal-mikula","kind":"person","name":"Michał Mikula","route":"/people/michal-mikula/","asOf":"2026-09-10","days":11},{"id":"andrzej-kawecki","kind":"person","name":"Andrzej Kawecki","route":"/people/andrzej-kawecki/","asOf":"2026-09-10","days":11},{"id":"martin-jan-schalij","kind":"person","name":"Martin Jan Schalij","route":"/people/martin-jan-schalij/","asOf":"2026-09-10","days":11},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","route":"/people/rafael-mariano-grossi/","asOf":"2026-09-10","days":11},{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","asOf":"2026-09-10","days":11},{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","route":"/people/antonio-cuneo/","asOf":"2026-09-10","days":11},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","asOf":"2026-09-10","days":11},{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","asOf":"2026-09-10","days":11},{"id":"shane-degaris","kind":"person","name":"Shane DeGaris","route":"/people/shane-degaris/","asOf":"2026-09-10","days":11},{"id":"ken-smith","kind":"person","name":"Ken Smith","route":"/people/ken-smith/","asOf":"2026-09-10","days":11},{"id":"marianne-van-rooijen","kind":"person","name":"Marianne van Rooijen","route":"/people/marianne-van-rooijen/","asOf":"2026-09-10","days":11},{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","asOf":"2026-09-10","days":11},{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","asOf":"2026-09-10","days":11},{"id":"purnima-sundaresan","kind":"person","name":"Purnima Sundaresan","route":"/people/purnima-sundaresan/","asOf":"2026-09-10","days":11},{"id":"hien-le","kind":"person","name":"Hien Le","route":"/people/hien-le/","asOf":"2026-09-10","days":11},{"id":"tammy-kang","kind":"person","name":"Tammy Kang","route":"/people/tammy-kang/","asOf":"2026-09-10","days":11},{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","asOf":"2026-09-10","days":11},{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","asOf":"2026-09-10","days":11},{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","route":"/people/eva-ciruelos/","asOf":"2026-09-10","days":11},{"id":"ofer-merin","kind":"person","name":"Ofer Merin","route":"/people/ofer-merin/","asOf":"2026-09-10","days":11},{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","asOf":"2026-09-10","days":11},{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","asOf":"2026-09-10","days":11},{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","asOf":"2026-09-10","days":11},{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","asOf":"2026-09-10","days":11},{"id":"jurgen-weitz","kind":"person","name":"Jürgen Weitz","route":"/people/jurgen-weitz/","asOf":"2026-09-10","days":11},{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","asOf":"2026-09-10","days":11},{"id":"marek-svoboda","kind":"person","name":"Marek Svoboda","route":"/people/marek-svoboda/","asOf":"2026-09-10","days":11},{"id":"tomas-kazda","kind":"person","name":"Tomáš Kazda","route":"/people/tomas-kazda/","asOf":"2026-09-10","days":11},{"id":"igor-kiss","kind":"person","name":"Igor Kiss","route":"/people/igor-kiss/","asOf":"2026-09-10","days":11},{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","asOf":"2026-09-10","days":11},{"id":"hidetoshi-hayashi","kind":"person","name":"Hidetoshi Hayashi","route":"/people/hidetoshi-hayashi/","asOf":"2026-09-10","days":11},{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","route":"/people/alexis-cortot/","asOf":"2026-09-10","days":11},{"id":"david-planchard","kind":"person","name":"David Planchard","route":"/people/david-planchard/","asOf":"2026-09-10","days":11},{"id":"sonja-optendrenk","kind":"person","name":"Sonja Optendrenk","route":"/people/sonja-optendrenk/","asOf":"2026-09-10","days":11},{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","route":"/people/thomas-kaiser/","asOf":"2026-09-10","days":11},{"id":"geerard-beets","kind":"person","name":"Geerard Beets","route":"/people/geerard-beets/","asOf":"2026-09-10","days":11},{"id":"isabel-rubio","kind":"person","name":"Isabel T. Rubio","route":"/people/isabel-rubio/","asOf":"2026-09-10","days":11},{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","asOf":"2026-09-10","days":11},{"id":"julio-saez-rodriguez","kind":"person","name":"Julio Saez-Rodriguez","route":"/people/julio-saez-rodriguez/","asOf":"2026-09-10","days":11},{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","route":"/people/charlie-gourley/","asOf":"2026-09-10","days":11},{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/","asOf":"2026-09-10","days":11},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/","asOf":"2026-09-10","days":11},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/","asOf":"2026-09-10","days":11},{"id":"chris-decker","kind":"person","name":"Chris Decker","route":"/people/chris-decker/","asOf":"2026-09-10","days":11},{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","route":"/people/maximilian-niyazi/","asOf":"2026-09-10","days":11},{"id":"lars-zender","kind":"person","name":"Lars Zender","route":"/people/lars-zender/","asOf":"2026-09-10","days":11},{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","route":"/people/sara-brucker/","asOf":"2026-09-10","days":11},{"id":"sharon-armstrong","kind":"person","name":"Sharon Armstrong","route":"/people/sharon-armstrong/","asOf":"2026-09-10","days":11},{"id":"owen-sansom","kind":"person","name":"Owen Sansom","route":"/people/owen-sansom/","asOf":"2026-09-10","days":11},{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","route":"/people/nikhil-tandon/","asOf":"2026-09-10","days":11},{"id":"rebecca-li","kind":"person","name":"Rebecca Li","route":"/people/rebecca-li/","asOf":"2026-09-10","days":11},{"id":"jackson-orem","kind":"person","name":"Jackson Orem","route":"/people/jackson-orem/","asOf":"2026-09-10","days":11},{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","route":"/people/diane-simeone/","asOf":"2026-09-10","days":11},{"id":"rana-mckay","kind":"person","name":"Rana McKay","route":"/people/rana-mckay/","asOf":"2026-09-10","days":11},{"id":"j-silvio-gutkind","kind":"person","name":"J. Silvio Gutkind","route":"/people/j-silvio-gutkind/","asOf":"2026-09-10","days":11},{"id":"cathryn-cox","kind":"person","name":"Cathryn Cox","route":"/people/cathryn-cox/","asOf":"2026-09-10","days":11},{"id":"louis-chesler","kind":"person","name":"Louis Chesler","route":"/people/louis-chesler/","asOf":"2026-09-10","days":11},{"id":"james-r-downing","kind":"person","name":"James R. Downing","route":"/people/james-r-downing/","asOf":"2026-09-10","days":11},{"id":"uta-dirksen","kind":"person","name":"Uta Dirksen","route":"/people/uta-dirksen/","asOf":"2026-09-10","days":11},{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","route":"/people/gilles-vassal/","asOf":"2026-09-10","days":11},{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","asOf":"2026-09-10","days":11},{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","asOf":"2026-09-10","days":11},{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","route":"/people/meredith-irwin/","asOf":"2026-09-10","days":11},{"id":"boubou-hallberg","kind":"person","name":"Boubou Hallberg","route":"/people/boubou-hallberg/","asOf":"2026-09-10","days":11},{"id":"vivek-lal","kind":"person","name":"Vivek Lal","route":"/people/vivek-lal/","asOf":"2026-09-10","days":11},{"id":"jin-seok-ahn","kind":"person","name":"Jin Seok Ahn","route":"/people/jin-seok-ahn/","asOf":"2026-09-10","days":11},{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","route":"/people/jean-pierre-delord/","asOf":"2026-09-10","days":11},{"id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","asOf":"2026-09-10","days":11},{"id":"rob-abbott","kind":"person","name":"Rob Abbott","route":"/people/rob-abbott/","asOf":"2026-09-10","days":11},{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/","asOf":"2026-09-10","days":11},{"id":"jaume-raventos-i-monjo","kind":"person","name":"Jaume Raventós i Monjo","route":"/people/jaume-raventos-i-monjo/","asOf":"2026-09-10","days":11},{"id":"karl-munslow-ong","kind":"person","name":"Karl Munslow-Ong","route":"/people/karl-munslow-ong/","asOf":"2026-09-10","days":11},{"id":"sophia-varadkar","kind":"person","name":"Sophia Varadkar","route":"/people/sophia-varadkar/","asOf":"2026-09-10","days":11},{"id":"elisabetta-zanon","kind":"person","name":"Elisabetta Zanon","route":"/people/elisabetta-zanon/","asOf":"2026-09-10","days":11},{"id":"georges-pascal-haber","kind":"person","name":"Georges-Pascal Haber","route":"/people/georges-pascal-haber/","asOf":"2026-09-10","days":11},{"id":"florian-roser","kind":"person","name":"Florian Roser","route":"/people/florian-roser/","asOf":"2026-09-10","days":11},{"id":"leonor-beleza","kind":"person","name":"Leonor Beleza","route":"/people/leonor-beleza/","asOf":"2026-09-10","days":11},{"id":"teresa-cotta-dias","kind":"person","name":"Teresa Cotta-Dias","route":"/people/teresa-cotta-dias/","asOf":"2026-09-10","days":11},{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/","asOf":"2026-09-10","days":11},{"id":"thomas-balle-kristensen","kind":"person","name":"Thomas Balle Kristensen","route":"/people/thomas-balle-kristensen/","asOf":"2026-09-10","days":11},{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","route":"/people/jens-overgaard/","asOf":"2026-09-10","days":11},{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","asOf":"2026-09-10","days":11},{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","asOf":"2026-09-10","days":11},{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","route":"/people/nobuyuki-yamamoto/","asOf":"2026-09-10","days":11},{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","asOf":"2026-09-10","days":11},{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","asOf":"2026-09-10","days":11},{"id":"thomas-kindler","kind":"person","name":"Thomas Kindler","route":"/people/thomas-kindler/","asOf":"2026-09-10","days":11},{"id":"christian-brandts","kind":"person","name":"Christian Brandts","route":"/people/christian-brandts/","asOf":"2026-09-10","days":11},{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","asOf":"2026-09-10","days":11},{"id":"hubert-serve","kind":"person","name":"Hubert Serve","route":"/people/hubert-serve/","asOf":"2026-09-10","days":11},{"id":"philip-chiu","kind":"person","name":"Philip Wai Yan Chiu","route":"/people/philip-chiu/","asOf":"2026-09-10","days":11},{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/","asOf":"2026-09-10","days":11},{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","route":"/people/anthony-chan/","asOf":"2026-09-10","days":11},{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","route":"/people/yasuhiro-fujiwara/","asOf":"2026-09-10","days":11},{"id":"zlata-stiblar-kisic","kind":"person","name":"Zlata Štiblar Kisić","route":"/people/zlata-stiblar-kisic/","asOf":"2026-09-10","days":11},{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","route":"/people/janja-ocvirk/","asOf":"2026-09-10","days":11},{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","route":"/people/shivaani-kummar/","asOf":"2026-09-10","days":11},{"id":"chee-cheng-ean","kind":"person","name":"Chee Cheng Ean","route":"/people/chee-cheng-ean/","asOf":"2026-09-10","days":11},{"id":"goh-boon-cher","kind":"person","name":"Goh Boon Cher","route":"/people/goh-boon-cher/","asOf":"2026-09-10","days":11},{"id":"jimmy-so","kind":"person","name":"Jimmy So","route":"/people/jimmy-so/","asOf":"2026-09-10","days":11},{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","route":"/people/matthew-vander-heiden/","asOf":"2026-09-10","days":11},{"id":"robert-langer","kind":"person","name":"Robert S. Langer","route":"/people/robert-langer/","asOf":"2026-09-10","days":11},{"id":"maike-sander","kind":"person","name":"Maike Sander","route":"/people/maike-sander/","asOf":"2026-09-10","days":11},{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","route":"/people/nikolaus-rajewsky/","asOf":"2026-09-10","days":11},{"id":"wasiu-lanre-adeyemo","kind":"person","name":"Wasiu Lanre Adeyemo","route":"/people/wasiu-lanre-adeyemo/","asOf":"2026-09-10","days":11},{"id":"carolina-samuelsson","kind":"person","name":"Carolina Samuelsson","route":"/people/carolina-samuelsson/","asOf":"2026-09-10","days":11},{"id":"asem-mansour","kind":"person","name":"Asem Mansour","route":"/people/asem-mansour/","asOf":"2026-09-10","days":11},{"id":"majid-alfayyadh","kind":"person","name":"Majid Ibrahim Alfayyadh","route":"/people/majid-alfayyadh/","asOf":"2026-09-10","days":11},{"id":"richard-lesiyampe","kind":"person","name":"Richard Lesiyampe","route":"/people/richard-lesiyampe/","asOf":"2026-09-10","days":11},{"id":"koichi-fukunaga","kind":"person","name":"Koichi Fukunaga","route":"/people/koichi-fukunaga/","asOf":"2026-09-10","days":11},{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","route":"/people/rachel-ramoni/","asOf":"2026-09-10","days":11},{"id":"theodore-levin","kind":"person","name":"Theodore R. Levin","route":"/people/theodore-levin/","asOf":"2026-09-10","days":11},{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","asOf":"2026-09-10","days":11},{"id":"patrizia-simionato","kind":"person","name":"Patrizia Simionato","route":"/people/patrizia-simionato/","asOf":"2026-09-10","days":11},{"id":"antonio-rosato","kind":"person","name":"Antonio Rosato","route":"/people/antonio-rosato/","asOf":"2026-09-10","days":11},{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","asOf":"2026-09-10","days":11},{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","route":"/people/suzette-delaloge/","asOf":"2026-09-10","days":11},{"id":"nicolas-scotte","kind":"person","name":"Nicolas Scotté","route":"/people/nicolas-scotte/","asOf":"2026-09-10","days":11},{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","route":"/people/bradley-cairns/","asOf":"2026-09-10","days":11},{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","route":"/people/erin-oshea/","asOf":"2026-09-10","days":11},{"id":"brasil-silva-neto","kind":"person","name":"Brasil Silva Neto","route":"/people/brasil-silva-neto/","asOf":"2026-09-10","days":11},{"id":"lionel-collet","kind":"person","name":"Lionel Collet","route":"/people/lionel-collet/","asOf":"2026-09-10","days":11},{"id":"jean-lessi","kind":"person","name":"Jean Lessi","route":"/people/jean-lessi/","asOf":"2026-09-10","days":11},{"id":"mark-suzman","kind":"person","name":"Mark Suzman","route":"/people/mark-suzman/","asOf":"2026-09-10","days":11},{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","asOf":"2026-09-10","days":11},{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","route":"/people/benjamin-kile/","asOf":"2026-09-10","days":11},{"id":"susan-clark","kind":"person","name":"Susan Clark","route":"/people/susan-clark/","asOf":"2026-09-10","days":11},{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","route":"/people/jay-schnitzer/","asOf":"2026-09-10","days":11},{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","route":"/people/suresh-ramalingam/","asOf":"2026-09-10","days":11},{"id":"richard-schulick","kind":"person","name":"Richard Schulick","route":"/people/richard-schulick/","asOf":"2026-09-10","days":11},{"id":"michael-gnant","kind":"person","name":"Michael Gnant","route":"/people/michael-gnant/","asOf":"2026-09-10","days":11},{"id":"christian-singer","kind":"person","name":"Christian Singer","route":"/people/christian-singer/","asOf":"2026-09-10","days":11},{"id":"john-arne-rottingen","kind":"person","name":"John-Arne Røttingen","route":"/people/john-arne-rottingen/","asOf":"2026-09-10","days":11},{"id":"shalene-curtis-micallef","kind":"person","name":"Shalene Curtis-Micallef","route":"/people/shalene-curtis-micallef/","asOf":"2026-09-10","days":11},{"id":"diep-bao-tuan","kind":"person","name":"Diệp Bảo Tuấn","route":"/people/diep-bao-tuan/","asOf":"2026-09-10","days":11},{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","asOf":"2026-09-10","days":11},{"id":"henrique-prata","kind":"person","name":"Henrique Prata","route":"/people/henrique-prata/","asOf":"2026-09-10","days":11},{"id":"johanna-mattson","kind":"person","name":"Johanna Mattson","route":"/people/johanna-mattson/","asOf":"2026-09-10","days":11},{"id":"nicolas-penel","kind":"person","name":"Nicolas Penel","route":"/people/nicolas-penel/","asOf":"2026-09-10","days":11},{"id":"renaud-witmeur","kind":"person","name":"Renaud Witmeur","route":"/people/renaud-witmeur/","asOf":"2026-09-10","days":11},{"id":"norbert-vey","kind":"person","name":"Norbert Vey","route":"/people/norbert-vey/","asOf":"2026-09-10","days":11},{"id":"yasmine-belkaid","kind":"person","name":"Yasmine Belkaid","route":"/people/yasmine-belkaid/","asOf":"2026-09-10","days":11},{"id":"senda-tounsi","kind":"person","name":"Senda Tounsi","route":"/people/senda-tounsi/","asOf":"2026-09-10","days":11},{"id":"david-baker","kind":"person","name":"David Baker","route":"/people/david-baker/","asOf":"2026-09-10","days":11},{"id":"bernardo-rubinstein","kind":"person","name":"Bernardo Rubinstein","route":"/people/bernardo-rubinstein/","asOf":"2026-09-10","days":11},{"id":"chen-wei-ming","kind":"person","name":"Chen Wei-ming","route":"/people/chen-wei-ming/","asOf":"2026-09-10","days":11},{"id":"sultan-mohamed-alkaram","kind":"person","name":"Sultan Mohamed Alkaram","route":"/people/sultan-mohamed-alkaram/","asOf":"2026-09-10","days":11},{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","route":"/people/eli-sprecher/","asOf":"2026-09-10","days":11},{"id":"ryan-schoenfeld","kind":"person","name":"Ryan Schoenfeld","route":"/people/ryan-schoenfeld/","asOf":"2026-09-10","days":11},{"id":"rebecca-auer","kind":"person","name":"Rebecca Auer","route":"/people/rebecca-auer/","asOf":"2026-09-10","days":11},{"id":"brandi-williams-broome","kind":"person","name":"Brandi Williams Broome","route":"/people/brandi-williams-broome/","asOf":"2026-09-10","days":11},{"id":"anthony-lawler","kind":"person","name":"Anthony Lawler","route":"/people/anthony-lawler/","asOf":"2026-09-10","days":11},{"id":"takashi-kamei","kind":"person","name":"Takashi Kamei","route":"/people/takashi-kamei/","asOf":"2026-09-10","days":11},{"id":"cary-adams","kind":"person","name":"Cary Adams","route":"/people/cary-adams/","asOf":"2026-09-10","days":11},{"id":"jonathan-brotherton","kind":"person","name":"Jonathan Brotherton","route":"/people/jonathan-brotherton/","asOf":"2026-09-10","days":11},{"id":"mohd-zukiflee-abu-bakar","kind":"person","name":"Mohd Zukiflee Abu Bakar","route":"/people/mohd-zukiflee-abu-bakar/","asOf":"2026-09-10","days":11},{"id":"paul-herijgers","kind":"person","name":"Paul Herijgers","route":"/people/paul-herijgers/","asOf":"2026-09-10","days":11},{"id":"carl-james","kind":"person","name":"Carl James","route":"/people/carl-james/","asOf":"2026-09-10","days":11},{"id":"laura-brady","kind":"person","name":"Laura Brady","route":"/people/laura-brady/","asOf":"2026-09-10","days":11},{"id":"laurene-powell-jobs","kind":"person","name":"Laurene Powell Jobs","route":"/people/laurene-powell-jobs/","asOf":"2026-09-10","days":11},{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","route":"/people/johanna-joyce/","asOf":"2026-09-10","days":11},{"id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","route":"/people/stanislaw-klek/","asOf":"2026-09-10","days":11},{"id":"r-angelo-de-claro","kind":"person","name":"R. Angelo de Claro","route":"/people/r-angelo-de-claro/","asOf":"2026-09-10","days":11},{"id":"dominique-bazy","kind":"person","name":"Dominique Bazy","route":"/people/dominique-bazy/","asOf":"2026-09-10","days":11},{"id":"andrea-sironi","kind":"person","name":"Andrea Sironi","route":"/people/andrea-sironi/","asOf":"2026-09-10","days":11},{"id":"cristian-ayala-munita","kind":"person","name":"Cristián Ayala Munita","route":"/people/cristian-ayala-munita/","asOf":"2026-09-10","days":11},{"id":"christiane-pott","kind":"person","name":"Christiane Pott","route":"/people/christiane-pott/","asOf":"2026-09-10","days":11},{"id":"tatsuya-ohno","kind":"person","name":"Tatsuya Ohno","route":"/people/tatsuya-ohno/","asOf":"2026-09-10","days":11},{"id":"amanda-pritchard","kind":"person","name":"Amanda Pritchard","route":"/people/amanda-pritchard/","asOf":"2026-09-10","days":11},{"id":"kadir-mutlu-hayran","kind":"person","name":"Kadir Mutlu Hayran","route":"/people/kadir-mutlu-hayran/","asOf":"2026-09-10","days":11},{"id":"robyn-ward","kind":"person","name":"Robyn Ward","route":"/people/robyn-ward/","asOf":"2026-09-10","days":11},{"id":"gerardo-legaspi","kind":"person","name":"Gerardo D. Legaspi","route":"/people/gerardo-legaspi/","asOf":"2026-09-10","days":11},{"id":"erik-wexler","kind":"person","name":"Erik G. Wexler","route":"/people/erik-wexler/","asOf":"2026-09-10","days":11},{"id":"brandon-wainwright","kind":"person","name":"Brandon Wainwright","route":"/people/brandon-wainwright/","asOf":"2026-09-10","days":11},{"id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","route":"/people/hitoshi-ishikawa/","asOf":"2026-09-10","days":11},{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","asOf":"2026-09-10","days":11},{"id":"atiporn-ingsathit","kind":"person","name":"Atiporn Ingsathit","route":"/people/atiporn-ingsathit/","asOf":"2026-09-10","days":11},{"id":"michal-mekel","kind":"person","name":"Michal Mekel","route":"/people/michal-mekel/","asOf":"2026-09-10","days":11},{"id":"john-stagg","kind":"person","name":"John Stagg","route":"/people/john-stagg/","asOf":"2026-09-10","days":11},{"id":"robert-peel","kind":"person","name":"Robert Peel","route":"/people/robert-peel/","asOf":"2026-09-10","days":11},{"id":"yoon-seung-kew","kind":"person","name":"Yoon Seung-kew","route":"/people/yoon-seung-kew/","asOf":"2026-09-10","days":11},{"id":"katsuhiko-uesaka","kind":"person","name":"Katsuhiko Uesaka","route":"/people/katsuhiko-uesaka/","asOf":"2026-09-10","days":11},{"id":"yongyut-sirivatanauksorn","kind":"person","name":"Yongyut Sirivatanauksorn","route":"/people/yongyut-sirivatanauksorn/","asOf":"2026-09-10","days":11},{"id":"monika-krzyzanowska","kind":"person","name":"Monika Krzyzanowska","route":"/people/monika-krzyzanowska/","asOf":"2026-09-10","days":11},{"id":"vincenza-trivigno","kind":"person","name":"Vincenza Trivigno","route":"/people/vincenza-trivigno/","asOf":"2026-09-10","days":11},{"id":"brendan-brown","kind":"person","name":"Brendan Brown","route":"/people/brendan-brown/","asOf":"2026-09-10","days":11},{"id":"philippe-bergerot","kind":"person","name":"Philippe Bergerot","route":"/people/philippe-bergerot/","asOf":"2026-09-10","days":11},{"id":"gemma-peters","kind":"person","name":"Gemma Peters","route":"/people/gemma-peters/","asOf":"2026-09-10","days":11},{"id":"matthew-reed","kind":"person","name":"Matthew Reed","route":"/people/matthew-reed/","asOf":"2026-09-10","days":11},{"id":"andrew-little","kind":"person","name":"Andrew Little","route":"/people/andrew-little/","asOf":"2026-09-10","days":11},{"id":"mohamed-abdel-moaty-samra","kind":"person","name":"Mohamed Abdel Moaty Samra","route":"/people/mohamed-abdel-moaty-samra/","asOf":"2026-09-10","days":11},{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","asOf":"2026-09-10","days":11},{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","route":"/people/magdolna-dank/","asOf":"2026-09-10","days":11},{"id":"timothy-robinson","kind":"person","name":"Timothy Robinson","route":"/people/timothy-robinson/","asOf":"2026-09-10","days":11},{"id":"senthil-muthuswamy","kind":"person","name":"Senthil K. Muthuswamy","route":"/people/senthil-muthuswamy/","asOf":"2026-09-10","days":11},{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","route":"/people/sirpa-leppa/","asOf":"2026-09-10","days":11},{"id":"richard-barakat","kind":"person","name":"Richard Barakat","route":"/people/richard-barakat/","asOf":"2026-09-10","days":11},{"id":"diwani-msemo","kind":"person","name":"Diwani Msemo","route":"/people/diwani-msemo/","asOf":"2026-09-10","days":11},{"id":"marco-herold","kind":"person","name":"Marco Herold","route":"/people/marco-herold/","asOf":"2026-09-10","days":11},{"id":"nariaki-matsuura","kind":"person","name":"Nariaki Matsuura","route":"/people/nariaki-matsuura/","asOf":"2026-09-10","days":11},{"id":"mark-middleton","kind":"person","name":"Mark Middleton","route":"/people/mark-middleton/","asOf":"2026-09-10","days":11},{"id":"alicia-jackson","kind":"person","name":"Alicia Jackson","route":"/people/alicia-jackson/","asOf":"2026-09-10","days":11},{"id":"leandro-pinheiro-safatle","kind":"person","name":"Leandro Pinheiro Safatle","route":"/people/leandro-pinheiro-safatle/","asOf":"2026-09-10","days":11},{"id":"yasumasa-niwa","kind":"person","name":"Yasumasa Niwa","route":"/people/yasumasa-niwa/","asOf":"2026-09-10","days":11},{"id":"robert-negrin","kind":"person","name":"Robert Negrin","route":"/people/robert-negrin/","asOf":"2026-09-10","days":11},{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","asOf":"2026-09-10","days":11},{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","route":"/people/sebastien-armanet/","asOf":"2026-09-10","days":11},{"id":"paris-ann-ingledew","kind":"person","name":"Paris-Ann Ingledew","route":"/people/paris-ann-ingledew/","asOf":"2026-09-10","days":11},{"id":"nadine-karema","kind":"person","name":"Nadine Karema","route":"/people/nadine-karema/","asOf":"2026-09-10","days":11},{"id":"andrea-seale","kind":"person","name":"Andrea Seale","route":"/people/andrea-seale/","asOf":"2026-09-10","days":11},{"id":"brenda-hubley","kind":"person","name":"Brenda Hubley","route":"/people/brenda-hubley/","asOf":"2026-09-10","days":11},{"id":"jacinta-reddan","kind":"person","name":"Jacinta Reddan","route":"/people/jacinta-reddan/","asOf":"2026-09-10","days":11},{"id":"seyed-rouhollah-miri","kind":"person","name":"Seyed Rouhollah Miri","route":"/people/seyed-rouhollah-miri/","asOf":"2026-09-10","days":11},{"id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","route":"/people/oscar-arrieta-rodriguez/","asOf":"2026-09-10","days":11},{"id":"francisco-berrospi-espinoza","kind":"person","name":"Francisco Berrospi Espinoza","route":"/people/francisco-berrospi-espinoza/","asOf":"2026-09-10","days":11},{"id":"carla-goncalo","kind":"person","name":"Carla Gonçalo","route":"/people/carla-goncalo/","asOf":"2026-09-10","days":11},{"id":"julio-oliveira","kind":"person","name":"Júlio Oliveira","route":"/people/julio-oliveira/","asOf":"2026-09-10","days":11},{"id":"derrick-haslem","kind":"person","name":"Derrick S. Haslem","route":"/people/derrick-haslem/","asOf":"2026-09-10","days":11},{"id":"franco-cavalli","kind":"person","name":"Franco Cavalli","route":"/people/franco-cavalli/","asOf":"2026-09-10","days":11},{"id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/","asOf":"2026-09-10","days":11},{"id":"cristina-marchesi","kind":"person","name":"Cristina Marchesi","route":"/people/cristina-marchesi/","asOf":"2026-09-10","days":11},{"id":"nikki-gallagher","kind":"person","name":"Nikki Gallagher","route":"/people/nikki-gallagher/","asOf":"2026-09-10","days":11},{"id":"maurizio-di-mauro","kind":"person","name":"Maurizio Di Mauro","route":"/people/maurizio-di-mauro/","asOf":"2026-09-10","days":11},{"id":"chris-hillis","kind":"person","name":"Chris Hillis","route":"/people/chris-hillis/","asOf":"2026-09-10","days":11},{"id":"nei-min-chu","kind":"person","name":"Nei-Min Chu","route":"/people/nei-min-chu/","asOf":"2026-09-10","days":11},{"id":"yakubu-seidu-adam","kind":"person","name":"Yakubu Seidu Adam","route":"/people/yakubu-seidu-adam/","asOf":"2026-09-10","days":11},{"id":"carla-van-gils","kind":"person","name":"Carla van Gils","route":"/people/carla-van-gils/","asOf":"2026-09-10","days":11},{"id":"yasuharu-nakashima","kind":"person","name":"Yasuharu Nakashima","route":"/people/yasuharu-nakashima/","asOf":"2026-09-10","days":11},{"id":"robert-figlin","kind":"person","name":"Robert Figlin","route":"/people/robert-figlin/","asOf":"2026-09-10","days":11},{"id":"emmanuel-barranger","kind":"person","name":"Emmanuel Barranger","route":"/people/emmanuel-barranger/","asOf":"2026-09-10","days":11},{"id":"marie-eve-desrosiers","kind":"person","name":"Marie-Eve Desrosiers","route":"/people/marie-eve-desrosiers/","asOf":"2026-09-10","days":11},{"id":"ashley-ball-gamble","kind":"person","name":"Ashley Ball-Gamble","route":"/people/ashley-ball-gamble/","asOf":"2026-09-10","days":11},{"id":"michael-boyer","kind":"person","name":"Michael Boyer","route":"/people/michael-boyer/","asOf":"2026-09-10","days":11},{"id":"princess-chulabhorn","kind":"person","name":"Princess Chulabhorn","route":"/people/princess-chulabhorn/","asOf":"2026-09-10","days":11},{"id":"annette-walker","kind":"person","name":"Annette Walker","route":"/people/annette-walker/","asOf":"2026-09-10","days":11},{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","asOf":"2026-09-10","days":11},{"id":"elisabeth-schorb","kind":"person","name":"Elisabeth Schorb","route":"/people/elisabeth-schorb/","asOf":"2026-09-10","days":11},{"id":"ralf-c-bargou","kind":"person","name":"Ralf C. Bargou","route":"/people/ralf-c-bargou/","asOf":"2026-09-10","days":11},{"id":"yung-s-lie","kind":"person","name":"Yung S. Lie","route":"/people/yung-s-lie/","asOf":"2026-09-10","days":11},{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","route":"/people/rita-schmutzler/","asOf":"2026-09-10","days":11},{"id":"eniarti","kind":"person","name":"Eniarti","route":"/people/eniarti/","asOf":"2026-09-10","days":11},{"id":"wayne-roberts","kind":"person","name":"Wayne Roberts","route":"/people/wayne-roberts/","asOf":"2026-09-10","days":11},{"id":"tariq-enver","kind":"person","name":"Tariq Enver","route":"/people/tariq-enver/","asOf":"2026-09-10","days":11},{"id":"axel-behrens","kind":"person","name":"Axel Behrens","route":"/people/axel-behrens/","asOf":"2026-09-10","days":11},{"id":"kent-stobart","kind":"person","name":"Kent Stobart","route":"/people/kent-stobart/","asOf":"2026-09-10","days":11},{"id":"ramon-salazar-soler","kind":"person","name":"Ramon Salazar i Soler","route":"/people/ramon-salazar-soler/","asOf":"2026-09-10","days":11},{"id":"rajeev-singh-raghuvanshi","kind":"person","name":"Rajeev Singh Raghuvanshi","route":"/people/rajeev-singh-raghuvanshi/","asOf":"2026-09-10","days":11},{"id":"renaud-de-crevoisier","kind":"person","name":"Renaud de Crevoisier","route":"/people/renaud-de-crevoisier/","asOf":"2026-09-10","days":11},{"id":"roman-rouzier","kind":"person","name":"Roman Rouzier","route":"/people/roman-rouzier/","asOf":"2026-09-10","days":11},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","asOf":"2026-09-10","days":11},{"id":"frederique-penault-llorca","kind":"person","name":"Frédérique Penault-Llorca","route":"/people/frederique-penault-llorca/","asOf":"2026-09-10","days":11},{"id":"giuseppe-tonutti","kind":"person","name":"Giuseppe Tonutti","route":"/people/giuseppe-tonutti/","asOf":"2026-09-10","days":11},{"id":"richard-van-etten","kind":"person","name":"Richard Van Etten","route":"/people/richard-van-etten/","asOf":"2026-09-10","days":11},{"id":"sandile-mfenyana","kind":"person","name":"Sandile Mfenyana","route":"/people/sandile-mfenyana/","asOf":"2026-09-10","days":11},{"id":"biju-george","kind":"person","name":"Biju George","route":"/people/biju-george/","asOf":"2026-09-10","days":11},{"id":"martin-beaumont","kind":"person","name":"Martin Beaumont","route":"/people/martin-beaumont/","asOf":"2026-09-10","days":11},{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","route":"/people/pavan-reddy/","asOf":"2026-09-10","days":11},{"id":"john-kennedy","kind":"person","name":"John Kennedy","route":"/people/john-kennedy/","asOf":"2026-09-10","days":11},{"id":"pia-vihinen","kind":"person","name":"Pia Vihinen","route":"/people/pia-vihinen/","asOf":"2026-09-10","days":11},{"id":"jesse-otegbayo","kind":"person","name":"Jesse Abiodun Otegbayo","route":"/people/jesse-otegbayo/","asOf":"2026-09-10","days":11},{"id":"ate-van-der-zee","kind":"person","name":"Ate van der Zee","route":"/people/ate-van-der-zee/","asOf":"2026-09-10","days":11},{"id":"dan-theodorescu","kind":"person","name":"Dan Theodorescu","route":"/people/dan-theodorescu/","asOf":"2026-09-10","days":11},{"id":"thomas-george","kind":"person","name":"Thomas J. George","route":"/people/thomas-george/","asOf":"2026-09-10","days":11},{"id":"michael-kerin","kind":"person","name":"Michael Kerin","route":"/people/michael-kerin/","asOf":"2026-09-10","days":11},{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","route":"/people/naoto-ueno/","asOf":"2026-09-10","days":11},{"id":"christian-capitini","kind":"person","name":"Christian Capitini","route":"/people/christian-capitini/","asOf":"2026-09-10","days":11},{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","route":"/people/thomas-loughran/","asOf":"2026-09-10","days":11},{"id":"robert-winn","kind":"person","name":"Robert A. Winn","route":"/people/robert-winn/","asOf":"2026-09-10","days":11},{"id":"christian-sauvr","kind":"person","name":"Christian Sauvr","route":"/people/christian-sauvr/","asOf":"2026-09-10","days":11},{"id":"tammy-quigley","kind":"person","name":"Tammy Quigley","route":"/people/tammy-quigley/","asOf":"2026-09-10","days":11},{"id":"kirsten-major","kind":"person","name":"Kirsten Major","route":"/people/kirsten-major/","asOf":"2026-09-10","days":11},{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","route":"/people/valdas-peceliunas/","asOf":"2026-09-10","days":11},{"id":"ls-shashidhara","kind":"person","name":"L. S. Shashidhara","route":"/people/ls-shashidhara/","asOf":"2026-09-10","days":11},{"id":"sunil-kumar-barnwal","kind":"person","name":"Sunil Kumar Barnwal","route":"/people/sunil-kumar-barnwal/","asOf":"2026-09-10","days":11},{"id":"mostafa-aziz-sumon","kind":"person","name":"Mostafa Aziz Sumon","route":"/people/mostafa-aziz-sumon/","asOf":"2026-09-10","days":11},{"id":"huang-guo","kind":"person","name":"Huang Guo","route":"/people/huang-guo/","asOf":"2026-09-10","days":11},{"id":"anthony-may","kind":"person","name":"Anthony May","route":"/people/anthony-may/","asOf":"2026-09-10","days":11},{"id":"nicole-boutilier","kind":"person","name":"Nicole Boutilier","route":"/people/nicole-boutilier/","asOf":"2026-09-10","days":11},{"id":"valery-lemmens","kind":"person","name":"Valery Lemmens","route":"/people/valery-lemmens/","asOf":"2026-09-10","days":11},{"id":"jon-irish","kind":"person","name":"Jon Irish","route":"/people/jon-irish/","asOf":"2026-09-10","days":11},{"id":"zhang-shuyang","kind":"person","name":"Zhang Shuyang","route":"/people/zhang-shuyang/","asOf":"2026-09-10","days":11},{"id":"lyn-simpson","kind":"person","name":"Lyn Simpson","route":"/people/lyn-simpson/","asOf":"2026-09-10","days":11},{"id":"bertine-lahuis","kind":"person","name":"Bertine Lahuis","route":"/people/bertine-lahuis/","asOf":"2026-09-10","days":11},{"id":"dharmendra-singh-gangwar","kind":"person","name":"Dharmendra Singh Gangwar","route":"/people/dharmendra-singh-gangwar/","asOf":"2026-09-10","days":11},{"id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","route":"/people/vadims-beluns/","asOf":"2026-09-10","days":11},{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","route":"/people/steven-k-libutti/","asOf":"2026-09-10","days":11},{"id":"christos-fasianos","kind":"person","name":"Christos Fasianos","route":"/people/christos-fasianos/","asOf":"2026-09-10","days":11},{"id":"nicole-scobie","kind":"person","name":"Nicole Scobie","route":"/people/nicole-scobie/","asOf":"2026-09-10","days":11},{"id":"farhat-abbas","kind":"person","name":"Farhat Abbas","route":"/people/farhat-abbas/","asOf":"2026-09-10","days":11},{"id":"rashid-khalani","kind":"person","name":"Rashid Khalani","route":"/people/rashid-khalani/","asOf":"2026-09-10","days":11},{"id":"ali-taher","kind":"person","name":"Ali Taher","route":"/people/ali-taher/","asOf":"2026-09-10","days":11},{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","route":"/people/hans-van-goudoever/","asOf":"2026-09-10","days":11},{"id":"timur-atsuren","kind":"person","name":"Timur Atsüren","route":"/people/timur-atsuren/","asOf":"2026-09-10","days":11},{"id":"luigi-cajazzo","kind":"person","name":"Luigi Cajazzo","route":"/people/luigi-cajazzo/","asOf":"2026-09-10","days":11},{"id":"ruben-mesa","kind":"person","name":"Ruben Mesa","route":"/people/ruben-mesa/","asOf":"2026-09-10","days":11},{"id":"dale-bramley","kind":"person","name":"Dale Bramley","route":"/people/dale-bramley/","asOf":"2026-09-10","days":11},{"id":"davide-fornaciari","kind":"person","name":"Davide Fornaciari","route":"/people/davide-fornaciari/","asOf":"2026-09-10","days":11},{"id":"inge-buyse","kind":"person","name":"Inge Buyse","route":"/people/inge-buyse/","asOf":"2026-09-10","days":11},{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","route":"/people/boris-pasche/","asOf":"2026-09-10","days":11},{"id":"patrick-morris","kind":"person","name":"Patrick G. Morris","route":"/people/patrick-morris/","asOf":"2026-09-10","days":11},{"id":"denise-soares-dos-santos","kind":"person","name":"Denise Soares dos Santos","route":"/people/denise-soares-dos-santos/","asOf":"2026-09-10","days":11},{"id":"maria-kane","kind":"person","name":"Maria Kane","route":"/people/maria-kane/","asOf":"2026-09-10","days":11},{"id":"rohit-bhargava","kind":"person","name":"Rohit Bhargava","route":"/people/rohit-bhargava/","asOf":"2026-09-10","days":11},{"id":"monica-calamai","kind":"person","name":"Monica Calamai","route":"/people/monica-calamai/","asOf":"2026-09-10","days":11},{"id":"claudio-cracco","kind":"person","name":"Claudio Cracco","route":"/people/claudio-cracco/","asOf":"2026-09-10","days":11},{"id":"paa-kwesi-baidoo","kind":"person","name":"Paa Kwesi Baidoo","route":"/people/paa-kwesi-baidoo/","asOf":"2026-09-10","days":11},{"id":"satu-tiainen","kind":"person","name":"Satu Tiainen","route":"/people/satu-tiainen/","asOf":"2026-09-10","days":11},{"id":"richard-mitchell","kind":"person","name":"Richard Mitchell","route":"/people/richard-mitchell/","asOf":"2026-09-10","days":11},{"id":"ida-danmark","kind":"person","name":"Ida Danmark","route":"/people/ida-danmark/","asOf":"2026-09-10","days":11},{"id":"helen-mertens","kind":"person","name":"Helen Mertens","route":"/people/helen-mertens/","asOf":"2026-09-10","days":11},{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","route":"/people/jeffrey-miller/","asOf":"2026-09-10","days":11},{"id":"abhay-soi","kind":"person","name":"Abhay Soi","route":"/people/abhay-soi/","asOf":"2026-09-10","days":11},{"id":"lei-zheng","kind":"person","name":"Lei Zheng","route":"/people/lei-zheng/","asOf":"2026-09-10","days":11},{"id":"lucie-opatrny","kind":"person","name":"Lucie Opatrny","route":"/people/lucie-opatrny/","asOf":"2026-09-10","days":11},{"id":"philip-kirwa","kind":"person","name":"Philip K. Kirwa","route":"/people/philip-kirwa/","asOf":"2026-09-10","days":11},{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","route":"/people/ulrich-steidl/","asOf":"2026-09-10","days":11},{"id":"martin-armstrong","kind":"person","name":"Martin Armstrong","route":"/people/martin-armstrong/","asOf":"2026-09-10","days":11},{"id":"raymond-dubois","kind":"person","name":"Raymond N. DuBois","route":"/people/raymond-dubois/","asOf":"2026-09-10","days":11},{"id":"erez-barenboim","kind":"person","name":"Erez Barenboim","route":"/people/erez-barenboim/","asOf":"2026-09-10","days":11},{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","asOf":"2026-09-10","days":11},{"id":"xiao-haipeng","kind":"person","name":"Xiao Haipeng","route":"/people/xiao-haipeng/","asOf":"2026-09-10","days":11},{"id":"robert-uzzo","kind":"person","name":"Robert G. Uzzo","route":"/people/robert-uzzo/","asOf":"2026-09-10","days":11},{"id":"joann-sweasy","kind":"person","name":"Joann B. Sweasy","route":"/people/joann-sweasy/","asOf":"2026-09-10","days":11},{"id":"antonio-llombart-bosch","kind":"person","name":"Antonio Llombart Bosch","route":"/people/antonio-llombart-bosch/","asOf":"2026-09-10","days":11},{"id":"vicente-borrero","kind":"person","name":"Vicente Borrero","route":"/people/vicente-borrero/","asOf":"2026-09-10","days":11},{"id":"zhang-jiangong","kind":"person","name":"Zhang Jiangong","route":"/people/zhang-jiangong/","asOf":"2026-09-10","days":11},{"id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/","asOf":"2026-09-10","days":11},{"id":"mark-burkard","kind":"person","name":"Mark E. Burkard","route":"/people/mark-burkard/","asOf":"2026-09-10","days":11},{"id":"jean-francois-fortin-verreault","kind":"person","name":"Jean-François Fortin Verreault","route":"/people/jean-francois-fortin-verreault/","asOf":"2026-09-10","days":11},{"id":"flavio-tomasich","kind":"person","name":"Flávio Daniel Saavedra Tomasich","route":"/people/flavio-tomasich/","asOf":"2026-09-10","days":11},{"id":"reuben-shaw","kind":"person","name":"Reuben Shaw","route":"/people/reuben-shaw/","asOf":"2026-09-10","days":11},{"id":"paul-boutros","kind":"person","name":"Paul Boutros","route":"/people/paul-boutros/","asOf":"2026-09-10","days":11},{"id":"deb-bulych","kind":"person","name":"Deb Bulych","route":"/people/deb-bulych/","asOf":"2026-09-10","days":11},{"id":"yu-jinming","kind":"person","name":"Yu Jinming","route":"/people/yu-jinming/","asOf":"2026-09-10","days":11},{"id":"faisal-sultan","kind":"person","name":"Faisal Sultan","route":"/people/faisal-sultan/","asOf":"2026-09-10","days":11},{"id":"lin-tongyu","kind":"person","name":"Lin Tongyu","route":"/people/lin-tongyu/","asOf":"2026-09-10","days":11},{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","asOf":"2026-09-10","days":11},{"id":"david-fennelly","kind":"person","name":"David Fennelly","route":"/people/david-fennelly/","asOf":"2026-09-10","days":11},{"id":"kathleen-ruddy","kind":"person","name":"Kathleen Ruddy","route":"/people/kathleen-ruddy/","asOf":"2026-09-10","days":11},{"id":"lehlohonolo-majake","kind":"person","name":"Lehlohonolo Majake","route":"/people/lehlohonolo-majake/","asOf":"2026-09-10","days":11},{"id":"priit-perens","kind":"person","name":"Priit Perens","route":"/people/priit-perens/","asOf":"2026-09-10","days":11},{"id":"annika-auranen","kind":"person","name":"Annika Auranen","route":"/people/annika-auranen/","asOf":"2026-09-10","days":11},{"id":"jim-woodgett","kind":"person","name":"Jim Woodgett","route":"/people/jim-woodgett/","asOf":"2026-09-10","days":11},{"id":"joan-spencer","kind":"person","name":"Joan Spencer","route":"/people/joan-spencer/","asOf":"2026-09-10","days":11},{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","route":"/people/karolina-palucka/","asOf":"2026-09-10","days":11},{"id":"ankita-mishra-bundela","kind":"person","name":"Ankita Mishra Bundela","route":"/people/ankita-mishra-bundela/","asOf":"2026-09-10","days":11},{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","route":"/people/dario-altieri/","asOf":"2026-09-10","days":11},{"id":"jihui-hao","kind":"person","name":"Jihui Hao","route":"/people/jihui-hao/","asOf":"2026-09-10","days":11},{"id":"hu-junbo","kind":"person","name":"Hu Junbo","route":"/people/hu-junbo/","asOf":"2026-09-10","days":11},{"id":"julian-redhead","kind":"person","name":"Julian Redhead","route":"/people/julian-redhead/","asOf":"2026-09-10","days":11},{"id":"govindan-rangarajan","kind":"person","name":"Govindan Rangarajan","route":"/people/govindan-rangarajan/","asOf":"2026-09-10","days":11},{"id":"d-wade-clapp","kind":"person","name":"D. Wade Clapp","route":"/people/d-wade-clapp/","asOf":"2026-09-10","days":11},{"id":"pamela-kearns","kind":"person","name":"Pamela Kearns","route":"/people/pamela-kearns/","asOf":"2026-09-10","days":11},{"id":"mario-campone","kind":"person","name":"Mario Campone","route":"/people/mario-campone/","asOf":"2026-09-10","days":11},{"id":"marc-ychou","kind":"person","name":"Marc Ychou","route":"/people/marc-ychou/","asOf":"2026-09-10","days":11},{"id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","asOf":"2026-09-10","days":11},{"id":"brahim-lakhal","kind":"person","name":"Brahim Lakhal","route":"/people/brahim-lakhal/","asOf":"2026-09-10","days":11},{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","asOf":"2026-09-10","days":11},{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/","asOf":"2026-09-10","days":11},{"id":"roxana-del-aguila","kind":"person","name":"Roxana del Águila","route":"/people/roxana-del-aguila/","asOf":"2026-09-10","days":11},{"id":"arthur-violante-sapia","kind":"person","name":"Arthur Violante Sapia","route":"/people/arthur-violante-sapia/","asOf":"2026-09-10","days":11},{"id":"susana-blanco","kind":"person","name":"Susana Blanco","route":"/people/susana-blanco/","asOf":"2026-09-10","days":11},{"id":"mauricio-cuello","kind":"person","name":"Mauricio Cuello","route":"/people/mauricio-cuello/","asOf":"2026-09-10","days":11},{"id":"ander-urruticoechea","kind":"person","name":"Ander Urruticoechea","route":"/people/ander-urruticoechea/","asOf":"2026-09-10","days":11},{"id":"mohammed-bin-khalifa-al-suwaidi","kind":"person","name":"Mohammed bin Khalifa Al Suwaidi","route":"/people/mohammed-bin-khalifa-al-suwaidi/","asOf":"2026-09-10","days":11},{"id":"rachel-dunscombe","kind":"person","name":"Rachel Dunscombe","route":"/people/rachel-dunscombe/","asOf":"2026-09-10","days":11},{"id":"zoe-robledo","kind":"person","name":"Zoé Robledo","route":"/people/zoe-robledo/","asOf":"2026-09-10","days":11},{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","route":"/people/esteban-langlois/","asOf":"2026-09-10","days":11},{"id":"jose-luis-poveda-andres","kind":"person","name":"José Luis Poveda Andrés","route":"/people/jose-luis-poveda-andres/","asOf":"2026-09-10","days":11},{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","asOf":"2026-09-10","days":11},{"id":"massimo-de-fino","kind":"person","name":"Massimo De Fino","route":"/people/massimo-de-fino/","asOf":"2026-09-10","days":11},{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","asOf":"2026-09-10","days":11},{"id":"t-naveen","kind":"person","name":"T. Naveen","route":"/people/t-naveen/","asOf":"2026-09-10","days":11},{"id":"shaheem-de-vries","kind":"person","name":"Shaheem de Vries","route":"/people/shaheem-de-vries/","asOf":"2026-09-10","days":11},{"id":"xiang-hua","kind":"person","name":"Xiang Hua","route":"/people/xiang-hua/","asOf":"2026-09-10","days":11},{"id":"shalini-singh","kind":"person","name":"Shalini Singh","route":"/people/shalini-singh/","asOf":"2026-09-10","days":11},{"id":"lp-mtshali","kind":"person","name":"L.P. Mtshali","route":"/people/lp-mtshali/","asOf":"2026-09-10","days":11},{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","route":"/people/joseph-gligorov/","asOf":"2026-09-10","days":11},{"id":"luis-eduardo-martin-rodriguez","kind":"person","name":"Luis Eduardo Martín Rodríguez","route":"/people/luis-eduardo-martin-rodriguez/","asOf":"2026-09-10","days":11},{"id":"berta-cerda-alvarez","kind":"person","name":"Berta Cerda Álvarez","route":"/people/berta-cerda-alvarez/","asOf":"2026-09-10","days":11},{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","asOf":"2026-09-10","days":11},{"id":"victor-piana-de-andrade","kind":"person","name":"Victor Piana de Andrade","route":"/people/victor-piana-de-andrade/","asOf":"2026-09-10","days":11},{"id":"laura-skaife-knight","kind":"person","name":"Laura Skaife-Knight","route":"/people/laura-skaife-knight/","asOf":"2026-09-10","days":11},{"id":"shaikh-fahad-bin-khalifa-al-khalifa","kind":"person","name":"Shaikh Fahad bin Khalifa bin Salman Al Khalifa","route":"/people/shaikh-fahad-bin-khalifa-al-khalifa/","asOf":"2026-09-10","days":11},{"id":"susan-msadabwe","kind":"person","name":"Susan C. Msadabwe","route":"/people/susan-msadabwe/","asOf":"2026-09-10","days":11},{"id":"nicolas-revel","kind":"person","name":"Nicolas Revel","route":"/people/nicolas-revel/","asOf":"2026-09-10","days":11},{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","asOf":"2026-09-10","days":11},{"id":"sherif-abouel-naga","kind":"person","name":"Sherif Abouel Naga","route":"/people/sherif-abouel-naga/","asOf":"2026-09-10","days":11},{"id":"fan-daiming","kind":"person","name":"Fan Daiming","route":"/people/fan-daiming/","asOf":"2026-09-10","days":11},{"id":"wang-ying","kind":"person","name":"Wang Ying","route":"/people/wang-ying/","asOf":"2026-09-10","days":11},{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","route":"/people/dearbhaile-collins/","asOf":"2026-09-10","days":11},{"id":"jennifer-welsh","kind":"person","name":"Jennifer Welsh","route":"/people/jennifer-welsh/","asOf":"2026-09-10","days":11},{"id":"rene-medema","kind":"person","name":"René Medema","route":"/people/rene-medema/","asOf":"2026-09-10","days":11},{"id":"andrew-mesecar","kind":"person","name":"Andrew Mesecar","route":"/people/andrew-mesecar/","asOf":"2026-09-10","days":11},{"id":"geraline-leusink","kind":"person","name":"Geraline Leusink","route":"/people/geraline-leusink/","asOf":"2026-09-10","days":11},{"id":"xia-jiahong","kind":"person","name":"Xia Jiahong","route":"/people/xia-jiahong/","asOf":"2026-09-10","days":11},{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","route":"/people/taofeek-owonikoko/","asOf":"2026-09-10","days":11},{"id":"tan-weihong","kind":"person","name":"Tan Weihong","route":"/people/tan-weihong/","asOf":"2026-09-10","days":11},{"id":"niels-norgaard-pedersen","kind":"person","name":"Niels Nørgaard Pedersen","route":"/people/niels-norgaard-pedersen/","asOf":"2026-09-10","days":11},{"id":"lars-dahl-pedersen","kind":"person","name":"Lars Dahl Pedersen","route":"/people/lars-dahl-pedersen/","asOf":"2026-09-10","days":11},{"id":"ricco-norman-dyhr","kind":"person","name":"Ricco Norman Dyhr","route":"/people/ricco-norman-dyhr/","asOf":"2026-09-10","days":11},{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","asOf":"2026-09-10","days":11},{"id":"tarmo-bakler","kind":"person","name":"Tarmo Bakler","route":"/people/tarmo-bakler/","asOf":"2026-09-10","days":11},{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","asOf":"2026-09-10","days":11},{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","asOf":"2026-09-10","days":11},{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","asOf":"2026-09-10","days":11},{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","asOf":"2026-09-10","days":11},{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","asOf":"2026-09-10","days":11},{"id":"didier-peiffert","kind":"person","name":"Didier Peiffert","route":"/people/didier-peiffert/","asOf":"2026-09-10","days":11},{"id":"vigdis-hallgrimsdottir","kind":"person","name":"Vigdís Hallgrímsdóttir","route":"/people/vigdis-hallgrimsdottir/","asOf":"2026-09-10","days":11},{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","asOf":"2026-09-10","days":11},{"id":"anne-coyle","kind":"person","name":"Anne Coyle","route":"/people/anne-coyle/","asOf":"2026-09-10","days":11},{"id":"jerome-coffey","kind":"person","name":"Jerome Coffey","route":"/people/jerome-coffey/","asOf":"2026-09-10","days":11},{"id":"emma-browne","kind":"person","name":"Emma Browne","route":"/people/emma-browne/","asOf":"2026-09-10","days":11},{"id":"ilaria-panzini","kind":"person","name":"Ilaria Panzini","route":"/people/ilaria-panzini/","asOf":"2026-09-10","days":11},{"id":"carlo-cimbri","kind":"person","name":"Carlo Cimbri","route":"/people/carlo-cimbri/","asOf":"2026-09-10","days":11},{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","route":"/people/andrea-agnelli/","asOf":"2026-09-10","days":11},{"id":"mario-taccolini","kind":"person","name":"Mario Taccolini","route":"/people/mario-taccolini/","asOf":"2026-09-10","days":11},{"id":"alessandro-venturi","kind":"person","name":"Alessandro Venturi","route":"/people/alessandro-venturi/","asOf":"2026-09-10","days":11},{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","asOf":"2026-09-10","days":11},{"id":"audrius-simaitis","kind":"person","name":"Audrius Šimaitis","route":"/people/audrius-simaitis/","asOf":"2026-09-10","days":11},{"id":"jakub-kraszewski","kind":"person","name":"Jakub Kraszewski","route":"/people/jakub-kraszewski/","asOf":"2026-09-10","days":11},{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","asOf":"2026-09-10","days":11},{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","asOf":"2026-09-10","days":11},{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","route":"/people/albert-salazar-soler/","asOf":"2026-09-10","days":11},{"id":"anton-benet-catala","kind":"person","name":"Anton Benet Català","route":"/people/anton-benet-catala/","asOf":"2026-09-10","days":11},{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","asOf":"2026-09-10","days":11},{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","asOf":"2026-09-10","days":11},{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","asOf":"2026-09-10","days":11},{"id":"ben-o-sullivan","kind":"person","name":"Ben O'Sullivan","route":"/people/ben-o-sullivan/","asOf":"2026-09-10","days":11},{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","asOf":"2026-09-10","days":11},{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","asOf":"2026-09-10","days":11},{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","asOf":"2026-09-10","days":11},{"id":"giuliana-cardenas-gamarra","kind":"person","name":"Giuliana Càrdenas Gamarra","route":"/people/giuliana-cardenas-gamarra/","asOf":"2026-09-10","days":11},{"id":"mirela-grosu","kind":"person","name":"Mirela Grosu","route":"/people/mirela-grosu/","asOf":"2026-09-10","days":11},{"id":"cesar-gregorio-munoz-sanchez-miguel","kind":"person","name":"César Gregorio Muñoz Sánchez-Miguel","route":"/people/cesar-gregorio-munoz-sanchez-miguel/","asOf":"2026-09-10","days":11},{"id":"jesus-fernandez-galan","kind":"person","name":"Jesús Fernández Galán","route":"/people/jesus-fernandez-galan/","asOf":"2026-09-10","days":11},{"id":"luis-ibanez-gadea","kind":"person","name":"Luis Ibáñez Gadea","route":"/people/luis-ibanez-gadea/","asOf":"2026-09-10","days":11},{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","asOf":"2026-09-10","days":11},{"id":"jonas-claesson","kind":"person","name":"Jonas Claesson","route":"/people/jonas-claesson/","asOf":"2026-09-10","days":11},{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","asOf":"2026-09-10","days":11},{"id":"rosaline-den-blanken","kind":"person","name":"Rosaline den Blanken","route":"/people/rosaline-den-blanken/","asOf":"2026-09-10","days":11},{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","asOf":"2026-09-10","days":11},{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","asOf":"2026-09-10","days":11},{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","asOf":"2026-09-10","days":11},{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","asOf":"2026-09-10","days":11},{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","route":"/people/sacha-gougnard/","asOf":"2026-09-10","days":11},{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","asOf":"2026-09-10","days":11},{"id":"rolando-medeiros","kind":"person","name":"Rolando Medeiros","route":"/people/rolando-medeiros/","asOf":"2026-09-10","days":11},{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","asOf":"2026-09-10","days":11},{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","asOf":"2026-09-10","days":11},{"id":"panos-ergatoudes","kind":"person","name":"Panos Ergatoudes","route":"/people/panos-ergatoudes/","asOf":"2026-09-10","days":11},{"id":"petr-poloucek","kind":"person","name":"Petr Polouček","route":"/people/petr-poloucek/","asOf":"2026-09-10","days":11},{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","asOf":"2026-09-10","days":11},{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","asOf":"2026-09-10","days":11},{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","asOf":"2026-09-10","days":11},{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","asOf":"2026-09-10","days":11},{"id":"panagiotis-klirides","kind":"person","name":"Panagiotis Klirides","route":"/people/panagiotis-klirides/","asOf":"2026-09-10","days":11},{"id":"sarantos-efstathopoulos","kind":"person","name":"Sarantos Efstathopoulos","route":"/people/sarantos-efstathopoulos/","asOf":"2026-09-10","days":11},{"id":"joseph-martin","kind":"person","name":"Joseph Martin","route":"/people/joseph-martin/","asOf":"2026-09-10","days":11},{"id":"tracey-fitzpatrick","kind":"person","name":"Tracey Fitzpatrick","route":"/people/tracey-fitzpatrick/","asOf":"2026-09-10","days":11},{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","asOf":"2026-09-10","days":11},{"id":"livio-de-angelis","kind":"person","name":"Livio De Angelis","route":"/people/livio-de-angelis/","asOf":"2026-09-10","days":11},{"id":"marco-centenari","kind":"person","name":"Marco Centenari","route":"/people/marco-centenari/","asOf":"2026-09-10","days":11},{"id":"riccardo-bui","kind":"person","name":"Riccardo Bui","route":"/people/riccardo-bui/","asOf":"2026-09-10","days":11},{"id":"roberto-cunsolo","kind":"person","name":"Roberto Cunsolo","route":"/people/roberto-cunsolo/","asOf":"2026-09-10","days":11},{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","asOf":"2026-09-10","days":11},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","route":"/people/daniele-piacentini/","asOf":"2026-09-10","days":11},{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","asOf":"2026-09-10","days":11},{"id":"lauris-vidzis","kind":"person","name":"Lauris Vidzis","route":"/people/lauris-vidzis/","asOf":"2026-09-10","days":11},{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","asOf":"2026-09-10","days":11},{"id":"oystein-maeland","kind":"person","name":"Øystein Mæland","route":"/people/oystein-maeland/","asOf":"2026-09-10","days":11},{"id":"helena-isabal-roca","kind":"person","name":"Helena Isàbal Roca","route":"/people/helena-isabal-roca/","asOf":"2026-09-10","days":11},{"id":"manuel-llombart-fuertes","kind":"person","name":"Manuel Llombart Fuertes","route":"/people/manuel-llombart-fuertes/","asOf":"2026-09-10","days":11},{"id":"carmen-martinez-de-pancorbo-gonzalez","kind":"person","name":"Carmen Martínez de Pancorbo González","route":"/people/carmen-martinez-de-pancorbo-gonzalez/","asOf":"2026-09-10","days":11},{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","asOf":"2026-09-10","days":11},{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","asOf":"2026-09-10","days":11},{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","asOf":"2026-09-10","days":11},{"id":"erik-johnsson","kind":"person","name":"Erik Johnsson","route":"/people/erik-johnsson/","asOf":"2026-09-10","days":11},{"id":"karl-landergren","kind":"person","name":"Karl Landergren","route":"/people/karl-landergren/","asOf":"2026-09-10","days":11},{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","asOf":"2026-09-10","days":11},{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","asOf":"2026-09-10","days":11},{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","asOf":"2026-09-10","days":11},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","asOf":"2026-09-10","days":11},{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","asOf":"2026-09-10","days":11},{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","asOf":"2026-09-10","days":11},{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","asOf":"2026-09-10","days":11},{"id":"hugo-ford","kind":"person","name":"Hugo Ford","route":"/people/hugo-ford/","asOf":"2026-09-10","days":11},{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","asOf":"2026-09-10","days":11},{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","asOf":"2026-09-10","days":11},{"id":"georgios-kapetanakis","kind":"person","name":"Georgios Kapetanakis","route":"/people/georgios-kapetanakis/","asOf":"2026-09-10","days":11},{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","asOf":"2026-09-10","days":11},{"id":"francesco-de-lorenzo","kind":"person","name":"Francesco De Lorenzo","route":"/people/francesco-de-lorenzo/","asOf":"2026-09-10","days":11},{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","asOf":"2026-09-10","days":11},{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","asOf":"2026-09-10","days":11},{"id":"ramon-reyes-bori","kind":"person","name":"Ramón Reyes Bori","route":"/people/ramon-reyes-bori/","asOf":"2026-09-10","days":11},{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","asOf":"2026-09-10","days":11},{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","asOf":"2026-09-10","days":11},{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","asOf":"2026-09-10","days":11},{"id":"wensheng-liu","kind":"person","name":"Wensheng Liu","route":"/people/wensheng-liu/","asOf":"2026-09-10","days":11},{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","asOf":"2026-09-10","days":11},{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","asOf":"2026-09-10","days":11},{"id":"breda-duggan","kind":"person","name":"Breda Duggan","route":"/people/breda-duggan/","asOf":"2026-09-10","days":11},{"id":"maria-rosaria-iardino","kind":"person","name":"Maria Rosaria Iardino","route":"/people/maria-rosaria-iardino/","asOf":"2026-09-10","days":11},{"id":"joanna-lorenc","kind":"person","name":"Joanna Lorenc","route":"/people/joanna-lorenc/","asOf":"2026-09-10","days":11},{"id":"delia-nicoara","kind":"person","name":"Delia Nicoară","route":"/people/delia-nicoara/","asOf":"2026-09-10","days":11},{"id":"gustaf-storm","kind":"person","name":"Gustaf Storm","route":"/people/gustaf-storm/","asOf":"2026-09-10","days":11},{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","asOf":"2026-09-10","days":11},{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","asOf":"2026-09-10","days":11},{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","asOf":"2026-09-10","days":11},{"id":"carlos-mingo-rodriguez","kind":"person","name":"Carlos Mingo Rodriguez","route":"/people/carlos-mingo-rodriguez/","asOf":"2026-09-10","days":11},{"id":"cesar-adolfo-gomez-derch","kind":"person","name":"César Adolfo Gómez Derch","route":"/people/cesar-adolfo-gomez-derch/","asOf":"2026-09-10","days":11},{"id":"jose-julian-diaz-melguizo","kind":"person","name":"Jose Julián Díaz Melguizo","route":"/people/jose-julian-diaz-melguizo/","asOf":"2026-09-10","days":11},{"id":"julio-garcia-pondal","kind":"person","name":"Julio García Pondal","route":"/people/julio-garcia-pondal/","asOf":"2026-09-10","days":11},{"id":"lisbet-isenbeg-ravn","kind":"person","name":"Lisbet Isenbeg Ravn","route":"/people/lisbet-isenbeg-ravn/","asOf":"2026-09-10","days":11},{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","asOf":"2026-09-10","days":11},{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","asOf":"2026-09-10","days":11},{"id":"philippe-leroy","kind":"person","name":"Philippe Leroy","route":"/people/philippe-leroy/","asOf":"2026-09-10","days":11},{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","asOf":"2026-09-10","days":11},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","asOf":"2026-09-10","days":11},{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","asOf":"2026-09-10","days":11},{"id":"olena-yefimenko","kind":"person","name":"Olena Yefimenko","route":"/people/olena-yefimenko/","asOf":"2026-09-10","days":11},{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","route":"/people/tomi-p-makela/","asOf":"2026-09-10","days":11},{"id":"poornima-parameswaran","kind":"person","name":"Poornima Parameswaran","route":"/people/poornima-parameswaran/","asOf":"2026-09-10","days":11},{"id":"bayli-divita-dean","kind":"person","name":"Bayli DiVita Dean","route":"/people/bayli-divita-dean/","asOf":"2026-09-10","days":11},{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","asOf":"2026-09-10","days":11},{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","asOf":"2026-09-10","days":11},{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","asOf":"2026-09-10","days":11},{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/","asOf":"2026-09-10","days":11},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/","asOf":"2026-09-10","days":11},{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/","asOf":"2026-09-10","days":11},{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","asOf":"2026-09-10","days":11},{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","route":"/people/jain-hasmukh/","asOf":"2026-09-10","days":11},{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","route":"/people/narula-gaurav/","asOf":"2026-09-10","days":11},{"id":"kapoor-akhil","kind":"person","name":"Akhil Kapoor","route":"/people/kapoor-akhil/","asOf":"2026-09-10","days":11},{"id":"mathur-prashant","kind":"person","name":"Prashant Mathur","route":"/people/mathur-prashant/","asOf":"2026-09-10","days":11},{"id":"shetty-devi","kind":"person","name":"Devi Shetty","route":"/people/shetty-devi/","asOf":"2026-09-10","days":11},{"id":"ajaikumar-b-s","kind":"person","name":"B. S. Ajaikumar","route":"/people/ajaikumar-b-s/","asOf":"2026-09-10","days":11},{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","route":"/people/huang-xiaojun/","asOf":"2026-09-10","days":11},{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","route":"/people/chen-saijuan/","asOf":"2026-09-10","days":11},{"id":"chen-zhu","kind":"person","name":"Zhu Chen","route":"/people/chen-zhu/","asOf":"2026-09-10","days":11},{"id":"qin-shukui","kind":"person","name":"Shukui Qin","route":"/people/qin-shukui/","asOf":"2026-09-10","days":11},{"id":"fan-jia","kind":"person","name":"Jia Fan","route":"/people/fan-jia/","asOf":"2026-09-10","days":11},{"id":"xu-jianming","kind":"person","name":"Jianming Xu","route":"/people/xu-jianming/","asOf":"2026-09-10","days":11},{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/","asOf":"2026-09-10","days":11},{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/","asOf":"2026-09-10","days":11},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/","asOf":"2026-09-10","days":11},{"id":"oyler-john","kind":"person","name":"John Oyler","route":"/people/oyler-john/","asOf":"2026-09-10","days":11},{"id":"xia-michelle","kind":"person","name":"Michelle Xia (Xia Yu)","route":"/people/xia-michelle/","asOf":"2026-09-10","days":11},{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","route":"/people/yu-michael/","asOf":"2026-09-10","days":11},{"id":"sun-piaoyang","kind":"person","name":"Piaoyang Sun","route":"/people/sun-piaoyang/","asOf":"2026-09-10","days":11},{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","route":"/people/du-samantha/","asOf":"2026-09-10","days":11},{"id":"li-ge","kind":"person","name":"Ge Li","route":"/people/li-ge/","asOf":"2026-09-10","days":11},{"id":"su-weiguo","kind":"person","name":"Weiguo Su","route":"/people/su-weiguo/","asOf":"2026-09-10","days":11},{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","route":"/people/zhang-fangliang/","asOf":"2026-09-10","days":11},{"id":"richard-finn","kind":"person","name":"Richard S. Finn","route":"/people/richard-finn/","asOf":"2026-09-10","days":11},{"id":"massimo-cristofanilli","kind":"person","name":"Massimo Cristofanilli","route":"/people/massimo-cristofanilli/","asOf":"2026-09-10","days":11},{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","route":"/people/gabriel-hortobagyi/","asOf":"2026-09-10","days":11},{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","route":"/people/stephen-johnston/","asOf":"2026-09-10","days":11},{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","route":"/people/komal-jhaveri/","asOf":"2026-09-10","days":11},{"id":"joseph-sparano","kind":"person","name":"Joseph A. Sparano","route":"/people/joseph-sparano/","asOf":"2026-09-10","days":11},{"id":"kevin-kalinsky","kind":"person","name":"Kevin Kalinsky","route":"/people/kevin-kalinsky/","asOf":"2026-09-10","days":11},{"id":"prudence-francis","kind":"person","name":"Prudence A. Francis","route":"/people/prudence-francis/","asOf":"2026-09-10","days":11},{"id":"nadia-harbeck","kind":"person","name":"Nadia Harbeck","route":"/people/nadia-harbeck/","asOf":"2026-09-10","days":11},{"id":"mitch-dowsett","kind":"person","name":"Mitch Dowsett","route":"/people/mitch-dowsett/","asOf":"2026-09-10","days":11},{"id":"jack-cuzick","kind":"person","name":"Jack Cuzick","route":"/people/jack-cuzick/","asOf":"2026-09-10","days":11},{"id":"charles-perou","kind":"person","name":"Charles M. Perou","route":"/people/charles-perou/","asOf":"2026-09-10","days":11},{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/","asOf":"2026-09-10","days":11},{"id":"ian-krop","kind":"person","name":"Ian E. Krop","route":"/people/ian-krop/","asOf":"2026-09-10","days":11},{"id":"shanu-modi","kind":"person","name":"Shanu Modi","route":"/people/shanu-modi/","asOf":"2026-09-10","days":11},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/","asOf":"2026-09-10","days":11},{"id":"helena-earl","kind":"person","name":"Helena Earl","route":"/people/helena-earl/","asOf":"2026-09-10","days":11},{"id":"aleix-prat","kind":"person","name":"Aleix Prat","route":"/people/aleix-prat/","asOf":"2026-09-10","days":11},{"id":"eleftherios-mamounas","kind":"person","name":"Eleftherios P. Mamounas","route":"/people/eleftherios-mamounas/","asOf":"2026-09-10","days":11},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","asOf":"2026-09-10","days":11},{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/","asOf":"2026-09-10","days":11},{"id":"lajos-pusztai","kind":"person","name":"Lajos Pusztai","route":"/people/lajos-pusztai/","asOf":"2026-09-10","days":11},{"id":"elizabeth-mittendorf","kind":"person","name":"Elizabeth A. Mittendorf","route":"/people/elizabeth-mittendorf/","asOf":"2026-09-10","days":11},{"id":"monica-morrow","kind":"person","name":"Monica Morrow","route":"/people/monica-morrow/","asOf":"2026-09-10","days":11},{"id":"armando-giuliano","kind":"person","name":"Armando E. Giuliano","route":"/people/armando-giuliano/","asOf":"2026-09-10","days":11},{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","asOf":"2026-09-10","days":11},{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/","asOf":"2026-09-10","days":11},{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","route":"/people/scott-antonia/","asOf":"2026-09-10","days":11},{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","route":"/people/charles-rudin/","asOf":"2026-09-10","days":11},{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","route":"/people/ross-camidge/","asOf":"2026-09-10","days":11},{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","asOf":"2026-09-10","days":11},{"id":"tina-cascone","kind":"person","name":"Tina Cascone","route":"/people/tina-cascone/","asOf":"2026-09-10","days":11},{"id":"qing-zhou","kind":"person","name":"Qing Zhou","route":"/people/qing-zhou/","asOf":"2026-09-10","days":11},{"id":"jonathan-spicer","kind":"person","name":"Jonathan Spicer","route":"/people/jonathan-spicer/","asOf":"2026-09-10","days":11},{"id":"harry-de-koning","kind":"person","name":"Harry J. de Koning","route":"/people/harry-de-koning/","asOf":"2026-09-10","days":11},{"id":"denise-aberle","kind":"person","name":"Denise R. Aberle","route":"/people/denise-aberle/","asOf":"2026-09-10","days":11},{"id":"robert-timmerman","kind":"person","name":"Robert D. Timmerman","route":"/people/robert-timmerman/","asOf":"2026-09-10","days":11},{"id":"joe-chang","kind":"person","name":"Joe Y. Chang","route":"/people/joe-chang/","asOf":"2026-09-10","days":11},{"id":"david-palma","kind":"person","name":"David A. Palma","route":"/people/david-palma/","asOf":"2026-09-10","days":11},{"id":"jeffrey-bradley","kind":"person","name":"Jeffrey D. Bradley","route":"/people/jeffrey-bradley/","asOf":"2026-09-10","days":11},{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/","asOf":"2026-09-10","days":11},{"id":"thierry-andre","kind":"person","name":"Thierry André","route":"/people/thierry-andre/","asOf":"2026-09-10","days":11},{"id":"scott-kopetz","kind":"person","name":"Scott Kopetz","route":"/people/scott-kopetz/","asOf":"2026-09-10","days":11},{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/","asOf":"2026-09-10","days":11},{"id":"heinz-josef-lenz","kind":"person","name":"Heinz-Josef Lenz","route":"/people/heinz-josef-lenz/","asOf":"2026-09-10","days":11},{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","route":"/people/jeanne-tie/","asOf":"2026-09-10","days":11},{"id":"julio-garcia-aguilar","kind":"person","name":"Julio Garcia-Aguilar","route":"/people/julio-garcia-aguilar/","asOf":"2026-09-10","days":11},{"id":"angelita-habr-gama","kind":"person","name":"Angelita Habr-Gama","route":"/people/angelita-habr-gama/","asOf":"2026-09-10","days":11},{"id":"michael-bretthauer","kind":"person","name":"Michael Bretthauer","route":"/people/michael-bretthauer/","asOf":"2026-09-10","days":11},{"id":"aimery-de-gramont","kind":"person","name":"Aimery de Gramont","route":"/people/aimery-de-gramont/","asOf":"2026-09-10","days":11},{"id":"thierry-conroy","kind":"person","name":"Thierry Conroy","route":"/people/thierry-conroy/","asOf":"2026-09-10","days":11},{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","route":"/people/daniel-von-hoff/","asOf":"2026-09-10","days":11},{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/","asOf":"2026-09-10","days":11},{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/","asOf":"2026-09-10","days":11},{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","route":"/people/hedy-kindler/","asOf":"2026-09-10","days":11},{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","route":"/people/zev-wainberg/","asOf":"2026-09-10","days":11},{"id":"marc-besselink","kind":"person","name":"Marc G. Besselink","route":"/people/marc-besselink/","asOf":"2026-09-10","days":11},{"id":"jaffer-ajani","kind":"person","name":"Jaffer A. Ajani","route":"/people/jaffer-ajani/","asOf":"2026-09-10","days":11},{"id":"florian-lordick","kind":"person","name":"Florian Lordick","route":"/people/florian-lordick/","asOf":"2026-09-10","days":11},{"id":"jan-van-lanschot","kind":"person","name":"J. Jan B. van Lanschot","route":"/people/jan-van-lanschot/","asOf":"2026-09-10","days":11},{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","route":"/people/ronan-kelly/","asOf":"2026-09-10","days":11},{"id":"ken-kato","kind":"person","name":"Ken Kato","route":"/people/ken-kato/","asOf":"2026-09-10","days":11},{"id":"mitsuru-sasako","kind":"person","name":"Mitsuru Sasako","route":"/people/mitsuru-sasako/","asOf":"2026-09-10","days":11},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","asOf":"2026-09-10","days":11},{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","route":"/people/ann-lii-cheng/","asOf":"2026-09-10","days":11},{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","route":"/people/masatoshi-kudo/","asOf":"2026-09-10","days":11},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/","asOf":"2026-09-10","days":11},{"id":"juan-valle","kind":"person","name":"Juan W. Valle","route":"/people/juan-valle/","asOf":"2026-09-10","days":11},{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","route":"/people/lipika-goyal/","asOf":"2026-09-10","days":11},{"id":"christopher-sweeney","kind":"person","name":"Christopher J. Sweeney","route":"/people/christopher-sweeney/","asOf":"2026-09-10","days":11},{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","asOf":"2026-09-10","days":11},{"id":"matthew-smith","kind":"person","name":"Matthew R. Smith","route":"/people/matthew-smith/","asOf":"2026-09-10","days":11},{"id":"kim-chi","kind":"person","name":"Kim N. Chi","route":"/people/kim-chi/","asOf":"2026-09-10","days":11},{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","asOf":"2026-09-10","days":11},{"id":"andrew-armstrong","kind":"person","name":"Andrew J. Armstrong","route":"/people/andrew-armstrong/","asOf":"2026-09-10","days":11},{"id":"freddie-hamdy","kind":"person","name":"Freddie C. Hamdy","route":"/people/freddie-hamdy/","asOf":"2026-09-10","days":11},{"id":"mark-emberton","kind":"person","name":"Mark Emberton","route":"/people/mark-emberton/","asOf":"2026-09-10","days":11},{"id":"hashim-ahmed","kind":"person","name":"Hashim U. Ahmed","route":"/people/hashim-ahmed/","asOf":"2026-09-10","days":11},{"id":"anthony-damico","kind":"person","name":"Anthony V. D'Amico","route":"/people/anthony-damico/","asOf":"2026-09-10","days":11},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","asOf":"2026-09-10","days":11},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/","asOf":"2026-09-10","days":11},{"id":"daniel-spratt","kind":"person","name":"Daniel E. Spratt","route":"/people/daniel-spratt/","asOf":"2026-09-10","days":11},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","asOf":"2026-09-10","days":11},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","asOf":"2026-09-10","days":11},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","asOf":"2026-09-10","days":11},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/","asOf":"2026-09-10","days":11},{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","route":"/people/joaquim-bellmunt/","asOf":"2026-09-10","days":11},{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","route":"/people/arjun-balar/","asOf":"2026-09-10","days":11},{"id":"ashish-kamat","kind":"person","name":"Ashish M. Kamat","route":"/people/ashish-kamat/","asOf":"2026-09-10","days":11},{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/","asOf":"2026-09-10","days":11},{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","route":"/people/robert-motzer/","asOf":"2026-09-10","days":11},{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/","asOf":"2026-09-10","days":11},{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","route":"/people/laurence-albiges/","asOf":"2026-09-10","days":11},{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","route":"/people/sumanta-pal/","asOf":"2026-09-10","days":11},{"id":"arnaud-mejean","kind":"person","name":"Arnaud Méjean","route":"/people/arnaud-mejean/","asOf":"2026-09-10","days":11},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","asOf":"2026-09-10","days":11},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/","asOf":"2026-09-10","days":11},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/","asOf":"2026-09-10","days":11},{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","route":"/people/robert-coleman/","asOf":"2026-09-10","days":11},{"id":"andreas-du-bois","kind":"person","name":"Andreas du Bois","route":"/people/andreas-du-bois/","asOf":"2026-09-10","days":11},{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","route":"/people/willemien-van-driel/","asOf":"2026-09-10","days":11},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/","asOf":"2026-09-10","days":11},{"id":"usha-menon","kind":"person","name":"Usha Menon","route":"/people/usha-menon/","asOf":"2026-09-10","days":11},{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/","asOf":"2026-09-10","days":11},{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","route":"/people/ramez-eskander/","asOf":"2026-09-10","days":11},{"id":"carien-creutzberg","kind":"person","name":"Carien L. Creutzberg","route":"/people/carien-creutzberg/","asOf":"2026-09-10","days":11},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/","asOf":"2026-09-10","days":11},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/","asOf":"2026-09-10","days":11},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/","asOf":"2026-09-10","days":11},{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/","asOf":"2026-09-10","days":11},{"id":"pedro-ramirez","kind":"person","name":"Pedro T. Ramirez","route":"/people/pedro-ramirez/","asOf":"2026-09-10","days":11},{"id":"mary-mccormack","kind":"person","name":"Mary McCormack","route":"/people/mary-mccormack/","asOf":"2026-09-10","days":11},{"id":"linda-mileshkin","kind":"person","name":"Linda Mileshkin","route":"/people/linda-mileshkin/","asOf":"2026-09-10","days":11},{"id":"georgina-long","kind":"person","name":"Georgina V. Long","route":"/people/georgina-long/","asOf":"2026-09-10","days":11},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","asOf":"2026-09-10","days":11},{"id":"caroline-robert","kind":"person","name":"Caroline Robert","route":"/people/caroline-robert/","asOf":"2026-09-10","days":11},{"id":"hussein-tawbi","kind":"person","name":"Hussein A. Tawbi","route":"/people/hussein-tawbi/","asOf":"2026-09-10","days":11},{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","route":"/people/paolo-ascierto/","asOf":"2026-09-10","days":11},{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/","asOf":"2026-09-10","days":11},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/","asOf":"2026-09-10","days":11},{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","route":"/people/sapna-patel/","asOf":"2026-09-10","days":11},{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/","asOf":"2026-09-10","days":11},{"id":"mark-faries","kind":"person","name":"Mark B. Faries","route":"/people/mark-faries/","asOf":"2026-09-10","days":11},{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","route":"/people/reinhard-dummer/","asOf":"2026-09-10","days":11},{"id":"paul-nathan","kind":"person","name":"Paul Nathan","route":"/people/paul-nathan/","asOf":"2026-09-10","days":11},{"id":"richard-carvajal","kind":"person","name":"Richard D. Carvajal","route":"/people/richard-carvajal/","asOf":"2026-09-10","days":11},{"id":"jennifer-wargo","kind":"person","name":"Jennifer A. Wargo","route":"/people/jennifer-wargo/","asOf":"2026-09-10","days":11},{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/","asOf":"2026-09-10","days":11},{"id":"patrick-wen","kind":"person","name":"Patrick Y. Wen","route":"/people/patrick-wen/","asOf":"2026-09-10","days":11},{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","asOf":"2026-09-10","days":11},{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","route":"/people/monika-hegi/","asOf":"2026-09-10","days":11},{"id":"mitchel-berger","kind":"person","name":"Mitchel S. Berger","route":"/people/mitchel-berger/","asOf":"2026-09-10","days":11},{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","route":"/people/timothy-cloughesy/","asOf":"2026-09-10","days":11},{"id":"michelle-monje","kind":"person","name":"Michelle Monje","route":"/people/michelle-monje/","asOf":"2026-09-10","days":11},{"id":"michael-taylor","kind":"person","name":"Michael D. Taylor","route":"/people/michael-taylor/","asOf":"2026-09-10","days":11},{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/","asOf":"2026-09-10","days":11},{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","route":"/people/jan-vermorken/","asOf":"2026-09-10","days":11},{"id":"maura-gillison","kind":"person","name":"Maura L. Gillison","route":"/people/maura-gillison/","asOf":"2026-09-10","days":11},{"id":"hisham-mehanna","kind":"person","name":"Hisham Mehanna","route":"/people/hisham-mehanna/","asOf":"2026-09-10","days":11},{"id":"ezra-cohen","kind":"person","name":"Ezra E. W. Cohen","route":"/people/ezra-cohen/","asOf":"2026-09-10","days":11},{"id":"ravindra-uppaluri","kind":"person","name":"Ravindra Uppaluri","route":"/people/ravindra-uppaluri/","asOf":"2026-09-10","days":11},{"id":"jean-bourhis","kind":"person","name":"Jean Bourhis","route":"/people/jean-bourhis/","asOf":"2026-09-10","days":11},{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","asOf":"2026-09-10","days":11},{"id":"william-tap","kind":"person","name":"William D. Tap","route":"/people/william-tap/","asOf":"2026-09-10","days":11},{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","route":"/people/sandra-dangelo/","asOf":"2026-09-10","days":11},{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","route":"/people/winette-van-der-graaf/","asOf":"2026-09-10","days":11},{"id":"silvia-stacchiotti","kind":"person","name":"Silvia Stacchiotti","route":"/people/silvia-stacchiotti/","asOf":"2026-09-10","days":11},{"id":"stefan-bielack","kind":"person","name":"Stefan S. Bielack","route":"/people/stefan-bielack/","asOf":"2026-09-10","days":11},{"id":"lori-wirth","kind":"person","name":"Lori J. Wirth","route":"/people/lori-wirth/","asOf":"2026-09-10","days":11},{"id":"martin-schlumberger","kind":"person","name":"Martin Schlumberger","route":"/people/martin-schlumberger/","asOf":"2026-09-10","days":11},{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","route":"/people/marcia-brose/","asOf":"2026-09-10","days":11},{"id":"maria-cabanillas","kind":"person","name":"Maria E. Cabanillas","route":"/people/maria-cabanillas/","asOf":"2026-09-10","days":11},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","asOf":"2026-09-10","days":11},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","asOf":"2026-09-10","days":11},{"id":"martyn-caplin","kind":"person","name":"Martyn E. Caplin","route":"/people/martyn-caplin/","asOf":"2026-09-10","days":11},{"id":"james-yao","kind":"person","name":"James C. Yao","route":"/people/james-yao/","asOf":"2026-09-10","days":11},{"id":"paul-baas","kind":"person","name":"Paul Baas","route":"/people/paul-baas/","asOf":"2026-09-10","days":11},{"id":"dean-fennell","kind":"person","name":"Dean A. Fennell","route":"/people/dean-fennell/","asOf":"2026-09-10","days":11},{"id":"anna-nowak","kind":"person","name":"Anna K. Nowak","route":"/people/anna-nowak/","asOf":"2026-09-10","days":11},{"id":"ruth-ladenstein","kind":"person","name":"Ruth Ladenstein","route":"/people/ruth-ladenstein/","asOf":"2026-09-10","days":11},{"id":"john-maris","kind":"person","name":"John M. Maris","route":"/people/john-maris/","asOf":"2026-09-10","days":11},{"id":"yael-mosse","kind":"person","name":"Yael P. Mossé","route":"/people/yael-mosse/","asOf":"2026-09-10","days":11},{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","route":"/people/nai-kong-cheung/","asOf":"2026-09-10","days":11},{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","route":"/people/stephen-hunger/","asOf":"2026-09-10","days":11},{"id":"ching-hon-pui","kind":"person","name":"Ching-Hon Pui","route":"/people/ching-hon-pui/","asOf":"2026-09-10","days":11},{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","route":"/people/sumit-gupta/","asOf":"2026-09-10","days":11},{"id":"jeffrey-dome","kind":"person","name":"Jeffrey S. Dome","route":"/people/jeffrey-dome/","asOf":"2026-09-10","days":11},{"id":"amar-gajjar","kind":"person","name":"Amar Gajjar","route":"/people/amar-gajjar/","asOf":"2026-09-10","days":11},{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","asOf":"2026-09-10","days":11},{"id":"richard-stone","kind":"person","name":"Richard M. Stone","route":"/people/richard-stone/","asOf":"2026-09-10","days":11},{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","route":"/people/alexander-perl/","asOf":"2026-09-10","days":11},{"id":"hartmut-dohner","kind":"person","name":"Hartmut Döhner","route":"/people/hartmut-dohner/","asOf":"2026-09-10","days":11},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","asOf":"2026-09-10","days":11},{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","route":"/people/ghayas-issa/","asOf":"2026-09-10","days":11},{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","route":"/people/andrew-wei/","asOf":"2026-09-10","days":11},{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","route":"/people/uwe-platzbecker/","asOf":"2026-09-10","days":11},{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","route":"/people/pierre-fenaux/","asOf":"2026-09-10","days":11},{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/","asOf":"2026-09-10","days":11},{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","route":"/people/timothy-hughes/","asOf":"2026-09-10","days":11},{"id":"elias-jabbour","kind":"person","name":"Elias Jabbour","route":"/people/elias-jabbour/","asOf":"2026-09-10","days":11},{"id":"nicola-gokbuget","kind":"person","name":"Nicola Gökbuget","route":"/people/nicola-gokbuget/","asOf":"2026-09-10","days":11},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","asOf":"2026-09-10","days":11},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/","asOf":"2026-09-10","days":11},{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/","asOf":"2026-09-10","days":11},{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","route":"/people/sattva-neelapu/","asOf":"2026-09-10","days":11},{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","route":"/people/stephen-schuster/","asOf":"2026-09-10","days":11},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/","asOf":"2026-09-10","days":11},{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","route":"/people/michael-dickinson/","asOf":"2026-09-10","days":11},{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/","asOf":"2026-09-10","days":11},{"id":"michael-wang","kind":"person","name":"Michael L. Wang","route":"/people/michael-wang/","asOf":"2026-09-10","days":11},{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","route":"/people/martin-dreyling/","asOf":"2026-09-10","days":11},{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","route":"/people/joseph-connors/","asOf":"2026-09-10","days":11},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/","asOf":"2026-09-10","days":11},{"id":"andreas-engert","kind":"person","name":"Andreas Engert","route":"/people/andreas-engert/","asOf":"2026-09-10","days":11},{"id":"kara-kelly","kind":"person","name":"Kara M. Kelly","route":"/people/kara-kelly/","asOf":"2026-09-10","days":11},{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","route":"/people/wyndham-wilson/","asOf":"2026-09-10","days":11},{"id":"steven-treon","kind":"person","name":"Steven P. Treon","route":"/people/steven-treon/","asOf":"2026-09-10","days":11},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/","asOf":"2026-09-10","days":11},{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","route":"/people/andres-ferreri/","asOf":"2026-09-10","days":11},{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","asOf":"2026-09-10","days":11},{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","route":"/people/jennifer-woyach/","asOf":"2026-09-10","days":11},{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","route":"/people/jennifer-brown/","asOf":"2026-09-10","days":11},{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","route":"/people/kirsten-fischer/","asOf":"2026-09-10","days":11},{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","route":"/people/barbara-eichhorst/","asOf":"2026-09-10","days":11},{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","route":"/people/peter-hillmen/","asOf":"2026-09-10","days":11},{"id":"john-seymour","kind":"person","name":"John F. Seymour","route":"/people/john-seymour/","asOf":"2026-09-10","days":11},{"id":"william-wierda","kind":"person","name":"William G. Wierda","route":"/people/william-wierda/","asOf":"2026-09-10","days":11},{"id":"constantine-tam","kind":"person","name":"Constantine S. Tam","route":"/people/constantine-tam/","asOf":"2026-09-10","days":11},{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/","asOf":"2026-09-10","days":11},{"id":"thierry-facon","kind":"person","name":"Thierry Facon","route":"/people/thierry-facon/","asOf":"2026-09-10","days":11},{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","route":"/people/pieter-sonneveld/","asOf":"2026-09-10","days":11},{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","route":"/people/maria-victoria-mateos/","asOf":"2026-09-10","days":11},{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/","asOf":"2026-09-10","days":11},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/","asOf":"2026-09-10","days":11},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/","asOf":"2026-09-10","days":11},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/","asOf":"2026-09-10","days":11},{"id":"ajai-chari","kind":"person","name":"Ajai Chari","route":"/people/ajai-chari/","asOf":"2026-09-10","days":11},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/","asOf":"2026-09-10","days":11},{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","route":"/people/sigurdur-kristinsson/","asOf":"2026-09-10","days":11},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/","asOf":"2026-09-10","days":11},{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/","asOf":"2026-09-10","days":11},{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","route":"/people/michel-sadelain/","asOf":"2026-09-10","days":11},{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","route":"/people/stephan-grupp/","asOf":"2026-09-10","days":11},{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","route":"/people/marcela-maus/","asOf":"2026-09-10","days":11},{"id":"waseem-qasim","kind":"person","name":"Waseem Qasim","route":"/people/waseem-qasim/","asOf":"2026-09-10","days":11},{"id":"katy-rezvani","kind":"person","name":"Katayoun Rezvani","route":"/people/katy-rezvani/","asOf":"2026-09-10","days":11},{"id":"inge-marie-svane","kind":"person","name":"Inge Marie Svane","route":"/people/inge-marie-svane/","asOf":"2026-09-10","days":11},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/","asOf":"2026-09-10","days":11},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","asOf":"2026-09-10","days":11},{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","route":"/people/wolfgang-weber/","asOf":"2026-09-10","days":11},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/","asOf":"2026-09-10","days":11},{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","asOf":"2026-09-10","days":11},{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","route":"/people/gordon-freeman/","asOf":"2026-09-10","days":11},{"id":"thomas-gajewski","kind":"person","name":"Thomas F. Gajewski","route":"/people/thomas-gajewski/","asOf":"2026-09-10","days":11},{"id":"shimon-sakaguchi","kind":"person","name":"Shimon Sakaguchi","route":"/people/shimon-sakaguchi/","asOf":"2026-09-10","days":11},{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","route":"/people/ugur-sahin/","asOf":"2026-09-10","days":11},{"id":"catherine-wu","kind":"person","name":"Catherine J. Wu","route":"/people/catherine-wu/","asOf":"2026-09-10","days":11},{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","route":"/people/howard-kaufman/","asOf":"2026-09-10","days":11},{"id":"ignacio-melero","kind":"person","name":"Ignacio Melero","route":"/people/ignacio-melero/","asOf":"2026-09-10","days":11},{"id":"michael-berger","kind":"person","name":"Michael F. Berger","route":"/people/michael-berger/","asOf":"2026-09-10","days":11},{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","route":"/people/serena-nik-zainal/","asOf":"2026-09-10","days":11},{"id":"ludmil-alexandrov","kind":"person","name":"Ludmil B. Alexandrov","route":"/people/ludmil-alexandrov/","asOf":"2026-09-10","days":11},{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","route":"/people/carlos-caldas/","asOf":"2026-09-10","days":11},{"id":"christina-curtis","kind":"person","name":"Christina Curtis","route":"/people/christina-curtis/","asOf":"2026-09-10","days":11},{"id":"nickolas-papadopoulos","kind":"person","name":"Nickolas Papadopoulos","route":"/people/nickolas-papadopoulos/","asOf":"2026-09-10","days":11},{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/","asOf":"2026-09-10","days":11},{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","route":"/people/nitzan-rosenfeld/","asOf":"2026-09-10","days":11},{"id":"viktor-adalsteinsson","kind":"person","name":"Viktor A. Adalsteinsson","route":"/people/viktor-adalsteinsson/","asOf":"2026-09-10","days":11},{"id":"thomas-helleday","kind":"person","name":"Thomas Helleday","route":"/people/thomas-helleday/","asOf":"2026-09-10","days":11},{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","route":"/people/alan-dandrea/","asOf":"2026-09-10","days":11},{"id":"razelle-kurzrock","kind":"person","name":"Razelle Kurzrock","route":"/people/razelle-kurzrock/","asOf":"2026-09-10","days":11},{"id":"charlotte-coles","kind":"person","name":"Charlotte E. Coles","route":"/people/charlotte-coles/","asOf":"2026-09-10","days":11},{"id":"murray-brunt","kind":"person","name":"A. Murray Brunt","route":"/people/murray-brunt/","asOf":"2026-09-10","days":11},{"id":"timothy-whelan","kind":"person","name":"Timothy J. Whelan","route":"/people/timothy-whelan/","asOf":"2026-09-10","days":11},{"id":"marie-catherine-vozenin","kind":"person","name":"Marie-Catherine Vozenin","route":"/people/marie-catherine-vozenin/","asOf":"2026-09-10","days":11},{"id":"bas-raaymakers","kind":"person","name":"Bas W. Raaymakers","route":"/people/bas-raaymakers/","asOf":"2026-09-10","days":11},{"id":"anthony-zietman","kind":"person","name":"Anthony L. Zietman","route":"/people/anthony-zietman/","asOf":"2026-09-10","days":11},{"id":"quynh-thu-le","kind":"person","name":"Quynh-Thu Le","route":"/people/quynh-thu-le/","asOf":"2026-09-10","days":11},{"id":"shankar-siva","kind":"person","name":"Shankar Siva","route":"/people/shankar-siva/","asOf":"2026-09-10","days":11},{"id":"cornelis-van-de-velde","kind":"person","name":"Cornelis J. H. van de Velde","route":"/people/cornelis-van-de-velde/","asOf":"2026-09-10","days":11},{"id":"yuman-fong","kind":"person","name":"Yuman Fong","route":"/people/yuman-fong/","asOf":"2026-09-10","days":11},{"id":"valerie-rusch","kind":"person","name":"Valerie W. Rusch","route":"/people/valerie-rusch/","asOf":"2026-09-10","days":11},{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","route":"/people/rebecca-fitzgerald/","asOf":"2026-09-10","days":11},{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","route":"/people/peter-sasieni/","asOf":"2026-09-10","days":11},{"id":"nubia-munoz","kind":"person","name":"Nubia Muñoz","route":"/people/nubia-munoz/","asOf":"2026-09-10","days":11},{"id":"mark-schiffman","kind":"person","name":"Mark Schiffman","route":"/people/mark-schiffman/","asOf":"2026-09-10","days":11},{"id":"kristina-lang","kind":"person","name":"Kristina Lång","route":"/people/kristina-lang/","asOf":"2026-09-10","days":11},{"id":"constance-lehman","kind":"person","name":"Constance D. Lehman","route":"/people/constance-lehman/","asOf":"2026-09-10","days":11},{"id":"eric-klein","kind":"person","name":"Eric A. Klein","route":"/people/eric-klein/","asOf":"2026-09-10","days":11},{"id":"deb-schrag","kind":"person","name":"Deborah Schrag","route":"/people/deb-schrag/","asOf":"2026-09-10","days":11},{"id":"faisal-mahmood","kind":"person","name":"Faisal Mahmood","route":"/people/faisal-mahmood/","asOf":"2026-09-10","days":11},{"id":"thomas-fuchs","kind":"person","name":"Thomas J. Fuchs","route":"/people/thomas-fuchs/","asOf":"2026-09-10","days":11},{"id":"jakob-nikolas-kather","kind":"person","name":"Jakob Nikolas Kather","route":"/people/jakob-nikolas-kather/","asOf":"2026-09-10","days":11},{"id":"regina-barzilay","kind":"person","name":"Regina Barzilay","route":"/people/regina-barzilay/","asOf":"2026-09-10","days":11},{"id":"jennifer-temel","kind":"person","name":"Jennifer S. Temel","route":"/people/jennifer-temel/","asOf":"2026-09-10","days":11},{"id":"ethan-basch","kind":"person","name":"Ethan Basch","route":"/people/ethan-basch/","asOf":"2026-09-10","days":11},{"id":"supriya-mohile","kind":"person","name":"Supriya G. Mohile","route":"/people/supriya-mohile/","asOf":"2026-09-10","days":11},{"id":"kerry-courneya","kind":"person","name":"Kerry S. Courneya","route":"/people/kerry-courneya/","asOf":"2026-09-10","days":11},{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","asOf":"2026-09-10","days":11},{"id":"ian-tannock","kind":"person","name":"Ian F. Tannock","route":"/people/ian-tannock/","asOf":"2026-09-10","days":11},{"id":"joseph-unger","kind":"person","name":"Joseph M. Unger","route":"/people/joseph-unger/","asOf":"2026-09-10","days":11},{"id":"richard-gray","kind":"person","name":"Richard Gray","route":"/people/richard-gray/","asOf":"2026-09-10","days":11},{"id":"richard-peto","kind":"person","name":"Sir Richard Peto","route":"/people/richard-peto/","asOf":"2026-09-10","days":11},{"id":"mahesh-parmar","kind":"person","name":"Mahesh K. B. Parmar","route":"/people/mahesh-parmar/","asOf":"2026-09-10","days":11},{"id":"judith-bliss","kind":"person","name":"Judith M. Bliss","route":"/people/judith-bliss/","asOf":"2026-09-10","days":11},{"id":"rolf-stahel","kind":"person","name":"Rolf A. Stahel","route":"/people/rolf-stahel/","asOf":"2026-09-10","days":11},{"id":"idea-cost-asp-flat-fee","kind":"idea","name":"Pay a flat fee for giving a Part B drug instead of 6% of its price","route":"/ideas/idea-cost-asp-flat-fee/","asOf":"2026-09-10","days":11},{"id":"idea-cost-site-neutral-infusion","kind":"idea","name":"Pay the same for an infusion whether it is given in a hospital or a clinic","route":"/ideas/idea-cost-site-neutral-infusion/","asOf":"2026-09-10","days":11},{"id":"idea-cost-340b-pass-through","kind":"idea","name":"Pass 340B discounts on cancer drugs through to the patient's bill","route":"/ideas/idea-cost-340b-pass-through/","asOf":"2026-09-10","days":11},{"id":"idea-cost-indication-based-pricing","kind":"idea","name":"Price a cancer drug by how well it works in each cancer","route":"/ideas/idea-cost-indication-based-pricing/","asOf":"2026-09-10","days":11},{"id":"idea-cost-inflation-rebates-commercial","kind":"idea","name":"Extend Medicare's inflation rebates to employer plans","route":"/ideas/idea-cost-inflation-rebates-commercial/","asOf":"2026-09-10","days":11},{"id":"idea-cost-part-b-cap","kind":"idea","name":"Cap what Original Medicare patients pay for Part B cancer drugs","route":"/ideas/idea-cost-part-b-cap/","asOf":"2026-09-10","days":11},{"id":"idea-cost-biosimilar-default-substitution","kind":"idea","name":"Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab","route":"/ideas/idea-cost-biosimilar-default-substitution/","asOf":"2026-09-10","days":11},{"id":"idea-cost-interchangeable-oncology-biosimilars","kind":"idea","name":"Drop the extra switching studies for interchangeable oncology biosimilars","route":"/ideas/idea-cost-interchangeable-oncology-biosimilars/","asOf":"2026-09-10","days":11},{"id":"idea-cost-nonprofit-generic-oncology","kind":"idea","name":"A non-profit manufacturer for shortage-prone generic chemotherapy","route":"/ideas/idea-cost-nonprofit-generic-oncology/","asOf":"2026-09-10","days":11},{"id":"idea-cost-transparent-generic-pricing","kind":"idea","name":"Transparent cost-plus pricing for every oral oncology generic","route":"/ideas/idea-cost-transparent-generic-pricing/","asOf":"2026-09-10","days":11},{"id":"idea-cost-low-dose-abiraterone-food","kind":"idea","name":"Prescribe a quarter dose of abiraterone with breakfast","route":"/ideas/idea-cost-low-dose-abiraterone-food/","asOf":"2026-09-10","days":11},{"id":"idea-cost-low-dose-immunotherapy-trials","kind":"idea","name":"Test one-tenth-dose immunotherapy where the full dose is unaffordable","route":"/ideas/idea-cost-low-dose-immunotherapy-trials/","asOf":"2026-09-10","days":11},{"id":"idea-cost-optimus-legacy-drugs","kind":"idea","name":"Apply Project Optimus to drugs already on the market","route":"/ideas/idea-cost-optimus-legacy-drugs/","asOf":"2026-09-10","days":11},{"id":"idea-cost-extended-interval-default","kind":"idea","name":"Make six-weekly immunotherapy the default schedule","route":"/ideas/idea-cost-extended-interval-default/","asOf":"2026-09-10","days":11},{"id":"idea-cost-shorter-course-trials","kind":"idea","name":"Fund trials that test shorter courses of the most expensive adjuvant drugs","route":"/ideas/idea-cost-shorter-course-trials/","asOf":"2026-09-10","days":11},{"id":"idea-cost-hypofractionation-payment","kind":"idea","name":"Pay for a course of radiotherapy, not for each fraction","route":"/ideas/idea-cost-hypofractionation-payment/","asOf":"2026-09-10","days":11},{"id":"idea-cost-subcutaneous-community","kind":"idea","name":"Give subcutaneous immunotherapy in community clinics and at home","route":"/ideas/idea-cost-subcutaneous-community/","asOf":"2026-09-10","days":11},{"id":"idea-cost-vial-sharing-dose-rounding","kind":"idea","name":"Share vials and round doses to stop throwing away expensive drug","route":"/ideas/idea-cost-vial-sharing-dose-rounding/","asOf":"2026-09-10","days":11},{"id":"idea-cost-gold-card-oncology","kind":"idea","name":"Exempt oncologists who follow the pathway from prior authorisation","route":"/ideas/idea-cost-gold-card-oncology/","asOf":"2026-09-10","days":11},{"id":"idea-cost-real-time-pa-fhir","kind":"idea","name":"Answer prior authorisation requests in seconds from the medical record","route":"/ideas/idea-cost-real-time-pa-fhir/","asOf":"2026-09-10","days":11},{"id":"idea-cost-federal-oral-parity","kind":"idea","name":"Federal oral chemotherapy parity for self-funded employer plans","route":"/ideas/idea-cost-federal-oral-parity/","asOf":"2026-09-10","days":11},{"id":"idea-cost-financial-toxicity-screening","kind":"idea","name":"Screen every patient for money trouble the way we screen for pain","route":"/ideas/idea-cost-financial-toxicity-screening/","asOf":"2026-09-10","days":11},{"id":"idea-cost-travel-teleoncology","kind":"idea","name":"Bring the oncologist to the local clinic by video and the drug to the local pharmacy","route":"/ideas/idea-cost-travel-teleoncology/","asOf":"2026-09-10","days":11},{"id":"idea-cost-early-palliative-default","kind":"idea","name":"Make early palliative care and a goals conversation part of every advanced-cancer pathway","route":"/ideas/idea-cost-early-palliative-default/","asOf":"2026-09-10","days":11},{"id":"idea-cost-trial-enrolment-cost-lever","kind":"idea","name":"Treat trial enrolment as a cost lever: the sponsor pays for the drug","route":"/ideas/idea-cost-trial-enrolment-cost-lever/","asOf":"2026-09-10","days":11},{"id":"idea-cost-value-scale-in-coverage","kind":"idea","name":"Tie coverage and copays to the ESMO benefit scale","route":"/ideas/idea-cost-value-scale-in-coverage/","asOf":"2026-09-10","days":11},{"id":"idea-cost-managed-access-everywhere","kind":"idea","name":"Copy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data","route":"/ideas/idea-cost-managed-access-everywhere/","asOf":"2026-09-10","days":11},{"id":"idea-cost-pooled-procurement-essential","kind":"idea","name":"Pool purchasing of essential cancer medicines across countries","route":"/ideas/idea-cost-pooled-procurement-essential/","asOf":"2026-09-10","days":11},{"id":"idea-cost-voluntary-licensing-oncology","kind":"idea","name":"Voluntary licences and price caps for patented cancer drugs in low-income countries","route":"/ideas/idea-cost-voluntary-licensing-oncology/","asOf":"2026-09-10","days":11},{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/","asOf":"2026-09-10","days":11},{"id":"az-groeninge-kortrijk","kind":"institution","name":"AZ Groeninge Kortrijk Cancer Centre","route":"/institutions/az-groeninge-kortrijk/","asOf":"2026-09-10","days":11},{"id":"vejle-cancer-centre","kind":"institution","name":"Vejle Hospital Cancer Centre (Lillebaelt Hospital)","route":"/institutions/vejle-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"tartu-university-hospital","kind":"institution","name":"Tartu University Hospital","route":"/institutions/tartu-university-hospital/","asOf":"2026-09-10","days":11},{"id":"kuopio-university-hospital","kind":"institution","name":"Kuopio University Hospital Cancer Center","route":"/institutions/kuopio-university-hospital/","asOf":"2026-09-10","days":11},{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","asOf":"2026-09-10","days":11},{"id":"tays-cancer-centre","kind":"institution","name":"Tays Cancer Centre, Tampere University Hospital","route":"/institutions/tays-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"linkoping-university-hospital","kind":"institution","name":"Linköping University Hospital Cancer Center","route":"/institutions/linkoping-university-hospital/","asOf":"2026-09-10","days":11},{"id":"riga-east-university-hospital","kind":"institution","name":"Riga East University Hospital / Oncology Centre of Latvia","route":"/institutions/riga-east-university-hospital/","asOf":"2026-09-10","days":11},{"id":"nci-vilnius","kind":"institution","name":"National Cancer Institute, Lithuania","route":"/institutions/nci-vilnius/","asOf":"2026-09-10","days":11},{"id":"icm-montpellier","kind":"institution","name":"Institut du Cancer de Montpellier (ICM)","route":"/institutions/icm-montpellier/","asOf":"2026-09-10","days":11},{"id":"centre-jean-perrin","kind":"institution","name":"Centre Jean Perrin","route":"/institutions/centre-jean-perrin/","asOf":"2026-09-10","days":11},{"id":"centre-henri-becquerel","kind":"institution","name":"Centre Henri Becquerel","route":"/institutions/centre-henri-becquerel/","asOf":"2026-09-10","days":11},{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","asOf":"2026-09-10","days":11},{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","asOf":"2026-09-10","days":11},{"id":"centre-francois-baclesse","kind":"institution","name":"Centre François Baclesse","route":"/institutions/centre-francois-baclesse/","asOf":"2026-09-10","days":11},{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/","asOf":"2026-09-10","days":11},{"id":"iuc-aphp-sorbonne","kind":"institution","name":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université","route":"/institutions/iuc-aphp-sorbonne/","asOf":"2026-09-10","days":11},{"id":"carpem-aphp-centre","kind":"institution","name":"Institut du Cancer Paris CARPEM, AP-HP Centre","route":"/institutions/carpem-aphp-centre/","asOf":"2026-09-10","days":11},{"id":"trinity-st-jamess-cancer-institute","kind":"institution","name":"Trinity St James's Cancer Institute","route":"/institutions/trinity-st-jamess-cancer-institute/","asOf":"2026-09-10","days":11},{"id":"st-vincents-ucd-cancer-centre","kind":"institution","name":"St Vincent's University Hospital / UCD Cancer Centre","route":"/institutions/st-vincents-ucd-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"cork-university-hospital","kind":"institution","name":"Cork University Hospital / UCC Cancer Centre","route":"/institutions/cork-university-hospital/","asOf":"2026-09-10","days":11},{"id":"galway-university-hospital-cancer-centre","kind":"institution","name":"University of Galway / Saolta Cancer Centre","route":"/institutions/galway-university-hospital-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"beaumont-rcsi-cancer-centre","kind":"institution","name":"Beaumont RCSI Cancer Centre","route":"/institutions/beaumont-rcsi-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"spedali-civili-brescia","kind":"institution","name":"ASST Spedali Civili di Brescia","route":"/institutions/spedali-civili-brescia/","asOf":"2026-09-10","days":11},{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","asOf":"2026-09-10","days":11},{"id":"crob-rionero","kind":"institution","name":"IRCCS CROB, Centro di Riferimento Oncologico della Basilicata","route":"/institutions/crob-rionero/","asOf":"2026-09-10","days":11},{"id":"istituto-tumori-bari","kind":"institution","name":"IRCCS Istituto Tumori Giovanni Paolo II","route":"/institutions/istituto-tumori-bari/","asOf":"2026-09-10","days":11},{"id":"san-martino-genoa","kind":"institution","name":"IRCCS Ospedale Policlinico San Martino","route":"/institutions/san-martino-genoa/","asOf":"2026-09-10","days":11},{"id":"ausl-irccs-reggio-emilia","kind":"institution","name":"AUSL-IRCCS di Reggio Emilia","route":"/institutions/ausl-irccs-reggio-emilia/","asOf":"2026-09-10","days":11},{"id":"cro-aviano","kind":"institution","name":"Centro di Riferimento Oncologico di Aviano (CRO)","route":"/institutions/cro-aviano/","asOf":"2026-09-10","days":11},{"id":"ipo-coimbra","kind":"institution","name":"Instituto Português de Oncologia de Coimbra Francisco Gentil","route":"/institutions/ipo-coimbra/","asOf":"2026-09-10","days":11},{"id":"fundacion-jimenez-diaz","kind":"institution","name":"Hospital Universitario Fundación Jiménez Díaz","route":"/institutions/fundacion-jimenez-diaz/","asOf":"2026-09-10","days":11},{"id":"ico-catalonia","kind":"institution","name":"Catalan Institute of Oncology (ICO)","route":"/institutions/ico-catalonia/","asOf":"2026-09-10","days":11},{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","asOf":"2026-09-10","days":11},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","asOf":"2026-09-10","days":11},{"id":"maastricht-umc","kind":"institution","name":"Maastricht UMC+ Comprehensive Cancer Center","route":"/institutions/maastricht-umc/","asOf":"2026-09-10","days":11},{"id":"oncozon","kind":"institution","name":"OncoZON Comprehensive Cancer Network","route":"/institutions/oncozon/","asOf":"2026-09-10","days":11},{"id":"rijnstate-arnhem","kind":"institution","name":"Rijnstate","route":"/institutions/rijnstate-arnhem/","asOf":"2026-09-10","days":11},{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","route":"/institutions/radboudumc/","asOf":"2026-09-10","days":11},{"id":"amsterdam-umc","kind":"institution","name":"Amsterdam UMC / Cancer Center Amsterdam","route":"/institutions/amsterdam-umc/","asOf":"2026-09-10","days":11},{"id":"anadolu-medical-center","kind":"institution","name":"Anadolu Medical Center","route":"/institutions/anadolu-medical-center/","asOf":"2026-09-10","days":11},{"id":"saint-savvas-athens","kind":"institution","name":"Saint Savvas General Oncology Hospital of Athens","route":"/institutions/saint-savvas-athens/","asOf":"2026-09-10","days":11},{"id":"clatterbridge","kind":"institution","name":"The Clatterbridge Cancer Centre NHS Foundation Trust","route":"/institutions/clatterbridge/","asOf":"2026-09-10","days":11},{"id":"weston-park-sheffield","kind":"institution","name":"Weston Park Cancer Centre, Sheffield Teaching Hospitals","route":"/institutions/weston-park-sheffield/","asOf":"2026-09-10","days":11},{"id":"mount-vernon-cancer-centre","kind":"institution","name":"Mount Vernon Cancer Centre","route":"/institutions/mount-vernon-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"nottingham-cancer-centre","kind":"institution","name":"Nottingham University Hospitals Cancer Centre (City Hospital)","route":"/institutions/nottingham-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"bristol-haematology-oncology-centre","kind":"institution","name":"Bristol Haematology and Oncology Centre","route":"/institutions/bristol-haematology-oncology-centre/","asOf":"2026-09-10","days":11},{"id":"northern-ireland-cancer-centre","kind":"institution","name":"Northern Ireland Cancer Centre, Belfast City Hospital","route":"/institutions/northern-ireland-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"imperial-cancer-centre","kind":"institution","name":"Imperial College Healthcare NHS Trust / Imperial College London Cancer Research","route":"/institutions/imperial-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"cruk-city-of-london-centre","kind":"institution","name":"Cancer Research UK City of London Centre","route":"/institutions/cruk-city-of-london-centre/","asOf":"2026-09-10","days":11},{"id":"cruk-convergence-science-centre","kind":"institution","name":"Cancer Research UK Convergence Science Centre","route":"/institutions/cruk-convergence-science-centre/","asOf":"2026-09-10","days":11},{"id":"queens-centre-hull","kind":"institution","name":"Queen's Centre for Oncology and Haematology, Castle Hill Hospital","route":"/institutions/queens-centre-hull/","asOf":"2026-09-10","days":11},{"id":"anchor-centre-aberdeen","kind":"institution","name":"ANCHOR Centre, Aberdeen Royal Infirmary","route":"/institutions/anchor-centre-aberdeen/","asOf":"2026-09-10","days":11},{"id":"leicester-cancer-research-centre","kind":"institution","name":"Leicester Cancer Research Centre / University Hospitals of Leicester","route":"/institutions/leicester-cancer-research-centre/","asOf":"2026-09-10","days":11},{"id":"cancercare-manitoba","kind":"institution","name":"CancerCare Manitoba","route":"/institutions/cancercare-manitoba/","asOf":"2026-09-10","days":11},{"id":"saskatchewan-cancer-agency","kind":"institution","name":"Saskatchewan Cancer Agency","route":"/institutions/saskatchewan-cancer-agency/","asOf":"2026-09-10","days":11},{"id":"ontario-health-cancer-care-ontario","kind":"institution","name":"Ontario Health (Cancer Care Ontario)","route":"/institutions/ontario-health-cancer-care-ontario/","asOf":"2026-09-10","days":11},{"id":"ciusss-emtl-maisonneuve-rosemont","kind":"institution","name":"Hôpital Maisonneuve-Rosemont / CIUSSS de l'Est-de-l'Île-de-Montréal","route":"/institutions/ciusss-emtl-maisonneuve-rosemont/","asOf":"2026-09-10","days":11},{"id":"muhc-cedars-cancer-centre","kind":"institution","name":"McGill University Health Centre / Cedars Cancer Centre","route":"/institutions/muhc-cedars-cancer-centre/","asOf":"2026-09-10","days":11},{"id":"lhsc-verspeeten","kind":"institution","name":"Verspeeten Family Cancer Centre, London Health Sciences Centre","route":"/institutions/lhsc-verspeeten/","asOf":"2026-09-10","days":11},{"id":"nova-scotia-cancer-care","kind":"institution","name":"Nova Scotia Health Cancer Care Program (QEII)","route":"/institutions/nova-scotia-cancer-care/","asOf":"2026-09-10","days":11},{"id":"chu-de-quebec","kind":"institution","name":"CHU de Québec - Université Laval","route":"/institutions/chu-de-quebec/","asOf":"2026-09-10","days":11},{"id":"terry-fox-research-institute","kind":"institution","name":"Terry Fox Research Institute","route":"/institutions/terry-fox-research-institute/","asOf":"2026-09-10","days":11},{"id":"aga-khan-university-hospital-nairobi","kind":"institution","name":"Aga Khan University Hospital, Nairobi","route":"/institutions/aga-khan-university-hospital-nairobi/","asOf":"2026-09-10","days":11},{"id":"tygerberg-hospital","kind":"institution","name":"Tygerberg Hospital / Stellenbosch University","route":"/institutions/tygerberg-hospital/","asOf":"2026-09-10","days":11},{"id":"cancer-diseases-hospital-lusaka","kind":"institution","name":"Cancer Diseases Hospital, Lusaka","route":"/institutions/cancer-diseases-hospital-lusaka/","asOf":"2026-09-10","days":11},{"id":"inkosi-albert-luthuli-hospital","kind":"institution","name":"Inkosi Albert Luthuli Central Hospital","route":"/institutions/inkosi-albert-luthuli-hospital/","asOf":"2026-09-10","days":11},{"id":"steve-biko-academic-hospital","kind":"institution","name":"Steve Biko Academic Hospital / University of Pretoria","route":"/institutions/steve-biko-academic-hospital/","asOf":"2026-09-10","days":11},{"id":"chris-hani-baragwanath","kind":"institution","name":"Chris Hani Baragwanath Academic Hospital","route":"/institutions/chris-hani-baragwanath/","asOf":"2026-09-10","days":11},{"id":"moi-teaching-referral-hospital","kind":"institution","name":"Moi Teaching and Referral Hospital / AMPATH Oncology","route":"/institutions/moi-teaching-referral-hospital/","asOf":"2026-09-10","days":11},{"id":"tikur-anbessa-hospital","kind":"institution","name":"Tikur Anbessa Specialized Hospital, Addis Ababa University","route":"/institutions/tikur-anbessa-hospital/","asOf":"2026-09-10","days":11},{"id":"komfo-anokye-teaching-hospital","kind":"institution","name":"Komfo Anokye Teaching Hospital","route":"/institutions/komfo-anokye-teaching-hospital/","asOf":"2026-09-10","days":11},{"id":"uch-ibadan","kind":"institution","name":"University College Hospital, Ibadan","route":"/institutions/uch-ibadan/","asOf":"2026-09-10","days":11},{"id":"aubmc-basile-cancer-institute","kind":"institution","name":"American University of Beirut Medical Center / Naef K. Basile Cancer Institute","route":"/institutions/aubmc-basile-cancer-institute/","asOf":"2026-09-10","days":11},{"id":"bahrain-oncology-centre","kind":"institution","name":"Bahrain Oncology Center, King Hamad University Hospital","route":"/institutions/bahrain-oncology-centre/","asOf":"2026-09-10","days":11},{"id":"sultan-qaboos-cccrc","kind":"institution","name":"Sultan Qaboos Comprehensive Cancer Care and Research Centre","route":"/institutions/sultan-qaboos-cccrc/","asOf":"2026-09-10","days":11},{"id":"rabin-davidoff-center","kind":"institution","name":"Davidoff Cancer Center, Rabin Medical Center","route":"/institutions/rabin-davidoff-center/","asOf":"2026-09-10","days":11},{"id":"soroka-medical-center","kind":"institution","name":"Soroka University Medical Center","route":"/institutions/soroka-medical-center/","asOf":"2026-09-10","days":11},{"id":"icesp","kind":"institution","name":"Instituto do Câncer do Estado de São Paulo (ICESP)","route":"/institutions/icesp/","asOf":"2026-09-10","days":11},{"id":"erasto-gaertner","kind":"institution","name":"Hospital Erasto Gaertner","route":"/institutions/erasto-gaertner/","asOf":"2026-09-10","days":11},{"id":"bp-beneficencia-portuguesa","kind":"institution","name":"BP - A Beneficência Portuguesa de São Paulo","route":"/institutions/bp-beneficencia-portuguesa/","asOf":"2026-09-10","days":11},{"id":"hospital-italiano-buenos-aires","kind":"institution","name":"Hospital Italiano de Buenos Aires","route":"/institutions/hospital-italiano-buenos-aires/","asOf":"2026-09-10","days":11},{"id":"instituto-roffo","kind":"institution","name":"Instituto de Oncología Ángel H. Roffo","route":"/institutions/instituto-roffo/","asOf":"2026-09-10","days":11},{"id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","asOf":"2026-09-10","days":11},{"id":"inca-uruguay","kind":"institution","name":"Instituto Nacional del Cáncer (Uruguay)","route":"/institutions/inca-uruguay/","asOf":"2026-09-10","days":11},{"id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","asOf":"2026-09-10","days":11},{"id":"fundacion-valle-del-lili","kind":"institution","name":"Fundación Valle del Lili","route":"/institutions/fundacion-valle-del-lili/","asOf":"2026-09-10","days":11},{"id":"imss-oncologia-siglo-xxi","kind":"institution","name":"Hospital de Oncología, Centro Médico Nacional Siglo XXI (IMSS)","route":"/institutions/imss-oncologia-siglo-xxi/","asOf":"2026-09-10","days":11},{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","route":"/institutions/inor-cuba/","asOf":"2026-09-10","days":11},{"id":"shaukat-khanum","kind":"institution","name":"Shaukat Khanum Memorial Cancer Hospital and Research Centre","route":"/institutions/shaukat-khanum/","asOf":"2026-09-10","days":11},{"id":"aku-karachi","kind":"institution","name":"Aga Khan University Hospital, Karachi","route":"/institutions/aku-karachi/","asOf":"2026-09-10","days":11},{"id":"nicrh-dhaka","kind":"institution","name":"National Institute of Cancer Research and Hospital","route":"/institutions/nicrh-dhaka/","asOf":"2026-09-10","days":11},{"id":"ludwig-cancer-research","kind":"institution","name":"Ludwig Cancer Research","route":"/institutions/ludwig-cancer-research/","asOf":"2026-09-10","days":11},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/","asOf":"2026-09-10","days":11},{"id":"pcf","kind":"institution","name":"Prostate Cancer Foundation","route":"/institutions/pcf/","asOf":"2026-09-10","days":11},{"id":"alsf","kind":"institution","name":"Alex's Lemonade Stand Foundation","route":"/institutions/alsf/","asOf":"2026-09-10","days":11},{"id":"st-baldricks-foundation","kind":"institution","name":"St. Baldrick's Foundation","route":"/institutions/st-baldricks-foundation/","asOf":"2026-09-10","days":11},{"id":"bowelbabe-fund","kind":"institution","name":"Bowelbabe Fund for Cancer Research UK","route":"/institutions/bowelbabe-fund/","asOf":"2026-09-10","days":11},{"id":"teenage-cancer-trust","kind":"institution","name":"Teenage Cancer Trust","route":"/institutions/teenage-cancer-trust/","asOf":"2026-09-10","days":11},{"id":"lasker-foundation","kind":"institution","name":"Lasker Foundation","route":"/institutions/lasker-foundation/","asOf":"2026-09-10","days":11},{"id":"terry-fox-foundation","kind":"institution","name":"Terry Fox Foundation","route":"/institutions/terry-fox-foundation/","asOf":"2026-09-10","days":11},{"id":"mra","kind":"institution","name":"Melanoma Research Alliance","route":"/institutions/mra/","asOf":"2026-09-10","days":11},{"id":"jimmy-fund","kind":"institution","name":"The Jimmy Fund","route":"/institutions/jimmy-fund/","asOf":"2026-09-10","days":11},{"id":"pan-mass-challenge","kind":"institution","name":"Pan-Mass Challenge","route":"/institutions/pan-mass-challenge/","asOf":"2026-09-10","days":11},{"id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","route":"/institutions/ellison-institute/","asOf":"2026-09-10","days":11},{"id":"li-ka-shing-foundation","kind":"institution","name":"Li Ka Shing Foundation","route":"/institutions/li-ka-shing-foundation/","asOf":"2026-09-10","days":11},{"id":"tata-trusts","kind":"institution","name":"Tata Trusts","route":"/institutions/tata-trusts/","asOf":"2026-09-10","days":11},{"id":"acupuncture-nausea","kind":"technology","name":"Acupuncture and acupressure for chemotherapy nausea","route":"/technologies/acupuncture-nausea/","asOf":"2026-09-10","days":11},{"id":"acupuncture-aromatase-inhibitor-arthralgia","kind":"technology","name":"Acupuncture for aromatase-inhibitor joint pain","route":"/technologies/acupuncture-aromatase-inhibitor-arthralgia/","asOf":"2026-09-10","days":11},{"id":"acupuncture-hot-flushes","kind":"technology","name":"Acupuncture for hot flushes on endocrine therapy","route":"/technologies/acupuncture-hot-flushes/","asOf":"2026-09-10","days":11},{"id":"acupuncture-xerostomia","kind":"technology","name":"Acupuncture for dry mouth after head and neck radiotherapy","route":"/technologies/acupuncture-xerostomia/","asOf":"2026-09-10","days":11},{"id":"acupuncture-chemotherapy-neuropathy","kind":"technology","name":"Acupuncture for chemotherapy-induced neuropathy","route":"/technologies/acupuncture-chemotherapy-neuropathy/","asOf":"2026-09-10","days":11},{"id":"mindfulness-based-interventions","kind":"technology","name":"Mindfulness-based stress reduction and cognitive therapy","route":"/technologies/mindfulness-based-interventions/","asOf":"2026-09-10","days":11},{"id":"cbt-insomnia-cancer","kind":"technology","name":"Cognitive behavioural therapy for insomnia (CBT-I)","route":"/technologies/cbt-insomnia-cancer/","asOf":"2026-09-10","days":11},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","asOf":"2026-09-10","days":11},{"id":"yoga-cancer","kind":"technology","name":"Yoga during and after cancer treatment","route":"/technologies/yoga-cancer/","asOf":"2026-09-10","days":11},{"id":"tai-chi-qigong","kind":"technology","name":"Tai chi and qigong","route":"/technologies/tai-chi-qigong/","asOf":"2026-09-10","days":11},{"id":"hypnosis-cancer-care","kind":"technology","name":"Clinical hypnosis for procedures, pain and hot flushes","route":"/technologies/hypnosis-cancer-care/","asOf":"2026-09-10","days":11},{"id":"relaxation-guided-imagery","kind":"technology","name":"Relaxation training and guided imagery","route":"/technologies/relaxation-guided-imagery/","asOf":"2026-09-10","days":11},{"id":"music-therapy-cancer","kind":"technology","name":"Music therapy and music medicine","route":"/technologies/music-therapy-cancer/","asOf":"2026-09-10","days":11},{"id":"dance-movement-therapy","kind":"technology","name":"Dance and movement therapy","route":"/technologies/dance-movement-therapy/","asOf":"2026-09-10","days":11},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","asOf":"2026-09-10","days":11},{"id":"massage-therapy-cancer","kind":"technology","name":"Massage therapy in cancer care","route":"/technologies/massage-therapy-cancer/","asOf":"2026-09-10","days":11},{"id":"aromatherapy-cancer","kind":"technology","name":"Aromatherapy","route":"/technologies/aromatherapy-cancer/","asOf":"2026-09-10","days":11},{"id":"reflexology-cancer","kind":"technology","name":"Reflexology","route":"/technologies/reflexology-cancer/","asOf":"2026-09-10","days":11},{"id":"reiki-energy-therapies","kind":"technology","name":"Reiki, healing touch and other energy therapies","route":"/technologies/reiki-energy-therapies/","asOf":"2026-09-10","days":11},{"id":"ginger-nausea","kind":"technology","name":"Ginger for chemotherapy nausea","route":"/technologies/ginger-nausea/","asOf":"2026-09-10","days":11},{"id":"curcumin-turmeric","kind":"technology","name":"Curcumin and turmeric","route":"/technologies/curcumin-turmeric/","asOf":"2026-09-10","days":11},{"id":"green-tea-egcg","kind":"technology","name":"Green tea and EGCG extracts","route":"/technologies/green-tea-egcg/","asOf":"2026-09-10","days":11},{"id":"american-ginseng-fatigue","kind":"technology","name":"American ginseng for cancer-related fatigue","route":"/technologies/american-ginseng-fatigue/","asOf":"2026-09-10","days":11},{"id":"melatonin-cancer","kind":"technology","name":"Melatonin as a cancer adjunct","route":"/technologies/melatonin-cancer/","asOf":"2026-09-10","days":11},{"id":"omega3-epa-cachexia","kind":"technology","name":"Fish oil (EPA) for cancer weight loss","route":"/technologies/omega3-epa-cachexia/","asOf":"2026-09-10","days":11},{"id":"probiotics-treatment-diarrhoea","kind":"technology","name":"Probiotics for chemotherapy and radiotherapy diarrhoea","route":"/technologies/probiotics-treatment-diarrhoea/","asOf":"2026-09-10","days":11},{"id":"glutamine-mucositis-neuropathy","kind":"technology","name":"Glutamine for mucositis and neuropathy","route":"/technologies/glutamine-mucositis-neuropathy/","asOf":"2026-09-10","days":11},{"id":"honey-radiation-mucositis","kind":"technology","name":"Honey for radiation mucositis","route":"/technologies/honey-radiation-mucositis/","asOf":"2026-09-10","days":11},{"id":"mistletoe-extracts","kind":"technology","name":"Mistletoe extracts (Iscador, Helixor)","route":"/technologies/mistletoe-extracts/","asOf":"2026-09-10","days":11},{"id":"high-dose-vitamin-c","kind":"technology","name":"High-dose intravenous vitamin C","route":"/technologies/high-dose-vitamin-c/","asOf":"2026-09-10","days":11},{"id":"psk-krestin-adjuvant","kind":"technology","name":"PSK (Krestin) mushroom polysaccharide as adjuvant therapy","route":"/technologies/psk-krestin-adjuvant/","asOf":"2026-09-10","days":11},{"id":"medicinal-mushrooms-reishi-turkey-tail","kind":"technology","name":"Medicinal mushrooms: reishi, turkey tail, shiitake and others","route":"/technologies/medicinal-mushrooms-reishi-turkey-tail/","asOf":"2026-09-10","days":11},{"id":"traditional-chinese-herbal-medicine","kind":"technology","name":"Traditional Chinese herbal medicine alongside treatment","route":"/technologies/traditional-chinese-herbal-medicine/","asOf":"2026-09-10","days":11},{"id":"ayurvedic-medicine-cancer","kind":"technology","name":"Ayurvedic medicine and cancer","route":"/technologies/ayurvedic-medicine-cancer/","asOf":"2026-09-10","days":11},{"id":"homeopathy-cancer","kind":"technology","name":"Homeopathy","route":"/technologies/homeopathy-cancer/","asOf":"2026-09-10","days":11},{"id":"st-johns-wort-interaction","kind":"technology","name":"St John's wort: an interaction to avoid","route":"/technologies/st-johns-wort-interaction/","asOf":"2026-09-10","days":11},{"id":"cannabinoids-nausea","kind":"technology","name":"Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)","route":"/technologies/cannabinoids-nausea/","asOf":"2026-09-10","days":11},{"id":"cannabinoids-pain-appetite","kind":"technology","name":"Cannabis and cannabinoids for pain, appetite and cancer control","route":"/technologies/cannabinoids-pain-appetite/","asOf":"2026-09-10","days":11},{"id":"oral-cryotherapy-mucositis","kind":"technology","name":"Oral cryotherapy (ice chips) to prevent mucositis","route":"/technologies/oral-cryotherapy-mucositis/","asOf":"2026-09-10","days":11},{"id":"frozen-gloves-compression-taxane","kind":"technology","name":"Frozen gloves, socks and compression for taxane nail and nerve damage","route":"/technologies/frozen-gloves-compression-taxane/","asOf":"2026-09-10","days":11},{"id":"photobiomodulation-mucositis","kind":"technology","name":"Photobiomodulation (low-level laser) for oral mucositis","route":"/technologies/photobiomodulation-mucositis/","asOf":"2026-09-10","days":11},{"id":"hyperbaric-oxygen-radiation-injury","kind":"technology","name":"Hyperbaric oxygen for late radiation injury","route":"/technologies/hyperbaric-oxygen-radiation-injury/","asOf":"2026-09-10","days":11},{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","asOf":"2026-09-10","days":11},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/","asOf":"2026-09-10","days":11},{"id":"bimatoprost-eyelash-regrowth","kind":"technology","name":"Bimatoprost for eyelash and eyebrow regrowth","route":"/technologies/bimatoprost-eyelash-regrowth/","asOf":"2026-09-10","days":11},{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/","asOf":"2026-09-10","days":11},{"id":"alternative-medicine-instead-of-treatment","kind":"technology","name":"Alternative medicine used instead of standard treatment","route":"/technologies/alternative-medicine-instead-of-treatment/","asOf":"2026-09-10","days":11},{"id":"laetrile-amygdalin","kind":"technology","name":"Laetrile (amygdalin, 'vitamin B17')","route":"/technologies/laetrile-amygdalin/","asOf":"2026-09-10","days":11},{"id":"gerson-therapy-detox-regimens","kind":"technology","name":"Gerson therapy, coffee enemas and 'detox' regimens","route":"/technologies/gerson-therapy-detox-regimens/","asOf":"2026-09-10","days":11},{"id":"shark-cartilage","kind":"technology","name":"Shark cartilage (AE-941, Neovastat)","route":"/technologies/shark-cartilage/","asOf":"2026-09-10","days":11},{"id":"hydrazine-sulfate","kind":"technology","name":"Hydrazine sulfate","route":"/technologies/hydrazine-sulfate/","asOf":"2026-09-10","days":11},{"id":"antineoplastons","kind":"technology","name":"Antineoplastons (Burzynski clinic)","route":"/technologies/antineoplastons/","asOf":"2026-09-10","days":11},{"id":"black-salve-escharotics","kind":"technology","name":"Black salve and other escharotic pastes","route":"/technologies/black-salve-escharotics/","asOf":"2026-09-10","days":11},{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/","asOf":"2026-09-10","days":11},{"id":"essiac-herbal-cancer-cures","kind":"technology","name":"Essiac, Hoxsey and other 'herbal cancer cures'","route":"/technologies/essiac-herbal-cancer-cures/","asOf":"2026-09-10","days":11},{"id":"paper-johnson-alternative-medicine-jnci-2018","kind":"paper","name":"Use of alternative medicine for cancer and its impact on survival","route":"/key-papers/paper-johnson-alternative-medicine-jnci-2018/","asOf":"2026-09-10","days":11},{"id":"paper-scalp-trial-jama-2017","kind":"paper","name":"SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer","route":"/key-papers/paper-scalp-trial-jama-2017/","asOf":"2026-09-10","days":11},{"id":"guardant360-cdx","kind":"drug","name":"Guardant360 CDx","route":"/drugs/guardant360-cdx/","asOf":"2026-09-10","days":11},{"id":"oncomine-dx-target-test","kind":"drug","name":"Oncomine Dx Target Test","route":"/drugs/oncomine-dx-target-test/","asOf":"2026-09-10","days":11},{"id":"cobas-egfr-mutation-test","kind":"drug","name":"cobas EGFR Mutation Test v2","route":"/drugs/cobas-egfr-mutation-test/","asOf":"2026-09-10","days":11},{"id":"therascreen-cdx","kind":"drug","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","route":"/drugs/therascreen-cdx/","asOf":"2026-09-10","days":11},{"id":"ventana-pd-l1-sp142","kind":"drug","name":"VENTANA PD-L1 (SP142) Assay","route":"/drugs/ventana-pd-l1-sp142/","asOf":"2026-09-10","days":11},{"id":"ventana-pd-l1-sp263","kind":"drug","name":"VENTANA PD-L1 (SP263) Assay","route":"/drugs/ventana-pd-l1-sp263/","asOf":"2026-09-10","days":11},{"id":"dako-pd-l1-22c3-pharmdx","kind":"drug","name":"PD-L1 IHC 22C3 pharmDx","route":"/drugs/dako-pd-l1-22c3-pharmdx/","asOf":"2026-09-10","days":11},{"id":"her2-testing-assays","kind":"drug","name":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)","route":"/drugs/her2-testing-assays/","asOf":"2026-09-10","days":11},{"id":"ventana-mmr-rxdx","kind":"drug","name":"VENTANA MMR RxDx Panel","route":"/drugs/ventana-mmr-rxdx/","asOf":"2026-09-10","days":11},{"id":"bracanalysis-cdx","kind":"drug","name":"BRACAnalysis CDx","route":"/drugs/bracanalysis-cdx/","asOf":"2026-09-10","days":11},{"id":"mychoice-cdx","kind":"drug","name":"myChoice CDx","route":"/drugs/mychoice-cdx/","asOf":"2026-09-10","days":11},{"id":"trusight-oncology-comprehensive","kind":"drug","name":"TruSight Oncology Comprehensive","route":"/drugs/trusight-oncology-comprehensive/","asOf":"2026-09-10","days":11},{"id":"tempus-xt-cdx","kind":"drug","name":"Tempus xT CDx","route":"/drugs/tempus-xt-cdx/","asOf":"2026-09-10","days":11},{"id":"caris-mi-cancer-seek","kind":"drug","name":"MI Cancer Seek","route":"/drugs/caris-mi-cancer-seek/","asOf":"2026-09-10","days":11},{"id":"resolution-ctdx-first","kind":"drug","name":"Resolution ctDx FIRST","route":"/drugs/resolution-ctdx-first/","asOf":"2026-09-10","days":11},{"id":"cologuard","kind":"drug","name":"Cologuard","route":"/drugs/cologuard/","asOf":"2026-09-10","days":11},{"id":"cologuard-plus","kind":"drug","name":"Cologuard Plus","route":"/drugs/cologuard-plus/","asOf":"2026-09-10","days":11},{"id":"simplescreen-crc","kind":"drug","name":"SimpleScreen CRC","route":"/drugs/simplescreen-crc/","asOf":"2026-09-10","days":11},{"id":"cancerguard","kind":"drug","name":"Cancerguard","route":"/drugs/cancerguard/","asOf":"2026-09-10","days":11},{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/","asOf":"2026-09-10","days":11},{"id":"guardant-reveal","kind":"drug","name":"Guardant Reveal","route":"/drugs/guardant-reveal/","asOf":"2026-09-10","days":11},{"id":"radar-mrd","kind":"drug","name":"RaDaR","route":"/drugs/radar-mrd/","asOf":"2026-09-10","days":11},{"id":"oncodetect","kind":"drug","name":"Oncodetect","route":"/drugs/oncodetect/","asOf":"2026-09-10","days":11},{"id":"prosigna","kind":"drug","name":"Prosigna (PAM50)","route":"/drugs/prosigna/","asOf":"2026-09-10","days":11},{"id":"endopredict","kind":"drug","name":"EndoPredict","route":"/drugs/endopredict/","asOf":"2026-09-10","days":11},{"id":"breast-cancer-index","kind":"drug","name":"Breast Cancer Index","route":"/drugs/breast-cancer-index/","asOf":"2026-09-10","days":11},{"id":"prolaris","kind":"drug","name":"Prolaris","route":"/drugs/prolaris/","asOf":"2026-09-10","days":11},{"id":"oncotype-dx-gps","kind":"drug","name":"Oncotype DX Genomic Prostate Score","route":"/drugs/oncotype-dx-gps/","asOf":"2026-09-10","days":11},{"id":"afirma","kind":"drug","name":"Afirma Genomic Sequencing Classifier","route":"/drugs/afirma/","asOf":"2026-09-10","days":11},{"id":"cxbladder","kind":"drug","name":"Cxbladder","route":"/drugs/cxbladder/","asOf":"2026-09-10","days":11},{"id":"urovysion","kind":"drug","name":"UroVysion Bladder Cancer Kit","route":"/drugs/urovysion/","asOf":"2026-09-10","days":11},{"id":"illuccix","kind":"drug","name":"Illuccix (kit for Ga-68 gozetotide)","route":"/drugs/illuccix/","asOf":"2026-09-10","days":11},{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","route":"/drugs/locametz/","asOf":"2026-09-10","days":11},{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","asOf":"2026-09-10","days":11},{"id":"paige-prostate","kind":"drug","name":"Paige Prostate Detect","route":"/drugs/paige-prostate/","asOf":"2026-09-10","days":11},{"id":"transpara","kind":"drug","name":"Transpara","route":"/drugs/transpara/","asOf":"2026-09-10","days":11},{"id":"lunit-insight-mmg","kind":"drug","name":"Lunit INSIGHT MMG","route":"/drugs/lunit-insight-mmg/","asOf":"2026-09-10","days":11},{"id":"optellum-virtual-nodule-clinic","kind":"drug","name":"Optellum Virtual Nodule Clinic","route":"/drugs/optellum-virtual-nodule-clinic/","asOf":"2026-09-10","days":11},{"id":"icad-profound-ai","kind":"drug","name":"ProFound AI (iCAD)","route":"/drugs/icad-profound-ai/","asOf":"2026-09-10","days":11},{"id":"kheiron-mia","kind":"drug","name":"Mia (Mammography Intelligent Assessment)","route":"/drugs/kheiron-mia/","asOf":"2026-09-10","days":11},{"id":"msi-mmr-testing","kind":"technology","name":"MSI and mismatch-repair testing","route":"/technologies/msi-mmr-testing/","asOf":"2026-09-10","days":11},{"id":"tmb-testing","kind":"technology","name":"Tumour mutational burden testing","route":"/technologies/tmb-testing/","asOf":"2026-09-10","days":11},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","asOf":"2026-09-10","days":11},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/","asOf":"2026-09-10","days":11},{"id":"skin-cancer-screening","kind":"technology","name":"Skin cancer screening (visual skin examination)","route":"/technologies/skin-cancer-screening/","asOf":"2026-09-10","days":11},{"id":"oral-visual-screening","kind":"technology","name":"Oral cancer visual screening","route":"/technologies/oral-visual-screening/","asOf":"2026-09-10","days":11},{"id":"gastric-endoscopic-screening","kind":"technology","name":"Gastric cancer endoscopic screening (East Asia)","route":"/technologies/gastric-endoscopic-screening/","asOf":"2026-09-10","days":11},{"id":"polygenic-risk-scores","kind":"technology","name":"Polygenic risk scores for cancer","route":"/technologies/polygenic-risk-scores/","asOf":"2026-09-10","days":11},{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/","asOf":"2026-09-10","days":11},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","asOf":"2026-09-10","days":11},{"id":"tmist","kind":"trial","name":"TMIST (Tomosynthesis Mammographic Imaging Screening Trial)","route":"/trials/tmist/","asOf":"2026-09-10","days":11},{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","asOf":"2026-09-10","days":11},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","asOf":"2026-09-10","days":11},{"id":"deep-c","kind":"trial","name":"DeeP-C","route":"/trials/deep-c/","asOf":"2026-09-10","days":11},{"id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","asOf":"2026-09-10","days":11},{"id":"goteborg-2","kind":"trial","name":"GÖTEBORG-2 (MRI-based prostate cancer screening)","route":"/trials/goteborg-2/","asOf":"2026-09-10","days":11},{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/","asOf":"2026-09-10","days":11},{"id":"agendia","kind":"company","name":"Agendia","route":"/companies/agendia/","asOf":"2026-09-10","days":11},{"id":"hologic","kind":"company","name":"Hologic","route":"/companies/hologic/","asOf":"2026-09-10","days":11},{"id":"screenpoint-medical","kind":"company","name":"ScreenPoint Medical","route":"/companies/screenpoint-medical/","asOf":"2026-09-10","days":11},{"id":"optellum","kind":"company","name":"Optellum","route":"/companies/optellum/","asOf":"2026-09-10","days":11},{"id":"icad","kind":"company","name":"iCAD (RadNet)","route":"/companies/icad/","asOf":"2026-09-10","days":11},{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/","asOf":"2026-09-10","days":11},{"id":"abbott","kind":"company","name":"Abbott Laboratories","route":"/companies/abbott/","asOf":"2026-09-10","days":11},{"id":"pacific-edge","kind":"company","name":"Pacific Edge","route":"/companies/pacific-edge/","asOf":"2026-09-10","days":11},{"id":"mdxhealth","kind":"company","name":"MDxHealth","route":"/companies/mdxhealth/","asOf":"2026-09-10","days":11},{"id":"on-target-laboratories","kind":"company","name":"On Target Laboratories","route":"/companies/on-target-laboratories/","asOf":"2026-09-10","days":11},{"id":"lumicell","kind":"company","name":"Lumicell","route":"/companies/lumicell/","asOf":"2026-09-10","days":11},{"id":"fda-ldt-rule","kind":"term","name":"FDA laboratory-developed test (LDT) rule","route":"/terms/fda-ldt-rule/","asOf":"2026-09-10","days":11},{"id":"ivdr","kind":"term","name":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","route":"/terms/ivdr/","asOf":"2026-09-10","days":11},{"id":"sensitivity-specificity","kind":"term","name":"Sensitivity and specificity","route":"/terms/sensitivity-specificity/","asOf":"2026-09-10","days":11},{"id":"overdiagnosis","kind":"term","name":"Overdiagnosis","route":"/terms/overdiagnosis/","asOf":"2026-09-10","days":11},{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/","asOf":"2026-09-10","days":11},{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","asOf":"2026-09-10","days":11},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","asOf":"2026-09-10","days":11},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","asOf":"2026-09-10","days":11},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","asOf":"2026-09-10","days":11},{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","asOf":"2026-09-10","days":11},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","asOf":"2026-09-10","days":11},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","asOf":"2026-09-10","days":11},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","asOf":"2026-09-10","days":11},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","asOf":"2026-09-10","days":11},{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/","asOf":"2026-09-10","days":11},{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","asOf":"2026-09-10","days":11},{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","asOf":"2026-09-10","days":11},{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","asOf":"2026-09-10","days":11},{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/","asOf":"2026-09-10","days":11},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","asOf":"2026-09-10","days":11},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","asOf":"2026-09-10","days":11},{"id":"nut-carcinoma","kind":"cancer","name":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement)","route":"/cancers/nut-carcinoma/","asOf":"2026-09-10","days":11},{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","asOf":"2026-09-10","days":11},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","asOf":"2026-09-10","days":11},{"id":"parathyroid-carcinoma","kind":"cancer","name":"Parathyroid carcinoma","route":"/cancers/parathyroid-carcinoma/","asOf":"2026-09-10","days":11},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","asOf":"2026-09-10","days":11},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","asOf":"2026-09-10","days":11},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","asOf":"2026-09-10","days":11},{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","asOf":"2026-09-10","days":11},{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","asOf":"2026-09-10","days":11},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","asOf":"2026-09-10","days":11},{"id":"urethral","kind":"cancer","name":"Urethral cancer","route":"/cancers/urethral/","asOf":"2026-09-10","days":11},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","asOf":"2026-09-10","days":11},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","asOf":"2026-09-10","days":11},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","asOf":"2026-09-10","days":11},{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","asOf":"2026-09-10","days":11},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","asOf":"2026-09-10","days":11},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","asOf":"2026-09-10","days":11},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","asOf":"2026-09-10","days":11},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","asOf":"2026-09-10","days":11},{"id":"firefly-1","kind":"trial","name":"FIREFLY-1","route":"/trials/firefly-1/","asOf":"2026-09-10","days":11},{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/","asOf":"2026-09-10","days":11},{"id":"action-dmg","kind":"trial","name":"ACTION","route":"/trials/action-dmg/","asOf":"2026-09-10","days":11},{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","asOf":"2026-09-10","days":11},{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/","asOf":"2026-09-10","days":11},{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","asOf":"2026-09-10","days":11},{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","asOf":"2026-09-10","days":11},{"id":"aaml0531","kind":"trial","name":"COG AAML0531","route":"/trials/aaml0531/","asOf":"2026-09-10","days":11},{"id":"inter-b-nhl-ritux-2010","kind":"trial","name":"Inter-B-NHL Ritux 2010","route":"/trials/inter-b-nhl-ritux-2010/","asOf":"2026-09-10","days":11},{"id":"lch-iii","kind":"trial","name":"LCH-III","route":"/trials/lch-iii/","asOf":"2026-09-10","days":11},{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","asOf":"2026-09-10","days":11},{"id":"accelerate-platform","kind":"institution","name":"ACCELERATE","route":"/institutions/accelerate-platform/","asOf":"2026-09-10","days":11},{"id":"itcc","kind":"institution","name":"Innovative Therapies for Children with Cancer (ITCC)","route":"/institutions/itcc/","asOf":"2026-09-10","days":11},{"id":"histiocyte-society","kind":"institution","name":"Histiocyte Society","route":"/institutions/histiocyte-society/","asOf":"2026-09-10","days":11},{"id":"race-for-children-act","kind":"term","name":"RACE for Children Act","route":"/terms/race-for-children-act/","asOf":"2026-09-10","days":11},{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","asOf":"2026-09-10","days":11},{"id":"homi-bhabha-cancer-hospital-varanasi","kind":"institution","name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi","route":"/institutions/homi-bhabha-cancer-hospital-varanasi/","asOf":"2026-09-10","days":11},{"id":"aiims-network","kind":"institution","name":"The new AIIMS network (PMSSY)","route":"/institutions/aiims-network/","asOf":"2026-09-10","days":11},{"id":"icmr","kind":"institution","name":"Indian Council of Medical Research","route":"/institutions/icmr/","asOf":"2026-09-10","days":11},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/","asOf":"2026-09-10","days":11},{"id":"icmr-nicpr","kind":"institution","name":"ICMR-National Institute of Cancer Prevention and Research","route":"/institutions/icmr-nicpr/","asOf":"2026-09-10","days":11},{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/","asOf":"2026-09-10","days":11},{"id":"nha-pmjay","kind":"institution","name":"National Health Authority (Ayushman Bharat PM-JAY)","route":"/institutions/nha-pmjay/","asOf":"2026-09-10","days":11},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/","asOf":"2026-09-10","days":11},{"id":"iisc","kind":"institution","name":"Indian Institute of Science","route":"/institutions/iisc/","asOf":"2026-09-10","days":11},{"id":"ncbs","kind":"institution","name":"National Centre for Biological Sciences","route":"/institutions/ncbs/","asOf":"2026-09-10","days":11},{"id":"instem","kind":"institution","name":"Institute for Stem Cell Science and Regenerative Medicine","route":"/institutions/instem/","asOf":"2026-09-10","days":11},{"id":"max-healthcare","kind":"institution","name":"Max Healthcare (Max Institute of Cancer Care)","route":"/institutions/max-healthcare/","asOf":"2026-09-10","days":11},{"id":"narayana-health","kind":"institution","name":"Narayana Health (Mazumdar Shaw Medical Centre)","route":"/institutions/narayana-health/","asOf":"2026-09-10","days":11},{"id":"biocon","kind":"company","name":"Biocon","route":"/companies/biocon/","asOf":"2026-09-10","days":11},{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/","asOf":"2026-09-10","days":11},{"id":"syngene","kind":"company","name":"Syngene International","route":"/companies/syngene/","asOf":"2026-09-10","days":11},{"id":"dr-reddys","kind":"company","name":"Dr. Reddy's Laboratories","route":"/companies/dr-reddys/","asOf":"2026-09-10","days":11},{"id":"aurigene","kind":"company","name":"Aurigene Oncology","route":"/companies/aurigene/","asOf":"2026-09-10","days":11},{"id":"sun-pharma","kind":"company","name":"Sun Pharmaceutical Industries","route":"/companies/sun-pharma/","asOf":"2026-09-10","days":11},{"id":"natco","kind":"company","name":"Natco Pharma","route":"/companies/natco/","asOf":"2026-09-10","days":11},{"id":"cipla","kind":"company","name":"Cipla","route":"/companies/cipla/","asOf":"2026-09-10","days":11},{"id":"zydus","kind":"company","name":"Zydus Lifesciences","route":"/companies/zydus/","asOf":"2026-09-10","days":11},{"id":"lupin","kind":"company","name":"Lupin","route":"/companies/lupin/","asOf":"2026-09-10","days":11},{"id":"intas","kind":"company","name":"Intas Pharmaceuticals (Accord Healthcare)","route":"/companies/intas/","asOf":"2026-09-10","days":11},{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/","asOf":"2026-09-10","days":11},{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/","asOf":"2026-09-10","days":11},{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","route":"/companies/immuneel/","asOf":"2026-09-10","days":11},{"id":"cellogen","kind":"company","name":"Cellogen Therapeutics","route":"/companies/cellogen/","asOf":"2026-09-10","days":11},{"id":"hetero","kind":"company","name":"Hetero Drugs","route":"/companies/hetero/","asOf":"2026-09-10","days":11},{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","route":"/companies/serum-institute-of-india/","asOf":"2026-09-10","days":11},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","asOf":"2026-09-10","days":11},{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/","asOf":"2026-09-10","days":11},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","asOf":"2026-09-10","days":11},{"id":"isb-2001","kind":"drug","name":"ISB 2001","route":"/drugs/isb-2001/","asOf":"2026-09-10","days":11},{"id":"low-dose-nivolumab-tmh","kind":"trial","name":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)","route":"/trials/low-dose-nivolumab-tmh/","asOf":"2026-09-10","days":11},{"id":"metronomic-vs-cisplatin-tmh","kind":"trial","name":"Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)","route":"/trials/metronomic-vs-cisplatin-tmh/","asOf":"2026-09-10","days":11},{"id":"metro-plus-varanasi","kind":"trial","name":"METRO PLUS (Tata Memorial Centre, Varanasi)","route":"/trials/metro-plus-varanasi/","asOf":"2026-09-10","days":11},{"id":"gefitinib-chemo-tmh","kind":"trial","name":"Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)","route":"/trials/gefitinib-chemo-tmh/","asOf":"2026-09-10","days":11},{"id":"progesterone-preop-tmh","kind":"trial","name":"Single-injection depot progesterone before breast surgery (Tata Memorial)","route":"/trials/progesterone-preop-tmh/","asOf":"2026-09-10","days":11},{"id":"lidocaine-peritumoral-tmh","kind":"trial","name":"Peritumoral lidocaine before breast cancer surgery (Tata Memorial)","route":"/trials/lidocaine-peritumoral-tmh/","asOf":"2026-09-10","days":11},{"id":"elective-neck-dissection-tmh","kind":"trial","name":"Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)","route":"/trials/elective-neck-dissection-tmh/","asOf":"2026-09-10","days":11},{"id":"osmanabad-hpv-screening","kind":"trial","name":"Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)","route":"/trials/osmanabad-hpv-screening/","asOf":"2026-09-10","days":11},{"id":"kerala-oral-screening","kind":"trial","name":"Kerala oral cancer visual screening trial (Trivandrum)","route":"/trials/kerala-oral-screening/","asOf":"2026-09-10","days":11},{"id":"mumbai-via-screening","kind":"trial","name":"Mumbai VIA cervical screening trial (Tata Memorial)","route":"/trials/mumbai-via-screening/","asOf":"2026-09-10","days":11},{"id":"iarc-india-hpv-dose-study","kind":"trial","name":"IARC India HPV vaccine dose study (one, two or three doses)","route":"/trials/iarc-india-hpv-dose-study/","asOf":"2026-09-10","days":11},{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/","asOf":"2026-09-10","days":11},{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/","asOf":"2026-09-10","days":11},{"id":"paper-patil-low-dose-nivolumab-jco-2023","kind":"paper","name":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)","route":"/key-papers/paper-patil-low-dose-nivolumab-jco-2023/","asOf":"2026-09-10","days":11},{"id":"paper-sankaranarayanan-hpv-screening-nejm-2009","kind":"paper","name":"HPV screening for cervical cancer in rural India (Osmanabad)","route":"/key-papers/paper-sankaranarayanan-hpv-screening-nejm-2009/","asOf":"2026-09-10","days":11},{"id":"paper-sankaranarayanan-oral-screening-lancet-2005","kind":"paper","name":"Effect of screening on oral cancer mortality in Kerala, India","route":"/key-papers/paper-sankaranarayanan-oral-screening-lancet-2005/","asOf":"2026-09-10","days":11},{"id":"paper-basu-single-dose-hpv-lancet-oncol-2021","kind":"paper","name":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India","route":"/key-papers/paper-basu-single-dose-hpv-lancet-oncol-2021/","asOf":"2026-09-10","days":11},{"id":"paper-badwe-progesterone-jco-2011","kind":"paper","name":"Single-injection depot progesterone before surgery and survival in operable breast cancer","route":"/key-papers/paper-badwe-progesterone-jco-2011/","asOf":"2026-09-10","days":11},{"id":"paper-dcruz-elective-neck-dissection-nejm-2015","kind":"paper","name":"Elective versus therapeutic neck dissection in node-negative oral cancer","route":"/key-papers/paper-dcruz-elective-neck-dissection-nejm-2015/","asOf":"2026-09-10","days":11},{"id":"paper-jain-talicabtagene-lancet-haem-2025","kind":"paper","name":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","route":"/key-papers/paper-jain-talicabtagene-lancet-haem-2025/","asOf":"2026-09-10","days":11},{"id":"paper-mathur-ncrp-cancer-statistics-2020","kind":"paper","name":"Cancer Statistics, 2020: Report from National Cancer Registry Programme, India","route":"/key-papers/paper-mathur-ncrp-cancer-statistics-2020/","asOf":"2026-09-10","days":11},{"id":"paper-pramesh-ncg-pooled-procurement-2023","kind":"paper","name":"A National Cancer Grid pooled procurement initiative, India","route":"/key-papers/paper-pramesh-ncg-pooled-procurement-2023/","asOf":"2026-09-10","days":11},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","asOf":"2026-09-10","days":11},{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/","asOf":"2026-09-10","days":11},{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/","asOf":"2026-09-10","days":11},{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","asOf":"2026-09-10","days":11},{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/","asOf":"2026-09-10","days":11},{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/","asOf":"2026-09-10","days":11},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/","asOf":"2026-09-10","days":11},{"id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/","asOf":"2026-09-10","days":11},{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/","asOf":"2026-09-10","days":11},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","asOf":"2026-09-10","days":11},{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/","asOf":"2026-09-10","days":11},{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/","asOf":"2026-09-10","days":11},{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","asOf":"2026-09-10","days":11},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/","asOf":"2026-09-10","days":11},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/","asOf":"2026-09-10","days":11},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","asOf":"2026-09-10","days":11},{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","asOf":"2026-09-10","days":11},{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","asOf":"2026-09-10","days":11},{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","asOf":"2026-09-10","days":11},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","asOf":"2026-09-10","days":11},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/","asOf":"2026-09-10","days":11},{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/","asOf":"2026-09-10","days":11},{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/","asOf":"2026-09-10","days":11},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/","asOf":"2026-09-10","days":11},{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/","asOf":"2026-09-10","days":11},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/","asOf":"2026-09-10","days":11},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/","asOf":"2026-09-10","days":11},{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","route":"/companies/wuxi-biologics/","asOf":"2026-09-10","days":11},{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/","asOf":"2026-09-10","days":11},{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","route":"/companies/iaso-bio/","asOf":"2026-09-10","days":11},{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","route":"/companies/cstone/","asOf":"2026-09-10","days":11},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/","asOf":"2026-09-10","days":11},{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/","asOf":"2026-09-10","days":11},{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/","asOf":"2026-09-10","days":11},{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/","asOf":"2026-09-10","days":11},{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/","asOf":"2026-09-10","days":11},{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/","asOf":"2026-09-10","days":11},{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/","asOf":"2026-09-10","days":11},{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/","asOf":"2026-09-10","days":11},{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","route":"/institutions/ncc-china/","asOf":"2026-09-10","days":11},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/","asOf":"2026-09-10","days":11},{"id":"caca","kind":"institution","name":"China Anti-Cancer Association","route":"/institutions/caca/","asOf":"2026-09-10","days":11},{"id":"ctong","kind":"institution","name":"Chinese Thoracic Oncology Group","route":"/institutions/ctong/","asOf":"2026-09-10","days":11},{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/","asOf":"2026-09-10","days":11},{"id":"cams-hematology","kind":"institution","name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-hematology/","asOf":"2026-09-10","days":11},{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/","asOf":"2026-09-10","days":11},{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","route":"/institutions/jilin-cancer-hospital/","asOf":"2026-09-10","days":11},{"id":"jiangsu-cancer-hospital","kind":"institution","name":"Jiangsu Cancer Hospital","route":"/institutions/jiangsu-cancer-hospital/","asOf":"2026-09-10","days":11},{"id":"chongqing-university-cancer-hospital","kind":"institution","name":"Chongqing University Cancer Hospital","route":"/institutions/chongqing-university-cancer-hospital/","asOf":"2026-09-10","days":11},{"id":"sichuan-cancer-hospital","kind":"institution","name":"Sichuan Cancer Hospital","route":"/institutions/sichuan-cancer-hospital/","asOf":"2026-09-10","days":11},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/","asOf":"2026-09-10","days":11},{"id":"orient-32","kind":"trial","name":"ORIENT-32","route":"/trials/orient-32/","asOf":"2026-09-10","days":11},{"id":"orient-16","kind":"trial","name":"ORIENT-16","route":"/trials/orient-16/","asOf":"2026-09-10","days":11},{"id":"rationale-302","kind":"trial","name":"RATIONALE-302","route":"/trials/rationale-302/","asOf":"2026-09-10","days":11},{"id":"camel","kind":"trial","name":"CameL","route":"/trials/camel/","asOf":"2026-09-10","days":11},{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/","asOf":"2026-09-10","days":11},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/","asOf":"2026-09-10","days":11},{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","route":"/trials/capstone-1/","asOf":"2026-09-10","days":11},{"id":"gemstone-302","kind":"trial","name":"GEMSTONE-302","route":"/trials/gemstone-302/","asOf":"2026-09-10","days":11},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/","asOf":"2026-09-10","days":11},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/","asOf":"2026-09-10","days":11},{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/","asOf":"2026-09-10","days":11},{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/","asOf":"2026-09-10","days":11},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","asOf":"2026-09-10","days":11},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","asOf":"2026-09-10","days":11},{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/","asOf":"2026-09-10","days":11},{"id":"dawna-1","kind":"trial","name":"DAWNA-1","route":"/trials/dawna-1/","asOf":"2026-09-10","days":11},{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/","asOf":"2026-09-10","days":11},{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/","asOf":"2026-09-10","days":11},{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/","asOf":"2026-09-10","days":11},{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/","asOf":"2026-09-10","days":11},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","asOf":"2026-09-10","days":11},{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","asOf":"2026-09-10","days":11},{"id":"chlorambucil","kind":"drug","name":"Chlorambucil","route":"/drugs/chlorambucil/","asOf":"2026-09-10","days":11},{"id":"clofarabine","kind":"drug","name":"Clofarabine","route":"/drugs/clofarabine/","asOf":"2026-09-10","days":11},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/","asOf":"2026-09-10","days":11},{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/","asOf":"2026-09-10","days":11},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/","asOf":"2026-09-10","days":11},{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","asOf":"2026-09-10","days":11},{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","asOf":"2026-09-10","days":11},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/","asOf":"2026-09-10","days":11},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/","asOf":"2026-09-10","days":11},{"id":"flutamide","kind":"drug","name":"Flutamide","route":"/drugs/flutamide/","asOf":"2026-09-10","days":11},{"id":"idarubicin","kind":"drug","name":"Idarubicin","route":"/drugs/idarubicin/","asOf":"2026-09-10","days":11},{"id":"ixabepilone","kind":"drug","name":"Ixabepilone","route":"/drugs/ixabepilone/","asOf":"2026-09-10","days":11},{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/","asOf":"2026-09-10","days":11},{"id":"megestrol","kind":"drug","name":"Megestrol acetate","route":"/drugs/megestrol/","asOf":"2026-09-10","days":11},{"id":"mercaptopurine","kind":"drug","name":"Mercaptopurine","route":"/drugs/mercaptopurine/","asOf":"2026-09-10","days":11},{"id":"mitoxantrone","kind":"drug","name":"Mitoxantrone","route":"/drugs/mitoxantrone/","asOf":"2026-09-10","days":11},{"id":"nelarabine","kind":"drug","name":"Nelarabine","route":"/drugs/nelarabine/","asOf":"2026-09-10","days":11},{"id":"omacetaxine","kind":"drug","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","asOf":"2026-09-10","days":11},{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/","asOf":"2026-09-10","days":11},{"id":"thioguanine","kind":"drug","name":"Thioguanine","route":"/drugs/thioguanine/","asOf":"2026-09-10","days":11},{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/","asOf":"2026-09-10","days":11},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/","asOf":"2026-09-10","days":11},{"id":"valrubicin","kind":"drug","name":"Valrubicin","route":"/drugs/valrubicin/","asOf":"2026-09-10","days":11},{"id":"vorinostat","kind":"drug","name":"Vorinostat","route":"/drugs/vorinostat/","asOf":"2026-09-10","days":11},{"id":"nilutamide","kind":"drug","name":"Nilutamide","route":"/drugs/nilutamide/","asOf":"2026-09-10","days":11},{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/","asOf":"2026-09-10","days":11},{"id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/","asOf":"2026-09-10","days":11},{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/","asOf":"2026-09-10","days":11},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/","asOf":"2026-09-10","days":11},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/","asOf":"2026-09-10","days":11},{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","asOf":"2026-09-10","days":11},{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","asOf":"2026-09-10","days":11},{"id":"denileukin-diftitox","kind":"drug","name":"Denileukin diftitox","route":"/drugs/denileukin-diftitox/","asOf":"2026-09-10","days":11},{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","asOf":"2026-09-10","days":11},{"id":"iobenguane-i-131","kind":"drug","name":"Iobenguane I-131 (therapeutic)","route":"/drugs/iobenguane-i-131/","asOf":"2026-09-10","days":11},{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/","asOf":"2026-09-10","days":11},{"id":"ofatumumab","kind":"drug","name":"Ofatumumab","route":"/drugs/ofatumumab/","asOf":"2026-09-10","days":11},{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/","asOf":"2026-09-10","days":11},{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/","asOf":"2026-09-10","days":11},{"id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/","asOf":"2026-09-10","days":11},{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","asOf":"2026-09-10","days":11},{"id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","asOf":"2026-09-10","days":11},{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/","asOf":"2026-09-10","days":11},{"id":"pamidronate","kind":"drug","name":"Pamidronate","route":"/drugs/pamidronate/","asOf":"2026-09-10","days":11},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/","asOf":"2026-09-10","days":11},{"id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/","asOf":"2026-09-10","days":11},{"id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","asOf":"2026-09-10","days":11},{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/","asOf":"2026-09-10","days":11},{"id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/","asOf":"2026-09-10","days":11},{"id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/","asOf":"2026-09-10","days":11},{"id":"netupitant-palonosetron","kind":"drug","name":"Netupitant and palonosetron","route":"/drugs/netupitant-palonosetron/","asOf":"2026-09-10","days":11},{"id":"rolapitant","kind":"drug","name":"Rolapitant","route":"/drugs/rolapitant/","asOf":"2026-09-10","days":11},{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","asOf":"2026-09-10","days":11},{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/","asOf":"2026-09-10","days":11},{"id":"glucarpidase","kind":"drug","name":"Glucarpidase","route":"/drugs/glucarpidase/","asOf":"2026-09-10","days":11},{"id":"uridine-triacetate","kind":"drug","name":"Uridine triacetate","route":"/drugs/uridine-triacetate/","asOf":"2026-09-10","days":11},{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/","asOf":"2026-09-10","days":11},{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/","asOf":"2026-09-10","days":11},{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/","asOf":"2026-09-10","days":11},{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/","asOf":"2026-09-10","days":11},{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/","asOf":"2026-09-10","days":11},{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","asOf":"2026-09-10","days":11},{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/","asOf":"2026-09-10","days":11},{"id":"defibrotide","kind":"drug","name":"Defibrotide","route":"/drugs/defibrotide/","asOf":"2026-09-10","days":11},{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","asOf":"2026-09-10","days":11},{"id":"talc-sclerosant","kind":"drug","name":"Talc (intrapleural)","route":"/drugs/talc-sclerosant/","asOf":"2026-09-10","days":11},{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","asOf":"2026-09-10","days":11},{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","asOf":"2026-09-10","days":11},{"id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/","asOf":"2026-09-10","days":11},{"id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/","asOf":"2026-09-10","days":11},{"id":"efbemalenograstim-alfa","kind":"drug","name":"Efbemalenograstim alfa","route":"/drugs/efbemalenograstim-alfa/","asOf":"2026-09-10","days":11},{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/","asOf":"2026-09-10","days":11},{"id":"telotristat-ethyl","kind":"drug","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/","asOf":"2026-09-10","days":11},{"id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/","asOf":"2026-09-10","days":11},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/","asOf":"2026-09-10","days":11},{"id":"vinflunine","kind":"drug","name":"Vinflunine","route":"/drugs/vinflunine/","asOf":"2026-09-10","days":11},{"id":"histamine-dihydrochloride","kind":"drug","name":"Histamine dihydrochloride","route":"/drugs/histamine-dihydrochloride/","asOf":"2026-09-10","days":11},{"id":"anagrelide","kind":"drug","name":"Anagrelide","route":"/drugs/anagrelide/","asOf":"2026-09-10","days":11},{"id":"temoporfin","kind":"drug","name":"Temoporfin","route":"/drugs/temoporfin/","asOf":"2026-09-10","days":11},{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","asOf":"2026-09-10","days":11},{"id":"tasonermin","kind":"drug","name":"Tasonermin","route":"/drugs/tasonermin/","asOf":"2026-09-10","days":11},{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","asOf":"2026-09-10","days":11},{"id":"ibandronic-acid","kind":"drug","name":"Ibandronic acid","route":"/drugs/ibandronic-acid/","asOf":"2026-09-10","days":11},{"id":"dorocubicel","kind":"drug","name":"Dorocubicel (UM171-expanded cord blood)","route":"/drugs/dorocubicel/","asOf":"2026-09-10","days":11},{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/","asOf":"2026-09-10","days":11},{"id":"hdac","kind":"target","name":"Histone deacetylases (HDAC)","route":"/targets/hdac/","asOf":"2026-09-10","days":11},{"id":"rxr","kind":"target","name":"Retinoid X receptor (RXR)","route":"/targets/rxr/","asOf":"2026-09-10","days":11},{"id":"rankl","kind":"target","name":"RANK ligand (RANKL)","route":"/targets/rankl/","asOf":"2026-09-10","days":11},{"id":"il6","kind":"target","name":"Interleukin-6 and IL-6 receptor","route":"/targets/il6/","asOf":"2026-09-10","days":11},{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/","asOf":"2026-09-10","days":11},{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/","asOf":"2026-09-10","days":11},{"id":"bausch-health","kind":"company","name":"Bausch Health","route":"/companies/bausch-health/","asOf":"2026-09-10","days":11},{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","route":"/companies/otsuka/","asOf":"2026-09-10","days":11},{"id":"helsinn","kind":"company","name":"Helsinn","route":"/companies/helsinn/","asOf":"2026-09-10","days":11},{"id":"recordati","kind":"company","name":"Recordati","route":"/companies/recordati/","asOf":"2026-09-10","days":11},{"id":"sandoz","kind":"company","name":"Sandoz","route":"/companies/sandoz/","asOf":"2026-09-10","days":11},{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","route":"/companies/teva/","asOf":"2026-09-10","days":11},{"id":"leadiant","kind":"company","name":"Leadiant Biosciences","route":"/companies/leadiant/","asOf":"2026-09-10","days":11},{"id":"adienne","kind":"company","name":"Adienne Pharma & Biotech","route":"/companies/adienne/","asOf":"2026-09-10","days":11},{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","route":"/companies/kyowa-kirin/","asOf":"2026-09-10","days":11},{"id":"verity-pharma","kind":"company","name":"Verity Pharmaceuticals","route":"/companies/verity-pharma/","asOf":"2026-09-10","days":11},{"id":"biofrontera","kind":"company","name":"Biofrontera","route":"/companies/biofrontera/","asOf":"2026-09-10","days":11},{"id":"heron-therapeutics","kind":"company","name":"Heron Therapeutics","route":"/companies/heron-therapeutics/","asOf":"2026-09-10","days":11},{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/","asOf":"2026-09-10","days":11},{"id":"citius-pharmaceuticals","kind":"company","name":"Citius Pharmaceuticals","route":"/companies/citius-pharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"serb-pharmaceuticals","kind":"company","name":"SERB Pharmaceuticals","route":"/companies/serb-pharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"tersera-therapeutics","kind":"company","name":"TerSera Therapeutics","route":"/companies/tersera-therapeutics/","asOf":"2026-09-10","days":11},{"id":"sobi","kind":"company","name":"Sobi (Swedish Orphan Biovitrum)","route":"/companies/sobi/","asOf":"2026-09-10","days":11},{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/","asOf":"2026-09-10","days":11},{"id":"evive-biotech","kind":"company","name":"Evive Biotech","route":"/companies/evive-biotech/","asOf":"2026-09-10","days":11},{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/","asOf":"2026-09-10","days":11},{"id":"biolitec","kind":"company","name":"biolitec","route":"/companies/biolitec/","asOf":"2026-09-10","days":11},{"id":"bikanta","kind":"company","name":"Bikanta","route":"/companies/bikanta/","asOf":"2026-09-10","days":11},{"id":"notable-labs","kind":"company","name":"Notable Labs","route":"/companies/notable-labs/","asOf":"2026-09-10","days":11},{"id":"x-zell","kind":"company","name":"X-Zell","route":"/companies/x-zell/","asOf":"2026-09-10","days":11},{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/","asOf":"2026-09-10","days":11},{"id":"zpredicta","kind":"company","name":"zPREDICTA","route":"/companies/zpredicta/","asOf":"2026-09-10","days":11},{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","route":"/companies/cofactor-genomics/","asOf":"2026-09-10","days":11},{"id":"isono-health","kind":"company","name":"iSono Health","route":"/companies/isono-health/","asOf":"2026-09-10","days":11},{"id":"histowiz","kind":"company","name":"HistoWiz","route":"/companies/histowiz/","asOf":"2026-09-10","days":11},{"id":"billiontoone","kind":"company","name":"BillionToOne","route":"/companies/billiontoone/","asOf":"2026-09-10","days":11},{"id":"mednet","kind":"company","name":"Mednet (theMednet)","route":"/companies/mednet/","asOf":"2026-09-10","days":11},{"id":"delee","kind":"company","name":"Delee","route":"/companies/delee/","asOf":"2026-09-10","days":11},{"id":"oncobox","kind":"company","name":"Oncobox","route":"/companies/oncobox/","asOf":"2026-09-10","days":11},{"id":"cambridge-cancer-genomics","kind":"company","name":"Cambridge Cancer Genomics (CCG.ai)","route":"/companies/cambridge-cancer-genomics/","asOf":"2026-09-10","days":11},{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","route":"/companies/tradewind-bioscience/","asOf":"2026-09-10","days":11},{"id":"persephone-biosciences","kind":"company","name":"Persephone Biosciences","route":"/companies/persephone-biosciences/","asOf":"2026-09-10","days":11},{"id":"reverie-labs","kind":"company","name":"Reverie Labs","route":"/companies/reverie-labs/","asOf":"2026-09-10","days":11},{"id":"fidocure","kind":"company","name":"FidoCure","route":"/companies/fidocure/","asOf":"2026-09-10","days":11},{"id":"data-driven-bioscience","kind":"company","name":"Data Driven Bioscience (Duoseq)","route":"/companies/data-driven-bioscience/","asOf":"2026-09-10","days":11},{"id":"clear-gene","kind":"company","name":"Clear Gene","route":"/companies/clear-gene/","asOf":"2026-09-10","days":11},{"id":"leah-labs","kind":"company","name":"LEAH Labs","route":"/companies/leah-labs/","asOf":"2026-09-10","days":11},{"id":"resistancebio","kind":"company","name":"ResistanceBio (Viosera Therapeutics)","route":"/companies/resistancebio/","asOf":"2026-09-10","days":11},{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","asOf":"2026-09-10","days":11},{"id":"arpeggio-bio","kind":"company","name":"Arpeggio Bio","route":"/companies/arpeggio-bio/","asOf":"2026-09-10","days":11},{"id":"asher-bio","kind":"company","name":"Asher Biotherapeutics","route":"/companies/asher-bio/","asOf":"2026-09-10","days":11},{"id":"altay-therapeutics","kind":"company","name":"Altay Therapeutics","route":"/companies/altay-therapeutics/","asOf":"2026-09-10","days":11},{"id":"isabl","kind":"company","name":"Isabl","route":"/companies/isabl/","asOf":"2026-09-10","days":11},{"id":"algen-biotechnologies","kind":"company","name":"Algen Biotechnologies","route":"/companies/algen-biotechnologies/","asOf":"2026-09-10","days":11},{"id":"known-medicine","kind":"company","name":"Known Medicine","route":"/companies/known-medicine/","asOf":"2026-09-10","days":11},{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","route":"/companies/kernal-biologics/","asOf":"2026-09-10","days":11},{"id":"liyfe","kind":"company","name":"Liyfe","route":"/companies/liyfe/","asOf":"2026-09-10","days":11},{"id":"valink-therapeutics","kind":"company","name":"Valink Therapeutics","route":"/companies/valink-therapeutics/","asOf":"2026-09-10","days":11},{"id":"triomics","kind":"company","name":"Triomics","route":"/companies/triomics/","asOf":"2026-09-10","days":11},{"id":"aoa-dx","kind":"company","name":"AOA Dx","route":"/companies/aoa-dx/","asOf":"2026-09-10","days":11},{"id":"ananya-health","kind":"company","name":"Ananya Health","route":"/companies/ananya-health/","asOf":"2026-09-10","days":11},{"id":"reprosent","kind":"company","name":"REPROSENT","route":"/companies/reprosent/","asOf":"2026-09-10","days":11},{"id":"yemaachi-biotech","kind":"company","name":"Yemaachi Biotech","route":"/companies/yemaachi-biotech/","asOf":"2026-09-10","days":11},{"id":"digistain","kind":"company","name":"Digistain","route":"/companies/digistain/","asOf":"2026-09-10","days":11},{"id":"harmonic-discovery","kind":"company","name":"Harmonic Discovery","route":"/companies/harmonic-discovery/","asOf":"2026-09-10","days":11},{"id":"humane-genomics","kind":"company","name":"Humane Genomics","route":"/companies/humane-genomics/","asOf":"2026-09-10","days":11},{"id":"luminate-medical","kind":"company","name":"Luminate Medical","route":"/companies/luminate-medical/","asOf":"2026-09-10","days":11},{"id":"alixia","kind":"company","name":"Alixia","route":"/companies/alixia/","asOf":"2026-09-10","days":11},{"id":"nearwave","kind":"company","name":"NearWave","route":"/companies/nearwave/","asOf":"2026-09-10","days":11},{"id":"serinus-biosciences","kind":"company","name":"Serinus Biosciences","route":"/companies/serinus-biosciences/","asOf":"2026-09-10","days":11},{"id":"signatur-biosciences","kind":"company","name":"Signatur Biosciences","route":"/companies/signatur-biosciences/","asOf":"2026-09-10","days":11},{"id":"guardian-bio","kind":"company","name":"Guardian Bio","route":"/companies/guardian-bio/","asOf":"2026-09-10","days":11},{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","route":"/companies/adventris-pharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"modulari-t","kind":"company","name":"Modulari-T","route":"/companies/modulari-t/","asOf":"2026-09-10","days":11},{"id":"numen","kind":"company","name":"Numen","route":"/companies/numen/","asOf":"2026-09-10","days":11},{"id":"synsorybio","kind":"company","name":"SynsoryBio","route":"/companies/synsorybio/","asOf":"2026-09-10","days":11},{"id":"velorum-therapeutics","kind":"company","name":"Velorum Therapeutics","route":"/companies/velorum-therapeutics/","asOf":"2026-09-10","days":11},{"id":"eris-biotech","kind":"company","name":"Eris Biotech","route":"/companies/eris-biotech/","asOf":"2026-09-10","days":11},{"id":"granza-bio","kind":"company","name":"Granza Bio","route":"/companies/granza-bio/","asOf":"2026-09-10","days":11},{"id":"kopra-bio","kind":"company","name":"Kopra Bio","route":"/companies/kopra-bio/","asOf":"2026-09-10","days":11},{"id":"aluna","kind":"company","name":"Aluna","route":"/companies/aluna/","asOf":"2026-09-10","days":11},{"id":"blank-bio","kind":"company","name":"Blank Bio","route":"/companies/blank-bio/","asOf":"2026-09-10","days":11},{"id":"nucleo-research","kind":"company","name":"Nucleo","route":"/companies/nucleo-research/","asOf":"2026-09-10","days":11},{"id":"origin-bio","kind":"company","name":"Origin Bio","route":"/companies/origin-bio/","asOf":"2026-09-10","days":11},{"id":"adialante","kind":"company","name":"Adialante","route":"/companies/adialante/","asOf":"2026-09-10","days":11},{"id":"tarebio","kind":"company","name":"TareBio","route":"/companies/tarebio/","asOf":"2026-09-10","days":11},{"id":"omanta","kind":"company","name":"Omanta","route":"/companies/omanta/","asOf":"2026-09-10","days":11},{"id":"gamgee","kind":"company","name":"Gamgee","route":"/companies/gamgee/","asOf":"2026-09-10","days":11},{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","asOf":"2026-09-10","days":11},{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/","asOf":"2026-09-10","days":11},{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","route":"/companies/alentis-therapeutics/","asOf":"2026-09-10","days":11},{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","asOf":"2026-09-10","days":11},{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","asOf":"2026-09-10","days":11},{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","asOf":"2026-09-10","days":11},{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","asOf":"2026-09-10","days":11},{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/","asOf":"2026-09-10","days":11},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/","asOf":"2026-09-10","days":11},{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/","asOf":"2026-09-10","days":11},{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/","asOf":"2026-09-10","days":11},{"id":"emergence-therapeutics","kind":"company","name":"Emergence Therapeutics","route":"/companies/emergence-therapeutics/","asOf":"2026-09-10","days":11},{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","route":"/companies/enlaza-therapeutics/","asOf":"2026-09-10","days":11},{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","asOf":"2026-09-10","days":11},{"id":"firefly-bio","kind":"company","name":"Firefly Bio","route":"/companies/firefly-bio/","asOf":"2026-09-10","days":11},{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","route":"/companies/iksuda-therapeutics/","asOf":"2026-09-10","days":11},{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","route":"/companies/mablink-bioscience/","asOf":"2026-09-10","days":11},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","asOf":"2026-09-10","days":11},{"id":"myricx-bio","kind":"company","name":"Myricx Bio","route":"/companies/myricx-bio/","asOf":"2026-09-10","days":11},{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/","asOf":"2026-09-10","days":11},{"id":"nbe-therapeutics","kind":"company","name":"NBE-Therapeutics","route":"/companies/nbe-therapeutics/","asOf":"2026-09-10","days":11},{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","asOf":"2026-09-10","days":11},{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","asOf":"2026-09-10","days":11},{"id":"pheon-therapeutics","kind":"company","name":"Pheon Therapeutics","route":"/companies/pheon-therapeutics/","asOf":"2026-09-10","days":11},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","asOf":"2026-09-10","days":11},{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/","asOf":"2026-09-10","days":11},{"id":"profoundbio","kind":"company","name":"ProfoundBio","route":"/companies/profoundbio/","asOf":"2026-09-10","days":11},{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","asOf":"2026-09-10","days":11},{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","asOf":"2026-09-10","days":11},{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/","asOf":"2026-09-10","days":11},{"id":"adicet-bio","kind":"company","name":"Adicet Bio","route":"/companies/adicet-bio/","asOf":"2026-09-10","days":11},{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","route":"/companies/affini-t-therapeutics/","asOf":"2026-09-10","days":11},{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","route":"/companies/allotera-therapeutics/","asOf":"2026-09-10","days":11},{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/","asOf":"2026-09-10","days":11},{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/","asOf":"2026-09-10","days":11},{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","asOf":"2026-09-10","days":11},{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","route":"/companies/capstan-therapeutics/","asOf":"2026-09-10","days":11},{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","asOf":"2026-09-10","days":11},{"id":"century-therapeutics","kind":"company","name":"Century Therapeutics","route":"/companies/century-therapeutics/","asOf":"2026-09-10","days":11},{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/","asOf":"2026-09-10","days":11},{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/","asOf":"2026-09-10","days":11},{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/","asOf":"2026-09-10","days":11},{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","route":"/companies/igm-biosciences/","asOf":"2026-09-10","days":11},{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/","asOf":"2026-09-10","days":11},{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","route":"/companies/janux-therapeutics/","asOf":"2026-09-10","days":11},{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/","asOf":"2026-09-10","days":11},{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","asOf":"2026-09-10","days":11},{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","route":"/companies/marengo-therapeutics/","asOf":"2026-09-10","days":11},{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/","asOf":"2026-09-10","days":11},{"id":"neogene-therapeutics","kind":"company","name":"Neogene Therapeutics","route":"/companies/neogene-therapeutics/","asOf":"2026-09-10","days":11},{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","asOf":"2026-09-10","days":11},{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","route":"/companies/onk-therapeutics/","asOf":"2026-09-10","days":11},{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","asOf":"2026-09-10","days":11},{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","route":"/companies/poseida-therapeutics/","asOf":"2026-09-10","days":11},{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","route":"/companies/tmunity-therapeutics/","asOf":"2026-09-10","days":11},{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","route":"/companies/turnstone-biologics/","asOf":"2026-09-10","days":11},{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/","asOf":"2026-09-10","days":11},{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/","asOf":"2026-09-10","days":11},{"id":"belong-life","kind":"company","name":"Belong.Life","route":"/companies/belong-life/","asOf":"2026-09-10","days":11},{"id":"canopy","kind":"company","name":"Canopy","route":"/companies/canopy/","asOf":"2026-09-10","days":11},{"id":"careology","kind":"company","name":"Careology","route":"/companies/careology/","asOf":"2026-09-10","days":11},{"id":"carevive-systems","kind":"company","name":"Carevive Systems","route":"/companies/carevive-systems/","asOf":"2026-09-10","days":11},{"id":"carrum-health","kind":"company","name":"Carrum Health","route":"/companies/carrum-health/","asOf":"2026-09-10","days":11},{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","asOf":"2026-09-10","days":11},{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/","asOf":"2026-09-10","days":11},{"id":"jasper-health","kind":"company","name":"Jasper Health","route":"/companies/jasper-health/","asOf":"2026-09-10","days":11},{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/","asOf":"2026-09-10","days":11},{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/","asOf":"2026-09-10","days":11},{"id":"oncohealth","kind":"company","name":"OncoHealth","route":"/companies/oncohealth/","asOf":"2026-09-10","days":11},{"id":"osara-health","kind":"company","name":"Osara Health","route":"/companies/osara-health/","asOf":"2026-09-10","days":11},{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/","asOf":"2026-09-10","days":11},{"id":"perci-health","kind":"company","name":"Perci Health","route":"/companies/perci-health/","asOf":"2026-09-10","days":11},{"id":"radformation","kind":"company","name":"Radformation","route":"/companies/radformation/","asOf":"2026-09-10","days":11},{"id":"reimagine-care","kind":"company","name":"Reimagine Care","route":"/companies/reimagine-care/","asOf":"2026-09-10","days":11},{"id":"tailormed","kind":"company","name":"TailorMed","route":"/companies/tailormed/","asOf":"2026-09-10","days":11},{"id":"thyme-care","kind":"company","name":"Thyme Care","route":"/companies/thyme-care/","asOf":"2026-09-10","days":11},{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/","asOf":"2026-09-10","days":11},{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/","asOf":"2026-09-10","days":11},{"id":"ataraxis-ai","kind":"company","name":"Ataraxis AI","route":"/companies/ataraxis-ai/","asOf":"2026-09-10","days":11},{"id":"biodesix","kind":"company","name":"Biodesix","route":"/companies/biodesix/","asOf":"2026-09-10","days":11},{"id":"c2i-genomics","kind":"company","name":"C2i Genomics","route":"/companies/c2i-genomics/","asOf":"2026-09-10","days":11},{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/","asOf":"2026-09-10","days":11},{"id":"cyted-health","kind":"company","name":"Cyted Health","route":"/companies/cyted-health/","asOf":"2026-09-10","days":11},{"id":"elypta","kind":"company","name":"Elypta","route":"/companies/elypta/","asOf":"2026-09-10","days":11},{"id":"exai-bio","kind":"company","name":"Exai Bio","route":"/companies/exai-bio/","asOf":"2026-09-10","days":11},{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","route":"/companies/haystack-oncology/","asOf":"2026-09-10","days":11},{"id":"helio-genomics","kind":"company","name":"Helio Genomics","route":"/companies/helio-genomics/","asOf":"2026-09-10","days":11},{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/","asOf":"2026-09-10","days":11},{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/","asOf":"2026-09-10","days":11},{"id":"inivata","kind":"company","name":"Inivata","route":"/companies/inivata/","asOf":"2026-09-10","days":11},{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","route":"/companies/insight-molecular-diagnostics/","asOf":"2026-09-10","days":11},{"id":"kheiron-medical-technologies","kind":"company","name":"Kheiron Medical Technologies","route":"/companies/kheiron-medical-technologies/","asOf":"2026-09-10","days":11},{"id":"lucence","kind":"company","name":"Lucence","route":"/companies/lucence/","asOf":"2026-09-10","days":11},{"id":"naveris","kind":"company","name":"Naveris","route":"/companies/naveris/","asOf":"2026-09-10","days":11},{"id":"nonagen-bioscience","kind":"company","name":"Nonagen Bioscience","route":"/companies/nonagen-bioscience/","asOf":"2026-09-10","days":11},{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/","asOf":"2026-09-10","days":11},{"id":"nucleix","kind":"company","name":"Nucleix","route":"/companies/nucleix/","asOf":"2026-09-10","days":11},{"id":"owlstone-medical","kind":"company","name":"Owlstone Medical","route":"/companies/owlstone-medical/","asOf":"2026-09-10","days":11},{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/","asOf":"2026-09-10","days":11},{"id":"therapixel","kind":"company","name":"Therapixel","route":"/companies/therapixel/","asOf":"2026-09-10","days":11},{"id":"universal-dx","kind":"company","name":"Universal DX","route":"/companies/universal-dx/","asOf":"2026-09-10","days":11},{"id":"valar-labs","kind":"company","name":"Valar Labs","route":"/companies/valar-labs/","asOf":"2026-09-10","days":11},{"id":"vara","kind":"company","name":"Vara","route":"/companies/vara/","asOf":"2026-09-10","days":11},{"id":"volitionrx","kind":"company","name":"VolitionRx","route":"/companies/volitionrx/","asOf":"2026-09-10","days":11},{"id":"volpara-health","kind":"company","name":"Volpara Health","route":"/companies/volpara-health/","asOf":"2026-09-10","days":11},{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","route":"/companies/empyrean-medical-systems/","asOf":"2026-09-10","days":11},{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/","asOf":"2026-09-10","days":11},{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","route":"/companies/intraop-medical/","asOf":"2026-09-10","days":11},{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","route":"/companies/leo-cancer-care/","asOf":"2026-09-10","days":11},{"id":"monteris-medical","kind":"company","name":"Monteris Medical","route":"/companies/monteris-medical/","asOf":"2026-09-10","days":11},{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","asOf":"2026-09-10","days":11},{"id":"p-cure","kind":"company","name":"P-Cure","route":"/companies/p-cure/","asOf":"2026-09-10","days":11},{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","asOf":"2026-09-10","days":11},{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","route":"/companies/quantum-surgical/","asOf":"2026-09-10","days":11},{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/","asOf":"2026-09-10","days":11},{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","route":"/companies/tae-life-sciences/","asOf":"2026-09-10","days":11},{"id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","asOf":"2026-09-10","days":11},{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","asOf":"2026-09-10","days":11},{"id":"xact-robotics","kind":"company","name":"XACT Robotics","route":"/companies/xact-robotics/","asOf":"2026-09-10","days":11},{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","route":"/companies/xcision-medical-systems/","asOf":"2026-09-10","days":11},{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","route":"/companies/zap-surgical-systems/","asOf":"2026-09-10","days":11},{"id":"aqemia","kind":"company","name":"Aqemia","route":"/companies/aqemia/","asOf":"2026-09-10","days":11},{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","route":"/companies/bighat-biosciences/","asOf":"2026-09-10","days":11},{"id":"certis-oncology-solutions","kind":"company","name":"Certis Oncology Solutions","route":"/companies/certis-oncology-solutions/","asOf":"2026-09-10","days":11},{"id":"curevac","kind":"company","name":"CureVac","route":"/companies/curevac/","asOf":"2026-09-10","days":11},{"id":"cytoreason","kind":"company","name":"CytoReason","route":"/companies/cytoreason/","asOf":"2026-09-10","days":11},{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","asOf":"2026-09-10","days":11},{"id":"exscientia","kind":"company","name":"Exscientia","route":"/companies/exscientia/","asOf":"2026-09-10","days":11},{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","route":"/companies/geneos-therapeutics/","asOf":"2026-09-10","days":11},{"id":"iktos","kind":"company","name":"Iktos","route":"/companies/iktos/","asOf":"2026-09-10","days":11},{"id":"immunai","kind":"company","name":"Immunai","route":"/companies/immunai/","asOf":"2026-09-10","days":11},{"id":"imugene","kind":"company","name":"Imugene","route":"/companies/imugene/","asOf":"2026-09-10","days":11},{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/","asOf":"2026-09-10","days":11},{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","route":"/companies/kanvas-biosciences/","asOf":"2026-09-10","days":11},{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","asOf":"2026-09-10","days":11},{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/","asOf":"2026-09-10","days":11},{"id":"microbiotica","kind":"company","name":"Microbiotica","route":"/companies/microbiotica/","asOf":"2026-09-10","days":11},{"id":"mission-bio","kind":"company","name":"Mission Bio","route":"/companies/mission-bio/","asOf":"2026-09-10","days":11},{"id":"noetik","kind":"company","name":"Noetik","route":"/companies/noetik/","asOf":"2026-09-10","days":11},{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/","asOf":"2026-09-10","days":11},{"id":"oncohost","kind":"company","name":"OncoHost","route":"/companies/oncohost/","asOf":"2026-09-10","days":11},{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/","asOf":"2026-09-10","days":11},{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","route":"/companies/strand-therapeutics/","asOf":"2026-09-10","days":11},{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","asOf":"2026-09-10","days":11},{"id":"turbine","kind":"company","name":"Turbine","route":"/companies/turbine/","asOf":"2026-09-10","days":11},{"id":"valo-health","kind":"company","name":"Valo Health","route":"/companies/valo-health/","asOf":"2026-09-10","days":11},{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/","asOf":"2026-09-10","days":11},{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","route":"/companies/ambagon-therapeutics/","asOf":"2026-09-10","days":11},{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/","asOf":"2026-09-10","days":11},{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","route":"/companies/black-diamond-therapeutics/","asOf":"2026-09-10","days":11},{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/","asOf":"2026-09-10","days":11},{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/","asOf":"2026-09-10","days":11},{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","route":"/companies/bridgebio-oncology-therapeutics/","asOf":"2026-09-10","days":11},{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/","asOf":"2026-09-10","days":11},{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/","asOf":"2026-09-10","days":11},{"id":"cullgen","kind":"company","name":"Cullgen","route":"/companies/cullgen/","asOf":"2026-09-10","days":11},{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/","asOf":"2026-09-10","days":11},{"id":"erasca","kind":"company","name":"Erasca","route":"/companies/erasca/","asOf":"2026-09-10","days":11},{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","asOf":"2026-09-10","days":11},{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/","asOf":"2026-09-10","days":11},{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/","asOf":"2026-09-10","days":11},{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/","asOf":"2026-09-10","days":11},{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/","asOf":"2026-09-10","days":11},{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/","asOf":"2026-09-10","days":11},{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/","asOf":"2026-09-10","days":11},{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/","asOf":"2026-09-10","days":11},{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/","asOf":"2026-09-10","days":11},{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","route":"/companies/photys-therapeutics/","asOf":"2026-09-10","days":11},{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/","asOf":"2026-09-10","days":11},{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","route":"/companies/prelude-therapeutics/","asOf":"2026-09-10","days":11},{"id":"proxygen","kind":"company","name":"Proxygen","route":"/companies/proxygen/","asOf":"2026-09-10","days":11},{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","route":"/companies/relay-therapeutics/","asOf":"2026-09-10","days":11},{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/","asOf":"2026-09-10","days":11},{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","route":"/companies/scorpion-therapeutics/","asOf":"2026-09-10","days":11},{"id":"stablix","kind":"company","name":"Stablix","route":"/companies/stablix/","asOf":"2026-09-10","days":11},{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/","asOf":"2026-09-10","days":11},{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/","asOf":"2026-09-10","days":11},{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/","asOf":"2026-09-10","days":11},{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/","asOf":"2026-09-10","days":11},{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"arden-bio","kind":"company","name":"Arden Bio","route":"/companies/arden-bio/","asOf":"2026-09-10","days":11},{"id":"echo-immune","kind":"company","name":"Echo Immune","route":"/companies/echo-immune/","asOf":"2026-09-10","days":11},{"id":"ignitus-bio","kind":"company","name":"Ignitus Bio","route":"/companies/ignitus-bio/","asOf":"2026-09-10","days":11},{"id":"invocata","kind":"company","name":"Invocata","route":"/companies/invocata/","asOf":"2026-09-10","days":11},{"id":"kernis-health","kind":"company","name":"Kernis Health","route":"/companies/kernis-health/","asOf":"2026-09-10","days":11},{"id":"minuteman-therapeutics","kind":"company","name":"Minuteman Therapeutics","route":"/companies/minuteman-therapeutics/","asOf":"2026-09-10","days":11},{"id":"palitra-bio","kind":"company","name":"Palitra Bio","route":"/companies/palitra-bio/","asOf":"2026-09-10","days":11},{"id":"perita-bio","kind":"company","name":"Perita Bio","route":"/companies/perita-bio/","asOf":"2026-09-10","days":11},{"id":"ranata-therapeutics","kind":"company","name":"Ranata Therapeutics","route":"/companies/ranata-therapeutics/","asOf":"2026-09-10","days":11},{"id":"rarivive","kind":"company","name":"Rarivive","route":"/companies/rarivive/","asOf":"2026-09-10","days":11},{"id":"relit-biosciences","kind":"company","name":"Relit Biosciences","route":"/companies/relit-biosciences/","asOf":"2026-09-10","days":11},{"id":"stitchpoint-bio","kind":"company","name":"Stitchpoint Bio","route":"/companies/stitchpoint-bio/","asOf":"2026-09-10","days":11},{"id":"valius-sciences","kind":"company","name":"Valius Sciences","route":"/companies/valius-sciences/","asOf":"2026-09-10","days":11},{"id":"yuga-bio","kind":"company","name":"Yuga Bio","route":"/companies/yuga-bio/","asOf":"2026-09-10","days":11},{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/","asOf":"2026-09-10","days":11},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/","asOf":"2026-09-10","days":11},{"id":"amgen-ventures","kind":"company","name":"Amgen Ventures","route":"/companies/amgen-ventures/","asOf":"2026-09-10","days":11},{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","asOf":"2026-09-10","days":11},{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","asOf":"2026-09-10","days":11},{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","asOf":"2026-09-10","days":11},{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","asOf":"2026-09-10","days":11},{"id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","asOf":"2026-09-10","days":11},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","asOf":"2026-09-10","days":11},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","asOf":"2026-09-10","days":11},{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/","asOf":"2026-09-10","days":11},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","asOf":"2026-09-10","days":11},{"id":"5am-ventures","kind":"company","name":"5AM Ventures","route":"/companies/5am-ventures/","asOf":"2026-09-10","days":11},{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/","asOf":"2026-09-10","days":11},{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/","asOf":"2026-09-10","days":11},{"id":"syncona","kind":"company","name":"Syncona","route":"/companies/syncona/","asOf":"2026-09-10","days":11},{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","asOf":"2026-09-10","days":11},{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","asOf":"2026-09-10","days":11},{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/","asOf":"2026-09-10","days":11},{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","asOf":"2026-09-10","days":11},{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","asOf":"2026-09-10","days":11},{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/","asOf":"2026-09-10","days":11},{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/","asOf":"2026-09-10","days":11},{"id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","asOf":"2026-09-10","days":11},{"id":"general-catalyst","kind":"company","name":"General Catalyst","route":"/companies/general-catalyst/","asOf":"2026-09-10","days":11},{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/","asOf":"2026-09-10","days":11},{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/","asOf":"2026-09-10","days":11},{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/","asOf":"2026-09-10","days":11},{"id":"omega-funds","kind":"company","name":"Omega Funds","route":"/companies/omega-funds/","asOf":"2026-09-10","days":11},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/","asOf":"2026-09-10","days":11},{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/","asOf":"2026-09-10","days":11},{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","asOf":"2026-09-10","days":11},{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/","asOf":"2026-09-10","days":11},{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/","asOf":"2026-09-10","days":11},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/","asOf":"2026-09-10","days":11},{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/","asOf":"2026-09-10","days":11},{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/","asOf":"2026-09-10","days":11},{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/","asOf":"2026-09-10","days":11},{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","route":"/companies/jjdc/","asOf":"2026-09-10","days":11},{"id":"roche-venture-fund","kind":"company","name":"Roche Venture Fund","route":"/companies/roche-venture-fund/","asOf":"2026-09-10","days":11},{"id":"msd-global-health-innovation-fund","kind":"company","name":"MSD Global Health Innovation Fund (Merck GHI)","route":"/companies/msd-global-health-innovation-fund/","asOf":"2026-09-10","days":11},{"id":"lilly-ventures","kind":"company","name":"Lilly Ventures","route":"/companies/lilly-ventures/","asOf":"2026-09-10","days":11},{"id":"abbvie-ventures","kind":"company","name":"AbbVie Ventures","route":"/companies/abbvie-ventures/","asOf":"2026-09-10","days":11},{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","route":"/companies/leaps-by-bayer/","asOf":"2026-09-10","days":11},{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/","asOf":"2026-09-10","days":11},{"id":"takeda-ventures","kind":"company","name":"Takeda Ventures","route":"/companies/takeda-ventures/","asOf":"2026-09-10","days":11},{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","route":"/companies/lls-therapy-acceleration-program/","asOf":"2026-09-10","days":11},{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/","asOf":"2026-09-10","days":11},{"id":"break-through-cancer","kind":"company","name":"Break Through Cancer","route":"/companies/break-through-cancer/","asOf":"2026-09-10","days":11},{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/","asOf":"2026-09-10","days":11},{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/","asOf":"2026-09-10","days":11},{"id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","route":"/companies/eqt-life-sciences/","asOf":"2026-09-10","days":11},{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/","asOf":"2026-09-10","days":11},{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/","asOf":"2026-09-10","days":11},{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/","asOf":"2026-09-10","days":11},{"id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/","asOf":"2026-09-10","days":11},{"id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/","asOf":"2026-09-10","days":11},{"id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/","asOf":"2026-09-10","days":11},{"id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","route":"/companies/ecor1-capital/","asOf":"2026-09-10","days":11},{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/","asOf":"2026-09-10","days":11},{"id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/","asOf":"2026-09-10","days":11},{"id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","asOf":"2026-09-10","days":11},{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/","asOf":"2026-09-10","days":11},{"id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/","asOf":"2026-09-10","days":11},{"id":"dcvc","kind":"company","name":"DCVC","route":"/companies/dcvc/","asOf":"2026-09-10","days":11},{"id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/","asOf":"2026-09-10","days":11},{"id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","route":"/companies/mckesson-ventures/","asOf":"2026-09-10","days":11},{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/","asOf":"2026-09-10","days":11},{"id":"sante-ventures","kind":"company","name":"Sante Ventures","route":"/companies/sante-ventures/","asOf":"2026-09-10","days":11},{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/","asOf":"2026-09-10","days":11},{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/","asOf":"2026-09-10","days":11},{"id":"surgery-roadmap","kind":"roadmap","name":"Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work","route":"/roadmaps/surgery-roadmap/","asOf":"2026-09-10","days":11},{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/","asOf":"2026-09-10","days":11},{"id":"hormonal-therapy-roadmap","kind":"roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/","asOf":"2026-09-10","days":11},{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/","asOf":"2026-09-10","days":11},{"id":"survivorship-roadmap","kind":"roadmap","name":"Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards","route":"/roadmaps/survivorship-roadmap/","asOf":"2026-09-10","days":11},{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/","asOf":"2026-09-10","days":11},{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/","asOf":"2026-09-10","days":11},{"id":"devices-roadmap","kind":"roadmap","name":"Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants","route":"/roadmaps/devices-roadmap/","asOf":"2026-09-10","days":11},{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/","asOf":"2026-09-10","days":11},{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/","asOf":"2026-09-10","days":11},{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/","asOf":"2026-09-10","days":11},{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/","asOf":"2026-09-10","days":11},{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/","asOf":"2026-09-10","days":11},{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/","asOf":"2026-09-10","days":11},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/","asOf":"2026-09-10","days":11},{"id":"micrornas-in-cancer","kind":"pathway","name":"MicroRNAs in cancer","route":"/pathways/micrornas-in-cancer/","asOf":"2026-09-10","days":11},{"id":"proteoglycans-in-cancer","kind":"pathway","name":"Proteoglycans in cancer","route":"/pathways/proteoglycans-in-cancer/","asOf":"2026-09-10","days":11},{"id":"chemical-carcinogenesis-receptor-activation","kind":"pathway","name":"Chemical carcinogenesis - receptor activation","route":"/pathways/chemical-carcinogenesis-receptor-activation/","asOf":"2026-09-10","days":11},{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/","asOf":"2026-09-10","days":11},{"id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"hepatocellular-carcinoma-signalling","kind":"pathway","name":"Hepatocellular carcinoma (KEGG map)","route":"/pathways/hepatocellular-carcinoma-signalling/","asOf":"2026-09-10","days":11},{"id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"glioma-signalling","kind":"pathway","name":"Glioma (KEGG map)","route":"/pathways/glioma-signalling/","asOf":"2026-09-10","days":11},{"id":"thyroid-cancer-signalling","kind":"pathway","name":"Thyroid cancer (KEGG map)","route":"/pathways/thyroid-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"aml-signalling","kind":"pathway","name":"Acute myeloid leukaemia (KEGG map)","route":"/pathways/aml-signalling/","asOf":"2026-09-10","days":11},{"id":"cml-signalling","kind":"pathway","name":"Chronic myeloid leukaemia (KEGG map)","route":"/pathways/cml-signalling/","asOf":"2026-09-10","days":11},{"id":"basal-cell-carcinoma-signalling","kind":"pathway","name":"Basal cell carcinoma (KEGG map)","route":"/pathways/basal-cell-carcinoma-signalling/","asOf":"2026-09-10","days":11},{"id":"melanoma-signalling","kind":"pathway","name":"Melanoma (KEGG map)","route":"/pathways/melanoma-signalling/","asOf":"2026-09-10","days":11},{"id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/","asOf":"2026-09-10","days":11},{"id":"bladder-cancer-signalling","kind":"pathway","name":"Bladder cancer (KEGG map)","route":"/pathways/bladder-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"endometrial-cancer-signalling","kind":"pathway","name":"Endometrial cancer (KEGG map)","route":"/pathways/endometrial-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","asOf":"2026-09-10","days":11},{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/","asOf":"2026-09-10","days":11},{"id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/","asOf":"2026-09-10","days":11},{"id":"acta-oncologica","kind":"journal","name":"Acta oncologica","route":"/journals/acta-oncologica/","asOf":"2026-09-10","days":11},{"id":"advances-in-cancer-research","kind":"journal","name":"Advances in cancer research","route":"/journals/advances-in-cancer-research/","asOf":"2026-09-10","days":11},{"id":"american-journal-of-clinical-oncology","kind":"journal","name":"American journal of clinical oncology","route":"/journals/american-journal-of-clinical-oncology/","asOf":"2026-09-10","days":11},{"id":"asco-educational-book","kind":"journal","name":"American Society of Clinical Oncology educational book","route":"/journals/asco-educational-book/","asOf":"2026-09-10","days":11},{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","route":"/journals/analytical-cellular-pathology/","asOf":"2026-09-10","days":11},{"id":"annals-of-surgical-oncology","kind":"journal","name":"Annals of surgical oncology","route":"/journals/annals-of-surgical-oncology/","asOf":"2026-09-10","days":11},{"id":"anticancer-research","kind":"journal","name":"Anticancer research","route":"/journals/anticancer-research/","asOf":"2026-09-10","days":11},{"id":"asia-pacific-journal-of-clinical-oncology","kind":"journal","name":"Asia-Pacific journal of clinical oncology","route":"/journals/asia-pacific-journal-of-clinical-oncology/","asOf":"2026-09-10","days":11},{"id":"asian-pacific-journal-of-cancer-prevention","kind":"journal","name":"Asian Pacific journal of cancer prevention","route":"/journals/asian-pacific-journal-of-cancer-prevention/","asOf":"2026-09-10","days":11},{"id":"bba-reviews-on-cancer","kind":"journal","name":"Biochimica et biophysica acta. Reviews on cancer","route":"/journals/bba-reviews-on-cancer/","asOf":"2026-09-10","days":11},{"id":"blood-cancer-discovery","kind":"journal","name":"Blood cancer discovery","route":"/journals/blood-cancer-discovery/","asOf":"2026-09-10","days":11},{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","route":"/journals/blood-cancer-journal/","asOf":"2026-09-10","days":11},{"id":"bmc-cancer","kind":"journal","name":"BMC cancer","route":"/journals/bmc-cancer/","asOf":"2026-09-10","days":11},{"id":"brain-tumor-pathology","kind":"journal","name":"Brain tumor pathology","route":"/journals/brain-tumor-pathology/","asOf":"2026-09-10","days":11},{"id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","asOf":"2026-09-10","days":11},{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","route":"/journals/breast-cancer-research/","asOf":"2026-09-10","days":11},{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","route":"/journals/breast-cancer-research-and-treatment/","asOf":"2026-09-10","days":11},{"id":"bulletin-du-cancer","kind":"journal","name":"Bulletin du cancer","route":"/journals/bulletin-du-cancer/","asOf":"2026-09-10","days":11},{"id":"cancer-biology-and-medicine","kind":"journal","name":"Cancer biology & medicine","route":"/journals/cancer-biology-and-medicine/","asOf":"2026-09-10","days":11},{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","route":"/journals/cancer-biology-and-therapy/","asOf":"2026-09-10","days":11},{"id":"cancer-biomarkers","kind":"journal","name":"Cancer biomarkers","route":"/journals/cancer-biomarkers/","asOf":"2026-09-10","days":11},{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","asOf":"2026-09-10","days":11},{"id":"cancer-causes-and-control","kind":"journal","name":"Cancer causes & control","route":"/journals/cancer-causes-and-control/","asOf":"2026-09-10","days":11},{"id":"cancer-chemotherapy-and-pharmacology","kind":"journal","name":"Cancer chemotherapy and pharmacology","route":"/journals/cancer-chemotherapy-and-pharmacology/","asOf":"2026-09-10","days":11},{"id":"cancer-communications","kind":"journal","name":"Cancer communications","route":"/journals/cancer-communications/","asOf":"2026-09-10","days":11},{"id":"cancer-control","kind":"journal","name":"Cancer control","route":"/journals/cancer-control/","asOf":"2026-09-10","days":11},{"id":"cancer-cytopathology","kind":"journal","name":"Cancer cytopathology","route":"/journals/cancer-cytopathology/","asOf":"2026-09-10","days":11},{"id":"cancer-epidemiology","kind":"journal","name":"Cancer epidemiology","route":"/journals/cancer-epidemiology/","asOf":"2026-09-10","days":11},{"id":"cancer-gene-therapy","kind":"journal","name":"Cancer gene therapy","route":"/journals/cancer-gene-therapy/","asOf":"2026-09-10","days":11},{"id":"cancer-genetics","kind":"journal","name":"Cancer genetics","route":"/journals/cancer-genetics/","asOf":"2026-09-10","days":11},{"id":"cancer-genomics-and-proteomics","kind":"journal","name":"Cancer genomics & proteomics","route":"/journals/cancer-genomics-and-proteomics/","asOf":"2026-09-10","days":11},{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","asOf":"2026-09-10","days":11},{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/","asOf":"2026-09-10","days":11},{"id":"cancer-investigation","kind":"journal","name":"Cancer investigation","route":"/journals/cancer-investigation/","asOf":"2026-09-10","days":11},{"id":"cancer-letters","kind":"journal","name":"Cancer letters","route":"/journals/cancer-letters/","asOf":"2026-09-10","days":11},{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","route":"/journals/cancer-medicine/","asOf":"2026-09-10","days":11},{"id":"cancer-metastasis-reviews","kind":"journal","name":"Cancer metastasis reviews","route":"/journals/cancer-metastasis-reviews/","asOf":"2026-09-10","days":11},{"id":"cancer-nursing","kind":"journal","name":"Cancer nursing","route":"/journals/cancer-nursing/","asOf":"2026-09-10","days":11},{"id":"cancer-prevention-research","kind":"journal","name":"Cancer prevention research","route":"/journals/cancer-prevention-research/","asOf":"2026-09-10","days":11},{"id":"cancer-radiotherapie","kind":"journal","name":"Cancer radiothérapie","route":"/journals/cancer-radiotherapie/","asOf":"2026-09-10","days":11},{"id":"cancer-reports","kind":"journal","name":"Cancer reports","route":"/journals/cancer-reports/","asOf":"2026-09-10","days":11},{"id":"cancer-research-and-treatment","kind":"journal","name":"Cancer research and treatment","route":"/journals/cancer-research-and-treatment/","asOf":"2026-09-10","days":11},{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","route":"/journals/cancer-research-communications/","asOf":"2026-09-10","days":11},{"id":"cancer-science","kind":"journal","name":"Cancer science","route":"/journals/cancer-science/","asOf":"2026-09-10","days":11},{"id":"cancer-treatment-and-research","kind":"journal","name":"Cancer treatment and research","route":"/journals/cancer-treatment-and-research/","asOf":"2026-09-10","days":11},{"id":"cancer-treatment-and-research-communications","kind":"journal","name":"Cancer treatment and research communications","route":"/journals/cancer-treatment-and-research-communications/","asOf":"2026-09-10","days":11},{"id":"cancer-treatment-reviews","kind":"journal","name":"Cancer treatment reviews","route":"/journals/cancer-treatment-reviews/","asOf":"2026-09-10","days":11},{"id":"carcinogenesis","kind":"journal","name":"Carcinogenesis","route":"/journals/carcinogenesis/","asOf":"2026-09-10","days":11},{"id":"cellular-oncology","kind":"journal","name":"Cellular oncology","route":"/journals/cellular-oncology/","asOf":"2026-09-10","days":11},{"id":"chinese-clinical-oncology","kind":"journal","name":"Chinese clinical oncology","route":"/journals/chinese-clinical-oncology/","asOf":"2026-09-10","days":11},{"id":"clinical-and-experimental-metastasis","kind":"journal","name":"Clinical & experimental metastasis","route":"/journals/clinical-and-experimental-metastasis/","asOf":"2026-09-10","days":11},{"id":"clinical-and-translational-oncology","kind":"journal","name":"Clinical & translational oncology","route":"/journals/clinical-and-translational-oncology/","asOf":"2026-09-10","days":11},{"id":"clinical-advances-in-hematology-and-oncology","kind":"journal","name":"Clinical advances in hematology & oncology","route":"/journals/clinical-advances-in-hematology-and-oncology/","asOf":"2026-09-10","days":11},{"id":"clinical-breast-cancer","kind":"journal","name":"Clinical breast cancer","route":"/journals/clinical-breast-cancer/","asOf":"2026-09-10","days":11},{"id":"clinical-colorectal-cancer","kind":"journal","name":"Clinical colorectal cancer","route":"/journals/clinical-colorectal-cancer/","asOf":"2026-09-10","days":11},{"id":"clinical-genitourinary-cancer","kind":"journal","name":"Clinical genitourinary cancer","route":"/journals/clinical-genitourinary-cancer/","asOf":"2026-09-10","days":11},{"id":"clinical-journal-of-oncology-nursing","kind":"journal","name":"Clinical journal of oncology nursing","route":"/journals/clinical-journal-of-oncology-nursing/","asOf":"2026-09-10","days":11},{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","route":"/journals/clinical-lung-cancer/","asOf":"2026-09-10","days":11},{"id":"clinical-lymphoma-myeloma-and-leukemia","kind":"journal","name":"Clinical lymphoma, myeloma & leukemia","route":"/journals/clinical-lymphoma-myeloma-and-leukemia/","asOf":"2026-09-10","days":11},{"id":"clinical-oncology-rcr","kind":"journal","name":"Clinical oncology","route":"/journals/clinical-oncology-rcr/","asOf":"2026-09-10","days":11},{"id":"cns-oncology","kind":"journal","name":"CNS oncology","route":"/journals/cns-oncology/","asOf":"2026-09-10","days":11},{"id":"critical-reviews-in-oncogenesis","kind":"journal","name":"Critical reviews in oncogenesis","route":"/journals/critical-reviews-in-oncogenesis/","asOf":"2026-09-10","days":11},{"id":"critical-reviews-in-oncology-hematology","kind":"journal","name":"Critical reviews in oncology/hematology","route":"/journals/critical-reviews-in-oncology-hematology/","asOf":"2026-09-10","days":11},{"id":"current-cancer-drug-targets","kind":"journal","name":"Current cancer drug targets","route":"/journals/current-cancer-drug-targets/","asOf":"2026-09-10","days":11},{"id":"current-hematologic-malignancy-reports","kind":"journal","name":"Current hematologic malignancy reports","route":"/journals/current-hematologic-malignancy-reports/","asOf":"2026-09-10","days":11},{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","route":"/journals/current-oncology-mdpi/","asOf":"2026-09-10","days":11},{"id":"current-oncology-reports","kind":"journal","name":"Current oncology reports","route":"/journals/current-oncology-reports/","asOf":"2026-09-10","days":11},{"id":"current-opinion-in-oncology","kind":"journal","name":"Current opinion in oncology","route":"/journals/current-opinion-in-oncology/","asOf":"2026-09-10","days":11},{"id":"current-problems-in-cancer","kind":"journal","name":"Current problems in cancer","route":"/journals/current-problems-in-cancer/","asOf":"2026-09-10","days":11},{"id":"current-treatment-options-in-oncology","kind":"journal","name":"Current treatment options in oncology","route":"/journals/current-treatment-options-in-oncology/","asOf":"2026-09-10","days":11},{"id":"endocrine-related-cancer","kind":"journal","name":"Endocrine-related cancer","route":"/journals/endocrine-related-cancer/","asOf":"2026-09-10","days":11},{"id":"esophagus-journal","kind":"journal","name":"Esophagus","route":"/journals/esophagus-journal/","asOf":"2026-09-10","days":11},{"id":"european-journal-of-cancer-prevention","kind":"journal","name":"European journal of cancer prevention","route":"/journals/european-journal-of-cancer-prevention/","asOf":"2026-09-10","days":11},{"id":"european-journal-of-oncology-nursing","kind":"journal","name":"European journal of oncology nursing","route":"/journals/european-journal-of-oncology-nursing/","asOf":"2026-09-10","days":11},{"id":"european-journal-of-surgical-oncology","kind":"journal","name":"European journal of surgical oncology","route":"/journals/european-journal-of-surgical-oncology/","asOf":"2026-09-10","days":11},{"id":"european-thyroid-journal","kind":"journal","name":"European thyroid journal","route":"/journals/european-thyroid-journal/","asOf":"2026-09-10","days":11},{"id":"experimental-oncology","kind":"journal","name":"Experimental oncology","route":"/journals/experimental-oncology/","asOf":"2026-09-10","days":11},{"id":"expert-review-of-anticancer-therapy","kind":"journal","name":"Expert review of anticancer therapy","route":"/journals/expert-review-of-anticancer-therapy/","asOf":"2026-09-10","days":11},{"id":"familial-cancer","kind":"journal","name":"Familial cancer","route":"/journals/familial-cancer/","asOf":"2026-09-10","days":11},{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/","asOf":"2026-09-10","days":11},{"id":"gan-to-kagaku-ryoho","kind":"journal","name":"Gan to kagaku ryoho. Cancer & chemotherapy","route":"/journals/gan-to-kagaku-ryoho/","asOf":"2026-09-10","days":11},{"id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","asOf":"2026-09-10","days":11},{"id":"genes-chromosomes-and-cancer","kind":"journal","name":"Genes, chromosomes & cancer","route":"/journals/genes-chromosomes-and-cancer/","asOf":"2026-09-10","days":11},{"id":"head-and-neck-journal","kind":"journal","name":"Head & neck","route":"/journals/head-and-neck-journal/","asOf":"2026-09-10","days":11},{"id":"head-and-neck-pathology","kind":"journal","name":"Head and neck pathology","route":"/journals/head-and-neck-pathology/","asOf":"2026-09-10","days":11},{"id":"hematological-oncology","kind":"journal","name":"Hematological oncology","route":"/journals/hematological-oncology/","asOf":"2026-09-10","days":11},{"id":"hematology-oncology-and-stem-cell-therapy","kind":"journal","name":"Hematology/oncology and stem cell therapy","route":"/journals/hematology-oncology-and-stem-cell-therapy/","asOf":"2026-09-10","days":11},{"id":"hematology-oncology-clinics-of-north-america","kind":"journal","name":"Hematology/oncology clinics of North America","route":"/journals/hematology-oncology-clinics-of-north-america/","asOf":"2026-09-10","days":11},{"id":"in-vivo","kind":"journal","name":"In vivo","route":"/journals/in-vivo/","asOf":"2026-09-10","days":11},{"id":"indian-journal-of-cancer","kind":"journal","name":"Indian journal of cancer","route":"/journals/indian-journal-of-cancer/","asOf":"2026-09-10","days":11},{"id":"integrative-cancer-therapies","kind":"journal","name":"Integrative cancer therapies","route":"/journals/integrative-cancer-therapies/","asOf":"2026-09-10","days":11},{"id":"international-journal-of-cancer","kind":"journal","name":"International journal of cancer","route":"/journals/international-journal-of-cancer/","asOf":"2026-09-10","days":11},{"id":"international-journal-of-clinical-oncology","kind":"journal","name":"International journal of clinical oncology","route":"/journals/international-journal-of-clinical-oncology/","asOf":"2026-09-10","days":11},{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","route":"/journals/international-journal-of-gynecological-cancer/","asOf":"2026-09-10","days":11},{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","route":"/journals/international-journal-of-hyperthermia/","asOf":"2026-09-10","days":11},{"id":"international-journal-of-oncology","kind":"journal","name":"International journal of oncology","route":"/journals/international-journal-of-oncology/","asOf":"2026-09-10","days":11},{"id":"japanese-journal-of-clinical-oncology","kind":"journal","name":"Japanese journal of clinical oncology","route":"/journals/japanese-journal-of-clinical-oncology/","asOf":"2026-09-10","days":11},{"id":"jco-clinical-cancer-informatics","kind":"journal","name":"JCO clinical cancer informatics","route":"/journals/jco-clinical-cancer-informatics/","asOf":"2026-09-10","days":11},{"id":"jco-global-oncology","kind":"journal","name":"JCO global oncology","route":"/journals/jco-global-oncology/","asOf":"2026-09-10","days":11},{"id":"jmir-cancer","kind":"journal","name":"JMIR cancer","route":"/journals/jmir-cancer/","asOf":"2026-09-10","days":11},{"id":"jnci-cancer-spectrum","kind":"journal","name":"JNCI cancer spectrum","route":"/journals/jnci-cancer-spectrum/","asOf":"2026-09-10","days":11},{"id":"journal-of-adolescent-and-young-adult-oncology","kind":"journal","name":"Journal of adolescent and young adult oncology","route":"/journals/journal-of-adolescent-and-young-adult-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-breast-imaging","kind":"journal","name":"Journal of breast imaging","route":"/journals/journal-of-breast-imaging/","asOf":"2026-09-10","days":11},{"id":"journal-of-cachexia-sarcopenia-and-muscle","kind":"journal","name":"Journal of cachexia, sarcopenia and muscle","route":"/journals/journal-of-cachexia-sarcopenia-and-muscle/","asOf":"2026-09-10","days":11},{"id":"journal-of-cancer-education","kind":"journal","name":"Journal of cancer education","route":"/journals/journal-of-cancer-education/","asOf":"2026-09-10","days":11},{"id":"journal-of-cancer-policy","kind":"journal","name":"Journal of cancer policy","route":"/journals/journal-of-cancer-policy/","asOf":"2026-09-10","days":11},{"id":"journal-of-cancer-research-and-clinical-oncology","kind":"journal","name":"Journal of cancer research and clinical oncology","route":"/journals/journal-of-cancer-research-and-clinical-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-cancer-research-and-therapeutics","kind":"journal","name":"Journal of cancer research and therapeutics","route":"/journals/journal-of-cancer-research-and-therapeutics/","asOf":"2026-09-10","days":11},{"id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","route":"/journals/journal-of-cancer-survivorship/","asOf":"2026-09-10","days":11},{"id":"journal-of-environmental-pathology-toxicology-and-oncology","kind":"journal","name":"Journal of environmental pathology, toxicology and oncology","route":"/journals/journal-of-environmental-pathology-toxicology-and-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-experimental-and-clinical-cancer-research","kind":"journal","name":"Journal of experimental & clinical cancer research","route":"/journals/journal-of-experimental-and-clinical-cancer-research/","asOf":"2026-09-10","days":11},{"id":"journal-of-gastric-cancer","kind":"journal","name":"Journal of gastric cancer","route":"/journals/journal-of-gastric-cancer/","asOf":"2026-09-10","days":11},{"id":"journal-of-gastrointestinal-cancer","kind":"journal","name":"Journal of gastrointestinal cancer","route":"/journals/journal-of-gastrointestinal-cancer/","asOf":"2026-09-10","days":11},{"id":"journal-of-geriatric-oncology","kind":"journal","name":"Journal of geriatric oncology","route":"/journals/journal-of-geriatric-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-immunotherapy","kind":"journal","name":"Journal of immunotherapy","route":"/journals/journal-of-immunotherapy/","asOf":"2026-09-10","days":11},{"id":"journal-of-mammary-gland-biology-and-neoplasia","kind":"journal","name":"Journal of mammary gland biology and neoplasia","route":"/journals/journal-of-mammary-gland-biology-and-neoplasia/","asOf":"2026-09-10","days":11},{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-neuro-oncology","kind":"journal","name":"Journal of neuro-oncology","route":"/journals/journal-of-neuro-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-oncology-pharmacy-practice","kind":"journal","name":"Journal of oncology pharmacy practice","route":"/journals/journal-of-oncology-pharmacy-practice/","asOf":"2026-09-10","days":11},{"id":"journal-of-pediatric-hematology-oncology","kind":"journal","name":"Journal of pediatric hematology/oncology","route":"/journals/journal-of-pediatric-hematology-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-pediatric-hematology-oncology-nursing","kind":"journal","name":"Journal of pediatric hematology/oncology nursing","route":"/journals/journal-of-pediatric-hematology-oncology-nursing/","asOf":"2026-09-10","days":11},{"id":"journal-of-psychosocial-oncology","kind":"journal","name":"Journal of psychosocial oncology","route":"/journals/journal-of-psychosocial-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-radiation-research","kind":"journal","name":"Journal of radiation research","route":"/journals/journal-of-radiation-research/","asOf":"2026-09-10","days":11},{"id":"journal-of-registry-management","kind":"journal","name":"Journal of registry management","route":"/journals/journal-of-registry-management/","asOf":"2026-09-10","days":11},{"id":"journal-of-surgical-oncology","kind":"journal","name":"Journal of surgical oncology","route":"/journals/journal-of-surgical-oncology/","asOf":"2026-09-10","days":11},{"id":"journal-of-the-egyptian-national-cancer-institute","kind":"journal","name":"Journal of the Egyptian National Cancer Institute","route":"/journals/journal-of-the-egyptian-national-cancer-institute/","asOf":"2026-09-10","days":11},{"id":"jnci-monographs","kind":"journal","name":"Journal of the National Cancer Institute. Monographs","route":"/journals/jnci-monographs/","asOf":"2026-09-10","days":11},{"id":"klinicka-onkologie","kind":"journal","name":"Klinická onkologie","route":"/journals/klinicka-onkologie/","asOf":"2026-09-10","days":11},{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","route":"/journals/leukemia-and-lymphoma/","asOf":"2026-09-10","days":11},{"id":"leukemia-research","kind":"journal","name":"Leukemia research","route":"/journals/leukemia-research/","asOf":"2026-09-10","days":11},{"id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","asOf":"2026-09-10","days":11},{"id":"magyar-onkologia","kind":"journal","name":"Magyar onkologia","route":"/journals/magyar-onkologia/","asOf":"2026-09-10","days":11},{"id":"medical-oncology","kind":"journal","name":"Medical oncology","route":"/journals/medical-oncology/","asOf":"2026-09-10","days":11},{"id":"melanoma-research","kind":"journal","name":"Melanoma research","route":"/journals/melanoma-research/","asOf":"2026-09-10","days":11},{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","route":"/journals/molecular-cancer/","asOf":"2026-09-10","days":11},{"id":"molecular-cancer-research","kind":"journal","name":"Molecular cancer research","route":"/journals/molecular-cancer-research/","asOf":"2026-09-10","days":11},{"id":"molecular-carcinogenesis","kind":"journal","name":"Molecular carcinogenesis","route":"/journals/molecular-carcinogenesis/","asOf":"2026-09-10","days":11},{"id":"molecular-oncology","kind":"journal","name":"Molecular oncology","route":"/journals/molecular-oncology/","asOf":"2026-09-10","days":11},{"id":"nar-cancer","kind":"journal","name":"NAR cancer","route":"/journals/nar-cancer/","asOf":"2026-09-10","days":11},{"id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","asOf":"2026-09-10","days":11},{"id":"neoplasma","kind":"journal","name":"Neoplasma","route":"/journals/neoplasma/","asOf":"2026-09-10","days":11},{"id":"nutrition-and-cancer","kind":"journal","name":"Nutrition and cancer","route":"/journals/nutrition-and-cancer/","asOf":"2026-09-10","days":11},{"id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","asOf":"2026-09-10","days":11},{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","route":"/journals/oncoimmunology/","asOf":"2026-09-10","days":11},{"id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/","asOf":"2026-09-10","days":11},{"id":"oncology-karger","kind":"journal","name":"Oncology","route":"/journals/oncology-karger/","asOf":"2026-09-10","days":11},{"id":"oncology-nursing-forum","kind":"journal","name":"Oncology nursing forum","route":"/journals/oncology-nursing-forum/","asOf":"2026-09-10","days":11},{"id":"oncology-reports","kind":"journal","name":"Oncology reports","route":"/journals/oncology-reports/","asOf":"2026-09-10","days":11},{"id":"oncology-research","kind":"journal","name":"Oncology research","route":"/journals/oncology-research/","asOf":"2026-09-10","days":11},{"id":"oncology-research-and-treatment","kind":"journal","name":"Oncology research and treatment","route":"/journals/oncology-research-and-treatment/","asOf":"2026-09-10","days":11},{"id":"oncotarget","kind":"journal","name":"Oncotarget","route":"/journals/oncotarget/","asOf":"2026-09-10","days":11},{"id":"oral-oncology","kind":"journal","name":"Oral oncology","route":"/journals/oral-oncology/","asOf":"2026-09-10","days":11},{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","route":"/journals/pathology-and-oncology-research/","asOf":"2026-09-10","days":11},{"id":"pediatric-hematology-and-oncology","kind":"journal","name":"Pediatric hematology and oncology","route":"/journals/pediatric-hematology-and-oncology/","asOf":"2026-09-10","days":11},{"id":"pigment-cell-and-melanoma-research","kind":"journal","name":"Pigment cell & melanoma research","route":"/journals/pigment-cell-and-melanoma-research/","asOf":"2026-09-10","days":11},{"id":"practical-radiation-oncology","kind":"journal","name":"Practical radiation oncology","route":"/journals/practical-radiation-oncology/","asOf":"2026-09-10","days":11},{"id":"prostate-cancer-and-prostatic-diseases","kind":"journal","name":"Prostate cancer and prostatic diseases","route":"/journals/prostate-cancer-and-prostatic-diseases/","asOf":"2026-09-10","days":11},{"id":"psycho-oncology-journal","kind":"journal","name":"Psycho-oncology","route":"/journals/psycho-oncology-journal/","asOf":"2026-09-10","days":11},{"id":"radiation-and-environmental-biophysics","kind":"journal","name":"Radiation and environmental biophysics","route":"/journals/radiation-and-environmental-biophysics/","asOf":"2026-09-10","days":11},{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","asOf":"2026-09-10","days":11},{"id":"radiology-and-oncology","kind":"journal","name":"Radiology and oncology","route":"/journals/radiology-and-oncology/","asOf":"2026-09-10","days":11},{"id":"radiology-imaging-cancer","kind":"journal","name":"Radiology. Imaging cancer","route":"/journals/radiology-imaging-cancer/","asOf":"2026-09-10","days":11},{"id":"recent-patents-on-anti-cancer-drug-discovery","kind":"journal","name":"Recent patents on anti-cancer drug discovery","route":"/journals/recent-patents-on-anti-cancer-drug-discovery/","asOf":"2026-09-10","days":11},{"id":"recent-results-in-cancer-research","kind":"journal","name":"Recent results in cancer research","route":"/journals/recent-results-in-cancer-research/","asOf":"2026-09-10","days":11},{"id":"seminars-in-cancer-biology","kind":"journal","name":"Seminars in cancer biology","route":"/journals/seminars-in-cancer-biology/","asOf":"2026-09-10","days":11},{"id":"seminars-in-oncology","kind":"journal","name":"Seminars in oncology","route":"/journals/seminars-in-oncology/","asOf":"2026-09-10","days":11},{"id":"seminars-in-oncology-nursing","kind":"journal","name":"Seminars in oncology nursing","route":"/journals/seminars-in-oncology-nursing/","asOf":"2026-09-10","days":11},{"id":"seminars-in-radiation-oncology","kind":"journal","name":"Seminars in radiation oncology","route":"/journals/seminars-in-radiation-oncology/","asOf":"2026-09-10","days":11},{"id":"strahlentherapie-und-onkologie","kind":"journal","name":"Strahlentherapie und Onkologie","route":"/journals/strahlentherapie-und-onkologie/","asOf":"2026-09-10","days":11},{"id":"supportive-care-in-cancer","kind":"journal","name":"Supportive care in cancer","route":"/journals/supportive-care-in-cancer/","asOf":"2026-09-10","days":11},{"id":"surgical-oncology","kind":"journal","name":"Surgical oncology","route":"/journals/surgical-oncology/","asOf":"2026-09-10","days":11},{"id":"surgical-oncology-clinics-of-north-america","kind":"journal","name":"Surgical oncology clinics of North America","route":"/journals/surgical-oncology-clinics-of-north-america/","asOf":"2026-09-10","days":11},{"id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","asOf":"2026-09-10","days":11},{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","route":"/journals/technology-in-cancer-research-and-treatment/","asOf":"2026-09-10","days":11},{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/","asOf":"2026-09-10","days":11},{"id":"the-breast-journal","kind":"journal","name":"The breast journal","route":"/journals/the-breast-journal/","asOf":"2026-09-10","days":11},{"id":"the-cancer-journal","kind":"journal","name":"The cancer journal","route":"/journals/the-cancer-journal/","asOf":"2026-09-10","days":11},{"id":"gulf-journal-of-oncology","kind":"journal","name":"The Gulf journal of oncology","route":"/journals/gulf-journal-of-oncology/","asOf":"2026-09-10","days":11},{"id":"international-journal-of-biological-markers","kind":"journal","name":"The International journal of biological markers","route":"/journals/international-journal-of-biological-markers/","asOf":"2026-09-10","days":11},{"id":"the-oncologist","kind":"journal","name":"The oncologist","route":"/journals/the-oncologist/","asOf":"2026-09-10","days":11},{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","route":"/journals/thoracic-cancer/","asOf":"2026-09-10","days":11},{"id":"trends-in-cancer","kind":"journal","name":"Trends in cancer","route":"/journals/trends-in-cancer/","asOf":"2026-09-10","days":11},{"id":"tumori","kind":"journal","name":"Tumori","route":"/journals/tumori/","asOf":"2026-09-10","days":11},{"id":"tumour-biology","kind":"journal","name":"Tumour biology","route":"/journals/tumour-biology/","asOf":"2026-09-10","days":11},{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","route":"/journals/tumour-virus-research/","asOf":"2026-09-10","days":11},{"id":"urologic-oncology","kind":"journal","name":"Urologic oncology","route":"/journals/urologic-oncology/","asOf":"2026-09-10","days":11},{"id":"veterinary-and-comparative-oncology","kind":"journal","name":"Veterinary and comparative oncology","route":"/journals/veterinary-and-comparative-oncology/","asOf":"2026-09-10","days":11},{"id":"world-journal-of-surgical-oncology","kind":"journal","name":"World journal of surgical oncology","route":"/journals/world-journal-of-surgical-oncology/","asOf":"2026-09-10","days":11},{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","route":"/journals/chinese-journal-of-lung-cancer/","asOf":"2026-09-10","days":11},{"id":"chinese-journal-of-oncology","kind":"journal","name":"Zhonghua zhong liu za zhi","route":"/journals/chinese-journal-of-oncology/","asOf":"2026-09-10","days":11},{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/","asOf":"2026-09-11","days":10},{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/","asOf":"2026-09-11","days":10},{"id":"inxmed-shanghai","kind":"company","name":"InxMed (Shanghai)","route":"/companies/inxmed-shanghai/","asOf":"2026-09-11","days":10},{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/","asOf":"2026-09-11","days":10},{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/","asOf":"2026-09-11","days":10},{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/","asOf":"2026-09-11","days":10},{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/","asOf":"2026-09-11","days":10},{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/","asOf":"2026-09-11","days":10},{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/","asOf":"2026-09-11","days":10},{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/","asOf":"2026-09-11","days":10},{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/","asOf":"2026-09-11","days":10},{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/","asOf":"2026-09-11","days":10},{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/","asOf":"2026-09-11","days":10},{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/","asOf":"2026-09-11","days":10},{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/","asOf":"2026-09-11","days":10},{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/","asOf":"2026-09-11","days":10},{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/","asOf":"2026-09-11","days":10},{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/","asOf":"2026-09-11","days":10},{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/","asOf":"2026-09-11","days":10},{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/","asOf":"2026-09-11","days":10},{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","route":"/companies/orion-orion-pharma/","asOf":"2026-09-11","days":10},{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/","asOf":"2026-09-11","days":10},{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","route":"/companies/bio-thera-solutions/","asOf":"2026-09-11","days":10},{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/","asOf":"2026-09-11","days":10},{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/","asOf":"2026-09-11","days":10},{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/","asOf":"2026-09-11","days":10},{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/","asOf":"2026-09-11","days":10},{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/","asOf":"2026-09-11","days":10},{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","route":"/companies/oncolytics-biotech/","asOf":"2026-09-11","days":10},{"id":"rakuten-medical","kind":"company","name":"Rakuten Medical","route":"/companies/rakuten-medical/","asOf":"2026-09-11","days":10},{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","route":"/companies/shanghai-kechow-pharma/","asOf":"2026-09-11","days":10},{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/","asOf":"2026-09-11","days":10},{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/","asOf":"2026-09-11","days":10},{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","route":"/companies/urogen-pharma/","asOf":"2026-09-11","days":10},{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","route":"/companies/xuanzhu-biopharmaceutical/","asOf":"2026-09-11","days":10},{"id":"ap-biosciences","kind":"company","name":"AP Biosciences","route":"/companies/ap-biosciences/","asOf":"2026-09-11","days":10},{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","route":"/companies/ascentawits-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"askgene-pharma","kind":"company","name":"AskGene Pharma","route":"/companies/askgene-pharma/","asOf":"2026-09-11","days":10},{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/","asOf":"2026-09-11","days":10},{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","route":"/companies/aveta-biomics/","asOf":"2026-09-11","days":10},{"id":"cebiotex","kind":"company","name":"CEBIOTEX","route":"/companies/cebiotex/","asOf":"2026-09-11","days":10},{"id":"cellectis-s-a","kind":"company","name":"Cellectis S.A.","route":"/companies/cellectis-s-a/","asOf":"2026-09-11","days":10},{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/","asOf":"2026-09-11","days":10},{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/","asOf":"2026-09-11","days":10},{"id":"civatech-oncology","kind":"company","name":"CivaTech Oncology","route":"/companies/civatech-oncology/","asOf":"2026-09-11","days":10},{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/","asOf":"2026-09-11","days":10},{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","route":"/companies/d3-bio-wuxi/","asOf":"2026-09-11","days":10},{"id":"elpiscience-suzhou-biopharma","kind":"company","name":"Elpiscience (Suzhou) Biopharma","route":"/companies/elpiscience-suzhou-biopharma/","asOf":"2026-09-11","days":10},{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","route":"/companies/forward-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","asOf":"2026-09-11","days":10},{"id":"genelux","kind":"company","name":"Genelux","route":"/companies/genelux/","asOf":"2026-09-11","days":10},{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/","asOf":"2026-09-11","days":10},{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/","asOf":"2026-09-11","days":10},{"id":"georgiamune","kind":"company","name":"Georgiamune","route":"/companies/georgiamune/","asOf":"2026-09-11","days":10},{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","route":"/companies/hangzhou-sumgen-biotech/","asOf":"2026-09-11","days":10},{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/","asOf":"2026-09-11","days":10},{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/","asOf":"2026-09-11","days":10},{"id":"ionctura","kind":"company","name":"iOnctura","route":"/companies/ionctura/","asOf":"2026-09-11","days":10},{"id":"italfarmaco","kind":"company","name":"Italfarmaco","route":"/companies/italfarmaco/","asOf":"2026-09-11","days":10},{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","route":"/companies/krystal-biotech/","asOf":"2026-09-11","days":10},{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","route":"/companies/laminar-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/","asOf":"2026-09-11","days":10},{"id":"mabxience-research-s-l","kind":"company","name":"mAbxience Research S.L.","route":"/companies/mabxience-research-s-l/","asOf":"2026-09-11","days":10},{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","route":"/companies/maia-biotechnology/","asOf":"2026-09-11","days":10},{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","route":"/companies/mbrace-therapeutics/","asOf":"2026-09-11","days":10},{"id":"molecular-partners","kind":"company","name":"Molecular Partners","route":"/companies/molecular-partners/","asOf":"2026-09-11","days":10},{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","route":"/companies/olema-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"oncoverity","kind":"company","name":"OncoVerity","route":"/companies/oncoverity/","asOf":"2026-09-11","days":10},{"id":"orca-biosystems","kind":"company","name":"Orca Biosystems","route":"/companies/orca-biosystems/","asOf":"2026-09-11","days":10},{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/","asOf":"2026-09-11","days":10},{"id":"qbiotics","kind":"company","name":"QBiotics","route":"/companies/qbiotics/","asOf":"2026-09-11","days":10},{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/","asOf":"2026-09-11","days":10},{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/","asOf":"2026-09-11","days":10},{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","route":"/companies/shanghai-abelzeta/","asOf":"2026-09-11","days":10},{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/","asOf":"2026-09-11","days":10},{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"spectracure","kind":"company","name":"SpectraCure","route":"/companies/spectracure/","asOf":"2026-09-11","days":10},{"id":"stcube","kind":"company","name":"STCube","route":"/companies/stcube/","asOf":"2026-09-11","days":10},{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","route":"/companies/suzhou-forlong-biotechnology/","asOf":"2026-09-11","days":10},{"id":"tiumbio","kind":"company","name":"TiumBio","route":"/companies/tiumbio/","asOf":"2026-09-11","days":10},{"id":"vyriad","kind":"company","name":"Vyriad","route":"/companies/vyriad/","asOf":"2026-09-11","days":10},{"id":"wigen-biomedicine-technology-shanghai","kind":"company","name":"Wigen Biomedicine Technology (Shanghai)","route":"/companies/wigen-biomedicine-technology-shanghai/","asOf":"2026-09-11","days":10},{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/","asOf":"2026-09-11","days":10},{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/","asOf":"2026-09-11","days":10},{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/","asOf":"2026-09-11","days":10},{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/","asOf":"2026-09-11","days":10},{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/","asOf":"2026-09-11","days":10},{"id":"immunome","kind":"company","name":"Immunome","route":"/companies/immunome/","asOf":"2026-09-11","days":10},{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/","asOf":"2026-09-11","days":10},{"id":"coherus","kind":"company","name":"Coherus BioSciences","route":"/companies/coherus/","asOf":"2026-09-11","days":10},{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/","asOf":"2026-09-11","days":10},{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","route":"/companies/checkpoint-therapeutics/","asOf":"2026-09-11","days":10},{"id":"xcovery","kind":"company","name":"Xcovery","route":"/companies/xcovery/","asOf":"2026-09-11","days":10},{"id":"medac","kind":"company","name":"medac","route":"/companies/medac/","asOf":"2026-09-11","days":10},{"id":"gamida-cell","kind":"company","name":"Gamida Cell","route":"/companies/gamida-cell/","asOf":"2026-09-11","days":10},{"id":"mesoblast","kind":"company","name":"Mesoblast","route":"/companies/mesoblast/","asOf":"2026-09-11","days":10},{"id":"delcath","kind":"company","name":"Delcath Systems","route":"/companies/delcath/","asOf":"2026-09-11","days":10},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/","asOf":"2026-09-11","days":10},{"id":"innopharmax","kind":"company","name":"InnoPharmax","route":"/companies/innopharmax/","asOf":"2026-09-11","days":10},{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/","asOf":"2026-09-11","days":10},{"id":"ab-science","kind":"company","name":"AB Science","route":"/companies/ab-science/","asOf":"2026-09-11","days":10},{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/","asOf":"2026-09-11","days":10},{"id":"leo-pharma","kind":"company","name":"LEO Pharma","route":"/companies/leo-pharma/","asOf":"2026-09-11","days":10},{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","asOf":"2026-09-11","days":10},{"id":"almirall","kind":"company","name":"Almirall","route":"/companies/almirall/","asOf":"2026-09-11","days":10},{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/","asOf":"2026-09-11","days":10},{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/","asOf":"2026-09-11","days":10},{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/","asOf":"2026-09-11","days":10},{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/","asOf":"2026-09-11","days":10},{"id":"beyondspring","kind":"company","name":"BeyondSpring Pharmaceuticals","route":"/companies/beyondspring/","asOf":"2026-09-11","days":10},{"id":"photocure","kind":"company","name":"Photocure","route":"/companies/photocure/","asOf":"2026-09-11","days":10},{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/","asOf":"2026-09-11","days":10},{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/","asOf":"2026-09-11","days":10},{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/","asOf":"2026-09-11","days":10},{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","route":"/companies/chugai/","asOf":"2026-09-11","days":10},{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/","asOf":"2026-09-11","days":10},{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","route":"/companies/tg-therapeutics/","asOf":"2026-09-11","days":10},{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/","asOf":"2026-09-11","days":10},{"id":"aop-health","kind":"company","name":"AOP Health","route":"/companies/aop-health/","asOf":"2026-09-11","days":10},{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/","asOf":"2026-09-11","days":10},{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/","asOf":"2026-09-11","days":10},{"id":"polaris-group","kind":"company","name":"Polaris Group","route":"/companies/polaris-group/","asOf":"2026-09-11","days":10},{"id":"securabio","kind":"company","name":"SecuraBio","route":"/companies/securabio/","asOf":"2026-09-11","days":10},{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","route":"/companies/phaxiam/","asOf":"2026-09-11","days":10},{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","asOf":"2026-09-11","days":10},{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/","asOf":"2026-09-11","days":10},{"id":"soligenix","kind":"company","name":"Soligenix","route":"/companies/soligenix/","asOf":"2026-09-11","days":10},{"id":"veru","kind":"company","name":"Veru","route":"/companies/veru/","asOf":"2026-09-11","days":10},{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","asOf":"2026-09-11","days":10},{"id":"gc-cell","kind":"company","name":"GC Cell","route":"/companies/gc-cell/","asOf":"2026-09-11","days":10},{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","route":"/companies/alaunos/","asOf":"2026-09-11","days":10},{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/","asOf":"2026-09-11","days":10},{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/","asOf":"2026-09-11","days":10},{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/","asOf":"2026-09-11","days":10},{"id":"mei-pharma","kind":"company","name":"MEI Pharma","route":"/companies/mei-pharma/","asOf":"2026-09-11","days":10},{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/","asOf":"2026-09-11","days":10},{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","route":"/companies/basilea/","asOf":"2026-09-11","days":10},{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","route":"/companies/nippon-kayaku/","asOf":"2026-09-11","days":10},{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/","asOf":"2026-09-11","days":10},{"id":"g1-therapeutics","kind":"company","name":"G1 Therapeutics","route":"/companies/g1-therapeutics/","asOf":"2026-09-11","days":10},{"id":"antengene","kind":"company","name":"Antengene","route":"/companies/antengene/","asOf":"2026-09-11","days":10},{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/","asOf":"2026-09-11","days":10},{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","route":"/companies/aprea-therapeutics/","asOf":"2026-09-11","days":10},{"id":"aptose","kind":"company","name":"Aptose Biosciences","route":"/companies/aptose/","asOf":"2026-09-11","days":10},{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/","asOf":"2026-09-11","days":10},{"id":"accuray","kind":"company","name":"Accuray","route":"/companies/accuray/","asOf":"2026-09-11","days":10},{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/","asOf":"2026-09-11","days":10},{"id":"sotio","kind":"company","name":"SOTIO Biotech","route":"/companies/sotio/","asOf":"2026-09-11","days":10},{"id":"tolmar","kind":"company","name":"Tolmar","route":"/companies/tolmar/","asOf":"2026-09-11","days":10},{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","route":"/companies/partner-therapeutics/","asOf":"2026-09-11","days":10},{"id":"pharmaand","kind":"company","name":"pharma&","route":"/companies/pharmaand/","asOf":"2026-09-11","days":10},{"id":"neovii","kind":"company","name":"Neovii","route":"/companies/neovii/","asOf":"2026-09-11","days":10},{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","asOf":"2026-09-11","days":10},{"id":"lees-pharmaceutical","kind":"company","name":"Lee's Pharmaceutical","route":"/companies/lees-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"biogen","kind":"company","name":"Biogen","route":"/companies/biogen/","asOf":"2026-09-11","days":10},{"id":"norgine","kind":"company","name":"Norgine","route":"/companies/norgine/","asOf":"2026-09-11","days":10},{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","route":"/companies/foresee-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"nobelpharma","kind":"company","name":"Nobelpharma","route":"/companies/nobelpharma/","asOf":"2026-09-11","days":10},{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/","asOf":"2026-09-11","days":10},{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","route":"/companies/changchun-genescience/","asOf":"2026-09-11","days":10},{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","asOf":"2026-09-11","days":10},{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/","asOf":"2026-09-11","days":10},{"id":"preglem","kind":"company","name":"PregLem","route":"/companies/preglem/","asOf":"2026-09-11","days":10},{"id":"telik","kind":"company","name":"Telik","route":"/companies/telik/","asOf":"2026-09-11","days":10},{"id":"agennix","kind":"company","name":"Agennix","route":"/companies/agennix/","asOf":"2026-09-11","days":10},{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/","asOf":"2026-09-11","days":10},{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","route":"/companies/insys-therapeutics/","asOf":"2026-09-11","days":10},{"id":"achieve-life-sciences","kind":"company","name":"Achieve Life Sciences (formerly OncoGenex)","route":"/companies/achieve-life-sciences/","asOf":"2026-09-11","days":10},{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/","asOf":"2026-09-11","days":10},{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/","asOf":"2026-09-11","days":10},{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","route":"/companies/merrimack-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"threshold-pharmaceuticals","kind":"company","name":"Threshold Pharmaceuticals","route":"/companies/threshold-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"peregrine-avid","kind":"company","name":"Peregrine Pharmaceuticals (now Avid Bioservices)","route":"/companies/peregrine-avid/","asOf":"2026-09-11","days":10},{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/","asOf":"2026-09-11","days":10},{"id":"dong-a-st","kind":"company","name":"Dong-A ST","route":"/companies/dong-a-st/","asOf":"2026-09-11","days":10},{"id":"harbour-biomed","kind":"company","name":"Harbour BioMed","route":"/companies/harbour-biomed/","asOf":"2026-09-11","days":10},{"id":"viatris","kind":"company","name":"Viatris","route":"/companies/viatris/","asOf":"2026-09-11","days":10},{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/","asOf":"2026-09-11","days":10},{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/","asOf":"2026-09-11","days":10},{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","route":"/companies/pharmacosmos/","asOf":"2026-09-11","days":10},{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","route":"/companies/kissei/","asOf":"2026-09-11","days":10},{"id":"zeria","kind":"company","name":"Zeria Pharmaceutical","route":"/companies/zeria/","asOf":"2026-09-11","days":10},{"id":"rovi","kind":"company","name":"Rovi","route":"/companies/rovi/","asOf":"2026-09-11","days":10},{"id":"denovo-biopharma","kind":"company","name":"Denovo Biopharma","route":"/companies/denovo-biopharma/","asOf":"2026-09-11","days":10},{"id":"cancer-prevention-pharmaceuticals","kind":"company","name":"Cancer Prevention Pharmaceuticals","route":"/companies/cancer-prevention-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"photonamic","kind":"company","name":"photonamic","route":"/companies/photonamic/","asOf":"2026-09-11","days":10},{"id":"oakwood-laboratories","kind":"company","name":"Oakwood Laboratories","route":"/companies/oakwood-laboratories/","asOf":"2026-09-11","days":10},{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","route":"/companies/daehwa-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"cellseed","kind":"company","name":"CellSeed","route":"/companies/cellseed/","asOf":"2026-09-11","days":10},{"id":"arog-pharmaceuticals","kind":"company","name":"Arog Pharmaceuticals","route":"/companies/arog-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","route":"/companies/cyclacel/","asOf":"2026-09-11","days":10},{"id":"galera-therapeutics","kind":"company","name":"Galera Therapeutics","route":"/companies/galera-therapeutics/","asOf":"2026-09-11","days":10},{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"infinity-pharmaceuticals","kind":"company","name":"Infinity Pharmaceuticals","route":"/companies/infinity-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","route":"/companies/halozyme/","asOf":"2026-09-11","days":10},{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/","asOf":"2026-09-11","days":10},{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/","asOf":"2026-09-11","days":10},{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","route":"/companies/cartesian-therapeutics/","asOf":"2026-09-11","days":10},{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","route":"/companies/atossa-therapeutics/","asOf":"2026-09-11","days":10},{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/","asOf":"2026-09-11","days":10},{"id":"ascletis","kind":"company","name":"Ascletis Pharma","route":"/companies/ascletis/","asOf":"2026-09-11","days":10},{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/","asOf":"2026-09-11","days":10},{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","route":"/companies/diffusion-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/","asOf":"2026-09-11","days":10},{"id":"hibercell","kind":"company","name":"HiberCell","route":"/companies/hibercell/","asOf":"2026-09-11","days":10},{"id":"isarna-therapeutics","kind":"company","name":"Isarna Therapeutics","route":"/companies/isarna-therapeutics/","asOf":"2026-09-11","days":10},{"id":"medigene","kind":"company","name":"Medigene","route":"/companies/medigene/","asOf":"2026-09-11","days":10},{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","asOf":"2026-09-11","days":10},{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/","asOf":"2026-09-11","days":10},{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","route":"/companies/acacia-pharma/","asOf":"2026-09-11","days":10},{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","route":"/companies/ionis/","asOf":"2026-09-11","days":10},{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","route":"/companies/emergent-biosolutions/","asOf":"2026-09-11","days":10},{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/","asOf":"2026-09-11","days":10},{"id":"mabion","kind":"company","name":"Mabion","route":"/companies/mabion/","asOf":"2026-09-11","days":10},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/","asOf":"2026-09-11","days":10},{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/","asOf":"2026-09-11","days":10},{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","route":"/companies/jw-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"ptc-therapeutics","kind":"company","name":"PTC Therapeutics","route":"/companies/ptc-therapeutics/","asOf":"2026-09-11","days":10},{"id":"sunesis","kind":"company","name":"Sunesis Pharmaceuticals","route":"/companies/sunesis/","asOf":"2026-09-11","days":10},{"id":"symbio-pharmaceuticals","kind":"company","name":"SymBio Pharmaceuticals","route":"/companies/symbio-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/","asOf":"2026-09-11","days":10},{"id":"tracon","kind":"company","name":"Tracon Pharmaceuticals","route":"/companies/tracon/","asOf":"2026-09-11","days":10},{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","route":"/companies/united-therapeutics/","asOf":"2026-09-11","days":10},{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","route":"/companies/vion-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"vor-biopharma","kind":"company","name":"Vor Biopharma","route":"/companies/vor-biopharma/","asOf":"2026-09-11","days":10},{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/","asOf":"2026-09-11","days":10},{"id":"mast-therapeutics","kind":"company","name":"Mast Therapeutics","route":"/companies/mast-therapeutics/","asOf":"2026-09-11","days":10},{"id":"sbi-pharmaceuticals","kind":"company","name":"SBI Pharmaceuticals","route":"/companies/sbi-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","route":"/companies/vasgene-therapeutics/","asOf":"2026-09-11","days":10},{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/","asOf":"2026-09-11","days":10},{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/","asOf":"2026-09-11","days":10},{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/","asOf":"2026-09-11","days":10},{"id":"immunitor","kind":"company","name":"Immunitor","route":"/companies/immunitor/","asOf":"2026-09-11","days":10},{"id":"moleculin","kind":"company","name":"Moleculin Biotech","route":"/companies/moleculin/","asOf":"2026-09-11","days":10},{"id":"lisata","kind":"company","name":"Lisata Therapeutics","route":"/companies/lisata/","asOf":"2026-09-11","days":10},{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","asOf":"2026-09-11","days":10},{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/","asOf":"2026-09-11","days":10},{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","route":"/companies/sijbrandij-foundation/","asOf":"2026-09-11","days":10},{"id":"future-of-cancer-care-today","kind":"company","name":"Future of Cancer Care Today (FCCT)","route":"/companies/future-of-cancer-care-today/","asOf":"2026-09-11","days":10},{"id":"specicare","kind":"company","name":"SpeciCare","route":"/companies/specicare/","asOf":"2026-09-11","days":10},{"id":"storemytumor","kind":"company","name":"StoreMyTumor","route":"/companies/storemytumor/","asOf":"2026-09-11","days":10},{"id":"belay-diagnostics","kind":"company","name":"Belay Diagnostics","route":"/companies/belay-diagnostics/","asOf":"2026-09-11","days":10},{"id":"cnside-diagnostics","kind":"company","name":"CNSide Diagnostics","route":"/companies/cnside-diagnostics/","asOf":"2026-09-11","days":10},{"id":"rgcc-international","kind":"company","name":"RGCC International","route":"/companies/rgcc-international/","asOf":"2026-09-11","days":10},{"id":"navignostics","kind":"company","name":"Navignostics","route":"/companies/navignostics/","asOf":"2026-09-11","days":10},{"id":"cegat","kind":"company","name":"CeGaT","route":"/companies/cegat/","asOf":"2026-09-11","days":10},{"id":"oncodna","kind":"company","name":"OncoDNA","route":"/companies/oncodna/","asOf":"2026-09-11","days":10},{"id":"hartwig-medical-foundation","kind":"company","name":"Hartwig Medical Foundation","route":"/companies/hartwig-medical-foundation/","asOf":"2026-09-11","days":10},{"id":"vicinity-bio","kind":"company","name":"Vicinity Bio","route":"/companies/vicinity-bio/","asOf":"2026-09-11","days":10},{"id":"protean-biodiagnostics","kind":"company","name":"Protean BioDiagnostics","route":"/companies/protean-biodiagnostics/","asOf":"2026-09-11","days":10},{"id":"travera","kind":"company","name":"Travera","route":"/companies/travera/","asOf":"2026-09-11","days":10},{"id":"first-ascent-biomedical","kind":"company","name":"First Ascent Biomedical","route":"/companies/first-ascent-biomedical/","asOf":"2026-09-11","days":10},{"id":"kiyatec","kind":"company","name":"Kiyatec","route":"/companies/kiyatec/","asOf":"2026-09-11","days":10},{"id":"cure-first","kind":"company","name":"Cure-First","route":"/companies/cure-first/","asOf":"2026-09-11","days":10},{"id":"sagemedic","kind":"company","name":"SageMedic","route":"/companies/sagemedic/","asOf":"2026-09-11","days":10},{"id":"kyan-technologies","kind":"company","name":"KYAN Technologies","route":"/companies/kyan-technologies/","asOf":"2026-09-11","days":10},{"id":"cancertain","kind":"company","name":"CanCertain","route":"/companies/cancertain/","asOf":"2026-09-11","days":10},{"id":"2curex","kind":"company","name":"2cureX","route":"/companies/2curex/","asOf":"2026-09-11","days":10},{"id":"pathfinder-oncology","kind":"company","name":"Pathfinder Oncology","route":"/companies/pathfinder-oncology/","asOf":"2026-09-11","days":10},{"id":"jaime-leandro-foundation","kind":"company","name":"Jaime Leandro Foundation","route":"/companies/jaime-leandro-foundation/","asOf":"2026-09-11","days":10},{"id":"invoke-bio","kind":"company","name":"Invoke Bio","route":"/companies/invoke-bio/","asOf":"2026-09-11","days":10},{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/","asOf":"2026-09-11","days":10},{"id":"ubivac","kind":"company","name":"UbiVac","route":"/companies/ubivac/","asOf":"2026-09-11","days":10},{"id":"cartx-therapeutics","kind":"company","name":"CARTx Therapeutics","route":"/companies/cartx-therapeutics/","asOf":"2026-09-11","days":10},{"id":"picnic-health","kind":"company","name":"Picnic Health","route":"/companies/picnic-health/","asOf":"2026-09-11","days":10},{"id":"antidote","kind":"company","name":"Antidote","route":"/companies/antidote/","asOf":"2026-09-11","days":10},{"id":"mytomorrows","kind":"company","name":"myTomorrows","route":"/companies/mytomorrows/","asOf":"2026-09-11","days":10},{"id":"klineo","kind":"company","name":"Klineo","route":"/companies/klineo/","asOf":"2026-09-11","days":10},{"id":"galen","kind":"company","name":"Galen","route":"/companies/galen/","asOf":"2026-09-11","days":10},{"id":"opencancerai","kind":"company","name":"OpenCancerAI","route":"/companies/opencancerai/","asOf":"2026-09-11","days":10},{"id":"patient-advocators","kind":"company","name":"Patient Advocators","route":"/companies/patient-advocators/","asOf":"2026-09-11","days":10},{"id":"private-health-management","kind":"company","name":"Private Health Management","route":"/companies/private-health-management/","asOf":"2026-09-11","days":10},{"id":"sagely-health","kind":"company","name":"Sagely Health","route":"/companies/sagely-health/","asOf":"2026-09-11","days":10},{"id":"outperform-cancer","kind":"company","name":"Outperform Cancer","route":"/companies/outperform-cancer/","asOf":"2026-09-11","days":10},{"id":"epistamai-biotech","kind":"company","name":"Epistamai Biotech","route":"/companies/epistamai-biotech/","asOf":"2026-09-11","days":10},{"id":"private-medical","kind":"company","name":"Private Medical","route":"/companies/private-medical/","asOf":"2026-09-11","days":10},{"id":"biostar-pharmaceuticals","kind":"company","name":"Biostar Pharmaceuticals","route":"/companies/biostar-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/","asOf":"2026-09-11","days":10},{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","route":"/companies/juventas-cell-therapy/","asOf":"2026-09-11","days":10},{"id":"shanghai-yingli","kind":"company","name":"Shanghai Yingli Pharmaceutical","route":"/companies/shanghai-yingli/","asOf":"2026-09-11","days":10},{"id":"shanghai-sunway-biotech","kind":"company","name":"Shanghai Sunway Biotech","route":"/companies/shanghai-sunway-biotech/","asOf":"2026-09-11","days":10},{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","route":"/companies/chengdu-zenitar-biomedical-technology/","asOf":"2026-09-11","days":10},{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","route":"/companies/beijing-konruns-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","route":"/companies/beijing-mabworks-biotech/","asOf":"2026-09-11","days":10},{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/","asOf":"2026-09-11","days":10},{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/","asOf":"2026-09-11","days":10},{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/","asOf":"2026-09-11","days":10},{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","route":"/companies/immvira-pharma/","asOf":"2026-09-11","days":10},{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/","asOf":"2026-09-11","days":10},{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","route":"/companies/beijing-tide-pharmaceutical/","asOf":"2026-09-11","days":10},{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/","asOf":"2026-09-11","days":10},{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","route":"/companies/nanjing-immunophage-biotech/","asOf":"2026-09-11","days":10},{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","route":"/companies/tj-biopharma/","asOf":"2026-09-11","days":10},{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","route":"/companies/zhuhai-yufan-biotechnologies/","asOf":"2026-09-11","days":10},{"id":"scirouter","kind":"company","name":"SciRouter","route":"/companies/scirouter/","asOf":"2026-09-11","days":10},{"id":"anocca","kind":"company","name":"Anocca","route":"/companies/anocca/","asOf":"2026-09-11","days":10},{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/","asOf":"2026-09-11","days":10},{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/","asOf":"2026-09-11","days":10},{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/","asOf":"2026-09-11","days":10},{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/","asOf":"2026-09-11","days":10},{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/","asOf":"2026-09-11","days":10},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/","asOf":"2026-09-11","days":10},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/","asOf":"2026-09-11","days":10},{"id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/","asOf":"2026-09-11","days":10},{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/","asOf":"2026-09-11","days":10},{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/","asOf":"2026-09-11","days":10},{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/","asOf":"2026-09-11","days":10},{"id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/","asOf":"2026-09-11","days":10},{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/","asOf":"2026-09-11","days":10},{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/","asOf":"2026-09-11","days":10},{"id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/","asOf":"2026-09-11","days":10},{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","asOf":"2026-09-11","days":10},{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/","asOf":"2026-09-11","days":10},{"id":"qlc5508","kind":"drug","name":"QLC5508","route":"/drugs/qlc5508/","asOf":"2026-09-11","days":10},{"id":"kc1036","kind":"drug","name":"KC1036","route":"/drugs/kc1036/","asOf":"2026-09-11","days":10},{"id":"budigalimab","kind":"drug","name":"Budigalimab","route":"/drugs/budigalimab/","asOf":"2026-09-11","days":10},{"id":"ceralasertib","kind":"drug","name":"Ceralasertib","route":"/drugs/ceralasertib/","asOf":"2026-09-11","days":10},{"id":"abexinostat","kind":"drug","name":"Abexinostat","route":"/drugs/abexinostat/","asOf":"2026-09-11","days":10},{"id":"hrs-8080","kind":"drug","name":"HRS-8080","route":"/drugs/hrs-8080/","asOf":"2026-09-11","days":10},{"id":"ipatasertib","kind":"drug","name":"Ipatasertib","route":"/drugs/ipatasertib/","asOf":"2026-09-11","days":10},{"id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/","asOf":"2026-09-11","days":10},{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/","asOf":"2026-09-11","days":10},{"id":"rc148","kind":"drug","name":"RC148","route":"/drugs/rc148/","asOf":"2026-09-11","days":10},{"id":"sph4336","kind":"drug","name":"SPH4336","route":"/drugs/sph4336/","asOf":"2026-09-11","days":10},{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/","asOf":"2026-09-11","days":10},{"id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/","asOf":"2026-09-11","days":10},{"id":"livmoniplimab","kind":"drug","name":"Livmoniplimab","route":"/drugs/livmoniplimab/","asOf":"2026-09-11","days":10},{"id":"jdq443","kind":"drug","name":"JDQ443","route":"/drugs/jdq443/","asOf":"2026-09-11","days":10},{"id":"tqb3616","kind":"drug","name":"TQB3616","route":"/drugs/tqb3616/","asOf":"2026-09-11","days":10},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/","asOf":"2026-09-11","days":10},{"id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/","asOf":"2026-09-11","days":10},{"id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/","asOf":"2026-09-11","days":10},{"id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/","asOf":"2026-09-11","days":10},{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/","asOf":"2026-09-11","days":10},{"id":"monalizumab","kind":"drug","name":"Monalizumab","route":"/drugs/monalizumab/","asOf":"2026-09-11","days":10},{"id":"navlimetostat","kind":"drug","name":"Navlimetostat","route":"/drugs/navlimetostat/","asOf":"2026-09-11","days":10},{"id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/","asOf":"2026-09-11","days":10},{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/","asOf":"2026-09-11","days":10},{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/","asOf":"2026-09-11","days":10},{"id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/","asOf":"2026-09-11","days":10},{"id":"quemliclustat","kind":"drug","name":"Quemliclustat","route":"/drugs/quemliclustat/","asOf":"2026-09-11","days":10},{"id":"mrg003","kind":"drug","name":"MRG003","route":"/drugs/mrg003/","asOf":"2026-09-11","days":10},{"id":"shr-a1921","kind":"drug","name":"SHR-A1921","route":"/drugs/shr-a1921/","asOf":"2026-09-11","days":10},{"id":"shr-1501","kind":"drug","name":"SHR-1501","route":"/drugs/shr-1501/","asOf":"2026-09-11","days":10},{"id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/","asOf":"2026-09-11","days":10},{"id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/","asOf":"2026-09-11","days":10},{"id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/","asOf":"2026-09-11","days":10},{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/","asOf":"2026-09-11","days":10},{"id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/","asOf":"2026-09-11","days":10},{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/","asOf":"2026-09-11","days":10},{"id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/","asOf":"2026-09-11","days":10},{"id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/","asOf":"2026-09-11","days":10},{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/","asOf":"2026-09-11","days":10},{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/","asOf":"2026-09-11","days":10},{"id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/","asOf":"2026-09-11","days":10},{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/","asOf":"2026-09-11","days":10},{"id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/","asOf":"2026-09-11","days":10},{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/","asOf":"2026-09-11","days":10},{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","asOf":"2026-09-11","days":10},{"id":"purinostat","kind":"drug","name":"Purinostat","route":"/drugs/purinostat/","asOf":"2026-09-11","days":10},{"id":"tqb2450","kind":"drug","name":"TQB2450","route":"/drugs/tqb2450/","asOf":"2026-09-11","days":10},{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/","asOf":"2026-09-11","days":10},{"id":"lam561","kind":"drug","name":"LAM561","route":"/drugs/lam561/","asOf":"2026-09-11","days":10},{"id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/","asOf":"2026-09-11","days":10},{"id":"velzatinib","kind":"drug","name":"Velzatinib","route":"/drugs/velzatinib/","asOf":"2026-09-11","days":10},{"id":"a166","kind":"drug","name":"A166","route":"/drugs/a166/","asOf":"2026-09-11","days":10},{"id":"shr-a2009","kind":"drug","name":"SHR-A2009","route":"/drugs/shr-a2009/","asOf":"2026-09-11","days":10},{"id":"mrg002","kind":"drug","name":"MRG002","route":"/drugs/mrg002/","asOf":"2026-09-11","days":10},{"id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/","asOf":"2026-09-11","days":10},{"id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/","asOf":"2026-09-11","days":10},{"id":"io102-io103","kind":"drug","name":"IO102-IO103","route":"/drugs/io102-io103/","asOf":"2026-09-11","days":10},{"id":"pf-07248144","kind":"drug","name":"PF-07248144","route":"/drugs/pf-07248144/","asOf":"2026-09-11","days":10},{"id":"abbv-706","kind":"drug","name":"ABBV-706","route":"/drugs/abbv-706/","asOf":"2026-09-11","days":10},{"id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/","asOf":"2026-09-11","days":10},{"id":"ty-9591","kind":"drug","name":"TY-9591","route":"/drugs/ty-9591/","asOf":"2026-09-11","days":10},{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/","asOf":"2026-09-11","days":10},{"id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/","asOf":"2026-09-11","days":10},{"id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/","asOf":"2026-09-11","days":10},{"id":"tgrx-326","kind":"drug","name":"TGRX-326","route":"/drugs/tgrx-326/","asOf":"2026-09-11","days":10},{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/","asOf":"2026-09-11","days":10},{"id":"uliledlimab","kind":"drug","name":"Uliledlimab","route":"/drugs/uliledlimab/","asOf":"2026-09-11","days":10},{"id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/","asOf":"2026-09-11","days":10},{"id":"bebt-209","kind":"drug","name":"BEBT-209","route":"/drugs/bebt-209/","asOf":"2026-09-11","days":10},{"id":"givinostat","kind":"drug","name":"Givinostat","route":"/drugs/givinostat/","asOf":"2026-09-11","days":10},{"id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","asOf":"2026-09-11","days":10},{"id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/","asOf":"2026-09-11","days":10},{"id":"js105","kind":"drug","name":"JS105","route":"/drugs/js105/","asOf":"2026-09-11","days":10},{"id":"jmt101","kind":"drug","name":"JMT101","route":"/drugs/jmt101/","asOf":"2026-09-11","days":10},{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/","asOf":"2026-09-11","days":10},{"id":"acasunlimab","kind":"drug","name":"Acasunlimab","route":"/drugs/acasunlimab/","asOf":"2026-09-11","days":10},{"id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/","asOf":"2026-09-11","days":10},{"id":"cobolimab","kind":"drug","name":"Cobolimab","route":"/drugs/cobolimab/","asOf":"2026-09-11","days":10},{"id":"icp-248","kind":"drug","name":"ICP-248","route":"/drugs/icp-248/","asOf":"2026-09-11","days":10},{"id":"emactuzumab","kind":"drug","name":"Emactuzumab","route":"/drugs/emactuzumab/","asOf":"2026-09-11","days":10},{"id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/","asOf":"2026-09-11","days":10},{"id":"olvimulogene-nanivacirepvec","kind":"drug","name":"Olvimulogene nanivacirepvec","route":"/drugs/olvimulogene-nanivacirepvec/","asOf":"2026-09-11","days":10},{"id":"setidegrasib","kind":"drug","name":"Setidegrasib","route":"/drugs/setidegrasib/","asOf":"2026-09-11","days":10},{"id":"hlx22","kind":"drug","name":"HLX22","route":"/drugs/hlx22/","asOf":"2026-09-11","days":10},{"id":"sctb41","kind":"drug","name":"SCTB41","route":"/drugs/sctb41/","asOf":"2026-09-11","days":10},{"id":"d07001","kind":"drug","name":"D07001","route":"/drugs/d07001/","asOf":"2026-09-11","days":10},{"id":"sctb35","kind":"drug","name":"SCTB35","route":"/drugs/sctb35/","asOf":"2026-09-11","days":10},{"id":"tersolisib","kind":"drug","name":"Tersolisib","route":"/drugs/tersolisib/","asOf":"2026-09-11","days":10},{"id":"arlocabtagene-autoleucel","kind":"drug","name":"Arlocabtagene Autoleucel","route":"/drugs/arlocabtagene-autoleucel/","asOf":"2026-09-11","days":10},{"id":"bezuclastinib","kind":"drug","name":"Bezuclastinib","route":"/drugs/bezuclastinib/","asOf":"2026-09-11","days":10},{"id":"tqb3454","kind":"drug","name":"TQB3454","route":"/drugs/tqb3454/","asOf":"2026-09-11","days":10},{"id":"shr-a1912","kind":"drug","name":"SHR-A1912","route":"/drugs/shr-a1912/","asOf":"2026-09-11","days":10},{"id":"hmpl-306","kind":"drug","name":"HMPL-306","route":"/drugs/hmpl-306/","asOf":"2026-09-11","days":10},{"id":"tak-928","kind":"drug","name":"TAK-928","route":"/drugs/tak-928/","asOf":"2026-09-11","days":10},{"id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/","asOf":"2026-09-11","days":10},{"id":"idrx-42","kind":"drug","name":"IDRX-42","route":"/drugs/idrx-42/","asOf":"2026-09-11","days":10},{"id":"elenestinib","kind":"drug","name":"Elenestinib","route":"/drugs/elenestinib/","asOf":"2026-09-11","days":10},{"id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/","asOf":"2026-09-11","days":10},{"id":"int230-6","kind":"drug","name":"INT230-6","route":"/drugs/int230-6/","asOf":"2026-09-11","days":10},{"id":"grt-c901","kind":"drug","name":"GRT-C901","route":"/drugs/grt-c901/","asOf":"2026-09-11","days":10},{"id":"grt-r902","kind":"drug","name":"GRT-R902","route":"/drugs/grt-r902/","asOf":"2026-09-11","days":10},{"id":"imp4927","kind":"drug","name":"IMP4927","route":"/drugs/imp4927/","asOf":"2026-09-11","days":10},{"id":"lerotinib","kind":"drug","name":"Lerotinib","route":"/drugs/lerotinib/","asOf":"2026-09-11","days":10},{"id":"azd5335","kind":"drug","name":"AZD5335","route":"/drugs/azd5335/","asOf":"2026-09-11","days":10},{"id":"tq-b3234","kind":"drug","name":"TQ-B3234","route":"/drugs/tq-b3234/","asOf":"2026-09-11","days":10},{"id":"ugn-103","kind":"drug","name":"UGN-103","route":"/drugs/ugn-103/","asOf":"2026-09-11","days":10},{"id":"hmpl-453","kind":"drug","name":"HMPL-453","route":"/drugs/hmpl-453/","asOf":"2026-09-11","days":10},{"id":"sctc21c","kind":"drug","name":"SCTC21C","route":"/drugs/sctc21c/","asOf":"2026-09-11","days":10},{"id":"bcd-100","kind":"drug","name":"BCD-100","route":"/drugs/bcd-100/","asOf":"2026-09-11","days":10},{"id":"hr070803","kind":"drug","name":"HR070803","route":"/drugs/hr070803/","asOf":"2026-09-11","days":10},{"id":"nb003","kind":"drug","name":"NB003","route":"/drugs/nb003/","asOf":"2026-09-11","days":10},{"id":"fda018-adc","kind":"drug","name":"FDA018-ADC","route":"/drugs/fda018-adc/","asOf":"2026-09-11","days":10},{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/","asOf":"2026-09-11","days":10},{"id":"d-0502","kind":"drug","name":"D-0502","route":"/drugs/d-0502/","asOf":"2026-09-11","days":10},{"id":"incb161734","kind":"drug","name":"INCB161734","route":"/drugs/incb161734/","asOf":"2026-09-11","days":10},{"id":"tar-210","kind":"drug","name":"TAR-210","route":"/drugs/tar-210/","asOf":"2026-09-11","days":10},{"id":"hmpl-760","kind":"drug","name":"HMPL-760","route":"/drugs/hmpl-760/","asOf":"2026-09-11","days":10},{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/","asOf":"2026-09-11","days":10},{"id":"sim0270","kind":"drug","name":"SIM0270","route":"/drugs/sim0270/","asOf":"2026-09-11","days":10},{"id":"asp2138","kind":"drug","name":"ASP2138","route":"/drugs/asp2138/","asOf":"2026-09-11","days":10},{"id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/","asOf":"2026-09-11","days":10},{"id":"zovegalisib","kind":"drug","name":"Zovegalisib","route":"/drugs/zovegalisib/","asOf":"2026-09-11","days":10},{"id":"vc004","kind":"drug","name":"VC004","route":"/drugs/vc004/","asOf":"2026-09-11","days":10},{"id":"hlx11","kind":"drug","name":"HLX11","route":"/drugs/hlx11/","asOf":"2026-09-11","days":10},{"id":"atigotatug","kind":"drug","name":"Atigotatug","route":"/drugs/atigotatug/","asOf":"2026-09-11","days":10},{"id":"sgm-101","kind":"drug","name":"SGM-101","route":"/drugs/sgm-101/","asOf":"2026-09-11","days":10},{"id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","route":"/drugs/precemtabart-tocentecan/","asOf":"2026-09-11","days":10},{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","asOf":"2026-09-11","days":10},{"id":"sasanlimab","kind":"drug","name":"Sasanlimab","route":"/drugs/sasanlimab/","asOf":"2026-09-11","days":10},{"id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/","asOf":"2026-09-11","days":10},{"id":"inca33890","kind":"drug","name":"INCA33890","route":"/drugs/inca33890/","asOf":"2026-09-11","days":10},{"id":"rph-051","kind":"drug","name":"RPH-051","route":"/drugs/rph-051/","asOf":"2026-09-11","days":10},{"id":"bms-986365","kind":"drug","name":"BMS-986365","route":"/drugs/bms-986365/","asOf":"2026-09-11","days":10},{"id":"lns8801","kind":"drug","name":"LNS8801","route":"/drugs/lns8801/","asOf":"2026-09-11","days":10},{"id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","route":"/drugs/rondecabtagene-autoleucel/","asOf":"2026-09-11","days":10},{"id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","asOf":"2026-09-11","days":10},{"id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/","asOf":"2026-09-11","days":10},{"id":"bomedemstat","kind":"drug","name":"Bomedemstat","route":"/drugs/bomedemstat/","asOf":"2026-09-11","days":10},{"id":"jnj-90301900","kind":"drug","name":"JNJ-90301900","route":"/drugs/jnj-90301900/","asOf":"2026-09-11","days":10},{"id":"m108","kind":"drug","name":"M108","route":"/drugs/m108/","asOf":"2026-09-11","days":10},{"id":"bgb-43395","kind":"drug","name":"BGB-43395","route":"/drugs/bgb-43395/","asOf":"2026-09-11","days":10},{"id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/","asOf":"2026-09-11","days":10},{"id":"vepugratinib","kind":"drug","name":"Vepugratinib","route":"/drugs/vepugratinib/","asOf":"2026-09-11","days":10},{"id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/","asOf":"2026-09-11","days":10},{"id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/","asOf":"2026-09-11","days":10},{"id":"asc40","kind":"drug","name":"ASC40","route":"/drugs/asc40/","asOf":"2026-09-11","days":10},{"id":"trabedersen","kind":"drug","name":"Trabedersen","route":"/drugs/trabedersen/","asOf":"2026-09-11","days":10},{"id":"adi-peg20","kind":"drug","name":"ADI-PEG20","route":"/drugs/adi-peg20/","asOf":"2026-09-11","days":10},{"id":"ro7771950","kind":"drug","name":"RO7771950","route":"/drugs/ro7771950/","asOf":"2026-09-11","days":10},{"id":"sctb14","kind":"drug","name":"SCTB14","route":"/drugs/sctb14/","asOf":"2026-09-11","days":10},{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/","asOf":"2026-09-11","days":10},{"id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/","asOf":"2026-09-11","days":10},{"id":"navitoclax","kind":"drug","name":"Navitoclax","route":"/drugs/navitoclax/","asOf":"2026-09-11","days":10},{"id":"pf-08046054","kind":"drug","name":"PF-08046054","route":"/drugs/pf-08046054/","asOf":"2026-09-11","days":10},{"id":"varegacestat","kind":"drug","name":"Varegacestat","route":"/drugs/varegacestat/","asOf":"2026-09-11","days":10},{"id":"hs-20117","kind":"drug","name":"HS-20117","route":"/drugs/hs-20117/","asOf":"2026-09-11","days":10},{"id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/","asOf":"2026-09-11","days":10},{"id":"ugn-104","kind":"drug","name":"UGN-104","route":"/drugs/ugn-104/","asOf":"2026-09-11","days":10},{"id":"qls31905","kind":"drug","name":"QLS31905","route":"/drugs/qls31905/","asOf":"2026-09-11","days":10},{"id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/","asOf":"2026-09-11","days":10},{"id":"ivospemin","kind":"drug","name":"Ivospemin","route":"/drugs/ivospemin/","asOf":"2026-09-11","days":10},{"id":"bnt113","kind":"drug","name":"BNT113","route":"/drugs/bnt113/","asOf":"2026-09-11","days":10},{"id":"chiauranib","kind":"drug","name":"Chiauranib","route":"/drugs/chiauranib/","asOf":"2026-09-11","days":10},{"id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","asOf":"2026-09-11","days":10},{"id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/","asOf":"2026-09-11","days":10},{"id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/","asOf":"2026-09-11","days":10},{"id":"bleximenib","kind":"drug","name":"Bleximenib","route":"/drugs/bleximenib/","asOf":"2026-09-11","days":10},{"id":"ibi310","kind":"drug","name":"IBI310","route":"/drugs/ibi310/","asOf":"2026-09-11","days":10},{"id":"ficlatuzumab","kind":"drug","name":"Ficlatuzumab","route":"/drugs/ficlatuzumab/","asOf":"2026-09-11","days":10},{"id":"azd0486","kind":"drug","name":"AZD0486","route":"/drugs/azd0486/","asOf":"2026-09-11","days":10},{"id":"ifupinostat","kind":"drug","name":"Ifupinostat","route":"/drugs/ifupinostat/","asOf":"2026-09-11","days":10},{"id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","asOf":"2026-09-11","days":10},{"id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/","asOf":"2026-09-11","days":10},{"id":"iah0968","kind":"drug","name":"IAH0968","route":"/drugs/iah0968/","asOf":"2026-09-11","days":10},{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/","asOf":"2026-09-11","days":10},{"id":"vs-7375","kind":"drug","name":"VS-7375","route":"/drugs/vs-7375/","asOf":"2026-09-11","days":10},{"id":"t3011","kind":"drug","name":"T3011","route":"/drugs/t3011/","asOf":"2026-09-11","days":10},{"id":"fpi-2265","kind":"drug","name":"FPI-2265","route":"/drugs/fpi-2265/","asOf":"2026-09-11","days":10},{"id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/","asOf":"2026-09-11","days":10},{"id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/","asOf":"2026-09-11","days":10},{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/","asOf":"2026-09-11","days":10},{"id":"trk-950","kind":"drug","name":"TRK-950","route":"/drugs/trk-950/","asOf":"2026-09-11","days":10},{"id":"tqb2825","kind":"drug","name":"TQB2825","route":"/drugs/tqb2825/","asOf":"2026-09-11","days":10},{"id":"tyra-300","kind":"drug","name":"TYRA-300","route":"/drugs/tyra-300/","asOf":"2026-09-11","days":10},{"id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/","asOf":"2026-09-11","days":10},{"id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/","asOf":"2026-09-11","days":10},{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/","asOf":"2026-09-11","days":10},{"id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/","asOf":"2026-09-11","days":10},{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","route":"/drugs/ssgj-705/","asOf":"2026-09-11","days":10},{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/","asOf":"2026-09-11","days":10},{"id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/","asOf":"2026-09-11","days":10},{"id":"xnw5004","kind":"drug","name":"XNW5004","route":"/drugs/xnw5004/","asOf":"2026-09-11","days":10},{"id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/","asOf":"2026-09-11","days":10},{"id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/","asOf":"2026-09-11","days":10},{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/","asOf":"2026-09-11","days":10},{"id":"ak119","kind":"drug","name":"AK119","route":"/drugs/ak119/","asOf":"2026-09-11","days":10},{"id":"anvumetostat","kind":"drug","name":"Anvumetostat","route":"/drugs/anvumetostat/","asOf":"2026-09-11","days":10},{"id":"xnw27011","kind":"drug","name":"XNW27011","route":"/drugs/xnw27011/","asOf":"2026-09-11","days":10},{"id":"azd9793","kind":"drug","name":"AZD9793","route":"/drugs/azd9793/","asOf":"2026-09-11","days":10},{"id":"tqb2922","kind":"drug","name":"TQB2922","route":"/drugs/tqb2922/","asOf":"2026-09-11","days":10},{"id":"cinrebafusp-alfa","kind":"drug","name":"Cinrebafusp alfa","route":"/drugs/cinrebafusp-alfa/","asOf":"2026-09-11","days":10},{"id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","route":"/drugs/e-edv-d682/","asOf":"2026-09-11","days":10},{"id":"abt-301","kind":"drug","name":"ABT-301","route":"/drugs/abt-301/","asOf":"2026-09-11","days":10},{"id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/","asOf":"2026-09-11","days":10},{"id":"tc011","kind":"drug","name":"TC011","route":"/drugs/tc011/","asOf":"2026-09-11","days":10},{"id":"englumafusp-alfa","kind":"drug","name":"Englumafusp alfa","route":"/drugs/englumafusp-alfa/","asOf":"2026-09-11","days":10},{"id":"azd4360","kind":"drug","name":"AZD4360","route":"/drugs/azd4360/","asOf":"2026-09-11","days":10},{"id":"ssgj-706","kind":"drug","name":"SSGJ-706","route":"/drugs/ssgj-706/","asOf":"2026-09-11","days":10},{"id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/","asOf":"2026-09-11","days":10},{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/","asOf":"2026-09-11","days":10},{"id":"absk061","kind":"drug","name":"ABSK061","route":"/drugs/absk061/","asOf":"2026-09-11","days":10},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/","asOf":"2026-09-11","days":10},{"id":"bio-106","kind":"drug","name":"BIO-106","route":"/drugs/bio-106/","asOf":"2026-09-11","days":10},{"id":"mavrostobart","kind":"drug","name":"Mavrostobart","route":"/drugs/mavrostobart/","asOf":"2026-09-11","days":10},{"id":"hb0036","kind":"drug","name":"HB0036","route":"/drugs/hb0036/","asOf":"2026-09-11","days":10},{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/","asOf":"2026-09-11","days":10},{"id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/","asOf":"2026-09-11","days":10},{"id":"crb-701","kind":"drug","name":"CRB-701","route":"/drugs/crb-701/","asOf":"2026-09-11","days":10},{"id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/","asOf":"2026-09-11","days":10},{"id":"jk08","kind":"drug","name":"JK08","route":"/drugs/jk08/","asOf":"2026-09-11","days":10},{"id":"ucart22","kind":"drug","name":"UCART22","route":"/drugs/ucart22/","asOf":"2026-09-11","days":10},{"id":"tri-611","kind":"drug","name":"TRI-611","route":"/drugs/tri-611/","asOf":"2026-09-11","days":10},{"id":"azd6621","kind":"drug","name":"AZD6621","route":"/drugs/azd6621/","asOf":"2026-09-11","days":10},{"id":"hdm2017","kind":"drug","name":"HDM2017","route":"/drugs/hdm2017/","asOf":"2026-09-11","days":10},{"id":"silevertinib","kind":"drug","name":"Silevertinib","route":"/drugs/silevertinib/","asOf":"2026-09-11","days":10},{"id":"crc01","kind":"drug","name":"CRC01","route":"/drugs/crc01/","asOf":"2026-09-11","days":10},{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/","asOf":"2026-09-11","days":10},{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/","asOf":"2026-09-11","days":10},{"id":"azd9750","kind":"drug","name":"AZD9750","route":"/drugs/azd9750/","asOf":"2026-09-11","days":10},{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/","asOf":"2026-09-11","days":10},{"id":"ep0062","kind":"drug","name":"EP0062","route":"/drugs/ep0062/","asOf":"2026-09-11","days":10},{"id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/","asOf":"2026-09-11","days":10},{"id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/","asOf":"2026-09-11","days":10},{"id":"ino-5401","kind":"drug","name":"INO-5401","route":"/drugs/ino-5401/","asOf":"2026-09-11","days":10},{"id":"rc118-adc","kind":"drug","name":"RC118-ADC","route":"/drugs/rc118-adc/","asOf":"2026-09-11","days":10},{"id":"adi-270","kind":"drug","name":"ADI-270","route":"/drugs/adi-270/","asOf":"2026-09-11","days":10},{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/","asOf":"2026-09-11","days":10},{"id":"qlh12016","kind":"drug","name":"QLH12016","route":"/drugs/qlh12016/","asOf":"2026-09-11","days":10},{"id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/","asOf":"2026-09-11","days":10},{"id":"azd4512","kind":"drug","name":"AZD4512","route":"/drugs/azd4512/","asOf":"2026-09-11","days":10},{"id":"eb-nk-301","kind":"drug","name":"EB-NK-301","route":"/drugs/eb-nk-301/","asOf":"2026-09-11","days":10},{"id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/","asOf":"2026-09-11","days":10},{"id":"bcb-276","kind":"drug","name":"BCB-276","route":"/drugs/bcb-276/","asOf":"2026-09-11","days":10},{"id":"azd5492","kind":"drug","name":"AZD5492","route":"/drugs/azd5492/","asOf":"2026-09-11","days":10},{"id":"jyp0015","kind":"drug","name":"JYP0015","route":"/drugs/jyp0015/","asOf":"2026-09-11","days":10},{"id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/","asOf":"2026-09-11","days":10},{"id":"hlx26","kind":"drug","name":"HLX26","route":"/drugs/hlx26/","asOf":"2026-09-11","days":10},{"id":"ba3071","kind":"drug","name":"BA3071","route":"/drugs/ba3071/","asOf":"2026-09-11","days":10},{"id":"env-501","kind":"drug","name":"ENV-501","route":"/drugs/env-501/","asOf":"2026-09-11","days":10},{"id":"gc012f","kind":"drug","name":"GC012F","route":"/drugs/gc012f/","asOf":"2026-09-11","days":10},{"id":"azd4045","kind":"drug","name":"AZD4045","route":"/drugs/azd4045/","asOf":"2026-09-11","days":10},{"id":"azd7789","kind":"drug","name":"AZD7789","route":"/drugs/azd7789/","asOf":"2026-09-11","days":10},{"id":"vrn110755","kind":"drug","name":"VRN110755","route":"/drugs/vrn110755/","asOf":"2026-09-11","days":10},{"id":"cgt4859","kind":"drug","name":"CGT4859","route":"/drugs/cgt4859/","asOf":"2026-09-11","days":10},{"id":"jnj-90014496","kind":"drug","name":"JNJ-90014496","route":"/drugs/jnj-90014496/","asOf":"2026-09-11","days":10},{"id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/","asOf":"2026-09-11","days":10},{"id":"eb-mf-car-nk-01","kind":"drug","name":"EB-MF-CAR-NK-01","route":"/drugs/eb-mf-car-nk-01/","asOf":"2026-09-11","days":10},{"id":"eb-car30-nk","kind":"drug","name":"EB-CAR30-NK","route":"/drugs/eb-car30-nk/","asOf":"2026-09-11","days":10},{"id":"ctx112","kind":"drug","name":"CTX112","route":"/drugs/ctx112/","asOf":"2026-09-11","days":10},{"id":"at101","kind":"drug","name":"AT101","route":"/drugs/at101/","asOf":"2026-09-11","days":10},{"id":"cart84","kind":"drug","name":"CART84","route":"/drugs/cart84/","asOf":"2026-09-11","days":10},{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/","asOf":"2026-09-11","days":10},{"id":"sys6023","kind":"drug","name":"SYS6023","route":"/drugs/sys6023/","asOf":"2026-09-11","days":10},{"id":"lirafugratinib","kind":"drug","name":"Lirafugratinib","route":"/drugs/lirafugratinib/","asOf":"2026-09-11","days":10},{"id":"sti-6129","kind":"drug","name":"STI-6129","route":"/drugs/sti-6129/","asOf":"2026-09-11","days":10},{"id":"men1703","kind":"drug","name":"MEN1703","route":"/drugs/men1703/","asOf":"2026-09-11","days":10},{"id":"allo-647","kind":"drug","name":"ALLO-647","route":"/drugs/allo-647/","asOf":"2026-09-11","days":10},{"id":"lb1410","kind":"drug","name":"LB1410","route":"/drugs/lb1410/","asOf":"2026-09-11","days":10},{"id":"lb4330","kind":"drug","name":"LB4330","route":"/drugs/lb4330/","asOf":"2026-09-11","days":10},{"id":"dji136","kind":"drug","name":"DJI136","route":"/drugs/dji136/","asOf":"2026-09-11","days":10},{"id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","asOf":"2026-09-11","days":10},{"id":"spevatamig","kind":"drug","name":"Spevatamig","route":"/drugs/spevatamig/","asOf":"2026-09-11","days":10},{"id":"azd5863","kind":"drug","name":"AZD5863","route":"/drugs/azd5863/","asOf":"2026-09-11","days":10},{"id":"tbi-1501","kind":"drug","name":"TBI-1501","route":"/drugs/tbi-1501/","asOf":"2026-09-11","days":10},{"id":"js111","kind":"drug","name":"JS111","route":"/drugs/js111/","asOf":"2026-09-11","days":10},{"id":"symbiotic-gi-03","kind":"trial","name":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","route":"/trials/symbiotic-gi-03/","asOf":"2026-09-11","days":10},{"id":"symbiotic-gi-16","kind":"trial","name":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","route":"/trials/symbiotic-gi-16/","asOf":"2026-09-11","days":10},{"id":"symbiotic-lung-04","kind":"trial","name":"Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","route":"/trials/symbiotic-lung-04/","asOf":"2026-09-11","days":10},{"id":"symbiotic-lung-01","kind":"trial","name":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/symbiotic-lung-01/","asOf":"2026-09-11","days":10},{"id":"nct06980272","kind":"trial","name":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06980272/","asOf":"2026-09-11","days":10},{"id":"nct07229625","kind":"trial","name":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07229625/","asOf":"2026-09-11","days":10},{"id":"taishan-301","kind":"trial","name":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)","route":"/trials/taishan-301/","asOf":"2026-09-11","days":10},{"id":"nct06612151","kind":"trial","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","route":"/trials/nct06612151/","asOf":"2026-09-11","days":10},{"id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07739758/","asOf":"2026-09-11","days":10},{"id":"nct07418749","kind":"trial","name":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","route":"/trials/nct07418749/","asOf":"2026-09-11","days":10},{"id":"nct07003074","kind":"trial","name":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07003074/","asOf":"2026-09-11","days":10},{"id":"nct06561607","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct06561607/","asOf":"2026-09-11","days":10},{"id":"nct07008976","kind":"trial","name":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","route":"/trials/nct07008976/","asOf":"2026-09-11","days":10},{"id":"nct07043725","kind":"trial","name":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct07043725/","asOf":"2026-09-11","days":10},{"id":"nct06616532","kind":"trial","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","route":"/trials/nct06616532/","asOf":"2026-09-11","days":10},{"id":"nct06419621","kind":"trial","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","route":"/trials/nct06419621/","asOf":"2026-09-11","days":10},{"id":"nct07174908","kind":"trial","name":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07174908/","asOf":"2026-09-11","days":10},{"id":"nct07525206","kind":"trial","name":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07525206/","asOf":"2026-09-11","days":10},{"id":"nct06614192","kind":"trial","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","asOf":"2026-09-11","days":10},{"id":"nct07155187","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07155187/","asOf":"2026-09-11","days":10},{"id":"nct07005102","kind":"trial","name":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07005102/","asOf":"2026-09-11","days":10},{"id":"nct05211895","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","route":"/trials/nct05211895/","asOf":"2026-09-11","days":10},{"id":"nct05502237","kind":"trial","name":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct05502237/","asOf":"2026-09-11","days":10},{"id":"nct05020769","kind":"trial","name":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05020769/","asOf":"2026-09-11","days":10},{"id":"nct05221840","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","route":"/trials/nct05221840/","asOf":"2026-09-11","days":10},{"id":"nct04658862","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","route":"/trials/nct04658862/","asOf":"2026-09-11","days":10},{"id":"hr-nmibc","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","route":"/trials/hr-nmibc/","asOf":"2026-09-11","days":10},{"id":"nct06935409","kind":"trial","name":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","route":"/trials/nct06935409/","asOf":"2026-09-11","days":10},{"id":"nct06498479","kind":"trial","name":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06498479/","asOf":"2026-09-11","days":10},{"id":"nct07189455","kind":"trial","name":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","route":"/trials/nct07189455/","asOf":"2026-09-11","days":10},{"id":"nct07554339","kind":"trial","name":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","route":"/trials/nct07554339/","asOf":"2026-09-11","days":10},{"id":"nct06345729","kind":"trial","name":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","route":"/trials/nct06345729/","asOf":"2026-09-11","days":10},{"id":"nct07431827","kind":"trial","name":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","route":"/trials/nct07431827/","asOf":"2026-09-11","days":10},{"id":"nct06997497","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","route":"/trials/nct06997497/","asOf":"2026-09-11","days":10},{"id":"nct07190248","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","route":"/trials/nct07190248/","asOf":"2026-09-11","days":10},{"id":"nct06943755","kind":"trial","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","route":"/trials/nct06943755/","asOf":"2026-09-11","days":10},{"id":"nct06082167","kind":"trial","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06082167/","asOf":"2026-09-11","days":10},{"id":"nct07227402","kind":"trial","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","route":"/trials/nct07227402/","asOf":"2026-09-11","days":10},{"id":"nct07489495","kind":"trial","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","route":"/trials/nct07489495/","asOf":"2026-09-11","days":10},{"id":"nct06601335","kind":"trial","name":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","route":"/trials/nct06601335/","asOf":"2026-09-11","days":10},{"id":"nct07463573","kind":"trial","name":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct07463573/","asOf":"2026-09-11","days":10},{"id":"nct06954246","kind":"trial","name":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06954246/","asOf":"2026-09-11","days":10},{"id":"nct06194734","kind":"trial","name":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","route":"/trials/nct06194734/","asOf":"2026-09-11","days":10},{"id":"nct06109272","kind":"trial","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","asOf":"2026-09-11","days":10},{"id":"nsclc-2","kind":"trial","name":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-2/","asOf":"2026-09-11","days":10},{"id":"nct05450692","kind":"trial","name":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","route":"/trials/nct05450692/","asOf":"2026-09-11","days":10},{"id":"renaviv","kind":"trial","name":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","route":"/trials/renaviv/","asOf":"2026-09-11","days":10},{"id":"nct07354022","kind":"trial","name":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy","route":"/trials/nct07354022/","asOf":"2026-09-11","days":10},{"id":"nct07024173","kind":"trial","name":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","route":"/trials/nct07024173/","asOf":"2026-09-11","days":10},{"id":"nct07349069","kind":"trial","name":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","route":"/trials/nct07349069/","asOf":"2026-09-11","days":10},{"id":"nct05862285","kind":"trial","name":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","route":"/trials/nct05862285/","asOf":"2026-09-11","days":10},{"id":"nct06136624","kind":"trial","name":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","route":"/trials/nct06136624/","asOf":"2026-09-11","days":10},{"id":"nct06136650","kind":"trial","name":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","route":"/trials/nct06136650/","asOf":"2026-09-11","days":10},{"id":"tai-shan6","kind":"trial","name":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","route":"/trials/tai-shan6/","asOf":"2026-09-11","days":10},{"id":"sqnsclc","kind":"trial","name":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","route":"/trials/sqnsclc/","asOf":"2026-09-11","days":10},{"id":"nct05744687","kind":"trial","name":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","route":"/trials/nct05744687/","asOf":"2026-09-11","days":10},{"id":"nct05860465","kind":"trial","name":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05860465/","asOf":"2026-09-11","days":10},{"id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07362186/","asOf":"2026-09-11","days":10},{"id":"nct07416994","kind":"trial","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07416994/","asOf":"2026-09-11","days":10},{"id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","route":"/trials/nct07461454/","asOf":"2026-09-11","days":10},{"id":"nct05132075","kind":"trial","name":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","route":"/trials/nct05132075/","asOf":"2026-09-11","days":10},{"id":"nct05780567","kind":"trial","name":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","route":"/trials/nct05780567/","asOf":"2026-09-11","days":10},{"id":"nct05365178","kind":"trial","name":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","route":"/trials/nct05365178/","asOf":"2026-09-11","days":10},{"id":"nct06952803","kind":"trial","name":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","route":"/trials/nct06952803/","asOf":"2026-09-11","days":10},{"id":"nct06120491","kind":"trial","name":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","route":"/trials/nct06120491/","asOf":"2026-09-11","days":10},{"id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","route":"/trials/nct05487391/","asOf":"2026-09-11","days":10},{"id":"nct06686576","kind":"trial","name":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct06686576/","asOf":"2026-09-11","days":10},{"id":"nct05690945","kind":"trial","name":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","route":"/trials/nct05690945/","asOf":"2026-09-11","days":10},{"id":"nct07377578","kind":"trial","name":"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct07377578/","asOf":"2026-09-11","days":10},{"id":"nct07342478","kind":"trial","name":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","route":"/trials/nct07342478/","asOf":"2026-09-11","days":10},{"id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","route":"/trials/nct07570173/","asOf":"2026-09-11","days":10},{"id":"nct07634471","kind":"trial","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","route":"/trials/nct07634471/","asOf":"2026-09-11","days":10},{"id":"nct04498117","kind":"trial","name":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","route":"/trials/nct04498117/","asOf":"2026-09-11","days":10},{"id":"nct04590963","kind":"trial","name":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","route":"/trials/nct04590963/","asOf":"2026-09-11","days":10},{"id":"nct07063745","kind":"trial","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","route":"/trials/nct07063745/","asOf":"2026-09-11","days":10},{"id":"mountaintap-30","kind":"trial","name":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","route":"/trials/mountaintap-30/","asOf":"2026-09-11","days":10},{"id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","route":"/trials/nct06247605/","asOf":"2026-09-11","days":10},{"id":"nct07459751","kind":"trial","name":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07459751/","asOf":"2026-09-11","days":10},{"id":"nct06927986","kind":"trial","name":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","route":"/trials/nct06927986/","asOf":"2026-09-11","days":10},{"id":"nct05294172","kind":"trial","name":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05294172/","asOf":"2026-09-11","days":10},{"id":"nct06608927","kind":"trial","name":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06608927/","asOf":"2026-09-11","days":10},{"id":"nct05751512","kind":"trial","name":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","route":"/trials/nct05751512/","asOf":"2026-09-11","days":10},{"id":"nct06394492","kind":"trial","name":"SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06394492/","asOf":"2026-09-11","days":10},{"id":"nct07424287","kind":"trial","name":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","route":"/trials/nct07424287/","asOf":"2026-09-11","days":10},{"id":"nct07726992","kind":"trial","name":"A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC","route":"/trials/nct07726992/","asOf":"2026-09-11","days":10},{"id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","route":"/trials/nct07804186/","asOf":"2026-09-11","days":10},{"id":"nct07015190","kind":"trial","name":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","route":"/trials/nct07015190/","asOf":"2026-09-11","days":10},{"id":"nct07555938","kind":"trial","name":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","route":"/trials/nct07555938/","asOf":"2026-09-11","days":10},{"id":"nct05838066","kind":"trial","name":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct05838066/","asOf":"2026-09-11","days":10},{"id":"nct07441460","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","route":"/trials/nct07441460/","asOf":"2026-09-11","days":10},{"id":"nct06747338","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","route":"/trials/nct06747338/","asOf":"2026-09-11","days":10},{"id":"nct06079983","kind":"trial","name":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","route":"/trials/nct06079983/","asOf":"2026-09-11","days":10},{"id":"nct06846437","kind":"trial","name":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","route":"/trials/nct06846437/","asOf":"2026-09-11","days":10},{"id":"nct06697301","kind":"trial","name":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma","route":"/trials/nct06697301/","asOf":"2026-09-11","days":10},{"id":"nct07365319","kind":"trial","name":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer","route":"/trials/nct07365319/","asOf":"2026-09-11","days":10},{"id":"nct07516093","kind":"trial","name":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","route":"/trials/nct07516093/","asOf":"2026-09-11","days":10},{"id":"nct07262567","kind":"trial","name":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","route":"/trials/nct07262567/","asOf":"2026-09-11","days":10},{"id":"nct07668752","kind":"trial","name":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","route":"/trials/nct07668752/","asOf":"2026-09-11","days":10},{"id":"nct05973773","kind":"trial","name":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","route":"/trials/nct05973773/","asOf":"2026-09-11","days":10},{"id":"nct07128199","kind":"trial","name":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","route":"/trials/nct07128199/","asOf":"2026-09-11","days":10},{"id":"aurora","kind":"trial","name":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","route":"/trials/aurora/","asOf":"2026-09-11","days":10},{"id":"nct07258511","kind":"trial","name":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07258511/","asOf":"2026-09-11","days":10},{"id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07518186/","asOf":"2026-09-11","days":10},{"id":"nct06754644","kind":"trial","name":"A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC","route":"/trials/nct06754644/","asOf":"2026-09-11","days":10},{"id":"nct07377643","kind":"trial","name":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","route":"/trials/nct07377643/","asOf":"2026-09-11","days":10},{"id":"nct06834672","kind":"trial","name":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","route":"/trials/nct06834672/","asOf":"2026-09-11","days":10},{"id":"nct05671510","kind":"trial","name":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","route":"/trials/nct05671510/","asOf":"2026-09-11","days":10},{"id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","asOf":"2026-09-11","days":10},{"id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","asOf":"2026-09-11","days":10},{"id":"nct07011056","kind":"trial","name":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","route":"/trials/nct07011056/","asOf":"2026-09-11","days":10},{"id":"nct04523272","kind":"trial","name":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","route":"/trials/nct04523272/","asOf":"2026-09-11","days":10},{"id":"nct05077449","kind":"trial","name":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","route":"/trials/nct05077449/","asOf":"2026-09-11","days":10},{"id":"nct04250922","kind":"trial","name":"LAM561 With RT and TMZ for Adults With Glioblastoma","route":"/trials/nct04250922/","asOf":"2026-09-11","days":10},{"id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","route":"/trials/dllevate/","asOf":"2026-09-11","days":10},{"id":"nct07585266","kind":"trial","name":"A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)","route":"/trials/nct07585266/","asOf":"2026-09-11","days":10},{"id":"nct06968585","kind":"trial","name":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","route":"/trials/nct06968585/","asOf":"2026-09-11","days":10},{"id":"nct06671379","kind":"trial","name":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct06671379/","asOf":"2026-09-11","days":10},{"id":"nct05754853","kind":"trial","name":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","route":"/trials/nct05754853/","asOf":"2026-09-11","days":10},{"id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07385703/","asOf":"2026-09-11","days":10},{"id":"nct07452198","kind":"trial","name":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07452198/","asOf":"2026-09-11","days":10},{"id":"nct05155254","kind":"trial","name":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","route":"/trials/nct05155254/","asOf":"2026-09-11","days":10},{"id":"nct07062965","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","route":"/trials/nct07062965/","asOf":"2026-09-11","days":10},{"id":"nct07365241","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","route":"/trials/nct07365241/","asOf":"2026-09-11","days":10},{"id":"nct06732323","kind":"trial","name":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06732323/","asOf":"2026-09-11","days":10},{"id":"nct06383767","kind":"trial","name":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06383767/","asOf":"2026-09-11","days":10},{"id":"fleteo","kind":"trial","name":"Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)","route":"/trials/fleteo/","asOf":"2026-09-11","days":10},{"id":"aspen-06","kind":"trial","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","route":"/trials/aspen-06/","asOf":"2026-09-11","days":10},{"id":"nct05732805","kind":"trial","name":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","route":"/trials/nct05732805/","asOf":"2026-09-11","days":10},{"id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","route":"/trials/nct05751928/","asOf":"2026-09-11","days":10},{"id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct07480356/","asOf":"2026-09-11","days":10},{"id":"nsclc-3","kind":"trial","name":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-3/","asOf":"2026-09-11","days":10},{"id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/","asOf":"2026-09-11","days":10},{"id":"nct06984588","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","route":"/trials/nct06984588/","asOf":"2026-09-11","days":10},{"id":"nct07138209","kind":"trial","name":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07138209/","asOf":"2026-09-11","days":10},{"id":"nct07544056","kind":"trial","name":"A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07544056/","asOf":"2026-09-11","days":10},{"id":"nct06998108","kind":"trial","name":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","route":"/trials/nct06998108/","asOf":"2026-09-11","days":10},{"id":"nct06093672","kind":"trial","name":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","route":"/trials/nct06093672/","asOf":"2026-09-11","days":10},{"id":"nct06416410","kind":"trial","name":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","route":"/trials/nct06416410/","asOf":"2026-09-11","days":10},{"id":"nct07214779","kind":"trial","name":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07214779/","asOf":"2026-09-11","days":10},{"id":"nct07207070","kind":"trial","name":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct07207070/","asOf":"2026-09-11","days":10},{"id":"nct06735391","kind":"trial","name":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","route":"/trials/nct06735391/","asOf":"2026-09-11","days":10},{"id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","route":"/trials/nct07533123/","asOf":"2026-09-11","days":10},{"id":"nct06635824","kind":"trial","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","route":"/trials/nct06635824/","asOf":"2026-09-11","days":10},{"id":"nct07365995","kind":"trial","name":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07365995/","asOf":"2026-09-11","days":10},{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","route":"/trials/nct04655976/","asOf":"2026-09-11","days":10},{"id":"apex-03","kind":"trial","name":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","route":"/trials/apex-03/","asOf":"2026-09-11","days":10},{"id":"nct05417789","kind":"trial","name":"Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)","route":"/trials/nct05417789/","asOf":"2026-09-11","days":10},{"id":"nct03768063","kind":"trial","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","route":"/trials/nct03768063/","asOf":"2026-09-11","days":10},{"id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/","asOf":"2026-09-11","days":10},{"id":"nct05281471","kind":"trial","name":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","route":"/trials/nct05281471/","asOf":"2026-09-11","days":10},{"id":"nct07409272","kind":"trial","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","route":"/trials/nct07409272/","asOf":"2026-09-11","days":10},{"id":"nct07566052","kind":"trial","name":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","route":"/trials/nct07566052/","asOf":"2026-09-11","days":10},{"id":"nct06532006","kind":"trial","name":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","route":"/trials/nct06532006/","asOf":"2026-09-11","days":10},{"id":"nct07662395","kind":"trial","name":"SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662395/","asOf":"2026-09-11","days":10},{"id":"nct05065957","kind":"trial","name":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","route":"/trials/nct05065957/","asOf":"2026-09-11","days":10},{"id":"nct06622057","kind":"trial","name":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06622057/","asOf":"2026-09-11","days":10},{"id":"nct07570823","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct07570823/","asOf":"2026-09-11","days":10},{"id":"nct07562022","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct07562022/","asOf":"2026-09-11","days":10},{"id":"pik3ca-2","kind":"trial","name":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","route":"/trials/pik3ca-2/","asOf":"2026-09-11","days":10},{"id":"quintessential-2","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","route":"/trials/quintessential-2/","asOf":"2026-09-11","days":10},{"id":"nct05208047","kind":"trial","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","route":"/trials/nct05208047/","asOf":"2026-09-11","days":10},{"id":"nct05987358","kind":"trial","name":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma","route":"/trials/nct05987358/","asOf":"2026-09-11","days":10},{"id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","asOf":"2026-09-11","days":10},{"id":"nct06387069","kind":"trial","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","route":"/trials/nct06387069/","asOf":"2026-09-11","days":10},{"id":"nct07217301","kind":"trial","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct07217301/","asOf":"2026-09-11","days":10},{"id":"nct05586074","kind":"trial","name":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","route":"/trials/nct05586074/","asOf":"2026-09-11","days":10},{"id":"nct07218926","kind":"trial","name":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","route":"/trials/nct07218926/","asOf":"2026-09-11","days":10},{"id":"nct04910685","kind":"trial","name":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","route":"/trials/nct04910685/","asOf":"2026-09-11","days":10},{"id":"nct05232916","kind":"trial","name":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","route":"/trials/nct05232916/","asOf":"2026-09-11","days":10},{"id":"invincible-3","kind":"trial","name":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","route":"/trials/invincible-3/","asOf":"2026-09-11","days":10},{"id":"nct05141721","kind":"trial","name":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05141721/","asOf":"2026-09-11","days":10},{"id":"nct04169997","kind":"trial","name":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","route":"/trials/nct04169997/","asOf":"2026-09-11","days":10},{"id":"nct04415853","kind":"trial","name":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","route":"/trials/nct04415853/","asOf":"2026-09-11","days":10},{"id":"nct07218809","kind":"trial","name":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","route":"/trials/nct07218809/","asOf":"2026-09-11","days":10},{"id":"nct07407803","kind":"trial","name":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","route":"/trials/nct07407803/","asOf":"2026-09-11","days":10},{"id":"nct06331299","kind":"trial","name":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","route":"/trials/nct06331299/","asOf":"2026-09-11","days":10},{"id":"nct04353375","kind":"trial","name":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct04353375/","asOf":"2026-09-11","days":10},{"id":"nct07297329","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","route":"/trials/nct07297329/","asOf":"2026-09-11","days":10},{"id":"nct05945901","kind":"trial","name":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer","route":"/trials/nct05945901/","asOf":"2026-09-11","days":10},{"id":"nct07379047","kind":"trial","name":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","route":"/trials/nct07379047/","asOf":"2026-09-11","days":10},{"id":"nct06519370","kind":"trial","name":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06519370/","asOf":"2026-09-11","days":10},{"id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/","asOf":"2026-09-11","days":10},{"id":"nct06954961","kind":"trial","name":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct06954961/","asOf":"2026-09-11","days":10},{"id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07522073/","asOf":"2026-09-11","days":10},{"id":"nct06919965","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06919965/","asOf":"2026-09-11","days":10},{"id":"nct07409428","kind":"trial","name":"A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct07409428/","asOf":"2026-09-11","days":10},{"id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/","asOf":"2026-09-11","days":10},{"id":"simrise","kind":"trial","name":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","route":"/trials/simrise/","asOf":"2026-09-11","days":10},{"id":"nct07673887","kind":"trial","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","route":"/trials/nct07673887/","asOf":"2026-09-11","days":10},{"id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07579234/","asOf":"2026-09-11","days":10},{"id":"nct06982521","kind":"trial","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","route":"/trials/nct06982521/","asOf":"2026-09-11","days":10},{"id":"nct06658353","kind":"trial","name":"Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors","route":"/trials/nct06658353/","asOf":"2026-09-11","days":10},{"id":"nct05346224","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","route":"/trials/nct05346224/","asOf":"2026-09-11","days":10},{"id":"nct06646276","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)","route":"/trials/nct06646276/","asOf":"2026-09-11","days":10},{"id":"nct03659448","kind":"trial","name":"Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer","route":"/trials/nct03659448/","asOf":"2026-09-11","days":10},{"id":"proceade-crc-03","kind":"trial","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","route":"/trials/proceade-crc-03/","asOf":"2026-09-11","days":10},{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","asOf":"2026-09-11","days":10},{"id":"nct04165317","kind":"trial","name":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","route":"/trials/nct04165317/","asOf":"2026-09-11","days":10},{"id":"companion-002","kind":"trial","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","route":"/trials/companion-002/","asOf":"2026-09-11","days":10},{"id":"nct07284849","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","route":"/trials/nct07284849/","asOf":"2026-09-11","days":10},{"id":"nct07386938","kind":"trial","name":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","route":"/trials/nct07386938/","asOf":"2026-09-11","days":10},{"id":"nct06764485","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct06764485/","asOf":"2026-09-11","days":10},{"id":"nct06624644","kind":"trial","name":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","route":"/trials/nct06624644/","asOf":"2026-09-11","days":10},{"id":"nct07188558","kind":"trial","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","route":"/trials/nct07188558/","asOf":"2026-09-11","days":10},{"id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","asOf":"2026-09-11","days":10},{"id":"nct06295731","kind":"trial","name":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","route":"/trials/nct06295731/","asOf":"2026-09-11","days":10},{"id":"nct06351631","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","route":"/trials/nct06351631/","asOf":"2026-09-11","days":10},{"id":"nct04892173","kind":"trial","name":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","route":"/trials/nct04892173/","asOf":"2026-09-11","days":10},{"id":"nct06177041","kind":"trial","name":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","route":"/trials/nct06177041/","asOf":"2026-09-11","days":10},{"id":"nct07492641","kind":"trial","name":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","route":"/trials/nct07492641/","asOf":"2026-09-11","days":10},{"id":"nct06561048","kind":"trial","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","route":"/trials/nct06561048/","asOf":"2026-09-11","days":10},{"id":"nct07218380","kind":"trial","name":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","route":"/trials/nct07218380/","asOf":"2026-09-11","days":10},{"id":"nct06401356","kind":"trial","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","route":"/trials/nct06401356/","asOf":"2026-09-11","days":10},{"id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/","asOf":"2026-09-11","days":10},{"id":"nct05118776","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","route":"/trials/nct05118776/","asOf":"2026-09-11","days":10},{"id":"nct06079346","kind":"trial","name":"A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct06079346/","asOf":"2026-09-11","days":10},{"id":"nct05317819","kind":"trial","name":"Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05317819/","asOf":"2026-09-11","days":10},{"id":"nct07413939","kind":"trial","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","route":"/trials/nct07413939/","asOf":"2026-09-11","days":10},{"id":"nct07362459","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer","route":"/trials/nct07362459/","asOf":"2026-09-11","days":10},{"id":"nct06472245","kind":"trial","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","route":"/trials/nct06472245/","asOf":"2026-09-11","days":10},{"id":"nct06508983","kind":"trial","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","route":"/trials/nct06508983/","asOf":"2026-09-11","days":10},{"id":"nct04468984","kind":"trial","name":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","route":"/trials/nct04468984/","asOf":"2026-09-11","days":10},{"id":"nsclc-4","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-4/","asOf":"2026-09-11","days":10},{"id":"nct04871282","kind":"trial","name":"A Study of AL102 in Patients With Progressing Desmoid Tumors","route":"/trials/nct04871282/","asOf":"2026-09-11","days":10},{"id":"nct06417008","kind":"trial","name":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct06417008/","asOf":"2026-09-11","days":10},{"id":"nct07673029","kind":"trial","name":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07673029/","asOf":"2026-09-11","days":10},{"id":"nct06774131","kind":"trial","name":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","route":"/trials/nct06774131/","asOf":"2026-09-11","days":10},{"id":"nct07079228","kind":"trial","name":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","route":"/trials/nct07079228/","asOf":"2026-09-11","days":10},{"id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","route":"/trials/nct07213804/","asOf":"2026-09-11","days":10},{"id":"nct05254171","kind":"trial","name":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer","route":"/trials/nct05254171/","asOf":"2026-09-11","days":10},{"id":"nct04534205","kind":"trial","name":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","route":"/trials/nct04534205/","asOf":"2026-09-11","days":10},{"id":"nct04921527","kind":"trial","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","route":"/trials/nct04921527/","asOf":"2026-09-11","days":10},{"id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","route":"/trials/himalayas-1/","asOf":"2026-09-11","days":10},{"id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07562152/","asOf":"2026-09-11","days":10},{"id":"g-hope-002","kind":"trial","name":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","route":"/trials/g-hope-002/","asOf":"2026-09-11","days":10},{"id":"nct06852222","kind":"trial","name":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","route":"/trials/nct06852222/","asOf":"2026-09-11","days":10},{"id":"nct07490262","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment","route":"/trials/nct07490262/","asOf":"2026-09-11","days":10},{"id":"nct06064877","kind":"trial","name":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06064877/","asOf":"2026-09-11","days":10},{"id":"nct07215585","kind":"trial","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","route":"/trials/nct07215585/","asOf":"2026-09-11","days":10},{"id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct06792253/","asOf":"2026-09-11","days":10},{"id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","asOf":"2026-09-11","days":10},{"id":"nct05303519","kind":"trial","name":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","route":"/trials/nct05303519/","asOf":"2026-09-11","days":10},{"id":"nct06504732","kind":"trial","name":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","route":"/trials/nct06504732/","asOf":"2026-09-11","days":10},{"id":"anetumab-vs-vinorelbine-mpm","kind":"trial","name":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma","route":"/trials/anetumab-vs-vinorelbine-mpm/","asOf":"2026-09-11","days":10},{"id":"nci-anetumab-pembrolizumab-mpm","kind":"trial","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","route":"/trials/nci-anetumab-pembrolizumab-mpm/","asOf":"2026-09-11","days":10},{"id":"aldoxorubicin-phase-3-sts","kind":"trial","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","route":"/trials/aldoxorubicin-phase-3-sts/","asOf":"2026-09-11","days":10},{"id":"ucl-proton-hemithoracic-mpm","kind":"trial","name":"Hemithoracic irradiation with proton therapy in malignant pleural mesothelioma (UCL)","route":"/trials/ucl-proton-hemithoracic-mpm/","asOf":"2026-09-11","days":10},{"id":"tazemetostat-doxorubicin-es","kind":"trial","name":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)","route":"/trials/tazemetostat-doxorubicin-es/","asOf":"2026-09-16","days":5},{"id":"tiger-trial","kind":"trial","name":"TIGER: standard-dose TIP versus high-dose TI-CE with stem cell transplant as first salvage for relapsed germ cell tumours","route":"/trials/tiger-trial/","asOf":"2026-09-16","days":5},{"id":"zen-3694-platinum-nut","kind":"trial","name":"ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)","route":"/trials/zen-3694-platinum-nut/","asOf":"2026-09-16","days":5},{"id":"zen-3694-abemaciclib-nut","kind":"trial","name":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)","route":"/trials/zen-3694-abemaciclib-nut/","asOf":"2026-09-16","days":5},{"id":"cemiplimab-nut","kind":"trial","name":"Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)","route":"/trials/cemiplimab-nut/","asOf":"2026-09-16","days":5},{"id":"sabr-comet","kind":"trial","name":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer","route":"/trials/sabr-comet/","asOf":"2026-09-16","days":5},{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/","asOf":"2026-09-16","days":5},{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/","asOf":"2026-09-16","days":5},{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","asOf":"2026-09-16","days":5},{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/","asOf":"2026-09-16","days":5},{"id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/","asOf":"2026-09-16","days":5},{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/","asOf":"2026-09-16","days":5},{"id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/","asOf":"2026-09-16","days":5},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/","asOf":"2026-09-16","days":5},{"id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","asOf":"2026-09-16","days":5},{"id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","route":"/drugs/rezvilutamide/","asOf":"2026-09-16","days":5},{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/","asOf":"2026-09-16","days":5},{"id":"socazolimab","kind":"drug","name":"Socazolimab","route":"/drugs/socazolimab/","asOf":"2026-09-16","days":5},{"id":"pirarubicin","kind":"drug","name":"Pirarubicin","route":"/drugs/pirarubicin/","asOf":"2026-09-16","days":5},{"id":"girentuximab-zr89","kind":"drug","name":"Zirconium-89 girentuximab","route":"/drugs/girentuximab-zr89/","asOf":"2026-09-16","days":5},{"id":"psma-1007-f18","kind":"drug","name":"PSMA-1007 F-18","route":"/drugs/psma-1007-f18/","asOf":"2026-09-16","days":5},{"id":"favezelimab","kind":"drug","name":"Favezelimab","route":"/drugs/favezelimab/","asOf":"2026-09-16","days":5},{"id":"elritercept","kind":"drug","name":"Elritercept","route":"/drugs/elritercept/","asOf":"2026-09-16","days":5},{"id":"adagloxad-simolenin","kind":"drug","name":"Adagloxad simolenin","route":"/drugs/adagloxad-simolenin/","asOf":"2026-09-16","days":5},{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/","asOf":"2026-09-16","days":5},{"id":"cam2029","kind":"drug","name":"CAM2029 (octreotide subcutaneous depot)","route":"/drugs/cam2029/","asOf":"2026-09-16","days":5},{"id":"m701","kind":"drug","name":"M701","route":"/drugs/m701/","asOf":"2026-09-16","days":5},{"id":"lerociclib","kind":"drug","name":"Lerociclib","route":"/drugs/lerociclib/","asOf":"2026-09-16","days":5},{"id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/","asOf":"2026-09-16","days":5},{"id":"iomab-b","kind":"drug","name":"Iomab-B","route":"/drugs/iomab-b/","asOf":"2026-09-16","days":5},{"id":"visugromab","kind":"drug","name":"Visugromab","route":"/drugs/visugromab/","asOf":"2026-09-16","days":5},{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/","asOf":"2026-09-16","days":5},{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/","asOf":"2026-09-16","days":5},{"id":"azd0120","kind":"drug","name":"AZD0120","route":"/drugs/azd0120/","asOf":"2026-09-16","days":5},{"id":"utomilumab","kind":"drug","name":"Utomilumab","route":"/drugs/utomilumab/","asOf":"2026-09-16","days":5},{"id":"alisertib","kind":"drug","name":"Alisertib","route":"/drugs/alisertib/","asOf":"2026-09-16","days":5},{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/","asOf":"2026-09-16","days":5},{"id":"roginolisib","kind":"drug","name":"Roginolisib","route":"/drugs/roginolisib/","asOf":"2026-09-16","days":5},{"id":"regn7075","kind":"drug","name":"REGN7075","route":"/drugs/regn7075/","asOf":"2026-09-16","days":5},{"id":"zalifrelimab","kind":"drug","name":"Zalifrelimab","route":"/drugs/zalifrelimab/","asOf":"2026-09-16","days":5},{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/","asOf":"2026-09-16","days":5},{"id":"tst001","kind":"drug","name":"TST001","route":"/drugs/tst001/","asOf":"2026-09-16","days":5},{"id":"tno155","kind":"drug","name":"TNO155","route":"/drugs/tno155/","asOf":"2026-09-16","days":5},{"id":"parsaclisib","kind":"drug","name":"Parsaclisib","route":"/drugs/parsaclisib/","asOf":"2026-09-16","days":5},{"id":"feladilimab","kind":"drug","name":"Feladilimab","route":"/drugs/feladilimab/","asOf":"2026-09-16","days":5},{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/","asOf":"2026-09-16","days":5},{"id":"azd8421","kind":"drug","name":"AZD8421","route":"/drugs/azd8421/","asOf":"2026-09-16","days":5},{"id":"enb003","kind":"drug","name":"ENB003","route":"/drugs/enb003/","asOf":"2026-09-16","days":5},{"id":"eik1005","kind":"drug","name":"EIK1005","route":"/drugs/eik1005/","asOf":"2026-09-16","days":5},{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/","asOf":"2026-09-16","days":5},{"id":"tng260","kind":"drug","name":"TNG260","route":"/drugs/tng260/","asOf":"2026-09-16","days":5},{"id":"onvansertib","kind":"drug","name":"Onvansertib","route":"/drugs/onvansertib/","asOf":"2026-09-16","days":5},{"id":"vistusertib","kind":"drug","name":"Vistusertib","route":"/drugs/vistusertib/","asOf":"2026-09-16","days":5},{"id":"ct3001","kind":"drug","name":"CT3001","route":"/drugs/ct3001/","asOf":"2026-09-16","days":5},{"id":"prtx007","kind":"drug","name":"PRTX007","route":"/drugs/prtx007/","asOf":"2026-09-16","days":5},{"id":"merestinib","kind":"drug","name":"Merestinib","route":"/drugs/merestinib/","asOf":"2026-09-16","days":5},{"id":"lvgn6051","kind":"drug","name":"LVGN6051","route":"/drugs/lvgn6051/","asOf":"2026-09-16","days":5},{"id":"amo959","kind":"drug","name":"AMO959","route":"/drugs/amo959/","asOf":"2026-09-16","days":5},{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/","asOf":"2026-09-16","days":5},{"id":"tilt-123","kind":"drug","name":"TILT-123","route":"/drugs/tilt-123/","asOf":"2026-09-16","days":5},{"id":"au-007","kind":"drug","name":"AU-007","route":"/drugs/au-007/","asOf":"2026-09-16","days":5},{"id":"or502","kind":"drug","name":"OR502","route":"/drugs/or502/","asOf":"2026-09-16","days":5},{"id":"pamiparib","kind":"drug","name":"Pamiparib","route":"/drugs/pamiparib/","asOf":"2026-09-16","days":5},{"id":"radotinib","kind":"drug","name":"Radotinib","route":"/drugs/radotinib/","asOf":"2026-09-16","days":5},{"id":"ponsegromab","kind":"drug","name":"Ponsegromab","route":"/drugs/ponsegromab/","asOf":"2026-09-16","days":5},{"id":"wjb001","kind":"drug","name":"WJB001","route":"/drugs/wjb001/","asOf":"2026-09-16","days":5},{"id":"mhb039a","kind":"drug","name":"MHB039A","route":"/drugs/mhb039a/","asOf":"2026-09-16","days":5},{"id":"mhb036c","kind":"drug","name":"MHB036C","route":"/drugs/mhb036c/","asOf":"2026-09-16","days":5},{"id":"flonoltinib","kind":"drug","name":"Flonoltinib","route":"/drugs/flonoltinib/","asOf":"2026-09-16","days":5},{"id":"samuraciclib","kind":"drug","name":"Samuraciclib","route":"/drugs/samuraciclib/","asOf":"2026-09-16","days":5},{"id":"jmt203","kind":"drug","name":"JMT203","route":"/drugs/jmt203/","asOf":"2026-09-16","days":5},{"id":"emavusertib","kind":"drug","name":"Emavusertib","route":"/drugs/emavusertib/","asOf":"2026-09-16","days":5},{"id":"doc1021","kind":"drug","name":"DOC1021","route":"/drugs/doc1021/","asOf":"2026-09-16","days":5},{"id":"jbi-802","kind":"drug","name":"JBI-802","route":"/drugs/jbi-802/","asOf":"2026-09-16","days":5},{"id":"befotertinib","kind":"drug","name":"Befotertinib","route":"/drugs/befotertinib/","asOf":"2026-09-16","days":5},{"id":"camonsertib","kind":"drug","name":"Camonsertib","route":"/drugs/camonsertib/","asOf":"2026-09-16","days":5},{"id":"selicrelumab","kind":"drug","name":"Selicrelumab","route":"/drugs/selicrelumab/","asOf":"2026-09-16","days":5},{"id":"fluzoparib","kind":"drug","name":"Fluzoparib","route":"/drugs/fluzoparib/","asOf":"2026-09-16","days":5},{"id":"evexomostat","kind":"drug","name":"Evexomostat","route":"/drugs/evexomostat/","asOf":"2026-09-16","days":5},{"id":"tst003","kind":"drug","name":"TST003","route":"/drugs/tst003/","asOf":"2026-09-16","days":5},{"id":"obi-902","kind":"drug","name":"OBI-902","route":"/drugs/obi-902/","asOf":"2026-09-16","days":5},{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/","asOf":"2026-09-16","days":5},{"id":"farletuzumab-ecteribulin","kind":"drug","name":"Farletuzumab ecteribulin","route":"/drugs/farletuzumab-ecteribulin/","asOf":"2026-09-16","days":5},{"id":"imp1734","kind":"drug","name":"IMP1734","route":"/drugs/imp1734/","asOf":"2026-09-16","days":5},{"id":"rv001v","kind":"drug","name":"RV001V","route":"/drugs/rv001v/","asOf":"2026-09-16","days":5},{"id":"dr-01","kind":"drug","name":"DR-01","route":"/drugs/dr-01/","asOf":"2026-09-16","days":5},{"id":"lp-184","kind":"drug","name":"LP-184","route":"/drugs/lp-184/","asOf":"2026-09-16","days":5},{"id":"skb105","kind":"drug","name":"SKB105","route":"/drugs/skb105/","asOf":"2026-09-16","days":5},{"id":"rvu120","kind":"drug","name":"RVU120","route":"/drugs/rvu120/","asOf":"2026-09-16","days":5},{"id":"tuspetinib","kind":"drug","name":"Tuspetinib","route":"/drugs/tuspetinib/","asOf":"2026-09-16","days":5},{"id":"avzo-023","kind":"drug","name":"AVZO-023","route":"/drugs/avzo-023/","asOf":"2026-09-16","days":5},{"id":"vudalimab","kind":"drug","name":"Vudalimab","route":"/drugs/vudalimab/","asOf":"2026-09-16","days":5},{"id":"np137","kind":"drug","name":"NP137","route":"/drugs/np137/","asOf":"2026-09-16","days":5},{"id":"tqb3702","kind":"drug","name":"TQB3702","route":"/drugs/tqb3702/","asOf":"2026-09-16","days":5},{"id":"rem-422","kind":"drug","name":"REM-422","route":"/drugs/rem-422/","asOf":"2026-09-16","days":5},{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","route":"/drugs/upifitamab-rilsodotin/","asOf":"2026-09-16","days":5},{"id":"stp938","kind":"drug","name":"STP938","route":"/drugs/stp938/","asOf":"2026-09-16","days":5},{"id":"tqb3909","kind":"drug","name":"TQB3909","route":"/drugs/tqb3909/","asOf":"2026-09-16","days":5},{"id":"obi-992","kind":"drug","name":"OBI-992","route":"/drugs/obi-992/","asOf":"2026-09-16","days":5},{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/","asOf":"2026-09-16","days":5},{"id":"pbp1510","kind":"drug","name":"PBP1510","route":"/drugs/pbp1510/","asOf":"2026-09-16","days":5},{"id":"rnk05047","kind":"drug","name":"RNK05047","route":"/drugs/rnk05047/","asOf":"2026-09-16","days":5},{"id":"bexmarilimab","kind":"drug","name":"Bexmarilimab","route":"/drugs/bexmarilimab/","asOf":"2026-09-16","days":5},{"id":"inlexisertib","kind":"drug","name":"Inlexisertib","route":"/drugs/inlexisertib/","asOf":"2026-09-16","days":5},{"id":"tenalisib","kind":"drug","name":"Tenalisib","route":"/drugs/tenalisib/","asOf":"2026-09-16","days":5},{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","route":"/drugs/mitazalimab/","asOf":"2026-09-16","days":5},{"id":"ipg1094","kind":"drug","name":"IPG1094","route":"/drugs/ipg1094/","asOf":"2026-09-16","days":5},{"id":"vibostolimab","kind":"drug","name":"Vibostolimab","route":"/drugs/vibostolimab/","asOf":"2026-09-16","days":5},{"id":"boserolimab","kind":"drug","name":"Boserolimab","route":"/drugs/boserolimab/","asOf":"2026-09-16","days":5},{"id":"hst-1011","kind":"drug","name":"HST-1011","route":"/drugs/hst-1011/","asOf":"2026-09-16","days":5},{"id":"spartalizumab","kind":"drug","name":"Spartalizumab","route":"/drugs/spartalizumab/","asOf":"2026-09-16","days":5},{"id":"sabatolimab","kind":"drug","name":"Sabatolimab","route":"/drugs/sabatolimab/","asOf":"2026-09-16","days":5},{"id":"evm14","kind":"drug","name":"EVM14","route":"/drugs/evm14/","asOf":"2026-09-16","days":5},{"id":"pimicotinib","kind":"drug","name":"Pimicotinib","route":"/drugs/pimicotinib/","asOf":"2026-09-16","days":5},{"id":"vb15010","kind":"drug","name":"VB15010","route":"/drugs/vb15010/","asOf":"2026-09-16","days":5},{"id":"tqb2868","kind":"drug","name":"TQB2868","route":"/drugs/tqb2868/","asOf":"2026-09-16","days":5},{"id":"ard103","kind":"drug","name":"ARD103","route":"/drugs/ard103/","asOf":"2026-09-16","days":5},{"id":"vactosertib","kind":"drug","name":"Vactosertib","route":"/drugs/vactosertib/","asOf":"2026-09-16","days":5},{"id":"adavosertib","kind":"drug","name":"Adavosertib","route":"/drugs/adavosertib/","asOf":"2026-09-16","days":5},{"id":"nuv-1511","kind":"drug","name":"NUV-1511","route":"/drugs/nuv-1511/","asOf":"2026-09-16","days":5},{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/","asOf":"2026-09-16","days":5},{"id":"iruplinalkib","kind":"drug","name":"Iruplinalkib","route":"/drugs/iruplinalkib/","asOf":"2026-09-16","days":5},{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/","asOf":"2026-09-16","days":5},{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/","asOf":"2026-09-16","days":5},{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/","asOf":"2026-09-16","days":5},{"id":"linperlisib","kind":"drug","name":"Linperlisib","route":"/drugs/linperlisib/","asOf":"2026-09-16","days":5},{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/","asOf":"2026-09-16","days":5},{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/","asOf":"2026-09-16","days":5},{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/","asOf":"2026-09-16","days":5},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/","asOf":"2026-09-16","days":5},{"id":"mecapegfilgrastim","kind":"drug","name":"Mecapegfilgrastim","route":"/drugs/mecapegfilgrastim/","asOf":"2026-09-16","days":5},{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/","asOf":"2026-09-16","days":5},{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/","asOf":"2026-09-16","days":5},{"id":"cyto-pv","kind":"trial","name":"CYTO-PV","route":"/trials/cyto-pv/","asOf":"2026-09-16","days":5},{"id":"response","kind":"trial","name":"RESPONSE","route":"/trials/response/","asOf":"2026-09-16","days":5},{"id":"response-2","kind":"trial","name":"RESPONSE-2","route":"/trials/response-2/","asOf":"2026-09-16","days":5},{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","asOf":"2026-09-16","days":5},{"id":"low-pv","kind":"trial","name":"Low-PV","route":"/trials/low-pv/","asOf":"2026-09-16","days":5},{"id":"majic-pv","kind":"trial","name":"MAJIC-PV","route":"/trials/majic-pv/","asOf":"2026-09-16","days":5},{"id":"verify","kind":"trial","name":"VERIFY","route":"/trials/verify/","asOf":"2026-09-16","days":5},{"id":"jak2-v617f","kind":"term","name":"JAK2 V617F","route":"/terms/jak2-v617f/","asOf":"2026-09-16","days":5},{"id":"phlebotomy","kind":"term","name":"Phlebotomy (venesection)","route":"/terms/phlebotomy/","asOf":"2026-09-16","days":5},{"id":"haematocrit","kind":"term","name":"Haematocrit","route":"/terms/haematocrit/","asOf":"2026-09-16","days":5},{"id":"erythrocytosis","kind":"term","name":"Erythrocytosis (primary vs secondary)","route":"/terms/erythrocytosis/","asOf":"2026-09-16","days":5},{"id":"hepcidin","kind":"term","name":"Hepcidin","route":"/terms/hepcidin/","asOf":"2026-09-16","days":5},{"id":"aquagenic-pruritus","kind":"term","name":"Aquagenic pruritus","route":"/terms/aquagenic-pruritus/","asOf":"2026-09-16","days":5},{"id":"erythromelalgia","kind":"term","name":"Erythromelalgia","route":"/terms/erythromelalgia/","asOf":"2026-09-16","days":5},{"id":"post-pv-myelofibrosis","kind":"term","name":"Post-PV myelofibrosis (spent phase)","route":"/terms/post-pv-myelofibrosis/","asOf":"2026-09-16","days":5},{"id":"idea-pv-clone-directed-therapy","kind":"idea","name":"Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission","route":"/ideas/idea-pv-clone-directed-therapy/","asOf":"2026-09-16","days":5},{"id":"idea-pv-hepcidin-first","kind":"idea","name":"Hepcidin-based control as first-line treatment in low-risk polycythaemia vera","route":"/ideas/idea-pv-hepcidin-first/","asOf":"2026-09-16","days":5},{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/","asOf":"2026-09-16","days":5},{"id":"pt-1","kind":"trial","name":"PT-1 (Primary Thrombocythaemia 1)","route":"/trials/pt-1/","asOf":"2026-09-16","days":5},{"id":"majic-et","kind":"trial","name":"MAJIC-ET","route":"/trials/majic-et/","asOf":"2026-09-16","days":5},{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/","asOf":"2026-09-16","days":5},{"id":"start-b","kind":"trial","name":"START-B (UK Standardisation of Breast Radiotherapy)","route":"/trials/start-b/","asOf":"2026-09-16","days":5},{"id":"fast-forward","kind":"trial","name":"FAST-Forward","route":"/trials/fast-forward/","asOf":"2026-09-16","days":5},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","asOf":"2026-09-16","days":5},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","asOf":"2026-09-16","days":5},{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","asOf":"2026-09-16","days":5},{"id":"rtog-0617","kind":"trial","name":"RTOG 0617","route":"/trials/rtog-0617/","asOf":"2026-09-16","days":5},{"id":"calgb-9343","kind":"trial","name":"CALGB 9343","route":"/trials/calgb-9343/","asOf":"2026-09-16","days":5},{"id":"prime-ii","kind":"trial","name":"PRIME II","route":"/trials/prime-ii/","asOf":"2026-09-16","days":5},{"id":"lumina","kind":"trial","name":"LUMINA","route":"/trials/lumina/","asOf":"2026-09-16","days":5},{"id":"import-low","kind":"trial","name":"IMPORT LOW","route":"/trials/import-low/","asOf":"2026-09-16","days":5},{"id":"nsabp-b39","kind":"trial","name":"NSABP B-39/RTOG 0413","route":"/trials/nsabp-b39/","asOf":"2026-09-16","days":5},{"id":"chisel","kind":"trial","name":"CHISEL (TROG 09.02)","route":"/trials/chisel/","asOf":"2026-09-16","days":5},{"id":"jcog0403","kind":"trial","name":"JCOG0403","route":"/trials/jcog0403/","asOf":"2026-09-16","days":5},{"id":"alliance-n0574","kind":"trial","name":"Alliance N0574 (NCCTG N0574)","route":"/trials/alliance-n0574/","asOf":"2026-09-16","days":5},{"id":"nrg-cc001","kind":"trial","name":"NRG CC001","route":"/trials/nrg-cc001/","asOf":"2026-09-16","days":5},{"id":"quartz","kind":"trial","name":"QUARTZ","route":"/trials/quartz/","asOf":"2026-09-16","days":5},{"id":"catnon","kind":"trial","name":"CATNON (EORTC 26053-22054)","route":"/trials/catnon/","asOf":"2026-09-16","days":5},{"id":"dahanca-5","kind":"trial","name":"DAHANCA 5","route":"/trials/dahanca-5/","asOf":"2026-09-16","days":5},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/","asOf":"2026-09-16","days":5},{"id":"peritoneal-mesothelioma","kind":"cancer","name":"Peritoneal mesothelioma","route":"/cancers/peritoneal-mesothelioma/","asOf":"2026-09-16","days":5},{"id":"nimorazole","kind":"drug","name":"Nimorazole","route":"/drugs/nimorazole/","asOf":"2026-09-16","days":5},{"id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/","asOf":"2026-09-16","days":5},{"id":"pilocarpine","kind":"drug","name":"Pilocarpine","route":"/drugs/pilocarpine/","asOf":"2026-09-16","days":5},{"id":"avasopasem-manganese","kind":"drug","name":"Avasopasem manganese","route":"/drugs/avasopasem-manganese/","asOf":"2026-09-16","days":5},{"id":"evofosfamide","kind":"drug","name":"Evofosfamide","route":"/drugs/evofosfamide/","asOf":"2026-09-16","days":5},{"id":"nanobiotix","kind":"company","name":"Nanobiotix","route":"/companies/nanobiotix/","asOf":"2026-09-16","days":5},{"id":"nct06423911","kind":"trial","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","route":"/trials/nct06423911/","asOf":"2026-09-16","days":5},{"id":"nct06640361","kind":"trial","name":"A Study of Olverembatinib in SDH-deficient GIST.","route":"/trials/nct06640361/","asOf":"2026-09-16","days":5},{"id":"nct06051409","kind":"trial","name":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)","route":"/trials/nct06051409/","asOf":"2026-09-16","days":5},{"id":"nct06265428","kind":"trial","name":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","route":"/trials/nct06265428/","asOf":"2026-09-16","days":5},{"id":"nct06018337","kind":"trial","name":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre","route":"/trials/nct06018337/","asOf":"2026-09-16","days":5},{"id":"nct05936658","kind":"trial","name":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","route":"/trials/nct05936658/","asOf":"2026-09-16","days":5},{"id":"nct05004285","kind":"trial","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","route":"/trials/nct05004285/","asOf":"2026-09-16","days":5},{"id":"nct06105619","kind":"trial","name":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","route":"/trials/nct06105619/","asOf":"2026-09-16","days":5},{"id":"nct05989542","kind":"trial","name":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","route":"/trials/nct05989542/","asOf":"2026-09-16","days":5},{"id":"nct06008106","kind":"trial","name":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","route":"/trials/nct06008106/","asOf":"2026-09-16","days":5},{"id":"nct06008119","kind":"trial","name":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","route":"/trials/nct06008119/","asOf":"2026-09-16","days":5},{"id":"nct06829459","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N","route":"/trials/nct06829459/","asOf":"2026-09-16","days":5},{"id":"nct05798819","kind":"trial","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","route":"/trials/nct05798819/","asOf":"2026-09-16","days":5},{"id":"nct03394365","kind":"trial","name":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu","route":"/trials/nct03394365/","asOf":"2026-09-16","days":5},{"id":"nct07241416","kind":"trial","name":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","route":"/trials/nct07241416/","asOf":"2026-09-16","days":5},{"id":"nct07234162","kind":"trial","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","route":"/trials/nct07234162/","asOf":"2026-09-16","days":5},{"id":"nct06459687","kind":"trial","name":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","route":"/trials/nct06459687/","asOf":"2026-09-16","days":5},{"id":"nct06750419","kind":"trial","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","route":"/trials/nct06750419/","asOf":"2026-09-16","days":5},{"id":"nct06122584","kind":"trial","name":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","route":"/trials/nct06122584/","asOf":"2026-09-16","days":5},{"id":"nct03486873","kind":"trial","name":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb","route":"/trials/nct03486873/","asOf":"2026-09-16","days":5},{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","route":"/trials/nct06499285/","asOf":"2026-09-16","days":5},{"id":"nct03562637","kind":"trial","name":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","route":"/trials/nct03562637/","asOf":"2026-09-16","days":5},{"id":"nct04950322","kind":"trial","name":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","route":"/trials/nct04950322/","asOf":"2026-09-16","days":5},{"id":"nct05050942","kind":"trial","name":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","route":"/trials/nct05050942/","asOf":"2026-09-16","days":5},{"id":"nct06432296","kind":"trial","name":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","route":"/trials/nct06432296/","asOf":"2026-09-16","days":5},{"id":"nct05851014","kind":"trial","name":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","route":"/trials/nct05851014/","asOf":"2026-09-16","days":5},{"id":"nct04143607","kind":"trial","name":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","route":"/trials/nct04143607/","asOf":"2026-09-16","days":5},{"id":"nct02665065","kind":"trial","name":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct02665065/","asOf":"2026-09-16","days":5},{"id":"nct07112196","kind":"trial","name":"Visugromab in Cachexia International Trial","route":"/trials/nct07112196/","asOf":"2026-09-16","days":5},{"id":"nct05652894","kind":"trial","name":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","route":"/trials/nct05652894/","asOf":"2026-09-16","days":5},{"id":"nct06212752","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With","route":"/trials/nct06212752/","asOf":"2026-09-16","days":5},{"id":"nct06097364","kind":"trial","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","route":"/trials/nct06097364/","asOf":"2026-09-16","days":5},{"id":"nct06199973","kind":"trial","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","route":"/trials/nct06199973/","asOf":"2026-09-16","days":5},{"id":"nct06828354","kind":"trial","name":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","route":"/trials/nct06828354/","asOf":"2026-09-16","days":5},{"id":"nct05059522","kind":"trial","name":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","route":"/trials/nct05059522/","asOf":"2026-09-16","days":5},{"id":"nct04639180","kind":"trial","name":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur","route":"/trials/nct04639180/","asOf":"2026-09-16","days":5},{"id":"nct06350097","kind":"trial","name":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L","route":"/trials/nct06350097/","asOf":"2026-09-16","days":5},{"id":"nct05089734","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05089734/","asOf":"2026-09-16","days":5},{"id":"nct06348199","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s","route":"/trials/nct06348199/","asOf":"2026-09-16","days":5},{"id":"nct04351555","kind":"trial","name":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S","route":"/trials/nct04351555/","asOf":"2026-09-16","days":5},{"id":"nct06712355","kind":"trial","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","route":"/trials/nct06712355/","asOf":"2026-09-16","days":5},{"id":"nct04854668","kind":"trial","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","route":"/trials/nct04854668/","asOf":"2026-09-16","days":5},{"id":"nct07625644","kind":"trial","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","route":"/trials/nct07625644/","asOf":"2026-09-16","days":5},{"id":"nct07010263","kind":"trial","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","route":"/trials/nct07010263/","asOf":"2026-09-16","days":5},{"id":"nct06758401","kind":"trial","name":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu","route":"/trials/nct06758401/","asOf":"2026-09-16","days":5},{"id":"nct06216301","kind":"trial","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","route":"/trials/nct06216301/","asOf":"2026-09-16","days":5},{"id":"nct04442022","kind":"trial","name":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly","route":"/trials/nct04442022/","asOf":"2026-09-16","days":5},{"id":"nct03873402","kind":"trial","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","route":"/trials/nct03873402/","asOf":"2026-09-16","days":5},{"id":"nct04529772","kind":"trial","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","route":"/trials/nct04529772/","asOf":"2026-09-16","days":5},{"id":"nct06838273","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas","route":"/trials/nct06838273/","asOf":"2026-09-16","days":5},{"id":"nct06767527","kind":"trial","name":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","route":"/trials/nct06767527/","asOf":"2026-09-16","days":5},{"id":"nct06313086","kind":"trial","name":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","route":"/trials/nct06313086/","asOf":"2026-09-16","days":5},{"id":"nct06868654","kind":"trial","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","route":"/trials/nct06868654/","asOf":"2026-09-16","days":5},{"id":"nct05920356","kind":"trial","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","route":"/trials/nct05920356/","asOf":"2026-09-16","days":5},{"id":"nct07502300","kind":"trial","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","route":"/trials/nct07502300/","asOf":"2026-09-16","days":5},{"id":"nct04094311","kind":"trial","name":"Study of Out of Specification for Tisagenlecleucel","route":"/trials/nct04094311/","asOf":"2026-09-16","days":5},{"id":"nct07044336","kind":"trial","name":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","route":"/trials/nct07044336/","asOf":"2026-09-16","days":5},{"id":"nct06717347","kind":"trial","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","route":"/trials/nct06717347/","asOf":"2026-09-16","days":5},{"id":"nct06054555","kind":"trial","name":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","route":"/trials/nct06054555/","asOf":"2026-09-16","days":5},{"id":"nct07226752","kind":"trial","name":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","route":"/trials/nct07226752/","asOf":"2026-09-16","days":5},{"id":"nct05730036","kind":"trial","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","route":"/trials/nct05730036/","asOf":"2026-09-16","days":5},{"id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/","asOf":"2026-09-16","days":5},{"id":"nct06340568","kind":"trial","name":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","route":"/trials/nct06340568/","asOf":"2026-09-16","days":5},{"id":"nct05120349","kind":"trial","name":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","route":"/trials/nct05120349/","asOf":"2026-09-16","days":5},{"id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/","asOf":"2026-09-16","days":5},{"id":"nct06581406","kind":"trial","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","route":"/trials/nct06581406/","asOf":"2026-09-16","days":5},{"id":"nct04940052","kind":"trial","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto","route":"/trials/nct04940052/","asOf":"2026-09-16","days":5},{"id":"nct03844048","kind":"trial","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","route":"/trials/nct03844048/","asOf":"2026-09-16","days":5},{"id":"nct06629779","kind":"trial","name":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","route":"/trials/nct06629779/","asOf":"2026-09-16","days":5},{"id":"nct06430866","kind":"trial","name":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","route":"/trials/nct06430866/","asOf":"2026-09-16","days":5},{"id":"nct06670196","kind":"trial","name":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan","route":"/trials/nct06670196/","asOf":"2026-09-16","days":5},{"id":"nct06788756","kind":"trial","name":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re","route":"/trials/nct06788756/","asOf":"2026-09-16","days":5},{"id":"nct06382129","kind":"trial","name":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU","route":"/trials/nct06382129/","asOf":"2026-09-16","days":5},{"id":"nct06305754","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","route":"/trials/nct06305754/","asOf":"2026-09-16","days":5},{"id":"nct05170204","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","route":"/trials/nct05170204/","asOf":"2026-09-16","days":5},{"id":"nct04842617","kind":"trial","name":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne","route":"/trials/nct04842617/","asOf":"2026-09-16","days":5},{"id":"nct06692738","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","route":"/trials/nct06692738/","asOf":"2026-09-16","days":5},{"id":"nct06448312","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06448312/","asOf":"2026-09-16","days":5},{"id":"nct05348577","kind":"trial","name":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct05348577/","asOf":"2026-09-16","days":5},{"id":"nct04384484","kind":"trial","name":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym","route":"/trials/nct04384484/","asOf":"2026-09-16","days":5},{"id":"nct06801834","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06801834/","asOf":"2026-09-16","days":5},{"id":"nct04002297","kind":"trial","name":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl","route":"/trials/nct04002297/","asOf":"2026-09-16","days":5},{"id":"nct02152631","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","route":"/trials/nct02152631/","asOf":"2026-09-16","days":5},{"id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","asOf":"2026-09-16","days":5},{"id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","route":"/trials/nct07154706/","asOf":"2026-09-16","days":5},{"id":"nct05445778","kind":"trial","name":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C","route":"/trials/nct05445778/","asOf":"2026-09-16","days":5},{"id":"nct04810078","kind":"trial","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","route":"/trials/nct04810078/","asOf":"2026-09-16","days":5},{"id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","asOf":"2026-09-16","days":5},{"id":"nct06956170","kind":"trial","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","route":"/trials/nct06956170/","asOf":"2026-09-16","days":5},{"id":"nct07221357","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","route":"/trials/nct07221357/","asOf":"2026-09-16","days":5},{"id":"nct06899126","kind":"trial","name":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","route":"/trials/nct06899126/","asOf":"2026-09-16","days":5},{"id":"nct05438043","kind":"trial","name":"A Study of Daratumumab","route":"/trials/nct05438043/","asOf":"2026-09-16","days":5},{"id":"nct05572515","kind":"trial","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","route":"/trials/nct05572515/","asOf":"2026-09-16","days":5},{"id":"nct05320692","kind":"trial","name":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","route":"/trials/nct05320692/","asOf":"2026-09-16","days":5},{"id":"nct06584032","kind":"trial","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","route":"/trials/nct06584032/","asOf":"2026-09-16","days":5},{"id":"nct07775287","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","route":"/trials/nct07775287/","asOf":"2026-09-16","days":5},{"id":"nct04379635","kind":"trial","name":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04379635/","asOf":"2026-09-16","days":5},{"id":"nct06698042","kind":"trial","name":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","route":"/trials/nct06698042/","asOf":"2026-09-16","days":5},{"id":"nct07216703","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","route":"/trials/nct07216703/","asOf":"2026-09-16","days":5},{"id":"nct04884360","kind":"trial","name":"D9319C00001- 1L OC Mono Global RCT","route":"/trials/nct04884360/","asOf":"2026-09-16","days":5},{"id":"nct07518173","kind":"trial","name":"A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M","route":"/trials/nct07518173/","asOf":"2026-09-16","days":5},{"id":"nct06435429","kind":"trial","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o","route":"/trials/nct06435429/","asOf":"2026-09-16","days":5},{"id":"nct04712097","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi","route":"/trials/nct04712097/","asOf":"2026-09-16","days":5},{"id":"nct04194775","kind":"trial","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","route":"/trials/nct04194775/","asOf":"2026-09-16","days":5},{"id":"nct07028853","kind":"trial","name":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En","route":"/trials/nct07028853/","asOf":"2026-09-16","days":5},{"id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/","asOf":"2026-09-16","days":5},{"id":"nct06246916","kind":"trial","name":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","route":"/trials/nct06246916/","asOf":"2026-09-16","days":5},{"id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","asOf":"2026-09-16","days":5},{"id":"nct02411448","kind":"trial","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","route":"/trials/nct02411448/","asOf":"2026-09-16","days":5},{"id":"nct06830889","kind":"trial","name":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","route":"/trials/nct06830889/","asOf":"2026-09-16","days":5},{"id":"nct03755791","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","route":"/trials/nct03755791/","asOf":"2026-09-16","days":5},{"id":"nct05429268","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (","route":"/trials/nct05429268/","asOf":"2026-09-16","days":5},{"id":"nct06549595","kind":"trial","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","route":"/trials/nct06549595/","asOf":"2026-09-16","days":5},{"id":"nct05353257","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage","route":"/trials/nct05353257/","asOf":"2026-09-16","days":5},{"id":"nct06699212","kind":"trial","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","route":"/trials/nct06699212/","asOf":"2026-09-16","days":5},{"id":"nct06041776","kind":"trial","name":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","route":"/trials/nct06041776/","asOf":"2026-09-16","days":5},{"id":"nct05727904","kind":"trial","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","route":"/trials/nct05727904/","asOf":"2026-09-16","days":5},{"id":"nct05800015","kind":"trial","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","route":"/trials/nct05800015/","asOf":"2026-09-16","days":5},{"id":"nct07318558","kind":"trial","name":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","route":"/trials/nct07318558/","asOf":"2026-09-16","days":5},{"id":"nct04613596","kind":"trial","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","route":"/trials/nct04613596/","asOf":"2026-09-16","days":5},{"id":"nct07805954","kind":"trial","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","route":"/trials/nct07805954/","asOf":"2026-09-16","days":5},{"id":"nct06149286","kind":"trial","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","route":"/trials/nct06149286/","asOf":"2026-09-16","days":5},{"id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","asOf":"2026-09-16","days":5},{"id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","route":"/trials/nct06765109/","asOf":"2026-09-16","days":5},{"id":"nct07640789","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s","route":"/trials/nct07640789/","asOf":"2026-09-16","days":5},{"id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","route":"/trials/nct07541170/","asOf":"2026-09-16","days":5},{"id":"nct04674683","kind":"trial","name":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","route":"/trials/nct04674683/","asOf":"2026-09-16","days":5},{"id":"nct06994195","kind":"trial","name":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK","route":"/trials/nct06994195/","asOf":"2026-09-16","days":5},{"id":"nct05489289","kind":"trial","name":"A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","route":"/trials/nct05489289/","asOf":"2026-09-16","days":5},{"id":"nct01436968","kind":"trial","name":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","route":"/trials/nct01436968/","asOf":"2026-09-16","days":5},{"id":"nct06585410","kind":"trial","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","route":"/trials/nct06585410/","asOf":"2026-09-16","days":5},{"id":"nct05623020","kind":"trial","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","route":"/trials/nct05623020/","asOf":"2026-09-16","days":5},{"id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","route":"/trials/nct05827016/","asOf":"2026-09-16","days":5},{"id":"nct06956001","kind":"trial","name":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","route":"/trials/nct06956001/","asOf":"2026-09-16","days":5},{"id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/","asOf":"2026-09-16","days":5},{"id":"nct06152575","kind":"trial","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","route":"/trials/nct06152575/","asOf":"2026-09-16","days":5},{"id":"nct07228832","kind":"trial","name":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07228832/","asOf":"2026-09-16","days":5},{"id":"nct03539744","kind":"trial","name":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ","route":"/trials/nct03539744/","asOf":"2026-09-16","days":5},{"id":"nct05519085","kind":"trial","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","route":"/trials/nct05519085/","asOf":"2026-09-16","days":5},{"id":"nct07412613","kind":"trial","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","route":"/trials/nct07412613/","asOf":"2026-09-16","days":5},{"id":"nct06508658","kind":"trial","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","route":"/trials/nct06508658/","asOf":"2026-09-16","days":5},{"id":"nct06824467","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","route":"/trials/nct06824467/","asOf":"2026-09-16","days":5},{"id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/","asOf":"2026-09-16","days":5},{"id":"nct06468033","kind":"trial","name":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","route":"/trials/nct06468033/","asOf":"2026-09-16","days":5},{"id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/","asOf":"2026-09-16","days":5},{"id":"nct06356311","kind":"trial","name":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","route":"/trials/nct06356311/","asOf":"2026-09-16","days":5},{"id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/","asOf":"2026-09-16","days":5},{"id":"nct06417814","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","route":"/trials/nct06417814/","asOf":"2026-09-16","days":5},{"id":"nct07168200","kind":"trial","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","route":"/trials/nct07168200/","asOf":"2026-09-16","days":5},{"id":"nct07005128","kind":"trial","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","route":"/trials/nct07005128/","asOf":"2026-09-16","days":5},{"id":"nct07509151","kind":"trial","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","route":"/trials/nct07509151/","asOf":"2026-09-16","days":5},{"id":"nct06514508","kind":"trial","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","route":"/trials/nct06514508/","asOf":"2026-09-16","days":5},{"id":"nct07361510","kind":"trial","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","route":"/trials/nct07361510/","asOf":"2026-09-16","days":5},{"id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06928389/","asOf":"2026-09-16","days":5},{"id":"nct06170788","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","route":"/trials/nct06170788/","asOf":"2026-09-16","days":5},{"id":"nct06459180","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With","route":"/trials/nct06459180/","asOf":"2026-09-16","days":5},{"id":"nct04717414","kind":"trial","name":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi","route":"/trials/nct04717414/","asOf":"2026-09-16","days":5},{"id":"nct06640530","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","route":"/trials/nct06640530/","asOf":"2026-09-16","days":5},{"id":"nct06072781","kind":"trial","name":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","route":"/trials/nct06072781/","asOf":"2026-09-16","days":5},{"id":"nct06911502","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","route":"/trials/nct06911502/","asOf":"2026-09-16","days":5},{"id":"nct06452277","kind":"trial","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","route":"/trials/nct06452277/","asOf":"2026-09-16","days":5},{"id":"nct06430437","kind":"trial","name":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","route":"/trials/nct06430437/","asOf":"2026-09-16","days":5},{"id":"nct06316531","kind":"trial","name":"A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","route":"/trials/nct06316531/","asOf":"2026-09-16","days":5},{"id":"nct03390686","kind":"trial","name":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ","route":"/trials/nct03390686/","asOf":"2026-09-16","days":5},{"id":"nct05654454","kind":"trial","name":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","route":"/trials/nct05654454/","asOf":"2026-09-16","days":5},{"id":"nct06311721","kind":"trial","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","route":"/trials/nct06311721/","asOf":"2026-09-16","days":5},{"id":"nct03706365","kind":"trial","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","route":"/trials/nct03706365/","asOf":"2026-09-16","days":5},{"id":"nct05116462","kind":"trial","name":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","route":"/trials/nct05116462/","asOf":"2026-09-16","days":5},{"id":"nct04076059","kind":"trial","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","route":"/trials/nct04076059/","asOf":"2026-09-16","days":5},{"id":"nct04975997","kind":"trial","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","route":"/trials/nct04975997/","asOf":"2026-09-16","days":5},{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04162210/","asOf":"2026-09-16","days":5},{"id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/","asOf":"2026-09-16","days":5},{"id":"nct06989112","kind":"trial","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","route":"/trials/nct06989112/","asOf":"2026-09-16","days":5},{"id":"nct03800134","kind":"trial","name":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","route":"/trials/nct03800134/","asOf":"2026-09-16","days":5},{"id":"nct05884398","kind":"trial","name":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","route":"/trials/nct05884398/","asOf":"2026-09-16","days":5},{"id":"nct05804370","kind":"trial","name":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","route":"/trials/nct05804370/","asOf":"2026-09-16","days":5},{"id":"nct06300177","kind":"trial","name":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar","route":"/trials/nct06300177/","asOf":"2026-09-16","days":5},{"id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/","asOf":"2026-09-16","days":5},{"id":"nct02767804","kind":"trial","name":"eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct02767804/","asOf":"2026-09-16","days":5},{"id":"nct07170995","kind":"trial","name":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva","route":"/trials/nct07170995/","asOf":"2026-09-16","days":5},{"id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/","asOf":"2026-09-16","days":5},{"id":"nct05425940","kind":"trial","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","route":"/trials/nct05425940/","asOf":"2026-09-16","days":5},{"id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/","asOf":"2026-09-16","days":5},{"id":"nct05607550","kind":"trial","name":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With","route":"/trials/nct05607550/","asOf":"2026-09-16","days":5},{"id":"nct07213674","kind":"trial","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","route":"/trials/nct07213674/","asOf":"2026-09-16","days":5},{"id":"nct05215340","kind":"trial","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","route":"/trials/nct05215340/","asOf":"2026-09-16","days":5},{"id":"nct06496178","kind":"trial","name":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P","route":"/trials/nct06496178/","asOf":"2026-09-16","days":5},{"id":"nct06158841","kind":"trial","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","route":"/trials/nct06158841/","asOf":"2026-09-16","days":5},{"id":"nct06230224","kind":"trial","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","route":"/trials/nct06230224/","asOf":"2026-09-16","days":5},{"id":"nct06976190","kind":"trial","name":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin","route":"/trials/nct06976190/","asOf":"2026-09-16","days":5},{"id":"nct04446117","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","route":"/trials/nct04446117/","asOf":"2026-09-16","days":5},{"id":"nct05317858","kind":"trial","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","route":"/trials/nct05317858/","asOf":"2026-09-16","days":5},{"id":"nct05020236","kind":"trial","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","route":"/trials/nct05020236/","asOf":"2026-09-16","days":5},{"id":"nct04224493","kind":"trial","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","route":"/trials/nct04224493/","asOf":"2026-09-16","days":5},{"id":"nct06711900","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P","route":"/trials/nct06711900/","asOf":"2026-09-16","days":5},{"id":"nct06252649","kind":"trial","name":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal","route":"/trials/nct06252649/","asOf":"2026-09-16","days":5},{"id":"nct04687241","kind":"trial","name":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations","route":"/trials/nct04687241/","asOf":"2026-09-16","days":5},{"id":"nct07473128","kind":"trial","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","route":"/trials/nct07473128/","asOf":"2026-09-16","days":5},{"id":"nct04969731","kind":"trial","name":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer","route":"/trials/nct04969731/","asOf":"2026-09-16","days":5},{"id":"nct07391657","kind":"trial","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","route":"/trials/nct07391657/","asOf":"2026-09-16","days":5},{"id":"nct06396065","kind":"trial","name":"Phase III Study of AK112 for NSCLC Patients","route":"/trials/nct06396065/","asOf":"2026-09-16","days":5},{"id":"nct04129502","kind":"trial","name":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct04129502/","asOf":"2026-09-16","days":5},{"id":"nct07095452","kind":"trial","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","route":"/trials/nct07095452/","asOf":"2026-09-16","days":5},{"id":"nct06712316","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","route":"/trials/nct06712316/","asOf":"2026-09-16","days":5},{"id":"nct06312137","kind":"trial","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","route":"/trials/nct06312137/","asOf":"2026-09-16","days":5},{"id":"nct01804686","kind":"trial","name":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","route":"/trials/nct01804686/","asOf":"2026-09-16","days":5},{"id":"nct07604766","kind":"trial","name":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can","route":"/trials/nct07604766/","asOf":"2026-09-16","days":5},{"id":"nct06486441","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im","route":"/trials/nct06486441/","asOf":"2026-09-16","days":5},{"id":"nct07166094","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","route":"/trials/nct07166094/","asOf":"2026-09-16","days":5},{"id":"nct03246529","kind":"trial","name":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl","route":"/trials/nct03246529/","asOf":"2026-09-16","days":5},{"id":"nct06921785","kind":"trial","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","route":"/trials/nct06921785/","asOf":"2026-09-16","days":5},{"id":"nct04951635","kind":"trial","name":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","route":"/trials/nct04951635/","asOf":"2026-09-16","days":5},{"id":"nct05608291","kind":"trial","name":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af","route":"/trials/nct05608291/","asOf":"2026-09-16","days":5},{"id":"nct06947928","kind":"trial","name":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car","route":"/trials/nct06947928/","asOf":"2026-09-16","days":5},{"id":"nct06952504","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan","route":"/trials/nct06952504/","asOf":"2026-09-16","days":5},{"id":"nct05625399","kind":"trial","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","route":"/trials/nct05625399/","asOf":"2026-09-16","days":5},{"id":"nct06496048","kind":"trial","name":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","route":"/trials/nct06496048/","asOf":"2026-09-16","days":5},{"id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","route":"/trials/nct05555732/","asOf":"2026-09-16","days":5},{"id":"nct05785767","kind":"trial","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","route":"/trials/nct05785767/","asOf":"2026-09-16","days":5},{"id":"nct04547166","kind":"trial","name":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta","route":"/trials/nct04547166/","asOf":"2026-09-16","days":5},{"id":"nct06208150","kind":"trial","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","route":"/trials/nct06208150/","asOf":"2026-09-16","days":5},{"id":"nct06077760","kind":"trial","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","route":"/trials/nct06077760/","asOf":"2026-09-16","days":5},{"id":"nct05797831","kind":"trial","name":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","route":"/trials/nct05797831/","asOf":"2026-09-16","days":5},{"id":"nct05043090","kind":"trial","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","route":"/trials/nct05043090/","asOf":"2026-09-16","days":5},{"id":"nct07185997","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W","route":"/trials/nct07185997/","asOf":"2026-09-16","days":5},{"id":"nct07361497","kind":"trial","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","route":"/trials/nct07361497/","asOf":"2026-09-16","days":5},{"id":"nct05862337","kind":"trial","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","route":"/trials/nct05862337/","asOf":"2026-09-16","days":5},{"id":"nct06679101","kind":"trial","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","route":"/trials/nct06679101/","asOf":"2026-09-16","days":5},{"id":"nct06819007","kind":"trial","name":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-","route":"/trials/nct06819007/","asOf":"2026-09-16","days":5},{"id":"nct06118333","kind":"trial","name":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)","route":"/trials/nct06118333/","asOf":"2026-09-16","days":5},{"id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","route":"/trials/nct04421963/","asOf":"2026-09-16","days":5},{"id":"nct03016819","kind":"trial","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","route":"/trials/nct03016819/","asOf":"2026-09-16","days":5},{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","route":"/trials/nct01933932/","asOf":"2026-09-16","days":5},{"id":"nct06132958","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","route":"/trials/nct06132958/","asOf":"2026-09-16","days":5},{"id":"nct06868667","kind":"trial","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","route":"/trials/nct06868667/","asOf":"2026-09-16","days":5},{"id":"nct05870319","kind":"trial","name":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","route":"/trials/nct05870319/","asOf":"2026-09-16","days":5},{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","route":"/trials/nct04680052/","asOf":"2026-09-16","days":5},{"id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/","asOf":"2026-09-16","days":5},{"id":"nct06726265","kind":"trial","name":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ","route":"/trials/nct06726265/","asOf":"2026-09-16","days":5},{"id":"nct07462143","kind":"trial","name":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07462143/","asOf":"2026-09-16","days":5},{"id":"nct06746116","kind":"trial","name":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment","route":"/trials/nct06746116/","asOf":"2026-09-16","days":5},{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/","asOf":"2026-09-16","days":5},{"id":"nct07472517","kind":"trial","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","route":"/trials/nct07472517/","asOf":"2026-09-16","days":5},{"id":"nct05468489","kind":"trial","name":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","route":"/trials/nct05468489/","asOf":"2026-09-16","days":5},{"id":"nct02362594","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","route":"/trials/nct02362594/","asOf":"2026-09-16","days":5},{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","route":"/trials/nct03690388/","asOf":"2026-09-16","days":5},{"id":"nct06561386","kind":"trial","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N","route":"/trials/nct06561386/","asOf":"2026-09-16","days":5},{"id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","route":"/trials/nct04624204/","asOf":"2026-09-16","days":5},{"id":"nct06091865","kind":"trial","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","route":"/trials/nct06091865/","asOf":"2026-09-16","days":5},{"id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","route":"/trials/nct06091254/","asOf":"2026-09-16","days":5},{"id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07011719/","asOf":"2026-09-16","days":5},{"id":"nct05883644","kind":"trial","name":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","route":"/trials/nct05883644/","asOf":"2026-09-16","days":5},{"id":"nct06465914","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","route":"/trials/nct06465914/","asOf":"2026-09-16","days":5},{"id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/","asOf":"2026-09-16","days":5},{"id":"nct03847428","kind":"trial","name":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","route":"/trials/nct03847428/","asOf":"2026-09-16","days":5},{"id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/","asOf":"2026-09-16","days":5},{"id":"nct06128837","kind":"trial","name":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","route":"/trials/nct06128837/","asOf":"2026-09-16","days":5},{"id":"nct06925737","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","route":"/trials/nct06925737/","asOf":"2026-09-16","days":5},{"id":"nct05552976","kind":"trial","name":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W","route":"/trials/nct05552976/","asOf":"2026-09-16","days":5},{"id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","asOf":"2026-09-16","days":5},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","asOf":"2026-09-16","days":5},{"id":"nct05722015","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With","route":"/trials/nct05722015/","asOf":"2026-09-16","days":5},{"id":"nct05047250","kind":"trial","name":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05047250/","asOf":"2026-09-16","days":5},{"id":"nct06123884","kind":"trial","name":"BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer","route":"/trials/nct06123884/","asOf":"2026-09-16","days":5},{"id":"nct05171816","kind":"trial","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","route":"/trials/nct05171816/","asOf":"2026-09-16","days":5},{"id":"nct07642024","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU","route":"/trials/nct07642024/","asOf":"2026-09-16","days":5},{"id":"nct06793215","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","route":"/trials/nct06793215/","asOf":"2026-09-16","days":5},{"id":"nct06174987","kind":"trial","name":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","route":"/trials/nct06174987/","asOf":"2026-09-16","days":5},{"id":"nct06506955","kind":"trial","name":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","route":"/trials/nct06506955/","asOf":"2026-09-16","days":5},{"id":"nct07454720","kind":"trial","name":"A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07454720/","asOf":"2026-09-16","days":5},{"id":"nct05270044","kind":"trial","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","route":"/trials/nct05270044/","asOf":"2026-09-16","days":5},{"id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/","asOf":"2026-09-16","days":5},{"id":"nct06687369","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L","route":"/trials/nct06687369/","asOf":"2026-09-16","days":5},{"id":"nct07722494","kind":"trial","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","route":"/trials/nct07722494/","asOf":"2026-09-16","days":5},{"id":"nct04099251","kind":"trial","name":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","route":"/trials/nct04099251/","asOf":"2026-09-16","days":5},{"id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","route":"/trials/nct06074588/","asOf":"2026-09-16","days":5},{"id":"nct05388669","kind":"trial","name":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)","route":"/trials/nct05388669/","asOf":"2026-09-16","days":5},{"id":"nct05048797","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N","route":"/trials/nct05048797/","asOf":"2026-09-16","days":5},{"id":"nct06497985","kind":"trial","name":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","route":"/trials/nct06497985/","asOf":"2026-09-16","days":5},{"id":"nct06117774","kind":"trial","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","route":"/trials/nct06117774/","asOf":"2026-09-16","days":5},{"id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","asOf":"2026-09-16","days":5},{"id":"nct05317416","kind":"trial","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","route":"/trials/nct05317416/","asOf":"2026-09-16","days":5},{"id":"nct05904886","kind":"trial","name":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell","route":"/trials/nct05904886/","asOf":"2026-09-16","days":5},{"id":"nct05022901","kind":"trial","name":"An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma","route":"/trials/nct05022901/","asOf":"2026-09-16","days":5},{"id":"nct05552222","kind":"trial","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","route":"/trials/nct05552222/","asOf":"2026-09-16","days":5},{"id":"nct06045806","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo","route":"/trials/nct06045806/","asOf":"2026-09-16","days":5},{"id":"nct04404283","kind":"trial","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","route":"/trials/nct04404283/","asOf":"2026-09-16","days":5},{"id":"nct07778316","kind":"trial","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","route":"/trials/nct07778316/","asOf":"2026-09-16","days":5},{"id":"nct03383458","kind":"trial","name":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","route":"/trials/nct03383458/","asOf":"2026-09-16","days":5},{"id":"nct06617416","kind":"trial","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","route":"/trials/nct06617416/","asOf":"2026-09-16","days":5},{"id":"nct06627647","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","route":"/trials/nct06627647/","asOf":"2026-09-16","days":5},{"id":"nct06742996","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac","route":"/trials/nct06742996/","asOf":"2026-09-16","days":5},{"id":"nct05549297","kind":"trial","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","route":"/trials/nct05549297/","asOf":"2026-09-16","days":5},{"id":"nct06564324","kind":"trial","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","route":"/trials/nct06564324/","asOf":"2026-09-16","days":5},{"id":"nct05100862","kind":"trial","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom","route":"/trials/nct05100862/","asOf":"2026-09-16","days":5},{"id":"nct04657991","kind":"trial","name":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","route":"/trials/nct04657991/","asOf":"2026-09-16","days":5},{"id":"nct07225270","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","route":"/trials/nct07225270/","asOf":"2026-09-16","days":5},{"id":"nct06363994","kind":"trial","name":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","route":"/trials/nct06363994/","asOf":"2026-09-16","days":5},{"id":"nct04956692","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan","route":"/trials/nct04956692/","asOf":"2026-09-16","days":5},{"id":"nct07291037","kind":"trial","name":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti","route":"/trials/nct07291037/","asOf":"2026-09-16","days":5},{"id":"nct07702032","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta","route":"/trials/nct07702032/","asOf":"2026-09-16","days":5},{"id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","route":"/trials/nct05888493/","asOf":"2026-09-16","days":5},{"id":"nct07182682","kind":"trial","name":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins","route":"/trials/nct07182682/","asOf":"2026-09-16","days":5},{"id":"nct07196774","kind":"trial","name":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","route":"/trials/nct07196774/","asOf":"2026-09-16","days":5},{"id":"nct05984277","kind":"trial","name":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung","route":"/trials/nct05984277/","asOf":"2026-09-16","days":5},{"id":"nct05409066","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct05409066/","asOf":"2026-09-16","days":5},{"id":"nct07361003","kind":"trial","name":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07361003/","asOf":"2026-09-16","days":5},{"id":"nct05455320","kind":"trial","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","route":"/trials/nct05455320/","asOf":"2026-09-16","days":5},{"id":"nct07393282","kind":"trial","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","route":"/trials/nct07393282/","asOf":"2026-09-16","days":5},{"id":"nct07513376","kind":"trial","name":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ","route":"/trials/nct07513376/","asOf":"2026-09-16","days":5},{"id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/","asOf":"2026-09-16","days":5},{"id":"nct04793958","kind":"trial","name":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","route":"/trials/nct04793958/","asOf":"2026-09-16","days":5},{"id":"nct04974398","kind":"trial","name":"A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct04974398/","asOf":"2026-09-16","days":5},{"id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","route":"/trials/nct06881784/","asOf":"2026-09-16","days":5},{"id":"nct03178552","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct03178552/","asOf":"2026-09-16","days":5},{"id":"nct04691804","kind":"trial","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver","route":"/trials/nct04691804/","asOf":"2026-09-16","days":5},{"id":"nct05557838","kind":"trial","name":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC","route":"/trials/nct05557838/","asOf":"2026-09-16","days":5},{"id":"nct05794906","kind":"trial","name":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer","route":"/trials/nct05794906/","asOf":"2026-09-16","days":5},{"id":"nct07777822","kind":"trial","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","route":"/trials/nct07777822/","asOf":"2026-09-16","days":5},{"id":"nct07178795","kind":"trial","name":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","route":"/trials/nct07178795/","asOf":"2026-09-16","days":5},{"id":"nct06097728","kind":"trial","name":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","route":"/trials/nct06097728/","asOf":"2026-09-16","days":5},{"id":"nct06371157","kind":"trial","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","route":"/trials/nct06371157/","asOf":"2026-09-16","days":5},{"id":"nct07100080","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy","route":"/trials/nct07100080/","asOf":"2026-09-16","days":5},{"id":"nct07195695","kind":"trial","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","route":"/trials/nct07195695/","asOf":"2026-09-16","days":5},{"id":"nct06500026","kind":"trial","name":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","route":"/trials/nct06500026/","asOf":"2026-09-16","days":5},{"id":"nct05668988","kind":"trial","name":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","route":"/trials/nct05668988/","asOf":"2026-09-16","days":5},{"id":"nct04765059","kind":"trial","name":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04765059/","asOf":"2026-09-16","days":5},{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","asOf":"2026-09-16","days":5},{"id":"nct07564141","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","route":"/trials/nct07564141/","asOf":"2026-09-16","days":5},{"id":"nct07022483","kind":"trial","name":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","route":"/trials/nct07022483/","asOf":"2026-09-16","days":5},{"id":"nct04712643","kind":"trial","name":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","route":"/trials/nct04712643/","asOf":"2026-09-16","days":5},{"id":"nct06891833","kind":"trial","name":"A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea","route":"/trials/nct06891833/","asOf":"2026-09-16","days":5},{"id":"nct04316364","kind":"trial","name":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","route":"/trials/nct04316364/","asOf":"2026-09-16","days":5},{"id":"nct07676162","kind":"trial","name":"A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal","route":"/trials/nct07676162/","asOf":"2026-09-16","days":5},{"id":"nct05371093","kind":"trial","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct05371093/","asOf":"2026-09-16","days":5},{"id":"nct05987332","kind":"trial","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","route":"/trials/nct05987332/","asOf":"2026-09-16","days":5},{"id":"nct04923906","kind":"trial","name":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut","route":"/trials/nct04923906/","asOf":"2026-09-16","days":5},{"id":"nct06382116","kind":"trial","name":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","route":"/trials/nct06382116/","asOf":"2026-09-16","days":5},{"id":"nct05840016","kind":"trial","name":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05840016/","asOf":"2026-09-16","days":5},{"id":"nct03556228","kind":"trial","name":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","route":"/trials/nct03556228/","asOf":"2026-09-16","days":5},{"id":"nct04619004","kind":"trial","name":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","route":"/trials/nct04619004/","asOf":"2026-09-16","days":5},{"id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","route":"/trials/nct07491497/","asOf":"2026-09-16","days":5},{"id":"nct07258979","kind":"trial","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","route":"/trials/nct07258979/","asOf":"2026-09-16","days":5},{"id":"nct05222555","kind":"trial","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","route":"/trials/nct05222555/","asOf":"2026-09-16","days":5},{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/","asOf":"2026-09-16","days":5},{"id":"nct07527858","kind":"trial","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","route":"/trials/nct07527858/","asOf":"2026-09-16","days":5},{"id":"nct05180799","kind":"trial","name":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","route":"/trials/nct05180799/","asOf":"2026-09-16","days":5},{"id":"nct06475300","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ","route":"/trials/nct06475300/","asOf":"2026-09-16","days":5},{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/","asOf":"2026-09-16","days":5},{"id":"nct06445062","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","route":"/trials/nct06445062/","asOf":"2026-09-16","days":5},{"id":"nct06498986","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06498986/","asOf":"2026-09-16","days":5},{"id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","route":"/trials/nct05652686/","asOf":"2026-09-16","days":5},{"id":"nct02227251","kind":"trial","name":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","route":"/trials/nct02227251/","asOf":"2026-09-16","days":5},{"id":"nct06710288","kind":"trial","name":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P","route":"/trials/nct06710288/","asOf":"2026-09-16","days":5},{"id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/","asOf":"2026-09-16","days":5},{"id":"nct05643742","kind":"trial","name":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct05643742/","asOf":"2026-09-16","days":5},{"id":"nct02343042","kind":"trial","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","route":"/trials/nct02343042/","asOf":"2026-09-16","days":5},{"id":"nct05256290","kind":"trial","name":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05256290/","asOf":"2026-09-16","days":5},{"id":"nct05422911","kind":"trial","name":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","route":"/trials/nct05422911/","asOf":"2026-09-16","days":5},{"id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/","asOf":"2026-09-16","days":5},{"id":"nct04205227","kind":"trial","name":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","route":"/trials/nct04205227/","asOf":"2026-09-16","days":5},{"id":"nct06140524","kind":"trial","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","route":"/trials/nct06140524/","asOf":"2026-09-16","days":5},{"id":"nct05952024","kind":"trial","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","route":"/trials/nct05952024/","asOf":"2026-09-16","days":5},{"id":"nct06589778","kind":"trial","name":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06589778/","asOf":"2026-09-16","days":5},{"id":"nct06601504","kind":"trial","name":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct06601504/","asOf":"2026-09-16","days":5},{"id":"nct05128825","kind":"trial","name":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05128825/","asOf":"2026-09-16","days":5},{"id":"nct07059221","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","route":"/trials/nct07059221/","asOf":"2026-09-16","days":5},{"id":"nct05446298","kind":"trial","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","route":"/trials/nct05446298/","asOf":"2026-09-16","days":5},{"id":"nct05784688","kind":"trial","name":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","route":"/trials/nct05784688/","asOf":"2026-09-16","days":5},{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","asOf":"2026-09-16","days":5},{"id":"nct06465329","kind":"trial","name":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce","route":"/trials/nct06465329/","asOf":"2026-09-16","days":5},{"id":"nct06535607","kind":"trial","name":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","route":"/trials/nct06535607/","asOf":"2026-09-16","days":5},{"id":"nct06014528","kind":"trial","name":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren","route":"/trials/nct06014528/","asOf":"2026-09-16","days":5},{"id":"nct06463028","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial ","route":"/trials/nct06463028/","asOf":"2026-09-16","days":5},{"id":"nct03970746","kind":"trial","name":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","route":"/trials/nct03970746/","asOf":"2026-09-16","days":5},{"id":"nct04986423","kind":"trial","name":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct04986423/","asOf":"2026-09-16","days":5},{"id":"nct02332668","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","route":"/trials/nct02332668/","asOf":"2026-09-16","days":5},{"id":"nct04152499","kind":"trial","name":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","route":"/trials/nct04152499/","asOf":"2026-09-16","days":5},{"id":"nct07790510","kind":"trial","name":"HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07790510/","asOf":"2026-09-16","days":5},{"id":"nct07084896","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","route":"/trials/nct07084896/","asOf":"2026-09-16","days":5},{"id":"nct05658562","kind":"trial","name":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","route":"/trials/nct05658562/","asOf":"2026-09-16","days":5},{"id":"nct06514027","kind":"trial","name":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","route":"/trials/nct06514027/","asOf":"2026-09-16","days":5},{"id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","route":"/trials/nct07545603/","asOf":"2026-09-16","days":5},{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","route":"/trials/nct01081951/","asOf":"2026-09-16","days":5},{"id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/","asOf":"2026-09-16","days":5},{"id":"nct06134232","kind":"trial","name":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","route":"/trials/nct06134232/","asOf":"2026-09-16","days":5},{"id":"nct02768363","kind":"trial","name":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","route":"/trials/nct02768363/","asOf":"2026-09-16","days":5},{"id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05751798/","asOf":"2026-09-16","days":5},{"id":"nct05482893","kind":"trial","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","route":"/trials/nct05482893/","asOf":"2026-09-16","days":5},{"id":"nct05283226","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck","route":"/trials/nct05283226/","asOf":"2026-09-16","days":5},{"id":"nct05822752","kind":"trial","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","route":"/trials/nct05822752/","asOf":"2026-09-16","days":5},{"id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/","asOf":"2026-09-16","days":5},{"id":"nct07023289","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o","route":"/trials/nct07023289/","asOf":"2026-09-16","days":5},{"id":"nct05775159","kind":"trial","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","route":"/trials/nct05775159/","asOf":"2026-09-16","days":5},{"id":"nct07219459","kind":"trial","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","route":"/trials/nct07219459/","asOf":"2026-09-16","days":5},{"id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct05955391/","asOf":"2026-09-16","days":5},{"id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","route":"/trials/nct07332000/","asOf":"2026-09-16","days":5},{"id":"nct02213926","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","route":"/trials/nct02213926/","asOf":"2026-09-16","days":5},{"id":"nct07287150","kind":"trial","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07287150/","asOf":"2026-09-16","days":5},{"id":"nct04140526","kind":"trial","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","route":"/trials/nct04140526/","asOf":"2026-09-16","days":5},{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/","asOf":"2026-09-16","days":5},{"id":"nct07262619","kind":"trial","name":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic","route":"/trials/nct07262619/","asOf":"2026-09-16","days":5},{"id":"nct06668961","kind":"trial","name":"A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq","route":"/trials/nct06668961/","asOf":"2026-09-16","days":5},{"id":"nct06194656","kind":"trial","name":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06194656/","asOf":"2026-09-16","days":5},{"id":"nct05830123","kind":"trial","name":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","route":"/trials/nct05830123/","asOf":"2026-09-16","days":5},{"id":"nct06512051","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06512051/","asOf":"2026-09-16","days":5},{"id":"nct06550895","kind":"trial","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","route":"/trials/nct06550895/","asOf":"2026-09-16","days":5},{"id":"nct04430738","kind":"trial","name":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","route":"/trials/nct04430738/","asOf":"2026-09-16","days":5},{"id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","route":"/trials/nct04930432/","asOf":"2026-09-16","days":5},{"id":"nct04843098","kind":"trial","name":"Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct04843098/","asOf":"2026-09-16","days":5},{"id":"nct07024784","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","route":"/trials/nct07024784/","asOf":"2026-09-16","days":5},{"id":"nct06769152","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct06769152/","asOf":"2026-09-16","days":5},{"id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/","asOf":"2026-09-16","days":5},{"id":"nct07306624","kind":"trial","name":"Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer","route":"/trials/nct07306624/","asOf":"2026-09-16","days":5},{"id":"nct07081633","kind":"trial","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07081633/","asOf":"2026-09-16","days":5},{"id":"nct06780137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","route":"/trials/nct06780137/","asOf":"2026-09-16","days":5},{"id":"nct07446322","kind":"trial","name":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","route":"/trials/nct07446322/","asOf":"2026-09-16","days":5},{"id":"nct06502977","kind":"trial","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","route":"/trials/nct06502977/","asOf":"2026-09-16","days":5},{"id":"nct03162536","kind":"trial","name":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","route":"/trials/nct03162536/","asOf":"2026-09-16","days":5},{"id":"nct06437522","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06437522/","asOf":"2026-09-16","days":5},{"id":"nct05801029","kind":"trial","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth","route":"/trials/nct05801029/","asOf":"2026-09-16","days":5},{"id":"nct06448754","kind":"trial","name":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","route":"/trials/nct06448754/","asOf":"2026-09-16","days":5},{"id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","route":"/trials/nct07589634/","asOf":"2026-09-16","days":5},{"id":"nct04083599","kind":"trial","name":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","route":"/trials/nct04083599/","asOf":"2026-09-16","days":5},{"id":"nct06785636","kind":"trial","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","route":"/trials/nct06785636/","asOf":"2026-09-16","days":5},{"id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/","asOf":"2026-09-16","days":5},{"id":"nct06946797","kind":"trial","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","route":"/trials/nct06946797/","asOf":"2026-09-16","days":5},{"id":"nct06107413","kind":"trial","name":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese","route":"/trials/nct06107413/","asOf":"2026-09-16","days":5},{"id":"nct07111520","kind":"trial","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","route":"/trials/nct07111520/","asOf":"2026-09-16","days":5},{"id":"nct05423262","kind":"trial","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","route":"/trials/nct05423262/","asOf":"2026-09-16","days":5},{"id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03600441/","asOf":"2026-09-16","days":5},{"id":"nct07054567","kind":"trial","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","route":"/trials/nct07054567/","asOf":"2026-09-16","days":5},{"id":"nct04827953","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C","route":"/trials/nct04827953/","asOf":"2026-09-16","days":5},{"id":"nct03314181","kind":"trial","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","route":"/trials/nct03314181/","asOf":"2026-09-16","days":5},{"id":"nct05887492","kind":"trial","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","route":"/trials/nct05887492/","asOf":"2026-09-16","days":5},{"id":"nct05372354","kind":"trial","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ","route":"/trials/nct05372354/","asOf":"2026-09-16","days":5},{"id":"nct06235229","kind":"trial","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06235229/","asOf":"2026-09-16","days":5},{"id":"nct03069469","kind":"trial","name":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor","route":"/trials/nct03069469/","asOf":"2026-09-16","days":5},{"id":"nct07519772","kind":"trial","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","route":"/trials/nct07519772/","asOf":"2026-09-16","days":5},{"id":"nct06962865","kind":"trial","name":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv","route":"/trials/nct06962865/","asOf":"2026-09-16","days":5},{"id":"nct03228667","kind":"trial","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","route":"/trials/nct03228667/","asOf":"2026-09-16","days":5},{"id":"nct06792695","kind":"trial","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","route":"/trials/nct06792695/","asOf":"2026-09-16","days":5},{"id":"nct07805551","kind":"trial","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07805551/","asOf":"2026-09-16","days":5},{"id":"nct04590326","kind":"trial","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","route":"/trials/nct04590326/","asOf":"2026-09-16","days":5},{"id":"nct07479485","kind":"trial","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","route":"/trials/nct07479485/","asOf":"2026-09-16","days":5},{"id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct07659782/","asOf":"2026-09-16","days":5},{"id":"nct04414475","kind":"trial","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","route":"/trials/nct04414475/","asOf":"2026-09-16","days":5},{"id":"nct07079631","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3","route":"/trials/nct07079631/","asOf":"2026-09-16","days":5},{"id":"nct07253142","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","route":"/trials/nct07253142/","asOf":"2026-09-16","days":5},{"id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","route":"/trials/nct06690775/","asOf":"2026-09-16","days":5},{"id":"nct07049926","kind":"trial","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","route":"/trials/nct07049926/","asOf":"2026-09-16","days":5},{"id":"nct05932212","kind":"trial","name":"AK104 for Recurrent or Metastatic Vulvar Cancer","route":"/trials/nct05932212/","asOf":"2026-09-16","days":5},{"id":"nct06114511","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","route":"/trials/nct06114511/","asOf":"2026-09-16","days":5},{"id":"nct07654400","kind":"trial","name":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07654400/","asOf":"2026-09-16","days":5},{"id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","asOf":"2026-09-16","days":5},{"id":"nct05633667","kind":"trial","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","route":"/trials/nct05633667/","asOf":"2026-09-16","days":5},{"id":"nct07586124","kind":"trial","name":"Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma","route":"/trials/nct07586124/","asOf":"2026-09-16","days":5},{"id":"nct05009069","kind":"trial","name":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","route":"/trials/nct05009069/","asOf":"2026-09-16","days":5},{"id":"nct06682988","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar","route":"/trials/nct06682988/","asOf":"2026-09-16","days":5},{"id":"nct04501120","kind":"trial","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","route":"/trials/nct04501120/","asOf":"2026-09-16","days":5},{"id":"nct06101134","kind":"trial","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed","route":"/trials/nct06101134/","asOf":"2026-09-16","days":5},{"id":"nct06829771","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","route":"/trials/nct06829771/","asOf":"2026-09-16","days":5},{"id":"nct05846867","kind":"trial","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","route":"/trials/nct05846867/","asOf":"2026-09-16","days":5},{"id":"nct06646055","kind":"trial","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct06646055/","asOf":"2026-09-16","days":5},{"id":"nct05925530","kind":"trial","name":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,","route":"/trials/nct05925530/","asOf":"2026-09-16","days":5},{"id":"nct03407144","kind":"trial","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","route":"/trials/nct03407144/","asOf":"2026-09-16","days":5},{"id":"nct06820463","kind":"trial","name":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,","route":"/trials/nct06820463/","asOf":"2026-09-16","days":5},{"id":"nct07230106","kind":"trial","name":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","route":"/trials/nct07230106/","asOf":"2026-09-16","days":5},{"id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07284758/","asOf":"2026-09-16","days":5},{"id":"nct04077723","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","route":"/trials/nct04077723/","asOf":"2026-09-16","days":5},{"id":"nct06099782","kind":"trial","name":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol","route":"/trials/nct06099782/","asOf":"2026-09-16","days":5},{"id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07098988/","asOf":"2026-09-16","days":5},{"id":"nct06797297","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat","route":"/trials/nct06797297/","asOf":"2026-09-16","days":5},{"id":"nct05970497","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05970497/","asOf":"2026-09-16","days":5},{"id":"nct04663347","kind":"trial","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","route":"/trials/nct04663347/","asOf":"2026-09-16","days":5},{"id":"nct03564340","kind":"trial","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","route":"/trials/nct03564340/","asOf":"2026-09-16","days":5},{"id":"nct06106308","kind":"trial","name":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo","route":"/trials/nct06106308/","asOf":"2026-09-16","days":5},{"id":"nct04745689","kind":"trial","name":"Study of AZD2811 + Durvalumab in ES-SCLC","route":"/trials/nct04745689/","asOf":"2026-09-16","days":5},{"id":"nct05676931","kind":"trial","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","route":"/trials/nct05676931/","asOf":"2026-09-16","days":5},{"id":"nct06689163","kind":"trial","name":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","route":"/trials/nct06689163/","asOf":"2026-09-16","days":5},{"id":"nct07486089","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","route":"/trials/nct07486089/","asOf":"2026-09-16","days":5},{"id":"nct04050436","kind":"trial","name":"Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer","route":"/trials/nct04050436/","asOf":"2026-09-16","days":5},{"id":"nct02628067","kind":"trial","name":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","route":"/trials/nct02628067/","asOf":"2026-09-16","days":5},{"id":"nct07227012","kind":"trial","name":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a","route":"/trials/nct07227012/","asOf":"2026-09-16","days":5},{"id":"nct04133636","kind":"trial","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","route":"/trials/nct04133636/","asOf":"2026-09-16","days":5},{"id":"nct03611868","kind":"trial","name":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","route":"/trials/nct03611868/","asOf":"2026-09-16","days":5},{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/","asOf":"2026-09-16","days":5},{"id":"nct06172478","kind":"trial","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06172478/","asOf":"2026-09-16","days":5},{"id":"nct05880706","kind":"trial","name":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ","route":"/trials/nct05880706/","asOf":"2026-09-16","days":5},{"id":"nct06606847","kind":"trial","name":"A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ","route":"/trials/nct06606847/","asOf":"2026-09-16","days":5},{"id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/","asOf":"2026-09-16","days":5},{"id":"nct06090539","kind":"trial","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","route":"/trials/nct06090539/","asOf":"2026-09-16","days":5},{"id":"nct07192614","kind":"trial","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","route":"/trials/nct07192614/","asOf":"2026-09-16","days":5},{"id":"nct04895709","kind":"trial","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct04895709/","asOf":"2026-09-16","days":5},{"id":"nct05112991","kind":"trial","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","route":"/trials/nct05112991/","asOf":"2026-09-16","days":5},{"id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","route":"/trials/nct04644289/","asOf":"2026-09-16","days":5},{"id":"nct06697184","kind":"trial","name":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","route":"/trials/nct06697184/","asOf":"2026-09-16","days":5},{"id":"nct06344052","kind":"trial","name":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","route":"/trials/nct06344052/","asOf":"2026-09-16","days":5},{"id":"nct07288177","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","route":"/trials/nct07288177/","asOf":"2026-09-16","days":5},{"id":"nct04440735","kind":"trial","name":"A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors","route":"/trials/nct04440735/","asOf":"2026-09-16","days":5},{"id":"nct05997017","kind":"trial","name":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","route":"/trials/nct05997017/","asOf":"2026-09-16","days":5},{"id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","route":"/trials/nct05583617/","asOf":"2026-09-16","days":5},{"id":"nct05956587","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other","route":"/trials/nct05956587/","asOf":"2026-09-16","days":5},{"id":"nct05601752","kind":"trial","name":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","route":"/trials/nct05601752/","asOf":"2026-09-16","days":5},{"id":"nct06030258","kind":"trial","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","route":"/trials/nct06030258/","asOf":"2026-09-16","days":5},{"id":"nct06693336","kind":"trial","name":"An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer","route":"/trials/nct06693336/","asOf":"2026-09-16","days":5},{"id":"nct04586426","kind":"trial","name":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct04586426/","asOf":"2026-09-16","days":5},{"id":"nct05219500","kind":"trial","name":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).","route":"/trials/nct05219500/","asOf":"2026-09-16","days":5},{"id":"nct04752826","kind":"trial","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","route":"/trials/nct04752826/","asOf":"2026-09-16","days":5},{"id":"nct06598007","kind":"trial","name":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","route":"/trials/nct06598007/","asOf":"2026-09-16","days":5},{"id":"nct06948448","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","route":"/trials/nct06948448/","asOf":"2026-09-16","days":5},{"id":"nct06679985","kind":"trial","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","route":"/trials/nct06679985/","asOf":"2026-09-16","days":5},{"id":"nct04542824","kind":"trial","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","route":"/trials/nct04542824/","asOf":"2026-09-16","days":5},{"id":"nct05593094","kind":"trial","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","route":"/trials/nct05593094/","asOf":"2026-09-16","days":5},{"id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/","asOf":"2026-09-16","days":5},{"id":"nct06161974","kind":"trial","name":"Study of Olutasidenib and Temozolomide in HGG","route":"/trials/nct06161974/","asOf":"2026-09-16","days":5},{"id":"nct05338931","kind":"trial","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","route":"/trials/nct05338931/","asOf":"2026-09-16","days":5},{"id":"nct04895722","kind":"trial","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","route":"/trials/nct04895722/","asOf":"2026-09-16","days":5},{"id":"nct02960022","kind":"trial","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","route":"/trials/nct02960022/","asOf":"2026-09-16","days":5},{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/","asOf":"2026-09-16","days":5},{"id":"nct06480565","kind":"trial","name":"A Phase 1/2 Trial of ADI-270 in ccRCC","route":"/trials/nct06480565/","asOf":"2026-09-16","days":5},{"id":"nct04792489","kind":"trial","name":"DALY II USA/ MB-CART2019.1 for DLBCL","route":"/trials/nct04792489/","asOf":"2026-09-16","days":5},{"id":"nct07049055","kind":"trial","name":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","route":"/trials/nct07049055/","asOf":"2026-09-16","days":5},{"id":"nct07659795","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","route":"/trials/nct07659795/","asOf":"2026-09-16","days":5},{"id":"nct06463665","kind":"trial","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","route":"/trials/nct06463665/","asOf":"2026-09-16","days":5},{"id":"nct07325136","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","route":"/trials/nct07325136/","asOf":"2026-09-16","days":5},{"id":"nct06873763","kind":"trial","name":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","route":"/trials/nct06873763/","asOf":"2026-09-16","days":5},{"id":"nct03989414","kind":"trial","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","route":"/trials/nct03989414/","asOf":"2026-09-16","days":5},{"id":"nct07680764","kind":"trial","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","route":"/trials/nct07680764/","asOf":"2026-09-16","days":5},{"id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/","asOf":"2026-09-16","days":5},{"id":"nct06731907","kind":"trial","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","route":"/trials/nct06731907/","asOf":"2026-09-16","days":5},{"id":"nct06784648","kind":"trial","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","route":"/trials/nct06784648/","asOf":"2026-09-16","days":5},{"id":"nct04068597","kind":"trial","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","route":"/trials/nct04068597/","asOf":"2026-09-16","days":5},{"id":"nct05990803","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","route":"/trials/nct05990803/","asOf":"2026-09-16","days":5},{"id":"nct05789082","kind":"trial","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","route":"/trials/nct05789082/","asOf":"2026-09-16","days":5},{"id":"nct07291076","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","route":"/trials/nct07291076/","asOf":"2026-09-16","days":5},{"id":"nct07189065","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","route":"/trials/nct07189065/","asOf":"2026-09-16","days":5},{"id":"nct07235293","kind":"trial","name":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","route":"/trials/nct07235293/","asOf":"2026-09-16","days":5},{"id":"nct05978284","kind":"trial","name":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct05978284/","asOf":"2026-09-16","days":5},{"id":"nct06253663","kind":"trial","name":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L","route":"/trials/nct06253663/","asOf":"2026-09-16","days":5},{"id":"nct03634540","kind":"trial","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","route":"/trials/nct03634540/","asOf":"2026-09-16","days":5},{"id":"nct06566547","kind":"trial","name":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06566547/","asOf":"2026-09-16","days":5},{"id":"nct05605535","kind":"trial","name":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","route":"/trials/nct05605535/","asOf":"2026-09-16","days":5},{"id":"nct07005336","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr","route":"/trials/nct07005336/","asOf":"2026-09-16","days":5},{"id":"nct05421663","kind":"trial","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05421663/","asOf":"2026-09-16","days":5},{"id":"nct07071714","kind":"trial","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","route":"/trials/nct07071714/","asOf":"2026-09-16","days":5},{"id":"nct05557591","kind":"trial","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","route":"/trials/nct05557591/","asOf":"2026-09-16","days":5},{"id":"nct05951959","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","route":"/trials/nct05951959/","asOf":"2026-09-16","days":5},{"id":"nct05608044","kind":"trial","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","route":"/trials/nct05608044/","asOf":"2026-09-16","days":5},{"id":"nct06699836","kind":"trial","name":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen","route":"/trials/nct06699836/","asOf":"2026-09-16","days":5},{"id":"nct06219941","kind":"trial","name":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","route":"/trials/nct06219941/","asOf":"2026-09-16","days":5},{"id":"nct04291105","kind":"trial","name":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients","route":"/trials/nct04291105/","asOf":"2026-09-16","days":5},{"id":"nct06922591","kind":"trial","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","route":"/trials/nct06922591/","asOf":"2026-09-16","days":5},{"id":"nct04068610","kind":"trial","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","route":"/trials/nct04068610/","asOf":"2026-09-16","days":5},{"id":"nct06284590","kind":"trial","name":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients","route":"/trials/nct06284590/","asOf":"2026-09-16","days":5},{"id":"nct05458297","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-","route":"/trials/nct05458297/","asOf":"2026-09-16","days":5},{"id":"nct05320588","kind":"trial","name":"A Study in Patients With Advanced Cancers","route":"/trials/nct05320588/","asOf":"2026-09-16","days":5},{"id":"nct05904379","kind":"trial","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","route":"/trials/nct05904379/","asOf":"2026-09-16","days":5},{"id":"nct07133750","kind":"trial","name":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07133750/","asOf":"2026-09-16","days":5},{"id":"nct03960840","kind":"trial","name":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","route":"/trials/nct03960840/","asOf":"2026-09-16","days":5},{"id":"nct07255664","kind":"trial","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","route":"/trials/nct07255664/","asOf":"2026-09-16","days":5},{"id":"nct05739981","kind":"trial","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05739981/","asOf":"2026-09-16","days":5},{"id":"nct07387471","kind":"trial","name":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu","route":"/trials/nct07387471/","asOf":"2026-09-16","days":5},{"id":"nct06521567","kind":"trial","name":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","route":"/trials/nct06521567/","asOf":"2026-09-16","days":5},{"id":"nct05086692","kind":"trial","name":"A Beta-only IL-2 ImmunoTherapY Study","route":"/trials/nct05086692/","asOf":"2026-09-16","days":5},{"id":"nct07124936","kind":"trial","name":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","route":"/trials/nct07124936/","asOf":"2026-09-16","days":5},{"id":"nct07052253","kind":"trial","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","route":"/trials/nct07052253/","asOf":"2026-09-16","days":5},{"id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","route":"/trials/nct07181161/","asOf":"2026-09-16","days":5},{"id":"nct06522828","kind":"trial","name":"A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","route":"/trials/nct06522828/","asOf":"2026-09-16","days":5},{"id":"nct05853575","kind":"trial","name":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","route":"/trials/nct05853575/","asOf":"2026-09-16","days":5},{"id":"nct03775486","kind":"trial","name":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","route":"/trials/nct03775486/","asOf":"2026-09-16","days":5},{"id":"nct07169994","kind":"trial","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07169994/","asOf":"2026-09-16","days":5},{"id":"nct03709680","kind":"trial","name":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","route":"/trials/nct03709680/","asOf":"2026-09-16","days":5},{"id":"nct07476287","kind":"trial","name":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed","route":"/trials/nct07476287/","asOf":"2026-09-16","days":5},{"id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/","asOf":"2026-09-16","days":5},{"id":"nct06943820","kind":"trial","name":"AK129 Combination Therapy for Advanced Solid Tumors","route":"/trials/nct06943820/","asOf":"2026-09-16","days":5},{"id":"nct06577025","kind":"trial","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","route":"/trials/nct06577025/","asOf":"2026-09-16","days":5},{"id":"nct04701476","kind":"trial","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","route":"/trials/nct04701476/","asOf":"2026-09-16","days":5},{"id":"nct07162181","kind":"trial","name":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","route":"/trials/nct07162181/","asOf":"2026-09-16","days":5},{"id":"nct04396821","kind":"trial","name":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04396821/","asOf":"2026-09-16","days":5},{"id":"nct07807163","kind":"trial","name":"A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC","route":"/trials/nct07807163/","asOf":"2026-09-16","days":5},{"id":"nct03897881","kind":"trial","name":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN","route":"/trials/nct03897881/","asOf":"2026-09-16","days":5},{"id":"nct07255404","kind":"trial","name":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N","route":"/trials/nct07255404/","asOf":"2026-09-16","days":5},{"id":"nct05950165","kind":"trial","name":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly","route":"/trials/nct05950165/","asOf":"2026-09-16","days":5},{"id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","route":"/trials/nct07296809/","asOf":"2026-09-16","days":5},{"id":"nct05919264","kind":"trial","name":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05919264/","asOf":"2026-09-16","days":5},{"id":"nct06283719","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P","route":"/trials/nct06283719/","asOf":"2026-09-16","days":5},{"id":"nct06241846","kind":"trial","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","route":"/trials/nct06241846/","asOf":"2026-09-16","days":5},{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","asOf":"2026-09-16","days":5},{"id":"nct06526793","kind":"trial","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","route":"/trials/nct06526793/","asOf":"2026-09-16","days":5},{"id":"nct05716087","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma","route":"/trials/nct05716087/","asOf":"2026-09-16","days":5},{"id":"nct05712902","kind":"trial","name":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","route":"/trials/nct05712902/","asOf":"2026-09-16","days":5},{"id":"nct06365853","kind":"trial","name":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit","route":"/trials/nct06365853/","asOf":"2026-09-16","days":5},{"id":"nct05651022","kind":"trial","name":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","route":"/trials/nct05651022/","asOf":"2026-09-16","days":5},{"id":"nct05471843","kind":"trial","name":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct05471843/","asOf":"2026-09-16","days":5},{"id":"nct05413850","kind":"trial","name":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","route":"/trials/nct05413850/","asOf":"2026-09-16","days":5},{"id":"nct04421820","kind":"trial","name":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","route":"/trials/nct04421820/","asOf":"2026-09-16","days":5},{"id":"nct07227415","kind":"trial","name":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With ","route":"/trials/nct07227415/","asOf":"2026-09-16","days":5},{"id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/","asOf":"2026-09-16","days":5},{"id":"nct07565285","kind":"trial","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","route":"/trials/nct07565285/","asOf":"2026-09-16","days":5},{"id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/","asOf":"2026-09-16","days":5},{"id":"nct04585750","kind":"trial","name":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","route":"/trials/nct04585750/","asOf":"2026-09-16","days":5},{"id":"nct05367440","kind":"trial","name":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","route":"/trials/nct05367440/","asOf":"2026-09-16","days":5},{"id":"nct07269782","kind":"trial","name":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","route":"/trials/nct07269782/","asOf":"2026-09-16","days":5},{"id":"nct07239596","kind":"trial","name":"Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","route":"/trials/nct07239596/","asOf":"2026-09-16","days":5},{"id":"nct07609862","kind":"trial","name":"A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","route":"/trials/nct07609862/","asOf":"2026-09-16","days":5},{"id":"nct05351788","kind":"trial","name":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","route":"/trials/nct05351788/","asOf":"2026-09-16","days":5},{"id":"nct06991556","kind":"trial","name":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc","route":"/trials/nct06991556/","asOf":"2026-09-16","days":5},{"id":"nct06006169","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor","route":"/trials/nct06006169/","asOf":"2026-09-16","days":5},{"id":"nct06644768","kind":"trial","name":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","route":"/trials/nct06644768/","asOf":"2026-09-16","days":5},{"id":"nct03785249","kind":"trial","name":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","route":"/trials/nct03785249/","asOf":"2026-09-16","days":5},{"id":"nct04302025","kind":"trial","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04302025/","asOf":"2026-09-16","days":5},{"id":"nct06081920","kind":"trial","name":"A Study of IBI363 in Subjects With Advanced Melanoma","route":"/trials/nct06081920/","asOf":"2026-09-16","days":5},{"id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07452224/","asOf":"2026-09-16","days":5},{"id":"nct07288203","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","route":"/trials/nct07288203/","asOf":"2026-09-16","days":5},{"id":"nct05280470","kind":"trial","name":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05280470/","asOf":"2026-09-16","days":5},{"id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","route":"/trials/nct07745361/","asOf":"2026-09-16","days":5},{"id":"nct06915246","kind":"trial","name":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","route":"/trials/nct06915246/","asOf":"2026-09-16","days":5},{"id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/","asOf":"2026-09-16","days":5},{"id":"nct05535244","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi","route":"/trials/nct05535244/","asOf":"2026-09-16","days":5},{"id":"nct05533775","kind":"trial","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","route":"/trials/nct05533775/","asOf":"2026-09-16","days":5},{"id":"nct03915184","kind":"trial","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","route":"/trials/nct03915184/","asOf":"2026-09-16","days":5},{"id":"nct05201248","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","route":"/trials/nct05201248/","asOf":"2026-09-16","days":5},{"id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","route":"/trials/nct07589543/","asOf":"2026-09-16","days":5},{"id":"nct05551507","kind":"trial","name":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","route":"/trials/nct05551507/","asOf":"2026-09-16","days":5},{"id":"nct05451810","kind":"trial","name":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr","route":"/trials/nct05451810/","asOf":"2026-09-16","days":5},{"id":"nct06265025","kind":"trial","name":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","route":"/trials/nct06265025/","asOf":"2026-09-16","days":5},{"id":"nct07221474","kind":"trial","name":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","route":"/trials/nct07221474/","asOf":"2026-09-16","days":5},{"id":"nct05585320","kind":"trial","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct05585320/","asOf":"2026-09-16","days":5},{"id":"nct07098338","kind":"trial","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07098338/","asOf":"2026-09-16","days":5},{"id":"nct05024214","kind":"trial","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","route":"/trials/nct05024214/","asOf":"2026-09-16","days":5},{"id":"nct05431270","kind":"trial","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","route":"/trials/nct05431270/","asOf":"2026-09-16","days":5},{"id":"nct03974022","kind":"trial","name":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","route":"/trials/nct03974022/","asOf":"2026-09-16","days":5},{"id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","route":"/trials/nct07288879/","asOf":"2026-09-16","days":5},{"id":"nct07326566","kind":"trial","name":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","route":"/trials/nct07326566/","asOf":"2026-09-16","days":5},{"id":"nct07450599","kind":"trial","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","route":"/trials/nct07450599/","asOf":"2026-09-16","days":5},{"id":"nct06988488","kind":"trial","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","route":"/trials/nct06988488/","asOf":"2026-09-16","days":5},{"id":"nct04787042","kind":"trial","name":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","route":"/trials/nct04787042/","asOf":"2026-09-16","days":5},{"id":"nct06568094","kind":"trial","name":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","route":"/trials/nct06568094/","asOf":"2026-09-16","days":5},{"id":"nct07432295","kind":"trial","name":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","route":"/trials/nct07432295/","asOf":"2026-09-16","days":5},{"id":"nct05609370","kind":"trial","name":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ","route":"/trials/nct05609370/","asOf":"2026-09-16","days":5},{"id":"nct07229729","kind":"trial","name":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07229729/","asOf":"2026-09-16","days":5},{"id":"nct06362369","kind":"trial","name":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","route":"/trials/nct06362369/","asOf":"2026-09-16","days":5},{"id":"nct02711553","kind":"trial","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct02711553/","asOf":"2026-09-16","days":5},{"id":"nct04924075","kind":"trial","name":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","route":"/trials/nct04924075/","asOf":"2026-09-16","days":5},{"id":"nct05949606","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05949606/","asOf":"2026-09-16","days":5},{"id":"nct06568939","kind":"trial","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","route":"/trials/nct06568939/","asOf":"2026-09-16","days":5},{"id":"nct05194995","kind":"trial","name":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","route":"/trials/nct05194995/","asOf":"2026-09-16","days":5},{"id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","route":"/trials/nct06087653/","asOf":"2026-09-16","days":5},{"id":"nct06378177","kind":"trial","name":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","route":"/trials/nct06378177/","asOf":"2026-09-16","days":5},{"id":"nct07483554","kind":"trial","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","route":"/trials/nct07483554/","asOf":"2026-09-16","days":5},{"id":"nct06445400","kind":"trial","name":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive ","route":"/trials/nct06445400/","asOf":"2026-09-16","days":5},{"id":"nct04920617","kind":"trial","name":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp","route":"/trials/nct04920617/","asOf":"2026-09-16","days":5},{"id":"nct05456685","kind":"trial","name":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov","route":"/trials/nct05456685/","asOf":"2026-09-16","days":5},{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/","asOf":"2026-09-16","days":5},{"id":"nct04616443","kind":"trial","name":"OH2 Injection in Combination With HX008 for Melanoma.","route":"/trials/nct04616443/","asOf":"2026-09-16","days":5},{"id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","route":"/trials/nct07510815/","asOf":"2026-09-16","days":5},{"id":"nct07170644","kind":"trial","name":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","route":"/trials/nct07170644/","asOf":"2026-09-16","days":5},{"id":"nct05620134","kind":"trial","name":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct05620134/","asOf":"2026-09-16","days":5},{"id":"nct05635708","kind":"trial","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","route":"/trials/nct05635708/","asOf":"2026-09-16","days":5},{"id":"nct05913089","kind":"trial","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","route":"/trials/nct05913089/","asOf":"2026-09-16","days":5},{"id":"nct07293351","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","route":"/trials/nct07293351/","asOf":"2026-09-16","days":5},{"id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/","asOf":"2026-09-16","days":5},{"id":"nct07123454","kind":"trial","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","route":"/trials/nct07123454/","asOf":"2026-09-16","days":5},{"id":"nct04675294","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","route":"/trials/nct04675294/","asOf":"2026-09-16","days":5},{"id":"nct03936153","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct03936153/","asOf":"2026-09-16","days":5},{"id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","route":"/trials/nct07680439/","asOf":"2026-09-16","days":5},{"id":"nct06162572","kind":"trial","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06162572/","asOf":"2026-09-16","days":5},{"id":"nct04471727","kind":"trial","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","route":"/trials/nct04471727/","asOf":"2026-09-16","days":5},{"id":"nct06434610","kind":"trial","name":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","route":"/trials/nct06434610/","asOf":"2026-09-16","days":5},{"id":"nct02180711","kind":"trial","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","route":"/trials/nct02180711/","asOf":"2026-09-16","days":5},{"id":"nct07150091","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","route":"/trials/nct07150091/","asOf":"2026-09-16","days":5},{"id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06996782/","asOf":"2026-09-16","days":5},{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/","asOf":"2026-09-16","days":5},{"id":"nct06496490","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","route":"/trials/nct06496490/","asOf":"2026-09-16","days":5},{"id":"nct06706076","kind":"trial","name":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","route":"/trials/nct06706076/","asOf":"2026-09-16","days":5},{"id":"nct05607420","kind":"trial","name":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05607420/","asOf":"2026-09-16","days":5},{"id":"nct06161441","kind":"trial","name":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth","route":"/trials/nct06161441/","asOf":"2026-09-16","days":5},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","asOf":"2026-09-16","days":5},{"id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","route":"/trials/nct05098132/","asOf":"2026-09-16","days":5},{"id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/","asOf":"2026-09-16","days":5},{"id":"nct05440708","kind":"trial","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05440708/","asOf":"2026-09-16","days":5},{"id":"nct06281678","kind":"trial","name":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","route":"/trials/nct06281678/","asOf":"2026-09-16","days":5},{"id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","route":"/trials/nct07082686/","asOf":"2026-09-16","days":5},{"id":"nct04639219","kind":"trial","name":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","route":"/trials/nct04639219/","asOf":"2026-09-16","days":5},{"id":"nct06297226","kind":"trial","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/","asOf":"2026-09-16","days":5},{"id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","route":"/trials/nct07617753/","asOf":"2026-09-16","days":5},{"id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","route":"/trials/nct07079475/","asOf":"2026-09-16","days":5},{"id":"nct06534437","kind":"trial","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","route":"/trials/nct06534437/","asOf":"2026-09-16","days":5},{"id":"nct05877430","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","route":"/trials/nct05877430/","asOf":"2026-09-16","days":5},{"id":"nct04782687","kind":"trial","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","route":"/trials/nct04782687/","asOf":"2026-09-16","days":5},{"id":"nct05661955","kind":"trial","name":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants","route":"/trials/nct05661955/","asOf":"2026-09-16","days":5},{"id":"nct03907852","kind":"trial","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","route":"/trials/nct03907852/","asOf":"2026-09-16","days":5},{"id":"nct06726148","kind":"trial","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","route":"/trials/nct06726148/","asOf":"2026-09-16","days":5},{"id":"nct06560112","kind":"trial","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","route":"/trials/nct06560112/","asOf":"2026-09-16","days":5},{"id":"nct04280081","kind":"trial","name":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a","route":"/trials/nct04280081/","asOf":"2026-09-16","days":5},{"id":"nct03393884","kind":"trial","name":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)","route":"/trials/nct03393884/","asOf":"2026-09-16","days":5},{"id":"nct06500884","kind":"trial","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","route":"/trials/nct06500884/","asOf":"2026-09-16","days":5},{"id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/","asOf":"2026-09-16","days":5},{"id":"nct03526835","kind":"trial","name":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","route":"/trials/nct03526835/","asOf":"2026-09-16","days":5},{"id":"nct04728893","kind":"trial","name":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","route":"/trials/nct04728893/","asOf":"2026-09-16","days":5},{"id":"nct07264816","kind":"trial","name":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS","route":"/trials/nct07264816/","asOf":"2026-09-16","days":5},{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","asOf":"2026-09-16","days":5},{"id":"nct05924841","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct05924841/","asOf":"2026-09-16","days":5},{"id":"nct05186753","kind":"trial","name":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","route":"/trials/nct05186753/","asOf":"2026-09-16","days":5},{"id":"nct07149857","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","route":"/trials/nct07149857/","asOf":"2026-09-16","days":5},{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/","asOf":"2026-09-16","days":5},{"id":"nct05565417","kind":"trial","name":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05565417/","asOf":"2026-09-16","days":5},{"id":"nct06589440","kind":"trial","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","route":"/trials/nct06589440/","asOf":"2026-09-16","days":5},{"id":"nct05669482","kind":"trial","name":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","route":"/trials/nct05669482/","asOf":"2026-09-16","days":5},{"id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","asOf":"2026-09-16","days":5},{"id":"nct04246086","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","route":"/trials/nct04246086/","asOf":"2026-09-16","days":5},{"id":"nct04657068","kind":"trial","name":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","route":"/trials/nct04657068/","asOf":"2026-09-16","days":5},{"id":"nct07005154","kind":"trial","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","route":"/trials/nct07005154/","asOf":"2026-09-16","days":5},{"id":"nct07246863","kind":"trial","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07246863/","asOf":"2026-09-16","days":5},{"id":"nct05468697","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6","route":"/trials/nct05468697/","asOf":"2026-09-16","days":5},{"id":"nct03916627","kind":"trial","name":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","route":"/trials/nct03916627/","asOf":"2026-09-16","days":5},{"id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/","asOf":"2026-09-16","days":5},{"id":"nct07042802","kind":"trial","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","route":"/trials/nct07042802/","asOf":"2026-09-16","days":5},{"id":"nct04868877","kind":"trial","name":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina","route":"/trials/nct04868877/","asOf":"2026-09-16","days":5},{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/","asOf":"2026-09-16","days":5},{"id":"nct07244705","kind":"trial","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","route":"/trials/nct07244705/","asOf":"2026-09-16","days":5},{"id":"nct06190951","kind":"trial","name":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","route":"/trials/nct06190951/","asOf":"2026-09-16","days":5},{"id":"nct04733183","kind":"trial","name":"Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma","route":"/trials/nct04733183/","asOf":"2026-09-16","days":5},{"id":"nct05734066","kind":"trial","name":"Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma","route":"/trials/nct05734066/","asOf":"2026-09-16","days":5},{"id":"nct07594106","kind":"trial","name":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate ","route":"/trials/nct07594106/","asOf":"2026-09-16","days":5},{"id":"nct06115135","kind":"trial","name":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06115135/","asOf":"2026-09-16","days":5},{"id":"nct07059650","kind":"trial","name":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","route":"/trials/nct07059650/","asOf":"2026-09-16","days":5},{"id":"nct05735080","kind":"trial","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","route":"/trials/nct05735080/","asOf":"2026-09-16","days":5},{"id":"nct07175220","kind":"trial","name":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","route":"/trials/nct07175220/","asOf":"2026-09-16","days":5},{"id":"nct07336446","kind":"trial","name":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","route":"/trials/nct07336446/","asOf":"2026-09-16","days":5},{"id":"nct04180371","kind":"trial","name":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","route":"/trials/nct04180371/","asOf":"2026-09-16","days":5},{"id":"nct06792435","kind":"trial","name":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","route":"/trials/nct06792435/","asOf":"2026-09-16","days":5},{"id":"nct05144698","kind":"trial","name":"RAPA-201 Therapy of Solid Tumors","route":"/trials/nct05144698/","asOf":"2026-09-16","days":5},{"id":"nct07521852","kind":"trial","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","route":"/trials/nct07521852/","asOf":"2026-09-16","days":5},{"id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/","asOf":"2026-09-16","days":5},{"id":"nct06754930","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","route":"/trials/nct06754930/","asOf":"2026-09-16","days":5},{"id":"nct06008054","kind":"trial","name":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric ","route":"/trials/nct06008054/","asOf":"2026-09-16","days":5},{"id":"nct06727565","kind":"trial","name":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst","route":"/trials/nct06727565/","asOf":"2026-09-16","days":5},{"id":"nct06892522","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","route":"/trials/nct06892522/","asOf":"2026-09-16","days":5},{"id":"nct02861573","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","route":"/trials/nct02861573/","asOf":"2026-09-16","days":5},{"id":"nct04938583","kind":"trial","name":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct04938583/","asOf":"2026-09-16","days":5},{"id":"nct06427941","kind":"trial","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","route":"/trials/nct06427941/","asOf":"2026-09-16","days":5},{"id":"nct07051486","kind":"trial","name":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","route":"/trials/nct07051486/","asOf":"2026-09-16","days":5},{"id":"nct06014190","kind":"trial","name":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","route":"/trials/nct06014190/","asOf":"2026-09-16","days":5},{"id":"nct05394103","kind":"trial","name":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","route":"/trials/nct05394103/","asOf":"2026-09-16","days":5},{"id":"nct07617805","kind":"trial","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","route":"/trials/nct07617805/","asOf":"2026-09-16","days":5},{"id":"nct04557449","kind":"trial","name":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","route":"/trials/nct04557449/","asOf":"2026-09-16","days":5},{"id":"nct06343064","kind":"trial","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","route":"/trials/nct06343064/","asOf":"2026-09-16","days":5},{"id":"nct03647163","kind":"trial","name":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","route":"/trials/nct03647163/","asOf":"2026-09-16","days":5},{"id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/","asOf":"2026-09-16","days":5},{"id":"nct07227298","kind":"trial","name":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","route":"/trials/nct07227298/","asOf":"2026-09-16","days":5},{"id":"nct06848699","kind":"trial","name":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06848699/","asOf":"2026-09-16","days":5},{"id":"nct05805501","kind":"trial","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","route":"/trials/nct05805501/","asOf":"2026-09-16","days":5},{"id":"nct05126719","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05126719/","asOf":"2026-09-16","days":5},{"id":"nct05067140","kind":"trial","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","route":"/trials/nct05067140/","asOf":"2026-09-16","days":5},{"id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","route":"/trials/nct06956690/","asOf":"2026-09-16","days":5},{"id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","asOf":"2026-09-16","days":5},{"id":"nct05318573","kind":"trial","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","route":"/trials/nct05318573/","asOf":"2026-09-16","days":5},{"id":"nct05816252","kind":"trial","name":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-","route":"/trials/nct05816252/","asOf":"2026-09-16","days":5},{"id":"nct07287917","kind":"trial","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","route":"/trials/nct07287917/","asOf":"2026-09-16","days":5},{"id":"nct06307431","kind":"trial","name":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","route":"/trials/nct06307431/","asOf":"2026-09-16","days":5},{"id":"nct03932331","kind":"trial","name":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign","route":"/trials/nct03932331/","asOf":"2026-09-16","days":5},{"id":"nct05442060","kind":"trial","name":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N","route":"/trials/nct05442060/","asOf":"2026-09-16","days":5},{"id":"nct06096779","kind":"trial","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","route":"/trials/nct06096779/","asOf":"2026-09-16","days":5},{"id":"nct07474727","kind":"trial","name":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","route":"/trials/nct07474727/","asOf":"2026-09-16","days":5},{"id":"nct06225843","kind":"trial","name":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","route":"/trials/nct06225843/","asOf":"2026-09-16","days":5},{"id":"nct03947385","kind":"trial","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","route":"/trials/nct03947385/","asOf":"2026-09-16","days":5},{"id":"nct06607458","kind":"trial","name":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme","route":"/trials/nct06607458/","asOf":"2026-09-16","days":5},{"id":"nct04988555","kind":"trial","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","route":"/trials/nct04988555/","asOf":"2026-09-16","days":5},{"id":"nct05103358","kind":"trial","name":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","route":"/trials/nct05103358/","asOf":"2026-09-16","days":5},{"id":"nct06437509","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct06437509/","asOf":"2026-09-16","days":5},{"id":"nct04553133","kind":"trial","name":"PF-07104091 as a Single Agent and in Combination Therapy","route":"/trials/nct04553133/","asOf":"2026-09-16","days":5},{"id":"nct06890338","kind":"trial","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","route":"/trials/nct06890338/","asOf":"2026-09-16","days":5},{"id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","route":"/trials/nct04644068/","asOf":"2026-09-16","days":5},{"id":"nct03767348","kind":"trial","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","route":"/trials/nct03767348/","asOf":"2026-09-16","days":5},{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/","asOf":"2026-09-16","days":5},{"id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","route":"/trials/nct05271318/","asOf":"2026-09-16","days":5},{"id":"nct07044908","kind":"trial","name":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","route":"/trials/nct07044908/","asOf":"2026-09-16","days":5},{"id":"nct06953960","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","route":"/trials/nct06953960/","asOf":"2026-09-16","days":5},{"id":"nct05267626","kind":"trial","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","route":"/trials/nct05267626/","asOf":"2026-09-16","days":5},{"id":"nct05632939","kind":"trial","name":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","route":"/trials/nct05632939/","asOf":"2026-09-16","days":5},{"id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct07465757/","asOf":"2026-09-16","days":5},{"id":"nct05061550","kind":"trial","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","route":"/trials/nct05061550/","asOf":"2026-09-16","days":5},{"id":"nct05207670","kind":"trial","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","route":"/trials/nct05207670/","asOf":"2026-09-16","days":5},{"id":"nct05006716","kind":"trial","name":"A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies","route":"/trials/nct05006716/","asOf":"2026-09-16","days":5},{"id":"nct06961006","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","route":"/trials/nct06961006/","asOf":"2026-09-16","days":5},{"id":"nct07310784","kind":"trial","name":"A Phase II Trial of LM103 in Advanced Melanoma","route":"/trials/nct07310784/","asOf":"2026-09-16","days":5},{"id":"nct07563738","kind":"trial","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","route":"/trials/nct07563738/","asOf":"2026-09-16","days":5},{"id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07312188/","asOf":"2026-09-16","days":5},{"id":"nct06840002","kind":"trial","name":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct06840002/","asOf":"2026-09-16","days":5},{"id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07623356/","asOf":"2026-09-16","days":5},{"id":"nct06708663","kind":"trial","name":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","route":"/trials/nct06708663/","asOf":"2026-09-16","days":5},{"id":"nct04996875","kind":"trial","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","route":"/trials/nct04996875/","asOf":"2026-09-16","days":5},{"id":"nct06859775","kind":"trial","name":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06859775/","asOf":"2026-09-16","days":5},{"id":"nct07217119","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","route":"/trials/nct07217119/","asOf":"2026-09-16","days":5},{"id":"nct06324357","kind":"trial","name":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit","route":"/trials/nct06324357/","asOf":"2026-09-16","days":5},{"id":"nct02864992","kind":"trial","name":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","route":"/trials/nct02864992/","asOf":"2026-09-16","days":5},{"id":"nct06481592","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","route":"/trials/nct06481592/","asOf":"2026-09-16","days":5},{"id":"nct05565807","kind":"trial","name":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05565807/","asOf":"2026-09-16","days":5},{"id":"nct07480928","kind":"trial","name":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07480928/","asOf":"2026-09-16","days":5},{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","route":"/trials/nct03260023/","asOf":"2026-09-16","days":5},{"id":"nct07644559","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","route":"/trials/nct07644559/","asOf":"2026-09-16","days":5},{"id":"nct06228326","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","route":"/trials/nct06228326/","asOf":"2026-09-16","days":5},{"id":"nct07155174","kind":"trial","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","route":"/trials/nct07155174/","asOf":"2026-09-16","days":5},{"id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/","asOf":"2026-09-16","days":5},{"id":"nct04495153","kind":"trial","name":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","route":"/trials/nct04495153/","asOf":"2026-09-16","days":5},{"id":"nct07449754","kind":"trial","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","route":"/trials/nct07449754/","asOf":"2026-09-16","days":5},{"id":"nct06090266","kind":"trial","name":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","route":"/trials/nct06090266/","asOf":"2026-09-16","days":5},{"id":"nct05682443","kind":"trial","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","route":"/trials/nct05682443/","asOf":"2026-09-16","days":5},{"id":"nct07288359","kind":"trial","name":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","route":"/trials/nct07288359/","asOf":"2026-09-16","days":5},{"id":"nct07023627","kind":"trial","name":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07023627/","asOf":"2026-09-16","days":5},{"id":"nct05382442","kind":"trial","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","route":"/trials/nct05382442/","asOf":"2026-09-16","days":5},{"id":"nct02955940","kind":"trial","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","route":"/trials/nct02955940/","asOf":"2026-09-16","days":5},{"id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","route":"/trials/nct06730347/","asOf":"2026-09-16","days":5},{"id":"nct07202364","kind":"trial","name":"A Study of YL202 in Patients With Advanced Solid Tumors","route":"/trials/nct07202364/","asOf":"2026-09-16","days":5},{"id":"nct05257993","kind":"trial","name":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv","route":"/trials/nct05257993/","asOf":"2026-09-16","days":5},{"id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/","asOf":"2026-09-16","days":5},{"id":"nct05704049","kind":"trial","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory","route":"/trials/nct05704049/","asOf":"2026-09-16","days":5},{"id":"nct07122687","kind":"trial","name":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small","route":"/trials/nct07122687/","asOf":"2026-09-16","days":5},{"id":"nct05074810","kind":"trial","name":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","route":"/trials/nct05074810/","asOf":"2026-09-16","days":5},{"id":"nct07070440","kind":"trial","name":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","route":"/trials/nct07070440/","asOf":"2026-09-16","days":5},{"id":"nct05283720","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","route":"/trials/nct05283720/","asOf":"2026-09-16","days":5},{"id":"nct03075696","kind":"trial","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","route":"/trials/nct03075696/","asOf":"2026-09-16","days":5},{"id":"nct03671018","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct03671018/","asOf":"2026-09-16","days":5},{"id":"nct06390995","kind":"trial","name":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","route":"/trials/nct06390995/","asOf":"2026-09-16","days":5},{"id":"nct04661007","kind":"trial","name":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL","route":"/trials/nct04661007/","asOf":"2026-09-16","days":5},{"id":"nct04245839","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct04245839/","asOf":"2026-09-16","days":5},{"id":"nct07473167","kind":"trial","name":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","route":"/trials/nct07473167/","asOf":"2026-09-16","days":5},{"id":"nct04502394","kind":"trial","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","route":"/trials/nct04502394/","asOf":"2026-09-16","days":5},{"id":"nct05020457","kind":"trial","name":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","route":"/trials/nct05020457/","asOf":"2026-09-16","days":5},{"id":"nct07087158","kind":"trial","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","route":"/trials/nct07087158/","asOf":"2026-09-16","days":5},{"id":"nct07329322","kind":"trial","name":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto","route":"/trials/nct07329322/","asOf":"2026-09-16","days":5},{"id":"nct07102381","kind":"trial","name":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","route":"/trials/nct07102381/","asOf":"2026-09-16","days":5},{"id":"nct05546866","kind":"trial","name":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","route":"/trials/nct05546866/","asOf":"2026-09-16","days":5},{"id":"nct07227311","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","route":"/trials/nct07227311/","asOf":"2026-09-16","days":5},{"id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","route":"/trials/nct07206498/","asOf":"2026-09-16","days":5},{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","asOf":"2026-09-16","days":5},{"id":"nct04370587","kind":"trial","name":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva","route":"/trials/nct04370587/","asOf":"2026-09-16","days":5},{"id":"nct05733598","kind":"trial","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","route":"/trials/nct05733598/","asOf":"2026-09-16","days":5},{"id":"nct04024696","kind":"trial","name":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients","route":"/trials/nct04024696/","asOf":"2026-09-16","days":5},{"id":"nct04669171","kind":"trial","name":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","route":"/trials/nct04669171/","asOf":"2026-09-16","days":5},{"id":"nct07459634","kind":"trial","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","route":"/trials/nct07459634/","asOf":"2026-09-16","days":5},{"id":"nct07020221","kind":"trial","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","route":"/trials/nct07020221/","asOf":"2026-09-16","days":5},{"id":"nct06841055","kind":"trial","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","route":"/trials/nct06841055/","asOf":"2026-09-16","days":5},{"id":"nct04730258","kind":"trial","name":"A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML","route":"/trials/nct04730258/","asOf":"2026-09-16","days":5},{"id":"nct06449209","kind":"trial","name":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","route":"/trials/nct06449209/","asOf":"2026-09-16","days":5},{"id":"nct06155396","kind":"trial","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","route":"/trials/nct06155396/","asOf":"2026-09-16","days":5},{"id":"nct06137144","kind":"trial","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","route":"/trials/nct06137144/","asOf":"2026-09-16","days":5},{"id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","route":"/trials/nct04665206/","asOf":"2026-09-16","days":5},{"id":"nct05335993","kind":"trial","name":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","route":"/trials/nct05335993/","asOf":"2026-09-16","days":5},{"id":"nct03836352","kind":"trial","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","route":"/trials/nct03836352/","asOf":"2026-09-16","days":5},{"id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","route":"/trials/nct07018050/","asOf":"2026-09-16","days":5},{"id":"nct07259590","kind":"trial","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct07259590/","asOf":"2026-09-16","days":5},{"id":"nct01843374","kind":"trial","name":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","route":"/trials/nct01843374/","asOf":"2026-09-16","days":5},{"id":"nct06277154","kind":"trial","name":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma","route":"/trials/nct06277154/","asOf":"2026-09-16","days":5},{"id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/","asOf":"2026-09-16","days":5},{"id":"nct05379595","kind":"trial","name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct05379595/","asOf":"2026-09-16","days":5},{"id":"nct06933329","kind":"trial","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06933329/","asOf":"2026-09-16","days":5},{"id":"nct07198633","kind":"trial","name":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","route":"/trials/nct07198633/","asOf":"2026-09-16","days":5},{"id":"nct06362252","kind":"trial","name":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-","route":"/trials/nct06362252/","asOf":"2026-09-16","days":5},{"id":"nct07254585","kind":"trial","name":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","route":"/trials/nct07254585/","asOf":"2026-09-16","days":5},{"id":"nct07407283","kind":"trial","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","route":"/trials/nct07407283/","asOf":"2026-09-16","days":5},{"id":"nct05910827","kind":"trial","name":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","route":"/trials/nct05910827/","asOf":"2026-09-16","days":5},{"id":"nct03888105","kind":"trial","name":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat","route":"/trials/nct03888105/","asOf":"2026-09-16","days":5},{"id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","route":"/trials/nct05288205/","asOf":"2026-09-16","days":5},{"id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/","asOf":"2026-09-16","days":5},{"id":"nct05642455","kind":"trial","name":"SPEARHEAD-3 Pediatric Study","route":"/trials/nct05642455/","asOf":"2026-09-16","days":5},{"id":"nct05955508","kind":"trial","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","route":"/trials/nct05955508/","asOf":"2026-09-16","days":5},{"id":"nct06669247","kind":"trial","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","route":"/trials/nct06669247/","asOf":"2026-09-16","days":5},{"id":"nct06992258","kind":"trial","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","route":"/trials/nct06992258/","asOf":"2026-09-16","days":5},{"id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","route":"/trials/nct05703971/","asOf":"2026-09-16","days":5},{"id":"nct05128487","kind":"trial","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","route":"/trials/nct05128487/","asOf":"2026-09-16","days":5},{"id":"nct06093841","kind":"trial","name":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","route":"/trials/nct06093841/","asOf":"2026-09-16","days":5},{"id":"nct05217446","kind":"trial","name":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic","route":"/trials/nct05217446/","asOf":"2026-09-16","days":5},{"id":"nct07489066","kind":"trial","name":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","route":"/trials/nct07489066/","asOf":"2026-09-16","days":5},{"id":"nct04478279","kind":"trial","name":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","route":"/trials/nct04478279/","asOf":"2026-09-16","days":5},{"id":"nct07310173","kind":"trial","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","route":"/trials/nct07310173/","asOf":"2026-09-16","days":5},{"id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/","asOf":"2026-09-16","days":5},{"id":"nct05841472","kind":"trial","name":"Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas","route":"/trials/nct05841472/","asOf":"2026-09-16","days":5},{"id":"nct06921928","kind":"trial","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","route":"/trials/nct06921928/","asOf":"2026-09-16","days":5},{"id":"nct06295432","kind":"trial","name":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","route":"/trials/nct06295432/","asOf":"2026-09-16","days":5},{"id":"nct04268706","kind":"trial","name":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","route":"/trials/nct04268706/","asOf":"2026-09-16","days":5},{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","route":"/trials/nct05246514/","asOf":"2026-09-16","days":5},{"id":"nct07564401","kind":"trial","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","route":"/trials/nct07564401/","asOf":"2026-09-16","days":5},{"id":"nct06106945","kind":"trial","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","route":"/trials/nct06106945/","asOf":"2026-09-16","days":5},{"id":"nct07699328","kind":"trial","name":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07699328/","asOf":"2026-09-16","days":5},{"id":"nct07217184","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","route":"/trials/nct07217184/","asOf":"2026-09-16","days":5},{"id":"nct02899052","kind":"trial","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","route":"/trials/nct02899052/","asOf":"2026-09-16","days":5},{"id":"nct03436485","kind":"trial","name":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct03436485/","asOf":"2026-09-16","days":5},{"id":"nct07164170","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","route":"/trials/nct07164170/","asOf":"2026-09-16","days":5},{"id":"nct05828511","kind":"trial","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","route":"/trials/nct05828511/","asOf":"2026-09-16","days":5},{"id":"nct07627711","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07627711/","asOf":"2026-09-16","days":5},{"id":"nct06190899","kind":"trial","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06190899/","asOf":"2026-09-16","days":5},{"id":"nct03259867","kind":"trial","name":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","route":"/trials/nct03259867/","asOf":"2026-09-16","days":5},{"id":"nct05195632","kind":"trial","name":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung","route":"/trials/nct05195632/","asOf":"2026-09-16","days":5},{"id":"nct05093907","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer","route":"/trials/nct05093907/","asOf":"2026-09-16","days":5},{"id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","asOf":"2026-09-16","days":5},{"id":"nct04836507","kind":"trial","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","route":"/trials/nct04836507/","asOf":"2026-09-16","days":5},{"id":"nct06843447","kind":"trial","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","route":"/trials/nct06843447/","asOf":"2026-09-16","days":5},{"id":"nct05358249","kind":"trial","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct05358249/","asOf":"2026-09-16","days":5},{"id":"nct04417621","kind":"trial","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","route":"/trials/nct04417621/","asOf":"2026-09-16","days":5},{"id":"nct06040099","kind":"trial","name":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat","route":"/trials/nct06040099/","asOf":"2026-09-16","days":5},{"id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/","asOf":"2026-09-16","days":5},{"id":"nct04675333","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","route":"/trials/nct04675333/","asOf":"2026-09-16","days":5},{"id":"nct07115043","kind":"trial","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","route":"/trials/nct07115043/","asOf":"2026-09-16","days":5},{"id":"nct05247684","kind":"trial","name":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","route":"/trials/nct05247684/","asOf":"2026-09-16","days":5},{"id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","route":"/trials/nct05907954/","asOf":"2026-09-16","days":5},{"id":"nct07029737","kind":"trial","name":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","route":"/trials/nct07029737/","asOf":"2026-09-16","days":5},{"id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/","asOf":"2026-09-16","days":5},{"id":"nct07322094","kind":"trial","name":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov","route":"/trials/nct07322094/","asOf":"2026-09-16","days":5},{"id":"nct03930953","kind":"trial","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","route":"/trials/nct03930953/","asOf":"2026-09-16","days":5},{"id":"nct05714839","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","route":"/trials/nct05714839/","asOf":"2026-09-16","days":5},{"id":"nct07190300","kind":"trial","name":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in ","route":"/trials/nct07190300/","asOf":"2026-09-16","days":5},{"id":"nct04126200","kind":"trial","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04126200/","asOf":"2026-09-16","days":5},{"id":"nct06493760","kind":"trial","name":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","route":"/trials/nct06493760/","asOf":"2026-09-16","days":5},{"id":"nct06413680","kind":"trial","name":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav","route":"/trials/nct06413680/","asOf":"2026-09-16","days":5},{"id":"nct04036682","kind":"trial","name":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","route":"/trials/nct04036682/","asOf":"2026-09-16","days":5},{"id":"nct07553988","kind":"trial","name":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07553988/","asOf":"2026-09-16","days":5},{"id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","route":"/trials/nct05438420/","asOf":"2026-09-16","days":5},{"id":"nct07227597","kind":"trial","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","route":"/trials/nct07227597/","asOf":"2026-09-16","days":5},{"id":"nct06589830","kind":"trial","name":"TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer","route":"/trials/nct06589830/","asOf":"2026-09-16","days":5},{"id":"nct06758557","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","route":"/trials/nct06758557/","asOf":"2026-09-16","days":5},{"id":"nct05824975","kind":"trial","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","route":"/trials/nct05824975/","asOf":"2026-09-16","days":5},{"id":"nct06005493","kind":"trial","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06005493/","asOf":"2026-09-16","days":5},{"id":"nct06769698","kind":"trial","name":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous ","route":"/trials/nct06769698/","asOf":"2026-09-16","days":5},{"id":"nct07500220","kind":"trial","name":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","route":"/trials/nct07500220/","asOf":"2026-09-16","days":5},{"id":"nct06895031","kind":"trial","name":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct06895031/","asOf":"2026-09-16","days":5},{"id":"nct04110301","kind":"trial","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","route":"/trials/nct04110301/","asOf":"2026-09-16","days":5},{"id":"nct03899792","kind":"trial","name":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","route":"/trials/nct03899792/","asOf":"2026-09-16","days":5},{"id":"nct07455851","kind":"trial","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07455851/","asOf":"2026-09-16","days":5},{"id":"nct06894511","kind":"trial","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","route":"/trials/nct06894511/","asOf":"2026-09-16","days":5},{"id":"nct05294731","kind":"trial","name":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","route":"/trials/nct05294731/","asOf":"2026-09-16","days":5},{"id":"nct07681596","kind":"trial","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07681596/","asOf":"2026-09-16","days":5},{"id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","route":"/trials/nct06047379/","asOf":"2026-09-16","days":5},{"id":"nct04495296","kind":"trial","name":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04495296/","asOf":"2026-09-16","days":5},{"id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct05186974/","asOf":"2026-09-16","days":5},{"id":"nct07669779","kind":"trial","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07669779/","asOf":"2026-09-16","days":5},{"id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct07038096/","asOf":"2026-09-16","days":5},{"id":"nct05044897","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC","route":"/trials/nct05044897/","asOf":"2026-09-16","days":5},{"id":"nct06558227","kind":"trial","name":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct06558227/","asOf":"2026-09-16","days":5},{"id":"nct04104776","kind":"trial","name":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","route":"/trials/nct04104776/","asOf":"2026-09-16","days":5},{"id":"nct05592626","kind":"trial","name":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","route":"/trials/nct05592626/","asOf":"2026-09-16","days":5},{"id":"nct05403385","kind":"trial","name":"Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct05403385/","asOf":"2026-09-16","days":5},{"id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/","asOf":"2026-09-16","days":5},{"id":"nct05061134","kind":"trial","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","route":"/trials/nct05061134/","asOf":"2026-09-16","days":5},{"id":"nct05903833","kind":"trial","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","route":"/trials/nct05903833/","asOf":"2026-09-16","days":5},{"id":"nct07406633","kind":"trial","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","route":"/trials/nct07406633/","asOf":"2026-09-16","days":5},{"id":"nct06479356","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","route":"/trials/nct06479356/","asOf":"2026-09-16","days":5},{"id":"nct04919811","kind":"trial","name":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","route":"/trials/nct04919811/","asOf":"2026-09-16","days":5},{"id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/","asOf":"2026-09-16","days":5},{"id":"nct06787612","kind":"trial","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","route":"/trials/nct06787612/","asOf":"2026-09-16","days":5},{"id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","route":"/trials/nct04198766/","asOf":"2026-09-16","days":5},{"id":"nct06530251","kind":"trial","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","route":"/trials/nct06530251/","asOf":"2026-09-16","days":5},{"id":"nct06007729","kind":"trial","name":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06007729/","asOf":"2026-09-16","days":5},{"id":"nct05276726","kind":"trial","name":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","route":"/trials/nct05276726/","asOf":"2026-09-16","days":5},{"id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/","asOf":"2026-09-16","days":5},{"id":"nct06702995","kind":"trial","name":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06702995/","asOf":"2026-09-16","days":5},{"id":"nct03944772","kind":"trial","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","route":"/trials/nct03944772/","asOf":"2026-09-16","days":5},{"id":"nct03476681","kind":"trial","name":"Study of NEO-201 in Solid Tumors Expansion Cohorts","route":"/trials/nct03476681/","asOf":"2026-09-16","days":5},{"id":"nct05280314","kind":"trial","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","route":"/trials/nct05280314/","asOf":"2026-09-16","days":5},{"id":"nct03175224","kind":"trial","name":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","route":"/trials/nct03175224/","asOf":"2026-09-16","days":5},{"id":"nct03731260","kind":"trial","name":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo ","route":"/trials/nct03731260/","asOf":"2026-09-16","days":5},{"id":"nct05297890","kind":"trial","name":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","route":"/trials/nct05297890/","asOf":"2026-09-16","days":5},{"id":"nct05257590","kind":"trial","name":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","route":"/trials/nct05257590/","asOf":"2026-09-16","days":5},{"id":"nct06745323","kind":"trial","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","route":"/trials/nct06745323/","asOf":"2026-09-16","days":5},{"id":"nct05309421","kind":"trial","name":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma","route":"/trials/nct05309421/","asOf":"2026-09-16","days":5},{"id":"nct06428409","kind":"trial","name":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","route":"/trials/nct06428409/","asOf":"2026-09-16","days":5},{"id":"nct07627698","kind":"trial","name":"Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma","route":"/trials/nct07627698/","asOf":"2026-09-16","days":5},{"id":"nct05117242","kind":"trial","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","route":"/trials/nct05117242/","asOf":"2026-09-16","days":5},{"id":"nct04931342","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","route":"/trials/nct04931342/","asOf":"2026-09-16","days":5},{"id":"nct02519348","kind":"trial","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct02519348/","asOf":"2026-09-16","days":5},{"id":"nct06395103","kind":"trial","name":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","route":"/trials/nct06395103/","asOf":"2026-09-16","days":5},{"id":"nct07223047","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","route":"/trials/nct07223047/","asOf":"2026-09-16","days":5},{"id":"nct04973605","kind":"trial","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","route":"/trials/nct04973605/","asOf":"2026-09-16","days":5},{"id":"nct06004661","kind":"trial","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","route":"/trials/nct06004661/","asOf":"2026-09-16","days":5},{"id":"nct06695845","kind":"trial","name":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","route":"/trials/nct06695845/","asOf":"2026-09-16","days":5},{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","asOf":"2026-09-16","days":5},{"id":"nct06710132","kind":"trial","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","route":"/trials/nct06710132/","asOf":"2026-09-16","days":5},{"id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/","asOf":"2026-09-16","days":5},{"id":"nct05742607","kind":"trial","name":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","route":"/trials/nct05742607/","asOf":"2026-09-16","days":5},{"id":"nct07641036","kind":"trial","name":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","route":"/trials/nct07641036/","asOf":"2026-09-16","days":5},{"id":"nct06787664","kind":"trial","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","route":"/trials/nct06787664/","asOf":"2026-09-16","days":5},{"id":"nct05054439","kind":"trial","name":"A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC","route":"/trials/nct05054439/","asOf":"2026-09-16","days":5},{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","route":"/trials/nct02773030/","asOf":"2026-09-16","days":5},{"id":"nct04524871","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","route":"/trials/nct04524871/","asOf":"2026-09-16","days":5},{"id":"nct07150104","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","route":"/trials/nct07150104/","asOf":"2026-09-16","days":5},{"id":"nct07059845","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","route":"/trials/nct07059845/","asOf":"2026-09-16","days":5},{"id":"nct06564272","kind":"trial","name":"A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","route":"/trials/nct06564272/","asOf":"2026-09-16","days":5},{"id":"nct07551349","kind":"trial","name":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07551349/","asOf":"2026-09-16","days":5},{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","route":"/trials/nct06574347/","asOf":"2026-09-16","days":5},{"id":"nct07610798","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","route":"/trials/nct07610798/","asOf":"2026-09-16","days":5},{"id":"nct05125016","kind":"trial","name":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","route":"/trials/nct05125016/","asOf":"2026-09-16","days":5},{"id":"nct05684965","kind":"trial","name":"XTX301 in Patients With Advanced Solid Tumors","route":"/trials/nct05684965/","asOf":"2026-09-16","days":5},{"id":"nct07100730","kind":"trial","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","route":"/trials/nct07100730/","asOf":"2026-09-16","days":5},{"id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/","asOf":"2026-09-16","days":5},{"id":"nct04567420","kind":"trial","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","route":"/trials/nct04567420/","asOf":"2026-09-16","days":5},{"id":"nct05287113","kind":"trial","name":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","route":"/trials/nct05287113/","asOf":"2026-09-16","days":5},{"id":"nct04165590","kind":"trial","name":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","route":"/trials/nct04165590/","asOf":"2026-09-16","days":5},{"id":"nct02908906","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","route":"/trials/nct02908906/","asOf":"2026-09-16","days":5},{"id":"nct04914598","kind":"trial","name":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","route":"/trials/nct04914598/","asOf":"2026-09-16","days":5},{"id":"nct06973187","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct06973187/","asOf":"2026-09-16","days":5},{"id":"nct06373406","kind":"trial","name":"A Study of MHB036C for Advanced Solid Tumor","route":"/trials/nct06373406/","asOf":"2026-09-16","days":5},{"id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/","asOf":"2026-09-16","days":5},{"id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","asOf":"2026-09-16","days":5},{"id":"nct04130516","kind":"trial","name":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","route":"/trials/nct04130516/","asOf":"2026-09-16","days":5},{"id":"nct06483334","kind":"trial","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","route":"/trials/nct06483334/","asOf":"2026-09-16","days":5},{"id":"nct05994131","kind":"trial","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","route":"/trials/nct05994131/","asOf":"2026-09-16","days":5},{"id":"nct07227870","kind":"trial","name":"L19IL2/TNF in Patients With Basal Cell Carcinoma","route":"/trials/nct07227870/","asOf":"2026-09-16","days":5},{"id":"nct05615623","kind":"trial","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG","route":"/trials/nct05615623/","asOf":"2026-09-16","days":5},{"id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","route":"/trials/nct07002203/","asOf":"2026-09-16","days":5},{"id":"nct06595186","kind":"trial","name":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","route":"/trials/nct06595186/","asOf":"2026-09-16","days":5},{"id":"nct06922383","kind":"trial","name":"A Clinical Study of Arfolitixorin in Patients With mCRC","route":"/trials/nct06922383/","asOf":"2026-09-16","days":5},{"id":"nct06650566","kind":"trial","name":"Study of LM-299 in Subjects Advanced Malignant Tumors","route":"/trials/nct06650566/","asOf":"2026-09-16","days":5},{"id":"nct06081959","kind":"trial","name":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06081959/","asOf":"2026-09-16","days":5},{"id":"nct07326488","kind":"trial","name":"A Study of MHB009C in Patients With Advanced Solid Tumors","route":"/trials/nct07326488/","asOf":"2026-09-16","days":5},{"id":"nct07589569","kind":"trial","name":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","route":"/trials/nct07589569/","asOf":"2026-09-16","days":5},{"id":"nct05120596","kind":"trial","name":"First in Human Study of T3P-Y058-739 (T3P)","route":"/trials/nct05120596/","asOf":"2026-09-16","days":5},{"id":"nct06386146","kind":"trial","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","route":"/trials/nct06386146/","asOf":"2026-09-16","days":5},{"id":"nct05192486","kind":"trial","name":"A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct05192486/","asOf":"2026-09-16","days":5},{"id":"nct07459998","kind":"trial","name":"SKB103 for Injection in Advanced Solid Tumors","route":"/trials/nct07459998/","asOf":"2026-09-16","days":5},{"id":"nct04956640","kind":"trial","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","route":"/trials/nct04956640/","asOf":"2026-09-16","days":5},{"id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/","asOf":"2026-09-16","days":5},{"id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07589517/","asOf":"2026-09-16","days":5},{"id":"nct04077099","kind":"trial","name":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","route":"/trials/nct04077099/","asOf":"2026-09-16","days":5},{"id":"nct03866525","kind":"trial","name":"OH2 Oncolytic Viral Therapy in Solid Tumors","route":"/trials/nct03866525/","asOf":"2026-09-16","days":5},{"id":"nct07441174","kind":"trial","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07441174/","asOf":"2026-09-16","days":5},{"id":"nct06500676","kind":"trial","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","route":"/trials/nct06500676/","asOf":"2026-09-16","days":5},{"id":"nct06581432","kind":"trial","name":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","route":"/trials/nct06581432/","asOf":"2026-09-16","days":5},{"id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/","asOf":"2026-09-16","days":5},{"id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","route":"/trials/nct06393374/","asOf":"2026-09-16","days":5},{"id":"nct07486817","kind":"trial","name":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","route":"/trials/nct07486817/","asOf":"2026-09-16","days":5},{"id":"nct03301168","kind":"trial","name":"Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant","route":"/trials/nct03301168/","asOf":"2026-09-16","days":5},{"id":"nct05243550","kind":"trial","name":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct05243550/","asOf":"2026-09-16","days":5},{"id":"nct07158918","kind":"trial","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","route":"/trials/nct07158918/","asOf":"2026-09-16","days":5},{"id":"nct06112704","kind":"trial","name":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","route":"/trials/nct06112704/","asOf":"2026-09-16","days":5},{"id":"nct03769506","kind":"trial","name":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","route":"/trials/nct03769506/","asOf":"2026-09-16","days":5},{"id":"nct06496971","kind":"trial","name":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","route":"/trials/nct06496971/","asOf":"2026-09-16","days":5},{"id":"nct05466799","kind":"trial","name":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","route":"/trials/nct05466799/","asOf":"2026-09-16","days":5},{"id":"nct05235516","kind":"trial","name":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","route":"/trials/nct05235516/","asOf":"2026-09-16","days":5},{"id":"nct05667506","kind":"trial","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","route":"/trials/nct05667506/","asOf":"2026-09-16","days":5},{"id":"nct06750185","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","route":"/trials/nct06750185/","asOf":"2026-09-16","days":5},{"id":"nct06985147","kind":"trial","name":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","route":"/trials/nct06985147/","asOf":"2026-09-16","days":5},{"id":"nct05565378","kind":"trial","name":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct05565378/","asOf":"2026-09-16","days":5},{"id":"nct06818643","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","route":"/trials/nct06818643/","asOf":"2026-09-16","days":5},{"id":"nct02174549","kind":"trial","name":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","route":"/trials/nct02174549/","asOf":"2026-09-16","days":5},{"id":"nct02704858","kind":"trial","name":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","route":"/trials/nct02704858/","asOf":"2026-09-16","days":5},{"id":"nct07070349","kind":"trial","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","route":"/trials/nct07070349/","asOf":"2026-09-16","days":5},{"id":"nct04464226","kind":"trial","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","route":"/trials/nct04464226/","asOf":"2026-09-16","days":5},{"id":"nct06640049","kind":"trial","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","route":"/trials/nct06640049/","asOf":"2026-09-16","days":5},{"id":"nct05609578","kind":"trial","name":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","route":"/trials/nct05609578/","asOf":"2026-09-16","days":5},{"id":"nct05170958","kind":"trial","name":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","route":"/trials/nct05170958/","asOf":"2026-09-16","days":5},{"id":"nct06382168","kind":"trial","name":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06382168/","asOf":"2026-09-16","days":5},{"id":"nct06542250","kind":"trial","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","route":"/trials/nct06542250/","asOf":"2026-09-16","days":5},{"id":"nct04752813","kind":"trial","name":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","route":"/trials/nct04752813/","asOf":"2026-09-16","days":5},{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","asOf":"2026-09-16","days":5},{"id":"nct07700667","kind":"trial","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","route":"/trials/nct07700667/","asOf":"2026-09-16","days":5},{"id":"nct06062420","kind":"trial","name":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","route":"/trials/nct06062420/","asOf":"2026-09-16","days":5},{"id":"nct06123754","kind":"trial","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","route":"/trials/nct06123754/","asOf":"2026-09-16","days":5},{"id":"nct06222879","kind":"trial","name":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","route":"/trials/nct06222879/","asOf":"2026-09-16","days":5},{"id":"nct04853342","kind":"trial","name":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","route":"/trials/nct04853342/","asOf":"2026-09-16","days":5},{"id":"nct05229497","kind":"trial","name":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","route":"/trials/nct05229497/","asOf":"2026-09-16","days":5},{"id":"nct05427383","kind":"trial","name":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","route":"/trials/nct05427383/","asOf":"2026-09-16","days":5},{"id":"nct05501886","kind":"trial","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","route":"/trials/nct05501886/","asOf":"2026-09-16","days":5},{"id":"nct07701486","kind":"trial","name":"A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer","route":"/trials/nct07701486/","asOf":"2026-09-16","days":5},{"id":"nct06623422","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","route":"/trials/nct06623422/","asOf":"2026-09-16","days":5},{"id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","asOf":"2026-09-16","days":5},{"id":"nct07815665","kind":"trial","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","route":"/trials/nct07815665/","asOf":"2026-09-16","days":5},{"id":"nct07196644","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan","route":"/trials/nct07196644/","asOf":"2026-09-16","days":5},{"id":"nct06460298","kind":"trial","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06460298/","asOf":"2026-09-16","days":5},{"id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","route":"/trials/nct07811037/","asOf":"2026-09-16","days":5},{"id":"nct07007312","kind":"trial","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","route":"/trials/nct07007312/","asOf":"2026-09-16","days":5},{"id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","asOf":"2026-09-16","days":5},{"id":"nct06948981","kind":"trial","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","route":"/trials/nct06948981/","asOf":"2026-09-16","days":5},{"id":"nct05898399","kind":"trial","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","route":"/trials/nct05898399/","asOf":"2026-09-16","days":5},{"id":"nct05498428","kind":"trial","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct05498428/","asOf":"2026-09-16","days":5},{"id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","route":"/trials/nct05304481/","asOf":"2026-09-16","days":5},{"id":"nct06459973","kind":"trial","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","route":"/trials/nct06459973/","asOf":"2026-09-16","days":5},{"id":"nct05663866","kind":"trial","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","route":"/trials/nct05663866/","asOf":"2026-09-16","days":5},{"id":"nct07678957","kind":"trial","name":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct07678957/","asOf":"2026-09-16","days":5},{"id":"nct06943872","kind":"trial","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","route":"/trials/nct06943872/","asOf":"2026-09-16","days":5},{"id":"nct06293651","kind":"trial","name":"Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06293651/","asOf":"2026-09-16","days":5},{"id":"nct06267729","kind":"trial","name":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","route":"/trials/nct06267729/","asOf":"2026-09-16","days":5},{"id":"nct04305795","kind":"trial","name":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","route":"/trials/nct04305795/","asOf":"2026-09-16","days":5},{"id":"nct05768139","kind":"trial","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","route":"/trials/nct05768139/","asOf":"2026-09-16","days":5},{"id":"nct05118789","kind":"trial","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","route":"/trials/nct05118789/","asOf":"2026-09-16","days":5},{"id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07209813/","asOf":"2026-09-16","days":5},{"id":"nct07328217","kind":"trial","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","route":"/trials/nct07328217/","asOf":"2026-09-16","days":5},{"id":"nct06131450","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","route":"/trials/nct06131450/","asOf":"2026-09-16","days":5},{"id":"nct04094610","kind":"trial","name":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","route":"/trials/nct04094610/","asOf":"2026-09-16","days":5},{"id":"nct07026279","kind":"trial","name":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07026279/","asOf":"2026-09-16","days":5},{"id":"nct07069062","kind":"trial","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","route":"/trials/nct07069062/","asOf":"2026-09-16","days":5},{"id":"nct05688280","kind":"trial","name":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","route":"/trials/nct05688280/","asOf":"2026-09-16","days":5},{"id":"nct07569042","kind":"trial","name":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct07569042/","asOf":"2026-09-16","days":5},{"id":"nct04752722","kind":"trial","name":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","route":"/trials/nct04752722/","asOf":"2026-09-16","days":5},{"id":"nct06361888","kind":"trial","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","route":"/trials/nct06361888/","asOf":"2026-09-16","days":5},{"id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","route":"/trials/nct06365840/","asOf":"2026-09-16","days":5},{"id":"nct03945162","kind":"trial","name":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","route":"/trials/nct03945162/","asOf":"2026-09-16","days":5},{"id":"nct06265727","kind":"trial","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","route":"/trials/nct06265727/","asOf":"2026-09-16","days":5},{"id":"nct07192120","kind":"trial","name":"A Study of MHB048C in Patients With Advanced Solid Tumors","route":"/trials/nct07192120/","asOf":"2026-09-16","days":5},{"id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/","asOf":"2026-09-16","days":5},{"id":"nct07450859","kind":"trial","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07450859/","asOf":"2026-09-16","days":5},{"id":"nct04233346","kind":"trial","name":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","route":"/trials/nct04233346/","asOf":"2026-09-16","days":5},{"id":"nct05802225","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","route":"/trials/nct05802225/","asOf":"2026-09-16","days":5},{"id":"nct01761968","kind":"trial","name":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","route":"/trials/nct01761968/","asOf":"2026-09-16","days":5},{"id":"nct04008797","kind":"trial","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","route":"/trials/nct04008797/","asOf":"2026-09-16","days":5},{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","asOf":"2026-09-16","days":5},{"id":"nct07216560","kind":"trial","name":"First-in-human Study of 7MW4911 in GI Cancer","route":"/trials/nct07216560/","asOf":"2026-09-16","days":5},{"id":"nct07612280","kind":"trial","name":"Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis","route":"/trials/nct07612280/","asOf":"2026-09-16","days":5},{"id":"nct05532696","kind":"trial","name":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","route":"/trials/nct05532696/","asOf":"2026-09-16","days":5},{"id":"nct06864169","kind":"trial","name":"A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)","route":"/trials/nct06864169/","asOf":"2026-09-16","days":5},{"id":"nct05300269","kind":"trial","name":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","route":"/trials/nct05300269/","asOf":"2026-09-16","days":5},{"id":"nct03725059","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","route":"/trials/nct03725059/","asOf":"2026-09-16","days":5},{"id":"nct04521231","kind":"trial","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","route":"/trials/nct04521231/","asOf":"2026-09-16","days":5},{"id":"nct06125522","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","route":"/trials/nct06125522/","asOf":"2026-09-16","days":5},{"id":"nct04562389","kind":"trial","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","route":"/trials/nct04562389/","asOf":"2026-09-16","days":5},{"id":"nct05909436","kind":"trial","name":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","route":"/trials/nct05909436/","asOf":"2026-09-16","days":5},{"id":"nct06795412","kind":"trial","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct06795412/","asOf":"2026-09-16","days":5},{"id":"nct07213830","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","route":"/trials/nct07213830/","asOf":"2026-09-16","days":5},{"id":"nct06994507","kind":"trial","name":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","route":"/trials/nct06994507/","asOf":"2026-09-16","days":5},{"id":"nct07181499","kind":"trial","name":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","route":"/trials/nct07181499/","asOf":"2026-09-16","days":5},{"id":"nct03934567","kind":"trial","name":"A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03934567/","asOf":"2026-09-16","days":5},{"id":"nct05458674","kind":"trial","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","route":"/trials/nct05458674/","asOf":"2026-09-16","days":5},{"id":"nct06015048","kind":"trial","name":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","route":"/trials/nct06015048/","asOf":"2026-09-16","days":5},{"id":"nct07211958","kind":"trial","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","route":"/trials/nct07211958/","asOf":"2026-09-16","days":5},{"id":"nct07143604","kind":"trial","name":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","route":"/trials/nct07143604/","asOf":"2026-09-16","days":5},{"id":"nct05435248","kind":"trial","name":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","route":"/trials/nct05435248/","asOf":"2026-09-16","days":5},{"id":"nct05914116","kind":"trial","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05914116/","asOf":"2026-09-16","days":5},{"id":"nct07554521","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","route":"/trials/nct07554521/","asOf":"2026-09-16","days":5},{"id":"nct04685226","kind":"trial","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","route":"/trials/nct04685226/","asOf":"2026-09-16","days":5},{"id":"nct06244771","kind":"trial","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","route":"/trials/nct06244771/","asOf":"2026-09-16","days":5},{"id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","route":"/trials/nct06525298/","asOf":"2026-09-16","days":5},{"id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04616209/","asOf":"2026-09-16","days":5},{"id":"nct03155191","kind":"trial","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct03155191/","asOf":"2026-09-16","days":5},{"id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","route":"/trials/nct07362940/","asOf":"2026-09-16","days":5},{"id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","route":"/trials/nct07612891/","asOf":"2026-09-16","days":5},{"id":"nct07354074","kind":"trial","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","route":"/trials/nct07354074/","asOf":"2026-09-16","days":5},{"id":"nct05980481","kind":"trial","name":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","route":"/trials/nct05980481/","asOf":"2026-09-16","days":5},{"id":"nct06731478","kind":"trial","name":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct06731478/","asOf":"2026-09-16","days":5},{"id":"nct06246110","kind":"trial","name":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","route":"/trials/nct06246110/","asOf":"2026-09-16","days":5},{"id":"nct07100106","kind":"trial","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","route":"/trials/nct07100106/","asOf":"2026-09-16","days":5},{"id":"nct06155084","kind":"trial","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients","route":"/trials/nct06155084/","asOf":"2026-09-16","days":5},{"id":"nct06667076","kind":"trial","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667076/","asOf":"2026-09-16","days":5},{"id":"nct05491525","kind":"trial","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","route":"/trials/nct05491525/","asOf":"2026-09-16","days":5},{"id":"nct06703255","kind":"trial","name":"A Phase 2 Study of HX301 in Patients with High-grade Giloma","route":"/trials/nct06703255/","asOf":"2026-09-16","days":5},{"id":"nct07232849","kind":"trial","name":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07232849/","asOf":"2026-09-16","days":5},{"id":"nct06256588","kind":"trial","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06256588/","asOf":"2026-09-16","days":5},{"id":"nct06631092","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","route":"/trials/nct06631092/","asOf":"2026-09-16","days":5},{"id":"nct04349436","kind":"trial","name":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","route":"/trials/nct04349436/","asOf":"2026-09-16","days":5},{"id":"nct07669467","kind":"trial","name":"Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer","route":"/trials/nct07669467/","asOf":"2026-09-16","days":5},{"id":"nct07692204","kind":"trial","name":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct07692204/","asOf":"2026-09-16","days":5},{"id":"nct06668103","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","route":"/trials/nct06668103/","asOf":"2026-09-16","days":5},{"id":"nct06839066","kind":"trial","name":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","route":"/trials/nct06839066/","asOf":"2026-09-16","days":5},{"id":"nct05888831","kind":"trial","name":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","route":"/trials/nct05888831/","asOf":"2026-09-16","days":5},{"id":"nct07523529","kind":"trial","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","route":"/trials/nct07523529/","asOf":"2026-09-16","days":5},{"id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","route":"/trials/nct07765446/","asOf":"2026-09-16","days":5},{"id":"nct06206837","kind":"trial","name":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","route":"/trials/nct06206837/","asOf":"2026-09-16","days":5},{"id":"nct06979596","kind":"trial","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","route":"/trials/nct06979596/","asOf":"2026-09-16","days":5},{"id":"nct07197827","kind":"trial","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","route":"/trials/nct07197827/","asOf":"2026-09-16","days":5},{"id":"nct05991583","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors","route":"/trials/nct05991583/","asOf":"2026-09-16","days":5},{"id":"nct06179524","kind":"trial","name":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","route":"/trials/nct06179524/","asOf":"2026-09-16","days":5},{"id":"nct06022861","kind":"trial","name":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct06022861/","asOf":"2026-09-16","days":5},{"id":"nct06223841","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06223841/","asOf":"2026-09-16","days":5},{"id":"nct05287945","kind":"trial","name":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","route":"/trials/nct05287945/","asOf":"2026-09-16","days":5},{"id":"nct05774951","kind":"trial","name":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","route":"/trials/nct05774951/","asOf":"2026-09-16","days":5},{"id":"nct04589845","kind":"trial","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","route":"/trials/nct04589845/","asOf":"2026-09-16","days":5},{"id":"nct04906395","kind":"trial","name":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","route":"/trials/nct04906395/","asOf":"2026-09-16","days":5},{"id":"nct04588922","kind":"trial","name":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","route":"/trials/nct04588922/","asOf":"2026-09-16","days":5},{"id":"nct06453902","kind":"trial","name":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","route":"/trials/nct06453902/","asOf":"2026-09-16","days":5},{"id":"nct03379428","kind":"trial","name":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","route":"/trials/nct03379428/","asOf":"2026-09-16","days":5},{"id":"nct07382531","kind":"trial","name":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","route":"/trials/nct07382531/","asOf":"2026-09-16","days":5},{"id":"nct06465433","kind":"trial","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","route":"/trials/nct06465433/","asOf":"2026-09-16","days":5},{"id":"nct05875168","kind":"trial","name":"First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors","route":"/trials/nct05875168/","asOf":"2026-09-16","days":5},{"id":"nct05302284","kind":"trial","name":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","route":"/trials/nct05302284/","asOf":"2026-09-16","days":5},{"id":"nct07114315","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07114315/","asOf":"2026-09-16","days":5},{"id":"nct06567015","kind":"trial","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","route":"/trials/nct06567015/","asOf":"2026-09-16","days":5},{"id":"nct06908304","kind":"trial","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","route":"/trials/nct06908304/","asOf":"2026-09-16","days":5},{"id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","asOf":"2026-09-16","days":5},{"id":"nct04485949","kind":"trial","name":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","route":"/trials/nct04485949/","asOf":"2026-09-16","days":5},{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct05020015/","asOf":"2026-09-16","days":5},{"id":"nct06245915","kind":"trial","name":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","route":"/trials/nct06245915/","asOf":"2026-09-16","days":5},{"id":"nct06413706","kind":"trial","name":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","route":"/trials/nct06413706/","asOf":"2026-09-16","days":5},{"id":"nct07720284","kind":"trial","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","route":"/trials/nct07720284/","asOf":"2026-09-16","days":5},{"id":"nct06465563","kind":"trial","name":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06465563/","asOf":"2026-09-16","days":5},{"id":"nct07108309","kind":"trial","name":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07108309/","asOf":"2026-09-16","days":5},{"id":"nct04270409","kind":"trial","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","route":"/trials/nct04270409/","asOf":"2026-09-16","days":5},{"id":"nct06609005","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06609005/","asOf":"2026-09-16","days":5},{"id":"nct05773820","kind":"trial","name":"A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors","route":"/trials/nct05773820/","asOf":"2026-09-16","days":5},{"id":"nct06578624","kind":"trial","name":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06578624/","asOf":"2026-09-16","days":5},{"id":"nct01744223","kind":"trial","name":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","route":"/trials/nct01744223/","asOf":"2026-09-16","days":5},{"id":"nct07263594","kind":"trial","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","route":"/trials/nct07263594/","asOf":"2026-09-16","days":5},{"id":"nct05363280","kind":"trial","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","route":"/trials/nct05363280/","asOf":"2026-09-16","days":5},{"id":"nct06202261","kind":"trial","name":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","route":"/trials/nct06202261/","asOf":"2026-09-16","days":5},{"id":"nct07497386","kind":"trial","name":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","route":"/trials/nct07497386/","asOf":"2026-09-16","days":5},{"id":"nct07130383","kind":"trial","name":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","route":"/trials/nct07130383/","asOf":"2026-09-16","days":5},{"id":"nct06065748","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","route":"/trials/nct06065748/","asOf":"2026-09-16","days":5},{"id":"nct07213817","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct07213817/","asOf":"2026-09-16","days":5},{"id":"nct04486833","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","route":"/trials/nct04486833/","asOf":"2026-09-16","days":5},{"id":"nct06383052","kind":"trial","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","route":"/trials/nct06383052/","asOf":"2026-09-16","days":5},{"id":"nct07488676","kind":"trial","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","route":"/trials/nct07488676/","asOf":"2026-09-16","days":5},{"id":"nct06904235","kind":"trial","name":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","route":"/trials/nct06904235/","asOf":"2026-09-16","days":5},{"id":"nct07023731","kind":"trial","name":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","route":"/trials/nct07023731/","asOf":"2026-09-16","days":5},{"id":"nct05765812","kind":"trial","name":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","route":"/trials/nct05765812/","asOf":"2026-09-16","days":5},{"id":"nct05944978","kind":"trial","name":"A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","route":"/trials/nct05944978/","asOf":"2026-09-16","days":5},{"id":"nct03257033","kind":"trial","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","route":"/trials/nct03257033/","asOf":"2026-09-16","days":5},{"id":"nct03899155","kind":"trial","name":"Pan Tumor Rollover Study","route":"/trials/nct03899155/","asOf":"2026-09-16","days":5},{"id":"nct06725758","kind":"trial","name":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","route":"/trials/nct06725758/","asOf":"2026-09-16","days":5},{"id":"nct05319314","kind":"trial","name":"LYL273 for Patients With Relapsed or Refractory mCRC","route":"/trials/nct05319314/","asOf":"2026-09-16","days":5},{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","asOf":"2026-09-16","days":5},{"id":"nct06474455","kind":"trial","name":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct06474455/","asOf":"2026-09-16","days":5},{"id":"nct07280832","kind":"trial","name":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors","route":"/trials/nct07280832/","asOf":"2026-09-16","days":5},{"id":"nct06665100","kind":"trial","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","route":"/trials/nct06665100/","asOf":"2026-09-16","days":5},{"id":"nct06953999","kind":"trial","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","route":"/trials/nct06953999/","asOf":"2026-09-16","days":5},{"id":"nct07276399","kind":"trial","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","route":"/trials/nct07276399/","asOf":"2026-09-16","days":5},{"id":"nct07070232","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","route":"/trials/nct07070232/","asOf":"2026-09-16","days":5},{"id":"nct02677922","kind":"trial","name":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","route":"/trials/nct02677922/","asOf":"2026-09-16","days":5},{"id":"nct06187402","kind":"trial","name":"A Study of LM-24C5 For Advanced Solid Tumors","route":"/trials/nct06187402/","asOf":"2026-09-16","days":5},{"id":"nct03067051","kind":"trial","name":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","route":"/trials/nct03067051/","asOf":"2026-09-16","days":5},{"id":"nct05947851","kind":"trial","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","route":"/trials/nct05947851/","asOf":"2026-09-16","days":5},{"id":"nct05702229","kind":"trial","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct05702229/","asOf":"2026-09-16","days":5},{"id":"nct06938867","kind":"trial","name":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","route":"/trials/nct06938867/","asOf":"2026-09-16","days":5},{"id":"nct06469944","kind":"trial","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","route":"/trials/nct06469944/","asOf":"2026-09-16","days":5},{"id":"nct05296798","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","route":"/trials/nct05296798/","asOf":"2026-09-16","days":5},{"id":"nct07455734","kind":"trial","name":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","route":"/trials/nct07455734/","asOf":"2026-09-16","days":5},{"id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","route":"/trials/nct07502287/","asOf":"2026-09-16","days":5},{"id":"nct06986811","kind":"trial","name":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","route":"/trials/nct06986811/","asOf":"2026-09-16","days":5},{"id":"nct07648264","kind":"trial","name":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","route":"/trials/nct07648264/","asOf":"2026-09-16","days":5},{"id":"nct06514534","kind":"trial","name":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","route":"/trials/nct06514534/","asOf":"2026-09-16","days":5},{"id":"nct05849298","kind":"trial","name":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","route":"/trials/nct05849298/","asOf":"2026-09-16","days":5},{"id":"nct06422936","kind":"trial","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct06422936/","asOf":"2026-09-16","days":5},{"id":"nct06330064","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","route":"/trials/nct06330064/","asOf":"2026-09-16","days":5},{"id":"nct06234098","kind":"trial","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","route":"/trials/nct06234098/","asOf":"2026-09-16","days":5},{"id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","route":"/trials/nct07374419/","asOf":"2026-09-16","days":5},{"id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","route":"/trials/nct07589530/","asOf":"2026-09-16","days":5},{"id":"nct06727630","kind":"trial","name":"A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma","route":"/trials/nct06727630/","asOf":"2026-09-16","days":5},{"id":"nct07108270","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","route":"/trials/nct07108270/","asOf":"2026-09-16","days":5},{"id":"nct07405151","kind":"trial","name":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","route":"/trials/nct07405151/","asOf":"2026-09-16","days":5},{"id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","route":"/trials/nct07510802/","asOf":"2026-09-16","days":5},{"id":"nct06010342","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","route":"/trials/nct06010342/","asOf":"2026-09-16","days":5},{"id":"nct06155383","kind":"trial","name":"Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct06155383/","asOf":"2026-09-16","days":5},{"id":"nct05814354","kind":"trial","name":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","route":"/trials/nct05814354/","asOf":"2026-09-16","days":5},{"id":"nct04271644","kind":"trial","name":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04271644/","asOf":"2026-09-16","days":5},{"id":"nct06049290","kind":"trial","name":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct06049290/","asOf":"2026-09-16","days":5},{"id":"nct06035497","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","route":"/trials/nct06035497/","asOf":"2026-09-16","days":5},{"id":"nct06515990","kind":"trial","name":"A Study of DM005 in Patients With Advanced Solid Tumors","route":"/trials/nct06515990/","asOf":"2026-09-16","days":5},{"id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","route":"/trials/nct06975410/","asOf":"2026-09-16","days":5},{"id":"nct06567782","kind":"trial","name":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","route":"/trials/nct06567782/","asOf":"2026-09-16","days":5},{"id":"nct05037279","kind":"trial","name":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","route":"/trials/nct05037279/","asOf":"2026-09-16","days":5},{"id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","route":"/trials/nct07314294/","asOf":"2026-09-16","days":5},{"id":"nct07429266","kind":"trial","name":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","route":"/trials/nct07429266/","asOf":"2026-09-16","days":5},{"id":"nct06634875","kind":"trial","name":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)","route":"/trials/nct06634875/","asOf":"2026-09-16","days":5},{"id":"nct07266428","kind":"trial","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","route":"/trials/nct07266428/","asOf":"2026-09-16","days":5},{"id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","route":"/trials/nct04183166/","asOf":"2026-09-16","days":5},{"id":"nct06163430","kind":"trial","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","route":"/trials/nct06163430/","asOf":"2026-09-16","days":5},{"id":"nct07439094","kind":"trial","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","route":"/trials/nct07439094/","asOf":"2026-09-16","days":5},{"id":"nct06868849","kind":"trial","name":"A Study of JMT203 in Patients With Cancer Cachexia","route":"/trials/nct06868849/","asOf":"2026-09-16","days":5},{"id":"nct05546268","kind":"trial","name":"Study of Oral MRT-2359 in Selected Cancer Patients","route":"/trials/nct05546268/","asOf":"2026-09-16","days":5},{"id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/","asOf":"2026-09-16","days":5},{"id":"nct06693375","kind":"trial","name":"To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.","route":"/trials/nct06693375/","asOf":"2026-09-16","days":5},{"id":"nct05120271","kind":"trial","name":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","route":"/trials/nct05120271/","asOf":"2026-09-16","days":5},{"id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","asOf":"2026-09-16","days":5},{"id":"nct06679036","kind":"trial","name":"A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients","route":"/trials/nct06679036/","asOf":"2026-09-16","days":5},{"id":"nct06581419","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06581419/","asOf":"2026-09-16","days":5},{"id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","route":"/trials/nct05941507/","asOf":"2026-09-16","days":5},{"id":"nct06533644","kind":"trial","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06533644/","asOf":"2026-09-16","days":5},{"id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","route":"/trials/nct06795022/","asOf":"2026-09-16","days":5},{"id":"nct05481151","kind":"trial","name":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","route":"/trials/nct05481151/","asOf":"2026-09-16","days":5},{"id":"nct02979522","kind":"trial","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","route":"/trials/nct02979522/","asOf":"2026-09-16","days":5},{"id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","asOf":"2026-09-16","days":5},{"id":"nct01594723","kind":"trial","name":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","route":"/trials/nct01594723/","asOf":"2026-09-16","days":5},{"id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/","asOf":"2026-09-16","days":5},{"id":"nct05334823","kind":"trial","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","route":"/trials/nct05334823/","asOf":"2026-09-16","days":5},{"id":"nct06732531","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06732531/","asOf":"2026-09-16","days":5},{"id":"nct06042894","kind":"trial","name":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","route":"/trials/nct06042894/","asOf":"2026-09-16","days":5},{"id":"nct07512583","kind":"trial","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","route":"/trials/nct07512583/","asOf":"2026-09-16","days":5},{"id":"nct07232602","kind":"trial","name":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","route":"/trials/nct07232602/","asOf":"2026-09-16","days":5},{"id":"nct03424005","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","route":"/trials/nct03424005/","asOf":"2026-09-16","days":5},{"id":"nct07415031","kind":"trial","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","route":"/trials/nct07415031/","asOf":"2026-09-16","days":5},{"id":"nct02503423","kind":"trial","name":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","route":"/trials/nct02503423/","asOf":"2026-09-16","days":5},{"id":"nct06554795","kind":"trial","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","route":"/trials/nct06554795/","asOf":"2026-09-16","days":5},{"id":"nct05624554","kind":"trial","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","route":"/trials/nct05624554/","asOf":"2026-09-16","days":5},{"id":"nct06901531","kind":"trial","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","route":"/trials/nct06901531/","asOf":"2026-09-16","days":5},{"id":"nct02966756","kind":"trial","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct02966756/","asOf":"2026-09-16","days":5},{"id":"nct07030257","kind":"trial","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07030257/","asOf":"2026-09-16","days":5},{"id":"nct05316701","kind":"trial","name":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","route":"/trials/nct05316701/","asOf":"2026-09-16","days":5},{"id":"nct05804045","kind":"trial","name":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","route":"/trials/nct05804045/","asOf":"2026-09-16","days":5},{"id":"nct07648030","kind":"trial","name":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","route":"/trials/nct07648030/","asOf":"2026-09-16","days":5},{"id":"nct06084936","kind":"trial","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct06084936/","asOf":"2026-09-16","days":5},{"id":"nct07172802","kind":"trial","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07172802/","asOf":"2026-09-16","days":5},{"id":"nct06209580","kind":"trial","name":"AMT-253 in Patients With Advanced Solid Tumours","route":"/trials/nct06209580/","asOf":"2026-09-16","days":5},{"id":"nct07283835","kind":"trial","name":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","route":"/trials/nct07283835/","asOf":"2026-09-16","days":5},{"id":"nct06926920","kind":"trial","name":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","route":"/trials/nct06926920/","asOf":"2026-09-16","days":5},{"id":"nct06208410","kind":"trial","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","route":"/trials/nct06208410/","asOf":"2026-09-16","days":5},{"id":"nct07766018","kind":"trial","name":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer","route":"/trials/nct07766018/","asOf":"2026-09-16","days":5},{"id":"nct06359860","kind":"trial","name":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","route":"/trials/nct06359860/","asOf":"2026-09-16","days":5},{"id":"nct05326243","kind":"trial","name":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","route":"/trials/nct05326243/","asOf":"2026-09-16","days":5},{"id":"nct07229586","kind":"trial","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","route":"/trials/nct07229586/","asOf":"2026-09-16","days":5},{"id":"nct06492005","kind":"trial","name":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06492005/","asOf":"2026-09-16","days":5},{"id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/","asOf":"2026-09-16","days":5},{"id":"nct07165886","kind":"trial","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","route":"/trials/nct07165886/","asOf":"2026-09-16","days":5},{"id":"nct03348670","kind":"trial","name":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","route":"/trials/nct03348670/","asOf":"2026-09-16","days":5},{"id":"nct06643754","kind":"trial","name":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct06643754/","asOf":"2026-09-16","days":5},{"id":"nct07249905","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","route":"/trials/nct07249905/","asOf":"2026-09-16","days":5},{"id":"nct05009329","kind":"trial","name":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","route":"/trials/nct05009329/","asOf":"2026-09-16","days":5},{"id":"nct06737081","kind":"trial","name":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","route":"/trials/nct06737081/","asOf":"2026-09-16","days":5},{"id":"nct05455619","kind":"trial","name":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer","route":"/trials/nct05455619/","asOf":"2026-09-16","days":5},{"id":"nct05883956","kind":"trial","name":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","route":"/trials/nct05883956/","asOf":"2026-09-16","days":5},{"id":"nct05768529","kind":"trial","name":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct05768529/","asOf":"2026-09-16","days":5},{"id":"nct04725474","kind":"trial","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","route":"/trials/nct04725474/","asOf":"2026-09-16","days":5},{"id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","asOf":"2026-09-16","days":5},{"id":"nct06249048","kind":"trial","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct06249048/","asOf":"2026-09-16","days":5},{"id":"nct07294508","kind":"trial","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07294508/","asOf":"2026-09-16","days":5},{"id":"nct03706690","kind":"trial","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","route":"/trials/nct03706690/","asOf":"2026-09-16","days":5},{"id":"nct07331155","kind":"trial","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","route":"/trials/nct07331155/","asOf":"2026-09-16","days":5},{"id":"nct06227117","kind":"trial","name":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","route":"/trials/nct06227117/","asOf":"2026-09-16","days":5},{"id":"nct07523555","kind":"trial","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","route":"/trials/nct07523555/","asOf":"2026-09-16","days":5},{"id":"nct06038578","kind":"trial","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","route":"/trials/nct06038578/","asOf":"2026-09-16","days":5},{"id":"nct06317311","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","route":"/trials/nct06317311/","asOf":"2026-09-16","days":5},{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","route":"/trials/nct03091192/","asOf":"2026-09-16","days":5},{"id":"nct06011109","kind":"trial","name":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","route":"/trials/nct06011109/","asOf":"2026-09-16","days":5},{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/","asOf":"2026-09-16","days":5},{"id":"nct07672236","kind":"trial","name":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.","route":"/trials/nct07672236/","asOf":"2026-09-16","days":5},{"id":"nct05731271","kind":"trial","name":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","route":"/trials/nct05731271/","asOf":"2026-09-16","days":5},{"id":"nct07102901","kind":"trial","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","route":"/trials/nct07102901/","asOf":"2026-09-16","days":5},{"id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","route":"/trials/nct07341100/","asOf":"2026-09-16","days":5},{"id":"nct07346144","kind":"trial","name":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","route":"/trials/nct07346144/","asOf":"2026-09-16","days":5},{"id":"nct05765032","kind":"trial","name":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","route":"/trials/nct05765032/","asOf":"2026-09-16","days":5},{"id":"nct05413018","kind":"trial","name":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission","route":"/trials/nct05413018/","asOf":"2026-09-16","days":5},{"id":"nct07160725","kind":"trial","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","route":"/trials/nct07160725/","asOf":"2026-09-16","days":5},{"id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","asOf":"2026-09-16","days":5},{"id":"nct07391813","kind":"trial","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","route":"/trials/nct07391813/","asOf":"2026-09-16","days":5},{"id":"nct06736704","kind":"trial","name":"SNV4818 in Participants With Advanced Solid Tumors","route":"/trials/nct06736704/","asOf":"2026-09-16","days":5},{"id":"nct06682793","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","route":"/trials/nct06682793/","asOf":"2026-09-16","days":5},{"id":"nct06319963","kind":"trial","name":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","route":"/trials/nct06319963/","asOf":"2026-09-16","days":5},{"id":"nct07122063","kind":"trial","name":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","route":"/trials/nct07122063/","asOf":"2026-09-16","days":5},{"id":"nct03816163","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","route":"/trials/nct03816163/","asOf":"2026-09-16","days":5},{"id":"nct03579836","kind":"trial","name":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","route":"/trials/nct03579836/","asOf":"2026-09-16","days":5},{"id":"nct07475806","kind":"trial","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","route":"/trials/nct07475806/","asOf":"2026-09-16","days":5},{"id":"nct04075292","kind":"trial","name":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct04075292/","asOf":"2026-09-16","days":5},{"id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07710885/","asOf":"2026-09-16","days":5},{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","route":"/trials/nct05224141/","asOf":"2026-09-16","days":5},{"id":"nct06276283","kind":"trial","name":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","route":"/trials/nct06276283/","asOf":"2026-09-16","days":5},{"id":"nct05263583","kind":"trial","name":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","route":"/trials/nct05263583/","asOf":"2026-09-16","days":5},{"id":"nct05771480","kind":"trial","name":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","route":"/trials/nct05771480/","asOf":"2026-09-16","days":5},{"id":"nct05785741","kind":"trial","name":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05785741/","asOf":"2026-09-16","days":5},{"id":"nct05133882","kind":"trial","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","route":"/trials/nct05133882/","asOf":"2026-09-16","days":5},{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/","asOf":"2026-09-16","days":5},{"id":"nct07036250","kind":"trial","name":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","route":"/trials/nct07036250/","asOf":"2026-09-16","days":5},{"id":"nct06566079","kind":"trial","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","route":"/trials/nct06566079/","asOf":"2026-09-16","days":5},{"id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","route":"/trials/nct05890742/","asOf":"2026-09-16","days":5},{"id":"nct04626479","kind":"trial","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","route":"/trials/nct04626479/","asOf":"2026-09-16","days":5},{"id":"nct06631989","kind":"trial","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06631989/","asOf":"2026-09-16","days":5},{"id":"nct07124117","kind":"trial","name":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","route":"/trials/nct07124117/","asOf":"2026-09-16","days":5},{"id":"nct06057610","kind":"trial","name":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct06057610/","asOf":"2026-09-16","days":5},{"id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","route":"/trials/nct07678684/","asOf":"2026-09-16","days":5},{"id":"nct05394831","kind":"trial","name":"A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC","route":"/trials/nct05394831/","asOf":"2026-09-16","days":5},{"id":"nct07252739","kind":"trial","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","route":"/trials/nct07252739/","asOf":"2026-09-16","days":5},{"id":"nct05440786","kind":"trial","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","route":"/trials/nct05440786/","asOf":"2026-09-16","days":5},{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","route":"/trials/nct05043922/","asOf":"2026-09-16","days":5},{"id":"nct06157151","kind":"trial","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06157151/","asOf":"2026-09-16","days":5},{"id":"nct03547973","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","route":"/trials/nct03547973/","asOf":"2026-09-16","days":5},{"id":"nct02763566","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","route":"/trials/nct02763566/","asOf":"2026-09-16","days":5},{"id":"nct06921837","kind":"trial","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","route":"/trials/nct06921837/","asOf":"2026-09-16","days":5},{"id":"nct05999994","kind":"trial","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","route":"/trials/nct05999994/","asOf":"2026-09-16","days":5},{"id":"nct07427394","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","route":"/trials/nct07427394/","asOf":"2026-09-16","days":5},{"id":"nct06247956","kind":"trial","name":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","route":"/trials/nct06247956/","asOf":"2026-09-16","days":5},{"id":"nct05142423","kind":"trial","name":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","route":"/trials/nct05142423/","asOf":"2026-09-16","days":5},{"id":"nct06312176","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","route":"/trials/nct06312176/","asOf":"2026-09-16","days":5},{"id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","asOf":"2026-09-16","days":5},{"id":"nct06062810","kind":"trial","name":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","route":"/trials/nct06062810/","asOf":"2026-09-16","days":5},{"id":"nct05168566","kind":"trial","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05168566/","asOf":"2026-09-16","days":5},{"id":"nct07446153","kind":"trial","name":"A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","route":"/trials/nct07446153/","asOf":"2026-09-16","days":5},{"id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06903377/","asOf":"2026-09-16","days":5},{"id":"nct05490472","kind":"trial","name":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","route":"/trials/nct05490472/","asOf":"2026-09-16","days":5},{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06974812/","asOf":"2026-09-16","days":5},{"id":"nct07286331","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","route":"/trials/nct07286331/","asOf":"2026-09-16","days":5},{"id":"nct07419295","kind":"trial","name":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","route":"/trials/nct07419295/","asOf":"2026-09-16","days":5},{"id":"nct06764875","kind":"trial","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","route":"/trials/nct06764875/","asOf":"2026-09-16","days":5},{"id":"nct05645692","kind":"trial","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","route":"/trials/nct05645692/","asOf":"2026-09-16","days":5},{"id":"nct06061809","kind":"trial","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","route":"/trials/nct06061809/","asOf":"2026-09-16","days":5},{"id":"nct05094336","kind":"trial","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","route":"/trials/nct05094336/","asOf":"2026-09-16","days":5},{"id":"nct05405595","kind":"trial","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct05405595/","asOf":"2026-09-16","days":5},{"id":"nct05840211","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","route":"/trials/nct05840211/","asOf":"2026-09-16","days":5},{"id":"nct07630974","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","route":"/trials/nct07630974/","asOf":"2026-09-16","days":5},{"id":"nct06343948","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)","route":"/trials/nct06343948/","asOf":"2026-09-16","days":5},{"id":"nct06084806","kind":"trial","name":"Test-retest Evaluation of [18F]F-AraG PET","route":"/trials/nct06084806/","asOf":"2026-09-16","days":5},{"id":"nct05985655","kind":"trial","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","route":"/trials/nct05985655/","asOf":"2026-09-16","days":5},{"id":"nct07558733","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","route":"/trials/nct07558733/","asOf":"2026-09-16","days":5},{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","asOf":"2026-09-16","days":5},{"id":"nct06710847","kind":"trial","name":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct06710847/","asOf":"2026-09-16","days":5},{"id":"nct06016738","kind":"trial","name":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct06016738/","asOf":"2026-09-16","days":5},{"id":"nct04718883","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","route":"/trials/nct04718883/","asOf":"2026-09-16","days":5},{"id":"nct04300556","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","route":"/trials/nct04300556/","asOf":"2026-09-16","days":5},{"id":"nct04488822","kind":"trial","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","route":"/trials/nct04488822/","asOf":"2026-09-16","days":5},{"id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/","asOf":"2026-09-16","days":5},{"id":"nct06593522","kind":"trial","name":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","route":"/trials/nct06593522/","asOf":"2026-09-16","days":5},{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/","asOf":"2026-09-16","days":5},{"id":"nct04771130","kind":"trial","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","route":"/trials/nct04771130/","asOf":"2026-09-16","days":5},{"id":"nct05596409","kind":"trial","name":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","route":"/trials/nct05596409/","asOf":"2026-09-16","days":5},{"id":"nct07129993","kind":"trial","name":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07129993/","asOf":"2026-09-16","days":5},{"id":"nct07243340","kind":"trial","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","route":"/trials/nct07243340/","asOf":"2026-09-16","days":5},{"id":"nct03682068","kind":"trial","name":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","route":"/trials/nct03682068/","asOf":"2026-09-16","days":5},{"id":"nct06971614","kind":"trial","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","route":"/trials/nct06971614/","asOf":"2026-09-16","days":5},{"id":"nct06783647","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","route":"/trials/nct06783647/","asOf":"2026-09-16","days":5},{"id":"nct06943833","kind":"trial","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","route":"/trials/nct06943833/","asOf":"2026-09-16","days":5},{"id":"nct05696626","kind":"trial","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","route":"/trials/nct05696626/","asOf":"2026-09-16","days":5},{"id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/","asOf":"2026-09-16","days":5},{"id":"nct05710848","kind":"trial","name":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","route":"/trials/nct05710848/","asOf":"2026-09-16","days":5},{"id":"nct05768919","kind":"trial","name":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","route":"/trials/nct05768919/","asOf":"2026-09-16","days":5},{"id":"nct06764628","kind":"trial","name":"A Study of SHR-4375 in Subjects With Solid Tumors","route":"/trials/nct06764628/","asOf":"2026-09-16","days":5},{"id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06995677/","asOf":"2026-09-16","days":5},{"id":"nct07280377","kind":"trial","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","route":"/trials/nct07280377/","asOf":"2026-09-16","days":5},{"id":"nct07498478","kind":"trial","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","route":"/trials/nct07498478/","asOf":"2026-09-16","days":5},{"id":"nct02952508","kind":"trial","name":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","route":"/trials/nct02952508/","asOf":"2026-09-16","days":5},{"id":"nct05485948","kind":"trial","name":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","route":"/trials/nct05485948/","asOf":"2026-09-16","days":5},{"id":"nct04208178","kind":"trial","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","route":"/trials/nct04208178/","asOf":"2026-09-16","days":5},{"id":"nct05498155","kind":"trial","name":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","route":"/trials/nct05498155/","asOf":"2026-09-16","days":5},{"id":"nct07302347","kind":"trial","name":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","route":"/trials/nct07302347/","asOf":"2026-09-16","days":5},{"id":"nct05844150","kind":"trial","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","route":"/trials/nct05844150/","asOf":"2026-09-16","days":5},{"id":"nct02584244","kind":"trial","name":"Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","route":"/trials/nct02584244/","asOf":"2026-09-16","days":5},{"id":"nct07282587","kind":"trial","name":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","route":"/trials/nct07282587/","asOf":"2026-09-16","days":5},{"id":"nct06008093","kind":"trial","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","route":"/trials/nct06008093/","asOf":"2026-09-16","days":5},{"id":"nct06643884","kind":"trial","name":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","route":"/trials/nct06643884/","asOf":"2026-09-16","days":5},{"id":"nct05459844","kind":"trial","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","route":"/trials/nct05459844/","asOf":"2026-09-16","days":5},{"id":"nct05709249","kind":"trial","name":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","route":"/trials/nct05709249/","asOf":"2026-09-16","days":5},{"id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","asOf":"2026-09-16","days":5},{"id":"nct04851717","kind":"trial","name":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","route":"/trials/nct04851717/","asOf":"2026-09-16","days":5},{"id":"nct07629726","kind":"trial","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","route":"/trials/nct07629726/","asOf":"2026-09-16","days":5},{"id":"nct04585035","kind":"trial","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","route":"/trials/nct04585035/","asOf":"2026-09-16","days":5},{"id":"nct07469774","kind":"trial","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07469774/","asOf":"2026-09-16","days":5},{"id":"nct06206174","kind":"trial","name":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies","route":"/trials/nct06206174/","asOf":"2026-09-16","days":5},{"id":"nct06214143","kind":"trial","name":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","route":"/trials/nct06214143/","asOf":"2026-09-16","days":5},{"id":"nct04969315","kind":"trial","name":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma","route":"/trials/nct04969315/","asOf":"2026-09-16","days":5},{"id":"nct07151040","kind":"trial","name":"Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","route":"/trials/nct07151040/","asOf":"2026-09-16","days":5},{"id":"nct07489716","kind":"trial","name":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","route":"/trials/nct07489716/","asOf":"2026-09-16","days":5},{"id":"nct05668858","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct05668858/","asOf":"2026-09-16","days":5},{"id":"nct04538664","kind":"trial","name":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","route":"/trials/nct04538664/","asOf":"2026-09-16","days":5},{"id":"nct04114825","kind":"trial","name":"Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer","route":"/trials/nct04114825/","asOf":"2026-09-16","days":5},{"id":"nct07436728","kind":"trial","name":"A Study of TAK-505 in Adults With Solid Tumors","route":"/trials/nct07436728/","asOf":"2026-09-16","days":5},{"id":"nct05948943","kind":"trial","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","route":"/trials/nct05948943/","asOf":"2026-09-16","days":5},{"id":"nct06951503","kind":"trial","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","route":"/trials/nct06951503/","asOf":"2026-09-16","days":5},{"id":"nct04864054","kind":"trial","name":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","route":"/trials/nct04864054/","asOf":"2026-09-16","days":5},{"id":"nct05687266","kind":"trial","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","route":"/trials/nct05687266/","asOf":"2026-09-16","days":5},{"id":"nct06235151","kind":"trial","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","route":"/trials/nct06235151/","asOf":"2026-09-16","days":5},{"id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06118788/","asOf":"2026-09-16","days":5},{"id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","route":"/trials/nct05862324/","asOf":"2026-09-16","days":5},{"id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","route":"/trials/nct06314373/","asOf":"2026-09-16","days":5},{"id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","route":"/trials/nct06971523/","asOf":"2026-09-16","days":5},{"id":"nct06771622","kind":"trial","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","route":"/trials/nct06771622/","asOf":"2026-09-16","days":5},{"id":"nct06555068","kind":"trial","name":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients","route":"/trials/nct06555068/","asOf":"2026-09-16","days":5},{"id":"nct06151574","kind":"trial","name":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","route":"/trials/nct06151574/","asOf":"2026-09-16","days":5},{"id":"nct06702618","kind":"trial","name":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","route":"/trials/nct06702618/","asOf":"2026-09-16","days":5},{"id":"nct05475925","kind":"trial","name":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","route":"/trials/nct05475925/","asOf":"2026-09-16","days":5},{"id":"nct04262466","kind":"trial","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","route":"/trials/nct04262466/","asOf":"2026-09-16","days":5},{"id":"nct06895928","kind":"trial","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","route":"/trials/nct06895928/","asOf":"2026-09-16","days":5},{"id":"nct04404595","kind":"trial","name":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","route":"/trials/nct04404595/","asOf":"2026-09-16","days":5},{"id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","asOf":"2026-09-16","days":5},{"id":"nct03671044","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients","route":"/trials/nct03671044/","asOf":"2026-09-16","days":5},{"id":"nct04589234","kind":"trial","name":"Saltikva for Metastatic Pancreatic Cancer","route":"/trials/nct04589234/","asOf":"2026-09-16","days":5},{"id":"nct04587830","kind":"trial","name":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","route":"/trials/nct04587830/","asOf":"2026-09-16","days":5},{"id":"nct07277231","kind":"trial","name":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct07277231/","asOf":"2026-09-16","days":5},{"id":"nct07586202","kind":"trial","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","route":"/trials/nct07586202/","asOf":"2026-09-16","days":5},{"id":"nct05862272","kind":"trial","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","route":"/trials/nct05862272/","asOf":"2026-09-16","days":5},{"id":"nct06687681","kind":"trial","name":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","route":"/trials/nct06687681/","asOf":"2026-09-16","days":5},{"id":"nct04521413","kind":"trial","name":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","route":"/trials/nct04521413/","asOf":"2026-09-16","days":5},{"id":"nct04025879","kind":"trial","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","route":"/trials/nct04025879/","asOf":"2026-09-16","days":5},{"id":"nct06730750","kind":"trial","name":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","route":"/trials/nct06730750/","asOf":"2026-09-16","days":5},{"id":"nct05945823","kind":"trial","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","route":"/trials/nct05945823/","asOf":"2026-09-16","days":5},{"id":"nct06414460","kind":"trial","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","route":"/trials/nct06414460/","asOf":"2026-09-16","days":5},{"id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","route":"/trials/nct06384807/","asOf":"2026-09-16","days":5},{"id":"nct05261399","kind":"trial","name":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","route":"/trials/nct05261399/","asOf":"2026-09-16","days":5},{"id":"nct05329532","kind":"trial","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","route":"/trials/nct05329532/","asOf":"2026-09-16","days":5},{"id":"nct06568692","kind":"trial","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","route":"/trials/nct06568692/","asOf":"2026-09-16","days":5},{"id":"nct07228247","kind":"trial","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","route":"/trials/nct07228247/","asOf":"2026-09-16","days":5},{"id":"nct06119581","kind":"trial","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","route":"/trials/nct06119581/","asOf":"2026-09-16","days":5},{"id":"nct06428019","kind":"trial","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct06428019/","asOf":"2026-09-16","days":5},{"id":"nct05933265","kind":"trial","name":"Study of LP-184 in Patients With Advanced Solid Tumors","route":"/trials/nct05933265/","asOf":"2026-09-16","days":5},{"id":"nct07192107","kind":"trial","name":"A Study of MHB042C in Patients With Advanced Solid Tumors","route":"/trials/nct07192107/","asOf":"2026-09-16","days":5},{"id":"nct07169851","kind":"trial","name":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","route":"/trials/nct07169851/","asOf":"2026-09-16","days":5},{"id":"nct06538857","kind":"trial","name":"CEB-01 in Locally Resectable Pancreatic Cancer","route":"/trials/nct06538857/","asOf":"2026-09-16","days":5},{"id":"nct04762069","kind":"trial","name":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","route":"/trials/nct04762069/","asOf":"2026-09-16","days":5},{"id":"nct07689201","kind":"trial","name":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","route":"/trials/nct07689201/","asOf":"2026-09-16","days":5},{"id":"nct07126665","kind":"trial","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07126665/","asOf":"2026-09-16","days":5},{"id":"nct07002177","kind":"trial","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","route":"/trials/nct07002177/","asOf":"2026-09-16","days":5},{"id":"nct07229612","kind":"trial","name":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07229612/","asOf":"2026-09-16","days":5},{"id":"nct07547553","kind":"trial","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","route":"/trials/nct07547553/","asOf":"2026-09-16","days":5},{"id":"nct07146672","kind":"trial","name":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","route":"/trials/nct07146672/","asOf":"2026-09-16","days":5},{"id":"nct07380386","kind":"trial","name":"SKB105 for Injection in Advanced Solid Tumors","route":"/trials/nct07380386/","asOf":"2026-09-16","days":5},{"id":"nct06909877","kind":"trial","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/","asOf":"2026-09-16","days":5},{"id":"nct07415863","kind":"trial","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","route":"/trials/nct07415863/","asOf":"2026-09-16","days":5},{"id":"nct06389006","kind":"trial","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","route":"/trials/nct06389006/","asOf":"2026-09-16","days":5},{"id":"nct07258121","kind":"trial","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","route":"/trials/nct07258121/","asOf":"2026-09-16","days":5},{"id":"nct04634357","kind":"trial","name":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","route":"/trials/nct04634357/","asOf":"2026-09-16","days":5},{"id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06911333/","asOf":"2026-09-16","days":5},{"id":"nct07111832","kind":"trial","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","route":"/trials/nct07111832/","asOf":"2026-09-16","days":5},{"id":"nct07225621","kind":"trial","name":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","route":"/trials/nct07225621/","asOf":"2026-09-16","days":5},{"id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","route":"/trials/nct06966700/","asOf":"2026-09-16","days":5},{"id":"nct06232096","kind":"trial","name":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","route":"/trials/nct06232096/","asOf":"2026-09-16","days":5},{"id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","route":"/trials/nct06380660/","asOf":"2026-09-16","days":5},{"id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/","asOf":"2026-09-16","days":5},{"id":"nct06060613","kind":"trial","name":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","route":"/trials/nct06060613/","asOf":"2026-09-16","days":5},{"id":"nct07185880","kind":"trial","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","route":"/trials/nct07185880/","asOf":"2026-09-16","days":5},{"id":"nct03148418","kind":"trial","name":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","route":"/trials/nct03148418/","asOf":"2026-09-16","days":5},{"id":"nct05867420","kind":"trial","name":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","route":"/trials/nct05867420/","asOf":"2026-09-16","days":5},{"id":"nct05833724","kind":"trial","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","route":"/trials/nct05833724/","asOf":"2026-09-16","days":5},{"id":"nct06144671","kind":"trial","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","route":"/trials/nct06144671/","asOf":"2026-09-16","days":5},{"id":"nct07795034","kind":"trial","name":"To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies","route":"/trials/nct07795034/","asOf":"2026-09-16","days":5},{"id":"nct05434234","kind":"trial","name":"A Study of YL201 in Patients With Advanced Solid Tumors","route":"/trials/nct05434234/","asOf":"2026-09-16","days":5},{"id":"nct07169734","kind":"trial","name":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","route":"/trials/nct07169734/","asOf":"2026-09-16","days":5},{"id":"nct06598787","kind":"trial","name":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","route":"/trials/nct06598787/","asOf":"2026-09-16","days":5},{"id":"nct05748171","kind":"trial","name":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","route":"/trials/nct05748171/","asOf":"2026-09-16","days":5},{"id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/","asOf":"2026-09-16","days":5},{"id":"nct06191263","kind":"trial","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","route":"/trials/nct06191263/","asOf":"2026-09-16","days":5},{"id":"nct04971226","kind":"trial","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","route":"/trials/nct04971226/","asOf":"2026-09-16","days":5},{"id":"nct07518147","kind":"trial","name":"A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment","route":"/trials/nct07518147/","asOf":"2026-09-16","days":5},{"id":"nct06588478","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct06588478/","asOf":"2026-09-16","days":5},{"id":"nct06769113","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","route":"/trials/nct06769113/","asOf":"2026-09-16","days":5},{"id":"nct06111235","kind":"trial","name":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","route":"/trials/nct06111235/","asOf":"2026-09-16","days":5},{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07299747/","asOf":"2026-09-16","days":5},{"id":"nct05601726","kind":"trial","name":"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","route":"/trials/nct05601726/","asOf":"2026-09-16","days":5},{"id":"nct07286149","kind":"trial","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","route":"/trials/nct07286149/","asOf":"2026-09-16","days":5},{"id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","route":"/trials/nct05523947/","asOf":"2026-09-16","days":5},{"id":"nct07147348","kind":"trial","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","route":"/trials/nct07147348/","asOf":"2026-09-16","days":5},{"id":"nct05700084","kind":"trial","name":"Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors","route":"/trials/nct05700084/","asOf":"2026-09-16","days":5},{"id":"nct05347134","kind":"trial","name":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct05347134/","asOf":"2026-09-16","days":5},{"id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","route":"/trials/nct07448116/","asOf":"2026-09-16","days":5},{"id":"nct04121455","kind":"trial","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","route":"/trials/nct04121455/","asOf":"2026-09-16","days":5},{"id":"nct02477696","kind":"trial","name":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct02477696/","asOf":"2026-09-16","days":5},{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","asOf":"2026-09-16","days":5},{"id":"nct06533579","kind":"trial","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","route":"/trials/nct06533579/","asOf":"2026-09-16","days":5},{"id":"nct06712680","kind":"trial","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","route":"/trials/nct06712680/","asOf":"2026-09-16","days":5},{"id":"nct03591510","kind":"trial","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","route":"/trials/nct03591510/","asOf":"2026-09-16","days":5},{"id":"nct06857175","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","route":"/trials/nct06857175/","asOf":"2026-09-16","days":5},{"id":"nct05315167","kind":"trial","name":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","route":"/trials/nct05315167/","asOf":"2026-09-16","days":5},{"id":"nct06846671","kind":"trial","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","route":"/trials/nct06846671/","asOf":"2026-09-16","days":5},{"id":"nct06305767","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","route":"/trials/nct06305767/","asOf":"2026-09-16","days":5},{"id":"nct05645107","kind":"trial","name":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","route":"/trials/nct05645107/","asOf":"2026-09-16","days":5},{"id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/","asOf":"2026-09-16","days":5},{"id":"nct07060807","kind":"trial","name":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","route":"/trials/nct07060807/","asOf":"2026-09-16","days":5},{"id":"nct07213609","kind":"trial","name":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct07213609/","asOf":"2026-09-16","days":5},{"id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","route":"/trials/nct07327034/","asOf":"2026-09-16","days":5},{"id":"nct07575191","kind":"trial","name":"Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","route":"/trials/nct07575191/","asOf":"2026-09-16","days":5},{"id":"nct05262010","kind":"trial","name":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","route":"/trials/nct05262010/","asOf":"2026-09-16","days":5},{"id":"nct05518045","kind":"trial","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","route":"/trials/nct05518045/","asOf":"2026-09-16","days":5},{"id":"nct06116136","kind":"trial","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","route":"/trials/nct06116136/","asOf":"2026-09-16","days":5},{"id":"nct06166836","kind":"trial","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","route":"/trials/nct06166836/","asOf":"2026-09-16","days":5},{"id":"nct06940739","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","route":"/trials/nct06940739/","asOf":"2026-09-16","days":5},{"id":"nct03444844","kind":"trial","name":"Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer","route":"/trials/nct03444844/","asOf":"2026-09-16","days":5},{"id":"nct02257736","kind":"trial","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/nct02257736/","asOf":"2026-09-16","days":5},{"id":"nct06083207","kind":"trial","name":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06083207/","asOf":"2026-09-16","days":5},{"id":"nct06055439","kind":"trial","name":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","route":"/trials/nct06055439/","asOf":"2026-09-16","days":5},{"id":"nct06973564","kind":"trial","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","route":"/trials/nct06973564/","asOf":"2026-09-16","days":5},{"id":"nct02938299","kind":"trial","name":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","route":"/trials/nct02938299/","asOf":"2026-09-16","days":5},{"id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","asOf":"2026-09-16","days":5},{"id":"nct02107703","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","route":"/trials/nct02107703/","asOf":"2026-09-16","days":5},{"id":"nct05299424","kind":"trial","name":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05299424/","asOf":"2026-09-16","days":5},{"id":"nct06038396","kind":"trial","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct06038396/","asOf":"2026-09-16","days":5},{"id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","route":"/trials/nct07538804/","asOf":"2026-09-16","days":5},{"id":"nct05544552","kind":"trial","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","route":"/trials/nct05544552/","asOf":"2026-09-16","days":5},{"id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","asOf":"2026-09-16","days":5},{"id":"nct06635447","kind":"trial","name":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","route":"/trials/nct06635447/","asOf":"2026-09-16","days":5},{"id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","route":"/trials/nct07253116/","asOf":"2026-09-16","days":5},{"id":"nct06431243","kind":"trial","name":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06431243/","asOf":"2026-09-16","days":5},{"id":"nct04925479","kind":"trial","name":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","route":"/trials/nct04925479/","asOf":"2026-09-16","days":5},{"id":"nct06807359","kind":"trial","name":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","route":"/trials/nct06807359/","asOf":"2026-09-16","days":5},{"id":"nct05023980","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05023980/","asOf":"2026-09-16","days":5},{"id":"nct06957379","kind":"trial","name":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","route":"/trials/nct06957379/","asOf":"2026-09-16","days":5},{"id":"nct04538742","kind":"trial","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","route":"/trials/nct04538742/","asOf":"2026-09-16","days":5},{"id":"nct04724980","kind":"trial","name":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","route":"/trials/nct04724980/","asOf":"2026-09-16","days":5},{"id":"nct04229979","kind":"trial","name":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","route":"/trials/nct04229979/","asOf":"2026-09-16","days":5},{"id":"nct03686124","kind":"trial","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct03686124/","asOf":"2026-09-16","days":5},{"id":"nct06669117","kind":"trial","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","route":"/trials/nct06669117/","asOf":"2026-09-16","days":5},{"id":"nct06980480","kind":"trial","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","route":"/trials/nct06980480/","asOf":"2026-09-16","days":5},{"id":"nct06349980","kind":"trial","name":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","route":"/trials/nct06349980/","asOf":"2026-09-16","days":5},{"id":"nct06319820","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","route":"/trials/nct06319820/","asOf":"2026-09-16","days":5},{"id":"nct07008703","kind":"trial","name":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","route":"/trials/nct07008703/","asOf":"2026-09-16","days":5},{"id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","route":"/trials/nct07359066/","asOf":"2026-09-16","days":5},{"id":"nct07070219","kind":"trial","name":"A Study of CTD402 in T-ALL/LBL Patients","route":"/trials/nct07070219/","asOf":"2026-09-16","days":5},{"id":"nct05562830","kind":"trial","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","route":"/trials/nct05562830/","asOf":"2026-09-16","days":5},{"id":"nct07421700","kind":"trial","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","route":"/trials/nct07421700/","asOf":"2026-09-16","days":5},{"id":"nct06211764","kind":"trial","name":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","route":"/trials/nct06211764/","asOf":"2026-09-16","days":5},{"id":"nct05482971","kind":"trial","name":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","route":"/trials/nct05482971/","asOf":"2026-09-16","days":5},{"id":"nct06467357","kind":"trial","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","route":"/trials/nct06467357/","asOf":"2026-09-16","days":5},{"id":"nct07582432","kind":"trial","name":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","route":"/trials/nct07582432/","asOf":"2026-09-16","days":5},{"id":"nct05429632","kind":"trial","name":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","route":"/trials/nct05429632/","asOf":"2026-09-16","days":5},{"id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","asOf":"2026-09-16","days":5},{"id":"nct06449222","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","route":"/trials/nct06449222/","asOf":"2026-09-16","days":5},{"id":"nct07297212","kind":"trial","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","route":"/trials/nct07297212/","asOf":"2026-09-16","days":5},{"id":"nct06778031","kind":"trial","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct06778031/","asOf":"2026-09-16","days":5},{"id":"nct06669975","kind":"trial","name":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","route":"/trials/nct06669975/","asOf":"2026-09-16","days":5},{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/","asOf":"2026-09-16","days":5},{"id":"nct06885281","kind":"trial","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","route":"/trials/nct06885281/","asOf":"2026-09-16","days":5},{"id":"nct07605728","kind":"trial","name":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","route":"/trials/nct07605728/","asOf":"2026-09-16","days":5},{"id":"nct05119907","kind":"trial","name":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","route":"/trials/nct05119907/","asOf":"2026-09-16","days":5},{"id":"nct06003231","kind":"trial","name":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","route":"/trials/nct06003231/","asOf":"2026-09-16","days":5},{"id":"nct07148128","kind":"trial","name":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","route":"/trials/nct07148128/","asOf":"2026-09-16","days":5},{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/","asOf":"2026-09-16","days":5},{"id":"nct07341737","kind":"trial","name":"SL-28 for Advanced Solid Tumours","route":"/trials/nct07341737/","asOf":"2026-09-16","days":5},{"id":"nct05876754","kind":"trial","name":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","route":"/trials/nct05876754/","asOf":"2026-09-16","days":5},{"id":"nct07112222","kind":"trial","name":"A Study of LM-350 in Subjects With Advanced Solid Tumours","route":"/trials/nct07112222/","asOf":"2026-09-16","days":5},{"id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/","asOf":"2026-09-16","days":5},{"id":"nct06797986","kind":"trial","name":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","route":"/trials/nct06797986/","asOf":"2026-09-16","days":5},{"id":"nct07566156","kind":"trial","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","route":"/trials/nct07566156/","asOf":"2026-09-16","days":5},{"id":"nct05827796","kind":"trial","name":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct05827796/","asOf":"2026-09-16","days":5},{"id":"nct06840483","kind":"trial","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","route":"/trials/nct06840483/","asOf":"2026-09-16","days":5},{"id":"nct06033586","kind":"trial","name":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","route":"/trials/nct06033586/","asOf":"2026-09-16","days":5},{"id":"nct06244992","kind":"trial","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06244992/","asOf":"2026-09-16","days":5},{"id":"nct07617493","kind":"trial","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","route":"/trials/nct07617493/","asOf":"2026-09-16","days":5},{"id":"nct05417321","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","route":"/trials/nct05417321/","asOf":"2026-09-16","days":5},{"id":"nct03036098","kind":"trial","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","route":"/trials/nct03036098/","asOf":"2026-09-16","days":5},{"id":"nct07093970","kind":"trial","name":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct07093970/","asOf":"2026-09-16","days":5},{"id":"nct05482568","kind":"trial","name":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct05482568/","asOf":"2026-09-16","days":5},{"id":"nct07492680","kind":"trial","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","route":"/trials/nct07492680/","asOf":"2026-09-16","days":5},{"id":"nct06385925","kind":"trial","name":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct06385925/","asOf":"2026-09-16","days":5},{"id":"nct04256317","kind":"trial","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","route":"/trials/nct04256317/","asOf":"2026-09-16","days":5},{"id":"nct07268040","kind":"trial","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07268040/","asOf":"2026-09-16","days":5},{"id":"nct06292208","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","route":"/trials/nct06292208/","asOf":"2026-09-16","days":5},{"id":"nct05563220","kind":"trial","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","route":"/trials/nct05563220/","asOf":"2026-09-16","days":5},{"id":"nct07231068","kind":"trial","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","route":"/trials/nct07231068/","asOf":"2026-09-16","days":5},{"id":"nct03850574","kind":"trial","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct03850574/","asOf":"2026-09-16","days":5},{"id":"nct06797635","kind":"trial","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","route":"/trials/nct06797635/","asOf":"2026-09-16","days":5},{"id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","route":"/trials/nct06898450/","asOf":"2026-09-16","days":5},{"id":"nct02671435","kind":"trial","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","route":"/trials/nct02671435/","asOf":"2026-09-16","days":5},{"id":"nct07028268","kind":"trial","name":"A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors","route":"/trials/nct07028268/","asOf":"2026-09-16","days":5},{"id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","route":"/trials/nct06877650/","asOf":"2026-09-16","days":5},{"id":"nct02970318","kind":"trial","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","route":"/trials/nct02970318/","asOf":"2026-09-16","days":5},{"id":"nct04603807","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","route":"/trials/nct04603807/","asOf":"2026-09-16","days":5},{"id":"nct07171606","kind":"trial","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","route":"/trials/nct07171606/","asOf":"2026-09-16","days":5},{"id":"nct05227664","kind":"trial","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05227664/","asOf":"2026-09-16","days":5},{"id":"nct07033598","kind":"trial","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","route":"/trials/nct07033598/","asOf":"2026-09-16","days":5},{"id":"nct06868199","kind":"trial","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","route":"/trials/nct06868199/","asOf":"2026-09-16","days":5},{"id":"nct06824064","kind":"trial","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","route":"/trials/nct06824064/","asOf":"2026-09-16","days":5},{"id":"nct06844357","kind":"trial","name":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","route":"/trials/nct06844357/","asOf":"2026-09-16","days":5},{"id":"nct07392736","kind":"trial","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","route":"/trials/nct07392736/","asOf":"2026-09-16","days":5},{"id":"nct06105021","kind":"trial","name":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","route":"/trials/nct06105021/","asOf":"2026-09-16","days":5},{"id":"nct05704244","kind":"trial","name":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","route":"/trials/nct05704244/","asOf":"2026-09-16","days":5},{"id":"nct06938321","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06938321/","asOf":"2026-09-16","days":5},{"id":"nct06440057","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.","route":"/trials/nct06440057/","asOf":"2026-09-16","days":5},{"id":"nct06797999","kind":"trial","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","route":"/trials/nct06797999/","asOf":"2026-09-16","days":5},{"id":"nct07743112","kind":"trial","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","route":"/trials/nct07743112/","asOf":"2026-09-16","days":5},{"id":"nct03485209","kind":"trial","name":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","route":"/trials/nct03485209/","asOf":"2026-09-16","days":5},{"id":"nct05205330","kind":"trial","name":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","route":"/trials/nct05205330/","asOf":"2026-09-16","days":5},{"id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/","asOf":"2026-09-16","days":5},{"id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","asOf":"2026-09-16","days":5},{"id":"nct05970016","kind":"trial","name":"A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.","route":"/trials/nct05970016/","asOf":"2026-09-16","days":5},{"id":"nct06636682","kind":"trial","name":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","route":"/trials/nct06636682/","asOf":"2026-09-16","days":5},{"id":"nct05678270","kind":"trial","name":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","route":"/trials/nct05678270/","asOf":"2026-09-16","days":5},{"id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/","asOf":"2026-09-16","days":5},{"id":"nct07102004","kind":"trial","name":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","route":"/trials/nct07102004/","asOf":"2026-09-16","days":5},{"id":"nct06431490","kind":"trial","name":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","route":"/trials/nct06431490/","asOf":"2026-09-16","days":5},{"id":"nct07287098","kind":"trial","name":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","route":"/trials/nct07287098/","asOf":"2026-09-16","days":5},{"id":"nct07109414","kind":"trial","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","route":"/trials/nct07109414/","asOf":"2026-09-16","days":5},{"id":"nct07324304","kind":"trial","name":"NWRD06 DNA Plasmid for HCC After Curative Resection.","route":"/trials/nct07324304/","asOf":"2026-09-16","days":5},{"id":"nct02516241","kind":"trial","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","route":"/trials/nct02516241/","asOf":"2026-09-16","days":5},{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/","asOf":"2026-09-16","days":5},{"id":"nct04078295","kind":"trial","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","route":"/trials/nct04078295/","asOf":"2026-09-16","days":5},{"id":"nct07056777","kind":"trial","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","route":"/trials/nct07056777/","asOf":"2026-09-16","days":5},{"id":"nct06998407","kind":"trial","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","route":"/trials/nct06998407/","asOf":"2026-09-16","days":5},{"id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","route":"/trials/nct07271667/","asOf":"2026-09-16","days":5},{"id":"nct04509700","kind":"trial","name":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","route":"/trials/nct04509700/","asOf":"2026-09-16","days":5},{"id":"nct06855771","kind":"trial","name":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","route":"/trials/nct06855771/","asOf":"2026-09-16","days":5},{"id":"nct06245330","kind":"trial","name":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","route":"/trials/nct06245330/","asOf":"2026-09-16","days":5},{"id":"nct06668792","kind":"trial","name":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06668792/","asOf":"2026-09-16","days":5},{"id":"nct07106892","kind":"trial","name":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","route":"/trials/nct07106892/","asOf":"2026-09-16","days":5},{"id":"nct07742215","kind":"trial","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","route":"/trials/nct07742215/","asOf":"2026-09-16","days":5},{"id":"nct03381274","kind":"trial","name":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","route":"/trials/nct03381274/","asOf":"2026-09-16","days":5},{"id":"nct06220318","kind":"trial","name":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","route":"/trials/nct06220318/","asOf":"2026-09-16","days":5},{"id":"nct04299191","kind":"trial","name":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","route":"/trials/nct04299191/","asOf":"2026-09-16","days":5},{"id":"nct06510374","kind":"trial","name":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06510374/","asOf":"2026-09-16","days":5},{"id":"nct01874353","kind":"trial","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","route":"/trials/nct01874353/","asOf":"2026-09-16","days":5},{"id":"nct07131202","kind":"trial","name":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","route":"/trials/nct07131202/","asOf":"2026-09-16","days":5},{"id":"nct05934331","kind":"trial","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","route":"/trials/nct05934331/","asOf":"2026-09-16","days":5},{"id":"nct06012695","kind":"trial","name":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","route":"/trials/nct06012695/","asOf":"2026-09-16","days":5},{"id":"nct04554914","kind":"trial","name":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","route":"/trials/nct04554914/","asOf":"2026-09-16","days":5},{"id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","route":"/trials/nct06082102/","asOf":"2026-09-16","days":5},{"id":"nct07548177","kind":"trial","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","route":"/trials/nct07548177/","asOf":"2026-09-16","days":5},{"id":"nct06863272","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","route":"/trials/nct06863272/","asOf":"2026-09-16","days":5},{"id":"nct05943106","kind":"trial","name":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","route":"/trials/nct05943106/","asOf":"2026-09-16","days":5},{"id":"nct05032040","kind":"trial","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","route":"/trials/nct05032040/","asOf":"2026-09-16","days":5},{"id":"nct05944224","kind":"trial","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","route":"/trials/nct05944224/","asOf":"2026-09-16","days":5},{"id":"nct05642780","kind":"trial","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","route":"/trials/nct05642780/","asOf":"2026-09-16","days":5},{"id":"nct06745908","kind":"trial","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","route":"/trials/nct06745908/","asOf":"2026-09-16","days":5},{"id":"nct07259317","kind":"trial","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07259317/","asOf":"2026-09-16","days":5},{"id":"nct06120140","kind":"trial","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","route":"/trials/nct06120140/","asOf":"2026-09-16","days":5},{"id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","asOf":"2026-09-16","days":5},{"id":"nct03386513","kind":"trial","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","route":"/trials/nct03386513/","asOf":"2026-09-16","days":5},{"id":"nct06468358","kind":"trial","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct06468358/","asOf":"2026-09-16","days":5},{"id":"nct07060989","kind":"trial","name":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","route":"/trials/nct07060989/","asOf":"2026-09-16","days":5},{"id":"nct06126510","kind":"trial","name":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","route":"/trials/nct06126510/","asOf":"2026-09-16","days":5},{"id":"nct07227350","kind":"trial","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct07227350/","asOf":"2026-09-16","days":5},{"id":"nct06662786","kind":"trial","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","route":"/trials/nct06662786/","asOf":"2026-09-16","days":5},{"id":"nct05261750","kind":"trial","name":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","route":"/trials/nct05261750/","asOf":"2026-09-16","days":5},{"id":"nct06055959","kind":"trial","name":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","route":"/trials/nct06055959/","asOf":"2026-09-16","days":5},{"id":"nct05322590","kind":"trial","name":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","route":"/trials/nct05322590/","asOf":"2026-09-16","days":5},{"id":"nct05263960","kind":"trial","name":"A Study of CM350 in Patients With Advanced Solid Tumors","route":"/trials/nct05263960/","asOf":"2026-09-16","days":5},{"id":"nct04652076","kind":"trial","name":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","route":"/trials/nct04652076/","asOf":"2026-09-16","days":5},{"id":"nct04044768","kind":"trial","name":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","route":"/trials/nct04044768/","asOf":"2026-09-16","days":5},{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05923008/","asOf":"2026-09-16","days":5},{"id":"nct05609968","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","route":"/trials/nct05609968/","asOf":"2026-09-16","days":5},{"id":"nct05265091","kind":"trial","name":"A Study of KL590586 in Patients With Advanced Solid Tumors","route":"/trials/nct05265091/","asOf":"2026-09-16","days":5},{"id":"nct06639347","kind":"trial","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","route":"/trials/nct06639347/","asOf":"2026-09-16","days":5},{"id":"nct04980885","kind":"trial","name":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","route":"/trials/nct04980885/","asOf":"2026-09-16","days":5},{"id":"nct05445843","kind":"trial","name":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","route":"/trials/nct05445843/","asOf":"2026-09-16","days":5},{"id":"nct03897543","kind":"trial","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","route":"/trials/nct03897543/","asOf":"2026-09-16","days":5},{"id":"nct07481058","kind":"trial","name":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","route":"/trials/nct07481058/","asOf":"2026-09-16","days":5},{"id":"nct06221748","kind":"trial","name":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","route":"/trials/nct06221748/","asOf":"2026-09-16","days":5},{"id":"nct06858618","kind":"trial","name":"FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms","route":"/trials/nct06858618/","asOf":"2026-09-16","days":5},{"id":"nct05658003","kind":"trial","name":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","route":"/trials/nct05658003/","asOf":"2026-09-16","days":5},{"id":"nct05902169","kind":"trial","name":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","route":"/trials/nct05902169/","asOf":"2026-09-16","days":5},{"id":"nct06953323","kind":"trial","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","route":"/trials/nct06953323/","asOf":"2026-09-16","days":5},{"id":"nct06385080","kind":"trial","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","route":"/trials/nct06385080/","asOf":"2026-09-16","days":5},{"id":"nct07192588","kind":"trial","name":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","route":"/trials/nct07192588/","asOf":"2026-09-16","days":5},{"id":"nct06566586","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","route":"/trials/nct06566586/","asOf":"2026-09-16","days":5},{"id":"nct06959082","kind":"trial","name":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","route":"/trials/nct06959082/","asOf":"2026-09-16","days":5},{"id":"nct06008288","kind":"trial","name":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","route":"/trials/nct06008288/","asOf":"2026-09-16","days":5},{"id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct05584670/","asOf":"2026-09-16","days":5},{"id":"nct05646862","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","route":"/trials/nct05646862/","asOf":"2026-09-16","days":5},{"id":"nct06109779","kind":"trial","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","route":"/trials/nct06109779/","asOf":"2026-09-16","days":5},{"id":"nct06118086","kind":"trial","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","route":"/trials/nct06118086/","asOf":"2026-09-16","days":5},{"id":"nct05479994","kind":"trial","name":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05479994/","asOf":"2026-09-16","days":5},{"id":"nct07110571","kind":"trial","name":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","route":"/trials/nct07110571/","asOf":"2026-09-16","days":5},{"id":"nct04977024","kind":"trial","name":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","route":"/trials/nct04977024/","asOf":"2026-09-16","days":5},{"id":"nct06667908","kind":"trial","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667908/","asOf":"2026-09-16","days":5},{"id":"nct07359820","kind":"trial","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","route":"/trials/nct07359820/","asOf":"2026-09-16","days":5},{"id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","route":"/trials/nct05548296/","asOf":"2026-09-16","days":5},{"id":"nct06178159","kind":"trial","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","route":"/trials/nct06178159/","asOf":"2026-09-16","days":5},{"id":"nct03812874","kind":"trial","name":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","route":"/trials/nct03812874/","asOf":"2026-09-16","days":5},{"id":"nct02453282","kind":"trial","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct02453282/","asOf":"2026-09-16","days":5},{"id":"nct04774718","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","route":"/trials/nct04774718/","asOf":"2026-09-16","days":5},{"id":"nct06549946","kind":"trial","name":"Ixovex-1 Single Agent and Combination Therapy","route":"/trials/nct06549946/","asOf":"2026-09-16","days":5},{"id":"nct05732103","kind":"trial","name":"A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","route":"/trials/nct05732103/","asOf":"2026-09-16","days":5},{"id":"nct05623982","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct05623982/","asOf":"2026-09-16","days":5},{"id":"nct06378242","kind":"trial","name":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","route":"/trials/nct06378242/","asOf":"2026-09-16","days":5},{"id":"nct04873362","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","route":"/trials/nct04873362/","asOf":"2026-09-16","days":5},{"id":"nct07644039","kind":"trial","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","route":"/trials/nct07644039/","asOf":"2026-09-16","days":5},{"id":"nct03319628","kind":"trial","name":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","route":"/trials/nct03319628/","asOf":"2026-09-16","days":5},{"id":"nct05112965","kind":"trial","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","route":"/trials/nct05112965/","asOf":"2026-09-16","days":5},{"id":"nct06157892","kind":"trial","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","route":"/trials/nct06157892/","asOf":"2026-09-16","days":5},{"id":"nct06962267","kind":"trial","name":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","route":"/trials/nct06962267/","asOf":"2026-09-16","days":5},{"id":"nct07085767","kind":"trial","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct07085767/","asOf":"2026-09-16","days":5},{"id":"nct06960577","kind":"trial","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","route":"/trials/nct06960577/","asOf":"2026-09-16","days":5},{"id":"nct06385678","kind":"trial","name":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct06385678/","asOf":"2026-09-16","days":5},{"id":"nct06754085","kind":"trial","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","asOf":"2026-09-16","days":5},{"id":"nct06545955","kind":"trial","name":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","route":"/trials/nct06545955/","asOf":"2026-09-16","days":5},{"id":"nct04915755","kind":"trial","name":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","route":"/trials/nct04915755/","asOf":"2026-09-16","days":5},{"id":"nct04684147","kind":"trial","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct04684147/","asOf":"2026-09-16","days":5},{"id":"nct06634589","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct06634589/","asOf":"2026-09-16","days":5},{"id":"nct05463263","kind":"trial","name":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","route":"/trials/nct05463263/","asOf":"2026-09-16","days":5},{"id":"nct07221149","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","route":"/trials/nct07221149/","asOf":"2026-09-16","days":5},{"id":"nct01906385","kind":"trial","name":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","route":"/trials/nct01906385/","asOf":"2026-09-16","days":5},{"id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","route":"/trials/nct07339176/","asOf":"2026-09-16","days":5},{"id":"nct06246643","kind":"trial","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","route":"/trials/nct06246643/","asOf":"2026-09-16","days":5},{"id":"nct04683250","kind":"trial","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","route":"/trials/nct04683250/","asOf":"2026-09-16","days":5},{"id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","route":"/trials/nct06635785/","asOf":"2026-09-16","days":5},{"id":"nct05664243","kind":"trial","name":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","route":"/trials/nct05664243/","asOf":"2026-09-16","days":5},{"id":"nct06341114","kind":"trial","name":"A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","route":"/trials/nct06341114/","asOf":"2026-09-16","days":5},{"id":"nct06781567","kind":"trial","name":"Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma","route":"/trials/nct06781567/","asOf":"2026-09-16","days":5},{"id":"nct07093814","kind":"trial","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","route":"/trials/nct07093814/","asOf":"2026-09-16","days":5},{"id":"nct07011186","kind":"trial","name":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","route":"/trials/nct07011186/","asOf":"2026-09-16","days":5},{"id":"nct07468851","kind":"trial","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","route":"/trials/nct07468851/","asOf":"2026-09-16","days":5},{"id":"nct07109219","kind":"trial","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","route":"/trials/nct07109219/","asOf":"2026-09-16","days":5},{"id":"nct07761533","kind":"trial","name":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS","route":"/trials/nct07761533/","asOf":"2026-09-16","days":5},{"id":"nct03600233","kind":"trial","name":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","route":"/trials/nct03600233/","asOf":"2026-09-16","days":5},{"id":"nct05727176","kind":"trial","name":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","route":"/trials/nct05727176/","asOf":"2026-09-16","days":5},{"id":"nct05803018","kind":"trial","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","route":"/trials/nct05803018/","asOf":"2026-09-16","days":5},{"id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","route":"/trials/nct06569420/","asOf":"2026-09-16","days":5},{"id":"nct06970847","kind":"trial","name":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","route":"/trials/nct06970847/","asOf":"2026-09-16","days":5},{"id":"nct06652633","kind":"trial","name":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","route":"/trials/nct06652633/","asOf":"2026-09-16","days":5},{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/","asOf":"2026-09-16","days":5},{"id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","asOf":"2026-09-16","days":5},{"id":"nct06194448","kind":"trial","name":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","route":"/trials/nct06194448/","asOf":"2026-09-16","days":5},{"id":"nct05320198","kind":"trial","name":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","route":"/trials/nct05320198/","asOf":"2026-09-16","days":5},{"id":"nct04821622","kind":"trial","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","route":"/trials/nct04821622/","asOf":"2026-09-16","days":5},{"id":"nct06737731","kind":"trial","name":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06737731/","asOf":"2026-09-16","days":5},{"id":"nct07230405","kind":"trial","name":"A Phase II Study of SKB571 in Patients With Lung Cancer","route":"/trials/nct07230405/","asOf":"2026-09-16","days":5},{"id":"nct07541079","kind":"trial","name":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","route":"/trials/nct07541079/","asOf":"2026-09-16","days":5},{"id":"nct02781883","kind":"trial","name":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","route":"/trials/nct02781883/","asOf":"2026-09-16","days":5},{"id":"nct05653453","kind":"trial","name":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","route":"/trials/nct05653453/","asOf":"2026-09-16","days":5},{"id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","route":"/trials/nct05377996/","asOf":"2026-09-16","days":5},{"id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","asOf":"2026-09-16","days":5},{"id":"nct05379946","kind":"trial","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","route":"/trials/nct05379946/","asOf":"2026-09-16","days":5},{"id":"nct07134088","kind":"trial","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","route":"/trials/nct07134088/","asOf":"2026-09-16","days":5},{"id":"nct06850623","kind":"trial","name":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","route":"/trials/nct06850623/","asOf":"2026-09-16","days":5},{"id":"nct04699188","kind":"trial","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct04699188/","asOf":"2026-09-16","days":5},{"id":"nct06914128","kind":"trial","name":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","route":"/trials/nct06914128/","asOf":"2026-09-16","days":5},{"id":"nct06805305","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","route":"/trials/nct06805305/","asOf":"2026-09-16","days":5},{"id":"nct07047365","kind":"trial","name":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","route":"/trials/nct07047365/","asOf":"2026-09-16","days":5},{"id":"nct03505320","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","route":"/trials/nct03505320/","asOf":"2026-09-16","days":5},{"id":"nct07669454","kind":"trial","name":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","route":"/trials/nct07669454/","asOf":"2026-09-16","days":5},{"id":"nct07724756","kind":"trial","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","route":"/trials/nct07724756/","asOf":"2026-09-16","days":5},{"id":"nct00781612","kind":"trial","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","route":"/trials/nct00781612/","asOf":"2026-09-16","days":5},{"id":"nct02586857","kind":"trial","name":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","route":"/trials/nct02586857/","asOf":"2026-09-16","days":5},{"id":"nct05319730","kind":"trial","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","route":"/trials/nct05319730/","asOf":"2026-09-16","days":5},{"id":"nct05329766","kind":"trial","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","route":"/trials/nct05329766/","asOf":"2026-09-16","days":5},{"id":"nct03040973","kind":"trial","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","route":"/trials/nct03040973/","asOf":"2026-09-16","days":5},{"id":"nct07109531","kind":"trial","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","route":"/trials/nct07109531/","asOf":"2026-09-16","days":5},{"id":"nct05688605","kind":"trial","name":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","route":"/trials/nct05688605/","asOf":"2026-09-16","days":5},{"id":"nct05456256","kind":"trial","name":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","route":"/trials/nct05456256/","asOf":"2026-09-16","days":5},{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/","asOf":"2026-09-16","days":5},{"id":"nct04954001","kind":"trial","name":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","route":"/trials/nct04954001/","asOf":"2026-09-16","days":5},{"id":"nct05211570","kind":"trial","name":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","route":"/trials/nct05211570/","asOf":"2026-09-16","days":5},{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/","asOf":"2026-09-16","days":5},{"id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/","asOf":"2026-09-16","days":5},{"id":"nct00099437","kind":"trial","name":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","route":"/trials/nct00099437/","asOf":"2026-09-16","days":5},{"id":"nct06772623","kind":"trial","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","route":"/trials/nct06772623/","asOf":"2026-09-16","days":5},{"id":"nct07572396","kind":"trial","name":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","route":"/trials/nct07572396/","asOf":"2026-09-16","days":5},{"id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07467863/","asOf":"2026-09-16","days":5},{"id":"nct05907057","kind":"trial","name":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","route":"/trials/nct05907057/","asOf":"2026-09-16","days":5},{"id":"nct05563844","kind":"trial","name":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","route":"/trials/nct05563844/","asOf":"2026-09-16","days":5},{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","route":"/trials/nct03673501/","asOf":"2026-09-16","days":5},{"id":"nct03837899","kind":"trial","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","route":"/trials/nct03837899/","asOf":"2026-09-16","days":5},{"id":"nct02138734","kind":"trial","name":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","route":"/trials/nct02138734/","asOf":"2026-09-16","days":5},{"id":"nct07154264","kind":"trial","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","route":"/trials/nct07154264/","asOf":"2026-09-16","days":5},{"id":"nct06760819","kind":"trial","name":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","route":"/trials/nct06760819/","asOf":"2026-09-16","days":5},{"id":"nct04503265","kind":"trial","name":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies","route":"/trials/nct04503265/","asOf":"2026-09-16","days":5},{"id":"nct07136142","kind":"trial","name":"A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07136142/","asOf":"2026-09-16","days":5},{"id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","route":"/trials/nct06926075/","asOf":"2026-09-16","days":5},{"id":"nct06596694","kind":"trial","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","route":"/trials/nct06596694/","asOf":"2026-09-16","days":5},{"id":"nct06117566","kind":"trial","name":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","route":"/trials/nct06117566/","asOf":"2026-09-16","days":5},{"id":"nct05584800","kind":"trial","name":"Study of ZGGS18 in Patients With Advanced Solid Tumors","route":"/trials/nct05584800/","asOf":"2026-09-16","days":5},{"id":"nct02650401","kind":"trial","name":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","route":"/trials/nct02650401/","asOf":"2026-09-16","days":5},{"id":"nct06938880","kind":"trial","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06938880/","asOf":"2026-09-16","days":5},{"id":"nct06616389","kind":"trial","name":"Study of ODX (OsteoDex) in Multiple Myeloma","route":"/trials/nct06616389/","asOf":"2026-09-16","days":5},{"id":"nct04711252","kind":"trial","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","route":"/trials/nct04711252/","asOf":"2026-09-16","days":5},{"id":"nct03567889","kind":"trial","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","route":"/trials/nct03567889/","asOf":"2026-09-16","days":5},{"id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/","asOf":"2026-09-16","days":5},{"id":"nct05144854","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","route":"/trials/nct05144854/","asOf":"2026-09-16","days":5},{"id":"nct05473156","kind":"trial","name":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","route":"/trials/nct05473156/","asOf":"2026-09-16","days":5},{"id":"nct06072131","kind":"trial","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","route":"/trials/nct06072131/","asOf":"2026-09-16","days":5},{"id":"nct07173751","kind":"trial","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","route":"/trials/nct07173751/","asOf":"2026-09-16","days":5},{"id":"nct05804669","kind":"trial","name":"A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","route":"/trials/nct05804669/","asOf":"2026-09-16","days":5},{"id":"nct06823427","kind":"trial","name":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct06823427/","asOf":"2026-09-16","days":5},{"id":"nct06637423","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","route":"/trials/nct06637423/","asOf":"2026-09-16","days":5},{"id":"nct05627856","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","route":"/trials/nct05627856/","asOf":"2026-09-16","days":5},{"id":"nct06041802","kind":"trial","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","route":"/trials/nct06041802/","asOf":"2026-09-16","days":5},{"id":"nct03934372","kind":"trial","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","route":"/trials/nct03934372/","asOf":"2026-09-16","days":5},{"id":"nct07387081","kind":"trial","name":"Phase II Study of LM-24C5","route":"/trials/nct07387081/","asOf":"2026-09-16","days":5},{"id":"nct05902988","kind":"trial","name":"A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer","route":"/trials/nct05902988/","asOf":"2026-09-16","days":5},{"id":"nct06015503","kind":"trial","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct06015503/","asOf":"2026-09-16","days":5},{"id":"nct06821503","kind":"trial","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","route":"/trials/nct06821503/","asOf":"2026-09-16","days":5},{"id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/","asOf":"2026-09-16","days":5},{"id":"nct04492488","kind":"trial","name":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","route":"/trials/nct04492488/","asOf":"2026-09-16","days":5},{"id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/","asOf":"2026-09-16","days":5},{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/","asOf":"2026-09-16","days":5},{"id":"nct07567846","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","route":"/trials/nct07567846/","asOf":"2026-09-16","days":5},{"id":"nct04581512","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of EP0042","route":"/trials/nct04581512/","asOf":"2026-09-16","days":5},{"id":"nct06526819","kind":"trial","name":"SMP-3124LP in Adults With Advanced Solid Tumors","route":"/trials/nct06526819/","asOf":"2026-09-16","days":5},{"id":"nct04214288","kind":"trial","name":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","route":"/trials/nct04214288/","asOf":"2026-09-16","days":5},{"id":"nct05566795","kind":"trial","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","route":"/trials/nct05566795/","asOf":"2026-09-16","days":5},{"id":"nct04225117","kind":"trial","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","route":"/trials/nct04225117/","asOf":"2026-09-16","days":5},{"id":"nct06126640","kind":"trial","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","route":"/trials/nct06126640/","asOf":"2026-09-16","days":5},{"id":"nct05499013","kind":"trial","name":"Study to Assess SLN124 in Patients With Polycythemia Vera","route":"/trials/nct05499013/","asOf":"2026-09-16","days":5},{"id":"nct04724369","kind":"trial","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","route":"/trials/nct04724369/","asOf":"2026-09-16","days":5},{"id":"nct06686394","kind":"trial","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","route":"/trials/nct06686394/","asOf":"2026-09-16","days":5},{"id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","route":"/trials/nct07480954/","asOf":"2026-09-16","days":5},{"id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","route":"/trials/nct04219254/","asOf":"2026-09-16","days":5},{"id":"nct07114861","kind":"trial","name":"The KN510713 Study in Combination With mFOLFIRINOX","route":"/trials/nct07114861/","asOf":"2026-09-16","days":5},{"id":"nct06480240","kind":"trial","name":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","route":"/trials/nct06480240/","asOf":"2026-09-16","days":5},{"id":"nct07636785","kind":"trial","name":"A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","route":"/trials/nct07636785/","asOf":"2026-09-16","days":5},{"id":"nct07389733","kind":"trial","name":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","route":"/trials/nct07389733/","asOf":"2026-09-16","days":5},{"id":"nct05965856","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","route":"/trials/nct05965856/","asOf":"2026-09-16","days":5},{"id":"nct04586231","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","route":"/trials/nct04586231/","asOf":"2026-09-16","days":5},{"id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","route":"/trials/nct06130553/","asOf":"2026-09-16","days":5},{"id":"nct07510828","kind":"trial","name":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","route":"/trials/nct07510828/","asOf":"2026-09-16","days":5},{"id":"nct05308264","kind":"trial","name":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","route":"/trials/nct05308264/","asOf":"2026-09-16","days":5},{"id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","route":"/trials/nct06618235/","asOf":"2026-09-16","days":5},{"id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","route":"/trials/nct05732831/","asOf":"2026-09-16","days":5},{"id":"nct05669430","kind":"trial","name":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","route":"/trials/nct05669430/","asOf":"2026-09-16","days":5},{"id":"nct02320435","kind":"trial","name":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","route":"/trials/nct02320435/","asOf":"2026-09-16","days":5},{"id":"nct04241185","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","route":"/trials/nct04241185/","asOf":"2026-09-16","days":5},{"id":"nct05899049","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","route":"/trials/nct05899049/","asOf":"2026-09-16","days":5},{"id":"nct06592326","kind":"trial","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06592326/","asOf":"2026-09-16","days":5},{"id":"nct06947291","kind":"trial","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","route":"/trials/nct06947291/","asOf":"2026-09-16","days":5},{"id":"nct06950086","kind":"trial","name":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06950086/","asOf":"2026-09-16","days":5},{"id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/","asOf":"2026-09-16","days":5},{"id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","route":"/trials/nct07697586/","asOf":"2026-09-16","days":5},{"id":"nct03533283","kind":"trial","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","route":"/trials/nct03533283/","asOf":"2026-09-16","days":5},{"id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06095505/","asOf":"2026-09-16","days":5},{"id":"nct07448922","kind":"trial","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct07448922/","asOf":"2026-09-16","days":5},{"id":"nct06600022","kind":"trial","name":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","route":"/trials/nct06600022/","asOf":"2026-09-16","days":5},{"id":"nct07691775","kind":"trial","name":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","route":"/trials/nct07691775/","asOf":"2026-09-16","days":5},{"id":"nct06080776","kind":"trial","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","route":"/trials/nct06080776/","asOf":"2026-09-16","days":5},{"id":"nct06764940","kind":"trial","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","route":"/trials/nct06764940/","asOf":"2026-09-16","days":5},{"id":"nct05204862","kind":"trial","name":"Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors","route":"/trials/nct05204862/","asOf":"2026-09-16","days":5},{"id":"nct05254743","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05254743/","asOf":"2026-09-16","days":5},{"id":"nct07582315","kind":"trial","name":"A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)","route":"/trials/nct07582315/","asOf":"2026-09-16","days":5},{"id":"nct04938817","kind":"trial","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","route":"/trials/nct04938817/","asOf":"2026-09-16","days":5},{"id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/","asOf":"2026-09-16","days":5},{"id":"nct06941272","kind":"trial","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","route":"/trials/nct06941272/","asOf":"2026-09-16","days":5},{"id":"nct05101070","kind":"trial","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","route":"/trials/nct05101070/","asOf":"2026-09-16","days":5},{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/","asOf":"2026-09-16","days":5},{"id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/","asOf":"2026-09-16","days":5},{"id":"nct06492616","kind":"trial","name":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","route":"/trials/nct06492616/","asOf":"2026-09-16","days":5},{"id":"nct07805252","kind":"trial","name":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","route":"/trials/nct07805252/","asOf":"2026-09-16","days":5},{"id":"nct02747004","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","route":"/trials/nct02747004/","asOf":"2026-09-16","days":5},{"id":"nct07606599","kind":"trial","name":"A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure","route":"/trials/nct07606599/","asOf":"2026-09-16","days":5},{"id":"nct06378593","kind":"trial","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","route":"/trials/nct06378593/","asOf":"2026-09-16","days":5},{"id":"nct02716116","kind":"trial","name":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct02716116/","asOf":"2026-09-16","days":5},{"id":"nct07075328","kind":"trial","name":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","route":"/trials/nct07075328/","asOf":"2026-09-16","days":5},{"id":"nct05949619","kind":"trial","name":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","route":"/trials/nct05949619/","asOf":"2026-09-16","days":5},{"id":"nct06580301","kind":"trial","name":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","route":"/trials/nct06580301/","asOf":"2026-09-16","days":5},{"id":"nct05520567","kind":"trial","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","route":"/trials/nct05520567/","asOf":"2026-09-16","days":5},{"id":"nct05583552","kind":"trial","name":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","route":"/trials/nct05583552/","asOf":"2026-09-16","days":5},{"id":"nct05141149","kind":"trial","name":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","route":"/trials/nct05141149/","asOf":"2026-09-16","days":5},{"id":"nct04891198","kind":"trial","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","route":"/trials/nct04891198/","asOf":"2026-09-16","days":5},{"id":"nct07216443","kind":"trial","name":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct07216443/","asOf":"2026-09-16","days":5},{"id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/","asOf":"2026-09-16","days":5},{"id":"nct04703192","kind":"trial","name":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","route":"/trials/nct04703192/","asOf":"2026-09-16","days":5},{"id":"nct04976634","kind":"trial","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","route":"/trials/nct04976634/","asOf":"2026-09-16","days":5},{"id":"nct02542293","kind":"trial","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","route":"/trials/nct02542293/","asOf":"2026-09-16","days":5},{"id":"nct04965493","kind":"trial","name":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","route":"/trials/nct04965493/","asOf":"2026-09-16","days":5},{"id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","route":"/trials/nct03459534/","asOf":"2026-09-16","days":5},{"id":"nct01954992","kind":"trial","name":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","route":"/trials/nct01954992/","asOf":"2026-09-16","days":5},{"id":"nct07125872","kind":"trial","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","route":"/trials/nct07125872/","asOf":"2026-09-16","days":5},{"id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","route":"/trials/nct07136181/","asOf":"2026-09-16","days":5},{"id":"nct07431281","kind":"trial","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","route":"/trials/nct07431281/","asOf":"2026-09-16","days":5},{"id":"nct05745623","kind":"trial","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","route":"/trials/nct05745623/","asOf":"2026-09-16","days":5},{"id":"nct07332455","kind":"trial","name":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","route":"/trials/nct07332455/","asOf":"2026-09-16","days":5},{"id":"nct04974008","kind":"trial","name":"Osteosarcoma Maintenance Therapy With OST31-164","route":"/trials/nct04974008/","asOf":"2026-09-16","days":5},{"id":"nct04895358","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","route":"/trials/nct04895358/","asOf":"2026-09-16","days":5},{"id":"nct06861088","kind":"trial","name":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","route":"/trials/nct06861088/","asOf":"2026-09-16","days":5},{"id":"nct07105215","kind":"trial","name":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","route":"/trials/nct07105215/","asOf":"2026-09-16","days":5},{"id":"nct04626518","kind":"trial","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","route":"/trials/nct04626518/","asOf":"2026-09-16","days":5},{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/","asOf":"2026-09-16","days":5},{"id":"nct05886920","kind":"trial","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","route":"/trials/nct05886920/","asOf":"2026-09-16","days":5},{"id":"nct07356973","kind":"trial","name":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","route":"/trials/nct07356973/","asOf":"2026-09-16","days":5},{"id":"nct06590246","kind":"trial","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","route":"/trials/nct06590246/","asOf":"2026-09-16","days":5},{"id":"nct07499674","kind":"trial","name":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","route":"/trials/nct07499674/","asOf":"2026-09-16","days":5},{"id":"nct06387342","kind":"trial","name":"Namodenoson Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06387342/","asOf":"2026-09-16","days":5},{"id":"nct07544654","kind":"trial","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","route":"/trials/nct07544654/","asOf":"2026-09-16","days":5},{"id":"nct05101096","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","route":"/trials/nct05101096/","asOf":"2026-09-16","days":5},{"id":"nct03478488","kind":"trial","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","route":"/trials/nct03478488/","asOf":"2026-09-16","days":5},{"id":"nct05487170","kind":"trial","name":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)","route":"/trials/nct05487170/","asOf":"2026-09-16","days":5},{"id":"nct06911827","kind":"trial","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","route":"/trials/nct06911827/","asOf":"2026-09-16","days":5},{"id":"nct03833154","kind":"trial","name":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","route":"/trials/nct03833154/","asOf":"2026-09-16","days":5},{"id":"nct06111274","kind":"trial","name":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","route":"/trials/nct06111274/","asOf":"2026-09-16","days":5},{"id":"nct06812260","kind":"trial","name":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","route":"/trials/nct06812260/","asOf":"2026-09-16","days":5},{"id":"nct06520488","kind":"trial","name":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","route":"/trials/nct06520488/","asOf":"2026-09-16","days":5},{"id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/","asOf":"2026-09-16","days":5},{"id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06873555/","asOf":"2026-09-16","days":5},{"id":"nct05428969","kind":"trial","name":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","route":"/trials/nct05428969/","asOf":"2026-09-16","days":5},{"id":"nct04999969","kind":"trial","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct04999969/","asOf":"2026-09-16","days":5},{"id":"nct05288166","kind":"trial","name":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","route":"/trials/nct05288166/","asOf":"2026-09-16","days":5},{"id":"nct03519230","kind":"trial","name":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","route":"/trials/nct03519230/","asOf":"2026-09-16","days":5},{"id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/","asOf":"2026-09-16","days":5},{"id":"nct07581002","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct07581002/","asOf":"2026-09-16","days":5},{"id":"nct06514794","kind":"trial","name":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","route":"/trials/nct06514794/","asOf":"2026-09-16","days":5},{"id":"nct06107686","kind":"trial","name":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","route":"/trials/nct06107686/","asOf":"2026-09-16","days":5},{"id":"nct06107374","kind":"trial","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","route":"/trials/nct06107374/","asOf":"2026-09-16","days":5},{"id":"nct06957886","kind":"trial","name":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","route":"/trials/nct06957886/","asOf":"2026-09-16","days":5},{"id":"nct06750094","kind":"trial","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","route":"/trials/nct06750094/","asOf":"2026-09-16","days":5},{"id":"nct04959903","kind":"trial","name":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","route":"/trials/nct04959903/","asOf":"2026-09-16","days":5},{"id":"nct04486378","kind":"trial","name":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","route":"/trials/nct04486378/","asOf":"2026-09-16","days":5},{"id":"nct07169552","kind":"trial","name":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","route":"/trials/nct07169552/","asOf":"2026-09-16","days":5},{"id":"nct03933735","kind":"trial","name":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct03933735/","asOf":"2026-09-16","days":5},{"id":"nct07023315","kind":"trial","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","route":"/trials/nct07023315/","asOf":"2026-09-16","days":5},{"id":"nct06747585","kind":"trial","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","route":"/trials/nct06747585/","asOf":"2026-09-16","days":5},{"id":"nct04365374","kind":"trial","name":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","route":"/trials/nct04365374/","asOf":"2026-09-16","days":5},{"id":"nct07315750","kind":"trial","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct07315750/","asOf":"2026-09-16","days":5},{"id":"nct06405425","kind":"trial","name":"A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct06405425/","asOf":"2026-09-16","days":5},{"id":"nct03431350","kind":"trial","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct03431350/","asOf":"2026-09-16","days":5},{"id":"nct06682780","kind":"trial","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","route":"/trials/nct06682780/","asOf":"2026-09-16","days":5},{"id":"nct05587296","kind":"trial","name":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","route":"/trials/nct05587296/","asOf":"2026-09-16","days":5},{"id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","route":"/trials/nct06678659/","asOf":"2026-09-16","days":5},{"id":"nct05761223","kind":"trial","name":"A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849","route":"/trials/nct05761223/","asOf":"2026-09-16","days":5},{"id":"nct05683886","kind":"trial","name":"A Study of KC1036 in Patients with Advanced Thymic Tumors","route":"/trials/nct05683886/","asOf":"2026-09-16","days":5},{"id":"nct07070518","kind":"trial","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","route":"/trials/nct07070518/","asOf":"2026-09-16","days":5},{"id":"nct04379596","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","route":"/trials/nct04379596/","asOf":"2026-09-16","days":5},{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","asOf":"2026-09-16","days":5},{"id":"nct07069712","kind":"trial","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","route":"/trials/nct07069712/","asOf":"2026-09-16","days":5},{"id":"nct05957367","kind":"trial","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","route":"/trials/nct05957367/","asOf":"2026-09-16","days":5},{"id":"nct06332092","kind":"trial","name":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06332092/","asOf":"2026-09-16","days":5},{"id":"nct05908734","kind":"trial","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05908734/","asOf":"2026-09-16","days":5},{"id":"nct05406401","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","route":"/trials/nct05406401/","asOf":"2026-09-16","days":5},{"id":"nct07209111","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","route":"/trials/nct07209111/","asOf":"2026-09-16","days":5},{"id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","route":"/trials/nct05850234/","asOf":"2026-09-16","days":5},{"id":"nct03328078","kind":"trial","name":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","route":"/trials/nct03328078/","asOf":"2026-09-16","days":5},{"id":"nct07024706","kind":"trial","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","route":"/trials/nct07024706/","asOf":"2026-09-16","days":5},{"id":"nct05488314","kind":"trial","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05488314/","asOf":"2026-09-16","days":5},{"id":"nct06298916","kind":"trial","name":"64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer","route":"/trials/nct06298916/","asOf":"2026-09-16","days":5},{"id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07299825/","asOf":"2026-09-16","days":5},{"id":"nct06780098","kind":"trial","name":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","route":"/trials/nct06780098/","asOf":"2026-09-16","days":5},{"id":"nct04115306","kind":"trial","name":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","route":"/trials/nct04115306/","asOf":"2026-09-16","days":5},{"id":"nct06806033","kind":"trial","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","route":"/trials/nct06806033/","asOf":"2026-09-16","days":5},{"id":"nct05316155","kind":"trial","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","route":"/trials/nct05316155/","asOf":"2026-09-16","days":5},{"id":"nct04586478","kind":"trial","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct04586478/","asOf":"2026-09-16","days":5},{"id":"nct05951608","kind":"trial","name":"A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors","route":"/trials/nct05951608/","asOf":"2026-09-16","days":5},{"id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","route":"/trials/nct07598955/","asOf":"2026-09-16","days":5},{"id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","route":"/trials/nct07367516/","asOf":"2026-09-16","days":5},{"id":"nct04454437","kind":"trial","name":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","route":"/trials/nct04454437/","asOf":"2026-09-16","days":5},{"id":"nct05948475","kind":"trial","name":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","route":"/trials/nct05948475/","asOf":"2026-09-16","days":5},{"id":"nct06842498","kind":"trial","name":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06842498/","asOf":"2026-09-16","days":5},{"id":"nct03742895","kind":"trial","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","route":"/trials/nct03742895/","asOf":"2026-09-16","days":5},{"id":"nct07232875","kind":"trial","name":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07232875/","asOf":"2026-09-16","days":5},{"id":"nct06752811","kind":"trial","name":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct06752811/","asOf":"2026-09-16","days":5},{"id":"nct07099898","kind":"trial","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","route":"/trials/nct07099898/","asOf":"2026-09-16","days":5},{"id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/","asOf":"2026-09-16","days":5},{"id":"nct05262400","kind":"trial","name":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","route":"/trials/nct05262400/","asOf":"2026-09-16","days":5},{"id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","route":"/trials/nct04390737/","asOf":"2026-09-16","days":5},{"id":"nct06644781","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","route":"/trials/nct06644781/","asOf":"2026-09-16","days":5},{"id":"nct03937154","kind":"trial","name":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","route":"/trials/nct03937154/","asOf":"2026-09-16","days":5},{"id":"nct03722420","kind":"trial","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","route":"/trials/nct03722420/","asOf":"2026-09-16","days":5},{"id":"nct04170283","kind":"trial","name":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib","route":"/trials/nct04170283/","asOf":"2026-09-16","days":5},{"id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","route":"/trials/nct07136779/","asOf":"2026-09-16","days":5},{"id":"nct03003962","kind":"trial","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","route":"/trials/nct03003962/","asOf":"2026-09-16","days":5},{"id":"nct05230810","kind":"trial","name":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","route":"/trials/nct05230810/","asOf":"2026-09-16","days":5},{"id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","asOf":"2026-09-16","days":5},{"id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","route":"/trials/nct07055594/","asOf":"2026-09-16","days":5},{"id":"nct04614103","kind":"trial","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct04614103/","asOf":"2026-09-16","days":5},{"id":"nct06605222","kind":"trial","name":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06605222/","asOf":"2026-09-16","days":5},{"id":"nct06428396","kind":"trial","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","route":"/trials/nct06428396/","asOf":"2026-09-16","days":5},{"id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","route":"/trials/nct07597629/","asOf":"2026-09-16","days":5},{"id":"nct05689853","kind":"trial","name":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","route":"/trials/nct05689853/","asOf":"2026-09-16","days":5},{"id":"nct06189209","kind":"trial","name":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","route":"/trials/nct06189209/","asOf":"2026-09-16","days":5},{"id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/","asOf":"2026-09-16","days":5},{"id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct06735144/","asOf":"2026-09-16","days":5},{"id":"nct06757634","kind":"trial","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","route":"/trials/nct06757634/","asOf":"2026-09-16","days":5},{"id":"nct04888312","kind":"trial","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","route":"/trials/nct04888312/","asOf":"2026-09-16","days":5},{"id":"nct07288112","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","route":"/trials/nct07288112/","asOf":"2026-09-16","days":5},{"id":"nct05315700","kind":"trial","name":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","route":"/trials/nct05315700/","asOf":"2026-09-16","days":5},{"id":"nct06439771","kind":"trial","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","route":"/trials/nct06439771/","asOf":"2026-09-16","days":5},{"id":"nct06922357","kind":"trial","name":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06922357/","asOf":"2026-09-16","days":5},{"id":"nct06827236","kind":"trial","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","route":"/trials/nct06827236/","asOf":"2026-09-16","days":5},{"id":"nct07368998","kind":"trial","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","route":"/trials/nct07368998/","asOf":"2026-09-16","days":5},{"id":"nct06630234","kind":"trial","name":"A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","route":"/trials/nct06630234/","asOf":"2026-09-16","days":5},{"id":"nct05558007","kind":"trial","name":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","route":"/trials/nct05558007/","asOf":"2026-09-16","days":5},{"id":"nct06127407","kind":"trial","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","route":"/trials/nct06127407/","asOf":"2026-09-16","days":5},{"id":"nct04862663","kind":"trial","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","route":"/trials/nct04862663/","asOf":"2026-09-16","days":5},{"id":"nct04086264","kind":"trial","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","route":"/trials/nct04086264/","asOf":"2026-09-16","days":5},{"id":"nct05771584","kind":"trial","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","route":"/trials/nct05771584/","asOf":"2026-09-16","days":5},{"id":"nct07229638","kind":"trial","name":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","route":"/trials/nct07229638/","asOf":"2026-09-16","days":5},{"id":"nct06212076","kind":"trial","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","route":"/trials/nct06212076/","asOf":"2026-09-16","days":5},{"id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","route":"/trials/nct07168226/","asOf":"2026-09-16","days":5},{"id":"nct04829604","kind":"trial","name":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","route":"/trials/nct04829604/","asOf":"2026-09-16","days":5},{"id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","route":"/trials/nct07586943/","asOf":"2026-09-16","days":5},{"id":"nct07508761","kind":"trial","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","route":"/trials/nct07508761/","asOf":"2026-09-16","days":5},{"id":"nct05755113","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","route":"/trials/nct05755113/","asOf":"2026-09-16","days":5},{"id":"nct07679360","kind":"trial","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","route":"/trials/nct07679360/","asOf":"2026-09-16","days":5},{"id":"nct07225946","kind":"trial","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07225946/","asOf":"2026-09-16","days":5},{"id":"nct06631079","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","route":"/trials/nct06631079/","asOf":"2026-09-16","days":5},{"id":"nct05909397","kind":"trial","name":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","route":"/trials/nct05909397/","asOf":"2026-09-16","days":5},{"id":"nct05514054","kind":"trial","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","route":"/trials/nct05514054/","asOf":"2026-09-16","days":5},{"id":"nct03876769","kind":"trial","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","route":"/trials/nct03876769/","asOf":"2026-09-16","days":5},{"id":"nct05163041","kind":"trial","name":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","route":"/trials/nct05163041/","asOf":"2026-09-16","days":5},{"id":"nct07605962","kind":"trial","name":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","route":"/trials/nct07605962/","asOf":"2026-09-16","days":5},{"id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","route":"/trials/nct06353386/","asOf":"2026-09-16","days":5},{"id":"nct06692166","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06692166/","asOf":"2026-09-16","days":5},{"id":"nct04165070","kind":"trial","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","route":"/trials/nct04165070/","asOf":"2026-09-16","days":5},{"id":"nct03949283","kind":"trial","name":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","route":"/trials/nct03949283/","asOf":"2026-09-16","days":5},{"id":"nct06906341","kind":"trial","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","route":"/trials/nct06906341/","asOf":"2026-09-16","days":5},{"id":"nct04576455","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","route":"/trials/nct04576455/","asOf":"2026-09-16","days":5},{"id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","asOf":"2026-09-16","days":5},{"id":"nct06969430","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct06969430/","asOf":"2026-09-16","days":5},{"id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","route":"/trials/nct06508931/","asOf":"2026-09-16","days":5},{"id":"nct05882058","kind":"trial","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct05882058/","asOf":"2026-09-16","days":5},{"id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","asOf":"2026-09-16","days":5},{"id":"nct07639450","kind":"trial","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","route":"/trials/nct07639450/","asOf":"2026-09-16","days":5},{"id":"nct06915142","kind":"trial","name":"A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour","route":"/trials/nct06915142/","asOf":"2026-09-16","days":5},{"id":"nct05963074","kind":"trial","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct05963074/","asOf":"2026-09-16","days":5},{"id":"nct02180724","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","route":"/trials/nct02180724/","asOf":"2026-09-16","days":5},{"id":"nct07276789","kind":"trial","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","route":"/trials/nct07276789/","asOf":"2026-09-16","days":5},{"id":"nct07314723","kind":"trial","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","route":"/trials/nct07314723/","asOf":"2026-09-16","days":5},{"id":"nct03964727","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","route":"/trials/nct03964727/","asOf":"2026-09-16","days":5},{"id":"nct07295821","kind":"trial","name":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","route":"/trials/nct07295821/","asOf":"2026-09-16","days":5},{"id":"nct06239155","kind":"trial","name":"A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors","route":"/trials/nct06239155/","asOf":"2026-09-16","days":5},{"id":"nct05173987","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","route":"/trials/nct05173987/","asOf":"2026-09-16","days":5},{"id":"nct06375733","kind":"trial","name":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","route":"/trials/nct06375733/","asOf":"2026-09-16","days":5},{"id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/","asOf":"2026-09-16","days":5},{"id":"nct06117540","kind":"trial","name":"A Study of WX390 in Patients With Advanced Solid Tumors","route":"/trials/nct06117540/","asOf":"2026-09-16","days":5},{"id":"nct05662397","kind":"trial","name":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","route":"/trials/nct05662397/","asOf":"2026-09-16","days":5},{"id":"nct02934568","kind":"trial","name":"Ribociclib (LEE011) Rollover Study for Continued Access","route":"/trials/nct02934568/","asOf":"2026-09-16","days":5},{"id":"nct05038735","kind":"trial","name":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","route":"/trials/nct05038735/","asOf":"2026-09-16","days":5},{"id":"nct05361174","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","route":"/trials/nct05361174/","asOf":"2026-09-16","days":5},{"id":"nct04041310","kind":"trial","name":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","route":"/trials/nct04041310/","asOf":"2026-09-16","days":5},{"id":"nct06875310","kind":"trial","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","route":"/trials/nct06875310/","asOf":"2026-09-16","days":5},{"id":"nct07466160","kind":"trial","name":"A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors","route":"/trials/nct07466160/","asOf":"2026-09-16","days":5},{"id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","route":"/trials/nct07471789/","asOf":"2026-09-16","days":5},{"id":"nct04023526","kind":"trial","name":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","route":"/trials/nct04023526/","asOf":"2026-09-16","days":5},{"id":"nct06959615","kind":"trial","name":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","route":"/trials/nct06959615/","asOf":"2026-09-16","days":5},{"id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","asOf":"2026-09-16","days":5},{"id":"nct05451602","kind":"trial","name":"HEC169096 in Participants With Advanced Solid Tumors","route":"/trials/nct05451602/","asOf":"2026-09-16","days":5},{"id":"nct03967977","kind":"trial","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","route":"/trials/nct03967977/","asOf":"2026-09-16","days":5},{"id":"nct06799637","kind":"trial","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","route":"/trials/nct06799637/","asOf":"2026-09-16","days":5},{"id":"nct07298772","kind":"trial","name":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07298772/","asOf":"2026-09-16","days":5},{"id":"nct04623541","kind":"trial","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","route":"/trials/nct04623541/","asOf":"2026-09-16","days":5},{"id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/","asOf":"2026-09-16","days":5},{"id":"nct05023486","kind":"trial","name":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","route":"/trials/nct05023486/","asOf":"2026-09-16","days":5},{"id":"nct05057494","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05057494/","asOf":"2026-09-16","days":5},{"id":"nct05986851","kind":"trial","name":"Azeliragon in MGMT Unmethylated Glioblastoma","route":"/trials/nct05986851/","asOf":"2026-09-16","days":5},{"id":"nct07087054","kind":"trial","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","route":"/trials/nct07087054/","asOf":"2026-09-16","days":5},{"id":"nct06896890","kind":"trial","name":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct06896890/","asOf":"2026-09-16","days":5},{"id":"nct07641023","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07641023/","asOf":"2026-09-16","days":5},{"id":"nct07256782","kind":"trial","name":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","route":"/trials/nct07256782/","asOf":"2026-09-16","days":5},{"id":"nct07111546","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","route":"/trials/nct07111546/","asOf":"2026-09-16","days":5},{"id":"nct06016920","kind":"trial","name":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma","route":"/trials/nct06016920/","asOf":"2026-09-16","days":5},{"id":"nct06031584","kind":"trial","name":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","route":"/trials/nct06031584/","asOf":"2026-09-16","days":5},{"id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","route":"/trials/nct07744763/","asOf":"2026-09-16","days":5},{"id":"nct06279364","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06279364/","asOf":"2026-09-16","days":5},{"id":"nct07308106","kind":"trial","name":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","route":"/trials/nct07308106/","asOf":"2026-09-16","days":5},{"id":"nct07407933","kind":"trial","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07407933/","asOf":"2026-09-16","days":5},{"id":"nct05384587","kind":"trial","name":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","route":"/trials/nct05384587/","asOf":"2026-09-16","days":5},{"id":"nct07116616","kind":"trial","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07116616/","asOf":"2026-09-16","days":5},{"id":"nct06679634","kind":"trial","name":"Retinoblastoma Phase II Expanded Access Clinical Trial","route":"/trials/nct06679634/","asOf":"2026-09-16","days":5},{"id":"nct06305247","kind":"trial","name":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06305247/","asOf":"2026-09-16","days":5},{"id":"nct05201066","kind":"trial","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","route":"/trials/nct05201066/","asOf":"2026-09-16","days":5},{"id":"nct05190445","kind":"trial","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","route":"/trials/nct05190445/","asOf":"2026-09-16","days":5},{"id":"nct07229599","kind":"trial","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","route":"/trials/nct07229599/","asOf":"2026-09-16","days":5},{"id":"nct06890884","kind":"trial","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","route":"/trials/nct06890884/","asOf":"2026-09-16","days":5},{"id":"nct06376136","kind":"trial","name":"A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors","route":"/trials/nct06376136/","asOf":"2026-09-16","days":5},{"id":"nct06667544","kind":"trial","name":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","route":"/trials/nct06667544/","asOf":"2026-09-16","days":5},{"id":"nct04497844","kind":"trial","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","route":"/trials/nct04497844/","asOf":"2026-09-16","days":5},{"id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","route":"/trials/nct05701306/","asOf":"2026-09-16","days":5},{"id":"nct07324629","kind":"trial","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","route":"/trials/nct07324629/","asOf":"2026-09-16","days":5},{"id":"nct05806099","kind":"trial","name":"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","route":"/trials/nct05806099/","asOf":"2026-09-16","days":5},{"id":"nct04414163","kind":"trial","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","route":"/trials/nct04414163/","asOf":"2026-09-16","days":5},{"id":"nct06064812","kind":"trial","name":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.","route":"/trials/nct06064812/","asOf":"2026-09-16","days":5},{"id":"nct07028281","kind":"trial","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07028281/","asOf":"2026-09-16","days":5},{"id":"nct06780111","kind":"trial","name":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","route":"/trials/nct06780111/","asOf":"2026-09-16","days":5},{"id":"nct06742892","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy","route":"/trials/nct06742892/","asOf":"2026-09-16","days":5},{"id":"nct07545265","kind":"trial","name":"SKB565 for Injection in Advanced Solid Tumors","route":"/trials/nct07545265/","asOf":"2026-09-16","days":5},{"id":"nct04895436","kind":"trial","name":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct04895436/","asOf":"2026-09-16","days":5},{"id":"nct05868707","kind":"trial","name":"OH2 Injection in Melanoma","route":"/trials/nct05868707/","asOf":"2026-09-16","days":5},{"id":"nct03315364","kind":"trial","name":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","route":"/trials/nct03315364/","asOf":"2026-09-16","days":5},{"id":"nct05908409","kind":"trial","name":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies","route":"/trials/nct05908409/","asOf":"2026-09-16","days":5},{"id":"nct04817007","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","route":"/trials/nct04817007/","asOf":"2026-09-16","days":5},{"id":"nct07032077","kind":"trial","name":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","route":"/trials/nct07032077/","asOf":"2026-09-16","days":5},{"id":"nct05911295","kind":"trial","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","route":"/trials/nct05911295/","asOf":"2026-09-16","days":5},{"id":"nct05410145","kind":"trial","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","route":"/trials/nct05410145/","asOf":"2026-09-16","days":5},{"id":"nct04721977","kind":"trial","name":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","route":"/trials/nct04721977/","asOf":"2026-09-16","days":5},{"id":"nct06854445","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","route":"/trials/nct06854445/","asOf":"2026-09-16","days":5},{"id":"nct05950945","kind":"trial","name":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","route":"/trials/nct05950945/","asOf":"2026-09-16","days":5},{"id":"nct05456191","kind":"trial","name":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","route":"/trials/nct05456191/","asOf":"2026-09-16","days":5},{"id":"nct07591090","kind":"trial","name":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","route":"/trials/nct07591090/","asOf":"2026-09-16","days":5},{"id":"nct06985355","kind":"trial","name":"A Study of MHB046C Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06985355/","asOf":"2026-09-16","days":5},{"id":"nct05920135","kind":"trial","name":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","route":"/trials/nct05920135/","asOf":"2026-09-16","days":5},{"id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07462650/","asOf":"2026-09-16","days":5},{"id":"nct06943521","kind":"trial","name":"A Study of MT-4561 in Patients With Various Advanced Solid Tumors","route":"/trials/nct06943521/","asOf":"2026-09-16","days":5},{"id":"nct06810804","kind":"trial","name":"A Phase IIa Study to Evaluate NBQ72S","route":"/trials/nct06810804/","asOf":"2026-09-16","days":5},{"id":"nct07446855","kind":"trial","name":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","route":"/trials/nct07446855/","asOf":"2026-09-16","days":5},{"id":"nct07095868","kind":"trial","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","route":"/trials/nct07095868/","asOf":"2026-09-16","days":5},{"id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","route":"/trials/nct06717126/","asOf":"2026-09-16","days":5},{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","route":"/trials/nct05673785/","asOf":"2026-09-16","days":5},{"id":"nct05615974","kind":"trial","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct05615974/","asOf":"2026-09-16","days":5},{"id":"nct04668690","kind":"trial","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","route":"/trials/nct04668690/","asOf":"2026-09-16","days":5},{"id":"nct04785196","kind":"trial","name":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","route":"/trials/nct04785196/","asOf":"2026-09-16","days":5},{"id":"nct07222969","kind":"trial","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","route":"/trials/nct07222969/","asOf":"2026-09-16","days":5},{"id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","route":"/trials/nct05966194/","asOf":"2026-09-16","days":5},{"id":"nct06271837","kind":"trial","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","route":"/trials/nct06271837/","asOf":"2026-09-16","days":5},{"id":"nct06225596","kind":"trial","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","route":"/trials/nct06225596/","asOf":"2026-09-16","days":5},{"id":"nct04494503","kind":"trial","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct04494503/","asOf":"2026-09-16","days":5},{"id":"nct04980222","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","route":"/trials/nct04980222/","asOf":"2026-09-16","days":5},{"id":"nct06706713","kind":"trial","name":"Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","route":"/trials/nct06706713/","asOf":"2026-09-16","days":5},{"id":"nct04802759","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","route":"/trials/nct04802759/","asOf":"2026-09-16","days":5},{"id":"nct05374603","kind":"trial","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","route":"/trials/nct05374603/","asOf":"2026-09-16","days":5},{"id":"nct06867705","kind":"trial","name":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","route":"/trials/nct06867705/","asOf":"2026-09-16","days":5},{"id":"nct07554456","kind":"trial","name":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","route":"/trials/nct07554456/","asOf":"2026-09-16","days":5},{"id":"nct05893888","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers","route":"/trials/nct05893888/","asOf":"2026-09-16","days":5},{"id":"nct06445972","kind":"trial","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","route":"/trials/nct06445972/","asOf":"2026-09-16","days":5},{"id":"nct07015242","kind":"trial","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","route":"/trials/nct07015242/","asOf":"2026-09-16","days":5},{"id":"nct07751042","kind":"trial","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct07751042/","asOf":"2026-09-16","days":5},{"id":"nct04443010","kind":"trial","name":"Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct04443010/","asOf":"2026-09-16","days":5},{"id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","route":"/trials/nct06656390/","asOf":"2026-09-16","days":5},{"id":"nct06756269","kind":"trial","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","route":"/trials/nct06756269/","asOf":"2026-09-16","days":5},{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/","asOf":"2026-09-16","days":5},{"id":"nct06471205","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","route":"/trials/nct06471205/","asOf":"2026-09-16","days":5},{"id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","route":"/trials/nct06506643/","asOf":"2026-09-16","days":5},{"id":"nct05466149","kind":"trial","name":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","route":"/trials/nct05466149/","asOf":"2026-09-16","days":5},{"id":"nct04274426","kind":"trial","name":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","route":"/trials/nct04274426/","asOf":"2026-09-16","days":5},{"id":"nct07235176","kind":"trial","name":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","route":"/trials/nct07235176/","asOf":"2026-09-16","days":5},{"id":"nct07498725","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","route":"/trials/nct07498725/","asOf":"2026-09-16","days":5},{"id":"nct07265674","kind":"trial","name":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","route":"/trials/nct07265674/","asOf":"2026-09-16","days":5},{"id":"nct07499362","kind":"trial","name":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","route":"/trials/nct07499362/","asOf":"2026-09-16","days":5},{"id":"nct05885464","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","route":"/trials/nct05885464/","asOf":"2026-09-16","days":5},{"id":"nct03767244","kind":"trial","name":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","route":"/trials/nct03767244/","asOf":"2026-09-16","days":5},{"id":"nct06992609","kind":"trial","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","route":"/trials/nct06992609/","asOf":"2026-09-16","days":5},{"id":"nct04390399","kind":"trial","name":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct04390399/","asOf":"2026-09-16","days":5},{"id":"nct06975293","kind":"trial","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","route":"/trials/nct06975293/","asOf":"2026-09-16","days":5},{"id":"nct05736406","kind":"trial","name":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","route":"/trials/nct05736406/","asOf":"2026-09-16","days":5},{"id":"nct07003321","kind":"trial","name":"A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07003321/","asOf":"2026-09-16","days":5},{"id":"nct06819215","kind":"trial","name":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06819215/","asOf":"2026-09-16","days":5},{"id":"nct07529717","kind":"trial","name":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","route":"/trials/nct07529717/","asOf":"2026-09-16","days":5},{"id":"nct06260774","kind":"trial","name":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","route":"/trials/nct06260774/","asOf":"2026-09-16","days":5},{"id":"nct07232290","kind":"trial","name":"Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","route":"/trials/nct07232290/","asOf":"2026-09-16","days":5},{"id":"nct04632108","kind":"trial","name":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04632108/","asOf":"2026-09-16","days":5},{"id":"nct05608876","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer","route":"/trials/nct05608876/","asOf":"2026-09-16","days":5},{"id":"nct07227025","kind":"trial","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07227025/","asOf":"2026-09-16","days":5},{"id":"nct06434597","kind":"trial","name":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","route":"/trials/nct06434597/","asOf":"2026-09-16","days":5},{"id":"nct06499350","kind":"trial","name":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct06499350/","asOf":"2026-09-16","days":5},{"id":"nct03865082","kind":"trial","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","route":"/trials/nct03865082/","asOf":"2026-09-16","days":5},{"id":"nct06016062","kind":"trial","name":"A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","route":"/trials/nct06016062/","asOf":"2026-09-16","days":5},{"id":"nct05533697","kind":"trial","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","route":"/trials/nct05533697/","asOf":"2026-09-16","days":5},{"id":"nct06154291","kind":"trial","name":"FIH XON7 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06154291/","asOf":"2026-09-16","days":5},{"id":"nct05205850","kind":"trial","name":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","route":"/trials/nct05205850/","asOf":"2026-09-16","days":5},{"id":"nct06137118","kind":"trial","name":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","route":"/trials/nct06137118/","asOf":"2026-09-16","days":5},{"id":"nct03459846","kind":"trial","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","route":"/trials/nct03459846/","asOf":"2026-09-16","days":5},{"id":"nct05594797","kind":"trial","name":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","route":"/trials/nct05594797/","asOf":"2026-09-16","days":5},{"id":"nct03602859","kind":"trial","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","route":"/trials/nct03602859/","asOf":"2026-09-16","days":5},{"id":"nct07393542","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07393542/","asOf":"2026-09-16","days":5},{"id":"nct07300943","kind":"trial","name":"Study in Advanced Solid Tumor Patients","route":"/trials/nct07300943/","asOf":"2026-09-16","days":5},{"id":"nct04579380","kind":"trial","name":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","route":"/trials/nct04579380/","asOf":"2026-09-16","days":5},{"id":"nct06667960","kind":"trial","name":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct06667960/","asOf":"2026-09-16","days":5},{"id":"nct04064060","kind":"trial","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","route":"/trials/nct04064060/","asOf":"2026-09-16","days":5},{"id":"nct06767813","kind":"trial","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","route":"/trials/nct06767813/","asOf":"2026-09-16","days":5},{"id":"nct05948813","kind":"trial","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","route":"/trials/nct05948813/","asOf":"2026-09-16","days":5},{"id":"nct06868277","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06868277/","asOf":"2026-09-16","days":5},{"id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","route":"/trials/nct07285694/","asOf":"2026-09-16","days":5},{"id":"nct07255872","kind":"trial","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","route":"/trials/nct07255872/","asOf":"2026-09-16","days":5},{"id":"nct04458272","kind":"trial","name":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","route":"/trials/nct04458272/","asOf":"2026-09-16","days":5},{"id":"nct04988295","kind":"trial","name":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","route":"/trials/nct04988295/","asOf":"2026-09-16","days":5},{"id":"nct06680752","kind":"trial","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","route":"/trials/nct06680752/","asOf":"2026-09-16","days":5},{"id":"nct06084884","kind":"trial","name":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","route":"/trials/nct06084884/","asOf":"2026-09-16","days":5},{"id":"nct06452706","kind":"trial","name":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","route":"/trials/nct06452706/","asOf":"2026-09-16","days":5},{"id":"nct07284433","kind":"trial","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct07284433/","asOf":"2026-09-16","days":5},{"id":"nct06824168","kind":"trial","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","route":"/trials/nct06824168/","asOf":"2026-09-16","days":5},{"id":"nct04496349","kind":"trial","name":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","route":"/trials/nct04496349/","asOf":"2026-09-16","days":5},{"id":"nct04868604","kind":"trial","name":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","route":"/trials/nct04868604/","asOf":"2026-09-16","days":5},{"id":"nct07387926","kind":"trial","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","route":"/trials/nct07387926/","asOf":"2026-09-16","days":5},{"id":"nct06243458","kind":"trial","name":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","route":"/trials/nct06243458/","asOf":"2026-09-16","days":5},{"id":"nct06885034","kind":"trial","name":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)","route":"/trials/nct06885034/","asOf":"2026-09-16","days":5},{"id":"nct07602777","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","route":"/trials/nct07602777/","asOf":"2026-09-16","days":5},{"id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/","asOf":"2026-09-16","days":5},{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","asOf":"2026-09-16","days":5},{"id":"nct05987956","kind":"trial","name":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","route":"/trials/nct05987956/","asOf":"2026-09-16","days":5},{"id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","asOf":"2026-09-16","days":5},{"id":"nct06632951","kind":"trial","name":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","route":"/trials/nct06632951/","asOf":"2026-09-16","days":5},{"id":"nct05838729","kind":"trial","name":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","route":"/trials/nct05838729/","asOf":"2026-09-16","days":5},{"id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","route":"/trials/nct05438329/","asOf":"2026-09-16","days":5},{"id":"nct06417554","kind":"trial","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","route":"/trials/nct06417554/","asOf":"2026-09-16","days":5},{"id":"nct07398339","kind":"trial","name":"Cosiporfin Sodium for Injection Photodynamic Therapy","route":"/trials/nct07398339/","asOf":"2026-09-16","days":5},{"id":"nct05521802","kind":"trial","name":"A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05521802/","asOf":"2026-09-16","days":5},{"id":"nct05460273","kind":"trial","name":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","route":"/trials/nct05460273/","asOf":"2026-09-16","days":5},{"id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","route":"/trials/nct05720130/","asOf":"2026-09-16","days":5},{"id":"nct03290534","kind":"trial","name":"Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","route":"/trials/nct03290534/","asOf":"2026-09-16","days":5},{"id":"nct06413745","kind":"trial","name":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","route":"/trials/nct06413745/","asOf":"2026-09-16","days":5},{"id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/","asOf":"2026-09-16","days":5},{"id":"nct05607004","kind":"trial","name":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","route":"/trials/nct05607004/","asOf":"2026-09-16","days":5},{"id":"nct06425926","kind":"trial","name":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","route":"/trials/nct06425926/","asOf":"2026-09-16","days":5},{"id":"nct06978114","kind":"trial","name":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06978114/","asOf":"2026-09-16","days":5},{"id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","asOf":"2026-09-16","days":5},{"id":"nct05872347","kind":"trial","name":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","route":"/trials/nct05872347/","asOf":"2026-09-16","days":5},{"id":"nct07669519","kind":"trial","name":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","route":"/trials/nct07669519/","asOf":"2026-09-16","days":5},{"id":"nct06050122","kind":"trial","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","route":"/trials/nct06050122/","asOf":"2026-09-16","days":5},{"id":"nct06389292","kind":"trial","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","route":"/trials/nct06389292/","asOf":"2026-09-16","days":5},{"id":"nct05629234","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","route":"/trials/nct05629234/","asOf":"2026-09-16","days":5},{"id":"nct06788912","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","route":"/trials/nct06788912/","asOf":"2026-09-16","days":5},{"id":"nct05251714","kind":"trial","name":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","route":"/trials/nct05251714/","asOf":"2026-09-16","days":5},{"id":"nct07396584","kind":"trial","name":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","route":"/trials/nct07396584/","asOf":"2026-09-16","days":5},{"id":"nct06127238","kind":"trial","name":"Study of ST-1898 in Advanced Renal Cell Carcinoma","route":"/trials/nct06127238/","asOf":"2026-09-16","days":5},{"id":"nct07220616","kind":"trial","name":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","route":"/trials/nct07220616/","asOf":"2026-09-16","days":5},{"id":"nct04662255","kind":"trial","name":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","route":"/trials/nct04662255/","asOf":"2026-09-16","days":5},{"id":"nct07150663","kind":"trial","name":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07150663/","asOf":"2026-09-16","days":5},{"id":"nct05269316","kind":"trial","name":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","route":"/trials/nct05269316/","asOf":"2026-09-16","days":5},{"id":"nct07823049","kind":"trial","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","route":"/trials/nct07823049/","asOf":"2026-09-16","days":5},{"id":"nct03711032","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","route":"/trials/nct03711032/","asOf":"2026-09-16","days":5},{"id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","route":"/trials/nct06777316/","asOf":"2026-09-16","days":5},{"id":"nct04539496","kind":"trial","name":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","route":"/trials/nct04539496/","asOf":"2026-09-16","days":5},{"id":"nct06782334","kind":"trial","name":"AMT-116 in Patients with Solid Tumors","route":"/trials/nct06782334/","asOf":"2026-09-16","days":5},{"id":"nct02637687","kind":"trial","name":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","route":"/trials/nct02637687/","asOf":"2026-09-16","days":5},{"id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","route":"/trials/nct05443126/","asOf":"2026-09-16","days":5},{"id":"nct05630209","kind":"trial","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)","route":"/trials/nct05630209/","asOf":"2026-09-16","days":5},{"id":"nct02717611","kind":"trial","name":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","route":"/trials/nct02717611/","asOf":"2026-09-16","days":5},{"id":"nct07405164","kind":"trial","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","route":"/trials/nct07405164/","asOf":"2026-09-16","days":5},{"id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/","asOf":"2026-09-16","days":5},{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","asOf":"2026-09-16","days":5},{"id":"nct05573555","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","route":"/trials/nct05573555/","asOf":"2026-09-16","days":5},{"id":"nct05884255","kind":"trial","name":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","route":"/trials/nct05884255/","asOf":"2026-09-16","days":5},{"id":"nct05150691","kind":"trial","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05150691/","asOf":"2026-09-16","days":5},{"id":"nct06780085","kind":"trial","name":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","route":"/trials/nct06780085/","asOf":"2026-09-16","days":5},{"id":"nct07195591","kind":"trial","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","route":"/trials/nct07195591/","asOf":"2026-09-16","days":5},{"id":"nct07155226","kind":"trial","name":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","route":"/trials/nct07155226/","asOf":"2026-09-16","days":5},{"id":"nct05367778","kind":"trial","name":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors","route":"/trials/nct05367778/","asOf":"2026-09-16","days":5},{"id":"nct07444437","kind":"trial","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","route":"/trials/nct07444437/","asOf":"2026-09-16","days":5},{"id":"nct07006077","kind":"trial","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","route":"/trials/nct07006077/","asOf":"2026-09-16","days":5},{"id":"nct06380751","kind":"trial","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","route":"/trials/nct06380751/","asOf":"2026-09-16","days":5},{"id":"nct06522737","kind":"trial","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","route":"/trials/nct06522737/","asOf":"2026-09-16","days":5},{"id":"nct06989437","kind":"trial","name":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","route":"/trials/nct06989437/","asOf":"2026-09-16","days":5},{"id":"nct05415072","kind":"trial","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","route":"/trials/nct05415072/","asOf":"2026-09-16","days":5},{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/","asOf":"2026-09-16","days":5},{"id":"nct07221253","kind":"trial","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","route":"/trials/nct07221253/","asOf":"2026-09-16","days":5},{"id":"nct07589257","kind":"trial","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","route":"/trials/nct07589257/","asOf":"2026-09-16","days":5},{"id":"nct06277219","kind":"trial","name":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","route":"/trials/nct06277219/","asOf":"2026-09-16","days":5},{"id":"nct06660654","kind":"trial","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","route":"/trials/nct06660654/","asOf":"2026-09-16","days":5},{"id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07454187/","asOf":"2026-09-16","days":5},{"id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","route":"/trials/nct07145255/","asOf":"2026-09-16","days":5},{"id":"nct06892548","kind":"trial","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","route":"/trials/nct06892548/","asOf":"2026-09-16","days":5},{"id":"nct07390383","kind":"trial","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","route":"/trials/nct07390383/","asOf":"2026-09-16","days":5},{"id":"nct06313983","kind":"trial","name":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","route":"/trials/nct06313983/","asOf":"2026-09-16","days":5},{"id":"nct06825494","kind":"trial","name":"Clinical Studies for the Treatment of Advanced Solid Tumors","route":"/trials/nct06825494/","asOf":"2026-09-16","days":5},{"id":"nct07238283","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct07238283/","asOf":"2026-09-16","days":5},{"id":"nct04928222","kind":"trial","name":"Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)","route":"/trials/nct04928222/","asOf":"2026-09-16","days":5},{"id":"nct06057922","kind":"trial","name":"A Study YL201 in Patients With Selected Advanced Solid Tumors","route":"/trials/nct06057922/","asOf":"2026-09-16","days":5},{"id":"nct06970639","kind":"trial","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","route":"/trials/nct06970639/","asOf":"2026-09-16","days":5},{"id":"nct07522151","kind":"trial","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","route":"/trials/nct07522151/","asOf":"2026-09-16","days":5},{"id":"nct06425302","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","route":"/trials/nct06425302/","asOf":"2026-09-16","days":5},{"id":"nct07154290","kind":"trial","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07154290/","asOf":"2026-09-16","days":5},{"id":"nct05852691","kind":"trial","name":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05852691/","asOf":"2026-09-16","days":5},{"id":"nct06697197","kind":"trial","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct06697197/","asOf":"2026-09-16","days":5},{"id":"nct03093116","kind":"trial","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","route":"/trials/nct03093116/","asOf":"2026-09-16","days":5},{"id":"nct05201404","kind":"trial","name":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","route":"/trials/nct05201404/","asOf":"2026-09-16","days":5},{"id":"nct07222488","kind":"trial","name":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","route":"/trials/nct07222488/","asOf":"2026-09-16","days":5},{"id":"nct05547061","kind":"trial","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","route":"/trials/nct05547061/","asOf":"2026-09-16","days":5},{"id":"nct06764186","kind":"trial","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","route":"/trials/nct06764186/","asOf":"2026-09-16","days":5},{"id":"nct06345482","kind":"trial","name":"A Study of MHB039A for Advanced Solid Tumor","route":"/trials/nct06345482/","asOf":"2026-09-16","days":5},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/","asOf":"2026-09-16","days":5},{"id":"nct05631262","kind":"trial","name":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","route":"/trials/nct05631262/","asOf":"2026-09-16","days":5},{"id":"nct07290088","kind":"trial","name":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients","route":"/trials/nct07290088/","asOf":"2026-09-16","days":5},{"id":"nct05744427","kind":"trial","name":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","route":"/trials/nct05744427/","asOf":"2026-09-16","days":5},{"id":"nct06940401","kind":"trial","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","route":"/trials/nct06940401/","asOf":"2026-09-16","days":5},{"id":"nct05855200","kind":"trial","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct05855200/","asOf":"2026-09-16","days":5},{"id":"nct07730021","kind":"trial","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","route":"/trials/nct07730021/","asOf":"2026-09-16","days":5},{"id":"nct04651634","kind":"trial","name":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","route":"/trials/nct04651634/","asOf":"2026-09-16","days":5},{"id":"nct04489771","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","route":"/trials/nct04489771/","asOf":"2026-09-16","days":5},{"id":"nct07283367","kind":"trial","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","route":"/trials/nct07283367/","asOf":"2026-09-16","days":5},{"id":"nct06079112","kind":"trial","name":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06079112/","asOf":"2026-09-16","days":5},{"id":"nct05759728","kind":"trial","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","route":"/trials/nct05759728/","asOf":"2026-09-16","days":5},{"id":"nct07647328","kind":"trial","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","route":"/trials/nct07647328/","asOf":"2026-09-16","days":5},{"id":"nct04524000","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04524000/","asOf":"2026-09-16","days":5},{"id":"nct06088004","kind":"trial","name":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","route":"/trials/nct06088004/","asOf":"2026-09-16","days":5},{"id":"nct06868485","kind":"trial","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06868485/","asOf":"2026-09-16","days":5},{"id":"nct04641247","kind":"trial","name":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","route":"/trials/nct04641247/","asOf":"2026-09-16","days":5},{"id":"nct06591520","kind":"trial","name":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","route":"/trials/nct06591520/","asOf":"2026-09-16","days":5},{"id":"nct07664150","kind":"trial","name":"CW-301 FIH Study of CAN016","route":"/trials/nct07664150/","asOf":"2026-09-16","days":5},{"id":"nct04098744","kind":"trial","name":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","route":"/trials/nct04098744/","asOf":"2026-09-16","days":5},{"id":"nct05566041","kind":"trial","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","route":"/trials/nct05566041/","asOf":"2026-09-16","days":5},{"id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","route":"/trials/nct06937177/","asOf":"2026-09-16","days":5},{"id":"nct06993844","kind":"trial","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","route":"/trials/nct06993844/","asOf":"2026-09-16","days":5},{"id":"nct07241767","kind":"trial","name":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","route":"/trials/nct07241767/","asOf":"2026-09-16","days":5},{"id":"nct07019675","kind":"trial","name":"A Study of SKB518 in Patients With Lung Cancer","route":"/trials/nct07019675/","asOf":"2026-09-16","days":5},{"id":"nct04906993","kind":"trial","name":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","route":"/trials/nct04906993/","asOf":"2026-09-16","days":5},{"id":"nct03182244","kind":"trial","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","route":"/trials/nct03182244/","asOf":"2026-09-16","days":5},{"id":"nct05579132","kind":"trial","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","route":"/trials/nct05579132/","asOf":"2026-09-16","days":5},{"id":"nct06879145","kind":"trial","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","route":"/trials/nct06879145/","asOf":"2026-09-16","days":5},{"id":"nct06962787","kind":"trial","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","route":"/trials/nct06962787/","asOf":"2026-09-16","days":5},{"id":"nct07140393","kind":"trial","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","route":"/trials/nct07140393/","asOf":"2026-09-16","days":5},{"id":"nct06730009","kind":"trial","name":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","route":"/trials/nct06730009/","asOf":"2026-09-16","days":5},{"id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","route":"/trials/nct07033026/","asOf":"2026-09-16","days":5},{"id":"nct06618287","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","route":"/trials/nct06618287/","asOf":"2026-09-16","days":5},{"id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","route":"/trials/nct07811193/","asOf":"2026-09-16","days":5},{"id":"nct05918133","kind":"trial","name":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct05918133/","asOf":"2026-09-16","days":5},{"id":"nct06391944","kind":"trial","name":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","route":"/trials/nct06391944/","asOf":"2026-09-16","days":5},{"id":"nct07122414","kind":"trial","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","route":"/trials/nct07122414/","asOf":"2026-09-16","days":5},{"id":"nct04960709","kind":"trial","name":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","route":"/trials/nct04960709/","asOf":"2026-09-16","days":5},{"id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","asOf":"2026-09-16","days":5},{"id":"nct07208149","kind":"trial","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07208149/","asOf":"2026-09-16","days":5},{"id":"nct05990452","kind":"trial","name":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","route":"/trials/nct05990452/","asOf":"2026-09-16","days":5},{"id":"nct07669415","kind":"trial","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","route":"/trials/nct07669415/","asOf":"2026-09-16","days":5},{"id":"nct05636215","kind":"trial","name":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct05636215/","asOf":"2026-09-16","days":5},{"id":"nct07520006","kind":"trial","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","route":"/trials/nct07520006/","asOf":"2026-09-16","days":5},{"id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","route":"/trials/nct06150885/","asOf":"2026-09-16","days":5},{"id":"nct04626635","kind":"trial","name":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","route":"/trials/nct04626635/","asOf":"2026-09-16","days":5},{"id":"nct05879055","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","route":"/trials/nct05879055/","asOf":"2026-09-16","days":5},{"id":"nct02531516","kind":"trial","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","route":"/trials/nct02531516/","asOf":"2026-09-16","days":5},{"id":"nct05588648","kind":"trial","name":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","route":"/trials/nct05588648/","asOf":"2026-09-16","days":5},{"id":"nct06472076","kind":"trial","name":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","route":"/trials/nct06472076/","asOf":"2026-09-16","days":5},{"id":"nct06930794","kind":"trial","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","route":"/trials/nct06930794/","asOf":"2026-09-16","days":5},{"id":"nct04079166","kind":"trial","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","route":"/trials/nct04079166/","asOf":"2026-09-16","days":5},{"id":"nct07354711","kind":"trial","name":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","route":"/trials/nct07354711/","asOf":"2026-09-16","days":5},{"id":"nct05257395","kind":"trial","name":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","route":"/trials/nct05257395/","asOf":"2026-09-16","days":5},{"id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/","asOf":"2026-09-16","days":5},{"id":"nct05543330","kind":"trial","name":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","route":"/trials/nct05543330/","asOf":"2026-09-16","days":5},{"id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","asOf":"2026-09-16","days":5},{"id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06241781/","asOf":"2026-09-16","days":5},{"id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","asOf":"2026-09-16","days":5},{"id":"nct06474468","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","route":"/trials/nct06474468/","asOf":"2026-09-16","days":5},{"id":"nct05312710","kind":"trial","name":"Safety and Efficacy of APG-157 in Head and Neck Cancer","route":"/trials/nct05312710/","asOf":"2026-09-16","days":5},{"id":"nct05787613","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","route":"/trials/nct05787613/","asOf":"2026-09-16","days":5},{"id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct05951179/","asOf":"2026-09-16","days":5},{"id":"nct04150497","kind":"trial","name":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","route":"/trials/nct04150497/","asOf":"2026-09-16","days":5},{"id":"nct04561362","kind":"trial","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","route":"/trials/nct04561362/","asOf":"2026-09-16","days":5},{"id":"nct03667170","kind":"trial","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","route":"/trials/nct03667170/","asOf":"2026-09-16","days":5},{"id":"nct07186842","kind":"trial","name":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","route":"/trials/nct07186842/","asOf":"2026-09-16","days":5},{"id":"nct06041061","kind":"trial","name":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","route":"/trials/nct06041061/","asOf":"2026-09-16","days":5},{"id":"nct06833073","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","route":"/trials/nct06833073/","asOf":"2026-09-16","days":5},{"id":"nct02029443","kind":"trial","name":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","route":"/trials/nct02029443/","asOf":"2026-09-16","days":5},{"id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct04879043/","asOf":"2026-09-16","days":5},{"id":"nct06649708","kind":"trial","name":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","route":"/trials/nct06649708/","asOf":"2026-09-16","days":5},{"id":"nct04570423","kind":"trial","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","route":"/trials/nct04570423/","asOf":"2026-09-16","days":5},{"id":"nct02365597","kind":"trial","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","route":"/trials/nct02365597/","asOf":"2026-09-16","days":5},{"id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","asOf":"2026-09-16","days":5},{"id":"nct07103668","kind":"trial","name":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","route":"/trials/nct07103668/","asOf":"2026-09-16","days":5},{"id":"nct05941897","kind":"trial","name":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","route":"/trials/nct05941897/","asOf":"2026-09-16","days":5},{"id":"nct04834024","kind":"trial","name":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","route":"/trials/nct04834024/","asOf":"2026-09-16","days":5},{"id":"nct05239741","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","route":"/trials/nct05239741/","asOf":"2026-09-16","days":5},{"id":"nct06637501","kind":"trial","name":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct06637501/","asOf":"2026-09-16","days":5},{"id":"nct06485219","kind":"trial","name":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","route":"/trials/nct06485219/","asOf":"2026-09-16","days":5},{"id":"nct05801237","kind":"trial","name":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","route":"/trials/nct05801237/","asOf":"2026-09-16","days":5},{"id":"nct07405801","kind":"trial","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","route":"/trials/nct07405801/","asOf":"2026-09-16","days":5},{"id":"nct02340117","kind":"trial","name":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct02340117/","asOf":"2026-09-16","days":5},{"id":"nct06493552","kind":"trial","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","route":"/trials/nct06493552/","asOf":"2026-09-16","days":5},{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/","asOf":"2026-09-16","days":5},{"id":"nct06456463","kind":"trial","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","route":"/trials/nct06456463/","asOf":"2026-09-16","days":5},{"id":"nct07371663","kind":"trial","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07371663/","asOf":"2026-09-16","days":5},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","asOf":"2026-09-16","days":5},{"id":"nct07281976","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","route":"/trials/nct07281976/","asOf":"2026-09-16","days":5},{"id":"nct06782555","kind":"trial","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","route":"/trials/nct06782555/","asOf":"2026-09-16","days":5},{"id":"nct05864014","kind":"trial","name":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.","route":"/trials/nct05864014/","asOf":"2026-09-16","days":5},{"id":"nct07205718","kind":"trial","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","route":"/trials/nct07205718/","asOf":"2026-09-16","days":5},{"id":"nct06012435","kind":"trial","name":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","route":"/trials/nct06012435/","asOf":"2026-09-16","days":5},{"id":"nct04643418","kind":"trial","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","asOf":"2026-09-16","days":5},{"id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/","asOf":"2026-09-16","days":5},{"id":"nct03441113","kind":"trial","name":"Extended Access of Momelotinib in Adults With Myelofibrosis","route":"/trials/nct03441113/","asOf":"2026-09-16","days":5},{"id":"nct05967689","kind":"trial","name":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","route":"/trials/nct05967689/","asOf":"2026-09-16","days":5},{"id":"nct05277168","kind":"trial","name":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","route":"/trials/nct05277168/","asOf":"2026-09-16","days":5},{"id":"nct06970743","kind":"trial","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","route":"/trials/nct06970743/","asOf":"2026-09-16","days":5},{"id":"nct05652920","kind":"trial","name":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","route":"/trials/nct05652920/","asOf":"2026-09-16","days":5},{"id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","route":"/trials/nct05827081/","asOf":"2026-09-16","days":5},{"id":"nct06703177","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","route":"/trials/nct06703177/","asOf":"2026-09-16","days":5},{"id":"nct06966453","kind":"trial","name":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","route":"/trials/nct06966453/","asOf":"2026-09-16","days":5},{"id":"nct04514419","kind":"trial","name":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","route":"/trials/nct04514419/","asOf":"2026-09-16","days":5},{"id":"nct06642545","kind":"trial","name":"Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer","route":"/trials/nct06642545/","asOf":"2026-09-16","days":5},{"id":"nct06243354","kind":"trial","name":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","route":"/trials/nct06243354/","asOf":"2026-09-16","days":5},{"id":"nct06123494","kind":"trial","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","route":"/trials/nct06123494/","asOf":"2026-09-16","days":5},{"id":"nct07231211","kind":"trial","name":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","route":"/trials/nct07231211/","asOf":"2026-09-16","days":5},{"id":"nct01064466","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","route":"/trials/nct01064466/","asOf":"2026-09-16","days":5},{"id":"nct06524375","kind":"trial","name":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","route":"/trials/nct06524375/","asOf":"2026-09-16","days":5},{"id":"nct06484829","kind":"trial","name":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06484829/","asOf":"2026-09-16","days":5},{"id":"nct07072728","kind":"trial","name":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","route":"/trials/nct07072728/","asOf":"2026-09-16","days":5},{"id":"nct03862430","kind":"trial","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","route":"/trials/nct03862430/","asOf":"2026-09-16","days":5},{"id":"nct05879822","kind":"trial","name":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","route":"/trials/nct05879822/","asOf":"2026-09-16","days":5},{"id":"nct07700160","kind":"trial","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","route":"/trials/nct07700160/","asOf":"2026-09-16","days":5},{"id":"nct03435796","kind":"trial","name":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","route":"/trials/nct03435796/","asOf":"2026-09-16","days":5},{"id":"nct07019779","kind":"trial","name":"Study of CM518D1 in Patients With Advanced Solid Tumors","route":"/trials/nct07019779/","asOf":"2026-09-16","days":5},{"id":"nct04879329","kind":"trial","name":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","route":"/trials/nct04879329/","asOf":"2026-09-16","days":5},{"id":"nct07106762","kind":"trial","name":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","route":"/trials/nct07106762/","asOf":"2026-09-16","days":5},{"id":"nct04270591","kind":"trial","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","route":"/trials/nct04270591/","asOf":"2026-09-16","days":5},{"id":"nct06147570","kind":"trial","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","route":"/trials/nct06147570/","asOf":"2026-09-16","days":5},{"id":"nct05879068","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","route":"/trials/nct05879068/","asOf":"2026-09-16","days":5},{"id":"nct06336291","kind":"trial","name":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","route":"/trials/nct06336291/","asOf":"2026-09-16","days":5},{"id":"nct05053880","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","route":"/trials/nct05053880/","asOf":"2026-09-16","days":5},{"id":"nct07444541","kind":"trial","name":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct07444541/","asOf":"2026-09-16","days":5},{"id":"nct06066203","kind":"trial","name":"A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies","route":"/trials/nct06066203/","asOf":"2026-09-16","days":5},{"id":"nct05589896","kind":"trial","name":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","route":"/trials/nct05589896/","asOf":"2026-09-16","days":5},{"id":"nct02972840","kind":"trial","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","route":"/trials/nct02972840/","asOf":"2026-09-16","days":5},{"id":"nct03473743","kind":"trial","name":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","route":"/trials/nct03473743/","asOf":"2026-09-16","days":5},{"id":"nct06654440","kind":"trial","name":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","route":"/trials/nct06654440/","asOf":"2026-09-16","days":5},{"id":"nct04550260","kind":"trial","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","route":"/trials/nct04550260/","asOf":"2026-09-16","days":5},{"id":"nct06619509","kind":"trial","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","route":"/trials/nct06619509/","asOf":"2026-09-16","days":5},{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/","asOf":"2026-09-16","days":5},{"id":"nct05526755","kind":"trial","name":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","route":"/trials/nct05526755/","asOf":"2026-09-16","days":5},{"id":"nct06014658","kind":"trial","name":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","route":"/trials/nct06014658/","asOf":"2026-09-16","days":5},{"id":"nct07648914","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)","route":"/trials/nct07648914/","asOf":"2026-09-16","days":5},{"id":"nct06556563","kind":"trial","name":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","route":"/trials/nct06556563/","asOf":"2026-09-16","days":5},{"id":"nct06296706","kind":"trial","name":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","route":"/trials/nct06296706/","asOf":"2026-09-16","days":5},{"id":"nct07157033","kind":"trial","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","route":"/trials/nct07157033/","asOf":"2026-09-16","days":5},{"id":"nct06760637","kind":"trial","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","route":"/trials/nct06760637/","asOf":"2026-09-16","days":5},{"id":"nct06056830","kind":"trial","name":"Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy","route":"/trials/nct06056830/","asOf":"2026-09-16","days":5},{"id":"nct02843945","kind":"trial","name":"Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","route":"/trials/nct02843945/","asOf":"2026-09-16","days":5},{"id":"nct07071337","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","route":"/trials/nct07071337/","asOf":"2026-09-16","days":5},{"id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","route":"/trials/nct07460375/","asOf":"2026-09-16","days":5},{"id":"nct06632912","kind":"trial","name":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","route":"/trials/nct06632912/","asOf":"2026-09-16","days":5},{"id":"nct06939595","kind":"trial","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","route":"/trials/nct06939595/","asOf":"2026-09-16","days":5},{"id":"nct04014205","kind":"trial","name":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","route":"/trials/nct04014205/","asOf":"2026-09-16","days":5},{"id":"nct04996121","kind":"trial","name":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04996121/","asOf":"2026-09-16","days":5},{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/","asOf":"2026-09-16","days":5},{"id":"nct07145333","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","route":"/trials/nct07145333/","asOf":"2026-09-16","days":5},{"id":"nct03330847","kind":"trial","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","route":"/trials/nct03330847/","asOf":"2026-09-16","days":5},{"id":"nct07022002","kind":"trial","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07022002/","asOf":"2026-09-16","days":5},{"id":"nct05952037","kind":"trial","name":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","route":"/trials/nct05952037/","asOf":"2026-09-16","days":5},{"id":"nct04725994","kind":"trial","name":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer","route":"/trials/nct04725994/","asOf":"2026-09-16","days":5},{"id":"nct06639256","kind":"trial","name":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","route":"/trials/nct06639256/","asOf":"2026-09-16","days":5},{"id":"nct05918445","kind":"trial","name":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct05918445/","asOf":"2026-09-16","days":5},{"id":"nct03899636","kind":"trial","name":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","route":"/trials/nct03899636/","asOf":"2026-09-16","days":5},{"id":"nct07541001","kind":"trial","name":"PRL3-Zumab in Patients With Advanced Solid Tumors","route":"/trials/nct07541001/","asOf":"2026-09-16","days":5},{"id":"nct06741644","kind":"trial","name":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","route":"/trials/nct06741644/","asOf":"2026-09-16","days":5},{"id":"nct07221734","kind":"trial","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","route":"/trials/nct07221734/","asOf":"2026-09-16","days":5},{"id":"nct05147467","kind":"trial","name":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct05147467/","asOf":"2026-09-16","days":5},{"id":"nct06987500","kind":"trial","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","route":"/trials/nct06987500/","asOf":"2026-09-16","days":5},{"id":"nct06840119","kind":"trial","name":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","route":"/trials/nct06840119/","asOf":"2026-09-16","days":5},{"id":"nct05208944","kind":"trial","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","route":"/trials/nct05208944/","asOf":"2026-09-16","days":5},{"id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","asOf":"2026-09-16","days":5},{"id":"nct07761429","kind":"trial","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","route":"/trials/nct07761429/","asOf":"2026-09-16","days":5},{"id":"nct07265622","kind":"trial","name":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","route":"/trials/nct07265622/","asOf":"2026-09-16","days":5},{"id":"nct06751329","kind":"trial","name":"A Study of DM002 in Patients With Advanced Solid Tumors","route":"/trials/nct06751329/","asOf":"2026-09-16","days":5},{"id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","route":"/trials/nct04910022/","asOf":"2026-09-16","days":5},{"id":"nct05541822","kind":"trial","name":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","route":"/trials/nct05541822/","asOf":"2026-09-16","days":5},{"id":"nct04576156","kind":"trial","name":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","route":"/trials/nct04576156/","asOf":"2026-09-16","days":5},{"id":"nct06603844","kind":"trial","name":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.","route":"/trials/nct06603844/","asOf":"2026-09-16","days":5},{"id":"nct06334432","kind":"trial","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","route":"/trials/nct06334432/","asOf":"2026-09-16","days":5},{"id":"nct06149559","kind":"trial","name":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","route":"/trials/nct06149559/","asOf":"2026-09-16","days":5},{"id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","asOf":"2026-09-16","days":5},{"id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","asOf":"2026-09-16","days":5},{"id":"nct06907615","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06907615/","asOf":"2026-09-16","days":5},{"id":"nct03815643","kind":"trial","name":"Avelumab Program Rollover Study","route":"/trials/nct03815643/","asOf":"2026-09-16","days":5},{"id":"nct05968326","kind":"trial","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","route":"/trials/nct05968326/","asOf":"2026-09-16","days":5},{"id":"nct06682572","kind":"trial","name":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients","route":"/trials/nct06682572/","asOf":"2026-09-16","days":5},{"id":"nct05894239","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05894239/","asOf":"2026-09-16","days":5},{"id":"nct07640295","kind":"trial","name":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","route":"/trials/nct07640295/","asOf":"2026-09-16","days":5},{"id":"nct05845814","kind":"trial","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","route":"/trials/nct05845814/","asOf":"2026-09-16","days":5},{"id":"nct06790693","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","route":"/trials/nct06790693/","asOf":"2026-09-16","days":5},{"id":"nct07172919","kind":"trial","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","route":"/trials/nct07172919/","asOf":"2026-09-16","days":5},{"id":"nct04639986","kind":"trial","name":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","route":"/trials/nct04639986/","asOf":"2026-09-16","days":5},{"id":"nct05671822","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","route":"/trials/nct05671822/","asOf":"2026-09-16","days":5},{"id":"nct07206056","kind":"trial","name":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","route":"/trials/nct07206056/","asOf":"2026-09-16","days":5},{"id":"nct04581473","kind":"trial","name":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","route":"/trials/nct04581473/","asOf":"2026-09-16","days":5},{"id":"nct04673942","kind":"trial","name":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","route":"/trials/nct04673942/","asOf":"2026-09-16","days":5},{"id":"nct04452955","kind":"trial","name":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors","route":"/trials/nct04452955/","asOf":"2026-09-16","days":5},{"id":"nct07450976","kind":"trial","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","route":"/trials/nct07450976/","asOf":"2026-09-16","days":5},{"id":"nct03851640","kind":"trial","name":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","route":"/trials/nct03851640/","asOf":"2026-09-16","days":5},{"id":"nct03736889","kind":"trial","name":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","route":"/trials/nct03736889/","asOf":"2026-09-16","days":5},{"id":"nct04995523","kind":"trial","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","route":"/trials/nct04995523/","asOf":"2026-09-16","days":5},{"id":"nct03793478","kind":"trial","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","route":"/trials/nct03793478/","asOf":"2026-09-16","days":5},{"id":"nct05859750","kind":"trial","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","route":"/trials/nct05859750/","asOf":"2026-09-16","days":5},{"id":"nct07529808","kind":"trial","name":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","route":"/trials/nct07529808/","asOf":"2026-09-16","days":5},{"id":"nct05386108","kind":"trial","name":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","route":"/trials/nct05386108/","asOf":"2026-09-16","days":5},{"id":"nct05197426","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","route":"/trials/nct05197426/","asOf":"2026-09-16","days":5},{"id":"nct07417189","kind":"trial","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","route":"/trials/nct07417189/","asOf":"2026-09-16","days":5},{"id":"nct06007690","kind":"trial","name":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","route":"/trials/nct06007690/","asOf":"2026-09-16","days":5},{"id":"nct07054190","kind":"trial","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","route":"/trials/nct07054190/","asOf":"2026-09-16","days":5},{"id":"nct06343311","kind":"trial","name":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","route":"/trials/nct06343311/","asOf":"2026-09-16","days":5},{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","route":"/trials/nct00248287/","asOf":"2026-09-16","days":5},{"id":"nct07241936","kind":"trial","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","route":"/trials/nct07241936/","asOf":"2026-09-16","days":5},{"id":"nct05874414","kind":"trial","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","route":"/trials/nct05874414/","asOf":"2026-09-16","days":5},{"id":"nct04380636","kind":"trial","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","route":"/trials/nct04380636/","asOf":"2026-09-16","days":5},{"id":"nct06196736","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06196736/","asOf":"2026-09-16","days":5},{"id":"nct06088290","kind":"trial","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","route":"/trials/nct06088290/","asOf":"2026-09-16","days":5},{"id":"nct06539182","kind":"trial","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","route":"/trials/nct06539182/","asOf":"2026-09-16","days":5},{"id":"nct05503797","kind":"trial","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","route":"/trials/nct05503797/","asOf":"2026-09-16","days":5},{"id":"nct04342910","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","route":"/trials/nct04342910/","asOf":"2026-09-16","days":5},{"id":"nct07551362","kind":"trial","name":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","route":"/trials/nct07551362/","asOf":"2026-09-16","days":5},{"id":"nct05934513","kind":"trial","name":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","route":"/trials/nct05934513/","asOf":"2026-09-16","days":5},{"id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06953089/","asOf":"2026-09-16","days":5},{"id":"nct04544189","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04544189/","asOf":"2026-09-16","days":5},{"id":"nct04285086","kind":"trial","name":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","route":"/trials/nct04285086/","asOf":"2026-09-16","days":5},{"id":"nct05736731","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","route":"/trials/nct05736731/","asOf":"2026-09-16","days":5},{"id":"nct05958121","kind":"trial","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct05958121/","asOf":"2026-09-16","days":5},{"id":"nct04851613","kind":"trial","name":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct04851613/","asOf":"2026-09-16","days":5},{"id":"nct07286266","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","route":"/trials/nct07286266/","asOf":"2026-09-16","days":5},{"id":"nct03980054","kind":"trial","name":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","route":"/trials/nct03980054/","asOf":"2026-09-16","days":5},{"id":"nct06841354","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","route":"/trials/nct06841354/","asOf":"2026-09-16","days":5},{"id":"nct07050641","kind":"trial","name":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","route":"/trials/nct07050641/","asOf":"2026-09-16","days":5},{"id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","route":"/trials/nct07221500/","asOf":"2026-09-16","days":5},{"id":"nct03669965","kind":"trial","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","route":"/trials/nct03669965/","asOf":"2026-09-16","days":5},{"id":"nct04819100","kind":"trial","name":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04819100/","asOf":"2026-09-16","days":5},{"id":"nct04931654","kind":"trial","name":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","route":"/trials/nct04931654/","asOf":"2026-09-16","days":5},{"id":"nct03491683","kind":"trial","name":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","route":"/trials/nct03491683/","asOf":"2026-09-16","days":5},{"id":"nct07293754","kind":"trial","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","route":"/trials/nct07293754/","asOf":"2026-09-16","days":5},{"id":"nct07749586","kind":"trial","name":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","route":"/trials/nct07749586/","asOf":"2026-09-16","days":5},{"id":"nct04592653","kind":"trial","name":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","route":"/trials/nct04592653/","asOf":"2026-09-16","days":5},{"id":"nct06800313","kind":"trial","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","route":"/trials/nct06800313/","asOf":"2026-09-16","days":5},{"id":"nct06239194","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","route":"/trials/nct06239194/","asOf":"2026-09-16","days":5},{"id":"nct06974929","kind":"trial","name":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","route":"/trials/nct06974929/","asOf":"2026-09-16","days":5},{"id":"nct06369285","kind":"trial","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct06369285/","asOf":"2026-09-16","days":5},{"id":"nct06077877","kind":"trial","name":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors","route":"/trials/nct06077877/","asOf":"2026-09-16","days":5},{"id":"nct07296341","kind":"trial","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07296341/","asOf":"2026-09-16","days":5},{"id":"nct06925581","kind":"trial","name":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","route":"/trials/nct06925581/","asOf":"2026-09-16","days":5},{"id":"nct05327530","kind":"trial","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","route":"/trials/nct05327530/","asOf":"2026-09-16","days":5},{"id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","route":"/trials/nct07367529/","asOf":"2026-09-16","days":5},{"id":"nct07439653","kind":"trial","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","route":"/trials/nct07439653/","asOf":"2026-09-16","days":5},{"id":"nct06832202","kind":"trial","name":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","route":"/trials/nct06832202/","asOf":"2026-09-16","days":5},{"id":"nct06262139","kind":"trial","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","route":"/trials/nct06262139/","asOf":"2026-09-16","days":5},{"id":"nct07541430","kind":"trial","name":"A Study in Adults With Desmoid Tumors","route":"/trials/nct07541430/","asOf":"2026-09-16","days":5},{"id":"nct07276373","kind":"trial","name":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","route":"/trials/nct07276373/","asOf":"2026-09-16","days":5},{"id":"nct06010329","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","route":"/trials/nct06010329/","asOf":"2026-09-16","days":5},{"id":"nct04395677","kind":"trial","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","route":"/trials/nct04395677/","asOf":"2026-09-16","days":5},{"id":"nct04634877","kind":"trial","name":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","route":"/trials/nct04634877/","asOf":"2026-09-16","days":5},{"id":"nct06827613","kind":"trial","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","route":"/trials/nct06827613/","asOf":"2026-09-16","days":5},{"id":"nct07073534","kind":"trial","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","route":"/trials/nct07073534/","asOf":"2026-09-16","days":5},{"id":"nct06140836","kind":"trial","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","route":"/trials/nct06140836/","asOf":"2026-09-16","days":5},{"id":"nct06075264","kind":"trial","name":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","route":"/trials/nct06075264/","asOf":"2026-09-16","days":5},{"id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","route":"/trials/nct07777211/","asOf":"2026-09-16","days":5},{"id":"nct04325828","kind":"trial","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","route":"/trials/nct04325828/","asOf":"2026-09-16","days":5},{"id":"nct07336732","kind":"trial","name":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","route":"/trials/nct07336732/","asOf":"2026-09-16","days":5},{"id":"nct05355298","kind":"trial","name":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","route":"/trials/nct05355298/","asOf":"2026-09-16","days":5},{"id":"nct04140500","kind":"trial","name":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","route":"/trials/nct04140500/","asOf":"2026-09-16","days":5},{"id":"nct06968221","kind":"trial","name":"Bovine Reinforcement in Stomach, Colorectal and Lung Operation","route":"/trials/nct06968221/","asOf":"2026-09-16","days":5},{"id":"nct07623616","kind":"trial","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","route":"/trials/nct07623616/","asOf":"2026-09-16","days":5},{"id":"nct06028074","kind":"trial","name":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","route":"/trials/nct06028074/","asOf":"2026-09-16","days":5},{"id":"nct07083323","kind":"trial","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","route":"/trials/nct07083323/","asOf":"2026-09-16","days":5},{"id":"nct07609823","kind":"trial","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct07609823/","asOf":"2026-09-16","days":5},{"id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/","asOf":"2026-09-16","days":5},{"id":"nct06883526","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","route":"/trials/nct06883526/","asOf":"2026-09-16","days":5},{"id":"nct05908643","kind":"trial","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","route":"/trials/nct05908643/","asOf":"2026-09-16","days":5},{"id":"nct06927687","kind":"trial","name":"Study of ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06927687/","asOf":"2026-09-16","days":5},{"id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/","asOf":"2026-09-16","days":5},{"id":"nct04776330","kind":"trial","name":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04776330/","asOf":"2026-09-16","days":5},{"id":"nct04329728","kind":"trial","name":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","route":"/trials/nct04329728/","asOf":"2026-09-16","days":5},{"id":"nct06890598","kind":"trial","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","route":"/trials/nct06890598/","asOf":"2026-09-16","days":5},{"id":"nct04243499","kind":"trial","name":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","route":"/trials/nct04243499/","asOf":"2026-09-16","days":5},{"id":"nct07734116","kind":"trial","name":"A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.","route":"/trials/nct07734116/","asOf":"2026-09-16","days":5},{"id":"nct06256328","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","route":"/trials/nct06256328/","asOf":"2026-09-16","days":5},{"id":"nct06796907","kind":"trial","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","route":"/trials/nct06796907/","asOf":"2026-09-16","days":5},{"id":"nct05374915","kind":"trial","name":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","route":"/trials/nct05374915/","asOf":"2026-09-16","days":5},{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","asOf":"2026-09-16","days":5},{"id":"nct05573126","kind":"trial","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","route":"/trials/nct05573126/","asOf":"2026-09-16","days":5},{"id":"nct06777433","kind":"trial","name":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","route":"/trials/nct06777433/","asOf":"2026-09-16","days":5},{"id":"nct06567743","kind":"trial","name":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","route":"/trials/nct06567743/","asOf":"2026-09-16","days":5},{"id":"nct07205822","kind":"trial","name":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","route":"/trials/nct07205822/","asOf":"2026-09-16","days":5},{"id":"nct05199272","kind":"trial","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","route":"/trials/nct05199272/","asOf":"2026-09-16","days":5},{"id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/","asOf":"2026-09-16","days":5},{"id":"nct05785039","kind":"trial","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","route":"/trials/nct05785039/","asOf":"2026-09-16","days":5},{"id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/","asOf":"2026-09-16","days":5},{"id":"nct06612281","kind":"trial","name":"Evaluation of Gixam's Performance in a FIT Negative Population","route":"/trials/nct06612281/","asOf":"2026-09-16","days":5},{"id":"nct06478719","kind":"trial","name":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","route":"/trials/nct06478719/","asOf":"2026-09-16","days":5},{"id":"nct06395519","kind":"trial","name":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","route":"/trials/nct06395519/","asOf":"2026-09-16","days":5},{"id":"nct06663137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","route":"/trials/nct06663137/","asOf":"2026-09-16","days":5},{"id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","route":"/trials/nct07562581/","asOf":"2026-09-16","days":5},{"id":"nct06198751","kind":"trial","name":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct06198751/","asOf":"2026-09-16","days":5},{"id":"nct06167694","kind":"trial","name":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer","route":"/trials/nct06167694/","asOf":"2026-09-16","days":5},{"id":"nct05226871","kind":"trial","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","route":"/trials/nct05226871/","asOf":"2026-09-16","days":5},{"id":"nct04655092","kind":"trial","name":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","route":"/trials/nct04655092/","asOf":"2026-09-16","days":5},{"id":"nct03096093","kind":"trial","name":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","route":"/trials/nct03096093/","asOf":"2026-09-16","days":5},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","asOf":"2026-09-17","days":4},{"id":"checkmate-143","kind":"trial","name":"CheckMate 143","route":"/trials/checkmate-143/","asOf":"2026-09-17","days":4},{"id":"checkmate-498","kind":"trial","name":"CheckMate 498","route":"/trials/checkmate-498/","asOf":"2026-09-17","days":4},{"id":"checkmate-548","kind":"trial","name":"CheckMate 548","route":"/trials/checkmate-548/","asOf":"2026-09-17","days":4},{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/","asOf":"2026-09-17","days":4},{"id":"extent-of-resection","kind":"term","name":"Extent of resection (RANO resect classes)","route":"/terms/extent-of-resection/","asOf":"2026-09-17","days":4},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/","asOf":"2026-09-17","days":4},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/","asOf":"2026-09-17","days":4},{"id":"carbon-ion","kind":"technology","name":"Carbon-ion therapy","route":"/technologies/carbon-ion/","asOf":"2026-09-17","days":4},{"id":"tregzi","kind":"drug","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","asOf":"2026-09-17","days":4},{"id":"paper-paganetti-proton-rbe-ijrobp-2014","kind":"paper","name":"Paganetti 2014: proton RBE is not a fixed 1.1","route":"/key-papers/paper-paganetti-proton-rbe-ijrobp-2014/","asOf":"2026-09-17","days":4},{"id":"paper-swog-8710-neoadjuvant-mvac-nejm-2003","kind":"paper","name":"SWOG 8710: neoadjuvant MVAC chemotherapy before cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-swog-8710-neoadjuvant-mvac-nejm-2003/","asOf":"2026-09-17","days":4},{"id":"paper-javelin-bladder-100-nejm-2020","kind":"paper","name":"JAVELIN Bladder 100: avelumab maintenance after first-line platinum chemotherapy in advanced urothelial cancer","route":"/key-papers/paper-javelin-bladder-100-nejm-2020/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-057-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-057: pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ","route":"/key-papers/paper-keynote-057-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-nadofaragene-firadenovec-lancet-oncol-2021","kind":"paper","name":"Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-sylvester-eortc-risk-tables-eur-urol-2006","kind":"paper","name":"EORTC risk tables for recurrence and progression in Ta and T1 bladder cancer","route":"/key-papers/paper-sylvester-eortc-risk-tables-eur-urol-2006/","asOf":"2026-09-17","days":4},{"id":"paper-eau-nmibc-guideline-eur-urol-2022","kind":"paper","name":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)","route":"/key-papers/paper-eau-nmibc-guideline-eur-urol-2022/","asOf":"2026-09-17","days":4},{"id":"paper-aza-aml-001-dombret-blood-2015","kind":"paper","name":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts","route":"/key-papers/paper-aza-aml-001-dombret-blood-2015/","asOf":"2026-09-17","days":4},{"id":"paper-eln-2022-aml-dohner-blood-2022","kind":"paper","name":"ELN 2022: diagnosis and management of acute myeloid leukaemia in adults","route":"/key-papers/paper-eln-2022-aml-dohner-blood-2022/","asOf":"2026-09-17","days":4},{"id":"paper-apl0406-lo-coco-nejm-2013","kind":"paper","name":"APL0406: retinoic acid plus arsenic trioxide without chemotherapy for low- and intermediate-risk acute promyelocytic leukaemia","route":"/key-papers/paper-apl0406-lo-coco-nejm-2013/","asOf":"2026-09-17","days":4},{"id":"paper-tallman-atra-apl-nejm-1997","kind":"paper","name":"North American Intergroup: all-trans retinoic acid in acute promyelocytic leukaemia","route":"/key-papers/paper-tallman-atra-apl-nejm-1997/","asOf":"2026-09-17","days":4},{"id":"paper-eln-apl-sanz-blood-2019","kind":"paper","name":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","route":"/key-papers/paper-eln-apl-sanz-blood-2019/","asOf":"2026-09-17","days":4},{"id":"paper-pace-ponatinib-nejm-2013","kind":"paper","name":"PACE: ponatinib in Philadelphia chromosome-positive leukaemias resistant to earlier tyrosine kinase inhibitors","route":"/key-papers/paper-pace-ponatinib-nejm-2013/","asOf":"2026-09-17","days":4},{"id":"paper-eln-2020-cml-hochhaus-leukemia-2020","kind":"paper","name":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia","route":"/key-papers/paper-eln-2020-cml-hochhaus-leukemia-2020/","asOf":"2026-09-17","days":4},{"id":"paper-ratify-midostaurin-nejm-2017","kind":"paper","name":"RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation","route":"/key-papers/paper-ratify-midostaurin-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-aza-001-fenaux-lancet-oncol-2009","kind":"paper","name":"AZA-001: azacitidine versus conventional care in higher-risk myelodysplastic syndromes","route":"/key-papers/paper-aza-001-fenaux-lancet-oncol-2009/","asOf":"2026-09-17","days":4},{"id":"paper-ipss-m-bernard-nejm-evidence-2022","kind":"paper","name":"IPSS-M: the molecular international prognostic scoring system for myelodysplastic syndromes","route":"/key-papers/paper-ipss-m-bernard-nejm-evidence-2022/","asOf":"2026-09-17","days":4},{"id":"paper-who-2022-myeloid-khoury-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms","route":"/key-papers/paper-who-2022-myeloid-khoury-leukemia-2022/","asOf":"2026-09-17","days":4},{"id":"paper-icc-2022-arber-blood-2022","kind":"paper","name":"International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)","route":"/key-papers/paper-icc-2022-arber-blood-2022/","asOf":"2026-09-17","days":4},{"id":"paper-ivosidenib-idh1-dinardo-nejm-2018","kind":"paper","name":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-ivosidenib-idh1-dinardo-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-enasidenib-idh2-stein-blood-2017","kind":"paper","name":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-enasidenib-idh2-stein-blood-2017/","asOf":"2026-09-17","days":4},{"id":"paper-cassiopeia-lancet-2019","kind":"paper","name":"CASSIOPEIA: daratumumab added to bortezomib, thalidomide and dexamethasone before and after transplant in newly diagnosed myeloma","route":"/key-papers/paper-cassiopeia-lancet-2019/","asOf":"2026-09-17","days":4},{"id":"paper-ifm-2009-attal-nejm-2017","kind":"paper","name":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma","route":"/key-papers/paper-ifm-2009-attal-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-r-iss-palumbo-jco-2015","kind":"paper","name":"Revised International Staging System (R-ISS) for multiple myeloma","route":"/key-papers/paper-r-iss-palumbo-jco-2015/","asOf":"2026-09-17","days":4},{"id":"paper-falini-npm1-nejm-2005","kind":"paper","name":"Cytoplasmic nucleophosmin in acute myeloid leukaemia with a normal karyotype","route":"/key-papers/paper-falini-npm1-nejm-2005/","asOf":"2026-09-17","days":4},{"id":"paper-ivey-npm1-mrd-nejm-2016","kind":"paper","name":"Molecular measurable residual disease in NPM1-mutated acute myeloid leukaemia (UK NCRI AML17)","route":"/key-papers/paper-ivey-npm1-mrd-nejm-2016/","asOf":"2026-09-17","days":4},{"id":"paper-imwg-plasma-cell-leukaemia-definition-bcj-2021","kind":"paper","name":"IMWG consensus definition of primary plasma cell leukaemia at 5 percent circulating plasma cells","route":"/key-papers/paper-imwg-plasma-cell-leukaemia-definition-bcj-2021/","asOf":"2026-09-17","days":4},{"id":"paper-royer-plasma-cell-leukaemia-ifm-jco-2016","kind":"paper","name":"IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia","route":"/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/","asOf":"2026-09-17","days":4},{"id":"paper-monumental-1-talquetamab-nejm-2022","kind":"paper","name":"MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma","route":"/key-papers/paper-monumental-1-talquetamab-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-rossi-richter-syndrome-blood-2018","kind":"paper","name":"Biology and treatment of Richter syndrome","route":"/key-papers/paper-rossi-richter-syndrome-blood-2018/","asOf":"2026-09-17","days":4},{"id":"paper-who-2022-lymphoid-alaggio-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms","route":"/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/","asOf":"2026-09-17","days":4},{"id":"paper-cpx-351-study-301-lancet-je-jco-2018","kind":"paper","name":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","route":"/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/","asOf":"2026-09-17","days":4},{"id":"paper-aquila-daratumumab-smouldering-nejm-2025","kind":"paper","name":"AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma","route":"/key-papers/paper-aquila-daratumumab-smouldering-nejm-2025/","asOf":"2026-09-17","days":4},{"id":"paper-e3a06-lenalidomide-smouldering-lonial-jco-2020","kind":"paper","name":"E3A06: lenalidomide versus observation in smouldering multiple myeloma","route":"/key-papers/paper-e3a06-lenalidomide-smouldering-lonial-jco-2020/","asOf":"2026-09-17","days":4},{"id":"paper-imwg-criteria-rajkumar-lancet-oncol-2014","kind":"paper","name":"IMWG updated criteria for the diagnosis of multiple myeloma (2014)","route":"/key-papers/paper-imwg-criteria-rajkumar-lancet-oncol-2014/","asOf":"2026-09-17","days":4},{"id":"paper-mateos-20-2-20-smouldering-bcj-2020","kind":"paper","name":"IMWG 20/2/20 risk stratification model for smouldering multiple myeloma","route":"/key-papers/paper-mateos-20-2-20-smouldering-bcj-2020/","asOf":"2026-09-17","days":4},{"id":"paper-aphinity-nejm-2017","kind":"paper","name":"APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer","route":"/key-papers/paper-aphinity-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-apt-tolaney-nejm-2015","kind":"paper","name":"APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer","route":"/key-papers/paper-apt-tolaney-nejm-2015/","asOf":"2026-09-17","days":4},{"id":"paper-train-2-lancet-oncol-2018","kind":"paper","name":"TRAIN-2: neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade","route":"/key-papers/paper-train-2-lancet-oncol-2018/","asOf":"2026-09-17","days":4},{"id":"paper-her2climb-nejm-2020","kind":"paper","name":"HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases","route":"/key-papers/paper-her2climb-nejm-2020/","asOf":"2026-09-17","days":4},{"id":"paper-her2climb-brain-lin-jco-2020","kind":"paper","name":"HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib","route":"/key-papers/paper-her2climb-brain-lin-jco-2020/","asOf":"2026-09-17","days":4},{"id":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","kind":"paper","name":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","route":"/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/","asOf":"2026-09-17","days":4},{"id":"paper-tailorx-nejm-2018","kind":"paper","name":"TAILORx: adjuvant chemotherapy guided by the 21-gene recurrence score in hormone receptor-positive, node-negative breast cancer","route":"/key-papers/paper-tailorx-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-emerald-elacestrant-jco-2022","kind":"paper","name":"EMERALD: elacestrant versus standard endocrine therapy after a CDK4/6 inhibitor","route":"/key-papers/paper-emerald-elacestrant-jco-2022/","asOf":"2026-09-17","days":4},{"id":"paper-capitello-291-nejm-2023","kind":"paper","name":"CAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-capitello-291-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-solar-1-alpelisib-nejm-2019","kind":"paper","name":"SOLAR-1: alpelisib plus fulvestrant for PIK3CA-mutated hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-solar-1-alpelisib-nejm-2019/","asOf":"2026-09-17","days":4},{"id":"paper-dawood-inflammatory-breast-consensus-ann-oncol-2011","kind":"paper","name":"International expert panel consensus on the diagnosis and treatment of inflammatory breast cancer","route":"/key-papers/paper-dawood-inflammatory-breast-consensus-ann-oncol-2011/","asOf":"2026-09-17","days":4},{"id":"paper-rueth-inflammatory-breast-trimodality-jco-2014","kind":"paper","name":"Underuse of trimodality treatment and survival in inflammatory breast cancer (National Cancer Data Base)","route":"/key-papers/paper-rueth-inflammatory-breast-trimodality-jco-2014/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-355-nejm-2022","kind":"paper","name":"KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer","route":"/key-papers/paper-keynote-355-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-olympiad-nejm-2017","kind":"paper","name":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","route":"/key-papers/paper-olympiad-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-kothari-paget-disease-nipple-multifocal-cancer-2002","kind":"paper","name":"Paget disease of the nipple as a marker of multifocal, higher-risk underlying breast cancer","route":"/key-papers/paper-kothari-paget-disease-nipple-multifocal-cancer-2002/","asOf":"2026-09-17","days":4},{"id":"paper-tan-phyllodes-consensus-histopathology-2016","kind":"paper","name":"Phyllodes tumours of the breast: a consensus review","route":"/key-papers/paper-tan-phyllodes-consensus-histopathology-2016/","asOf":"2026-09-17","days":4},{"id":"paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009","kind":"paper","name":"Prospective multi-institutional study of adjuvant radiotherapy after resection of borderline and malignant phyllodes tumours","route":"/key-papers/paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009/","asOf":"2026-09-17","days":4},{"id":"paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009","kind":"paper","name":"Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: multi-institutional registry","route":"/key-papers/paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009/","asOf":"2026-09-17","days":4},{"id":"paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021","kind":"paper","name":"Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma","route":"/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-743-lancet-2021","kind":"paper","name":"CheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma","route":"/key-papers/paper-checkmate-743-lancet-2021/","asOf":"2026-09-17","days":4},{"id":"paper-vogelzang-pemetrexed-mesothelioma-jco-2003","kind":"paper","name":"Phase 3 trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","route":"/key-papers/paper-vogelzang-pemetrexed-mesothelioma-jco-2003/","asOf":"2026-09-17","days":4},{"id":"paper-mars-2-lancet-respir-med-2024","kind":"paper","name":"MARS 2: extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma","route":"/key-papers/paper-mars-2-lancet-respir-med-2024/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-483-lancet-2023","kind":"paper","name":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma","route":"/key-papers/paper-keynote-483-lancet-2023/","asOf":"2026-09-17","days":4},{"id":"paper-who-2021-cns-louis-neuro-oncology-2021","kind":"paper","name":"The 2021 WHO classification of tumours of the central nervous system: a summary","route":"/key-papers/paper-who-2021-cns-louis-neuro-oncology-2021/","asOf":"2026-09-17","days":4},{"id":"paper-rtog-9802-buckner-nejm-2016","kind":"paper","name":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma","route":"/key-papers/paper-rtog-9802-buckner-nejm-2016/","asOf":"2026-09-17","days":4},{"id":"paper-catnon-lancet-2017","kind":"paper","name":"CATNON: concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion","route":"/key-papers/paper-catnon-lancet-2017/","asOf":"2026-09-17","days":4},{"id":"paper-alliance-n0574-brown-jama-2016","kind":"paper","name":"Alliance N0574: radiosurgery alone versus radiosurgery plus whole-brain radiotherapy for one to three brain metastases","route":"/key-papers/paper-alliance-n0574-brown-jama-2016/","asOf":"2026-09-17","days":4},{"id":"paper-n107c-brown-lancet-oncol-2017","kind":"paper","name":"N107C/CEC.3: postoperative radiosurgery versus whole-brain radiotherapy after resection of a brain metastasis","route":"/key-papers/paper-n107c-brown-lancet-oncol-2017/","asOf":"2026-09-17","days":4},{"id":"paper-nrg-cc001-brown-jco-2020","kind":"paper","name":"NRG CC001: hippocampal-avoidance whole-brain radiotherapy plus memantine for brain metastases","route":"/key-papers/paper-nrg-cc001-brown-jco-2020/","asOf":"2026-09-17","days":4},{"id":"paper-quartz-lancet-2016","kind":"paper","name":"QUARTZ: whole-brain radiotherapy versus supportive care alone for brain metastases from non-small-cell lung cancer","route":"/key-papers/paper-quartz-lancet-2016/","asOf":"2026-09-17","days":4},{"id":"paper-siop-cns-gct-96-calaminus-neuro-oncology-2013","kind":"paper","name":"SIOP CNS GCT 96: outcomes for children and adults with intracranial germinoma treated with radiotherapy alone or chemotherapy plus reduced radiotherapy","route":"/key-papers/paper-siop-cns-gct-96-calaminus-neuro-oncology-2013/","asOf":"2026-09-17","days":4},{"id":"paper-acns1123-germinoma-neuro-oncology-2022","kind":"paper","name":"ACNS1123: response-based reduced-dose whole-ventricular radiotherapy for localised germinoma","route":"/key-papers/paper-acns1123-germinoma-neuro-oncology-2022/","asOf":"2026-09-17","days":4},{"id":"paper-eano-meningioma-goldbrunner-neuro-oncology-2021","kind":"paper","name":"EANO guideline on the diagnosis and management of meningiomas (2021)","route":"/key-papers/paper-eano-meningioma-goldbrunner-neuro-oncology-2021/","asOf":"2026-09-17","days":4},{"id":"paper-sahm-meningioma-methylation-lancet-oncol-2017","kind":"paper","name":"DNA methylation-based classification and grading system for meningioma","route":"/key-papers/paper-sahm-meningioma-methylation-lancet-oncol-2017/","asOf":"2026-09-17","days":4},{"id":"paper-rtog-9402-cairncross-jco-2013","kind":"paper","name":"RTOG 9402: PCV chemotherapy before radiotherapy for anaplastic oligodendroglioma, long-term results","route":"/key-papers/paper-rtog-9402-cairncross-jco-2013/","asOf":"2026-09-17","days":4},{"id":"paper-eortc-26951-van-den-bent-jco-2013","kind":"paper","name":"EORTC 26951: adjuvant PCV after radiotherapy for anaplastic oligodendroglial tumours, long-term follow-up","route":"/key-papers/paper-eortc-26951-van-den-bent-jco-2013/","asOf":"2026-09-17","days":4},{"id":"paper-mackay-paediatric-hgg-cancer-cell-2017","kind":"paper","name":"Integrated molecular meta-analysis of 1,000 paediatric high-grade and diffuse intrinsic pontine gliomas","route":"/key-papers/paper-mackay-paediatric-hgg-cancer-cell-2017/","asOf":"2026-09-17","days":4},{"id":"paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023","kind":"paper","name":"Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma","route":"/key-papers/paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023/","asOf":"2026-09-17","days":4},{"id":"paper-belzutifan-vhl-jonasch-nejm-2021","kind":"paper","name":"Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease","route":"/key-papers/paper-belzutifan-vhl-jonasch-nejm-2021/","asOf":"2026-09-17","days":4},{"id":"paper-plotkin-bevacizumab-nf2-nejm-2009","kind":"paper","name":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","route":"/key-papers/paper-plotkin-bevacizumab-nf2-nejm-2009/","asOf":"2026-09-17","days":4},{"id":"paper-carlson-link-vestibular-schwannomas-nejm-2021","kind":"paper","name":"Vestibular schwannomas (review)","route":"/key-papers/paper-carlson-link-vestibular-schwannomas-nejm-2021/","asOf":"2026-09-17","days":4},{"id":"paper-beacon-crc-kopetz-nejm-2019","kind":"paper","name":"BEACON CRC: encorafenib and cetuximab with or without binimetinib in BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-beacon-crc-kopetz-nejm-2019/","asOf":"2026-09-17","days":4},{"id":"paper-cms-guinney-nat-med-2015","kind":"paper","name":"The consensus molecular subtypes of colorectal cancer","route":"/key-papers/paper-cms-guinney-nat-med-2015/","asOf":"2026-09-17","days":4},{"id":"paper-sinicrope-early-onset-crc-nejm-2022","kind":"paper","name":"Increasing incidence of early-onset colorectal cancer (review)","route":"/key-papers/paper-sinicrope-early-onset-crc-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-uspstf-crc-screening-45-jama-2021","kind":"paper","name":"US Preventive Services Task Force recommendation: colorectal cancer screening from age 45","route":"/key-papers/paper-uspstf-crc-screening-45-jama-2021/","asOf":"2026-09-17","days":4},{"id":"paper-siegel-crc-incidence-1974-2013-jnci-2017","kind":"paper","name":"Colorectal cancer incidence patterns in the United States, 1974 to 2013","route":"/key-papers/paper-siegel-crc-incidence-1974-2013-jnci-2017/","asOf":"2026-09-17","days":4},{"id":"paper-mountaineer-lancet-oncol-2023","kind":"paper","name":"MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer","route":"/key-papers/paper-mountaineer-lancet-oncol-2023/","asOf":"2026-09-17","days":4},{"id":"paper-heracles-lancet-oncol-2016","kind":"paper","name":"HERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer","route":"/key-papers/paper-heracles-lancet-oncol-2016/","asOf":"2026-09-17","days":4},{"id":"paper-destiny-crc01-lancet-oncol-2021","kind":"paper","name":"DESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer","route":"/key-papers/paper-destiny-crc01-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-krystal-1-crc-yaeger-nejm-2023","kind":"paper","name":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer","route":"/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-sunlight-nejm-2023","kind":"paper","name":"SUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer","route":"/key-papers/paper-sunlight-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-8hw-lancet-2025","kind":"paper","name":"CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer","route":"/key-papers/paper-checkmate-8hw-lancet-2025/","asOf":"2026-09-17","days":4},{"id":"paper-dunleavy-da-epoch-r-pmbcl-nejm-2013","kind":"paper","name":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","route":"/key-papers/paper-dunleavy-da-epoch-r-pmbcl-nejm-2013/","asOf":"2026-09-17","days":4},{"id":"paper-ielsg37-pmbcl-martelli-jco-2024","kind":"paper","name":"IELSG37: omission of radiotherapy in primary mediastinal B-cell lymphoma after a negative PET scan","route":"/key-papers/paper-ielsg37-pmbcl-martelli-jco-2024/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019","kind":"paper","name":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","route":"/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/","asOf":"2026-09-17","days":4},{"id":"paper-rapido-lancet-oncol-2021","kind":"paper","name":"RAPIDO: short-course radiotherapy followed by chemotherapy before surgery for high-risk locally advanced rectal cancer","route":"/key-papers/paper-rapido-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-prodige-23-lancet-oncol-2021","kind":"paper","name":"PRODIGE 23: induction FOLFIRINOX before chemoradiotherapy and surgery for locally advanced rectal cancer","route":"/key-papers/paper-prodige-23-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-prospect-nejm-2023","kind":"paper","name":"PROSPECT: neoadjuvant FOLFOX with selective use of chemoradiotherapy for locally advanced rectal cancer","route":"/key-papers/paper-prospect-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-nrg-gy018-nejm-2023","kind":"paper","name":"NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer","route":"/key-papers/paper-nrg-gy018-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-775-nejm-2022","kind":"paper","name":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer","route":"/key-papers/paper-keynote-775-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","route":"/key-papers/paper-duo-e-jco-2023/","asOf":"2026-09-17","days":4},{"id":"paper-lacc-nejm-2018","kind":"paper","name":"LACC: minimally invasive versus open radical hysterectomy for early cervical cancer","route":"/key-papers/paper-lacc-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-shape-nejm-2024","kind":"paper","name":"SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer","route":"/key-papers/paper-shape-nejm-2024/","asOf":"2026-09-17","days":4},{"id":"paper-promise-talhouk-cancer-2017","kind":"paper","name":"Confirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer","route":"/key-papers/paper-promise-talhouk-cancer-2017/","asOf":"2026-09-17","days":4},{"id":"paper-portec-2-lancet-2010","kind":"paper","name":"PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer","route":"/key-papers/paper-portec-2-lancet-2010/","asOf":"2026-09-17","days":4},{"id":"paper-esgo-estro-esp-endometrial-concin-ijgc-2021","kind":"paper","name":"ESGO/ESTRO/ESP guidelines for the management of endometrial carcinoma (2021)","route":"/key-papers/paper-esgo-estro-esp-endometrial-concin-ijgc-2021/","asOf":"2026-09-17","days":4},{"id":"paper-tcga-endometrial-nature-2013","kind":"paper","name":"Integrated genomic characterisation of endometrial carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-endometrial-nature-2013/","asOf":"2026-09-17","days":4},{"id":"paper-interlace-lancet-2024","kind":"paper","name":"INTERLACE: induction chemotherapy before chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-interlace-lancet-2024/","asOf":"2026-09-17","days":4},{"id":"paper-outback-lancet-oncol-2023","kind":"paper","name":"OUTBACK: adjuvant carboplatin-paclitaxel after chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-outback-lancet-oncol-2023/","asOf":"2026-09-17","days":4},{"id":"paper-rose-cisplatin-chemoradiation-cervical-nejm-1999","kind":"paper","name":"GOG 120: concurrent cisplatin-based chemotherapy with radiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-rose-cisplatin-chemoradiation-cervical-nejm-1999/","asOf":"2026-09-17","days":4},{"id":"paper-garnet-dostarlimab-oaknin-jama-oncol-2020","kind":"paper","name":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer","route":"/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-portec-3-molecular-leon-castillo-jco-2020","kind":"paper","name":"Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group","route":"/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/","asOf":"2026-09-17","days":4},{"id":"paper-portec-3-lancet-oncol-2018","kind":"paper","name":"PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer","route":"/key-papers/paper-portec-3-lancet-oncol-2018/","asOf":"2026-09-17","days":4},{"id":"paper-fader-trastuzumab-uterine-serous-jco-2018","kind":"paper","name":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","route":"/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/","asOf":"2026-09-17","days":4},{"id":"paper-destiny-pantumor02-jco-2024","kind":"paper","name":"DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours","route":"/key-papers/paper-destiny-pantumor02-jco-2024/","asOf":"2026-09-17","days":4},{"id":"paper-mirasol-nejm-2023","kind":"paper","name":"MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer","route":"/key-papers/paper-mirasol-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-aurelia-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","route":"/key-papers/paper-aurelia-jco-2014/","asOf":"2026-09-17","days":4},{"id":"paper-rosella-relacorilant-lancet-2025","kind":"paper","name":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","route":"/key-papers/paper-rosella-relacorilant-lancet-2025/","asOf":"2026-09-17","days":4},{"id":"paper-prima-niraparib-nejm-2019","kind":"paper","name":"PRIMA: niraparib maintenance in newly diagnosed advanced ovarian cancer","route":"/key-papers/paper-prima-niraparib-nejm-2019/","asOf":"2026-09-17","days":4},{"id":"paper-desktop-iii-nejm-2021","kind":"paper","name":"DESKTOP III: secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer","route":"/key-papers/paper-desktop-iii-nejm-2021/","asOf":"2026-09-17","days":4},{"id":"paper-church-pole-endometrial-jnci-2015","kind":"paper","name":"Prognostic significance of POLE proofreading mutations in endometrial cancer","route":"/key-papers/paper-church-pole-endometrial-jnci-2015/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-826-nejm-2021","kind":"paper","name":"KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer","route":"/key-papers/paper-keynote-826-nejm-2021/","asOf":"2026-09-17","days":4},{"id":"paper-innovatv-301-tisotumab-nejm-2024","kind":"paper","name":"innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer","route":"/key-papers/paper-innovatv-301-tisotumab-nejm-2024/","asOf":"2026-09-17","days":4},{"id":"paper-empower-cervical-1-cemiplimab-nejm-2022","kind":"paper","name":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum","route":"/key-papers/paper-empower-cervical-1-cemiplimab-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-gog-240-bevacizumab-cervical-nejm-2014","kind":"paper","name":"GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer","route":"/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/","asOf":"2026-09-17","days":4},{"id":"paper-gog-0261-carcinosarcoma-powell-jco-2022","kind":"paper","name":"GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma","route":"/key-papers/paper-gog-0261-carcinosarcoma-powell-jco-2022/","asOf":"2026-09-17","days":4},{"id":"paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019","kind":"paper","name":"Phase 2 study of lenvatinib in progressive, recurrent or metastatic adenoid cystic carcinoma","route":"/key-papers/paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019/","asOf":"2026-09-17","days":4},{"id":"paper-persson-myb-nfib-pnas-2009","kind":"paper","name":"Recurrent fusion of MYB and NFIB transcription factor genes in adenoid cystic carcinoma","route":"/key-papers/paper-persson-myb-nfib-pnas-2009/","asOf":"2026-09-17","days":4},{"id":"paper-bonner-cetuximab-radiotherapy-nejm-2006","kind":"paper","name":"Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck","route":"/key-papers/paper-bonner-cetuximab-radiotherapy-nejm-2006/","asOf":"2026-09-17","days":4},{"id":"paper-bernier-eortc-22931-nejm-2004","kind":"paper","name":"EORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer","route":"/key-papers/paper-bernier-eortc-22931-nejm-2004/","asOf":"2026-09-17","days":4},{"id":"paper-cooper-rtog-9501-nejm-2004","kind":"paper","name":"RTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma","route":"/key-papers/paper-cooper-rtog-9501-nejm-2004/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-689-nejm-2025","kind":"paper","name":"KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer","route":"/key-papers/paper-keynote-689-nejm-2025/","asOf":"2026-09-17","days":4},{"id":"paper-ang-hpv-oropharyngeal-nejm-2010","kind":"paper","name":"Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)","route":"/key-papers/paper-ang-hpv-oropharyngeal-nejm-2010/","asOf":"2026-09-17","days":4},{"id":"paper-rtog-1016-lancet-2019","kind":"paper","name":"NRG Oncology RTOG 1016: radiotherapy plus cetuximab versus cisplatin in HPV-positive oropharyngeal cancer","route":"/key-papers/paper-rtog-1016-lancet-2019/","asOf":"2026-09-17","days":4},{"id":"paper-de-escalate-lancet-2019","kind":"paper","name":"De-ESCALaTE HPV: radiotherapy plus cisplatin or cetuximab in low-risk HPV-positive oropharyngeal cancer","route":"/key-papers/paper-de-escalate-lancet-2019/","asOf":"2026-09-17","days":4},{"id":"paper-e3311-transoral-surgery-ferris-jco-2022","kind":"paper","name":"ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer","route":"/key-papers/paper-e3311-transoral-surgery-ferris-jco-2022/","asOf":"2026-09-17","days":4},{"id":"paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996","kind":"paper","name":"EORTC 24891: larynx preservation with induction chemotherapy in pyriform sinus (hypopharyngeal) cancer","route":"/key-papers/paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996/","asOf":"2026-09-17","days":4},{"id":"paper-empower-cscc-1-cemiplimab-migden-nejm-2018","kind":"paper","name":"PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)","route":"/key-papers/paper-empower-cscc-1-cemiplimab-migden-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-tonon-crtc1-maml2-nat-genet-2003","kind":"paper","name":"The t(11;19) translocation in mucoepidermoid carcinoma creates a CRTC1-MAML2 fusion","route":"/key-papers/paper-tonon-crtc1-maml2-nat-genet-2003/","asOf":"2026-09-17","days":4},{"id":"paper-laurie-licitra-salivary-systemic-jco-2006","kind":"paper","name":"Systemic therapy in the palliative management of advanced salivary gland cancers (review)","route":"/key-papers/paper-laurie-licitra-salivary-systemic-jco-2006/","asOf":"2026-09-17","days":4},{"id":"paper-extreme-vermorken-nejm-2008","kind":"paper","name":"EXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-extreme-vermorken-nejm-2008/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-141-ferris-nejm-2016","kind":"paper","name":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum","route":"/key-papers/paper-checkmate-141-ferris-nejm-2016/","asOf":"2026-09-17","days":4},{"id":"paper-tpextreme-lancet-oncol-2021","kind":"paper","name":"TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-tpextreme-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019","kind":"paper","name":"Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma","route":"/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/","asOf":"2026-09-17","days":4},{"id":"paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018","kind":"paper","name":"Combined androgen blockade in androgen receptor-positive salivary gland carcinoma","route":"/key-papers/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018/","asOf":"2026-09-17","days":4},{"id":"paper-rtog-91-11-forastiere-nejm-2003","kind":"paper","name":"RTOG 91-11: concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","route":"/key-papers/paper-rtog-91-11-forastiere-nejm-2003/","asOf":"2026-09-17","days":4},{"id":"paper-rtog-91-11-long-term-forastiere-jco-2013","kind":"paper","name":"Long-term results of RTOG 91-11: three non-surgical strategies to preserve the larynx","route":"/key-papers/paper-rtog-91-11-long-term-forastiere-jco-2013/","asOf":"2026-09-17","days":4},{"id":"paper-va-larynx-induction-chemotherapy-nejm-1991","kind":"paper","name":"Department of Veterans Affairs Laryngeal Cancer Study: induction chemotherapy plus radiation versus surgery plus radiation","route":"/key-papers/paper-va-larynx-induction-chemotherapy-nejm-1991/","asOf":"2026-09-17","days":4},{"id":"paper-who-2022-gu-moch-eur-urol-2022","kind":"paper","name":"WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours","route":"/key-papers/paper-who-2022-gu-moch-eur-urol-2022/","asOf":"2026-09-17","days":4},{"id":"paper-tcga-chromophobe-davis-cancer-cell-2014","kind":"paper","name":"The somatic genomic landscape of chromophobe renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-chromophobe-davis-cancer-cell-2014/","asOf":"2026-09-17","days":4},{"id":"paper-aspen-armstrong-lancet-oncol-2016","kind":"paper","name":"ASPEN: everolimus versus sunitinib in metastatic non-clear cell renal cell carcinoma","route":"/key-papers/paper-aspen-armstrong-lancet-oncol-2016/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-426-nejm-2019","kind":"paper","name":"KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma","route":"/key-papers/paper-keynote-426-nejm-2019/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-214-nejm-2018","kind":"paper","name":"CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma","route":"/key-papers/paper-checkmate-214-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-papmet-pal-lancet-2021","kind":"paper","name":"PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma","route":"/key-papers/paper-papmet-pal-lancet-2021/","asOf":"2026-09-17","days":4},{"id":"paper-tcga-papillary-rcc-nejm-2016","kind":"paper","name":"Comprehensive molecular characterisation of papillary renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-papillary-rcc-nejm-2016/","asOf":"2026-09-17","days":4},{"id":"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016","kind":"paper","name":"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016/","asOf":"2026-09-17","days":4},{"id":"paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017","kind":"paper","name":"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017/","asOf":"2026-09-17","days":4},{"id":"paper-pharos-encorafenib-binimetinib-riely-jco-2023","kind":"paper","name":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/","asOf":"2026-09-17","days":4},{"id":"paper-destiny-lung01-nejm-2022","kind":"paper","name":"DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung01-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-destiny-lung02-goto-jco-2023","kind":"paper","name":"DESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung02-goto-jco-2023/","asOf":"2026-09-17","days":4},{"id":"paper-beamion-lung-1-zongertinib-nejm-2025","kind":"paper","name":"Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-beamion-lung-1-zongertinib-nejm-2025/","asOf":"2026-09-17","days":4},{"id":"paper-geometry-mono-1-capmatinib-nejm-2020","kind":"paper","name":"GEOMETRY mono-1: capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","route":"/key-papers/paper-geometry-mono-1-capmatinib-nejm-2020/","asOf":"2026-09-17","days":4},{"id":"paper-vision-tepotinib-paik-nejm-2020","kind":"paper","name":"VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","route":"/key-papers/paper-vision-tepotinib-paik-nejm-2020/","asOf":"2026-09-17","days":4},{"id":"paper-frampton-met-exon-14-cancer-discov-2015","kind":"paper","name":"MET exon 14 splicing alterations across tumour types and their sensitivity to MET inhibitors","route":"/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/","asOf":"2026-09-17","days":4},{"id":"paper-drilon-larotrectinib-nejm-2018","kind":"paper","name":"Larotrectinib in TRK fusion-positive cancers in adults and children","route":"/key-papers/paper-drilon-larotrectinib-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-doebele-entrectinib-ntrk-lancet-oncol-2020","kind":"paper","name":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials","route":"/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-trident-1-repotrectinib-nejm-2024","kind":"paper","name":"TRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-trident-1-repotrectinib-nejm-2024/","asOf":"2026-09-17","days":4},{"id":"paper-libretto-001-selpercatinib-nsclc-nejm-2020","kind":"paper","name":"LIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/","asOf":"2026-09-17","days":4},{"id":"paper-libretto-431-nejm-2023","kind":"paper","name":"LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer","route":"/key-papers/paper-libretto-431-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-arrow-pralsetinib-gainor-lancet-oncol-2021","kind":"paper","name":"ARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-arrow-pralsetinib-gainor-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-shaw-crizotinib-ros1-nejm-2014","kind":"paper","name":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","route":"/key-papers/paper-shaw-crizotinib-ros1-nejm-2014/","asOf":"2026-09-17","days":4},{"id":"paper-drilon-entrectinib-ros1-lancet-oncol-2020","kind":"paper","name":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials","route":"/key-papers/paper-drilon-entrectinib-ros1-lancet-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-nordic-nec-sorbye-ann-oncol-2013","kind":"paper","name":"NORDIC NEC: predictive and prognostic factors in 305 patients with advanced gastrointestinal neuroendocrine carcinoma","route":"/key-papers/paper-nordic-nec-sorbye-ann-oncol-2013/","asOf":"2026-09-17","days":4},{"id":"paper-rindi-common-classification-framework-mod-pathol-2018","kind":"paper","name":"A common classification framework for neuroendocrine neoplasms (IARC and WHO expert consensus)","route":"/key-papers/paper-rindi-common-classification-framework-mod-pathol-2018/","asOf":"2026-09-17","days":4},{"id":"paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020","kind":"paper","name":"DART (SWOG 1609): nivolumab plus ipilimumab in rare tumours, non-pancreatic neuroendocrine neoplasms cohort","route":"/key-papers/paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020/","asOf":"2026-09-17","days":4},{"id":"paper-heetfeld-grade-3-net-erc-2015","kind":"paper","name":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","route":"/key-papers/paper-heetfeld-grade-3-net-erc-2015/","asOf":"2026-09-17","days":4},{"id":"paper-radiant-4-everolimus-lancet-2016","kind":"paper","name":"RADIANT-4: everolimus for advanced non-functional neuroendocrine tumours of the lung or gastrointestinal tract","route":"/key-papers/paper-radiant-4-everolimus-lancet-2016/","asOf":"2026-09-17","days":4},{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/","asOf":"2026-09-17","days":4},{"id":"paper-enets-lung-net-consensus-caplin-ann-oncol-2015","kind":"paper","name":"ENETS expert consensus on pulmonary neuroendocrine (carcinoid) tumours","route":"/key-papers/paper-enets-lung-net-consensus-caplin-ann-oncol-2015/","asOf":"2026-09-17","days":4},{"id":"paper-clarinet-lanreotide-nejm-2014","kind":"paper","name":"CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours","route":"/key-papers/paper-clarinet-lanreotide-nejm-2014/","asOf":"2026-09-17","days":4},{"id":"paper-radiant-3-everolimus-pnet-yao-nejm-2011","kind":"paper","name":"RADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours","route":"/key-papers/paper-radiant-3-everolimus-pnet-yao-nejm-2011/","asOf":"2026-09-17","days":4},{"id":"paper-raymond-sunitinib-pnet-nejm-2011","kind":"paper","name":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumours","route":"/key-papers/paper-raymond-sunitinib-pnet-nejm-2011/","asOf":"2026-09-17","days":4},{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-promid-rinke-jco-2009","kind":"paper","name":"PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours","route":"/key-papers/paper-promid-rinke-jco-2009/","asOf":"2026-09-17","days":4},{"id":"paper-shah-foxl2-granulosa-nejm-2009","kind":"paper","name":"Mutation of FOXL2 in granulosa cell tumours of the ovary","route":"/key-papers/paper-shah-foxl2-granulosa-nejm-2009/","asOf":"2026-09-17","days":4},{"id":"paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018","kind":"paper","name":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018/","asOf":"2026-09-17","days":4},{"id":"paper-wiegand-arid1a-clear-cell-nejm-2010","kind":"paper","name":"ARID1A mutations in endometriosis-associated ovarian carcinomas","route":"/key-papers/paper-wiegand-arid1a-clear-cell-nejm-2010/","asOf":"2026-09-17","days":4},{"id":"paper-jones-arid1a-clear-cell-science-2010","kind":"paper","name":"Frequent mutations of the chromatin remodelling gene ARID1A in ovarian clear cell carcinoma","route":"/key-papers/paper-jones-arid1a-clear-cell-science-2010/","asOf":"2026-09-17","days":4},{"id":"paper-tcga-ovarian-nature-2011","kind":"paper","name":"Integrated genomic analyses of ovarian carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-ovarian-nature-2011/","asOf":"2026-09-17","days":4},{"id":"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","kind":"paper","name":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/","asOf":"2026-09-17","days":4},{"id":"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017","kind":"paper","name":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","route":"/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/","asOf":"2026-09-17","days":4},{"id":"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025","kind":"paper","name":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/","asOf":"2026-09-17","days":4},{"id":"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019","kind":"paper","name":"The molecular origin and taxonomy of mucinous ovarian carcinoma","route":"/key-papers/paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019/","asOf":"2026-09-17","days":4},{"id":"paper-morice-mucinous-ovarian-carcinoma-nejm-2019","kind":"paper","name":"Mucinous ovarian carcinoma (review)","route":"/key-papers/paper-morice-mucinous-ovarian-carcinoma-nejm-2019/","asOf":"2026-09-17","days":4},{"id":"paper-aaml0531-gemtuzumab-gamis-jco-2014","kind":"paper","name":"AAML0531: gemtuzumab ozogamicin added to chemotherapy for children and adolescents with acute myeloid leukaemia","route":"/key-papers/paper-aaml0531-gemtuzumab-gamis-jco-2014/","asOf":"2026-09-17","days":4},{"id":"paper-aaml1031-sorafenib-flt3-pollard-jco-2022","kind":"paper","name":"AAML1031: sorafenib combined with chemotherapy for children with high allelic ratio FLT3-ITD acute myeloid leukaemia","route":"/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/","asOf":"2026-09-17","days":4},{"id":"paper-bolouri-paediatric-aml-genomics-nat-med-2018","kind":"paper","name":"The molecular landscape of paediatric acute myeloid leukaemia (TARGET)","route":"/key-papers/paper-bolouri-paediatric-aml-genomics-nat-med-2018/","asOf":"2026-09-17","days":4},{"id":"paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012","kind":"paper","name":"Molecular subgroups of medulloblastoma: the current consensus","route":"/key-papers/paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012/","asOf":"2026-09-17","days":4},{"id":"paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017","kind":"paper","name":"Intertumoural heterogeneity within medulloblastoma subgroups","route":"/key-papers/paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017/","asOf":"2026-09-17","days":4},{"id":"paper-acns0331-michalski-jco-2021","kind":"paper","name":"ACNS0331: reduced-dose and reduced-volume radiotherapy with chemotherapy for average-risk medulloblastoma","route":"/key-papers/paper-acns0331-michalski-jco-2021/","asOf":"2026-09-17","days":4},{"id":"paper-acns0332-leary-jama-oncol-2021","kind":"paper","name":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma","route":"/key-papers/paper-acns0332-leary-jama-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-aall0232-larsen-jco-2016","kind":"paper","name":"AALL0232: dexamethasone and high-dose methotrexate improve outcome in high-risk B-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0232-larsen-jco-2016/","asOf":"2026-09-17","days":4},{"id":"paper-aall0434-nelarabine-t-all-dunsmore-jco-2020","kind":"paper","name":"AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0434-nelarabine-t-all-dunsmore-jco-2020/","asOf":"2026-09-17","days":4},{"id":"paper-hunger-mullighan-all-children-nejm-2015","kind":"paper","name":"Acute lymphoblastic leukaemia in children (review)","route":"/key-papers/paper-hunger-mullighan-all-children-nejm-2015/","asOf":"2026-09-17","days":4},{"id":"paper-inrg-cohn-jco-2009","kind":"paper","name":"The International Neuroblastoma Risk Group (INRG) classification system","route":"/key-papers/paper-inrg-cohn-jco-2009/","asOf":"2026-09-17","days":4},{"id":"paper-yu-anti-gd2-neuroblastoma-nejm-2010","kind":"paper","name":"Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for high-risk neuroblastoma (COG ANBL0032)","route":"/key-papers/paper-yu-anti-gd2-neuroblastoma-nejm-2010/","asOf":"2026-09-17","days":4},{"id":"paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017","kind":"paper","name":"HR-NBL1/SIOPEN: busulfan-melphalan versus carboplatin-etoposide-melphalan high-dose chemotherapy for high-risk neuroblastoma","route":"/key-papers/paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017/","asOf":"2026-09-17","days":4},{"id":"paper-anbl0532-tandem-transplant-park-jama-2019","kind":"paper","name":"ANBL0532: tandem versus single autologous stem cell transplant for high-risk neuroblastoma","route":"/key-papers/paper-anbl0532-tandem-transplant-park-jama-2019/","asOf":"2026-09-17","days":4},{"id":"paper-interfant-06-pieters-jco-2019","kind":"paper","name":"Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-06-pieters-jco-2019/","asOf":"2026-09-17","days":4},{"id":"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023","kind":"paper","name":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","route":"/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-interfant-99-lancet-2007","kind":"paper","name":"Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-99-lancet-2007/","asOf":"2026-09-17","days":4},{"id":"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010","kind":"paper","name":"A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010/","asOf":"2026-09-17","days":4},{"id":"paper-anbl0531-twist-jco-2019","kind":"paper","name":"ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-anbl0531-twist-jco-2019/","asOf":"2026-09-17","days":4},{"id":"paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012","kind":"paper","name":"ANBL00P2: expectant observation as primary therapy for neuroblastoma in young infants","route":"/key-papers/paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012/","asOf":"2026-09-17","days":4},{"id":"paper-p9641-low-risk-neuroblastoma-strother-jco-2012","kind":"paper","name":"COG P9641: surgery alone or with restricted chemotherapy for low-risk neuroblastoma","route":"/key-papers/paper-p9641-low-risk-neuroblastoma-strother-jco-2012/","asOf":"2026-09-17","days":4},{"id":"paper-roberts-ph-like-all-nejm-2014","kind":"paper","name":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukaemia","route":"/key-papers/paper-roberts-ph-like-all-nejm-2014/","asOf":"2026-09-17","days":4},{"id":"paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009","kind":"paper","name":"A subtype of childhood acute lymphoblastic leukaemia with poor outcome: genome-wide classification study (BCR-ABL1-like ALL)","route":"/key-papers/paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009/","asOf":"2026-09-17","days":4},{"id":"paper-mullighan-ikzf1-nejm-2009","kind":"paper","name":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia","route":"/key-papers/paper-mullighan-ikzf1-nejm-2009/","asOf":"2026-09-17","days":4},{"id":"paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009","kind":"paper","name":"AALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children","route":"/key-papers/paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009/","asOf":"2026-09-17","days":4},{"id":"paper-esphall-imatinib-biondi-lancet-oncol-2012","kind":"paper","name":"EsPhALL: imatinib after induction for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukaemia","route":"/key-papers/paper-esphall-imatinib-biondi-lancet-oncol-2012/","asOf":"2026-09-17","days":4},{"id":"paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020","kind":"paper","name":"Dasatinib versus imatinib with chemotherapy for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CCCG-ALL-2015)","route":"/key-papers/paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-robinson-vismodegib-shh-medulloblastoma-jco-2015","kind":"paper","name":"Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)","route":"/key-papers/paper-robinson-vismodegib-shh-medulloblastoma-jco-2015/","asOf":"2026-09-17","days":4},{"id":"paper-zhukova-tp53-medulloblastoma-jco-2013","kind":"paper","name":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","route":"/key-papers/paper-zhukova-tp53-medulloblastoma-jco-2013/","asOf":"2026-09-17","days":4},{"id":"paper-embark-nejm-2023","kind":"paper","name":"EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer","route":"/key-papers/paper-embark-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-radicals-rt-lancet-2020","kind":"paper","name":"RADICALS-RT: timing of radiotherapy after radical prostatectomy","route":"/key-papers/paper-radicals-rt-lancet-2020/","asOf":"2026-09-17","days":4},{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/","asOf":"2026-09-17","days":4},{"id":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","kind":"paper","name":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","route":"/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/","asOf":"2026-09-17","days":4},{"id":"paper-bolla-eortc-22863-nejm-1997","kind":"paper","name":"EORTC 22863: improved survival with radiotherapy plus goserelin in locally advanced prostate cancer","route":"/key-papers/paper-bolla-eortc-22863-nejm-1997/","asOf":"2026-09-17","days":4},{"id":"paper-damico-risk-groups-jama-1998","kind":"paper","name":"D'Amico risk groups: biochemical outcome after radical prostatectomy, external beam radiotherapy or brachytherapy","route":"/key-papers/paper-damico-risk-groups-jama-1998/","asOf":"2026-09-17","days":4},{"id":"paper-protect-nejm-2016","kind":"paper","name":"ProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer","route":"/key-papers/paper-protect-nejm-2016/","asOf":"2026-09-17","days":4},{"id":"paper-protect-15-year-nejm-2023","kind":"paper","name":"ProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer","route":"/key-papers/paper-protect-15-year-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-chhip-lancet-oncol-2016","kind":"paper","name":"CHHiP: conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer","route":"/key-papers/paper-chhip-lancet-oncol-2016/","asOf":"2026-09-17","days":4},{"id":"paper-rtog-9408-short-term-adt-jones-nejm-2011","kind":"paper","name":"RTOG 9408: radiotherapy with short-term androgen deprivation for localised prostate cancer","route":"/key-papers/paper-rtog-9408-short-term-adt-jones-nejm-2011/","asOf":"2026-09-17","days":4},{"id":"paper-klotz-active-surveillance-jco-2015","kind":"paper","name":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer (Sunnybrook)","route":"/key-papers/paper-klotz-active-surveillance-jco-2015/","asOf":"2026-09-17","days":4},{"id":"paper-precision-mri-targeted-biopsy-nejm-2018","kind":"paper","name":"PRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis","route":"/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-profound-nejm-2020","kind":"paper","name":"PROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations","route":"/key-papers/paper-profound-nejm-2020/","asOf":"2026-09-17","days":4},{"id":"paper-cou-aa-301-abiraterone-de-bono-nejm-2011","kind":"paper","name":"COU-AA-301: abiraterone and increased survival in metastatic castration-resistant prostate cancer after docetaxel","route":"/key-papers/paper-cou-aa-301-abiraterone-de-bono-nejm-2011/","asOf":"2026-09-17","days":4},{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/","asOf":"2026-09-17","days":4},{"id":"paper-latitude-nejm-2017","kind":"paper","name":"LATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-latitude-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-arasens-nejm-2022","kind":"paper","name":"ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-arasens-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-chaarted-nejm-2015","kind":"paper","name":"CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-chaarted-nejm-2015/","asOf":"2026-09-17","days":4},{"id":"paper-beltran-nepc-divergent-evolution-nat-med-2016","kind":"paper","name":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","route":"/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/","asOf":"2026-09-17","days":4},{"id":"paper-aggarwal-t-sccpc-jco-2018","kind":"paper","name":"Clinical and genomic characterisation of treatment-emergent small-cell neuroendocrine prostate cancer","route":"/key-papers/paper-aggarwal-t-sccpc-jco-2018/","asOf":"2026-09-17","days":4},{"id":"paper-aparicio-aggressive-variant-ccr-2013","kind":"paper","name":"Platinum-based chemotherapy for variant castration-resistant prostate cancer (aggressive variant criteria)","route":"/key-papers/paper-aparicio-aggressive-variant-ccr-2013/","asOf":"2026-09-17","days":4},{"id":"paper-spartan-nejm-2018","kind":"paper","name":"SPARTAN: apalutamide for non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-spartan-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-prosper-nejm-2018","kind":"paper","name":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-prosper-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-aramis-nejm-2019","kind":"paper","name":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-aramis-nejm-2019/","asOf":"2026-09-17","days":4},{"id":"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023","kind":"paper","name":"Atezolizumab for advanced alveolar soft part sarcoma","route":"/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-ladanyi-aspl-tfe3-oncogene-2001","kind":"paper","name":"The der(17)t(X;17) of alveolar soft part sarcoma fuses TFE3 to ASPL","route":"/key-papers/paper-ladanyi-aspl-tfe3-oncogene-2001/","asOf":"2026-09-17","days":4},{"id":"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008","kind":"paper","name":"ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma","route":"/key-papers/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008/","asOf":"2026-09-17","days":4},{"id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","asOf":"2026-09-17","days":4},{"id":"paper-amary-idh-cartilaginous-tumours-j-pathol-2011","kind":"paper","name":"IDH1 and IDH2 mutations are frequent in central chondrosarcoma and central and periosteal chondromas","route":"/key-papers/paper-amary-idh-cartilaginous-tumours-j-pathol-2011/","asOf":"2026-09-17","days":4},{"id":"paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021","kind":"paper","name":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline","route":"/key-papers/paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-errani-wwtr1-camta1-ehe-gcc-2011","kind":"paper","name":"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid haemangioendothelioma","route":"/key-papers/paper-errani-wwtr1-camta1-ehe-gcc-2011/","asOf":"2026-09-17","days":4},{"id":"paper-ehe-consensus-stacchiotti-esmo-open-2021","kind":"paper","name":"Epithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","route":"/key-papers/paper-ehe-consensus-stacchiotti-esmo-open-2021/","asOf":"2026-09-17","days":4},{"id":"paper-sirolimus-ehe-stacchiotti-cancer-2021","kind":"paper","name":"Activity of sirolimus in progressive epithelioid haemangioendothelioma (Italian Rare Cancer Network)","route":"/key-papers/paper-sirolimus-ehe-stacchiotti-cancer-2021/","asOf":"2026-09-17","days":4},{"id":"paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011","kind":"paper","name":"First-line chemotherapy for malignant peripheral nerve sheath tumour versus other soft tissue sarcomas (EORTC pooled analysis)","route":"/key-papers/paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011/","asOf":"2026-09-17","days":4},{"id":"paper-lee-prc2-mpnst-nat-genet-2014","kind":"paper","name":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumours","route":"/key-papers/paper-lee-prc2-mpnst-nat-genet-2014/","asOf":"2026-09-17","days":4},{"id":"paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014","kind":"paper","name":"EORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma","route":"/key-papers/paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014/","asOf":"2026-09-17","days":4},{"id":"paper-esmo-sts-guideline-gronchi-ann-oncol-2021","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline","route":"/key-papers/paper-esmo-sts-guideline-gronchi-ann-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-myxofibrosarcoma-mentzel-ajsp-1996","kind":"paper","name":"Myxofibrosarcoma: clinicopathological analysis of 75 cases with emphasis on the low-grade variant","route":"/key-papers/paper-myxofibrosarcoma-mentzel-ajsp-1996/","asOf":"2026-09-17","days":4},{"id":"paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021","kind":"paper","name":"AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021/","asOf":"2026-09-17","days":4},{"id":"paper-wagner-sirolimus-pecoma-jco-2010","kind":"paper","name":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-wagner-sirolimus-pecoma-jco-2010/","asOf":"2026-09-17","days":4},{"id":"paper-strass-lancet-oncol-2020","kind":"paper","name":"STRASS (EORTC 62092): preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma","route":"/key-papers/paper-strass-lancet-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016","kind":"paper","name":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (TARPSWG)","route":"/key-papers/paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016/","asOf":"2026-09-17","days":4},{"id":"paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009","kind":"paper","name":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control","route":"/key-papers/paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009/","asOf":"2026-09-17","days":4},{"id":"paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002","kind":"paper","name":"NCIC SR2: preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs","route":"/key-papers/paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002/","asOf":"2026-09-17","days":4},{"id":"paper-isg-sts-1001-gronchi-lancet-oncol-2017","kind":"paper","name":"ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma","route":"/key-papers/paper-isg-sts-1001-gronchi-lancet-oncol-2017/","asOf":"2026-09-17","days":4},{"id":"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022","kind":"paper","name":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma","route":"/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/","asOf":"2026-09-17","days":4},{"id":"paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017","kind":"paper","name":"SARC028: pembrolizumab in advanced soft tissue and bone sarcoma","route":"/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/","asOf":"2026-09-17","days":4},{"id":"paper-mavoric-mogamulizumab-lancet-oncol-2018","kind":"paper","name":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","route":"/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/","asOf":"2026-09-17","days":4},{"id":"paper-alcanza-brentuximab-vedotin-lancet-2017","kind":"paper","name":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","route":"/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/","asOf":"2026-09-17","days":4},{"id":"paper-olsen-mycosis-fungoides-staging-blood-2007","kind":"paper","name":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)","route":"/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/","asOf":"2026-09-17","days":4},{"id":"paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002","kind":"paper","name":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase 2 trial","route":"/key-papers/paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002/","asOf":"2026-09-17","days":4},{"id":"paper-eribulin-liposarcoma-schoffski-lancet-2016","kind":"paper","name":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","route":"/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/","asOf":"2026-09-17","days":4},{"id":"paper-trabectedin-vs-dacarbazine-demetri-jco-2016","kind":"paper","name":"Trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure","route":"/key-papers/paper-trabectedin-vs-dacarbazine-demetri-jco-2016/","asOf":"2026-09-17","days":4},{"id":"paper-wotherspoon-h-pylori-malt-lancet-1993","kind":"paper","name":"Regression of primary low-grade gastric MALT lymphoma after eradication of Helicobacter pylori","route":"/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/","asOf":"2026-09-17","days":4},{"id":"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","kind":"paper","name":"Marginal zone lymphomas: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-magnolia-zanubrutinib-mzl-ccr-2021","kind":"paper","name":"MAGNOLIA: zanubrutinib in relapsed or refractory marginal zone lymphoma","route":"/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/","asOf":"2026-09-17","days":4},{"id":"paper-augment-lenalidomide-rituximab-leonard-jco-2019","kind":"paper","name":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","route":"/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/","asOf":"2026-09-17","days":4},{"id":"paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994","kind":"paper","name":"Identification of SYT and SSX, the genes fused by the t(X;18) translocation in synovial sarcoma","route":"/key-papers/paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994/","asOf":"2026-09-17","days":4},{"id":"paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018","kind":"paper","name":"NY-ESO-1 c259 T-cell receptor therapy in synovial sarcoma: prolonged persistence and antitumour activity","route":"/key-papers/paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018/","asOf":"2026-09-17","days":4},{"id":"paper-hayward-melanoma-whole-genome-nature-2017","kind":"paper","name":"Whole-genome landscapes of major melanoma subtypes","route":"/key-papers/paper-hayward-melanoma-whole-genome-nature-2017/","asOf":"2026-09-17","days":4},{"id":"paper-curtin-melanoma-genetic-alterations-nejm-2005","kind":"paper","name":"Distinct sets of genetic alterations in melanoma","route":"/key-papers/paper-curtin-melanoma-genetic-alterations-nejm-2005/","asOf":"2026-09-17","days":4},{"id":"paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020","kind":"paper","name":"Anti-PD-1 checkpoint inhibitor therapy in acral melanoma: a multicentre study of 193 Japanese patients","route":"/key-papers/paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-629-pembrolizumab-cscc-grob-jco-2020","kind":"paper","name":"KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-keynote-629-pembrolizumab-cscc-grob-jco-2020/","asOf":"2026-09-17","days":4},{"id":"paper-c-post-adjuvant-cemiplimab-nejm-2025","kind":"paper","name":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma","route":"/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/","asOf":"2026-09-17","days":4},{"id":"paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022","kind":"paper","name":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma","route":"/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-dreamseq-jco-2023","kind":"paper","name":"DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma","route":"/key-papers/paper-dreamseq-jco-2023/","asOf":"2026-09-17","days":4},{"id":"paper-combi-d-long-lancet-2015","kind":"paper","name":"COMBI-d: dabrafenib and trametinib versus dabrafenib alone for BRAF V600-mutant melanoma","route":"/key-papers/paper-combi-d-long-lancet-2015/","asOf":"2026-09-17","days":4},{"id":"paper-columbus-lancet-oncol-2018","kind":"paper","name":"COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma","route":"/key-papers/paper-columbus-lancet-oncol-2018/","asOf":"2026-09-17","days":4},{"id":"paper-combi-ad-nejm-2017","kind":"paper","name":"COMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","route":"/key-papers/paper-combi-ad-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-chapman-vemurafenib-nejm-2011","kind":"paper","name":"BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation","route":"/key-papers/paper-chapman-vemurafenib-nejm-2011/","asOf":"2026-09-17","days":4},{"id":"paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010","kind":"paper","name":"Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)","route":"/key-papers/paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010/","asOf":"2026-09-17","days":4},{"id":"paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997","kind":"paper","name":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with COL1A1 in dermatofibrosarcoma protuberans","route":"/key-papers/paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997/","asOf":"2026-09-17","days":4},{"id":"paper-erivance-vismodegib-sekulic-nejm-2012","kind":"paper","name":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma","route":"/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/","asOf":"2026-09-17","days":4},{"id":"paper-bolt-sonidegib-migden-lancet-oncol-2015","kind":"paper","name":"BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma","route":"/key-papers/paper-bolt-sonidegib-migden-lancet-oncol-2015/","asOf":"2026-09-17","days":4},{"id":"paper-cemiplimab-bcc-stratigos-lancet-oncol-2021","kind":"paper","name":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy","route":"/key-papers/paper-cemiplimab-bcc-stratigos-lancet-oncol-2021/","asOf":"2026-09-17","days":4},{"id":"paper-dangelo-mucosal-melanoma-pooled-jco-2017","kind":"paper","name":"Nivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis","route":"/key-papers/paper-dangelo-mucosal-melanoma-pooled-jco-2017/","asOf":"2026-09-17","days":4},{"id":"paper-hodi-imatinib-kit-melanoma-jco-2013","kind":"paper","name":"Imatinib for melanomas harbouring mutationally activated or amplified KIT arising on mucosal, acral and chronically sun-damaged skin","route":"/key-papers/paper-hodi-imatinib-kit-melanoma-jco-2013/","asOf":"2026-09-17","days":4},{"id":"paper-curtin-kit-melanoma-jco-2006","kind":"paper","name":"Somatic activation of KIT in distinct subtypes of melanoma","route":"/key-papers/paper-curtin-kit-melanoma-jco-2006/","asOf":"2026-09-17","days":4},{"id":"paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013","kind":"paper","name":"Adjuvant temozolomide plus cisplatin versus high-dose interferon versus observation in resected mucosal melanoma","route":"/key-papers/paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-716-lancet-2022","kind":"paper","name":"KEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma","route":"/key-papers/paper-keynote-716-lancet-2022/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-76k-nat-med-2023","kind":"paper","name":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","route":"/key-papers/paper-checkmate-76k-nat-med-2023/","asOf":"2026-09-17","days":4},{"id":"paper-ajcc-8-melanoma-gershenwald-ca-2017","kind":"paper","name":"Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual","route":"/key-papers/paper-ajcc-8-melanoma-gershenwald-ca-2017/","asOf":"2026-09-17","days":4},{"id":"paper-mslt-ii-faries-nejm-2017","kind":"paper","name":"MSLT-II: completion lymph node dissection or observation for sentinel-node metastasis in melanoma","route":"/key-papers/paper-mslt-ii-faries-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-238-nejm-2017","kind":"paper","name":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","route":"/key-papers/paper-checkmate-238-nejm-2017/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-054-eggermont-nejm-2018","kind":"paper","name":"KEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma","route":"/key-papers/paper-keynote-054-eggermont-nejm-2018/","asOf":"2026-09-17","days":4},{"id":"paper-igcccg-classification-jco-1997","kind":"paper","name":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers","route":"/key-papers/paper-igcccg-classification-jco-1997/","asOf":"2026-09-17","days":4},{"id":"paper-igcccg-update-gillessen-jco-2021","kind":"paper","name":"IGCCCG Update Consortium: predicting outcomes in men with metastatic non-seminomatous germ cell tumours","route":"/key-papers/paper-igcccg-update-gillessen-jco-2021/","asOf":"2026-09-17","days":4},{"id":"paper-getug-13-fizazi-lancet-oncol-2014","kind":"paper","name":"GETUG 13: personalised chemotherapy based on tumour marker decline in poor-prognosis germ cell tumours","route":"/key-papers/paper-getug-13-fizazi-lancet-oncol-2014/","asOf":"2026-09-17","days":4},{"id":"paper-williams-bep-vs-pvb-nejm-1987","kind":"paper","name":"Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide","route":"/key-papers/paper-williams-bep-vs-pvb-nejm-1987/","asOf":"2026-09-17","days":4},{"id":"paper-flot4-lancet-2019","kind":"paper","name":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-flot4-lancet-2019/","asOf":"2026-09-17","days":4},{"id":"paper-cross-nejm-2012","kind":"paper","name":"CROSS: preoperative chemoradiotherapy for oesophageal or junctional cancer","route":"/key-papers/paper-cross-nejm-2012/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-648-nejm-2022","kind":"paper","name":"CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma","route":"/key-papers/paper-checkmate-648-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-590-lancet-2021","kind":"paper","name":"KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer","route":"/key-papers/paper-keynote-590-lancet-2021/","asOf":"2026-09-17","days":4},{"id":"paper-checkmate-577-nejm-2021","kind":"paper","name":"CheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer","route":"/key-papers/paper-checkmate-577-nejm-2021/","asOf":"2026-09-17","days":4},{"id":"paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005","kind":"paper","name":"MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma","route":"/key-papers/paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005/","asOf":"2026-09-17","days":4},{"id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","asOf":"2026-09-17","days":4},{"id":"paper-subbiah-dabrafenib-trametinib-atc-jco-2018","kind":"paper","name":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)","route":"/key-papers/paper-subbiah-dabrafenib-trametinib-atc-jco-2018/","asOf":"2026-09-17","days":4},{"id":"paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021","kind":"paper","name":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","route":"/key-papers/paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021/","asOf":"2026-09-17","days":4},{"id":"paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020","kind":"paper","name":"Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition","route":"/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016","kind":"paper","name":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","route":"/key-papers/paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016/","asOf":"2026-09-17","days":4},{"id":"paper-select-lenvatinib-nejm-2015","kind":"paper","name":"SELECT: lenvatinib versus placebo in radioiodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-select-lenvatinib-nejm-2015/","asOf":"2026-09-17","days":4},{"id":"paper-decision-sorafenib-lancet-2014","kind":"paper","name":"DECISION: sorafenib in radioactive iodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-decision-sorafenib-lancet-2014/","asOf":"2026-09-17","days":4},{"id":"paper-libretto-531-nejm-2023","kind":"paper","name":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer","route":"/key-papers/paper-libretto-531-nejm-2023/","asOf":"2026-09-17","days":4},{"id":"paper-ata-medullary-thyroid-guideline-wells-thyroid-2015","kind":"paper","name":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","route":"/key-papers/paper-ata-medullary-thyroid-guideline-wells-thyroid-2015/","asOf":"2026-09-17","days":4},{"id":"paper-exam-cabozantinib-mtc-elisei-jco-2013","kind":"paper","name":"EXAM: cabozantinib in progressive medullary thyroid cancer","route":"/key-papers/paper-exam-cabozantinib-mtc-elisei-jco-2013/","asOf":"2026-09-17","days":4},{"id":"paper-zeta-vandetanib-mtc-wells-jco-2012","kind":"paper","name":"ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer","route":"/key-papers/paper-zeta-vandetanib-mtc-wells-jco-2012/","asOf":"2026-09-17","days":4},{"id":"paper-estimabl2-leboulleux-nejm-2022","kind":"paper","name":"ESTIMABL2: thyroidectomy without radioiodine in patients with low-risk thyroid cancer","route":"/key-papers/paper-estimabl2-leboulleux-nejm-2022/","asOf":"2026-09-17","days":4},{"id":"paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014","kind":"paper","name":"Active surveillance of papillary thyroid microcarcinoma at Kuma Hospital: patient age and progression","route":"/key-papers/paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014/","asOf":"2026-09-17","days":4},{"id":"paper-himalaya-nejm-evidence-2022","kind":"paper","name":"HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","route":"/key-papers/paper-himalaya-nejm-evidence-2022/","asOf":"2026-09-17","days":4},{"id":"paper-sharp-sorafenib-nejm-2008","kind":"paper","name":"SHARP: sorafenib in advanced hepatocellular carcinoma","route":"/key-papers/paper-sharp-sorafenib-nejm-2008/","asOf":"2026-09-17","days":4},{"id":"paper-reflect-lenvatinib-lancet-2018","kind":"paper","name":"REFLECT: lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma","route":"/key-papers/paper-reflect-lenvatinib-lancet-2018/","asOf":"2026-09-17","days":4},{"id":"paper-glow-zolbetuximab-nat-med-2023","kind":"paper","name":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-glow-zolbetuximab-nat-med-2023/","asOf":"2026-09-17","days":4},{"id":"paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000","kind":"paper","name":"Incidence of lymph node metastasis from early gastric cancer: estimation from 5,265 patients at two large centres","route":"/key-papers/paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000/","asOf":"2026-09-17","days":4},{"id":"paper-klass-01-kim-jama-oncol-2019","kind":"paper","name":"KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival","route":"/key-papers/paper-klass-01-kim-jama-oncol-2019/","asOf":"2026-09-17","days":4},{"id":"paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020","kind":"paper","name":"JCOG0912: laparoscopy-assisted versus open distal gastrectomy for clinical stage IA or IB gastric cancer","route":"/key-papers/paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023","kind":"paper","name":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","route":"/key-papers/paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023/","asOf":"2026-09-17","days":4},{"id":"paper-mazzaferro-milan-criteria-nejm-1996","kind":"paper","name":"Liver transplantation for small hepatocellular carcinomas in patients with cirrhosis (the Milan criteria)","route":"/key-papers/paper-mazzaferro-milan-criteria-nejm-1996/","asOf":"2026-09-17","days":4},{"id":"paper-bclc-2022-reig-j-hepatol-2022","kind":"paper","name":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","route":"/key-papers/paper-bclc-2022-reig-j-hepatol-2022/","asOf":"2026-09-17","days":4},{"id":"paper-imbrave050-lancet-2023","kind":"paper","name":"IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma","route":"/key-papers/paper-imbrave050-lancet-2023/","asOf":"2026-09-17","days":4},{"id":"paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015","kind":"paper","name":"STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma","route":"/key-papers/paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015/","asOf":"2026-09-17","days":4},{"id":"paper-bilcap-lancet-oncol-2019","kind":"paper","name":"BILCAP: capecitabine compared with observation in resected biliary tract cancer","route":"/key-papers/paper-bilcap-lancet-oncol-2019/","asOf":"2026-09-17","days":4},{"id":"paper-abc-02-gemcitabine-cisplatin-nejm-2010","kind":"paper","name":"ABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer","route":"/key-papers/paper-abc-02-gemcitabine-cisplatin-nejm-2010/","asOf":"2026-09-17","days":4},{"id":"paper-topaz-1-nejm-evidence-2022","kind":"paper","name":"TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","route":"/key-papers/paper-topaz-1-nejm-evidence-2022/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-966-lancet-2023","kind":"paper","name":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","route":"/key-papers/paper-keynote-966-lancet-2023/","asOf":"2026-09-17","days":4},{"id":"paper-fight-202-pemigatinib-lancet-oncol-2020","kind":"paper","name":"FIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements","route":"/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-811-janjigian-lancet-2023","kind":"paper","name":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-keynote-811-janjigian-lancet-2023/","asOf":"2026-09-17","days":4},{"id":"paper-destiny-gastric01-nejm-2020","kind":"paper","name":"DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","route":"/key-papers/paper-destiny-gastric01-nejm-2020/","asOf":"2026-09-17","days":4},{"id":"paper-demetri-sunitinib-gist-lancet-2006","kind":"paper","name":"Sunitinib in advanced gastrointestinal stromal tumour after failure of imatinib","route":"/key-papers/paper-demetri-sunitinib-gist-lancet-2006/","asOf":"2026-09-17","days":4},{"id":"paper-grid-regorafenib-gist-lancet-2013","kind":"paper","name":"GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib","route":"/key-papers/paper-grid-regorafenib-gist-lancet-2013/","asOf":"2026-09-17","days":4},{"id":"paper-invictus-ripretinib-lancet-oncol-2020","kind":"paper","name":"INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors","route":"/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-intrigue-ripretinib-vs-sunitinib-jco-2022","kind":"paper","name":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","route":"/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/","asOf":"2026-09-17","days":4},{"id":"paper-llovet-tace-lancet-2002","kind":"paper","name":"Arterial embolisation or chemoembolisation versus symptomatic treatment in unresectable hepatocellular carcinoma","route":"/key-papers/paper-llovet-tace-lancet-2002/","asOf":"2026-09-17","days":4},{"id":"paper-emerald-1-lancet-2025","kind":"paper","name":"EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma","route":"/key-papers/paper-emerald-1-lancet-2025/","asOf":"2026-09-17","days":4},{"id":"paper-leap-012-lancet-2025","kind":"paper","name":"LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma","route":"/key-papers/paper-leap-012-lancet-2025/","asOf":"2026-09-17","days":4},{"id":"paper-demetri-imatinib-gist-nejm-2002","kind":"paper","name":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours","route":"/key-papers/paper-demetri-imatinib-gist-nejm-2002/","asOf":"2026-09-17","days":4},{"id":"paper-hirota-kit-gist-science-1998","kind":"paper","name":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours","route":"/key-papers/paper-hirota-kit-gist-science-1998/","asOf":"2026-09-17","days":4},{"id":"paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012","kind":"paper","name":"SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour","route":"/key-papers/paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012/","asOf":"2026-09-17","days":4},{"id":"paper-heinrich-kit-mutation-imatinib-response-jco-2003","kind":"paper","name":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour","route":"/key-papers/paper-heinrich-kit-mutation-imatinib-response-jco-2003/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-062-shitara-jama-oncol-2020","kind":"paper","name":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer","route":"/key-papers/paper-keynote-062-shitara-jama-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-pietrantonio-msi-gastric-meta-analysis-jco-2019","kind":"paper","name":"Individual patient data meta-analysis of microsatellite instability as a biomarker in gastric cancer (MAGIC, CLASSIC, ARTIST, ITACA-S)","route":"/key-papers/paper-pietrantonio-msi-gastric-meta-analysis-jco-2019/","asOf":"2026-09-17","days":4},{"id":"paper-tcga-gastric-nature-2014","kind":"paper","name":"Comprehensive molecular characterisation of gastric adenocarcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-gastric-nature-2014/","asOf":"2026-09-17","days":4},{"id":"paper-keynote-859-lancet-oncol-2023","kind":"paper","name":"KEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer","route":"/key-papers/paper-keynote-859-lancet-oncol-2023/","asOf":"2026-09-17","days":4},{"id":"paper-matterhorn-nejm-2025","kind":"paper","name":"MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer","route":"/key-papers/paper-matterhorn-nejm-2025/","asOf":"2026-09-17","days":4},{"id":"paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014","kind":"paper","name":"RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer","route":"/key-papers/paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014/","asOf":"2026-09-17","days":4},{"id":"paper-navigator-avapritinib-heinrich-lancet-oncol-2020","kind":"paper","name":"NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour","route":"/key-papers/paper-navigator-avapritinib-heinrich-lancet-oncol-2020/","asOf":"2026-09-17","days":4},{"id":"paper-heinrich-pdgfra-gist-science-2003","kind":"paper","name":"PDGFRA activating mutations in gastrointestinal stromal tumours","route":"/key-papers/paper-heinrich-pdgfra-gist-science-2003/","asOf":"2026-09-17","days":4},{"id":"small-molecule","kind":"term","name":"Small molecule drug","route":"/terms/small-molecule/","asOf":"2026-09-17","days":4},{"id":"vaccines-and-oncolytic-viruses","kind":"term","name":"Cancer vaccines and oncolytic viruses","route":"/terms/vaccines-and-oncolytic-viruses/","asOf":"2026-09-17","days":4},{"id":"non-inferiority-margin","kind":"term","name":"Non-inferiority margin and equivalence trials","route":"/terms/non-inferiority-margin/","asOf":"2026-09-17","days":4},{"id":"stratified-randomisation","kind":"term","name":"Stratified randomisation, allocation concealment and minimisation","route":"/terms/stratified-randomisation/","asOf":"2026-09-17","days":4},{"id":"clinical-equipoise","kind":"term","name":"Clinical equipoise","route":"/terms/clinical-equipoise/","asOf":"2026-09-17","days":4},{"id":"basket-trial","kind":"term","name":"Basket trial","route":"/terms/basket-trial/","asOf":"2026-09-17","days":4},{"id":"umbrella-trial","kind":"term","name":"Umbrella trial","route":"/terms/umbrella-trial/","asOf":"2026-09-17","days":4},{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/","asOf":"2026-09-17","days":4},{"id":"response-adaptive-randomisation","kind":"term","name":"Response-adaptive randomisation","route":"/terms/response-adaptive-randomisation/","asOf":"2026-09-17","days":4},{"id":"bayesian-trial-design","kind":"term","name":"Bayesian trial design","route":"/terms/bayesian-trial-design/","asOf":"2026-09-17","days":4},{"id":"smart-design","kind":"term","name":"SMART design (sequential multiple assignment randomised trial)","route":"/terms/smart-design/","asOf":"2026-09-17","days":4},{"id":"biomarker-stratified-design","kind":"term","name":"Enrichment and biomarker-stratified designs","route":"/terms/biomarker-stratified-design/","asOf":"2026-09-17","days":4},{"id":"pragmatic-trial","kind":"term","name":"Pragmatic trial","route":"/terms/pragmatic-trial/","asOf":"2026-09-17","days":4},{"id":"registry-based-trial","kind":"term","name":"Registry-based randomised trial","route":"/terms/registry-based-trial/","asOf":"2026-09-17","days":4},{"id":"decentralised-trial","kind":"term","name":"Decentralised trial","route":"/terms/decentralised-trial/","asOf":"2026-09-17","days":4},{"id":"n-of-1-trial","kind":"term","name":"N-of-1 trial","route":"/terms/n-of-1-trial/","asOf":"2026-09-17","days":4},{"id":"cluster-randomised-trial","kind":"term","name":"Cluster-randomised trial","route":"/terms/cluster-randomised-trial/","asOf":"2026-09-17","days":4},{"id":"stepped-wedge-design","kind":"term","name":"Stepped-wedge design","route":"/terms/stepped-wedge-design/","asOf":"2026-09-17","days":4},{"id":"kaplan-meier-curve","kind":"term","name":"Kaplan-Meier curve, censoring and proportional hazards","route":"/terms/kaplan-meier-curve/","asOf":"2026-09-17","days":4},{"id":"group-sequential-design","kind":"term","name":"Group sequential design, stopping rules and alpha spending","route":"/terms/group-sequential-design/","asOf":"2026-09-17","days":4},{"id":"absolute-benefit","kind":"term","name":"Absolute versus relative benefit (number needed to treat)","route":"/terms/absolute-benefit/","asOf":"2026-09-17","days":4},{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","asOf":"2026-09-17","days":4},{"id":"surrogate-validation","kind":"term","name":"Surrogate endpoint validation: which stand-ins have earned trust","route":"/terms/surrogate-validation/","asOf":"2026-09-17","days":4},{"id":"quality-adjusted-survival","kind":"term","name":"Quality-adjusted survival (QALYs and Q-TWiST)","route":"/terms/quality-adjusted-survival/","asOf":"2026-09-17","days":4},{"id":"data-monitoring-committee","kind":"term","name":"Data monitoring committee (DSMB, IDMC)","route":"/terms/data-monitoring-committee/","asOf":"2026-09-17","days":4},{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/","asOf":"2026-09-17","days":4},{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/","asOf":"2026-09-17","days":4},{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","asOf":"2026-09-17","days":4},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/","asOf":"2026-09-17","days":4},{"id":"trial-lifecycle","kind":"term","name":"Trial lifecycle: from protocol to label","route":"/terms/trial-lifecycle/","asOf":"2026-09-17","days":4},{"id":"trial-failure-modes","kind":"term","name":"Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover","route":"/terms/trial-failure-modes/","asOf":"2026-09-17","days":4},{"id":"fdca","kind":"term","name":"Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments","route":"/terms/fdca/","asOf":"2026-09-17","days":4},{"id":"fdora-2022","kind":"term","name":"FDORA 2022 accelerated approval reforms","route":"/terms/fdora-2022/","asOf":"2026-09-17","days":4},{"id":"fdasia-2012","kind":"term","name":"FDASIA 2012 and the origins of the expedited programmes","route":"/terms/fdasia-2012/","asOf":"2026-09-17","days":4},{"id":"21st-century-cures-act","kind":"term","name":"21st Century Cures Act","route":"/terms/21st-century-cures-act/","asOf":"2026-09-17","days":4},{"id":"orphan-drug-act","kind":"term","name":"Orphan Drug Act 1983","route":"/terms/orphan-drug-act/","asOf":"2026-09-17","days":4},{"id":"bpca-prea","kind":"term","name":"Paediatric drug laws: BPCA and PREA","route":"/terms/bpca-prea/","asOf":"2026-09-17","days":4},{"id":"right-to-try","kind":"term","name":"Right to Try Act 2018 and state right-to-try laws","route":"/terms/right-to-try/","asOf":"2026-09-17","days":4},{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/","asOf":"2026-09-17","days":4},{"id":"abigail-alliance","kind":"term","name":"Abigail Alliance v. von Eschenbach (2007)","route":"/terms/abigail-alliance/","asOf":"2026-09-17","days":4},{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/","asOf":"2026-09-17","days":4},{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/","asOf":"2026-09-17","days":4},{"id":"us-regulatory-exclusivity","kind":"term","name":"US regulatory exclusivity periods","route":"/terms/us-regulatory-exclusivity/","asOf":"2026-09-17","days":4},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","asOf":"2026-09-17","days":4},{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/","asOf":"2026-09-17","days":4},{"id":"hipaa","kind":"term","name":"HIPAA (Health Insurance Portability and Accountability Act)","route":"/terms/hipaa/","asOf":"2026-09-17","days":4},{"id":"gina","kind":"term","name":"GINA (Genetic Information Nondiscrimination Act 2008)","route":"/terms/gina/","asOf":"2026-09-17","days":4},{"id":"common-rule","kind":"term","name":"The Common Rule (45 CFR 46)","route":"/terms/common-rule/","asOf":"2026-09-17","days":4},{"id":"myriad-ruling","kind":"term","name":"Association for Molecular Pathology v. Myriad Genetics (2013)","route":"/terms/myriad-ruling/","asOf":"2026-09-17","days":4},{"id":"state-biomarker-testing-laws","kind":"term","name":"State biomarker testing coverage laws","route":"/terms/state-biomarker-testing-laws/","asOf":"2026-09-17","days":4},{"id":"tobacco-control-act","kind":"term","name":"Family Smoking Prevention and Tobacco Control Act 2009","route":"/terms/tobacco-control-act/","asOf":"2026-09-17","days":4},{"id":"tobacco-21","kind":"term","name":"Tobacco 21","route":"/terms/tobacco-21/","asOf":"2026-09-17","days":4},{"id":"eu-regulation-726-2004","kind":"term","name":"Regulation (EC) No 726/2004: the EU centralised procedure","route":"/terms/eu-regulation-726-2004/","asOf":"2026-09-17","days":4},{"id":"eu-orphan-regulation","kind":"term","name":"Regulation (EC) No 141/2000: EU orphan medicines","route":"/terms/eu-orphan-regulation/","asOf":"2026-09-17","days":4},{"id":"eu-paediatric-regulation","kind":"term","name":"Regulation (EC) No 1901/2006: EU paediatric medicines","route":"/terms/eu-paediatric-regulation/","asOf":"2026-09-17","days":4},{"id":"eu-clinical-trials-regulation","kind":"term","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","route":"/terms/eu-clinical-trials-regulation/","asOf":"2026-09-17","days":4},{"id":"gdpr","kind":"term","name":"GDPR and health data (Regulation (EU) 2016/679)","route":"/terms/gdpr/","asOf":"2026-09-17","days":4},{"id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/","asOf":"2026-09-17","days":4},{"id":"eu-hta-regulation","kind":"term","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","route":"/terms/eu-hta-regulation/","asOf":"2026-09-17","days":4},{"id":"eu-pharma-package","kind":"term","name":"EU pharmaceutical package reform (2023 proposal)","route":"/terms/eu-pharma-package/","asOf":"2026-09-17","days":4},{"id":"spc","kind":"term","name":"Supplementary protection certificate (EU)","route":"/terms/spc/","asOf":"2026-09-17","days":4},{"id":"eu-data-exclusivity","kind":"term","name":"EU data and market protection (8+2+1)","route":"/terms/eu-data-exclusivity/","asOf":"2026-09-17","days":4},{"id":"ilap","kind":"term","name":"ILAP (Innovative Licensing and Access Pathway)","route":"/terms/ilap/","asOf":"2026-09-17","days":4},{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/","asOf":"2026-09-17","days":4},{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/","asOf":"2026-09-17","days":4},{"id":"innovative-medicines-fund","kind":"term","name":"Innovative Medicines Fund (England)","route":"/terms/innovative-medicines-fund/","asOf":"2026-09-17","days":4},{"id":"medicines-medical-devices-act-2021","kind":"term","name":"Medicines and Medical Devices Act 2021","route":"/terms/medicines-medical-devices-act-2021/","asOf":"2026-09-17","days":4},{"id":"uk-data-protection-act","kind":"term","name":"UK Data Protection Act 2018 and health data law","route":"/terms/uk-data-protection-act/","asOf":"2026-09-17","days":4},{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","asOf":"2026-09-17","days":4},{"id":"france-early-access","kind":"term","name":"France: early access (accès précoce), formerly ATU","route":"/terms/france-early-access/","asOf":"2026-09-17","days":4},{"id":"sakigake","kind":"term","name":"Sakigake designation (Japan)","route":"/terms/sakigake/","asOf":"2026-09-17","days":4},{"id":"japan-conditional-early-approval","kind":"term","name":"Japan conditional early approval and time-limited approval","route":"/terms/japan-conditional-early-approval/","asOf":"2026-09-17","days":4},{"id":"china-drug-administration-law","kind":"term","name":"China Drug Administration Law (2019) and expedited pathways","route":"/terms/china-drug-administration-law/","asOf":"2026-09-17","days":4},{"id":"pipl","kind":"term","name":"PIPL (China Personal Information Protection Law 2021)","route":"/terms/pipl/","asOf":"2026-09-17","days":4},{"id":"china-hgr-rules","kind":"term","name":"China Human Genetic Resources rules (2019, 2023)","route":"/terms/china-hgr-rules/","asOf":"2026-09-17","days":4},{"id":"china-vbp-nrdl","kind":"term","name":"China National Reimbursement Drug List negotiation and volume-based procurement","route":"/terms/china-vbp-nrdl/","asOf":"2026-09-17","days":4},{"id":"india-new-drugs-rules-2019","kind":"term","name":"India New Drugs and Clinical Trials Rules 2019","route":"/terms/india-new-drugs-rules-2019/","asOf":"2026-09-17","days":4},{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/","asOf":"2026-09-17","days":4},{"id":"novartis-glivec-ruling","kind":"term","name":"Novartis v. Union of India (Glivec, 2013)","route":"/terms/novartis-glivec-ruling/","asOf":"2026-09-17","days":4},{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","asOf":"2026-09-17","days":4},{"id":"declaration-of-helsinki","kind":"term","name":"Declaration of Helsinki","route":"/terms/declaration-of-helsinki/","asOf":"2026-09-17","days":4},{"id":"ich-gcp","kind":"term","name":"ICH good clinical practice (E6)","route":"/terms/ich-gcp/","asOf":"2026-09-17","days":4},{"id":"medulloblastoma-molecular-groups","kind":"term","name":"Medulloblastoma molecular groups (WNT, SHH, group 3, group 4)","route":"/terms/medulloblastoma-molecular-groups/","asOf":"2026-09-17","days":4},{"id":"pole-ultramutation","kind":"term","name":"POLE ultramutation (POLEmut)","route":"/terms/pole-ultramutation/","asOf":"2026-09-17","days":4},{"id":"nsmp","kind":"term","name":"No specific molecular profile (NSMP) endometrial cancer","route":"/terms/nsmp/","asOf":"2026-09-17","days":4},{"id":"ependymoma-molecular-groups","kind":"term","name":"Ependymoma molecular groups (PF-A, PF-B, ZFTA, YAP1, MYCN)","route":"/terms/ependymoma-molecular-groups/","asOf":"2026-09-17","days":4},{"id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","asOf":"2026-09-17","days":4},{"id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","asOf":"2026-09-17","days":4},{"id":"interferon-gamma-signature","kind":"term","name":"Interferon-gamma gene signature (T-cell-inflamed signature)","route":"/terms/interferon-gamma-signature/","asOf":"2026-09-17","days":4},{"id":"ipss-m-ipss-r","kind":"term","name":"IPSS-R and IPSS-M (myelodysplastic syndrome risk scores)","route":"/terms/ipss-m-ipss-r/","asOf":"2026-09-17","days":4},{"id":"sokal-elts-scores","kind":"term","name":"Sokal and ELTS risk scores (chronic myeloid leukaemia)","route":"/terms/sokal-elts-scores/","asOf":"2026-09-17","days":4},{"id":"flipi","kind":"term","name":"FLIPI, FLIPI2 and POD24 (follicular lymphoma risk)","route":"/terms/flipi/","asOf":"2026-09-17","days":4},{"id":"mipi","kind":"term","name":"MIPI (Mantle Cell Lymphoma International Prognostic Index)","route":"/terms/mipi/","asOf":"2026-09-17","days":4},{"id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/","asOf":"2026-09-17","days":4},{"id":"dipss-mipss70","kind":"term","name":"DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)","route":"/terms/dipss-mipss70/","asOf":"2026-09-17","days":4},{"id":"ipset-thrombosis","kind":"term","name":"IPSET-thrombosis score (essential thrombocythaemia)","route":"/terms/ipset-thrombosis/","asOf":"2026-09-17","days":4},{"id":"li-rads","kind":"term","name":"LI-RADS (Liver Imaging Reporting and Data System)","route":"/terms/li-rads/","asOf":"2026-09-17","days":4},{"id":"pretext-chic","kind":"term","name":"PRETEXT and CHIC risk groups (hepatoblastoma)","route":"/terms/pretext-chic/","asOf":"2026-09-17","days":4},{"id":"wilms-risk-markers","kind":"term","name":"Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)","route":"/terms/wilms-risk-markers/","asOf":"2026-09-17","days":4},{"id":"b-all-cytogenetic-risk","kind":"term","name":"B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)","route":"/terms/b-all-cytogenetic-risk/","asOf":"2026-09-17","days":4},{"id":"disease-volume-chaarted","kind":"term","name":"Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk","route":"/terms/disease-volume-chaarted/","asOf":"2026-09-17","days":4},{"id":"graded-prognostic-assessment","kind":"term","name":"Graded Prognostic Assessment (GPA) for brain metastases","route":"/terms/graded-prognostic-assessment/","asOf":"2026-09-17","days":4},{"id":"ph-like-all","kind":"term","name":"Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia","route":"/terms/ph-like-all/","asOf":"2026-09-17","days":4},{"id":"abl1-kinase-domain-mutations","kind":"term","name":"BCR::ABL1 kinase domain mutations (T315I and others)","route":"/terms/abl1-kinase-domain-mutations/","asOf":"2026-09-17","days":4},{"id":"mpn-driver-mutations","kind":"term","name":"MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden","route":"/terms/mpn-driver-mutations/","asOf":"2026-09-17","days":4},{"id":"aml-myelodysplasia-related","kind":"term","name":"AML with myelodysplasia-related gene mutations (AML-MR)","route":"/terms/aml-myelodysplasia-related/","asOf":"2026-09-17","days":4},{"id":"sf3b1-mutation","kind":"term","name":"SF3B1 mutation","route":"/terms/sf3b1-mutation/","asOf":"2026-09-17","days":4},{"id":"del5q","kind":"term","name":"del(5q) (5q- syndrome and lenalidomide response)","route":"/terms/del5q/","asOf":"2026-09-17","days":4},{"id":"myd88-l265p","kind":"term","name":"MYD88 L265P and CXCR4 mutations","route":"/terms/myd88-l265p/","asOf":"2026-09-17","days":4},{"id":"cyclin-d1-t11-14","kind":"term","name":"t(11;14), cyclin D1 and SOX11","route":"/terms/cyclin-d1-t11-14/","asOf":"2026-09-17","days":4},{"id":"btki-bcl2i-resistance-mutations","kind":"term","name":"BTK C481S, PLCG2 and BCL2 G101V resistance mutations","route":"/terms/btki-bcl2i-resistance-mutations/","asOf":"2026-09-17","days":4},{"id":"brca-reversion-mutations","kind":"term","name":"BRCA reversion mutations","route":"/terms/brca-reversion-mutations/","asOf":"2026-09-17","days":4},{"id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","asOf":"2026-09-17","days":4},{"id":"mlh1-promoter-methylation","kind":"term","name":"MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)","route":"/terms/mlh1-promoter-methylation/","asOf":"2026-09-17","days":4},{"id":"1p19q-codeletion","kind":"term","name":"1p/19q codeletion","route":"/terms/1p19q-codeletion/","asOf":"2026-09-17","days":4},{"id":"cdkn2a-homozygous-deletion","kind":"term","name":"CDKN2A/B homozygous deletion","route":"/terms/cdkn2a-homozygous-deletion/","asOf":"2026-09-17","days":4},{"id":"pten-loss","kind":"term","name":"PTEN loss","route":"/terms/pten-loss/","asOf":"2026-09-17","days":4},{"id":"bap1-loss","kind":"term","name":"BAP1 loss","route":"/terms/bap1-loss/","asOf":"2026-09-17","days":4},{"id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","asOf":"2026-09-17","days":4},{"id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/","asOf":"2026-09-17","days":4},{"id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/","asOf":"2026-09-17","days":4},{"id":"mcpyv-status","kind":"term","name":"Merkel cell polyomavirus (MCPyV) status","route":"/terms/mcpyv-status/","asOf":"2026-09-17","days":4},{"id":"hhv8-kshv","kind":"term","name":"HHV-8 (KSHV) status and LANA-1 immunohistochemistry","route":"/terms/hhv8-kshv/","asOf":"2026-09-17","days":4},{"id":"gist-risk-stratification","kind":"term","name":"GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)","route":"/terms/gist-risk-stratification/","asOf":"2026-09-17","days":4},{"id":"histological-response-induction","kind":"term","name":"Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma)","route":"/terms/histological-response-induction/","asOf":"2026-09-17","days":4},{"id":"extranodal-extension","kind":"term","name":"Extranodal extension (ENE)","route":"/terms/extranodal-extension/","asOf":"2026-09-17","days":4},{"id":"depth-of-invasion","kind":"term","name":"Depth of invasion (DOI)","route":"/terms/depth-of-invasion/","asOf":"2026-09-17","days":4},{"id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/","asOf":"2026-09-17","days":4},{"id":"urinary-catecholamines","kind":"term","name":"Urinary catecholamine metabolites (VMA and HVA)","route":"/terms/urinary-catecholamines/","asOf":"2026-09-17","days":4},{"id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","asOf":"2026-09-17","days":4},{"id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","asOf":"2026-09-17","days":4},{"id":"m-protein-free-light-chains","kind":"term","name":"M-protein, immunofixation and serum free light chains","route":"/terms/m-protein-free-light-chains/","asOf":"2026-09-17","days":4},{"id":"dktk","kind":"institution","name":"German Cancer Consortium (DKTK)","route":"/institutions/dktk/","asOf":"2026-09-17","days":4},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","asOf":"2026-09-17","days":4},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","asOf":"2026-09-17","days":4},{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/","asOf":"2026-09-17","days":4},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","asOf":"2026-09-17","days":4},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","asOf":"2026-09-17","days":4},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","asOf":"2026-09-17","days":4},{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","asOf":"2026-09-17","days":4},{"id":"minghui-pharmaceutical","kind":"company","name":"Minghui Pharmaceutical","route":"/companies/minghui-pharmaceutical/","asOf":"2026-09-17","days":4},{"id":"disc-medicine","kind":"company","name":"Disc Medicine","route":"/companies/disc-medicine/","asOf":"2026-09-17","days":4},{"id":"teclison","kind":"company","name":"Teclison","route":"/companies/teclison/","asOf":"2026-09-17","days":4},{"id":"grit-bio","kind":"company","name":"Grit Bio","route":"/companies/grit-bio/","asOf":"2026-09-17","days":4},{"id":"amplia-therapeutics","kind":"company","name":"Amplia Therapeutics","route":"/companies/amplia-therapeutics/","asOf":"2026-09-17","days":4},{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/","asOf":"2026-09-17","days":4},{"id":"anbogen-therapeutics","kind":"company","name":"Anbogen Therapeutics","route":"/companies/anbogen-therapeutics/","asOf":"2026-09-17","days":4},{"id":"nec-bio","kind":"company","name":"NEC Bio","route":"/companies/nec-bio/","asOf":"2026-09-17","days":4},{"id":"natureceuticals","kind":"company","name":"NatureCeuticals","route":"/companies/natureceuticals/","asOf":"2026-09-17","days":4},{"id":"sunho-biopharmaceutical","kind":"company","name":"SunHo Biopharmaceutical","route":"/companies/sunho-biopharmaceutical/","asOf":"2026-09-17","days":4},{"id":"norroy-bioscience","kind":"company","name":"Norroy Bioscience","route":"/companies/norroy-bioscience/","asOf":"2026-09-17","days":4},{"id":"yuhan","kind":"company","name":"Yuhan Corporation","route":"/companies/yuhan/","asOf":"2026-09-17","days":4},{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/","asOf":"2026-09-17","days":4},{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","route":"/companies/modex-therapeutics/","asOf":"2026-09-17","days":4},{"id":"unicar-therapy","kind":"company","name":"Unicar-Therapy","route":"/companies/unicar-therapy/","asOf":"2026-09-17","days":4},{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","route":"/companies/a2-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","route":"/companies/wayshine-biopharm/","asOf":"2026-09-17","days":4},{"id":"cellsight-technologies","kind":"company","name":"CellSight Technologies","route":"/companies/cellsight-technologies/","asOf":"2026-09-17","days":4},{"id":"eureka-therapeutics","kind":"company","name":"Eureka Therapeutics","route":"/companies/eureka-therapeutics/","asOf":"2026-09-17","days":4},{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/","asOf":"2026-09-17","days":4},{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"precigen","kind":"company","name":"Precigen","route":"/companies/precigen/","asOf":"2026-09-17","days":4},{"id":"guangzhou-virotech","kind":"company","name":"Guangzhou Virotech Pharmaceutical","route":"/companies/guangzhou-virotech/","asOf":"2026-09-17","days":4},{"id":"tairx","kind":"company","name":"TaiRx","route":"/companies/tairx/","asOf":"2026-09-17","days":4},{"id":"tyk-medicines","kind":"company","name":"TYK Medicines","route":"/companies/tyk-medicines/","asOf":"2026-09-17","days":4},{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","route":"/companies/il-yang-pharmaceutical/","asOf":"2026-09-17","days":4},{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","route":"/companies/gv20-therapeutics/","asOf":"2026-09-17","days":4},{"id":"shanghai-jiatan-pharmatech","kind":"company","name":"Shanghai Jiatan Pharmatech","route":"/companies/shanghai-jiatan-pharmatech/","asOf":"2026-09-17","days":4},{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/","asOf":"2026-09-17","days":4},{"id":"aosaikang-pharmaceutical","kind":"company","name":"Aosaikang Pharmaceutical","route":"/companies/aosaikang-pharmaceutical/","asOf":"2026-09-17","days":4},{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","route":"/companies/salubris-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"suzhou-bluehorse-therapeutics","kind":"company","name":"Suzhou BlueHorse Therapeutics","route":"/companies/suzhou-bluehorse-therapeutics/","asOf":"2026-09-17","days":4},{"id":"frantz-viral-therapeutics","kind":"company","name":"Frantz Viral Therapeutics","route":"/companies/frantz-viral-therapeutics/","asOf":"2026-09-17","days":4},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","asOf":"2026-09-17","days":4},{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","route":"/companies/torl-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","route":"/companies/lupeng-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"obi-pharma","kind":"company","name":"OBI Pharma","route":"/companies/obi-pharma/","asOf":"2026-09-17","days":4},{"id":"aulos-bioscience","kind":"company","name":"Aulos Bioscience","route":"/companies/aulos-bioscience/","asOf":"2026-09-17","days":4},{"id":"bioatla","kind":"company","name":"BioAtla","route":"/companies/bioatla/","asOf":"2026-09-17","days":4},{"id":"bolt-biotherapeutics","kind":"company","name":"Bolt Biotherapeutics","route":"/companies/bolt-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","route":"/companies/faron-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"camurus","kind":"company","name":"Camurus","route":"/companies/camurus/","asOf":"2026-09-17","days":4},{"id":"lindis-biotech","kind":"company","name":"Lindis Biotech","route":"/companies/lindis-biotech/","asOf":"2026-09-17","days":4},{"id":"pieris-pharmaceuticals","kind":"company","name":"Pieris Pharmaceuticals","route":"/companies/pieris-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","route":"/companies/crispr-therapeutics/","asOf":"2026-09-17","days":4},{"id":"excellthera","kind":"company","name":"ExCellThera","route":"/companies/excellthera/","asOf":"2026-09-17","days":4},{"id":"dren-bio","kind":"company","name":"Dren Bio","route":"/companies/dren-bio/","asOf":"2026-09-17","days":4},{"id":"engeneic","kind":"company","name":"EnGeneIC","route":"/companies/engeneic/","asOf":"2026-09-17","days":4},{"id":"keros-therapeutics","kind":"company","name":"Keros Therapeutics","route":"/companies/keros-therapeutics/","asOf":"2026-09-17","days":4},{"id":"enb-therapeutics","kind":"company","name":"ENB Therapeutics","route":"/companies/enb-therapeutics/","asOf":"2026-09-17","days":4},{"id":"guerbet","kind":"company","name":"Guerbet","route":"/companies/guerbet/","asOf":"2026-09-17","days":4},{"id":"syndevrx","kind":"company","name":"SynDevRx","route":"/companies/syndevrx/","asOf":"2026-09-17","days":4},{"id":"everest-medicines","kind":"company","name":"Everest Medicines","route":"/companies/everest-medicines/","asOf":"2026-09-17","days":4},{"id":"gracell-biotechnologies","kind":"company","name":"Gracell Biotechnologies","route":"/companies/gracell-biotechnologies/","asOf":"2026-09-17","days":4},{"id":"globeimmune","kind":"company","name":"GlobeImmune","route":"/companies/globeimmune/","asOf":"2026-09-17","days":4},{"id":"greenwich-lifesciences","kind":"company","name":"Greenwich LifeSciences","route":"/companies/greenwich-lifesciences/","asOf":"2026-09-17","days":4},{"id":"genrix-bio","kind":"company","name":"Genrix Bio","route":"/companies/genrix-bio/","asOf":"2026-09-17","days":4},{"id":"hookipa-pharma","kind":"company","name":"Hookipa Pharma","route":"/companies/hookipa-pharma/","asOf":"2026-09-17","days":4},{"id":"huabo-biopharm","kind":"company","name":"Huabo Biopharm","route":"/companies/huabo-biopharm/","asOf":"2026-09-17","days":4},{"id":"hummingbird-bioscience","kind":"company","name":"Hummingbird Bioscience","route":"/companies/hummingbird-bioscience/","asOf":"2026-09-17","days":4},{"id":"hotspot-therapeutics","kind":"company","name":"HotSpot Therapeutics","route":"/companies/hotspot-therapeutics/","asOf":"2026-09-17","days":4},{"id":"intensity-therapeutics","kind":"company","name":"Intensity Therapeutics","route":"/companies/intensity-therapeutics/","asOf":"2026-09-17","days":4},{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","route":"/companies/panbela-therapeutics/","asOf":"2026-09-17","days":4},{"id":"jubilant-therapeutics","kind":"company","name":"Jubilant Therapeutics","route":"/companies/jubilant-therapeutics/","asOf":"2026-09-17","days":4},{"id":"humanigen","kind":"company","name":"Humanigen","route":"/companies/humanigen/","asOf":"2026-09-17","days":4},{"id":"linnaeus-therapeutics","kind":"company","name":"Linnaeus Therapeutics","route":"/companies/linnaeus-therapeutics/","asOf":"2026-09-17","days":4},{"id":"nextsource-biotechnology","kind":"company","name":"NextSource Biotechnology","route":"/companies/nextsource-biotechnology/","asOf":"2026-09-17","days":4},{"id":"lantern-pharma","kind":"company","name":"Lantern Pharma","route":"/companies/lantern-pharma/","asOf":"2026-09-17","days":4},{"id":"lyvgen-biopharma","kind":"company","name":"Lyvgen Biopharma","route":"/companies/lyvgen-biopharma/","asOf":"2026-09-17","days":4},{"id":"x4-pharmaceuticals","kind":"company","name":"X4 Pharmaceuticals","route":"/companies/x4-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","route":"/companies/phanes-therapeutics/","asOf":"2026-09-17","days":4},{"id":"alligator-bioscience","kind":"company","name":"Alligator Bioscience","route":"/companies/alligator-bioscience/","asOf":"2026-09-17","days":4},{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","route":"/companies/shanghai-miracogen/","asOf":"2026-09-17","days":4},{"id":"shionogi","kind":"company","name":"Shionogi","route":"/companies/shionogi/","asOf":"2026-09-17","days":4},{"id":"cimab","kind":"company","name":"CIMAB","route":"/companies/cimab/","asOf":"2026-09-17","days":4},{"id":"netris-pharma","kind":"company","name":"Netris Pharma","route":"/companies/netris-pharma/","asOf":"2026-09-17","days":4},{"id":"immix-biopharma","kind":"company","name":"Immix Biopharma","route":"/companies/immix-biopharma/","asOf":"2026-09-17","days":4},{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","route":"/companies/hanmi-pharmaceutical/","asOf":"2026-09-17","days":4},{"id":"cardiff-oncology","kind":"company","name":"Cardiff Oncology","route":"/companies/cardiff-oncology/","asOf":"2026-09-17","days":4},{"id":"oncoresponse","kind":"company","name":"OncoResponse","route":"/companies/oncoresponse/","asOf":"2026-09-17","days":4},{"id":"canariabio","kind":"company","name":"CanariaBio","route":"/companies/canariabio/","asOf":"2026-09-17","days":4},{"id":"steba-biotech","kind":"company","name":"Steba Biotech","route":"/companies/steba-biotech/","asOf":"2026-09-17","days":4},{"id":"pellepharm","kind":"company","name":"PellePharm","route":"/companies/pellepharm/","asOf":"2026-09-17","days":4},{"id":"prestige-biopharma","kind":"company","name":"Prestige Biopharma","route":"/companies/prestige-biopharma/","asOf":"2026-09-17","days":4},{"id":"pinnacle-biologics","kind":"company","name":"Pinnacle Biologics","route":"/companies/pinnacle-biologics/","asOf":"2026-09-17","days":4},{"id":"primmune-therapeutics","kind":"company","name":"Primmune Therapeutics","route":"/companies/primmune-therapeutics/","asOf":"2026-09-17","days":4},{"id":"remix-therapeutics","kind":"company","name":"Remix Therapeutics","route":"/companies/remix-therapeutics/","asOf":"2026-09-17","days":4},{"id":"rhovac","kind":"company","name":"RhoVac","route":"/companies/rhovac/","asOf":"2026-09-17","days":4},{"id":"rhythm-pharmaceuticals","kind":"company","name":"Rhythm Pharmaceuticals","route":"/companies/rhythm-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"surgimab","kind":"company","name":"Surgimab","route":"/companies/surgimab/","asOf":"2026-09-17","days":4},{"id":"aadi-bioscience","kind":"company","name":"Aadi Bioscience","route":"/companies/aadi-bioscience/","asOf":"2026-09-17","days":4},{"id":"fennec-pharmaceuticals","kind":"company","name":"Fennec Pharmaceuticals","route":"/companies/fennec-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"corvus-pharmaceuticals","kind":"company","name":"Corvus Pharmaceuticals","route":"/companies/corvus-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"alethia-biotherapeutics","kind":"company","name":"Alethia Biotherapeutics","route":"/companies/alethia-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"shanghai-pharmaceuticals","kind":"company","name":"Shanghai Pharmaceuticals","route":"/companies/shanghai-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"step-pharma","kind":"company","name":"Step Pharma","route":"/companies/step-pharma/","asOf":"2026-09-17","days":4},{"id":"atara-biotherapeutics","kind":"company","name":"Atara Biotherapeutics","route":"/companies/atara-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","route":"/companies/triumvira-immunologics/","asOf":"2026-09-17","days":4},{"id":"rhizen-pharmaceuticals","kind":"company","name":"Rhizen Pharmaceuticals","route":"/companies/rhizen-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"theolytics","kind":"company","name":"Theolytics","route":"/companies/theolytics/","asOf":"2026-09-17","days":4},{"id":"tilt-biotherapeutics","kind":"company","name":"TILT Biotherapeutics","route":"/companies/tilt-biotherapeutics/","asOf":"2026-09-17","days":4},{"id":"oncternal-therapeutics","kind":"company","name":"Oncternal Therapeutics","route":"/companies/oncternal-therapeutics/","asOf":"2026-09-17","days":4},{"id":"byondis","kind":"company","name":"Byondis","route":"/companies/byondis/","asOf":"2026-09-17","days":4},{"id":"toray-industries","kind":"company","name":"Toray Industries","route":"/companies/toray-industries/","asOf":"2026-09-17","days":4},{"id":"transcenta","kind":"company","name":"Transcenta","route":"/companies/transcenta/","asOf":"2026-09-17","days":4},{"id":"i-mab","kind":"company","name":"I-Mab","route":"/companies/i-mab/","asOf":"2026-09-17","days":4},{"id":"medpacto","kind":"company","name":"MedPacto","route":"/companies/medpacto/","asOf":"2026-09-17","days":4},{"id":"zenith-epigenetics","kind":"company","name":"Zenith Epigenetics","route":"/companies/zenith-epigenetics/","asOf":"2026-09-17","days":4},{"id":"abclon","kind":"company","name":"AbClon","route":"/companies/abclon/","asOf":"2026-09-17","days":4},{"id":"devimistat","kind":"drug","name":"Devimistat","route":"/drugs/devimistat/","asOf":"2026-09-17","days":4},{"id":"pamrevlumab","kind":"drug","name":"Pamrevlumab","route":"/drugs/pamrevlumab/","asOf":"2026-09-17","days":4},{"id":"eryaspase","kind":"drug","name":"Eryaspase","route":"/drugs/eryaspase/","asOf":"2026-09-17","days":4},{"id":"algenpantucel-l","kind":"drug","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/","asOf":"2026-09-17","days":4},{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/","asOf":"2026-09-17","days":4},{"id":"avenger-500","kind":"trial","name":"AVENGER 500","route":"/trials/avenger-500/","asOf":"2026-09-17","days":4},{"id":"lapis-trial","kind":"trial","name":"LAPIS","route":"/trials/lapis-trial/","asOf":"2026-09-17","days":4},{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/","asOf":"2026-09-17","days":4},{"id":"impress-trial","kind":"trial","name":"IMPRESS (algenpantucel-L)","route":"/trials/impress-trial/","asOf":"2026-09-17","days":4},{"id":"notable-trial","kind":"trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","route":"/trials/notable-trial/","asOf":"2026-09-17","days":4},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","asOf":"2026-09-17","days":4},{"id":"cornerstone-pharmaceuticals","kind":"company","name":"Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)","route":"/companies/cornerstone-pharmaceuticals/","asOf":"2026-09-17","days":4},{"id":"fibrogen","kind":"company","name":"FibroGen","route":"/companies/fibrogen/","asOf":"2026-09-17","days":4},{"id":"newlink-genetics","kind":"company","name":"NewLink Genetics (now Lumos Pharma)","route":"/companies/newlink-genetics/","asOf":"2026-09-17","days":4},{"id":"actuate-therapeutics","kind":"company","name":"Actuate Therapeutics","route":"/companies/actuate-therapeutics/","asOf":"2026-09-17","days":4},{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/","asOf":"2026-09-17","days":4},{"id":"zanidatamab-zovodotin","kind":"drug","name":"Zanidatamab zovodotin","route":"/drugs/zanidatamab-zovodotin/","asOf":"2026-09-17","days":4},{"id":"acitretin","kind":"drug","name":"Acitretin","route":"/drugs/acitretin/","asOf":"2026-09-17","days":4},{"id":"nicotinamide","kind":"drug","name":"Nicotinamide","route":"/drugs/nicotinamide/","asOf":"2026-09-17","days":4},{"id":"patidegib","kind":"drug","name":"Patidegib","route":"/drugs/patidegib/","asOf":"2026-09-17","days":4},{"id":"hypericin-sgx301","kind":"drug","name":"Synthetic hypericin","route":"/drugs/hypericin-sgx301/","asOf":"2026-09-17","days":4},{"id":"daromun","kind":"drug","name":"Daromun","route":"/drugs/daromun/","asOf":"2026-09-17","days":4},{"id":"celecoxib","kind":"drug","name":"Celecoxib","route":"/drugs/celecoxib/","asOf":"2026-09-17","days":4},{"id":"xevinapant","kind":"drug","name":"Xevinapant","route":"/drugs/xevinapant/","asOf":"2026-09-17","days":4},{"id":"hb-200","kind":"drug","name":"HB-200","route":"/drugs/hb-200/","asOf":"2026-09-17","days":4},{"id":"depatuxizumab-mafodotin","kind":"drug","name":"Depatuxizumab mafodotin","route":"/drugs/depatuxizumab-mafodotin/","asOf":"2026-09-17","days":4},{"id":"neovax","kind":"drug","name":"NeoVax","route":"/drugs/neovax/","asOf":"2026-09-17","days":4},{"id":"gsk2256098","kind":"drug","name":"GSK2256098","route":"/drugs/gsk2256098/","asOf":"2026-09-17","days":4},{"id":"mifepristone","kind":"drug","name":"Mifepristone","route":"/drugs/mifepristone/","asOf":"2026-09-17","days":4},{"id":"memantine","kind":"drug","name":"Memantine","route":"/drugs/memantine/","asOf":"2026-09-17","days":4},{"id":"setmelanotide","kind":"drug","name":"Setmelanotide","route":"/drugs/setmelanotide/","asOf":"2026-09-17","days":4},{"id":"bromocriptine","kind":"drug","name":"Bromocriptine","route":"/drugs/bromocriptine/","asOf":"2026-09-17","days":4},{"id":"cabergoline","kind":"drug","name":"Cabergoline","route":"/drugs/cabergoline/","asOf":"2026-09-17","days":4},{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/","asOf":"2026-09-17","days":4},{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/","asOf":"2026-09-17","days":4},{"id":"osilodrostat","kind":"drug","name":"Osilodrostat","route":"/drugs/osilodrostat/","asOf":"2026-09-17","days":4},{"id":"metyrapone","kind":"drug","name":"Metyrapone","route":"/drugs/metyrapone/","asOf":"2026-09-17","days":4},{"id":"paltusotine","kind":"drug","name":"Paltusotine","route":"/drugs/paltusotine/","asOf":"2026-09-17","days":4},{"id":"obrixtamig","kind":"drug","name":"Obrixtamig","route":"/drugs/obrixtamig/","asOf":"2026-09-17","days":4},{"id":"diazoxide","kind":"drug","name":"Diazoxide","route":"/drugs/diazoxide/","asOf":"2026-09-17","days":4},{"id":"brigimadlin","kind":"drug","name":"Brigimadlin","route":"/drugs/brigimadlin/","asOf":"2026-09-17","days":4},{"id":"cediranib","kind":"drug","name":"Cediranib","route":"/drugs/cediranib/","asOf":"2026-09-17","days":4},{"id":"carotuximab","kind":"drug","name":"Carotuximab","route":"/drugs/carotuximab/","asOf":"2026-09-17","days":4},{"id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/","asOf":"2026-09-17","days":4},{"id":"gi-6301","kind":"drug","name":"GI-6301","route":"/drugs/gi-6301/","asOf":"2026-09-17","days":4},{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/","asOf":"2026-09-17","days":4},{"id":"aminopterin","kind":"drug","name":"Aminopterin","route":"/drugs/aminopterin/","asOf":"2026-09-17","days":4},{"id":"pevonedistat","kind":"drug","name":"Pevonedistat","route":"/drugs/pevonedistat/","asOf":"2026-09-17","days":4},{"id":"lenzilumab","kind":"drug","name":"Lenzilumab","route":"/drugs/lenzilumab/","asOf":"2026-09-17","days":4},{"id":"inca033989","kind":"drug","name":"INCA033989","route":"/drugs/inca033989/","asOf":"2026-09-17","days":4},{"id":"danazol","kind":"drug","name":"Danazol","route":"/drugs/danazol/","asOf":"2026-09-17","days":4},{"id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","asOf":"2026-09-17","days":4},{"id":"mavorixafor","kind":"drug","name":"Mavorixafor","route":"/drugs/mavorixafor/","asOf":"2026-09-17","days":4},{"id":"isotretinoin","kind":"drug","name":"Isotretinoin","route":"/drugs/isotretinoin/","asOf":"2026-09-17","days":4},{"id":"stride-dna-break-detection","kind":"technology","name":"STRIDE DNA break detection (intoDNA)","route":"/technologies/stride-dna-break-detection/","asOf":"2026-09-17","days":4},{"id":"intodna","kind":"company","name":"intoDNA","route":"/companies/intodna/","asOf":"2026-09-17","days":4},{"id":"strata-oncology","kind":"company","name":"Strata Oncology","route":"/companies/strata-oncology/","asOf":"2026-09-17","days":4},{"id":"rad51-foci-assay","kind":"technology","name":"RAD51 foci assay (functional HRD test)","route":"/technologies/rad51-foci-assay/","asOf":"2026-09-17","days":4},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/","asOf":"2026-09-17","days":4},{"id":"cellsearch-ctc-count","kind":"technology","name":"CellSearch circulating tumour cell count","route":"/technologies/cellsearch-ctc-count/","asOf":"2026-09-17","days":4},{"id":"parsortix-ctc-harvest","kind":"technology","name":"Parsortix label-free circulating tumour cell harvest","route":"/technologies/parsortix-ctc-harvest/","asOf":"2026-09-17","days":4},{"id":"functional-precision-medicine-haematology","kind":"technology","name":"Ex vivo drug sensitivity screening in blood cancers (EXALT)","route":"/technologies/functional-precision-medicine-haematology/","asOf":"2026-09-17","days":4},{"id":"sarcoma-methylation-classifier","kind":"technology","name":"Methylation classifier for sarcomas","route":"/technologies/sarcoma-methylation-classifier/","asOf":"2026-09-17","days":4},{"id":"urine-bladder-cancer-tests","kind":"technology","name":"Urine tests for bladder cancer (cytology, FISH, RNA and methylation)","route":"/technologies/urine-bladder-cancer-tests/","asOf":"2026-09-17","days":4},{"id":"bladder-epicheck","kind":"technology","name":"Bladder EpiCheck urine methylation test","route":"/technologies/bladder-epicheck/","asOf":"2026-09-17","days":4},{"id":"multitarget-stool-rna-test","kind":"technology","name":"Multitarget stool RNA test (ColoSense)","route":"/technologies/multitarget-stool-rna-test/","asOf":"2026-09-17","days":4},{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/","asOf":"2026-09-17","days":4},{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","asOf":"2026-09-17","days":4},{"id":"ct-body-composition-sarcopenia","kind":"technology","name":"CT body composition and sarcopenia measurement","route":"/technologies/ct-body-composition-sarcopenia/","asOf":"2026-09-17","days":4},{"id":"dpyd-genotyping","kind":"technology","name":"DPYD genotyping and DPD phenotyping before fluoropyrimidines","route":"/technologies/dpyd-genotyping/","asOf":"2026-09-17","days":4},{"id":"ugt1a1-genotyping","kind":"technology","name":"UGT1A1 genotyping before irinotecan","route":"/technologies/ugt1a1-genotyping/","asOf":"2026-09-17","days":4},{"id":"tpmt-nudt15-genotyping","kind":"technology","name":"TPMT and NUDT15 genotyping before thiopurines","route":"/technologies/tpmt-nudt15-genotyping/","asOf":"2026-09-17","days":4},{"id":"cardiac-biomarker-monitoring","kind":"technology","name":"Troponin and natriuretic peptide monitoring during cancer treatment","route":"/technologies/cardiac-biomarker-monitoring/","asOf":"2026-09-17","days":4},{"id":"strain-echocardiography-gls","kind":"technology","name":"Strain echocardiography (global longitudinal strain)","route":"/technologies/strain-echocardiography-gls/","asOf":"2026-09-17","days":4},{"id":"g8-geriatric-screening","kind":"technology","name":"G8 geriatric screening tool","route":"/technologies/g8-geriatric-screening/","asOf":"2026-09-17","days":4},{"id":"via-cervical-screening","kind":"technology","name":"Visual inspection with acetic acid (VIA) for cervical screening","route":"/technologies/via-cervical-screening/","asOf":"2026-09-17","days":4},{"id":"hand-held-ultrasound","kind":"technology","name":"Hand-held and point-of-care ultrasound","route":"/technologies/hand-held-ultrasound/","asOf":"2026-09-17","days":4},{"id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/","asOf":"2026-09-17","days":4},{"id":"germ-cell-tumour-markers","kind":"technology","name":"AFP, hCG and LDH in germ cell tumours (IGCCCG risk groups)","route":"/technologies/germ-cell-tumour-markers/","asOf":"2026-09-17","days":4},{"id":"thyroid-cancer-markers","kind":"technology","name":"Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up","route":"/technologies/thyroid-cancer-markers/","asOf":"2026-09-17","days":4},{"id":"cea-surveillance-colorectal","kind":"technology","name":"CEA surveillance after colorectal cancer surgery","route":"/technologies/cea-surveillance-colorectal/","asOf":"2026-09-17","days":4},{"id":"menarini-silicon-biosystems","kind":"company","name":"Menarini Silicon Biosystems","route":"/companies/menarini-silicon-biosystems/","asOf":"2026-09-17","days":4},{"id":"angle-plc","kind":"company","name":"ANGLE plc","route":"/companies/angle-plc/","asOf":"2026-09-17","days":4},{"id":"geneoscopy","kind":"company","name":"Geneoscopy","route":"/companies/geneoscopy/","asOf":"2026-09-17","days":4},{"id":"butterfly-network","kind":"company","name":"Butterfly Network","route":"/companies/butterfly-network/","asOf":"2026-09-17","days":4},{"id":"fujirebio","kind":"company","name":"Fujirebio","route":"/companies/fujirebio/","asOf":"2026-09-17","days":4},{"id":"i-spy-1","kind":"trial","name":"I-SPY 1 (CALGB 150007/150012, ACRIN 6657)","route":"/trials/i-spy-1/","asOf":"2026-09-17","days":4},{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/","asOf":"2026-09-17","days":4},{"id":"i-spy-2-2","kind":"trial","name":"I-SPY 2.2","route":"/trials/i-spy-2-2/","asOf":"2026-09-17","days":4},{"id":"wisdom-trial","kind":"trial","name":"WISDOM (Women Informed to Screen Depending on Measures of Risk)","route":"/trials/wisdom-trial/","asOf":"2026-09-17","days":4},{"id":"quantum-leap-healthcare-collaborative","kind":"company","name":"Quantum Leap Healthcare Collaborative","route":"/companies/quantum-leap-healthcare-collaborative/","asOf":"2026-09-17","days":4},{"id":"vmat","kind":"technology","name":"Volumetric modulated arc therapy (VMAT)","route":"/technologies/vmat/","asOf":"2026-09-17","days":4},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/","asOf":"2026-09-17","days":4},{"id":"adaptive-radiotherapy","kind":"technology","name":"Adaptive radiotherapy (online replanning)","route":"/technologies/adaptive-radiotherapy/","asOf":"2026-09-17","days":4},{"id":"surface-guided-radiotherapy","kind":"technology","name":"Surface-guided radiotherapy (SGRT)","route":"/technologies/surface-guided-radiotherapy/","asOf":"2026-09-17","days":4},{"id":"respiratory-motion-management","kind":"technology","name":"Respiratory motion management (4D-CT, gating, breath-hold, tracking)","route":"/technologies/respiratory-motion-management/","asOf":"2026-09-17","days":4},{"id":"hypofractionated-radiotherapy","kind":"technology","name":"Hypofractionated radiotherapy","route":"/technologies/hypofractionated-radiotherapy/","asOf":"2026-09-17","days":4},{"id":"sabr-oligometastases","kind":"technology","name":"Stereotactic ablative radiotherapy for oligometastatic disease","route":"/technologies/sabr-oligometastases/","asOf":"2026-09-17","days":4},{"id":"hdr-brachytherapy","kind":"technology","name":"High-dose-rate brachytherapy","route":"/technologies/hdr-brachytherapy/","asOf":"2026-09-17","days":4},{"id":"ldr-seed-brachytherapy","kind":"technology","name":"Low-dose-rate seed brachytherapy","route":"/technologies/ldr-seed-brachytherapy/","asOf":"2026-09-17","days":4},{"id":"intensity-modulated-proton-therapy","kind":"technology","name":"Pencil-beam scanning and intensity-modulated proton therapy","route":"/technologies/intensity-modulated-proton-therapy/","asOf":"2026-09-17","days":4},{"id":"total-body-irradiation","kind":"technology","name":"Total body and total marrow irradiation","route":"/technologies/total-body-irradiation/","asOf":"2026-09-17","days":4},{"id":"total-skin-electron-therapy","kind":"technology","name":"Total skin electron beam therapy","route":"/technologies/total-skin-electron-therapy/","asOf":"2026-09-17","days":4},{"id":"superficial-radiotherapy","kind":"technology","name":"Superficial and orthovoltage radiotherapy for skin cancer","route":"/technologies/superficial-radiotherapy/","asOf":"2026-09-17","days":4},{"id":"cobalt-60-teletherapy","kind":"technology","name":"Cobalt-60 teletherapy","route":"/technologies/cobalt-60-teletherapy/","asOf":"2026-09-17","days":4},{"id":"radiotherapy-access-gap","kind":"technology","name":"Radiotherapy access and the global machine gap","route":"/technologies/radiotherapy-access-gap/","asOf":"2026-09-17","days":4},{"id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/","asOf":"2026-09-17","days":4},{"id":"radioprotectors","kind":"technology","name":"Radioprotectors and normal-tissue sparing drugs","route":"/technologies/radioprotectors/","asOf":"2026-09-17","days":4},{"id":"linear-quadratic-model","kind":"technology","name":"The linear-quadratic model and fractionation","route":"/technologies/linear-quadratic-model/","asOf":"2026-09-17","days":4},{"id":"tumour-hypoxia-modification","kind":"technology","name":"Tumour hypoxia: imaging and modification","route":"/technologies/tumour-hypoxia-modification/","asOf":"2026-09-17","days":4},{"id":"dose-painting","kind":"technology","name":"Dose painting and biologically guided radiotherapy","route":"/technologies/dose-painting/","asOf":"2026-09-17","days":4},{"id":"knowledge-based-planning","kind":"technology","name":"Knowledge-based and automated treatment planning","route":"/technologies/knowledge-based-planning/","asOf":"2026-09-17","days":4},{"id":"in-vivo-dosimetry","kind":"technology","name":"In vivo dosimetry and patient-specific quality assurance","route":"/technologies/in-vivo-dosimetry/","asOf":"2026-09-17","days":4},{"id":"radiogenomics","kind":"technology","name":"Radiogenomics: predicting radiation sensitivity from genes","route":"/technologies/radiogenomics/","asOf":"2026-09-17","days":4},{"id":"alpha-beta-ratio","kind":"term","name":"Alpha/beta ratio","route":"/terms/alpha-beta-ratio/","asOf":"2026-09-17","days":4},{"id":"biologically-effective-dose","kind":"term","name":"Biologically effective dose (BED) and EQD2","route":"/terms/biologically-effective-dose/","asOf":"2026-09-17","days":4},{"id":"planning-target-volume","kind":"term","name":"GTV, CTV and PTV (target volumes)","route":"/terms/planning-target-volume/","asOf":"2026-09-17","days":4},{"id":"organs-at-risk","kind":"term","name":"Organs at risk and dose constraints","route":"/terms/organs-at-risk/","asOf":"2026-09-17","days":4},{"id":"deep-inspiration-breath-hold","kind":"term","name":"Deep inspiration breath-hold (DIBH)","route":"/terms/deep-inspiration-breath-hold/","asOf":"2026-09-17","days":4},{"id":"fiducial-markers","kind":"term","name":"Fiducial markers","route":"/terms/fiducial-markers/","asOf":"2026-09-17","days":4},{"id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","asOf":"2026-09-17","days":4},{"id":"oxygen-enhancement-ratio","kind":"term","name":"Oxygen enhancement ratio","route":"/terms/oxygen-enhancement-ratio/","asOf":"2026-09-17","days":4},{"id":"radiation-dermatitis","kind":"term","name":"Radiation dermatitis (skin reaction)","route":"/terms/radiation-dermatitis/","asOf":"2026-09-17","days":4},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/","asOf":"2026-09-17","days":4},{"id":"radiation-necrosis","kind":"term","name":"Radiation necrosis (brain)","route":"/terms/radiation-necrosis/","asOf":"2026-09-17","days":4},{"id":"second-cancers-after-radiotherapy","kind":"term","name":"Second cancers after radiotherapy","route":"/terms/second-cancers-after-radiotherapy/","asOf":"2026-09-17","days":4},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","asOf":"2026-09-17","days":4},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","asOf":"2026-09-17","days":4},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","asOf":"2026-09-17","days":4},{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/","asOf":"2026-09-17","days":4},{"id":"int-0116","kind":"trial","name":"INT-0116 (Macdonald trial)","route":"/trials/int-0116/","asOf":"2026-09-17","days":4},{"id":"cao-aro-aio-94","kind":"trial","name":"CAO/ARO/AIO-94 (German Rectal Cancer Study)","route":"/trials/cao-aro-aio-94/","asOf":"2026-09-17","days":4},{"id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","asOf":"2026-09-17","days":4},{"id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","asOf":"2026-09-17","days":4},{"id":"act-ii","kind":"trial","name":"ACT II","route":"/trials/act-ii/","asOf":"2026-09-17","days":4},{"id":"rtog-91-11","kind":"trial","name":"RTOG 91-11","route":"/trials/rtog-91-11/","asOf":"2026-09-17","days":4},{"id":"bonner-cetuximab-rt","kind":"trial","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","asOf":"2026-09-17","days":4},{"id":"rtog-1016","kind":"trial","name":"RTOG 1016","route":"/trials/rtog-1016/","asOf":"2026-09-17","days":4},{"id":"de-escalate","kind":"trial","name":"De-ESCALaTE HPV","route":"/trials/de-escalate/","asOf":"2026-09-17","days":4},{"id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","asOf":"2026-09-17","days":4},{"id":"horrad","kind":"trial","name":"HORRAD","route":"/trials/horrad/","asOf":"2026-09-17","days":4},{"id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","asOf":"2026-09-17","days":4},{"id":"slotman-pci-es-sclc","kind":"trial","name":"EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer","route":"/trials/slotman-pci-es-sclc/","asOf":"2026-09-17","days":4},{"id":"takahashi-pci","kind":"trial","name":"Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer","route":"/trials/takahashi-pci/","asOf":"2026-09-17","days":4},{"id":"eortc-22922","kind":"trial","name":"EORTC 22922/10925","route":"/trials/eortc-22922/","asOf":"2026-09-17","days":4},{"id":"ma-20","kind":"trial","name":"NCIC MA.20","route":"/trials/ma-20/","asOf":"2026-09-17","days":4},{"id":"dbcg-82bc","kind":"trial","name":"DBCG 82b and 82c","route":"/trials/dbcg-82bc/","asOf":"2026-09-17","days":4},{"id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","asOf":"2026-09-17","days":4},{"id":"eortc-26951","kind":"trial","name":"EORTC 26951","route":"/trials/eortc-26951/","asOf":"2026-09-17","days":4},{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","asOf":"2026-09-17","days":4},{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","asOf":"2026-09-17","days":4},{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","asOf":"2026-09-17","days":4},{"id":"bragg-peak","kind":"term","name":"Bragg peak","route":"/terms/bragg-peak/","asOf":"2026-09-17","days":4},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","asOf":"2026-09-17","days":4},{"id":"radcomp","kind":"trial","name":"RADCOMP","route":"/trials/radcomp/","asOf":"2026-09-17","days":4},{"id":"papillary-thyroid-cancer","kind":"cancer","name":"Papillary thyroid cancer","route":"/cancers/papillary-thyroid-cancer/","asOf":"2026-09-17","days":4},{"id":"follicular-thyroid-cancer","kind":"cancer","name":"Follicular thyroid cancer","route":"/cancers/follicular-thyroid-cancer/","asOf":"2026-09-17","days":4},{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/","asOf":"2026-09-17","days":4},{"id":"anaplastic-thyroid-cancer","kind":"cancer","name":"Anaplastic thyroid cancer","route":"/cancers/anaplastic-thyroid-cancer/","asOf":"2026-09-17","days":4},{"id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","asOf":"2026-09-17","days":4},{"id":"laryngeal-cancer","kind":"cancer","name":"Laryngeal and hypopharyngeal cancer","route":"/cancers/laryngeal-cancer/","asOf":"2026-09-17","days":4},{"id":"oral-cavity-cancer","kind":"cancer","name":"Oral cavity cancer (mouth and tongue)","route":"/cancers/oral-cavity-cancer/","asOf":"2026-09-17","days":4},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/","asOf":"2026-09-17","days":4},{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","asOf":"2026-09-17","days":4},{"id":"clear-cell-ovarian-cancer","kind":"cancer","name":"Clear cell ovarian cancer","route":"/cancers/clear-cell-ovarian-cancer/","asOf":"2026-09-17","days":4},{"id":"mucinous-ovarian-cancer","kind":"cancer","name":"Mucinous ovarian cancer","route":"/cancers/mucinous-ovarian-cancer/","asOf":"2026-09-17","days":4},{"id":"granulosa-cell-tumour","kind":"cancer","name":"Adult granulosa cell tumour of the ovary","route":"/cancers/granulosa-cell-tumour/","asOf":"2026-09-17","days":4},{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/","asOf":"2026-09-17","days":4},{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/","asOf":"2026-09-17","days":4},{"id":"chromophobe-rcc","kind":"cancer","name":"Chromophobe renal cell carcinoma","route":"/cancers/chromophobe-rcc/","asOf":"2026-09-17","days":4},{"id":"seminoma","kind":"cancer","name":"Seminoma","route":"/cancers/seminoma/","asOf":"2026-09-17","days":4},{"id":"non-seminoma","kind":"cancer","name":"Non-seminomatous germ cell tumour","route":"/cancers/non-seminoma/","asOf":"2026-09-17","days":4},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/","asOf":"2026-09-17","days":4},{"id":"oesophageal-adenocarcinoma","kind":"cancer","name":"Oesophageal and junctional adenocarcinoma","route":"/cancers/oesophageal-adenocarcinoma/","asOf":"2026-09-17","days":4},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","asOf":"2026-09-17","days":4},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/","asOf":"2026-09-17","days":4},{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/","asOf":"2026-09-17","days":4},{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/","asOf":"2026-09-17","days":4},{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/","asOf":"2026-09-17","days":4},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/","asOf":"2026-09-17","days":4},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","asOf":"2026-09-17","days":4},{"id":"gompertzian-growth-model","kind":"technology","name":"Gompertzian tumour growth","route":"/technologies/gompertzian-growth-model/","asOf":"2026-09-17","days":4},{"id":"log-kill-hypothesis","kind":"technology","name":"Log-kill hypothesis (Skipper)","route":"/technologies/log-kill-hypothesis/","asOf":"2026-09-17","days":4},{"id":"norton-simon-hypothesis","kind":"technology","name":"Norton-Simon hypothesis and dose-dense chemotherapy","route":"/technologies/norton-simon-hypothesis/","asOf":"2026-09-17","days":4},{"id":"goldie-coldman-model","kind":"technology","name":"Goldie-Coldman model of resistance","route":"/technologies/goldie-coldman-model/","asOf":"2026-09-17","days":4},{"id":"drug-resistance-dynamics","kind":"technology","name":"Evolutionary dynamics of drug resistance","route":"/technologies/drug-resistance-dynamics/","asOf":"2026-09-17","days":4},{"id":"adaptive-therapy-dynamics","kind":"technology","name":"Adaptive therapy (evolution-based dosing)","route":"/technologies/adaptive-therapy-dynamics/","asOf":"2026-09-17","days":4},{"id":"evolutionary-game-theory-cancer","kind":"technology","name":"Evolutionary game theory in cancer","route":"/technologies/evolutionary-game-theory-cancer/","asOf":"2026-09-17","days":4},{"id":"clonal-evolution-models","kind":"technology","name":"Clonal evolution and branching models","route":"/technologies/clonal-evolution-models/","asOf":"2026-09-17","days":4},{"id":"reaction-diffusion-glioma-model","kind":"technology","name":"Proliferation-invasion (reaction-diffusion) models of glioma","route":"/technologies/reaction-diffusion-glioma-model/","asOf":"2026-09-17","days":4},{"id":"agent-based-tumour-models","kind":"technology","name":"Agent-based and multicellular simulations","route":"/technologies/agent-based-tumour-models/","asOf":"2026-09-17","days":4},{"id":"immune-tumour-dynamics-models","kind":"technology","name":"Tumour-immune dynamics models","route":"/technologies/immune-tumour-dynamics-models/","asOf":"2026-09-17","days":4},{"id":"quantitative-systems-pharmacology","kind":"technology","name":"Quantitative systems pharmacology (QSP)","route":"/technologies/quantitative-systems-pharmacology/","asOf":"2026-09-17","days":4},{"id":"pkpd-modelling","kind":"technology","name":"Pharmacokinetic and pharmacodynamic modelling","route":"/technologies/pkpd-modelling/","asOf":"2026-09-17","days":4},{"id":"body-surface-area-dosing","kind":"technology","name":"Body-surface-area dosing","route":"/technologies/body-surface-area-dosing/","asOf":"2026-09-17","days":4},{"id":"tumour-control-probability-models","kind":"technology","name":"Tumour control and normal tissue complication probability (TCP and NTCP)","route":"/technologies/tumour-control-probability-models/","asOf":"2026-09-17","days":4},{"id":"fractionation-repopulation-models","kind":"technology","name":"The four Rs and accelerated repopulation","route":"/technologies/fractionation-repopulation-models/","asOf":"2026-09-17","days":4},{"id":"tumour-doubling-time","kind":"technology","name":"Tumour volume doubling time","route":"/technologies/tumour-doubling-time/","asOf":"2026-09-17","days":4},{"id":"angiogenesis-models","kind":"technology","name":"Angiogenesis and vascular normalisation models","route":"/technologies/angiogenesis-models/","asOf":"2026-09-17","days":4},{"id":"tumour-mechanics-models","kind":"technology","name":"Solid stress and tumour mechanobiology models","route":"/technologies/tumour-mechanics-models/","asOf":"2026-09-17","days":4},{"id":"metastasis-seeding-models","kind":"technology","name":"Metastatic seeding and dormancy models","route":"/technologies/metastasis-seeding-models/","asOf":"2026-09-17","days":4},{"id":"mrd-kinetics-models","kind":"technology","name":"Residual disease kinetics (BCR-ABL halving and ctDNA slopes)","route":"/technologies/mrd-kinetics-models/","asOf":"2026-09-17","days":4},{"id":"digital-twin-patient-models","kind":"technology","name":"Patient digital twins","route":"/technologies/digital-twin-patient-models/","asOf":"2026-09-17","days":4},{"id":"mathematical-oncology","kind":"technology","name":"Mathematical models of cancer (mathematical oncology)","route":"/technologies/mathematical-oncology/","asOf":"2026-09-17","days":4},{"id":"x-ray-radiography-fluoroscopy","kind":"technology","name":"X-ray radiography and fluoroscopy","route":"/technologies/x-ray-radiography-fluoroscopy/","asOf":"2026-09-17","days":4},{"id":"photon-counting-ct","kind":"technology","name":"Photon-counting CT","route":"/technologies/photon-counting-ct/","asOf":"2026-09-17","days":4},{"id":"dual-energy-spectral-ct","kind":"technology","name":"Dual-energy and spectral CT","route":"/technologies/dual-energy-spectral-ct/","asOf":"2026-09-17","days":4},{"id":"ultrasound-elastography-ceus","kind":"technology","name":"Elastography and contrast-enhanced ultrasound","route":"/technologies/ultrasound-elastography-ceus/","asOf":"2026-09-17","days":4},{"id":"mri-field-strengths","kind":"technology","name":"MRI field strengths: 1.5 T, 3 T and 7 T","route":"/technologies/mri-field-strengths/","asOf":"2026-09-17","days":4},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","asOf":"2026-09-17","days":4},{"id":"intraoperative-mri-ct","kind":"technology","name":"Intraoperative MRI and CT","route":"/technologies/intraoperative-mri-ct/","asOf":"2026-09-17","days":4},{"id":"c-arm-linac","kind":"technology","name":"C-arm medical linear accelerators (TrueBeam, Versa HD and others)","route":"/technologies/c-arm-linac/","asOf":"2026-09-17","days":4},{"id":"ring-gantry-linac","kind":"technology","name":"Ring-gantry linacs (Halcyon, Ethos)","route":"/technologies/ring-gantry-linac/","asOf":"2026-09-17","days":4},{"id":"tomotherapy","kind":"technology","name":"TomoTherapy and Radixact (helical radiotherapy)","route":"/technologies/tomotherapy/","asOf":"2026-09-17","days":4},{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/","asOf":"2026-09-17","days":4},{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/","asOf":"2026-09-17","days":4},{"id":"zap-x","kind":"technology","name":"ZAP-X gyroscopic radiosurgery","route":"/technologies/zap-x/","asOf":"2026-09-17","days":4},{"id":"biology-guided-radiotherapy","kind":"technology","name":"Biology-guided radiotherapy (RefleXion X1, SCINTIX)","route":"/technologies/biology-guided-radiotherapy/","asOf":"2026-09-17","days":4},{"id":"brachytherapy-afterloaders","kind":"technology","name":"Remote afterloaders for HDR brachytherapy","route":"/technologies/brachytherapy-afterloaders/","asOf":"2026-09-17","days":4},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/","asOf":"2026-09-17","days":4},{"id":"carbon-ion-synchrotrons","kind":"technology","name":"Carbon-ion synchrotrons and facilities","route":"/technologies/carbon-ion-synchrotrons/","asOf":"2026-09-17","days":4},{"id":"cryoablation-systems","kind":"technology","name":"Cryoablation systems","route":"/technologies/cryoablation-systems/","asOf":"2026-09-17","days":4},{"id":"microwave-rf-ablation","kind":"technology","name":"Microwave and radiofrequency ablation systems","route":"/technologies/microwave-rf-ablation/","asOf":"2026-09-17","days":4},{"id":"surgical-robot-platforms","kind":"technology","name":"Surgical robots: da Vinci, Hugo, Versius and single-port systems","route":"/technologies/surgical-robot-platforms/","asOf":"2026-09-17","days":4},{"id":"flow-cytometers","kind":"technology","name":"Flow cytometers","route":"/technologies/flow-cytometers/","asOf":"2026-09-17","days":4},{"id":"hitachi","kind":"company","name":"Hitachi (particle therapy)","route":"/companies/hitachi/","asOf":"2026-09-17","days":4},{"id":"viewray","kind":"company","name":"ViewRay (MRIdian)","route":"/companies/viewray/","asOf":"2026-09-17","days":4},{"id":"medtronic","kind":"company","name":"Medtronic","route":"/companies/medtronic/","asOf":"2026-09-17","days":4},{"id":"cmr-surgical","kind":"company","name":"CMR Surgical","route":"/companies/cmr-surgical/","asOf":"2026-09-17","days":4},{"id":"angiodynamics","kind":"company","name":"AngioDynamics","route":"/companies/angiodynamics/","asOf":"2026-09-17","days":4},{"id":"fujifilm","kind":"company","name":"FUJIFILM Healthcare","route":"/companies/fujifilm/","asOf":"2026-09-17","days":4},{"id":"shimadzu","kind":"company","name":"Shimadzu","route":"/companies/shimadzu/","asOf":"2026-09-17","days":4},{"id":"sumitomo-heavy-industries","kind":"company","name":"Sumitomo Heavy Industries","route":"/companies/sumitomo-heavy-industries/","asOf":"2026-09-17","days":4},{"id":"toshiba-energy-systems","kind":"company","name":"Toshiba Energy Systems & Solutions","route":"/companies/toshiba-energy-systems/","asOf":"2026-09-17","days":4},{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","asOf":"2026-09-17","days":4},{"id":"carl-zeiss-meditec","kind":"company","name":"Carl Zeiss Meditec","route":"/companies/carl-zeiss-meditec/","asOf":"2026-09-17","days":4},{"id":"profound-medical","kind":"company","name":"Profound Medical","route":"/companies/profound-medical/","asOf":"2026-09-17","days":4},{"id":"icecure-medical","kind":"company","name":"IceCure Medical","route":"/companies/icecure-medical/","asOf":"2026-09-17","days":4},{"id":"beckman-coulter","kind":"company","name":"Beckman Coulter","route":"/companies/beckman-coulter/","asOf":"2026-09-17","days":4},{"id":"cytek-biosciences","kind":"company","name":"Cytek Biosciences","route":"/companies/cytek-biosciences/","asOf":"2026-09-17","days":4},{"id":"mindray","kind":"company","name":"Mindray","route":"/companies/mindray/","asOf":"2026-09-17","days":4},{"id":"protom","kind":"company","name":"ProTom International","route":"/companies/protom/","asOf":"2026-09-17","days":4},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/","asOf":"2026-09-17","days":4},{"id":"oral-solid-dose-manufacturing","kind":"technology","name":"Oral solid dose manufacturing (tablets and capsules)","route":"/technologies/oral-solid-dose-manufacturing/","asOf":"2026-09-17","days":4},{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/","asOf":"2026-09-17","days":4},{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/","asOf":"2026-09-17","days":4},{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","route":"/technologies/downstream-purification-chromatography/","asOf":"2026-09-17","days":4},{"id":"single-use-bioprocessing","kind":"technology","name":"Single-use bioprocessing systems","route":"/technologies/single-use-bioprocessing/","asOf":"2026-09-17","days":4},{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/","asOf":"2026-09-17","days":4},{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/","asOf":"2026-09-17","days":4},{"id":"adc-supply-chain","kind":"technology","name":"The ADC supply chain (antibody, payload-linker, conjugation, fill)","route":"/technologies/adc-supply-chain/","asOf":"2026-09-17","days":4},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/","asOf":"2026-09-17","days":4},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/","asOf":"2026-09-17","days":4},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/","asOf":"2026-09-17","days":4},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","asOf":"2026-09-17","days":4},{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","asOf":"2026-09-17","days":4},{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/","asOf":"2026-09-17","days":4},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","asOf":"2026-09-17","days":4},{"id":"radiotherapy-equipment-manufacturing","kind":"technology","name":"Linac, proton system and brachytherapy machine manufacturing","route":"/technologies/radiotherapy-equipment-manufacturing/","asOf":"2026-09-17","days":4},{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","asOf":"2026-09-17","days":4},{"id":"sterling-pharma-solutions","kind":"company","name":"Sterling Pharma Solutions","route":"/companies/sterling-pharma-solutions/","asOf":"2026-09-17","days":4},{"id":"sartorius","kind":"company","name":"Sartorius","route":"/companies/sartorius/","asOf":"2026-09-17","days":4},{"id":"hikma","kind":"company","name":"Hikma Pharmaceuticals","route":"/companies/hikma/","asOf":"2026-09-17","days":4},{"id":"amneal","kind":"company","name":"Amneal Pharmaceuticals","route":"/companies/amneal/","asOf":"2026-09-17","days":4},{"id":"samsung-bioepis","kind":"company","name":"Samsung Bioepis","route":"/companies/samsung-bioepis/","asOf":"2026-09-17","days":4},{"id":"cellectis","kind":"company","name":"Cellectis","route":"/companies/cellectis/","asOf":"2026-09-17","days":4},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/","asOf":"2026-09-17","days":4},{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/","asOf":"2026-09-17","days":4},{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/","asOf":"2026-09-17","days":4},{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","route":"/companies/nordion/","asOf":"2026-09-17","days":4},{"id":"bruce-power","kind":"company","name":"Bruce Power","route":"/companies/bruce-power/","asOf":"2026-09-17","days":4},{"id":"nusano","kind":"company","name":"Nusano","route":"/companies/nusano/","asOf":"2026-09-17","days":4},{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/","asOf":"2026-09-17","days":4},{"id":"theories-of-cancer","kind":"pathway","name":"Theories of cancer: how the ideas connect","route":"/pathways/theories-of-cancer/","asOf":"2026-09-17","days":4},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","asOf":"2026-09-17","days":4},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","asOf":"2026-09-17","days":4},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","asOf":"2026-09-17","days":4},{"id":"hallmarks-synthesis","kind":"term","name":"Hallmarks of cancer as a synthesis of the theories","route":"/terms/hallmarks-synthesis/","asOf":"2026-09-17","days":4},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","asOf":"2026-09-17","days":4},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","asOf":"2026-09-17","days":4},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","asOf":"2026-09-17","days":4},{"id":"metabolic-theory-of-cancer","kind":"term","name":"Metabolic theory of cancer: from Warburg to oncometabolites","route":"/terms/metabolic-theory-of-cancer/","asOf":"2026-09-17","days":4},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","asOf":"2026-09-17","days":4},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","asOf":"2026-09-17","days":4},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","asOf":"2026-09-17","days":4},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","asOf":"2026-09-17","days":4},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","asOf":"2026-09-17","days":4},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","asOf":"2026-09-17","days":4},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","asOf":"2026-09-17","days":4},{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","asOf":"2026-09-17","days":4},{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/","asOf":"2026-09-17","days":4},{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","asOf":"2026-09-17","days":4},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/","asOf":"2026-09-17","days":4},{"id":"lung-map-s1800a","kind":"trial","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","route":"/trials/lung-map-s1800a/","asOf":"2026-09-17","days":4},{"id":"national-lung-matrix-trial","kind":"trial","name":"National Lung Matrix Trial","route":"/trials/national-lung-matrix-trial/","asOf":"2026-09-17","days":4},{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/","asOf":"2026-09-17","days":4},{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","asOf":"2026-09-17","days":4},{"id":"combomatch","kind":"trial","name":"ComboMATCH (EAY191)","route":"/trials/combomatch/","asOf":"2026-09-17","days":4},{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/","asOf":"2026-09-17","days":4},{"id":"dart-s1609","kind":"trial","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","route":"/trials/dart-s1609/","asOf":"2026-09-17","days":4},{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","asOf":"2026-09-17","days":4},{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/","asOf":"2026-09-17","days":4},{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/","asOf":"2026-09-17","days":4},{"id":"cupisco","kind":"trial","name":"CUPISCO","route":"/trials/cupisco/","asOf":"2026-09-17","days":4},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","asOf":"2026-09-17","days":4},{"id":"target-national","kind":"trial","name":"TARGET National","route":"/trials/target-national/","asOf":"2026-09-17","days":4},{"id":"determine-trial","kind":"trial","name":"DETERMINE","route":"/trials/determine-trial/","asOf":"2026-09-17","days":4},{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","asOf":"2026-09-17","days":4},{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/","asOf":"2026-09-17","days":4},{"id":"precision-promise","kind":"trial","name":"Precision Promise","route":"/trials/precision-promise/","asOf":"2026-09-17","days":4},{"id":"beat-aml-master-trial","kind":"trial","name":"Beat AML Master Trial","route":"/trials/beat-aml-master-trial/","asOf":"2026-09-17","days":4},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","asOf":"2026-09-17","days":4},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","asOf":"2026-09-17","days":4},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","asOf":"2026-09-17","days":4},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","asOf":"2026-09-17","days":4},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","asOf":"2026-09-17","days":4},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","asOf":"2026-09-17","days":4},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","asOf":"2026-09-17","days":4},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","asOf":"2026-09-17","days":4},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","asOf":"2026-09-17","days":4},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","asOf":"2026-09-17","days":4},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","asOf":"2026-09-17","days":4},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","asOf":"2026-09-17","days":4},{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/","asOf":"2026-09-17","days":4},{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","asOf":"2026-09-17","days":4},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","asOf":"2026-09-17","days":4},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","asOf":"2026-09-17","days":4},{"id":"bnct-accelerator-systems","kind":"technology","name":"Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex)","route":"/technologies/bnct-accelerator-systems/","asOf":"2026-09-17","days":4},{"id":"flash-research-accelerators","kind":"technology","name":"FLASH research accelerators (Oriatron, Mobetron FLASH, ProBeam FLASH)","route":"/technologies/flash-research-accelerators/","asOf":"2026-09-17","days":4},{"id":"electron-beam-therapy-systems","kind":"technology","name":"Electron beam therapy systems (linac electrons, total skin electron units, mobile electron IORT)","route":"/technologies/electron-beam-therapy-systems/","asOf":"2026-09-17","days":4},{"id":"oncology-information-systems","kind":"technology","name":"Oncology information and record-and-verify systems (ARIA, MOSAIQ)","route":"/technologies/oncology-information-systems/","asOf":"2026-09-17","days":4},{"id":"patient-positioning-surface-guidance-systems","kind":"technology","name":"Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)","route":"/technologies/patient-positioning-surface-guidance-systems/","asOf":"2026-09-17","days":4},{"id":"respiratory-gating-tumour-tracking-systems","kind":"technology","name":"Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)","route":"/technologies/respiratory-gating-tumour-tracking-systems/","asOf":"2026-09-17","days":4},{"id":"in-room-imaging-systems","kind":"technology","name":"In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)","route":"/technologies/in-room-imaging-systems/","asOf":"2026-09-17","days":4},{"id":"radiotherapy-qa-phantoms-dosimeters","kind":"technology","name":"Radiotherapy QA phantoms and dosimeters (Sun Nuclear, IBA Dosimetry, PTW)","route":"/technologies/radiotherapy-qa-phantoms-dosimeters/","asOf":"2026-09-17","days":4},{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","asOf":"2026-09-17","days":4},{"id":"photodynamic-therapy-lasers","kind":"technology","name":"Photodynamic therapy lasers and light sources","route":"/technologies/photodynamic-therapy-lasers/","asOf":"2026-09-17","days":4},{"id":"litt-systems","kind":"technology","name":"Laser interstitial thermal therapy systems (NeuroBlate, Visualase)","route":"/technologies/litt-systems/","asOf":"2026-09-17","days":4},{"id":"transcranial-focused-ultrasound-systems","kind":"technology","name":"Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud)","route":"/technologies/transcranial-focused-ultrasound-systems/","asOf":"2026-09-17","days":4},{"id":"electrochemotherapy-devices","kind":"technology","name":"Electrochemotherapy devices (Cliniporator)","route":"/technologies/electrochemotherapy-devices/","asOf":"2026-09-17","days":4},{"id":"hipec-pipac-devices","kind":"technology","name":"HIPEC perfusion pumps and PIPAC nebulisers","route":"/technologies/hipec-pipac-devices/","asOf":"2026-09-17","days":4},{"id":"intraoperative-fluorescence-imaging-systems","kind":"technology","name":"Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)","route":"/technologies/intraoperative-fluorescence-imaging-systems/","asOf":"2026-09-17","days":4},{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","asOf":"2026-09-17","days":4},{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/","asOf":"2026-09-17","days":4},{"id":"capsule-endoscopy-systems","kind":"technology","name":"Capsule endoscopy (PillCam, EndoCapsule, CapsoCam)","route":"/technologies/capsule-endoscopy-systems/","asOf":"2026-09-17","days":4},{"id":"colposcopes-digital-cervical-screening","kind":"technology","name":"Colposcopes and digital cervical screening devices (DYSIS, EVA System, AVE)","route":"/technologies/colposcopes-digital-cervical-screening/","asOf":"2026-09-17","days":4},{"id":"confocal-oct-skin-imaging","kind":"technology","name":"Confocal microscopy and optical coherence tomography for skin (VivaScope, VivoSight, deepLive)","route":"/technologies/confocal-oct-skin-imaging/","asOf":"2026-09-17","days":4},{"id":"contrast-enhanced-mammography","kind":"technology","name":"Contrast-enhanced mammography","route":"/technologies/contrast-enhanced-mammography/","asOf":"2026-09-17","days":4},{"id":"breast-mri-coils-abbreviated-mri","kind":"technology","name":"Breast MRI coils and abbreviated breast MRI","route":"/technologies/breast-mri-coils-abbreviated-mri/","asOf":"2026-09-17","days":4},{"id":"closed-system-transfer-devices","kind":"technology","name":"Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)","route":"/technologies/closed-system-transfer-devices/","asOf":"2026-09-17","days":4},{"id":"stella-pharma","kind":"company","name":"Stella Pharma","route":"/companies/stella-pharma/","asOf":"2026-09-17","days":4},{"id":"neuboron-medtech","kind":"company","name":"Neuboron Medtech","route":"/companies/neuboron-medtech/","asOf":"2026-09-17","days":4},{"id":"pyrexar-medical","kind":"company","name":"Pyrexar Medical","route":"/companies/pyrexar-medical/","asOf":"2026-09-17","days":4},{"id":"oncotherm","kind":"company","name":"Oncotherm","route":"/companies/oncotherm/","asOf":"2026-09-17","days":4},{"id":"modulight","kind":"company","name":"Modulight","route":"/companies/modulight/","asOf":"2026-09-17","days":4},{"id":"carthera","kind":"company","name":"Carthera","route":"/companies/carthera/","asOf":"2026-09-17","days":4},{"id":"igea","kind":"company","name":"IGEA","route":"/companies/igea/","asOf":"2026-09-17","days":4},{"id":"belmont-medical-technologies","kind":"company","name":"Belmont Medical Technologies","route":"/companies/belmont-medical-technologies/","asOf":"2026-09-17","days":4},{"id":"capnomed","kind":"company","name":"Capnomed (Reger Medizintechnik)","route":"/companies/capnomed/","asOf":"2026-09-17","days":4},{"id":"stryker","kind":"company","name":"Stryker","route":"/companies/stryker/","asOf":"2026-09-17","days":4},{"id":"karl-storz","kind":"company","name":"Karl Storz","route":"/companies/karl-storz/","asOf":"2026-09-17","days":4},{"id":"olympus","kind":"company","name":"Olympus","route":"/companies/olympus/","asOf":"2026-09-17","days":4},{"id":"pentax-medical","kind":"company","name":"Pentax Medical (HOYA)","route":"/companies/pentax-medical/","asOf":"2026-09-17","days":4},{"id":"cook-medical","kind":"company","name":"Cook Medical","route":"/companies/cook-medical/","asOf":"2026-09-17","days":4},{"id":"capsovision","kind":"company","name":"CapsoVision","route":"/companies/capsovision/","asOf":"2026-09-17","days":4},{"id":"lightpoint-medical","kind":"company","name":"Lightpoint Medical","route":"/companies/lightpoint-medical/","asOf":"2026-09-17","days":4},{"id":"mammotome","kind":"company","name":"Mammotome (Danaher)","route":"/companies/mammotome/","asOf":"2026-09-17","days":4},{"id":"dysis-medical","kind":"company","name":"DYSIS Medical","route":"/companies/dysis-medical/","asOf":"2026-09-17","days":4},{"id":"mobileodt","kind":"company","name":"MobileODT","route":"/companies/mobileodt/","asOf":"2026-09-17","days":4},{"id":"canfield-scientific","kind":"company","name":"Canfield Scientific","route":"/companies/canfield-scientific/","asOf":"2026-09-17","days":4},{"id":"fotofinder","kind":"company","name":"FotoFinder Systems","route":"/companies/fotofinder/","asOf":"2026-09-17","days":4},{"id":"caliber-imaging-diagnostics","kind":"company","name":"Caliber Imaging and Diagnostics","route":"/companies/caliber-imaging-diagnostics/","asOf":"2026-09-17","days":4},{"id":"michelson-diagnostics","kind":"company","name":"Michelson Diagnostics","route":"/companies/michelson-diagnostics/","asOf":"2026-09-17","days":4},{"id":"damae-medical","kind":"company","name":"DAMAE Medical","route":"/companies/damae-medical/","asOf":"2026-09-17","days":4},{"id":"vision-rt","kind":"company","name":"Vision RT","route":"/companies/vision-rt/","asOf":"2026-09-17","days":4},{"id":"c-rad","kind":"company","name":"C-RAD","route":"/companies/c-rad/","asOf":"2026-09-17","days":4},{"id":"ptw-freiburg","kind":"company","name":"PTW Freiburg","route":"/companies/ptw-freiburg/","asOf":"2026-09-17","days":4},{"id":"standard-imaging","kind":"company","name":"Standard Imaging","route":"/companies/standard-imaging/","asOf":"2026-09-17","days":4},{"id":"icu-medical","kind":"company","name":"ICU Medical","route":"/companies/icu-medical/","asOf":"2026-09-17","days":4},{"id":"equashield","kind":"company","name":"Equashield","route":"/companies/equashield/","asOf":"2026-09-17","days":4},{"id":"loccioni","kind":"company","name":"Loccioni","route":"/companies/loccioni/","asOf":"2026-09-17","days":4},{"id":"paxman","kind":"company","name":"Paxman","route":"/companies/paxman/","asOf":"2026-09-17","days":4},{"id":"dignitana","kind":"company","name":"Dignitana","route":"/companies/dignitana/","asOf":"2026-09-17","days":4},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","asOf":"2026-09-17","days":4},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","asOf":"2026-09-17","days":4},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","asOf":"2026-09-17","days":4},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","asOf":"2026-09-17","days":4},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","asOf":"2026-09-17","days":4},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","asOf":"2026-09-17","days":4},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","asOf":"2026-09-17","days":4},{"id":"opra","kind":"trial","name":"OPRA","route":"/trials/opra/","asOf":"2026-09-17","days":4},{"id":"prospect","kind":"trial","name":"PROSPECT (Alliance N1048)","route":"/trials/prospect/","asOf":"2026-09-17","days":4},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","asOf":"2026-09-17","days":4},{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","asOf":"2026-09-17","days":4},{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","asOf":"2026-09-17","days":4},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/","asOf":"2026-09-17","days":4},{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/","asOf":"2026-09-17","days":4},{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/","asOf":"2026-09-17","days":4},{"id":"gastric-msi-high","kind":"cancer","name":"Microsatellite-unstable (MSI-high) gastric cancer","route":"/cancers/gastric-msi-high/","asOf":"2026-09-17","days":4},{"id":"early-gastric-cancer","kind":"cancer","name":"Early gastric cancer","route":"/cancers/early-gastric-cancer/","asOf":"2026-09-17","days":4},{"id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","asOf":"2026-09-17","days":4},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/","asOf":"2026-09-17","days":4},{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/","asOf":"2026-09-17","days":4},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/","asOf":"2026-09-17","days":4},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/","asOf":"2026-09-17","days":4},{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/","asOf":"2026-09-17","days":4},{"id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/","asOf":"2026-09-17","days":4},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/","asOf":"2026-09-17","days":4},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","asOf":"2026-09-17","days":4},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","asOf":"2026-09-17","days":4},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","asOf":"2026-09-17","days":4},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","asOf":"2026-09-17","days":4},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","asOf":"2026-09-17","days":4},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","asOf":"2026-09-17","days":4},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/","asOf":"2026-09-17","days":4},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","asOf":"2026-09-17","days":4},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","asOf":"2026-09-17","days":4},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","asOf":"2026-09-17","days":4},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","asOf":"2026-09-17","days":4},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","asOf":"2026-09-17","days":4},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","asOf":"2026-09-17","days":4},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","asOf":"2026-09-17","days":4},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","asOf":"2026-09-17","days":4},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","asOf":"2026-09-17","days":4},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","asOf":"2026-09-17","days":4},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","asOf":"2026-09-17","days":4},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","asOf":"2026-09-17","days":4},{"id":"endometrial-pole-ultramutated","kind":"cancer","name":"POLE-ultramutated endometrial cancer","route":"/cancers/endometrial-pole-ultramutated/","asOf":"2026-09-17","days":4},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/","asOf":"2026-09-17","days":4},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/","asOf":"2026-09-17","days":4},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/","asOf":"2026-09-17","days":4},{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/","asOf":"2026-09-17","days":4},{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/","asOf":"2026-09-17","days":4},{"id":"early-cervical-cancer","kind":"cancer","name":"Early cervical cancer and fertility-sparing surgery","route":"/cancers/early-cervical-cancer/","asOf":"2026-09-17","days":4},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/","asOf":"2026-09-17","days":4},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/","asOf":"2026-09-17","days":4},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/","asOf":"2026-09-17","days":4},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/","asOf":"2026-09-17","days":4},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","asOf":"2026-09-17","days":4},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","asOf":"2026-09-17","days":4},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","asOf":"2026-09-17","days":4},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","asOf":"2026-09-17","days":4},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","asOf":"2026-09-17","days":4},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","asOf":"2026-09-17","days":4},{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","asOf":"2026-09-17","days":4},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","asOf":"2026-09-17","days":4},{"id":"dermatofibrosarcoma-protuberans","kind":"cancer","name":"Dermatofibrosarcoma protuberans","route":"/cancers/dermatofibrosarcoma-protuberans/","asOf":"2026-09-17","days":4},{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","asOf":"2026-09-17","days":4},{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/","asOf":"2026-09-17","days":4},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/","asOf":"2026-09-17","days":4},{"id":"checkmate-204","kind":"trial","name":"CheckMate 204","route":"/trials/checkmate-204/","asOf":"2026-09-17","days":4},{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","asOf":"2026-09-17","days":4},{"id":"keynote-629","kind":"trial","name":"KEYNOTE-629","route":"/trials/keynote-629/","asOf":"2026-09-17","days":4},{"id":"erivance","kind":"trial","name":"ERIVANCE BCC","route":"/trials/erivance/","asOf":"2026-09-17","days":4},{"id":"bolt","kind":"trial","name":"BOLT","route":"/trials/bolt/","asOf":"2026-09-17","days":4},{"id":"javelin-merkel-200","kind":"trial","name":"JAVELIN Merkel 200","route":"/trials/javelin-merkel-200/","asOf":"2026-09-17","days":4},{"id":"keynote-017","kind":"trial","name":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)","route":"/trials/keynote-017/","asOf":"2026-09-17","days":4},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","asOf":"2026-09-17","days":4},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","asOf":"2026-09-17","days":4},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","asOf":"2026-09-17","days":4},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","asOf":"2026-09-17","days":4},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","asOf":"2026-09-17","days":4},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/","asOf":"2026-09-17","days":4},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","asOf":"2026-09-17","days":4},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","asOf":"2026-09-17","days":4},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/","asOf":"2026-09-17","days":4},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","asOf":"2026-09-17","days":4},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","asOf":"2026-09-17","days":4},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","asOf":"2026-09-17","days":4},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","asOf":"2026-09-17","days":4},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","asOf":"2026-09-17","days":4},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","asOf":"2026-09-17","days":4},{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/","asOf":"2026-09-17","days":4},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/","asOf":"2026-09-17","days":4},{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/","asOf":"2026-09-17","days":4},{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","asOf":"2026-09-17","days":4},{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/","asOf":"2026-09-17","days":4},{"id":"pharos","kind":"trial","name":"PHAROS","route":"/trials/pharos/","asOf":"2026-09-17","days":4},{"id":"destiny-lung02","kind":"trial","name":"DESTINY-Lung02","route":"/trials/destiny-lung02/","asOf":"2026-09-17","days":4},{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/","asOf":"2026-09-17","days":4},{"id":"calgb-140503","kind":"trial","name":"CALGB 140503 (Alliance)","route":"/trials/calgb-140503/","asOf":"2026-09-17","days":4},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/","asOf":"2026-09-17","days":4},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/","asOf":"2026-09-17","days":4},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/","asOf":"2026-09-17","days":4},{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/","asOf":"2026-09-17","days":4},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/","asOf":"2026-09-17","days":4},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/","asOf":"2026-09-17","days":4},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/","asOf":"2026-09-17","days":4},{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/","asOf":"2026-09-17","days":4},{"id":"paget-disease-of-the-nipple","kind":"cancer","name":"Paget disease of the nipple","route":"/cancers/paget-disease-of-the-nipple/","asOf":"2026-09-17","days":4},{"id":"phyllodes-tumour","kind":"cancer","name":"Phyllodes tumour of the breast","route":"/cancers/phyllodes-tumour/","asOf":"2026-09-17","days":4},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/","asOf":"2026-09-17","days":4},{"id":"kristine","kind":"trial","name":"KRISTINE","route":"/trials/kristine/","asOf":"2026-09-17","days":4},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","asOf":"2026-09-17","days":4},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","asOf":"2026-09-17","days":4},{"id":"impassion031","kind":"trial","name":"IMpassion031","route":"/trials/impassion031/","asOf":"2026-09-17","days":4},{"id":"chondrosarcoma","kind":"cancer","name":"Chondrosarcoma","route":"/cancers/chondrosarcoma/","asOf":"2026-09-17","days":4},{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/","asOf":"2026-09-17","days":4},{"id":"undifferentiated-pleomorphic-sarcoma","kind":"cancer","name":"Undifferentiated pleomorphic sarcoma (UPS)","route":"/cancers/undifferentiated-pleomorphic-sarcoma/","asOf":"2026-09-17","days":4},{"id":"myxofibrosarcoma","kind":"cancer","name":"Myxofibrosarcoma","route":"/cancers/myxofibrosarcoma/","asOf":"2026-09-17","days":4},{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/","asOf":"2026-09-17","days":4},{"id":"pecoma","kind":"cancer","name":"Perivascular epithelioid cell tumour (PEComa)","route":"/cancers/pecoma/","asOf":"2026-09-17","days":4},{"id":"epithelioid-haemangioendothelioma","kind":"cancer","name":"Epithelioid haemangioendothelioma","route":"/cancers/epithelioid-haemangioendothelioma/","asOf":"2026-09-17","days":4},{"id":"malignant-peripheral-nerve-sheath-tumour","kind":"cancer","name":"Malignant peripheral nerve sheath tumour (MPNST)","route":"/cancers/malignant-peripheral-nerve-sheath-tumour/","asOf":"2026-09-17","days":4},{"id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/","asOf":"2026-09-17","days":4},{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/","asOf":"2026-09-17","days":4},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","asOf":"2026-09-17","days":4},{"id":"eortc-62012","kind":"trial","name":"EORTC 62012","route":"/trials/eortc-62012/","asOf":"2026-09-17","days":4},{"id":"lms-04","kind":"trial","name":"LMS-04","route":"/trials/lms-04/","asOf":"2026-09-17","days":4},{"id":"angiotax","kind":"trial","name":"ANGIOTAX","route":"/trials/angiotax/","asOf":"2026-09-17","days":4},{"id":"enliven","kind":"trial","name":"ENLIVEN","route":"/trials/enliven/","asOf":"2026-09-17","days":4},{"id":"ampect","kind":"trial","name":"AMPECT","route":"/trials/ampect/","asOf":"2026-09-17","days":4},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","asOf":"2026-09-17","days":4},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","asOf":"2026-09-17","days":4},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","asOf":"2026-09-17","days":4},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","asOf":"2026-09-17","days":4},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","asOf":"2026-09-17","days":4},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","asOf":"2026-09-17","days":4},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","asOf":"2026-09-17","days":4},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","asOf":"2026-09-17","days":4},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","asOf":"2026-09-17","days":4},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","asOf":"2026-09-17","days":4},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","asOf":"2026-09-17","days":4},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","asOf":"2026-09-17","days":4},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","asOf":"2026-09-17","days":4},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","asOf":"2026-09-17","days":4},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","asOf":"2026-09-17","days":4},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","asOf":"2026-09-17","days":4},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","asOf":"2026-09-17","days":4},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","asOf":"2026-09-17","days":4},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","asOf":"2026-09-17","days":4},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","asOf":"2026-09-17","days":4},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","asOf":"2026-09-17","days":4},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","asOf":"2026-09-17","days":4},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","asOf":"2026-09-17","days":4},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","asOf":"2026-09-17","days":4},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","asOf":"2026-09-17","days":4},{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/","asOf":"2026-09-17","days":4},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","asOf":"2026-09-17","days":4},{"id":"buccal-mucosa-cancer","kind":"cancer","name":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","route":"/cancers/buccal-mucosa-cancer/","asOf":"2026-09-17","days":4},{"id":"lip-cancer","kind":"cancer","name":"Lip cancer","route":"/cancers/lip-cancer/","asOf":"2026-09-17","days":4},{"id":"nivopostop","kind":"trial","name":"NIVOPOSTOP (GORTEC 2018-01)","route":"/trials/nivopostop/","asOf":"2026-09-17","days":4},{"id":"ecog-e3311","kind":"trial","name":"ECOG-ACRIN E3311","route":"/trials/ecog-e3311/","asOf":"2026-09-17","days":4},{"id":"pathos","kind":"trial","name":"PATHOS","route":"/trials/pathos/","asOf":"2026-09-17","days":4},{"id":"captain-1st","kind":"trial","name":"CAPTAIN-1st","route":"/trials/captain-1st/","asOf":"2026-09-17","days":4},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","asOf":"2026-09-17","days":4},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/","asOf":"2026-09-17","days":4},{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","asOf":"2026-09-17","days":4},{"id":"pacific-2","kind":"trial","name":"PACIFIC-2","route":"/trials/pacific-2/","asOf":"2026-09-17","days":4},{"id":"chrysalis","kind":"trial","name":"CHRYSALIS","route":"/trials/chrysalis/","asOf":"2026-09-17","days":4},{"id":"destiny-gastric01","kind":"trial","name":"DESTINY-Gastric01","route":"/trials/destiny-gastric01/","asOf":"2026-09-17","days":4},{"id":"destiny-gastric02","kind":"trial","name":"DESTINY-Gastric02","route":"/trials/destiny-gastric02/","asOf":"2026-09-17","days":4},{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/","asOf":"2026-09-17","days":4},{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/","asOf":"2026-09-17","days":4},{"id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/","asOf":"2026-09-17","days":4},{"id":"esopec","kind":"trial","name":"ESOPEC","route":"/trials/esopec/","asOf":"2026-09-17","days":4},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","asOf":"2026-09-17","days":4},{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/","asOf":"2026-09-17","days":4},{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/","asOf":"2026-09-17","days":4},{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/","asOf":"2026-09-17","days":4},{"id":"spinet","kind":"trial","name":"SPINET","route":"/trials/spinet/","asOf":"2026-09-17","days":4},{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/","asOf":"2026-09-17","days":4},{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/","asOf":"2026-09-17","days":4},{"id":"cartitude-6","kind":"trial","name":"CARTITUDE-6","route":"/trials/cartitude-6/","asOf":"2026-09-17","days":4},{"id":"apl0406","kind":"trial","name":"APL0406","route":"/trials/apl0406/","asOf":"2026-09-17","days":4},{"id":"commands","kind":"trial","name":"COMMANDS","route":"/trials/commands/","asOf":"2026-09-17","days":4},{"id":"medalist","kind":"trial","name":"MEDALIST","route":"/trials/medalist/","asOf":"2026-09-17","days":4},{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/","asOf":"2026-09-17","days":4},{"id":"verona","kind":"trial","name":"VERONA","route":"/trials/verona/","asOf":"2026-09-17","days":4},{"id":"momentum","kind":"trial","name":"MOMENTUM","route":"/trials/momentum/","asOf":"2026-09-17","days":4},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","asOf":"2026-09-17","days":4},{"id":"dasision","kind":"trial","name":"DASISION","route":"/trials/dasision/","asOf":"2026-09-17","days":4},{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/","asOf":"2026-09-17","days":4},{"id":"augment","kind":"trial","name":"AUGMENT","route":"/trials/augment/","asOf":"2026-09-17","days":4},{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/","asOf":"2026-09-17","days":4},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","asOf":"2026-09-17","days":4},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","asOf":"2026-09-17","days":4},{"id":"aspen-wm","kind":"trial","name":"ASPEN (Waldenström macroglobulinaemia)","route":"/trials/aspen-wm/","asOf":"2026-09-17","days":4},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/","asOf":"2026-09-17","days":4},{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/","asOf":"2026-09-17","days":4},{"id":"aall0434","kind":"trial","name":"COG AALL0434","route":"/trials/aall0434/","asOf":"2026-09-17","days":4},{"id":"aren0532","kind":"trial","name":"COG AREN0532","route":"/trials/aren0532/","asOf":"2026-09-17","days":4},{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/","asOf":"2026-09-17","days":4},{"id":"cabone","kind":"trial","name":"CABONE","route":"/trials/cabone/","asOf":"2026-09-17","days":4},{"id":"sarc028","kind":"trial","name":"SARC028","route":"/trials/sarc028/","asOf":"2026-09-17","days":4},{"id":"regobone","kind":"trial","name":"REGOBONE","route":"/trials/regobone/","asOf":"2026-09-17","days":4},{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/","asOf":"2026-09-17","days":4},{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/","asOf":"2026-09-17","days":4},{"id":"grid","kind":"trial","name":"GRID","route":"/trials/grid/","asOf":"2026-09-17","days":4},{"id":"tam-01","kind":"trial","name":"TAM-01","route":"/trials/tam-01/","asOf":"2026-09-17","days":4},{"id":"comet-dcis","kind":"trial","name":"COMET (Comparison of Operative versus Monitoring and Endocrine Therapy)","route":"/trials/comet-dcis/","asOf":"2026-09-17","days":4},{"id":"penelope-b","kind":"trial","name":"PENELOPE-B","route":"/trials/penelope-b/","asOf":"2026-09-17","days":4},{"id":"bolero-2","kind":"trial","name":"BOLERO-2","route":"/trials/bolero-2/","asOf":"2026-09-17","days":4},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","asOf":"2026-09-17","days":4},{"id":"patina","kind":"trial","name":"PATINA","route":"/trials/patina/","asOf":"2026-09-17","days":4},{"id":"atempt","kind":"trial","name":"ATEMPT","route":"/trials/atempt/","asOf":"2026-09-17","days":4},{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/","asOf":"2026-09-17","days":4},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","asOf":"2026-09-17","days":4},{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/","asOf":"2026-09-17","days":4},{"id":"stamp-merkel","kind":"trial","name":"STAMP (EA6174)","route":"/trials/stamp-merkel/","asOf":"2026-09-17","days":4},{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/","asOf":"2026-09-17","days":4},{"id":"tpextreme","kind":"trial","name":"TPExtreme (GORTEC 2014-01)","route":"/trials/tpextreme/","asOf":"2026-09-17","days":4},{"id":"orator","kind":"trial","name":"ORATOR","route":"/trials/orator/","asOf":"2026-09-17","days":4},{"id":"exam","kind":"trial","name":"EXAM","route":"/trials/exam/","asOf":"2026-09-17","days":4},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","asOf":"2026-09-17","days":4},{"id":"aramis","kind":"trial","name":"ARAMIS","route":"/trials/aramis/","asOf":"2026-09-17","days":4},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","asOf":"2026-09-17","days":4},{"id":"aranote","kind":"trial","name":"ARANOTE","route":"/trials/aranote/","asOf":"2026-09-17","days":4},{"id":"checkmate-025","kind":"trial","name":"CheckMate 025","route":"/trials/checkmate-025/","asOf":"2026-09-17","days":4},{"id":"carmena","kind":"trial","name":"CARMENA","route":"/trials/carmena/","asOf":"2026-09-17","days":4},{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/","asOf":"2026-09-17","days":4},{"id":"keynote-057","kind":"trial","name":"KEYNOTE-057","route":"/trials/keynote-057/","asOf":"2026-09-17","days":4},{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/","asOf":"2026-09-17","days":4},{"id":"shape","kind":"trial","name":"SHAPE (CCTG CX.5)","route":"/trials/shape/","asOf":"2026-09-17","days":4},{"id":"garnet","kind":"trial","name":"GARNET","route":"/trials/garnet/","asOf":"2026-09-17","days":4},{"id":"soraya","kind":"trial","name":"SORAYA","route":"/trials/soraya/","asOf":"2026-09-17","days":4},{"id":"portec-2","kind":"trial","name":"PORTEC-2","route":"/trials/portec-2/","asOf":"2026-09-17","days":4},{"id":"intellance-1","kind":"trial","name":"INTELLANCE-1","route":"/trials/intellance-1/","asOf":"2026-09-17","days":4},{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","route":"/trials/attraction-2/","asOf":"2026-09-17","days":4},{"id":"gatsby","kind":"trial","name":"GATSBY","route":"/trials/gatsby/","asOf":"2026-09-17","days":4},{"id":"klass-01","kind":"trial","name":"KLASS-01","route":"/trials/klass-01/","asOf":"2026-09-17","days":4},{"id":"aza-001","kind":"trial","name":"AZA-001","route":"/trials/aza-001/","asOf":"2026-09-17","days":4},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/","asOf":"2026-09-17","days":4},{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/","asOf":"2026-09-17","days":4},{"id":"aquila","kind":"trial","name":"AQUILA","route":"/trials/aquila/","asOf":"2026-09-17","days":4},{"id":"resonate-2","kind":"trial","name":"RESONATE-2","route":"/trials/resonate-2/","asOf":"2026-09-17","days":4},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/","asOf":"2026-09-17","days":4},{"id":"herby","kind":"trial","name":"HERBY","route":"/trials/herby/","asOf":"2026-09-17","days":4},{"id":"avaglio","kind":"trial","name":"AVAglio","route":"/trials/avaglio/","asOf":"2026-09-17","days":4},{"id":"codel","kind":"trial","name":"CODEL","route":"/trials/codel/","asOf":"2026-09-17","days":4},{"id":"neosphere","kind":"trial","name":"NeoSphere","route":"/trials/neosphere/","asOf":"2026-09-17","days":4},{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/","asOf":"2026-09-17","days":4},{"id":"imspire150","kind":"trial","name":"IMspire150","route":"/trials/imspire150/","asOf":"2026-09-17","days":4},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","asOf":"2026-09-17","days":4},{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/","asOf":"2026-09-17","days":4},{"id":"pancan-know-your-tumor","kind":"collection","name":"PanCAN Know Your Tumor","route":"/collections/pancan-know-your-tumor/","asOf":"2026-09-17","days":4},{"id":"prostate-cancer-promise","kind":"collection","name":"PROMISE registry: free germline testing in prostate cancer","route":"/collections/prostate-cancer-promise/","asOf":"2026-09-17","days":4},{"id":"nhs-genomic-medicine-service","kind":"collection","name":"NHS Genomic Medicine Service","route":"/collections/nhs-genomic-medicine-service/","asOf":"2026-09-17","days":4},{"id":"nhs-jewish-brca-testing","kind":"collection","name":"NHS Jewish BRCA Testing Programme","route":"/collections/nhs-jewish-brca-testing/","asOf":"2026-09-17","days":4},{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/","asOf":"2026-09-17","days":4},{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","route":"/collections/australia-cancer-screening-programs/","asOf":"2026-09-17","days":4},{"id":"ireland-national-screening-service","kind":"collection","name":"Ireland's National Screening Service","route":"/collections/ireland-national-screening-service/","asOf":"2026-09-17","days":4},{"id":"nz-time-to-screen","kind":"collection","name":"Time to Screen (New Zealand national screening)","route":"/collections/nz-time-to-screen/","asOf":"2026-09-17","days":4},{"id":"cdc-nbccedp","kind":"collection","name":"CDC National Breast and Cervical Cancer Early Detection Program","route":"/collections/cdc-nbccedp/","asOf":"2026-09-17","days":4},{"id":"nhs-hpv-vaccination","kind":"collection","name":"NHS HPV vaccination programme","route":"/collections/nhs-hpv-vaccination/","asOf":"2026-09-17","days":4},{"id":"us-vaccines-for-children","kind":"collection","name":"Vaccines for Children program (US)","route":"/collections/us-vaccines-for-children/","asOf":"2026-09-17","days":4},{"id":"gavi-hpv-programme","kind":"collection","name":"Gavi HPV vaccine support","route":"/collections/gavi-hpv-programme/","asOf":"2026-09-17","days":4},{"id":"nci-cancer-information-service","kind":"collection","name":"NCI Cancer Information Service","route":"/collections/nci-cancer-information-service/","asOf":"2026-09-17","days":4},{"id":"macmillan-support-line","kind":"collection","name":"Macmillan Support Line","route":"/collections/macmillan-support-line/","asOf":"2026-09-17","days":4},{"id":"cruk-nurse-helpline","kind":"collection","name":"Cancer Research UK nurse helpline","route":"/collections/cruk-nurse-helpline/","asOf":"2026-09-17","days":4},{"id":"acs-cancer-helpline","kind":"collection","name":"American Cancer Society helpline","route":"/collections/acs-cancer-helpline/","asOf":"2026-09-17","days":4},{"id":"cancercare","kind":"collection","name":"CancerCare","route":"/collections/cancercare/","asOf":"2026-09-17","days":4},{"id":"cancer-support-community","kind":"collection","name":"Cancer Support Community","route":"/collections/cancer-support-community/","asOf":"2026-09-17","days":4},{"id":"krebsinformationsdienst","kind":"collection","name":"Krebsinformationsdienst (KID)","route":"/collections/krebsinformationsdienst/","asOf":"2026-09-17","days":4},{"id":"breast-cancer-now-helpline","kind":"collection","name":"Breast Cancer Now helpline","route":"/collections/breast-cancer-now-helpline/","asOf":"2026-09-17","days":4},{"id":"acs-road-to-recovery","kind":"collection","name":"ACS Road To Recovery","route":"/collections/acs-road-to-recovery/","asOf":"2026-09-17","days":4},{"id":"acs-hope-lodge","kind":"collection","name":"ACS Hope Lodge","route":"/collections/acs-hope-lodge/","asOf":"2026-09-17","days":4},{"id":"corporate-angel-network","kind":"collection","name":"Corporate Angel Network","route":"/collections/corporate-angel-network/","asOf":"2026-09-17","days":4},{"id":"ronald-mcdonald-house-charities","kind":"collection","name":"Ronald McDonald House Charities","route":"/collections/ronald-mcdonald-house-charities/","asOf":"2026-09-17","days":4},{"id":"nhs-healthcare-travel-costs-scheme","kind":"collection","name":"NHS Healthcare Travel Costs Scheme","route":"/collections/nhs-healthcare-travel-costs-scheme/","asOf":"2026-09-17","days":4},{"id":"young-lives-vs-cancer","kind":"collection","name":"Young Lives vs Cancer","route":"/collections/young-lives-vs-cancer/","asOf":"2026-09-17","days":4},{"id":"thesecondopinion","kind":"collection","name":"thesecondopinion","route":"/collections/thesecondopinion/","asOf":"2026-09-17","days":4},{"id":"lazarex-cancer-foundation","kind":"collection","name":"Lazarex Cancer Foundation","route":"/collections/lazarex-cancer-foundation/","asOf":"2026-09-17","days":4},{"id":"nihr-be-part-of-research","kind":"collection","name":"Be Part of Research (NIHR)","route":"/collections/nihr-be-part-of-research/","asOf":"2026-09-17","days":4},{"id":"force-facing-our-risk","kind":"collection","name":"FORCE: Facing Our Risk of Cancer Empowered","route":"/collections/force-facing-our-risk/","asOf":"2026-09-17","days":4},{"id":"sharsheret","kind":"collection","name":"Sharsheret","route":"/collections/sharsheret/","asOf":"2026-09-17","days":4},{"id":"maggies-centres","kind":"collection","name":"Maggie's","route":"/collections/maggies-centres/","asOf":"2026-09-17","days":4},{"id":"penny-brohn-uk","kind":"collection","name":"Penny Brohn UK","route":"/collections/penny-brohn-uk/","asOf":"2026-09-17","days":4},{"id":"livestrong-at-the-ymca","kind":"collection","name":"LIVESTRONG at the YMCA","route":"/collections/livestrong-at-the-ymca/","asOf":"2026-09-17","days":4},{"id":"look-good-feel-better","kind":"collection","name":"Look Good Feel Better","route":"/collections/look-good-feel-better/","asOf":"2026-09-17","days":4},{"id":"imerman-angels","kind":"collection","name":"Imerman Angels","route":"/collections/imerman-angels/","asOf":"2026-09-17","days":4},{"id":"first-descents","kind":"collection","name":"First Descents","route":"/collections/first-descents/","asOf":"2026-09-17","days":4},{"id":"kesem","kind":"collection","name":"Kesem","route":"/collections/kesem/","asOf":"2026-09-17","days":4},{"id":"little-princess-trust","kind":"collection","name":"The Little Princess Trust","route":"/collections/little-princess-trust/","asOf":"2026-09-17","days":4},{"id":"knitted-knockers","kind":"collection","name":"Knitted Knockers","route":"/collections/knitted-knockers/","asOf":"2026-09-17","days":4},{"id":"wigs-for-kids","kind":"collection","name":"Wigs for Kids","route":"/collections/wigs-for-kids/","asOf":"2026-09-17","days":4},{"id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","asOf":"2026-09-18","days":3},{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","asOf":"2026-09-18","days":3},{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","asOf":"2026-09-18","days":3},{"id":"robert-doebele","kind":"person","name":"Robert C. Doebele","route":"/people/robert-doebele/","asOf":"2026-09-18","days":3},{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","asOf":"2026-09-18","days":3},{"id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","asOf":"2026-09-18","days":3},{"id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","asOf":"2026-09-18","days":3},{"id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","asOf":"2026-09-18","days":3},{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","asOf":"2026-09-18","days":3},{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","asOf":"2026-09-18","days":3},{"id":"jens-hoeppner","kind":"person","name":"Jens Höppner","route":"/people/jens-hoeppner/","asOf":"2026-09-18","days":3},{"id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","route":"/people/hyung-ho-kim/","asOf":"2026-09-18","days":3},{"id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/","asOf":"2026-09-18","days":3},{"id":"manish-shah","kind":"person","name":"Manish A. Shah","route":"/people/manish-shah/","asOf":"2026-09-18","days":3},{"id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","route":"/people/hansjochen-wilke/","asOf":"2026-09-18","days":3},{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","asOf":"2026-09-18","days":3},{"id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","asOf":"2026-09-18","days":3},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","asOf":"2026-09-18","days":3},{"id":"angela-lamarca","kind":"person","name":"Angela Lamarca","route":"/people/angela-lamarca/","asOf":"2026-09-18","days":3},{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","asOf":"2026-09-18","days":3},{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","asOf":"2026-09-18","days":3},{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","asOf":"2026-09-18","days":3},{"id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","asOf":"2026-09-18","days":3},{"id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","asOf":"2026-09-18","days":3},{"id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","route":"/people/francesco-lo-coco/","asOf":"2026-09-18","days":3},{"id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/","asOf":"2026-09-18","days":3},{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","asOf":"2026-09-18","days":3},{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/","asOf":"2026-09-18","days":3},{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","asOf":"2026-09-18","days":3},{"id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","asOf":"2026-09-18","days":3},{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","asOf":"2026-09-18","days":3},{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","asOf":"2026-09-18","days":3},{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","asOf":"2026-09-18","days":3},{"id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","asOf":"2026-09-18","days":3},{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","asOf":"2026-09-18","days":3},{"id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","asOf":"2026-09-18","days":3},{"id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","asOf":"2026-09-18","days":3},{"id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","route":"/people/rashmi-murthy/","asOf":"2026-09-18","days":3},{"id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","route":"/people/rupert-bartsch/","asOf":"2026-09-18","days":3},{"id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","asOf":"2026-09-18","days":3},{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","asOf":"2026-09-18","days":3},{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","asOf":"2026-09-18","days":3},{"id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","asOf":"2026-09-18","days":3},{"id":"jose-baselga","kind":"person","name":"José Baselga","route":"/people/jose-baselga/","asOf":"2026-09-18","days":3},{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","asOf":"2026-09-18","days":3},{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","asOf":"2026-09-18","days":3},{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","asOf":"2026-09-18","days":3},{"id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","route":"/people/jeffrey-gershenwald/","asOf":"2026-09-18","days":3},{"id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","asOf":"2026-09-18","days":3},{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","asOf":"2026-09-18","days":3},{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","asOf":"2026-09-18","days":3},{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","asOf":"2026-09-18","days":3},{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","asOf":"2026-09-18","days":3},{"id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","asOf":"2026-09-18","days":3},{"id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","asOf":"2026-09-18","days":3},{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","asOf":"2026-09-18","days":3},{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","asOf":"2026-09-18","days":3},{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","asOf":"2026-09-18","days":3},{"id":"joel-guigay","kind":"person","name":"Joël Guigay","route":"/people/joel-guigay/","asOf":"2026-09-18","days":3},{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","asOf":"2026-09-18","days":3},{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","asOf":"2026-09-18","days":3},{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","asOf":"2026-09-18","days":3},{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","asOf":"2026-09-18","days":3},{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","asOf":"2026-09-18","days":3},{"id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","asOf":"2026-09-18","days":3},{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","asOf":"2026-09-18","days":3},{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","asOf":"2026-09-18","days":3},{"id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/","asOf":"2026-09-18","days":3},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","asOf":"2026-09-18","days":3},{"id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","route":"/people/gerhardt-attard/","asOf":"2026-09-18","days":3},{"id":"david-dearnaley","kind":"person","name":"David Dearnaley","route":"/people/david-dearnaley/","asOf":"2026-09-18","days":3},{"id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/","asOf":"2026-09-18","days":3},{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","asOf":"2026-09-18","days":3},{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","asOf":"2026-09-18","days":3},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","asOf":"2026-09-18","days":3},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","asOf":"2026-09-18","days":3},{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","asOf":"2026-09-18","days":3},{"id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/","asOf":"2026-09-18","days":3},{"id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","asOf":"2026-09-18","days":3},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","asOf":"2026-09-18","days":3},{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","asOf":"2026-09-18","days":3},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","asOf":"2026-09-18","days":3},{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","asOf":"2026-09-18","days":3},{"id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","asOf":"2026-09-18","days":3},{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","asOf":"2026-09-18","days":3},{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","asOf":"2026-09-18","days":3},{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","asOf":"2026-09-18","days":3},{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","asOf":"2026-09-18","days":3},{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","asOf":"2026-09-18","days":3},{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","asOf":"2026-09-18","days":3},{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","asOf":"2026-09-18","days":3},{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","asOf":"2026-09-18","days":3},{"id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","route":"/people/kimberly-dunsmore/","asOf":"2026-09-18","days":3},{"id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","asOf":"2026-09-18","days":3},{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","asOf":"2026-09-18","days":3},{"id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","asOf":"2026-09-18","days":3},{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","asOf":"2026-09-18","days":3},{"id":"patricia-pautier","kind":"person","name":"Patricia Pautier","route":"/people/patricia-pautier/","asOf":"2026-09-18","days":3},{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","route":"/people/patrick-schoffski/","asOf":"2026-09-18","days":3},{"id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","asOf":"2026-09-18","days":3},{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","asOf":"2026-09-18","days":3},{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","asOf":"2026-09-18","days":3},{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","asOf":"2026-09-18","days":3},{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","asOf":"2026-09-18","days":3},{"id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","asOf":"2026-09-18","days":3},{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","asOf":"2026-09-18","days":3},{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/","asOf":"2026-09-18","days":3},{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","asOf":"2026-09-18","days":3},{"id":"gerald-prager","kind":"person","name":"Gerald W. Prager","route":"/people/gerald-prager/","asOf":"2026-09-18","days":3},{"id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","asOf":"2026-09-18","days":3},{"id":"maria-de-santis","kind":"person","name":"Maria De Santis","route":"/people/maria-de-santis/","asOf":"2026-09-18","days":3},{"id":"paper-anchor-anal-hsil-treatment-nejm-2022","kind":"paper","name":"ANCHOR: treating anal high-grade squamous intraepithelial lesions to prevent anal cancer in people living with HIV","route":"/key-papers/paper-anchor-anal-hsil-treatment-nejm-2022/","asOf":"2026-09-18","days":3},{"id":"paper-ians-anal-cancer-screening-guidelines-ijc-2024","kind":"paper","name":"International Anal Neoplasia Society consensus guidelines for anal cancer screening","route":"/key-papers/paper-ians-anal-cancer-screening-guidelines-ijc-2024/","asOf":"2026-09-18","days":3},{"id":"paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013","kind":"paper","name":"ACT II: mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for squamous cell carcinoma of the anus","route":"/key-papers/paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013/","asOf":"2026-09-18","days":3},{"id":"paper-esmo-anal-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline on anal cancer: diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-anal-cancer-guideline-ann-oncol-2021/","asOf":"2026-09-18","days":3},{"id":"paper-interaact-anal-cancer-carboplatin-paclitaxel-jco-2020","kind":"paper","name":"InterAACT: cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer","route":"/key-papers/paper-interaact-anal-cancer-carboplatin-paclitaxel-jco-2020/","asOf":"2026-09-18","days":3},{"id":"paper-eau-asco-penile-cancer-guideline-eur-urol-2023","kind":"paper","name":"EAU-ASCO collaborative guideline on penile cancer, 2023 update","route":"/key-papers/paper-eau-asco-penile-cancer-guideline-eur-urol-2023/","asOf":"2026-09-18","days":3},{"id":"paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010","kind":"paper","name":"Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases","route":"/key-papers/paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010/","asOf":"2026-09-18","days":3},{"id":"paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008","kind":"paper","name":"GROINSS-V: sentinel node dissection is safe in early-stage vulvar cancer","route":"/key-papers/paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008/","asOf":"2026-09-18","days":3},{"id":"paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021","kind":"paper","name":"GROINSS-V II: radiotherapy versus inguinofemoral lymphadenectomy for vulvar cancer with sentinel node micrometastases","route":"/key-papers/paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021/","asOf":"2026-09-18","days":3},{"id":"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006","kind":"paper","name":"Carcinoma of the vagina: FIGO 26th Annual Report on the results of treatment in gynecological cancer","route":"/key-papers/paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006/","asOf":"2026-09-18","days":3},{"id":"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018","kind":"paper","name":"FIGO Cancer Report 2018: cancer of the vagina","route":"/key-papers/paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018/","asOf":"2026-09-18","days":3},{"id":"paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971","kind":"paper","name":"Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumour appearance in young women","route":"/key-papers/paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971/","asOf":"2026-09-18","days":3},{"id":"paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015","kind":"paper","name":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015/","asOf":"2026-09-18","days":3},{"id":"paper-masaoka-thymoma-clinical-staging-cancer-1981","kind":"paper","name":"Masaoka staging: follow-up study of thymomas with special reference to their clinical stages","route":"/key-papers/paper-masaoka-thymoma-clinical-staging-cancer-1981/","asOf":"2026-09-18","days":3},{"id":"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022","kind":"paper","name":"The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours","route":"/key-papers/paper-who-2021-thymus-mediastinum-classification-marx-jto-2022/","asOf":"2026-09-18","days":3},{"id":"paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020","kind":"paper","name":"REMORA: lenvatinib in advanced or metastatic thymic carcinoma","route":"/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/","asOf":"2026-09-18","days":3},{"id":"paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018","kind":"paper","name":"Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study","route":"/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/","asOf":"2026-09-18","days":3},{"id":"paper-adiuvo-adjuvant-mitotane-acc-lancet-diabetes-endocrinol-2023","kind":"paper","name":"ADIUVO: adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma","route":"/key-papers/paper-adiuvo-adjuvant-mitotane-acc-lancet-diabetes-endocrinol-2023/","asOf":"2026-09-18","days":3},{"id":"paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018","kind":"paper","name":"European Society of Endocrinology and ENSAT clinical practice guidelines on the management of adrenocortical carcinoma in adults","route":"/key-papers/paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018/","asOf":"2026-09-18","days":3},{"id":"paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012","kind":"paper","name":"FIRM-ACT: combination chemotherapy in advanced adrenocortical carcinoma","route":"/key-papers/paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012/","asOf":"2026-09-18","days":3},{"id":"paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016","kind":"paper","name":"PSOGI consensus for classification and pathological reporting of pseudomyxoma peritonei and associated appendiceal neoplasia","route":"/key-papers/paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016/","asOf":"2026-09-18","days":3},{"id":"paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020","kind":"paper","name":"The 2019 WHO classification of tumours of the digestive system","route":"/key-papers/paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020/","asOf":"2026-09-18","days":3},{"id":"paper-chicago-consensus-appendiceal-neoplasms-cancer-2020","kind":"paper","name":"The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms","route":"/key-papers/paper-chicago-consensus-appendiceal-neoplasms-cancer-2020/","asOf":"2026-09-18","days":3},{"id":"paper-overman-capox-small-bowel-adenocarcinoma-jco-2009","kind":"paper","name":"Phase 2 study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","route":"/key-papers/paper-overman-capox-small-bowel-adenocarcinoma-jco-2009/","asOf":"2026-09-18","days":3},{"id":"paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021","kind":"paper","name":"ZEBRA: pembrolizumab in advanced small bowel adenocarcinoma","route":"/key-papers/paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021/","asOf":"2026-09-18","days":3},{"id":"paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023","kind":"paper","name":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023/","asOf":"2026-09-18","days":3},{"id":"paper-cupisco-molecularly-guided-therapy-cup-lancet-2024","kind":"paper","name":"CUPISCO: molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary","route":"/key-papers/paper-cupisco-molecularly-guided-therapy-cup-lancet-2024/","asOf":"2026-09-18","days":3},{"id":"paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019","kind":"paper","name":"Randomised phase 2 trial of site-specific treatment based on gene expression profiling versus carboplatin and paclitaxel in cancer of unknown primary","route":"/key-papers/paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019/","asOf":"2026-09-18","days":3},{"id":"paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018","kind":"paper","name":"VE-BASKET: vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis","route":"/key-papers/paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018/","asOf":"2026-09-18","days":3},{"id":"paper-erdheim-chester-disease-consensus-recommendations-blood-2020","kind":"paper","name":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis and treatment in the molecular era","route":"/key-papers/paper-erdheim-chester-disease-consensus-recommendations-blood-2020/","asOf":"2026-09-18","days":3},{"id":"paper-emile-revised-classification-of-histiocytoses-blood-2016","kind":"paper","name":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","route":"/key-papers/paper-emile-revised-classification-of-histiocytoses-blood-2016/","asOf":"2026-09-18","days":3},{"id":"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018","kind":"paper","name":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","route":"/key-papers/paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018/","asOf":"2026-09-18","days":3},{"id":"paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013","kind":"paper","name":"LCH-III: therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","route":"/key-papers/paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013/","asOf":"2026-09-18","days":3},{"id":"paper-badalian-very-braf-mutations-lch-blood-2010","kind":"paper","name":"Recurrent BRAF mutations in Langerhans cell histiocytosis","route":"/key-papers/paper-badalian-very-braf-mutations-lch-blood-2010/","asOf":"2026-09-18","days":3},{"id":"paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019","kind":"paper","name":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","route":"/key-papers/paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019/","asOf":"2026-09-18","days":3},{"id":"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023","kind":"paper","name":"PIONEER: avapritinib versus placebo in indolent systemic mastocytosis","route":"/key-papers/paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023/","asOf":"2026-09-18","days":3},{"id":"paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016","kind":"paper","name":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","route":"/key-papers/paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016/","asOf":"2026-09-18","days":3},{"id":"paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"EXPLORER: safety and efficacy of avapritinib in advanced systemic mastocytosis (phase 1)","route":"/key-papers/paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","asOf":"2026-09-18","days":3},{"id":"paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"PATHFINDER: efficacy and safety of avapritinib in advanced systemic mastocytosis (phase 2 interim analysis)","route":"/key-papers/paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","asOf":"2026-09-18","days":3},{"id":"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","kind":"paper","name":"GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/","asOf":"2026-09-18","days":3},{"id":"paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015","kind":"paper","name":"RAPID: PET-directed therapy for early-stage Hodgkin lymphoma","route":"/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/","asOf":"2026-09-18","days":3},{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/","asOf":"2026-09-18","days":3},{"id":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","kind":"paper","name":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/","asOf":"2026-09-18","days":3},{"id":"paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015","kind":"paper","name":"AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse","route":"/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/","asOf":"2026-09-18","days":3},{"id":"paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-204: pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma","route":"/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/","asOf":"2026-09-18","days":3},{"id":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","kind":"paper","name":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","route":"/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/","asOf":"2026-09-18","days":3},{"id":"paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020","kind":"paper","name":"Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials","route":"/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/","asOf":"2026-09-18","days":3},{"id":"paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002","kind":"paper","name":"FIGO staging for gestational trophoblastic neoplasia 2000","route":"/key-papers/paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002/","asOf":"2026-09-18","days":3},{"id":"paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011","kind":"paper","name":"GOG 174: weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia","route":"/key-papers/paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011/","asOf":"2026-09-18","days":3},{"id":"paper-trophimmun-avelumab-chemoresistant-gtn-jco-2020","kind":"paper","name":"TROPHIMMUN cohort A: avelumab in gestational trophoblastic tumours resistant to single-agent chemotherapy","route":"/key-papers/paper-trophimmun-avelumab-chemoresistant-gtn-jco-2020/","asOf":"2026-09-18","days":3},{"id":"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997","kind":"paper","name":"EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients","route":"/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/","asOf":"2026-09-18","days":3},{"id":"paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021","kind":"paper","name":"FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease","route":"/key-papers/paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021/","asOf":"2026-09-18","days":3},{"id":"paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009","kind":"paper","name":"Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study","route":"/key-papers/paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009/","asOf":"2026-09-18","days":3},{"id":"paper-froeling-pstt-ett-intensified-therapy-bjc-2019","kind":"paper","name":"Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours","route":"/key-papers/paper-froeling-pstt-ett-intensified-therapy-bjc-2019/","asOf":"2026-09-18","days":3},{"id":"paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002","kind":"paper","name":"Germline mutations in nonsyndromic pheochromocytoma","route":"/key-papers/paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002/","asOf":"2026-09-18","days":3},{"id":"paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014","kind":"paper","name":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","route":"/key-papers/paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014/","asOf":"2026-09-18","days":3},{"id":"paper-firstmappp-sunitinib-metastatic-ppgl-lancet-2024","kind":"paper","name":"FIRSTMAPPP: sunitinib for metastatic progressive pheochromocytomas and paragangliomas","route":"/key-papers/paper-firstmappp-sunitinib-metastatic-ppgl-lancet-2024/","asOf":"2026-09-18","days":3},{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/","asOf":"2026-09-18","days":3},{"id":"paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998","kind":"paper","name":"Intergroup 0099: chemoradiotherapy versus radiotherapy in advanced nasopharyngeal cancer","route":"/key-papers/paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998/","asOf":"2026-09-18","days":3},{"id":"paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019","kind":"paper","name":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019/","asOf":"2026-09-18","days":3},{"id":"paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021","kind":"paper","name":"CSCO and ASCO guideline: chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma","route":"/key-papers/paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021/","asOf":"2026-09-18","days":3},{"id":"paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016","kind":"paper","name":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016/","asOf":"2026-09-18","days":3},{"id":"paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021","kind":"paper","name":"JUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma","route":"/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/","asOf":"2026-09-18","days":3},{"id":"paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021","kind":"paper","name":"CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/","asOf":"2026-09-18","days":3},{"id":"paper-kadish-olfactory-neuroblastoma-staging-cancer-1976","kind":"paper","name":"Kadish staging: olfactory neuroblastoma, a clinical analysis of 17 cases","route":"/key-papers/paper-kadish-olfactory-neuroblastoma-staging-cancer-1976/","asOf":"2026-09-18","days":3},{"id":"paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001","kind":"paper","name":"Esthesioneuroblastoma: a meta-analysis and review","route":"/key-papers/paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001/","asOf":"2026-09-18","days":3},{"id":"paper-amit-induction-chemotherapy-response-snuc-jco-2019","kind":"paper","name":"Induction chemotherapy response as a guide to treatment optimisation in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-amit-induction-chemotherapy-response-snuc-jco-2019/","asOf":"2026-09-18","days":3},{"id":"paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017","kind":"paper","name":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017/","asOf":"2026-09-18","days":3},{"id":"krankenhaus-nordwest","kind":"institution","name":"Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF)","route":"/institutions/krankenhaus-nordwest/","asOf":"2026-09-18","days":3},{"id":"kliniken-essen-mitte","kind":"institution","name":"Kliniken Essen-Mitte","route":"/institutions/kliniken-essen-mitte/","asOf":"2026-09-18","days":3},{"id":"lungenclinic-grosshansdorf","kind":"institution","name":"LungenClinic Grosshansdorf","route":"/institutions/lungenclinic-grosshansdorf/","asOf":"2026-09-18","days":3},{"id":"university-hospital-leipzig","kind":"institution","name":"Leipzig University Hospital / University Cancer Center Leipzig (UCCL)","route":"/institutions/university-hospital-leipzig/","asOf":"2026-09-18","days":3},{"id":"klinikum-stuttgart-olgahospital","kind":"institution","name":"Klinikum Stuttgart / Olgahospital","route":"/institutions/klinikum-stuttgart-olgahospital/","asOf":"2026-09-18","days":3},{"id":"ulm-university-hospital","kind":"institution","name":"Ulm University Hospital / Comprehensive Cancer Center Ulm","route":"/institutions/ulm-university-hospital/","asOf":"2026-09-18","days":3},{"id":"st-anna-ccri-vienna","kind":"institution","name":"St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI)","route":"/institutions/st-anna-ccri-vienna/","asOf":"2026-09-18","days":3},{"id":"iosi-bellinzona","kind":"institution","name":"Oncology Institute of Southern Switzerland (IOSI)","route":"/institutions/iosi-bellinzona/","asOf":"2026-09-18","days":3},{"id":"ap-hm-timone","kind":"institution","name":"Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille","route":"/institutions/ap-hm-timone/","asOf":"2026-09-18","days":3},{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","route":"/institutions/chu-nantes/","asOf":"2026-09-18","days":3},{"id":"chu-lille","kind":"institution","name":"Lille University Hospital (CHU de Lille)","route":"/institutions/chu-lille/","asOf":"2026-09-18","days":3},{"id":"antwerp-university-hospital","kind":"institution","name":"Antwerp University Hospital (UZA)","route":"/institutions/antwerp-university-hospital/","asOf":"2026-09-18","days":3},{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","route":"/institutions/niguarda-cancer-center/","asOf":"2026-09-18","days":3},{"id":"fondazione-michelangelo","kind":"institution","name":"Fondazione Michelangelo","route":"/institutions/fondazione-michelangelo/","asOf":"2026-09-18","days":3},{"id":"ospedali-galliera","kind":"institution","name":"E.O. Ospedali Galliera","route":"/institutions/ospedali-galliera/","asOf":"2026-09-18","days":3},{"id":"university-of-pisa","kind":"institution","name":"University of Pisa / Azienda Ospedaliero-Universitaria Pisana","route":"/institutions/university-of-pisa/","asOf":"2026-09-18","days":3},{"id":"hospital-universitario-salamanca","kind":"institution","name":"University Hospital of Salamanca / IBSAL","route":"/institutions/hospital-universitario-salamanca/","asOf":"2026-09-18","days":3},{"id":"nkua-athens","kind":"institution","name":"National and Kapodistrian University of Athens, School of Medicine","route":"/institutions/nkua-athens/","asOf":"2026-09-18","days":3},{"id":"royal-free-hospital","kind":"institution","name":"Royal Free Hospital, Royal Free London NHS Foundation Trust","route":"/institutions/royal-free-hospital/","asOf":"2026-09-18","days":3},{"id":"weill-cornell-meyer-cancer-center","kind":"institution","name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","route":"/institutions/weill-cornell-meyer-cancer-center/","asOf":"2026-09-18","days":3},{"id":"seattle-childrens","kind":"institution","name":"Seattle Children's Hospital","route":"/institutions/seattle-childrens/","asOf":"2026-09-18","days":3},{"id":"carilion-clinic","kind":"institution","name":"Carilion Clinic / Virginia Tech Carilion School of Medicine","route":"/institutions/carilion-clinic/","asOf":"2026-09-18","days":3},{"id":"tennessee-oncology","kind":"institution","name":"Tennessee Oncology / Greco-Hainsworth Centers for Research","route":"/institutions/tennessee-oncology/","asOf":"2026-09-18","days":3},{"id":"us-oncology-network","kind":"institution","name":"The US Oncology Network / US Oncology Research","route":"/institutions/us-oncology-network/","asOf":"2026-09-18","days":3},{"id":"orlando-health-cancer-institute","kind":"institution","name":"Orlando Health Cancer Institute","route":"/institutions/orlando-health-cancer-institute/","asOf":"2026-09-18","days":3},{"id":"baylor-sammons-dallas","kind":"institution","name":"Charles A. Sammons Cancer Center, Baylor University Medical Center","route":"/institutions/baylor-sammons-dallas/","asOf":"2026-09-18","days":3},{"id":"tgen","kind":"institution","name":"Translational Genomics Research Institute (TGen)","route":"/institutions/tgen/","asOf":"2026-09-18","days":3},{"id":"houston-methodist-neal-cancer-center","kind":"institution","name":"Houston Methodist Dr. Mary and Ron Neal Cancer Center","route":"/institutions/houston-methodist-neal-cancer-center/","asOf":"2026-09-18","days":3},{"id":"childrens-national-hospital","kind":"institution","name":"Children's National Hospital","route":"/institutions/childrens-national-hospital/","asOf":"2026-09-18","days":3},{"id":"cincinnati-cancer-center","kind":"institution","name":"University of Cincinnati Cancer Center","route":"/institutions/cincinnati-cancer-center/","asOf":"2026-09-18","days":3},{"id":"mcw-cancer-center","kind":"institution","name":"Medical College of Wisconsin Cancer Center","route":"/institutions/mcw-cancer-center/","asOf":"2026-09-18","days":3},{"id":"university-of-alberta","kind":"institution","name":"University of Alberta","route":"/institutions/university-of-alberta/","asOf":"2026-09-18","days":3},{"id":"queens-university-kingston","kind":"institution","name":"Queen's University / Kingston Health Sciences Centre","route":"/institutions/queens-university-kingston/","asOf":"2026-09-18","days":3},{"id":"osaka-university","kind":"institution","name":"Osaka University Graduate School of Medicine / Osaka University Hospital","route":"/institutions/osaka-university/","asOf":"2026-09-18","days":3},{"id":"kindai-university-hospital","kind":"institution","name":"Kindai University Faculty of Medicine and Hospital","route":"/institutions/kindai-university-hospital/","asOf":"2026-09-18","days":3},{"id":"snu-bundang-hospital","kind":"institution","name":"Seoul National University Bundang Hospital","route":"/institutions/snu-bundang-hospital/","asOf":"2026-09-18","days":3},{"id":"melanoma-institute-australia","kind":"institution","name":"Melanoma Institute Australia","route":"/institutions/melanoma-institute-australia/","asOf":"2026-09-18","days":3},{"id":"saigenci-adelaide","kind":"institution","name":"South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide","route":"/institutions/saigenci-adelaide/","asOf":"2026-09-18","days":3},{"id":"alfred-health-monash","kind":"institution","name":"Alfred Health / Monash University","route":"/institutions/alfred-health-monash/","asOf":"2026-09-18","days":3},{"id":"university-of-western-australia","kind":"institution","name":"University of Western Australia","route":"/institutions/university-of-western-australia/","asOf":"2026-09-18","days":3},{"id":"uq-frazer-institute","kind":"institution","name":"The University of Queensland Frazer Institute","route":"/institutions/uq-frazer-institute/","asOf":"2026-09-18","days":3},{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/","asOf":"2026-09-18","days":3},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","asOf":"2026-09-18","days":3},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","asOf":"2026-09-18","days":3},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","asOf":"2026-09-18","days":3},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","asOf":"2026-09-18","days":3},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","asOf":"2026-09-18","days":3},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","asOf":"2026-09-18","days":3},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","asOf":"2026-09-18","days":3},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","asOf":"2026-09-18","days":3},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","asOf":"2026-09-18","days":3},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","asOf":"2026-09-18","days":3},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","asOf":"2026-09-18","days":3},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","asOf":"2026-09-18","days":3},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","asOf":"2026-09-18","days":3},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","asOf":"2026-09-18","days":3},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","asOf":"2026-09-18","days":3},{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","asOf":"2026-09-18","days":3},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","asOf":"2026-09-18","days":3},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","asOf":"2026-09-18","days":3},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","asOf":"2026-09-18","days":3},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","asOf":"2026-09-18","days":3},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","asOf":"2026-09-18","days":3},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","asOf":"2026-09-18","days":3},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","asOf":"2026-09-18","days":3},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","asOf":"2026-09-18","days":3},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","asOf":"2026-09-18","days":3},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","asOf":"2026-09-18","days":3},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","asOf":"2026-09-18","days":3},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","asOf":"2026-09-18","days":3},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","asOf":"2026-09-18","days":3},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","asOf":"2026-09-18","days":3},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","asOf":"2026-09-18","days":3},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","asOf":"2026-09-18","days":3},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","asOf":"2026-09-18","days":3},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","asOf":"2026-09-18","days":3},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","asOf":"2026-09-18","days":3},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","asOf":"2026-09-18","days":3},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","asOf":"2026-09-18","days":3},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","asOf":"2026-09-18","days":3},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","asOf":"2026-09-18","days":3},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","asOf":"2026-09-18","days":3},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","asOf":"2026-09-18","days":3},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","asOf":"2026-09-18","days":3},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","asOf":"2026-09-18","days":3},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","asOf":"2026-09-18","days":3},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","asOf":"2026-09-18","days":3},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","asOf":"2026-09-18","days":3},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","asOf":"2026-09-18","days":3},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","asOf":"2026-09-18","days":3},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","asOf":"2026-09-18","days":3},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","asOf":"2026-09-18","days":3}],"summary":{"soc-cites-dead":2,"approvals-vs-regional":125,"asof-before-regulatory-event":1,"duplicate-name":113,"future-year-in-text":1978,"near-duplicate-levenshtein":16,"outcome-no-source":47,"pipeline-cites-dead":9,"status-vs-approvals":24,"text-vs-structured":2,"unsourced-numbers":30,"approved-only-live-trials":88,"name-collision-across-kinds":131,"near-duplicate-name":7,"orphan":115,"regional-approval-only":1,"text-says-approved":26,"unsourced":171}}